-DOCSTART- (6794356)

Tricuspid	ADJ	O	B-Entity
valve	NOUN	O	I-Entity
regurgitation	NOUN	O	I-Entity
and	CCONJ	O	O
lithium	NOUN	O	B-Entity
carbonate	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
newborn	ADJ	O	O
infant	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
newborn	ADJ	O	O
with	ADP	O	O
massive	ADJ	O	O
tricuspid	NOUN	O	B-Entity
regurgitation	NOUN	O	I-Entity
,	PUNCT	O	O
atrial	ADJ	O	B-Entity
flutter	NOUN	O	I-Entity
,	PUNCT	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
high	ADJ	O	O
serum	NOUN	O	O
lithium	NOUN	O	I-Entity
level	NOUN	O	O
is	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
patient	NOUN	O	O
to	PART	O	O
initially	ADV	O	O
manifest	VERB	O	O
tricuspid	NOUN	O	B-Entity
regurgitation	NOUN	O	I-Entity
and	CCONJ	O	O
atrial	ADJ	O	B-Entity
flutter	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
11th	ADJ	O	O
described	VERB	O	O
patient	NOUN	O	O
with	ADP	O	O
cardiac	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
among	ADP	O	O
infants	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
lithium	NOUN	O	I-Entity
compounds	NOUN	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
trimester	NOUN	O	O
of	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

Lithium	ADJ	O	B-Entity
carbonate	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
factor	NOUN	O	O
in	ADP	O	O
the	DET	O	O
increasing	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
congenital	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
when	ADV	O	O
taken	VERB	O	O
during	ADP	O	O
early	ADJ	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
also	ADV	O	O
causes	VERB	O	O
neurologic	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
,	PUNCT	O	O
cyanosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
cardiac	ADJ	O	B-Entity
arrhythmia	NOUN	O	I-Entity
when	ADV	O	O
consumed	VERB	O	O
prior	ADV	O	O
to	ADP	O	O
delivery	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6504332)

Phenobarbital	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
neurologically	ADV	O	B-Entity
-	PUNCT	O	I-Entity
impaired	ADJ	O	I-Entity
child	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
2-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
child	NOUN	O	O
with	ADP	O	O
known	ADJ	O	O
neurologic	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
developed	VERB	O	O
a	DET	O	O
dyskinesia	NOUN	O	I-Entity
soon	ADV	O	O
after	ADP	O	O
starting	VERB	O	O
phenobarbital	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Known	VERB	O	O
causes	NOUN	O	O
of	ADP	O	O
movement	NOUN	O	B-Entity
disorders	NOUN	O	I-Entity
were	VERB	O	O
eliminated	VERB	O	O
after	ADP	O	O
evaluation	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
repeat	NOUN	O	O
challenge	NOUN	O	O
with	ADP	O	O
phenobarbital	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
dyskinesia	NOUN	O	I-Entity
recurred	VERB	O	O
.	PUNCT	O	O

Phenobarbital	PROPN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
added	VERB	O	O
to	ADP	O	O
the	DET	O	O
list	NOUN	O	O
of	ADP	O	O
anticonvulsant	ADJ	O	O
drugs	NOUN	O	O
that	ADJ	O	O
can	VERB	O	O
cause	VERB	O	O
movement	NOUN	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6436733)

Acute	ADJ	O	O
changes	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
ammonia	NOUN	O	I-Entity
may	VERB	O	O
predict	VERB	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
valproic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

Valproic	PROPN	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
VPA	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
given	VERB	O	O
to	ADP	O	O
24	NUM	O	O
epileptic	ADJ	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
already	ADV	O	O
being	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
other	ADJ	O	O
antiepileptic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
standardized	ADJ	O	O
loading	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
VPA	PROPN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
venous	ADJ	O	O
blood	NOUN	O	O
was	VERB	O	O
sampled	VERB	O	O
at	ADP	O	O
0	NUM	O	O
,	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
4	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

Ammonia	PROPN	O	I-Entity
(	PUNCT	O	O
NH3	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
higher	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
,	PUNCT	O	O
during	ADP	O	O
continuous	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
complained	VERB	O	O
of	ADP	O	O
drowsiness	NOUN	O	I-Entity
(	PUNCT	O	O
7	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
than	ADP	O	O
in	ADP	O	O
those	DET	O	O
who	NOUN	O	O
were	VERB	O	O
symptom	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
(	PUNCT	O	O
17	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
although	ADP	O	O
VPA	PROPN	O	I-Entity
plasma	NOUN	O	O
levels	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
measuring	VERB	O	O
VPA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
changes	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
NH3	PROPN	O	I-Entity
content	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
may	VERB	O	O
be	VERB	O	O
possible	ADJ	O	O
to	PART	O	O
identify	VERB	O	O
patients	NOUN	O	O
at	ADP	O	O
higher	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
obtundation	NOUN	O	O
when	ADV	O	O
VPA	PROPN	O	I-Entity
is	VERB	O	O
given	VERB	O	O
chronically	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (6293644)

Calcitonin	PROPN	O	O
injection	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
potentiation	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
partial	ADJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
.	PUNCT	O	O

Moreover	ADV	O	O
calcitonin	NOUN	O	O
induced	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
nigral	ADJ	O	O
GAD	PROPN	O	O
activity	NOUN	O	O
but	CCONJ	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
striatal	NOUN	O	O
DA	NOUN	O	I-Entity
and	CCONJ	O	O
DOPAC	PROPN	O	I-Entity
concentration	NOUN	O	O
or	CCONJ	O	O
GAD	PROPN	O	O
activity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
in	ADP	O	O
view	NOUN	O	O
of	ADP	O	O
a	DET	O	O
primary	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
calcitonin	NOUN	O	O
on	ADP	O	O
the	DET	O	O
striatonigral	ADJ	O	O
GABAergic	PROPN	O	O
pathway	NOUN	O	O
mediating	VERB	O	O
the	DET	O	O
DA	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
behavioral	ADJ	O	O
messages	NOUN	O	O
of	ADP	O	O
striatal	ADJ	O	O
origin	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6203632)

Development	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
development	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
adult	NOUN	O	O
female	ADJ	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
following	VERB	O	O
daily	ADV	O	O
subcutaneous	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
ISO	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
0.3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
time	NOUN	O	O
course	NOUN	O	O
was	VERB	O	O
established	VERB	O	O
for	ADP	O	O
the	DET	O	O
change	NOUN	O	O
in	ADP	O	O
tissue	NOUN	O	O
mass	NOUN	O	O
,	PUNCT	O	O
RNA	PROPN	O	O
and	CCONJ	O	O
DNA	PROPN	O	O
content	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
hydroxyproline	NOUN	O	I-Entity
content	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
total	ADJ	O	O
content	NOUN	O	O
of	ADP	O	O
hydroxyproline	NOUN	O	I-Entity
remained	VERB	O	O
stable	ADJ	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
2	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
but	CCONJ	O	O
increased	VERB	O	O
46%	NUM	O	O
after	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Ventricular	ADJ	O	O
DNA	NOUN	O	O
content	NOUN	O	O
was	VERB	O	O
unchanged	ADJ	O	O
during	ADP	O	O
the	DET	O	O
early	ADJ	O	O
stage	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
4	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
hypertrophic	ADJ	O	I-Entity
growth	NOUN	O	O
but	CCONJ	O	O
increased	VERB	O	O
to	ADP	O	O
a	DET	O	O
new	ADJ	O	O
steady	ADJ	O	O
-	PUNCT	O	O
state	NOUN	O	O
level	NOUN	O	O
19%	NUM	O	O
above	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
after	ADP	O	O
8	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Intraventricular	ADJ	O	O
pressures	NOUN	O	O
and	CCONJ	O	O
coronary	ADJ	O	O
flow	NOUN	O	O
measures	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
control	NOUN	O	O
and	CCONJ	O	O
experimental	ADJ	O	O
animals	NOUN	O	O
following	VERB	O	O
4	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
developed	VERB	O	O
hypertrophy	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
dP	PROPN	O	O
/	PUNCT	O	O
dt	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ISO	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
hearts	NOUN	O	O
was	VERB	O	O
slightly	ADV	O	O
but	CCONJ	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
elevated	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
adaptive	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
ISO	PROPN	O	I-Entity
shows	VERB	O	O
an	DET	O	O
early	ADJ	O	O
hypertrophic	ADJ	O	I-Entity
phase	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
4	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
characterized	VERB	O	O
by	ADP	O	O
a	DET	O	O
substantial	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
RNA	PROPN	O	O
content	NOUN	O	O
and	CCONJ	O	O
cardiac	ADJ	O	O
mass	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
DNA	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
prolonged	ADJ	O	O
stimulation	NOUN	O	O
(	PUNCT	O	O
8	NUM	O	O
-	SYM	O	O
12	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
appears	VERB	O	O
to	PART	O	O
represent	VERB	O	O
a	DET	O	O
complex	ADJ	O	O
integration	NOUN	O	O
of	ADP	O	O
both	DET	O	O
cellular	ADJ	O	O
hypertrophy	NOUN	O	I-Entity
and	CCONJ	O	O
hyperplasia	NOUN	O	I-Entity
within	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3131282)

Co	PROPN	O	O
-	PUNCT	O	O
carcinogenic	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
retinyl	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
on	ADP	O	O
forestomach	NOUN	O	B-Entity
carcinogenesis	NOUN	O	I-Entity
of	ADP	O	O
male	ADJ	O	O
F344	PROPN	O	O
rats	NOUN	O	O
induced	VERB	O	O
with	ADP	O	O
butylated	VERB	O	B-Entity
hydroxyanisole	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
potential	ADJ	O	O
modifying	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
retinyl	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
(	PUNCT	O	O
RA	PROPN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
butylated	VERB	O	B-Entity
hydroxyanisole	NOUN	O	I-Entity
(	PUNCT	O	O
BHA)-induced	VERB	O	I-Entity
rat	NOUN	O	O
forestomach	NOUN	O	B-Entity
tumorigenesis	NOUN	O	I-Entity
was	VERB	O	O
examined	VERB	O	O
.	PUNCT	O	O

Male	PROPN	O	O
F344	PROPN	O	O
rats	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
maintained	VERB	O	O
on	ADP	O	O
diet	NOUN	O	O
containing	VERB	O	O
1%	NUM	O	O
or	CCONJ	O	O
2%	NUM	O	O
BHA	NOUN	O	I-Entity
by	ADP	O	O
weight	NOUN	O	O
and	CCONJ	O	O
simultaneously	ADV	O	O
on	ADP	O	O
drinking	NOUN	O	O
water	NOUN	O	O
supplemented	VERB	O	O
with	ADP	O	O
RA	PROPN	O	I-Entity
at	ADP	O	O
various	ADJ	O	O
concentrations	NOUN	O	O
(	PUNCT	O	O
w	PROPN	O	O
/	SYM	O	O
v	PUNCT	O	O
)	PUNCT	O	O
for	ADP	O	O
52	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
groups	NOUN	O	O
given	VERB	O	O
2%	NUM	O	O
BHA	PROPN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
marked	VERB	O	O
hyperplastic	ADJ	O	O
changes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
forestomach	NOUN	O	O
epithelium	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
all	DET	O	O
animals	NOUN	O	O
,	PUNCT	O	O
co	ADV	O	O
-	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
0.25%	NUM	O	O
RA	PROPN	O	I-Entity
significantly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
increased	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
forestomach	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
(	PUNCT	O	O
squamous	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
papilloma	NOUN	O	I-Entity
and	CCONJ	O	O
carcinoma	NOUN	O	I-Entity
)	PUNCT	O	O
to	ADP	O	O
60%	NUM	O	O
(	PUNCT	O	O
9/15	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
rats	NOUN	O	O
with	ADP	O	O
carcinoma	NOUN	O	I-Entity
)	PUNCT	O	O
from	ADP	O	O
15%	NUM	O	O
(	PUNCT	O	O
3/20	NUM	O	O
,	PUNCT	O	O
one	NUM	O	O
rat	NOUN	O	O
with	ADP	O	O
carcinoma	NOUN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
given	VERB	O	O
RA	PROPN	O	I-Entity
-	PUNCT	O	O
free	ADJ	O	O
water	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
rats	NOUN	O	O
given	VERB	O	O
1%	NUM	O	O
BHA	PROPN	O	I-Entity
,	PUNCT	O	O
RA	PROPN	O	I-Entity
co	NOUN	O	O
-	PUNCT	O	O
administered	VERB	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
0.05	NUM	O	O
,	PUNCT	O	O
0.1	NUM	O	O
,	PUNCT	O	O
0.2	NUM	O	O
or	CCONJ	O	O
0.25%	NUM	O	O
showed	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
enhancing	VERB	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
the	DET	O	O
BHA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
epithelial	ADJ	O	B-Entity
hyperplasia	NOUN	O	I-Entity
.	PUNCT	O	O

Tumors	NOUN	O	I-Entity
,	PUNCT	O	O
all	DET	O	O
papillomas	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
induced	VERB	O	O
in	ADP	O	O
3	NUM	O	O
rats	NOUN	O	O
(	PUNCT	O	O
17%	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
0.25%	NUM	O	O
RA	PROPN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
one	NUM	O	O
rat	NOUN	O	O
(	PUNCT	O	O
10%	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
0.05%	NUM	O	O
RA	PROPN	O	I-Entity
co	NOUN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
.	PUNCT	O	O

RA	PROPN	O	I-Entity
alone	ADV	O	O
did	VERB	O	O
not	ADV	O	O
induce	VERB	O	O
hyperplastic	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
forestomach	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
RA	PROPN	O	I-Entity
acted	VERB	O	O
as	ADP	O	O
a	DET	O	O
co	NOUN	O	O
-	PUNCT	O	O
carcinogen	NOUN	O	O
in	ADP	O	O
the	DET	O	O
BHA	PROPN	O	I-Entity
forestomach	NOUN	O	B-Entity
carcinogenesis	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3115150)

Ketanserin	PROPN	O	I-Entity
pretreatment	NOUN	O	O
reverses	VERB	O	O
alfentanil	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
.	PUNCT	O	O

Systemic	ADJ	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
ketanserin	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
relatively	ADV	O	O
specific	ADJ	O	O
type-2	X	O	O
serotonin	NOUN	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
significantly	ADV	O	O
attenuated	VERB	O	O
the	DET	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
produced	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
by	ADP	O	O
the	DET	O	O
potent	ADJ	O	O
short	ADJ	O	O
-	PUNCT	O	O
acting	VERB	O	O
opiate	NOUN	O	O
agonist	NOUN	O	O
alfentanil	NOUN	O	I-Entity
.	PUNCT	O	O

Following	VERB	O	O
placement	NOUN	O	O
of	ADP	O	O
subcutaneous	ADJ	O	O
electrodes	NOUN	O	O
in	ADP	O	O
each	DET	O	O
animal	NOUN	O	O
's	PART	O	O
left	VERB	O	O
gastrocnemius	NOUN	O	O
muscle	NOUN	O	O
,	PUNCT	O	O
rigidity	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
analyzing	VERB	O	O
root	NOUN	O	O
-	PUNCT	O	O
mean	NOUN	O	O
-	PUNCT	O	O
square	ADJ	O	O
electromyographic	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

Intraperitoneal	PROPN	O	O
ketanserin	VERB	O	I-Entity
administration	NOUN	O	O
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
0.63	NUM	O	O
and	CCONJ	O	O
2.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
prevented	VERB	O	O
the	DET	O	O
alfentanil	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
electromyographic	ADJ	O	O
activity	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
animals	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
.	PUNCT	O	O

Chlordiazepoxide	PROPN	O	I-Entity
at	ADP	O	O
doses	NOUN	O	O
up	ADP	O	O
to	ADP	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
significantly	ADV	O	O
influence	VERB	O	O
the	DET	O	O
rigidity	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
alfentanil	NOUN	O	I-Entity
.	PUNCT	O	O

Despite	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
ketanserin	NOUN	O	I-Entity
(	PUNCT	O	O
greater	ADJ	O	O
than	ADP	O	O
0.31	NUM	O	O

followed	VERB	O	O
by	ADP	O	O
alfentanil	NOUN	O	I-Entity
were	VERB	O	O
motionless	ADJ	O	O
,	PUNCT	O	O
flaccid	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
less	ADV	O	O
responsive	ADJ	O	O
to	ADP	O	O
external	ADJ	O	O
stimuli	NOUN	O	O
than	ADP	O	O
were	VERB	O	O
animals	NOUN	O	O
receiving	VERB	O	O
alfentanil	ADV	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
ketanserin	NOUN	O	I-Entity
and	CCONJ	O	O
alfentanil	NOUN	O	I-Entity
exhibited	VERB	O	O
less	ADV	O	O
rearing	NOUN	O	O
and	CCONJ	O	O
exploratory	ADJ	O	O
behavior	NOUN	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
60-min	NOUN	O	O
recording	NOUN	O	O
period	NOUN	O	O
than	ADP	O	O
did	VERB	O	O
animals	NOUN	O	O
that	ADJ	O	O
received	VERB	O	O
ketanserin	ADV	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
previous	ADJ	O	O
work	NOUN	O	O
,	PUNCT	O	O
suggest	VERB	O	O
that	ADP	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
side	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
of	ADP	O	O
parenteral	ADJ	O	O
narcotic	ADJ	O	O
administration	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
partly	ADV	O	O
mediated	VERB	O	O
via	ADP	O	O
serotonergic	ADJ	O	O
pathways	NOUN	O	O
.	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
type-2	DET	O	O
serotonin	NOUN	O	I-Entity
antagonists	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
clinically	ADV	O	O
useful	ADJ	O	O
in	ADP	O	O
attenuating	VERB	O	O
opiate	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
further	ADJ	O	O
studies	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
necessary	ADJ	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
interaction	NOUN	O	O
of	ADP	O	O
possibly	ADV	O	O
enhanced	VERB	O	O
CNS	PROPN	O	O
,	PUNCT	O	O
cardiovascular	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
respiratory	ADJ	O	I-Entity
depression	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2917114)

Glycopyrronium	NOUN	O	I-Entity
requirements	NOUN	O	O
for	ADP	O	O
antagonism	NOUN	O	O
of	ADP	O	O
the	DET	O	O
muscarinic	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
edrophonium	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
compared	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
60	NUM	O	O
adult	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
cardiovascular	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
glycopyrronium	NOUN	O	I-Entity
5	NUM	O	O
micrograms	NOUN	O	O
kg-1	PROPN	O	O
and	CCONJ	O	O
10	NUM	O	O
micrograms	NOUN	O	O
kg-1	PUNCT	O	O
given	VERB	O	O
either	CCONJ	O	O
simultaneously	ADV	O	O
or	CCONJ	O	O
1	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
edrophonium	NOUN	O	I-Entity
1	NUM	O	O
mg	NUM	O	O
kg-1	NOUN	O	O
.	PUNCT	O	O

Use	NOUN	O	O
of	ADP	O	O
glycopyrronium	NOUN	O	I-Entity
5	NUM	O	O
micrograms	NOUN	O	O
kg-1	VERB	O	O
provided	VERB	O	O
greater	ADJ	O	O
cardiovascular	ADJ	O	O
stability	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
given	VERB	O	O
1	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
the	DET	O	O
edrophonium	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
sufficient	ADJ	O	O
to	PART	O	O
minimize	VERB	O	O
early	ADV	O	O
,	PUNCT	O	O
edrophonium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
bradycardias	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
low	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
glycopyrronium	NOUN	O	I-Entity
provided	VERB	O	O
good	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
oropharyngeal	ADJ	O	O
secretions	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2564649)

Involvement	NOUN	O	O
of	ADP	O	O
locus	NOUN	O	O
coeruleus	NOUN	O	O
and	CCONJ	O	O
noradrenergic	ADJ	O	O
neurotransmission	NOUN	O	O
in	ADP	O	O
fentanyl	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
muscular	ADJ	O	B-Entity
rigidity	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Whereas	ADP	O	O
muscular	ADJ	O	B-Entity
rigidity	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
known	VERB	O	O
side	NOUN	O	O
effect	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
fentanyl	NOUN	O	I-Entity
anesthesia	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
paucity	NOUN	O	O
of	ADP	O	O
information	NOUN	O	O
exists	VERB	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
its	ADJ	O	O
underlying	ADJ	O	O
mechanism(s	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
the	DET	O	O
possible	ADJ	O	O
engagement	NOUN	O	O
of	ADP	O	O
locus	NOUN	O	O
coeruleus	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pons	NOUN	O	O
in	ADP	O	O
this	DET	O	O
phenomenon	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
male	ADJ	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
anesthetized	VERB	O	O
with	ADP	O	O
ketamine	NOUN	O	I-Entity
.	PUNCT	O	O

Under	ADP	O	O
proper	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
respiration	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	O
temperature	NOUN	O	O
and	CCONJ	O	O
end	NOUN	O	O
-	PUNCT	O	O
tidal	ADJ	O	O
CO2	NOUN	O	I-Entity
,	PUNCT	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
or	CCONJ	O	O
100	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
consistently	ADV	O	O
promoted	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
electromyographic	ADJ	O	O
activity	NOUN	O	O
recorded	VERB	O	O
from	ADP	O	O
the	DET	O	O
gastrocnemius	NOUN	O	O
and	CCONJ	O	O
abdominal	ADJ	O	O
rectus	NOUN	O	O
muscles	NOUN	O	O
.	PUNCT	O	O

Such	ADJ	O	O
an	DET	O	O
induced	VERB	O	O
muscular	ADJ	O	B-Entity
rigidity	NOUN	O	I-Entity
by	ADP	O	O
the	DET	O	O
narcotic	ADJ	O	O
agent	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
antagonized	VERB	O	O
or	CCONJ	O	O
even	ADV	O	O
reduced	VERB	O	O
by	ADP	O	O
prior	ADJ	O	O
electrolytic	ADJ	O	O
lesions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
locus	NOUN	O	O
coeruleus	NOUN	O	O
or	CCONJ	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
the	DET	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
blocker	NOUN	O	O
,	PUNCT	O	O
prazosin	NOUN	O	I-Entity
.	PUNCT	O	O

Microinjection	PROPN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
(	PUNCT	O	O
2.5	NUM	O	O
micrograms/50	NUM	O	O
nl	NOUN	O	O
)	PUNCT	O	O
directly	ADV	O	O
into	ADP	O	O
this	DET	O	O
pontine	NOUN	O	O
nucleus	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
elicited	VERB	O	O
discernible	ADJ	O	O
electromyographic	ADJ	O	O
excitation	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
speculated	VERB	O	O
that	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
muscular	ADJ	O	B-Entity
rigidity	NOUN	O	I-Entity
by	ADP	O	O
fentanyl	NOUN	O	I-Entity
may	VERB	O	O
involve	VERB	O	O
the	DET	O	O
coerulospinal	ADJ	O	O
noradrenergic	ADJ	O	O
fibers	NOUN	O	O
to	ADP	O	O
the	DET	O	O
spinal	ADJ	O	O
motoneurons	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2339463)

Cerebral	ADJ	O	B-Entity
sinus	ADJ	O	I-Entity
thrombosis	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
potential	ADJ	O	O
hazard	NOUN	O	O
of	ADP	O	O
antifibrinolytic	ADJ	O	O
treatment	NOUN	O	O
in	ADP	O	O
menorrhagia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
42-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
superior	ADJ	O	O
sagittal	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
left	VERB	O	I-Entity
transverse	ADJ	O	I-Entity
sinus	ADJ	O	I-Entity
thrombosis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
prolonged	VERB	O	O
epsilon	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminocaproic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
menorrhagia	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
antifibrinolytic	ADJ	O	O
agent	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
used	VERB	O	O
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
menorrhagia	NOUN	O	I-Entity
to	PART	O	O
promote	VERB	O	O
clotting	NOUN	O	O
and	CCONJ	O	O
reduce	VERB	O	O
blood	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
thromboembolic	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
during	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
epsilon	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminocaproic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
cerebral	ADJ	O	B-Entity
sinus	ADJ	O	I-Entity
thrombosis	NOUN	O	I-Entity
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
previously	ADV	O	O
described	VERB	O	O
.	PUNCT	O	O

Careful	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
epsilon	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminocaproic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
therapy	NOUN	O	O
is	VERB	O	O
recommended	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (1545575)

Hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
complicating	VERB	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

Hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
potentially	ADV	O	O
serious	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
cyclophosphamide	NOUN	O	I-Entity
therapy	NOUN	O	O
administered	VERB	O	O
before	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
an	DET	O	O
attempt	NOUN	O	O
to	PART	O	O
obviate	VERB	O	O
the	DET	O	O
inconvenience	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	O
irrigation	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
feasibility	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
uroprophylaxis	NOUN	O	O
with	ADP	O	O
mesna	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
neutralizes	VERB	O	O
the	DET	O	O
hepatic	ADJ	O	O
metabolite	NOUN	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
that	ADJ	O	O
causes	VERB	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
97	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
standard	NOUN	O	O
prophylaxis	NOUN	O	O
,	PUNCT	O	O
4	NUM	O	O
had	VERB	O	O
symptomatic	ADJ	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
two	NUM	O	O
of	ADP	O	O
four	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
mesna	NOUN	O	I-Entity
uroprophylaxis	NOUN	O	O
before	ADP	O	O
allogeneic	ADJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplantation	NOUN	O	O
had	VERB	O	O
severe	ADJ	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
for	ADP	O	O
at	ADV	O	O
least	ADV	O	O
2	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
of	ADP	O	O
this	DET	O	O
suboptimal	ADJ	O	O
result	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
resumed	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	O
irrigation	NOUN	O	O
and	CCONJ	O	O
forced	VERB	O	O
hydration	NOUN	O	O
to	PART	O	O
minimize	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1286498)

Reversal	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
benzodiazepine	ADJ	O	I-Entity
effects	NOUN	O	O
by	ADP	O	O
flumazenil	NOUN	O	I-Entity
after	ADP	O	O
intravenous	ADJ	O	O
conscious	ADJ	O	O
sedation	NOUN	O	O
with	ADP	O	O
diazepam	NOUN	O	I-Entity
and	CCONJ	O	O
opioids	NOUN	O	O
:	PUNCT	O	O
report	NOUN	O	O
of	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
multicenter	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Flumazenil	PROPN	O	I-Entity
in	ADP	O	O
Intravenous	PROPN	O	O
Conscious	PROPN	O	O
Sedation	PROPN	O	O
with	ADP	O	O
Diazepam	PROPN	O	I-Entity
Multicenter	PROPN	O	O
Study	PROPN	O	O
Group	PROPN	O	O
II	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
benzodiazepine	NOUN	O	I-Entity
antagonist	NOUN	O	O
,	PUNCT	O	O
flumazenil	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
multicenter	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Flumazenil	PROPN	O	I-Entity
(	PUNCT	O	O
mean	VERB	O	O
dose	NOUN	O	O
,	PUNCT	O	O
0.76	NUM	O	O
mg	CCONJ	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
dose	NOUN	O	O
,	PUNCT	O	O
8.9	NUM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
intravenously	ADV	O	O
to	ADP	O	O
130	NUM	O	O
and	CCONJ	O	O
67	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
who	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
given	VERB	O	O
diazepam	NOUN	O	I-Entity
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
an	DET	O	O
opioid	NOUN	O	O
(	PUNCT	O	O
fentanyl	NOUN	O	I-Entity
,	PUNCT	O	O
meperidine	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
morphine	NOUN	O	I-Entity
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
and	CCONJ	O	O
maintenance	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
conscious	ADJ	O	O
sedation	NOUN	O	O
for	ADP	O	O
diagnostic	ADJ	O	O
or	CCONJ	O	O
therapeutic	ADJ	O	O
surgical	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
group	NOUN	O	O
assessable	NOUN	O	O
for	ADP	O	O
efficacy	NOUN	O	O
comprised	VERB	O	O
122	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
flumazenil	NOUN	O	I-Entity
and	CCONJ	O	O
64	NUM	O	O
patients	NOUN	O	O
given	VERB	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
5	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
80/115	NUM	O	O
(	PUNCT	O	O
70%	NUM	O	O
)	PUNCT	O	O
flumazenil	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
21/63	NUM	O	O
(	PUNCT	O	O
33%	NUM	O	O
)	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
completely	ADV	O	O
awake	ADJ	O	O
and	CCONJ	O	O
alert	ADJ	O	O
,	PUNCT	O	O
as	ADP	O	O
indicated	VERB	O	O
by	ADP	O	O
a	DET	O	O
score	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
on	ADP	O	O
the	DET	O	O
Observer	PROPN	O	O
's	PART	O	O
Assessment	PROPN	O	O
of	ADP	O	O
Alertness	PROPN	O	O
/	SYM	O	O
Sedation	PROPN	O	O
Scale	PROPN	O	O
.	PUNCT	O	O

Flumazenil	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
also	ADV	O	O
performed	VERB	O	O
significantly	ADV	O	O
better	ADJ	O	O
on	ADP	O	O
the	DET	O	O
Finger	PROPN	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
Nose	PROPN	O	O
Test	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
recall	NOUN	O	O
of	ADP	O	O
pictures	NOUN	O	O
shown	VERB	O	O
at	ADP	O	O
the	DET	O	O
5-minute	NUM	O	O
assessment	NOUN	O	O
.	PUNCT	O	O

Flumazenil	PROPN	O	I-Entity
was	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
serious	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
reported	VERB	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
nine	NUM	O	O
(	PUNCT	O	O
30%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
flumazenil	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
17	NUM	O	O
(	PUNCT	O	O
25%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
had	VERB	O	O
one	NUM	O	O
or	CCONJ	O	O
more	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
adverse	ADJ	O	O
experiences	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
nausea	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
flumazenil	NOUN	O	I-Entity
group	NOUN	O	O
and	CCONJ	O	O
nausea	NOUN	O	I-Entity
and	CCONJ	O	O
injection	NOUN	O	O
-	PUNCT	O	O
site	NOUN	O	O
pain	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Flumazenil	PROPN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
promptly	ADV	O	O
reverse	VERB	O	O
sedation	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
diazepam	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
opioids	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (839274)

Hepatic	ADJ	O	O
adenomas	NOUN	O	I-Entity
and	CCONJ	O	O
focal	ADJ	O	B-Entity
nodular	ADJ	O	I-Entity
hyperplasia	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
in	ADP	O	O
young	ADJ	O	O
women	NOUN	O	O
on	ADP	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
:	PUNCT	O	O
case	NOUN	O	O
reports	VERB	O	O
.	PUNCT	O	O

Two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	O
adenoma	NOUN	O	I-Entity
and	CCONJ	O	O
one	NUM	O	O
of	ADP	O	O
focal	ADJ	O	B-Entity
nodular	ADJ	O	I-Entity
hyperplasia	NOUN	O	I-Entity
presumably	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
,	PUNCT	O	O
are	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

Histologic	ADJ	O	O
differences	NOUN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
similarities	NOUN	O	O
between	ADP	O	O
hepatic	ADJ	O	O
adenoma	NOUN	O	I-Entity
and	CCONJ	O	O
focal	ADJ	O	B-Entity
nodular	ADJ	O	I-Entity
hyperplasia	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (591536)

Arterial	ADJ	O	O
thromboembolism	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
systemic	ADJ	O	O
heparin	NOUN	O	I-Entity
therapy	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
complication	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
.	PUNCT	O	O

Arterial	ADJ	O	O
thromboembolism	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
recognized	VERB	O	O
complication	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
heparin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Characteristic	PROPN	O	O
of	ADP	O	O
the	DET	O	O
entity	NOUN	O	O
is	VERB	O	O
arterial	ADJ	O	B-Entity
occlusion	NOUN	O	I-Entity
by	ADP	O	O
platelet	NOUN	O	O
-	PUNCT	O	O
fibrin	NOUN	O	O
thrombi	NOUN	O	I-Entity
with	ADP	O	O
distal	NOUN	O	O
ischemia	NOUN	O	I-Entity
occurring	VERB	O	O
four	NUM	O	O
to	PART	O	O
twenty	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
preceded	VERB	O	O
by	ADP	O	O
profound	ADJ	O	O
thrombocytopenia	NOUN	O	I-Entity
with	ADP	O	O
platelet	NOUN	O	O
counts	NOUN	O	O
in	ADP	O	O
the	DET	O	O
range	NOUN	O	O
of	ADP	O	O
30,000	NUM	O	O
to	PART	O	O
40,000	NUM	O	O
per	ADP	O	O
cubic	ADJ	O	O
millimeter	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinically	ADV	O	O
apparent	ADJ	O	O
occlusion	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
preceded	VERB	O	O
by	ADP	O	O
gastrointestinal	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
musculoskeletal	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
that	ADJ	O	O
appear	VERB	O	O
to	PART	O	O
be	VERB	O	O
ischemic	ADJ	O	I-Entity
in	ADP	O	O
origin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
might	VERB	O	O
serve	VERB	O	O
to	PART	O	O
warn	VERB	O	O
the	DET	O	O
clinician	NOUN	O	O
of	ADP	O	O
these	DET	O	O
complications	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
reports	NOUN	O	O
of	ADP	O	O
these	DET	O	O
phenomena	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
recent	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
are	VERB	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
common	ADJ	O	O
factor	NOUN	O	O
relating	VERB	O	O
thromboembolism	NOUN	O	I-Entity
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
is	VERB	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
platelet	NOUN	O	B-Entity
aggregation	NOUN	O	I-Entity
.	PUNCT	O	O

Appropriate	ADJ	O	O
treatment	NOUN	O	O
consists	VERB	O	O
of	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
anticoagulation	NOUN	O	O
with	ADP	O	O
sodium	NOUN	O	B-Entity
warfarin	NOUN	O	I-Entity
if	ADP	O	O
necessary	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (20735774)

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
prognosis	NOUN	O	O
for	ADP	O	O
transplant	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
survivors	NOUN	O	O
of	ADP	O	O
paracetamol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
prognosis	NOUN	O	O
for	ADP	O	O
transplant	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
survivors	NOUN	O	O
of	ADP	O	O
paracetamol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
remains	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
examine	VERB	O	O
whether	ADP	O	O
paracetamol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
increases	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
mortality	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
followed	VERB	O	O
up	PART	O	O
all	DET	O	O
transplant	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
survivors	NOUN	O	O
of	ADP	O	O
paracetamol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
hospitalized	VERB	O	O
in	ADP	O	O
a	DET	O	O
Danish	ADJ	O	O
national	ADJ	O	O
referral	NOUN	O	O
centre	NOUN	O	O
during	ADP	O	O
1984	NUM	O	O
-	SYM	O	O
2004	NUM	O	O
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
age	NOUN	O	O
-	PUNCT	O	O
specific	ADJ	O	O
mortality	NOUN	O	O
rates	NOUN	O	O
from	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
post	NOUN	O	O
-	PUNCT	O	O
discharge	NOUN	O	O
through	ADP	O	O
2008	NUM	O	O
between	ADP	O	O
those	DET	O	O
in	ADP	O	O
whom	NOUN	O	O
the	DET	O	O
liver	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
an	DET	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
those	DET	O	O
in	ADP	O	O
whom	NOUN	O	O
it	PRON	O	O
did	VERB	O	O
not	ADV	O	O
.	PUNCT	O	O

On	ADP	O	O
average	ADJ	O	O
,	PUNCT	O	O
age	NOUN	O	O
-	PUNCT	O	O
specific	ADJ	O	O
mortality	NOUN	O	O
rates	NOUN	O	O
were	VERB	O	O
slightly	ADV	O	O
higher	ADJ	O	O
for	ADP	O	O
the	DET	O	O
101	NUM	O	O
patients	NOUN	O	O
whose	ADJ	O	O
paracetamol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
liver	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
had	VERB	O	O
caused	VERB	O	O
an	DET	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
adjusted	VERB	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
ratio	NOUN	O	O
=	SYM	O	O
1.70	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.02	NUM	O	O
-	SYM	O	O
2.85	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
association	NOUN	O	O
was	VERB	O	O
age	NOUN	O	O
-	PUNCT	O	O
dependent	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
survivors	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
died	VERB	O	O
of	ADP	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
suicides	NOUN	O	O
were	VERB	O	O
frequent	ADJ	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
observations	NOUN	O	O
speak	VERB	O	O
against	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

More	ADV	O	O
likely	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
elevated	ADJ	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
ratio	NOUN	O	O
resulted	VERB	O	O
from	ADP	O	O
incomplete	ADJ	O	O
adjustment	NOUN	O	O
for	ADP	O	O
the	DET	O	O
greater	ADJ	O	O
prevalence	NOUN	O	O
of	ADP	O	O
substance	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
among	ADP	O	O
survivors	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Paracetamol	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
mortality	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
justified	VERB	O	O
by	ADP	O	O
the	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
the	DET	O	O
liver	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
by	ADP	O	O
the	DET	O	O
liver	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
itself	PRON	O	O
.	PUNCT	O	O


-DOCSTART- (20705401)

Serotonin	NOUN	O	I-Entity
6	NUM	O	O
receptor	NOUN	O	O
gene	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychosis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
Japanese	ADJ	O	O
population	NOUN	O	O
.	PUNCT	O	O

Altered	ADJ	O	O
serotonergic	ADJ	O	O
neural	ADJ	O	O
transmission	NOUN	O	O
is	VERB	O	O
hypothesized	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
susceptibility	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
psychotic	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
such	ADJ	O	O
as	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
serotonin	NOUN	O	I-Entity
6	NUM	O	O
(	PUNCT	O	O
5-HT6	NUM	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
is	VERB	O	O
therapeutically	ADV	O	O
targeted	VERB	O	O
by	ADP	O	O
several	ADJ	O	O
second	ADJ	O	O
generation	NOUN	O	O
antipsychotics	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
clozapine	NOUN	O	I-Entity
and	CCONJ	O	O
olanzapine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
d	PUNCT	O	B-Entity
-	PUNCT	O	I-Entity
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
is	VERB	O	O
corrected	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
selective	ADJ	O	O
5-HT6	ADJ	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
disrupted	VERB	O	O
prepulse	NOUN	O	O
inhibition	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
amphetamine	NOUN	O	I-Entity
or	CCONJ	O	O
phencyclidine	NOUN	O	I-Entity
was	VERB	O	O
restored	VERB	O	O
by	ADP	O	O
5-HT6	NUM	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
in	ADP	O	O
an	DET	O	O
animal	NOUN	O	O
study	NOUN	O	O
using	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
animal	NOUN	O	O
models	NOUN	O	O
were	VERB	O	O
considered	VERB	O	O
to	PART	O	O
reflect	VERB	O	O
the	DET	O	O
positive	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
above	ADJ	O	O
evidence	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
altered	VERB	O	O
5-HT6	NUM	O	I-Entity
receptors	NOUN	O	O
are	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
pathophysiology	NOUN	O	O
of	ADP	O	O
psychotic	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
symptoms	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
METH)-induced	PROPN	O	I-Entity
psychosis	NOUN	O	I-Entity
are	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
of	ADP	O	O
paranoid	ADJ	O	B-Entity
type	NOUN	O	I-Entity
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
conducted	VERB	O	O
an	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
association	NOUN	O	O
of	ADP	O	O
the	DET	O	O
5-HT6	ADJ	O	I-Entity
gene	NOUN	O	O
(	PUNCT	O	O
HTR6	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
METH	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychosis	NOUN	O	I-Entity
.	PUNCT	O	O

Using	VERB	O	O
five	NUM	O	O
tagging	VERB	O	O
SNPs	NOUN	O	O
(	PUNCT	O	O
rs6693503	NOUN	O	O
,	PUNCT	O	O
rs1805054	NOUN	O	O
,	PUNCT	O	O
rs4912138	NOUN	O	O
,	PUNCT	O	O
rs3790757	NOUN	O	O
and	CCONJ	O	O
rs9659997	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
we	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
genetic	ADJ	O	O
association	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
samples	NOUN	O	O
(	PUNCT	O	O
197	NUM	O	O
METH	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychosis	NOUN	O	I-Entity
patients	NOUN	O	O
and	CCONJ	O	O
337	NUM	O	O
controls	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
Japanese	ADJ	O	O
population	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
age	NOUN	O	O
and	CCONJ	O	O
sex	NOUN	O	O
of	ADP	O	O
the	DET	O	O
control	NOUN	O	O
subjects	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
from	ADP	O	O
those	DET	O	O
of	ADP	O	O
the	DET	O	O
methamphetamine	NOUN	O	I-Entity
dependence	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

rs6693503	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
METH	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychosis	NOUN	O	I-Entity
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
allele	NOUN	O	O
/	PUNCT	O	O
genotype	NOUN	O	O
-	PUNCT	O	O
wise	ADJ	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
haplotype	NOUN	O	O
-	PUNCT	O	O
wise	ADJ	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
detected	VERB	O	O
an	DET	O	O
association	NOUN	O	O
between	ADP	O	O
two	NUM	O	O
markers	NOUN	O	O
(	PUNCT	O	O
rs6693503	PUNCT	O	O
and	CCONJ	O	O
rs1805054	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
three	NUM	O	O
markers	NOUN	O	O
(	PUNCT	O	O
rs6693503	NOUN	O	O
,	PUNCT	O	O
rs1805054	NOUN	O	O
and	CCONJ	O	O
rs4912138	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
HTR6	PROPN	O	O
and	CCONJ	O	O
METH	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychosis	NOUN	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
HTR6	PROPN	O	O
may	VERB	O	O
play	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathophysiology	NOUN	O	O
of	ADP	O	O
METH	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychosis	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
Japanese	ADJ	O	O
population	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19105845)

Effect	PROPN	O	O
of	ADP	O	O
increasing	VERB	O	O
intraperitoneal	ADJ	O	O
infusion	NOUN	O	O
rates	NOUN	O	O
on	ADP	O	O
bupropion	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
It	PRON	O	O
is	VERB	O	O
not	ADV	O	O
known	VERB	O	O
if	ADP	O	O
there	ADV	O	O
is	VERB	O	O
a	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
input	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
important	ADJ	O	O
,	PUNCT	O	O
since	ADP	O	O
different	ADJ	O	O
controlled	VERB	O	O
release	NOUN	O	O
formulations	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	I-Entity
release	VERB	O	O
the	DET	O	O
active	ADJ	O	O
drug	NOUN	O	O
at	ADP	O	O
different	ADJ	O	O
rates	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
varying	VERB	O	O
the	DET	O	O
intraperitoneal	ADJ	O	O
infusion	NOUN	O	O
rates	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	B-Entity
HCl	PROPN	O	I-Entity
120	NUM	O	O

mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
a	DET	O	O
known	VERB	O	O
convulsive	ADJ	O	I-Entity
dose	NOUN	O	O
50	NUM	O	O
(	PUNCT	O	O
CD50	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
Swiss	ADJ	O	O
albino	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
69	NUM	O	O
mice	NOUN	O	O
,	PUNCT	O	O
approximately	ADV	O	O
7	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
weighing	VERB	O	O
21.0	NUM	O	O
to	ADP	O	O
29.1	NUM	O	O
g	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
bupropion	NOUN	O	B-Entity
HCl	PROPN	O	I-Entity
120	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
treatment	NOUN	O	O
by	ADP	O	O
intraperitoneal	NOUN	O	O
(	PUNCT	O	O
IP	PROPN	O	O
)	PUNCT	O	O
administration	NOUN	O	O
in	ADP	O	O
7	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
9	NUM	O	O
to	PART	O	O
10	NUM	O	O
animals	NOUN	O	O
per	ADP	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Bupropion	PROPN	O	B-Entity
HCl	PROPN	O	I-Entity
was	VERB	O	O
infused	VERB	O	O
through	ADP	O	O
a	DET	O	O
surgically	ADV	O	O
implanted	VERB	O	O
IP	PROPN	O	O
dosing	VERB	O	O
catheter	NOUN	O	O
with	ADP	O	O
infusions	NOUN	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
of	ADP	O	O
0	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
15	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
60	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
90	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
120	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
240	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
,	PUNCT	O	O
time	NOUN	O	O
of	ADP	O	O
onset	NOUN	O	O
,	PUNCT	O	O
duration	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
intensity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
convulsions	NOUN	O	I-Entity
or	CCONJ	O	O
absence	NOUN	O	O
of	ADP	O	O
convulsions	NOUN	O	I-Entity
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
IP	PROPN	O	O
administration	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	B-Entity
HCl	PROPN	O	I-Entity
120	NUM	O	O
mg	PROPN	O	O
/	PUNCT	O	O
kg	NOUN	O	O
by	ADP	O	O
bolus	NOUN	O	O
injection	NOUN	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
in	ADP	O	O
6	NUM	O	O
out	ADP	O	O
of	ADP	O	O
10	NUM	O	O
mice	NOUN	O	O
(	PUNCT	O	O
60%	NUM	O	O
of	ADP	O	O
convulsing	VERB	O	O
mice	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
.	PUNCT	O	O

Logistic	ADJ	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
infusion	NOUN	O	O
time	NOUN	O	O
was	VERB	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0004	NUM	O	O
;	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
=	SYM	O	O
0.974	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
increasing	VERB	O	O
the	DET	O	O
IP	PROPN	O	O
infusion	NOUN	O	O
time	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	B-Entity
HCl	PROPN	O	I-Entity
120	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
91%	NUM	O	O
reduced	VERB	O	O
odds	NOUN	O	O
of	ADP	O	O
convulsions	NOUN	O	I-Entity
at	ADP	O	O
infusion	NOUN	O	O
times	NOUN	O	O
of	ADP	O	O
15	NUM	O	O
to	PART	O	O
90	NUM	O	O
min	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
bolus	NOUN	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Further	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
infusion	NOUN	O	O
time	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
further	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
odds	NOUN	O	O
of	ADP	O	O
convulsions	NOUN	O	I-Entity
to	ADP	O	O
99.8%	NUM	O	O
reduction	NOUN	O	O
at	ADP	O	O
240	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
demonstration	NOUN	O	O
of	ADP	O	O
an	DET	O	O
inverse	NOUN	O	O
relationship	NOUN	O	O
between	ADP	O	O
infusion	NOUN	O	O
time	NOUN	O	O
of	ADP	O	O
a	DET	O	O
fixed	VERB	O	O
and	CCONJ	O	O
convulsive	ADJ	O	I-Entity
dose	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
convulsions	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
is	VERB	O	O
novel	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18657397)

Detailed	VERB	O	O
spectral	ADJ	O	O
profile	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
penicillin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
epileptiform	NOUN	O	B-Entity
activity	NOUN	O	I-Entity
in	ADP	O	O
anesthetized	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Penicillin	PROPN	O	I-Entity
model	NOUN	O	O
is	VERB	O	O
a	DET	O	O
widely	ADV	O	O
used	VERB	O	O
experimental	ADJ	O	O
model	NOUN	O	O
for	ADP	O	O
epilepsy	NOUN	O	I-Entity
research	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
we	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
portray	VERB	O	O
a	DET	O	O
detailed	VERB	O	O
spectral	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
penicillin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
epileptiform	NOUN	O	B-Entity
activity	NOUN	O	I-Entity
in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
basal	ADJ	O	O
brain	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
anesthetized	ADJ	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

urethane	NOUN	O	I-Entity
and	CCONJ	O	O
connected	VERB	O	O
to	ADP	O	O
an	DET	O	O
electrocorticogram	NOUN	O	O
setup	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
a	DET	O	O
short	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
basal	NOUN	O	O
activity	NOUN	O	O
recording	NOUN	O	O
,	PUNCT	O	O
epileptic	ADJ	O	I-Entity
focus	NOUN	O	O
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
injecting	VERB	O	O
400IU/2	NUM	O	O
microl	NOUN	O	O
penicillin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
G	NOUN	O	I-Entity
potassium	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
left	ADJ	O	O
lateral	ADJ	O	O
ventricle	NOUN	O	O
while	ADP	O	O
the	DET	O	O
cortical	ADJ	O	O
activity	NOUN	O	O
was	VERB	O	O
continuously	ADV	O	O
recorded	VERB	O	O
.	PUNCT	O	O

Basal	ADJ	O	O
activity	NOUN	O	O
,	PUNCT	O	O
latent	ADJ	O	O
period	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
penicillin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
epileptiform	NOUN	O	B-Entity
activity	NOUN	O	I-Entity
periods	NOUN	O	O
were	VERB	O	O
then	ADV	O	O
analyzed	VERB	O	O
using	VERB	O	O
both	DET	O	O
conventional	ADJ	O	O
methods	NOUN	O	O
and	CCONJ	O	O
spectral	ADJ	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
the	DET	O	O
most	ADV	O	O
affected	ADJ	O	O
frequency	NOUN	O	O
bands	NOUN	O	O
were	VERB	O	O
delta	NOUN	O	O
,	PUNCT	O	O
theta	NOUN	O	O
,	PUNCT	O	O
beta-2	NOUN	O	O
and	CCONJ	O	O
gamma-2	NOUN	O	O
bands	NOUN	O	O
during	ADP	O	O
the	DET	O	O
epileptiform	NOUN	O	B-Entity
activity	NOUN	O	I-Entity
and	CCONJ	O	O
there	ADV	O	O
were	VERB	O	O
marked	VERB	O	O
differences	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
spectral	ADJ	O	O
densities	NOUN	O	O
between	ADP	O	O
three	NUM	O	O
investigated	VERB	O	O
episodes	NOUN	O	O
(	PUNCT	O	O
basal	ADJ	O	O
activity	NOUN	O	O
,	PUNCT	O	O
latent	ADJ	O	O
period	NOUN	O	O
and	CCONJ	O	O
epileptiform	NOUN	O	B-Entity
activity	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
may	VERB	O	O
help	VERB	O	O
to	PART	O	O
analyze	VERB	O	O
novel	ADJ	O	O
data	NOUN	O	O
obtained	VERB	O	O
using	VERB	O	O
similar	ADJ	O	O
experimental	ADJ	O	O
models	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
simple	ADJ	O	O
analysis	NOUN	O	O
method	NOUN	O	O
described	VERB	O	O
here	ADV	O	O
can	VERB	O	O
be	VERB	O	O
used	VERB	O	O
in	ADP	O	O
similar	ADJ	O	O
studies	NOUN	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
basic	ADJ	O	O
neuronal	ADJ	O	O
mechanism	NOUN	O	O
of	ADP	O	O
this	DET	O	O
or	CCONJ	O	O
other	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
experimental	ADJ	O	O
epilepsies	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18363626)

High	ADJ	O	O
dose	NOUN	O	O
dexmedetomidine	NOUN	O	I-Entity
as	ADP	O	O
the	DET	O	O
sole	ADJ	O	O
sedative	NOUN	O	O
for	ADP	O	O
pediatric	ADJ	O	O
MRI	PROPN	O	O
.	PUNCT	O	O

This	DET	O	O
large	ADJ	O	O
-	PUNCT	O	O
scale	NOUN	O	O
retrospective	NOUN	O	O
review	NOUN	O	O
evaluates	VERB	O	O
the	DET	O	O
sedation	NOUN	O	O
profile	NOUN	O	O
of	ADP	O	O
dexmedetomidine	NOUN	O	I-Entity
.	PUNCT	O	O

AIM	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
determine	VERB	O	O
the	DET	O	O
hemodynamic	NOUN	O	O
responses	NOUN	O	O
,	PUNCT	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
dose	NOUN	O	O
dexmedetomidine	NOUN	O	I-Entity
as	ADP	O	O
the	DET	O	O
sole	ADJ	O	O
sedative	NOUN	O	O
for	ADP	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
(	PUNCT	O	O
MRI	PROPN	O	O
)	PUNCT	O	O
studies	NOUN	O	O
.	PUNCT	O	O

Dexmedetomidine	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
used	VERB	O	O
at	ADP	O	O
our	ADJ	O	O
institution	NOUN	O	O
since	ADP	O	O
2005	NUM	O	O
to	PART	O	O
provide	VERB	O	O
sedation	NOUN	O	O
for	ADP	O	O
pediatric	ADJ	O	O
radiological	ADJ	O	O
imaging	NOUN	O	O
studies	NOUN	O	O
.	PUNCT	O	O

Over	ADP	O	O
time	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
effective	ADJ	O	O
protocol	NOUN	O	O
utilizing	VERB	O	O
high	ADJ	O	O
dose	NOUN	O	O
dexmedetomidine	NOUN	O	I-Entity
as	ADP	O	O
the	DET	O	O
sole	ADJ	O	O
sedative	NOUN	O	O
agent	NOUN	O	O
has	VERB	O	O
evolved	VERB	O	O
.	PUNCT	O	O

Data	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
from	ADP	O	O
all	DET	O	O
747	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
dexmedetomidine	NOUN	O	I-Entity
for	ADP	O	O
MRI	PROPN	O	O
sedation	NOUN	O	O
from	ADP	O	O
April	PROPN	O	O
2005	NUM	O	O
to	ADP	O	O
April	PROPN	O	O
2007	NUM	O	O
.	PUNCT	O	O

Since	ADP	O	O
2005	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
10-min	NOUN	O	O
loading	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
our	ADJ	O	O
dexmedetomidine	NOUN	O	I-Entity
protocol	NOUN	O	O
increased	VERB	O	O
from	ADP	O	O
2	NUM	O	O
to	ADP	O	O
3	NUM	O	O
microg.kg(-1	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
infusion	NOUN	O	O
rate	NOUN	O	O
increased	VERB	O	O
from	ADP	O	O
1	NUM	O	O
to	ADP	O	O
1.5	NUM	O	O
to	PART	O	O
2	NUM	O	O
microg.kg(-1).h(-1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
sedation	NOUN	O	O
protocol	NOUN	O	O
progressively	ADV	O	O
increased	VERB	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
successful	ADJ	O	O
sedation	NOUN	O	O
(	PUNCT	O	O
able	ADJ	O	O
to	PART	O	O
complete	VERB	O	O
the	DET	O	O
imaging	NOUN	O	O
study	NOUN	O	O
)	PUNCT	O	O
when	ADV	O	O
using	VERB	O	O
dexmedetomidine	NOUN	O	I-Entity
alone	ADV	O	O
from	ADP	O	O
91.8%	NUM	O	O
to	ADP	O	O
97.6%	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.009	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
reducing	VERB	O	O
the	DET	O	O
requirement	NOUN	O	O
for	ADP	O	O
adjuvant	ADJ	O	O
pentobarbital	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
event	NOUN	O	O
of	ADP	O	O
sedation	NOUN	O	O
failure	NOUN	O	O
with	ADP	O	O
dexmedetomidine	NOUN	O	I-Entity
alone	ADV	O	O
and	CCONJ	O	O
decreased	VERB	O	O
the	DET	O	O
mean	ADJ	O	O
recovery	NOUN	O	O
time	NOUN	O	O
by	ADP	O	O
10	NUM	O	O
min	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O

Although	ADP	O	O
dexmedetomidine	ADJ	O	I-Entity
sedation	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
16%	NUM	O	O
incidence	NOUN	O	O
of	ADP	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
all	DET	O	O
concomitant	ADJ	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressures	NOUN	O	O
were	VERB	O	O
within	ADP	O	O
20%	NUM	O	O
of	ADP	O	O
age	NOUN	O	O
-	PUNCT	O	O
adjusted	VERB	O	O
normal	ADJ	O	O
range	NOUN	O	O
and	CCONJ	O	O

oxygen	NOUN	O	I-Entity
saturations	NOUN	O	O
were	VERB	O	O
95%	NUM	O	O
or	CCONJ	O	O
higher	ADJ	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Dexmedetomidine	PROPN	O	I-Entity
in	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
provides	VERB	O	O
adequate	ADJ	O	O
sedation	NOUN	O	O
for	ADP	O	O
pediatric	ADJ	O	O
MRI	PROPN	O	O
studies	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
dose	NOUN	O	O
dexmedetomidine	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
decreases	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
outside	ADP	O	O
the	DET	O	O
established	VERB	O	O
'	PUNCT	O	O
awake	ADJ	O	O
'	PUNCT	O	O
norms	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
deviation	NOUN	O	O
is	VERB	O	O
generally	ADV	O	O
within	ADP	O	O
20%	NUM	O	O
of	ADP	O	O
norms	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
is	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
adverse	ADJ	O	O
sequelae	NOUN	O	O
.	PUNCT	O	O

Dexmedetomidine	PROPN	O	I-Entity
is	VERB	O	O
useful	ADJ	O	O
as	ADP	O	O
the	DET	O	O
sole	ADJ	O	O
sedative	NOUN	O	O
for	ADP	O	O
pediatric	ADJ	O	O
MRI	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (16192988)

Methamphetamine	NOUN	O	I-Entity
causes	VERB	O	O
alterations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
MAP	PROPN	O	O
kinase	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
pathways	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brains	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
that	ADJ	O	O
display	VERB	O	O
increased	VERB	O	O
aggressiveness	NOUN	O	I-Entity
.	PUNCT	O	O

Aggressive	ADJ	O	B-Entity
behaviors	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
suffer	VERB	O	O
from	ADP	O	O
some	DET	O	O
psychiatric	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
are	VERB	O	O
common	ADJ	O	O
in	ADP	O	O
methamphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
METH	PROPN	O	I-Entity
)	PUNCT	O	O
abusers	NOUN	O	O
.	PUNCT	O	O

Herein	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
report	VERB	O	O
that	ADP	O	O
multiple	ADJ	O	O
(	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
single	ADJ	O	O
)	PUNCT	O	O
injections	NOUN	O	O
of	ADP	O	O
METH	PROPN	O	I-Entity
significantly	ADV	O	O
increased	VERB	O	O
aggressiveness	NOUN	O	I-Entity
in	ADP	O	O
male	ADJ	O	O
CD-1	PROPN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
aggressiveness	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
secondary	ADJ	O	O
to	ADP	O	O
METH	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
.	PUNCT	O	O

Analysis	NOUN	O	O
of	ADP	O	O
protein	NOUN	O	O
expression	NOUN	O	O
using	VERB	O	O
antibody	NOUN	O	O
microarrays	NOUN	O	O
and	CCONJ	O	O
Western	ADJ	O	O
blotting	NOUN	O	O
revealed	VERB	O	O
differential	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
MAP	PROPN	O	O
kinase	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
pathways	NOUN	O	O
after	ADP	O	O
multiple	ADJ	O	O
and	CCONJ	O	O
single	ADJ	O	O
METH	PROPN	O	I-Entity
injections	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p<0.05	NOUN	O	O
)	PUNCT	O	O
decreases	VERB	O	O
in	ADP	O	O
MEK1	PROPN	O	O
,	PUNCT	O	O
Erk2p	PROPN	O	O
,	PUNCT	O	O
GSK3alpha	PROPN	O	O
,	PUNCT	O	O
14	NUM	O	O
-	SYM	O	O
3	NUM	O	O
-	PUNCT	O	O
3e	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
MEK7	PROPN	O	O
in	ADP	O	O
the	DET	O	O
striata	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
after	ADP	O	O
multiple	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
METH	PROPN	O	I-Entity
.	PUNCT	O	O

MEK1	PROPN	O	O
was	VERB	O	O
significantly	ADV	O	O
decreased	VERB	O	O
also	ADV	O	O
after	ADP	O	O
a	DET	O	O
single	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
METH	PROPN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
much	ADV	O	O
lesser	ADJ	O	O
degree	NOUN	O	O
than	ADP	O	O
after	ADP	O	O
multiple	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
METH	PROPN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
frontal	NOUN	O	O
cortex	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
GSK3alpha	PROPN	O	O
after	ADP	O	O
multiple	ADJ	O	O
(	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
single	ADJ	O	O
)	PUNCT	O	O
injections	NOUN	O	O
of	ADP	O	O
METH	PROPN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
alterations	NOUN	O	O
in	ADP	O	O
MAP	PROPN	O	O
kinase	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
pathways	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prefronto	NOUN	O	O
-	PUNCT	O	O
striatal	ADJ	O	O
circuitries	NOUN	O	O
might	VERB	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
manifestation	NOUN	O	O
of	ADP	O	O
aggressive	ADJ	O	B-Entity
behaviors	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16157917)

Lamotrigine	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
exacerbation	NOUN	O	O
or	CCONJ	O	O
de	X	O	O
novo	X	O	O
myoclonus	NOUN	O	I-Entity
in	ADP	O	O
idiopathic	ADJ	O	B-Entity
generalized	ADJ	O	I-Entity
epilepsies	NOUN	O	I-Entity
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
idiopathic	ADJ	O	B-Entity
generalized	ADJ	O	I-Entity
epilepsies	NOUN	O	I-Entity
(	PUNCT	O	O
IGE	PROPN	O	I-Entity
)	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
lamotrigine	NOUN	O	I-Entity
(	PUNCT	O	O
LTG	PROPN	O	I-Entity
)	PUNCT	O	O
experienced	ADJ	O	O
exacerbation	NOUN	O	O
or	CCONJ	O	O
de	X	O	O
novo	ADJ	O	O
appearance	NOUN	O	O
of	ADP	O	O
myoclonic	ADJ	O	B-Entity
jerks	NOUN	O	I-Entity
(	PUNCT	O	O
MJ	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
three	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
LTG	PROPN	O	I-Entity
exacerbated	VERB	O	O
MJ	PROPN	O	I-Entity
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
with	ADP	O	O
early	ADJ	O	O
aggravation	NOUN	O	O
during	ADP	O	O
titration	NOUN	O	O
.	PUNCT	O	O

MJ	PROPN	O	I-Entity
disappeared	VERB	O	O
when	ADV	O	O
LTG	PROPN	O	I-Entity
dose	NOUN	O	O
was	VERB	O	O
decreased	VERB	O	O
by	ADP	O	O
25	NUM	O	O
to	PART	O	O
50%	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
LTG	PROPN	O	I-Entity
exacerbated	VERB	O	O
MJ	PROPN	O	I-Entity
in	ADP	O	O
a	DET	O	O
delayed	VERB	O	O
but	CCONJ	O	O
more	ADV	O	O
severe	ADJ	O	O
manner	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
myoclonic	ADJ	O	B-Entity
status	NOUN	O	I-Entity
that	ADJ	O	O
only	ADV	O	O
ceased	VERB	O	O
after	ADP	O	O
LTG	PROPN	O	I-Entity
withdrawal	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16116131)

rTMS	NOUN	O	O
of	ADP	O	O
supplementary	ADJ	O	O
motor	NOUN	O	O
area	NOUN	O	O
modulates	VERB	O	O
therapy	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
neural	ADJ	O	O
mechanisms	NOUN	O	O
and	CCONJ	O	O
circuitry	NOUN	O	O
involved	VERB	O	O
in	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesia	NOUN	O	I-Entity
are	VERB	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

Using	VERB	O	O
repetitive	ADJ	O	O
transcranial	ADJ	O	O
magnetic	ADJ	O	O
stimulation	NOUN	O	O
(	PUNCT	O	O
rTMS	PROPN	O	O
)	PUNCT	O	O
over	ADP	O	O
the	DET	O	O
supplementary	ADJ	O	O
motor	NOUN	O	O
area	NOUN	O	O
(	PUNCT	O	O
SMA	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
Parkinson	PROPN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
investigated	VERB	O	O
whether	ADP	O	O
modulation	NOUN	O	O
of	ADP	O	O
SMA	PROPN	O	O
excitability	NOUN	O	O
may	VERB	O	O
result	VERB	O	O
in	ADP	O	O
a	DET	O	O
modification	NOUN	O	O
of	ADP	O	O
a	DET	O	O
dyskinetic	ADJ	O	I-Entity
state	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
continuous	ADJ	O	O
apomorphine	ADJ	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

rTMS	NOUN	O	O
at	ADP	O	O
1	NUM	O	O
Hz	PROPN	O	O
was	VERB	O	O
observed	VERB	O	O
to	PART	O	O
markedly	ADV	O	O
reduce	VERB	O	O
drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
dyskinesias	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
5-Hz	NUM	O	O
rTMS	PROPN	O	O
induced	VERB	O	O
a	DET	O	O
slight	ADJ	O	O
but	CCONJ	O	O
not	ADV	O	O
significant	ADJ	O	O
increase	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15930398)

Assessment	PROPN	O	O
of	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
and	CCONJ	O	O
persistence	NOUN	O	O
of	ADP	O	O
amnesia	NOUN	O	I-Entity
during	ADP	O	O
procedural	ADJ	O	O
sedation	NOUN	O	O
with	ADP	O	O
propofol	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
assess	VERB	O	O
patients	NOUN	O	O
'	PART	O	O
ability	NOUN	O	O
to	PART	O	O
repeat	VERB	O	O
and	CCONJ	O	O
recall	VERB	O	O
words	NOUN	O	O
presented	VERB	O	O
to	ADP	O	O
them	PRON	O	O
while	ADP	O	O
undergoing	VERB	O	O
procedural	ADJ	O	O
sedation	NOUN	O	O
with	ADP	O	O
propofol	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
correlate	VERB	O	O
their	ADJ	O	O
recall	NOUN	O	O
with	ADP	O	O
their	ADJ	O	O
level	NOUN	O	O
of	ADP	O	O
awareness	NOUN	O	O
as	ADP	O	O
measured	VERB	O	O
by	ADP	O	O
bispectral	ADJ	O	O
index	NOUN	O	O
(	PUNCT	O	O
BIS	PROPN	O	O
)	PUNCT	O	O
monitoring	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
single	ADJ	O	O
-	PUNCT	O	O
intervention	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
consenting	VERB	O	O
adult	NOUN	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
procedural	ADJ	O	O
sedation	NOUN	O	O
with	ADP	O	O
propofol	NOUN	O	I-Entity
between	ADP	O	O
December	PROPN	O	O
28	NUM	O	O
,	PUNCT	O	O
2002	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
October	PROPN	O	O
31	NUM	O	O
,	PUNCT	O	O
2003	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
highest	ADJ	O	O
BIS	PROPN	O	O
score	NOUN	O	O
corresponding	VERB	O	O
to	ADP	O	O
the	DET	O	O
inability	NOUN	O	B-Entity
to	PART	O	I-Entity
repeat	VERB	O	I-Entity
words	NOUN	O	I-Entity
was	VERB	O	O
81.5	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	NOUN	O	O
=	SYM	O	O
78.1	NUM	O	O
to	ADP	O	O
84.8	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
patients	NOUN	O	O
had	VERB	O	O
no	DET	O	O
recall	NOUN	O	O
of	ADP	O	O
words	NOUN	O	O
repeated	VERB	O	O
prior	ADV	O	O
to	ADP	O	O
procedural	ADJ	O	O
sedation	NOUN	O	O
in	ADP	O	O
BIS	PROPN	O	O
ranges	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
recall	NOUN	O	O
after	ADP	O	O
procedural	ADJ	O	O
sedation	NOUN	O	O
,	PUNCT	O	O
suggestive	ADJ	O	O
of	ADP	O	O
retrograde	ADJ	O	B-Entity
amnesia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15867025)

Assessment	PROPN	O	O
of	ADP	O	O
perinatal	NOUN	O	O
hepatitis	NOUN	O	B-Entity
B	NOUN	O	I-Entity
and	CCONJ	O	O
rubella	NOUN	O	I-Entity
prevention	NOUN	O	O
in	ADP	O	O
New	PROPN	O	O
Hampshire	PROPN	O	O
delivery	NOUN	O	O
hospitals	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
current	ADJ	O	O
performance	NOUN	O	O
on	ADP	O	O
recommended	VERB	O	O
perinatal	NOUN	O	O
hepatitis	NOUN	O	B-Entity
B	NOUN	O	I-Entity
and	CCONJ	O	O
rubella	NOUN	O	I-Entity
prevention	NOUN	O	O
practices	NOUN	O	O
in	ADP	O	O
New	PROPN	O	O
Hampshire	PROPN	O	O
.	PUNCT	O	O

Assessment	PROPN	O	O
was	VERB	O	O
done	VERB	O	O
on	ADP	O	O
the	DET	O	O
following	VERB	O	O
:	PUNCT	O	O
prenatal	NOUN	O	O
screening	NOUN	O	O
for	ADP	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
and	CCONJ	O	O
rubella	NOUN	O	I-Entity
,	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
vaccine	NOUN	O	O
birth	NOUN	O	O
dose	NOUN	O	O
to	ADP	O	O
all	DET	O	O
infants	NOUN	O	O
,	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
hepatitis	PROPN	O	B-Entity
B	PROPN	O	I-Entity
immune	ADJ	O	O
globulin	NOUN	O	O
to	ADP	O	O
infants	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
born	VERB	O	O
to	ADP	O	O
hepatitis	PROPN	O	B-Entity
B	PROPN	O	I-Entity
surface	NOUN	O	I-Entity
antigen	NOUN	O	I-Entity
-	PUNCT	O	O
positive	ADJ	O	O
mothers	NOUN	O	O
,	PUNCT	O	O
rubella	NOUN	O	I-Entity
immunity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
administration	NOUN	O	O
of	ADP	O	O
in	ADP	O	O
-	PUNCT	O	O
hospital	NOUN	O	O
postpartum	NOUN	O	O
rubella	NOUN	O	I-Entity
vaccine	NOUN	O	O
to	ADP	O	O
rubella	VERB	O	I-Entity
nonimmune	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

RESULTS	ADV	O	O
:	PUNCT	O	O
Prenatal	ADJ	O	O
screening	NOUN	O	O
rates	NOUN	O	O
for	ADP	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
(	PUNCT	O	O
98.8%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
rubella	NOUN	O	I-Entity
(	PUNCT	O	O
99.4%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
high	ADJ	O	O
.	PUNCT	O	O

Hepatitis	PROPN	O	B-Entity
B	PROPN	O	I-Entity
vaccine	NOUN	O	O
birth	NOUN	O	O
dose	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
76.2%	NUM	O	O
of	ADP	O	O
all	DET	O	O
infants	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
infants	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
born	VERB	O	O
to	ADP	O	O
hepatitis	PROPN	O	B-Entity
B	PROPN	O	I-Entity
surface	NOUN	O	I-Entity
antigen	NOUN	O	I-Entity
-	PUNCT	O	O
positive	ADJ	O	O
mothers	NOUN	O	O
also	ADV	O	O
received	VERB	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
immune	ADJ	O	O
globulin	NOUN	O	O
.	PUNCT	O	O

Multivariate	ADJ	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
the	DET	O	O
month	NOUN	O	O
of	ADP	O	O
delivery	NOUN	O	O
and	CCONJ	O	O
infant	NOUN	O	O
birth	NOUN	O	O
weight	NOUN	O	O
were	VERB	O	O
independent	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
vaccination	NOUN	O	O
.	PUNCT	O	O

Women	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
born	VERB	O	O
between	ADP	O	O
1971	NUM	O	O
and	CCONJ	O	O
1975	NUM	O	O
had	VERB	O	O
the	DET	O	O
highest	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
rubella	NOUN	O	I-Entity
nonimmunity	NOUN	O	O
(	PUNCT	O	O
9.5%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
-	PUNCT	O	O
hospital	NOUN	O	O
postpartum	NOUN	O	O
rubella	NOUN	O	I-Entity
vaccine	NOUN	O	O
administration	NOUN	O	O
was	VERB	O	O
documented	VERB	O	O
for	ADP	O	O
75.6%	NUM	O	O
of	ADP	O	O
nonimmune	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
documents	VERB	O	O
good	ADJ	O	O
compliance	NOUN	O	O
in	ADP	O	O
New	PROPN	O	O
Hampshire	PROPN	O	O
's	PART	O	O
birthing	NOUN	O	O
hospitals	NOUN	O	O
with	ADP	O	O
national	ADJ	O	O
guidelines	NOUN	O	O
for	ADP	O	O
perinatal	NOUN	O	O
hepatitis	NOUN	O	B-Entity
B	NOUN	O	I-Entity
and	CCONJ	O	O
rubella	NOUN	O	I-Entity
prevention	NOUN	O	O
and	CCONJ	O	O
highlights	NOUN	O	O
potential	ADJ	O	O
areas	NOUN	O	O
for	ADP	O	O
improvement	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (14975762)

Doxorubicin	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
tumor	NOUN	O	I-Entity
agent	NOUN	O	O
that	ADJ	O	O
represses	VERB	O	O
cardiac	ADJ	O	O
-	PUNCT	O	O
specific	ADJ	O	O
gene	NOUN	O	O
expression	NOUN	O	O
and	CCONJ	O	O
induces	VERB	O	O
myocardial	ADJ	O	O
cell	NOUN	O	O
apoptosis	NOUN	O	O
.	PUNCT	O	O

Doxorubicin	PROPN	O	I-Entity
depletes	VERB	O	O
cardiac	ADJ	O	O
p300	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
transcriptional	ADJ	O	O
coactivator	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
required	VERB	O	O
for	ADP	O	O
the	DET	O	O
maintenance	NOUN	O	O
of	ADP	O	O
the	DET	O	O
differentiated	ADJ	O	O
phenotype	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
myocytes	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
p300	NOUN	O	O
in	ADP	O	O
protection	NOUN	O	O
against	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
apoptosis	NOUN	O	O
is	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

Transgenic	ADJ	O	O
mice	NOUN	O	O
overexpressing	VERB	O	O
p300	NOUN	O	O
in	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
and	CCONJ	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
mice	NOUN	O	O
were	VERB	O	O
subjected	VERB	O	O
to	ADP	O	O
doxorubicin	VERB	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Doxorubicin	PROPN	O	I-Entity
induced	VERB	O	O
myocardial	ADJ	O	O
cell	NOUN	O	O
apoptosis	NOUN	O	O
in	ADP	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
mice	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
transgenic	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
overexpression	NOUN	O	O
of	ADP	O	O
p300	NOUN	O	O
protects	VERB	O	O
cardiac	ADJ	O	O
myocytes	NOUN	O	O
from	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
apoptosis	NOUN	O	O
and	CCONJ	O	O
reduces	VERB	O	O
the	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
adult	NOUN	O	O
mice	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (14736955)

Mitochondrial	ADJ	O	O
DNA	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
respiratory	ADJ	O	O
chain	NOUN	O	O
products	NOUN	O	O
are	VERB	O	O
defective	ADJ	O	O
in	ADP	O	O
doxorubicin	NOUN	O	I-Entity
nephrosis	NOUN	O	I-Entity
.	PUNCT	O	O

Doxorubicin	PROPN	O	I-Entity
induces	VERB	O	O
a	DET	O	O
self	NOUN	O	O
-	PUNCT	O	O
perpetuating	VERB	O	O
nephropathy	NOUN	O	I-Entity
characterized	VERB	O	O
by	ADP	O	O
early	ADJ	O	O
glomerular	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
late	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
onset	NOUN	O	I-Entity
tubular	ADJ	O	I-Entity
lesions	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
mitochondrial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
these	DET	O	O
lesions	NOUN	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
kg(-1	NOUN	O	O
)	PUNCT	O	O

Glomerular	PROPN	O	B-Entity
and	CCONJ	O	I-Entity
tubular	ADJ	O	I-Entity
injury	NOUN	O	I-Entity
was	VERB	O	O
monitored	ADJ	O	O
and	CCONJ	O	O
correlated	VERB	O	O
to	ADP	O	O
the	DET	O	O
activity	NOUN	O	O
or	CCONJ	O	O
expression	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	O
chain	NOUN	O	O
components	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
quantified	VERB	O	O
both	DET	O	O
nuclear	ADJ	O	O
and	CCONJ	O	O
mitochondrial	ADJ	O	O
DNA	PROPN	O	O
(	PUNCT	O	O
mtDNA	PROPN	O	O
)	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
superoxide	NOUN	O	I-Entity
production	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
4834	NUM	O	O
base	NOUN	O	O
pair	NOUN	O	O
'	PUNCT	O	O
common	ADJ	O	O
'	PUNCT	O	O
mtDNA	PROPN	O	O
deletion	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
'	PUNCT	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
'	PUNCT	O	O
group	NOUN	O	O
had	VERB	O	O
significant	ADJ	O	O
glomerular	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
tubular	ADJ	O	I-Entity
lesions	NOUN	O	I-Entity
,	PUNCT	O	O
depressed	ADJ	O	O
activities	NOUN	O	O
of	ADP	O	O
mtDNA	PROPN	O	O
-	PUNCT	O	O
encoded	VERB	O	O
NADH	PROPN	O	O
dehydrogenase	NOUN	O	O
and	CCONJ	O	O
cytochrome	NOUN	O	O
-	PUNCT	O	O
c	NOUN	O	O
oxidase	NOUN	O	O
(	PUNCT	O	O
COX	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
citrate	ADJ	O	I-Entity
synthase	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
'	PUNCT	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
'	PUNCT	O	O
rats	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
were	VERB	O	O
fewer	ADJ	O	O
tubular	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
similar	ADJ	O	O
numbers	NOUN	O	O
of	ADP	O	O
glomerular	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
activity	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
all	DET	O	O
animals	NOUN	O	O
,	PUNCT	O	O
glomerular	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
tubular	ADJ	O	I-Entity
injury	NOUN	O	I-Entity
were	VERB	O	O
inversely	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
mtDNA	PROPN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
mtDNA	PROPN	O	O
-	PUNCT	O	O
encoded	VERB	O	O
respiratory	ADJ	O	O
chain	NOUN	O	O
activities	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mtDNA	PROPN	O	O
-	PUNCT	O	O
encoded	VERB	O	O
respiratory	NOUN	O	O
chain	NOUN	O	O
subunit	NOUN	O	O
COX	PROPN	O	O
-	PUNCT	O	O
I.	PROPN	O	O
Injury	PROPN	O	O
was	VERB	O	O
positively	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
superoxide	NOUN	O	I-Entity
production	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
activities	NOUN	O	O
of	ADP	O	O
nucleus	NOUN	O	O
-	PUNCT	O	O
encoded	VERB	O	O
mitochondrial	NOUN	O	O
or	CCONJ	O	O
cytoplasmic	NOUN	O	O
enzymes	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
for	ADP	O	O
quantitative	ADJ	O	O
and	CCONJ	O	O
qualitative	ADJ	O	O
mtDNA	NOUN	O	O
alterations	NOUN	O	O
through	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
mtDNA	PROPN	O	O
-	PUNCT	O	O
encoded	VERB	O	O
respiratory	NOUN	O	O
chain	NOUN	O	O
function	NOUN	O	O
and	CCONJ	O	O
induction	NOUN	O	O
of	ADP	O	O
superoxide	NOUN	O	I-Entity
in	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11573852)

Amphotericin	PROPN	O	B-Entity
B	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
AIDS	PROPN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
multiple	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
seizure	NOUN	O	I-Entity
activity	NOUN	O	O
in	ADP	O	O
an	DET	O	O
AIDS	PROPN	O	I-Entity
patent	NOUN	O	O
following	VERB	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
46-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
African	ADJ	O	O
-	PUNCT	O	O
American	ADJ	O	O
man	NOUN	O	O
experienced	VERB	O	O
recurrent	ADJ	O	O
grand	ADJ	O	B-Entity
mal	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
during	ADP	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
amphotericin	NOUN	O	B-Entity
B	NOUN	O	I-Entity
,	PUNCT	O	O
then	ADV	O	O
petit	NOUN	O	O
mal	ADJ	O	O
seizures	NOUN	O	I-Entity
as	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
was	VERB	O	O
stopped	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
drug	NOUN	O	O
concentrations	NOUN	O	O
decreased	VERB	O	O
with	ADP	O	O
time	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
concurrent	ADJ	O	O
medications	NOUN	O	O
included	VERB	O	O
didanosine	NOUN	O	I-Entity
,	PUNCT	O	O
hydroxyzine	NOUN	O	I-Entity
,	PUNCT	O	O
promethazine	NOUN	O	I-Entity
,	PUNCT	O	O
hydrocortisone	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
prochlorperazine	NOUN	O	I-Entity
.	PUNCT	O	O

Despite	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
phenytoin	NOUN	O	I-Entity
and	CCONJ	O	O
lorazepam	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
seizures	NOUN	O	I-Entity
persisted	VERB	O	O
and	CCONJ	O	O
occurred	VERB	O	O
only	ADV	O	O
during	ADP	O	O
amphotercin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
:	PUNCT	O	O
AIDS	PROPN	O	I-Entity
and	CCONJ	O	O
cryptococcal	ADJ	O	B-Entity
meningitis	NOUN	O	I-Entity
,	PUNCT	O	O
both	DET	O	O
of	ADP	O	O
which	ADJ	O	O
the	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
,	PUNCT	O	O
can	VERB	O	O
potentially	ADV	O	O
cause	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
;	PUNCT	O	O
alcohol	NOUN	O	I-Entity
intake	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
withdrawal	NOUN	O	O
can	VERB	O	O
also	ADV	O	O
cause	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Didanosine	PROPN	O	I-Entity
also	ADV	O	O
has	VERB	O	O
a	DET	O	O
potential	NOUN	O	O
for	ADP	O	O
inducing	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
other	ADJ	O	O
potential	ADJ	O	O
causes	NOUN	O	O
of	ADP	O	O
seizure	NOUN	O	I-Entity
were	VERB	O	O
ruled	VERB	O	O
out	PART	O	O
.	PUNCT	O	O

The	DET	O	O
time	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
events	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
was	VERB	O	O
the	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
the	DET	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
AIDS	PROPN	O	I-Entity
patient	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Amphotericin	PROPN	O	B-Entity
B	PROPN	O	I-Entity
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
probable	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
the	DET	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

To	ADP	O	O
date	NOUN	O	O
,	PUNCT	O	O
only	ADV	O	O
three	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
amphotericin	NOUN	O	B-Entity
B	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
healthcare	ADJ	O	O
providers	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
the	DET	O	O
potential	NOUN	O	O
for	ADP	O	O
this	DET	O	O
rare	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9875685)

Therapeutic	PROPN	O	O
drug	NOUN	O	O
monitoring	NOUN	O	O
of	ADP	O	O
tobramycin	NOUN	O	I-Entity
:	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
dosage	NOUN	O	O
regimen	NOUN	O	O
(	PUNCT	O	O
once	ADV	O	O
-	PUNCT	O	O
daily	ADV	O	O
vs.	NOUN	O	O
twice	ADV	O	O
-	PUNCT	O	O
daily	ADJ	O	O
)	PUNCT	O	O
of	ADP	O	O
tobramicyn	NOUN	O	I-Entity
on	ADP	O	O
steady	ADJ	O	O
-	PUNCT	O	O
state	NOUN	O	O
serum	NOUN	O	O
concentrations	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

tobramycin	NOUN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomised	VERB	O	O
to	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Group	PROPN	O	O
OD	PROPN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
22	NUM	O	O
)	PUNCT	O	O
received	VERB	O	O
a	DET	O	O
once	ADV	O	O
-	PUNCT	O	O
daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
tobramycin	NOUN	O	I-Entity
and	CCONJ	O	O
group	NOUN	O	O
TD	PROPN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
21	NUM	O	O
)	PUNCT	O	O
received	VERB	O	O
the	DET	O	O
same	ADJ	O	O
dose	NOUN	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
doses	NOUN	O	O
daily	ADV	O	O
.	PUNCT	O	O

Tobramycin	PROPN	O	I-Entity
serum	NOUN	O	O
concentrations	NOUN	O	O
(	PUNCT	O	O
peak	NOUN	O	O
and	CCONJ	O	O
trough	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
enzyme	NOUN	O	O
multiplied	VERB	O	O
immunoassay	NOUN	O	O
.	PUNCT	O	O

Increased	VERB	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
73%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
OD	PROPN	O	O
versus	ADP	O	O
57%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
TD	NOUN	O	O
,	PUNCT	O	O
without	ADP	O	O
evidence	NOUN	O	O
of	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
TD	PROPN	O	O
group	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
decreased	ADJ	O	B-Entity
auditory	ADJ	O	I-Entity
function	NOUN	O	I-Entity
,	PUNCT	O	O
of	ADP	O	O
which	ADJ	O	O
one	NUM	O	O
presented	VERB	O	O
with	ADP	O	O
an	DET	O	O
auditory	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
of	ADP	O	O
-30	PROPN	O	O
dB	PROPN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
in	ADP	O	O
the	DET	O	O
OD	PROPN	O	O
group	NOUN	O	O
only	ADV	O	O
one	NUM	O	O
patient	NOUN	O	O
presented	VERB	O	O
decreased	VERB	O	B-Entity
auditory	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
small	ADJ	O	O
study	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
a	DET	O	O
once	ADV	O	O
-	PUNCT	O	O
daily	ADJ	O	O
dosing	NOUN	O	O
regimen	NOUN	O	O
of	ADP	O	O
tobramycin	NOUN	O	I-Entity
is	VERB	O	O
at	ADV	O	O
least	ADJ	O	O
as	ADV	O	O
effective	ADJ	O	O
as	ADP	O	O
and	CCONJ	O	O
is	VERB	O	O
no	DET	O	O
more	ADJ	O	O
and	CCONJ	O	O
possibly	ADV	O	O
less	ADV	O	O
toxic	ADJ	O	O
than	ADP	O	O
the	DET	O	O
twice	ADV	O	O
-	PUNCT	O	O
daily	ADJ	O	O
regimen	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9848575)

Chronic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
novel	NOUN	O	O
synthetic	ADJ	O	O
anthracycline	NOUN	O	I-Entity
derivative	ADJ	O	O
(	PUNCT	O	O
SM-5887	PROPN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
normal	ADJ	O	O
heart	NOUN	O	O
and	CCONJ	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
in	ADP	O	O
beagle	NOUN	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
chronic	ADJ	O	O
cardiotoxic	ADJ	O	I-Entity
potential	NOUN	O	O
of	ADP	O	O
SM-5887	PROPN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
possible	ADJ	O	O
deteriorating	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
SM-5887	PROPN	O	I-Entity
on	ADP	O	O
low	ADJ	O	O
-	PUNCT	O	O
grade	NOUN	O	O
cardiotoxicity	NOUN	O	I-Entity

pre	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
by	ADP	O	O
doxorubicin	NOUN	O	I-Entity
in	ADP	O	O
beagle	NOUN	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
chronic	ADJ	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
beagle	ADJ	O	O
dogs	NOUN	O	O
of	ADP	O	O
each	DET	O	O
sex	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
intravenously	ADV	O	O
once	ADV	O	O
every	DET	O	O
3	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
either	CCONJ	O	O
a	DET	O	O
sublethal	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
1.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
SM-5887	PROPN	O	I-Entity
(	PUNCT	O	O
2.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Animals	NOUN	O	O
which	ADJ	O	O
received	VERB	O	O
over	ADP	O	O
six	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
demonstrated	VERB	O	O
the	DET	O	O
electrocardiogram	NOUN	O	O
(	PUNCT	O	O
ECG	PROPN	O	O
)	PUNCT	O	O
changes	NOUN	O	O
,	PUNCT	O	O
decrease	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
grade	NOUN	O	O
histopathological	ADJ	O	O
cardiomyopathy	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
animals	NOUN	O	O
which	ADJ	O	O
were	VERB	O	O
terminally	ADV	O	O
sacrificed	VERB	O	O
after	ADP	O	O
the	DET	O	O
SM-5887	PROPN	O	I-Entity
administration	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
show	VERB	O	O
any	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
ECG	PROPN	O	O
,	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
histopathological	ADJ	O	O
examinations	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
examine	VERB	O	O
a	DET	O	O
possibly	ADV	O	O
deteriorating	VERB	O	O
cardiotoxic	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
SM-5887	PROPN	O	I-Entity
,	PUNCT	O	O
low	ADJ	O	O
-	PUNCT	O	O
grade	NOUN	O	O
cardiomyopathy	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
in	ADP	O	O
dogs	NOUN	O	O
by	ADP	O	O
four	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
1.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Nine	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
dogs	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
four	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
either	DET	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
1.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
SM-5887	PROPN	O	I-Entity
(	PUNCT	O	O
2.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
once	ADV	O	O
every	DET	O	O
3	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
low	ADJ	O	O
-	PUNCT	O	O
grade	NOUN	O	O
cardiotoxic	NOUN	O	I-Entity
changes	NOUN	O	O
were	VERB	O	O
enhanced	VERB	O	O
by	ADP	O	O
the	DET	O	O
additional	ADJ	O	O
doxorubicin	ADJ	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
contrary	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
SM-5887	PROPN	O	I-Entity
treatment	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
progress	VERB	O	O
the	DET	O	O
grade	NOUN	O	O
of	ADP	O	O
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
SM-5887	PROPN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
have	VERB	O	O
any	DET	O	O
potential	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
deteriorating	VERB	O	O
effect	NOUN	O	O
on	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
in	ADP	O	O
dogs	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9321531)

Posteroventral	ADJ	O	O
medial	ADJ	O	O
pallidotomy	NOUN	O	O
in	ADP	O	O
advanced	ADJ	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

medial	ADJ	O	O
pallidotomy	NOUN	O	O
sometimes	ADV	O	O
produces	VERB	O	O
striking	VERB	O	O
improvement	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
studies	NOUN	O	O
to	ADP	O	O
date	NOUN	O	O
have	VERB	O	O
involved	VERB	O	O
small	ADJ	O	O
numbers	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Forty	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
underwent	VERB	O	O
serial	ADJ	O	O
,	PUNCT	O	O
detailed	ADJ	O	O
assessments	NOUN	O	O
both	DET	O	O
after	ADP	O	O
drug	NOUN	O	O
withdrawal	NOUN	O	O
(	PUNCT	O	O
"	PUNCT	O	O
off	ADP	O	O
"	PUNCT	O	O
period	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
while	ADP	O	O
taking	VERB	O	O
their	ADJ	O	O
optimal	ADJ	O	O
medical	ADJ	O	O
regimens	NOUN	O	O
(	PUNCT	O	O
"	PUNCT	O	O
on	ADP	O	O
"	PUNCT	O	O
period	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
percent	NOUN	O	O
improvements	NOUN	O	O
at	ADP	O	O
six	NUM	O	O
months	NOUN	O	O
were	VERB	O	O
as	ADP	O	O
follows	VERB	O	O
:	PUNCT	O	O
off	ADP	O	O
-	PUNCT	O	O
period	NOUN	O	O
score	NOUN	O	O
for	ADP	O	O
overall	ADJ	O	O
motor	NOUN	O	O
function	NOUN	O	O
,	PUNCT	O	O
28	NUM	O	O
percent	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
19	NUM	O	O
to	PART	O	O
38	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
most	ADJ	O	O
of	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
contralateral	ADJ	O	O
limbs	NOUN	O	O
;	PUNCT	O	O
off	ADP	O	O
-	PUNCT	O	O
period	NOUN	O	O
score	NOUN	O	O
for	ADP	O	O
activities	NOUN	O	O
of	ADP	O	O
daily	ADV	O	O
living	VERB	O	O
,	PUNCT	O	O
29	NUM	O	O
percent	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
19	NUM	O	O
to	PART	O	O
39	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
on	ADP	O	O
-	PUNCT	O	O
period	NOUN	O	O
score	NOUN	O	O
for	ADP	O	O
contralateral	ADJ	O	O
dyskinesias	NOUN	O	I-Entity
,	PUNCT	O	O
82	NUM	O	O
percent	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
72	NUM	O	O
to	PART	O	O
91	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
-	PUNCT	O	O
period	NOUN	O	O
score	NOUN	O	O
for	ADP	O	O
ipsilateral	ADJ	O	O
dyskinesias	NOUN	O	I-Entity
,	PUNCT	O	O
44	NUM	O	O
percent	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
29	NUM	O	O
to	PART	O	O
59	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
improvements	NOUN	O	O
in	ADP	O	O
dyskinesias	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
total	ADJ	O	O
scores	NOUN	O	O
for	ADP	O	O
off	ADP	O	O
-	PUNCT	O	O
period	NOUN	O	O
parkinsonism	NOUN	O	I-Entity
,	PUNCT	O	O
contralateral	ADJ	O	O
bradykinesia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
rigidity	NOUN	O	I-Entity
were	VERB	O	O
sustained	VERB	O	O
in	ADP	O	O
the	DET	O	O
11	NUM	O	O
patients	NOUN	O	O
examined	VERB	O	O
at	ADP	O	O
two	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
ipsilateral	ADJ	O	O
dyskinesias	NOUN	O	I-Entity
was	VERB	O	O
lost	VERB	O	O
after	ADP	O	O
one	NUM	O	O
year	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
improvements	NOUN	O	O
in	ADP	O	O
postural	ADJ	O	O
stability	NOUN	O	O
and	CCONJ	O	O
gait	NOUN	O	O
lasted	VERB	O	O
only	ADV	O	O
three	NUM	O	O
to	PART	O	O
six	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
late	ADJ	O	O
-	PUNCT	O	O
stage	NOUN	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
pallidotomy	NOUN	O	O
significantly	ADV	O	O
reduces	VERB	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
and	CCONJ	O	O
off	ADP	O	O
-	PUNCT	O	O
period	NOUN	O	O
disability	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9305828)

Neuropeptide	PROPN	O	O
-	PUNCT	O	O
Y	PROPN	O	O
immunoreactivity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pilocarpine	NOUN	O	I-Entity
model	NOUN	O	O
of	ADP	O	O
temporal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O

Neuropeptide	PROPN	O	O
-	PUNCT	O	O
Y	PROPN	O	O
(	PUNCT	O	O
NPY	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
expressed	VERB	O	O
by	ADP	O	O
granule	NOUN	O	O
cells	NOUN	O	O
and	CCONJ	O	O
mossy	NOUN	O	O
fibres	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampal	ADJ	O	O
dentate	NOUN	O	O
gyrus	NOUN	O	O
during	ADP	O	O
experimental	ADJ	O	O
temporal	ADJ	O	B-Entity
lobe	NOUN	O	I-Entity
epilepsy	NOUN	O	I-Entity
(	PUNCT	O	O
TLE	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
expression	NOUN	O	O
may	VERB	O	O
represent	VERB	O	O
an	DET	O	O
endogenous	ADJ	O	O
damping	NOUN	O	O
mechanism	NOUN	O	O
since	ADP	O	O
NPY	PROPN	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
block	VERB	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
events	NOUN	O	O
following	VERB	O	O
high	ADJ	O	O
-	PUNCT	O	O
frequency	NOUN	O	O
stimulation	NOUN	O	O
in	ADP	O	O
hippocampal	ADJ	O	O
slices	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pilocarpine	NOUN	O	I-Entity
(	PUNCT	O	O
PILO	PROPN	O	I-Entity
)	PUNCT	O	O
model	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
is	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
followed	VERB	O	O
by	ADP	O	O
spontaneous	ADJ	O	O
recurrent	ADJ	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
related	ADJ	O	O
brain	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

PILO	PROPN	O	I-Entity
-	PUNCT	O	O
injected	VERB	O	O
animals	NOUN	O	O
exhibited	VERB	O	O
NPY	PROPN	O	O
immunoreactivity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
region	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mossy	NOUN	O	O
fibre	NOUN	O	O
terminals	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
dentate	NOUN	O	O
gyrus	NOUN	O	O
inner	ADJ	O	O
molecular	ADJ	O	O
layer	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
few	ADJ	O	O
cases	NOUN	O	O
,	PUNCT	O	O
within	ADP	O	O
presumed	VERB	O	O
granule	ADJ	O	O
cells	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
PILO	PROPN	O	I-Entity
injected	VERB	O	O
animals	NOUN	O	O
exhibited	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
NPY	PROPN	O	O
-	PUNCT	O	O
immunoreactive	ADJ	O	O
interneurons	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
NPY	PROPN	O	O
expression	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
expression	NOUN	O	O
in	ADP	O	O
the	DET	O	O
granule	NOUN	O	O
cells	NOUN	O	O
and	CCONJ	O	O
mossy	NOUN	O	O
fibres	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
loss	NOUN	O	O
of	ADP	O	O
vulnerable	ADJ	O	O
NPY	PROPN	O	O
neurons	NOUN	O	O
,	PUNCT	O	O
are	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
the	DET	O	O
PILO	PROPN	O	I-Entity
model	NOUN	O	O
of	ADP	O	O
TLE	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9041081)

During	ADP	O	O
the	DET	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
12%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
steroid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
elevated	ADJ	O	B-Entity
intraocular	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
(	PUNCT	O	O
IOP	PROPN	O	O
)	PUNCT	O	O
that	DET	O	O
resolved	VERB	O	O
after	ADP	O	O
corticosteroid	NOUN	O	I-Entity
therapy	NOUN	O	O
was	VERB	O	O
discontinued	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
transient	ADJ	O	O
steroid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
IOP	PROPN	O	B-Entity
rise	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
seem	VERB	O	O
to	PART	O	O
cause	VERB	O	O
functional	ADJ	O	O
impairment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8305357)

Liposomal	PROPN	O	O
daunorubicin	NOUN	O	I-Entity
in	ADP	O	O
advanced	ADJ	O	O
Kaposi	PROPN	O	B-Entity
's	PART	O	I-Entity
sarcoma	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
phase	NOUN	O	O
II	PROPN	O	O
study	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
randomized	ADJ	O	O
Phase	NOUN	O	O
II	PROPN	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
liposomal	ADJ	O	O
daunorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
DaunoXome	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
AIDS	PROPN	O	I-Entity
related	VERB	O	O
Kaposi	PROPN	O	B-Entity
's	PART	O	I-Entity
sarcoma	NOUN	O	I-Entity
.	PUNCT	O	O

Eleven	NUM	O	O
homosexual	ADJ	O	O
men	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
Kaposi	PROPN	O	B-Entity
's	PART	O	I-Entity
sarcoma	NOUN	O	I-Entity
were	VERB	O	O
entered	VERB	O	O
in	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
size	NOUN	O	O
,	PUNCT	O	O
colour	NOUN	O	O
and	CCONJ	O	O
associated	VERB	O	O
oedema	NOUN	O	I-Entity
of	ADP	O	O
selected	VERB	O	O
'	PUNCT	O	O
target	NOUN	O	O
'	PUNCT	O	O
lesions	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
,	PUNCT	O	O
biochemical	ADJ	O	O
and	CCONJ	O	O
haematological	ADJ	O	O
toxicities	NOUN	O	I-Entity
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

Stabilization	NOUN	O	O
of	ADP	O	O
Kaposi	PROPN	O	B-Entity
's	PART	O	I-Entity
sarcoma	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
six	NUM	O	O
,	PUNCT	O	O
maintained	VERB	O	O
until	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
period	NOUN	O	O
in	ADP	O	O
four	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
drug	NOUN	O	O
was	VERB	O	O
generally	ADV	O	O
well	ADV	O	O
tolerated	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
few	ADJ	O	O
mild	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
problem	NOUN	O	O
encountered	VERB	O	O
was	VERB	O	O
haematological	ADJ	O	O
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
three	NUM	O	O
subjects	NOUN	O	O
experiencing	VERB	O	O
severe	ADJ	O	O
neutropenia	NOUN	O	I-Entity
(	PUNCT	O	O
neutrophil	ADJ	O	O
count	NOUN	O	O
<	X	O	O
0.5	NUM	O	O
x	SYM	O	O
10(9)/l	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
small	ADJ	O	O
patient	NOUN	O	O
sample	NOUN	O	O
,	PUNCT	O	O
liposomal	ADJ	O	O
daunorubicin	NOUN	O	I-Entity
was	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
and	CCONJ	O	O
well	ADV	O	O
tolerated	VERB	O	O
agent	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
Kaposi	PROPN	O	B-Entity
's	PART	O	I-Entity
sarcoma	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8012887)

Failure	NOUN	O	O
of	ADP	O	O
ancrod	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
arterial	ADJ	O	O
thrombosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombosis	NOUN	O	I-Entity
remain	VERB	O	O
high	ADJ	O	O
despite	ADP	O	O
numerous	ADJ	O	O
empirical	ADJ	O	O
therapies	NOUN	O	O
.	PUNCT	O	O

Ancrod	PROPN	O	O
has	VERB	O	O
been	VERB	O	O
used	VERB	O	O
successfully	ADV	O	O
for	ADP	O	O
prophylaxis	NOUN	O	O
against	ADP	O	O
development	NOUN	O	O
of	ADP	O	O
thrombosis	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
heparin	NOUN	O	I-Entity
induced	VERB	O	O
platelet	NOUN	O	B-Entity
aggregation	NOUN	O	I-Entity
who	NOUN	O	O
require	VERB	O	O
brief	ADJ	O	O
reexposure	NOUN	O	O
to	ADP	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
its	ADJ	O	O
success	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
developed	VERB	O	O
the	DET	O	O
thrombosis	NOUN	O	I-Entity
syndrome	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
well	ADV	O	O
defined	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
present	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
failure	NOUN	O	O
of	ADP	O	O
ancrod	NOUN	O	O
treatment	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombosis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7651879)

Seizure	NOUN	O	I-Entity
after	ADP	O	O
flumazenil	ADJ	O	I-Entity
administration	NOUN	O	O
in	ADP	O	O
a	DET	O	O
pediatric	ADJ	O	O
patient	NOUN	O	O
.	PUNCT	O	O

Flumazenil	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
benzodiazepine	ADJ	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
used	VERB	O	O
to	PART	O	O
reverse	VERB	O	O
sedation	NOUN	O	O
and	CCONJ	O	O
respiratory	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
benzodiazepines	NOUN	O	I-Entity
.	PUNCT	O	O

Seizures	NOUN	O	I-Entity
and	CCONJ	O	O
cardiac	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
have	VERB	O	O
complicated	VERB	O	O
its	ADJ	O	O
use	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Overdose	NOUN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
coingested	VERB	O	O
tricyclic	ADJ	O	O
antidepressants	NOUN	O	O
have	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
these	DET	O	O
complications	NOUN	O	O
.	PUNCT	O	O

Little	ADJ	O	O
information	NOUN	O	O
exists	VERB	O	O
concerning	VERB	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
flumazenil	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
generalized	ADJ	O	O
tonic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
clonic	ADJ	O	I-Entity
seizure	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
pediatric	ADJ	O	O
patient	NOUN	O	O
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
flumazenil	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3015327)

Remodelling	NOUN	O	O
of	ADP	O	O
nerve	NOUN	O	O
structure	NOUN	O	O
in	ADP	O	O
experimental	ADJ	O	O
isoniazid	NOUN	O	I-Entity
neuropathy	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
neuropathy	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
isoniazid	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
with	ADP	O	O
a	DET	O	O
computer	NOUN	O	O
-	PUNCT	O	O
assisted	VERB	O	O
morphometric	ADJ	O	O
method	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2980315)

Selective	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
iopentol	NOUN	O	I-Entity
,	PUNCT	O	O
iohexol	NOUN	O	I-Entity
and	CCONJ	O	O
metrizoate	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
left	ADJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dog	NOUN	O	O
.	PUNCT	O	O

Induction	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
and	CCONJ	O	O
decrease	NOUN	O	O
of	ADP	O	O
aortic	ADJ	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
twenty	NUM	O	O
beagle	ADJ	O	O
dogs	NOUN	O	O
selective	ADJ	O	O
injections	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
into	ADP	O	O
the	DET	O	O
left	ADJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
with	ADP	O	O
iopentol	NOUN	O	I-Entity
,	PUNCT	O	O
iohexol	NOUN	O	I-Entity
and	CCONJ	O	O
metrizoate	NOUN	O	I-Entity
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
ml	PROPN	O	O
,	PUNCT	O	O
8	NUM	O	O
ml	NOUN	O	O
and	CCONJ	O	O
16	NUM	O	O
ml	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
iopentol	NOUN	O	I-Entity
injections	NOUN	O	O
,	PUNCT	O	O
35	NUM	O	O
iohexol	ADJ	O	I-Entity
injections	NOUN	O	O
and	CCONJ	O	O
37	NUM	O	O
metrizoate	NOUN	O	I-Entity
injections	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
.	PUNCT	O	O

Frequencies	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
were	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.05	NUM	O	O
)	PUNCT	O	O
after	ADP	O	O
iopentol	NOUN	O	I-Entity
(	PUNCT	O	O
0%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
iohexol	NOUN	O	I-Entity
(	PUNCT	O	O
3%	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
after	ADP	O	O
metrizoate	NOUN	O	I-Entity
(	PUNCT	O	O
22%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Iopentol	PROPN	O	I-Entity
and	CCONJ	O	O
iohexol	NOUN	O	I-Entity
also	ADV	O	O
produced	VERB	O	O
significantly	ADV	O	O
less	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
aortic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
than	ADP	O	O
metrizoate	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
different	ADJ	O	O
doses	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2819587)

Magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
of	ADP	O	O
cerebral	ADJ	O	O
venous	ADJ	O	B-Entity
thrombosis	NOUN	O	I-Entity
secondary	NOUN	O	O
to	PART	O	O
"	PUNCT	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
"	PUNCT	O	O
birth	NOUN	O	O
control	NOUN	O	O
pills	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
radiographic	ADJ	O	O
features	NOUN	O	O
of	ADP	O	O
cerebral	ADJ	O	O
deep	ADJ	O	B-Entity
venous	ADJ	O	I-Entity
thrombosis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
21-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
white	ADJ	O	O
woman	NOUN	O	O
are	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
only	ADJ	O	O
known	VERB	O	O
risk	NOUN	O	O
factor	NOUN	O	O
was	VERB	O	O
"	PUNCT	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
"	PUNCT	O	O
oral	ADJ	O	B-Entity
contraceptive	NOUN	O	I-Entity
pills	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1564236)

Relation	NOUN	O	O
of	ADP	O	O
perfusion	NOUN	O	O
defects	NOUN	O	O
observed	VERB	O	O
with	ADP	O	O
myocardial	ADJ	O	O
contrast	NOUN	O	O
echocardiography	NOUN	O	O
to	ADP	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
stenosis	NOUN	O	I-Entity
:	PUNCT	O	O
correlation	NOUN	O	O
with	ADP	O	O
thallium-201	DET	O	I-Entity
single	ADJ	O	O
-	PUNCT	O	O
photon	NOUN	O	O
emission	NOUN	O	O
tomography	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
been	VERB	O	O
previously	ADV	O	O
shown	VERB	O	O
that	ADP	O	O
myocardial	ADJ	O	O
contrast	NOUN	O	O
echocardiography	NOUN	O	O
is	VERB	O	O
a	DET	O	O
valuable	ADJ	O	O
technique	NOUN	O	O
for	ADP	O	O
delineating	VERB	O	O
regions	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	O
underperfusion	NOUN	O	O
secondary	ADJ	O	O
to	ADP	O	O
coronary	ADJ	O	B-Entity
occlusion	NOUN	O	I-Entity
and	CCONJ	O	O
to	ADP	O	O
critical	ADJ	O	O
coronary	ADJ	O	B-Entity
stenoses	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
hyperemic	ADJ	O	I-Entity
stimulation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
myocardial	ADJ	O	O
contrast	NOUN	O	O
echocardiography	NOUN	O	O
performed	VERB	O	O
with	ADP	O	O
a	DET	O	O
stable	ADJ	O	O
solution	NOUN	O	O
of	ADP	O	O
sonicated	VERB	O	O
albumin	PRON	O	O
could	VERB	O	O
detect	VERB	O	O
regions	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	O
underperfusion	NOUN	O	O
resulting	VERB	O	O
from	ADP	O	O
various	ADJ	O	O
degrees	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
stenosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
perfusion	NOUN	O	O
defect	NOUN	O	O
produced	VERB	O	O
in	ADP	O	O
16	NUM	O	O
open	ADJ	O	O
chest	NOUN	O	O
dogs	NOUN	O	O
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
anatomic	ADJ	O	O
area	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
measured	VERB	O	O
by	ADP	O	O
the	DET	O	O
postmortem	NOUN	O	O
dual	ADJ	O	O
-	PUNCT	O	O
perfusion	NOUN	O	O
technique	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
thallium-201	DET	O	I-Entity
single	ADJ	O	O
-	PUNCT	O	O
photon	NOUN	O	O
emission	NOUN	O	O
tomography	NOUN	O	O
(	PUNCT	O	O
SPECT	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

During	ADP	O	O
a	DET	O	O
transient	NOUN	O	O
(	PUNCT	O	O
20-s	PUNCT	O	O
)	PUNCT	O	O
coronary	ADJ	O	B-Entity
occlusion	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
perfusion	NOUN	O	O
defect	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
with	ADP	O	O
contrast	NOUN	O	O
echocardiography	NOUN	O	O
in	ADP	O	O
14	NUM	O	O
of	ADP	O	O
the	DET	O	O
15	NUM	O	O
dogs	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
the	DET	O	O
occlusion	NOUN	O	O
was	VERB	O	O
produced	VERB	O	O
.	PUNCT	O	O

During	ADP	O	O
dipyridamole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperemia	NOUN	O	I-Entity
,	PUNCT	O	O
12	NUM	O	O
of	ADP	O	O
the	DET	O	O
16	NUM	O	O
dogs	NOUN	O	O
with	ADP	O	O
a	DET	O	O
partial	ADJ	O	O
coronary	ADJ	O	B-Entity
stenosis	NOUN	O	I-Entity
had	VERB	O	O
a	DET	O	O
visible	ADJ	O	O
area	NOUN	O	O
of	ADP	O	O
hypoperfusion	NOUN	O	O
by	ADP	O	O
contrast	NOUN	O	O
echocardiography	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
four	NUM	O	O
dogs	NOUN	O	O
without	ADP	O	O
a	DET	O	O
perfusion	NOUN	O	O
defect	NOUN	O	O
had	VERB	O	O
a	DET	O	O
stenosis	NOUN	O	O
that	ADJ	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
mild	ADJ	O	O
(	PUNCT	O	O
0%	PUNCT	O	O
to	ADP	O	O
50%	NUM	O	O
)	PUNCT	O	O
reduction	NOUN	O	O
in	ADP	O	O
dipyridamole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperemia	NOUN	O	I-Entity
.	PUNCT	O	O

Thallium-201	PUNCT	O	I-Entity

SPECT	PROPN	O	O
demonstrated	VERB	O	O
a	DET	O	O
perfusion	NOUN	O	O
defect	NOUN	O	O
in	ADP	O	O
all	DET	O	O
14	NUM	O	O
dogs	NOUN	O	O
analyzed	VERB	O	O
during	ADP	O	O
dipyridamole	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperemia	NOUN	O	I-Entity
;	PUNCT	O	O
the	DET	O	O
size	NOUN	O	O
of	ADP	O	O
the	DET	O	O
perfusion	NOUN	O	O
defect	NOUN	O	O
correlated	VERB	O	O
with	ADP	O	O
the	DET	O	O
anatomic	ADJ	O	O
area	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.58	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.03	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
with	ADP	O	O
the	DET	O	O
perfusion	NOUN	O	O
defect	NOUN	O	O
by	ADP	O	O
contrast	NOUN	O	O
echocardiography	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.58	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.03	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
myocardial	ADJ	O	O
contrast	NOUN	O	O
echocardiography	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
visualize	VERB	O	O
and	CCONJ	O	O
quantitate	VERB	O	O
the	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
jeopardized	VERB	O	O
myocardium	NOUN	O	O
during	ADP	O	O
moderate	ADJ	O	O
to	PART	O	O
severe	ADJ	O	O
degrees	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
stenosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
obtained	VERB	O	O
show	VERB	O	O
a	DET	O	O
correlation	NOUN	O	O
with	ADP	O	O
the	DET	O	O
anatomic	ADJ	O	O
area	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
obtained	VERB	O	O
with	ADP	O	O
thallium-201	DET	O	I-Entity
SPECT	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (1300436)

Potential	ADJ	O	O
deleterious	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
furosemide	NOUN	O	I-Entity
in	ADP	O	O
radiocontrast	NOUN	O	O
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
furosemide	NOUN	O	I-Entity
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
intravenous	ADJ	O	O
fluids	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
radiocontrast	NOUN	O	O
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

18	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
referred	VERB	O	O
to	ADP	O	O
a	DET	O	O
radiocontrast	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
considered	VERB	O	O
at	ADP	O	O
risk	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
preexisting	VERB	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
performed	VERB	O	O
at	ADP	O	O
the	DET	O	O
secondary	ADJ	O	O
care	NOUN	O	O
center	NOUN	O	O
of	ADP	O	O
a	DET	O	O
1,100-bed	NUM	O	O
private	ADJ	O	O
university	NOUN	O	O
hospital	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
fluids	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
furosemide	NOUN	O	I-Entity
(	PUNCT	O	O
mean	VERB	O	O
dose	VERB	O	O
110	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
intravenously	ADV	O	O
30	NUM	O	O
min	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
contrast	NOUN	O	O
material	NOUN	O	O
.	PUNCT	O	O

Renal	ADJ	O	B-Entity
function	NOUN	O	I-Entity
significantly	ADV	O	I-Entity
deteriorated	VERB	O	I-Entity
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
furosemide	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O

<	X	O	O
0.005	NUM	O	O
by	ADP	O	O
ANOVA	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
rise	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
from	ADP	O	O
145	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
weight	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
furosemide	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

Furosemide	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
deleterious	ADJ	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
radiocontrast	NOUN	O	O
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1141447)

The	DET	O	O
renal	ADJ	O	O
pathology	NOUN	O	O
in	ADP	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetes	NOUN	O	B-Entity
insipidus	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetes	NOUN	O	B-Entity
insipidus	NOUN	O	I-Entity
is	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
these	DET	O	O
changes	NOUN	O	O
represent	VERB	O	O
a	DET	O	O
specific	ADJ	O	O
toxic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
,	PUNCT	O	O
reported	VERB	O	O
here	ADV	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (188339)

Etiologic	ADJ	O	O
factors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
.	PUNCT	O	O

Within	ADP	O	O
the	DET	O	O
last	ADJ	O	O
several	ADJ	O	O
years	NOUN	O	O
,	PUNCT	O	O
previously	ADV	O	O
rare	ADJ	O	O
liver	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
young	ADJ	O	O
women	NOUN	O	O
using	VERB	O	O
oral	ADJ	O	B-Entity
contraceptive	NOUN	O	I-Entity
steroids	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
Registry	PROPN	O	O
for	ADP	O	O
Liver	PROPN	O	B-Entity
Tumors	PROPN	O	I-Entity
Associated	PROPN	O	O
with	ADP	O	O
Oral	ADJ	O	B-Entity
Contraceptives	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
University	PROPN	O	O
of	ADP	O	O
California	PROPN	O	O
,	PUNCT	O	O
Irvine	PROPN	O	O
,	PUNCT	O	O
has	VERB	O	O
clearly	ADV	O	O
identified	VERB	O	O
27	NUM	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Common	ADJ	O	O
to	ADP	O	O
these	DET	O	O
71	NUM	O	O
cases	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
a	DET	O	O
histopathologic	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
focal	ADJ	O	B-Entity
nodular	ADJ	O	I-Entity
hyperplasia	NOUN	O	I-Entity
,	PUNCT	O	O
adenoma	NOUN	O	I-Entity
,	PUNCT	O	O
hamartoma	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hepatoma	NOUN	O	I-Entity
.	PUNCT	O	O

Significant	ADJ	O	O
statistical	ADJ	O	O
etiologic	NOUN	O	O
factors	NOUN	O	O
include	VERB	O	O
prolonged	VERB	O	O
uninterrupted	ADJ	O	O
usage	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	B-Entity
contraceptive	NOUN	O	I-Entity
steroids	NOUN	O	I-Entity
.	PUNCT	O	O

Eight	NUM	O	O
deaths	NOUN	O	O
and	CCONJ	O	O
liver	NOUN	O	O
rupture	NOUN	O	I-Entity
in	ADP	O	O
18	NUM	O	O
patients	NOUN	O	O
attest	VERB	O	O
to	ADP	O	O
the	DET	O	O
seriousness	NOUN	O	O
of	ADP	O	O
this	DET	O	O
new	ADJ	O	O
potentially	ADV	O	O
lethal	ADJ	O	O
adverse	ADJ	O	O
phenomenon	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19135948)

Graft	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
versus	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
host	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
prophylaxis	VERB	O	O
with	ADP	O	O
everolimus	NOUN	O	I-Entity
and	CCONJ	O	O
tacrolimus	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
high	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
sinusoidal	ADJ	O	B-Entity
obstruction	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
microangiopathy	NOUN	O	I-Entity
:	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
EVTAC	PROPN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
calcineurin	ADJ	O	O
inhibitor	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
methotrexate	NOUN	O	I-Entity
is	VERB	O	O
the	DET	O	O
standard	ADJ	O	O
prophylaxis	NOUN	O	O
for	ADP	O	O
graft	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
versus	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
host	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
GVHD	PROPN	O	I-Entity
)	PUNCT	O	O
after	ADP	O	O
allogeneic	NOUN	O	O
hematopoietic	ADJ	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplantation	NOUN	O	O
(	PUNCT	O	O
HSCT	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Everolimus	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
derivative	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
,	PUNCT	O	O
seems	VERB	O	O
to	PART	O	O
mediate	VERB	O	O
antileukemia	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
on	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
everolimus	NOUN	O	I-Entity
and	CCONJ	O	O
tacrolimus	NOUN	O	I-Entity
in	ADP	O	O
24	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
62	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
either	DET	O	O
myelodysplastic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
MDS	PROPN	O	I-Entity
;	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
17	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
acute	ADJ	O	B-Entity
myeloid	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
(	PUNCT	O	O
AML	PROPN	O	I-Entity
;	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
undergoing	VERB	O	O
intensive	ADJ	O	O
conditioning	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
HSCT	PROPN	O	O
from	ADP	O	O
related	ADJ	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
4	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
unrelated	ADJ	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
20	NUM	O	O
)	PUNCT	O	O
donors	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
engrafted	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
only	ADV	O	O
1	NUM	O	O
patient	ADJ	O	O
experienced	ADJ	O	O
grade	NOUN	O	O
IV	PROPN	O	O
mucositis	NOUN	O	I-Entity
.	PUNCT	O	O

Nine	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
37%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
acute	ADJ	O	O
grade	NOUN	O	O
II	PROPN	O	O
-	PUNCT	O	O
IV	PROPN	O	O
GVHD	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
11	NUM	O	O
of	ADP	O	O
17	NUM	O	O
evaluable	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
64%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
chronic	ADJ	O	O
extensive	ADJ	O	O
GVHD	PROPN	O	I-Entity
.	PUNCT	O	O

Transplantation	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
associated	VERB	O	I-Entity
microangiopathy	NOUN	O	I-Entity
(	PUNCT	O	O
TMA	PROPN	O	I-Entity
)	PUNCT	O	O
occurred	VERB	O	O
in	ADP	O	O
7	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
29%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
2	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
was	VERB	O	O
terminated	VERB	O	O
prematurely	ADV	O	O
because	ADP	O	O
an	DET	O	O
additional	ADJ	O	O
6	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
25%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
sinusoidal	ADJ	O	B-Entity
obstruction	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
SOS	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
fatal	ADJ	O	O
in	ADP	O	O
2	NUM	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
this	DET	O	O
new	ADJ	O	O
combination	NOUN	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
effective	ADJ	O	O
as	ADP	O	O
a	DET	O	O
prophylactic	ADJ	O	O
regimen	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
GVHD	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
TMA	PROPN	O	I-Entity
and	CCONJ	O	O
SOS	PROPN	O	I-Entity
is	VERB	O	O
considerably	ADV	O	O
higher	ADJ	O	O
than	ADP	O	O
seen	VERB	O	O
with	ADP	O	O
other	ADJ	O	O
regimens	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (14704468)

Effect	NOUN	O	O
of	ADP	O	O
some	DET	O	O
convulsants	NOUN	O	O
on	ADP	O	O
the	DET	O	O
protective	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
loreclezole	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
combinations	NOUN	O	O
with	ADP	O	O
valproate	NOUN	O	I-Entity
or	CCONJ	O	O
clonazepam	NOUN	O	I-Entity
in	ADP	O	O
amygdala	NOUN	O	O
-	PUNCT	O	O
kindled	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Loreclezole	PROPN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
exerted	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
protective	ADJ	O	O
action	NOUN	O	O
in	ADP	O	O
amygdala	NOUN	O	O
-	PUNCT	O	O
kindled	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
reducing	VERB	O	O
both	DET	O	O
seizure	NOUN	O	I-Entity
and	CCONJ	O	O
afterdischarge	NOUN	O	O
durations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
combinations	NOUN	O	O
of	ADP	O	O
loreclezole	NOUN	O	I-Entity
(	PUNCT	O	O
2.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
valproate	NOUN	O	I-Entity
,	PUNCT	O	O
clonazepam	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
carbamazepine	NOUN	O	I-Entity
(	PUNCT	O	O
applied	VERB	O	O
at	ADP	O	O
their	ADJ	O	O
subprotective	ADJ	O	O
doses	NOUN	O	O
)	PUNCT	O	O
also	ADV	O	O
exhibited	VERB	O	O
antiseizure	NOUN	O	O
effect	NOUN	O	O
in	ADP	O	O
this	DET	O	O
test	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
several	ADJ	O	O
chemoconvulsants	NOUN	O	O
,	PUNCT	O	O
bicuculline	NOUN	O	I-Entity
,	PUNCT	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
and	CCONJ	O	O
BAY	PROPN	O	B-Entity
k-8644	PROPN	O	I-Entity
(	PUNCT	O	O
the	DET	O	O
opener	NOUN	O	O
of	ADP	O	O
L	PROPN	O	O
-	PUNCT	O	O
type	NOUN	O	O
calcium	NOUN	O	I-Entity
channels	NOUN	O	O
)	PUNCT	O	O
reversed	VERB	O	O
the	DET	O	O
protective	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
loreclezole	NOUN	O	I-Entity
alone	ADV	O	O
and	CCONJ	O	O
its	ADJ	O	O
combination	NOUN	O	O
with	ADP	O	O
valproate	NOUN	O	I-Entity
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
bicuculline	NOUN	O	I-Entity
,	PUNCT	O	O
aminophylline	NOUN	O	I-Entity
and	CCONJ	O	O
BAY	PROPN	O	B-Entity
k-8644	PROPN	O	I-Entity
inhibited	VERB	O	O
the	DET	O	O
anticonvulsive	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
loreclezole	NOUN	O	I-Entity
combined	VERB	O	O
with	ADP	O	O
clonazepam	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
support	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
the	DET	O	O
protective	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
loreclezole	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
combinations	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
antiepileptics	NOUN	O	O
may	VERB	O	O
involve	VERB	O	O
potentiation	NOUN	O	O
of	ADP	O	O
GABAergic	PROPN	O	O
neurotransmission	NOUN	O	O
and	CCONJ	O	O
blockade	NOUN	O	O
of	ADP	O	O
L	PROPN	O	O
-	PUNCT	O	O
type	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
channels	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12549952)

Acute	PROPN	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
with	ADP	O	O
concurrent	ADJ	O	O
bupropion	NOUN	O	I-Entity
and	CCONJ	O	O
carbimazole	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
fatal	ADJ	O	O
liver	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
possibly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
concurrent	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	I-Entity
and	CCONJ	O	O
carbimazole	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
41-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
Chinese	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
hyperthyroidism	NOUN	O	I-Entity
had	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
carbimazole	NOUN	O	I-Entity
and	CCONJ	O	O
propranolol	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
past	ADJ	O	O
5	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
received	VERB	O	O
a	DET	O	O
10-day	ADJ	O	O
course	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	I-Entity
as	ADP	O	O
an	DET	O	O
aid	NOUN	O	O
for	ADP	O	O
smoking	VERB	O	O
cessation	NOUN	O	O
10	NUM	O	O
weeks	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
presentation	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
developed	VERB	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
with	ADP	O	O
rapid	ADJ	O	O
deterioration	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

Liver	PROPN	O	O
biopsy	NOUN	O	O
showed	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
nonspecific	ADJ	O	O
drug	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
induced	VERB	O	I-Entity
acute	ADJ	O	I-Entity
liver	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

His	ADJ	O	O
condition	NOUN	O	O
was	VERB	O	O
further	ADV	O	O
complicated	VERB	O	O
by	ADP	O	O
sepsis	NOUN	O	I-Entity
and	CCONJ	O	O
coagulopathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
likelihood	NOUN	O	O
that	ADJ	O	O
bupropion	NOUN	O	I-Entity
induced	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
in	ADP	O	O
our	ADJ	O	O
patient	NOUN	O	O
was	VERB	O	O
possible	ADJ	O	O
,	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
Naranjo	PROPN	O	O
probability	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
:	PUNCT	O	O
Although	ADP	O	O
there	ADV	O	O
is	VERB	O	O
increasing	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
hepatotoxicity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
bupropion	NOUN	O	I-Entity
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
fatality	NOUN	O	O
that	ADJ	O	O
could	VERB	O	O
have	VERB	O	O
resulted	VERB	O	O
from	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
receiving	VERB	O	O
bupropion	NOUN	O	I-Entity
while	ADP	O	O
on	ADP	O	O
concomitant	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
carbimazole	NOUN	O	I-Entity
.	PUNCT	O	O

Clinicians	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
insult	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
bupropion	NOUN	O	I-Entity
given	VERB	O	O
concurrently	ADV	O	O
with	ADP	O	O
other	ADJ	O	O
hepatotoxic	ADJ	O	I-Entity
drugs	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19370593)

Hormone	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
HT	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
widely	ADV	O	O
used	VERB	O	O
for	ADP	O	O
controlling	VERB	O	O
menopausal	NOUN	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
has	VERB	O	O
also	ADV	O	O
been	VERB	O	O
used	VERB	O	O
for	ADP	O	O
the	DET	O	O
management	NOUN	O	O
and	CCONJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
osteoporosis	NOUN	O	I-Entity
and	CCONJ	O	O
dementia	NOUN	O	I-Entity
in	ADP	O	O
older	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
assess	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
HT	PROPN	O	O
on	ADP	O	O
mortality	NOUN	O	O
,	PUNCT	O	O
cardiovascular	ADJ	O	O
outcomes	NOUN	O	O
,	PUNCT	O	O
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
gallbladder	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
cognition	NOUN	O	O
,	PUNCT	O	O
fractures	NOUN	O	I-Entity
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
searched	VERB	O	O
the	DET	O	O
following	VERB	O	O
databases	NOUN	O	O
to	ADP	O	O
November	PROPN	O	O
2007	NUM	O	O
:	PUNCT	O	O
Trials	NOUN	O	O
Register	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Cochrane	PROPN	O	O
Menstrual	PROPN	O	B-Entity
Disorders	PROPN	O	I-Entity
and	CCONJ	O	O
Subfertility	PROPN	O	O
Group	PROPN	O	O
,	PUNCT	O	O
Cochrane	PROPN	O	O
Central	PROPN	O	O
Register	PROPN	O	O
of	ADP	O	O
Controlled	PROPN	O	O
Trials	PROPN	O	O
,	PUNCT	O	O
MEDLINE	PROPN	O	O
,	PUNCT	O	O
EMBASE	PROPN	O	O
,	PUNCT	O	O
Biological	PROPN	O	O
Abstracts	PROPN	O	O
.	PUNCT	O	O

HT	NOUN	O	O
included	VERB	O	O
oestrogens	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
progestogens	NOUN	O	I-Entity
,	PUNCT	O	O
via	ADP	O	O
oral	ADJ	O	O
,	PUNCT	O	O
transdermal	ADJ	O	O
,	PUNCT	O	O
subcutaneous	ADJ	O	O
or	CCONJ	O	O
transnasal	ADJ	O	O
routes	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
relatively	ADV	O	O
healthy	ADJ	O	O
women	NOUN	O	O
,	PUNCT	O	O
combined	VERB	O	O
continuous	ADJ	O	O
HT	PROPN	O	O
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thrombo	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
embolism	NOUN	O	I-Entity
or	CCONJ	O	O
coronary	ADJ	O	O
event	NOUN	O	O
(	PUNCT	O	O
after	ADP	O	O
one	NUM	O	O
year	NOUN	O	O
's	PART	O	O
use	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
stroke	NOUN	O	I-Entity
(	PUNCT	O	O
after	ADP	O	O
three	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
and	CCONJ	O	O
gallbladder	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
oestrogen	NOUN	O	I-Entity
-	PUNCT	O	O
only	ADV	O	O
HT	PROPN	O	O
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thrombo	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
embolism	NOUN	O	I-Entity
,	PUNCT	O	O
stroke	NOUN	O	I-Entity
and	CCONJ	O	O
gallbladder	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
after	ADP	O	O
one	NUM	O	O
to	ADP	O	O
two	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
seven	NUM	O	O
years	NOUN	O	O
'	PART	O	O
use	NOUN	O	O
respectively	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
only	ADJ	O	O
statistically	ADV	O	O
significant	ADJ	O	O
benefits	NOUN	O	O
of	ADP	O	O
HT	PROPN	O	O
were	VERB	O	O
a	DET	O	O
decreased	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
fractures	NOUN	O	I-Entity
and	CCONJ	O	O
(	PUNCT	O	O
for	ADP	O	O
combined	VERB	O	O
HT	PROPN	O	O
)	PUNCT	O	O
colon	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
women	NOUN	O	O
aged	VERB	O	O
over	ADP	O	O
65	NUM	O	O
who	NOUN	O	O
were	VERB	O	O
relatively	ADV	O	O
healthy	ADJ	O	O
(	PUNCT	O	O
i.e.	X	O	O
generally	ADV	O	O
fit	VERB	O	O
,	PUNCT	O	O
without	ADP	O	O
overt	ADJ	O	O
disease	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
taking	VERB	O	O
continuous	ADJ	O	O
combined	ADJ	O	O
HT	PROPN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
dementia	NOUN	O	I-Entity
.	PUNCT	O	O

Among	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
of	ADP	O	O
combined	ADJ	O	O
continuous	ADJ	O	O
HT	PROPN	O	O
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thrombo	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
embolism	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
trial	NOUN	O	O
analysed	VERB	O	O
subgroups	NOUN	O	O
of	ADP	O	O
2839	NUM	O	O
relatively	ADV	O	O
healthy	ADJ	O	O
50	NUM	O	O
to	PART	O	O
59	NUM	O	O
year	NOUN	O	O
old	ADJ	O	O
women	NOUN	O	O
taking	VERB	O	O
combined	VERB	O	O
continuous	ADJ	O	O
HT	PROPN	O	O
and	CCONJ	O	O
1637	NUM	O	O
taking	VERB	O	O
oestrogen	NOUN	O	I-Entity
-	PUNCT	O	O
only	ADV	O	O
HT	PROPN	O	O
,	PUNCT	O	O
versus	ADP	O	O
similar	ADJ	O	O
-	PUNCT	O	O
sized	ADJ	O	O
placebo	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
only	ADJ	O	O
significantly	ADV	O	O
increased	VERB	O	O
risk	NOUN	O	O
reported	VERB	O	O
was	VERB	O	O
for	ADP	O	O
venous	ADJ	O	B-Entity
thrombo	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
embolism	NOUN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
taking	VERB	O	O
combined	VERB	O	O
continuous	ADJ	O	O
HT	NOUN	O	O
:	PUNCT	O	O
their	ADJ	O	O
absolute	ADJ	O	O
risk	NOUN	O	O
remained	VERB	O	O
low	ADJ	O	O
,	PUNCT	O	O
at	ADP	O	O
less	ADJ	O	O
than	ADP	O	O
1/500	NUM	O	O
.	PUNCT	O	O


-DOCSTART- (17019386)

Passage	NOUN	O	O
of	ADP	O	O
mannitol	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
around	ADP	O	O
gliomas	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
potential	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
rebound	NOUN	O	O
phenomenon	NOUN	O	O
.	PUNCT	O	O

Widespread	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
mannitol	NOUN	O	I-Entity
to	PART	O	O
reduce	VERB	O	O
brain	NOUN	O	B-Entity
edema	NOUN	O	I-Entity
and	CCONJ	O	O
lower	ADV	O	O
elevated	ADJ	O	B-Entity
ICP	NOUN	O	I-Entity
in	ADP	O	O
brain	NOUN	O	B-Entity
tumor	NOUN	O	I-Entity
patients	NOUN	O	O
continues	VERB	O	O
to	PART	O	O
be	VERB	O	O
afflicted	VERB	O	O
by	ADP	O	O
the	DET	O	O
so	ADV	O	O
-	PUNCT	O	O
called	VERB	O	O
rebound	NOUN	O	O
phenomenon	NOUN	O	O
.	PUNCT	O	O

Leakage	NOUN	O	O
of	ADP	O	O
mannitol	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
parenchyma	NOUN	O	O
through	ADP	O	O
an	DET	O	O
altered	ADJ	O	O
BBB	PROPN	O	O
and	CCONJ	O	O
secondary	ADJ	O	O
reversal	NOUN	O	O
of	ADP	O	O
osmotic	ADJ	O	O
gradient	NOUN	O	O
is	VERB	O	O
considered	VERB	O	O
the	DET	O	O
major	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
rebound	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
contribution	NOUN	O	O
to	ADP	O	O
this	DET	O	O
issue	NOUN	O	O
we	PRON	O	O
decided	VERB	O	O
to	PART	O	O
research	VERB	O	O
the	DET	O	O
possible	ADJ	O	O
passage	NOUN	O	O
of	ADP	O	O
mannitol	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
to	ADP	O	O
21	NUM	O	O
brain	NOUN	O	B-Entity
tumor	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Mannitol	PROPN	O	I-Entity
(	PUNCT	O	O
18%	NUM	O	O
solution	NOUN	O	O
;	PUNCT	O	O
1	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
as	ADP	O	O
a	DET	O	O
bolus	NOUN	O	O
to	ADP	O	O
patients	NOUN	O	O
(	PUNCT	O	O
ten	NUM	O	O
had	VERB	O	O
malignant	ADJ	O	B-Entity
glioma	NOUN	O	I-Entity
,	PUNCT	O	O

seven	NUM	O	O
brain	NOUN	O	O
metastases	NOUN	O	I-Entity
and	CCONJ	O	O
four	NUM	O	O
meningioma	NOUN	O	I-Entity
)	PUNCT	O	O
about	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
before	ADP	O	O
craniotomy	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
resection	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
sample	NOUN	O	O
of	ADP	O	O
the	DET	O	O
surrounding	VERB	O	O
edematous	ADJ	O	I-Entity
white	ADJ	O	O
matter	NOUN	O	O
was	VERB	O	O
taken	VERB	O	O
at	ADP	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
as	ADP	O	O
a	DET	O	O
10	NUM	O	O
ml	NOUN	O	O
venous	ADJ	O	O
blood	NOUN	O	O
sample	NOUN	O	O
.	PUNCT	O	O

Mannitol	ADJ	O	I-Entity
concentrations	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
white	ADJ	O	O
matter	NOUN	O	O
by	ADP	O	O
a	DET	O	O
modified	VERB	O	O
version	NOUN	O	O
of	ADP	O	O
the	DET	O	O
enzyme	NOUN	O	O
assay	NOUN	O	O
of	ADP	O	O
Blonquist	PROPN	O	O
et	PROPN	O	O
al	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
most	ADJ	O	O
glioma	NOUN	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
mannitol	ADJ	O	I-Entity
concentrations	NOUN	O	O
in	ADP	O	O
white	ADJ	O	O
matter	NOUN	O	O
were	VERB	O	O
2	NUM	O	O
to	ADP	O	O
6	NUM	O	O
times	NOUN	O	O
higher	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
plasma	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
3.5	NUM	O	O
times	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
meningioma	NOUN	O	I-Entity
and	CCONJ	O	O
metastases	NOUN	O	I-Entity
patients	NOUN	O	O
plasma	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
mannitol	NOUN	O	I-Entity
were	VERB	O	O
higher	ADJ	O	O
than	ADP	O	O
white	ADJ	O	O
matter	NOUN	O	O
concentrations	NOUN	O	O
except	ADP	O	O
in	ADP	O	O
three	NUM	O	O
cases	NOUN	O	O
with	ADP	O	O
infiltration	NOUN	O	O
by	ADP	O	O
neoplastic	ADJ	O	O
cells	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
our	ADJ	O	O
study	NOUN	O	O
show	NOUN	O	O
that	ADP	O	O
even	ADV	O	O
after	ADP	O	O
a	DET	O	O
single	ADJ	O	O
bolus	NOUN	O	O
,	PUNCT	O	O
mannitol	NOUN	O	I-Entity
may	VERB	O	O
leak	VERB	O	O
through	ADP	O	O
the	DET	O	O
altered	ADJ	O	O
BBB	PROPN	O	O
near	ADP	O	O
gliomas	NOUN	O	I-Entity
,	PUNCT	O	O
reversing	VERB	O	O
the	DET	O	O
initial	ADJ	O	O
plasma	NOUN	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
blood	NOUN	O	O
osmotic	ADJ	O	O
gradient	NOUN	O	O
,	PUNCT	O	O
aggravating	VERB	O	O
peritumoral	ADJ	O	O
edema	NOUN	O	I-Entity
and	CCONJ	O	O
promoting	VERB	O	O
rebound	NOUN	O	O
of	ADP	O	O
ICP	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (12452237)

Can	VERB	O	O
lidocaine	VERB	O	I-Entity
reduce	VERB	O	O
succinylcholine	NOUN	O	I-Entity
induced	VERB	O	O
postoperative	ADJ	O	B-Entity
myalgia	NOUN	O	I-Entity
?	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
pretreatment	NOUN	O	O
on	ADP	O	O
reduction	NOUN	O	O
of	ADP	O	O
succinylcholine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myalgia	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
for	ADP	O	O
gynecological	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Group	PROPN	O	O
PS	PROPN	O	O
,	PUNCT	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
received	VERB	O	O
normal	ADJ	O	O
saline	ADJ	O	O
and	CCONJ	O	O
succinylcholine	VERB	O	I-Entity
1.5	NUM	O	O
mg	NUM	O	O
x	SYM	O	O
kg(-1	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
Group	PROPN	O	O
LS	PROPN	O	O
,	PUNCT	O	O
lidocaine	VERB	O	I-Entity
1.5	NUM	O	O
mg	NUM	O	O
x	SYM	O	O
kg(-1	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
succinylcholine	VERB	O	I-Entity
1.5	NUM	O	O
mg	NUM	O	O
x	SYM	O	O
kg(-1	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
Group	PROPN	O	O
PR	PROPN	O	O
,	PUNCT	O	O
normal	ADJ	O	O
saline	NOUN	O	O
and	CCONJ	O	O
rocuronium	NOUN	O	I-Entity
0.6	NUM	O	O
mg	NUM	O	O
x	SYM	O	O
kg(-1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Morphine	PROPN	O	I-Entity
0.1	NUM	O	O
mg	NUM	O	O
x	SYM	O	O
kg(-1	NUM	O	O
)	PUNCT	O	O

thiopental	ADJ	O	I-Entity
iv	NOUN	O	O
.	PUNCT	O	O

followed	VERB	O	O
by	ADP	O	O
succinylcholine	NOUN	O	I-Entity
(	PUNCT	O	O
Group	PROPN	O	O
PS	PROPN	O	O
,	PUNCT	O	O
LS	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
rocuronium	NOUN	O	I-Entity
(	PUNCT	O	O
Group	PROPN	O	O
PR	PROPN	O	O
)	PUNCT	O	O
for	ADP	O	O
tracheal	NOUN	O	O
intubation	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
these	DET	O	O
agents	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
presence	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
degree	NOUN	O	O
of	ADP	O	O
fasciculation	NOUN	O	I-Entity
were	VERB	O	O
assessed	VERB	O	O
visually	ADV	O	O
on	ADP	O	O
a	DET	O	O
four	NUM	O	O
point	NOUN	O	O
scale	NOUN	O	O
by	ADP	O	O
one	NUM	O	O
investigator	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
blinded	VERB	O	O
to	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
administered	VERB	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
hours	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
any	DET	O	O
myalgia	NOUN	O	I-Entity
experienced	VERB	O	O
was	VERB	O	O
assessed	VERB	O	O
according	VERB	O	O
to	ADP	O	O
a	DET	O	O
structured	ADJ	O	O
questionaire	NOUN	O	O
and	CCONJ	O	O
graded	VERB	O	O
by	ADP	O	O
a	DET	O	O
four	NUM	O	O
point	NOUN	O	O
scale	NOUN	O	O
by	ADP	O	O
one	NUM	O	O
investigator	NOUN	O	O
blinded	VERB	O	O
to	ADP	O	O
the	DET	O	O
intraoperative	ADJ	O	O
management	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
muscle	NOUN	O	B-Entity
fasciculation	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
found	VERB	O	O
in	ADP	O	O
Group	PROPN	O	O
PR	PROPN	O	O
while	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
Group	PROPN	O	O
LS	PROPN	O	O
had	VERB	O	O
a	DET	O	O
lower	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
muscle	NOUN	O	B-Entity
fasciculation	NOUN	O	I-Entity
than	ADP	O	O
those	DET	O	O
in	ADP	O	O
Group	PROPN	O	O
PS	PROPN	O	O
(	PUNCT	O	O
p	NOUN	O	O

At	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
myalgia	NOUN	O	I-Entity
was	VERB	O	O
higher	ADJ	O	O
in	ADP	O	O
Group	PROPN	O	O
PS	PROPN	O	O
than	ADP	O	O
in	ADP	O	O
Group	PROPN	O	O
LS	PROPN	O	O
and	CCONJ	O	O
PR	PROPN	O	O
(	PUNCT	O	O

A	DET	O	O
correlation	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
found	VERB	O	O
between	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
myalgia	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
muscle	NOUN	O	B-Entity
fasciculation	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
where	ADV	O	O
succinylcholine	NOUN	O	I-Entity
is	VERB	O	O
used	VERB	O	O
,	PUNCT	O	O
lidocaine	NOUN	O	I-Entity
is	VERB	O	O
proven	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
useful	ADJ	O	O
pretreatment	NOUN	O	O
agent	NOUN	O	O
for	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-Entity
myalgia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9564988)

Open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
assessment	NOUN	O	O
of	ADP	O	O
levofloxacin	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
bacterial	ADJ	O	O
sinusitis	NOUN	O	I-Entity
in	ADP	O	O
adults	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
levofloxacin	NOUN	O	I-Entity
(	PUNCT	O	O
500	NUM	O	O
mg	NUM	O	O
orally	ADV	O	O
once	ADV	O	O
daily	ADJ	O	O
for	ADP	O	O
10	NUM	O	O
to	PART	O	O
14	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
treating	VERB	O	O
adult	NOUN	O	O
outpatients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
bacterial	ADJ	O	O
sinusitis	NOUN	O	I-Entity
.	PUNCT	O	O

Adverse	ADJ	O	O
events	NOUN	O	O
considered	VERB	O	O
to	PART	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
levofloxacin	NOUN	O	I-Entity
administration	NOUN	O	O
were	VERB	O	O
reported	VERB	O	O
by	ADP	O	O
29	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
9%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
adverse	ADJ	O	O
events	NOUN	O	O
were	VERB	O	O
diarrhea	NOUN	O	I-Entity
,	PUNCT	O	O
flatulence	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
nausea	NOUN	O	I-Entity
;	PUNCT	O	O
most	ADV	O	O
adverse	ADJ	O	O
events	NOUN	O	O
were	VERB	O	O
mild	ADJ	O	O
to	PART	O	O
moderate	VERB	O	O
in	ADP	O	O
severity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
levofloxacin	NOUN	O	I-Entity
500	NUM	O	O
mg	NUM	O	O
once	ADP	O	O
daily	ADV	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
and	CCONJ	O	O
safe	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
bacterial	ADJ	O	O
sinusitis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7596955)

Clinical	ADJ	O	O
evaluation	NOUN	O	O
on	ADP	O	O
combined	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
prostacyclin	NOUN	O	I-Entity
analogue	NOUN	O	O
beraprost	NOUN	O	I-Entity
and	CCONJ	O	O
phosphodiesterase	NOUN	O	O
inhibitor	NOUN	O	O
cilostazol	NOUN	O	I-Entity
.	PUNCT	O	O

Among	ADP	O	O
various	ADJ	O	O
oral	ADJ	O	O
antiplatelets	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
a	DET	O	O
novel	NOUN	O	O
prostacyclin	NOUN	O	I-Entity
analogue	NOUN	O	O
beraprost	NOUN	O	I-Entity
(	PUNCT	O	O
BPT	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
potent	ADJ	O	O
phosphodiesterase	NOUN	O	O
inhibitor	NOUN	O	O
cilostazol	NOUN	O	I-Entity
(	PUNCT	O	O
CLZ	PROPN	O	I-Entity
)	PUNCT	O	O
may	VERB	O	O
result	VERB	O	O
in	ADP	O	O
untoward	ADJ	O	O
clinical	ADJ	O	O
effects	NOUN	O	O
due	ADP	O	O
to	ADP	O	O
possible	ADJ	O	O
synergistic	ADJ	O	O
elevation	NOUN	O	O
of	ADP	O	O
intracellular	ADJ	O	O
cAMP	NOUN	O	I-Entity
(	PUNCT	O	O
cyclic	ADJ	O	B-Entity
adenosine	NOUN	O	I-Entity
3',5'-monophosphate	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Twelve	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
to	PART	O	O
take	VERB	O	O
BPT	PROPN	O	I-Entity
/	SYM	O	O
CLZ	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
following	VERB	O	O
schedule	NOUN	O	O
;	PUNCT	O	O
BPT	PROPN	O	I-Entity
:	PUNCT	O	O
40	NUM	O	O
micrograms	NOUN	O	O
at	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
120	NUM	O	O
micrograms	NOUN	O	O
t.i.d	NUM	O	O
.	PUNCT	O	O

from	ADP	O	O
day	NOUN	O	O
7	NUM	O	O
to	ADP	O	O
14	NUM	O	O
,	PUNCT	O	O
CLZ	PROPN	O	I-Entity
:	PUNCT	O	O
200	NUM	O	O
mg	NUM	O	O
t.i.d	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
various	ADJ	O	O
time	NOUN	O	O
intervals	NOUN	O	O
,	PUNCT	O	O
physical	ADJ	O	O
examination	NOUN	O	O
and	CCONJ	O	O
blood	NOUN	O	O
collection	NOUN	O	O
for	ADP	O	O
ex	NOUN	O	O
vivo	NOUN	O	O
platelet	NOUN	O	B-Entity
aggregation	NOUN	O	I-Entity
and	CCONJ	O	O
determination	NOUN	O	O
of	ADP	O	O
intraplatelet	NOUN	O	O
cAMP	NOUN	O	I-Entity
were	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

Seven	NUM	O	O
out	ADP	O	O
of	ADP	O	O
12	NUM	O	O
subjects	NOUN	O	O
experienced	ADJ	O	O
headache	NOUN	O	I-Entity
of	ADP	O	O
a	DET	O	O
short	ADJ	O	O
duration	NOUN	O	O
accompanying	VERB	O	O
facial	ADJ	O	B-Entity
flush	NOUN	O	I-Entity
in	ADP	O	O
one	NUM	O	O
and	CCONJ	O	O
nausea	NOUN	O	I-Entity
in	ADP	O	O
one	NUM	O	O
,	PUNCT	O	O
especially	ADV	O	O
after	ADP	O	O
ingestion	NOUN	O	O
of	ADP	O	O
CLZ	PROPN	O	I-Entity
.	PUNCT	O	O

Intraplatelet	PROPN	O	O
cAMP	PROPN	O	I-Entity
content	NOUN	O	O
was	VERB	O	O
gradually	ADV	O	O
but	CCONJ	O	O
significantly	ADV	O	O
increased	VERB	O	O
to	ADP	O	O
9.84	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
combined	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
BPT	PROPN	O	I-Entity
/	SYM	O	O
CLZ	PROPN	O	I-Entity
is	VERB	O	O
safe	ADJ	O	O
at	ADP	O	O
doses	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
though	ADP	O	O
the	DET	O	O
beneficial	ADJ	O	O
clinical	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
combined	ADJ	O	O
administration	NOUN	O	O
has	VERB	O	O
yet	ADV	O	O
to	PART	O	O
be	VERB	O	O
elucidated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (17965424)

Gastrointestinal	ADJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
etoricoxib	NOUN	O	I-Entity
in	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
patients	NOUN	O	O
:	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
etoricoxib	NOUN	O	I-Entity
vs	ADP	O	O
diclofenac	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
gastrointestinal	ADJ	O	O
tolerability	NOUN	O	O
and	CCONJ	O	O
effectiveness	NOUN	O	O
trial	NOUN	O	O
(	PUNCT	O	O
EDGE	PROPN	O	O
-	PUNCT	O	O
II	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
A	DET	O	O
randomised	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
study	NOUN	O	O
to	PART	O	O
compare	VERB	O	O
the	DET	O	O
gastrointestinal	ADJ	O	O
(	PUNCT	O	O
GI	PROPN	O	O
)	PUNCT	O	O
tolerability	NOUN	O	O
,	PUNCT	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
etoricoxib	NOUN	O	I-Entity
and	CCONJ	O	O
diclofenac	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatoid	ADJ	O	B-Entity
arthritis	NOUN	O	I-Entity
(	PUNCT	O	O
RA	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
4086	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
age	NOUN	O	O
60.8	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
diagnosed	VERB	O	O
with	ADP	O	O
RA	PROPN	O	I-Entity
were	VERB	O	O
enrolled	VERB	O	O
and	CCONJ	O	O
received	VERB	O	O
etoricoxib	ADJ	O	I-Entity
90	NUM	O	O
mg	X	O	O
daily	ADV	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
2032	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
diclofenac	NOUN	O	I-Entity
75	NUM	O	O
mg	NUM	O	O
twice	ADV	O	O
daily	ADV	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
2054	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Use	NOUN	O	O
of	ADP	O	O
gastroprotective	ADJ	O	O
agents	NOUN	O	O
and	CCONJ	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
aspirin	NOUN	O	I-Entity
was	VERB	O	O
allowed	VERB	O	O
.	PUNCT	O	O

General	ADJ	O	O
safety	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
assessed	VERB	O	O
,	PUNCT	O	O
including	VERB	O	O
adjudicated	VERB	O	O
thrombotic	ADJ	O	B-Entity
cardiovascular	ADJ	O	I-Entity
event	NOUN	O	O
data	NOUN	O	O
.	PUNCT	O	O

;	PUNCT	O	O
maximum	ADJ	O	O
)	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
was	VERB	O	O
19.3	NUM	O	O
(	PUNCT	O	O
10.3	NUM	O	O
;	PUNCT	O	O
32.9	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
19.1	NUM	O	O
(	PUNCT	O	O
10.4	NUM	O	O
;	PUNCT	O	O
33.1	NUM	O	O
)	PUNCT	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
etoricoxib	NOUN	O	I-Entity
and	CCONJ	O	O
diclofenac	NOUN	O	I-Entity
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
cumulative	ADJ	O	O
discontinuation	NOUN	O	O
rate	NOUN	O	O
due	ADP	O	O
to	ADP	O	O
GI	PROPN	O	B-Entity
AEs	PROPN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
with	ADP	O	O
etoricoxib	NOUN	O	I-Entity
than	ADP	O	O
diclofenac	NOUN	O	I-Entity
(	PUNCT	O	O
5.2	NUM	O	O
vs	ADP	O	O
8.5	NUM	O	O
events	NOUN	O	O
per	ADP	O	O
100	NUM	O	O
patient	ADJ	O	O
-	PUNCT	O	O
years	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
0.62	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	NOUN	O	O
:	PUNCT	O	O
0.47	NUM	O	O
,	PUNCT	O	O
0.81	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
<	X	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
discontinuations	NOUN	O	O
for	ADP	O	O
hypertension	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
and	CCONJ	O	O
oedema	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
AEs	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
with	ADP	O	O
etoricoxib	NOUN	O	I-Entity
(	PUNCT	O	O
2.5%	NUM	O	O
and	CCONJ	O	O
1.1%	NUM	O	O
respectively	ADV	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
diclofenac	NOUN	O	I-Entity
(	PUNCT	O	O
1.5%	NUM	O	O
and	CCONJ	O	O
0.4%	NUM	O	O
respectively	ADV	O	O
;	PUNCT	O	O
p<0.001	NOUN	O	O
for	ADP	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
p<0.01	NOUN	O	O
for	ADP	O	O
oedema	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Etoricoxib	PROPN	O	I-Entity
and	CCONJ	O	O
diclofenac	ADJ	O	I-Entity
treatment	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
similar	ADJ	O	O
efficacy	NOUN	O	O
(	PUNCT	O	O
PGADS	PROPN	O	O
mean	VERB	O	O
changes	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
-0.62	PROPN	O	O
vs	ADP	O	O
-0.58	PROPN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Etoricoxib	PROPN	O	I-Entity
90	NUM	O	O
mg	NUM	O	O
demonstrated	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
lower	ADJ	O	O
risk	NOUN	O	O
for	ADP	O	O
discontinuing	VERB	O	O
treatment	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
GI	PROPN	O	B-Entity
AEs	PROPN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
diclofenac	NOUN	O	I-Entity
150	NUM	O	O
mg	NUM	O	O
.	PUNCT	O	O

Discontinuations	NOUN	O	O
from	ADP	O	O
renovascular	ADJ	O	O
AEs	PROPN	O	O
,	PUNCT	O	O
although	ADP	O	O
less	ADJ	O	O
common	ADJ	O	O
than	ADP	O	O
discontinuations	NOUN	O	O
from	ADP	O	O
GI	PROPN	O	B-Entity
AEs	PROPN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
with	ADP	O	O
etoricoxib	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17042884)

Placebo	PROPN	O	O
-	PUNCT	O	O
level	NOUN	O	O
incidence	NOUN	O	O
of	ADP	O	O
extrapyramidal	NOUN	O	B-Entity
symptoms	NOUN	O	I-Entity
(	PUNCT	O	O
EPS	PROPN	O	I-Entity
)	PUNCT	O	O
with	ADP	O	O
quetiapine	NOUN	O	I-Entity
in	ADP	O	O
controlled	VERB	O	O
studies	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
bipolar	ADJ	O	B-Entity
mania	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
extrapyramidal	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
(	PUNCT	O	O
EPS	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
including	VERB	O	O
akathisia	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
quetiapine	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
bipolar	ADJ	O	B-Entity
mania	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
studies	NOUN	O	O
evaluated	VERB	O	O
quetiapine	NOUN	O	I-Entity
monotherapy	NOUN	O	O
(	PUNCT	O	O
up	ADP	O	O
to	ADP	O	O
800	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
n	VERB	O	O
=	SYM	O	O
209	NUM	O	O
)	PUNCT	O	O
versus	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
198	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
or	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
monotherapy	NOUN	O	O
as	ADP	O	O
respective	ADJ	O	O
active	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
studies	NOUN	O	O
evaluated	VERB	O	O
quetiapine	NOUN	O	I-Entity
(	PUNCT	O	O
up	ADP	O	O
to	ADP	O	O
800	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
a	DET	O	O
mood	NOUN	O	O
stabilizer	NOUN	O	O
(	PUNCT	O	O
lithium	NOUN	O	I-Entity
or	CCONJ	O	O
divalproex	NOUN	O	I-Entity
,	PUNCT	O	O
QTP	PROPN	O	I-Entity

+	PROPN	O	O
Li	PROPN	O	I-Entity
/	PUNCT	O	O
DVP	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
n	VERB	O	O
=	SYM	O	O
196	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
mood	NOUN	O	O
stabilizer	NOUN	O	O
(	PUNCT	O	O
PBO	PROPN	O	O

+	PROPN	O	O
Li	PROPN	O	I-Entity
/	PUNCT	O	O
DVP	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
n	VERB	O	O
=	SYM	O	O
203	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Extrapyramidal	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
were	VERB	O	O
evaluated	VERB	O	O
using	VERB	O	O
the	DET	O	O
Simpson	PROPN	O	O
-	PUNCT	O	O
Angus	PROPN	O	O
Scale	PROPN	O	O
(	PUNCT	O	O
SAS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
Barnes	PROPN	O	O
Akathisia	PROPN	O	O
Rating	PROPN	O	O
Scale	PROPN	O	O
(	PUNCT	O	O
BARS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
adverse	ADJ	O	O
event	NOUN	O	O
reports	NOUN	O	O
and	CCONJ	O	O
anticholinergic	ADJ	O	O
drug	NOUN	O	O
usage	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
EPS	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
adverse	ADJ	O	O
events	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
akathisia	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
no	ADV	O	O
different	ADJ	O	O
with	ADP	O	O
quetiapine	NOUN	O	I-Entity
monotherapy	NOUN	O	O
(	PUNCT	O	O
12.9%	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
13.1%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
EPS	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
adverse	ADJ	O	O
events	NOUN	O	O
with	ADP	O	O
QTP	PROPN	O	I-Entity
+	PROPN	O	O
Li	PROPN	O	I-Entity
/	PUNCT	O	O
DVP	PROPN	O	I-Entity
(	PUNCT	O	O
21.4%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
no	ADV	O	O
different	ADJ	O	O
than	ADP	O	O
with	ADP	O	O
PBO	PROPN	O	O
+	PROPN	O	O
Li	PROPN	O	I-Entity
/	PUNCT	O	O
DVP	PROPN	O	I-Entity
(	PUNCT	O	O
19.2%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
events	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
EPS	PROPN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
59.6%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
haloperidol	NOUN	O	I-Entity
(	PUNCT	O	O

n	CCONJ	O	O
=	SYM	O	O
99	NUM	O	O
)	PUNCT	O	O
monotherapy	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
26.5%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
(	PUNCT	O	O

n	CCONJ	O	O
=	SYM	O	O
98	NUM	O	O
)	PUNCT	O	O
monotherapy	NOUN	O	O
experienced	VERB	O	O
adverse	ADJ	O	O
events	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
EPS	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
akathisia	NOUN	O	I-Entity
was	VERB	O	O
low	ADJ	O	O
and	CCONJ	O	O
similar	ADJ	O	O
with	ADP	O	O
quetiapine	NOUN	O	I-Entity
monotherapy	NOUN	O	O
(	PUNCT	O	O
3.3%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
6.1%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
with	ADP	O	O
QTP	PROPN	O	I-Entity
+	PROPN	O	O
Li	PROPN	O	I-Entity
/	PUNCT	O	O
DVP	PROPN	O	I-Entity
(	PUNCT	O	O
3.6%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
PBO	PROPN	O	O
+	PROPN	O	O
Li	PROPN	O	I-Entity
/	PUNCT	O	O
DVP	PROPN	O	I-Entity
(	PUNCT	O	O
4.9%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Lithium	PROPN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
significantly	ADV	O	O
higher	ADJ	O	O
incidence	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
tremor	NOUN	O	I-Entity
(	PUNCT	O	O
18.4%	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
quetiapine	NOUN	O	I-Entity
(	PUNCT	O	O
5.6%	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
cerebellar	ADJ	O	O
tremor	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
a	DET	O	O
known	VERB	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
,	PUNCT	O	O
may	VERB	O	O
have	VERB	O	O
contributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
elevated	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
tremor	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Haloperidol	PROPN	O	I-Entity
induced	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
higher	ADJ	O	O
incidence	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O

<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
akathisia	NOUN	O	I-Entity
(	PUNCT	O	O
33.3%	NUM	O	O
versus	ADP	O	O
5.9%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
tremor	NOUN	O	I-Entity
(	PUNCT	O	O
30.3%	NUM	O	O
versus	NOUN	O	O
7.8%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
extrapyramidal	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
35.4%	NUM	O	O
versus	ADP	O	O
5.9%	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
quetiapine	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
quetiapine	NOUN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
on	ADP	O	O
SAS	PROPN	O	O
and	CCONJ	O	O
BARS	PROPN	O	O
scores	NOUN	O	O
.	PUNCT	O	O

Anticholinergic	ADJ	O	O
use	NOUN	O	O
was	VERB	O	O
low	ADJ	O	O
and	CCONJ	O	O
similar	ADJ	O	O
with	ADP	O	O
quetiapine	NOUN	O	I-Entity
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
bipolar	ADJ	O	B-Entity
mania	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
EPS	PROPN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
akathisia	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
quetiapine	NOUN	O	I-Entity
therapy	NOUN	O	O
is	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8586822)

Contribution	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sympathetic	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
to	ADP	O	O
salt	NOUN	O	O
-	PUNCT	O	O
sensitivity	NOUN	O	O
in	ADP	O	O
lifetime	NOUN	O	O
captopril	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
test	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
,	PUNCT	O	O
in	ADP	O	O
lifetime	NOUN	O	O
captopril	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
(	PUNCT	O	O
SHR	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
sympathetic	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
contributes	VERB	O	O
importantly	ADV	O	O
to	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
dietary	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
chloride	NOUN	O	I-Entity
supplementation	NOUN	O	O
.	PUNCT	O	O

Male	NOUN	O	O
SHR	NOUN	O	O
(	PUNCT	O	O
aged	ADJ	O	O
6	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
that	ADJ	O	O
had	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
from	ADP	O	O
conception	NOUN	O	O
onward	ADV	O	O
with	ADP	O	O
either	CCONJ	O	O
captopril	NOUN	O	I-Entity
or	CCONJ	O	O
vehicle	NOUN	O	O
remained	VERB	O	O
on	ADP	O	O
a	DET	O	O
basal	ADJ	O	O
sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
diet	NOUN	O	O
or	CCONJ	O	O
were	VERB	O	O
fed	VERB	O	O
a	DET	O	O
high	ADJ	O	O
sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
diet	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
rats	NOUN	O	O
were	VERB	O	O
subjected	VERB	O	O
to	ADP	O	O
ganglionic	VERB	O	O
blockade	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
days	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
an	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
.	PUNCT	O	O

Lifetime	PROPN	O	O
captopril	NOUN	O	I-Entity
treatment	NOUN	O	O
significantly	ADV	O	O
lowered	VERB	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ganglionic	ADJ	O	O
blocker	NOUN	O	O
hexamethonium	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
rapid	ADJ	O	O
decline	NOUN	O	O
in	ADP	O	O
MAP	PROPN	O	O
that	ADJ	O	O
eliminated	VERB	O	O
the	DET	O	O
dietary	ADJ	O	B-Entity
sodium	NOUN	O	I-Entity
chloride	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increase	NOUN	O	B-Entity
in	ADP	O	I-Entity
MAP	PROPN	O	I-Entity
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Infusion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
alpha2-adrenergic	ADJ	O	B-Entity
receptor	NOUN	O	I-Entity
agonist	NOUN	O	I-Entity
clonidine	NOUN	O	I-Entity
also	ADV	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
greater	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
MAP	PROPN	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
of	ADP	O	O
SHR	PROPN	O	O
that	ADJ	O	O
were	VERB	O	O
fed	VERB	O	O
the	DET	O	O
high	ADJ	O	O
(	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
basal	NOUN	O	O
)	PUNCT	O	O
sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
diet	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
both	DET	O	O
lifetime	NOUN	O	O
captopril	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
and	CCONJ	O	O
control	NOUN	O	O

SHR	PROPN	O	O
,	PUNCT	O	O
the	DET	O	O
sympathetic	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
contributes	VERB	O	O
to	ADP	O	O
the	DET	O	O
pressor	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
high	ADJ	O	O
sodium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
diet	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3961813)

Dose	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
beneficial	ADJ	O	O
and	CCONJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
dietary	ADJ	O	O
corticosterone	NOUN	O	I-Entity
on	ADP	O	O
organophosphorus	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
delayed	VERB	O	O
neuropathy	NOUN	O	I-Entity
in	ADP	O	O
chickens	NOUN	O	O
.	PUNCT	O	O

Tri	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
ortho	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
tolyl	ADJ	O	I-Entity
phosphate	NOUN	O	I-Entity
(	PUNCT	O	O
TOTP	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
360	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
po	INTJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
0,0'-diisopropyl	NUM	O	B-Entity
phosphorofluoridate	NOUN	O	I-Entity
(	PUNCT	O	O
DFP	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
1	NUM	O	O
mg	INTJ	O	O
/	SYM	O	O
kg	X	O	O
sc	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
adult	NOUN	O	O
White	PROPN	O	O
Leghorn	PROPN	O	O
chickens	VERB	O	O
24	NUM	O	O
hr	NOUN	O	O
after	ADP	O	O
they	PRON	O	O
were	VERB	O	O
placed	VERB	O	O
on	ADP	O	O
diets	NOUN	O	O
containing	VERB	O	O
0	NUM	O	O
to	ADP	O	O
300	NUM	O	O
ppm	NOUN	O	O
corticosterone	NOUN	O	I-Entity
.	PUNCT	O	O

Supplemented	VERB	O	O
diets	NOUN	O	O
were	VERB	O	O
continued	VERB	O	O
until	ADP	O	O
clinical	ADJ	O	O
signs	NOUN	O	O
and	CCONJ	O	O
lesions	NOUN	O	O
of	ADP	O	O
delayed	VERB	O	O
neuropathy	NOUN	O	I-Entity
appeared	VERB	O	O
.	PUNCT	O	O

Although	ADP	O	O
low	ADJ	O	O
concentrations	NOUN	O	O
(	PUNCT	O	O
less	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
50	NUM	O	O
ppm	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
corticosterone	NOUN	O	I-Entity
had	VERB	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
TOTP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neuropathy	NOUN	O	I-Entity
,	PUNCT	O	O
greater	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
200	NUM	O	O
ppm	ADV	O	O
exacerbated	ADJ	O	O
clinical	ADJ	O	O
signs	NOUN	O	O
in	ADP	O	O
chickens	NOUN	O	O
given	VERB	O	O
either	CCONJ	O	O
TOTP	PROPN	O	I-Entity
or	CCONJ	O	O
DFP	PROPN	O	I-Entity
.	PUNCT	O	O

Neurotoxic	ADJ	O	I-Entity
esterase	NOUN	O	O
activities	NOUN	O	O
24	NUM	O	O
hr	NOUN	O	O
after	ADP	O	O
TOTP	PROPN	O	I-Entity
or	CCONJ	O	O
DFP	PROPN	O	I-Entity
were	VERB	O	O
less	ADJ	O	O
than	ADP	O	O
20%	NUM	O	O
of	ADP	O	O
values	NOUN	O	O
measured	VERB	O	O
in	ADP	O	O
chickens	NOUN	O	O
not	ADV	O	O
given	VERB	O	O
organophosphorous	ADJ	O	I-Entity
compounds	NOUN	O	O
.	PUNCT	O	O

corticosterone	NOUN	O	I-Entity
without	ADP	O	O
TOTP	PROPN	O	I-Entity
or	CCONJ	O	O
DFP	PROPN	O	I-Entity
had	VERB	O	O
significantly	ADV	O	O
elevated	VERB	O	O
activity	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
cholinesterase	NOUN	O	O
and	CCONJ	O	O
significantly	ADV	O	O
inhibited	VERB	O	O
activity	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	O
carboxylesterase	NOUN	O	O
.	PUNCT	O	O

Degenerating	VERB	O	B-Entity
myelinated	VERB	O	I-Entity
fibers	NOUN	O	I-Entity
were	VERB	O	O
also	ADV	O	O
evident	ADJ	O	O
in	ADP	O	O
distal	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
nerves	NOUN	O	O
of	ADP	O	O
chickens	NOUN	O	O
given	VERB	O	O
TOTP	PROPN	O	I-Entity
or	CCONJ	O	O
DFP	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20973483)

In	ADP	O	O
vivo	ADJ	O	O
characterization	NOUN	O	O
of	ADP	O	O
a	DET	O	O
dual	ADJ	O	O
adenosine	NOUN	O	B-Entity
A2A	PROPN	O	I-Entity
/	SYM	O	I-Entity
A1	PROPN	O	I-Entity
receptor	NOUN	O	I-Entity
antagonist	NOUN	O	I-Entity
in	ADP	O	O
animal	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
in	ADP	O	O
vivo	ADJ	O	O
characterization	NOUN	O	O
of	ADP	O	O
a	DET	O	O
dual	ADJ	O	O
adenosine	NOUN	O	B-Entity
A(2A)/A(1	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
receptor	NOUN	O	I-Entity
antagonist	NOUN	O	I-Entity
in	ADP	O	O
several	ADJ	O	O
animal	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
is	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

nM	PUNCT	O	O
)	PUNCT	O	O
that	ADJ	O	O
has	VERB	O	O
excellent	ADJ	O	O
activity	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
oral	ADJ	O	O
administration	NOUN	O	O
,	PUNCT	O	O
across	ADP	O	O
a	DET	O	O
number	NOUN	O	O
of	ADP	O	O
animal	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
including	VERB	O	O
mouse	NOUN	O	O
and	CCONJ	O	O
rat	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
,	PUNCT	O	O
mouse	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
reserpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
akinesia	NOUN	O	I-Entity
,	PUNCT	O	O
rat	NOUN	O	O
6-hydroxydopamine	NUM	O	I-Entity
(	PUNCT	O	O
6-OHDA	NUM	O	I-Entity
)	PUNCT	O	O
lesion	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
rotation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
MPTP	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
non	ADJ	O	O
-	PUNCT	O	O
human	ADJ	O	O
primate	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17511042)

An	DET	O	O
extremely	ADV	O	O
rare	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
delusional	ADJ	O	B-Entity
parasitosis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
C	NOUN	O	I-Entity
patient	NOUN	O	O
during	ADP	O	O
pegylated	ADJ	O	B-Entity
interferon	NOUN	O	I-Entity
alpha-2b	X	O	I-Entity
and	CCONJ	O	O
ribavirin	VERB	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
C	NOUN	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
interferon	NOUN	O	O
and	CCONJ	O	O
ribavirin	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
lot	NOUN	O	O
of	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
are	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
three	NUM	O	O
percent	NOUN	O	O
to	ADP	O	O
44%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
develop	VERB	O	O
depression	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
minority	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
evolve	VERB	O	O
to	ADP	O	O
psychosis	NOUN	O	I-Entity
.	PUNCT	O	O

To	ADP	O	O
the	DET	O	O
best	ADJ	O	O
of	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
psychogenic	ADJ	O	B-Entity
parasitosis	NOUN	O	I-Entity
occurring	VERB	O	O
during	ADP	O	O
interferon	NOUN	O	O
therapy	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
described	VERB	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
present	VERB	O	O
a	DET	O	O
49-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
delusional	ADJ	O	B-Entity
parasitosis	NOUN	O	I-Entity
during	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
pegylated	ADJ	O	B-Entity
interferon	NOUN	O	I-Entity
alpha-2b	X	O	I-Entity
weekly	ADJ	O	O
and	CCONJ	O	O
ribavirin	NOUN	O	I-Entity
.	PUNCT	O	O

All	ADJ	O	O
the	DET	O	O
complaints	NOUN	O	O
disappeared	VERB	O	O
after	ADP	O	O
stopping	VERB	O	O
pegylated	ADJ	O	B-Entity
interferon	NOUN	O	I-Entity
alpha-2b	X	O	I-Entity
and	CCONJ	O	O
reappeared	VERB	O	O
after	ADP	O	O
restarting	VERB	O	O
it	PRON	O	O
.	PUNCT	O	O


-DOCSTART- (16720068)

Possible	ADJ	O	O
neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
concomitant	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
paroxetine	NOUN	O	I-Entity
and	CCONJ	O	O
alprazolam	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
74-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
depressive	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
was	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
a	DET	O	O
psychiatric	ADJ	O	I-Entity
hospital	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
insomnia	NOUN	O	I-Entity
,	PUNCT	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
appetite	NOUN	O	I-Entity
,	PUNCT	O	O
exhaustion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
agitation	NOUN	O	I-Entity
.	PUNCT	O	O

Medical	ADJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
initiated	VERB	O	O
at	ADP	O	O
a	DET	O	O
daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
mg	NUM	O	O
paroxetine	NOUN	O	I-Entity
and	CCONJ	O	O
1.2	NUM	O	O
mg	NUM	O	O
alprazolam	NOUN	O	I-Entity
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
10th	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
paroxetine	NOUN	O	I-Entity
and	CCONJ	O	O
alprazolam	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
exhibited	VERB	O	O
marked	ADJ	O	O
psychomotor	NOUN	O	B-Entity
retardation	NOUN	O	I-Entity
,	PUNCT	O	O
disorientation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
severe	ADJ	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
with	ADP	O	O
tremors	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
a	DET	O	O
fever	NOUN	O	I-Entity
(	PUNCT	O	O
38.2	NUM	O	O
degrees	NOUN	O	O
C	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
fluctuating	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
between	ADP	O	O
165/90	NUM	O	O
and	CCONJ	O	O
130/70	NUM	O	O
mg	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
severe	ADJ	O	O
extrapyramidal	NOUN	O	B-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O

Laboratory	ADJ	O	O
tests	NOUN	O	O
showed	VERB	O	O
an	DET	O	O
elevation	NOUN	O	O
of	ADP	O	O
creatine	NOUN	O	I-Entity
phosphokinase	NOUN	O	O
(	PUNCT	O	O
2218	NUM	O	O
IU	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
aspartate	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
(	PUNCT	O	O
134	NUM	O	O
IU	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
alanine	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
(	PUNCT	O	O
78	NUM	O	O
IU	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
BUN	PROPN	O	O
(	PUNCT	O	O
27.9	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
received	VERB	O	O
bromocriptine	NOUN	O	I-Entity
and	CCONJ	O	O
diazepam	NOUN	O	I-Entity
to	PART	O	O
treat	VERB	O	O
his	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

7	NUM	O	O
days	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
fever	NOUN	O	I-Entity
disappeared	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
serum	NOUN	O	O
CPK	PROPN	O	O
levels	NOUN	O	O
were	VERB	O	O
normalized	ADJ	O	O
(	PUNCT	O	O
175	NUM	O	O
IU	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
patient	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
symptoms	NOUN	O	O
of	ADP	O	O
neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
NMS	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
thus	ADV	O	O
demonstrating	VERB	O	O
that	ADP	O	O
NMS	PROPN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
symptoms	NOUN	O	O
can	VERB	O	O
occur	VERB	O	O
after	ADP	O	O
combined	VERB	O	O
paroxetine	NOUN	O	I-Entity
and	CCONJ	O	O
alprazolam	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
reaction	NOUN	O	O
score	NOUN	O	O
obtained	VERB	O	O
by	ADP	O	O
the	DET	O	O
Naranjo	PROPN	O	O
algorithm	NOUN	O	O
was	VERB	O	O
6	NUM	O	O
in	ADP	O	O
our	ADJ	O	O
case	NOUN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
a	DET	O	O
probable	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
NMS	PROPN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
adverse	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
combined	ADJ	O	O
treatment	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
this	DET	O	O
case	NOUN	O	O
.	PUNCT	O	O

Several	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
NMS	PROPN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
elderly	ADJ	O	O
depressive	ADJ	O	I-Entity
patients	NOUN	O	O
whose	ADJ	O	O
symptoms	NOUN	O	O
often	ADV	O	O
include	VERB	O	O
dehydration	NOUN	O	I-Entity
,	PUNCT	O	O
agitation	NOUN	O	I-Entity
,	PUNCT	O	O
malnutrition	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
exhaustion	NOUN	O	O
.	PUNCT	O	O

Careful	ADJ	O	O
therapeutic	ADJ	O	O
intervention	NOUN	O	O
is	VERB	O	O
necessary	ADJ	O	O
in	ADP	O	O
cases	NOUN	O	O
involving	VERB	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
suffer	VERB	O	O
from	ADP	O	O
depression	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16596970)

Pilocarpine	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
cause	VERB	O	O
age	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
impairment	NOUN	O	B-Entity
in	ADP	O	I-Entity
auditory	ADJ	O	I-Entity
location	NOUN	O	I-Entity
discrimination	NOUN	O	I-Entity
.	PUNCT	O	O

Children	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
have	VERB	O	O
continuous	ADJ	O	O
or	CCONJ	O	O
rapidly	ADV	O	O
repeating	VERB	O	O
seizures	NOUN	O	I-Entity
that	ADJ	O	O
may	VERB	O	O
be	VERB	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
and	CCONJ	O	O
may	VERB	O	O
cause	VERB	O	O
life	NOUN	O	O
-	PUNCT	O	O
long	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
brain	NOUN	O	O
and	CCONJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
extent	NOUN	O	O
to	ADP	O	O
which	ADJ	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
causes	VERB	O	O
deficits	NOUN	O	B-Entity
in	ADP	O	I-Entity
auditory	ADJ	O	I-Entity
discrimination	NOUN	O	I-Entity
is	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

A	DET	O	O
naturalistic	ADJ	O	O
auditory	ADJ	O	O
location	NOUN	O	O
discrimination	NOUN	O	O
method	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
this	DET	O	O
question	NOUN	O	O
using	VERB	O	O
an	DET	O	O
animal	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
.	PUNCT	O	O

Male	PROPN	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
injected	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
on	ADP	O	O
postnatal	ADJ	O	O
day	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
)	PUNCT	O	O
20	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
convulsant	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
on	ADP	O	O
P20	PROPN	O	O
or	CCONJ	O	O
P45	PROPN	O	O
.	PUNCT	O	O

Pilocarpine	NOUN	O	I-Entity
on	ADP	O	O
either	DET	O	O
day	NOUN	O	O
induced	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
;	PUNCT	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
at	ADP	O	O
P45	PROPN	O	O
resulted	VERB	O	O
in	ADP	O	O
CA3	PROPN	O	O
cell	NOUN	O	O
loss	NOUN	O	O
and	CCONJ	O	O
spontaneous	ADJ	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
P20	PROPN	O	O
rats	NOUN	O	O
had	VERB	O	O
no	DET	O	O
cell	NOUN	O	O
loss	NOUN	O	O
or	CCONJ	O	O
spontaneous	ADJ	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
(	PUNCT	O	O
P20	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
,	PUNCT	O	O
acquisition	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sound	NOUN	O	O
-	PUNCT	O	O
source	NOUN	O	O
location	NOUN	O	O
discrimination	NOUN	O	O
was	VERB	O	O
moderately	ADV	O	O
impaired	VERB	O	O
.	PUNCT	O	O

Status	PROPN	O	B-Entity
epilepticus	NOUN	O	I-Entity
(	PUNCT	O	O
P45	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
acquire	VERB	O	O
either	CCONJ	O	O
sound	VERB	O	O
-	PUNCT	O	O
source	NOUN	O	O
location	NOUN	O	O
or	CCONJ	O	O
sound	NOUN	O	O
-	PUNCT	O	O
silence	NOUN	O	O
discriminations	NOUN	O	O
.	PUNCT	O	O

Status	PROPN	O	B-Entity
epilepticus	NOUN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
causes	VERB	O	O
an	DET	O	O
age	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
,	PUNCT	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
impairment	NOUN	O	B-Entity
in	ADP	O	I-Entity
auditory	ADJ	O	I-Entity
discrimination	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
impairment	NOUN	O	O
may	VERB	O	O
explain	VERB	O	O
one	NUM	O	O
cause	NOUN	O	O
of	ADP	O	O
impaired	ADJ	O	B-Entity
auditory	ADJ	O	I-Entity
location	NOUN	O	I-Entity
discrimination	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16586083)

Cardiovascular	ADJ	O	O
risk	NOUN	O	O
with	ADP	O	O
cyclooxygenase	NOUN	O	B-Entity
inhibitors	NOUN	O	I-Entity
:	PUNCT	O	O
general	ADJ	O	O
problem	NOUN	O	O
with	ADP	O	O
substance	NOUN	O	O
specific	ADJ	O	O
differences	NOUN	O	O
?	PUNCT	O	O

Randomised	VERB	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
and	CCONJ	O	O
observational	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
shown	VERB	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
,	PUNCT	O	O
stroke	NOUN	O	I-Entity
,	PUNCT	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
during	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
cyclooxygenase	NOUN	O	B-Entity
inhibitors	NOUN	O	I-Entity
.	PUNCT	O	O

Cyclooxygenase	ADJ	O	B-Entity
inhibitors	NOUN	O	I-Entity
cause	VERB	O	O
complex	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
,	PUNCT	O	O
vascular	ADJ	O	O
and	CCONJ	O	O
cardiac	ADJ	O	O
prostanoid	NOUN	O	O
profiles	NOUN	O	O
thereby	ADV	O	O
increasing	VERB	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
and	CCONJ	O	O
fluid	ADJ	O	O
retention	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
individual	ADJ	O	O
selective	ADJ	O	O
and	CCONJ	O	O
unselective	ADJ	O	O
cyclooxygenase	NOUN	O	B-Entity
inhibitors	NOUN	O	I-Entity
suggests	VERB	O	O
substance	NOUN	O	O
-	PUNCT	O	O
specific	ADJ	O	O
differences	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
depend	VERB	O	O
on	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
pharmacokinetic	ADJ	O	O
parameters	NOUN	O	O
or	CCONJ	O	O
inhibitory	ADJ	O	O
potency	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
contributed	VERB	O	O
by	ADP	O	O
prostaglandin	NOUN	O	I-Entity
-	PUNCT	O	O
independent	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Diagnostic	ADJ	O	O
markers	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
terminal	ADJ	O	I-Entity
pro	ADJ	O	I-Entity
brain	NOUN	O	I-Entity
natriuretic	ADJ	O	I-Entity
peptide	NOUN	O	I-Entity
(	PUNCT	O	O
NT	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
proBNP	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
sensitive	ADJ	O	O
C	PROPN	O	O
-	PUNCT	O	O
reactive	ADJ	O	O
protein	NOUN	O	O
might	VERB	O	O
help	VERB	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
identification	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
,	PUNCT	O	O
thus	ADV	O	O
avoiding	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
serious	ADJ	O	O
cardiovascular	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10539815)

Predictors	NOUN	O	O
of	ADP	O	O
decreased	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
during	ADP	O	O
angiotensin	NOUN	O	I-Entity
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
therapy	NOUN	O	O
:	PUNCT	O	O
results	NOUN	O	O
from	ADP	O	O
the	DET	O	O
studies	NOUN	O	O
of	ADP	O	O
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
(	PUNCT	O	O
SOLVD	PROPN	O	O
)	PUNCT	O	O
BACKGROUND	NOUN	O	O
:	PUNCT	O	O

Although	ADP	O	O
angiotensin	NOUN	O	I-Entity
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
therapy	NOUN	O	O
reduces	VERB	O	O
mortality	NOUN	O	O
rates	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
CHF	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
it	PRON	O	O
may	VERB	O	O
also	ADV	O	O
cause	VERB	O	O
decreased	VERB	O	B-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
quantify	VERB	O	O
specific	ADJ	O	O
clinical	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
reduction	NOUN	O	B-Entity
in	ADP	O	I-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
CHF	PROPN	O	I-Entity
who	NOUN	O	O
are	VERB	O	O
prescribed	VERB	O	O
angiotensin	NOUN	O	I-Entity
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
analyzed	VERB	O	O
data	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Studies	PROPN	O	O
of	ADP	O	O
Left	PROPN	O	B-Entity
Ventricular	PROPN	O	I-Entity
Dysfunction	PROPN	O	I-Entity
(	PUNCT	O	O
SOLVD	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
enalapril	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
CHF	PROPN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
3379	NUM	O	O
patients	NOUN	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
enalapril	VERB	O	I-Entity
with	ADP	O	O
a	DET	O	O
median	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
of	ADP	O	O
974	NUM	O	O
days	NOUN	O	O
and	CCONJ	O	O
3379	NUM	O	O
patients	NOUN	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
with	ADP	O	O
a	DET	O	O
mean	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
of	ADP	O	O
967	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Decreased	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
a	DET	O	O
rise	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
>	X	O	O
/=0.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
(	PUNCT	O	O
44	NUM	O	O
micromol	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
from	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
used	VERB	O	O
time	NOUN	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
event	NOUN	O	O
analysis	NOUN	O	O
to	PART	O	O
identify	VERB	O	O
potential	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
decrease	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
including	VERB	O	O
age	NOUN	O	O
,	PUNCT	O	O
baseline	NOUN	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
,	PUNCT	O	O
baseline	NOUN	O	O
creatinine	NOUN	O	I-Entity
,	PUNCT	O	O
low	ADJ	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
<	SYM	O	O
100	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
history	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
diabetes	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
use	NOUN	O	O
of	ADP	O	O
antiplatelet	NOUN	O	O
,	PUNCT	O	O
diuretic	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocker	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
enalapril	NOUN	O	I-Entity
had	VERB	O	O
a	DET	O	O
33%	NUM	O	O
greater	ADJ	O	O
likelihood	NOUN	O	O
of	ADP	O	O
decreased	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
than	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.003	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

By	ADP	O	O
multivariate	ADJ	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
enalapril	NOUN	O	I-Entity
groups	NOUN	O	O
older	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
diuretic	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
diabetes	NOUN	O	I-Entity
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
decreased	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocker	NOUN	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
higher	ADJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
were	VERB	O	O
renoprotective	NOUN	O	O
.	PUNCT	O	O

Older	ADJ	O	O
age	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
greater	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
decreased	VERB	O	B-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
significantly	ADV	O	O
more	ADV	O	O
so	ADV	O	O
in	ADP	O	O
the	DET	O	O
enalapril	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
enalapril	NOUN	O	I-Entity
:	PUNCT	O	O
risk	NOUN	O	O
ratio	NOUN	O	O
[	PUNCT	O	O
RR	NOUN	O	O
]	PUNCT	O	O
1.42	NUM	O	O
per	ADP	O	O
10	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
[	PUNCT	O	O
CI	PROPN	O	O
]	PUNCT	O	O
1.32	NUM	O	O
-	SYM	O	O
1.52	NUM	O	O
with	ADP	O	O
enalapril	NOUN	O	I-Entity
;	PUNCT	O	O
placebo	NOUN	O	O
:	PUNCT	O	O
RR	NOUN	O	O
1.18	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.12	NUM	O	O
-	SYM	O	O
1.25	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Diuretic	NOUN	O	I-Entity
therapy	NOUN	O	O
was	VERB	O	O
likewise	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
greater	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
decreased	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
enalapril	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
RR	PROPN	O	O
1.89	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.70	NUM	O	O
-	SYM	O	O
2.08	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
RR	PROPN	O	O
1.35	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.09	NUM	O	O
-	SYM	O	O
1.66	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Conversely	ADV	O	O
,	PUNCT	O	O
enalapril	NOUN	O	I-Entity
had	VERB	O	O
a	DET	O	O
relative	ADJ	O	O
renoprotective	ADJ	O	O
effect	NOUN	O	O
(	PUNCT	O	O
RR	PROPN	O	O
1.33	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.13	NUM	O	O
-	SYM	O	O
1.53	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
RR	PROPN	O	O
1.96	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.57	NUM	O	O
-	SYM	O	O
2.44	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
lower	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
with	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocker	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
RR	PROPN	O	O
0.70	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.57	NUM	O	O
-	SYM	O	O
0.85	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
higher	ADJ	O	O
baseline	NOUN	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
(	PUNCT	O	O
RR	PROPN	O	O
0.93	NUM	O	O
per	ADP	O	O
5%	NUM	O	O
increment	NOUN	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.91	NUM	O	O
-	SYM	O	O
0	NUM	O	O
.	PUNCT	O	O

Enalapril	PROPN	O	I-Entity
use	NOUN	O	O
caused	VERB	O	O
a	DET	O	O
33%	NUM	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
decreased	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
CHF	PROPN	O	I-Entity
.	PUNCT	O	O

Diuretic	ADJ	O	I-Entity
use	NOUN	O	O
and	CCONJ	O	O
advanced	ADJ	O	O
age	NOUN	O	O
increased	VERB	O	O
this	DET	O	O
risk	NOUN	O	O
.	PUNCT	O	O

Diabetes	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
CHF	PROPN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
this	DET	O	O
risk	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
the	DET	O	O
enalapril	NOUN	O	I-Entity
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9022662)

Pemoline	PROPN	O	I-Entity
induced	VERB	O	O
acute	ADJ	O	O
choreoathetosis	NOUN	O	I-Entity
:	PUNCT	O	O
case	NOUN	O	O
report	NOUN	O	O
and	CCONJ	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

Pemoline	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
oxazolidine	ADJ	O	I-Entity
derivative	ADJ	O	O
that	DET	O	O
is	VERB	O	O
structurally	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
amphetamines	NOUN	O	I-Entity
and	CCONJ	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
attention	NOUN	O	B-Entity
deficit	NOUN	O	I-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

Pemoline	NOUN	O	I-Entity
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
commonly	ADV	O	O
associated	VERB	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
as	ADP	O	O
a	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
movement	NOUN	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
following	VERB	O	O
case	NOUN	O	O
describes	VERB	O	O
two	NUM	O	O
children	NOUN	O	O
acutely	ADV	O	O
poisoned	VERB	O	O
with	ADP	O	O
pemoline	NOUN	O	I-Entity
who	NOUN	O	O
experienced	VERB	O	O
profound	ADJ	O	O
choreoathetosis	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
,	PUNCT	O	O
3-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	NOUN	O	O
,	PUNCT	O	O
identical	ADJ	O	O
twin	ADJ	O	O
siblings	NOUN	O	O
presented	VERB	O	O
to	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
after	ADP	O	O
found	VERB	O	O
playing	VERB	O	O
with	ADP	O	O
a	DET	O	O
an	DET	O	O
empty	ADJ	O	O
bottle	NOUN	O	O
of	ADP	O	O
pemoline	NOUN	O	I-Entity
originally	ADV	O	O
containing	VERB	O	O
59	NUM	O	O
tablets	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
children	NOUN	O	O
had	VERB	O	O
a	DET	O	O
medical	ADJ	O	O
history	NOUN	O	O
significant	ADJ	O	O
for	ADP	O	O
attention	NOUN	O	B-Entity
deficit	NOUN	O	I-Entity
disorder	NOUN	O	I-Entity
previously	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
methylphenidate	NOUN	O	I-Entity
without	ADP	O	O
success	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
their	ADJ	O	O
first	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
pemoline	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
choreoathetoid	ADJ	O	I-Entity
movements	NOUN	O	O
began	VERB	O	O
45	NUM	O	O
min	NOUN	O	O
to	ADP	O	O
1	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
ingestion	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
children	NOUN	O	O
gave	VERB	O	O
no	DET	O	O
history	NOUN	O	O
of	ADP	O	O
prior	ADJ	O	O
movement	NOUN	O	B-Entity
disorders	NOUN	O	I-Entity
and	CCONJ	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
family	NOUN	O	O
history	NOUN	O	O
of	ADP	O	O
movement	NOUN	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
children	NOUN	O	O
received	VERB	O	O
gastrointestinal	ADJ	O	O
decontamination	NOUN	O	O
and	CCONJ	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
benzodiazepines	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
attempt	NOUN	O	O
to	PART	O	O
control	VERB	O	O
the	DET	O	O
choreoathetoid	ADJ	O	I-Entity
movements	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
children	NOUN	O	O
continued	VERB	O	O
to	PART	O	O
have	VERB	O	O
choreoathetosis	NOUN	O	I-Entity
for	ADP	O	O
approximately	ADV	O	O
24	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

Pemoline	PROPN	O	I-Entity
associated	ADJ	O	O
movement	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
rarely	ADV	O	O
reported	VERB	O	O
in	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
toxicology	NOUN	O	O
literature	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
choreoathetoid	ADJ	O	I-Entity
movements	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
presenting	VERB	O	O
after	ADP	O	O
pemoline	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8677458)

Continuous	PROPN	O	O
subcutaneous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
mesna	NOUN	O	I-Entity
to	PART	O	O
prevent	VERB	O	O
ifosfamide	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

Hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
potential	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
that	ADJ	O	O
can	VERB	O	O
be	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
administering	VERB	O	O
mesna	NOUN	O	I-Entity
along	ADP	O	O
with	ADP	O	O
the	DET	O	O
cytotoxic	ADJ	O	O
agent	NOUN	O	O
.	PUNCT	O	O

Mesna	PROPN	O	I-Entity
is	VERB	O	O
generally	ADV	O	O
administered	VERB	O	O
by	ADP	O	O
the	DET	O	O
intravenous	ADJ	O	O
route	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
experience	NOUN	O	O
with	ADP	O	O
oral	ADJ	O	O
delivery	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
has	VERB	O	O
increased	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
continuous	ADJ	O	O
subcutaneous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
mesna	NOUN	O	I-Entity
has	VERB	O	O
the	DET	O	O
advantage	NOUN	O	O
of	ADP	O	O
not	ADV	O	O
requiring	VERB	O	O
intravenous	ADJ	O	O
access	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
subcutaneous	ADJ	O	O
delivery	NOUN	O	O
of	ADP	O	O
the	DET	O	O
neutralizing	VERB	O	O
agent	NOUN	O	O
will	VERB	O	O
not	ADV	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
inadequate	ADJ	O	O
urinary	ADJ	O	O
mesna	NOUN	O	I-Entity
concentrations	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
taking	VERB	O	O
oral	ADJ	O	O
mesna	NOUN	O	I-Entity
who	NOUN	O	O
experiences	VERB	O	O
severe	ADJ	O	O
ifosfamide	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
emesis	NOUN	O	I-Entity
and	CCONJ	O	O
is	VERB	O	O
unable	ADJ	O	O
to	PART	O	O
absorb	VERB	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Limited	ADJ	O	O
clinical	ADJ	O	O
experience	NOUN	O	O
with	ADP	O	O
continuous	ADJ	O	O
subcutaneous	ADJ	O	O
mesna	ADJ	O	I-Entity
administration	NOUN	O	O
suggests	VERB	O	O
it	PRON	O	O
is	VERB	O	O
a	DET	O	O
safe	ADJ	O	O
,	PUNCT	O	O
practical	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
economic	ADJ	O	O
method	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
delivery	NOUN	O	O
that	ADJ	O	O
permits	VERB	O	O
ifosfamide	NOUN	O	I-Entity
to	PART	O	O
be	VERB	O	O
administered	VERB	O	O
successfully	ADV	O	O
in	ADP	O	O
the	DET	O	O
outpatient	NOUN	O	O
setting	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6323692)

Modification	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
action	NOUN	O	O
by	ADP	O	O
hyperammonemia	NOUN	O	I-Entity
.	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
ammonium	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
(	PUNCT	O	O
NH4Ac	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
6	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O
kg	ADV	O	O
s.c	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

approximately	ADV	O	O
doubled	VERB	O	O
the	DET	O	O
time	NOUN	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
mice	NOUN	O	O
remained	VERB	O	O
on	ADP	O	O
a	DET	O	O
hot	ADJ	O	O
surface	NOUN	O	O
and	CCONJ	O	O
similarly	ADV	O	O
increased	VERB	O	O
muscular	ADJ	O	O
incoordination	NOUN	O	I-Entity
by	ADP	O	O
diazepam	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
NH4Ac	DET	O	I-Entity
treatment	NOUN	O	O
alone	ADV	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
hyperammonemia	NOUN	O	I-Entity
is	VERB	O	O
capable	ADJ	O	O
of	ADP	O	O
altering	VERB	O	O
drug	NOUN	O	O
action	NOUN	O	O
and	CCONJ	O	O
must	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
along	PART	O	O
with	ADP	O	O
impaired	ADJ	O	O
drug	NOUN	O	O
metabolism	NOUN	O	O
in	ADP	O	O
enhanced	VERB	O	O
drug	NOUN	O	O
responses	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Experiments	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
acetylcholine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catecholamine	NOUN	O	I-Entity
release	NOUN	O	O
from	ADP	O	O
bovine	ADJ	O	O
adrenal	ADJ	O	O
medulla	NOUN	O	O
is	VERB	O	O
depressed	VERB	O	O
as	ADV	O	O
much	ADV	O	O
as	ADP	O	O
50%	NUM	O	O
by	ADP	O	O
0.3	NUM	O	O
mM	PROPN	O	O
NH4Ac	PROPN	O	I-Entity
and	CCONJ	O	O
KCl	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
contractions	NOUN	O	O
of	ADP	O	O
guinea	NOUN	O	O
-	PUNCT	O	O
pig	NOUN	O	O
ileum	NOUN	O	O
were	VERB	O	O
inhibited	VERB	O	O
20%	NUM	O	O
by	ADP	O	O
5	NUM	O	O
mM	PROPN	O	O
NH4Ac	PROPN	O	I-Entity
.	PUNCT	O	O

Addition	NOUN	O	O
of	ADP	O	O
excess	ADJ	O	O
calcium	NOUN	O	I-Entity
reversed	VERB	O	O
the	DET	O	O
depression	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
tissues	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
calcium	NOUN	O	I-Entity
-	PUNCT	O	O
independent	ADJ	O	O
catecholamine	NOUN	O	I-Entity
release	NOUN	O	O
by	ADP	O	O
acetaldehyde	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
blocked	VERB	O	O
by	ADP	O	O
NH4Ac	PROPN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
ammonia	NOUN	O	I-Entity
blocks	NOUN	O	O
calcium	NOUN	O	I-Entity
channels	NOUN	O	O
.	PUNCT	O	O

Parallels	NOUN	O	O
in	ADP	O	O
the	DET	O	O
actions	NOUN	O	O
of	ADP	O	O
NH4Ac	PROPN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blocker	NOUN	O	O
verapamil	ADV	O	I-Entity
support	NOUN	O	O
this	DET	O	O
concept	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
verapamil	X	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

and	CCONJ	O	O
NH4Ac	PROPN	O	I-Entity
pretreatment	NOUN	O	O
enhanced	VERB	O	O
morphine	NOUN	O	I-Entity
analgesia-	X	O	I-Entity
and	CCONJ	O	O
diazepam	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
muscular	ADJ	O	O
incoordination	NOUN	O	I-Entity
and	CCONJ	O	O
antagonized	VERB	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
motor	NOUN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
neither	DET	O	O
verapamil	ADJ	O	I-Entity
nor	CCONJ	O	O
NH4Ac	PROPN	O	I-Entity
affected	VERB	O	O
the	DET	O	O
convulsant	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
metrazol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
hyperammonemia	NOUN	O	I-Entity
exerts	VERB	O	O
a	DET	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blocking	VERB	O	O
action	NOUN	O	O
which	ADJ	O	O
enhances	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
depressants	NOUN	O	O
and	CCONJ	O	O
certain	ADJ	O	O
opioid	ADJ	O	O
analgesics	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20195852)

Risk	NOUN	O	O
of	ADP	O	O
nephropathy	ADJ	O	I-Entity
after	ADP	O	O
consumption	NOUN	O	O
of	ADP	O	O
nonionic	ADJ	O	O
contrast	NOUN	O	B-Entity
media	NOUN	O	I-Entity
by	ADP	O	O
children	NOUN	O	O
undergoing	VERB	O	O
cardiac	ADJ	O	O
angiography	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
increasing	VERB	O	O
reports	NOUN	O	O
on	ADP	O	O
nonionic	ADJ	O	O
contrast	NOUN	O	B-Entity
media	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
(	PUNCT	O	O
CIN	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
hospitalized	VERB	O	O
adult	NOUN	O	O
patients	NOUN	O	O
during	ADP	O	O
cardiac	ADJ	O	O
procedures	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
studies	NOUN	O	O
in	ADP	O	O
pediatrics	NOUN	O	O
are	VERB	O	O
limited	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
even	ADV	O	O
less	ADJ	O	O
focus	NOUN	O	O
on	ADP	O	O
possible	ADJ	O	O
predisposing	NOUN	O	O
factors	NOUN	O	O
and	CCONJ	O	O
preventive	ADJ	O	O
measures	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
cardiac	ADJ	O	O
angiography	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
determined	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
CIN	PROPN	O	I-Entity
for	ADP	O	O
two	NUM	O	O
nonionic	ADJ	O	O
contrast	NOUN	O	B-Entity
media	NOUN	O	I-Entity
(	PUNCT	O	O
CM	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
iopromide	NOUN	O	I-Entity
and	CCONJ	O	O
iohexol	NOUN	O	I-Entity
,	PUNCT	O	O
among	ADP	O	O
80	NUM	O	O
patients	NOUN	O	O
younger	ADJ	O	O
than	ADP	O	O
18	NUM	O	O
years	NOUN	O	O
and	CCONJ	O	O
compared	VERB	O	O
the	DET	O	O
rates	NOUN	O	O
for	ADP	O	O
this	DET	O	O
complication	NOUN	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
the	DET	O	O
type	NOUN	O	O
and	CCONJ	O	O
dosage	NOUN	O	O
of	ADP	O	O
CM	PROPN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
cyanosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
80	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
consecutively	ADV	O	O
received	VERB	O	O
either	CCONJ	O	O
iopromide	NOUN	O	I-Entity
(	PUNCT	O	O
group	NOUN	O	O
A	PROPN	O	O
,	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
40	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
iohexol	NOUN	O	I-Entity

Serum	PROPN	O	O
sodium	NOUN	O	I-Entity
(	PUNCT	O	O
Na	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
potassium	NOUN	O	I-Entity
(	PUNCT	O	O
K	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
creatinine	NOUN	O	I-Entity
(	PUNCT	O	O
Cr	PROPN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
24	NUM	O	O
h	NOUN	O	O
before	ADP	O	O
angiography	NOUN	O	O
as	ADP	O	O
baseline	NOUN	O	O
values	NOUN	O	O
,	PUNCT	O	O
then	ADV	O	O
measured	VERB	O	O
again	ADV	O	O
at	ADP	O	O
12-	NUM	O	O
,	PUNCT	O	O
24-	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
48-h	NUM	O	O
intervals	NOUN	O	O
after	ADP	O	O
CM	PROPN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

Urine	ADJ	O	O
samples	NOUN	O	O
for	ADP	O	O
Na	PROPN	O	I-Entity
and	CCONJ	O	O
Cr	PROPN	O	I-Entity
also	ADV	O	O
were	VERB	O	O
checked	VERB	O	O
at	ADP	O	O
the	DET	O	O
same	ADJ	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

Risk	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
Injury	PROPN	O	B-Entity
to	ADP	O	I-Entity
the	DET	O	I-Entity
kidney	NOUN	O	I-Entity
,	PUNCT	O	O
Failure	NOUN	O	B-Entity
of	ADP	O	I-Entity
kidney	NOUN	O	I-Entity
function	NOUN	O	I-Entity
,	PUNCT	O	O
Loss	PROPN	O	B-Entity
of	ADP	O	I-Entity
kidney	NOUN	O	I-Entity
function	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
End	PROPN	O	O
-	PUNCT	O	O
stage	NOUN	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
(	PUNCT	O	O
RIFLE	PROPN	O	O
criteria	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
define	VERB	O	O
CIN	PROPN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
incidence	NOUN	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
population	NOUN	O	O
.	PUNCT	O	O

Accordingly	ADV	O	O
,	PUNCT	O	O
among	ADP	O	O
the	DET	O	O
15	NUM	O	O
CIN	PROPN	O	I-Entity
patients	NOUN	O	O
(	PUNCT	O	O
18.75%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
7.5%	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
A	PROPN	O	O
had	VERB	O	O
increased	VERB	O	O
risk	NOUN	O	O
and	CCONJ	O	O
3.75%	NUM	O	O
had	VERB	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
5%	NUM	O	O
of	ADP	O	O
group	NOUN	O	O
B	PROPN	O	O
had	VERB	O	O
increased	VERB	O	O
risk	NOUN	O	O
and	CCONJ	O	O
2.5%	NUM	O	O
had	VERB	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

Whereas	ADP	O	O
33.3%	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
CIN	PROPN	O	I-Entity
were	VERB	O	O
among	ADP	O	O
those	DET	O	O
who	NOUN	O	O
received	VERB	O	O
the	DET	O	O
proper	ADJ	O	O
dosage	NOUN	O	O
of	ADP	O	O
CM	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
percentage	NOUN	O	O
increased	VERB	O	O
to	ADP	O	O
66.6%	NUM	O	O
among	ADP	O	O
those	DET	O	O
who	NOUN	O	O
received	VERB	O	O
larger	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
CIN	PROPN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
different	ADJ	O	O
dosages	NOUN	O	O
of	ADP	O	O
CM	PROPN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.014	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
the	DET	O	O
15	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
CIN	PROPN	O	I-Entity
,	PUNCT	O	O
6	NUM	O	O
had	VERB	O	O
cyanotic	ADJ	O	O
congenital	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
diseases	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
incidence	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
significantly	ADV	O	O
from	ADP	O	O
that	DET	O	O
for	ADP	O	O
the	DET	O	O
noncyanotic	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.243	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Although	ADP	O	O
clinically	ADV	O	O
silent	ADJ	O	O
,	PUNCT	O	O
CIN	PROPN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
rare	ADJ	O	O
in	ADP	O	O
pediatrics	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
depends	VERB	O	O
on	ADP	O	O
dosage	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
on	ADP	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
consumed	VERB	O	O
nonionic	ADJ	O	O
CM	PROPN	O	I-Entity
,	PUNCT	O	O
nor	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
cyanosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
although	ADP	O	O
CIN	PROPN	O	I-Entity
usually	ADV	O	O
is	VERB	O	O
reversible	ADJ	O	O
,	PUNCT	O	O
more	ADJ	O	O
concern	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
such	ADJ	O	O
a	DET	O	O
complication	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18997632)

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
caffeine	NOUN	O	I-Entity
pretreatment	NOUN	O	O
.	PUNCT	O	O

Suboptimal	ADJ	O	O
seizure	NOUN	O	I-Entity
duration	NOUN	O	O
is	VERB	O	O
commonly	ADV	O	O
encountered	VERB	O	O
in	ADP	O	O
electroconvulsive	ADJ	O	O
therapy	NOUN	O	O
practice	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
older	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
higher	ADJ	O	O
seizure	NOUN	O	I-Entity
thresholds	NOUN	O	O
.	PUNCT	O	O

Intravenous	ADJ	O	O
caffeine	NOUN	O	I-Entity
is	VERB	O	O
commonly	ADV	O	O
used	VERB	O	O
to	PART	O	O
improve	VERB	O	O
seizure	NOUN	O	I-Entity
duration	NOUN	O	O
and	CCONJ	O	O
quality	NOUN	O	O
in	ADP	O	O
such	ADJ	O	O
patients	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
generally	ADV	O	O
well	ADV	O	O
tolerated	VERB	O	O
aside	ADV	O	O
from	ADP	O	O
occasional	ADJ	O	O
reports	NOUN	O	O
of	ADP	O	O
relatively	ADV	O	O
benign	ADJ	O	O
ventricular	ADJ	O	B-Entity
ectopy	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
no	DET	O	O
previous	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
or	CCONJ	O	O
arrhythmia	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
sustained	ADJ	O	O
bigeminy	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
brief	NOUN	O	O
runs	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
after	ADP	O	O
caffeine	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
intravenous	ADJ	O	O
caffeine	NOUN	O	I-Entity
is	VERB	O	O
generally	ADV	O	O
well	ADV	O	O
tolerated	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
clinician	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
the	DET	O	O
potential	ADJ	O	O
for	ADP	O	O
unpredictable	ADJ	O	O
and	CCONJ	O	O
serious	ADJ	O	O
ventricular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15565293)

Optical	ADJ	O	O
coherence	NOUN	O	O
tomography	NOUN	O	O
can	VERB	O	O
measure	VERB	O	O
axonal	ADJ	O	O
loss	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ethambutol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
optic	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

PURPOSE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
map	VERB	O	O
and	CCONJ	O	O
identify	VERB	O	O
the	DET	O	O
pattern	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
axonal	ADJ	O	B-Entity
degeneration	NOUN	O	I-Entity
in	ADP	O	O
ethambutol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
optic	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
using	VERB	O	O
optical	ADJ	O	O
coherence	NOUN	O	O
tomography	NOUN	O	O
(	PUNCT	O	O
OCT	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Ethambutol	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
antimycobacterial	ADJ	O	O
agent	NOUN	O	O
often	ADV	O	O
used	VERB	O	O
to	PART	O	O
treat	VERB	O	O
tuberculosis	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
serious	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
ethambutol	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
optic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
that	ADJ	O	O
impairs	ADP	O	O
visual	ADJ	O	O
acuity	NOUN	O	O
,	PUNCT	O	O
contrast	NOUN	O	O
sensitivity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
color	NOUN	O	O
vision	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
early	ADV	O	O
on	ADV	O	O
,	PUNCT	O	O
when	ADV	O	O
the	DET	O	O
toxic	ADJ	O	O
optic	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
is	VERB	O	O
mild	ADJ	O	O
and	CCONJ	O	O
partly	ADV	O	O
reversible	ADJ	O	O
,	PUNCT	O	O
the	DET	O	O
funduscopic	ADJ	O	O
findings	NOUN	O	O
are	VERB	O	O
often	ADV	O	O
subtle	ADJ	O	O
and	CCONJ	O	O
easy	ADJ	O	O
to	PART	O	O
miss	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Three	NUM	O	O
subjects	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
ethambutol	NOUN	O	I-Entity
(	PUNCT	O	O
EMB)-induced	ADJ	O	I-Entity
optic	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
of	ADP	O	O
short-	NOUN	O	O
,	PUNCT	O	O
intermediate-	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
visual	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
were	VERB	O	O
administered	VERB	O	O
a	DET	O	O
full	ADJ	O	O
neuro	NOUN	O	O
-	PUNCT	O	O
ophthalmologic	ADJ	O	O
examination	NOUN	O	O
including	VERB	O	O
visual	ADJ	O	O
acuity	NOUN	O	O
,	PUNCT	O	O
color	NOUN	O	O
vision	NOUN	O	O
,	PUNCT	O	O
contrast	NOUN	O	O
sensitivity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
fundus	ADJ	O	O
examination	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
all	DET	O	O
subjects	NOUN	O	O
with	ADP	O	O
history	NOUN	O	O
of	ADP	O	O
EMB	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
optic	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
mean	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
72%	NUM	O	O
nerve	NOUN	O	O
fiber	NOUN	O	O
layer	NOUN	O	O
thickness	NOUN	O	O
in	ADP	O	O
the	DET	O	O
temporal	ADJ	O	O
quadrant	NOUN	O	O
(	PUNCT	O	O
patient	NOUN	O	O
A	PROPN	O	O
,	PUNCT	O	O
with	ADP	O	O
eventual	ADJ	O	O
recovery	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	O
acuity	NOUN	O	O
and	CCONJ	O	O
fields	NOUN	O	O
,	PUNCT	O	O
58%	NUM	O	O
loss	NOUN	O	O
;	PUNCT	O	O
patient	NOUN	O	O
B	PROPN	O	O
,	PUNCT	O	O
with	ADP	O	O
intermediate	ADJ	O	O
visual	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
,	PUNCT	O	O
68%	NUM	O	O
loss	NOUN	O	O
;	PUNCT	O	O
patient	NOUN	O	O
C	PROPN	O	O
,	PUNCT	O	O
with	ADP	O	O
chronic	ADJ	O	O
visual	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
,	PUNCT	O	O
90%	NUM	O	O
loss	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
average	ADJ	O	O
mean	ADJ	O	O
optic	ADJ	O	O
nerve	NOUN	O	O
thickness	NOUN	O	O
of	ADP	O	O
26+/-16	NUM	O	O
microm	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
both	DET	O	O
sets	NOUN	O	O
(	PUNCT	O	O
four	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
eyes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
with	ADP	O	O
persistent	ADJ	O	O
visual	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
(	PUNCT	O	O
patients	NOUN	O	O
B	PROPN	O	O
and	CCONJ	O	O
C	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
an	DET	O	O
average	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
79%	NUM	O	O
of	ADP	O	O
nerve	NOUN	O	O
fiber	NOUN	O	O
thickness	NOUN	O	O
in	ADP	O	O
the	DET	O	O
temporal	ADJ	O	O
quadrant	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
OCT	PROPN	O	O
results	NOUN	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
EMB	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
optic	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
show	VERB	O	O
considerable	ADJ	O	O
loss	NOUN	O	O
especially	ADV	O	O
of	ADP	O	O
the	DET	O	O
temporal	ADJ	O	O
fibers	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
prior	ADJ	O	O
histopathological	ADJ	O	O
studies	NOUN	O	O
that	ADJ	O	O
show	VERB	O	O
predominant	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
parvo	NOUN	O	O
-	PUNCT	O	O
cellular	ADJ	O	O
axons	NOUN	O	O
(	PUNCT	O	O
or	CCONJ	O	O
small	ADJ	O	O
-	PUNCT	O	O
caliber	NOUN	O	O
axons	NOUN	O	O
)	PUNCT	O	O
within	ADP	O	O
the	DET	O	O
papillo	NOUN	O	O
-	PUNCT	O	O
macular	ADJ	O	O
bundle	NOUN	O	O
in	ADP	O	O
toxic	ADJ	O	O
or	CCONJ	O	O
hereditary	ADJ	O	O
optic	NOUN	O	B-Entity
neuropathies	NOUN	O	I-Entity
.	PUNCT	O	O

OCT	PROPN	O	O
can	VERB	O	O
be	VERB	O	O
a	DET	O	O
valuable	ADJ	O	O
tool	NOUN	O	O
in	ADP	O	O
the	DET	O	O
quantitative	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
optic	NOUN	O	B-Entity
neuropathies	NOUN	O	I-Entity
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
management	NOUN	O	O
of	ADP	O	O
EMB	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
optic	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
important	ADJ	O	O
to	PART	O	O
properly	ADV	O	O
manage	VERB	O	O
ethambutol	NOUN	O	I-Entity
dosing	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
renal	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
and	CCONJ	O	O
to	PART	O	O
achieve	VERB	O	O
proper	ADJ	O	O
transition	NOUN	O	O
to	ADP	O	O
a	DET	O	O
maintenance	NOUN	O	O
dose	NOUN	O	O
once	ADV	O	O
an	DET	O	O
appropriate	ADJ	O	O
loading	NOUN	O	O
dose	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
reached	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (15266215)

Effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cyclooxygenase-2	PROPN	O	O
specific	ADJ	O	O
inhibitor	NOUN	O	O
valdecoxib	NOUN	O	I-Entity
versus	ADP	O	O
nonsteroidal	ADJ	O	O
antiinflammatory	ADJ	O	O
agents	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
on	ADP	O	O
cardiovascular	ADJ	O	O
thrombotic	ADJ	O	I-Entity
events	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
have	VERB	O	O
been	VERB	O	O
concerns	NOUN	O	O
that	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	O
thrombotic	ADJ	O	I-Entity
events	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
higher	ADJ	O	O
with	ADP	O	O
cyclooxygenase	NOUN	O	O
(	PUNCT	O	O
COX)-2-specific	ADJ	O	O
inhibitors	NOUN	O	O
than	ADP	O	O
nonselective	ADJ	O	O
nonsteroidal	NOUN	O	O
antiinflammatory	NOUN	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
NSAIDs	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
cardiovascular	ADJ	O	O
event	NOUN	O	O
data	NOUN	O	O
for	ADP	O	O
valdecoxib	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
COX-2-specific	ADJ	O	O
inhibitor	NOUN	O	O
in	ADP	O	O
approximately	ADV	O	O
8000	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
osteoarthritis	NOUN	O	I-Entity
and	CCONJ	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
this	DET	O	O
agent	NOUN	O	O
in	ADP	O	O
randomized	ADJ	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	O
thrombotic	ADJ	O	I-Entity
events	NOUN	O	O
(	PUNCT	O	O
cardiac	ADJ	O	O
,	PUNCT	O	O
cerebrovascular	ADJ	O	O
and	CCONJ	O	O
peripheral	ADJ	O	O
vascular	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
arterial	ADJ	O	O
thrombotic	NOUN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
analyzing	VERB	O	O
pooled	VERB	O	O
valdecoxib	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
-	SYM	O	O
80	NUM	O	O
mg	NUM	O	O
daily	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nonselective	ADJ	O	O
NSAID	PROPN	O	O
(	PUNCT	O	O
diclofenac	ADV	O	I-Entity
75	NUM	O	O
mg	NUM	O	O
bid	NOUN	O	O
,	PUNCT	O	O
ibuprofen	NOUN	O	I-Entity
800	NUM	O	O
mg	NUM	O	O
tid	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
naproxen	ADJ	O	I-Entity
500	NUM	O	O
mg	NUM	O	O
bid	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
data	NOUN	O	O
from	ADP	O	O
10	NUM	O	O
randomized	ADJ	O	O
osteoarthritis	NOUN	O	I-Entity
and	CCONJ	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
trials	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
6	NUM	O	O
-	SYM	O	O
52	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
duration	NOUN	O	O
.	PUNCT	O	O

in	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
(	PUNCT	O	O
<	PUNCT	O	O
or	CCONJ	O	O
=	SYM	O	O
325	NUM	O	O
mg	NUM	O	O
daily	ADV	O	O
)	PUNCT	O	O
aspirin	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
1051	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
nonusers	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
6883	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Crude	ADJ	O	O
and	CCONJ	O	O
exposure	NOUN	O	O
-	PUNCT	O	O
adjusted	VERB	O	O
incidences	NOUN	O	O
of	ADP	O	O
thrombotic	ADJ	O	I-Entity
events	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
valdecoxib	NOUN	O	I-Entity
,	PUNCT	O	O
NSAIDs	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
serious	ADJ	O	O
thrombotic	ADJ	O	I-Entity
events	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
similar	ADJ	O	O
for	ADP	O	O
each	DET	O	O
valdecoxib	NOUN	O	I-Entity
dose	NOUN	O	O
.	PUNCT	O	O

Thrombotic	ADJ	O	I-Entity
risk	NOUN	O	O
was	VERB	O	O
consistently	ADV	O	O
higher	ADJ	O	O
for	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
users	NOUN	O	O
than	ADP	O	O
nonusers	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
(	PUNCT	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
1.4%	NUM	O	O
vs.	CCONJ	O	O
0%	NUM	O	O
;	PUNCT	O	O
valdecoxib	NOUN	O	I-Entity
,	PUNCT	O	O
1.7%	NUM	O	O
vs.	CCONJ	O	O
0.2%	NUM	O	O
;	PUNCT	O	O
NSAIDs	PROPN	O	O
,	PUNCT	O	O
1.9%	NUM	O	O
vs.	NOUN	O	O
0.5%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
rates	NOUN	O	O
of	ADP	O	O
events	NOUN	O	O
in	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
were	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
all	DET	O	O
3	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
and	CCONJ	O	O
across	ADP	O	O
valdecoxib	NOUN	O	I-Entity
doses	NOUN	O	O
.	PUNCT	O	O

valdecoxib	NOUN	O	I-Entity
doses	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
thrombotic	ADJ	O	I-Entity
events	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
nonselective	ADJ	O	O
NSAIDs	PROPN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
osteoarthritis	NOUN	O	I-Entity
and	CCONJ	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
patients	NOUN	O	O
in	ADP	O	O
controlled	VERB	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (14742097)

A	DET	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
crossover	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
ephedrine	NOUN	O	I-Entity
for	ADP	O	O
SSRI	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
female	ADJ	O	O
sexual	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
ephedrine	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
alpha-	NOUN	O	O
and	CCONJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	NOUN	O	O
agonist	NOUN	O	O
previously	ADV	O	O
shown	VERB	O	O
to	PART	O	O
enhance	VERB	O	O
genital	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
reversing	VERB	O	O
antidepressant	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
sexual	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Nineteen	ADJ	O	O
sexually	ADV	O	B-Entity
dysfunctional	ADJ	O	I-Entity
women	NOUN	O	O
receiving	VERB	O	O
either	CCONJ	O	O
fluoxetine	NOUN	O	I-Entity
,	PUNCT	O	O
sertraline	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
paroxetine	NOUN	O	I-Entity
participated	VERB	O	O
in	ADP	O	O
an	DET	O	O
eight	NUM	O	O
-	PUNCT	O	O
week	NOUN	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
cross	VERB	O	O
-	PUNCT	O	O
over	PART	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
ephedrine	NOUN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
self	NOUN	O	O
-	PUNCT	O	O
report	NOUN	O	O
measures	NOUN	O	O
of	ADP	O	O
sexual	ADJ	O	O
desire	NOUN	O	O
,	PUNCT	O	O
arousal	NOUN	O	O
,	PUNCT	O	O
orgasm	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sexual	ADJ	O	O
satisfaction	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
there	ADV	O	O
were	VERB	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
sexual	ADJ	O	O
desire	NOUN	O	O
and	CCONJ	O	O
orgasm	ADJ	O	O
intensity	NOUN	O	O
/	PUNCT	O	O
pleasure	NOUN	O	O
on	ADP	O	O
50	NUM	O	O
mg	NUM	O	O
ephedrine	NOUN	O	I-Entity
1-hr	NUM	O	O
prior	ADV	O	O
to	ADP	O	O
sexual	ADJ	O	O
activity	NOUN	O	O
,	PUNCT	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
these	DET	O	O
measures	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
in	ADP	O	O
sexual	ADJ	O	O
arousal	NOUN	O	O
and	CCONJ	O	O
orgasmic	NOUN	O	O
ability	NOUN	O	O
also	ADV	O	O
were	VERB	O	O
noted	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11890511)

Erectile	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
occurs	VERB	O	O
following	VERB	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
lesions	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Erectile	ADJ	O	O
function	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
6	NUM	O	O
weeks	NOUN	O	O
following	VERB	O	O
uni-	ADJ	O	O
and	CCONJ	O	O
bilateral	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
6-hydroxydopamine	NUM	O	I-Entity
in	ADP	O	O
the	DET	O	O
substantia	NOUN	O	O
nigra	ADJ	O	O
nucleus	NOUN	O	O
of	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
.	PUNCT	O	O

Behavioral	ADJ	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
penile	ADJ	O	O
erections	NOUN	O	O
were	VERB	O	O
reduced	VERB	O	O
(	PUNCT	O	O
5/8	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
(	PUNCT	O	O
3/8	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
uni-	NOUN	O	O
and	CCONJ	O	O
bilateral	ADJ	O	O
lesioned	ADJ	O	O
animals	NOUN	O	O
.	PUNCT	O	O

Concentration	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
metabolites	NOUN	O	O
were	VERB	O	O
decreased	VERB	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
of	ADP	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
lesioned	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Lesions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
are	VERB	O	O
therefore	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
erectile	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
serve	VERB	O	O
as	ADP	O	O
a	DET	O	O
model	NOUN	O	O
to	PART	O	O
study	VERB	O	O
erectile	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9270571)

Potential	ADJ	O	O
therapeutic	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
selective	ADJ	O	O
dopamine	NOUN	O	I-Entity
D1	PROPN	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
A-86929	PROPN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
acute	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
parkinsonian	ADJ	O	I-Entity
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
primed	VERB	O	O
monkeys	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
utility	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
(	PUNCT	O	O
DA	PROPN	O	I-Entity
)	PUNCT	O	O

D1	PROPN	O	O
receptor	NOUN	O	O
agonists	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
still	ADV	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
therapeutic	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
selective	ADJ	O	O
DA	NOUN	O	I-Entity
D1	PROPN	O	O
receptor	NOUN	O	O
agonists	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
SKF-82958	PROPN	O	I-Entity
(	PUNCT	O	O
6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze	NUM	O	B-Entity
pine	NOUN	O	I-Entity
hydrobromide	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
A-77636	PROPN	O	I-Entity
(	PUNCT	O	O
[	PUNCT	O	B-Entity
1R	NUM	O	I-Entity
,	PUNCT	O	I-Entity
3S	NOUN	O	I-Entity
]	PUNCT	O	I-Entity
3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo	NUM	O	I-Entity
pyran	NOUN	O	I-Entity
hydrochloride	NOUN	O	I-Entity
)	PUNCT	O	O
seems	VERB	O	O
limited	ADJ	O	O
because	ADP	O	O
of	ADP	O	O
their	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
too	ADV	O	O
short	ADJ	O	O
for	ADP	O	O
SKF-82958	PROPN	O	I-Entity
(	PUNCT	O	O
<	SYM	O	O
1	NUM	O	O
hr	INTJ	O	O
)	PUNCT	O	O
and	CCONJ	O	O
too	ADV	O	O
long	ADV	O	O
for	ADP	O	O
A-77636	PROPN	O	I-Entity
(	PUNCT	O	O
>	SYM	O	O
20	NUM	O	O

We	PRON	O	O
therefore	ADV	O	O
conducted	VERB	O	O
the	DET	O	O
present	ADJ	O	O
acute	ADJ	O	O
dose	NOUN	O	O
-	PUNCT	O	O
response	NOUN	O	O
study	NOUN	O	O
in	ADP	O	O
four	NUM	O	O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	NUM	O	I-Entity
(	PUNCT	O	O
MPTP)-exposed	VERB	O	I-Entity
cynomolgus	ADJ	O	O
monkeys	NOUN	O	O
primed	VERB	O	O
to	PART	O	O
exhibit	VERB	O	O
levodopa	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
locomotor	NOUN	O	O
and	CCONJ	O	O
dyskinetic	ADJ	O	I-Entity
effects	NOUN	O	O
on	ADP	O	O
challenge	NOUN	O	O
with	ADP	O	O
four	NUM	O	O
doses	NOUN	O	O
(	PUNCT	O	O
from	ADP	O	O
0.03	NUM	O	O
to	ADP	O	O
1.0	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
A-86929	PROPN	O	I-Entity
(	PUNCT	O	O
[	PUNCT	O	B-Entity
-]-[5aR,11bS]-4,5,5a,6,7,11b	NUM	O	I-Entity
-	PUNCT	O	I-Entity
hexahydro-2-propyl-3-thia-5-+	NOUN	O	I-Entity
+	CCONJ	O	I-Entity
+	CCONJ	O	I-Entity
azacyclopent-1-	PUNCT	O	I-Entity
ena[c]phenathrene-9	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
10-diol	NUM	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
selective	ADJ	O	O
and	CCONJ	O	O
full	ADJ	O	O
DA	NOUN	O	I-Entity
D1-like	ADP	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
with	ADP	O	O
an	DET	O	O
intermediate	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
.	PUNCT	O	O

Levodopa	PROPN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
DA	NOUN	O	I-Entity

D2-like	ADP	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
LY-171555	PROPN	O	I-Entity
(	PUNCT	O	O
[	PUNCT	O	B-Entity
4aR	NUM	O	I-Entity
-	PUNCT	O	I-Entity
trans]-4,4a,5,6,7,8,8a,9-o	NUM	O	I-Entity
-	PUNCT	O	I-Entity
dihydro-5n	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
propyl-2H	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
pyrazo	NOUN	O	I-Entity
lo-3	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
4-quinoline	NUM	O	I-Entity
hydrochloride	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
also	ADV	O	O
used	VERB	O	O
for	ADP	O	O
comparison	NOUN	O	O
.	PUNCT	O	O

Acute	PROPN	O	O
administration	NOUN	O	O
of	ADP	O	O
A-86929	PROPN	O	I-Entity
was	VERB	O	O
as	ADP	O	O
efficacious	ADJ	O	O
in	ADP	O	O
alleviating	VERB	O	O
MPTP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
parkinsonism	NOUN	O	I-Entity
as	ADP	O	O
levodopa	NOUN	O	I-Entity
and	CCONJ	O	O
LY-171555	PROPN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
less	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
reproduce	VERB	O	O
the	DET	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
these	DET	O	O
animals	NOUN	O	O
than	ADP	O	O
with	ADP	O	O
either	CCONJ	O	O
LY-171555	PROPN	O	I-Entity
or	CCONJ	O	O
subsequent	ADJ	O	O
challenge	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
.	PUNCT	O	O

Selective	ADJ	O	O
stimulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
DA	NOUN	O	I-Entity
D1	PROPN	O	O
receptor	NOUN	O	O
may	VERB	O	O
provide	VERB	O	O
better	ADJ	O	O
integration	NOUN	O	O
of	ADP	O	O
neural	ADJ	O	O
inputs	NOUN	O	O
transmitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
internal	ADJ	O	O
segment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
globus	NOUN	O	O
pallidus	NOUN	O	O
(	PUNCT	O	O
referred	VERB	O	O
to	ADP	O	O
as	ADP	O	O
the	DET	O	O
basal	NOUN	O	O
ganglia	NOUN	O	O
output	NOUN	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
levodopa	NOUN	O	I-Entity
and	CCONJ	O	O
selective	ADJ	O	O
DA	NOUN	O	I-Entity
D2	PROPN	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
.	PUNCT	O	O

Potent	PROPN	O	O
DA	PROPN	O	I-Entity
D1	PROPN	O	O
receptor	NOUN	O	O
agents	NOUN	O	O
with	ADP	O	O
an	DET	O	O
intermediate	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
A-86929	PROPN	O	I-Entity
(	PUNCT	O	O
approximately	ADV	O	O
4	NUM	O	O
hr	NOUN	O	O
at	ADP	O	O
higher	ADJ	O	O
doses	NOUN	O	O
tested	VERB	O	O
)	PUNCT	O	O
are	VERB	O	O
potential	ADJ	O	O
therapeutic	ADJ	O	O
tools	NOUN	O	O
in	ADP	O	O
PD	PROPN	O	I-Entity
and	CCONJ	O	O
merit	NOUN	O	O
further	ADJ	O	O
attention	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7189975)

Deaths	NOUN	O	O
from	ADP	O	O
local	ADJ	O	O
anesthetic	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Median	ADJ	O	O
convulsant	NOUN	O	O
(	PUNCT	O	O
CD50	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
median	ADJ	O	O
lethal	ADJ	O	O
(	PUNCT	O	O
LD50	PROPN	O	O
)	PUNCT	O	O
doses	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
representative	ADJ	O	O
local	ADJ	O	O
anesthetics	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
in	ADP	O	O
adult	NOUN	O	O
mice	NOUN	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
threat	NOUN	O	O
to	ADP	O	O
life	NOUN	O	O
of	ADP	O	O
local	ADJ	O	O
anesthetic	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
CD50	PROPN	O	O
and	CCONJ	O	O
LD50	PROPN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
were	VERB	O	O
57.7	NUM	O	O
and	CCONJ	O	O
58.7	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
for	ADP	O	O
bupivacaine	NOUN	O	I-Entity
,	PUNCT	O	O
111.0	NUM	O	O
and	CCONJ	O	O
133.1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
for	ADP	O	O
lidocaine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
243.4	NUM	O	O
and	CCONJ	O	O
266.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
for	ADP	O	O
chloroprocaine	NOUN	O	I-Entity
.	PUNCT	O	O

When	ADV	O	O
given	VERB	O	O
intraperitoneally	ADV	O	O
,	PUNCT	O	O
bupivacaine	NOUN	O	I-Entity
thus	ADV	O	O
was	VERB	O	O
only	ADV	O	O
about	ADV	O	O
twice	ADV	O	O
as	ADV	O	O
toxic	ADJ	O	O
as	ADP	O	O
lidocaine	NOUN	O	I-Entity
and	CCONJ	O	O
four	NUM	O	O
times	NOUN	O	O
as	ADP	O	O
toxic	ADJ	O	O
as	ADP	O	O
chloroprocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Convulsions	NOUN	O	I-Entity
always	ADV	O	O
preceded	VERB	O	O
death	NOUN	O	O
,	PUNCT	O	O
except	ADP	O	O
after	ADP	O	O
precipitous	ADJ	O	O
cardiopulmonary	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
from	ADP	O	O
extreme	ADJ	O	O
doses	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
CD50	PROPN	O	O
dose	NOUN	O	O
of	ADP	O	O
local	ADJ	O	O
anesthetic	NOUN	O	O
(	PUNCT	O	O
causing	VERB	O	O
convulsions	NOUN	O	I-Entity
in	ADP	O	O
50%	NUM	O	O
of	ADP	O	O
mice	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
fatal	ADJ	O	O
in	ADP	O	O
90%	NUM	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
57%	NUM	O	O
of	ADP	O	O
the	DET	O	O
chloroprocaine	NOUN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
6%	NUM	O	O
of	ADP	O	O
the	DET	O	O
lidocaine	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
narrow	ADJ	O	O
gap	NOUN	O	O
between	ADP	O	O
convulsant	NOUN	O	O
and	CCONJ	O	O
lethal	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
local	ADJ	O	O
anesthetics	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
untreated	ADJ	O	O
convulsions	NOUN	O	I-Entity
present	ADJ	O	O
much	ADV	O	O
more	ADJ	O	O
of	ADP	O	O
a	DET	O	O
threat	NOUN	O	O
to	ADP	O	O
life	NOUN	O	O
than	ADP	O	O
heretofore	ADV	O	O
appreciated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (6415512)

Myoclonic	PROPN	O	B-Entity
,	PUNCT	O	I-Entity
atonic	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
absence	NOUN	O	I-Entity
seizures	NOUN	O	I-Entity
following	VERB	O	O
institution	NOUN	O	O
of	ADP	O	O
carbamazepine	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
children	NOUN	O	O
,	PUNCT	O	O
aged	VERB	O	O
3	NUM	O	O
to	ADP	O	O
11	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
carbamazepine	NOUN	O	I-Entity
for	ADP	O	O
epilepsy	NOUN	O	I-Entity
,	PUNCT	O	O
had	VERB	O	O
an	DET	O	O
acute	ADJ	O	O
aberrant	ADJ	O	O
reaction	NOUN	O	O
characterized	VERB	O	O
by	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
myoclonic	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
atypical	ADJ	O	I-Entity
absence	NOUN	O	I-Entity
and/or	CCONJ	O	I-Entity
atonic	ADJ	O	I-Entity
(	PUNCT	O	I-Entity
minor	ADJ	O	I-Entity
motor	NOUN	O	I-Entity
)	PUNCT	O	I-Entity
seizures	NOUN	O	I-Entity
within	ADP	O	O
a	DET	O	O
few	ADJ	O	O
days	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
the	DET	O	O
carbamazepine	NOUN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
,	PUNCT	O	O
two	NUM	O	O
of	ADP	O	O
the	DET	O	O
children	NOUN	O	O
returned	VERB	O	O
to	ADP	O	O
their	ADJ	O	O
former	ADJ	O	O
state	NOUN	O	O
very	ADV	O	O
quickly	ADV	O	O
,	PUNCT	O	O
two	NUM	O	O
had	VERB	O	O
the	DET	O	O
minor	ADJ	O	O
motor	NOUN	O	O
seizures	NOUN	O	I-Entity
resolve	VERB	O	O
in	ADP	O	O
3	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
one	NUM	O	O
had	VERB	O	O
the	DET	O	O
seizures	NOUN	O	I-Entity
persist	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
child	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
the	DET	O	O
seizures	NOUN	O	I-Entity
persisted	VERB	O	O
was	VERB	O	O
later	ADV	O	O
found	VERB	O	O
to	PART	O	O
have	VERB	O	O
ceroid	ADJ	O	B-Entity
lipofuscinosis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1928887)

Naloxone	PROPN	O	I-Entity
reversal	NOUN	O	O
of	ADP	O	O
hypotension	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
captopril	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
hemodynamic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
captopril	NOUN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
angiotensin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
converting	VERB	O	I-Entity
enzyme	NOUN	O	I-Entity
inhibitors	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
the	DET	O	O
endogenous	ADJ	O	O
opioid	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
opioid	ADJ	O	O
antagonist	NOUN	O	O
naloxone	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
block	VERB	O	O
or	CCONJ	O	O
reverse	VERB	O	O
the	DET	O	O
hypotensive	ADJ	O	I-Entity
actions	NOUN	O	O
of	ADP	O	O
captopril	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
an	DET	O	O
intentional	ADJ	O	O
captopril	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
,	PUNCT	O	O
manifested	VERB	O	O
by	ADP	O	O
marked	VERB	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
that	DET	O	O
resolved	VERB	O	O
promptly	ADV	O	O
with	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
naloxone	NOUN	O	I-Entity
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
reported	VERB	O	O
case	NOUN	O	O
of	ADP	O	O
captopril	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
naloxone	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
experience	NOUN	O	O
demonstrates	VERB	O	O
a	DET	O	O
possible	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
naloxone	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
reversal	NOUN	O	O
of	ADP	O	O
hypotension	NOUN	O	I-Entity
resulting	VERB	O	O
from	ADP	O	O
captopril	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1728915)

Carbamazepine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
sinus	ADJ	O	O
bradycardia	NOUN	O	I-Entity
and	CCONJ	O	O
atrioventricular	ADJ	O	B-Entity
block	NOUN	O	I-Entity
,	PUNCT	O	O
induced	VERB	O	O
by	ADP	O	O
carbamazepine	NOUN	O	I-Entity
,	PUNCT	O	O
prompted	VERB	O	O
an	DET	O	O
extensive	ADJ	O	O
literature	NOUN	O	O
review	NOUN	O	O
of	ADP	O	O
all	DET	O	O
previously	ADV	O	O
reported	VERB	O	O
cases	NOUN	O	O
.	PUNCT	O	O

From	ADP	O	O
the	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
these	DET	O	O
cases	NOUN	O	O
,	PUNCT	O	O
two	NUM	O	O
distinct	ADJ	O	O
forms	NOUN	O	O
of	ADP	O	O
carbamazepine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
emerged	VERB	O	O
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
group	NOUN	O	O
developed	VERB	O	O
sinus	ADJ	O	B-Entity
tachycardias	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
setting	NOUN	O	O
of	ADP	O	O
a	DET	O	O
massive	ADJ	O	O
carbamazepine	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
second	ADJ	O	O
group	NOUN	O	O
consisted	VERB	O	O
almost	ADV	O	O
exclusively	ADV	O	O
of	ADP	O	O
elderly	ADJ	O	O
women	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
potentially	ADV	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
bradyarrhythmias	NOUN	O	I-Entity
or	CCONJ	O	O
atrioventricular	ADJ	O	B-Entity
conduction	NOUN	O	I-Entity
delay	NOUN	O	I-Entity
,	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
either	CCONJ	O	O
therapeutic	ADJ	O	O
or	CCONJ	O	O
modestly	ADV	O	O
elevated	VERB	O	O
carbamazepine	NOUN	O	I-Entity
serum	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
carbamazepine	NOUN	O	I-Entity
is	VERB	O	O
widely	ADV	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
many	ADJ	O	O
neurologic	ADJ	O	O
and	CCONJ	O	O
psychiatric	ADJ	O	I-Entity
conditions	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
recognition	NOUN	O	O
of	ADP	O	O
the	DET	O	O
latter	ADJ	O	O
syndrome	NOUN	O	O
has	VERB	O	O
important	ADJ	O	O
implications	NOUN	O	O
for	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20558148)

Glutamatergic	PROPN	O	O
neurotransmission	NOUN	O	O
mediated	VERB	O	O
by	ADP	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
inferior	ADJ	O	O
colliculus	NOUN	O	O
can	VERB	O	O
modulate	VERB	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
.	PUNCT	O	O

Functional	ADJ	O	O
evidence	NOUN	O	O
relating	VERB	O	O
the	DET	O	O
IC	PROPN	O	O
to	ADP	O	O
motor	NOUN	O	O
behavior	NOUN	O	O
derives	VERB	O	O
from	ADP	O	O
experiments	NOUN	O	O
showing	VERB	O	O
that	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
IC	PROPN	O	O
by	ADP	O	O
electrical	ADJ	O	O
stimulation	NOUN	O	O
or	CCONJ	O	O
excitatory	NOUN	O	O
amino	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
microinjection	NOUN	O	O
causes	VERB	O	O
freezing	VERB	O	O
,	PUNCT	O	O
escape	VERB	O	O
-	PUNCT	O	O
like	ADJ	O	O
behavior	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
immobility	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
excitatory	ADJ	O	O
amino	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
mechanisms	NOUN	O	O
in	ADP	O	O
the	DET	O	O
IC	PROPN	O	O
on	ADP	O	O
the	DET	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
dopamine	NOUN	O	I-Entity
receptor	NOUN	O	O
blocker	NOUN	O	O
haloperidol	NOUN	O	I-Entity
administered	VERB	O	O

Haloperidol	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
was	VERB	O	O
challenged	VERB	O	O
with	ADP	O	O
prior	ADV	O	O
intracollicular	ADJ	O	O
microinjections	NOUN	O	O
of	ADP	O	O
glutamate	NOUN	O	I-Entity
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
antagonists	NOUN	O	O
,	PUNCT	O	O
MK-801	PROPN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
or	CCONJ	O	O
30	NUM	O	O
mmol/0.5	NOUN	O	O
microl	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
AP7	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
or	CCONJ	O	O
20	NUM	O	O
nmol/0.5	NUM	O	O
microl	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
of	ADP	O	O
the	DET	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
agonist	NOUN	O	O
N	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
d	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA	PROPN	O	I-Entity
,	PUNCT	O	O
20	NUM	O	O
or	CCONJ	O	O
30	NUM	O	O
nmol/0.5	ADJ	O	O
microl	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
intracollicular	ADJ	O	O
microinjection	NOUN	O	O
of	ADP	O	O
MK-801	PROPN	O	I-Entity
and	CCONJ	O	O
AP7	PROPN	O	I-Entity
previous	ADJ	O	O
to	ADP	O	O
systemic	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
significantly	ADV	O	O
attenuated	VERB	O	O
the	DET	O	O
catalepsy	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
indicated	VERB	O	O
by	ADP	O	O
a	DET	O	O
reduced	VERB	O	O
latency	NOUN	O	O
to	PART	O	O
step	VERB	O	O
down	ADV	O	O
from	ADP	O	O
a	DET	O	O
horizontal	ADJ	O	O
bar	NOUN	O	O
.	PUNCT	O	O

Accordingly	ADV	O	O
,	PUNCT	O	O
intracollicular	ADJ	O	O
microinjection	NOUN	O	O
of	ADP	O	O
NMDA	PROPN	O	I-Entity
increased	VERB	O	O
the	DET	O	O
latency	NOUN	O	O
to	PART	O	O
step	VERB	O	O
down	PART	O	O
the	DET	O	O
bar	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
glutamate	NOUN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
mechanisms	NOUN	O	O
in	ADP	O	O
the	DET	O	O
neural	ADJ	O	O
circuits	NOUN	O	O
at	ADP	O	O
the	DET	O	O
IC	PROPN	O	O
level	NOUN	O	O
influence	NOUN	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
and	CCONJ	O	O
participate	VERB	O	O
in	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19940105)

Metabotropic	ADJ	O	O
glutamate	NOUN	O	I-Entity
7	NUM	O	O
receptor	NOUN	O	O
subtype	NOUN	O	O
modulates	VERB	O	O
motor	NOUN	O	O
symptoms	NOUN	O	O
in	ADP	O	O
rodent	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Metabotropic	ADJ	O	O
glutamate	NOUN	O	I-Entity
(	PUNCT	O	O
mGlu	PROPN	O	O
)	PUNCT	O	O

receptors	NOUN	O	O
modulate	VERB	O	O
synaptic	ADJ	O	O
transmission	NOUN	O	O
in	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
and	CCONJ	O	O
represent	VERB	O	O
promising	ADJ	O	O
therapeutic	ADJ	O	O
targets	NOUN	O	O
for	ADP	O	O
symptomatic	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Among	ADP	O	O
the	DET	O	O
eight	NUM	O	O
mGlu	PROPN	O	O
receptor	NOUN	O	O
subtypes	NOUN	O	O
,	PUNCT	O	O
mGlu7	ADJ	O	O
receptor	NOUN	O	O
is	VERB	O	O
prominently	ADV	O	O
expressed	VERB	O	O
in	ADP	O	O
the	DET	O	O
basal	NOUN	O	O
ganglia	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
its	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
restoring	VERB	O	O
motor	NOUN	O	O
function	NOUN	O	O
in	ADP	O	O
animal	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
PD	PROPN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
known	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
N	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
N'-dibenzhydrylethane-1,2-diamine	PROPN	O	I-Entity
dihydrochloride	NOUN	O	I-Entity
(	PUNCT	O	O
AMN082	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
first	ADJ	O	O
selective	ADJ	O	O
allosteric	NOUN	O	O
activator	NOUN	O	O
of	ADP	O	O
mGlu7	NOUN	O	O
receptors	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
thus	ADV	O	O
tested	VERB	O	O
in	ADP	O	O
different	ADJ	O	O
rodent	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
PD	PROPN	O	I-Entity
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
show	VERB	O	O
that	ADP	O	O
oral	ADJ	O	O
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
intrastriatal	ADJ	O	O
administration	NOUN	O	O
(	PUNCT	O	O
0.1	NUM	O	O
and	CCONJ	O	O
0.5	NUM	O	O
nmol	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
AMN082	PROPN	O	I-Entity
reverses	VERB	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

AMN082	NOUN	O	I-Entity
(	PUNCT	O	O
2.5	NUM	O	O
and	CCONJ	O	O
5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
reduces	VERB	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rotations	NOUN	O	O
in	ADP	O	O
unilateral	ADJ	O	O
6-hydroxydopamine	NUM	O	I-Entity
(	PUNCT	O	O
6-OHDA)-lesioned	VERB	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
more	ADV	O	O
complex	ADJ	O	O
task	NOUN	O	O
commonly	ADV	O	O
used	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
major	ADJ	O	O
akinetic	ADJ	O	I-Entity
symptoms	NOUN	O	O
of	ADP	O	O
PD	PROPN	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
AMN082	PROPN	O	I-Entity
reverses	VERB	O	O
the	DET	O	O
increased	VERB	O	O
reaction	NOUN	O	O
time	NOUN	O	O
to	PART	O	O
respond	VERB	O	O
to	ADP	O	O
a	DET	O	O
cue	NOUN	O	O
of	ADP	O	O
bilateral	ADJ	O	O
6-OHDA	NUM	O	I-Entity
-	PUNCT	O	O
lesioned	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
AMN082	PROPN	O	I-Entity
reduces	VERB	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
mGlu7	ADJ	O	O
receptor	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
in	ADP	O	O
wild	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
mGlu7	ADJ	O	O
receptor	NOUN	O	O
knockout	NOUN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Higher	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
AMN082	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
p.o	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

have	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
same	ADJ	O	O
models	NOUN	O	O
of	ADP	O	O
PD	PROPN	O	I-Entity
.	PUNCT	O	O

Overall	ADV	O	O
these	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
mGlu7	ADJ	O	O
receptor	NOUN	O	O
activation	NOUN	O	O
can	VERB	O	O
reverse	VERB	O	O
motor	NOUN	O	O
dysfunction	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
reduced	VERB	O	O
dopamine	NOUN	O	I-Entity
activity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19923525)

Nimodipine	NOUN	O	I-Entity
prevents	VERB	O	O
memory	NOUN	O	B-Entity
impairment	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
adult	NOUN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Hypotension	PROPN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
resultant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
cerebral	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
cognitive	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
tested	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
nimodipine	NOUN	O	I-Entity
(	PUNCT	O	O
NIMO	PROPN	O	I-Entity
)	PUNCT	O	O
administered	VERB	O	O
at	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
nitroglycerin	NOUN	O	I-Entity
(	PUNCT	O	O
NTG)-induced	PROPN	O	I-Entity
hypotension	NOUN	O	I-Entity
would	VERB	O	O
preserve	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
associative	ADJ	O	O
memory	NOUN	O	O
.	PUNCT	O	O

Ninety	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
Swiss	ADJ	O	O
-	PUNCT	O	O
Webster	PROPN	O	O
mice	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
-	SYM	O	O
35	NUM	O	O
g	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
-	SYM	O	O
8	NUM	O	O
wk	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
6	NUM	O	O
groups	NOUN	O	O
1	NUM	O	O
)	PUNCT	O	O
saline	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
NTG	PROPN	O	I-Entity
immediately	ADV	O	O
after	ADP	O	O
learning	VERB	O	O
,	PUNCT	O	O
3	PUNCT	O	O
)	PUNCT	O	O
NTG	PROPN	O	I-Entity
3	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
learning	VERB	O	O
,	PUNCT	O	O
4	PUNCT	O	O
)	PUNCT	O	O
NTG	PROPN	O	I-Entity
and	CCONJ	O	O
NIMO	PROPN	O	I-Entity
,	PUNCT	O	O
5	NUM	O	O
)	PUNCT	O	O
vehicle	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
6	NUM	O	O
)	PUNCT	O	O

NIMO	ADV	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
changes	NOUN	O	O
in	ADP	O	O
brain	NOUN	O	O
tissue	NOUN	O	O
oxygenation	NOUN	O	O
(	PUNCT	O	O
PbtO(2	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
cerebral	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
a	DET	O	O
separate	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
animals	NOUN	O	O
.	PUNCT	O	O

Mice	NOUN	O	O
subjected	VERB	O	O
to	ADP	O	O
hypotensive	VERB	O	I-Entity
episodes	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
latency	ADJ	O	O
time	NOUN	O	O
(	PUNCT	O	O
178	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

156	NUM	O	O
s	PUNCT	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
injected	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
,	PUNCT	O	O
NTG	PROPN	O	I-Entity
+	PROPN	O	O
NIMO	PROPN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
delayed	VERB	O	O
NTG	PROPN	O	I-Entity
(	PUNCT	O	O
580	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
separate	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
not	ADV	O	O
subjected	VERB	O	O
to	ADP	O	O
behavioral	ADJ	O	O
studies	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
same	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
NTG	PROPN	O	I-Entity
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
3	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
NTG	PROPN	O	I-Entity
+	SYM	O	O
NIMO	PROPN	O	I-Entity
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
3	NUM	O	O
)	PUNCT	O	O
caused	VERB	O	O
mean	VERB	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
to	PART	O	O
decrease	VERB	O	O
from	ADP	O	O
85.9	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Mean	ADJ	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
NIMO	PROPN	O	I-Entity
alone	ADV	O	O
decreased	VERB	O	O
from	ADP	O	O
88.1	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

5.2	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
sem	NOUN	O	O
in	ADP	O	O
the	DET	O	O
NTG	PROPN	O	I-Entity
group	NOUN	O	O
and	CCONJ	O	O
from	ADP	O	O
38.6	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

2.0	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
sem	NOUN	O	O
in	ADP	O	O
the	DET	O	O
NTG	PROPN	O	I-Entity
+	SYM	O	O
NIMO	PROPN	O	I-Entity
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
PA	PROPN	O	O
retention	NOUN	O	O
paradigm	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
NTG	PROPN	O	I-Entity
immediately	ADV	O	O
after	ADP	O	O
learning	VERB	O	O
produced	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
impairment	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
associative	ADJ	O	O
memory	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
delayed	VERB	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

NIMO	ADV	O	I-Entity
attenuated	VERB	O	O
the	DET	O	O
disruption	NOUN	O	O
in	ADP	O	O
consolidation	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
memory	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
NTG	PROPN	O	I-Entity
but	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
improve	VERB	O	O
latency	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
observed	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
NIMO	PROPN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
been	VERB	O	O
attributable	ADJ	O	O
to	ADP	O	O
the	DET	O	O
preservation	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
homeostasis	NOUN	O	O
during	ADP	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
because	ADP	O	O
there	ADV	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PbtO(2	PROPN	O	O
)	PUNCT	O	O
indices	NOUN	O	O
among	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19058474)

Fatal	ADJ	O	O
haemopericardium	NOUN	O	I-Entity
and	CCONJ	O	O
gastrointestinal	ADJ	O	B-Entity
haemorrhage	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
possible	ADJ	O	O
interaction	NOUN	O	O
of	ADP	O	O
cranberry	NOUN	O	O
juice	NOUN	O	O
with	ADP	O	O
warfarin	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
fatal	ADJ	O	O
internal	ADJ	O	O
haemorrhage	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
elderly	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
consumed	VERB	O	O
only	ADV	O	O
cranberry	ADJ	O	O
juice	NOUN	O	O
for	ADP	O	O
two	NUM	O	O
weeks	NOUN	O	O
while	ADP	O	O
maintaining	VERB	O	O
his	ADJ	O	O
usual	ADJ	O	O
dosage	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
propose	VERB	O	O
that	DET	O	O
naturally	ADV	O	O
occurring	VERB	O	O
compounds	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
flavonoids	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
are	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
fruit	NOUN	O	O
juices	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
increase	VERB	O	O
the	DET	O	O
potency	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
by	ADP	O	O
competing	VERB	O	O
for	ADP	O	O
the	DET	O	O
enzymes	NOUN	O	O
that	ADJ	O	O
normally	ADV	O	O
inactivate	VERB	O	O
warfarin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18808529)

Isoproterenol	NOUN	O	I-Entity
induces	VERB	O	O
primary	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
dystrophin	NOUN	O	O
in	ADP	O	O
rat	NOUN	O	O
hearts	NOUN	O	O
:	PUNCT	O	O
correlation	NOUN	O	O
with	ADP	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
is	VERB	O	O
unknown	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
a	DET	O	O
mismatch	NOUN	O	O
of	ADP	O	O
oxygen	NOUN	O	I-Entity
supply	NOUN	O	O
vs.	ADP	O	O
demand	NOUN	O	O
following	VERB	O	O
coronary	ADJ	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
myocardial	ADJ	O	B-Entity
hyperactivity	NOUN	O	I-Entity
is	VERB	O	O
the	DET	O	O
best	ADJ	O	O
explanation	NOUN	O	O
for	ADP	O	O
the	DET	O	O
complex	ADJ	O	O
morphological	ADJ	O	O
alterations	NOUN	O	O
observed	VERB	O	O
.	PUNCT	O	O

Severe	ADJ	O	O
alterations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
structural	ADJ	O	O
integrity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sarcolemma	NOUN	O	O
of	ADP	O	O
cardiomyocytes	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
demonstrated	VERB	O	O
to	PART	O	O
be	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
isoproterenol	NOUN	O	I-Entity
.	PUNCT	O	O

Taking	VERB	O	O
into	ADP	O	O
account	NOUN	O	O
that	ADP	O	O
the	DET	O	O
sarcolemmal	ADJ	O	O
integrity	NOUN	O	O
is	VERB	O	O
stabilized	VERB	O	O
by	ADP	O	O
the	DET	O	O
dystrophin	NOUN	O	O
-	PUNCT	O	O
glycoprotein	NOUN	O	O
complex	NOUN	O	O
(	PUNCT	O	O
DGC	PROPN	O	O
)	PUNCT	O	O
that	ADJ	O	O
connects	VERB	O	O
actin	NOUN	O	O
and	CCONJ	O	O
laminin	NOUN	O	O
in	ADP	O	O
contractile	NOUN	O	O
machinery	NOUN	O	O
and	CCONJ	O	O
extracellular	ADJ	O	O
matrix	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
integrins	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
study	NOUN	O	O
tests	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
isoproterenol	NOUN	O	I-Entity
affects	VERB	O	O
sarcolemmal	ADJ	O	O
stability	NOUN	O	O
through	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
DGC	PROPN	O	O
and	CCONJ	O	O
integrins	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
different	ADJ	O	O
sensitivity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
DGC	PROPN	O	O
and	CCONJ	O	O
integrin	NOUN	O	O
to	ADP	O	O
isoproterenol	VERB	O	I-Entity
subcutaneous	ADJ	O	O
administration	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
isoproterenol	NOUN	O	I-Entity
to	ADP	O	O
rats	NOUN	O	O
results	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
dystrophin	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
most	ADV	O	O
sensitive	ADJ	O	O
among	ADP	O	O
the	DET	O	O
structural	ADJ	O	O
proteins	NOUN	O	O
that	ADJ	O	O
form	VERB	O	O
the	DET	O	O
DGC	PROPN	O	O
that	ADJ	O	O
connects	VERB	O	O
the	DET	O	O
extracellular	ADJ	O	O
matrix	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
cytoskeleton	NOUN	O	O
in	ADP	O	O
cardiomyocyte	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
changes	NOUN	O	O
,	PUNCT	O	O
related	VERB	O	O
to	ADP	O	O
ischaemic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
explain	VERB	O	O
the	DET	O	O
severe	ADJ	O	O
alterations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
structural	ADJ	O	O
integrity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sarcolemma	NOUN	O	O
of	ADP	O	O
cardiomyocytes	NOUN	O	O
and	CCONJ	O	O
hence	ADV	O	O
severe	ADJ	O	O
and	CCONJ	O	O
irreversible	ADJ	O	O
injury	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
isoproterenol	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18674790)

High	ADJ	O	O
fat	ADJ	O	I-Entity
diet	NOUN	O	O
-	PUNCT	O	O
fed	VERB	O	O
obese	ADJ	O	I-Entity
rats	NOUN	O	O
are	VERB	O	O
highly	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
doxorubicin	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Often	ADV	O	O
,	PUNCT	O	O
chemotherapy	NOUN	O	O
by	ADP	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
Adriamycin	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
limited	VERB	O	O
due	ADP	O	O
to	ADP	O	O
life	NOUN	O	O
threatening	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
during	ADP	O	O
and	CCONJ	O	O
posttherapy	NOUN	O	O
.	PUNCT	O	O

Recently	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
have	VERB	O	O
shown	VERB	O	O
that	DET	O	O
moderate	ADJ	O	O
diet	NOUN	O	O
restriction	NOUN	O	O
remarkably	ADV	O	O
protects	VERB	O	O
against	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
cardioprotection	NOUN	O	O
is	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
decreased	VERB	O	O
cardiac	ADJ	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
triglycerides	NOUN	O	I-Entity
and	CCONJ	O	O
increased	VERB	O	O
cardiac	ADJ	O	O
fatty	NOUN	O	O
-	PUNCT	O	O
acid	NOUN	O	O
oxidation	NOUN	O	O
,	PUNCT	O	O
ATP	PROPN	O	I-Entity
synthesis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
upregulated	ADJ	O	O
JAK	PROPN	O	O
/	SYM	O	O
STAT3	PROPN	O	O
pathway	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
whether	ADP	O	O
a	DET	O	O
physiological	ADJ	O	O
intervention	NOUN	O	O
by	ADP	O	O
feeding	VERB	O	O
40%	NUM	O	O
high	ADJ	O	O
fat	ADJ	O	I-Entity
diet	NOUN	O	O
(	PUNCT	O	O
HFD	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
induces	VERB	O	O
obesity	NOUN	O	I-Entity
in	ADP	O	O
male	ADJ	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
(	PUNCT	O	O
250	NUM	O	O
-	SYM	O	O
275	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
sensitizes	VERB	O	O
to	ADP	O	O
doxorubicin	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
LD(10	PROPN	O	O
)	PUNCT	O	O
dose	NOUN	O	O
(	PUNCT	O	O
8	NUM	O	O
mg	NUM	O	O
doxorubicin	NOUN	O	I-Entity
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
ip	PUNCT	O	O
)	PUNCT	O	O
administered	VERB	O	O
on	ADP	O	O
day	NOUN	O	O
43	NUM	O	O
of	ADP	O	O
the	DET	O	O
HFD	PROPN	O	O
feeding	NOUN	O	O
regimen	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
higher	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
80%	NUM	O	O
mortality	NOUN	O	O
in	ADP	O	O
the	DET	O	O
obese	ADJ	O	I-Entity
(	PUNCT	O	O
OB	PROPN	O	I-Entity
)	PUNCT	O	O
rats	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
any	DET	O	O
significant	ADJ	O	O
renal	NOUN	O	B-Entity
or	CCONJ	O	I-Entity
hepatic	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Doxorubicin	ADJ	O	I-Entity
toxicokinetics	NOUN	O	O
studies	NOUN	O	O
revealed	VERB	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
accumulation	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
and	CCONJ	O	O
doxorubicinol	NOUN	O	I-Entity
(	PUNCT	O	O
toxic	ADJ	O	O
metabolite	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
diet	NOUN	O	O
-	PUNCT	O	O
fed	VERB	O	O
(	PUNCT	O	O
ND	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
OB	PROPN	O	I-Entity
hearts	NOUN	O	O
.	PUNCT	O	O

Mechanistic	ADJ	O	O
studies	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
OB	PROPN	O	I-Entity
rats	NOUN	O	O
are	VERB	O	O
sensitized	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	PUNCT	O	O
)	PUNCT	O	O
higher	ADJ	O	O
oxyradical	ADJ	O	O
stress	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
upregulation	NOUN	O	O
of	ADP	O	O
uncoupling	VERB	O	O
proteins	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
,	PUNCT	O	O
(	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
downregulation	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
peroxisome	NOUN	O	O
proliferators	NOUN	O	O
activated	VERB	O	O
receptor	NOUN	O	O
-	PUNCT	O	O
alpha	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
3	PUNCT	O	O
)	PUNCT	O	O
decreased	VERB	O	O
plasma	NOUN	O	O
adiponectin	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
4	PUNCT	O	O
)	PUNCT	O	O
decreased	VERB	O	O
cardiac	ADJ	O	O
fatty	ADJ	O	O
-	PUNCT	O	O
acid	NOUN	O	O
oxidation	NOUN	O	O
(	PUNCT	O	O
666.9+/-14.0	PROPN	O	O
nmol	PROPN	O	O
/	SYM	O	O
min	PROPN	O	O
/	SYM	O	O
g	ADJ	O	O
heart	NOUN	O	O
in	ADP	O	O
ND	PROPN	O	O
versus	ADP	O	O
400.2+/-11.8	NUM	O	O
nmol	NOUN	O	O

/	SYM	O	O
min	NOUN	O	O
/	SYM	O	O
g	NOUN	O	O
heart	NOUN	O	O
in	ADP	O	O
OB	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
5	PUNCT	O	O
)	PUNCT	O	O
decreased	VERB	O	O
mitochondrial	ADJ	O	O
AMP	PROPN	O	I-Entity
-	PUNCT	O	O
alpha2	PROPN	O	O
protein	NOUN	O	O
kinase	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
86%	NUM	O	O
drop	NOUN	O	O
in	ADP	O	O
cardiac	ADJ	O	O
ATP	PROPN	O	I-Entity
levels	NOUN	O	O
accompanied	VERB	O	O
by	ADP	O	O
decreased	VERB	O	O
ATP	PROPN	O	I-Entity
/	SYM	O	O
ADP	PROPN	O	I-Entity
ratio	NOUN	O	O
after	ADP	O	O
doxorubicin	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
HFD	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
obese	ADJ	O	I-Entity
rats	NOUN	O	O
are	VERB	O	O
highly	ADV	O	O
sensitized	ADJ	O	O
to	ADP	O	O
doxorubicin	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
by	ADP	O	O
substantially	ADV	O	O
downregulating	VERB	O	O
cardiac	ADJ	O	O
mitochondrial	ADJ	O	O
ATP	PROPN	O	I-Entity
generation	NOUN	O	O
,	PUNCT	O	O
increasing	VERB	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
downregulating	VERB	O	O
the	DET	O	O
JAK	PROPN	O	O
/	SYM	O	O
STAT3	PROPN	O	O
pathway	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18441470)

Complete	ADJ	O	O
atrioventricular	ADJ	O	B-Entity
block	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Sinus	ADJ	O	B-Entity
node	NOUN	O	I-Entity
dysfunction	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
most	ADV	O	O
frequently	ADV	O	O
among	ADP	O	O
the	DET	O	O
adverse	ADJ	O	O
cardiovascular	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
case	NOUN	O	O
,	PUNCT	O	O
complete	ADJ	O	O
atrioventricular	NOUN	O	B-Entity
(	PUNCT	O	I-Entity
AV	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
block	NOUN	O	I-Entity
with	ADP	O	O
syncopal	ADJ	O	B-Entity
attacks	NOUN	O	I-Entity
developed	VERB	O	O
secondary	ADJ	O	O
to	ADP	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
necessitating	VERB	O	O
permanent	ADJ	O	O
pacemaker	NOUN	O	O
implantation	NOUN	O	O
.	PUNCT	O	O

Serum	PROPN	O	O
lithium	NOUN	O	I-Entity
levels	NOUN	O	O
remained	VERB	O	O
under	ADP	O	O
or	CCONJ	O	O
within	ADP	O	O
the	DET	O	O
therapeutic	ADJ	O	O
range	NOUN	O	O
during	ADP	O	O
the	DET	O	O
syncopal	ADJ	O	B-Entity
attacks	NOUN	O	I-Entity
.	PUNCT	O	O

Lithium	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
with	ADP	O	O
extreme	ADJ	O	O
caution	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
disturbance	NOUN	O	O
of	ADP	O	O
AV	PROPN	O	O
conduction	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17366349)

Neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
ziprasidone	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
second	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
NMS	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
the	DET	O	O
rarest	ADJ	O	O
and	CCONJ	O	O
most	ADV	O	O
serious	ADJ	O	O
of	ADP	O	O
the	DET	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
movement	NOUN	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
NMS	PROPN	O	I-Entity
)	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
ziprasidone	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
conventional	ADJ	O	O
neuroleptics	NOUN	O	O
are	VERB	O	O
more	ADV	O	O
frequently	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
NMS	PROPN	O	I-Entity
,	PUNCT	O	O
atypical	ADJ	O	O
antipsychotic	ADJ	O	O
drugs	NOUN	O	O
like	ADP	O	O
ziprasidone	NOUN	O	I-Entity
may	VERB	O	O
also	ADV	O	O
be	VERB	O	O
a	DET	O	O
cause	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
is	VERB	O	O
a	DET	O	O
24-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
signs	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
NMS	PROPN	O	I-Entity
after	ADP	O	O
2	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
an	DET	O	O
80-mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
orally	ADV	O	O
administrated	VERB	O	O
ziprasidone	NOUN	O	I-Entity
.	PUNCT	O	O

NMS	PROPN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
ziprasidone	NOUN	O	I-Entity
reported	VERB	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16584858)

Role	NOUN	O	O
of	ADP	O	O
mangiferin	NOUN	O	I-Entity
on	ADP	O	O
biochemical	ADJ	O	O
alterations	NOUN	O	O
and	CCONJ	O	O
antioxidant	ADJ	O	O
status	NOUN	O	O
in	ADP	O	O
isoproterenol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
dealt	VERB	O	O
with	ADP	O	O
the	DET	O	O
protective	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
mangiferin	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
polyphenol	NOUN	O	I-Entity
from	ADP	O	O
Mangifera	PROPN	O	O
indica	PROPN	O	O
Linn	PROPN	O	O
.	PUNCT	O	O

(	PUNCT	O	O
Anacardiaceae	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
on	ADP	O	O
isoproterenol	NOUN	O	I-Entity
(	PUNCT	O	O
ISPH)-induced	VERB	O	I-Entity
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
MI	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
rats	NOUN	O	O
through	ADP	O	O
its	ADJ	O	O
antioxidative	ADJ	O	O
mechanism	NOUN	O	O
.	PUNCT	O	O

Subcutaneous	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
ISPH	PROPN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
in	ADP	O	O
1	NUM	O	O
ml	INTJ	O	O
saline	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
rats	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
caused	VERB	O	O
myocardial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
heart	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
the	DET	O	O
increased	VERB	O	O
activity	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
lactate	NOUN	O	I-Entity
dehydrogenase	NOUN	O	O
(	PUNCT	O	O
LDH	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
creatine	NOUN	O	I-Entity
phosphokinase	NOUN	O	O
isoenzymes	NOUN	O	O
(	PUNCT	O	O
CK	PROPN	O	O
-	PUNCT	O	O
MB	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
increased	VERB	O	O
uric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
level	NOUN	O	O
and	CCONJ	O	O
reduced	VERB	O	O
plasma	NOUN	O	O
iron	NOUN	O	I-Entity
binding	VERB	O	O
capacity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
protective	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
mangiferin	NOUN	O	I-Entity
was	VERB	O	O
analyzed	VERB	O	O
by	ADP	O	O
triphenyl	NOUN	O	B-Entity
tetrazolium	NOUN	O	I-Entity
chloride	NOUN	O	I-Entity
(	PUNCT	O	O
TTC	PROPN	O	I-Entity
)	PUNCT	O	O
test	NOUN	O	O
used	VERB	O	O
for	ADP	O	O
macroscopic	ADJ	O	O
enzyme	NOUN	O	O
mapping	NOUN	O	O
assay	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ischemic	ADJ	O	B-Entity
myocardium	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
heart	NOUN	O	O
tissue	NOUN	O	O
antioxidant	NOUN	O	O
enzymes	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
superoxide	NOUN	O	I-Entity
dismutase	NOUN	O	O
,	PUNCT	O	O
catalase	NOUN	O	O
,	PUNCT	O	O
glutathione	NOUN	O	I-Entity
peroxidase	NOUN	O	O
,	PUNCT	O	O
glutathione	NOUN	O	I-Entity
transferase	NOUN	O	O
and	CCONJ	O	O
glutathione	NOUN	O	I-Entity
reductase	NOUN	O	O
activities	NOUN	O	O
,	PUNCT	O	O
non	ADJ	O	O
-	PUNCT	O	O
enzymic	ADJ	O	O
antioxidants	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
cerruloplasmin	NOUN	O	O
,	PUNCT	O	O
Vitamin	PROPN	O	B-Entity
C	PROPN	O	I-Entity
,	PUNCT	O	O
Vitamin	PROPN	O	B-Entity
E	PROPN	O	I-Entity
and	CCONJ	O	O

glutathione	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
altered	VERB	O	O
in	ADP	O	O
MI	PROPN	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

Upon	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
mangiferin	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
suspended	VERB	O	O
in	ADP	O	O
2	NUM	O	O
ml	NOUN	O	O
of	ADP	O	O
dimethyl	NOUN	O	B-Entity
sulphoxide	NOUN	O	I-Entity
)	PUNCT	O	O
given	VERB	O	O
intraperitoneally	NOUN	O	O
for	ADP	O	O
28	NUM	O	O
days	NOUN	O	O
to	ADP	O	O
MI	PROPN	O	I-Entity
rats	NOUN	O	O
protected	VERB	O	O
the	DET	O	O
above	ADV	O	O
-	PUNCT	O	O
mentioned	VERB	O	O
parameters	NOUN	O	O
to	PART	O	O
fall	VERB	O	O
from	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Activities	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	O
tissue	NOUN	O	O
enzymic	NOUN	O	O
antioxidants	NOUN	O	O
and	CCONJ	O	O
serum	NOUN	O	O
non	NOUN	O	O
-	PUNCT	O	O
enzymic	NOUN	O	O
antioxidants	NOUN	O	O
levels	NOUN	O	O
rose	VERB	O	O
significantly	ADV	O	O
upon	ADP	O	O
mangiferin	ADJ	O	I-Entity
administration	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
ISPH	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
MI	PROPN	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

From	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
it	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
mangiferin	NOUN	O	I-Entity
exerts	VERB	O	O
a	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
against	ADP	O	O
ISPH	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
MI	PROPN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
its	ADJ	O	O
antioxidant	ADJ	O	O
potential	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
regulated	VERB	O	O
the	DET	O	O
tissues	NOUN	O	O
defense	NOUN	O	O
system	NOUN	O	O
against	ADP	O	O
cardiac	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16563323)

Remifentanil	PROPN	O	I-Entity
pretreatment	NOUN	O	O
reduces	VERB	O	O
myoclonus	NOUN	O	I-Entity
after	ADP	O	O
etomidate	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
compare	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
remifentanil	NOUN	O	I-Entity
1	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
gender	NOUN	O	O
on	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
myoclonus	NOUN	O	I-Entity
after	ADP	O	O
anesthesia	NOUN	O	O
induction	NOUN	O	O
with	ADP	O	O
etomidate	NOUN	O	I-Entity
.	PUNCT	O	O

Sixty	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
pretreated	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	ADJ	O	O
double	ADJ	O	O
-	PUNCT	O	O
blinded	ADJ	O	O
fashion	NOUN	O	O
with	ADP	O	O
remifentanil	NOUN	O	I-Entity
1	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
remifentanil	NOUN	O	I-Entity
or	CCONJ	O	O
placebo	NOUN	O	O
injection	NOUN	O	O
,	PUNCT	O	O
etomidate	NOUN	O	I-Entity
0.3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
was	VERB	O	O
given	VERB	O	O
.	PUNCT	O	O

Myoclonus	PROPN	O	I-Entity
was	VERB	O	O
recorded	VERB	O	O
with	ADP	O	O
a	DET	O	O
scale	NOUN	O	O
of	ADP	O	O
0	NUM	O	O
to	PART	O	O
3	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
grade	NOUN	O	O
of	ADP	O	O
sedation	NOUN	O	O
(	PUNCT	O	O
none	NOUN	O	O
,	PUNCT	O	O
mild	ADJ	O	O
,	PUNCT	O	O
moderate	ADJ	O	O
,	PUNCT	O	O
severe	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
pruritus	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
apnea	NOUN	O	I-Entity
were	VERB	O	O
recorded	VERB	O	O
after	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
both	DET	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
myoclonus	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
in	ADP	O	O
the	DET	O	O
remifentanil	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
6.7%	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
70%	NUM	O	O
)	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
experienced	VERB	O	O
sedation	NOUN	O	O
,	PUNCT	O	O
apnea	NOUN	O	I-Entity
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
pruritus	NOUN	O	I-Entity
after	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
both	DET	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
male	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
significantly	ADV	O	O
increased	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
myoclonus	NOUN	O	I-Entity
after	ADP	O	O
etomidate	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Pretreatment	NOUN	O	O
with	ADP	O	O
remifentanil	NOUN	O	I-Entity
1	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O

kg	ADV	O	O
reduced	VERB	O	O
myoclonus	NOUN	O	I-Entity
after	ADP	O	O
etomidate	NOUN	O	I-Entity
induction	NOUN	O	O
without	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
sedation	NOUN	O	O
,	PUNCT	O	O
apnea	NOUN	O	I-Entity
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
pruritus	NOUN	O	I-Entity
.	PUNCT	O	O

Men	NOUN	O	O
experience	NOUN	O	O
increased	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
myoclonus	NOUN	O	I-Entity
than	ADP	O	O
women	NOUN	O	O
after	ADP	O	O
etomidate	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16428827)

Daidzein	PROPN	O	I-Entity
activates	VERB	O	O
choline	NOUN	O	I-Entity
acetyltransferase	NOUN	O	O
from	ADP	O	O
MC	PROPN	O	O
-	PUNCT	O	O
IXC	PROPN	O	O
cells	NOUN	O	O
and	CCONJ	O	O
improves	VERB	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
choline	NOUN	O	I-Entity
acetyltransferase	NOUN	O	O
(	PUNCT	O	O
ChAT	PROPN	O	O
)	PUNCT	O	O
activator	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
enhances	VERB	O	O
cholinergic	ADJ	O	O
transmission	NOUN	O	O
via	ADP	O	O
an	DET	O	O
augmentation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
enzymatic	ADJ	O	O
production	NOUN	O	O
of	ADP	O	O
acetylcholine	NOUN	O	I-Entity
(	PUNCT	O	O
ACh	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
important	ADJ	O	O
factor	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
AD	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Via	VERB	O	O
the	DET	O	O
sequential	ADJ	O	O
isolation	NOUN	O	O
of	ADP	O	O
Pueraria	PROPN	O	O
thunbergiana	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
active	ADJ	O	O
component	NOUN	O	O
was	VERB	O	O
ultimately	ADV	O	O
identified	VERB	O	O
as	ADP	O	O
daidzein	NOUN	O	I-Entity
(	PUNCT	O	O
4',7-dihydroxy	NUM	O	B-Entity
-	PUNCT	O	I-Entity
isoflavone	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
daidzein	NOUN	O	I-Entity
from	ADP	O	O
Pueraria	PROPN	O	O
thunbergiana	NOUN	O	O
on	ADP	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
impairments	NOUN	O	B-Entity
of	ADP	O	I-Entity
learning	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
memory	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
series	NOUN	O	O
of	ADP	O	O
in	ADP	O	O
vivo	NOUN	O	O
tests	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
daidzein	NOUN	O	I-Entity
(	PUNCT	O	O
4.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
mice	NOUN	O	O
was	VERB	O	O
shown	VERB	O	O
significantly	ADV	O	O
to	PART	O	O
reverse	VERB	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
,	PUNCT	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
a	DET	O	O
Y	NOUN	O	O
-	PUNCT	O	O
maze	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

Injections	NOUN	O	O
of	ADP	O	O
scopolamine	NOUN	O	I-Entity
into	ADP	O	O
mice	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
impaired	ADJ	O	O
performance	NOUN	O	O
on	ADP	O	O
Y	PROPN	O	O
-	PUNCT	O	O
maze	NOUN	O	O
tests	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
37%	NUM	O	O
decreases	NOUN	O	O
in	ADP	O	O
alternation	NOUN	O	O
behavior	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

By	ADP	O	O
way	NOUN	O	O
of	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
mice	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
daidzein	NOUN	O	I-Entity
prior	ADV	O	O
to	ADP	O	O
the	DET	O	O
scopolamine	NOUN	O	I-Entity
injections	NOUN	O	O
were	VERB	O	O
noticeably	ADV	O	O
protected	VERB	O	O
from	ADP	O	O
this	DET	O	O
performance	NOUN	O	O
impairment	NOUN	O	O
(	PUNCT	O	O
an	DET	O	O
approximately	ADV	O	O
12%-21%	NUM	O	O
decrease	NOUN	O	O
in	ADP	O	O
alternation	NOUN	O	O
behavior	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
daidzein	NOUN	O	I-Entity
might	VERB	O	O
play	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
acetylcholine	NOUN	O	I-Entity
biosynthesis	NOUN	O	O
as	ADP	O	O
a	DET	O	O
ChAT	PROPN	O	O
activator	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
it	PRON	O	O
also	ADV	O	O
ameliorates	VERB	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15985056)

Possible	ADJ	O	O
azithromycin	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
hiccups	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
persistent	ADJ	O	O
hiccups	NOUN	O	I-Entity
associated	VERB	O	O
by	ADP	O	O
azithromycin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
76-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
persistent	ADJ	O	O
hiccups	NOUN	O	I-Entity
after	ADP	O	O
beginning	VERB	O	O
azithromycin	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
pharyngitis	NOUN	O	I-Entity
.	PUNCT	O	O

Hiccups	NOUN	O	I-Entity
were	VERB	O	O
persistent	ADJ	O	O
and	CCONJ	O	O
exhausting	NOUN	O	O
.	PUNCT	O	O

Discontinuation	NOUN	O	O
of	ADP	O	O
azithromycin	NOUN	O	I-Entity
and	CCONJ	O	O
therapy	NOUN	O	O
with	ADP	O	O
baclofen	NOUN	O	I-Entity
finally	ADV	O	O
resolved	VERB	O	O
hiccups	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
organic	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
hiccups	NOUN	O	I-Entity
was	VERB	O	O
identified	VERB	O	O
despite	ADP	O	O
extensive	ADJ	O	O
investigation	NOUN	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
:	PUNCT	O	O
Pharmacotherapeutic	ADJ	O	O
agents	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
uncommonly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
hiccups	NOUN	O	I-Entity
.	PUNCT	O	O

Corticosteroids	NOUN	O	O
(	PUNCT	O	O
dexamethasone	NOUN	O	I-Entity
and	CCONJ	O	O
methylprednisolone	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
benzodiazepines	NOUN	O	I-Entity
(	PUNCT	O	O
midazolam	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
general	ADJ	O	O
anaesthesia	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
the	DET	O	O
specific	ADJ	O	O
agents	NOUN	O	O
mentioned	VERB	O	O
most	ADV	O	O
frequently	ADV	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
as	ADP	O	O
being	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
hiccups	NOUN	O	I-Entity
.	PUNCT	O	O

Few	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hiccups	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
related	VERB	O	O
to	ADP	O	O
macrolide	NOUN	O	I-Entity
antimicrobials	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
the	DET	O	O
Naranjo	PROPN	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
reaction	NOUN	O	O
probability	NOUN	O	O
scale	NOUN	O	O
this	DET	O	O
event	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
classified	VERB	O	O
as	ADP	O	O
possible	ADJ	O	O
(	PUNCT	O	O
score	VERB	O	O
5	NUM	O	O
points	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
mostly	ADV	O	O
because	ADP	O	O
of	ADP	O	O
the	DET	O	O
close	ADJ	O	O
temporal	ADJ	O	O
sequence	NOUN	O	O
,	PUNCT	O	O
previous	ADJ	O	O
reports	NOUN	O	O
on	ADP	O	O
this	DET	O	O
reaction	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
macrolides	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
any	DET	O	O
alternative	ADJ	O	O
explanation	NOUN	O	O
for	ADP	O	O
hiccups	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
hypothesis	NOUN	O	O
is	VERB	O	O
that	ADP	O	O
a	DET	O	O
vagal	NOUN	O	O
mechanism	NOUN	O	O
mediated	VERB	O	O
by	ADP	O	O
azithromycin	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
hiccups	NOUN	O	I-Entity
in	ADP	O	O
our	ADJ	O	O
patient	NOUN	O	O
.	PUNCT	O	O

Diagnosis	PROPN	O	O
of	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hiccups	NOUN	O	I-Entity
is	VERB	O	O
difficult	ADJ	O	O
and	CCONJ	O	O
often	ADV	O	O
achieved	VERB	O	O
only	ADV	O	O
by	ADP	O	O
a	DET	O	O
process	NOUN	O	O
of	ADP	O	O
elimination	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
macrolide	ADJ	O	I-Entity
antimicrobials	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
hiccups	NOUN	O	I-Entity
and	CCONJ	O	O
vagal	ADJ	O	O
mechanism	NOUN	O	O
could	VERB	O	O
explain	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
this	DET	O	O
side	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15276120)

Time	PROPN	O	O
trends	VERB	O	O
in	ADP	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
hemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
annual	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
bleeding	NOUN	O	I-Entity
at	ADP	O	O
Brigham	PROPN	O	O
and	CCONJ	O	O
Women	PROPN	O	O
's	PART	O	O
Hospital	PROPN	O	O
increased	VERB	O	O
from	ADP	O	O
0.97/1,000	NUM	O	O
patient	ADJ	O	O
admissions	NOUN	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
period	NOUN	O	O
(	PUNCT	O	O
January	PROPN	O	O
1995	NUM	O	O
to	ADP	O	O
October	PROPN	O	O
1998	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
1.19/1,000	NUM	O	O
patient	ADJ	O	O
admissions	NOUN	O	O
in	ADP	O	O
the	DET	O	O
second	ADJ	O	O
time	NOUN	O	O
period	NOUN	O	O
(	PUNCT	O	O
November	PROPN	O	O
1998	NUM	O	O
to	ADP	O	O
August	PROPN	O	O
2002	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
major	ADJ	O	O
and	CCONJ	O	O
intracranial	ADJ	O	B-Entity
bleeding	NOUN	O	I-Entity
increased	VERB	O	O
from	ADP	O	O
20.2%	NUM	O	O
and	CCONJ	O	O
1.9%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
to	ADP	O	O
33.3%	NUM	O	O
and	CCONJ	O	O
7.8%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
second	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (11271907)

Fatal	ADJ	O	O
haemorrhagic	ADJ	O	B-Entity
myocarditis	NOUN	O	I-Entity
secondary	ADJ	O	O
to	PART	O	O
cyclophosphamide	VERB	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Haemorrhagic	PROPN	O	B-Entity
myocarditis	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
but	CCONJ	O	O
important	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10524660)

Glyceryl	PROPN	O	B-Entity
trinitrate	NOUN	O	I-Entity
induces	VERB	O	O
attacks	NOUN	O	O
of	ADP	O	O
migraine	NOUN	O	B-Entity
without	ADP	O	I-Entity
aura	NOUN	O	I-Entity
in	ADP	O	O
sufferers	NOUN	O	O
of	ADP	O	O
migraine	NOUN	O	B-Entity
with	ADP	O	I-Entity
aura	NOUN	O	I-Entity
.	PUNCT	O	O

Migraine	PROPN	O	B-Entity
with	ADP	O	I-Entity
aura	NOUN	O	I-Entity
and	CCONJ	O	O
migraine	NOUN	O	B-Entity
without	ADP	O	I-Entity
aura	NOUN	O	I-Entity
have	VERB	O	O
the	DET	O	O
same	ADJ	O	O
pain	NOUN	O	I-Entity
phase	NOUN	O	O
,	PUNCT	O	O
thus	ADV	O	O
indicating	VERB	O	O
that	ADP	O	O
migraine	NOUN	O	B-Entity
with	ADP	O	I-Entity
aura	NOUN	O	I-Entity
and	CCONJ	O	O
migraine	NOUN	O	B-Entity
without	ADP	O	I-Entity
aura	NOUN	O	I-Entity
share	NOUN	O	O
a	DET	O	O
common	ADJ	O	O
pathway	NOUN	O	O
of	ADP	O	O
nociception	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
recent	ADJ	O	O
years	NOUN	O	O
,	PUNCT	O	O
increasing	VERB	O	O
evidence	NOUN	O	O
has	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
the	DET	O	O
messenger	NOUN	O	O
molecule	NOUN	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
(	PUNCT	O	O
NO	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
pain	NOUN	O	I-Entity
mechanisms	NOUN	O	O
of	ADP	O	O
migraine	NOUN	O	B-Entity
without	ADP	O	I-Entity
aura	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
clarify	VERB	O	O
whether	ADP	O	O
the	DET	O	O
same	ADJ	O	O
is	VERB	O	O
true	ADJ	O	O
for	ADP	O	O
migraine	NOUN	O	B-Entity
with	ADP	O	I-Entity
aura	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
we	PRON	O	O
examined	VERB	O	O
the	DET	O	O
headache	NOUN	O	I-Entity
response	NOUN	O	O
to	ADP	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
glyceryl	NOUN	O	B-Entity
trinitrate	NOUN	O	I-Entity
(	PUNCT	O	O
GTN	PROPN	O	I-Entity
)	PUNCT	O	O

(	PUNCT	O	O
0.5	PUNCT	O	O
microg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
for	ADP	O	O
20	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
12	NUM	O	O
sufferers	NOUN	O	O
of	ADP	O	O
migraine	NOUN	O	B-Entity
with	ADP	O	I-Entity
aura	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
specific	ADJ	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
elucidate	VERB	O	O
whether	ADP	O	O
an	DET	O	O
aura	NOUN	O	O
and/or	CCONJ	O	O
an	DET	O	O
attack	NOUN	O	O
of	ADP	O	O
migraine	NOUN	O	B-Entity
without	ADP	O	I-Entity
aura	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
induced	VERB	O	O
.	PUNCT	O	O

Headache	PROPN	O	I-Entity
was	VERB	O	O
more	ADV	O	O
severe	ADJ	O	O
in	ADP	O	O
migraineurs	NOUN	O	I-Entity
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
during	ADP	O	O
and	CCONJ	O	O
immediately	ADV	O	O
after	ADP	O	O
GTN	PROPN	O	I-Entity
infusion	NOUN	O	O
(	PUNCT	O	O
p=0.037	NOUN	O	O
)	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
during	ADP	O	O
the	DET	O	O
following	VERB	O	O
11	NUM	O	O
h	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.008	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
GTN	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
headache	NOUN	O	I-Entity
gradually	ADV	O	O
disappeared	VERB	O	O
,	PUNCT	O	O
whereas	ADP	O	O
in	ADP	O	O
migraineurs	NOUN	O	I-Entity
peak	ADJ	O	O
headache	NOUN	O	I-Entity
intensity	NOUN	O	O
occurred	VERB	O	O
at	ADP	O	O
a	DET	O	O
mean	ADJ	O	O
time	NOUN	O	O
of	ADP	O	O
240	NUM	O	O
min	NOUN	O	O
post	NOUN	O	O
-	PUNCT	O	O
infusion	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
this	DET	O	O
time	NOUN	O	O
the	DET	O	O
induced	VERB	O	O
headache	NOUN	O	I-Entity
in	ADP	O	O
6	NUM	O	O
of	ADP	O	O
12	NUM	O	O
migraineurs	NOUN	O	I-Entity
fulfilled	VERB	O	O
the	DET	O	O
diagnostic	ADJ	O	O
criteria	NOUN	O	O
for	ADP	O	O
migraine	NOUN	O	B-Entity
without	ADP	O	I-Entity
aura	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
International	PROPN	O	O
Headache	PROPN	O	I-Entity
Society	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
therefore	ADV	O	O
suggest	VERB	O	O
that	ADP	O	O
NO	PROPN	O	I-Entity
is	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
pain	NOUN	O	I-Entity
mechanisms	NOUN	O	O
of	ADP	O	O
migraine	ADJ	O	B-Entity
with	ADP	O	I-Entity
aura	NOUN	O	I-Entity
.	PUNCT	O	O

Since	ADP	O	O
cortical	ADJ	O	O
spreading	VERB	O	O
depression	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
liberate	VERB	O	O
NO	NOUN	O	I-Entity
in	ADP	O	O
animals	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
finding	NOUN	O	O
may	VERB	O	O
help	VERB	O	O
our	ADJ	O	O
understanding	NOUN	O	O
of	ADP	O	O
the	DET	O	O
coupling	NOUN	O	O
between	ADP	O	O
cortical	NOUN	O	O
spreading	VERB	O	O
depression	NOUN	O	I-Entity
and	CCONJ	O	O
headache	NOUN	O	I-Entity
in	ADP	O	O
migraine	NOUN	O	B-Entity
with	ADP	O	I-Entity
aura	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9799166)

Stroke	PROPN	O	I-Entity
and	CCONJ	O	O
cocaine	NOUN	O	I-Entity
or	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
association	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
use	NOUN	O	O
with	ADP	O	O
hemorrhagic	ADJ	O	O
and	CCONJ	O	O
ischemic	ADJ	O	I-Entity
stroke	NOUN	O	I-Entity
is	VERB	O	O
based	VERB	O	O
almost	ADV	O	O
solely	ADV	O	O
on	ADP	O	O
data	NOUN	O	O
from	ADP	O	O
case	NOUN	O	O
series	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
limited	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
epidemiologic	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
stroke	NOUN	O	I-Entity
and	CCONJ	O	O
use	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
and/or	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
done	VERB	O	O
in	ADP	O	O
settings	NOUN	O	O
that	ADJ	O	O
serve	VERB	O	O
mostly	ADV	O	O
the	DET	O	O
poor	ADJ	O	O
and/or	CCONJ	O	O
minorities	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
attempted	VERB	O	O
to	PART	O	O
identify	VERB	O	O
all	DET	O	O
incident	NOUN	O	O
strokes	NOUN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
ages	VERB	O	O
15	NUM	O	O
-	SYM	O	O
44	NUM	O	O
years	NOUN	O	O
during	ADP	O	O
a	DET	O	O
3-year	ADJ	O	O
period	NOUN	O	O
using	VERB	O	O
hospital	NOUN	O	O
admission	NOUN	O	O
and	CCONJ	O	O
discharge	NOUN	O	O
records	NOUN	O	O
,	PUNCT	O	O
emergency	NOUN	O	O
department	NOUN	O	O
logs	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
payment	NOUN	O	O
requests	NOUN	O	O
for	ADP	O	O
out	ADV	O	O
-	PUNCT	O	O
of	ADP	O	O
-	PUNCT	O	O
plan	NOUN	O	O
hospitalizations	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
347	NUM	O	O
confirmed	VERB	O	O
stroke	NOUN	O	I-Entity
cases	NOUN	O	O
and	CCONJ	O	O
1,021	NUM	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
univariate	NOUN	O	O
matched	VERB	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
for	ADP	O	O
stroke	NOUN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
admitted	VERB	O	O
to	ADP	O	O
using	VERB	O	O
cocaine	NOUN	O	I-Entity
and/or	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
was	VERB	O	O
8.5	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
=	SYM	O	O
3.6	NUM	O	O
-	SYM	O	O
20.0	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
further	ADJ	O	O
adjustment	NOUN	O	O
for	ADP	O	O
potential	ADJ	O	O
confounders	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
reported	VERB	O	O
using	VERB	O	O
cocaine	NOUN	O	I-Entity
and/or	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
was	VERB	O	O
7.0	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
=	SYM	O	O
2.8	NUM	O	O
-	SYM	O	O
17.9	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
and/or	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
strong	ADJ	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
stroke	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
socioeconomically	ADV	O	O
heterogeneous	ADJ	O	O
,	PUNCT	O	O
insured	VERB	O	O
urban	ADJ	O	O
population	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9672273)

Prevention	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
with	ADP	O	O
tamoxifen	NOUN	O	I-Entity
:	PUNCT	O	O
preliminary	ADJ	O	O
findings	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Italian	PROPN	O	O
randomised	VERB	O	O
trial	NOUN	O	O
among	ADP	O	O
hysterectomised	VERB	O	O
women	NOUN	O	O
.	PUNCT	O	O

Italian	ADJ	O	O
Tamoxifen	PROPN	O	I-Entity
Prevention	PROPN	O	O
Study	PROPN	O	O
.	PUNCT	O	O

Tamoxifen	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
candidate	NOUN	O	O
chemopreventive	ADJ	O	O
agent	NOUN	O	O
in	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
endometrial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Therefore	ADV	O	O
we	PRON	O	O
did	VERB	O	O
a	DET	O	O
trial	NOUN	O	O
in	ADP	O	O
hysterectomised	VERB	O	O
women	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
chemopreventive	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
October	PROPN	O	O
,	PUNCT	O	O
1992	NUM	O	O
,	PUNCT	O	O
we	PRON	O	O
started	VERB	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
randomised	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
(	PUNCT	O	O
mainly	ADV	O	O
in	ADP	O	O
Italy	PROPN	O	O
)	PUNCT	O	O
who	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
have	VERB	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
and	CCONJ	O	O
who	NOUN	O	O
had	VERB	O	O
had	VERB	O	O
a	DET	O	O
hysterectomy	NOUN	O	O
.	PUNCT	O	O

Women	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	VERB	O	O
tamoxifen	NOUN	O	I-Entity
20	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
day	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
both	DET	O	O
orally	ADV	O	O
for	ADP	O	O
5	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
endpoints	NOUN	O	O
are	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
and	CCONJ	O	O
deaths	NOUN	O	O
from	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

41	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
occurred	VERB	O	O
so	ADV	O	O
far	ADV	O	O
;	PUNCT	O	O
there	ADV	O	O
have	VERB	O	O
been	VERB	O	O
no	DET	O	O
deaths	NOUN	O	O
from	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
breast	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
cancer	NOUN	O	I-Entity
frequency	NOUN	O	O
between	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
22	NUM	O	O
cases	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
tamoxifen	NOUN	O	I-Entity
(	PUNCT	O	O
19	NUM	O	O
)	PUNCT	O	O
arms	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
among	ADP	O	O
women	NOUN	O	O
receiving	VERB	O	O
tamoxifen	NOUN	O	I-Entity
who	NOUN	O	O
also	ADV	O	O
used	VERB	O	O
hormone	NOUN	O	O
-	PUNCT	O	O
replacement	NOUN	O	O
therapy	NOUN	O	O
during	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
:	PUNCT	O	O
among	ADP	O	O
390	NUM	O	O
women	NOUN	O	O
on	ADP	O	O
such	ADJ	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
allocated	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
found	VERB	O	O
eight	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
one	NUM	O	O
case	NOUN	O	O
among	ADP	O	O
362	NUM	O	O
women	NOUN	O	O
allocated	VERB	O	O
to	ADP	O	O
tamoxifen	NOUN	O	I-Entity
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
vascular	ADJ	O	B-Entity
events	NOUN	O	I-Entity
and	CCONJ	O	O
hypertriglyceridaemia	NOUN	O	I-Entity
among	ADP	O	O
women	NOUN	O	O
on	ADP	O	O
tamoxifen	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
this	DET	O	O
preliminary	ADJ	O	O
analysis	NOUN	O	O
has	VERB	O	O
low	ADJ	O	O
power	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
this	DET	O	O
cohort	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
at	ADP	O	O
low	ADV	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
normal	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
postulated	ADJ	O	O
protective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	I-Entity
are	VERB	O	O
not	ADV	O	O
yet	ADV	O	O
apparent	ADJ	O	O
.	PUNCT	O	O

Women	NOUN	O	O
using	VERB	O	O
hormone	NOUN	O	O
-	PUNCT	O	O
replacement	NOUN	O	O
therapy	NOUN	O	O
appear	VERB	O	O
to	PART	O	O
have	VERB	O	O
benefited	VERB	O	O
from	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
no	DET	O	O
deaths	NOUN	O	O
from	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
recorded	VERB	O	O
in	ADP	O	O
women	NOUN	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
essential	ADJ	O	O
to	PART	O	O
continue	VERB	O	O
follow	VERB	O	O
-	PUNCT	O	O
up	NOUN	O	O
to	PART	O	O
quantify	VERB	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
risks	NOUN	O	O
and	CCONJ	O	O
benefits	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8854309)

A	DET	O	O
measure	NOUN	O	O
of	ADP	O	O
pupillary	ADJ	O	B-Entity
oscillation	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
marker	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
paranoia	NOUN	O	I-Entity
.	PUNCT	O	O

Cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
paranoia	NOUN	O	I-Entity
(	PUNCT	O	O
CIP	PROPN	O	I-Entity
)	PUNCT	O	O
remains	VERB	O	O
an	DET	O	O
important	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
model	NOUN	O	O
of	ADP	O	O
idiopathic	ADJ	O	O
paranoia	NOUN	O	I-Entity
for	ADP	O	O
which	ADJ	O	O
no	DET	O	O
psychophysiologic	ADJ	O	O
marker	NOUN	O	O
has	VERB	O	O
yet	ADV	O	O
emerged	VERB	O	O
.	PUNCT	O	O

Measures	NOUN	O	O
of	ADP	O	O
pupillary	ADJ	O	B-Entity
oscillation	NOUN	O	I-Entity
were	VERB	O	O
able	ADJ	O	O
to	PART	O	O
significantly	ADV	O	O
distinguish	VERB	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
abstinent	ADJ	O	O
crack	NOUN	O	B-Entity
cocaine	NOUN	O	I-Entity
abusers	NOUN	O	O
endorsing	VERB	O	O
past	ADP	O	O
CIP	PROPN	O	I-Entity
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
32	NUM	O	O
)	PUNCT	O	O
from	ADP	O	O
another	DET	O	O
group	NOUN	O	O
of	ADP	O	O
crack	NOUN	O	I-Entity
addicts	NOUN	O	O
who	NOUN	O	O
denied	VERB	O	O
past	ADP	O	O
CIP	PROPN	O	I-Entity
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
29	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O


-DOCSTART- (8473723)

Seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
combined	VERB	O	O
levomepromazine	NOUN	O	I-Entity
-	PUNCT	O	O
fluvoxamine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
combined	VERB	O	O
levomepromazine	NOUN	O	I-Entity
-	PUNCT	O	O
fluvoxamine	NOUN	O	I-Entity
treatment	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
seems	VERB	O	O
that	ADP	O	O
combined	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
fluvoxamine	NOUN	O	I-Entity
with	ADP	O	O
phenothiazines	NOUN	O	I-Entity
may	VERB	O	O
possess	VERB	O	O
proconvulsive	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6674249)

Why	ADV	O	O
may	VERB	O	O
epsilon	VERB	O	B-Entity
-	PUNCT	O	I-Entity
aminocaproic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
EACA	PROPN	O	I-Entity
)	PUNCT	O	O
induce	VERB	O	O
myopathy	NOUN	O	I-Entity
in	ADP	O	O
man	NOUN	O	O
?	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
necrotizing	VERB	O	B-Entity
myopathy	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
a	DET	O	O
short	ADJ	O	O
epsilon	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminocaproic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
EACA	PROPN	O	I-Entity
)	PUNCT	O	O
treatment	NOUN	O	O
in	ADP	O	O
a	DET	O	O
72	NUM	O	O
year	NOUN	O	O
-	PUNCT	O	O
old	ADJ	O	O
patient	NOUN	O	O
with	ADP	O	O
subarachnoid	ADJ	O	B-Entity
haemorrhage	NOUN	O	I-Entity
(	PUNCT	O	O
SAH	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (6150641)

Comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
ranitidine	NOUN	O	I-Entity
and	CCONJ	O	O
cimetidine	NOUN	O	I-Entity
in	ADP	O	O
inhibiting	VERB	O	O
acid	NOUN	O	O
secretion	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
gastric	ADJ	O	O
hypersecretory	NOUN	O	O
states	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
H2-histamine	ADJ	O	I-Entity
receptor	NOUN	O	O
antagonists	NOUN	O	O
ranitidine	VERB	O	I-Entity
and	CCONJ	O	O
cimetidine	VERB	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
for	ADP	O	O
their	ADJ	O	O
abilities	NOUN	O	O
to	PART	O	O
control	VERB	O	O
gastric	ADJ	O	O
acid	NOUN	O	O
hypersecretion	NOUN	O	O
on	ADP	O	O
a	DET	O	O
short-	NOUN	O	O
and	CCONJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
basis	NOUN	O	O
in	ADP	O	O
22	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
gastric	ADJ	O	O
acid	NOUN	O	O
hypersecretory	NOUN	O	O
states	NOUN	O	O
.	PUNCT	O	O

Nineteen	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
Zollinger	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Ellison	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
,	PUNCT	O	O
one	NUM	O	O
patient	NOUN	O	O
had	VERB	O	O
systemic	ADJ	O	B-Entity
mastocytosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
idiopathic	ADJ	O	O
hypersecretion	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rates	NOUN	O	O
of	ADP	O	O
onset	NOUN	O	O
of	ADP	O	O
the	DET	O	O
action	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
and	CCONJ	O	O
ranitidine	NOUN	O	I-Entity
were	VERB	O	O
the	DET	O	O
same	ADJ	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
ranitidine	NOUN	O	I-Entity
was	VERB	O	O
threefold	ADV	O	O
more	ADV	O	O
potent	ADJ	O	O
than	ADP	O	O
cimetidine	NOUN	O	I-Entity
both	CCONJ	O	O
in	ADP	O	O
acute	ADJ	O	O
inhibition	NOUN	O	O
studies	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
median	ADJ	O	O
maintenance	NOUN	O	O
dose	NOUN	O	O
needed	VERB	O	O
(	PUNCT	O	O
1.2	NUM	O	O
g	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
for	ADP	O	O
ranitidine	NOUN	O	I-Entity
and	CCONJ	O	O
3.6	NUM	O	O
g	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
for	ADP	O	O
cimetidine	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Sixty	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
the	DET	O	O
males	NOUN	O	O
developed	VERB	O	O
breast	NOUN	O	O
changes	NOUN	O	O
or	CCONJ	O	O
impotence	NOUN	O	I-Entity
while	ADP	O	O
taking	VERB	O	O
cimetidine	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
all	DET	O	O
cases	NOUN	O	O
these	DET	O	O
changes	NOUN	O	O
disappeared	VERB	O	O
when	ADV	O	O
cimetidine	NOUN	O	I-Entity
was	VERB	O	O
replaced	VERB	O	O
by	ADP	O	O
ranitidine	NOUN	O	I-Entity
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
(	PUNCT	O	O
one	NOUN	O	O
to	ADP	O	O
60	NUM	O	O
months	NOUN	O	O
;	PUNCT	O	O
median	ADJ	O	O
,	PUNCT	O	O
11	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
ranitidine	NOUN	O	I-Entity
(	PUNCT	O	O
two	NUM	O	O
to	PART	O	O
31	NUM	O	O
months	NOUN	O	O
;	PUNCT	O	O
median	ADJ	O	O
,	PUNCT	O	O
14	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
hepatic	ADJ	O	B-Entity
or	CCONJ	O	I-Entity
hematologic	ADJ	O	I-Entity
toxicity	NOUN	O	I-Entity
or	CCONJ	O	O
alterations	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
gastrin	NOUN	O	O
concentrations	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
ranitidine	NOUN	O	I-Entity
therapy	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
significantly	ADV	O	O
lower	ADJ	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
level	NOUN	O	O
than	ADP	O	O
seen	VERB	O	O
with	ADP	O	O
cimetidine	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
are	VERB	O	O
safe	ADJ	O	O
at	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
ranitidine	NOUN	O	I-Entity
is	VERB	O	O
threefold	ADV	O	O
more	ADV	O	O
potent	ADJ	O	O
and	CCONJ	O	O
does	VERB	O	O
not	ADV	O	O
cause	VERB	O	O
the	DET	O	O
antiandrogen	NOUN	O	O
side	NOUN	O	O
effects	NOUN	O	O
frequently	ADV	O	O
seen	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
cimetidine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3670965)

A	DET	O	O
catch	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Reye	PROPN	O	I-Entity
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
Reye	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
from	ADP	O	O
The	DET	O	O
Children	PROPN	O	O
's	PART	O	O
Hospital	PROPN	O	O
,	PUNCT	O	O
Camperdown	PROPN	O	O
,	PUNCT	O	O
Australia	PROPN	O	O
,	PUNCT	O	O
occurring	VERB	O	O
between	ADP	O	O
1973	NUM	O	O
and	CCONJ	O	O
1982	NUM	O	O
were	VERB	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

Of	ADP	O	O
these	DET	O	O
,	PUNCT	O	O
20	NUM	O	O
cases	NOUN	O	O
met	VERB	O	O
the	DET	O	O
US	PROPN	O	O
Public	PROPN	O	O
Health	PROPN	O	O
Service	PROPN	O	O
Centers	PROPN	O	O
for	ADP	O	O
Disease	PROPN	O	O
Control	PROPN	O	O
criteria	NOUN	O	O
for	ADP	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
Reye	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Aspirin	PROPN	O	I-Entity
or	CCONJ	O	O
salicylate	ADJ	O	I-Entity

ingestion	NOUN	O	O
had	VERB	O	O
occurred	VERB	O	O
in	ADP	O	O
only	ADV	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
20	NUM	O	O
cases	NOUN	O	O
(	PUNCT	O	O
5%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
paracetamol	NOUN	O	I-Entity
(	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
)	PUNCT	O	O
had	VERB	O	O
been	VERB	O	O
administered	VERB	O	O
in	ADP	O	O
only	ADV	O	O
six	NUM	O	O
of	ADP	O	O
the	DET	O	O
cases	NOUN	O	O
(	PUNCT	O	O
30%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Pathologic	ADJ	O	O
confirmation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
Reye	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
was	VERB	O	O
accomplished	VERB	O	O
in	ADP	O	O
90%	NUM	O	O
of	ADP	O	O
the	DET	O	O
cases	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
Reye	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
New	PROPN	O	O
South	PROPN	O	O
Wales	PROPN	O	O
,	PUNCT	O	O
Australia	PROPN	O	O
,	PUNCT	O	O
is	VERB	O	O
estimated	VERB	O	O
from	ADP	O	O
this	DET	O	O
study	NOUN	O	O
to	PART	O	O
be	VERB	O	O
approximately	ADV	O	O
nine	NUM	O	O
cases	NOUN	O	O
per	ADP	O	O
1	NUM	O	O
million	NUM	O	O
children	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
recent	ADJ	O	O
US	PROPN	O	O
data	NOUN	O	O
of	ADP	O	O
ten	NUM	O	O
to	ADP	O	O
20	NUM	O	O
cases	NOUN	O	O
per	ADP	O	O
1	NUM	O	O
million	NUM	O	O
children	NOUN	O	O
and	CCONJ	O	O
three	NUM	O	O
to	ADP	O	O
seven	NUM	O	O
cases	NOUN	O	O
per	ADP	O	O
1	NUM	O	O
million	NUM	O	O
children	NOUN	O	O
in	ADP	O	O
Great	PROPN	O	O
Britain	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
mortality	NOUN	O	O
for	ADP	O	O
these	DET	O	O
Reye	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
cases	NOUN	O	O
in	ADP	O	O
Australia	PROPN	O	O
was	VERB	O	O
45%	NUM	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
a	DET	O	O
32%	NUM	O	O
case	NOUN	O	O
-	PUNCT	O	O
fatality	NOUN	O	O
rate	NOUN	O	O
in	ADP	O	O
the	DET	O	O
United	PROPN	O	O
States	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
Australia	PROPN	O	O
,	PUNCT	O	O
the	DET	O	O
pediatric	ADJ	O	O
usage	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
extremely	ADV	O	O
low	ADJ	O	O
for	ADP	O	O
the	DET	O	O
past	ADJ	O	O
25	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
less	ADJ	O	O
than	ADP	O	O
1%	NUM	O	O
of	ADP	O	O
total	ADJ	O	O
dosage	NOUN	O	O
units	NOUN	O	O
sold	VERB	O	O
)	PUNCT	O	O
,	PUNCT	O	O
with	ADP	O	O
paracetamol	NOUN	O	I-Entity
(	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
)	PUNCT	O	O
dominating	VERB	O	O
the	DET	O	O
pediatric	ADJ	O	O
analgesic	NOUN	O	O
and	CCONJ	O	O
antipyretic	ADJ	O	O
market	NOUN	O	O
.	PUNCT	O	O

Reye	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
disappearing	VERB	O	O
from	ADP	O	O
Australia	PROPN	O	O
despite	ADP	O	O
a	DET	O	O
total	ADJ	O	O
lack	NOUN	O	O
of	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
salicylates	NOUN	O	I-Entity
or	CCONJ	O	O
aspirin	NOUN	O	I-Entity
ingestion	NOUN	O	O
,	PUNCT	O	O
since	ADP	O	O
there	ADV	O	O
were	VERB	O	O
no	DET	O	O
cases	NOUN	O	O
found	VERB	O	O
at	ADP	O	O
The	PROPN	O	O
Children	PROPN	O	O
's	PART	O	O
Hospital	PROPN	O	O
in	ADP	O	O
1983	NUM	O	O
,	PUNCT	O	O
1984	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
1985	NUM	O	O
.	PUNCT	O	O


-DOCSTART- (3300918)

St.	PROPN	O	B-Entity
Anthony	PROPN	O	I-Entity
's	PART	O	I-Entity
fire	NOUN	O	I-Entity
,	PUNCT	O	O
then	ADV	O	O
and	CCONJ	O	O
now	ADV	O	O
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
and	CCONJ	O	O
historical	ADJ	O	O
review	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
rare	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
morbid	ADJ	O	O
vasospasm	NOUN	O	I-Entity
,	PUNCT	O	O
together	ADV	O	O
with	ADP	O	O
striking	VERB	O	O
angiographic	ADJ	O	O
findings	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
described	VERB	O	O
secondary	ADJ	O	O
to	ADP	O	O
the	DET	O	O
ingestion	NOUN	O	O
of	ADP	O	O
methysergide	NOUN	O	I-Entity
by	ADP	O	O
a	DET	O	O
48-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
discussion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
history	NOUN	O	O
of	ADP	O	O
ergot	NOUN	O	I-Entity
includes	VERB	O	O
its	ADJ	O	O
original	ADJ	O	O
discovery	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
epidemics	NOUN	O	O
of	ADP	O	O
gangrene	NOUN	O	I-Entity
that	ADJ	O	O
it	PRON	O	O
has	VERB	O	O
caused	VERB	O	O
through	ADP	O	O
the	DET	O	O
ages	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
past	ADJ	O	O
and	CCONJ	O	O
present	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
migraine	ADJ	O	B-Entity
headache	NOUN	O	I-Entity
.	PUNCT	O	O

Despite	ADP	O	O
the	DET	O	O
advent	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
and	CCONJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
antagonists	NOUN	O	O
,	PUNCT	O	O
ergot	ADJ	O	I-Entity
preparations	NOUN	O	O
continue	VERB	O	O
to	PART	O	O
play	VERB	O	O
a	DET	O	O
major	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
migraine	ADJ	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
so	ADP	O	O
that	ADP	O	O
the	DET	O	O
danger	NOUN	O	O
of	ADP	O	O
St.	PROPN	O	B-Entity
Anthony	PROPN	O	I-Entity
's	PART	O	I-Entity
fire	NOUN	O	I-Entity
persists	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (2826064)

Beta-2-adrenoceptor	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
hypokalemia	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
abolishment	NOUN	O	O
by	ADP	O	O
oxprenolol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
time	NOUN	O	O
course	NOUN	O	O
and	CCONJ	O	O
concentration	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
relationship	NOUN	O	O
of	ADP	O	O
terbutaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypokalemia	NOUN	O	I-Entity
was	VERB	O	O
studied	VERB	O	O
,	PUNCT	O	O
using	VERB	O	O
computer	NOUN	O	O
-	PUNCT	O	O
aided	VERB	O	O
pharmacokinetic	ADJ	O	O
-	PUNCT	O	O
dynamic	ADJ	O	O
modeling	NOUN	O	O
.	PUNCT	O	O

Subsequently	ADV	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
oxprenolol	NOUN	O	I-Entity
in	ADP	O	O
antagonizing	VERB	O	O
such	ADJ	O	O
hypokalemia	NOUN	O	I-Entity
,	PUNCT	O	O
together	ADV	O	O
with	ADP	O	O
the	DET	O	O
pharmacokinetic	ADJ	O	O
interaction	NOUN	O	O
between	ADP	O	O
both	DET	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Six	NUM	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
a	DET	O	O
0.5	NUM	O	O
mg	NUM	O	O
subcutaneous	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
terbutaline	NOUN	O	I-Entity
on	ADP	O	O
two	NUM	O	O
occasions	NOUN	O	O
:	PUNCT	O	O
1	PUNCT	O	O
hour	NOUN	O	O
after	ADP	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
a	DET	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
1	NUM	O	O
hour	NOUN	O	O
after	ADP	O	O
80	NUM	O	O
mg	NUM	O	O
oxprenolol	NOUN	O	I-Entity
orally	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
7-hour	NUM	O	O
period	NOUN	O	O
after	ADP	O	O
terbutaline	NOUN	O	I-Entity
administration	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
for	ADP	O	O
determination	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
potassium	NOUN	O	I-Entity
levels	NOUN	O	O
and	CCONJ	O	O
drug	NOUN	O	O
concentrations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
sigmoid	ADJ	O	O
Emax	PROPN	O	O
model	NOUN	O	O
offered	VERB	O	O
a	DET	O	O
good	ADJ	O	O
description	NOUN	O	O
of	ADP	O	O
the	DET	O	O
relation	NOUN	O	O
between	ADP	O	O
terbutaline	NOUN	O	I-Entity
concentrations	NOUN	O	O
and	CCONJ	O	O
potassium	NOUN	O	I-Entity
effects	NOUN	O	O
.	PUNCT	O	O

Oxprenolol	PROPN	O	I-Entity
caused	VERB	O	O
decreases	NOUN	O	O
of	ADP	O	O
65%	NUM	O	O
and	CCONJ	O	O
56%	NUM	O	O
of	ADP	O	O
terbutaline	NOUN	O	I-Entity
volume	NOUN	O	O
of	ADP	O	O
distribution	NOUN	O	O
and	CCONJ	O	O
clearance	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
130%	NUM	O	O
of	ADP	O	O
its	ADJ	O	O
AUC	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
spite	NOUN	O	O
of	ADP	O	O
higher	ADJ	O	O
terbutaline	NOUN	O	I-Entity
concentrations	NOUN	O	O
after	ADP	O	O
oxprenolol	NOUN	O	I-Entity
pretreatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
hypokalemia	NOUN	O	I-Entity
was	VERB	O	O
almost	ADV	O	O
completely	ADV	O	O
antagonized	VERB	O	O
by	ADP	O	O
the	DET	O	O
beta	NOUN	O	O
2-blocking	VERB	O	O
action	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2422478)

Midline	PROPN	O	O
B3	PROPN	O	O
serotonin	NOUN	O	I-Entity
nerves	NOUN	O	O
in	ADP	O	O
rat	NOUN	O	O
medulla	NOUN	O	O
are	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
hypotensive	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
methyldopa	NOUN	O	I-Entity
.	PUNCT	O	O

Previous	ADJ	O	O
experiments	NOUN	O	O
in	ADP	O	O
this	DET	O	O
laboratory	NOUN	O	O
have	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
microinjection	NOUN	O	O
of	ADP	O	O
methyldopa	NOUN	O	I-Entity
onto	ADP	O	O
the	DET	O	O
ventrolateral	ADJ	O	O
cells	NOUN	O	O
of	ADP	O	O
the	DET	O	O
B3	PROPN	O	O
serotonin	NOUN	O	I-Entity
neurons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
medulla	NOUN	O	O
elicits	VERB	O	O
a	DET	O	O
hypotensive	ADJ	O	I-Entity
response	NOUN	O	O
mediated	VERB	O	O
by	ADP	O	O
a	DET	O	O
projection	NOUN	O	O
descending	VERB	O	O
into	ADP	O	O
the	DET	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
experiments	NOUN	O	O
were	VERB	O	O
designed	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
the	DET	O	O
midline	NOUN	O	O
cells	NOUN	O	O
of	ADP	O	O
the	DET	O	O
B3	PROPN	O	O
serotonin	NOUN	O	I-Entity
neurons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
medulla	NOUN	O	O
,	PUNCT	O	O
coinciding	VERB	O	O
with	ADP	O	O
the	DET	O	O
raphe	NOUN	O	O
magnus	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
,	PUNCT	O	O
stroke	NOUN	O	I-Entity
-	PUNCT	O	O
prone	ADJ	O	O
rats	NOUN	O	O
,	PUNCT	O	O
microinjection	NOUN	O	O
of	ADP	O	O
methyldopa	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
area	NOUN	O	O
of	ADP	O	O
the	DET	O	O
midline	NOUN	O	O
B3	PROPN	O	O
serotonin	NOUN	O	I-Entity
cell	NOUN	O	O
group	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ventral	ADJ	O	O
medulla	NOUN	O	O
caused	VERB	O	O
a	DET	O	O
potent	ADJ	O	O
hypotension	NOUN	O	I-Entity
of	ADP	O	O
30	NUM	O	O
-	SYM	O	O
40	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
maximal	ADJ	O	O
2	NUM	O	O
-	SYM	O	O
3	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
abolished	VERB	O	O
by	ADP	O	O
the	DET	O	O
serotonin	NOUN	O	I-Entity
neurotoxin	NOUN	O	O
5,7-dihydroxytryptamine	NUM	O	I-Entity
(	PUNCT	O	O
5,7-DHT	NUM	O	I-Entity
)	PUNCT	O	O
injected	VERB	O	O
intracerebroventricularly	ADV	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
intraspinal	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
5,7-DHT	NUM	O	I-Entity
to	PART	O	O
produce	VERB	O	O
a	DET	O	O
more	ADV	O	O
selective	ADJ	O	O
lesion	NOUN	O	O
of	ADP	O	O
only	ADV	O	O
descending	VERB	O	O
serotonin	NOUN	O	I-Entity
projections	NOUN	O	O
in	ADP	O	O
the	DET	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
this	DET	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Further	ADV	O	O
,	PUNCT	O	O
5,7-DHT	NUM	O	I-Entity
lesion	NOUN	O	O
of	ADP	O	O
serotonin	NOUN	O	I-Entity
nerves	NOUN	O	O
travelling	VERB	O	O
in	ADP	O	O
the	DET	O	O
median	ADJ	O	O
forebrain	NOUN	O	O
bundle	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
main	ADJ	O	O
ascending	VERB	O	O
pathways	NOUN	O	O
from	ADP	O	O
the	DET	O	O
B3	PROPN	O	O
serotonin	NOUN	O	I-Entity
cells	NOUN	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
the	DET	O	O
fall	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
midline	NOUN	O	O
B3	PROPN	O	O
serotonin	NOUN	O	I-Entity
methyldopa	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
therefore	ADV	O	O
that	ADP	O	O
,	PUNCT	O	O
unlike	ADP	O	O
the	DET	O	O
ventrolateral	ADJ	O	O
B3	NOUN	O	O
cells	NOUN	O	O
which	ADJ	O	O
mediate	VERB	O	O
a	DET	O	O
methyldopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
via	ADP	O	O
descending	VERB	O	O
projections	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
midline	NOUN	O	O
serotonin	NOUN	O	I-Entity
B3	NOUN	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
medulla	NOUN	O	O
contribute	VERB	O	O
to	ADP	O	O
the	DET	O	O
hypotensive	ADJ	O	I-Entity
action	NOUN	O	O
of	ADP	O	O
methyldopa	NOUN	O	I-Entity
,	PUNCT	O	O
either	ADV	O	O
by	ADP	O	O
way	NOUN	O	O
of	ADP	O	O
an	DET	O	O
ascending	VERB	O	O
projection	NOUN	O	O
which	ADJ	O	O
does	VERB	O	O
not	ADV	O	O
pass	VERB	O	O
through	ADP	O	O
the	DET	O	O
median	ADJ	O	O
forebrain	NOUN	O	O
bundle	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
through	ADP	O	O
a	DET	O	O
projection	NOUN	O	O
restricted	VERB	O	O
to	ADP	O	O
the	DET	O	O
caudal	NOUN	O	O
brainstem	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1535072)

Yohimbine	ADJ	O	I-Entity
treatment	NOUN	O	O
of	ADP	O	O
sexual	ADJ	O	B-Entity
side	NOUN	O	I-Entity
effects	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
blockers	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
Preclinical	ADJ	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
yohimbine	NOUN	O	I-Entity
facilitates	VERB	O	O
sexual	ADJ	O	O
behavior	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
helpful	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
male	ADJ	O	B-Entity
impotence	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
single	ADJ	O	O
case	NOUN	O	O
report	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
yohimbine	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
treat	VERB	O	O
the	DET	O	O
sexual	ADJ	O	B-Entity
side	NOUN	O	I-Entity
effects	NOUN	O	I-Entity
of	ADP	O	O
clomipramine	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
evaluated	VERB	O	O
yohimbine	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
treatment	NOUN	O	O
for	ADP	O	O
the	DET	O	O
sexual	ADJ	O	B-Entity
side	NOUN	O	I-Entity
effects	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
blockers	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
:	PUNCT	O	O
Six	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
obsessive	ADJ	O	B-Entity
compulsive	ADJ	O	I-Entity
disorder	NOUN	O	I-Entity
,	PUNCT	O	O
trichotillomania	ADV	O	I-Entity
,	PUNCT	O	O
anxiety	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
affective	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
who	NOUN	O	O
suffered	VERB	O	O
sexual	ADJ	O	B-Entity
side	NOUN	O	I-Entity
effects	NOUN	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
blockers	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
yohimbine	NOUN	O	I-Entity
on	ADP	O	O
a	DET	O	O
p.r.n	NOUN	O	O
.	PUNCT	O	O

Various	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
yohimbine	NOUN	O	I-Entity
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
ideal	ADJ	O	O
dose	NOUN	O	O
for	ADP	O	O
each	DET	O	O
patient	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
of	ADP	O	O
the	DET	O	O
six	NUM	O	O
patients	NOUN	O	O
experienced	VERB	O	O
improved	VERB	O	O
sexual	ADJ	O	O
functioning	NOUN	O	O
after	ADP	O	O
taking	VERB	O	O
yohimbine	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
who	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
comply	VERB	O	O
with	ADP	O	O
yohimbine	NOUN	O	I-Entity
treatment	NOUN	O	O
had	VERB	O	O
no	DET	O	O
therapeutic	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Side	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
yohimbine	NOUN	O	I-Entity
included	VERB	O	O
excessive	ADJ	O	O
sweating	NOUN	O	O
,	PUNCT	O	O
increased	VERB	O	O
anxiety	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
wound	NOUN	O	O
-	PUNCT	O	O
up	PART	O	O
feeling	NOUN	O	O
in	ADP	O	O
some	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
yohimbine	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
the	DET	O	O
sexual	ADJ	O	B-Entity
side	NOUN	O	I-Entity
effects	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
blockers	NOUN	O	O
.	PUNCT	O	O

Future	NOUN	O	O
controlled	VERB	O	O
studies	NOUN	O	O
are	VERB	O	O
needed	VERB	O	O
to	PART	O	O
further	ADV	O	O
investigate	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
yohimbine	NOUN	O	I-Entity
for	ADP	O	O
this	DET	O	O
indication	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1504402)

Hypersensitivity	PROPN	O	I-Entity
immune	ADJ	O	O
reaction	NOUN	O	O
as	ADP	O	O
a	DET	O	O
mechanism	NOUN	O	O
for	ADP	O	O
dilevalol	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
assess	VERB	O	O
lymphocyte	NOUN	O	O
reactivity	NOUN	O	O
to	ADP	O	O
dilevalol	VERB	O	I-Entity
and	CCONJ	O	O
to	PART	O	O
serum	VERB	O	O
containing	VERB	O	O
putative	ADJ	O	O
ex	NOUN	O	O
vivo	NOUN	O	O
dilevalol	NOUN	O	I-Entity
antigens	NOUN	O	O
or	CCONJ	O	O
metabolites	NOUN	O	O
in	ADP	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
dilevalol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
liver	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
58-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
dilevalol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
liver	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

Peripheral	ADJ	O	O
blood	NOUN	O	O
mononuclear	NOUN	O	O
cells	NOUN	O	O
collected	VERB	O	O
from	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
were	VERB	O	O
cultured	VERB	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
solution	NOUN	O	O
of	ADP	O	O
dilevalol	NOUN	O	I-Entity
and	CCONJ	O	O
also	ADV	O	O
with	ADP	O	O
sera	NOUN	O	O
collected	VERB	O	O
from	ADP	O	O
a	DET	O	O
volunteer	NOUN	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
dilevalol	NOUN	O	I-Entity
intake	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
lymphocyte	NOUN	O	O
proliferation	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
either	ADV	O	O
in	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
or	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
healthy	ADJ	O	O
volunteer	NOUN	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
dilevalol	ADJ	O	I-Entity
solutions	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
proliferative	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
serum	NOUN	O	O
collected	VERB	O	O
after	ADP	O	O
dilevalol	NOUN	O	I-Entity
intake	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
proliferative	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
collected	VERB	O	O
before	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
intake	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
methodology	NOUN	O	O
used	VERB	O	O
allowed	VERB	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
lymphocyte	NOUN	O	O
sensitization	NOUN	O	O
to	ADP	O	O
sera	NOUN	O	O
containing	VERB	O	O
ex	NOUN	O	O
vivo	NOUN	O	O
-	PUNCT	O	O
prepared	ADJ	O	O
dilevalol	NOUN	O	I-Entity
antigens	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
the	DET	O	O
involvement	NOUN	O	O
of	ADP	O	O
an	DET	O	O
immunologic	ADJ	O	O
mechanism	NOUN	O	O
in	ADP	O	O
dilevalol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
liver	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19917396)

Reversible	ADJ	O	O
myocardial	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
tacrolimus	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
pediatric	ADJ	O	O
heart	NOUN	O	O
transplant	NOUN	O	O
recipient	NOUN	O	O
:	PUNCT	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

Tacrolimus	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
potent	ADJ	O	O
immunosuppressant	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
frequently	ADV	O	O
used	VERB	O	O
in	ADP	O	O
organ	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
include	VERB	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Herein	PROPN	O	O
we	PRON	O	O
describe	VERB	O	O
transient	ADJ	O	O
myocardial	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
tacrolimus	NOUN	O	I-Entity
after	ADP	O	O
heart	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hypertrophy	NOUN	O	I-Entity
caused	VERB	O	O
no	DET	O	O
clinical	ADJ	O	O
symptoms	NOUN	O	O
but	CCONJ	O	O
was	VERB	O	O
noted	VERB	O	O
because	ADP	O	O
of	ADP	O	O
elevation	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
brain	NOUN	O	O
natriuretic	ADJ	O	O
peptide	NOUN	O	O
concentration	NOUN	O	O
and	CCONJ	O	O
confirmed	VERB	O	O
at	ADP	O	O
echocardiography	NOUN	O	O
.	PUNCT	O	O

Initially	ADV	O	O
,	PUNCT	O	O
allograft	NOUN	O	O
rejection	NOUN	O	O
was	VERB	O	O
feared	VERB	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
myocardial	ADJ	O	O
biopsy	NOUN	O	O
samples	NOUN	O	O
revealed	VERB	O	O
only	ADV	O	O
interstitial	ADJ	O	O
edema	NOUN	O	I-Entity
and	CCONJ	O	O
mild	ADJ	O	O
myocardial	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
;	PUNCT	O	O
neither	CCONJ	O	O
cellular	ADJ	O	O
nor	CCONJ	O	O
humoral	ADJ	O	O
rejection	NOUN	O	O
was	VERB	O	O
detected	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
blood	NOUN	O	O
tacrolimus	NOUN	O	I-Entity
concentration	NOUN	O	O
was	VERB	O	O
higher	ADJ	O	O
than	ADP	O	O
usual	ADJ	O	O
at	ADP	O	O
that	DET	O	O
time	NOUN	O	O
;	PUNCT	O	O
thus	ADV	O	O
,	PUNCT	O	O
tacrolimus	NOUN	O	I-Entity
dosage	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
.	PUNCT	O	O

Myocardial	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
completely	ADV	O	O
resolved	VERB	O	O
upon	ADP	O	O
reducing	VERB	O	O
the	DET	O	O
target	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
tacrolimus	NOUN	O	I-Entity
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
recur	VERB	O	O
,	PUNCT	O	O
as	ADP	O	O
confirmed	VERB	O	O
at	ADP	O	O
echocardiography	NOUN	O	O
and	CCONJ	O	O
myocardial	ADJ	O	O
biopsy	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
tacrolimus	NOUN	O	I-Entity
induces	VERB	O	O
reversible	ADJ	O	O
myocardial	ADJ	O	B-Entity
hypertrophy	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
tacrolimus	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
blood	NOUN	O	O
concentration	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
carefully	ADV	O	O
controlled	VERB	O	O
and	CCONJ	O	O
extreme	ADJ	O	O
attention	NOUN	O	O
paid	VERB	O	O
to	ADP	O	O
cardiac	ADJ	O	O
involvement	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19234905)

Comparison	NOUN	O	O
of	ADP	O	O
unilateral	ADJ	O	O
pallidotomy	NOUN	O	O
and	CCONJ	O	O
subthalamotomy	NOUN	O	O
findings	NOUN	O	O
in	ADP	O	O
advanced	ADJ	O	O
idiopathic	ADJ	O	B-Entity
Parkinson	PROPN	O	I-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
pilot	NOUN	O	O
study	NOUN	O	O
to	PART	O	O
compare	VERB	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
stereotactic	ADJ	O	O
unilateral	ADJ	O	O
pallidotomy	NOUN	O	O
and	CCONJ	O	O
subthalamotomy	NOUN	O	O
in	ADP	O	O
advanced	ADJ	O	O
idiopathic	ADJ	O	B-Entity
Parkinson	PROPN	O	I-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
refractory	ADJ	O	O
to	ADP	O	O
medical	ADJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
.	PUNCT	O	O

3.5	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
disabling	VERB	O	O
motor	NOUN	O	O
fluctuations	NOUN	O	O
(	PUNCT	O	O
Hoehn	PROPN	O	O
_	PUNCT	O	O
Yahr	PROPN	O	O
stage	NOUN	O	O
3	NUM	O	O
-	SYM	O	O
5	NUM	O	O
in	ADP	O	O
off	ADV	O	O
-	PUNCT	O	O
drug	NOUN	O	O
phases	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
were	VERB	O	O
selected	VERB	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
bilateral	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
levodopa	NOUN	O	I-Entity
equivalent	ADJ	O	O
dosing	VERB	O	O
were	VERB	O	O
analysed	VERB	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
evaluation	NOUN	O	O
included	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Unified	PROPN	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
Disease	PROPN	O	I-Entity
Rating	PROPN	O	O
Scale	PROPN	O	O
(	PUNCT	O	O
UPDRS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Hoehn_Yahr	PROPN	O	O
score	NOUN	O	O
and	CCONJ	O	O
Schwab	PROPN	O	O
England	PROPN	O	O
activities	NOUN	O	O
of	ADP	O	O
daily	ADJ	O	O
living	NOUN	O	O
(	PUNCT	O	O
ADL	PROPN	O	O
)	PUNCT	O	O
score	NOUN	O	O
in	ADP	O	O
'	PUNCT	O	O
on'-	NUM	O	O
and	CCONJ	O	O
'	PUNCT	O	O
off'-drug	ADJ	O	O
conditions	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
all	DET	O	O
contralateral	ADJ	O	O
major	ADJ	O	O
parkinsonian	ADJ	O	I-Entity
motor	NOUN	O	O
signs	NOUN	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
followed	VERB	O	O
for	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Levodopa	PROPN	O	I-Entity
equivalent	ADJ	O	O
daily	ADJ	O	O
intake	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
in	ADP	O	O
the	DET	O	O
STN	PROPN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Complications	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
:	PUNCT	O	O
one	NUM	O	O
had	VERB	O	O
a	DET	O	O
left	ADJ	O	O
homonymous	ADJ	O	B-Entity
hemianopsia	NOUN	O	I-Entity
after	ADP	O	O
pallidotomy	NOUN	O	O
and	CCONJ	O	O
another	DET	O	O
one	NOUN	O	O
developed	VERB	O	O
left	ADJ	O	O
hemiballistic	ADJ	O	O
movements	NOUN	O	O
3	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
subthalamotomy	NOUN	O	O
which	ADJ	O	O
partly	ADV	O	O
improved	VERB	O	O
within	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
with	ADP	O	O
Valproate	PROPN	O	I-Entity
1000	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
findings	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
lesions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
unilateral	ADJ	O	O
STN	PROPN	O	O
and	CCONJ	O	O
GPi	NOUN	O	O
are	VERB	O	O
equally	ADV	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
PD	PROPN	O	I-Entity
refractory	ADJ	O	O
to	ADP	O	O
medical	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18541230)

Protective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
antithrombin	NOUN	O	O
on	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
nephrosis	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
antithrombin	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
plasma	NOUN	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
coagulation	NOUN	O	O
factors	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrosis	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
an	DET	O	O
experimental	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Antithrombin	PROPN	O	O
(	PUNCT	O	O
50	NUM	O	O
or	CCONJ	O	O
500	NUM	O	O
IU	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
i.v	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
rats	NOUN	O	O
once	ADP	O	O
a	DET	O	O
day	NOUN	O	O
for	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
immediately	ADV	O	O
after	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
i.v	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
antithrombin	NOUN	O	O
attenuated	VERB	O	O
the	DET	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hematological	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
.	PUNCT	O	O

Puromycin	PROPN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
hyperlipidemia	NOUN	O	I-Entity
were	VERB	O	O
also	ADV	O	O
suppressed	VERB	O	O
.	PUNCT	O	O

Histopathological	ADJ	O	O
examination	NOUN	O	O
revealed	VERB	O	O
severe	ADJ	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
such	ADJ	O	O
as	ADP	O	O
proteinaceous	ADJ	O	O
casts	NOUN	O	O
in	ADP	O	O
tubuli	NOUN	O	O
and	CCONJ	O	O
tubular	ADJ	O	O
expansion	NOUN	O	O
in	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
of	ADP	O	O
control	NOUN	O	O
rats	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
an	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
damage	NOUN	O	O
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
antithrombin	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
antithrombin	ADJ	O	O
treatment	NOUN	O	O
markedly	ADV	O	O
suppressed	VERB	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
apoptosis	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
tubular	ADJ	O	O
epithelial	ADJ	O	O
cells	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
puromycin	VERB	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increases	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
cytokine	NOUN	O	O
content	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
decreased	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
thrombin	NOUN	O	O
plays	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
antithrombin	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
clinically	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18177388)

Reverse	ADJ	O	O
or	CCONJ	O	O
inverted	ADJ	O	O
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
apical	ADJ	O	I-Entity
ballooning	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
reverse	VERB	O	O
Takotsubo	PROPN	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
young	ADJ	O	O
woman	NOUN	O	O
in	ADP	O	O
the	DET	O	O
setting	NOUN	O	O
of	ADP	O	O
amphetamine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

Transient	PROPN	O	O
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
apical	ADJ	O	I-Entity
ballooning	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
was	VERB	O	O
first	ADV	O	O
described	VERB	O	O
in	ADP	O	O
Japan	PROPN	O	O
as	ADP	O	O
"	PUNCT	O	O
Takotsubo	PROPN	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
of	ADP	O	O
the	DET	O	O
rarest	ADJ	O	O
is	VERB	O	O
the	DET	O	O
reverse	ADJ	O	O
type	NOUN	O	O
of	ADP	O	O
this	DET	O	O
syndrome	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
hyperdynamic	ADJ	O	O
apex	NOUN	O	O
and	CCONJ	O	O
complete	ADJ	O	O
akinesia	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
base	NOUN	O	O
(	PUNCT	O	O
as	ADP	O	O
opposed	VERB	O	O
to	ADP	O	O
the	DET	O	O
classic	ADJ	O	O
apical	ADJ	O	B-Entity
ballooning	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
article	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
report	VERB	O	O
an	DET	O	O
interesting	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
young	ADJ	O	O
woman	NOUN	O	O
who	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
this	DET	O	O
rare	ADJ	O	O
type	NOUN	O	O
of	ADP	O	O
reverse	NOUN	O	O
apical	ADJ	O	B-Entity
ballooning	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
occurring	VERB	O	O
after	ADP	O	O
amphetamine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17490864)

Attenuated	ADJ	O	O
disruption	NOUN	O	O
of	ADP	O	O
prepulse	NOUN	O	O
inhibition	NOUN	O	O
by	ADP	O	O
dopaminergic	ADJ	O	O
stimulation	NOUN	O	O
after	ADP	O	O
maternal	ADJ	O	O
deprivation	NOUN	O	O
and	CCONJ	O	O
adolescent	ADJ	O	O
corticosterone	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
development	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
may	VERB	O	O
include	VERB	O	O
an	DET	O	O
early	ADJ	O	O
neurodevelopmental	ADJ	O	O
stress	NOUN	O	O
component	NOUN	O	O
which	ADJ	O	O
increases	VERB	O	O
vulnerability	NOUN	O	O
to	PART	O	O
later	ADV	O	O
stressful	ADJ	O	O
life	NOUN	O	O
events	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
combination	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
overt	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
an	DET	O	O
early	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
form	NOUN	O	O
of	ADP	O	O
maternal	ADJ	O	O
deprivation	NOUN	O	O
,	PUNCT	O	O
combined	VERB	O	O
with	ADP	O	O
a	DET	O	O
later	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
simulated	VERB	O	O
by	ADP	O	O
chronic	ADJ	O	O
periadolescent	NOUN	O	O
corticosterone	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
behaviour	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
apomorphine	NOUN	O	I-Entity
caused	VERB	O	O
disruption	NOUN	O	O
of	ADP	O	O
prepulse	ADJ	O	O
inhibition	NOUN	O	O
(	PUNCT	O	O
PPI	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
controls	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
rats	NOUN	O	O
that	ADJ	O	O
had	VERB	O	O
undergone	VERB	O	O
either	ADV	O	O
maternal	ADJ	O	O
deprivation	NOUN	O	O
or	CCONJ	O	O
corticosterone	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
surprisingly	ADV	O	O
absent	ADJ	O	O
in	ADP	O	O
rats	NOUN	O	O
that	ADJ	O	O
had	VERB	O	O
undergone	VERB	O	O
the	DET	O	O
combined	VERB	O	O
early	ADV	O	O
and	CCONJ	O	O
late	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

Amphetamine	ADJ	O	I-Entity
treatment	NOUN	O	O
significantly	ADV	O	O
disrupted	VERB	O	O
PPI	PROPN	O	O
in	ADP	O	O
both	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
deprived	ADJ	O	O
groups	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
absent	ADJ	O	O
in	ADP	O	O
both	DET	O	O
maternally	ADV	O	O
deprived	ADJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
serotonin-1A	ADJ	O	I-Entity
receptor	NOUN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
8-OH	NUM	O	B-Entity
-	PUNCT	O	I-Entity
DPAT	PROPN	O	I-Entity
,	PUNCT	O	O
induced	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
disruption	NOUN	O	O
of	ADP	O	O
PPI	PROPN	O	O
in	ADP	O	O
all	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	B-Entity
hyperactivity	NOUN	O	I-Entity
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
all	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
show	VERB	O	O
an	DET	O	O
inhibitory	ADJ	O	O
interaction	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
caused	VERB	O	O
by	ADP	O	O
maternal	ADJ	O	O
deprivation	NOUN	O	O
,	PUNCT	O	O
combined	VERB	O	O
with	ADP	O	O
'	PUNCT	O	O
adolescent	NOUN	O	O
'	PUNCT	O	O
stress	NOUN	O	O
,	PUNCT	O	O
simulated	VERB	O	O
by	ADP	O	O
corticosterone	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
dopaminergic	ADJ	O	O
regulation	NOUN	O	O
of	ADP	O	O
PPI	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
altered	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
apomorphine	NOUN	O	I-Entity
and	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
could	VERB	O	O
indicate	VERB	O	O
differential	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
dopamine	NOUN	O	I-Entity
receptor	NOUN	O	O
signalling	VERB	O	O
leading	VERB	O	O
to	ADP	O	O
functional	ADJ	O	O
desensitisation	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
altered	VERB	O	O
modulation	NOUN	O	O
of	ADP	O	O
sensory	ADJ	O	O
gating	NOUN	O	O
in	ADP	O	O
the	DET	O	O
nucleus	NOUN	O	O
accumbens	VERB	O	O
by	ADP	O	O
limbic	ADJ	O	O
structures	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17490790)

Peripheral	ADJ	O	O
iron	NOUN	O	B-Entity
dextran	NOUN	O	I-Entity
induced	VERB	O	O
degeneration	NOUN	O	B-Entity
of	ADP	O	I-Entity
dopaminergic	ADJ	O	I-Entity
neurons	NOUN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
.	PUNCT	O	O

Iron	PROPN	O	I-Entity
accumulation	NOUN	O	O
is	VERB	O	O
considered	VERB	O	O
to	PART	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
demonstrate	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
peripheral	ADJ	O	O
iron	NOUN	O	I-Entity
overload	NOUN	O	O
and	CCONJ	O	O
dopaminergic	ADJ	O	O
neuron	NOUN	O	O
loss	NOUN	O	O
in	ADP	O	O
rat	NOUN	O	O
substantia	NOUN	O	O
nigra	NOUN	O	O
(	PUNCT	O	O
SN	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
we	PRON	O	O
used	VERB	O	O
fast	ADV	O	O
cyclic	ADJ	O	O
voltammetry	NOUN	O	O
,	PUNCT	O	O
tyrosine	NOUN	O	I-Entity
hydroxylase	NOUN	O	O
(	PUNCT	O	O
TH	PROPN	O	O
)	PUNCT	O	O

immunohistochemistry	NOUN	O	O
,	PUNCT	O	O
Perls	PROPN	O	O
'	PART	O	O
iron	NOUN	O	I-Entity
staining	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
high	ADJ	O	O
performance	NOUN	O	O
liquid	NOUN	O	O
chromatography	NOUN	O	O
-	PUNCT	O	O
electrochemical	ADJ	O	O
detection	NOUN	O	O
to	PART	O	O
study	VERB	O	O
the	DET	O	O
degeneration	NOUN	O	B-Entity
of	ADP	O	I-Entity
dopaminergic	ADJ	O	I-Entity
neurons	NOUN	O	I-Entity
and	CCONJ	O	O
increased	VERB	O	O
iron	NOUN	O	I-Entity
content	NOUN	O	O
in	ADP	O	O
the	DET	O	O
SN	PROPN	O	O
of	ADP	O	O
iron	NOUN	O	B-Entity
dextran	NOUN	O	I-Entity
overloaded	ADJ	O	O
animals	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
findings	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
peripheral	ADJ	O	O
iron	NOUN	O	B-Entity
dextran	NOUN	O	I-Entity
overload	NOUN	O	O
increased	VERB	O	O
the	DET	O	O
iron	NOUN	O	I-Entity
staining	VERB	O	O
positive	ADJ	O	O
cells	NOUN	O	O
and	CCONJ	O	O
reduced	VERB	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
TH	PROPN	O	O
-	PUNCT	O	O
immunoreactive	ADJ	O	O
neurons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
SN	PROPN	O	O
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
result	NOUN	O	O
,	PUNCT	O	O
dopamine	NOUN	O	I-Entity
release	NOUN	O	O
and	CCONJ	O	O
content	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
its	ADJ	O	O
metabolites	NOUN	O	O
contents	NOUN	O	O
were	VERB	O	O
decreased	VERB	O	O
in	ADP	O	O
caudate	NOUN	O	O
putamen	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
peripheral	ADJ	O	O
iron	NOUN	O	B-Entity
dextran	NOUN	O	I-Entity
can	VERB	O	O
increase	VERB	O	O
the	DET	O	O
iron	NOUN	O	I-Entity
level	NOUN	O	O
in	ADP	O	O
the	DET	O	O
SN	PROPN	O	O
,	PUNCT	O	O
where	ADV	O	O
excessive	ADJ	O	O
iron	NOUN	O	I-Entity
causes	VERB	O	O
the	DET	O	O
degeneration	NOUN	O	B-Entity
of	ADP	O	I-Entity
dopaminergic	ADJ	O	I-Entity
neurons	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
chronic	ADJ	O	O
iron	NOUN	O	I-Entity
overload	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
more	ADV	O	O
destructive	ADJ	O	O
to	ADP	O	O
dopaminergic	ADJ	O	O
neurons	NOUN	O	O
than	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
iron	NOUN	O	I-Entity
overload	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16047871)

Warfarin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
leukocytoclastic	ADJ	O	B-Entity
vasculitis	NOUN	O	I-Entity
.	PUNCT	O	O

Skin	PROPN	O	O
reactions	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
oral	ADJ	O	O
coumarin	NOUN	O	I-Entity
-	PUNCT	O	O
derived	VERB	O	O
anticoagulants	NOUN	O	O
are	VERB	O	O
an	DET	O	O
uncommon	ADJ	O	O
occurrence	NOUN	O	O
.	PUNCT	O	O

Leukocytoclastic	ADJ	O	B-Entity
vasculitis	NOUN	O	I-Entity
(	PUNCT	O	O
LV	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
primarily	ADV	O	O
a	DET	O	O
cutaneous	ADJ	O	B-Entity
small	ADJ	O	I-Entity
vessel	NOUN	O	I-Entity
vasculitis	NOUN	O	I-Entity
,	PUNCT	O	O
though	ADP	O	O
systemic	ADJ	O	O
involvement	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
encountered	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
4	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
late	ADV	O	O
-	PUNCT	O	O
onset	NOUN	O	O
LV	PROPN	O	I-Entity
probably	ADV	O	O
due	ADP	O	O
to	ADP	O	O
warfarin	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
4	NUM	O	O
patients	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
skin	NOUN	O	B-Entity
eruptions	NOUN	O	I-Entity
that	ADJ	O	O
developed	VERB	O	O
after	ADP	O	O
receiving	VERB	O	O
warfarin	NOUN	O	I-Entity
for	ADP	O	O
several	ADJ	O	O
years	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
skin	NOUN	O	B-Entity
lesion	NOUN	O	I-Entity
biopsies	NOUN	O	O
were	VERB	O	O
available	ADJ	O	O
in	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
confirming	VERB	O	O
LV	PROPN	O	B-Entity
Cutaneous	PROPN	O	I-Entity
lesions	NOUN	O	I-Entity
resolved	VERB	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
after	ADP	O	O
warfarin	NOUN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
2	NUM	O	O
of	ADP	O	O
the	DET	O	O
4	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
rechallenge	NOUN	O	O
with	ADP	O	O
warfarin	NOUN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
recurrence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lesions	NOUN	O	O
.	PUNCT	O	O

LV	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
late	ADJ	O	O
-	PUNCT	O	O
onset	NOUN	O	O
adverse	ADJ	O	O
reaction	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
warfarin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15673851)

The	DET	O	O
activation	NOUN	O	O
of	ADP	O	O
spinal	ADJ	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
receptors	NOUN	O	O
may	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
degeneration	NOUN	O	O
of	ADP	O	O
spinal	ADJ	O	O
motor	NOUN	O	O
neurons	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
neuraxial	ADJ	O	O
morphine	NOUN	O	I-Entity
after	ADP	O	O
a	DET	O	O
noninjurious	ADJ	O	O
interval	NOUN	O	O
of	ADP	O	O
spinal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
ischemia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
degeneration	NOUN	O	O
of	ADP	O	O
spinal	ADJ	O	O
motor	NOUN	O	O
neurons	NOUN	O	O
and	CCONJ	O	O
activation	NOUN	O	O
of	ADP	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
d	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA	PROPN	O	I-Entity
)	PUNCT	O	O
receptors	NOUN	O	O
after	ADP	O	O
neuraxial	ADJ	O	O
morphine	NOUN	O	I-Entity
following	VERB	O	O
a	DET	O	O
noninjurious	ADJ	O	O
interval	NOUN	O	O
of	ADP	O	O
aortic	ADJ	O	B-Entity
occlusion	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Spinal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
ischemia	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
aortic	ADJ	O	B-Entity
occlusion	NOUN	O	I-Entity
for	ADP	O	O
6	NUM	O	O
min	NOUN	O	O
with	ADP	O	O
a	DET	O	O
balloon	NOUN	O	O
catheter	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
microdialysis	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
muL	NOUN	O	O
of	ADP	O	O
saline	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
C	PROPN	O	O
;	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
8)	NUM	O	O
or	CCONJ	O	O
30	NUM	O	O
mug	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
(	PUNCT	O	O
group	NOUN	O	O
M	PROPN	O	O
;	PUNCT	O	O
n	CCONJ	O	O

=	SYM	O	O
8)	NUM	O	O
was	VERB	O	O
injected	VERB	O	O
intrathecally	ADV	O	O
(	PUNCT	O	O
IT	NOUN	O	O
)	PUNCT	O	O
0.5	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
reflow	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
30	NUM	O	O
mug	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
(	PUNCT	O	O
group	NOUN	O	O
SM	PROPN	O	O
;	PUNCT	O	O

Second	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
IT	NOUN	O	O
MK-801	PROPN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
mug	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
histopathologic	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
after	ADP	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
spastic	ADJ	O	B-Entity
paraparesis	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
IT	PROPN	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
(	PUNCT	O	O
CSF	PROPN	O	O
)	PUNCT	O	O
glutamate	NOUN	O	I-Entity
concentration	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
in	ADP	O	O
group	NOUN	O	O
M	PROPN	O	O
relative	ADJ	O	O
to	ADP	O	O
both	DET	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
group	NOUN	O	O
C	PROPN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

IT	PRON	O	O
MK-801	VERB	O	I-Entity
significantly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
dark	ADJ	O	O
-	PUNCT	O	O
stained	VERB	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
motoneurons	NOUN	O	O
after	ADP	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
spastic	ADJ	O	B-Entity
paraparesis	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
saline	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
IT	PRON	O	O
morphine	NOUN	O	I-Entity
induces	VERB	O	O
spastic	ADJ	O	B-Entity
paraparesis	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
concomitant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
CSF	PROPN	O	O
glutamate	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
activation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
opioids	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
neurotoxic	ADJ	O	I-Entity
in	ADP	O	O
the	DET	O	O
setting	NOUN	O	O
of	ADP	O	O
spinal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
ischemia	NOUN	O	I-Entity
via	ADP	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
activation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12481039)

Reduced	ADJ	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
density	NOUN	O	O
,	PUNCT	O	O
altered	VERB	O	O
voltage	NOUN	O	O
dependence	NOUN	O	O
of	ADP	O	O
inactivation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
lacking	VERB	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
beta	NOUN	O	O
2-subunits	NOUN	O	O
.	PUNCT	O	O

Sodium	NOUN	O	I-Entity
channel	NOUN	O	O
beta	NOUN	O	O
-	PUNCT	O	O
subunits	NOUN	O	O
modulate	VERB	O	O
channel	NOUN	O	O
gating	NOUN	O	O
,	PUNCT	O	O
assembly	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cell	NOUN	O	O
surface	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
heterologous	ADJ	O	O
cell	NOUN	O	O
systems	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
generated	VERB	O	O
beta2(-/-	NOUN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
beta2	NOUN	O	O
in	ADP	O	O
control	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
density	NOUN	O	O
,	PUNCT	O	O
localization	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
function	NOUN	O	O
in	ADP	O	O
neurons	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O

Measurements	NOUN	O	O
of	ADP	O	O
[	PUNCT	O	O
(	PUNCT	O	O
3)H]saxitoxin	PROPN	O	I-Entity
(	PUNCT	O	O
STX	PROPN	O	I-Entity
)	PUNCT	O	O
binding	VERB	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
membrane	NOUN	O	O
sodium	NOUN	O	I-Entity
channels	NOUN	O	O
in	ADP	O	O
beta2(-/-	NOUN	O	O
)	PUNCT	O	O
neurons	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
loss	NOUN	O	O
of	ADP	O	O
beta2	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
negative	ADJ	O	O
shifts	NOUN	O	O
in	ADP	O	O
the	DET	O	O
voltage	NOUN	O	O
dependence	NOUN	O	O
of	ADP	O	O
inactivation	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
significant	ADJ	O	O
decreases	NOUN	O	O
in	ADP	O	O
sodium	NOUN	O	I-Entity
current	ADJ	O	O
density	NOUN	O	O
in	ADP	O	O
acutely	ADV	O	O
dissociated	VERB	O	O
hippocampal	ADJ	O	O
neurons	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
integral	ADJ	O	O
of	ADP	O	O
the	DET	O	O
compound	NOUN	O	O
action	NOUN	O	O
potential	NOUN	O	O
in	ADP	O	O
optic	ADJ	O	O
nerve	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
threshold	NOUN	O	O
for	ADP	O	O
action	NOUN	O	O
potential	ADJ	O	O
generation	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
,	PUNCT	O	O
indicating	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
functional	ADJ	O	O
plasma	NOUN	O	O
membrane	NOUN	O	O
sodium	NOUN	O	I-Entity
channels	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
conduction	NOUN	O	O
velocity	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
number	NOUN	O	O
and	CCONJ	O	O
size	NOUN	O	O
of	ADP	O	O
axons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
optic	ADJ	O	O
nerve	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
specific	ADJ	O	O
localization	NOUN	O	O
of	ADP	O	O
Na(v)1.6	ADJ	O	I-Entity
channels	NOUN	O	O
in	ADP	O	O
the	DET	O	O
nodes	NOUN	O	O
of	ADP	O	O
Ranvier	PROPN	O	O
were	VERB	O	O
unchanged	ADJ	O	O
.	PUNCT	O	O

beta2(-/-	PUNCT	O	O
)	PUNCT	O	O
mice	NOUN	O	O
displayed	VERB	O	O
increased	VERB	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
indicated	VERB	O	O
by	ADP	O	O
reduced	ADJ	O	O
latency	NOUN	O	O
and	CCONJ	O	O
threshold	NOUN	O	O
for	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
seemed	VERB	O	O
normal	ADJ	O	O
in	ADP	O	O
other	ADJ	O	O
neurological	ADJ	O	O
tests	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
observations	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
beta2-subunits	NOUN	O	O
play	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	I-Entity
channel	NOUN	O	O
density	NOUN	O	O
and	CCONJ	O	O
function	NOUN	O	O
in	ADP	O	O
neurons	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
and	CCONJ	O	O
are	VERB	O	O
required	VERB	O	O
for	ADP	O	O
normal	ADJ	O	O
action	NOUN	O	O
potential	ADJ	O	O
generation	NOUN	O	O
and	CCONJ	O	O
control	NOUN	O	O
of	ADP	O	O
excitability	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11185967)

Screening	VERB	O	O
for	ADP	O	O
stimulant	NOUN	O	O
use	NOUN	O	O
in	ADP	O	O
adult	ADJ	O	O
emergency	NOUN	O	O
department	NOUN	O	O
seizure	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
positive	ADJ	O	O
plasma	NOUN	O	O
drug	NOUN	O	O
screening	NOUN	O	O
for	ADP	O	O
cocaine	NOUN	O	I-Entity
or	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
in	ADP	O	O
adult	ADJ	O	O
emergency	NOUN	O	O
department	NOUN	O	O
seizure	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
evaluated	VERB	O	O
consecutive	ADJ	O	O
eligible	ADJ	O	O
seizure	NOUN	O	I-Entity
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
a	DET	O	O
plasma	NOUN	O	O
sample	NOUN	O	O
collected	VERB	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
their	ADJ	O	O
clinical	ADJ	O	O
evaluation	NOUN	O	O
.	PUNCT	O	O

Plasma	PROPN	O	O
was	VERB	O	O
tested	VERB	O	O
for	ADP	O	O
amphetamine	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
cocaine	NOUN	O	I-Entity
metabolite	NOUN	O	O
benzoylecgonine	NOUN	O	I-Entity

Plasma	PROPN	O	O
samples	NOUN	O	O
with	ADP	O	O
benzoylecgonine	NOUN	O	I-Entity
greater	ADJ	O	O
than	ADP	O	O
150	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
or	CCONJ	O	O
an	DET	O	O
amphetamine	NOUN	O	I-Entity
greater	ADJ	O	O
than	ADP	O	O
500	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
were	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
positive	ADJ	O	O
.	PUNCT	O	O

Patient	ADJ	O	O
demographics	NOUN	O	O
,	PUNCT	O	O
history	NOUN	O	O
of	ADP	O	O
underlying	ADJ	O	O
drug	NOUN	O	O
or	CCONJ	O	O
alcohol	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
seizure	NOUN	O	I-Entity
disorder	NOUN	O	O
,	PUNCT	O	O
estimated	VERB	O	O
time	NOUN	O	O
from	ADP	O	O
seizure	NOUN	O	I-Entity
to	ADP	O	O
sample	NOUN	O	O
collection	NOUN	O	O
,	PUNCT	O	O
history	NOUN	O	O
or	CCONJ	O	O
suspicion	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	B-Entity
or	CCONJ	O	I-Entity
amphetamine	NOUN	O	I-Entity
abuse	NOUN	O	I-Entity
,	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
urine	NOUN	O	O
testing	NOUN	O	O
for	ADP	O	O
drugs	NOUN	O	O
of	ADP	O	O
abuse	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
assay	NOUN	O	O
results	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
without	ADP	O	O
patient	ADJ	O	O
identifiers	NOUN	O	O
.	PUNCT	O	O

Fourteen	NUM	O	O
of	ADP	O	O
248	NUM	O	O
(	PUNCT	O	O
5.6%	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
2.7%-8.5%	NUM	O	O
)	PUNCT	O	O
plasma	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
positive	ADJ	O	O
by	ADP	O	O
immunoassay	ADJ	O	O
testing	NOUN	O	O
for	ADP	O	O
benzoylecgonine	NOUN	O	I-Entity
and	CCONJ	O	O
no	DET	O	O
samples	NOUN	O	O
(	PUNCT	O	O
0%	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0	NUM	O	O
-	PUNCT	O	O
1.2%	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
positive	ADJ	O	O
for	ADP	O	O
amphetamine	NOUN	O	I-Entity
.	PUNCT	O	O

Positive	ADJ	O	O
test	NOUN	O	O
results	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
common	ADJ	O	O
in	ADP	O	O
patient	ADJ	O	O
visits	NOUN	O	O
where	ADV	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
history	NOUN	O	O
or	CCONJ	O	O
suspicion	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	B-Entity
or	CCONJ	O	I-Entity
amphetamine	NOUN	O	I-Entity
abuse	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O

During	ADP	O	O
this	DET	O	O
study	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
routine	ADJ	O	O
plasma	NOUN	O	O
screening	NOUN	O	O
for	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
amphetamines	NOUN	O	I-Entity
in	ADP	O	O
adult	NOUN	O	O
seizure	NOUN	O	I-Entity
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
low	ADJ	O	O
yield	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
a	DET	O	O
result	NOUN	O	O
,	PUNCT	O	O
routine	ADJ	O	O
plasma	NOUN	O	O
screening	NOUN	O	O
would	VERB	O	O
yield	VERB	O	O
few	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
stimulant	ADJ	O	O
drug	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
there	ADV	O	O
was	VERB	O	O
neither	DET	O	O
a	DET	O	O
history	NOUN	O	O
nor	CCONJ	O	O
suspicion	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
population	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11099450)

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
explore	VERB	O	O
the	DET	O	O
functional	ADJ	O	O
anatomy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
globus	NOUN	O	O
pallidus	NOUN	O	O
internus	NOUN	O	O
(	PUNCT	O	O
GPi	PROPN	O	O
)	PUNCT	O	O
by	ADP	O	O
studying	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
unilateral	ADJ	O	O
pallidotomy	NOUN	O	O
on	ADP	O	O
parkinsonian	NOUN	O	I-Entity
'	PUNCT	O	O
off	ADP	O	O
'	PUNCT	O	O
signs	NOUN	O	O
and	CCONJ	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
(	PUNCT	O	O
LID	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
significant	ADJ	O	O
positive	ADJ	O	O
correlations	NOUN	O	O
between	ADP	O	O
the	DET	O	O
preoperative	ADJ	O	O
levodopa	NOUN	O	I-Entity
responsiveness	NOUN	O	O
of	ADP	O	O
motor	NOUN	O	O
signs	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
levodopa	NOUN	O	I-Entity
responsiveness	NOUN	O	O
of	ADP	O	O
scores	NOUN	O	O
in	ADP	O	O
timed	VERB	O	O
tests	NOUN	O	O
(	PUNCT	O	O
Core	PROPN	O	O
Assessment	PROPN	O	O
Program	PROPN	O	O
for	ADP	O	O
Intracerebral	PROPN	O	O
Transplantations	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
contralateral	ADJ	O	O
limbs	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
these	DET	O	O
scores	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
correlation	NOUN	O	O
with	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
LID	PROPN	O	I-Entity
.	PUNCT	O	O

0.0001	PUNCT	O	O
,	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.8	NUM	O	O
)	PUNCT	O	O
between	ADP	O	O
the	DET	O	O
volume	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ventral	ADJ	O	O
lesion	NOUN	O	O
in	ADP	O	O
the	DET	O	O
GPi	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
LID	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
contralateral	ADJ	O	O
limbs	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
correlation	NOUN	O	O
between	ADP	O	O
the	DET	O	O
ventral	ADJ	O	O
volume	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
parkinsonian	NOUN	O	I-Entity
'	PUNCT	O	O
off	ADP	O	O
'	PUNCT	O	O
signs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
volumes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
total	ADJ	O	O
lesion	NOUN	O	O
cylinder	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
dorsal	NOUN	O	O
lesion	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
correlate	VERB	O	O
with	ADP	O	O
the	DET	O	O
outcome	NOUN	O	O
of	ADP	O	O
either	DET	O	O
dyskinesias	NOUN	O	I-Entity
or	CCONJ	O	O
parkinsonian	NOUN	O	I-Entity
'	PUNCT	O	O
off	ADP	O	O
'	PUNCT	O	O
signs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
differential	NOUN	O	O
predictive	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
responsiveness	NOUN	O	O
for	ADP	O	O
the	DET	O	O
outcome	NOUN	O	O
of	ADP	O	O
parkinsonian	NOUN	O	I-Entity
'	PUNCT	O	O
off	ADP	O	O
'	PUNCT	O	O
signs	NOUN	O	O
and	CCONJ	O	O
LID	PROPN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
different	ADJ	O	O
correlations	NOUN	O	O
of	ADP	O	O
ventral	ADJ	O	O
lesion	NOUN	O	O
volume	NOUN	O	O
with	ADP	O	O
dyskinesias	NOUN	O	I-Entity
and	CCONJ	O	O
parkinsonian	NOUN	O	I-Entity
'	PUNCT	O	O
off	ADP	O	O
'	PUNCT	O	O
signs	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
different	ADJ	O	O
anatomical	ADJ	O	O
or	CCONJ	O	O
pathophysiological	ADJ	O	O
substrates	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
responsible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
generation	NOUN	O	O
of	ADP	O	O
parkinsonian	NOUN	O	I-Entity
'	PUNCT	O	O
off	ADP	O	O
'	PUNCT	O	O
signs	NOUN	O	O
and	CCONJ	O	O
dyskinesias	NOUN	O	I-Entity
.	PUNCT	O	O

Whereas	ADP	O	O
cells	NOUN	O	O
in	ADP	O	O
a	DET	O	O
wider	ADJ	O	O
area	NOUN	O	O
of	ADP	O	O
the	DET	O	O
GPi	PROPN	O	O
may	VERB	O	O
be	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
parkinsonism	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
ventral	ADJ	O	O
GPi	PROPN	O	O
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
crucial	ADJ	O	O
for	ADP	O	O
the	DET	O	O
manifestation	NOUN	O	O
of	ADP	O	O
LID	PROPN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
our	ADJ	O	O
observations	NOUN	O	O
are	VERB	O	O
additional	ADJ	O	O
proof	NOUN	O	O
of	ADP	O	O
the	DET	O	O
functional	ADJ	O	O
somatotopy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
systems	NOUN	O	O
within	ADP	O	O
the	DET	O	O
GPi	PROPN	O	O
that	ADJ	O	O
mediate	VERB	O	O
parkinsonism	NOUN	O	I-Entity
and	CCONJ	O	O
dyskinesias	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
along	ADP	O	O
the	DET	O	O
dorsoventral	ADJ	O	O
trajectory	NOUN	O	O
used	VERB	O	O
in	ADP	O	O
pallidotomy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11027904)

Pain	PROPN	O	I-Entity
responses	NOUN	O	O
in	ADP	O	O
methadone	NOUN	O	I-Entity
-	PUNCT	O	O
maintained	VERB	O	O
opioid	ADJ	O	O
abusers	NOUN	O	O
.	PUNCT	O	O

Providing	VERB	O	O
pain	NOUN	O	I-Entity
management	NOUN	O	O
for	ADP	O	O
known	VERB	O	O
opioid	ADJ	O	O
abusers	NOUN	O	O
is	VERB	O	O
a	DET	O	O
challenging	VERB	O	O
clinical	ADJ	O	O
task	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
part	NOUN	O	O
because	ADP	O	O
little	ADJ	O	O
is	VERB	O	O
known	VERB	O	O
about	ADP	O	O
their	ADJ	O	O
pain	NOUN	O	I-Entity
experience	NOUN	O	O
and	CCONJ	O	O
analgesic	NOUN	O	O
requirements	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
describe	VERB	O	O
pain	NOUN	O	I-Entity
tolerance	NOUN	O	O
and	CCONJ	O	O
analgesic	NOUN	O	O
response	NOUN	O	O
in	ADP	O	O
a	DET	O	O
sample	NOUN	O	O
of	ADP	O	O
opioid	ADJ	O	B-Entity
addicts	NOUN	O	I-Entity
stabilized	VERB	O	O
in	ADP	O	O
methadone	NOUN	O	I-Entity
-	PUNCT	O	O
maintenance	NOUN	O	O
(	PUNCT	O	O
MM	PROPN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
60	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
comparison	NOUN	O	O
to	PART	O	O
matched	VERB	O	O
nondependent	ADJ	O	O
control	NOUN	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
60	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

By	ADP	O	O
using	VERB	O	O
a	DET	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
two	NUM	O	O
-	PUNCT	O	O
way	NOUN	O	O
factorial	ADJ	O	O
design	NOUN	O	O
,	PUNCT	O	O
tolerance	NOUN	O	O
to	ADP	O	O
cold	ADJ	O	O
-	PUNCT	O	O
pressor	NOUN	O	O
(	PUNCT	O	O
CP	PROPN	O	O
)	PUNCT	O	O
pain	NOUN	O	I-Entity
was	VERB	O	O
examined	VERB	O	O
,	PUNCT	O	O
both	DET	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
common	ADJ	O	O
opioid	NOUN	O	O
(	PUNCT	O	O
hydromorphone	NOUN	O	I-Entity
2	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
nonsteroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
(	PUNCT	O	O
ketorolac	NOUN	O	I-Entity
10	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
analgesic	NOUN	O	O
agents	NOUN	O	O
.	PUNCT	O	O

Results	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
MM	PROPN	O	O
individuals	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
less	ADV	O	O
tolerant	ADJ	O	O
of	ADP	O	O
CP	PROPN	O	O
pain	NOUN	O	I-Entity
than	ADP	O	O
control	NOUN	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
replicating	VERB	O	O
previous	ADJ	O	O
work	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
MM	PROPN	O	O
opioid	NOUN	O	O
abusers	NOUN	O	O
represent	VERB	O	O
a	DET	O	O
pain	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
intolerant	ADJ	O	I-Entity
subset	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Their	ADJ	O	O
complaints	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
evaluated	VERB	O	O
seriously	ADV	O	O
and	CCONJ	O	O
managed	VERB	O	O
aggressively	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (10193809)

Although	ADP	O	O
an	DET	O	O
indicator	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
tubular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
increased	VERB	O	O
urinary	NOUN	O	O
N	NOUN	O	O
-	PUNCT	O	O
acetyl	NOUN	O	O
-	PUNCT	O	O
beta	NOUN	O	O

Puromycin	PROPN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
PAN	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
Sprague	PROPN	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
to	PART	O	O
induce	VERB	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O

Following	VERB	O	O
intravenous	ADJ	O	O
PAN	PROPN	O	I-Entity
urine	NOUN	O	O
volume	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
NAG	NOUN	O	O
activity	NOUN	O	O
increased	VERB	O	O
significantly	ADV	O	O
by	ADP	O	O
day	NOUN	O	O
two	NUM	O	O
,	PUNCT	O	O
but	CCONJ	O	O
returned	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
by	ADP	O	O
day	NOUN	O	O
four	NUM	O	O
.	PUNCT	O	O

Peak	PROPN	O	O
urine	NOUN	O	O
NAG	PROPN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
change	NOUN	O	O
in	ADP	O	O
NAG	PROPN	O	O
isoenzyme	NOUN	O	O
pattern	NOUN	O	O
coincided	VERB	O	O
with	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
peak	NOUN	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
intracellular	ADJ	O	O
protein	NOUN	O	O
and	CCONJ	O	O
NAG	NOUN	O	O
droplets	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
six	NUM	O	O
onwards	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O


-DOCSTART- (9214597)

Over	ADP	O	O
expression	NOUN	O	O
of	ADP	O	O
vascular	ADJ	O	O
endothelial	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
receptor	NOUN	O	O
during	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
estrogen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rat	NOUN	O	O
pituitary	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
may	VERB	O	O
mediate	VERB	O	O
estrogen	NOUN	O	I-Entity
-	PUNCT	O	O
initiated	VERB	O	O
tumor	NOUN	O	I-Entity
angiogenesis	NOUN	O	O
.	PUNCT	O	O

Estrogens	PROPN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
have	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
several	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
human	NOUN	O	O
and	CCONJ	O	O
animal	NOUN	O	O
cancers	NOUN	O	I-Entity
,	PUNCT	O	O
can	VERB	O	O
induce	VERB	O	O
tumor	NOUN	O	I-Entity
angiogenesis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pituitary	NOUN	O	O
of	ADP	O	O
Fischer	PROPN	O	O
344	NUM	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mechanistic	ADJ	O	O
details	NOUN	O	O
of	ADP	O	O
tumor	NOUN	O	I-Entity
angiogenesis	NOUN	O	O
induction	NOUN	O	O
,	PUNCT	O	O
during	ADP	O	O
estrogen	NOUN	O	I-Entity
carcinogenesis	NOUN	O	I-Entity
,	PUNCT	O	O
are	VERB	O	O
still	ADV	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

To	PART	O	O
elucidate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
estrogen	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
tumor	NOUN	O	I-Entity
angiogenesis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pituitary	NOUN	O	O
of	ADP	O	O
female	ADJ	O	O
rats	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
density	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
vessels	NOUN	O	O
was	VERB	O	O
analysed	VERB	O	O
using	VERB	O	O
factor	NOUN	O	O
VIII	PROPN	O	O
related	VERB	O	O
antigen	NOUN	O	O
(	PUNCT	O	O
FVIIIRAg	PROPN	O	O
)	PUNCT	O	O
immunohistochemistry	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
vascular	ADJ	O	O
endothelial	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
/	SYM	O	O
vascular	ADJ	O	O
permeability	NOUN	O	O
factor	NOUN	O	O
(	PUNCT	O	O
VEGF	PROPN	O	O
/	SYM	O	O
VPF	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
examined	VERB	O	O
by	ADP	O	O
Western	ADJ	O	O
blot	NOUN	O	O
and	CCONJ	O	O
immunohistochemical	ADJ	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
17beta	NUM	O	B-Entity
-	PUNCT	O	I-Entity
estradiol	NOUN	O	I-Entity
(	PUNCT	O	O
E2	PROPN	O	I-Entity
)	PUNCT	O	O
induces	VERB	O	O
neovascularization	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
the	DET	O	O
growth	NOUN	O	O
and	CCONJ	O	O
enlargement	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
vessels	NOUN	O	O
after	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
exposure	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
high	ADJ	O	O
tumor	NOUN	O	I-Entity
angiogenic	ADJ	O	O
potential	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
elevated	VERB	O	O
VEGF	PROPN	O	O
/	SYM	O	O
VPF	PROPN	O	O
protein	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
the	DET	O	O
E2	PROPN	O	I-Entity
exposed	VERB	O	O
pituitary	NOUN	O	O
of	ADP	O	O
ovariectomized	VERB	O	O
(	PUNCT	O	O
OVEX	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
15	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
E2	PROPN	O	I-Entity
exposure	NOUN	O	O
,	PUNCT	O	O
VEGF	PROPN	O	O
/	PUNCT	O	O
VPF	PROPN	O	O
protein	NOUN	O	O
expression	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
endothelial	ADJ	O	O
cell	NOUN	O	O
population	NOUN	O	O
,	PUNCT	O	O
sharply	ADV	O	O
declined	VERB	O	O
and	CCONJ	O	O
was	VERB	O	O
restricted	VERB	O	O
to	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
vessels	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
immunohistochemical	ADJ	O	O
studies	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
VEGFR-2	PROPN	O	O
(	PUNCT	O	O
flk-1/KDR	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
expression	NOUN	O	O
was	VERB	O	O
elevated	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
the	DET	O	O
endothelial	ADJ	O	O
cells	NOUN	O	O
of	ADP	O	O
microblood	NOUN	O	O
vessels	NOUN	O	O
after	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
E2	PROPN	O	I-Entity
exposure	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
over	ADP	O	O
expression	NOUN	O	O
of	ADP	O	O
VEGF	PROPN	O	O
and	CCONJ	O	O
its	ADJ	O	O
receptor	NOUN	O	O
(	PUNCT	O	O
VEGFR-2	PROPN	O	O
)	PUNCT	O	O
may	VERB	O	O
play	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
step	NOUN	O	O
of	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
estrogen	NOUN	O	I-Entity
induced	VERB	O	O
tumor	NOUN	O	I-Entity
angiogenesis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
pituitary	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7604176)

Pravastatin	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
myopathy	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
inflammatory	ADJ	O	B-Entity
myopathy	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
pravastatin	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
hydrophilic	NOUN	O	O
3-hydroxy-3	NUM	O	O

The	DET	O	O
patient	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
69-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
was	VERB	O	O
affected	VERB	O	O
by	ADP	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
insulin	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
dependent	ADJ	O	I-Entity
diabetes	NOUN	O	I-Entity
mellitus	NOUN	O	I-Entity
and	CCONJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
assumed	VERB	O	O
pravastatin	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
because	ADP	O	O
of	ADP	O	O
hypercholesterolemia	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
admitted	VERB	O	O
with	ADP	O	O
acute	ADJ	O	O
myopathy	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
lower	ADJ	O	O
limbs	NOUN	O	O
which	ADJ	O	O
resolved	VERB	O	O
in	ADP	O	O
a	DET	O	O
few	ADJ	O	O
days	NOUN	O	O
after	ADP	O	O
pravastatin	NOUN	O	I-Entity
discontinuation	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
previously	ADV	O	O
unknown	ADJ	O	O
hypothyroidism	NOUN	O	I-Entity
,	PUNCT	O	O
probably	ADV	O	O
due	ADJ	O	O
to	ADP	O	O
chronic	ADJ	O	O
autoimmune	ADJ	O	B-Entity
thyroiditis	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
evidenced	VERB	O	O
.	PUNCT	O	O

While	ADP	O	O
lovastatin	NOUN	O	I-Entity
and	CCONJ	O	O
simvastatin	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
toxic	ADJ	O	O
myopathy	NOUN	O	I-Entity
,	PUNCT	O	O
pravastatin	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
myopathy	NOUN	O	I-Entity
could	VERB	O	O
represent	VERB	O	O
a	DET	O	O
distinct	ADJ	O	O
,	PUNCT	O	O
inflammatory	ADJ	O	O
entity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7282516)

Dose	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
and	CCONJ	O	O
structure	NOUN	O	O
-	PUNCT	O	O
function	NOUN	O	O
relationships	NOUN	O	O
in	ADP	O	O
doxorubicin	NOUN	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
cardiomyopathy	NOUN	O	I-Entity
(	PUNCT	O	O
CM	PROPN	O	I-Entity
)	PUNCT	O	O
produced	VERB	O	O
by	ADP	O	O
the	DET	O	O
anticancer	NOUN	O	O
drug	NOUN	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
DXR	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
Adriamycin	PROPN	O	I-Entity
)	PUNCT	O	O
provides	VERB	O	O
a	DET	O	O
unique	ADJ	O	O
opportunity	NOUN	O	O
to	PART	O	O
analyze	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
and	CCONJ	O	O
structure	NOUN	O	O
-	PUNCT	O	O
function	NOUN	O	O
relationships	NOUN	O	O
during	ADP	O	O
development	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
measured	VERB	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
morphologic	ADJ	O	O
damage	NOUN	O	O
by	ADP	O	O
ultrastructural	ADJ	O	O
examination	NOUN	O	O
of	ADP	O	O
endomyocardial	ADJ	O	O
biopsy	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
performance	NOUN	O	O
abnormally	ADV	O	O
by	ADP	O	O
right	ADJ	O	O
heart	NOUN	O	O
catheterization	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
DXR	PROPN	O	I-Entity
.	PUNCT	O	O

Morphologic	ADJ	O	O
damage	NOUN	O	O
was	VERB	O	O
variable	ADJ	O	O
but	CCONJ	O	O
was	VERB	O	O
proportional	ADJ	O	O
to	ADP	O	O
the	DET	O	O
total	ADJ	O	O
cumulative	ADJ	O	O
DXR	PROPN	O	I-Entity
dose	NOUN	O	O
between	ADP	O	O
100	NUM	O	O
and	CCONJ	O	O
600	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
DXR	PROPN	O	I-Entity
-	PUNCT	O	O
CM	PROPN	O	I-Entity
myocardial	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
is	VERB	O	O
proportional	ADJ	O	O
to	ADP	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
cytotoxic	ADJ	O	O
insult	NOUN	O	O
(	PUNCT	O	O
DXR	PROPN	O	I-Entity
dose	NOUN	O	O
)	PUNCT	O	O
while	ADP	O	O
myocardial	ADJ	O	O
function	NOUN	O	O
is	VERB	O	O
preserved	VERB	O	O
until	ADP	O	O
a	DET	O	O
critical	ADJ	O	O
dose	NOUN	O	O
or	CCONJ	O	O
degree	NOUN	O	O
of	ADP	O	O
damage	NOUN	O	O
is	VERB	O	O
reached	VERB	O	O
,	PUNCT	O	O
after	ADP	O	O
which	ADJ	O	O
myocardial	ADJ	O	O
performance	NOUN	O	O
deteriorates	VERB	O	O
rapidly	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (7072798)

Fatal	ADJ	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
following	VERB	O	O
topical	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
ophthalmic	ADJ	O	O
chloramphenicol	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
73-year	NOUN	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
died	VERB	O	O
of	ADP	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
less	ADJ	O	O
than	ADP	O	O
two	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
undergoing	VERB	O	O
cataract	ADJ	O	I-Entity
extraction	NOUN	O	O
and	CCONJ	O	O
beginning	VERB	O	O
topical	ADJ	O	O
therapy	NOUN	O	O
with	ADP	O	O
chloramphenicol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
pancytopenia	NOUN	O	I-Entity
began	VERB	O	O
within	ADP	O	O
one	NUM	O	O
month	NOUN	O	O
of	ADP	O	O
the	DET	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pattern	NOUN	O	O
of	ADP	O	O
the	DET	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
idiosyncratic	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
chloramphenicol	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
the	DET	O	O
second	ADJ	O	O
report	NOUN	O	O
of	ADP	O	O
fatal	ADJ	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
after	ADP	O	O
topical	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
chloramphenicol	NOUN	O	I-Entity
for	ADP	O	O
ocular	ADJ	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
reversible	ADJ	O	O
bone	NOUN	O	B-Entity
marrow	NOUN	O	I-Entity
hypoplasia	NOUN	O	I-Entity
have	VERB	O	O
also	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

Any	DET	O	O
other	ADJ	O	O
suspected	VERB	O	O
cases	NOUN	O	O
of	ADP	O	O
ocular	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
topically	ADV	O	O
applied	VERB	O	O
chloramphenicol	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
reported	VERB	O	O
to	ADP	O	O
the	DET	O	O
National	PROPN	O	O
Registry	PROPN	O	O
of	ADP	O	O
Drug	PROPN	O	O
-	PUNCT	O	O
Induced	PROPN	O	O
Ocular	PROPN	O	O
Side	PROPN	O	O
Effects	PROPN	O	O
,	PUNCT	O	O
Oregon	PROPN	O	O
Health	PROPN	O	O
Sciences	PROPN	O	O
University	PROPN	O	O
,	PUNCT	O	O
Portland	PROPN	O	O
,	PUNCT	O	O
OR	PROPN	O	O
97201	NUM	O	O
.	PUNCT	O	O


-DOCSTART- (3769769)

Bradycardia	PROPN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
trihexyphenidyl	DET	O	B-Entity
hydrochloride	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
chronic	ADJ	O	O
schizophrenic	ADJ	O	I-Entity
patient	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
an	DET	O	O
anticholinergic	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
trihexyphenidyl	DET	O	B-Entity
hydrochloride	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
,	PUNCT	O	O
paradoxically	ADV	O	O
,	PUNCT	O	O
sinus	ADJ	O	O
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
reaction	NOUN	O	O
was	VERB	O	O
specific	ADJ	O	O
to	ADP	O	O
trihexyphenidyl	NOUN	O	I-Entity
and	CCONJ	O	O
not	ADV	O	O
to	ADP	O	O
other	ADJ	O	O
anticholinergic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
antidyskinetic	ADJ	O	O
drug	NOUN	O	O
is	VERB	O	O
widely	ADV	O	O
used	VERB	O	O
in	ADP	O	O
clinical	ADJ	O	O
psychiatric	ADJ	O	I-Entity
practice	NOUN	O	O
and	CCONJ	O	O
physicians	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
this	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3708922)

Experimental	ADJ	O	O
cyclosporine	NOUN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
:	PUNCT	O	O
risk	NOUN	O	O
of	ADP	O	O
concomitant	ADJ	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
cyclosporine	NOUN	O	I-Entity
(	PUNCT	O	O
CSA	PROPN	O	I-Entity
)	PUNCT	O	O
alone	ADV	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
various	ADJ	O	O
chemotherapeutics	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
CSA	NOUN	O	I-Entity
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
caused	VERB	O	O
renal	ADJ	O	O
functional	ADJ	O	O
and	CCONJ	O	O
structural	ADJ	O	O
changes	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
reported	VERB	O	O
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
combined	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
CSA	PROPN	O	I-Entity
and	CCONJ	O	O
various	ADJ	O	O
chemotherapeutic	ADJ	O	O
drugs	NOUN	O	O
with	ADP	O	O
a	DET	O	O
nephrotoxic	ADJ	O	I-Entity
potential	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
gentamicin	NOUN	O	I-Entity
(	PUNCT	O	O
at	ADP	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
amphothericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
and	CCONJ	O	O
ketoconazole	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
are	VERB	O	O
frequently	ADV	O	O
used	VERB	O	O
in	ADP	O	O
immunosuppressed	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
aggravate	VERB	O	O
the	DET	O	O
CSA	PROPN	O	I-Entity
induced	VERB	O	O
toxicity	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

Gentamicin	PROPN	O	I-Entity
at	ADP	O	O
toxic	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
increased	VERB	O	O
CSA	PROPN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
nephrotoxicity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
CSA	PROPN	O	I-Entity
has	VERB	O	O
a	DET	O	O
different	ADJ	O	O
pathogenetic	ADJ	O	O
mechanism	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3220106)

Receptor	NOUN	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	B-Entity
hyperactivity	NOUN	O	I-Entity
in	ADP	O	O
chronic	ADJ	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
were	VERB	O	O
pretreated	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
or	CCONJ	O	O
nicotine	NOUN	O	I-Entity
(	PUNCT	O	O
1.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
)	PUNCT	O	O
by	ADP	O	O
subcutaneously	ADV	O	O
implanting	VERB	O	O
each	DET	O	O
animal	NOUN	O	O
with	ADP	O	O
an	DET	O	O
Alzet	PROPN	O	O
osmotic	ADJ	O	O
mini	NOUN	O	O
-	PUNCT	O	O
pump	NOUN	O	O
which	ADJ	O	O
continuously	ADV	O	O
released	VERB	O	O
saline	NOUN	O	O
or	CCONJ	O	O
nicotine	NOUN	O	I-Entity
for	ADP	O	O
1	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
and	CCONJ	O	O
14	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
each	DET	O	O
pretreatment	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
animals	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
for	ADP	O	O
(	PUNCT	O	O
i	PUNCT	O	O
)	PUNCT	O	O
determining	VERB	O	O
their	ADJ	O	O
locomotor	NOUN	O	O
response	NOUN	O	O
to	PART	O	O
acutely	ADV	O	O
injected	VERB	O	O
nicotine	NOUN	O	I-Entity
(	PUNCT	O	O
0.2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
s.c	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
ii	PUNCT	O	O
)	PUNCT	O	O
measuring	VERB	O	O
the	DET	O	O
density	NOUN	O	O
of	ADP	O	O
L-[3H]nicotine	PROPN	O	I-Entity
and	CCONJ	O	O
[	PUNCT	O	O
3H]spiperone	NUM	O	I-Entity
binding	VERB	O	O
sites	NOUN	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
observed	VERB	O	O
no	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	O
response	NOUN	O	O
,	PUNCT	O	O
striatal	ADJ	O	O
L-[3H]nicotine	PROPN	O	I-Entity
and	CCONJ	O	O
[	PUNCT	O	O
3H]spiperone	NUM	O	I-Entity
binding	VERB	O	O
in	ADP	O	O
the	DET	O	O
animals	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
nicotine	NOUN	O	I-Entity
for	ADP	O	O
1	NUM	O	O
day	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
rats	NOUN	O	O
which	ADJ	O	O
were	VERB	O	O
pretreated	VERB	O	O
with	ADP	O	O
nicotine	NOUN	O	I-Entity
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
stimulated	VERB	O	O
locomotor	NOUN	O	O
response	NOUN	O	O
which	ADJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
L-[3H]nicotine	NUM	O	I-Entity
binding	VERB	O	O
sites	NOUN	O	O
and	CCONJ	O	O
also	ADV	O	O
with	ADP	O	O
an	DET	O	O
elevated	VERB	O	O
dopamine	NOUN	O	I-Entity
(	PUNCT	O	O
DA	PROPN	O	I-Entity
)	PUNCT	O	O
level	NOUN	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
striatal	NOUN	O	O
[	PUNCT	O	O
3H]spiperone	NUM	O	I-Entity
binding	VERB	O	O
sites	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
animals	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
nicotine	NOUN	O	I-Entity
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
locomotor	NOUN	O	O
response	NOUN	O	O
remained	VERB	O	O
to	PART	O	O
be	VERB	O	O
potentiated	VERB	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
this	DET	O	O
response	NOUN	O	O
was	VERB	O	O
correlated	VERB	O	O
with	ADP	O	O
an	DET	O	O
elevated	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
striatal	NOUN	O	O
[	PUNCT	O	O
3H]spiperone	NUM	O	I-Entity
binding	VERB	O	O
sites	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
striatal	ADJ	O	O
L-[3H]nicotine	NOUN	O	I-Entity
binding	VERB	O	O
sites	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
striatal	ADJ	O	O
DA	NOUN	O	I-Entity
level	NOUN	O	O
were	VERB	O	O
normal	ADJ	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
chronic	ADJ	O	O
nicotine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
develop	VERB	O	O
locomotor	NOUN	O	B-Entity
hyperactivity	NOUN	O	I-Entity
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
nicotine	NOUN	O	I-Entity
initially	ADV	O	O
due	ADJ	O	O
to	ADP	O	O
increases	NOUN	O	O
of	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
density	NOUN	O	O
of	ADP	O	O
nicotinic	ADJ	O	O
receptors	NOUN	O	O
and	CCONJ	O	O
DA	PROPN	O	I-Entity
concentration	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
inducing	VERB	O	O
DA	PROPN	O	I-Entity
receptor	NOUN	O	O
supersensitivity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2722224)

Hydrocortisone	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
:	PUNCT	O	O
pressor	NOUN	O	O
responsiveness	NOUN	O	O
and	CCONJ	O	O
sympathetic	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

Oral	PROPN	O	O
hydrocortisone	NOUN	O	I-Entity
increases	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
enhances	VERB	O	O
pressor	NOUN	O	O
responsiveness	NOUN	O	O
in	ADP	O	O
normal	ADJ	O	O
human	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
week	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
hydrocortisone	NOUN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
,	PUNCT	O	O
total	ADJ	O	O
peripheral	ADJ	O	O
resistance	NOUN	O	O
,	PUNCT	O	O
forearm	NOUN	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
norepinephrine	ADJ	O	I-Entity
spillover	NOUN	O	O
to	ADP	O	O
plasma	NOUN	O	O
in	ADP	O	O
eight	NUM	O	O
healthy	ADJ	O	O
male	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

3.4	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	B-Entity
cardiac	ADJ	O	I-Entity
output	NOUN	O	I-Entity
(	PUNCT	O	O
5.85	NUM	O	O
-	SYM	O	O
7.73	NUM	O	O
l	NOUN	O	O
/	SYM	O	O
min	NOUN	O	O
,	PUNCT	O	O
SED	PROPN	O	O
+	X	O	O
/-	PUNCT	O	O

The	DET	O	O
rise	NOUN	O	O
in	ADP	O	O
forearm	NOUN	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
accompanying	VERB	O	O
intra	NOUN	O	O
-	PUNCT	O	O
arterial	NOUN	O	O
norepinephrine	NOUN	O	I-Entity
(	PUNCT	O	O
25	NUM	O	O
,	PUNCT	O	O
50	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
100	NUM	O	O
ng	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
also	ADV	O	O
significantly	ADV	O	O
greater	ADJ	O	O
after	ADP	O	O
hydrocortisone	NOUN	O	I-Entity
,	PUNCT	O	O
increasing	VERB	O	O
from	ADP	O	O
an	DET	O	O
average	NOUN	O	O
of	ADP	O	O
14.9	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

5.5	NUM	O	O
R	NOUN	O	O
units	NOUN	O	O
after	ADP	O	O
hydrocortisone	NOUN	O	I-Entity

A	DET	O	O
shift	NOUN	O	O
to	ADP	O	O
the	DET	O	O
left	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
response	NOUN	O	O
relation	NOUN	O	O
and	CCONJ	O	O
fall	VERB	O	O
in	ADP	O	O
threshold	NOUN	O	O
suggested	VERB	O	O
increased	VERB	O	O
sensitivity	NOUN	O	O
to	ADP	O	O
norepinephrine	VERB	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Measurement	NOUN	O	O
of	ADP	O	O
resting	VERB	O	O
norepinephrine	ADJ	O	I-Entity
spillover	NOUN	O	O
rate	NOUN	O	O
to	ADP	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
norepinephrine	NOUN	O	I-Entity
uptake	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
overall	ADJ	O	O
resting	VERB	O	O
sympathetic	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
activity	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
increased	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
rise	NOUN	O	B-Entity
in	ADP	O	I-Entity
resting	VERB	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
with	ADP	O	O
hydrocortisone	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	B-Entity
cardiac	ADJ	O	I-Entity
output	NOUN	O	I-Entity
(	PUNCT	O	O
presumably	ADV	O	O
due	ADJ	O	O
to	ADP	O	O
increased	VERB	O	O
blood	NOUN	O	O
volume).(ABSTRACT	X	O	O
TRUNCATED	ADJ	O	O
AT	NOUN	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O


-DOCSTART- (1636026)

Effects	NOUN	O	O
of	ADP	O	O
suprofen	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
isolated	ADJ	O	O
perfused	ADJ	O	O
rat	NOUN	O	O
kidney	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
suprofen	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
greater	ADJ	O	O
than	ADP	O	O
100	NUM	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
damage	NOUN	O	O
remains	VERB	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
direct	ADJ	O	O
nephrotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
15	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
suprofen	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
the	DET	O	O
recirculating	NOUN	O	O
isolated	ADJ	O	O
rat	NOUN	O	O
kidney	NOUN	O	O
perfused	VERB	O	O
with	ADP	O	O
cell	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
buffer	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
dL	PROPN	O	O
of	ADP	O	O
uric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
sodium	NOUN	O	I-Entity
excretion	NOUN	O	O
,	PUNCT	O	O
oxygen	NOUN	O	I-Entity
consumption	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
urinary	ADJ	O	O
flow	NOUN	O	O
rates	NOUN	O	O
in	ADP	O	O
kidneys	NOUN	O	O
perfused	VERB	O	O
with	ADP	O	O
suprofen	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
control	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
decline	NOUN	O	O
in	ADP	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
rate	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
after	ADP	O	O
the	DET	O	O
introduction	NOUN	O	O
of	ADP	O	O
suprofen	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
perfused	VERB	O	O
with	ADP	O	O
uric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
;	PUNCT	O	O
no	DET	O	O
changes	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
with	ADP	O	O
suprofen	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
uric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
excretion	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
uric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
given	VERB	O	O
suprofen	NOUN	O	I-Entity
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
fractional	ADJ	O	O
excretion	NOUN	O	O
of	ADP	O	O
uric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
was	VERB	O	O
unchanged	ADJ	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
over	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
summary	NOUN	O	O
,	PUNCT	O	O
suprofen	ADJ	O	I-Entity
causes	VERB	O	O
acute	ADJ	O	B-Entity
declines	NOUN	O	I-Entity
in	ADP	O	I-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
,	PUNCT	O	O
most	ADV	O	O
likely	ADJ	O	O
by	ADP	O	O
directly	ADV	O	O
altering	VERB	O	O
the	DET	O	O
intrarenal	ADJ	O	O
distribution	NOUN	O	O
of	ADP	O	O
uric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1610717)

Cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
brainstem	NOUN	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O

electrical	ADJ	O	O
current	ADJ	O	O
stimulations	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
acute	ADJ	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Cocaine	NOUN	O	I-Entity
(	PUNCT	O	O
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
injected	VERB	O	O
subcutaneously	ADV	O	O
for	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
experiment	NOUN	O	O
and	CCONJ	O	O
subsequent	ADJ	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
doses	NOUN	O	O
twice	ADV	O	O
daily	ADV	O	O
for	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
a	DET	O	O
chronic	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Cocaine	NOUN	O	I-Entity
generated	VERB	O	O
more	ADV	O	O
abnormal	ADJ	O	O
behaviors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brainstem	NOUN	O	O
perturbation	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
the	DET	O	O
electrically	ADV	O	O
perturbated	VERB	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
abnormal	ADJ	O	O
behaviors	NOUN	O	O
were	VERB	O	O
yawning	VERB	O	O
,	PUNCT	O	O
retrocollis	NOUN	O	O
,	PUNCT	O	O
hyperactivity	NOUN	O	I-Entity
,	PUNCT	O	O
hypersensitivity	NOUN	O	I-Entity
,	PUNCT	O	O
"	PUNCT	O	O
beating	VERB	O	O
drum	NOUN	O	O
"	PUNCT	O	O
behavior	NOUN	O	O
,	PUNCT	O	O
squealing	VERB	O	O
,	PUNCT	O	O
head	NOUN	O	O
bobbing	NOUN	O	O
,	PUNCT	O	O
circling	VERB	O	O
,	PUNCT	O	O
sniffing	VERB	O	O
,	PUNCT	O	O
abnormal	ADJ	O	O
posturing	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
facial	ADJ	O	O
twitching	NOUN	O	O
.	PUNCT	O	O

Hypersensitivity	PROPN	O	I-Entity
to	ADP	O	O
various	ADJ	O	O
auditory	NOUN	O	O
,	PUNCT	O	O
tactile	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
visual	ADJ	O	O
stimulation	NOUN	O	O
was	VERB	O	O
present	ADJ	O	O
and	CCONJ	O	O
shifts	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brainstem	NOUN	O	O
ambient	NOUN	O	O
power	NOUN	O	O
spectral	ADJ	O	O
frequency	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
tactile	ADJ	O	O
stimulation	NOUN	O	O
.	PUNCT	O	O

Cocaine	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
activate	VERB	O	O
the	DET	O	O
discharge	NOUN	O	O
system	NOUN	O	O
and	CCONJ	O	O
thus	ADV	O	O
induce	VERB	O	O
abnormal	ADJ	O	O
behaviors	NOUN	O	O
that	ADJ	O	O
are	VERB	O	O
generated	VERB	O	O
at	ADP	O	O
the	DET	O	O
discharge	NOUN	O	O
site	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
distant	ADJ	O	O
sites	NOUN	O	O
to	PART	O	O
which	ADJ	O	O
the	DET	O	O
discharge	NOUN	O	O
propagates	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (873132)

Increased	VERB	O	O
sulfation	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
7alpha	NUM	O	O
-	PUNCT	O	O
hydroxylation	NOUN	O	O
of	ADP	O	O
deoxycholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
ethinyl	NOUN	O	B-Entity
estradiol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cholestasis	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Deoxycholic	PROPN	O	B-Entity
acid	NOUN	O	I-Entity
conjugation	NOUN	O	O
,	PUNCT	O	O
transport	NOUN	O	O
capacity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
metabolism	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
control	NOUN	O	O
and	CCONJ	O	O
ethinyl	NOUN	O	B-Entity
estradiol	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Control	NOUN	O	O
rats	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
have	VERB	O	O
a	DET	O	O
lower	ADJ	O	O
capacity	NOUN	O	O
to	PART	O	O
transport	VERB	O	O
deoxycholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
than	ADP	O	O
taurodeoxycholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
both	DET	O	O
were	VERB	O	O
decreased	VERB	O	O
by	ADP	O	O
ethinyl	NOUN	O	B-Entity
estradiol	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
[	PUNCT	O	O
24	NUM	O	O
-	PUNCT	O	O
14C]sodium	NUM	O	B-Entity
deoxycholate	NOUN	O	I-Entity
infusion	NOUN	O	O
,	PUNCT	O	O
[	PUNCT	O	O
14C]biliary	ADJ	O	O
bile	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
secretion	NOUN	O	O
increased	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
bile	NOUN	O	O
flow	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
either	DET	O	O
control	NOUN	O	O
or	CCONJ	O	O
ethinyl	NOUN	O	B-Entity
estradiol	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Ethinyl	PROPN	O	B-Entity
estradiol	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
excreted	VERB	O	O
significantly	ADV	O	O
less	ADJ	O	O
14C	NUM	O	O
as	ADP	O	O
taurocholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
than	ADP	O	O
did	VERB	O	O
control	VERB	O	O
animals	NOUN	O	O
,	PUNCT	O	O
consistent	ADJ	O	O
with	ADP	O	O
an	DET	O	O
impairment	NOUN	O	O
of	ADP	O	O
7alpha	NUM	O	O
-	PUNCT	O	O
hydroxylation	NOUN	O	O
of	ADP	O	O
taurodeoxycholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

Ethinyl	PROPN	O	B-Entity
estradiol	NOUN	O	I-Entity
treatment	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
impair	VERB	O	O
conjugation	NOUN	O	O
of	ADP	O	O
deoxycholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
did	VERB	O	O
result	VERB	O	O
in	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
sulfation	NOUN	O	O
of	ADP	O	O
taurodeoxycholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
from	ADP	O	O
1.5%	NUM	O	O
in	ADP	O	O
controls	NOUN	O	O
to	ADP	O	O
nearly	ADV	O	O
4.0%	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
are	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
has	VERB	O	O
a	DET	O	O
poorer	ADJ	O	O
tolerance	NOUN	O	O
for	ADP	O	O
deoxycholic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
than	ADP	O	O
do	VERB	O	O
certain	VERB	O	O
other	ADJ	O	O
species	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
rat	NOUN	O	O
converts	VERB	O	O
deoxycholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
poor	ADJ	O	O
choleretic	NOUN	O	O
,	PUNCT	O	O
to	ADP	O	O
taurocholic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
good	ADJ	O	O
choleretic	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
this	DET	O	O
conversion	NOUN	O	O
is	VERB	O	O
impaired	VERB	O	O
with	ADP	O	O
ethinyl	NOUN	O	B-Entity
estradiol	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
sulfation	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
an	DET	O	O
important	ADJ	O	O
alternate	ADJ	O	O
pathway	NOUN	O	O
for	ADP	O	O
excretion	NOUN	O	O
of	ADP	O	O
this	DET	O	O
potentially	ADV	O	O
harmful	ADJ	O	O
bile	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (783197)

Effects	NOUN	O	O
of	ADP	O	O
ouabain	NOUN	O	I-Entity
on	ADP	O	O
myocardial	ADJ	O	O
oxygen	NOUN	O	I-Entity
supply	NOUN	O	O
and	CCONJ	O	O
demand	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
hemodynamic	NOUN	O	O
,	PUNCT	O	O
volumetric	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
metabolic	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
digitalis	NOUN	O	B-Entity
glycosides	NOUN	O	I-Entity
on	ADP	O	O
myocardial	ADJ	O	O
oxygen	NOUN	O	I-Entity
supply	NOUN	O	O
and	CCONJ	O	O
demand	NOUN	O	O
are	VERB	O	O
of	ADP	O	O
particular	ADJ	O	O
interest	NOUN	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
obstructive	ADJ	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
have	VERB	O	O
not	ADV	O	O
been	VERB	O	O
measured	VERB	O	O
previously	ADV	O	O
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
assessed	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
ouabain	NOUN	O	I-Entity
(	PUNCT	O	O
0.015	NUM	O	O
mg	PROPN	O	O

/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
hemodynamic	NOUN	O	O
,	PUNCT	O	O
volumetric	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
metabolic	ADJ	O	O
parameters	NOUN	O	O
in	ADP	O	O
11	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
chronic	ADJ	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
without	ADP	O	O
clinical	ADJ	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Because	ADP	O	O
the	DET	O	O
protocol	NOUN	O	O
was	VERB	O	O
long	ADV	O	O
and	CCONJ	O	O
involved	ADJ	O	O
interventions	NOUN	O	O
which	ADJ	O	O
might	VERB	O	O
affect	VERB	O	O
the	DET	O	O
determinations	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
also	ADV	O	O
studied	VERB	O	O
in	ADP	O	O
nine	NUM	O	O
patients	NOUN	O	O
using	VERB	O	O
an	DET	O	O
identical	ADJ	O	O
protocol	NOUN	O	O
except	ADP	O	O
that	DET	O	O
ouabain	ADJ	O	I-Entity
administration	NOUN	O	O
was	VERB	O	O
omitted	VERB	O	O
.	PUNCT	O	O

Left	PROPN	O	O
ventricular	ADJ	O	O
end	NOUN	O	O
-	PUNCT	O	O
diastolic	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
left	VERB	O	O
ventricular	ADJ	O	O
end	NOUN	O	O
-	PUNCT	O	O
diastolic	NOUN	O	O
volume	NOUN	O	O
fell	VERB	O	O
in	ADP	O	O
each	DET	O	O
patient	NOUN	O	O
given	VERB	O	O
ouabain	NOUN	O	I-Entity
,	PUNCT	O	O
even	ADV	O	O
though	ADP	O	O
they	PRON	O	O
were	VERB	O	O
initially	ADV	O	O
elevated	VERB	O	O
in	ADP	O	O
only	ADV	O	O
two	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Left	VERB	O	O
ventricular	ADJ	O	O
end	NOUN	O	O
-	PUNCT	O	O
diastolic	NOUN	O	O
pressure	NOUN	O	O
fell	VERB	O	O
from	ADP	O	O
11.5+/-1.4	NUM	O	O
(	PUNCT	O	O
mean+/-SE	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
5.6+/-0.9	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
left	VERB	O	O
ventricular	ADJ	O	O
end	NOUN	O	O
-	PUNCT	O	O
diastolic	NOUN	O	O
volume	NOUN	O	O
fell	VERB	O	O
from	ADP	O	O
100+/-17	NUM	O	O
to	ADP	O	O
82+/-12	NUM	O	O
ml	PROPN	O	O
/	SYM	O	O
m2	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.01	NUM	O	O
)	PUNCT	O	O
1	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
ouabain	NOUN	O	I-Entity
infusion	NOUN	O	O
was	VERB	O	O
completed	VERB	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
myocardial	ADJ	O	O
oxygen	NOUN	O	I-Entity
consumption	NOUN	O	O
occurred	VERB	O	O
after	ADP	O	O
ouabain	ADJ	O	I-Entity
administration	NOUN	O	O
but	CCONJ	O	O
this	DET	O	O
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
a	DET	O	O
greater	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ouabain	NOUN	O	I-Entity
patients	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
who	NOUN	O	O
are	VERB	O	O
not	ADV	O	O
in	ADP	O	O
clinical	ADJ	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
end	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
diastolic	NOUN	O	I-Entity
volume	NOUN	O	I-Entity
falls	VERB	O	I-Entity
after	ADP	O	O
ouabain	ADV	O	I-Entity
administration	NOUN	O	O
even	ADV	O	O
when	ADV	O	O
it	PRON	O	O
is	VERB	O	O
initially	ADV	O	O
normal	ADJ	O	O
.	PUNCT	O	O

Though	ADP	O	O
this	DET	O	O
fall	NOUN	O	O
would	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
wall	NOUN	O	O
tension	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
,	PUNCT	O	O
therefore	ADV	O	O
,	PUNCT	O	O
of	ADP	O	O
myocardial	ADJ	O	O
oxygen	NOUN	O	I-Entity
consumption	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
may	VERB	O	O
not	ADV	O	O
be	VERB	O	O
of	ADP	O	O
sufficient	ADJ	O	O
magnitude	NOUN	O	O
to	PART	O	O
prevent	VERB	O	O
a	DET	O	O
net	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
myocardial	ADJ	O	O
oxygen	NOUN	O	I-Entity
consumption	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9545159)

Prolongation	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
QT	PROPN	O	I-Entity
interval	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
cisapride	VERB	O	I-Entity
-	PUNCT	O	O
diltiazem	NOUN	O	I-Entity
interaction	NOUN	O	O
.	PUNCT	O	O

Cisapride	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
cytochrome	NOUN	O	O
P450	PROPN	O	O
3A4	PROPN	O	O
(	PUNCT	O	O
CYP3A4	PROPN	O	O
)	PUNCT	O	O
substrate	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
widely	ADV	O	O
prescribed	VERB	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
gastrointestinal	ADJ	O	B-Entity
motility	NOUN	O	I-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

Prolongation	NOUN	O	B-Entity
of	ADP	O	I-Entity
QT	PROPN	O	I-Entity
interval	NOUN	O	I-Entity
,	PUNCT	O	O
torsades	VERB	O	B-Entity
de	X	O	I-Entity
pointes	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
sudden	ADJ	O	B-Entity
cardiac	ADJ	O	I-Entity
death	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
after	ADP	O	O
concomitant	ADJ	O	O
administration	NOUN	O	O
with	ADP	O	O
erythromycin	NOUN	O	I-Entity
or	CCONJ	O	O
azole	NOUN	O	I-Entity
antifungal	ADJ	O	O
agents	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
with	ADP	O	O
other	ADJ	O	O
CYP3A4	PROPN	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
possible	ADJ	O	O
drug	NOUN	O	O
interaction	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
a	DET	O	O
45-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
taking	VERB	O	O
cisapride	NOUN	O	I-Entity
for	ADP	O	O
gastroesophageal	NOUN	O	B-Entity
reflux	NOUN	O	I-Entity
disorder	NOUN	O	I-Entity
and	CCONJ	O	O
diltiazem	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
agent	NOUN	O	O
that	ADJ	O	O
has	VERB	O	O
inhibitory	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
CYP3A4	PROPN	O	O
,	PUNCT	O	O
for	ADP	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
in	ADP	O	O
near	ADJ	O	O
syncope	NOUN	O	I-Entity
and	CCONJ	O	O
had	VERB	O	O
QT	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
interval	ADJ	O	I-Entity
prolongation	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
discontinuing	VERB	O	O
cisapride	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
QT	PROPN	O	O
interval	NOUN	O	O
returned	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
recur	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
caution	NOUN	O	O
be	VERB	O	O
taken	VERB	O	O
when	ADV	O	O
cisapride	NOUN	O	I-Entity
is	VERB	O	O
prescribed	VERB	O	O
with	ADP	O	O
any	DET	O	O
potent	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
CYP3A4	PROPN	O	O
,	PUNCT	O	O
including	VERB	O	O
diltiazem	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8643973)

Paclitaxel	PROPN	O	I-Entity
combined	VERB	O	O
with	ADP	O	O
carboplatin	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
advanced	ADJ	O	O
ovarian	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
phase	NOUN	O	O
I	PRON	O	O
study	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
maximum	NOUN	O	O
tolerated	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
paclitaxel	NOUN	O	I-Entity
(	PUNCT	O	O
Taxol	PROPN	O	I-Entity
;	PUNCT	O	O
Bristol	PROPN	O	O
-	PUNCT	O	O
Myers	PROPN	O	O
Squibb	PROPN	O	O
Company	PROPN	O	O
,	PUNCT	O	O
Princeton	PROPN	O	O
,	PUNCT	O	O
NJ	PROPN	O	O
)	PUNCT	O	O

given	VERB	O	O
as	ADP	O	O
a	DET	O	O
3-hour	NUM	O	O
infusion	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
carboplatin	NOUN	O	I-Entity
administered	VERB	O	O
every	DET	O	O
21	NUM	O	O
days	NOUN	O	O
to	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
ovarian	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
paclitaxel	NOUN	O	I-Entity
doses	NOUN	O	O
were	VERB	O	O
escalated	VERB	O	O
as	ADP	O	O
follows	VERB	O	O
:	PUNCT	O	O
level	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
135	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m2	NOUN	O	O
;	PUNCT	O	O
level	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
160	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m2	NOUN	O	O
;	PUNCT	O	O
level	NOUN	O	O
3	NUM	O	O
,	PUNCT	O	O
185	NUM	O	O
mg	CCONJ	O	O
/	SYM	O	O
m2	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
level	VERB	O	O
4,210	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
fixed	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
carboplatin	NOUN	O	I-Entity
at	ADP	O	O
levels	NOUN	O	O
1	NUM	O	O
through	ADP	O	O
4	NUM	O	O
was	VERB	O	O
given	VERB	O	O
to	PART	O	O
achieve	VERB	O	O
an	DET	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
concentration	NOUN	O	O
-	PUNCT	O	O
time	NOUN	O	O
curve	NOUN	O	O
(	PUNCT	O	O
AUC	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
5	NUM	O	O
using	VERB	O	O
the	DET	O	O
Calvert	PROPN	O	O
formula	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
levels	NOUN	O	O
5	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
the	DET	O	O
carboplatin	NOUN	O	I-Entity
dose	NOUN	O	O
was	VERB	O	O
targeted	VERB	O	O
at	ADP	O	O
AUCs	PROPN	O	O
of	ADP	O	O
6	NUM	O	O
and	CCONJ	O	O
7.5	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
combined	VERB	O	O
with	ADP	O	O
a	DET	O	O
fixed	VERB	O	O
paclitaxel	NOUN	O	I-Entity
dose	NOUN	O	O
of	ADP	O	O
185	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
was	VERB	O	O
myelosuppression	NOUN	O	I-Entity
(	PUNCT	O	O
leukopenia	NOUN	O	I-Entity
,	PUNCT	O	O
granulocytopenia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Neurotoxicity	PROPN	O	I-Entity
was	VERB	O	O
largely	ADV	O	O
moderate	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
paclitaxel	NOUN	O	I-Entity
185	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
administered	VERB	O	O
as	ADP	O	O
a	DET	O	O
3-hour	NUM	O	O
infusion	NOUN	O	O
followed	VERB	O	O
immediately	ADV	O	O
by	ADP	O	O
a	DET	O	O
1-hour	NUM	O	O
infusion	NOUN	O	O
of	ADP	O	O
carboplatin	NOUN	O	I-Entity
at	ADP	O	O
an	DET	O	O
AUC	PROPN	O	O
of	ADP	O	O
6	NUM	O	O
can	VERB	O	O
be	VERB	O	O
administered	VERB	O	O
safely	ADV	O	O
in	ADP	O	O
a	DET	O	O
21-day	NOUN	O	O
schedule	NOUN	O	O
in	ADP	O	O
the	DET	O	O
outpatient	NOUN	O	O
setting	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
recommended	VERB	O	O
dose	NOUN	O	O
for	ADP	O	O
phase	NOUN	O	O
III	NUM	O	O
studies	NOUN	O	O
is	VERB	O	O
paclitaxel	ADJ	O	I-Entity
185	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
and	CCONJ	O	O
carboplatin	NOUN	O	I-Entity
AUC	PROPN	O	O
6	NUM	O	O
.	PUNCT	O	O


-DOCSTART- (10743694)

Treatment	NOUN	O	O
of	ADP	O	O
tacrolimus	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
by	ADP	O	O
conversion	NOUN	O	O
to	ADP	O	O
cyclosporine	NOUN	O	I-Entity
in	ADP	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
tacrolimus	DET	O	I-Entity
side	NOUN	O	O
effects	NOUN	O	O
persist	VERB	O	O
despite	ADP	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
,	PUNCT	O	O
conversion	NOUN	O	O
to	ADP	O	O
cyclosporine	VERB	O	I-Entity
-	PUNCT	O	O
based	VERB	O	O
immunosuppression	NOUN	O	O
(	PUNCT	O	O
CyA	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
necessary	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
characterized	VERB	O	O
tacrolimus	DET	O	I-Entity
side	NOUN	O	O
effects	NOUN	O	O
that	ADJ	O	O
warranted	VERB	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
outcomes	NOUN	O	O
after	ADP	O	O
conversion	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
388	NUM	O	O
liver	NOUN	O	O
recipients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
tacrolimus	NOUN	O	I-Entity
as	ADP	O	O
primary	ADJ	O	O
immunosuppression	NOUN	O	O
,	PUNCT	O	O
70	NUM	O	O
required	VERB	O	O
conversion	NOUN	O	O
to	ADP	O	O
CyA.	PROPN	O	O
We	PRON	O	O
recorded	VERB	O	O
indication	NOUN	O	O
for	ADP	O	O
conversion	NOUN	O	O
,	PUNCT	O	O
whether	ADP	O	O
conversion	NOUN	O	O
was	VERB	O	O
early	ADJ	O	O
or	CCONJ	O	O
late	ADJ	O	O
after	ADP	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
tacrolimus	NOUN	O	I-Entity
dose	NOUN	O	O
and	CCONJ	O	O
trough	NOUN	O	O
blood	NOUN	O	O
level	NOUN	O	O
at	ADP	O	O
conversion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
rejection	NOUN	O	O
after	ADP	O	O
conversion	NOUN	O	O
.	PUNCT	O	O

Indications	NOUN	O	O
for	ADP	O	O
early	ADJ	O	O
conversion	NOUN	O	O
were	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	B-Entity
insulin	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
dependent	ADJ	O	I-Entity
)	PUNCT	O	I-Entity
diabetes	NOUN	O	I-Entity
mellitus	NOUN	O	I-Entity
(	PUNCT	O	O
IDDM	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
5	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nephrotoxicity	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
gastrointestinal	ADJ	O	B-Entity
(	PUNCT	O	I-Entity
GI	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
toxicity	NOUN	O	I-Entity
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cardiomyopathy	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
for	ADP	O	O
late	ADJ	O	O
conversion	NOUN	O	O
were	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
IDDM	PROPN	O	I-Entity
(	PUNCT	O	O
12	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nephrotoxicity	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
GI	PROPN	O	B-Entity
toxicity	NOUN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hepatotoxicity	NOUN	O	I-Entity
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
post	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
transplant	NOUN	O	I-Entity
lmphoproliferate	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PTLD	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
cardiomyopathy	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
pruritus	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

When	ADV	O	O
tacrolimus	DET	O	I-Entity
side	NOUN	O	O
effects	NOUN	O	O
are	VERB	O	O
unresponsive	ADJ	O	O
to	PART	O	O
dose	VERB	O	O
reduction	NOUN	O	O
,	PUNCT	O	O
conversion	NOUN	O	O
to	ADP	O	O
CyA	PROPN	O	O
can	VERB	O	O
be	VERB	O	O
accomplished	VERB	O	O
safely	ADV	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
rejection	NOUN	O	O
and	CCONJ	O	O
excellent	ADJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
outcome	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3535719)

Relative	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
netilmicin	NOUN	O	I-Entity
and	CCONJ	O	O
tobramycin	NOUN	O	I-Entity
in	ADP	O	O
oncology	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
prospectively	ADV	O	O
compared	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
netilmicin	ADJ	O	B-Entity
sulfate	NOUN	O	I-Entity
or	CCONJ	O	O
tobramycin	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
piperacillin	NOUN	O	B-Entity
sodium	NOUN	O	I-Entity
in	ADP	O	O
118	NUM	O	O
immunocompromised	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
presumed	VERB	O	O
severe	ADJ	O	O
infections	NOUN	O	I-Entity
.	PUNCT	O	O

Nephrotoxicity	PROPN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
a	DET	O	O
similar	ADJ	O	O
proportion	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
netilmicin	NOUN	O	I-Entity
and	CCONJ	O	O
tobramycin	NOUN	O	I-Entity
(	PUNCT	O	O
17%	NUM	O	O
vs	ADP	O	O
11%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Ototoxicity	PROPN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
four	NUM	O	O
(	PUNCT	O	O
9.5%	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
42	NUM	O	O
netilmicin	NOUN	O	I-Entity
and	CCONJ	O	O
piperacillin	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
12	NUM	O	O
(	PUNCT	O	O
22%	NUM	O	O
)	PUNCT	O	O

of	ADP	O	O
54	NUM	O	O
tobramycin	NOUN	O	I-Entity
and	CCONJ	O	O
piperacillin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
those	DET	O	O
evaluated	VERB	O	O
with	ADP	O	O
posttherapy	NOUN	O	O
audiograms	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
of	ADP	O	O
four	NUM	O	O
netilmicin	NOUN	O	I-Entity
and	CCONJ	O	O
piperacillin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
had	VERB	O	O
auditory	ADJ	O	O
thresholds	NOUN	O	O
return	VERB	O	O
to	ADP	O	O
baseline	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
one	NUM	O	O
of	ADP	O	O
nine	NUM	O	O
tobramycin	NOUN	O	I-Entity
and	CCONJ	O	O
piperacillin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
greater	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
15-dB	NUM	O	O
increases	NOUN	O	O
in	ADP	O	O
auditory	ADJ	O	O
threshold	NOUN	O	O
as	ADP	O	O
a	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
total	NOUN	O	O
greater	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
15-dB	NUM	O	O
changes	NOUN	O	O
(	PUNCT	O	O
increases	NOUN	O	O
and	CCONJ	O	O
decreases	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
in	ADP	O	O
netilmicin	NOUN	O	I-Entity
and	CCONJ	O	O
piperacillin-	ADJ	O	I-Entity
vs	ADP	O	O
tobramycin	NOUN	O	I-Entity
and	CCONJ	O	O
piperacillin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
18	NUM	O	O
of	ADP	O	O
78	NUM	O	O
vs	ADP	O	O
67	NUM	O	O
of	ADP	O	O
115	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
aminoglycoside	ADV	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
ototoxicity	NOUN	O	I-Entity
was	VERB	O	O
less	ADV	O	O
severe	ADJ	O	O
and	CCONJ	O	O
more	ADV	O	O
often	ADV	O	O
reversible	ADJ	O	O
with	ADP	O	O
netilmicin	NOUN	O	I-Entity
than	ADP	O	O
with	ADP	O	O
tobramycin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6433367)

Effect	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	I-Entity
synthetase	NOUN	O	O
inhibitors	NOUN	O	O
on	ADP	O	O
experimentally	ADV	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
investigate	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
of	ADP	O	O
prostaglandins	NOUN	O	I-Entity
(	PUNCT	O	O
PGs	PROPN	O	I-Entity
)	PUNCT	O	O
to	ADP	O	O
seizure	NOUN	O	I-Entity
induction	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
six	NUM	O	O
PG	PROPN	O	O
synthetase	NOUN	O	O
inhibitors	NOUN	O	O
on	ADP	O	O
convulsions	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
flurothyl	NOUN	O	I-Entity
,	PUNCT	O	O
picrotoxin	NOUN	O	I-Entity
,	PUNCT	O	O
pentetrazol	NOUN	O	I-Entity
(	PUNCT	O	O
PTZ	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
electroshock	NOUN	O	O
or	CCONJ	O	O
bicuculline	NOUN	O	I-Entity
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Ibuprofen	PROPN	O	I-Entity
,	PUNCT	O	O
sulindac	NOUN	O	I-Entity
,	PUNCT	O	O
mefenamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
low	ADJ	O	O
dose	NOUN	O	O
meclofenamic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
increased	VERB	O	O
the	DET	O	O
latency	NOUN	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
onset	NOUN	O	O
in	ADP	O	O
the	DET	O	O
flurothyl	NOUN	O	I-Entity
and/or	CCONJ	O	O
PTZ	NOUN	O	I-Entity
models	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
electroshock	NOUN	O	O
,	PUNCT	O	O
picrotoxin	NOUN	O	I-Entity
and	CCONJ	O	O
bicuculline	NOUN	O	I-Entity
models	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
pretreatment	NOUN	O	O
agents	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
PGs	NOUN	O	I-Entity
are	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
mechanism(s	PROPN	O	O
)	PUNCT	O	O
underlying	VERB	O	O
fluorthyl-	NOUN	O	I-Entity
and	CCONJ	O	O
PTZ	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
picrotoxin-	ADJ	O	I-Entity
,	PUNCT	O	O
electroshock-	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
bicuculline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17285209)

Angiotensin	PROPN	O	O
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
(	PUNCT	O	O
ACE	PROPN	O	O
)	PUNCT	O	O
inhibitor	NOUN	O	O
-	PUNCT	O	O
associated	VERB	O	O
angioedema	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
stomach	NOUN	O	O
and	CCONJ	O	O
small	ADJ	O	O
intestine	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
on	ADP	O	O
a	DET	O	O
45-year	ADJ	O	O
old	ADJ	O	O
African	ADJ	O	O
-	PUNCT	O	O
American	ADJ	O	O
female	NOUN	O	O
with	ADP	O	O
newly	ADV	O	O
diagnosed	VERB	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
who	NOUN	O	O
was	VERB	O	O
started	VERB	O	O
on	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
pill	NOUN	O	O
of	ADP	O	O
amlodipine	NOUN	O	I-Entity
/	SYM	O	O
benazapril	ADV	O	I-Entity
10/5	NUM	O	O
mg	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
very	ADV	O	O
next	ADJ	O	O
day	NOUN	O	O
,	PUNCT	O	O
she	PRON	O	O
presented	VERB	O	O
at	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
room	NOUN	O	O
(	PUNCT	O	O
ER	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	NOUN	O	I-Entity
.	PUNCT	O	O

Angiotensin	PROPN	O	O
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
ACEI)-induced	PROPN	O	O
angioedema	NOUN	O	I-Entity
was	VERB	O	O
suspected	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
hypertensive	ADJ	O	I-Entity
medications	NOUN	O	O
were	VERB	O	O
discontinued	VERB	O	O
.	PUNCT	O	O

Her	ADJ	O	O
symptoms	NOUN	O	O
improved	VERB	O	O
within	ADP	O	O
the	DET	O	O
next	ADJ	O	O
24	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
repeat	VERB	O	O
CT	PROPN	O	O
after	ADP	O	O
72	NUM	O	O
hours	NOUN	O	O
revealed	VERB	O	O
marked	VERB	O	O
improvement	NOUN	O	O
in	ADP	O	O
stomach	NOUN	O	O
and	CCONJ	O	O
small	ADJ	O	O
bowel	NOUN	O	O
thickening	NOUN	O	O
and	CCONJ	O	O
resolution	NOUN	O	O
of	ADP	O	O
ascites	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
recognition	NOUN	O	O
of	ADP	O	O
angiotensin	NOUN	O	I-Entity
-	PUNCT	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
(	PUNCT	O	O
ACE	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
angiotensin	VERB	O	I-Entity
receptor	NOUN	O	O
blocker	NOUN	O	O
(	PUNCT	O	O
ARB	PROPN	O	O
)	PUNCT	O	O

intestinal	ADJ	O	B-Entity
angioedema	NOUN	O	I-Entity
constitutes	VERB	O	O
a	DET	O	O
challenge	NOUN	O	O
to	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
physicians	NOUN	O	O
,	PUNCT	O	O
internists	NOUN	O	O
,	PUNCT	O	O
emergency	NOUN	O	O
room	NOUN	O	O
personal	ADJ	O	O
and	CCONJ	O	O
surgeons	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15858223)

Valproic	PROPN	O	B-Entity
acid	NOUN	O	I-Entity

I	PRON	O	O
:	PUNCT	O	O
time	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
biomarkers	NOUN	O	O
,	PUNCT	O	O
liver	NOUN	O	B-Entity
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
valproic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
metabolite	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
valproic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
VPA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
a	DET	O	O
widely	ADV	O	O
used	VERB	O	O
antiepileptic	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
recently	ADV	O	O
demonstrated	VERB	O	O
by	ADP	O	O
elevated	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
15-F(2t)-isoprostane	NUM	O	I-Entity
(	PUNCT	O	O
15-F(2t)-IsoP	NUM	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

To	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
temporal	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
VPA	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
hepatotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
adult	ADJ	O	O
male	ADJ	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
ip	ADP	O	O
with	ADP	O	O
VPA	PROPN	O	I-Entity
(	PUNCT	O	O
500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
0.9%	NUM	O	O
saline	NOUN	O	O
(	PUNCT	O	O
vehicle	NOUN	O	O
)	PUNCT	O	O
once	ADV	O	O
daily	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
7	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
14	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Oxidative	ADJ	O	O
stress	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
determining	VERB	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
liver	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
15-F(2t)-IsoP	NUM	O	I-Entity
,	PUNCT	O	O
lipid	ADJ	O	B-Entity
hydroperoxides	NOUN	O	I-Entity
(	PUNCT	O	O
LPO	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
thiobarbituric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
reactive	ADJ	O	I-Entity
substances	NOUN	O	I-Entity
(	PUNCT	O	O
TBARs	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Plasma	PROPN	O	O
and	CCONJ	O	O
liver	NOUN	O	O
15-F(2t)-IsoP	NUM	O	I-Entity
were	VERB	O	O
elevated	ADJ	O	O
and	CCONJ	O	O
reached	VERB	O	O
a	DET	O	O
plateau	NOUN	O	O
after	ADP	O	O
day	NOUN	O	O
2	NUM	O	O
of	ADP	O	O
VPA	PROPN	O	I-Entity
treatment	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
control	NOUN	O	O
.	PUNCT	O	O

Liver	PROPN	O	O
LPO	PROPN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
elevated	VERB	O	O
until	ADP	O	O
day	NOUN	O	O
7	NUM	O	O
of	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
1.8-fold	PUNCT	O	O
versus	X	O	O
control	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Liver	PROPN	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
TBARs	NOUN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
increased	VERB	O	O
until	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
(	PUNCT	O	O
2-fold	NUM	O	O
vs.	X	O	O
control	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Liver	PROPN	O	B-Entity
toxicity	NOUN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
based	VERB	O	O
on	ADP	O	O
serum	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
glutathione	NOUN	O	I-Entity
S	NOUN	O	O
-	PUNCT	O	O
transferase	NOUN	O	O
(	PUNCT	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
GST	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
by	ADP	O	O
histology	NOUN	O	O
.	PUNCT	O	O

Serum	PROPN	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
GST	PROPN	O	O
levels	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
elevated	VERB	O	O
by	ADP	O	O
day	NOUN	O	O
4	NUM	O	O
,	PUNCT	O	O
which	ADJ	O	O
corresponded	VERB	O	O
to	ADP	O	O
hepatotoxicity	NOUN	O	I-Entity
as	ADP	O	O
shown	VERB	O	O
by	ADP	O	O
the	DET	O	O
increasing	VERB	O	O
incidence	NOUN	O	O
of	ADP	O	O
inflammation	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
capsule	NOUN	O	O
,	PUNCT	O	O
necrosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
steatosis	NOUN	O	I-Entity
throughout	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
liver	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
oxidation	NOUN	O	O
metabolites	NOUN	O	O
of	ADP	O	O
VPA	PROPN	O	I-Entity
were	VERB	O	O
decreased	VERB	O	O
by	ADP	O	O
day	NOUN	O	O
14	NUM	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
4-ene	NUM	O	B-Entity
-	PUNCT	O	I-Entity
VPA	PROPN	O	I-Entity
and	CCONJ	O	O
(	PUNCT	O	O
E)-2,4-diene	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
VPA	PROPN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
elevated	VERB	O	O
throughout	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Overall	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
VPA	PROPN	O	I-Entity
treatment	NOUN	O	O
results	NOUN	O	O
in	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
measured	VERB	O	O
by	ADP	O	O
levels	NOUN	O	O
of	ADP	O	O
15-F(2t)-IsoP	NUM	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
precedes	VERB	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
necrosis	NOUN	O	I-Entity
,	PUNCT	O	O
steatosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
elevated	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
GST	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (15811908)

Pheochromocytoma	PROPN	O	I-Entity
unmasked	VERB	O	O
by	ADP	O	O
amisulpride	NOUN	O	I-Entity
and	CCONJ	O	O
tiapride	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
describe	VERB	O	O
the	DET	O	O
unmasking	NOUN	O	O
of	ADP	O	O
pheochromocytoma	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
amisulpride	NOUN	O	I-Entity
and	CCONJ	O	O
tiapride	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
42-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
white	ADJ	O	O
man	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	O
hypertension	NOUN	O	I-Entity
with	ADP	O	O
severe	ADJ	O	O
headache	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	VERB	O	I-Entity
2	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
first	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
amisulpride	ADV	O	I-Entity
100	NUM	O	O
mg	NUM	O	O
and	CCONJ	O	O
tiapride	VERB	O	I-Entity
100	NUM	O	O
mg	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
drugs	NOUN	O	O
were	VERB	O	O
immediately	ADV	O	O
discontinued	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
recovered	VERB	O	O
after	ADP	O	O
subsequent	ADJ	O	O
nicardipine	NOUN	O	I-Entity
and	CCONJ	O	O
verapamil	ADJ	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Abdominal	ADJ	O	O
ultrasound	NOUN	O	O
showed	VERB	O	O
an	DET	O	O
adrenal	ADJ	O	O
mass	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
postoperative	ADJ	O	O
histologic	ADJ	O	O
examination	NOUN	O	O
confirmed	VERB	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
pheochromocytoma	NOUN	O	I-Entity
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
:	PUNCT	O	O
Drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
symptoms	NOUN	O	O
of	ADP	O	O
pheochromocytoma	NOUN	O	I-Entity
are	VERB	O	O
often	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
substituted	VERB	O	O
benzamide	NOUN	O	I-Entity
drugs	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
underlying	ADJ	O	O
mechanism	NOUN	O	O
is	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
our	ADJ	O	O
case	NOUN	O	O
,	PUNCT	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Naranjo	PROPN	O	O
probability	NOUN	O	O
scale	NOUN	O	O
indicated	VERB	O	O
a	DET	O	O
possible	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	I-Entity
crisis	NOUN	O	O
and	CCONJ	O	O
amisulpride	NOUN	O	I-Entity
and	CCONJ	O	O
tiapride	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
of	ADP	O	O
March	PROPN	O	O
24	NUM	O	O
,	PUNCT	O	O
2005	NUM	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
reported	VERB	O	O
case	NOUN	O	O
of	ADP	O	O
amisulpride-	ADJ	O	I-Entity
and	CCONJ	O	O
tiapride	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertensive	ADJ	O	I-Entity
crisis	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
pheochromocytoma	NOUN	O	I-Entity
.	PUNCT	O	O

Physicians	NOUN	O	O
and	CCONJ	O	O
other	ADJ	O	O
healthcare	NOUN	O	O
professionals	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
this	DET	O	O
potential	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
tiapride	NOUN	O	I-Entity
and	CCONJ	O	O
amisulpride	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15764424)

Quantitative	ADJ	O	O
drug	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
stimulant	NOUN	O	O
psychosis	NOUN	O	I-Entity
:	PUNCT	O	O
relationship	NOUN	O	O
to	PART	O	O
symptom	VERB	O	O
severity	NOUN	O	O
,	PUNCT	O	O
catecholamines	NOUN	O	I-Entity
and	CCONJ	O	O
hyperkinesia	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
examine	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
quantitative	ADJ	O	O
stimulant	NOUN	O	O
drug	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
catecholamines	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
psychotic	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
,	PUNCT	O	O
nineteen	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
a	DET	O	O
psychiatric	ADJ	O	I-Entity
emergency	NOUN	O	O
service	NOUN	O	O
with	ADP	O	O
a	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
amphetamine-	ADJ	O	I-Entity
or	CCONJ	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychosis	NOUN	O	I-Entity
were	VERB	O	O
interviewed	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
for	ADP	O	O
quantitative	ADJ	O	O
assays	NOUN	O	O
of	ADP	O	O
stimulant	ADJ	O	O
drug	NOUN	O	O
and	CCONJ	O	O
catecholamine	NOUN	O	I-Entity
metabolite	ADJ	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Methamphetamine	NOUN	O	I-Entity
or	CCONJ	O	O
amphetamine	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
related	VERB	O	O
to	ADP	O	O
several	ADJ	O	O
psychopathology	NOUN	O	O
scores	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
global	ADJ	O	O
hyperkinesia	NOUN	O	I-Entity
rating	NOUN	O	O
.	PUNCT	O	O

HVA	NOUN	O	O
levels	NOUN	O	O
were	VERB	O	O
related	VERB	O	O
to	ADP	O	O
global	ADJ	O	O
hyperkinesia	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
to	PART	O	O
psychopathology	VERB	O	O
ratings	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
many	ADJ	O	O
other	ADJ	O	O
factors	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
sensitization	NOUN	O	O
may	VERB	O	O
play	VERB	O	O
a	DET	O	O
role	NOUN	O	O
,	PUNCT	O	O
intensity	NOUN	O	O
of	ADP	O	O
stimulant	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
psychotic	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
and	CCONJ	O	O
stereotypies	NOUN	O	I-Entity
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
at	ADP	O	O
least	ADJ	O	O
in	ADP	O	O
part	NOUN	O	O
dose	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (12101159)

Delayed	VERB	O	O
asystolic	ADJ	O	I-Entity
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
after	ADP	O	O
diltiazem	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
;	PUNCT	O	O
resuscitation	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
dose	NOUN	O	O
intravenous	ADJ	O	O
calcium	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
51	NUM	O	O
year	NOUN	O	O
old	ADJ	O	O
man	NOUN	O	O
took	VERB	O	O
a	DET	O	O
mixed	ADJ	O	O
overdose	NOUN	O	I-Entity
including	VERB	O	O
1.8	NUM	O	O
-	PUNCT	O	O
3.6	NUM	O	O
g	NOUN	O	O
of	ADP	O	O
diltiazem	NOUN	O	I-Entity
,	PUNCT	O	O
paracetamol	NOUN	O	I-Entity
,	PUNCT	O	O
aspirin	NOUN	O	I-Entity
,	PUNCT	O	O
isosorbide	ADJ	O	I-Entity
nitrate	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
alcohol	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
initially	ADV	O	O
presented	VERB	O	O
to	ADP	O	O
hospital	NOUN	O	O
after	ADP	O	O
six	NUM	O	O
hours	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
activated	VERB	O	O
charcoal	NOUN	O	O
and	CCONJ	O	O
intravenous	ADJ	O	O
fluids	NOUN	O	O
.	PUNCT	O	O

Eighteen	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
overdose	NOUN	O	I-Entity
he	PRON	O	O
had	VERB	O	O
two	NUM	O	O
generalised	VERB	O	O
tonic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
clonic	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
remained	VERB	O	O
unresponsive	ADJ	O	O
with	ADP	O	O
junctional	ADJ	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
unrecordable	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
then	ADV	O	O
became	VERB	O	O
asystolic	ADJ	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
resuscitated	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
13.5	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
intravenous	ADJ	O	O
calcium	NOUN	O	I-Entity
and	CCONJ	O	O
adrenaline	NOUN	O	I-Entity
(	PUNCT	O	O
epinephrine	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
suggests	VERB	O	O
there	ADV	O	O
is	VERB	O	O
a	DET	O	O
role	NOUN	O	O
for	ADP	O	O
aggressive	ADJ	O	O
high	ADJ	O	O
dose	NOUN	O	O
intravenous	ADJ	O	O
calcium	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
severe	ADJ	O	O
diltiazem	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
,	PUNCT	O	O
particularly	ADV	O	O
with	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
asystole	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
early	ADV	O	O
in	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
after	ADP	O	O
diltiazem	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
case	NOUN	O	O
also	ADV	O	O
highlights	VERB	O	O
the	DET	O	O
problems	NOUN	O	O
with	ADP	O	O
delayed	VERB	O	O
toxicity	NOUN	O	I-Entity
when	ADV	O	O
whole	ADJ	O	O
bowel	NOUN	O	O
irrigation	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
administered	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (6699841)

Renal	ADJ	O	B-Entity
papillary	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
naproxen	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
31-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
rheumatoid	ADJ	O	B-Entity
arthritis	NOUN	O	I-Entity
,	PUNCT	O	O
who	NOUN	O	O
had	VERB	O	O
previously	ADV	O	O
been	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
sulindac	NOUN	O	I-Entity
,	PUNCT	O	O
fenoprofen	ADJ	O	B-Entity
calcium	NOUN	O	I-Entity
,	PUNCT	O	O
high	ADJ	O	O
dose	NOUN	O	O
salicylates	NOUN	O	I-Entity
and	CCONJ	O	O
gold	NOUN	O	I-Entity
salts	NOUN	O	O
,	PUNCT	O	O
developed	VERB	O	O
renal	ADJ	O	B-Entity
papillary	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
(	PUNCT	O	O
RPN	PROPN	O	I-Entity
)	PUNCT	O	O
4	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
institution	NOUN	O	O
of	ADP	O	O
naproxen	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
other	ADJ	O	O
factor	NOUN	O	O
predisposing	NOUN	O	O
to	ADP	O	O
RPN	PROPN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
discovered	VERB	O	O
.	PUNCT	O	O

Sulindac	PROPN	O	I-Entity
was	VERB	O	O
substituted	VERB	O	O
for	ADP	O	O
naproxen	NOUN	O	I-Entity
and	CCONJ	O	O
no	DET	O	O
further	ADV	O	O
adverse	ADJ	O	O
renal	ADJ	O	O
effects	NOUN	O	O
occurred	VERB	O	O
over	ADP	O	O
the	DET	O	O
next	ADJ	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
review	VERB	O	O
previous	ADJ	O	O
reports	NOUN	O	O
linking	VERB	O	O
RPN	PROPN	O	I-Entity
to	ADP	O	O
antiinflammatory	ADJ	O	O
drug	NOUN	O	O
use	NOUN	O	O
and	CCONJ	O	O
discuss	VERB	O	O
possible	ADJ	O	O
advantages	NOUN	O	O
of	ADP	O	O
sulindac	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
experienced	VERB	O	O
renal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
from	ADP	O	O
other	ADJ	O	O
antiinflammatory	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6127992)

Adverse	ADJ	O	O
interaction	NOUN	O	O
between	ADP	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
adrenergic	NOUN	O	I-Entity
blocking	VERB	O	I-Entity
drugs	NOUN	O	I-Entity
and	CCONJ	O	O
verapamil	NOUN	O	I-Entity
--	PUNCT	O	O
report	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
ischaemic	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
developed	VERB	O	O
profound	ADJ	O	O
cardiac	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
during	ADP	O	O
combined	VERB	O	O
therapy	NOUN	O	O
with	ADP	O	O
verapamil	NOUN	O	I-Entity
and	CCONJ	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
adrenergic	NOUN	O	I-Entity
blocking	NOUN	O	I-Entity
drugs	NOUN	O	I-Entity
.	PUNCT	O	O

Simultaneously	ADV	O	O
administration	NOUN	O	O
of	ADP	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
adrenergic	NOUN	O	I-Entity
blocking	VERB	O	I-Entity
drugs	NOUN	O	I-Entity
and	CCONJ	O	O
verapamil	NOUN	O	I-Entity
may	VERB	O	O
result	VERB	O	O
in	ADP	O	O
profound	ADJ	O	O
adverse	ADJ	O	O
interactions	NOUN	O	O
and	CCONJ	O	O
should	VERB	O	O
only	ADV	O	O
be	VERB	O	O
administered	VERB	O	O
with	ADP	O	O
great	ADJ	O	O
caution	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6115999)

Adverse	ADJ	O	O
reactions	NOUN	O	O
to	PART	O	O
bendrofluazide	VERB	O	I-Entity
and	CCONJ	O	O
propranolol	VERB	O	I-Entity
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
mild	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Report	PROPN	O	O
of	ADP	O	O
Medical	PROPN	O	O
Research	PROPN	O	O
Council	PROPN	O	O
Working	PROPN	O	O
Party	PROPN	O	O
on	ADP	O	O
Mild	PROPN	O	O
to	PART	O	O
Moderate	PROPN	O	O
Hypertension	PROPN	O	I-Entity
.	PUNCT	O	O

Participants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Medical	PROPN	O	O
Research	PROPN	O	O
Council	PROPN	O	O
treatment	NOUN	O	O
trial	NOUN	O	O
for	ADP	O	O
mild	ADJ	O	O
hypertension	NOUN	O	I-Entity
are	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
one	NUM	O	O
of	ADP	O	O
four	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
:	PUNCT	O	O

bendrofluazide	NOUN	O	I-Entity
,	PUNCT	O	O
propranolol	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
placebo	NOUN	O	O
for	ADP	O	O
either	DET	O	O
of	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
show	VERB	O	O
an	DET	O	O
association	NOUN	O	O
between	ADP	O	O
bendrofluazide	NOUN	O	I-Entity
treatment	NOUN	O	O
and	CCONJ	O	O
impotence	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
impotence	NOUN	O	I-Entity
also	ADV	O	O
occurred	VERB	O	O
more	ADV	O	O
frequently	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
taking	VERB	O	O
propranolol	NOUN	O	I-Entity
than	ADP	O	O
in	ADP	O	O
those	DET	O	O
taking	VERB	O	O
placebos	NOUN	O	O
.	PUNCT	O	O

Other	ADJ	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
significantly	ADV	O	O
linked	VERB	O	O
with	ADP	O	O
active	ADJ	O	O
drugs	NOUN	O	O
include	VERB	O	O
impaired	VERB	O	B-Entity
glucose	NOUN	O	I-Entity
tolerance	NOUN	O	I-Entity
in	ADP	O	O
men	NOUN	O	O
and	CCONJ	O	O
women	NOUN	O	O
and	CCONJ	O	O
gout	NOUN	O	I-Entity
in	ADP	O	O
men	NOUN	O	O
,	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
bendrofluazide	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Raynaud	PROPN	O	B-Entity
's	PART	O	I-Entity
phenomenon	NOUN	O	I-Entity
and	CCONJ	O	O
dyspnoea	NOUN	O	I-Entity
in	ADP	O	O
men	NOUN	O	O
and	CCONJ	O	O
women	NOUN	O	O
taking	VERB	O	O
propranolol	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
corneal	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
is	VERB	O	O
known	VERB	O	O
to	PART	O	O
have	VERB	O	O
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
propranolol	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
serum	NOUN	O	O
potassium	NOUN	O	I-Entity
level	NOUN	O	O
fell	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
urea	NOUN	O	I-Entity
and	CCONJ	O	O
uric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
levels	NOUN	O	O
rose	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
men	NOUN	O	O
and	CCONJ	O	O
women	NOUN	O	O
taking	VERB	O	O
bendrofluazide	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
propranolol	NOUN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
potassium	NOUN	O	I-Entity
and	CCONJ	O	O
uric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
levels	NOUN	O	O
rose	VERB	O	O
in	ADP	O	O
both	DET	O	O
sexes	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
urea	NOUN	O	I-Entity
level	NOUN	O	O
rose	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
women	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (18086064)

Dexmedetomidine	PROPN	O	I-Entity
and	CCONJ	O	O
cardiac	ADJ	O	O
protection	NOUN	O	O
for	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
meta	NOUN	O	O
-	PUNCT	O	O
analysis	NOUN	O	O
of	ADP	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trials	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
systematic	ADJ	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
dexmedetomidine	NOUN	O	I-Entity
on	ADP	O	O
cardiac	ADJ	O	O
outcomes	NOUN	O	O
following	VERB	O	O
non	ADJ	O	O
-	PUNCT	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
included	VERB	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomised	ADJ	O	O
peri	NOUN	O	O
-	PUNCT	O	O
operative	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
dexmedetomidine	NOUN	O	I-Entity
that	ADJ	O	O
reported	VERB	O	O
mortality	NOUN	O	O
,	PUNCT	O	O
cardiac	ADJ	O	O
morbidity	NOUN	O	O
or	CCONJ	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
events	NOUN	O	O
.	PUNCT	O	O

Dexmedetomidine	PROPN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
trend	NOUN	O	O
towards	ADP	O	O
improved	VERB	O	O
cardiac	ADJ	O	O
outcomes	NOUN	O	O
;	PUNCT	O	O
all	DET	O	O
-	PUNCT	O	O
cause	NOUN	O	O
mortality	NOUN	O	O
(	PUNCT	O	O
OR	PROPN	O	O
0.27	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.01	NUM	O	O
-	SYM	O	O
7.13	NUM	O	O
,	PUNCT	O	O

p	NOUN	O	O
=	SYM	O	O
0.44	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
non	ADJ	O	O
-	PUNCT	O	O
fatal	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
OR	PROPN	O	O
0.26	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.04	NUM	O	O
-	SYM	O	O
1.60	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.14	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
myocardial	ADJ	O	B-Entity
ischaemia	NOUN	O	I-Entity
(	PUNCT	O	O
OR	PROPN	O	O
0.65	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
0.26	NUM	O	O
-	SYM	O	O
1.63	NUM	O	O
,	PUNCT	O	O

Peri	PROPN	O	O
-	PUNCT	O	O
operative	ADJ	O	O
hypotension	NOUN	O	I-Entity
(	PUNCT	O	O
26%	NUM	O	O
,	PUNCT	O	O
OR	CCONJ	O	O
3.80	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O

CI	PROPN	O	O
1.91	NUM	O	O
-	SYM	O	O
7.54	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
(	PUNCT	O	O
17%	NUM	O	O
,	PUNCT	O	O
OR	CCONJ	O	O
5.45	NUM	O	O
,	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
2.98	NUM	O	O
-	SYM	O	O
9.95	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O

An	DET	O	O
anticholinergic	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
reduce	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
bradycardia	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.43	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
randomised	ADJ	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
dexmedetomidine	NOUN	O	I-Entity
is	VERB	O	O
warranted	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (12739036)

Differential	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
serum	NOUN	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
systemic	ADJ	O	B-Entity
lupus	NOUN	O	I-Entity
erythematosus	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
bioptic	ADJ	O	O
findings	NOUN	O	O
for	ADP	O	O
a	DET	O	O
57-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
chloroquine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myopathy	NOUN	O	I-Entity
.	PUNCT	O	O

Since	ADP	O	O
1989	NUM	O	O
,	PUNCT	O	O
she	PRON	O	O
had	VERB	O	O
been	VERB	O	O
suffering	VERB	O	O
from	ADP	O	O
systemic	ADJ	O	B-Entity
lupus	NOUN	O	I-Entity
erythematosus	NOUN	O	I-Entity
(	PUNCT	O	O
SLE	PROPN	O	I-Entity
)	PUNCT	O	O
with	ADP	O	O
renal	ADJ	O	B-Entity
involvement	NOUN	O	I-Entity
and	CCONJ	O	O
undergone	ADJ	O	O
periods	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
azathioprine	NOUN	O	I-Entity
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
.	PUNCT	O	O

Additional	ADJ	O	O
therapy	NOUN	O	O
with	ADP	O	O
chloroquine	NOUN	O	I-Entity
(	PUNCT	O	O
CQ	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
started	VERB	O	O
because	ADP	O	O
of	ADP	O	O
arthralgia	NOUN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
,	PUNCT	O	O
slightly	ADV	O	O
increased	VERB	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
(	PUNCT	O	O
CK	PROPN	O	O
)	PUNCT	O	O

Myositis	PROPN	O	I-Entity
was	VERB	O	O
suspected	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
steroids	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
CK	PROPN	O	O
increase	NOUN	O	O
persisted	VERB	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
she	PRON	O	O
developed	VERB	O	O
progressive	ADJ	O	O
muscular	ADJ	O	B-Entity
weakness	NOUN	O	I-Entity
and	CCONJ	O	O
muscular	ADJ	O	B-Entity
atrophy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
neurological	ADJ	O	O
and	CCONJ	O	O
electrophysiological	ADJ	O	O
findings	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
typical	ADJ	O	O
of	ADP	O	O
myositis	NOUN	O	I-Entity
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
muscle	NOUN	O	O
biopsy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
deltoid	ADJ	O	O
muscle	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
exclude	VERB	O	O
polymyositis	NOUN	O	I-Entity
or	CCONJ	O	O
toxic	ADJ	O	O
myopathy	NOUN	O	I-Entity
.	PUNCT	O	O

As	ADP	O	O
it	PRON	O	O
revealed	VERB	O	O
chloroquine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myopathy	NOUN	O	I-Entity
,	PUNCT	O	O
medication	NOUN	O	O
was	VERB	O	O
stopped	VERB	O	O
.	PUNCT	O	O

Discriminating	VERB	O	O
between	ADP	O	O
primary	ADJ	O	O
SLE	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
affection	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
musculoskeletal	ADJ	O	I-Entity
system	NOUN	O	I-Entity
and	CCONJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
side	NOUN	O	O
effects	NOUN	O	O
is	VERB	O	O
important	ADJ	O	O
for	ADP	O	O
appropriate	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
SLE	PROPN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12093990)

Intravenous	ADJ	O	O
ribavirin	NOUN	O	I-Entity
treatment	NOUN	O	O
for	ADP	O	O
severe	ADJ	O	O
adenovirus	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
immunocompromised	VERB	O	O
children	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
adenovirus	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
pediatrics	NOUN	O	O
is	VERB	O	O
increasing	VERB	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
growing	VERB	O	O
numbers	NOUN	O	O
of	ADP	O	O
immunocompromised	VERB	O	O
children	NOUN	O	O
,	PUNCT	O	O
where	ADV	O	O
case	NOUN	O	O
fatality	NOUN	O	O
rates	NOUN	O	O
as	ADV	O	O
high	ADJ	O	O
as	ADP	O	O
50%	NUM	O	O
to	PART	O	O
80%	NUM	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

There	ADV	O	O
are	VERB	O	O
no	DET	O	O
approved	VERB	O	O
antiviral	ADJ	O	O
agents	NOUN	O	O
with	ADP	O	O
proven	VERB	O	O
efficacy	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
adenovirus	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
nor	CCONJ	O	O
are	VERB	O	O
there	ADV	O	O
any	DET	O	O
prospective	NOUN	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trials	NOUN	O	O
of	ADP	O	O
potentially	ADV	O	O
useful	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
adenovirus	NOUN	O	O
therapies	NOUN	O	O
.	PUNCT	O	O

Apparent	ADJ	O	O
clinical	ADJ	O	O
success	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
adenovirus	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
is	VERB	O	O
limited	VERB	O	O
to	ADP	O	O
a	DET	O	O
few	ADJ	O	O
case	NOUN	O	O
reports	NOUN	O	O
and	CCONJ	O	O
small	ADJ	O	O
series	NOUN	O	O
.	PUNCT	O	O

Experience	NOUN	O	O
is	VERB	O	O
greatest	ADJ	O	O
with	ADP	O	O
intravenous	ADJ	O	O
ribavirin	NOUN	O	I-Entity
and	CCONJ	O	O
cidofovir	NOUN	O	I-Entity
.	PUNCT	O	O

Ribavirin	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
guanosine	NOUN	O	I-Entity
analogue	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
broad	ADJ	O	O
antiviral	ADJ	O	O
activity	NOUN	O	O
against	ADP	O	O
both	CCONJ	O	O
RNA	PROPN	O	O
and	CCONJ	O	O
DNA	PROPN	O	O
viruses	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
documented	VERB	O	O
activity	NOUN	O	O
against	ADP	O	O
adenovirus	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
.	PUNCT	O	O

Ribavirin	PROPN	O	I-Entity
is	VERB	O	O
licensed	VERB	O	O
in	ADP	O	O
aerosol	ADJ	O	O
form	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	B-Entity
syncytial	ADJ	O	I-Entity
virus	NOUN	O	I-Entity
infection	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
orally	ADV	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
interferon	NOUN	O	O
to	PART	O	O
treat	VERB	O	O
hepatitis	NOUN	O	B-Entity
C.	PROPN	O	I-Entity
Intravenous	PROPN	O	O

ribavirin	NOUN	O	I-Entity
is	VERB	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
choice	NOUN	O	O
for	ADP	O	O
infection	NOUN	O	B-Entity
with	ADP	O	I-Entity
hemorrhagic	ADJ	O	I-Entity
fever	NOUN	O	I-Entity
viruses	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
ribavirin	NOUN	O	I-Entity
is	VERB	O	O
reversible	ADJ	O	O
mild	ADJ	O	O
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
cidofovir	NOUN	O	I-Entity
in	ADP	O	O
severe	ADJ	O	O
adenovirus	NOUN	O	B-Entity
infection	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
limited	VERB	O	O
by	ADP	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
most	ADV	O	O
significant	ADJ	O	O
of	ADP	O	O
which	ADJ	O	O
is	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
report	VERB	O	O
our	ADJ	O	O
experience	NOUN	O	O
with	ADP	O	O
intravenous	ADJ	O	O
ribavirin	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
severe	ADJ	O	O
adenovirus	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
series	NOUN	O	O
of	ADP	O	O
immunocompromised	ADJ	O	O
children	NOUN	O	O
and	CCONJ	O	O
review	VERB	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
retrospectively	ADV	O	O
reviewed	VERB	O	O
the	DET	O	O
medical	ADJ	O	O
records	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
children	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
ribavirin	NOUN	O	I-Entity
for	ADP	O	O
documented	VERB	O	O
severe	ADJ	O	O
adenovirus	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
adenovirus	ADJ	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
after	ADP	O	O
cardiac	NOUN	O	O
and	CCONJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplants	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplant	NOUN	O	O
patient	NOUN	O	O
also	ADV	O	O
received	VERB	O	O
intravenous	ADJ	O	O
cidofovir	NOUN	O	I-Entity
for	ADP	O	O
progressive	ADJ	O	O
disseminated	VERB	O	O
disease	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
additional	ADJ	O	O
3	NUM	O	O
children	NOUN	O	O
developed	VERB	O	O
adenovirus	NOUN	O	B-Entity
pneumonia	NOUN	O	I-Entity
;	PUNCT	O	O
2	NUM	O	O
were	VERB	O	O
neonates	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
had	VERB	O	O
partial	ADJ	O	O
DiGeorge	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Intravenous	PROPN	O	O
ribavirin	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
on	ADP	O	O
a	DET	O	O
compassionate	ADJ	O	O
-	PUNCT	O	O
use	NOUN	O	O
protocol	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Complete	ADJ	O	O
clinical	ADJ	O	O
recovery	NOUN	O	O
followed	VERB	O	O
later	ADV	O	O
by	ADP	O	O
viral	ADJ	O	O
clearance	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
2	NUM	O	O
children	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
cardiac	ADJ	O	O
transplant	NOUN	O	O
recipient	NOUN	O	O
with	ADP	O	O
adenovirus	NOUN	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
immunocompetent	NOUN	O	O
neonate	NOUN	O	O
with	ADP	O	O
adenovirus	NOUN	O	B-Entity
pneumonia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
remaining	VERB	O	O
3	NUM	O	O
children	NOUN	O	O
died	VERB	O	O
of	ADP	O	O
adenovirus	DET	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Intravenous	ADJ	O	O
ribavirin	NOUN	O	I-Entity
therapy	NOUN	O	O
was	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
.	PUNCT	O	O

Use	VERB	O	O
of	ADP	O	O
cidofovir	NOUN	O	I-Entity
in	ADP	O	O
1	NUM	O	O
child	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
progressive	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
neutropenia	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
series	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
is	VERB	O	O
representative	ADJ	O	O
of	ADP	O	O
the	DET	O	O
spectrum	NOUN	O	O
of	ADP	O	O
immunocompromised	ADJ	O	O
children	NOUN	O	O
at	ADP	O	O
greatest	ADJ	O	O
risk	NOUN	O	O
for	ADP	O	O
severe	ADJ	O	O
adenovirus	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
namely	ADV	O	O
solid	ADJ	O	O
-	PUNCT	O	O
organ	NOUN	O	O
and	CCONJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
,	PUNCT	O	O
neonates	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
children	NOUN	O	O
with	ADP	O	O
immunodeficiency	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
intravenous	ADJ	O	O
ribavirin	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
effective	ADJ	O	O
for	ADP	O	O
all	DET	O	O
children	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
adenovirus	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
series	NOUN	O	O
or	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
,	PUNCT	O	O
therapy	NOUN	O	O
is	VERB	O	O
unlikely	ADJ	O	O
to	PART	O	O
be	VERB	O	O
of	ADP	O	O
benefit	NOUN	O	O
if	ADP	O	O
begun	VERB	O	O
late	ADV	O	O
in	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
the	DET	O	O
infection	NOUN	O	I-Entity
.	PUNCT	O	O

Early	ADJ	O	O
identification	NOUN	O	O
,	PUNCT	O	O
eg	X	O	O
by	ADP	O	O
polymerase	NOUN	O	O
chain	NOUN	O	O
reaction	NOUN	O	O
of	ADP	O	O
those	DET	O	O
patients	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
of	ADP	O	O
disseminated	VERB	O	O
adenovirus	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
may	VERB	O	O
permit	VERB	O	O
earlier	ADJ	O	O
antiviral	ADJ	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
better	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
therapeutic	ADJ	O	O
response	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
of	ADP	O	O
5	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
adenovirus	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
ribavirin	NOUN	O	I-Entity
recovered	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
availability	NOUN	O	O
of	ADP	O	O
newer	NOUN	O	O
rapid	ADJ	O	O
diagnostic	ADJ	O	O
techniques	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
polymerase	NOUN	O	O
chain	NOUN	O	O
reaction	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
make	VERB	O	O
earlier	ADJ	O	O
,	PUNCT	O	O
more	ADV	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
adenovirus	NOUN	O	B-Entity
infection	NOUN	O	I-Entity
possible	ADJ	O	O
.	PUNCT	O	O

Given	VERB	O	O
the	DET	O	O
seriousness	NOUN	O	O
and	CCONJ	O	O
increasing	VERB	O	O
prevalence	NOUN	O	O
of	ADP	O	O
adenovirus	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
certain	ADJ	O	O
hosts	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
children	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
large	ADJ	O	O
,	PUNCT	O	O
multicenter	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
potentially	ADV	O	O
useful	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
adenoviral	ADJ	O	O
therapies	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
intravenous	ADJ	O	O
ribavirin	NOUN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
clearly	ADV	O	O
required	VERB	O	O
to	PART	O	O
demonstrate	VERB	O	O
the	DET	O	O
most	ADV	O	O
effective	ADJ	O	O
and	CCONJ	O	O
least	ADJ	O	O
toxic	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3962737)

Hepatotoxicity	NOUN	O	I-Entity
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
.	PUNCT	O	O

Amiodarone	PROPN	O	I-Entity
has	VERB	O	O
proved	VERB	O	O
very	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
otherwise	ADV	O	O
resistant	ADJ	O	O
cardiac	ADJ	O	O
tachyarrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
has	VERB	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
been	VERB	O	O
limited	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
its	ADJ	O	O
serious	ADJ	O	O
side	NOUN	O	O
-	PUNCT	O	O
effects	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
cholestatic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
amiodarone	NOUN	O	I-Entity
treatment	NOUN	O	O
is	VERB	O	O
presented	VERB	O	O
below	ADP	O	O
and	CCONJ	O	O
a	DET	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hepatotoxicity	NOUN	O	I-Entity
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
is	VERB	O	O
given	VERB	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
solid	ADJ	O	O
evidence	NOUN	O	O
exists	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
amiodarone	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
steatosis	NOUN	O	I-Entity
,	PUNCT	O	O
alterations	NOUN	O	O
resembling	VERB	O	O
alcoholic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
cholestatic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
and	CCONJ	O	O
micronodular	ADJ	O	O
cirrhosis	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
liver	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
receiving	VERB	O	O
amiodarone	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
regularly	ADV	O	O
screened	VERB	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
hepatic	ADJ	O	O
enzyme	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Therapy	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
discontinued	VERB	O	O
on	ADP	O	O
the	DET	O	O
suspicion	NOUN	O	O
of	ADP	O	O
cholestatic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
or	CCONJ	O	O
hepatomegaly	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2716967)

Catalepsy	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
combinations	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
and	CCONJ	O	O
morphine	NOUN	O	I-Entity
:	PUNCT	O	O
potentiation	NOUN	O	O
,	PUNCT	O	O
antagonism	NOUN	O	O
,	PUNCT	O	O
tolerance	NOUN	O	O
and	CCONJ	O	O
cross	VERB	O	O
-	PUNCT	O	O
tolerance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
studies	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
both	DET	O	O
ketamine	NOUN	O	I-Entity
and	CCONJ	O	O
morphine	NOUN	O	I-Entity
induced	VERB	O	O
analgesia	NOUN	O	I-Entity
and	CCONJ	O	O
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Pre	PROPN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
ketamine	NOUN	O	I-Entity
produced	VERB	O	O
cross	NOUN	O	O
-	PUNCT	O	O
tolerance	NOUN	O	O
to	ADP	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
morphine	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
induce	VERB	O	O
cross	NOUN	O	O
-	PUNCT	O	O
tolerance	NOUN	O	O
to	PART	O	O
ketamine	VERB	O	I-Entity
but	CCONJ	O	O
rather	ADV	O	O
augmented	VERB	O	O
the	DET	O	O
cataleptic	ADJ	O	I-Entity
response	NOUN	O	O
;	PUNCT	O	O
this	DET	O	O
augmentation	NOUN	O	O
was	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
residual	ADJ	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
studies	NOUN	O	O
explored	VERB	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
loss	NOUN	O	O
of	ADP	O	O
righting	VERB	O	O
reflex	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
sub	NOUN	O	O
-	PUNCT	O	O
effective	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
and	CCONJ	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
administered	VERB	O	O
simultaneously	ADV	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
mutual	ADJ	O	O
potentiation	NOUN	O	O
between	ADP	O	O
sub	NOUN	O	O
-	PUNCT	O	O
effective	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
and	CCONJ	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
sub	NOUN	O	O
-	PUNCT	O	O
effective	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
partly	ADV	O	O
antagonized	VERB	O	O
fully	ADV	O	O
-	PUNCT	O	O
effective	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O

Latency	NOUN	O	O
to	ADP	O	O
the	DET	O	O
loss	NOUN	O	O
of	ADP	O	O
righting	VERB	O	O
reflex	NOUN	O	O
,	PUNCT	O	O
rigidity	NOUN	O	I-Entity
and	CCONJ	O	O
behavior	NOUN	O	O
on	ADP	O	O
recovery	NOUN	O	O
,	PUNCT	O	O
reflected	VERB	O	O
the	DET	O	O
relative	ADJ	O	O
predominance	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
or	CCONJ	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
each	DET	O	O
combination	NOUN	O	O
.	PUNCT	O	O

Naloxone	PROPN	O	I-Entity
inhibited	VERB	O	O
the	DET	O	O
induced	VERB	O	O
cataleptic	ADJ	O	I-Entity
effects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
degree	NOUN	O	O
and	CCONJ	O	O
time	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
development	NOUN	O	O
of	ADP	O	O
tolerance	NOUN	O	O
to	ADP	O	O
daily	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
sub	NOUN	O	O
-	PUNCT	O	O
effective	ADJ	O	O
dose	NOUN	O	O
combinations	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
and	CCONJ	O	O
morphine	NOUN	O	I-Entity
were	VERB	O	O
similar	ADJ	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
,	PUNCT	O	O
tolerant	ADJ	O	O
to	ADP	O	O
ketamine	VERB	O	I-Entity
-	PUNCT	O	O
dominant	ADJ	O	O
combinations	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
cross	ADJ	O	O
-	PUNCT	O	O
tolerant	ADJ	O	O
to	ADP	O	O
both	DET	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
those	DET	O	O
tolerant	ADJ	O	O
to	ADP	O	O
morphine	VERB	O	I-Entity
-	PUNCT	O	O
dominant	ADJ	O	O
combinations	NOUN	O	O
were	VERB	O	O
cross	ADJ	O	O
-	PUNCT	O	O
tolerant	ADJ	O	O
to	PART	O	O
morphine	NOUN	O	I-Entity
but	CCONJ	O	O
showed	VERB	O	O
either	CCONJ	O	O
no	DET	O	O
cross	NOUN	O	O
-	PUNCT	O	O
tolerance	NOUN	O	O
or	CCONJ	O	O
an	DET	O	O
augmented	VERB	O	O
response	NOUN	O	O
to	ADP	O	O
ketamine	NOUN	O	I-Entity
.	PUNCT	O	O

While	ADP	O	O
the	DET	O	O
mutual	ADJ	O	O
potentiation	NOUN	O	O
,	PUNCT	O	O
antagonism	NOUN	O	O
and	CCONJ	O	O
tolerance	NOUN	O	O
suggest	VERB	O	O
common	ADJ	O	O
mechanisms	NOUN	O	O
for	ADP	O	O
the	DET	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
,	PUNCT	O	O
differences	NOUN	O	O
in	ADP	O	O
latency	NOUN	O	O
,	PUNCT	O	O
rigidity	NOUN	O	I-Entity
and	CCONJ	O	O
behavior	NOUN	O	O
,	PUNCT	O	O
asymmetry	NOUN	O	O
of	ADP	O	O
cross	NOUN	O	O
-	PUNCT	O	O
tolerance	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
widely	ADV	O	O
-	PUNCT	O	O
different	ADJ	O	O
ID50	NOUN	O	O
for	ADP	O	O
naloxone	NOUN	O	I-Entity
would	VERB	O	O
argue	VERB	O	O
against	ADP	O	O
an	DET	O	O
action	NOUN	O	O
at	ADP	O	O
a	DET	O	O
single	ADJ	O	O
opioid	NOUN	O	O
site	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19642243)

Acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
AIDS	PROPN	O	I-Entity
on	ADP	O	O
tenofovir	NOUN	O	I-Entity
while	ADP	O	O
receiving	VERB	O	O
prolonged	ADJ	O	O
vancomycin	NOUN	O	I-Entity
course	NOUN	O	O
for	ADP	O	O
osteomyelitis	NOUN	O	I-Entity
.	PUNCT	O	O

Renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
developed	VERB	O	O
after	ADP	O	O
a	DET	O	O
prolonged	ADJ	O	O
course	NOUN	O	O
of	ADP	O	O
vancomycin	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
2	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
receiving	VERB	O	O
tenofovir	NOUN	O	B-Entity
disoproxil	NOUN	O	I-Entity
fumarate	NOUN	O	I-Entity
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
an	DET	O	O
antiretroviral	ADJ	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

Tenofovir	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
Fanconi	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
because	ADP	O	O
of	ADP	O	O
its	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
proximal	ADJ	O	O
renal	ADJ	O	O
tubule	NOUN	O	O
.	PUNCT	O	O

Vancomycin	PROPN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
is	VERB	O	O
infrequent	ADJ	O	O
but	CCONJ	O	O
may	VERB	O	O
result	VERB	O	O
from	ADP	O	O
coadministration	NOUN	O	O
with	ADP	O	O
a	DET	O	O
nephrotoxic	ADJ	O	I-Entity
agent	NOUN	O	O
.	PUNCT	O	O

Clinicians	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
that	ADP	O	O
tenofovir	NOUN	O	I-Entity
may	VERB	O	O
raise	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
during	ADP	O	O
prolonged	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
vancomycin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17682013)

Delayed	VERB	O	O
leukoencephalopathy	NOUN	O	I-Entity
with	ADP	O	O
stroke	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
presentation	NOUN	O	O
in	ADP	O	O
chemotherapy	NOUN	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
transient	ADJ	O	O
leukoencephalopathy	NOUN	O	I-Entity
mimicking	VERB	O	O
cerebrovascular	ADJ	O	B-Entity
accident	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
described	VERB	O	O
as	ADP	O	O
a	DET	O	O
complication	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
,	PUNCT	O	O
most	ADV	O	O
commonly	ADV	O	O
in	ADP	O	O
recipients	NOUN	O	O
of	ADP	O	O
intrathecal	ADJ	O	O
methotrexate	NOUN	O	I-Entity
for	ADP	O	O
childhood	NOUN	O	O
leukaemia	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
reviewed	VERB	O	O
the	DET	O	O
medical	ADJ	O	O
literature	NOUN	O	O
for	ADP	O	O
single	ADJ	O	O
reports	NOUN	O	O
and	CCONJ	O	O
case	NOUN	O	O
series	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
presenting	VERB	O	O
with	ADP	O	O
stroke	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
episodes	NOUN	O	O
while	ADP	O	O
receiving	VERB	O	O
systemic	ADJ	O	O
or	CCONJ	O	O
intrathecal	ADJ	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
cerebrovascular	ADJ	O	B-Entity
accidents	NOUN	O	I-Entity
were	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
identified	VERB	O	O
27	NUM	O	O
reports	NOUN	O	O
of	ADP	O	O
toxic	ADJ	O	O
leukoencephalopathy	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
methotrexate	NOUN	O	I-Entity
(	PUNCT	O	O
intrathecal	ADJ	O	O
,	PUNCT	O	O
systemic	ADJ	O	O
)	PUNCT	O	O
,	PUNCT	O	O
5-fluorouracil	NUM	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
derivative	ADJ	O	O
carmofur	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
capecitabine	NOUN	O	I-Entity
.	PUNCT	O	O

Diffusion	NOUN	O	O
weighted	VERB	O	O
imaging	NOUN	O	O
(	PUNCT	O	O
DWI	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
revealed	VERB	O	O
well	ADV	O	O
demarcated	ADJ	O	O
hyperintense	NOUN	O	O
lesions	NOUN	O	B-Entity
within	ADP	O	I-Entity
the	DET	O	I-Entity
subcortical	ADJ	O	I-Entity
white	ADJ	O	I-Entity
matter	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
cerebral	ADJ	O	O
hemispheres	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
corpus	NOUN	O	O
callosum	NOUN	O	O
,	PUNCT	O	O
corresponding	VERB	O	O
to	ADP	O	O
areas	NOUN	O	O
of	ADP	O	O
decreased	ADJ	O	O
proton	NOUN	O	O
diffusion	NOUN	O	O
on	ADP	O	O
apparent	ADJ	O	O
diffusion	NOUN	O	O
coefficient	NOUN	O	O
(	PUNCT	O	O
ADC	PROPN	O	O
)	PUNCT	O	O
maps	NOUN	O	O
(	PUNCT	O	O
available	ADJ	O	O
in	ADP	O	O
21/27	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
fluid	ADJ	O	O
attenuated	ADJ	O	O
inversion	NOUN	O	O
recovery	NOUN	O	O
(	PUNCT	O	O
FLAIR	PROPN	O	O
)	PUNCT	O	O
sequences	NOUN	O	O
frequently	ADV	O	O
revealed	VERB	O	O
persistent	ADJ	O	O
white	ADJ	O	B-Entity
matter	NOUN	O	I-Entity
abnormalities	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Several	ADJ	O	O
pathophysiological	ADJ	O	O
models	NOUN	O	O
of	ADP	O	O
delayed	VERB	O	O
leukoencephalopathy	NOUN	O	I-Entity
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
intrathecal	ADJ	O	O
or	CCONJ	O	O
systemic	ADJ	O	O
chemotherapy	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
proposed	VERB	O	O
.	PUNCT	O	O

DWI	PROPN	O	O
findings	NOUN	O	O
in	ADP	O	O
this	DET	O	O
cohort	NOUN	O	O
are	VERB	O	O
indicative	ADJ	O	O
of	ADP	O	O
cytotoxic	NOUN	O	B-Entity
oedema	NOUN	O	I-Entity
within	ADP	O	I-Entity
cerebral	ADJ	O	I-Entity
white	ADJ	O	I-Entity
matter	NOUN	O	I-Entity
and	CCONJ	O	O
lend	VERB	O	O
support	NOUN	O	O
to	ADP	O	O
an	DET	O	O
at	ADP	O	O
least	ADV	O	O
partially	ADV	O	O
reversible	ADJ	O	O
metabolic	NOUN	O	O
derangement	NOUN	O	O
as	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
for	ADP	O	O
this	DET	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16725121)

Down	ADV	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
norepinephrine	ADJ	O	I-Entity
transporter	NOUN	O	O
function	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
chronic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
desipramine	NOUN	O	I-Entity
linking	VERB	O	O
to	ADP	O	O
the	DET	O	O
alteration	NOUN	O	O
of	ADP	O	O
sensitivity	NOUN	O	O
of	ADP	O	O
local	ADJ	O	O
-	PUNCT	O	O
anesthetics	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
counteraction	NOUN	O	O
by	ADP	O	O
co	PROPN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
with	ADP	O	O
local	ADJ	O	O
anesthetics	NOUN	O	O
.	PUNCT	O	O

Alterations	NOUN	O	O
of	ADP	O	O
norepinephrine	ADJ	O	I-Entity
transporter	NOUN	O	O
(	PUNCT	O	O
NET	PROPN	O	O
)	PUNCT	O	O
function	NOUN	O	O
by	ADP	O	O
chronic	ADJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
NET	PROPN	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
sensitization	NOUN	O	O
to	PART	O	O
seizures	NOUN	O	I-Entity
induce	VERB	O	O
by	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
local	ADJ	O	O
anesthetics	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Daily	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
desipramine	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
the	DET	O	O
NET	PROPN	O	O
,	PUNCT	O	O
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
decreased	VERB	O	O
[	PUNCT	O	O
(	PUNCT	O	O
3)H]norepinephrine	NUM	O	I-Entity
uptake	NOUN	O	O
in	ADP	O	O
the	DET	O	O
P2	PROPN	O	O
fractions	NOUN	O	O
of	ADP	O	O
hippocampus	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
cortex	NOUN	O	O
,	PUNCT	O	O
striatum	NOUN	O	O
or	CCONJ	O	O
amygdalae	NOUN	O	O
.	PUNCT	O	O

Co	PROPN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
,	PUNCT	O	O
bupivacaine	NOUN	O	I-Entity
or	CCONJ	O	O
tricaine	NOUN	O	I-Entity
with	ADP	O	O
desipramine	NOUN	O	I-Entity
reversed	VERB	O	O
this	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Daily	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
increased	VERB	O	O
[	PUNCT	O	O
(	PUNCT	O	O
3)H]norepinephrine	NUM	O	I-Entity
uptake	NOUN	O	O
into	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
.	PUNCT	O	O

Daily	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
desipramine	NOUN	O	I-Entity
increased	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
appearance	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
and	CCONJ	O	O
decreased	VERB	O	O
that	ADP	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

Co	PROPN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
with	ADP	O	O
desipramine	NOUN	O	I-Entity
reversed	VERB	O	O
the	DET	O	O
changes	NOUN	O	O
of	ADP	O	O
convulsive	ADJ	O	I-Entity
activity	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
and	CCONJ	O	O
cocaine	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
repeated	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
desipramine	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
down	ADV	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
hippocampal	ADJ	O	O
NET	PROPN	O	O
induced	VERB	O	O
by	ADP	O	O
chronic	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
desipramine	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
relevant	ADJ	O	O
to	ADP	O	O
desipramine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
sensitization	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

Inhibition	NOUN	O	O
of	ADP	O	O
Na(+	PROPN	O	I-Entity
)	PUNCT	O	O
channels	NOUN	O	O
by	ADP	O	O
local	ADJ	O	O
anesthetics	NOUN	O	O
may	VERB	O	O
regulate	VERB	O	O
desipramine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
down	ADV	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
NET	PROPN	O	O
function	NOUN	O	O
.	PUNCT	O	O

Repeated	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
induces	VERB	O	O
up	ADP	O	O
-	PUNCT	O	O
regulation	NOUN	O	O
of	ADP	O	O
hippocampal	ADJ	O	O
NET	PROPN	O	O
function	NOUN	O	O
.	PUNCT	O	O

Desipramine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
sensitization	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
seizures	NOUN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
a	DET	O	O
mechanism	NOUN	O	O
distinct	ADV	O	O
from	ADP	O	O
kindling	VERB	O	O
resulting	VERB	O	O
from	ADP	O	O
repeated	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16629641)

Definition	PROPN	O	O
and	CCONJ	O	O
management	NOUN	O	O
of	ADP	O	O
anemia	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
infected	VERB	O	B-Entity
with	ADP	O	I-Entity
hepatitis	NOUN	O	I-Entity
C	PROPN	O	I-Entity
virus	NOUN	O	I-Entity
.	PUNCT	O	O

Chronic	ADJ	O	B-Entity
infection	NOUN	O	I-Entity
with	ADP	O	I-Entity
hepatitis	NOUN	O	I-Entity
C	PROPN	O	I-Entity
virus	NOUN	O	I-Entity
(	PUNCT	O	O
HCV	PROPN	O	O
)	PUNCT	O	O
can	VERB	O	O
progress	VERB	O	O
to	ADP	O	O
cirrhosis	NOUN	O	I-Entity
,	PUNCT	O	O
hepatocellular	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
end	VERB	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
liver	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
best	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
HCV	PROPN	O	B-Entity
infection	NOUN	O	I-Entity
is	VERB	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
pegylated	ADJ	O	O
interferon	NOUN	O	I-Entity
and	CCONJ	O	O
ribavirin	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
this	DET	O	O
regimen	NOUN	O	O
produces	VERB	O	O
sustained	VERB	O	O
virologic	ADJ	O	O
responses	NOUN	O	O
(	PUNCT	O	O
SVRs	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
approximately	ADV	O	O
50%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
can	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
potentially	ADV	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

Hemoglobin	PROPN	O	O
concentrations	NOUN	O	O
decrease	VERB	O	O
mainly	ADV	O	O
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemolysis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
this	DET	O	O
anemia	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
problematic	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
HCV	PROPN	O	B-Entity
infection	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
those	DET	O	O
who	NOUN	O	O
have	VERB	O	O
comorbid	VERB	O	O
renal	ADJ	O	B-Entity
or	CCONJ	O	I-Entity
cardiovascular	ADJ	O	I-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
general	ADJ	O	O
,	PUNCT	O	O
anemia	NOUN	O	I-Entity
can	VERB	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
may	VERB	O	O
have	VERB	O	O
negative	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
cerebral	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
ribavirin	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
anemia	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
reversed	VERB	O	O
by	ADP	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
or	CCONJ	O	O
discontinuation	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
approach	NOUN	O	O
compromises	VERB	O	O
outcomes	NOUN	O	O
by	ADP	O	O
significantly	ADV	O	O
decreasing	VERB	O	O
SVR	PROPN	O	O
rates	NOUN	O	O
.	PUNCT	O	O

Recombinant	ADJ	O	O
human	ADJ	O	O
erythropoietin	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
used	VERB	O	O
to	PART	O	O
manage	VERB	O	O
ribavirin	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
anemia	NOUN	O	I-Entity
but	CCONJ	O	O
has	VERB	O	O
other	ADJ	O	O
potential	ADJ	O	O
disadvantages	NOUN	O	O
.	PUNCT	O	O

Viramidine	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
liver	NOUN	O	O
-	PUNCT	O	O
targeting	VERB	O	O
prodrug	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
,	PUNCT	O	O
has	VERB	O	O
the	DET	O	O
potential	NOUN	O	O
to	PART	O	O
maintain	VERB	O	O
the	DET	O	O
virologic	ADJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
while	ADP	O	O
decreasing	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
C.	PROPN	O	I-Entity


-DOCSTART- (16006300)

Calcium	NOUN	O	B-Entity
carbonate	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
:	PUNCT	O	O
the	DET	O	O
updated	ADJ	O	O
milk	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alkali	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
;	PUNCT	O	O
report	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
cases	NOUN	O	O
and	CCONJ	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
describe	VERB	O	O
3	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
calcium	NOUN	O	B-Entity
carbonate	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypercalcemia	NOUN	O	I-Entity
and	CCONJ	O	O
gain	VERB	O	O
insights	NOUN	O	O
into	ADP	O	O
the	DET	O	O
cause	NOUN	O	O
and	CCONJ	O	O
management	NOUN	O	O
of	ADP	O	O
the	DET	O	O
milk	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alkali	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
report	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
laboratory	NOUN	O	O
data	NOUN	O	O
in	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
severe	ADJ	O	O
hypercalcemia	NOUN	O	I-Entity
(	PUNCT	O	O
corrected	VERB	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
>	X	O	O
or	CCONJ	O	O
=	SYM	O	O
14	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
review	VERB	O	O
the	DET	O	O
pertinent	ADJ	O	O
literature	NOUN	O	O
on	ADP	O	O
milk	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alkali	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
3	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
insufficiency	NOUN	O	I-Entity
,	PUNCT	O	O
relative	ADJ	O	O
metabolic	NOUN	O	B-Entity
alkalosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
low	ADJ	O	O
parathyroid	ADJ	O	O
hormone	NOUN	O	O
(	PUNCT	O	O
PTH	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
PTH	PROPN	O	O
-	PUNCT	O	O
related	VERB	O	O
peptide	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1,25-dihydroxyvitamin	NUM	O	B-Entity
D	ADJ	O	I-Entity
concentrations	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
included	VERB	O	O
aggressive	ADJ	O	O
hydration	NOUN	O	O
and	CCONJ	O	O
varied	ADJ	O	O
amounts	NOUN	O	O
of	ADP	O	O
furosemide	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
2	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
the	DET	O	O
higher	ADJ	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
concentrations	NOUN	O	O
received	VERB	O	O
pamidronate	NOUN	O	I-Entity
intravenously	ADV	O	O
(	PUNCT	O	O
60	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
mg	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	ADJ	O	O
caused	VERB	O	O
severe	ADJ	O	O
hypocalcemia	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
3	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
2	NUM	O	O
were	VERB	O	O
ingesting	VERB	O	O
acceptable	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
elemental	ADJ	O	O
calcium	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
g	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
g	NOUN	O	O
daily	ADV	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
form	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	B-Entity
carbonate	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
our	ADJ	O	O
highlighted	VERB	O	O
cases	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
review	VERB	O	O
the	DET	O	O
history	NOUN	O	O
,	PUNCT	O	O
classification	NOUN	O	O
,	PUNCT	O	O
pathophysiologic	ADJ	O	O
features	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
milk	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alkali	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
summarize	VERB	O	O
the	DET	O	O
cases	NOUN	O	O
reported	VERB	O	O
from	ADP	O	O
early	ADJ	O	O
1995	NUM	O	O
to	ADP	O	O
November	PROPN	O	O
2003	NUM	O	O
.	PUNCT	O	O

Milk	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alkali	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
common	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
unexplained	ADJ	O	O
hypercalcemia	NOUN	O	I-Entity
and	CCONJ	O	O
can	VERB	O	O
be	VERB	O	O
precipitated	VERB	O	O
by	ADP	O	O
small	ADJ	O	O
amounts	NOUN	O	O
of	ADP	O	O
orally	ADV	O	O
ingested	VERB	O	O
calcium	NOUN	O	B-Entity
carbonate	NOUN	O	I-Entity
in	ADP	O	O
susceptible	ADJ	O	O
persons	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
hydration	NOUN	O	O
,	PUNCT	O	O
furosemide	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
calcium	NOUN	O	I-Entity
and	CCONJ	O	O
vitamin	NOUN	O	B-Entity
D	NOUN	O	I-Entity
source	NOUN	O	O
is	VERB	O	O
adequate	ADJ	O	O
.	PUNCT	O	O

Pamidronate	ADJ	O	I-Entity
treatment	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
considerable	ADJ	O	O
risk	NOUN	O	O
for	ADP	O	O
hypocalcemia	NOUN	O	I-Entity
,	PUNCT	O	O
even	ADV	O	O
in	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
initially	ADV	O	O
severe	ADJ	O	O
hypercalcemia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11705128)

Management	NOUN	O	O
strategies	NOUN	O	O
for	ADP	O	O
ribavirin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	B-Entity
C	NOUN	O	I-Entity
:	PUNCT	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
economic	ADJ	O	O
implications	NOUN	O	O
.	PUNCT	O	O

Recently	ADV	O	O
published	VERB	O	O
studies	NOUN	O	O
have	VERB	O	O
demonstrated	VERB	O	O
increased	VERB	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
cost	NOUN	O	O
-	PUNCT	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
interferon	NOUN	O	O
and	CCONJ	O	O
alpha-2b	PROPN	O	O
/	SYM	O	O
ribavirin	ADV	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
interferon	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alpha	NOUN	O	I-Entity
monotherapy	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
C	PROPN	O	I-Entity
(	PUNCT	O	O
CHC	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Combination	NOUN	O	O
therapy	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
clinically	ADV	O	O
important	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
:	PUNCT	O	O
ribavirin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
(	PUNCT	O	O
RIHA	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
direct	ADJ	O	O
health	NOUN	O	O
-	PUNCT	O	O
care	NOUN	O	O
costs	NOUN	O	O
and	CCONJ	O	O
management	NOUN	O	O
of	ADP	O	O
RIHA	PROPN	O	I-Entity
during	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
CHC	PROPN	O	I-Entity
in	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
setting	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
systematic	ADJ	O	O
literature	NOUN	O	O
review	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
synthesize	VERB	O	O
information	NOUN	O	O
on	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
management	NOUN	O	O
of	ADP	O	O
RIHA	PROPN	O	I-Entity
.	PUNCT	O	O

Decision	PROPN	O	O
-	PUNCT	O	O
analytic	ADJ	O	O
techniques	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
estimate	VERB	O	O
the	DET	O	O
cost	NOUN	O	O
of	ADP	O	O
treating	VERB	O	O
RIHA	PROPN	O	I-Entity
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
RIHA	NOUN	O	I-Entity
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
hemoglobin	NOUN	O	O
to	ADP	O	O
less	ADJ	O	O
than	ADP	O	O
100	NUM	O	O
g	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
,	PUNCT	O	O
occurs	VERB	O	O
in	ADP	O	O
approximately	ADV	O	O
7%	NUM	O	O
to	ADP	O	O
9%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
standard	NOUN	O	O
of	ADP	O	O
care	NOUN	O	O
for	ADP	O	O
management	NOUN	O	O
of	ADP	O	O
RIHA	PROPN	O	I-Entity
is	VERB	O	O
reduction	NOUN	O	O
or	CCONJ	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ribavirin	NOUN	O	I-Entity
dosage	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
estimated	VERB	O	O
the	DET	O	O
direct	ADJ	O	O
cost	NOUN	O	O
of	ADP	O	O
treating	VERB	O	O
clinically	ADV	O	O
significant	ADJ	O	O
RIHA	PROPN	O	I-Entity
to	PART	O	O
be	VERB	O	O
170	NUM	O	O
per	ADP	O	O
patient	NOUN	O	O
receiving	VERB	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
per	ADP	O	O
48-week	NUM	O	O
treatment	NOUN	O	O
course	NOUN	O	O
(	PUNCT	O	O
range	VERB	O	O
68-	NUM	O	O
692	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
direct	ADJ	O	O
cost	NOUN	O	O
of	ADP	O	O
treating	VERB	O	O
clinically	ADV	O	O
significant	ADJ	O	O
RIHA	PROPN	O	I-Entity
is	VERB	O	O
1%	NUM	O	O
(	PUNCT	O	O
170/	NUM	O	O
16,459	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
drug	NOUN	O	O
treatment	NOUN	O	O
costs	NOUN	O	O
.	PUNCT	O	O

Questions	NOUN	O	O
remain	VERB	O	O
about	ADP	O	O
the	DET	O	O
optimal	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
RIHA	PROPN	O	I-Entity
in	ADP	O	O
a	DET	O	O
real	ADJ	O	O
-	PUNCT	O	O
world	NOUN	O	O
population	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
these	DET	O	O
uncertainties	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
initial	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
direct	ADJ	O	O
cost	NOUN	O	O
of	ADP	O	O
treating	VERB	O	O
RIHA	PROPN	O	I-Entity
provides	VERB	O	O
an	DET	O	O
estimate	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cost	NOUN	O	O
and	CCONJ	O	O
management	NOUN	O	O
implications	NOUN	O	O
of	ADP	O	O
this	DET	O	O
clinically	ADV	O	O
important	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6540303)

Effects	NOUN	O	O
of	ADP	O	O
amine	NOUN	O	I-Entity
pretreatment	NOUN	O	O
on	ADP	O	O
ketamine	NOUN	O	I-Entity
catatonia	NOUN	O	I-Entity
in	ADP	O	O
pinealectomized	VERB	O	O
or	CCONJ	O	O
hypophysectomized	VERB	O	O
animals	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
studies	NOUN	O	O
were	VERB	O	O
designed	VERB	O	O
to	PART	O	O
clarify	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
catecholamines	NOUN	O	I-Entity
and	CCONJ	O	O
pineal	ADJ	O	O
idolamines	NOUN	O	O
on	ADP	O	O
ketamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catatonia	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
intact	ADJ	O	O
,	PUNCT	O	O
pinealectomized	VERB	O	O
or	CCONJ	O	O
hypophysectomized	VERB	O	O
chick	NOUN	O	O
and	CCONJ	O	O
rat	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
pinealectomized	ADJ	O	O
chick	NOUN	O	O
,	PUNCT	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
dopamine	NOUN	O	I-Entity
increased	VERB	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
catatonia	NOUN	O	I-Entity
(	PUNCT	O	O
DOC	PROPN	O	O
)	PUNCT	O	O
after	ADP	O	O
ketamine	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
norepinephrine	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
.	PUNCT	O	O

Serotonin	PROPN	O	I-Entity
and	CCONJ	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
acetyl	PROPN	O	I-Entity
serotonin	NOUN	O	I-Entity
which	ADJ	O	O
augmented	VERB	O	O
ketamine	NOUN	O	I-Entity
DOC	PROPN	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
do	VERB	O	O
so	ADV	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pineal	ADJ	O	O
gland	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
melatonin	NOUN	O	I-Entity
potentiated	VERB	O	O
the	DET	O	O
ketamine	NOUN	O	I-Entity
DOC	NOUN	O	O
in	ADP	O	O
both	DET	O	O
the	DET	O	O
intact	ADJ	O	O
and	CCONJ	O	O
pinealectomized	ADJ	O	O
chick	NOUN	O	O
.	PUNCT	O	O

Ketamine	PROPN	O	I-Entity
was	VERB	O	O
more	ADV	O	O
potent	ADJ	O	O
in	ADP	O	O
the	DET	O	O
hypophysectomized	ADJ	O	O
chick	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
circadian	ADJ	O	O
rhythm	NOUN	O	O
noted	VERB	O	O
in	ADP	O	O
the	DET	O	O
intact	ADJ	O	O
chick	NOUN	O	O
was	VERB	O	O
absent	ADJ	O	O
;	PUNCT	O	O
furthermore	ADV	O	O
,	PUNCT	O	O
melatonin	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
augment	VERB	O	O
the	DET	O	O
ketamine	NOUN	O	I-Entity
DOC	PROPN	O	O
whereas	ADP	O	O
dopamine	NOUN	O	I-Entity
continued	VERB	O	O
to	PART	O	O
do	VERB	O	O
so	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
demonstrate	VERB	O	O
a	DET	O	O
species	NOUN	O	O
difference	NOUN	O	O
regarding	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
the	DET	O	O
amines	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
pineal	NOUN	O	O
in	ADP	O	O
spite	NOUN	O	O
of	ADP	O	O
the	DET	O	O
immature	ADJ	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
in	ADP	O	O
the	DET	O	O
young	ADJ	O	O
chick	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
intact	ADJ	O	O
barrier	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
these	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
a	DET	O	O
direct	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pituitary	NOUN	O	O
in	ADP	O	O
the	DET	O	O
augmentation	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
DOC	PROPN	O	O
induced	VERB	O	O
by	ADP	O	O
melatonin	NOUN	O	I-Entity
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
dopamine	NOUN	O	I-Entity
appeared	VERB	O	O
to	PART	O	O
act	VERB	O	O
on	ADP	O	O
systems	NOUN	O	O
more	ADV	O	O
closely	ADV	O	O
involved	VERB	O	O
with	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
catatonia	NOUN	O	I-Entity
rather	ADV	O	O
than	ADP	O	O
directly	ADV	O	O
on	ADP	O	O
the	DET	O	O
pituitary	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3057041)

Multicenter	PROPN	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
,	PUNCT	O	O
multiple	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
,	PUNCT	O	O
parallel	ADJ	O	O
-	PUNCT	O	O
groups	NOUN	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
azelastine	NOUN	O	I-Entity
,	PUNCT	O	O
chlorpheniramine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
spring	NOUN	O	B-Entity
allergic	ADJ	O	I-Entity
rhinitis	NOUN	O	I-Entity
.	PUNCT	O	O

Azelastine	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
novel	NOUN	O	O
antiallergic	ADJ	O	O
medication	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
chlorpheniramine	NOUN	O	B-Entity
maleate	NOUN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
spring	NOUN	O	B-Entity
allergic	ADJ	O	I-Entity
rhinitis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
,	PUNCT	O	O
multiple	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
,	PUNCT	O	O
parallel	ADJ	O	O
-	PUNCT	O	O
groups	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
ranged	VERB	O	O
in	ADP	O	O
age	NOUN	O	O
from	ADP	O	O
18	NUM	O	O
to	PART	O	O
60	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
had	VERB	O	O
at	ADP	O	O
least	ADJ	O	O
a	DET	O	O
2-year	NUM	O	O
history	NOUN	O	O
of	ADP	O	O
spring	NOUN	O	B-Entity
allergic	ADJ	O	I-Entity
rhinitis	NOUN	O	I-Entity
,	PUNCT	O	O
confirmed	VERB	O	O
by	ADP	O	O
positive	ADJ	O	O
skin	NOUN	O	O
test	NOUN	O	O
to	ADP	O	O
spring	NOUN	O	O
aeroallergens	NOUN	O	O
.	PUNCT	O	O

Medications	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
four	NUM	O	O
times	NOUN	O	O
daily	ADV	O	O
;	PUNCT	O	O
the	DET	O	O
azelastine	NOUN	O	I-Entity
groups	NOUN	O	O
received	VERB	O	O
0.5	NUM	O	O
,	PUNCT	O	O
1.0	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
2.0	NUM	O	O
mg	NUM	O	O
in	ADP	O	O
the	DET	O	O
morning	NOUN	O	O
and	CCONJ	O	O
evening	NOUN	O	O
with	ADP	O	O
placebo	NOUN	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
and	CCONJ	O	O
late	ADJ	O	O
afternoon	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
chlorpheniramine	NOUN	O	I-Entity
group	NOUN	O	O
received	VERB	O	O
4.0	NUM	O	O
mg	NUM	O	O
four	NUM	O	O
times	NOUN	O	O
daily	ADV	O	O
.	PUNCT	O	O

Symptoms	NOUN	O	O
relief	NOUN	O	O
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
receiving	VERB	O	O
the	DET	O	O
highest	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
azelastine	NOUN	O	I-Entity
(	PUNCT	O	O
2.0	NUM	O	O
mg	NUM	O	O
twice	ADV	O	O
daily	ADV	O	O
)	PUNCT	O	O
was	VERB	O	O
statistically	ADV	O	O
greater	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
during	ADP	O	O
all	DET	O	O
weeks	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Lower	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
azelastine	NOUN	O	I-Entity
were	VERB	O	O
statistically	ADV	O	O
more	ADV	O	O
effective	ADJ	O	O
than	ADP	O	O
placebo	NOUN	O	O
only	ADV	O	O
during	ADP	O	O
portions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
first	ADJ	O	O
3	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
the	DET	O	O
chlorpheniramine	NOUN	O	I-Entity
group	NOUN	O	O
did	VERB	O	O
have	VERB	O	O
fewer	ADJ	O	O
symptoms	NOUN	O	O
than	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
during	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
difference	NOUN	O	O
never	ADV	O	O
reached	VERB	O	O
statistical	ADJ	O	O
significance	NOUN	O	O
during	ADP	O	O
any	DET	O	O
week	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Drowsiness	NOUN	O	I-Entity
and	CCONJ	O	O
altered	VERB	O	B-Entity
taste	NOUN	O	I-Entity
perception	NOUN	O	I-Entity
were	VERB	O	O
increased	VERB	O	O
significantly	ADV	O	O
over	ADP	O	O
placebo	NOUN	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
azelastine	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

Azelastine	NOUN	O	I-Entity
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
safe	ADJ	O	O
,	PUNCT	O	O
efficacious	ADJ	O	O
medication	NOUN	O	O
for	ADP	O	O
seasonal	ADJ	O	B-Entity
allergic	ADJ	O	I-Entity
rhinitis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (625456)

One	NUM	O	O
case	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
hypercalcaemia	NOUN	O	I-Entity
and	CCONJ	O	O
two	NUM	O	O
of	ADP	O	O
recurrent	ADJ	O	O
nephrolithiasis	NOUN	O	I-Entity
are	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
regularly	ADV	O	O
consumed	VERB	O	O
large	ADJ	O	O
amounts	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	B-Entity
carbon	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
ate	NOUN	O	I-Entity
-	PUNCT	O	O
sodium	NOUN	O	B-Entity
bicarbonate	NOUN	O	I-Entity
powders	NOUN	O	O
for	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
20	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7910951)

Prolonged	VERB	O	O
paralysis	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
nondepolarizing	VERB	O	B-Entity
neuromuscular	ADJ	O	I-Entity
blocking	VERB	O	I-Entity
agents	NOUN	O	I-Entity
and	CCONJ	O	O
corticosteroids	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
of	ADP	O	O
nondepolarizing	VERB	O	B-Entity
neuromuscular	ADJ	O	I-Entity
blocking	VERB	O	I-Entity
agents	NOUN	O	I-Entity
(	PUNCT	O	O
ND	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NMBA	PROPN	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
recently	ADV	O	O
been	VERB	O	O
implicated	VERB	O	O
as	ADP	O	O
a	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
prolonged	ADJ	O	O
muscle	NOUN	O	B-Entity
weakness	NOUN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
the	DET	O	O
site	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lesion	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
predisposing	NOUN	O	O
factors	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
3	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
37	NUM	O	O
-	PUNCT	O	O
52	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
acute	ADJ	O	O
respiratory	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
prolonged	ADJ	O	O
weakness	NOUN	O	I-Entity
following	VERB	O	O
the	DET	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
ND	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NMBAs	PROPN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
also	ADV	O	O
received	VERB	O	O
intravenous	ADJ	O	O
corticosteroids	NOUN	O	I-Entity
.	PUNCT	O	O

Renal	ADJ	O	O
function	NOUN	O	O
was	VERB	O	O
normal	ADJ	O	O
but	CCONJ	O	O
hepatic	ADJ	O	O
function	NOUN	O	O
was	VERB	O	O
impaired	VERB	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
all	DET	O	O
had	VERB	O	O
acidosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
serum	NOUN	O	O
vecuronium	NOUN	O	I-Entity
level	NOUN	O	O
measured	VERB	O	O
in	ADP	O	O
1	NUM	O	O
patient	ADJ	O	O
14	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
discontinued	VERB	O	O
was	VERB	O	O
172	NUM	O	O
ng	INTJ	O	O
/	SYM	O	O
mL.	PROPN	O	O

A	DET	O	O
muscle	NOUN	O	O
biopsy	NOUN	O	O
in	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
showed	VERB	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
thick	ADJ	O	I-Entity
,	PUNCT	O	I-Entity
myosin	ADJ	O	I-Entity
filaments	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
weakness	NOUN	O	I-Entity
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
is	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
pathology	NOUN	O	B-Entity
at	ADP	O	I-Entity
both	CCONJ	O	I-Entity
the	DET	O	I-Entity
neuromuscular	ADJ	O	I-Entity
junction	NOUN	O	I-Entity
(	PUNCT	O	O
most	ADV	O	O
likely	ADJ	O	O
due	ADJ	O	O
to	ADP	O	O
ND	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NMBA	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
muscle	NOUN	O	O
(	PUNCT	O	O
most	ADV	O	O
likely	ADJ	O	O
due	ADJ	O	O
to	ADP	O	O
corticosteroids	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Hepatic	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
acidosis	NOUN	O	I-Entity
are	VERB	O	O
contributing	VERB	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7752389)

Prostaglandin	PROPN	O	B-Entity
E2-induced	VERB	O	I-Entity
bladder	NOUN	O	B-Entity
hyperactivity	NOUN	O	I-Entity
in	ADP	O	O
normal	ADJ	O	O
,	PUNCT	O	O
conscious	ADJ	O	O
rats	NOUN	O	O
:	PUNCT	O	O
involvement	NOUN	O	O
of	ADP	O	O
tachykinins	NOUN	O	I-Entity
?	PUNCT	O	O

In	ADP	O	O
normal	ADJ	O	O
conscious	ADJ	O	O
rats	NOUN	O	O
investigated	VERB	O	O
by	ADP	O	O
continuous	ADJ	O	O
cystometry	NOUN	O	O
,	PUNCT	O	O
intravesically	ADV	O	O
instilled	VERB	O	O
prostaglandin	NOUN	O	B-Entity
(	PUNCT	O	I-Entity
PG	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
E2	PROPN	O	I-Entity
facilitated	VERB	O	O
micturition	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
basal	ADJ	O	O
intravesical	ADJ	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
attenuated	VERB	O	O
by	ADP	O	O
both	DET	O	O
the	DET	O	O
NK1	PROPN	O	O
receptor	NOUN	O	O
selective	ADJ	O	O
antagonist	NOUN	O	O
RP	PROPN	O	B-Entity
67,580	NUM	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
NK2	PROPN	O	O
receptor	NOUN	O	O
selective	ADJ	O	O
antagonist	NOUN	O	O
SR	NOUN	O	B-Entity
48,968	NUM	O	I-Entity
,	PUNCT	O	O
given	VERB	O	O
intra	NOUN	O	O
-	PUNCT	O	O
arterially	ADV	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
it	PRON	O	O
was	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
stimulation	NOUN	O	O
of	ADP	O	O
both	CCONJ	O	O
NK1	PROPN	O	O
and	CCONJ	O	O
NK2	PROPN	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

Intra	PROPN	O	O
-	PUNCT	O	O
arterially	ADV	O	O
given	VERB	O	O
PGE2	PROPN	O	I-Entity
produced	VERB	O	O
a	DET	O	O
distinct	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
bladder	NOUN	O	O
pressure	NOUN	O	O
before	ADP	O	O
initiating	VERB	O	O
a	DET	O	O
micturition	NOUN	O	O
reflex	NOUN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
the	DET	O	O
PG	PROPN	O	I-Entity
had	VERB	O	O
a	DET	O	O
direct	ADJ	O	O
contractant	NOUN	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
detrusor	NOUN	O	O
smooth	ADJ	O	O
muscle	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
intra	NOUN	O	O
-	PUNCT	O	O
arterial	NOUN	O	O
PGE2	NOUN	O	I-Entity
could	VERB	O	O
not	ADV	O	O
be	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
intra	NOUN	O	O
-	PUNCT	O	O
arterial	NOUN	O	O
RP	PROPN	O	B-Entity
67,580	NUM	O	I-Entity
or	CCONJ	O	O
SR	PROPN	O	B-Entity
48,968	NUM	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
opens	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
the	DET	O	O
micturition	NOUN	O	O
reflex	NOUN	O	O
elicited	VERB	O	O
by	ADP	O	O
intra	NOUN	O	O
-	PUNCT	O	O
arterial	NOUN	O	O
PGE2	PROPN	O	I-Entity
was	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
pathways	NOUN	O	O
other	ADJ	O	O
than	ADP	O	O
the	DET	O	O
reflex	NOUN	O	O
initiated	VERB	O	O
when	ADV	O	O
the	DET	O	O
PG	PROPN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
intravesically	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
results	NOUN	O	O
thus	ADV	O	O
suggest	VERB	O	O
that	ADP	O	O
intra	ADV	O	O
-	PUNCT	O	O
arterial	ADJ	O	O
PGE2	PROPN	O	I-Entity
,	PUNCT	O	O
given	VERB	O	O
near	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
initiate	VERB	O	O
micturition	NOUN	O	O
in	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
rat	NOUN	O	O
chiefly	ADV	O	O
by	ADP	O	O
directly	ADV	O	O
contracting	VERB	O	O
the	DET	O	O
smooth	ADJ	O	O
muscle	NOUN	O	O
of	ADP	O	O
the	DET	O	O
detrusor	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
when	ADV	O	O
given	VERB	O	O
intravesically	ADV	O	O
,	PUNCT	O	O
PGE2	PROPN	O	I-Entity
may	VERB	O	O
stimulate	VERB	O	O
micturition	NOUN	O	O
by	ADP	O	O
releasing	VERB	O	O
tachykinins	NOUN	O	I-Entity
from	ADP	O	O
nerves	NOUN	O	O
in	ADP	O	O
and/or	CCONJ	O	O
immediately	ADV	O	O
below	ADP	O	O
the	DET	O	O
urothelium	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
tachykinins	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
turn	NOUN	O	O
,	PUNCT	O	O
initiate	VERB	O	O
a	DET	O	O
micturition	NOUN	O	O
reflex	NOUN	O	O
by	ADP	O	O
stimulating	VERB	O	O
NK1	PROPN	O	O
and	CCONJ	O	O
NK2	PROPN	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

Prostanoids	NOUN	O	I-Entity
may	VERB	O	O
,	PUNCT	O	O
via	ADP	O	O
release	NOUN	O	O
of	ADP	O	O
tachykinins	NOUN	O	I-Entity
,	PUNCT	O	O
contribute	VERB	O	O
to	ADP	O	O
both	DET	O	O
urge	NOUN	O	O
and	CCONJ	O	O
bladder	NOUN	O	B-Entity
hyperactivity	NOUN	O	I-Entity
seen	VERB	O	O
in	ADP	O	O
inflammatory	ADJ	O	O
conditions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lower	ADJ	O	O
urinary	ADJ	O	O
tract	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6942642)

Thiazide	PROPN	O	I-Entity
diuretics	NOUN	O	O
,	PUNCT	O	O
hypokalemia	NOUN	O	I-Entity
and	CCONJ	O	O
cardiac	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

Thiazide	PROPN	O	I-Entity
diuretics	NOUN	O	O
are	VERB	O	O
widely	ADV	O	O
accepted	VERB	O	O
as	ADP	O	O
the	DET	O	O
cornerstone	NOUN	O	O
of	ADP	O	O
antihypertensive	ADJ	O	O
treatment	NOUN	O	O
programs	NOUN	O	O
.	PUNCT	O	O

Hypokalemia	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
commonly	ADV	O	O
encountered	VERB	O	O
metabolic	ADJ	O	O
consequence	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
thiazide	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
treated	VERB	O	O
38	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
22	NUM	O	O
low	ADJ	O	O
renin	NOUN	O	O
,	PUNCT	O	O
16	NUM	O	O
normal	ADJ	O	O
renin	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
moderate	ADJ	O	O
diastolic	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
with	ADP	O	O
hydrochlorothiazide	NOUN	O	I-Entity
(	PUNCT	O	O
HCTC	PROPN	O	I-Entity
)	PUNCT	O	O
administered	VERB	O	O
on	ADP	O	O
a	DET	O	O
twice	ADV	O	O
daily	ADJ	O	O
schedule	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
serum	NOUN	O	O
K	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
control	NOUN	O	O
period	NOUN	O	O
was	VERB	O	O
4.5	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

/	SYM	O	O
l	VERB	O	O
an	DET	O	O
on	ADP	O	O
50	NUM	O	O
,	PUNCT	O	O
100	NUM	O	O
,	PUNCT	O	O
150	NUM	O	O
and	CCONJ	O	O
200	NUM	O	O
mg	NUM	O	O
HCTZ	PROPN	O	I-Entity
daily	ADV	O	O
3.9	NUM	O	O

Corresponding	VERB	O	O
figures	NOUN	O	O
for	ADP	O	O
whole	ADJ	O	O
body	NOUN	O	O
K	PROPN	O	I-Entity
were	VERB	O	O
4107	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

In	ADP	O	O
13	NUM	O	O
patients	NOUN	O	O
we	PRON	O	O
observed	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
HCTZ	PROPN	O	I-Entity
therapy	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
mg	NUM	O	O
daily	ADJ	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
PVC	PROPN	O	O
's	PART	O	O
during	ADJ	O	O
rest	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
during	ADP	O	O
static	ADJ	O	O
and	CCONJ	O	O
dynamic	ADJ	O	O
exercise	NOUN	O	O
.	PUNCT	O	O

Corresponding	VERB	O	O
figures	NOUN	O	O
during	ADP	O	O
HCTZ	PROPN	O	I-Entity
therapy	NOUN	O	O
100	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
were	VERB	O	O
1.4	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

K+	PROPN	O	I-Entity
observed	VERB	O	O
r	NOUN	O	O
=	SYM	O	O
0.72	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
we	PRON	O	O
found	VERB	O	O
that	DET	O	O
thiazide	ADP	O	I-Entity
diuretics	NOUN	O	O
cause	VERB	O	O
hypokalemia	NOUN	O	I-Entity
and	CCONJ	O	O
depletion	NOUN	O	O
of	ADP	O	O
body	NOUN	O	O
potassium	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
more	ADV	O	O
profound	ADJ	O	O
hypokalemia	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
greater	ADJ	O	O
the	DET	O	O
propensity	NOUN	O	O
for	ADP	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
PVC	PROPN	O	O
's	PART	O	O
.	PUNCT	O	O


-DOCSTART- (3732088)

Diuretics	NOUN	O	O
,	PUNCT	O	O
potassium	NOUN	O	I-Entity
and	CCONJ	O	O
arrhythmias	NOUN	O	I-Entity
in	ADP	O	O
hypertensive	ADJ	O	I-Entity
coronary	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
been	VERB	O	O
proposed	VERB	O	O
that	ADP	O	O
modest	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
potassium	NOUN	O	I-Entity
can	VERB	O	O
alter	VERB	O	O
the	DET	O	O
tendency	NOUN	O	O
towards	ADP	O	O
cardiac	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

If	ADP	O	O
this	DET	O	O
were	VERB	O	O
so	ADV	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
might	VERB	O	O
be	VERB	O	O
especially	ADV	O	O
susceptible	ADJ	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
myocardial	ADJ	O	O
electrical	ADJ	O	O
excitability	NOUN	O	O
was	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
essential	ADJ	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
known	VERB	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
after	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
potassium	NOUN	O	I-Entity
-	PUNCT	O	O
conserving	VERB	O	O
diuretic	NOUN	O	O
(	PUNCT	O	O
amiloride	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
similar	ADJ	O	O
period	NOUN	O	O
on	ADP	O	O
a	DET	O	O
potassium	NOUN	O	I-Entity
-	PUNCT	O	O
losing	VERB	O	O
diuretic	NOUN	O	O
(	PUNCT	O	O
chlorthalidone	NOUN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
randomised	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Plasma	PROPN	O	O
potassium	NOUN	O	I-Entity
concentrations	NOUN	O	O
were	VERB	O	O
on	ADP	O	O
average	ADJ	O	O
1	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O
L	NOUN	O	O
lower	ADJ	O	O
during	ADP	O	O
the	DET	O	O
chlorthalidone	NOUN	O	I-Entity
phase	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
amiloride	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
volume	NOUN	O	O
states	NOUN	O	O
as	ADP	O	O
assessed	VERB	O	O
by	ADP	O	O
bodyweight	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
renin	NOUN	O	O
and	CCONJ	O	O
noradrenaline	NOUN	O	I-Entity
(	PUNCT	O	O
norepinephrine	NOUN	O	I-Entity
)	PUNCT	O	O

Compared	VERB	O	O
to	ADP	O	O
amiloride	VERB	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
chlorthalidone	NOUN	O	I-Entity
phase	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
frequency	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
ectopic	NOUN	O	I-Entity
beats	NOUN	O	I-Entity
(	PUNCT	O	O
24-hour	ADJ	O	O
Holter	PROPN	O	O
monitoring	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
higher	ADJ	O	O
Lown	PROPN	O	O
grading	NOUN	O	O
,	PUNCT	O	O
increased	VERB	O	O
upslope	NOUN	O	O
and	CCONJ	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
monophasic	ADJ	O	O
action	NOUN	O	O
potential	NOUN	O	O
,	PUNCT	O	O
prolonged	ADJ	O	O
ventricular	ADJ	O	O
effective	ADJ	O	O
refractory	ADJ	O	O
period	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
electrical	ADJ	O	O
instability	NOUN	O	O
during	ADP	O	O
programmed	VERB	O	O
ventricular	ADJ	O	O
stimulation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
above	ADJ	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
because	ADP	O	O
potassium	NOUN	O	I-Entity
-	PUNCT	O	O
losing	VERB	O	O
diuretic	NOUN	O	O
therapy	NOUN	O	O
can	VERB	O	O
increase	VERB	O	O
myocardial	ADJ	O	O
electrical	ADJ	O	O
excitability	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ischaemic	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
even	ADV	O	O
minor	ADJ	O	O
falls	VERB	O	O
in	ADP	O	O
plasma	NOUN	O	O
potassium	NOUN	O	I-Entity
concentrations	NOUN	O	O
are	VERB	O	O
probably	ADV	O	O
best	ADJ	O	O
avoided	VERB	O	O
in	ADP	O	O
such	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2893236)

GABA	ADJ	O	I-Entity
involvement	NOUN	O	O
in	ADP	O	O
naloxone	NOUN	O	I-Entity
induced	VERB	O	O
reversal	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	B-Entity
paralysis	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
thiopental	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
agent	NOUN	O	O
is	VERB	O	O
yet	ADV	O	O
available	ADJ	O	O
to	PART	O	O
reverse	VERB	O	O
respiratory	ADJ	O	B-Entity
paralysis	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
CNS	PROPN	O	O
depressants	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
general	ADJ	O	O
anesthetics	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
naloxone	NOUN	O	I-Entity
reversed	VERB	O	O
respiratory	ADJ	O	B-Entity
paralysis	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
thiopental	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

thiopental	ADV	O	I-Entity
produced	VERB	O	O
anesthesia	NOUN	O	O
without	ADP	O	O
altering	VERB	O	O
respiratory	ADJ	O	O
rate	NOUN	O	O
,	PUNCT	O	O
increased	VERB	O	O
GABA	PROPN	O	I-Entity
,	PUNCT	O	O
decreased	VERB	O	O
glutamate	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
aspartate	NOUN	O	I-Entity
or	CCONJ	O	O
glycine	NOUN	O	I-Entity
levels	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
in	ADP	O	O
rat	NOUN	O	O
cortex	NOUN	O	O
and	CCONJ	O	O
brain	NOUN	O	O
stem	NOUN	O	O
.	PUNCT	O	O

Pretreatment	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
thiosemicarbazide	NOUN	O	I-Entity
for	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
abolished	VERB	O	O
the	DET	O	O
anesthetic	ADJ	O	O
action	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
the	DET	O	O
respiratory	ADJ	O	O
depressant	NOUN	O	O
action	NOUN	O	O
of	ADP	O	O
thiopental	NOUN	O	I-Entity
.	PUNCT	O	O

thiopental	ADV	O	I-Entity
produced	VERB	O	O
respiratory	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
with	ADP	O	O
further	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
GABA	PROPN	O	I-Entity
and	CCONJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
glutamate	NOUN	O	I-Entity
again	ADV	O	O
in	ADP	O	O
cortex	NOUN	O	O
and	CCONJ	O	O
brain	NOUN	O	O
stem	VERB	O	O
without	ADP	O	O
affecting	VERB	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
amino	NOUN	O	B-Entity
acids	NOUN	O	I-Entity
studied	VERB	O	O
in	ADP	O	O
four	NUM	O	O
regions	NOUN	O	O
of	ADP	O	O
rat	NOUN	O	O
brain	NOUN	O	O
.	PUNCT	O	O

Naloxone	PROPN	O	I-Entity
(	PUNCT	O	O
2.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.v	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

reversed	VERB	O	O
respiratory	ADJ	O	B-Entity
paralysis	NOUN	O	I-Entity
,	PUNCT	O	O
glutamate	NOUN	O	I-Entity
and	CCONJ	O	O
GABA	PROPN	O	I-Entity
levels	NOUN	O	O
to	PART	O	O
control	VERB	O	O
values	NOUN	O	O
in	ADP	O	O
brain	NOUN	O	O
stem	NOUN	O	O
and	CCONJ	O	O
cortex	NOUN	O	O
with	ADP	O	O
no	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
caudate	NOUN	O	O
or	CCONJ	O	O
cerebellum	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
naloxone	NOUN	O	I-Entity
reverses	VERB	O	O
respiratory	ADJ	O	B-Entity
paralysis	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
thiopental	ADJ	O	I-Entity
and	CCONJ	O	O
involves	VERB	O	O
GABA	PROPN	O	I-Entity
in	ADP	O	O
its	ADJ	O	O
action	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2533791)

National	ADJ	O	O
project	NOUN	O	O
on	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
mother	NOUN	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
infant	NOUN	O	O
infection	NOUN	O	B-Entity
by	ADP	O	I-Entity
hepatitis	NOUN	O	I-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	I-Entity
in	ADP	O	O
Japan	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
Japan	PROPN	O	O
,	PUNCT	O	O
a	DET	O	O
nationwide	ADJ	O	O
prevention	NOUN	O	O
program	NOUN	O	O
against	ADP	O	O
mother	NOUN	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
infant	NOUN	O	O
infection	NOUN	O	B-Entity
by	ADP	O	I-Entity
hepatitis	NOUN	O	I-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	I-Entity
(	PUNCT	O	O
HBV	PROPN	O	O
)	PUNCT	O	O
started	VERB	O	O
in	ADP	O	O
1985	NUM	O	O
.	PUNCT	O	O

This	DET	O	O
program	NOUN	O	O
consists	VERB	O	O
of	ADP	O	O
double	ADJ	O	O
screenings	NOUN	O	O
of	ADP	O	O
pregnant	ADJ	O	O
women	NOUN	O	O
and	CCONJ	O	O
prophylactic	ADJ	O	O
treatment	NOUN	O	O
to	ADP	O	O
the	DET	O	O
infants	NOUN	O	O
born	VERB	O	O
to	ADP	O	O
both	DET	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
surface	NOUN	O	I-Entity
antigen	NOUN	O	I-Entity
(	PUNCT	O	O
HBsAg	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
e	PROPN	O	I-Entity
antigen	NOUN	O	I-Entity
(	PUNCT	O	O
HBeAg	PROPN	O	I-Entity
)	PUNCT	O	O
positive	ADJ	O	O
mothers	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
infants	NOUN	O	O
are	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
two	NUM	O	O
injections	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
immune	ADJ	O	O
globulin	NOUN	O	O
(	PUNCT	O	O
HBIG	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
least	ADV	O	O
three	NUM	O	O
injections	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
derived	VERB	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
vaccine	NOUN	O	I-Entity
.	PUNCT	O	O

93.4%	NUM	O	O
pregnant	ADJ	O	O
women	NOUN	O	O
had	VERB	O	O
the	DET	O	O
chance	NOUN	O	O
to	PART	O	O
be	VERB	O	O
examined	VERB	O	O
for	ADP	O	O
HBsAg	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
positive	ADJ	O	O
rate	NOUN	O	O
was	VERB	O	O
1.4	NUM	O	O
to	ADP	O	O
1.5%	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
HBeAg	PROPN	O	I-Entity
positive	ADJ	O	O
rate	NOUN	O	O
in	ADP	O	O
HBsAg	PROPN	O	I-Entity
positive	ADJ	O	O
was	VERB	O	O
23	NUM	O	O
to	ADP	O	O
26%	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
HBsAg	PROPN	O	I-Entity
positive	ADJ	O	O
rate	NOUN	O	O
in	ADP	O	O
neonates	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
infants	NOUN	O	O
before	ADP	O	O
two	NUM	O	O
months	NOUN	O	O
were	VERB	O	O
3%	NUM	O	O
and	CCONJ	O	O
2%	NUM	O	O
respectively	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (2322844)

Nociceptive	ADJ	O	O
effects	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
intrathecal	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	B-Entity
D2	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
E2	PROPN	O	I-Entity
,	PUNCT	O	I-Entity
or	CCONJ	O	I-Entity
F2	NUM	O	I-Entity
alpha	NOUN	O	I-Entity
to	ADP	O	O
conscious	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
intrathecal	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
prostaglandins	NOUN	O	I-Entity
on	ADP	O	O
pain	NOUN	O	I-Entity
responses	NOUN	O	O
in	ADP	O	O
conscious	ADJ	O	O
mice	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
using	VERB	O	O
hot	ADJ	O	O
plate	NOUN	O	O
and	CCONJ	O	O
acetic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
writhing	VERB	O	O
tests	NOUN	O	O
.	PUNCT	O	O

Prostaglandin	PROPN	O	B-Entity
D2	PROPN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
-	SYM	O	O
3	NUM	O	O
ng	PROPN	O	O
/	SYM	O	O
mouse	NOUN	O	O
)	PUNCT	O	O
had	VERB	O	O
a	DET	O	O
hyperalgesic	ADJ	O	I-Entity
action	NOUN	O	O
on	ADP	O	O
the	DET	O	O
response	NOUN	O	O
to	ADP	O	O
a	DET	O	O
hot	ADJ	O	O
plate	NOUN	O	O
during	ADP	O	O
a	DET	O	O
3	NUM	O	O
-	SYM	O	O
60	NUM	O	O
min	NOUN	O	O
period	NOUN	O	O
after	ADP	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Prostaglandin	NOUN	O	B-Entity
E2	NOUN	O	I-Entity
showed	VERB	O	O
a	DET	O	O
hyperalgesic	ADJ	O	I-Entity
effect	NOUN	O	O
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
pg	NOUN	O	I-Entity
to	ADP	O	O
10	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
mouse	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
effect	NOUN	O	O
lasted	VERB	O	O
shorter	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
-	SYM	O	O
30	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
prostaglandin	NOUN	O	B-Entity
D2	NOUN	O	I-Entity
.	PUNCT	O	O

Similar	ADJ	O	O
results	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
by	ADP	O	O
acetic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
writhing	VERB	O	O
tests	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hyperalgesic	ADJ	O	I-Entity
effect	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	B-Entity
D2	NOUN	O	I-Entity
was	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
simultaneous	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
a	DET	O	O
substance	NOUN	O	O
P	NOUN	O	O
antagonist	NOUN	O	O
(	PUNCT	O	O
greater	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
100	NUM	O	O
ng	NOUN	O	O
)	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
by	ADP	O	O
AH6809	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
prostanoid	ADJ	O	O
EP1-receptor	NOUN	O	O
antagonist	NOUN	O	O
.	PUNCT	O	O

Conversely	ADV	O	O
,	PUNCT	O	O
prostaglandin	NOUN	O	B-Entity
E2-induced	PROPN	O	I-Entity
hyperalgesia	NOUN	O	I-Entity
was	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
AH6809	PROPN	O	I-Entity
(	PUNCT	O	O
greater	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
500	NUM	O	O
ng	NOUN	O	O
)	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
by	ADP	O	O
the	DET	O	O
substance	NOUN	O	O
P	NOUN	O	O
antagonist	NOUN	O	O
.	PUNCT	O	O

Prostaglandin	ADJ	O	B-Entity
F2	PROPN	O	I-Entity
alpha	NOUN	O	I-Entity
had	VERB	O	O
little	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
pain	NOUN	O	I-Entity
responses	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
both	DET	O	O
prostaglandin	NOUN	O	B-Entity
D2	NOUN	O	I-Entity
and	CCONJ	O	O
prostaglandin	NOUN	O	B-Entity
E2	PROPN	O	I-Entity
exert	NOUN	O	O
hyperalgesia	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
spinal	ADJ	O	O
cord	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
in	ADP	O	O
different	ADJ	O	O
ways	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20552622)

Swallowing	VERB	O	O
-	PUNCT	O	O
induced	VERB	O	O
atrial	NOUN	O	B-Entity
tachyarrhythmia	NOUN	O	I-Entity
triggered	VERB	O	O
by	ADP	O	O
salbutamol	NOUN	O	I-Entity
:	PUNCT	O	O
case	NOUN	O	O
report	NOUN	O	O
and	CCONJ	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
electrocardiogram	NOUN	O	O
,	PUNCT	O	O
episodes	NOUN	O	O
of	ADP	O	O
atrial	ADJ	O	B-Entity
tachyarrhythmia	NOUN	O	I-Entity
were	VERB	O	O
recorded	VERB	O	O
immediately	ADV	O	O
after	ADP	O	O
swallowing	VERB	O	O
;	PUNCT	O	O
24-hour	NUM	O	O
Holter	NOUN	O	O
monitoring	NOUN	O	O
recorded	VERB	O	O
several	ADJ	O	O
events	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
arrhythmia	NOUN	O	I-Entity
resolved	VERB	O	O
after	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
atenolol	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
recurred	VERB	O	O
a	DET	O	O
year	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
noticed	VERB	O	O
that	ADP	O	O
before	ADP	O	O
these	DET	O	O
episodes	NOUN	O	O
he	PRON	O	O
had	VERB	O	O
been	VERB	O	O
using	VERB	O	O
an	DET	O	O
inhalator	NOUN	O	O
of	ADP	O	O
salbutamol	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
stopping	VERB	O	O
the	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
a	DET	O	O
week	NOUN	O	O
with	ADP	O	O
the	DET	O	O
atenolol	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
arrhythmia	NOUN	O	I-Entity
disappeared	VERB	O	O
.	PUNCT	O	O

DISCUSSION	NOUN	O	O
:	PUNCT	O	O
Swallowing	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
atrial	ADJ	O	B-Entity
tachyarrhythmia	NOUN	O	I-Entity
(	PUNCT	O	O
SIAT	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
phenomenon	NOUN	O	O
.	PUNCT	O	O

Fewer	ADJ	O	O
than	ADP	O	O
50	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
SIAT	PROPN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
described	VERB	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
article	NOUN	O	O
summarizes	VERB	O	O
all	ADJ	O	O
the	DET	O	O
cases	NOUN	O	O
published	VERB	O	O
,	PUNCT	O	O
creating	VERB	O	O
a	DET	O	O
comprehensive	ADJ	O	O
review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
current	ADJ	O	O
knowledge	NOUN	O	O
and	CCONJ	O	O
approach	NOUN	O	O
to	ADP	O	O
SIAT	PROPN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
discusses	VERB	O	O
demographics	NOUN	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
characteristics	NOUN	O	O
and	CCONJ	O	O
types	NOUN	O	O
of	ADP	O	O
arrhythmia	NOUN	O	I-Entity
,	PUNCT	O	O
postulated	VERB	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
SIAT	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
different	ADJ	O	O
treatment	NOUN	O	O
possibilities	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
medications	NOUN	O	O
,	PUNCT	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
radiofrequency	NOUN	O	O
catheter	NOUN	O	O
ablation	NOUN	O	O
(	PUNCT	O	O
RFCA	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Salbutamol	PROPN	O	I-Entity
is	VERB	O	O
presented	VERB	O	O
here	ADV	O	O
as	ADP	O	O
a	DET	O	O
possible	ADJ	O	O
trigger	NOUN	O	O
for	ADP	O	O
SIAT	PROPN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
it	PRON	O	O
is	VERB	O	O
difficult	ADJ	O	O
to	PART	O	O
define	VERB	O	O
causality	NOUN	O	O
in	ADP	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
logical	ADJ	O	O
to	PART	O	O
think	VERB	O	O
that	ADP	O	O
a	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
agonist	NOUN	O	O
like	ADP	O	O
salbutamol	NOUN	O	I-Entity
(	PUNCT	O	O
known	VERB	O	O
to	PART	O	O
induce	VERB	O	O
tachycardia	NOUN	O	I-Entity
)	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
trigger	NOUN	O	O
of	ADP	O	O
adrenergic	ADJ	O	O
reflexes	NOUN	O	O
originating	VERB	O	O
in	ADP	O	O
the	DET	O	O
esophagus	NOUN	O	O
while	ADP	O	O
swallowing	VERB	O	O
and	CCONJ	O	O
that	ADP	O	O
a	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocker	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
atenolol	NOUN	O	I-Entity
(	PUNCT	O	O
that	ADP	O	O
blocks	NOUN	O	O
the	DET	O	O
adrenergic	ADJ	O	O
activity	NOUN	O	O
)	PUNCT	O	O
may	VERB	O	O
relieve	VERB	O	O
it	PRON	O	O
.	PUNCT	O	O


-DOCSTART- (20510337)

Coenzyme	PROPN	O	B-Entity
Q10	PROPN	O	I-Entity
treatment	NOUN	O	O
ameliorates	VERB	O	O
acute	ADJ	O	O
cisplatin	NOUN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
nephroprotective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
coenzyme	NOUN	O	B-Entity
Q10	PROPN	O	I-Entity
was	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
injury	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
single	ADJ	O	O
i.p	NOUN	O	O
.	PUNCT	O	O

injection	NOUN	O	O
of	ADP	O	O
cisplatin	NOUN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Coenzyme	PROPN	O	B-Entity
Q10	PROPN	O	I-Entity
treatment	NOUN	O	O

(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
applied	VERB	O	O
for	ADP	O	O
6	NUM	O	O
consecutive	ADJ	O	O
days	NOUN	O	O
,	PUNCT	O	O
starting	VERB	O	O
1	NUM	O	O
day	NOUN	O	O
before	ADP	O	O
cisplatin	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Coenzyme	PROPN	O	B-Entity
Q10	PROPN	O	I-Entity
significantly	ADV	O	O
reduced	VERB	O	O
blood	NOUN	O	B-Entity
urea	NOUN	O	I-Entity
nitrogen	NOUN	O	I-Entity
and	CCONJ	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
which	ADJ	O	O
were	VERB	O	O
increased	VERB	O	O
by	ADP	O	O
cisplatin	NOUN	O	I-Entity
.	PUNCT	O	O

Coenzyme	PROPN	O	B-Entity
Q10	PROPN	O	I-Entity
significantly	ADV	O	O
compensated	VERB	O	O
deficits	NOUN	O	O
in	ADP	O	O
the	DET	O	O
antioxidant	ADJ	O	O
defense	NOUN	O	O
mechanisms	NOUN	O	O
(	PUNCT	O	O
reduced	VERB	O	B-Entity
glutathione	NOUN	O	I-Entity
level	NOUN	O	O
and	CCONJ	O	O
superoxide	NOUN	O	I-Entity
dismutase	NOUN	O	O
activity	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
suppressed	VERB	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
,	PUNCT	O	O
decreased	VERB	O	O
the	DET	O	O
elevations	NOUN	O	O
of	ADP	O	O
tumor	NOUN	O	I-Entity
necrosis	NOUN	O	I-Entity
factor	NOUN	O	O
-	PUNCT	O	O
alpha	NOUN	O	O
,	PUNCT	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
and	CCONJ	O	O
platinum	NOUN	O	I-Entity
ion	NOUN	O	O
concentration	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
attenuated	VERB	O	O
the	DET	O	O
reductions	NOUN	O	O
of	ADP	O	O
selenium	NOUN	O	I-Entity
and	CCONJ	O	O
zinc	NOUN	O	I-Entity
ions	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
tissue	NOUN	O	O
resulted	VERB	O	O
from	ADP	O	O
cisplatin	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
histopathological	ADJ	O	O
renal	ADJ	O	B-Entity
tissue	NOUN	O	I-Entity
damage	NOUN	O	I-Entity
mediated	VERB	O	O
by	ADP	O	O
cisplatin	NOUN	O	I-Entity
was	VERB	O	O
ameliorated	VERB	O	O
by	ADP	O	O
coenzyme	NOUN	O	B-Entity
Q10	PROPN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Immunohistochemical	ADJ	O	O
analysis	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
coenzyme	NOUN	O	B-Entity
Q10	PROPN	O	I-Entity
significantly	ADV	O	O
decreased	VERB	O	O
the	DET	O	O
cisplatin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
overexpression	NOUN	O	O
of	ADP	O	O
inducible	ADJ	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
synthase	NOUN	O	O
,	PUNCT	O	O
nuclear	ADJ	O	O
factor	NOUN	O	O
-	PUNCT	O	O
kappaB	PROPN	O	O
,	PUNCT	O	O
caspase-3	NOUN	O	O
and	CCONJ	O	O
p53	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
tissue	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
coenzyme	NOUN	O	B-Entity
Q10	PROPN	O	I-Entity
represents	VERB	O	O
a	DET	O	O
potential	ADJ	O	O
therapeutic	ADJ	O	O
option	NOUN	O	O
to	PART	O	O
protect	VERB	O	O
against	ADP	O	O
acute	ADJ	O	O
cisplatin	NOUN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
commonly	ADV	O	O
encountered	VERB	O	O
in	ADP	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20164825)

Metformin	NOUN	O	I-Entity
prevents	VERB	O	O
experimental	ADJ	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	NOUN	O	I-Entity
by	ADP	O	O
a	DET	O	O
mitochondria	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
pathway	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
antidiabetic	ADJ	O	O
drug	NOUN	O	O
metformin	NOUN	O	I-Entity
can	VERB	O	O
diminish	VERB	O	O
apoptosis	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
in	ADP	O	O
endothelial	ADJ	O	O
cells	NOUN	O	O
and	CCONJ	O	O
prevent	VERB	O	O
vascular	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
even	ADV	O	O
in	ADP	O	O
nondiabetic	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
we	PRON	O	O
tested	VERB	O	O
whether	ADP	O	O
it	PRON	O	O
has	VERB	O	O
a	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
a	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
gentamicin	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Mitochondrial	ADJ	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
respiration	NOUN	O	O
intensity	NOUN	O	O
,	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
species	NOUN	O	O
,	PUNCT	O	O
permeability	NOUN	O	O
transition	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cytochrome	VERB	O	O
c	NOUN	O	O
release	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
3	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
gentamicin	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Metformin	PROPN	O	I-Entity
treatment	NOUN	O	O
fully	ADV	O	O
blocked	VERB	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Metformin	PROPN	O	I-Entity
also	ADV	O	O
protected	VERB	O	O
the	DET	O	O
kidney	NOUN	O	O
from	ADP	O	O
histological	ADJ	O	O
damage	NOUN	O	O
6	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
gentamicin	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
in	ADP	O	O
vivo	ADJ	O	O
markers	NOUN	O	O
of	ADP	O	O
kidney	NOUN	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
their	ADJ	O	O
correction	NOUN	O	O
by	ADP	O	O
metformin	NOUN	O	I-Entity
were	VERB	O	O
complemented	VERB	O	O
by	ADP	O	O
in	ADP	O	O
vitro	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
mitochondrial	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
that	ADP	O	O
gentamicin	NOUN	O	I-Entity
treatment	NOUN	O	O
depleted	VERB	O	O
respiratory	ADJ	O	O
components	NOUN	O	O
(	PUNCT	O	O
cytochrome	NOUN	O	O
c	NOUN	O	O
,	PUNCT	O	O
NADH	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
probably	ADV	O	O
due	ADP	O	O
to	ADP	O	O
the	DET	O	O
opening	NOUN	O	O
of	ADP	O	O
mitochondrial	ADJ	O	O
transition	NOUN	O	O
pores	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
injuries	NOUN	O	O
,	PUNCT	O	O
partly	ADV	O	O
mediated	VERB	O	O
by	ADP	O	O
a	DET	O	O
rise	NOUN	O	O
in	ADP	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
species	NOUN	O	O
from	ADP	O	O
the	DET	O	O
electron	ADJ	O	O
transfer	NOUN	O	O
chain	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
significantly	ADV	O	O
decreased	VERB	O	O
by	ADP	O	O
metformin	NOUN	O	I-Entity
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
our	ADJ	O	O
study	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
pleiotropic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
metformin	NOUN	O	I-Entity
can	VERB	O	O
lessen	VERB	O	O
gentamicin	NOUN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
improve	VERB	O	O
mitochondrial	ADJ	O	O
homeostasis	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20042557)

Sedation	PROPN	O	O
depth	NOUN	O	O
during	ADP	O	O
spinal	ADJ	O	O
anesthesia	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-Entity
delirium	NOUN	O	I-Entity
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
hip	ADJ	O	B-Entity
fracture	NOUN	O	I-Entity
repair	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
limiting	VERB	O	O
intraoperative	ADJ	O	O
sedation	NOUN	O	O
depth	NOUN	O	O
during	ADP	O	O
spinal	ADJ	O	O
anesthesia	NOUN	O	O
for	ADP	O	O
hip	NOUN	O	B-Entity
fracture	NOUN	O	I-Entity
repair	NOUN	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
can	VERB	O	O
decrease	VERB	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-Entity
delirium	NOUN	O	I-Entity
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
at	ADP	O	O
an	DET	O	O
academic	ADJ	O	O
medical	ADJ	O	O
center	NOUN	O	O
of	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
>	PUNCT	O	O
or=65	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
without	ADP	O	O
preoperative	ADJ	O	O
delirium	NOUN	O	I-Entity
or	CCONJ	O	O
severe	ADJ	O	O
dementia	NOUN	O	I-Entity
who	NOUN	O	O
underwent	VERB	O	O
hip	NOUN	O	B-Entity
fracture	NOUN	O	I-Entity
repair	NOUN	O	O
under	ADP	O	O
spinal	ADJ	O	O
anesthesia	NOUN	O	O
with	ADP	O	O
propofol	ADJ	O	I-Entity
sedation	NOUN	O	O
.	PUNCT	O	O

Postoperative	ADJ	O	B-Entity
delirium	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
as	ADP	O	O
defined	VERB	O	O
by	ADP	O	O
Diagnostic	PROPN	O	O
and	CCONJ	O	O
Statistical	PROPN	O	O
Manual	PROPN	O	O
of	ADP	O	O
Mental	PROPN	O	B-Entity
Disorders	PROPN	O	I-Entity
(	PUNCT	O	O
Third	PROPN	O	O
Edition	PROPN	O	O
Revised	PROPN	O	O
)	PUNCT	O	O
criteria	NOUN	O	O
using	VERB	O	O
the	DET	O	O
Confusion	PROPN	O	O
Assessment	PROPN	O	O
Method	PROPN	O	O
beginning	VERB	O	O
at	ADP	O	O
any	DET	O	O
time	NOUN	O	O
from	ADP	O	O
the	DET	O	O
second	ADJ	O	O
day	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-Entity
delirium	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
in	ADP	O	O
the	DET	O	O
light	ADJ	O	O
sedation	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
11/57	NUM	O	O
[	PUNCT	O	O
19%	NUM	O	O
]	PUNCT	O	O
vs	ADP	O	O
23/57	NUM	O	O
[	PUNCT	O	O
40%	NUM	O	O
]	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
deep	ADJ	O	O
sedation	NOUN	O	O
group	NOUN	O	O
;	PUNCT	O	O
P=.02	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
1	NUM	O	O
incident	NOUN	O	O
of	ADP	O	O
delirium	NOUN	O	I-Entity
will	VERB	O	O
be	VERB	O	O
prevented	VERB	O	O
for	ADP	O	O
every	DET	O	O
4.7	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
light	ADJ	O	O
sedation	NOUN	O	O
.	PUNCT	O	O

SD	NOUN	O	O
number	NOUN	O	O
of	ADP	O	O
days	NOUN	O	O
of	ADP	O	O
delirium	NOUN	O	I-Entity
during	ADP	O	O
hospitalization	NOUN	O	O
was	VERB	O	O
lower	ADJ	O	O
in	ADP	O	O
the	DET	O	O
light	ADJ	O	O
sedation	NOUN	O	O
group	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
deep	ADJ	O	O
sedation	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
0.5+/-1.5	PUNCT	O	O
days	NOUN	O	O
vs	ADP	O	O
1.4+/-4.0	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
P=.01	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
light	ADJ	O	O
propofol	ADJ	O	I-Entity
sedation	NOUN	O	O
decreased	VERB	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-Entity
delirium	NOUN	O	I-Entity
by	ADP	O	O
50%	NUM	O	O
compared	VERB	O	O
with	ADP	O	O
deep	ADJ	O	O
sedation	NOUN	O	O
.	PUNCT	O	O

Limiting	VERB	O	O
depth	NOUN	O	O
of	ADP	O	O
sedation	NOUN	O	O
during	ADP	O	O
spinal	ADJ	O	O
anesthesia	NOUN	O	O
is	VERB	O	O
a	DET	O	O
simple	ADJ	O	O
,	PUNCT	O	O
safe	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cost	NOUN	O	O
-	PUNCT	O	O
effective	ADJ	O	O
intervention	NOUN	O	O
for	ADP	O	O
preventing	VERB	O	O
postoperative	ADJ	O	B-Entity
delirium	NOUN	O	I-Entity
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
that	ADJ	O	O
could	VERB	O	O
be	VERB	O	O
widely	ADV	O	O
and	CCONJ	O	O
readily	ADV	O	O
adopted	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (19944333)

Sorafenib	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
spasm	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
65-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
renal	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
was	VERB	O	O
admitted	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
continuing	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
at	ADP	O	O
rest	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
weeks	NOUN	O	O
before	ADP	O	O
his	ADJ	O	O
admission	NOUN	O	O
,	PUNCT	O	O
sorafenib	NOUN	O	I-Entity
had	VERB	O	O
been	VERB	O	O
started	VERB	O	O
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
diagnosed	VERB	O	O
with	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
ST	NOUN	O	O
-	PUNCT	O	O
elevation	NOUN	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
by	ADP	O	O
laboratory	NOUN	O	O
data	NOUN	O	O
and	CCONJ	O	O
electrocardiogram	NOUN	O	O
.	PUNCT	O	O

Enhanced	ADJ	O	O
heart	NOUN	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
imaging	NOUN	O	O
also	ADV	O	O
showed	VERB	O	O
subendocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
spasm	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
provocative	ADJ	O	O
test	NOUN	O	O
.	PUNCT	O	O

Cessation	PROPN	O	O
of	ADP	O	O
sorafenib	NOUN	O	I-Entity
and	CCONJ	O	O
administration	NOUN	O	O
of	ADP	O	O
Ca	PROPN	O	I-Entity
-	PUNCT	O	O
channel	NOUN	O	O
blocker	NOUN	O	O
and	CCONJ	O	O
nitrates	NOUN	O	I-Entity
ameliorated	VERB	O	O
his	ADJ	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
relapse	VERB	O	O
occurred	VERB	O	O
after	ADP	O	O
resumption	NOUN	O	O
of	ADP	O	O
sorafenib	NOUN	O	I-Entity
.	PUNCT	O	O

Addition	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
nicorandil	NOUN	O	I-Entity
reduced	VERB	O	O
his	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
maintained	VERB	O	O
stable	ADJ	O	B-Entity
angina	NOUN	O	I-Entity
status	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
sorafenib	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
spasm	NOUN	O	I-Entity
.	PUNCT	O	O

Sorafenib	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
multikinase	NOUN	O	O
inhibitor	NOUN	O	O
that	ADJ	O	O
targets	NOUN	O	O
signaling	VERB	O	O
pathways	NOUN	O	O
necessary	ADJ	O	O
for	ADP	O	O
cellular	ADJ	O	O
proliferation	NOUN	O	O
and	CCONJ	O	O
survival	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Rho	PROPN	O	O
/	SYM	O	O
ROCK	PROPN	O	O
pathway	NOUN	O	O
has	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
spasm	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
report	NOUN	O	O
may	VERB	O	O
show	VERB	O	O
an	DET	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
Rho	PROPN	O	O
/	SYM	O	O
ROCK	PROPN	O	O
pathway	NOUN	O	O
by	ADP	O	O
sorafenib	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17975693)

Anxiogenic	ADJ	O	O
potential	NOUN	O	O
of	ADP	O	O
ciprofloxacin	NOUN	O	I-Entity
and	CCONJ	O	O
norfloxacin	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
anxiogenic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
fluoroquinolones	NOUN	O	I-Entity
,	PUNCT	O	O
namely	ADV	O	O
ciprofloxacin	NOUN	O	I-Entity
and	CCONJ	O	O
norfloxacin	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
adult	NOUN	O	O
Charles	PROPN	O	O
Foster	PROPN	O	O
albino	ADJ	O	O
rats	NOUN	O	O
of	ADP	O	O
either	DET	O	O
sex	NOUN	O	O
,	PUNCT	O	O
weighing	VERB	O	O
150	NUM	O	O
-	PUNCT	O	O
200	NUM	O	O
g.	NOUN	O	O
METHODS	NOUN	O	O
:	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
ciprofloxacin-	NOUN	O	I-Entity
and	CCONJ	O	O
norfloxacin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
showed	VERB	O	O
anxious	ADJ	O	B-Entity
behaviour	NOUN	O	I-Entity
in	ADP	O	O
comparison	NOUN	O	O
to	PART	O	O
control	VERB	O	O
rats	NOUN	O	O
in	ADP	O	O
all	ADJ	O	O
the	DET	O	O
parameters	NOUN	O	O
studied	VERB	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
ciprofloxacin-	X	O	I-Entity
and	CCONJ	O	O
norfloxacin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
significantly	ADV	O	O
from	ADP	O	O
each	DET	O	O
other	ADJ	O	O
in	ADP	O	O
various	ADJ	O	O
behavioural	ADJ	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
present	ADJ	O	O
experimental	ADJ	O	O
findings	NOUN	O	O
substantiate	VERB	O	O
the	DET	O	O
clinically	ADV	O	O
observed	VERB	O	O
anxiogenic	ADJ	O	O
potential	NOUN	O	O
of	ADP	O	O
ciprofloxacin	NOUN	O	I-Entity
and	CCONJ	O	O
norfloxacin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17943461)

Myocardial	PROPN	O	O
Fas	PROPN	O	O
ligand	NOUN	O	O
expression	NOUN	O	O
increases	VERB	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
AZT	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Dilated	VERB	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
(	PUNCT	O	O
DCM	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
myocarditis	NOUN	O	I-Entity
occur	VERB	O	O
in	ADP	O	O
many	ADJ	O	O
HIV	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
infected	VERB	O	I-Entity
individuals	NOUN	O	O
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
symptomatic	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
up	ADP	O	O
to	PART	O	O
5%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Highly	ADV	O	O
active	ADJ	O	O
antiretroviral	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
HAART	PROPN	O	O
)	PUNCT	O	O
has	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
of	ADP	O	O
acquired	VERB	O	B-Entity
immunodeficiency	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
AIDS	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
has	VERB	O	O
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
cardiac	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
skeletal	ADJ	O	I-Entity
myopathies	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
investigate	VERB	O	O
whether	ADP	O	O
the	DET	O	O
HAART	PROPN	O	O
component	NOUN	O	O
zidovudine	NOUN	O	I-Entity
(	PUNCT	O	O
3'-azido-2',3'-deoxythymidine	NUM	O	I-Entity
;	PUNCT	O	O
AZT	PROPN	O	I-Entity
)	PUNCT	O	O
triggers	VERB	O	O
the	DET	O	O
Fas	PROPN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
cell	NOUN	O	O
-	PUNCT	O	O
death	NOUN	O	O
pathway	NOUN	O	O
and	CCONJ	O	O
cause	VERB	O	O
cytoskeletal	ADJ	O	O
disruption	NOUN	O	O
in	ADP	O	O
a	DET	O	O
murine	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
DCM	PROPN	O	I-Entity
,	PUNCT	O	O
8-week	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
transgenic	NOUN	O	O
(	PUNCT	O	O
expressing	VERB	O	O
Fas	PROPN	O	O
ligand	NOUN	O	O
in	ADP	O	O
the	DET	O	O
myocardium	NOUN	O	O
:	PUNCT	O	O
FasL	PROPN	O	O
Tg	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
transgenic	NOUN	O	O
(	PUNCT	O	O
NTg	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
received	VERB	O	O
water	NOUN	O	O
ad	NOUN	O	O
libitum	NOUN	O	O
containing	VERB	O	O
different	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
AZT	PROPN	O	I-Entity
(	PUNCT	O	O
0	PUNCT	O	O
,	PUNCT	O	O
0.07	NUM	O	O
,	PUNCT	O	O
0.2	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
0.7	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
AZT	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
FasL	PROPN	O	O
Tg	PROPN	O	O
mice	NOUN	O	O
developed	VERB	O	O
cardiac	ADJ	O	B-Entity
dilation	NOUN	O	I-Entity
and	CCONJ	O	O
depressed	ADJ	O	O
cardiac	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
concomitant	ADJ	O	O
inflammatory	ADJ	O	O
infiltration	NOUN	O	O
of	ADP	O	O
both	DET	O	O
ventricles	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
Fas	PROPN	O	O
ligand	NOUN	O	O
in	ADP	O	O
the	DET	O	O
myocardium	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
identified	VERB	O	O
in	ADP	O	O
HIV	PROPN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
might	VERB	O	O
increase	VERB	O	O
the	DET	O	O
susceptibility	NOUN	O	O
to	ADP	O	O
HAART	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
apoptotic	ADJ	O	O
pathways	NOUN	O	O
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
cardiac	ADJ	O	B-Entity
dilation	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17074608)

Valproate	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
chorea	NOUN	O	I-Entity
and	CCONJ	O	O
encephalopathy	NOUN	O	I-Entity
in	ADP	O	O
atypical	ADJ	O	O
nonketotic	ADJ	O	B-Entity
hyperglycinemia	NOUN	O	I-Entity
.	PUNCT	O	O

Nonketotic	PROPN	O	B-Entity
hyperglycinemia	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
disorder	NOUN	O	B-Entity
of	ADP	O	I-Entity
amino	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
metabolism	NOUN	O	I-Entity
in	ADP	O	O
which	ADJ	O	O
a	DET	O	O
defect	NOUN	O	O
in	ADP	O	O
the	DET	O	O
glycine	NOUN	O	I-Entity
cleavage	NOUN	O	O
system	NOUN	O	O
leads	VERB	O	O
to	ADP	O	O
an	DET	O	O
accumulation	NOUN	O	O
of	ADP	O	O
glycine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
and	CCONJ	O	O
other	ADJ	O	O
body	NOUN	O	O
compartments	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
classical	ADJ	O	O
form	NOUN	O	O
it	PRON	O	O
presents	VERB	O	O
as	ADP	O	O
neonatal	ADJ	O	O
apnea	NOUN	O	I-Entity
,	PUNCT	O	O
intractable	ADJ	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hypotonia	NOUN	O	I-Entity
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
significant	ADJ	O	O
psychomotor	NOUN	O	B-Entity
retardation	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
important	ADJ	O	O
subset	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
nonketotic	ADJ	O	B-Entity
hyperglycinemia	NOUN	O	I-Entity
are	VERB	O	O
atypical	ADJ	O	O
variants	NOUN	O	O
who	NOUN	O	O
present	VERB	O	O
in	ADP	O	O
a	DET	O	O
heterogeneous	ADJ	O	O
manner	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
describes	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
language	NOUN	O	B-Entity
delay	NOUN	O	I-Entity
and	CCONJ	O	O
mental	ADJ	O	B-Entity
retardation	NOUN	O	I-Entity
,	PUNCT	O	O
who	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
have	VERB	O	O
nonketotic	ADJ	O	B-Entity
hyperglycinemia	NOUN	O	I-Entity
following	VERB	O	O
her	ADJ	O	O
presentation	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
encephalopathy	NOUN	O	I-Entity
and	CCONJ	O	O
chorea	NOUN	O	I-Entity
shortly	ADV	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
valproate	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16364460)

Microinjection	PROPN	O	O
of	ADP	O	O
ritanserin	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
CA1	PROPN	O	O
region	NOUN	O	O
of	ADP	O	O
hippocampus	NOUN	O	O
improves	VERB	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
in	ADP	O	O
adult	NOUN	O	O
male	NOUN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
ritanserin	NOUN	O	I-Entity
(	PUNCT	O	O
5-HT2	ADJ	O	O
antagonist	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
scopolamine	NOUN	O	I-Entity
(	PUNCT	O	O
muscarinic	ADJ	O	O
cholinergic	NOUN	O	O
antagonist)-induced	ADJ	O	O
amnesia	NOUN	O	I-Entity
in	ADP	O	O
Morris	PROPN	O	O
water	NOUN	O	O
maze	NOUN	O	O
(	PUNCT	O	O
MWM	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

One	NUM	O	O
week	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
they	PRON	O	O
received	VERB	O	O
repeatedly	ADV	O	O
vehicles	NOUN	O	O
(	PUNCT	O	O
saline	ADJ	O	O
,	PUNCT	O	O
DMSO	PROPN	O	I-Entity
,	PUNCT	O	O
saline+DMSO	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
scopolamine	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
microg/0.5	NUM	O	O
microl	NOUN	O	O
saline	ADJ	O	O
/	SYM	O	O
side	NOUN	O	O
;	PUNCT	O	O
30	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
training	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ritanserin	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
microg/0.5	NUM	O	O
microl	NOUN	O	O
DMSO	PROPN	O	I-Entity
/	SYM	O	O
side	NOUN	O	O
;	PUNCT	O	O
20	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
training	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
scopolamine	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
microg/0.5	NUM	O	O
microl	NOUN	O	O
;	PUNCT	O	O

30	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
ritanserin	NOUN	O	I-Entity
injection)+ritanserin	NOUN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
microg/0.5	ADJ	O	O
microl	NOUN	O	O
DMSO	PROPN	O	I-Entity
)	PUNCT	O	O
through	ADP	O	O
cannulae	NOUN	O	O
each	DET	O	O
day	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
escape	NOUN	O	O
latencies	NOUN	O	O
and	CCONJ	O	O
traveled	VERB	O	O
distances	NOUN	O	O
to	PART	O	O
find	VERB	O	O
platform	NOUN	O	O
in	ADP	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
saline	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

Ritanserin	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
(	PUNCT	O	O
4	NUM	O	O
microg/0.5	NUM	O	O
microl	NOUN	O	O
/	SYM	O	O
side	NOUN	O	O
)	PUNCT	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mentioned	VERB	O	O
parameters	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
DMSO	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
scopolamine	NOUN	O	I-Entity
and	CCONJ	O	O
ritanserin	VERB	O	I-Entity
co	NOUN	O	O
-	PUNCT	O	O
administration	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
escape	NOUN	O	O
latencies	NOUN	O	O
and	CCONJ	O	O
traveled	VERB	O	O
distances	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
findings	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
microinjection	NOUN	O	O
of	ADP	O	O
ritanserin	NOUN	O	I-Entity
into	ADP	O	O
the	DET	O	O
CA1	PROPN	O	O
region	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
improves	VERB	O	O
the	DET	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15579441)

Hypoxia	PROPN	O	I-Entity
in	ADP	O	O
renal	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
with	ADP	O	O
proteinuria	NOUN	O	I-Entity
and/or	CCONJ	O	O
glomerular	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
developed	VERB	O	O
a	DET	O	O
new	ADJ	O	O
hypoxia	NOUN	O	I-Entity
-	PUNCT	O	O
responsive	ADJ	O	O
reporter	NOUN	O	O
vector	NOUN	O	O
using	VERB	O	O
a	DET	O	O
hypoxia	NOUN	O	I-Entity
-	PUNCT	O	O
responsive	ADJ	O	O
element	NOUN	O	O
of	ADP	O	O
the	DET	O	O
5	NUM	O	O
'	PUNCT	O	O
vascular	ADJ	O	O
endothelial	NOUN	O	O
growth	NOUN	O	O
factor	NOUN	O	O
untranslated	ADJ	O	O
region	NOUN	O	O
and	CCONJ	O	O
generated	VERB	O	O
a	DET	O	O
novel	NOUN	O	O
hypoxia	NOUN	O	I-Entity
-	PUNCT	O	O
sensing	VERB	O	O
transgenic	ADJ	O	O
rat	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
then	ADV	O	O
applied	VERB	O	O
this	DET	O	O
animal	NOUN	O	O
model	NOUN	O	O
to	ADP	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
tubulointerstitial	ADJ	O	O
hypoxia	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
diseased	ADJ	O	B-Entity
kidney	NOUN	O	I-Entity
.	PUNCT	O	O

With	ADP	O	O
this	DET	O	O
model	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
were	VERB	O	O
able	ADJ	O	O
to	PART	O	O
identify	VERB	O	O
diffuse	NOUN	O	O
cortical	ADJ	O	O
hypoxia	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
focal	ADJ	O	O
and	CCONJ	O	O
segmental	ADJ	O	O
hypoxia	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
remnant	ADJ	O	O
kidney	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

Expression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hypoxia	NOUN	O	I-Entity
-	PUNCT	O	O
responsive	ADJ	O	O
transgene	NOUN	O	O
increased	VERB	O	O
throughout	ADP	O	O
the	DET	O	O
observation	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
reaching	VERB	O	O
2.2-fold	NUM	O	O
at	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
the	DET	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
model	NOUN	O	O
and	CCONJ	O	O
2.6-fold	NUM	O	O
at	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
the	DET	O	O
remnant	ADJ	O	O
kidney	NOUN	O	O
model	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
that	DET	O	O
of	ADP	O	O
vascular	ADJ	O	O
endothelial	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
mild	ADJ	O	O
decrease	NOUN	O	O
,	PUNCT	O	O
reflecting	VERB	O	O
distinct	ADJ	O	O
behaviors	NOUN	O	O
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
genes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
hypoxia	NOUN	O	I-Entity
showed	VERB	O	O
a	DET	O	O
positive	ADJ	O	O
correlation	NOUN	O	O
with	ADP	O	O
microscopic	ADJ	O	O
tubulointerstitial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
models	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
identified	VERB	O	O
the	DET	O	O
localization	NOUN	O	O
of	ADP	O	O
proliferating	VERB	O	O
cell	NOUN	O	O
nuclear	ADJ	O	O
antigen	NOUN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
,	PUNCT	O	O
ED-1-positive	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
terminal	ADJ	O	O
dUTP	PROPN	O	O
nick	NOUN	O	O
-	PUNCT	O	O
end	NOUN	O	O
labeled	VERB	O	O
-	PUNCT	O	O
positive	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hypoxic	ADJ	O	I-Entity
cortical	ADJ	O	O
area	NOUN	O	O
in	ADP	O	O
the	DET	O	O
remnant	ADJ	O	O
kidney	NOUN	O	O
model	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
propose	VERB	O	O
here	ADV	O	O
a	DET	O	O
possible	ADJ	O	O
pathological	ADJ	O	O
tie	NOUN	O	O
between	ADP	O	O
chronic	ADJ	O	O
tubulointerstitial	ADJ	O	O
hypoxia	NOUN	O	I-Entity
and	CCONJ	O	O
progressive	ADJ	O	O
glomerular	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15517007)

Consensus	PROPN	O	O
statement	NOUN	O	O
concerning	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
occurring	VERB	O	O
during	ADP	O	O
haematopoietic	ADJ	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplantation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
autoimmune	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
special	ADJ	O	O
reference	NOUN	O	O
to	ADP	O	O
systemic	ADJ	O	B-Entity
sclerosis	NOUN	O	I-Entity
and	CCONJ	O	O
multiple	ADJ	O	B-Entity
sclerosis	NOUN	O	I-Entity
.	PUNCT	O	O

Autologous	ADJ	O	O
haematopoietic	ADJ	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplantation	NOUN	O	O
is	VERB	O	O
now	ADV	O	O
a	DET	O	O
feasible	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
selected	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
autoimmune	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
primarily	ADV	O	O
due	ADJ	O	O
to	ADP	O	O
complications	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
stage	NOUN	O	O
of	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
at	ADP	O	O
transplant	NOUN	O	O
or	CCONJ	O	O
due	ADJ	O	O
to	ADP	O	O
infections	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
deaths	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
is	VERB	O	O
low	ADJ	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
caution	NOUN	O	O
is	VERB	O	O
required	VERB	O	O
when	ADV	O	O
cyclophosphamide	NOUN	O	I-Entity
or	CCONJ	O	O
anthracyclines	NOUN	O	I-Entity
such	ADJ	O	O
as	ADP	O	O
mitoxantrone	NOUN	O	I-Entity
are	VERB	O	O
used	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
possible	ADJ	O	O
underlying	ADJ	O	O
heart	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
,	PUNCT	O	O
for	ADP	O	O
example	NOUN	O	O
,	PUNCT	O	O
systemic	ADJ	O	B-Entity
sclerosis	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
object	NOUN	O	O
of	ADP	O	O
the	DET	O	O
meeting	NOUN	O	O
was	VERB	O	O
to	PART	O	O
analyse	VERB	O	O
existing	VERB	O	O
data	NOUN	O	O
,	PUNCT	O	O
both	DET	O	O
published	VERB	O	O
or	CCONJ	O	O
available	ADJ	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
European	PROPN	O	O
Group	PROPN	O	O
for	ADP	O	O
Blood	PROPN	O	O
and	CCONJ	O	O
Marrow	PROPN	O	O
Transplantation	PROPN	O	O
autoimmune	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
database	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
propose	VERB	O	O
a	DET	O	O
safe	ADJ	O	O
approach	NOUN	O	O
to	ADP	O	O
such	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12180796)

Immunohistochemical	ADJ	O	O
study	NOUN	O	O
on	ADP	O	O
inducible	ADJ	O	O
type	NOUN	O	O
of	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
(	PUNCT	O	O
iNOS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
basic	ADJ	O	O
fibroblast	NOUN	O	O
growth	NOUN	O	O
factor	NOUN	O	O
(	PUNCT	O	O
bFGF	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
tumor	NOUN	O	I-Entity
growth	NOUN	O	O
factor	NOUN	O	O
-	PUNCT	O	O
beta1	NOUN	O	O
(	PUNCT	O	O
TGF	PROPN	O	O
-	PUNCT	O	O
beta1	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
arteritis	NOUN	O	I-Entity
induced	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
by	ADP	O	O
fenoldopam	NOUN	O	I-Entity
and	CCONJ	O	O
theophylline	NOUN	O	I-Entity
,	PUNCT	O	O
vasodilators	NOUN	O	O
.	PUNCT	O	O

Arteritis	PROPN	O	I-Entity
induced	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
by	ADP	O	O
vasodilators	NOUN	O	O
,	PUNCT	O	O
fenoldopam	NOUN	O	I-Entity
and	CCONJ	O	O
theophylline	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
examined	VERB	O	O
immunohistochemically	ADV	O	O
for	ADP	O	O
expressions	NOUN	O	O
of	ADP	O	O
inducible	ADJ	O	O
type	NOUN	O	O
of	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
synthase	NOUN	O	O
(	PUNCT	O	O
iNOS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
basic	ADJ	O	O
fibroblast	NOUN	O	O
growth	NOUN	O	O
factor	NOUN	O	O
(	PUNCT	O	O
bFGF	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
tumor	NOUN	O	I-Entity
growth	NOUN	O	O
factor	NOUN	O	O
-	PUNCT	O	O
beta1	NOUN	O	O
(	PUNCT	O	O
TGF	PROPN	O	O
-	PUNCT	O	O
beta1	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
fenoldopam	NOUN	O	I-Entity
for	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
by	ADP	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
following	VERB	O	O
repeated	VERB	O	O
daily	ADJ	O	O
oral	ADJ	O	O
administrations	NOUN	O	O
of	ADP	O	O
theophylline	NOUN	O	I-Entity
.	PUNCT	O	O

Irrespective	PROPN	O	O
of	ADP	O	O
theophylline	PROPN	O	I-Entity
administration	NOUN	O	O
,	PUNCT	O	O
iNOS	NOUN	O	O
antigens	NOUN	O	O
were	VERB	O	O
remarkably	ADV	O	O
abundant	ADJ	O	O
in	ADP	O	O
ED-1-positive	ADJ	O	O
cells	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
5	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
post	NOUN	O	O
-	PUNCT	O	O
fenoldopam	NOUN	O	I-Entity
-	PUNCT	O	O
infusion	NOUN	O	O
(	PUNCT	O	O
DPI	PROPN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
bFGF	NOUN	O	O
antigens	NOUN	O	O
were	VERB	O	O
remarkably	ADV	O	O
abundant	ADJ	O	O
in	ADP	O	O
ED-1-positive	ADJ	O	O
cells	NOUN	O	O
on	ADP	O	O
1	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
DPI	PROPN	O	O
;	PUNCT	O	O
TGF	PROPN	O	O
-	PUNCT	O	O
beta1	NOUN	O	O
antigens	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
ED-1-positive	ADJ	O	O
cells	NOUN	O	O
on	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
5	NUM	O	O
DPI	PROPN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
peak	NOUN	O	O
expression	NOUN	O	O
of	ADP	O	O
iNOS	PROPN	O	O
antigen	NOUN	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
that	DET	O	O
of	ADP	O	O
bFGF	PROPN	O	O
antigen	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
bFGF	PROPN	O	O
may	VERB	O	O
have	VERB	O	O
a	DET	O	O
suppressive	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
iNOS	PROPN	O	O
expression	NOUN	O	O
in	ADP	O	O
these	DET	O	O
rat	NOUN	O	O
arteritis	NOUN	O	I-Entity
models	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12109865)

Low	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
molecular	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
weight	NOUN	O	I-Entity
heparin	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
mechanical	ADJ	O	O
heart	NOUN	O	O
valves	NOUN	O	O
.	PUNCT	O	O

Unfractionated	VERB	O	B-Entity
heparin	NOUN	O	I-Entity
(	PUNCT	O	O
UH	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
currently	ADV	O	O
the	DET	O	O
substitute	NOUN	O	O
for	ADP	O	O
selected	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Low	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
molecular	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
weight	NOUN	O	I-Entity
heparin	NOUN	O	I-Entity
(	PUNCT	O	O
LMWH	PROPN	O	I-Entity
)	PUNCT	O	O
offers	VERB	O	O
theoretical	ADJ	O	O
advantages	NOUN	O	O
over	ADP	O	O
UH	PROPN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
is	VERB	O	O
not	ADV	O	O
currently	ADV	O	O
considered	VERB	O	O
in	ADP	O	O
clinical	ADJ	O	O
guidelines	NOUN	O	O
as	ADP	O	O
an	DET	O	O
alternative	NOUN	O	O
to	ADP	O	O
UH	PROPN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
prosthetic	ADJ	O	O
valves	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
review	VERB	O	O
the	DET	O	O
data	NOUN	O	O
accumulated	VERB	O	O
so	ADV	O	O
far	ADV	O	O
on	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
LMWH	PROPN	O	I-Entity
in	ADP	O	O
this	DET	O	O
patient	ADJ	O	O
population	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
discuss	VERB	O	O
its	ADJ	O	O
applicability	NOUN	O	O
in	ADP	O	O
common	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
For	ADP	O	O
this	DET	O	O
paper	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
current	ADJ	O	O
medical	ADJ	O	O
literature	NOUN	O	O
on	ADP	O	O
LMWH	PROPN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
mechanical	ADJ	O	O
heart	NOUN	O	O
valves	NOUN	O	O
was	VERB	O	O
extensively	ADV	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

Data	NOUN	O	O
to	PART	O	O
establish	VERB	O	O
the	DET	O	O
thromboembolic	NOUN	O	I-Entity
risk	NOUN	O	O
were	VERB	O	O
incomplete	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
thromboembolism	NOUN	O	I-Entity
was	VERB	O	O
0.9%	NUM	O	O
for	ADP	O	O
all	ADJ	O	O
the	DET	O	O
studies	NOUN	O	O
and	CCONJ	O	O
0.5	NUM	O	O
,	PUNCT	O	O
0	NUM	O	O
,	PUNCT	O	O
20	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
0%	NUM	O	O
in	ADP	O	O
groups	NOUN	O	O
a	DET	O	O
,	PUNCT	O	O
b	NOUN	O	O
,	PUNCT	O	O
c	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
d	X	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
for	ADP	O	O
hemorrhage	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
overall	ADJ	O	O
rate	NOUN	O	O
was	VERB	O	O
3.4%	NUM	O	O
(	PUNCT	O	O
3.8	NUM	O	O
,	PUNCT	O	O
2.6	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
0%	NUM	O	O
for	ADP	O	O
the	DET	O	O
respective	ADJ	O	O
groups	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
mechanical	ADJ	O	O
heart	NOUN	O	O
valves	NOUN	O	O
,	PUNCT	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
LMWH	PROPN	O	I-Entity
therapy	NOUN	O	O
compares	VERB	O	O
favorably	ADV	O	O
with	ADP	O	O
UH	PROPN	O	I-Entity
.	PUNCT	O	O

Data	NOUN	O	O
on	ADP	O	O
mid-	NOUN	O	O
and	CCONJ	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
LMWH	PROPN	O	I-Entity
administration	NOUN	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
are	VERB	O	O
sparse	ADJ	O	O
.	PUNCT	O	O

Further	ADV	O	O
randomized	ADJ	O	O
studies	NOUN	O	O
are	VERB	O	O
needed	VERB	O	O
to	PART	O	O
confirm	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
precise	ADJ	O	O
indications	NOUN	O	O
for	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
LMWH	PROPN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
mechanical	ADJ	O	O
heart	NOUN	O	O
valves	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12042105)

Topiramate	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrolithiasis	NOUN	O	I-Entity
.	PUNCT	O	O

Topiramate	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
recently	ADV	O	O
developed	VERB	O	O
antiepileptic	ADJ	O	O
medication	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
becoming	VERB	O	O
more	ADV	O	O
widely	ADV	O	O
prescribed	VERB	O	O
because	ADP	O	O
of	ADP	O	O
its	ADJ	O	O
efficacy	NOUN	O	O
in	ADP	O	O
treating	VERB	O	O
refractory	ADJ	O	B-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Urologists	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
that	ADP	O	O
this	DET	O	O
medication	NOUN	O	O
can	VERB	O	O
cause	VERB	O	O
metabolic	ADJ	O	B-Entity
acidosis	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
secondary	ADJ	O	O
to	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
carbonic	ADJ	O	O
anhydrase	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
factors	NOUN	O	O
can	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	B-Entity
phosphate	NOUN	O	I-Entity
nephrolithiasis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
first	ADJ	O	O
two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
topiramate	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrolithiasis	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
urologic	ADJ	O	O
literature	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11868798)

Spironolactone	NOUN	O	I-Entity
:	PUNCT	O	O
is	VERB	O	O
it	PRON	O	O
a	DET	O	O
novel	ADJ	O	O
drug	NOUN	O	O
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
hypokalemia	NOUN	O	I-Entity
in	ADP	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
?	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
Nephrotoxicity	PROPN	O	I-Entity
is	VERB	O	O
the	DET	O	O
major	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
amphotericin	NOUN	O	B-Entity
B	PROPN	O	I-Entity
(	PUNCT	O	O
AmB	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
often	ADV	O	O
limiting	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
full	ADJ	O	O
dosage	NOUN	O	O
.	PUNCT	O	O

Selective	ADJ	O	O
distal	ADJ	O	O
tubular	NOUN	O	O
epithelial	ADJ	O	O
toxicity	NOUN	O	I-Entity
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
responsible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
profound	ADJ	O	O
potassium	NOUN	O	I-Entity
wasting	VERB	O	O
that	DET	O	O
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
clinical	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
AmB.	DET	O	I-Entity
Potassium	NOUN	O	I-Entity
depletion	NOUN	O	O
also	ADV	O	O
potentiates	VERB	O	O
the	DET	O	O
tubular	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
AmB.	PROPN	O	I-Entity

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
spironolactone	NOUN	O	I-Entity
to	PART	O	O
reduce	VERB	O	O
potassium	NOUN	O	I-Entity
requirements	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
prevent	VERB	O	O
hypokalemia	NOUN	O	I-Entity
in	ADP	O	O
neutropenic	ADJ	O	I-Entity
patients	NOUN	O	O
on	ADP	O	O
AmB	PROPN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
26	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
various	ADJ	O	O
hematological	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	VERB	O	O
either	CCONJ	O	O
intravenous	ADJ	O	O
AmB	PROPN	O	I-Entity
alone	ADV	O	O
or	CCONJ	O	O
AmB	PROPN	O	I-Entity
and	CCONJ	O	O
oral	ADJ	O	O
spironolactone	NOUN	O	I-Entity
100	NUM	O	O
mg	NUM	O	O
twice	ADV	O	O
daily	ADV	O	O
when	ADV	O	O
developing	VERB	O	O
a	DET	O	O
proven	VERB	O	O
or	CCONJ	O	O
suspected	VERB	O	O
fungal	ADJ	O	B-Entity
infection	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
receiving	VERB	O	O
concomitant	ADJ	O	O
AmB	PROPN	O	I-Entity
and	CCONJ	O	O
spironolactone	NOUN	O	I-Entity
had	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
plasma	NOUN	O	O
potassium	NOUN	O	I-Entity
levels	NOUN	O	O
than	ADP	O	O
those	DET	O	O
receiving	VERB	O	O
AmB	PROPN	O	I-Entity
alone	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.0027	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Those	DET	O	O
patients	NOUN	O	O
receiving	VERB	O	O
AmB	PROPN	O	I-Entity
and	CCONJ	O	O
spironolactone	NOUN	O	I-Entity
required	VERB	O	O
significantly	ADV	O	O
less	ADJ	O	O
potassium	NOUN	O	I-Entity
supplementation	NOUN	O	O
to	PART	O	O
maintain	VERB	O	O
their	ADJ	O	O
plasma	NOUN	O	O
potassium	NOUN	O	I-Entity
within	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
range	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.022	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
urinary	ADJ	O	O
potassium	NOUN	O	I-Entity
losses	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
less	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
AmB	PROPN	O	I-Entity
and	CCONJ	O	O
spironolactone	NOUN	O	I-Entity
than	ADP	O	O
those	DET	O	O
receiving	VERB	O	O
AmB	PROPN	O	I-Entity
alone	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.040	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
spironolactone	NOUN	O	I-Entity
can	VERB	O	O
reduce	VERB	O	O
potassium	NOUN	O	I-Entity
requirements	NOUN	O	O
and	CCONJ	O	O
prevent	VERB	O	O
hypokalemia	NOUN	O	I-Entity
by	ADP	O	O
reducing	VERB	O	O
urinary	ADJ	O	O
potassium	NOUN	O	I-Entity
loss	NOUN	O	O
in	ADP	O	O
neutropenic	ADJ	O	I-Entity
patients	NOUN	O	O
on	ADP	O	O
AmB	PROPN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11860278)

Dopamine	PROPN	O	I-Entity
D2	PROPN	O	O
receptor	NOUN	O	O
signaling	VERB	O	O
controls	NOUN	O	O
neuronal	ADJ	O	O
cell	NOUN	O	O
death	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
muscarinic	NOUN	O	O
and	CCONJ	O	O
glutamatergic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Dopamine	PROPN	O	I-Entity
(	PUNCT	O	O
DA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
through	ADP	O	O
D1/D2	PROPN	O	O
receptor	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
signaling	NOUN	O	O
,	PUNCT	O	O
plays	VERB	O	O
a	DET	O	O
major	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
of	ADP	O	O
epileptic	ADJ	O	B-Entity
seizures	NOUN	O	I-Entity
arising	VERB	O	O
in	ADP	O	O
the	DET	O	O
limbic	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O

Excitotoxicity	NOUN	O	I-Entity
leading	VERB	O	O
to	ADP	O	O
neuronal	ADJ	O	O
cell	NOUN	O	O
death	NOUN	O	O
in	ADP	O	O
the	DET	O	O
affected	ADJ	O	O
areas	NOUN	O	O
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
consequence	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
cellular	ADJ	O	O
level	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
respect	NOUN	O	O
,	PUNCT	O	O
little	ADJ	O	O
is	VERB	O	O
known	VERB	O	O
about	ADP	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
DA	PROPN	O	I-Entity
receptors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neuronal	ADJ	O	O
cell	NOUN	O	O
death	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
we	PRON	O	O
analyze	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
neurotoxicity	NOUN	O	I-Entity
in	ADP	O	O
D2R	PROPN	O	O
-/-	PUNCT	O	O
mice	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
cholinergic	NOUN	O	O
agonist	NOUN	O	O
pilocarpine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
these	DET	O	O
results	NOUN	O	O
with	ADP	O	O
those	DET	O	O
previously	ADV	O	O
obtained	VERB	O	O
with	ADP	O	O
kainic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
KA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
potent	ADJ	O	O
glutamate	NOUN	O	I-Entity
agonist	NOUN	O	O
.	PUNCT	O	O

Importantly	ADV	O	O
,	PUNCT	O	O
D2R	PROPN	O	O
-/-	PUNCT	O	O
mice	NOUN	O	O
develop	VERB	O	O
seizures	NOUN	O	I-Entity
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
both	DET	O	O
drugs	NOUN	O	O
that	ADJ	O	O
are	VERB	O	O
not	ADV	O	O
epileptogenic	ADJ	O	O
for	ADP	O	O
WT	PROPN	O	O
littermates	NOUN	O	O
and	CCONJ	O	O
show	VERB	O	O
greater	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
result	VERB	O	O
in	ADP	O	O
a	DET	O	O
more	ADV	O	O
widespread	ADJ	O	O
neuronal	ADJ	O	O
death	NOUN	O	O
in	ADP	O	O
both	DET	O	O
WT	PROPN	O	O
and	CCONJ	O	O
D2R	PROPN	O	O
-/-	PUNCT	O	O
brains	NOUN	O	O
in	ADP	O	O
comparison	NOUN	O	O
to	ADP	O	O
KA	PROPN	O	I-Entity
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
D2R	PROPN	O	O
lowers	VERB	O	O
the	DET	O	O
threshold	NOUN	O	O
for	ADP	O	O
seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
both	DET	O	O
glutamate	NOUN	O	I-Entity
and	CCONJ	O	O
acetylcholine	NOUN	O	I-Entity
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
dopaminergic	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurodegeneration	NOUN	O	I-Entity
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
distinct	ADJ	O	O
interactions	NOUN	O	O
of	ADP	O	O
D2R	PROPN	O	O
signaling	VERB	O	O
with	ADP	O	O
these	DET	O	O
two	NUM	O	O
neurotransmitters	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11838826)

Treatment	NOUN	O	O
of	ADP	O	O
risperidone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
dopamine	NOUN	O	I-Entity
agonist	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

Risperidone	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
potent	ADJ	O	O
antagonist	NOUN	O	O
of	ADP	O	O
both	DET	O	O
serotonergic	NOUN	O	O
(	PUNCT	O	O
5HT2A	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
dopaminergic	ADJ	O	O
D2	NOUN	O	O
receptors	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
in	ADP	O	O
adults	NOUN	O	O
and	CCONJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

Chronically	ADV	O	O
elevated	VERB	O	O
prolactin	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
prolactinomas	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
arrested	VERB	O	O
growth	NOUN	O	O
and	CCONJ	O	O
development	NOUN	O	O
resulting	VERB	O	O
in	ADP	O	O
either	CCONJ	O	O
delayed	VERB	O	B-Entity
puberty	NOUN	O	I-Entity
or	CCONJ	O	O
short	ADJ	O	O
stature	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
possibilities	NOUN	O	O
stress	VERB	O	O
the	DET	O	O
importance	NOUN	O	O
of	ADP	O	O
developing	VERB	O	O
a	DET	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
approach	NOUN	O	O
to	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
in	ADP	O	O
youth	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
successful	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
risperidone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
with	ADP	O	O
cabergoline	NOUN	O	I-Entity
in	ADP	O	O
youth	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
undertook	VERB	O	O
a	DET	O	O
retrospective	ADJ	O	O
case	NOUN	O	O
review	NOUN	O	O
of	ADP	O	O
four	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
cabergoline	NOUN	O	I-Entity
.	PUNCT	O	O

Four	NUM	O	O
males	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
6	NUM	O	O
-	PUNCT	O	O
11	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
Diagnostic	PROPN	O	O
and	CCONJ	O	O
Statistical	PROPN	O	O
Manual	PROPN	O	O
of	ADP	O	O
Mental	PROPN	O	B-Entity
Disorders	PROPN	O	I-Entity
(	PUNCT	O	O
fourth	ADJ	O	O
edition	NOUN	O	O
)	PUNCT	O	O
bipolar	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
or	CCONJ	O	O
psychoses	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
elevations	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
prolactin	NOUN	O	O
levels	NOUN	O	O
(	PUNCT	O	O
57.5	NUM	O	O
-	SYM	O	O
129	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
,	PUNCT	O	O
normal	ADJ	O	O
5	NUM	O	O
-	SYM	O	O
15	NUM	O	O
ng	NOUN	O	O
/	SYM	O	O
mL	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
cabergoline	NOUN	O	I-Entity

10.9	NUM	O	O
ng	INTJ	O	O
/	SYM	O	O
mL	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
cabergoline	NOUN	O	I-Entity
dose	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
to	ADP	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
week	NOUN	O	O
in	ADP	O	O
three	NUM	O	O
of	ADP	O	O
four	NUM	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
cabergoline	NOUN	O	I-Entity
was	VERB	O	O
523.5	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

129.7	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
mean	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
was	VERB	O	O
788.5	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Cabergoline	PROPN	O	I-Entity
was	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
without	ADP	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Cabergoline	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
risperidone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
in	ADP	O	O
youth	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
further	ADJ	O	O
research	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (11467664)

Cholestatic	ADJ	O	B-Entity
jaundice	ADV	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
metformin	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
cholestatic	ADJ	O	B-Entity
jaundice	ADV	O	I-Entity
shortly	ADV	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
metformin	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
percutaneous	ADJ	O	O
liver	NOUN	O	O
biopsy	NOUN	O	O
was	VERB	O	O
obtained	VERB	O	O
showing	VERB	O	O
marked	ADJ	O	O
cholestasis	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
portal	ADJ	O	O
edema	NOUN	O	I-Entity
,	PUNCT	O	O
ductular	ADJ	O	O
proliferation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
acute	ADJ	O	O
inflammation	NOUN	O	I-Entity
.	PUNCT	O	O

Metformin	PROPN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
jaundice	NOUN	O	I-Entity
resolved	VERB	O	O
slowly	ADV	O	O
over	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
several	ADJ	O	O
months	NOUN	O	O
.	PUNCT	O	O

Given	VERB	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
his	ADJ	O	O
jaundice	NOUN	O	I-Entity
2	NUM	O	O
wk	NOUN	O	O
after	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
metformin	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
believe	VERB	O	O
that	ADP	O	O
this	DET	O	O
case	NOUN	O	O
represents	VERB	O	O
an	DET	O	O
example	NOUN	O	O
of	ADP	O	O
metformin	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
first	ADJ	O	O
such	ADJ	O	O
case	NOUN	O	O
reported	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (11077455)

Electro	PROPN	O	O
-	PUNCT	O	O
oculography	NOUN	O	O
,	PUNCT	O	O
electroretinography	NOUN	O	O
,	PUNCT	O	O
visual	ADJ	O	O
evoked	VERB	O	O
potentials	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
multifocal	ADJ	O	O
electroretinography	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
vigabatrin	NOUN	O	I-Entity
-	PUNCT	O	O
attributed	VERB	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
constriction	NOUN	O	I-Entity
.	PUNCT	O	O

Symptomatic	ADJ	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
constriction	NOUN	O	I-Entity
thought	VERB	O	O
to	PART	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
vigabatrin	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
investigated	VERB	O	O
the	DET	O	O
visual	ADJ	O	O
fields	NOUN	O	O
and	CCONJ	O	O
visual	ADJ	O	O
electrophysiology	NOUN	O	O
of	ADP	O	O
eight	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
known	VERB	O	O
vigabatrin	NOUN	O	I-Entity
-	PUNCT	O	O
attributed	VERB	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
loss	NOUN	O	I-Entity
,	PUNCT	O	O
three	NUM	O	O
of	ADP	O	O
whom	NOUN	O	O
were	VERB	O	O
reported	VERB	O	O
previously	ADV	O	O
.	PUNCT	O	O

Six	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
no	ADV	O	O
longer	ADV	O	O
receiving	VERB	O	O
vigabatrin	NOUN	O	I-Entity
.	PUNCT	O	O

Seven	NUM	O	O
patients	NOUN	O	O
showed	VERB	O	O
marked	ADJ	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
constriction	NOUN	O	I-Entity
with	ADP	O	O
some	DET	O	O
sparing	NOUN	O	O
of	ADP	O	O
the	DET	O	O
temporal	ADJ	O	O
visual	ADJ	O	O
field	NOUN	O	O
.	PUNCT	O	O

Marked	ADJ	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
constriction	NOUN	O	I-Entity
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
vigabatrin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
field	NOUN	O	O
defects	NOUN	O	O
and	CCONJ	O	O
some	DET	O	O
electrophysiological	ADJ	O	O
abnormalities	NOUN	O	O
persist	VERB	O	O
when	ADV	O	O
vigabatrin	NOUN	O	I-Entity
therapy	NOUN	O	O
is	VERB	O	O
withdrawn	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (11063349)

Conversion	NOUN	O	O
to	ADP	O	O
rapamycin	VERB	O	I-Entity
immunosuppression	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
:	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
is	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
RAPA	PROPN	O	I-Entity
conversion	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
cyclosporine	NOUN	O	I-Entity
(	PUNCT	O	O
CsA	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
tacrolimus	NOUN	O	I-Entity
(	PUNCT	O	O
Tac	PROPN	O	I-Entity
)	PUNCT	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Twenty	NUM	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
were	VERB	O	O
switched	VERB	O	O
to	ADP	O	O
fixed	VERB	O	O
dose	NOUN	O	O
rapamycin	NOUN	O	I-Entity
(	PUNCT	O	O
RAPA	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
0	NUM	O	O
to	ADP	O	O
204	NUM	O	O
months	NOUN	O	O
posttransplant	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
indications	NOUN	O	O
for	ADP	O	O
switch	NOUN	O	O
were	VERB	O	O
chronic	ADJ	O	O
CsA	NOUN	O	I-Entity
or	CCONJ	O	O
Tac	PROPN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
(	PUNCT	O	O
12	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
acute	ADJ	O	O
CsA	NOUN	O	I-Entity
or	CCONJ	O	O
Tac	PROPN	O	I-Entity
toxicity	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
severe	ADJ	O	O
facial	ADJ	O	B-Entity
dysmorphism	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
posttransplant	NOUN	O	B-Entity
lymphoproliferative	ADJ	O	I-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
PTLD	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
remission	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
hepatotoxicity	NOUN	O	I-Entity
in	ADP	O	O
1	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
12	NUM	O	O
patients	NOUN	O	O
switched	VERB	O	O
because	ADP	O	O
of	ADP	O	O
chronic	ADJ	O	O
nephrotoxicity	NOUN	O	I-Entity
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
[	PUNCT	O	O
233+/-34	NOUN	O	O
to	ADP	O	O
210+/-56	NUM	O	O
micromol	NOUN	O	O
/	SYM	O	O
liter	NOUN	O	O
(	PUNCT	O	O
P<0.05	PROPN	O	O
)	PUNCT	O	O
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Facial	ADJ	O	B-Entity
dysmorphism	NOUN	O	I-Entity
improved	VERB	O	O
in	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
relapse	NOUN	O	O
of	ADP	O	O
PTLD	PROPN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
pneumonia	NOUN	O	I-Entity
(	PUNCT	O	O
two	NUM	O	O
Pneumocystis	PROPN	O	B-Entity
carinii	NOUN	O	I-Entity
pneumonia	NOUN	O	I-Entity
,	PUNCT	O	O
one	NUM	O	O
infectious	ADJ	O	B-Entity
mononucleosis	NOUN	O	I-Entity
with	ADP	O	O
polyclonal	ADJ	O	O
PTLD	PROPN	O	I-Entity
lung	NOUN	O	O
infiltrate	VERB	O	O
)	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
had	VERB	O	O
bronchiolitis	NOUN	O	B-Entity
obliterans	NOUN	O	I-Entity
.	PUNCT	O	O

RAPA	PROPN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
in	ADP	O	O
four	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
because	ADP	O	O
of	ADP	O	O
pneumonia	NOUN	O	I-Entity
in	ADP	O	O
two	NUM	O	O
,	PUNCT	O	O
PTLD	PROPN	O	I-Entity
in	ADP	O	O
one	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
oral	ADJ	O	O
aphtous	ADJ	O	B-Entity
ulcers	NOUN	O	I-Entity
in	ADP	O	O
one	NUM	O	O
.	PUNCT	O	O

RAPA	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
high	ADJ	O	O
(	PUNCT	O	O
>	SYM	O	O
15	NUM	O	O
ng	INTJ	O	O
/	SYM	O	O
ml	INTJ	O	O
)	PUNCT	O	O
in	ADP	O	O
7	NUM	O	O
of	ADP	O	O
13	NUM	O	O
(	PUNCT	O	O
54%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
.	PUNCT	O	O

RAPA	PROPN	O	I-Entity
conversion	NOUN	O	O
provides	VERB	O	O
adequate	ADJ	O	O
immunosuppression	NOUN	O	O
to	PART	O	O
enable	VERB	O	O
CsA	PROPN	O	I-Entity
withdrawal	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
when	ADV	O	O
converting	VERB	O	O
patients	NOUN	O	O
to	PART	O	O
RAPA	PROPN	O	I-Entity
drug	NOUN	O	O
levels	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
monitored	VERB	O	O
to	PART	O	O
avoid	VERB	O	O
over	ADP	O	O
-	PUNCT	O	O
immunosuppression	NOUN	O	O
and	CCONJ	O	O
adequate	ADJ	O	O
antiviral	ADJ	O	O
and	CCONJ	O	O
Pneumocystis	PROPN	O	B-Entity
carinii	NOUN	O	I-Entity
pneumonia	NOUN	O	I-Entity
prophylaxis	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
given	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (10091616)

Worsening	PROPN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
by	ADP	O	O
motor	NOUN	O	O
and	CCONJ	O	O
mental	ADJ	O	O
tasks	NOUN	O	O
.	PUNCT	O	O

Ten	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
with	ADP	O	O
disabling	VERB	O	O
dyskinesia	NOUN	O	I-Entity
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
mental	ADJ	O	O
(	PUNCT	O	O
mental	ADJ	O	O
calculation	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
motor	NOUN	O	O
(	PUNCT	O	O
flexion	NOUN	O	O
/	PUNCT	O	O
extension	NOUN	O	O
of	ADP	O	O
right	ADJ	O	O
fingers	NOUN	O	O
,	PUNCT	O	O
flexion	NOUN	O	O
/	PUNCT	O	O
extension	NOUN	O	O
of	ADP	O	O
left	ADJ	O	O
fingers	NOUN	O	O
,	PUNCT	O	O
flexion	NOUN	O	O
/	PUNCT	O	O
extension	NOUN	O	O
of	ADP	O	O
the	DET	O	O
neck	NOUN	O	O
,	PUNCT	O	O
speaking	VERB	O	O
aloud	ADV	O	O
)	PUNCT	O	O
tasks	NOUN	O	O
on	ADP	O	O
the	DET	O	O
worsening	NOUN	O	O
of	ADP	O	O
peak	NOUN	O	O
-	PUNCT	O	O
dose	NOUN	O	O
dyskinesia	NOUN	O	I-Entity
following	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
an	DET	O	O
effective	ADJ	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
apomorphine	NOUN	O	I-Entity
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
score	NOUN	O	O
at	ADP	O	O
rest	NOUN	O	O
(	PUNCT	O	O
1.3+/-0.3	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
aggravation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dyskinesia	NOUN	O	I-Entity
score	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
during	ADP	O	O
speaking	VERB	O	O
aloud	ADV	O	O
(	PUNCT	O	O
5.2+/-1.1	INTJ	O	O
,	PUNCT	O	O
p<0.05	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
movements	NOUN	O	O
of	ADP	O	O
right	NOUN	O	O
(	PUNCT	O	O
4.5+/-1.0	NOUN	O	O
,	PUNCT	O	O
p<0.05	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
left	VERB	O	O
(	PUNCT	O	O
3.7+/-0.8	NOUN	O	O
,	PUNCT	O	O
p<0.05	PUNCT	O	O
)	PUNCT	O	O
fingers	NOUN	O	O
,	PUNCT	O	O
movements	NOUN	O	O
of	ADP	O	O
the	DET	O	O
neck	NOUN	O	O
(	PUNCT	O	O
5.1+/-1.0	PROPN	O	O
,	PUNCT	O	O
p<0.05	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
mental	ADJ	O	O
calculation	NOUN	O	O
(	PUNCT	O	O
3.1+/-1.0	PROPN	O	O
,	PUNCT	O	O
p<0.05	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
activation	NOUN	O	O
tasks	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
"	PUNCT	O	O
speaking	VERB	O	O
aloud	ADV	O	O
"	PUNCT	O	O
could	VERB	O	O
be	VERB	O	O
used	VERB	O	O
for	ADP	O	O
objective	ADJ	O	O
assessment	NOUN	O	O
of	ADP	O	O
dyskinesia	ADJ	O	I-Entity
severity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9952311)

Structural	PROPN	O	B-Entity
and	CCONJ	O	I-Entity
functional	ADJ	O	I-Entity
impairment	NOUN	O	I-Entity
of	ADP	O	I-Entity
mitochondria	NOUN	O	I-Entity
in	ADP	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
:	PUNCT	O	O
suppression	NOUN	O	O
of	ADP	O	O
cytochrome	NOUN	O	O
c	NOUN	O	O
oxidase	NOUN	O	O
II	PROPN	O	O
gene	NOUN	O	O
expression	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
adriamycin	ADJ	O	I-Entity
(	PUNCT	O	O
ADR	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
cancer	NOUN	O	I-Entity
chemotherapy	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
limited	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
its	ADJ	O	O
cumulative	ADJ	O	O
cardiovascular	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Earlier	ADJ	O	O
observations	NOUN	O	O
that	ADJ	O	O
ADR	PROPN	O	I-Entity
interacts	VERB	O	O
with	ADP	O	O
mitochondrial	ADJ	O	O
cytochrome	NOUN	O	O
c	NOUN	O	O
oxidase	NOUN	O	O
(	PUNCT	O	O
COX	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
suppresses	VERB	O	O
its	ADJ	O	O
enzyme	NOUN	O	O
activity	NOUN	O	O
led	VERB	O	O
us	PRON	O	O
to	PART	O	O
investigate	VERB	O	O
ADR	PROPN	O	I-Entity
's	PART	O	O
action	NOUN	O	O
on	ADP	O	O
the	DET	O	O
cardiovascular	ADJ	O	O
functions	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
mitochondrial	ADJ	O	O
morphology	NOUN	O	O
in	ADP	O	O
Balb	PROPN	O	O
-	PUNCT	O	O
c	PROPN	O	O
mice	NOUN	O	O
i.p	X	O	O
.	PUNCT	O	O

treated	VERB	O	O
with	ADP	O	O
ADR	NOUN	O	I-Entity
for	ADP	O	O
several	ADJ	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
1	PUNCT	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
with	ADP	O	O
ADR	PROPN	O	I-Entity
caused	VERB	O	O
cardiovascular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
characterized	VERB	O	O
by	ADP	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
extension	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	O
depolarization	NOUN	O	O
time	NOUN	O	O
(	PUNCT	O	O
tQRS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
failure	NOUN	O	O
of	ADP	O	O
QRS	PROPN	O	O
at	ADP	O	O
high	ADJ	O	O
concentrations	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
-	SYM	O	O
14	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
weight	NOUN	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
the	DET	O	O
heart	NOUN	O	O
mitochondria	NOUN	O	O
underwent	VERB	O	O
swelling	VERB	O	I-Entity
,	PUNCT	O	O
fusion	NOUN	O	O
,	PUNCT	O	O
dissolution	NOUN	O	O
,	PUNCT	O	O
and/or	CCONJ	O	O
disruption	NOUN	O	O
of	ADP	O	O
mitochondrial	ADJ	O	O
cristae	NOUN	O	O
after	ADP	O	O
several	ADJ	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Such	ADJ	O	O
abnormalities	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
mitochondria	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	O
tissue	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
3	PUNCT	O	O
)	PUNCT	O	O
among	ADP	O	O
the	DET	O	O
three	NUM	O	O
genes	NOUN	O	O
of	ADP	O	O
COX	PROPN	O	O
enzyme	NOUN	O	O
examined	VERB	O	O
,	PUNCT	O	O
only	ADV	O	O
COXII	PROPN	O	O
gene	NOUN	O	O
expression	NOUN	O	O
was	VERB	O	O
suppressed	VERB	O	O
by	ADP	O	O
ADR	PROPN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
mainly	ADV	O	O
after	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
both	DET	O	O
heart	NOUN	O	O
and	CCONJ	O	O
liver	NOUN	O	O
.	PUNCT	O	O

Knowing	VERB	O	O
that	DET	O	O
heart	NOUN	O	O
mitochondria	VERB	O	O
represent	VERB	O	O
almost	ADV	O	O
40%	NUM	O	O
of	ADP	O	O
heart	NOUN	O	O
muscle	NOUN	O	O
by	ADP	O	O
weight	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
the	DET	O	O
deteriorating	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
ADR	NOUN	O	I-Entity
on	ADP	O	O
cardiovascular	ADJ	O	O
function	NOUN	O	O
involve	VERB	O	O
mitochondrial	ADJ	O	B-Entity
structural	ADJ	O	I-Entity
and	CCONJ	O	I-Entity
functional	ADJ	O	I-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9915601)

Enhanced	ADJ	O	O
bradycardia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
antagonists	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
isoniazid	NOUN	O	I-Entity
.	PUNCT	O	O

High	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
isoniazid	NOUN	O	I-Entity
increase	NOUN	O	O
hypotension	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
vasodilators	NOUN	O	O
and	CCONJ	O	O
change	VERB	O	O
the	DET	O	O
accompanying	NOUN	O	O
reflex	NOUN	O	O
tachycardia	NOUN	O	I-Entity
to	ADP	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
interaction	NOUN	O	O
attributed	VERB	O	O
to	ADP	O	O
decreased	ADJ	O	O
synthesis	NOUN	O	O
of	ADP	O	O
brain	NOUN	O	O
gamma	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
GABA	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
possible	ADJ	O	O
enhancement	NOUN	O	O
by	ADP	O	O
isoniazid	NOUN	O	I-Entity
of	ADP	O	O
bradycardia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
antagonists	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
anaesthetised	VERB	O	O
with	ADP	O	O
chloralose	NOUN	O	I-Entity
-	PUNCT	O	O
urethane	NOUN	O	I-Entity
.	PUNCT	O	O

Isoniazid	NOUN	O	I-Entity
significantly	ADV	O	O
increased	VERB	O	O
bradycardia	NOUN	O	I-Entity
after	ADP	O	O
propranolol	NOUN	O	I-Entity
,	PUNCT	O	O
pindolol	NOUN	O	I-Entity
,	PUNCT	O	O
labetalol	NOUN	O	I-Entity
and	CCONJ	O	O
atenolol	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
after	ADP	O	O
clonidine	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
after	ADP	O	O
hexamethonium	NOUN	O	I-Entity
or	CCONJ	O	O
carbachol	NOUN	O	I-Entity
.	PUNCT	O	O

Enhancement	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
methylatropine	NOUN	O	I-Entity
or	CCONJ	O	O
previously	ADV	O	O
vagotomised	VERB	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
are	VERB	O	O
compatible	ADJ	O	O
with	ADP	O	O
interference	NOUN	O	O
by	ADP	O	O
isoniazid	NOUN	O	I-Entity
with	ADP	O	O
GABAergic	PROPN	O	O
inhibition	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
parasympathetic	ADJ	O	O
tone	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9758264)

Epileptogenic	ADJ	O	O
activity	NOUN	O	O
of	ADP	O	O
folic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
after	ADP	O	O
drug	NOUN	O	O
induces	VERB	O	O
SLE	PROPN	O	I-Entity
(	PUNCT	O	O
folic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
and	CCONJ	O	O
epilepsy	NOUN	O	I-Entity
)	PUNCT	O	O
OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
study	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
folic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
multivitamin	NOUN	O	O
supplementation	NOUN	O	O
in	ADP	O	O
epileptic	ADJ	O	I-Entity
women	NOUN	O	O
before	ADV	O	O
and	CCONJ	O	O
during	ADP	O	O
pregnancy	NOUN	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
structural	ADJ	O	O
birth	NOUN	O	B-Entity
defects	NOUN	O	I-Entity
and	CCONJ	O	O
epilepsy	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
60	NUM	O	O
epileptic	ADJ	O	I-Entity
women	NOUN	O	O
with	ADP	O	O
periconceptional	ADJ	O	O
folic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
0.8	NUM	O	O
mg)-containing	VERB	O	O
multivitamin	NOUN	O	O
supplementation	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
one	NOUN	O	O
developed	VERB	O	O
epilepsy	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
side	NOUN	O	O
effects	NOUN	O	O
during	ADP	O	O
the	DET	O	O
periconception	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
epileptic	ADJ	O	I-Entity
woman	NOUN	O	O
delivered	VERB	O	O
a	DET	O	O
newborn	ADJ	O	O
with	ADP	O	O
cleft	NOUN	O	B-Entity
lip	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
palate	NOUN	O	I-Entity
.	PUNCT	O	O

Another	DET	O	O
patient	NOUN	O	O
exhibited	VERB	O	O
with	ADP	O	O
a	DET	O	O
cluster	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
periconception	NOUN	O	O
period	NOUN	O	O
using	VERB	O	O
another	DET	O	O
multivitamin	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
22-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
epileptic	ADJ	O	I-Entity
woman	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
continuously	ADV	O	O
by	ADP	O	O
carbamazepine	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
folic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg)-containing	VERB	O	O
multivitamin	NOUN	O	O
from	ADP	O	O
the	DET	O	O
20th	ADJ	O	O
week	NOUN	O	O
of	ADP	O	O
gestation	NOUN	O	O
.	PUNCT	O	O

She	PRON	O	O
developed	VERB	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
and	CCONJ	O	O
later	ADJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	B-Entity
lupus	NOUN	O	I-Entity
erythematodes	NOUN	O	I-Entity
.	PUNCT	O	O

Her	ADJ	O	O
pregnancy	NOUN	O	O
ended	VERB	O	O
with	ADP	O	O
stillbirth	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
epileptic	ADJ	O	I-Entity
pregnant	ADJ	O	O
patient	NOUN	O	O
's	PART	O	O
autoimmune	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
probably	ADV	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
lupus	NOUN	O	I-Entity
)	PUNCT	O	O
could	VERB	O	O
damage	VERB	O	O
the	DET	O	O
blood	NOUN	O	O
-	PUNCT	O	O
brain	NOUN	O	O
barrier	NOUN	O	O
,	PUNCT	O	O
therefore	ADV	O	O
the	DET	O	O
therapeutic	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
>	PUNCT	O	O
or	CCONJ	O	O
=	SYM	O	O
1	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
folic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
triggered	VERB	O	O
a	DET	O	O
cluster	NOUN	O	O
of	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Physiological	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
<	SYM	O	O
1	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
folic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
both	DET	O	O
in	ADP	O	O
healthy	ADJ	O	O
and	CCONJ	O	O
60	NUM	O	O
epileptic	ADJ	O	I-Entity
women	NOUN	O	O
,	PUNCT	O	O
all	ADV	O	O
without	ADP	O	O
any	DET	O	O
autoimmune	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
epileptic	ADJ	O	B-Entity
seizures	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9669632)

Effects	NOUN	O	O
of	ADP	O	O
cisapride	NOUN	O	I-Entity
on	ADP	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
postcibal	ADJ	O	O
small	ADJ	O	O
-	PUNCT	O	O
bowel	NOUN	O	O
motor	NOUN	O	O
function	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
irritable	ADJ	O	B-Entity
bowel	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Irritable	ADJ	O	B-Entity
bowel	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
common	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
and	CCONJ	O	O
discomfort	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
disordered	ADJ	O	B-Entity
gastrointestinal	ADJ	O	I-Entity
motility	NOUN	O	I-Entity
.	PUNCT	O	O

Our	ADJ	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
prokinetic	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
cisapride	NOUN	O	I-Entity
,	PUNCT	O	O
on	ADP	O	O
postprandial	ADJ	O	O
jejunal	ADJ	O	O
motility	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
in	ADP	O	O
the	DET	O	O
irritable	ADJ	O	B-Entity
bowel	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
IBS	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Thirty	NUM	O	O
-	PUNCT	O	O
eight	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
IBS	PROPN	O	I-Entity
(	PUNCT	O	O
constipation	NOUN	O	I-Entity
-	PUNCT	O	O
predominant	NOUN	O	O
,	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
17	NUM	O	O
;	PUNCT	O	O

diarrhoea	ADV	O	I-Entity
-	PUNCT	O	O
predominant	ADJ	O	O
,	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
21	NUM	O	O
)	PUNCT	O	O
underwent	VERB	O	O
24-h	NUM	O	O
ambulatory	ADJ	O	O
jejunal	ADJ	O	O
manometry	NOUN	O	O
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
12	NUM	O	O
week	NOUN	O	O
's	PART	O	O
treatment	NOUN	O	O
[	PUNCT	O	O
cisapride	NOUN	O	I-Entity
,	PUNCT	O	O
5	NUM	O	O
mg	NUM	O	O
three	NUM	O	O
times	NOUN	O	O
daily	ADV	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
19	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O

In	ADP	O	O
diarrhoea	NOUN	O	I-Entity
-	PUNCT	O	O
predominant	ADJ	O	O
patients	NOUN	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
contraction	NOUN	O	O
characteristics	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
the	DET	O	O
cisapride	NOUN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
cisapride	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
diarrhoea	NOUN	O	I-Entity
-	PUNCT	O	O
predominant	ADJ	O	O
patients	NOUN	O	O
the	DET	O	O
mean	ADJ	O	O
contraction	NOUN	O	O
amplitude	NOUN	O	O
was	VERB	O	O
higher	ADJ	O	O
(	PUNCT	O	O
29.3	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

2.6	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
,	PUNCT	O	O
cisapride	NOUN	O	I-Entity
versus	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
pretreatment	NOUN	O	O
,	PUNCT	O	O
25.7	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

0.2	NUM	O	O
sec	PROPN	O	O
,	PUNCT	O	O
cisapride	NOUN	O	I-Entity
versus	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
pretreatment	NOUN	O	O
,	PUNCT	O	O
3.1	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

0.4	NUM	O	O
cont./min	NOUN	O	O
,	PUNCT	O	O
cisapride	NOUN	O	I-Entity
versus	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O

No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
jejunal	ADJ	O	O
motility	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
constipation	NOUN	O	I-Entity
-	PUNCT	O	O
predominant	ADJ	O	O
IBS	PROPN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

Symptom	NOUN	O	O
scores	NOUN	O	O
relating	VERB	O	O
to	ADP	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
constipation	NOUN	O	I-Entity
were	VERB	O	O
lower	ADJ	O	O
in	ADP	O	O
cisapride	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
constipation	NOUN	O	I-Entity
-	PUNCT	O	O
predominant	ADJ	O	O
IBS	PROPN	O	I-Entity
patients	NOUN	O	O
[	PUNCT	O	O
score	NOUN	O	O
,	PUNCT	O	O
54	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

14	NUM	O	O
mm	PROPN	O	O
,	PUNCT	O	O
cisapride	NOUN	O	I-Entity
versus	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
pretreatment	NOUN	O	O
,	PUNCT	O	O
62	NUM	O	O
+	CCONJ	O	O
/-	PUNCT	O	O

Diarrhoea	PROPN	O	I-Entity
-	PUNCT	O	O
predominant	ADJ	O	O
IBS	PROPN	O	I-Entity
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
pain	NOUN	O	I-Entity
score	NOUN	O	O
after	ADP	O	O
cisapride	NOUN	O	I-Entity
therapy	NOUN	O	O
[	PUNCT	O	O
score	NOUN	O	O
,	PUNCT	O	O
55	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

12	NUM	O	O
mm	NOUN	O	O
,	PUNCT	O	O
cisapride	NOUN	O	I-Entity
versus	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
pretreatment	NOUN	O	O
,	PUNCT	O	O
67	NUM	O	O
+	CCONJ	O	O
/-	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Cisapride	PROPN	O	I-Entity
affects	VERB	O	O
jejunal	ADJ	O	O
contraction	NOUN	O	O
characteristics	NOUN	O	O
and	CCONJ	O	O
some	DET	O	O
symptoms	NOUN	O	O
in	ADP	O	O
IBS	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9326871)

Clarithromycin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
.	PUNCT	O	O

Clarithromycin	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
relatively	ADV	O	O
new	ADJ	O	O
macrolide	ADJ	O	I-Entity
antibiotic	NOUN	O	O
that	ADJ	O	O
offers	VERB	O	O
twice	ADV	O	O
-	PUNCT	O	O
daily	ADJ	O	O
dosing	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
differs	VERB	O	O
from	ADP	O	O
erythromycin	NOUN	O	I-Entity
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
methylation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hydroxyl	NOUN	O	O
group	NOUN	O	O
at	ADP	O	O
position	NOUN	O	O
6	NUM	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
side	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
profile	NOUN	O	O
of	ADP	O	O
erythromycin	NOUN	O	I-Entity
is	VERB	O	O
established	VERB	O	O
,	PUNCT	O	O
including	VERB	O	O
gastroenteritis	NOUN	O	I-Entity
and	CCONJ	O	O
interactions	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
drugs	NOUN	O	O
subject	ADJ	O	O
to	ADP	O	O
hepatic	ADJ	O	O
mixed	ADJ	O	O
-	PUNCT	O	O
function	NOUN	O	O
oxidase	NOUN	O	O
metabolism	NOUN	O	O
,	PUNCT	O	O
experience	NOUN	O	O
with	ADP	O	O
the	DET	O	O
newer	NOUN	O	O
macrolides	NOUN	O	I-Entity
is	VERB	O	O
still	ADV	O	O
being	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

Cardiotoxicity	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
demonstrated	VERB	O	O
after	ADP	O	O
both	DET	O	O
intravenous	ADJ	O	O
and	CCONJ	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
erythromycin	NOUN	O	I-Entity
but	CCONJ	O	O
has	VERB	O	O
never	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
with	ADP	O	O
the	DET	O	O
newer	NOUN	O	O
macrolides	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
dysrhythmias	NOUN	O	I-Entity
that	ADJ	O	O
occurred	VERB	O	O
after	ADP	O	O
six	NUM	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
clarithromycin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
dysrhythmias	NOUN	O	I-Entity
resolved	VERB	O	O
after	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9226773)

Persistent	ADJ	O	O
nephrogenic	ADJ	O	B-Entity
diabetes	NOUN	O	I-Entity
insipidus	ADV	O	I-Entity
following	VERB	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
severe	ADJ	O	O
hypernatraemic	ADJ	O	O
dehydration	NOUN	O	I-Entity
following	VERB	O	O
a	DET	O	O
head	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

Ten	NUM	O	O
years	NOUN	O	O
previously	ADV	O	O
he	PRON	O	O
had	VERB	O	O
been	VERB	O	O
diagnosed	VERB	O	O
to	PART	O	O
have	VERB	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrogenic	ADJ	O	B-Entity
diabetes	NOUN	O	I-Entity
insipidus	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
discontinued	VERB	O	O
.	PUNCT	O	O

He	PRON	O	O
remained	VERB	O	O
thirsty	ADJ	O	O
and	CCONJ	O	O
polyuric	ADJ	O	I-Entity
despite	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
and	CCONJ	O	O
investigations	NOUN	O	O
on	ADP	O	O
admission	NOUN	O	O
showed	VERB	O	O
him	PRON	O	O
to	PART	O	O
have	VERB	O	O
normal	ADJ	O	O
osmoregulated	VERB	O	O
thirst	NOUN	O	O
and	CCONJ	O	O
vasopressin	NOUN	O	I-Entity
secretion	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
clear	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
nephrogenic	ADJ	O	B-Entity
diabetes	NOUN	O	I-Entity
insipidus	VERB	O	I-Entity
.	PUNCT	O	O

Lithium	NOUN	O	I-Entity
induced	VERB	O	O
nephrogenic	ADJ	O	B-Entity
diabetes	NOUN	O	I-Entity
insipidus	NOUN	O	I-Entity
is	VERB	O	O
considered	VERB	O	O
to	PART	O	O
be	VERB	O	O
reversible	ADJ	O	O
on	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
but	CCONJ	O	O
polyuria	NOUN	O	I-Entity
persisted	VERB	O	O
in	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
for	ADP	O	O
ten	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
lithium	NOUN	O	I-Entity
was	VERB	O	O
stopped	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
discuss	VERB	O	O
the	DET	O	O
possible	ADJ	O	O
renal	ADJ	O	O
mechanisms	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
implications	NOUN	O	O
for	ADP	O	O
management	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrogenic	ADJ	O	B-Entity
diabetes	NOUN	O	I-Entity
insipidus	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8600333)

Late	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
a	DET	O	O
malignant	ADJ	O	O
bone	NOUN	O	B-Entity
tumor	NOUN	O	I-Entity
.	PUNCT	O	O

Cardiac	PROPN	O	O
function	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
survivors	NOUN	O	O
of	ADP	O	O
malignant	ADJ	O	O
bone	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
who	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
according	VERB	O	O
to	ADP	O	O
Rosen	PROPN	O	B-Entity
's	PART	O	I-Entity
T5	PROPN	O	I-Entity
or	CCONJ	O	I-Entity
T10	PROPN	O	I-Entity
protocol	NOUN	O	I-Entity
,	PUNCT	O	O
both	DET	O	O
including	VERB	O	O
doxorubicin	NOUN	O	I-Entity
.	PUNCT	O	O

Cumulative	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
were	VERB	O	O
225	NUM	O	O
-	SYM	O	O
550	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
dose	NOUN	O	O
360	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Eighteen	NUM	O	O
of	ADP	O	O
31	NUM	O	O
(	PUNCT	O	O
58%	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
showed	VERB	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
having	VERB	O	O
one	NUM	O	O
or	CCONJ	O	O
more	ADJ	O	O
of	ADP	O	O
the	DET	O	O
following	ADJ	O	O
abnormalities	NOUN	O	O
:	PUNCT	O	O
late	ADJ	O	O
potentials	NOUN	O	O
,	PUNCT	O	O
complex	ADJ	O	O
ventricular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
left	VERB	O	O
ventricular	ADJ	O	B-Entity
dilation	NOUN	O	I-Entity
,	PUNCT	O	O
decreased	VERB	O	O
shortening	VERB	O	O
fraction	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
decreased	VERB	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
increased	VERB	O	O
with	ADP	O	O
length	NOUN	O	O
of	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
(	PUNCT	O	O
P	PROPN	O	O
<	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
correlation	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
demonstrated	VERB	O	O
between	ADP	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
and	CCONJ	O	O
cardiac	ADJ	O	O
status	NOUN	O	O
,	PUNCT	O	O
except	ADP	O	O
for	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
variability	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
is	VERB	O	O
high	ADJ	O	O
and	CCONJ	O	O
increases	VERB	O	O
with	ADP	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
,	PUNCT	O	O
irrespective	ADV	O	O
of	ADP	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
our	ADJ	O	O
study	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
variability	NOUN	O	O
and	CCONJ	O	O
LVPW	PROPN	O	O
index	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
sensitive	ADJ	O	O
indicators	NOUN	O	O
for	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8514073)

Venous	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
of	ADP	O	O
midazolam	NOUN	O	I-Entity
versus	ADP	O	O
diazepam	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
some	DET	O	O
studies	NOUN	O	O
have	VERB	O	O
suggested	VERB	O	O
fewer	ADJ	O	O
venous	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
midazolam	NOUN	O	I-Entity
than	ADP	O	O
with	ADP	O	O
diazepam	NOUN	O	I-Entity
for	ADP	O	O
endoscopic	NOUN	O	O
procedures	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
variable	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
well	ADV	O	O
documented	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
prospectively	ADV	O	O
evaluated	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
after	ADP	O	O
intravenous	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
diazepam	NOUN	O	I-Entity
or	CCONJ	O	O
midazolam	NOUN	O	I-Entity
in	ADP	O	O
122	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
colonoscopy	NOUN	O	O
and	CCONJ	O	O
esophagogastroduodenoscopy	NOUN	O	O
.	PUNCT	O	O

Overall	ADV	O	O
,	PUNCT	O	O
venous	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
were	VERB	O	O
more	ADV	O	O
frequent	ADJ	O	O
with	ADP	O	O
diazepam	NOUN	O	I-Entity
(	PUNCT	O	O
22	NUM	O	O
of	ADP	O	O
62	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
than	ADP	O	O
with	ADP	O	O
midazolam	NOUN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
of	ADP	O	O
60	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
palpable	ADJ	O	O
venous	ADJ	O	O
cord	NOUN	O	O
was	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
23%	NUM	O	O
(	PUNCT	O	O
14	NUM	O	O
of	ADP	O	O
62	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
diazepam	NOUN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
2%	NUM	O	O
(	PUNCT	O	O
1	NUM	O	O
of	ADP	O	O
60	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
midazolam	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O

Pain	PROPN	O	I-Entity
at	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
site	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
35%	NUM	O	O
(	PUNCT	O	O
22	NUM	O	O
of	ADP	O	O
62	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
diazepam	NOUN	O	I-Entity
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
7%	NUM	O	O
(	PUNCT	O	O
4	NUM	O	O
of	ADP	O	O
60	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
midazolam	NOUN	O	I-Entity
group	NOUN	O	O

Swelling	VERB	O	I-Entity
and	CCONJ	O	O
warmth	NOUN	O	O
at	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
site	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Smoking	VERB	O	O
,	PUNCT	O	O
nonsteroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drug	NOUN	O	O
use	NOUN	O	O
,	PUNCT	O	O
intravenous	ADJ	O	O
catheter	NOUN	O	O
site	NOUN	O	O
,	PUNCT	O	O
dwell	ADJ	O	O
time	NOUN	O	O
of	ADP	O	O
the	DET	O	O
needle	NOUN	O	O
,	PUNCT	O	O
alcohol	NOUN	O	I-Entity
use	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
pain	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8492347)

Tetany	PROPN	O	I-Entity
and	CCONJ	O	O
rhabdomyolysis	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
surreptitious	ADJ	O	O
furosemide	NOUN	O	I-Entity
--	PUNCT	O	O
importance	NOUN	O	O
of	ADP	O	O
magnesium	NOUN	O	I-Entity
supplementation	NOUN	O	O
.	PUNCT	O	O

Diuretics	NOUN	O	O
may	VERB	O	O
induce	VERB	O	O
hypokalemia	NOUN	O	I-Entity
,	PUNCT	O	O
hypocalcemia	NOUN	O	I-Entity
and	CCONJ	O	O
hypomagnesemia	NOUN	O	I-Entity
.	PUNCT	O	O

While	ADP	O	O
severe	ADJ	O	O
hypokalemia	NOUN	O	I-Entity
may	VERB	O	O
cause	VERB	O	O
muscle	NOUN	O	B-Entity
weakness	NOUN	O	I-Entity
,	PUNCT	O	O
severe	ADJ	O	O
hypomagnesemia	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
muscle	NOUN	O	B-Entity
spasms	NOUN	O	I-Entity
and	CCONJ	O	O
tetany	DET	O	I-Entity
which	ADJ	O	O
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
corrected	VERB	O	O
by	ADP	O	O
potassium	NOUN	O	I-Entity
and	CCONJ	O	O
calcium	NOUN	O	I-Entity
supplementation	NOUN	O	O
alone	ADV	O	O
(	PUNCT	O	O
1,2	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Surreptitious	ADJ	O	O
diuretic	NOUN	O	O
ingestion	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
described	VERB	O	O
,	PUNCT	O	O
mainly	ADV	O	O
in	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
concerned	VERB	O	O
that	ADP	O	O
they	PRON	O	O
are	VERB	O	O
obese	ADJ	O	I-Entity
or	CCONJ	O	O
edematous	ADJ	O	I-Entity
.	PUNCT	O	O

Symptomatic	ADJ	O	O
hypokalemia	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
such	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
-	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
one	NUM	O	O
case	NOUN	O	O
hypocalcemia	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
(	PUNCT	O	O
8)	NUM	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
magnesium	NOUN	O	I-Entity
depletion	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
noted	VERB	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8410199)

Loss	NOUN	O	O
of	ADP	O	O
glutamate	NOUN	O	I-Entity
decarboxylase	NOUN	O	O
mRNA	NOUN	O	O
-	PUNCT	O	O
containing	VERB	O	O
neurons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
dentate	NOUN	O	O
gyrus	NOUN	O	O
following	VERB	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
situ	NOUN	O	O
hybridization	NOUN	O	O
methods	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
determine	VERB	O	O
if	ADP	O	O
glutamic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
decarboxylase	NOUN	O	O
(	PUNCT	O	O
GAD	PROPN	O	O
)	PUNCT	O	O

mRNA	PROPN	O	O
-	PUNCT	O	O
containing	VERB	O	O
neurons	NOUN	O	O
within	ADP	O	O
the	DET	O	O
hilus	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dentate	NOUN	O	O
gyrus	NOUN	O	O
are	VERB	O	O
vulnerable	ADJ	O	O
to	ADP	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
damage	NOUN	O	O
in	ADP	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
injected	VERB	O	O
intraperitoneally	ADV	O	O
with	ADP	O	O
pilocarpine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
hippocampal	ADJ	O	O
formation	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
histologically	ADV	O	O
at	ADP	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
8	NUM	O	O
week	NOUN	O	O
intervals	NOUN	O	O
after	ADP	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
situ	NOUN	O	O
hybridization	NOUN	O	O
histochemistry	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
a	DET	O	O
digoxigenin	NOUN	O	I-Entity
-	PUNCT	O	O
labeled	VERB	O	O
GAD	PROPN	O	O
cRNA	PROPN	O	O
probe	NOUN	O	O
,	PUNCT	O	O
demonstrated	VERB	O	O
a	DET	O	O
substantial	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
GAD	PROPN	O	O
mRNA	PROPN	O	O
-	PUNCT	O	O
containing	VERB	O	O
neurons	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hilus	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dentate	NOUN	O	O
gyrus	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
controls	NOUN	O	O
at	ADV	O	O
all	DET	O	O
time	NOUN	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
neuronanatomical	ADJ	O	O
studies	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
cresyl	NOUN	O	B-Entity
violet	NOUN	O	I-Entity
staining	NOUN	O	O
,	PUNCT	O	O
neuronal	ADJ	O	B-Entity
degeneration	NOUN	O	I-Entity
methods	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
histochemical	ADJ	O	O
localization	NOUN	O	O
of	ADP	O	O
glial	ADJ	O	O
fibrillary	ADJ	O	O
acidic	ADJ	O	O
protein	NOUN	O	O
,	PUNCT	O	O
suggested	VERB	O	O
that	ADP	O	O
the	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
GAD	PROPN	O	O
mRNA	PROPN	O	O
-	PUNCT	O	O
containing	VERB	O	O
neurons	NOUN	O	O
was	VERB	O	O
related	VERB	O	O
to	ADP	O	O
neuronal	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
rather	ADV	O	O
than	ADP	O	O
to	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
GAD	PROPN	O	O
mRNA	PROPN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
in	ADP	O	O
this	DET	O	O
model	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
subpopulation	NOUN	O	O
of	ADP	O	O
GAD	PROPN	O	O
mRNA	PROPN	O	O
-	PUNCT	O	O
containing	VERB	O	O
neurons	NOUN	O	O
within	ADP	O	O
the	DET	O	O
dentate	ADJ	O	O
gyrus	NOUN	O	O
is	VERB	O	O
selectively	ADV	O	O
vulnerable	ADJ	O	O
to	ADP	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
damage	NOUN	O	O
.	PUNCT	O	O

Such	ADJ	O	O
differential	NOUN	O	O
vulnerability	NOUN	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
another	DET	O	O
indication	NOUN	O	O
of	ADP	O	O
the	DET	O	O
heterogeneity	NOUN	O	O
of	ADP	O	O
GABA	PROPN	O	I-Entity
neurons	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7791169)

Protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	I-Entity
on	ADP	O	O
indomethacin	NOUN	O	I-Entity
induced	VERB	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
possible	ADJ	O	O
protective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	I-Entity
on	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
hospitalized	VERB	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
indomethacin	NOUN	O	I-Entity
.	PUNCT	O	O

Forty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
hospitalized	VERB	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
>	SYM	O	O
65	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
)	PUNCT	O	O
who	NOUN	O	O
required	VERB	O	O
therapy	NOUN	O	O
with	ADP	O	O
nonsteroidal	NOUN	O	O
antiinflammatory	ADJ	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
NSAID	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	VERB	O	O
either	CCONJ	O	O
indomethacin	NOUN	O	I-Entity
,	PUNCT	O	O
150	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
(	PUNCT	O	O
Group	PROPN	O	O
A	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
indomethacin	ADV	O	I-Entity
150	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
plus	CCONJ	O	O
misoprostol	NOUN	O	I-Entity
at	ADP	O	O
0.6	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
(	PUNCT	O	O
Group	PROPN	O	O
B	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Laboratory	PROPN	O	O
variables	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
[	PUNCT	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
,	PUNCT	O	O
blood	NOUN	O	B-Entity
urea	NOUN	O	I-Entity
nitrogen	NOUN	O	I-Entity
(	PUNCT	O	O
BUN	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
electrolytes	NOUN	O	O
]	PUNCT	O	O
were	VERB	O	O
evaluated	VERB	O	O
before	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
every	DET	O	O
2	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
until	ADP	O	O
termination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
at	ADV	O	O
least	ADJ	O	O
6	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Response	NOUN	O	O
to	ADP	O	O
treatment	NOUN	O	O
was	VERB	O	O
estimated	VERB	O	O
by	ADP	O	O
the	DET	O	O
visual	ADJ	O	O
analog	NOUN	O	O
scale	NOUN	O	O
for	ADP	O	O
severity	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Forty	NUM	O	O
-	PUNCT	O	O
two	NUM	O	O
patients	NOUN	O	O
completed	VERB	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
22	NUM	O	O
in	ADP	O	O
Group	PROPN	O	O
A	PROPN	O	O
and	CCONJ	O	O
20	NUM	O	O
in	ADP	O	O
Group	PROPN	O	O
B.	PROPN	O	O
BUN	PROPN	O	I-Entity
and	CCONJ	O	O
creatinine	NOUN	O	I-Entity
increased	VERB	O	O
by	ADP	O	O
>	X	O	O
50%	NUM	O	O
of	ADP	O	O
baseline	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
54	NUM	O	O
and	CCONJ	O	O
45%	NUM	O	O
of	ADP	O	O
Group	PROPN	O	O
A	PROPN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
only	ADV	O	O
20	NUM	O	O
and	CCONJ	O	O
10%	NUM	O	O
of	ADP	O	O
Group	PROPN	O	O
B	PROPN	O	O
patients	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Potassium	NOUN	O	I-Entity
(	PUNCT	O	O
K	PROPN	O	I-Entity
)	PUNCT	O	O
increment	NOUN	O	O
of	ADP	O	O
0.6	NUM	O	O

The	DET	O	O
mean	ADJ	O	O
increments	NOUN	O	O
in	ADP	O	O
BUN	PROPN	O	I-Entity
,	PUNCT	O	O
creatinine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
K	PROPN	O	I-Entity
were	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
63	NUM	O	O
,	PUNCT	O	O
80	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
42%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
Group	PROPN	O	O
B	PROPN	O	O
patients	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
Group	PROPN	O	O
A.	PROPN	O	O
Response	PROPN	O	O
to	ADP	O	O
treatment	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
significantly	ADV	O	O
between	ADP	O	O
the	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Hospitalized	VERB	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
are	VERB	O	O
at	ADP	O	O
risk	NOUN	O	O
for	ADP	O	O
developing	VERB	O	O
indomethacin	NOUN	O	I-Entity
related	ADJ	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Addition	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	I-Entity
can	VERB	O	O
minimize	VERB	O	O
this	DET	O	O
renal	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
without	ADP	O	O
affecting	VERB	O	O
pain	NOUN	O	I-Entity
control	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6728084)

Nephrotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
aminoglycoside	NOUN	O	I-Entity
treatment	NOUN	O	O
on	ADP	O	O
renal	NOUN	O	O
protein	NOUN	O	O
reabsorption	NOUN	O	O
and	CCONJ	O	O
accumulation	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
quantify	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
gentamicin	NOUN	O	I-Entity
,	PUNCT	O	O
kanamycin	NOUN	O	I-Entity
and	CCONJ	O	O
netilmicin	NOUN	O	I-Entity
on	ADP	O	O
renal	ADJ	O	O
protein	NOUN	O	O
reabsorption	NOUN	O	O
and	CCONJ	O	O
accumulation	NOUN	O	O
,	PUNCT	O	O
these	DET	O	O
drugs	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
rats	NOUN	O	O
intraperitoneally	ADV	O	O
(	PUNCT	O	O
30	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
7	NUM	O	O
,	PUNCT	O	O
14	NUM	O	O
or	CCONJ	O	O
21	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Scanning	VERB	O	O
electron	NOUN	O	O
microscopy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glomerular	ADJ	O	O
endothelia	NOUN	O	O
,	PUNCT	O	O
urinary	ADJ	O	O
measurements	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	I-Entity
,	PUNCT	O	O
potassium	NOUN	O	I-Entity
,	PUNCT	O	O
endogenous	ADJ	O	O
lysozyme	NOUN	O	O
,	PUNCT	O	O
N	PROPN	O	O
-	PUNCT	O	O
acetyl	NOUN	O	O
-	PUNCT	O	O
beta	NOUN	O	O
-	PUNCT	O	O
D	NOUN	O	O
-	PUNCT	O	O
glucosaminidase	NOUN	O	O
(	PUNCT	O	O
NAG	PROPN	O	O
)	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
clearance	NOUN	O	O
and	CCONJ	O	O
accumulation	NOUN	O	O
experiments	NOUN	O	O
after	ADP	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

Gentamicin	PROPN	O	I-Entity
administration	NOUN	O	O
decreased	VERB	O	O
diameter	NOUN	O	O
,	PUNCT	O	O
density	NOUN	O	O
and	CCONJ	O	O
shape	NOUN	O	O
of	ADP	O	O
endothelial	ADJ	O	O
fenestrae	NOUN	O	O
.	PUNCT	O	O

Kanamycin	PROPN	O	I-Entity
and	CCONJ	O	O
netilmicin	NOUN	O	I-Entity
appeared	VERB	O	O
to	PART	O	O
have	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
at	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
used	VERB	O	O
.	PUNCT	O	O

All	DET	O	O
three	NUM	O	O
aminoglycosides	NOUN	O	I-Entity
decreased	VERB	O	O
GFR	PROPN	O	O
and	CCONJ	O	O
increased	VERB	O	O
urinary	ADJ	O	O
excretion	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	I-Entity
and	CCONJ	O	O
potassium	NOUN	O	I-Entity
.	PUNCT	O	O

While	ADP	O	O
gentamicin	NOUN	O	I-Entity
and	CCONJ	O	O
kanamycin	NOUN	O	I-Entity
decreased	VERB	O	O
the	DET	O	O
percentage	NOUN	O	O
reabsorption	NOUN	O	O
and	CCONJ	O	O
accumulation	NOUN	O	O
of	ADP	O	O
lysozyme	NOUN	O	O
after	ADP	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

administration	NOUN	O	O
of	ADP	O	O
egg	NOUN	O	O
-	PUNCT	O	O
white	ADJ	O	O
lysozyme	NOUN	O	O
netilmicin	NOUN	O	I-Entity
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Daily	ADJ	O	O
excretion	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
protein	NOUN	O	O
,	PUNCT	O	O
endogenous	ADJ	O	O
lysozyme	NOUN	O	O
and	CCONJ	O	O
NAG	PROPN	O	O
increased	VERB	O	O
only	ADV	O	O
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
kanamycin	NOUN	O	I-Entity
and	CCONJ	O	O
gentamicin	NOUN	O	I-Entity
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
aminoglycosides	NOUN	O	I-Entity
may	VERB	O	O
act	VERB	O	O
as	ADP	O	O
nephrotoxicants	NOUN	O	O
at	ADP	O	O
glomerular	NOUN	O	O
and/or	CCONJ	O	O
tubular	ADJ	O	O
level	NOUN	O	O
inducing	VERB	O	O
impairment	NOUN	O	B-Entity
of	ADP	O	I-Entity
renal	ADJ	O	I-Entity
reabsorption	NOUN	O	I-Entity
and	CCONJ	O	O
accumulation	NOUN	O	O
of	ADP	O	O
proteins	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6111982)

Pharmacology	NOUN	O	O
of	ADP	O	O
GYKI-41	PROPN	O	B-Entity
099	NUM	O	I-Entity
(	PUNCT	O	O
chlorpropanol	NOUN	O	I-Entity
,	PUNCT	O	O
Tobanum	PROPN	O	I-Entity
)	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
potent	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
antagonist	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
compound	NOUN	O	O
GYKI-41	PROPN	O	B-Entity
099	NUM	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenergic	ADJ	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
3	NUM	O	O
-	SYM	O	O
8	NUM	O	O
times	NOUN	O	O
more	ADV	O	O
potent	ADJ	O	O
than	ADP	O	O
propranolol	NOUN	O	I-Entity
in	ADP	O	O
vitro	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O

Its	ADJ	O	O
antiarrhythmic	ADJ	O	O
effectiveness	NOUN	O	O
surpasses	ADP	O	O
that	DET	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
and	CCONJ	O	O
pindolol	NOUN	O	I-Entity
inhibiting	VERB	O	O
the	DET	O	O
ouabain	NOUN	O	I-Entity
arrhythmia	NOUN	O	I-Entity
in	ADP	O	O
dogs	NOUN	O	O
and	CCONJ	O	O
cats	NOUN	O	O
.	PUNCT	O	O

GYKI-41	SYM	O	B-Entity
900	NUM	O	I-Entity
has	VERB	O	O
a	DET	O	O
negligible	ADJ	O	O
cardiodepressant	NOUN	O	O
activity	NOUN	O	O
;	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
not	ADV	O	O
cardioselective	ADJ	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
prolonged	ADJ	O	O
elimination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
radioactivity	NOUN	O	O
after	ADP	O	O
the	DET	O	O
injection	NOUN	O	O
of	ADP	O	O
14C-41	NUM	O	B-Entity
099	NUM	O	I-Entity
to	ADP	O	O
rats	NOUN	O	O
and	CCONJ	O	O
dogs	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3123611)

Chorea	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
oral	ADJ	O	B-Entity
contraception	NOUN	O	I-Entity
.	PUNCT	O	O

Three	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
chorea	NOUN	O	I-Entity
while	ADP	O	O
receiving	VERB	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
were	VERB	O	O
young	ADJ	O	O
patients	NOUN	O	O
whose	ADJ	O	O
chorea	NOUN	O	I-Entity
developed	VERB	O	O
long	ADV	O	O
after	ADP	O	O
treatment	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
started	VERB	O	O
and	CCONJ	O	O
disappeared	VERB	O	O
soon	ADV	O	O
after	ADP	O	O
it	PRON	O	O
had	VERB	O	O
been	VERB	O	O
discontinued	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
third	ADJ	O	O
patient	NOUN	O	O
had	VERB	O	O
acute	ADJ	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
chorea	NOUN	O	I-Entity
after	ADP	O	O
prolonged	ADJ	O	O
oral	ADJ	O	B-Entity
contraception	NOUN	O	I-Entity
.	PUNCT	O	O

Prolonged	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
female	ADJ	O	O
sex	NOUN	O	O
hormones	NOUN	O	O
is	VERB	O	O
a	DET	O	O
possible	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
chorea	NOUN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
not	ADV	O	O
previously	ADV	O	O
had	VERB	O	O
chorea	NOUN	O	I-Entity
or	CCONJ	O	O
rheumatic	ADJ	O	B-Entity
fever	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (761833)

Reversal	NOUN	O	O
of	ADP	O	O
ammonia	NOUN	O	I-Entity
coma	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
by	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
peripheral	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Ammonia	PROPN	O	I-Entity
coma	NOUN	O	I-Entity
was	VERB	O	O
produced	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
within	ADP	O	O
10	NUM	O	O
to	PART	O	O
15	NUM	O	O
minutes	NOUN	O	O
of	ADP	O	O
an	DET	O	O
intraperitonealinjection	NOUN	O	O
of	ADP	O	O
1.7	NUM	O	O
mmol	NOUN	O	O
NH4CL	PROPN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
coma	NOUN	O	I-Entity
was	VERB	O	O
prevented	VERB	O	O
with	ADP	O	O
1.68	NUM	O	O
mmol	NOUN	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
given	VERB	O	O
by	ADP	O	O
gastric	ADJ	O	O
intubation	NOUN	O	O
15	NUM	O	O
minutes	NOUN	O	O
before	ADP	O	O
the	DET	O	O
ammonium	NOUN	O	B-Entity
salt	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	PROPN	O	I-Entity
was	VERB	O	O
correlated	VERB	O	O
with	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
and	CCONJ	O	O
brain	NOUN	O	O
ammonia	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
brain	NOUN	O	O
dopamine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
excretion	NOUN	O	O
of	ADP	O	O
ammonia	NOUN	O	I-Entity
and	CCONJ	O	O
urea	NOUN	O	I-Entity
.	PUNCT	O	O

Intraventricular	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
sufficient	ADJ	O	O
to	PART	O	O
raise	VERB	O	O
the	DET	O	O
brain	NOUN	O	O
dopamine	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
same	ADJ	O	O
extent	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
prevent	VERB	O	O
the	DET	O	O
ammonia	NOUN	O	I-Entity
coma	NOUN	O	I-Entity
nor	CCONJ	O	O
affect	VERB	O	O
the	DET	O	O
blood	NOUN	O	O
and	CCONJ	O	O
brain	NOUN	O	O
ammonia	NOUN	O	I-Entity
concentrations	NOUN	O	O
.	PUNCT	O	O

Bilateral	ADJ	O	O
nephrectomy	NOUN	O	O
eliminated	VERB	O	O
the	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
on	ADP	O	O
blood	NOUN	O	O
and	CCONJ	O	O
brain	NOUN	O	O
ammonia	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
ammonia	NOUN	O	I-Entity
coma	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
prevented	VERB	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
and	CCONJ	O	O
brain	NOUN	O	O
ammonia	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
ammonia	NOUN	O	I-Entity
coma	NOUN	O	I-Entity
after	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
,	PUNCT	O	O
can	VERB	O	O
be	VERB	O	O
accounted	VERB	O	O
for	ADP	O	O
by	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
on	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
rather	ADV	O	O
than	ADP	O	O
its	ADJ	O	O
central	ADJ	O	O
action	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
provide	VERB	O	O
a	DET	O	O
reasonable	ADJ	O	O
explanation	NOUN	O	O
for	ADP	O	O
the	DET	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
some	DET	O	O
encephalopathic	ADJ	O	I-Entity
patients	NOUN	O	O
receiving	VERB	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18589141)

Heparin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
after	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

Unfractionated	PROPN	O	B-Entity
heparin	NOUN	O	I-Entity
sodium	NOUN	O	I-Entity
(	PUNCT	O	O
UFH	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
low	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
molecular	ADJ	O	I-Entity
weight	NOUN	O	I-Entity
heparin	NOUN	O	I-Entity
(	PUNCT	O	O
LMWH	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
used	VERB	O	O
in	ADP	O	O
anticoagulant	NOUN	O	O
protocols	NOUN	O	O
at	ADP	O	O
several	ADJ	O	O
institutions	NOUN	O	O
to	PART	O	O
prevent	VERB	O	O
thrombosis	NOUN	O	I-Entity
after	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

Heparin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
(	PUNCT	O	O
HIT	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
adverse	ADJ	O	O
immune	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
reaction	NOUN	O	O
to	ADP	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
platelet	NOUN	O	O
count	NOUN	O	O
decreases	NOUN	O	O
of	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
50%	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
frequencies	NOUN	O	O
of	ADP	O	O
HIT	PROPN	O	I-Entity
after	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
and	CCONJ	O	O
platelet	NOUN	O	O
factor	NOUN	O	O
4/heparin	NUM	O	I-Entity
-	PUNCT	O	O
reactive	ADJ	O	O
antibody	NOUN	O	O
(	PUNCT	O	O
HIT	PROPN	O	I-Entity
antibody	NOUN	O	O
)	PUNCT	O	O
positivity	NOUN	O	O
in	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
are	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
started	VERB	O	O
LMWH	PROPN	O	O
(	PUNCT	O	O
25	NUM	O	O
IU	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
h	PUNCT	O	O
)	PUNCT	O	O
on	ADP	O	O
postoperative	ADJ	O	O
day	NOUN	O	O
(	PUNCT	O	O
POD	PROPN	O	O
)	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
switching	VERB	O	O
to	ADP	O	O
UFH	PROPN	O	I-Entity
(	PUNCT	O	O
5000	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
d	PUNCT	O	O
)	PUNCT	O	O
on	ADP	O	O
POD	NOUN	O	O
2	NUM	O	O
or	CCONJ	O	O
3	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
UFH	PROPN	O	I-Entity
was	VERB	O	O
changed	VERB	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
activated	ADJ	O	O
clotting	NOUN	O	O
time	NOUN	O	O
level	NOUN	O	O
.	PUNCT	O	O

HIT	ADP	O	I-Entity
antibody	NOUN	O	O
levels	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
the	DET	O	O
day	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
POD	PROPN	O	O
7	NUM	O	O
and	CCONJ	O	O
14	NUM	O	O
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
hepatic	ADJ	O	O
artery	NOUN	O	O
thrombosis	NOUN	O	I-Entity
on	ADP	O	O
POD	NOUN	O	O
11	NUM	O	O
and	CCONJ	O	O
19	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
although	ADP	O	O
they	PRON	O	O
were	VERB	O	O
HIT	VERB	O	I-Entity
antibody	NOUN	O	O
-	PUNCT	O	O
negative	ADJ	O	O
and	CCONJ	O	O
their	ADJ	O	O
platelet	NOUN	O	O
counts	NOUN	O	O
were	VERB	O	O
stable	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
platelet	NOUN	O	B-Entity
aggregation	NOUN	O	I-Entity
test	NOUN	O	O
was	VERB	O	O
negative	ADJ	O	O
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
HIT	PROPN	O	I-Entity
antibody	NOUN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
patients	NOUN	O	O
was	VERB	O	O
0.5%	NUM	O	O
preoperatively	ADV	O	O
,	PUNCT	O	O
5.6%	NUM	O	O
on	ADP	O	O
POD	PROPN	O	O
7	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
5.6%	NUM	O	O
on	ADP	O	O
POD	PROPN	O	O
14	NUM	O	O
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
/	SYM	O	O
patients	NOUN	O	O
developed	VERB	O	O
UFH	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
HIT	PROPN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
our	ADJ	O	O
series	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
HIT	PROPN	O	I-Entity
after	ADP	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
was	VERB	O	O
uncommon	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (16418614)

PTU	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
vasculitis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
girl	NOUN	O	O
with	ADP	O	O
Turner	PROPN	O	B-Entity
Syndrome	PROPN	O	I-Entity
and	CCONJ	O	O
Graves	PROPN	O	B-Entity
'	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Palpable	ADJ	O	O
purpura	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
concerning	VERB	O	O
clinical	ADJ	O	O
finding	VERB	O	O
in	ADP	O	O
pediatric	ADJ	O	O
patients	NOUN	O	O
and	CCONJ	O	O
can	VERB	O	O
have	VERB	O	O
many	ADJ	O	O
causes	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
infectious	ADJ	O	O
and	CCONJ	O	O
autoimmune	ADJ	O	O
processes	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
rare	ADJ	O	O
cause	NOUN	O	O
,	PUNCT	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
vasculitis	NOUN	O	I-Entity
,	PUNCT	O	O
may	VERB	O	O
result	VERB	O	O
from	ADP	O	O
the	DET	O	O
production	NOUN	O	O
of	ADP	O	O
antineutrophil	NOUN	O	O
cytoplasmic	ADJ	O	O
antibodies	NOUN	O	O
(	PUNCT	O	O
ANCAs	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
a	DET	O	O
medication	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
girl	NOUN	O	O
with	ADP	O	O
Turner	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
Graves	PROPN	O	B-Entity
'	PART	O	I-Entity
disease	NOUN	O	I-Entity
who	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
palpable	ADJ	O	O
purpuric	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
propylthiouracil	NOUN	O	I-Entity
(	PUNCT	O	O
PTU)-associated	VERB	O	I-Entity
vasculitis	NOUN	O	I-Entity
was	VERB	O	O
made	VERB	O	O
by	ADP	O	O
observation	NOUN	O	O
of	ADP	O	O
consistent	ADJ	O	O
clinical	ADJ	O	O
features	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
elevated	ADJ	O	O
ANA	PROPN	O	O
and	CCONJ	O	O
ANCA	PROPN	O	O
in	ADP	O	O
the	DET	O	O
blood	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
observed	ADJ	O	O
clinical	ADJ	O	O
resolution	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
following	VERB	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
PTU	PROPN	O	I-Entity
.	PUNCT	O	O

Subsequent	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
persistent	ADJ	O	O
hyperthyroidism	NOUN	O	I-Entity
with	ADP	O	O
radioablation	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
result	VERB	O	O
in	ADP	O	O
an	DET	O	O
exacerbation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
vasculitis	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
complication	NOUN	O	O
described	VERB	O	O
in	ADP	O	O
prior	ADJ	O	O
case	NOUN	O	O
reports	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15893386)

Succinylcholine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
masseter	NOUN	O	B-Entity
muscle	NOUN	O	I-Entity
rigidity	NOUN	O	I-Entity
during	ADP	O	O
bronchoscopic	NOUN	O	O
removal	NOUN	O	O
of	ADP	O	O
a	DET	O	O
tracheal	ADJ	O	O
foreign	ADJ	O	O
body	NOUN	O	O
.	PUNCT	O	O

Masseter	NOUN	O	B-Entity
muscle	NOUN	O	I-Entity
rigidity	NOUN	O	I-Entity
during	ADP	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
is	VERB	O	O
considered	VERB	O	O
an	DET	O	O
early	ADJ	O	O
warning	NOUN	O	O
sign	NOUN	O	O
of	ADP	O	O
a	DET	O	O
possible	ADJ	O	O
episode	NOUN	O	O
of	ADP	O	O
malignant	ADJ	O	B-Entity
hyperthermia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
decision	NOUN	O	O
whether	ADP	O	O
to	PART	O	O
continue	VERB	O	O
or	CCONJ	O	O
discontinue	VERB	O	O
the	DET	O	O
procedure	NOUN	O	O
depends	VERB	O	O
on	ADP	O	O
the	DET	O	O
urgency	NOUN	O	O
of	ADP	O	O
the	DET	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
masseter	NOUN	O	B-Entity
muscle	NOUN	O	I-Entity
rigidity	NOUN	O	I-Entity
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
describe	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
masseter	NOUN	O	B-Entity
muscle	NOUN	O	I-Entity
rigidity	NOUN	O	I-Entity
(	PUNCT	O	O
jaw	NOUN	O	B-Entity
of	ADP	O	I-Entity
steel	NOUN	O	I-Entity
)	PUNCT	O	O
after	ADP	O	O
succinylcholine	NOUN	O	I-Entity
(	PUNCT	O	O
Sch	PROPN	O	I-Entity
)	PUNCT	O	O
administration	NOUN	O	O
during	ADP	O	O
general	ADJ	O	O
anesthetic	NOUN	O	O
management	NOUN	O	O
for	ADP	O	O
rigid	ADJ	O	O
bronchoscopic	NOUN	O	O
removal	NOUN	O	O
of	ADP	O	O
a	DET	O	O
tracheal	ADJ	O	O
foreign	ADJ	O	O
body	NOUN	O	O
.	PUNCT	O	O

Anesthesia	NOUN	O	O
was	VERB	O	O
continued	VERB	O	O
uneventfully	ADV	O	O
with	ADP	O	O
propofol	NOUN	O	I-Entity
infusion	NOUN	O	O
while	ADP	O	O
all	DET	O	O
facilities	NOUN	O	O
were	VERB	O	O
available	ADJ	O	O
to	PART	O	O
detect	VERB	O	O
and	CCONJ	O	O
treat	VERB	O	O
malignant	ADJ	O	B-Entity
hyperthermia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15814210)

Minor	ADJ	O	O
neurological	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
cognitive	ADJ	O	O
development	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
somatic	ADJ	O	O
development	NOUN	O	O
at	ADP	O	O
the	DET	O	O
age	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
to	PART	O	O
7	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
dexamethasone	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
very	ADV	O	O
-	PUNCT	O	O
low	ADJ	O	O
birth	NOUN	O	O
-	PUNCT	O	O
weight	NOUN	O	O
infants	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	VERB	O	O
minor	ADJ	O	O
neurological	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
,	PUNCT	O	O
cognitive	ADJ	O	O
development	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
somatic	ADJ	O	O
development	NOUN	O	O
after	ADP	O	O
dexamethasone	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
very	ADV	O	O
-	PUNCT	O	O
low	ADJ	O	O
-	PUNCT	O	O
birthweight	NOUN	O	O
infants	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
three	NUM	O	O
children	NOUN	O	O
after	ADP	O	O
dexamethasone	NOUN	O	I-Entity
treatment	NOUN	O	O
were	VERB	O	O
matched	VERB	O	O
to	ADP	O	O
33	NUM	O	O
children	NOUN	O	O
without	ADP	O	O
dexamethasone	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Dexamethasone	PROPN	O	I-Entity
was	VERB	O	O
started	VERB	O	O
between	ADP	O	O
the	DET	O	O
7th	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
28th	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
over	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
with	ADP	O	O
a	DET	O	O
total	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
2.35	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
.	PUNCT	O	O

Exclusion	NOUN	O	O
criteria	NOUN	O	O
were	VERB	O	O
asphyxia	ADJ	O	I-Entity
,	PUNCT	O	O
malformations	NOUN	O	I-Entity
,	PUNCT	O	O
major	ADJ	O	O
surgical	ADJ	O	O
interventions	NOUN	O	O
,	PUNCT	O	O
small	ADJ	O	O
for	ADP	O	O
gestational	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
intraventricular	ADJ	O	O
haemorrhage	NOUN	O	I-Entity
grades	NOUN	O	O
III	PROPN	O	O
and	CCONJ	O	O
IV	PROPN	O	O
,	PUNCT	O	O
periventricular	ADJ	O	B-Entity
leukomalacia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
severe	ADJ	O	O
psychomotor	NOUN	O	B-Entity
retardation	NOUN	O	I-Entity
.	PUNCT	O	O

Each	DET	O	O
child	NOUN	O	O
was	VERB	O	O
examined	VERB	O	O
by	ADP	O	O
a	DET	O	O
neuropediatrician	ADJ	O	O
for	ADP	O	O
minor	ADJ	O	O
neurological	ADJ	O	B-Entity
dysfunctions	NOUN	O	I-Entity
and	CCONJ	O	O
tested	VERB	O	O
by	ADP	O	O
a	DET	O	O
psychologist	NOUN	O	O
for	ADP	O	O
cognitive	ADJ	O	O
development	NOUN	O	O
with	ADP	O	O
a	DET	O	O
Kaufman	PROPN	O	O
Assessment	PROPN	O	O
Battery	PROPN	O	O
for	ADP	O	O
Children	PROPN	O	O
and	CCONJ	O	O
a	DET	O	O
Draw	PROPN	O	O
-	PUNCT	O	O
a	DET	O	O
-	PUNCT	O	O
Man	PROPN	O	O
Test	PROPN	O	O
.	PUNCT	O	O

After	ADP	O	O
dexamethasone	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
children	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
minor	ADJ	O	O
neurological	ADJ	O	B-Entity
dysfunctions	NOUN	O	I-Entity
.	PUNCT	O	O

Further	ADV	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
studies	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
necessary	ADJ	O	O
to	PART	O	O
fully	ADV	O	O
evaluate	VERB	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
dexamethasone	NOUN	O	I-Entity
on	ADP	O	O
neurological	ADJ	O	O
and	CCONJ	O	O
cognitive	ADJ	O	O
development	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11912119)

Force	PROPN	O	O
overflow	NOUN	O	O
and	CCONJ	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
assessed	VERB	O	O
force	NOUN	O	O
coordination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hand	NOUN	O	O
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
relationship	NOUN	O	O
to	ADP	O	O
motor	NOUN	O	O
complications	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
to	ADP	O	O
levodopa	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
(	PUNCT	O	O
LID	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
two	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
(	PUNCT	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
+	CCONJ	O	O
LID	NOUN	O	I-Entity
,	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
23	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
without	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
(	PUNCT	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
-	PUNCT	O	O
LID	PROPN	O	I-Entity
,	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
age	NOUN	O	O
-	PUNCT	O	O
matched	VERB	O	O
healthy	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
motor	NOUN	O	O
score	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Unified	PROPN	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
Disease	PROPN	O	I-Entity
Rating	PROPN	O	O
Scale	PROPN	O	O
,	PUNCT	O	O
a	DET	O	O
dyskinesia	NOUN	O	I-Entity
score	NOUN	O	O
and	CCONJ	O	O
force	NOUN	O	O
in	ADP	O	O
a	DET	O	O
grip	NOUN	O	O
-	PUNCT	O	O
lift	NOUN	O	O
paradigm	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
ON	PROPN	O	O
and	CCONJ	O	O
OFF	PROPN	O	O
levodopa	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
pathological	ADJ	O	O
increase	NOUN	O	O
of	ADP	O	O
forces	NOUN	O	O
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
ON	PROPN	O	O
-	PUNCT	O	O
state	NOUN	O	O
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
+	CCONJ	O	O
LID	NOUN	O	I-Entity
only	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
+	CCONJ	O	O
LID	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
force	NOUN	O	O
involved	VERB	O	O
in	ADP	O	O
pressing	VERB	O	O
down	PART	O	O
the	DET	O	O
object	NOUN	O	O
before	ADP	O	O
lifting	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
by	ADP	O	O
levodopa	NOUN	O	I-Entity
(	PUNCT	O	O
by	ADP	O	O
61%	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
excessive	ADJ	O	O
force	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
-	PUNCT	O	O
LID	PROPN	O	I-Entity
.	PUNCT	O	O

Peak	PROPN	O	O
grip	NOUN	O	O
force	NOUN	O	O
in	ADP	O	O
ON	PROPN	O	O
-	PUNCT	O	O
state	NOUN	O	O
was	VERB	O	O
140%	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
higher	ADJ	O	O
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
+	CCONJ	O	O
LID	NOUN	O	I-Entity
than	ADP	O	O
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
-	PUNCT	O	O
LID	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
static	ADJ	O	O
grip	NOUN	O	O
force	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
by	ADP	O	O
138%	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Severity	NOUN	O	O
of	ADP	O	O
peak	NOUN	O	O
-	PUNCT	O	O
dose	NOUN	O	O
dyskinesias	NOUN	O	I-Entity
was	VERB	O	O
strongly	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
grip	NOUN	O	O
force	NOUN	O	O
in	ADP	O	O
ON	PROPN	O	O
-	PUNCT	O	O
state	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.79	NUM	O	O
with	ADP	O	O
peak	NOUN	O	O
force	NOUN	O	O
,	PUNCT	O	O
P	PROPN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Force	PROPN	O	O
excess	NOUN	O	O
was	VERB	O	O
only	ADV	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
LID	PROPN	O	I-Entity
and	CCONJ	O	O
motor	NOUN	O	O
fluctuations	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
close	ADJ	O	O
relationship	NOUN	O	O
was	VERB	O	O
seen	VERB	O	O
between	ADP	O	O
the	DET	O	O
overshooting	NOUN	O	O
of	ADP	O	O
forces	NOUN	O	O
and	CCONJ	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
ON	PROPN	O	O
-	PUNCT	O	O
drug	NOUN	O	O
condition	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
postulate	VERB	O	O
that	ADP	O	O
both	DET	O	O
LID	PROPN	O	I-Entity
and	CCONJ	O	O
grip	NOUN	O	O
force	NOUN	O	O
excess	ADJ	O	O
share	NOUN	O	O
common	ADJ	O	O
pathophysiological	ADJ	O	O
mechanisms	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
motor	NOUN	O	O
fluctuations	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9105126)

Postinfarction	PROPN	O	O
ventricular	ADJ	O	B-Entity
septal	ADJ	O	I-Entity
defect	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
steroid	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
postinfarction	NOUN	O	O
ventricular	ADJ	O	B-Entity
septal	NOUN	O	I-Entity
rupture	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
steroid	NOUN	O	I-Entity
therapy	NOUN	O	O
are	VERB	O	O
presented	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
favourable	ADJ	O	O
outcome	NOUN	O	O
in	ADP	O	O
both	DET	O	O
cases	NOUN	O	O
described	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
possible	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
steroid	NOUN	O	I-Entity
therapy	NOUN	O	O
and	CCONJ	O	O
subsequent	ADJ	O	O
postinfarction	NOUN	O	O
septal	ADJ	O	B-Entity
rupture	NOUN	O	I-Entity
is	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (8599504)

Angioedema	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
droperidol	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Angioedema	PROPN	O	I-Entity
,	PUNCT	O	O
also	ADV	O	O
known	VERB	O	O
as	ADP	O	O
angioneurotic	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
or	CCONJ	O	O
Quincke	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
demarcated	VERB	O	O
,	PUNCT	O	O
localized	VERB	O	O
edema	NOUN	O	I-Entity
involving	VERB	O	O
the	DET	O	O
subcutaneous	ADJ	O	O
tissues	NOUN	O	O
that	ADJ	O	O
may	VERB	O	O
cause	VERB	O	O
upper	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
airway	NOUN	O	I-Entity
obstruction	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
previously	ADV	O	O
healthy	ADJ	O	O
19-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
no	DET	O	O
known	VERB	O	O
drug	NOUN	O	B-Entity
allergies	NOUN	O	I-Entity
in	ADP	O	O
whom	NOUN	O	O
angioedema	VERB	O	I-Entity
with	ADP	O	O
significant	ADJ	O	O
tongue	NOUN	O	B-Entity
swelling	VERB	O	I-Entity
and	CCONJ	O	O
protrusion	NOUN	O	O
developed	VERB	O	O
within	ADP	O	O
10	NUM	O	O
minutes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
IV	PROPN	O	O
dose	NOUN	O	O
of	ADP	O	O
droperidol	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8546130)

Clarithromycin	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
visual	ADJ	O	B-Entity
hallucinations	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
on	ADP	O	O
continuous	ADJ	O	O
ambulatory	ADJ	O	O
peritoneal	NOUN	O	O
dialysis	NOUN	O	O
.	PUNCT	O	O

Visual	ADJ	O	B-Entity
hallucinations	NOUN	O	I-Entity
are	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
event	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
not	ADV	O	O
related	VERB	O	O
to	ADP	O	O
uremia	NOUN	O	I-Entity
per	X	O	O
se	X	O	O
.	PUNCT	O	O

Unreported	PROPN	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
is	VERB	O	O
visual	ADJ	O	B-Entity
hallucinations	NOUN	O	I-Entity
occurring	VERB	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
the	DET	O	O
new	ADJ	O	O
macrolide	NOUN	O	I-Entity
antibiotic	NOUN	O	O
,	PUNCT	O	O
clarithromycin	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
such	ADJ	O	O
a	DET	O	O
case	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
end	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
renal	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
ESRD	PROPN	O	I-Entity
)	PUNCT	O	O
maintained	VERB	O	O
on	ADP	O	O
continuous	ADJ	O	O
ambulatory	ADJ	O	O
peritoneal	NOUN	O	O
dialysis	NOUN	O	O
(	PUNCT	O	O
CAPD	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
a	DET	O	O
relatively	ADV	O	O
high	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
clarithromycin	NOUN	O	I-Entity
in	ADP	O	O
face	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
functionally	ADV	O	O
anephric	ADJ	O	O
patient	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
underlying	ADJ	O	O
aluminum	NOUN	O	I-Entity
intoxication	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
have	VERB	O	O
facilitated	VERB	O	O
the	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
this	DET	O	O
neurotoxic	ADJ	O	I-Entity
side	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
important	ADJ	O	O
to	PART	O	O
understand	VERB	O	O
the	DET	O	O
pharmacokinetics	NOUN	O	O
of	ADP	O	O
medications	NOUN	O	O
in	ADP	O	O
face	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
interactions	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
how	ADV	O	O
these	DET	O	O
factors	NOUN	O	O
should	VERB	O	O
help	VERB	O	O
guide	VERB	O	O
medication	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ESRD	PROPN	O	I-Entity
patient	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7724492)

Acute	PROPN	O	O
renal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
adriamycin)-loaded	VERB	O	I-Entity
cyanoacrylate	NOUN	O	I-Entity
nanoparticles	NOUN	O	O
.	PUNCT	O	O

Acute	PROPN	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
loaded	VERB	O	O
nanoparticle	NOUN	O	O
(	PUNCT	O	O
DXNP	PROPN	O	O
)	PUNCT	O	O
renal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
was	VERB	O	O
explored	VERB	O	O
in	ADP	O	O
both	DET	O	O
normal	ADJ	O	O
rats	NOUN	O	O
and	CCONJ	O	O
rats	NOUN	O	O
with	ADP	O	O
experimental	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
normal	ADJ	O	O
rats	NOUN	O	O
,	PUNCT	O	O
2/6	NUM	O	O
rats	NOUN	O	O
given	VERB	O	O
free	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
DX	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
died	VERB	O	O
within	ADP	O	O
one	NUM	O	O
week	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
all	DET	O	O
control	NOUN	O	O
animals	NOUN	O	O
and	CCONJ	O	O
all	DET	O	O
rats	NOUN	O	O
having	VERB	O	O
received	VERB	O	O
free	ADJ	O	O
NP	PROPN	O	O
or	CCONJ	O	O
DXNP	PROPN	O	O
survived	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
3	NUM	O	O
times	NOUN	O	O
higher	ADJ	O	O
proteinuria	NOUN	O	I-Entity
appeared	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
DXNP	PROPN	O	O
than	ADP	O	O
in	ADP	O	O
those	DET	O	O
treated	VERB	O	O
with	ADP	O	O
DX	PROPN	O	I-Entity
.	PUNCT	O	O

Free	ADJ	O	O
NP	PROPN	O	O
did	VERB	O	O
not	ADV	O	O
provoke	VERB	O	O
any	DET	O	O
proteinuria	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
hr	ADJ	O	O
post	NOUN	O	O
-	PUNCT	O	O
injection	NOUN	O	O
,	PUNCT	O	O
DXNP	PROPN	O	O
was	VERB	O	O
2.7	NUM	O	O
times	NOUN	O	O
more	ADV	O	O
concentrated	ADJ	O	O
in	ADP	O	O
kidneys	NOUN	O	O
than	ADP	O	O
free	ADJ	O	O
DX	PROPN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.025	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
immune	ADJ	O	O
experimental	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
,	PUNCT	O	O
5/6	NUM	O	O
rats	NOUN	O	O
given	VERB	O	O
DX	PROPN	O	I-Entity
died	VERB	O	O
within	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
animals	NOUN	O	O
treated	VERB	O	O
by	ADP	O	O
DXNP	PROPN	O	O
,	PUNCT	O	O
NP	PROPN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
untreated	ADJ	O	O
,	PUNCT	O	O
which	ADJ	O	O
all	DET	O	O
survived	VERB	O	O
.	PUNCT	O	O

Proteinuria	PROPN	O	I-Entity
appeared	VERB	O	O
in	ADP	O	O
all	DET	O	O
series	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
2	NUM	O	O
-	SYM	O	O
5	NUM	O	O
times	NOUN	O	O
more	ADV	O	O
intense	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
prolonged	VERB	O	O
after	ADP	O	O
doxorubicin	ADJ	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
400	NUM	O	O
-	SYM	O	O
700	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
without	ADP	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
DXNP	PROPN	O	O
and	CCONJ	O	O
DX	PROPN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
in	ADP	O	O
these	DET	O	O
experimental	ADJ	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
DXNP	PROPN	O	O
killed	VERB	O	O
less	ADJ	O	O
animals	NOUN	O	O
than	ADP	O	O
free	ADJ	O	O
DX	PROPN	O	I-Entity
,	PUNCT	O	O
despite	ADP	O	O
of	ADP	O	O
an	DET	O	O
enhanced	ADJ	O	O
renal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
former	ADJ	O	O
.	PUNCT	O	O

Both	DET	O	O
effects	NOUN	O	O
(	PUNCT	O	O
better	ADJ	O	O
survival	NOUN	O	O
and	CCONJ	O	O
nephrosis	NOUN	O	I-Entity
)	PUNCT	O	O
are	VERB	O	O
most	ADV	O	O
probably	ADV	O	O
related	VERB	O	O
to	ADP	O	O
an	DET	O	O
enhanced	ADJ	O	O
capture	NOUN	O	O
of	ADP	O	O
DXNP	PROPN	O	O
by	ADP	O	O
cells	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mononuclear	NOUN	O	O
phagocyte	NOUN	O	O
system	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
mesangial	ADJ	O	O
cells	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7619765)

Etoposide	ADV	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
is	VERB	O	O
reported	VERB	O	O
after	ADP	O	O
chemotherapy	NOUN	O	O
containing	VERB	O	O
etoposide	ADV	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
man	NOUN	O	O
with	ADP	O	O
no	DET	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
coronary	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7416947)

Subjective	ADJ	O	O
assessment	NOUN	O	O
of	ADP	O	O
sexual	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
of	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
administration	NOUN	O	O
of	ADP	O	O
digoxin	NOUN	O	I-Entity
.	PUNCT	O	O

Various	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
male	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
received	VERB	O	O
digoxin	NOUN	O	I-Entity
on	ADP	O	O
a	DET	O	O
longterm	NOUN	O	O
basis	NOUN	O	O
have	VERB	O	O
increased	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
estrogen	NOUN	O	I-Entity
and	CCONJ	O	O
decreased	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
testosterone	NOUN	O	I-Entity
and	CCONJ	O	O
luteinizing	VERB	O	O
hormone	NOUN	O	O
(	PUNCT	O	O
LH	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
links	NOUN	O	O
between	ADP	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
administration	NOUN	O	O
of	ADP	O	O
digoxin	NOUN	O	I-Entity
therapy	NOUN	O	O
and	CCONJ	O	O
sexual	ADJ	O	O
behavior	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
digoxin	NOUN	O	I-Entity
on	ADP	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
estradiol	NOUN	O	I-Entity
,	PUNCT	O	O
testosterone	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
LH	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
and	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
without	ADP	O	O
digoxin	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
of	ADP	O	O
similar	ADJ	O	O
cardiac	ADJ	O	O
functional	ADJ	O	O
capacity	NOUN	O	O
and	CCONJ	O	O
age	NOUN	O	O
(	PUNCT	O	O
25	NUM	O	O
-	SYM	O	O
40	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
randomly	ADV	O	O
selected	VERB	O	O
from	ADP	O	O
the	DET	O	O
rheumatic	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
findings	NOUN	O	O
support	VERB	O	O
the	DET	O	O
reports	NOUN	O	O
concerning	VERB	O	O
digoxin	ADJ	O	I-Entity
effect	NOUN	O	O
on	ADP	O	O
plasma	NOUN	O	O
estradiol	NOUN	O	I-Entity
,	PUNCT	O	O
testosterone	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
LH	PROPN	O	O
.	PUNCT	O	O

Tests	NOUN	O	O
used	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
sexual	ADJ	O	O
behavior	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	B-Entity
in	ADP	O	I-Entity
sexual	ADJ	O	I-Entity
desire	NOUN	O	I-Entity
,	PUNCT	O	O
sexual	ADJ	O	O
excitement	NOUN	O	O
phase	NOUN	O	O
(	PUNCT	O	O
erection	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
frequency	NOUN	O	O
of	ADP	O	O
sexual	ADJ	O	O
relations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7263204)

Fatal	ADJ	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
indomethacin	NOUN	O	I-Entity
--	PUNCT	O	O
lymphocyte	NOUN	O	O
transformation	NOUN	O	O
tests	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
indomethacin	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
implicated	VERB	O	O
as	ADP	O	O
a	DET	O	O
possible	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
a	DET	O	O
few	ADJ	O	O
clinical	ADJ	O	O
observations	NOUN	O	O
,	PUNCT	O	O
its	ADJ	O	O
role	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
definitely	ADV	O	O
established	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
fatal	ADJ	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
is	VERB	O	O
described	VERB	O	O
in	ADP	O	O
which	ADJ	O	O
no	DET	O	O
drugs	NOUN	O	O
other	ADJ	O	O
than	ADP	O	O
allopurinol	NOUN	O	I-Entity
and	CCONJ	O	O
indomethacin	NOUN	O	I-Entity
were	VERB	O	O
given	VERB	O	O
.	PUNCT	O	O

Indomethacin	PROPN	O	I-Entity
was	VERB	O	O
first	ADV	O	O
given	VERB	O	O
four	NUM	O	O
weeks	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
positive	ADJ	O	O
lymphocyte	NOUN	O	O
transformation	NOUN	O	O
test	NOUN	O	O
with	ADP	O	O
indomethacin	NOUN	O	I-Entity
in	ADP	O	O
vitro	NOUN	O	O
further	ADV	O	O
substantiates	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
in	ADP	O	O
causing	VERB	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
susceptible	ADJ	O	O
patient	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7066357)

Plasma	PROPN	O	O
and	CCONJ	O	O
urinary	ADJ	O	O
lipids	NOUN	O	O
and	CCONJ	O	O
lipoproteins	NOUN	O	O
during	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
induced	VERB	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
by	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
ascertain	VERB	O	O
whether	ADP	O	O
the	DET	O	O
alterations	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
lipoproteins	NOUN	O	O
found	VERB	O	O
in	ADP	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
were	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
per	X	O	O
se	X	O	O
,	PUNCT	O	O
or	CCONJ	O	O
,	PUNCT	O	O
at	ADP	O	O
least	ADJ	O	O
in	ADP	O	O
part	NOUN	O	O
,	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
aminonucleoside	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
and	CCONJ	O	O
urinary	ADJ	O	O
lipoproteins	NOUN	O	O
during	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
subsequent	ADJ	O	O
development	NOUN	O	O
of	ADP	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Since	ADP	O	O
massive	ADJ	O	O
albuminuria	NOUN	O	I-Entity
occurred	VERB	O	O
after	ADP	O	O
6	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
time	NOUN	O	O
-	PUNCT	O	O
course	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
two	NUM	O	O
stages	NOUN	O	O
:	PUNCT	O	O
pre	NOUN	O	O
-	PUNCT	O	O
nephrotic	ADJ	O	I-Entity
stage	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
1	NUM	O	O
-	SYM	O	O
5	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
nephrotic	ADJ	O	I-Entity
stage	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
6	NUM	O	O
-	PUNCT	O	O
11	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
nephrotic	ADJ	O	I-Entity
stage	NOUN	O	O
the	DET	O	O
plasma	NOUN	O	O
level	NOUN	O	O
of	ADP	O	O
fatty	ADJ	O	B-Entity
acids	NOUN	O	I-Entity
,	PUNCT	O	O
triacylglycerol	NOUN	O	I-Entity
and	CCONJ	O	O
VLDL	PROPN	O	O
decreased	VERB	O	O
while	ADP	O	O
that	DET	O	O
of	ADP	O	O
phospholipid	NOUN	O	O
,	PUNCT	O	O
cholesteryl	NOUN	O	B-Entity
esters	NOUN	O	I-Entity
and	CCONJ	O	O
HDL	PROPN	O	O
remained	VERB	O	O
constant	ADJ	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
beginning	NOUN	O	O
of	ADP	O	O
nephrotic	ADJ	O	I-Entity
stage	NOUN	O	O
(	PUNCT	O	O
day	NOUN	O	O
6	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
albumin	NOUN	O	O
dropped	VERB	O	O
to	ADP	O	O
a	DET	O	O
very	ADV	O	O
low	ADJ	O	O
level	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
that	DET	O	O
of	ADP	O	O
apolipoprotein	NOUN	O	O
A	PROPN	O	O
-	PUNCT	O	O
I	PRON	O	O
increased	VERB	O	O
abruptly	ADV	O	O
(	PUNCT	O	O
4-fold	ADJ	O	O
increase	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
continued	VERB	O	O
to	PART	O	O
rise	VERB	O	O
,	PUNCT	O	O
although	ADP	O	O
less	ADV	O	O
steeply	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
following	VERB	O	O
days	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
pre	NOUN	O	O
-	PUNCT	O	O
nephrotic	ADJ	O	I-Entity
stage	NOUN	O	O
lipoproteinuria	NOUN	O	O
was	VERB	O	O
negligible	ADJ	O	O
,	PUNCT	O	O
while	ADP	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
nephrotic	ADJ	O	I-Entity
stage	NOUN	O	O
the	DET	O	O
urinary	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
lipoproteins	NOUN	O	O
consisted	VERB	O	O
mainly	ADV	O	O
of	ADP	O	O
HDL	PROPN	O	O
.	PUNCT	O	O

These	DET	O	O
observations	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
alters	VERB	O	O
plasma	NOUN	O	O
lipoproteins	NOUN	O	O
by	ADP	O	O
lowering	VERB	O	O
VLDL	PROPN	O	O
and	CCONJ	O	O
increasing	VERB	O	O
HDL	PROPN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
likely	ADJ	O	O
that	ADP	O	O
the	DET	O	O
early	ADJ	O	O
and	CCONJ	O	O
striking	ADJ	O	O
increase	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
HDL	PROPN	O	O
found	VERB	O	O
in	ADP	O	O
nephrotic	ADJ	O	I-Entity
rats	NOUN	O	O
is	VERB	O	O
related	VERB	O	O
to	ADP	O	O
a	DET	O	O
direct	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
on	ADP	O	O
HDL	PROPN	O	O
metabolism	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7007443)

Circulating	VERB	O	O
lysosomal	ADJ	O	O
enzymes	NOUN	O	O
and	CCONJ	O	O
acute	ADJ	O	B-Entity
hepatic	ADJ	O	I-Entity
necrosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
activities	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lysosomal	ADJ	O	O
enzymes	NOUN	O	O
acid	NOUN	O	O
and	CCONJ	O	O
neutral	ADJ	O	O
protease	NOUN	O	O
,	PUNCT	O	O
N	PROPN	O	O
-	PUNCT	O	O
acetylglucosaminidase	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
acid	NOUN	O	O
phosphatase	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
fulminant	ADJ	O	B-Entity
hepatic	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

(	PUNCT	O	O
cathepsin	NOUN	O	O
D	PROPN	O	O
)	PUNCT	O	O
activity	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
about	ADP	O	O
tenfold	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
died	VERB	O	O
and	CCONJ	O	O
nearly	ADV	O	O
fourfold	VERB	O	O
in	ADP	O	O
those	DET	O	O
who	NOUN	O	O
survived	VERB	O	O
fulminant	ADJ	O	B-Entity
hepatic	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
paracetamol	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
activities	NOUN	O	O
were	VERB	O	O
increased	VERB	O	O
equally	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
fulminant	ADJ	O	B-Entity
hepatic	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
viral	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
whether	ADP	O	O
or	CCONJ	O	O
not	ADV	O	O
they	PRON	O	O
survived	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
correlation	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
serum	NOUN	O	O
acid	NOUN	O	O
protease	NOUN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
prothrombin	NOUN	O	O
time	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
cathepsin	NOUN	O	O
D	NOUN	O	O
activity	NOUN	O	O
was	VERB	O	O
sustained	VERB	O	O
over	ADP	O	O
several	ADJ	O	O
days	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
aspartate	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
showed	VERB	O	O
a	DET	O	O
sharp	ADJ	O	O
early	ADJ	O	O
peak	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
a	DET	O	O
fall	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3762968)

Transketolase	PROPN	O	O
abnormality	NOUN	O	O
in	ADP	O	O
tolazamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
Wernicke	PROPN	O	B-Entity
's	PART	O	I-Entity
encephalopathy	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
a	DET	O	O
thiamine	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
enzyme	NOUN	O	O
,	PUNCT	O	O
transketolase	NOUN	O	O
,	PUNCT	O	O
from	ADP	O	O
fibroblasts	NOUN	O	O
of	ADP	O	O
a	DET	O	O
diabetic	ADJ	O	I-Entity
patient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
Wernicke	PROPN	O	B-Entity
's	PART	O	I-Entity
encephalopathy	NOUN	O	I-Entity
when	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
tolazamide	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
delineate	VERB	O	O
if	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
also	ADV	O	O
had	VERB	O	O
transketolase	VERB	O	O
abnormality	NOUN	O	O
[	PUNCT	O	O
high	ADJ	O	O
Km	PROPN	O	O
for	ADP	O	O
thiamine	NOUN	O	B-Entity
pyrophosphate	NOUN	O	I-Entity
(	PUNCT	O	O
TPP	PROPN	O	I-Entity
)	PUNCT	O	O
]	PUNCT	O	O
,	PUNCT	O	O
as	ADP	O	O
previously	ADV	O	O
reported	VERB	O	O
in	ADP	O	O
postalcoholic	ADJ	O	O
Wernicke	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Korsakoff	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
also	ADV	O	O
studied	VERB	O	O
this	DET	O	O
enzyme	NOUN	O	O
from	ADP	O	O
three	NUM	O	O
diabetic	ADJ	O	I-Entity
kindreds	NOUN	O	O
without	ADP	O	O
any	DET	O	O
history	NOUN	O	O
of	ADP	O	O
Wernicke	PROPN	O	B-Entity
's	PART	O	I-Entity
encephalopathy	NOUN	O	I-Entity
and	CCONJ	O	O
from	ADP	O	O
four	NUM	O	O
normal	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
that	ADP	O	O
the	DET	O	O
above	ADV	O	O
-	PUNCT	O	O
mentioned	VERB	O	O
patient	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
diabetic	ADJ	O	I-Entity
kindreds	NOUN	O	O
with	ADP	O	O
no	DET	O	O
history	NOUN	O	O
of	ADP	O	O
Wernicke	PROPN	O	B-Entity
's	PART	O	I-Entity
encephalopathy	NOUN	O	I-Entity
had	VERB	O	O
abnormal	ADJ	O	O
transketolase	NOUN	O	O
as	ADP	O	O
determined	VERB	O	O
by	ADP	O	O
its	ADJ	O	O
Km	PROPN	O	O
for	ADP	O	O
TPP	PROPN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
a	DET	O	O
similarity	NOUN	O	O
between	ADP	O	O
postalcoholic	ADJ	O	O
Wernicke	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Korsakoff	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
tolazamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O

Wernicke	PROPN	O	B-Entity
's	PART	O	I-Entity
encephalopathy	NOUN	O	I-Entity
from	ADP	O	O
the	DET	O	O
standpoint	NOUN	O	O
of	ADP	O	O
transketolase	NOUN	O	O
abnormality	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3413271)

Mechanisms	PROPN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
epinephrine	NOUN	O	I-Entity
:	PUNCT	O	O
comparison	NOUN	O	O
with	ADP	O	O
exercise	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
ischemia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
epinephrine	NOUN	O	I-Entity
in	ADP	O	O
eliciting	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
was	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Objective	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
ischemia	NOUN	O	I-Entity
and	CCONJ	O	O
factors	NOUN	O	O
increasing	VERB	O	O
myocardial	ADJ	O	O
oxygen	NOUN	O	I-Entity
consumption	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
during	ADP	O	O
epinephrine	NOUN	O	I-Entity
infusion	NOUN	O	O
and	CCONJ	O	O
supine	ADJ	O	O
bicycle	NOUN	O	O
exercise	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
epinephrine	NOUN	O	I-Entity
and	CCONJ	O	O
exercise	NOUN	O	O
produced	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
as	ADP	O	O
evidenced	VERB	O	O
by	ADP	O	O
ST	PROPN	O	O
segment	NOUN	O	O
depression	NOUN	O	I-Entity
and	CCONJ	O	O
angina	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
epinephrine	NOUN	O	I-Entity
were	VERB	O	O
significantly	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
those	DET	O	O
of	ADP	O	O
exercise	NOUN	O	O
.	PUNCT	O	O

Exercise	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
was	VERB	O	O
marked	VERB	O	O
predominantly	ADV	O	O
by	ADP	O	O
increased	VERB	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
rate	NOUN	O	O
-	PUNCT	O	O
pressure	NOUN	O	O
product	NOUN	O	O
with	ADP	O	O
a	DET	O	O
minor	ADJ	O	O
contribution	NOUN	O	O
of	ADP	O	O
end	NOUN	O	O
-	PUNCT	O	O
diastolic	NOUN	O	O
volume	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
epinephrine	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ischemia	NOUN	O	I-Entity
was	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
a	DET	O	O
marked	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
contractility	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
less	ADV	O	O
pronounced	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
rate	NOUN	O	O
-	PUNCT	O	O
pressure	NOUN	O	O
product	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
ischemia	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
epinephrine	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
may	VERB	O	O
occur	VERB	O	O
during	ADP	O	O
states	NOUN	O	O
of	ADP	O	O
emotional	ADJ	O	O
distress	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
a	DET	O	O
mechanism	NOUN	O	O
distinct	ADJ	O	O
from	ADP	O	O
that	DET	O	O
due	ADJ	O	O
to	ADP	O	O
physical	ADJ	O	O
exertion	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3088349)

Transient	PROPN	O	O
contralateral	ADJ	O	B-Entity
rotation	NOUN	O	I-Entity
following	VERB	O	O
unilateral	ADJ	O	O
substantia	NOUN	O	B-Entity
nigra	NOUN	O	I-Entity
lesion	NOUN	O	I-Entity
reflects	VERB	O	O
susceptibility	NOUN	O	O
of	ADP	O	O
the	DET	O	O
nigrostriatal	ADJ	O	O
system	NOUN	O	O
to	ADP	O	O
exhaustion	NOUN	O	O
by	ADP	O	O
amphetamine	NOUN	O	I-Entity
.	PUNCT	O	O

Following	VERB	O	O
unilateral	ADJ	O	O
6-OHDA	PROPN	O	I-Entity
induced	VERB	O	O
SN	PROPN	O	B-Entity
lesion	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
transient	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
contralateral	ADJ	O	B-Entity
rotation	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
precede	VERB	O	O
the	DET	O	O
predominant	ADJ	O	O
ipsilateral	ADJ	O	B-Entity
circling	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
clarify	VERB	O	O
the	DET	O	O
nature	NOUN	O	O
of	ADP	O	O
this	DET	O	O
initial	ADJ	O	O
contralateral	ADJ	O	B-Entity
rotation	NOUN	O	I-Entity
we	PRON	O	O
examined	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
recovery	NOUN	O	O
period	NOUN	O	O
after	ADP	O	O
the	DET	O	O
lesion	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rotational	ADJ	O	B-Entity
behavior	NOUN	O	I-Entity
.	PUNCT	O	O

Such	ADJ	O	O
contralateral	ADJ	O	B-Entity
rotation	NOUN	O	I-Entity
may	VERB	O	O
result	VERB	O	O
from	ADP	O	O
either	DET	O	O
degeneration	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
breakdown	NOUN	O	O
of	ADP	O	O
the	DET	O	O
DA	PROPN	O	O
pool	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
lesion	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
increase	NOUN	O	O
of	ADP	O	O
DA	PROPN	O	O
turnover	NOUN	O	O
in	ADP	O	O
the	DET	O	O
spared	VERB	O	O
neurons	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
substantial	ADJ	O	O
degree	NOUN	O	O
of	ADP	O	O
contralateral	ADJ	O	O
preference	NOUN	O	O
was	VERB	O	O
still	ADV	O	O
evident	ADJ	O	O
when	ADV	O	O
amphetamine	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
24	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
lesioning	VERB	O	O
,	PUNCT	O	O
indicating	VERB	O	O
involvement	NOUN	O	O
of	ADP	O	O
spared	VERB	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
contralateral	ADJ	O	B-Entity
rotation	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
regardless	ADV	O	O
of	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
recovery	NOUN	O	O
(	PUNCT	O	O
and	CCONJ	O	O
irrespective	ADV	O	O
of	ADP	O	O
either	DET	O	O
lesion	NOUN	O	O
volume	NOUN	O	O
,	PUNCT	O	O
amphetamine	NOUN	O	I-Entity
dose	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
post	VERB	O	O
-	PUNCT	O	O
lesion	NOUN	O	O
motor	NOUN	O	O
exercise	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rotation	NOUN	O	I-Entity
tended	VERB	O	O
to	PART	O	O
become	VERB	O	O
gradually	ADV	O	O
more	ADJ	O	O
ipsilateral	ADJ	O	O
as	ADP	O	O
the	DET	O	O
observation	NOUN	O	O
session	NOUN	O	O
progressed	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
all	DET	O	O
rats	NOUN	O	O
circled	VERB	O	O
ipsilaterally	ADV	O	O
to	ADP	O	O
the	DET	O	O
lesion	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
further	ADJ	O	O
amphetamine	NOUN	O	I-Entity
injections	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
amphetamine	NOUN	O	I-Entity
has	VERB	O	O
an	DET	O	O
irreversible	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
post	NOUN	O	O
-	PUNCT	O	O
lesion	NOUN	O	O
DA	PROPN	O	O
pool	NOUN	O	O
contributing	VERB	O	O
to	ADP	O	O
contralateral	ADJ	O	B-Entity
rotation	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3001299)

Thyroid	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
-	PUNCT	O	O
concentrating	VERB	O	O
ability	NOUN	O	O
during	ADP	O	O
lithium	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
been	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
adenylate	VERB	O	O
cyclase	NOUN	O	O
inhibition	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
important	ADJ	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
both	DET	O	O
nephrogenic	ADJ	O	B-Entity
diabetes	NOUN	O	I-Entity
insipidus	VERB	O	I-Entity
and	CCONJ	O	O
hypothyroidism	NOUN	O	I-Entity
during	ADP	O	O
lithium	ADJ	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
measured	VERB	O	O
serum	NOUN	O	O
thyroxine	NOUN	O	I-Entity
and	CCONJ	O	O
urine	NOUN	O	O
-	PUNCT	O	O
concentrating	VERB	O	O
ability	NOUN	O	O
(	PUNCT	O	O
Umax	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
desmopressin	NOUN	O	O
(	PUNCT	O	O
DDAVP	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
85	NUM	O	O
patients	NOUN	O	O
receiving	VERB	O	O
lithium	NOUN	O	I-Entity
.	PUNCT	O	O

Hypothyroidism	PROPN	O	I-Entity
developed	VERB	O	O
in	ADP	O	O
eight	NUM	O	O
patients	NOUN	O	O
while	ADP	O	O
they	PRON	O	O
were	VERB	O	O
taking	VERB	O	O
lithium	NOUN	O	I-Entity
.	PUNCT	O	O

Impaired	ADJ	O	O
Umax	PROPN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
both	DET	O	O
euthyroid	NOUN	O	O
and	CCONJ	O	O
hypothyroid	ADJ	O	I-Entity
patients	NOUN	O	O
while	ADP	O	O
some	DET	O	O
hypothyroid	ADJ	O	I-Entity
patients	NOUN	O	O
concentrated	VERB	O	O
their	ADJ	O	O
urine	NOUN	O	O
well	ADV	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
the	DET	O	O
dominant	ADJ	O	O
mechanisms	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
lithium	NOUN	O	I-Entity
exerts	VERB	O	O
these	DET	O	O
two	NUM	O	O
effects	NOUN	O	O
are	VERB	O	O
different	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (2004015)

Sensitivity	NOUN	O	O
of	ADP	O	O
erythroid	ADJ	O	O
progenitor	NOUN	O	O
colonies	NOUN	O	O
to	ADP	O	O
erythropoietin	NOUN	O	O
in	ADP	O	O
azidothymidine	NOUN	O	I-Entity
treated	VERB	O	O
immunodeficient	NOUN	O	I-Entity
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
anaemia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
3'-azido-3'dideoxythymidine	NUM	O	I-Entity
(	PUNCT	O	O
AZT	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
poorly	ADV	O	O
understood	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
used	VERB	O	O
a	DET	O	O
murine	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
AIDS	PROPN	O	I-Entity
,	PUNCT	O	O
infection	NOUN	O	I-Entity
of	ADP	O	O
female	ADJ	O	O
C57BL/6	PROPN	O	O
mice	NOUN	O	O
with	ADP	O	O
LP	PROPN	O	O
-	PUNCT	O	O
BM5	PROPN	O	O
murine	NOUN	O	O
leukaemia	NOUN	O	I-Entity
(	PUNCT	O	O
MuLV	PROPN	O	O
)	PUNCT	O	O
virus	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
determine	VERB	O	O
if	ADP	O	O
AZT	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anaemia	NOUN	O	I-Entity
is	VERB	O	O
due	ADJ	O	O
,	PUNCT	O	O
in	ADP	O	O
part	NOUN	O	O
,	PUNCT	O	O
to	ADP	O	O
decreased	VERB	O	O
responsiveness	NOUN	O	O
of	ADP	O	O
erythropoietic	ADJ	O	O
precursors	NOUN	O	O
(	PUNCT	O	O
BFU	PROPN	O	O
-	PUNCT	O	O
e	PROPN	O	O
)	PUNCT	O	O
to	ADP	O	O
erythropoietin	NOUN	O	O
(	PUNCT	O	O
EPO	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mice	NOUN	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
stage	NOUN	O	O
of	ADP	O	O
LP	PROPN	O	O
-	PUNCT	O	O
BM5	PROPN	O	O
MuLV	PROPN	O	O
disease	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
AZT	PROPN	O	I-Entity
in	ADP	O	O
their	ADJ	O	O
drinking	NOUN	O	O
water	NOUN	O	O
at	ADP	O	O
1.0	NUM	O	O
and	CCONJ	O	O
2.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
ml	NOUN	O	O
.	PUNCT	O	O

AZT	PROPN	O	I-Entity
produced	VERB	O	O
anaemia	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
fashion	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
the	DET	O	O
anaemia	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
splenic	NOUN	O	O
and	CCONJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
BFU	PROPN	O	O
-	PUNCT	O	O
e	PROPN	O	O
in	ADP	O	O
AZT	PROPN	O	I-Entity
treated	VERB	O	O
mice	NOUN	O	O
increased	VERB	O	O
up	PART	O	O
to	ADP	O	O
five	NUM	O	O
-	PUNCT	O	O
fold	NOUN	O	O
over	ADP	O	O
levels	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
infected	VERB	O	O
untreated	ADJ	O	O
animals	NOUN	O	O
after	ADP	O	O
15	NUM	O	O
d	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Colony	PROPN	O	O
formation	NOUN	O	O
by	ADP	O	O
splenic	NOUN	O	O
and	CCONJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
BFUe	NOUN	O	O
was	VERB	O	O
stimulated	VERB	O	O
at	ADP	O	O
lower	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
EPO	PROPN	O	O
in	ADP	O	O
mice	NOUN	O	O
receiving	VERB	O	O
AZT	PROPN	O	I-Entity
for	ADP	O	O
15	NUM	O	O
d	NOUN	O	O
than	ADP	O	O
for	ADP	O	O
infected	ADJ	O	O
,	PUNCT	O	O
untreated	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
EPO	PROPN	O	O
observed	VERB	O	O
in	ADP	O	O
AZT	PROPN	O	I-Entity
treated	VERB	O	O
mice	NOUN	O	O
were	VERB	O	O
appropriate	ADJ	O	O
for	ADP	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
anaemia	NOUN	O	I-Entity
observed	VERB	O	O
when	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
phenylhydrazine	NOUN	O	I-Entity
(	PUNCT	O	O
PHZ	PROPN	O	I-Entity
)	PUNCT	O	O
treated	VERB	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
numbers	NOUN	O	O
of	ADP	O	O
BFU	PROPN	O	O
-	PUNCT	O	O
e	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
erythroblasts	NOUN	O	O
observed	VERB	O	O
were	VERB	O	O
comparable	ADJ	O	O
in	ADP	O	O
AZT	PROPN	O	I-Entity
and	CCONJ	O	O
PHZ	PROPN	O	I-Entity
treated	VERB	O	O
mice	NOUN	O	O
with	ADP	O	O
similar	ADJ	O	O
degrees	NOUN	O	O
of	ADP	O	O
anaemia	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
reticulocytosis	NOUN	O	I-Entity
was	VERB	O	O
inappropriate	ADJ	O	O
for	ADP	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
anaemia	NOUN	O	I-Entity
observed	VERB	O	O
in	ADP	O	O
AZT	PROPN	O	I-Entity
treated	VERB	O	O
infected	ADJ	O	O
mice	NOUN	O	O
.	PUNCT	O	O

AZT	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
peripheral	ADJ	O	O
anaemia	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
face	NOUN	O	O
of	ADP	O	O
increased	VERB	O	O
numbers	NOUN	O	O
of	ADP	O	O
BFU	PROPN	O	O
-	PUNCT	O	O
e	PROPN	O	O
and	CCONJ	O	O
increased	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
EPO	PROPN	O	O
suggest	VERB	O	O
a	DET	O	O
lesion	NOUN	O	O
in	ADP	O	O
terminal	ADJ	O	O
differentiation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1732442)

Detection	NOUN	O	O
of	ADP	O	O
abnormal	ADJ	O	O
cardiac	ADJ	O	O
adrenergic	ADJ	O	O
neuron	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
with	ADP	O	O
iodine-125-metaiodobenzylguanidine	PRON	O	I-Entity
.	PUNCT	O	O

Radiolabeled	VERB	O	B-Entity
metaiodobenzylguanidine	NOUN	O	I-Entity
(	PUNCT	O	O
MIBG	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
analog	NOUN	O	O
of	ADP	O	O
norepinephrine	NOUN	O	I-Entity
(	PUNCT	O	O
NE	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
serves	VERB	O	O
as	ADP	O	O
an	DET	O	O
index	NOUN	O	O
of	ADP	O	O
adrenergic	ADJ	O	O
neuron	NOUN	O	O
integrity	NOUN	O	O
and	CCONJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
a	DET	O	O
rat	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
tested	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
abnormal	ADJ	O	O
cardiac	ADJ	O	O
adrenergic	ADJ	O	O
neuron	NOUN	O	O
activity	NOUN	O	O
may	VERB	O	O
appear	VERB	O	O
and	CCONJ	O	O
be	VERB	O	O
exacerbated	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
in	ADP	O	O
adriamycin	ADJ	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
vacuolar	ADJ	O	B-Entity
degeneration	NOUN	O	I-Entity
of	ADP	O	I-Entity
myocardial	ADJ	O	I-Entity
cells	NOUN	O	I-Entity
was	VERB	O	O
analyzed	VERB	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
adriamycin	ADJ	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
,	PUNCT	O	O
once	ADV	O	O
a	DET	O	O
week	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Myocardial	ADJ	O	O
accumulation	NOUN	O	O
of	ADP	O	O
[	PUNCT	O	O
125I]MIBG	NUM	O	I-Entity
4	NUM	O	O
hr	NOUN	O	O
after	ADP	O	O
intravenous	ADJ	O	O
injection	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
between	ADP	O	O
the	DET	O	O
controls	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
groups	NOUN	O	O
treated	VERB	O	O
3	NUM	O	O
wk	NOUN	O	O
or	CCONJ	O	O
less	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
5-wk	NUM	O	O
group	NOUN	O	O
,	PUNCT	O	O
MIBG	PROPN	O	I-Entity
accumulation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
right	NOUN	O	O
and	CCONJ	O	O
left	VERB	O	O
ventricular	ADJ	O	O
wall	NOUN	O	O
was	VERB	O	O
35%	NUM	O	O
and	CCONJ	O	O
27%	NUM	O	O
of	ADP	O	O
that	DET	O	O
in	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
8-wk	NUM	O	O
group	NOUN	O	O
,	PUNCT	O	O
MIBG	PROPN	O	I-Entity
accumulation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
right	NOUN	O	O
and	CCONJ	O	O
left	VERB	O	O
ventricular	ADJ	O	O
wall	NOUN	O	O
was	VERB	O	O
18%	NUM	O	O
and	CCONJ	O	O
14%	NUM	O	O
of	ADP	O	O
that	DET	O	O
in	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
MIBG	PROPN	O	I-Entity
accumulation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
myocardium	NOUN	O	O
decreased	VERB	O	O
in	ADP	O	O
an	DET	O	O
adriamycin	ADJ	O	I-Entity
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
impaired	ADJ	O	O
cardiac	ADJ	O	O
adrenergic	NOUN	O	O
neuron	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
slight	ADJ	O	O
myocardial	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
(	PUNCT	O	O
scattered	VERB	O	O
or	CCONJ	O	O
focal	ADJ	O	O
vacuolar	ADJ	O	B-Entity
degeneration	NOUN	O	I-Entity
)	PUNCT	O	O
indicates	VERB	O	O
that	ADP	O	O
MIBG	PROPN	O	I-Entity
scintigraphy	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
method	NOUN	O	O
for	ADP	O	O
detection	NOUN	O	O
of	ADP	O	O
adriamycin	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1423339)

Amnestic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
propranolol	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
elderly	ADJ	O	O
woman	NOUN	O	O
developed	VERB	O	O
an	DET	O	O
Alzheimer	PROPN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
subacute	NOUN	O	O
dementia	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
evidence	NOUN	O	O
that	ADP	O	O
cerebral	ADJ	O	O
reactions	NOUN	O	O
to	ADP	O	O
drug	NOUN	O	O
toxicity	NOUN	O	I-Entity
can	VERB	O	O
exhibit	VERB	O	O
patterns	NOUN	O	O
that	ADJ	O	O
suggest	VERB	O	O
highly	ADV	O	O
selective	ADJ	O	O
involvement	NOUN	O	O
of	ADP	O	O
functional	ADJ	O	O
subdivisions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (921394)

Biphasic	ADJ	O	O
response	NOUN	O	O
of	ADP	O	O
the	DET	O	O
SA	PROPN	O	O
node	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dog	NOUN	O	O
heart	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
to	ADP	O	O
selective	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
.	PUNCT	O	O

Effect	PROPN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
SA	PROPN	O	O
node	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dog	NOUN	O	O
heart	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
vivo	NOUN	O	O
using	VERB	O	O
a	DET	O	O
selective	ADJ	O	O
perfusion	NOUN	O	O
technique	NOUN	O	O
of	ADP	O	O
the	DET	O	O
SA	PROPN	O	O
node	NOUN	O	O
artery	NOUN	O	O
.	PUNCT	O	O

Injections	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
in	ADP	O	O
doses	NOUN	O	O
from	ADP	O	O
100	NUM	O	O
microgram	NOUN	O	O
to	ADP	O	O
3	NUM	O	O
mg	NUM	O	O
into	ADP	O	O
the	DET	O	O
artery	NOUN	O	O
produced	VERB	O	O
a	DET	O	O
depression	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
SA	PROPN	O	O
nodal	NOUN	O	O
activity	NOUN	O	O
by	ADP	O	O
a	DET	O	O
direct	ADJ	O	O
action	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
depression	NOUN	O	I-Entity
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
the	DET	O	O
sudden	ADJ	O	O
appearance	NOUN	O	O
of	ADP	O	O
a	DET	O	O
stimulatory	ADJ	O	O
phase	NOUN	O	O
.	PUNCT	O	O

Bilateral	ADJ	O	O
vagotomy	NOUN	O	O
and	CCONJ	O	O
sympathectomy	NOUN	O	O
or	CCONJ	O	O
prior	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
a	DET	O	O
ganglion	NOUN	O	O
blocker	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
inhibit	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ketamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tachycardia	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
it	PRON	O	O
was	VERB	O	O
completely	ADV	O	O
abolished	VERB	O	O
in	ADP	O	O
the	DET	O	O
reserpinized	ADJ	O	O
dogs	NOUN	O	O
or	CCONJ	O	O
by	ADP	O	O
a	DET	O	O
prior	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
a	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocking	VERB	O	O
agent	NOUN	O	O
into	ADP	O	O
the	DET	O	O
SA	PROPN	O	O
node	NOUN	O	O
artery	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
may	VERB	O	O
indicate	VERB	O	O
that	ADP	O	O
an	DET	O	O
activation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
adrenergic	ADJ	O	O
mechanism	NOUN	O	O
plays	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
excitatory	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
injected	VERB	O	O
in	ADP	O	O
the	DET	O	O
SA	PROPN	O	O
node	NOUN	O	O
artery	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (871943)

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
cholinesterase	NOUN	O	O
in	ADP	O	O
succinylcholine	NOUN	O	I-Entity
apnoea	NOUN	O	I-Entity
.	PUNCT	O	O

Fifteen	NUM	O	O
patients	NOUN	O	O
demonstrating	VERB	O	O
unexpected	ADJ	O	O
prolonged	ADJ	O	O
apnoea	NOUN	O	I-Entity
lasting	VERB	O	O
several	ADJ	O	O
hours	NOUN	O	O
after	ADP	O	O
succinylcholine	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
a	DET	O	O
new	ADJ	O	O
preparation	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
serum	NOUN	O	O
cholinesterase	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
therefore	ADV	O	O
supposed	VERB	O	O
that	DET	O	O
other	ADJ	O	O
unknown	ADJ	O	O
variants	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
cholinesterase	NOUN	O	O
exist	VERB	O	O
which	ADJ	O	O
can	VERB	O	O
not	ADV	O	O
hydrolyze	VERB	O	O
succinylcholine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
cholinesterase	NOUN	O	O
in	ADP	O	O
succinylcholine	NOUN	O	I-Entity
apnoea	NOUN	O	I-Entity
provided	VERB	O	O
considerable	ADJ	O	O
relief	NOUN	O	O
to	ADP	O	O
both	DET	O	O
patient	NOUN	O	O
and	CCONJ	O	O
anaesthetist	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1355091)

Orthostatic	ADJ	O	B-Entity
hypotension	NOUN	O	I-Entity
occurs	VERB	O	O
following	VERB	O	O
alpha	NOUN	O	O
2-adrenoceptor	NOUN	O	O
blockade	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
prazosin	NOUN	O	I-Entity
-	PUNCT	O	O
pretreated	VERB	O	O
conscious	ADJ	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O
1	NUM	O	O
.	PUNCT	O	O

Studies	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
whether	ADP	O	O
chronic	ADJ	O	O
prazosin	NOUN	O	I-Entity
treatment	NOUN	O	O
alters	VERB	O	O
the	DET	O	O
alpha	NOUN	O	O
2-adrenoceptor	NOUN	O	O
function	NOUN	O	O
for	ADP	O	O
orthostatic	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
in	ADP	O	O
conscious	ADJ	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
(	PUNCT	O	O
SHR	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Conscious	ADJ	O	O
SHR	PROPN	O	O
(	PUNCT	O	O
male	ADJ	O	O
300	NUM	O	O
-	SYM	O	O
350	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
subjected	VERB	O	O
to	ADP	O	O
90	NUM	O	O
degrees	NOUN	O	O
head	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
tilts	NOUN	O	O
for	ADP	O	O
60	NUM	O	O
s	NOUN	O	O
following	VERB	O	O
acute	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
prazosin	NOUN	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
mg	NUM	O	O
kg-1	NUM	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
rauwolscine	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
mg	NUM	O	O
kg-1	NOUN	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Orthostatic	ADJ	O	B-Entity
hypotension	NOUN	O	I-Entity
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
the	DET	O	O
average	ADJ	O	O
decrease	NOUN	O	O
(	PUNCT	O	O
%	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
MAP	PROPN	O	O
femoral	PROPN	O	O
)	PUNCT	O	O
over	ADP	O	O
the	DET	O	O
60-s	NUM	O	O
tilt	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
basal	NOUN	O	O
MAP	PROPN	O	O
of	ADP	O	O
conscious	ADJ	O	O
SHR	PROPN	O	O
was	VERB	O	O
reduced	VERB	O	O
to	ADP	O	O
a	DET	O	O
similar	ADJ	O	O
extent	NOUN	O	O
by	ADP	O	O
prazosin	NOUN	O	I-Entity
(	PUNCT	O	O
-23%(-)-26%	PROPN	O	O
MAP	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
rauwolscine	NOUN	O	I-Entity
(	PUNCT	O	O
-16%(-)-33%	PROPN	O	O
MAP	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
head	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
tilt	NOUN	O	O
induced	VERB	O	O
orthostatic	ADJ	O	B-Entity
hypotension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
SHR	PROPN	O	O
treated	VERB	O	O
with	ADP	O	O
prazosin	NOUN	O	I-Entity
(	PUNCT	O	O
-16%	PROPN	O	O
MAP	PROPN	O	O
,	PUNCT	O	O
n	X	O	O
=	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
SHR	PROPN	O	O
treated	VERB	O	O
with	ADP	O	O
rauwolscine	NOUN	O	I-Entity
(	PUNCT	O	O
less	ADJ	O	O
than	ADP	O	O
+	SYM	O	O
2%	NUM	O	O
MAP	PROPN	O	O
,	PUNCT	O	O
n	X	O	O
=	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Conscious	ADJ	O	O
SHR	PROPN	O	O
were	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
with	ADP	O	O
prazosin	NOUN	O	I-Entity
at	ADP	O	O
2	NUM	O	O
mg	NUM	O	O
kg-1	NOUN	O	O
day-1	NOUN	O	O
i.p	NOUN	O	O
.	PUNCT	O	O

MAP	PROPN	O	O
in	ADP	O	O
conscious	ADJ	O	O
SHR	PROPN	O	O
after	ADP	O	O
chronic	ADJ	O	O
prazosin	NOUN	O	I-Entity
treatment	NOUN	O	O
was	VERB	O	O
14%	NUM	O	O
lower	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
untreated	ADJ	O	O
SHR	PROPN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
8)	NUM	O	O
.	PUNCT	O	O

Head	PROPN	O	O
-	PUNCT	O	O
up	PART	O	O
tilts	NOUN	O	O
in	ADP	O	O
these	DET	O	O
rats	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
produce	VERB	O	O
orthostatic	ADJ	O	B-Entity
hypotension	NOUN	O	I-Entity
when	ADV	O	O
performed	VERB	O	O
either	ADV	O	O
prior	ADV	O	O
to	ADP	O	O
or	CCONJ	O	O
after	ADP	O	O
acute	ADJ	O	O
dosing	NOUN	O	O
of	ADP	O	O
prazosin	NOUN	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
mg	NUM	O	O
kg-1	NUM	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Conversely	ADV	O	O
,	PUNCT	O	O
administration	NOUN	O	O
of	ADP	O	O
rauwolscine	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	O
mg	NUM	O	O
kg-1	NOUN	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
chronic	ADJ	O	O
prazosin	NOUN	O	I-Entity
treated	VERB	O	O
SHR	PROPN	O	O
decreased	VERB	O	O
the	DET	O	O
basal	NOUN	O	O
MAP	PROPN	O	O
by	ADP	O	O
12	NUM	O	O
-	PUNCT	O	O
31%	NUM	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
subsequent	ADJ	O	O
tilts	NOUN	O	O
induced	VERB	O	O
further	ADJ	O	O
drops	NOUN	O	O
of	ADP	O	O
MAP	PROPN	O	O
by	ADP	O	O
19	NUM	O	O
-	PUNCT	O	O
23%	NUM	O	O
in	ADP	O	O
these	DET	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pressor	NOUN	O	O
responses	NOUN	O	O
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
alpha	NOUN	O	O
1-agonist	NUM	O	O
cirazoline	NOUN	O	I-Entity
(	PUNCT	O	O
0.6	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
micrograms	NOUN	O	O
kg-1	ADJ	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
alpha	NOUN	O	O
2-agonist	NOUN	O	O
Abbott-53693	PROPN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
micrograms	NOUN	O	O
kg-1	PROPN	O	O
i.v	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
noradrenaline	NOUN	O	I-Entity
(	PUNCT	O	O
0.1	PUNCT	O	O
and	CCONJ	O	O
1.0	NUM	O	O
micrograms	NOUN	O	O
kg-1	SYM	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
were	VERB	O	O
determined	VERB	O	O
in	ADP	O	O
conscious	ADJ	O	O
SHR	PROPN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
chronic	ADJ	O	O
prazosin	NOUN	O	I-Entity
pretreatment	NOUN	O	O
.	PUNCT	O	O

Both	CCONJ	O	O
the	DET	O	O
pressor	NOUN	O	O
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
cirazoline	NOUN	O	I-Entity
were	VERB	O	O
abolished	VERB	O	O
in	ADP	O	O
chronic	ADJ	O	O
prazosin	NOUN	O	I-Entity
treated	VERB	O	O
SHR	PROPN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
4	PUNCT	O	O
)	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
untreated	ADJ	O	O
SHR	PROPN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
4	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
pressor	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
Abbott-53693	PROPN	O	I-Entity
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
of	ADP	O	O
SHR	PROPN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
accompanying	ADJ	O	O
bradycardia	NOUN	O	I-Entity
was	VERB	O	O
greater	ADJ	O	O
in	ADP	O	O
SHR	PROPN	O	O
with	ADP	O	O
chronic	ADJ	O	O
prazosin	NOUN	O	I-Entity
treatment	NOUN	O	O
than	ADP	O	O
without	ADP	O	O
such	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
bradycardia	NOUN	O	I-Entity
that	ADJ	O	O
accompanied	VERB	O	O
the	DET	O	O
noradrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
pressor	NOUN	O	O
effect	NOUN	O	O
in	ADP	O	O
SHR	PROPN	O	O
was	VERB	O	O
similar	ADJ	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
chronic	ADJ	O	O
prazosin	NOUN	O	I-Entity
treatment	NOUN	O	O
despite	ADP	O	O
a	DET	O	O
47	NUM	O	O
-	PUNCT	O	O
71%	NUM	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pressor	NOUN	O	O
effect	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
alpha	NOUN	O	O
1-receptor	NOUN	O	O
blocked	VERB	O	O
SHR.(ABSTRACT	ADJ	O	O
TRUNCATED	ADJ	O	O
AT	NOUN	O	O
400	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O


-DOCSTART- (8638876)

Coexistence	NOUN	O	O
of	ADP	O	O
cerebral	ADJ	O	B-Entity
venous	ADJ	O	I-Entity
sinus	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
internal	ADJ	O	I-Entity
carotid	ADJ	O	I-Entity
artery	NOUN	O	I-Entity
thrombosis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
exogenous	ADJ	O	O
sex	NOUN	O	O
hormones	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
forty	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
year	NOUN	O	O
-	PUNCT	O	O
old	ADJ	O	O
premenopausal	NOUN	O	O
woman	NOUN	O	O
developed	VERB	O	O
headache	NOUN	O	I-Entity
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	NOUN	O	I-Entity
,	PUNCT	O	O
left	VERB	O	O
hemiparesis	NOUN	O	I-Entity
and	CCONJ	O	O
seizure	NOUN	O	I-Entity
two	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
parenteral	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
progesterone	NOUN	O	I-Entity
and	CCONJ	O	O
estradiol	NOUN	O	I-Entity
.	PUNCT	O	O

Diabetes	NOUN	O	B-Entity
mellitus	VERB	O	I-Entity
(	PUNCT	O	O
DM	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
found	VERB	O	O
during	ADP	O	O
admission	NOUN	O	O
.	PUNCT	O	O

Computed	VERB	O	O
tomography	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
hemorrhagic	ADJ	O	B-Entity
infarct	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
right	ADJ	O	O
frontal	NOUN	O	O
lobe	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
density	NOUN	O	O
in	ADP	O	O
the	DET	O	O
superior	ADJ	O	O
sagittal	ADJ	O	O
sinus	NOUN	O	O
(	PUNCT	O	O
SSS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Left	VERB	O	O
carotid	ADJ	O	O
angiography	NOUN	O	O
found	VERB	O	O
occlusion	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
left	ADJ	O	I-Entity
internal	ADJ	O	I-Entity
carotid	ADJ	O	I-Entity
artery	NOUN	O	I-Entity
(	PUNCT	O	O
ICA	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Right	ADJ	O	O
carotid	NOUN	O	O
angiograms	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
show	VERB	O	O
the	DET	O	O
SSS	PROPN	O	O
and	CCONJ	O	O
inferior	ADJ	O	O
sagittal	ADJ	O	O
sinus	NOUN	O	O
,	PUNCT	O	O
suggestive	ADJ	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
sinus	ADJ	O	I-Entity
thrombosis	NOUN	O	I-Entity
.	PUNCT	O	O

Coexistence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cerebral	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
the	DET	O	I-Entity
venous	ADJ	O	I-Entity
sinus	ADJ	O	I-Entity
occlusion	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
described	VERB	O	O
infrequently	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
case	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
postulate	VERB	O	O
that	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
estradiol	NOUN	O	I-Entity
and	CCONJ	O	O
progesterone	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
underlying	ADJ	O	O
DM	PROPN	O	I-Entity
increased	VERB	O	O
vascular	ADJ	O	O
thrombogenicity	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
provided	VERB	O	O
a	DET	O	O
common	ADJ	O	O
denominator	NOUN	O	O
for	ADP	O	O
thrombosis	NOUN	O	B-Entity
of	ADP	O	I-Entity
both	CCONJ	O	I-Entity
the	DET	O	I-Entity
ICA	PROPN	O	I-Entity
and	CCONJ	O	I-Entity
the	DET	O	I-Entity
venous	ADJ	O	I-Entity
sinus	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1628552)

Chloroquine	PROPN	O	I-Entity
related	ADJ	O	O
complete	ADJ	O	O
heart	NOUN	O	B-Entity
block	NOUN	O	I-Entity
with	ADP	O	O
blindness	NOUN	O	I-Entity
:	PUNCT	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
27-year	ADJ	O	O
old	ADJ	O	O
African	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
history	NOUN	O	O
of	ADP	O	O
regular	ADJ	O	O
chloroquine	ADJ	O	I-Entity
ingestion	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
progressive	ADJ	O	O
deterioration	NOUN	O	B-Entity
of	ADP	O	I-Entity
vision	NOUN	O	I-Entity
,	PUNCT	O	O
easy	ADJ	O	O
fatiguability	NOUN	O	I-Entity
,	PUNCT	O	O
dyspnoea	NOUN	O	I-Entity
,	PUNCT	O	O
dizziness	NOUN	O	I-Entity
progressing	VERB	O	O
to	ADP	O	O
syncopal	VERB	O	B-Entity
attacks	NOUN	O	I-Entity
.	PUNCT	O	O

Ophthalmological	ADJ	O	O
assessment	NOUN	O	O
revealed	VERB	O	O
features	NOUN	O	O
of	ADP	O	O
chloroquine	NOUN	O	I-Entity
retinopathy	NOUN	O	I-Entity
,	PUNCT	O	O
cardiac	ADJ	O	O
assessment	NOUN	O	O
revealed	VERB	O	O
features	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
complete	ADJ	O	O
heart	NOUN	O	B-Entity
block	NOUN	O	I-Entity
with	ADP	O	O
right	ADJ	O	B-Entity
bundle	ADJ	O	I-Entity
branch	NOUN	O	I-Entity
block	NOUN	O	I-Entity
pattern	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
heart	NOUN	O	B-Entity
block	NOUN	O	I-Entity
was	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
pacemaker	NOUN	O	O
insertion	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
resolved	VERB	O	O
spontaneously	ADV	O	O
following	VERB	O	O
chloroquine	NOUN	O	I-Entity
discontinuation	NOUN	O	O
.	PUNCT	O	O

She	PRON	O	O
however	ADV	O	O
remains	VERB	O	O
blind	ADJ	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11524350)

Systemic	ADJ	O	O
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
resuscitation	NOUN	O	O
in	ADP	O	O
bupivacaine-	NOUN	O	I-Entity
,	PUNCT	O	O
levobupivacaine-	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
ropivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
infused	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
compared	VERB	O	O
the	DET	O	O
systemic	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
,	PUNCT	O	O
levobupivacaine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
ropivacaine	NOUN	O	I-Entity
in	ADP	O	O
anesthetized	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Bupivacaine	PROPN	O	I-Entity
,	PUNCT	O	O
levobupivacaine	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
ropivacaine	NOUN	O	I-Entity
was	VERB	O	O
infused	VERB	O	O
at	ADP	O	O
a	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
mg	NUM	O	O
.	PUNCT	O	O

When	ADV	O	O
asystole	NOUN	O	I-Entity
was	VERB	O	O
recorded	VERB	O	O
,	PUNCT	O	O
drug	NOUN	O	O
infusion	NOUN	O	O
was	VERB	O	O
stopped	VERB	O	O
and	CCONJ	O	O
a	DET	O	O
resuscitation	NOUN	O	O
sequence	NOUN	O	O
was	VERB	O	O
begun	VERB	O	O
.	PUNCT	O	O

Epinephrine	PROPN	O	I-Entity
0.01	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
was	VERB	O	O
administered	VERB	O	O
at	ADP	O	O
1-min	NUM	O	O
intervals	NOUN	O	O
while	ADP	O	O
external	ADJ	O	O
cardiac	ADJ	O	O
compressions	NOUN	O	O
were	VERB	O	O
applied	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
cumulative	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
levobupivacaine	NOUN	O	I-Entity
and	CCONJ	O	O
ropivacaine	NOUN	O	I-Entity
that	ADJ	O	O
produced	VERB	O	O
seizures	NOUN	O	I-Entity
were	VERB	O	O
similar	ADJ	O	O
and	CCONJ	O	O
were	VERB	O	O
larger	ADJ	O	O
than	ADP	O	O
those	DET	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
cumulative	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
levobupivacaine	NOUN	O	I-Entity
that	ADJ	O	O
produced	VERB	O	O
dysrhythmias	NOUN	O	I-Entity
and	CCONJ	O	O
asystole	NOUN	O	I-Entity
were	VERB	O	O
smaller	ADJ	O	O
than	ADP	O	O
the	DET	O	O
corresponding	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
ropivacaine	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
they	PRON	O	O
were	VERB	O	O
larger	ADJ	O	O
than	ADP	O	O
those	DET	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
smaller	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
epinephrine	NOUN	O	I-Entity
was	VERB	O	O
required	VERB	O	O
in	ADP	O	O
the	DET	O	O
Ropivacaine	PROPN	O	I-Entity
group	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
the	DET	O	O
systemic	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
levobupivacaine	NOUN	O	I-Entity
is	VERB	O	O
intermediate	ADJ	O	O
between	ADP	O	O
that	DET	O	O
of	ADP	O	O
ropivacaine	NOUN	O	I-Entity
and	CCONJ	O	O
bupivacaine	NOUN	O	I-Entity
when	ADV	O	O
administered	VERB	O	O
at	ADP	O	O
the	DET	O	O
same	ADJ	O	O
rate	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
ropivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
more	ADV	O	O
susceptible	ADJ	O	O
to	ADP	O	O
treatment	NOUN	O	O
than	ADP	O	O
that	DET	O	O
induced	VERB	O	O
by	ADP	O	O
bupivacaine	NOUN	O	I-Entity
or	CCONJ	O	O
levobupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10027919)

22-oxacalcitriol	NUM	O	I-Entity
suppresses	VERB	O	O
secondary	ADJ	O	B-Entity
hyperparathyroidism	NOUN	O	I-Entity
without	ADP	O	O
inducing	VERB	O	O
low	ADJ	O	B-Entity
bone	NOUN	O	I-Entity
turnover	NOUN	O	I-Entity
in	ADP	O	O
dogs	NOUN	O	O
with	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Calcitriol	PROPN	O	I-Entity
therapy	NOUN	O	O
suppresses	VERB	O	O
serum	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
parathyroid	ADJ	O	O
hormone	NOUN	O	O
(	PUNCT	O	O
PTH	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
but	CCONJ	O	O
has	VERB	O	O
several	ADJ	O	O
drawbacks	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
hypercalcemia	NOUN	O	I-Entity
and/or	CCONJ	O	O
marked	VERB	O	O
suppression	NOUN	O	B-Entity
of	ADP	O	I-Entity
bone	NOUN	O	I-Entity
turnover	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
adynamic	ADJ	O	B-Entity
bone	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
new	ADJ	O	O
vitamin	NOUN	O	B-Entity
D	PROPN	O	I-Entity
analogue	NOUN	O	O
,	PUNCT	O	O
22-oxacalcitriol	NUM	O	I-Entity
(	PUNCT	O	O
OCT	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
have	VERB	O	O
promising	ADJ	O	O
characteristics	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
OCT	PROPN	O	I-Entity
on	ADP	O	O
serum	NOUN	O	O
PTH	PROPN	O	O
levels	NOUN	O	O
and	CCONJ	O	O
bone	NOUN	O	O
turnover	NOUN	O	O
in	ADP	O	O
states	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
or	CCONJ	O	O
impaired	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
animals	NOUN	O	O
received	VERB	O	O
supplemental	ADJ	O	O
phosphate	NOUN	O	I-Entity
to	PART	O	O
enhance	VERB	O	O
PTH	PROPN	O	O
secretion	NOUN	O	O
.	PUNCT	O	O

Fourteen	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
phosphate	NOUN	O	I-Entity
supplementation	NOUN	O	O
,	PUNCT	O	O
half	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Nx	PROPN	O	O
and	CCONJ	O	O
Sham	PROPN	O	O
dogs	NOUN	O	O
received	VERB	O	O
doses	NOUN	O	O
of	ADP	O	O
OCT	PROPN	O	I-Entity
(	PUNCT	O	O
three	NUM	O	O
times	NOUN	O	O
per	ADP	O	O
week	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
the	DET	O	O
other	ADJ	O	O
half	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
vehicle	NOUN	O	O
for	ADP	O	O
60	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Biochemical	ADJ	O	O
and	CCONJ	O	O
hormonal	ADJ	O	O
indices	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
and	CCONJ	O	O
bone	NOUN	O	O
metabolism	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
throughout	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
bone	NOUN	O	O
biopsies	NOUN	O	O
were	VERB	O	O
done	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
60	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
OCT	PROPN	O	I-Entity
or	CCONJ	O	O
vehicle	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
crossover	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
Nx	PROPN	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
OCT	PROPN	O	I-Entity
significantly	ADV	O	O
decreased	VERB	O	O
serum	NOUN	O	O
PTH	PROPN	O	O
levels	NOUN	O	O
soon	ADV	O	O
after	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
long	ADV	O	O
-	PUNCT	O	O
standing	VERB	O	O
secondary	ADJ	O	B-Entity
hyperparathyroidism	NOUN	O	I-Entity
,	PUNCT	O	O
OCT	PROPN	O	I-Entity
(	PUNCT	O	O
0.03	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
stabilized	VERB	O	O
serum	NOUN	O	O
PTH	PROPN	O	O
levels	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
months	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
effects	NOUN	O	O
were	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
episodes	NOUN	O	O
of	ADP	O	O
hypercalcemia	NOUN	O	I-Entity
and	CCONJ	O	O
hyperphosphatemia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
animals	NOUN	O	O
with	ADP	O	O
normal	ADJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
OCT	PROPN	O	I-Entity
induced	VERB	O	O
a	DET	O	O
transient	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
PTH	PROPN	O	O
levels	NOUN	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
0.1	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
not	ADV	O	O
sustained	VERB	O	O
with	ADP	O	O
lowering	NOUN	O	O
of	ADP	O	O
the	DET	O	O
doses	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
Nx	PROPN	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
OCT	PROPN	O	I-Entity
reversed	VERB	O	O
abnormal	ADJ	O	O
bone	NOUN	O	O
formation	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
woven	VERB	O	B-Entity
osteoid	NOUN	O	I-Entity
and	CCONJ	O	O
fibrosis	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
alter	VERB	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
bone	NOUN	O	O
turnover	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
OCT	PROPN	O	I-Entity
improved	VERB	O	O
mineralization	NOUN	O	O
lag	NOUN	O	O
time	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
that	DET	O	O
is	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
rate	NOUN	O	O
at	ADP	O	O
which	ADJ	O	O
osteoid	NOUN	O	O
mineralizes	VERB	O	O
)	PUNCT	O	O
in	ADP	O	O
both	DET	O	O
Nx	PROPN	O	O
and	CCONJ	O	O
Sham	PROPN	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
even	ADV	O	O
though	ADP	O	O
OCT	PROPN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
completely	ADV	O	O
prevent	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
hypercalcemia	NOUN	O	I-Entity
in	ADP	O	O
experimental	ADJ	O	O
dogs	NOUN	O	O
with	ADP	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
,	PUNCT	O	O
it	PRON	O	O
may	VERB	O	O
be	VERB	O	O
of	ADP	O	O
use	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
secondary	ADJ	O	B-Entity
hyperparathyroidism	NOUN	O	I-Entity
because	ADP	O	O
it	PRON	O	O
does	VERB	O	O
not	ADV	O	O
induce	VERB	O	O
low	ADJ	O	B-Entity
bone	NOUN	O	I-Entity
turnover	NOUN	O	I-Entity
and	CCONJ	O	O
,	PUNCT	O	O
therefore	ADV	O	O
,	PUNCT	O	O
does	VERB	O	O
not	ADV	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
adynamic	ADJ	O	B-Entity
bone	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8643966)

Chemotherapy	PROPN	O	O
of	ADP	O	O
advanced	ADJ	O	O
inoperable	ADJ	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
small	ADJ	O	I-Entity
cell	NOUN	O	I-Entity
lung	NOUN	O	I-Entity
cancer	NOUN	O	I-Entity
with	ADP	O	O
paclitaxel	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
phase	NOUN	O	O
II	PROPN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Paclitaxel	PROPN	O	I-Entity
(	PUNCT	O	O
Taxol	PROPN	O	I-Entity
;	PUNCT	O	O
Bristol	PROPN	O	O
-	PUNCT	O	O
Myers	PROPN	O	O
Squibb	PROPN	O	O
Company	PROPN	O	O
,	PUNCT	O	O
Princeton	PROPN	O	O
,	PUNCT	O	O
NJ	PROPN	O	O
)	PUNCT	O	O
has	VERB	O	O
demonstrated	VERB	O	O
significant	ADJ	O	O
antineoplastic	ADJ	O	O
activity	NOUN	O	O
against	ADP	O	O
different	ADJ	O	O
tumor	NOUN	O	I-Entity
types	NOUN	O	O
,	PUNCT	O	O
notably	ADV	O	O
ovarian	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
breast	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
phase	NOUN	O	O
II	NUM	O	O
trials	NOUN	O	O
of	ADP	O	O
24-hour	ADJ	O	O
paclitaxel	NOUN	O	I-Entity
infusions	NOUN	O	O
in	ADP	O	O
chemotherapy	NOUN	O	O
-	PUNCT	O	O
naive	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
stage	NOUN	O	O

IIIB	PROPN	O	O
or	CCONJ	O	O
IV	PROPN	O	O
non	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
small	ADJ	O	I-Entity
cell	NOUN	O	I-Entity
lung	NOUN	O	I-Entity
cancer	NOUN	O	I-Entity
(	PUNCT	O	O
NSCLC	PROPN	O	I-Entity
)	PUNCT	O	O
reported	VERB	O	O
response	NOUN	O	O
rates	NOUN	O	O
of	ADP	O	O
21%	NUM	O	O
and	CCONJ	O	O
24%	NUM	O	O
.	PUNCT	O	O

Leukopenia	PROPN	O	I-Entity
was	VERB	O	O
dose	NOUN	O	O
limiting	VERB	O	O
:	PUNCT	O	O
as	ADV	O	O
many	ADJ	O	O
as	ADP	O	O
62.5%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
experienced	VERB	O	O
grade	NOUN	O	O
4	NUM	O	O
leukopenia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
a	DET	O	O
3-hour	NUM	O	O
paclitaxel	NOUN	O	I-Entity
infusion	NOUN	O	O
in	ADP	O	O
a	DET	O	O
phase	NOUN	O	O
II	PROPN	O	O
trial	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
inoperable	ADJ	O	O
stage	NOUN	O	O
IIIB	PROPN	O	O
or	CCONJ	O	O
IV	PROPN	O	O
NSCLC	PROPN	O	I-Entity
.	PUNCT	O	O

Most	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
72.4%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
stage	NOUN	O	O
IV	PROPN	O	O
NSCLC	PROPN	O	I-Entity
.	PUNCT	O	O

Paclitaxel	PROPN	O	I-Entity

Hematologic	PROPN	O	O
toxicities	NOUN	O	I-Entity
were	VERB	O	O
mild	ADJ	O	O
:	PUNCT	O	O
only	ADV	O	O
one	NUM	O	O
patient	NOUN	O	O
(	PUNCT	O	O
2%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
grade	NOUN	O	O
3	NUM	O	O
or	CCONJ	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
29%	NUM	O	O
had	VERB	O	O
grade	NOUN	O	O
1	NUM	O	O
or	CCONJ	O	O
2	NUM	O	O
.	PUNCT	O	O

Grade	PROPN	O	O
1	NUM	O	O
or	CCONJ	O	O
2	NUM	O	O
polyneuropathy	NOUN	O	I-Entity
affected	VERB	O	O
56%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
while	ADP	O	O
only	ADV	O	O
one	NUM	O	O
(	PUNCT	O	O
2%	NUM	O	O
)	PUNCT	O	O
experienced	VERB	O	O
severe	ADJ	O	O
polyneuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
grade	NOUN	O	O
1	NUM	O	O
or	CCONJ	O	O
2	NUM	O	O
myalgia	NOUN	O	I-Entity
/	SYM	O	O
arthralgia	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
63.2%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
14.3%	NUM	O	O
experienced	VERB	O	O
grade	NOUN	O	O
3	NUM	O	O
or	CCONJ	O	O
4	NUM	O	O
.	PUNCT	O	O

Nausea	NOUN	O	I-Entity
and	CCONJ	O	O
vomiting	VERB	O	I-Entity
were	VERB	O	O
infrequent	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
14%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
experiencing	VERB	O	O
grade	NOUN	O	O
1	NUM	O	O
or	CCONJ	O	O
2	NUM	O	O
and	CCONJ	O	O
only	ADV	O	O
2%	NUM	O	O
experiencing	VERB	O	O
grade	NOUN	O	O
3	NUM	O	O
or	CCONJ	O	O
4	NUM	O	O
.	PUNCT	O	O

Paclitaxel	PROPN	O	I-Entity
is	VERB	O	O
thus	ADV	O	O
an	DET	O	O
active	ADJ	O	O
single	ADJ	O	O
agent	NOUN	O	O
in	ADP	O	O
this	DET	O	O
patient	ADJ	O	O
population	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
3-hour	NUM	O	O
infusion	NOUN	O	O
proving	VERB	O	O
comparably	ADV	O	O
effective	ADJ	O	O
to	ADP	O	O
a	DET	O	O
24-hour	NUM	O	O
infusion	NOUN	O	O
and	CCONJ	O	O
superior	ADJ	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
hematologic	NOUN	O	O
and	CCONJ	O	O
nonhematologic	ADJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Further	ADJ	O	O
phase	NOUN	O	O
II	PROPN	O	O
studies	NOUN	O	O
with	ADP	O	O
paclitaxel	NOUN	O	I-Entity
combined	VERB	O	O
with	ADP	O	O
other	ADJ	O	O
drugs	NOUN	O	O
active	ADJ	O	O
against	ADP	O	O
NSCLC	PROPN	O	I-Entity
are	VERB	O	O
indicated	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
phase	NOUN	O	O
III	NUM	O	O
studies	NOUN	O	O
comparing	VERB	O	O
paclitaxel	NOUN	O	I-Entity
with	ADP	O	O
standard	NOUN	O	O
chemotherapy	NOUN	O	O
remain	VERB	O	O
to	PART	O	O
be	VERB	O	O
completed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (6695415)

Cerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
phenylpropanolamine	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
caffeine	NOUN	O	I-Entity
.	PUNCT	O	O

Phenylpropanolamine	PROPN	O	I-Entity
(	PUNCT	O	O
PPA	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
drug	NOUN	O	O
that	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
serious	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
including	VERB	O	O
stroke	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
often	ADV	O	O
combined	VERB	O	O
with	ADP	O	O
caffeine	NOUN	O	I-Entity
in	ADP	O	O
diet	NOUN	O	O
preparations	NOUN	O	O
and	CCONJ	O	O
"	PUNCT	O	O
look	VERB	O	O
-	PUNCT	O	O
alike	ADV	O	O
"	PUNCT	O	O
pills	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
determine	VERB	O	O
if	ADP	O	O
PPA	PROPN	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
can	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
stroke	NOUN	O	I-Entity
in	ADP	O	O
normotensive	ADJ	O	O
and/or	CCONJ	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
administered	VERB	O	O
the	DET	O	O
combination	NOUN	O	O
in	ADP	O	O
six	NUM	O	O
times	NOUN	O	O
the	DET	O	O
allowed	VERB	O	O
human	NOUN	O	O
dose	NOUN	O	O
calculated	VERB	O	O
on	ADP	O	O
a	DET	O	O
per	NOUN	O	O
weight	NOUN	O	O
basis	NOUN	O	O
for	ADP	O	O
the	DET	O	O
rats	NOUN	O	O
two	NUM	O	O
times	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
for	ADP	O	O
five	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Subarachnoid	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
cerebral	ADJ	O	I-Entity
hemorrhage	NOUN	O	I-Entity
was	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
18%	NUM	O	O
of	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
single	ADJ	O	O
PPA	PROPN	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
administration	NOUN	O	O
(	PUNCT	O	O
same	ADJ	O	O
dose	NOUN	O	O
)	PUNCT	O	O
lead	NOUN	O	O
to	ADP	O	O
acute	ADJ	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
normotensive	ADJ	O	O
and	CCONJ	O	O
hypertensive	ADJ	O	I-Entity
animals	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
PPA	PROPN	O	I-Entity
/	SYM	O	O
caffeine	NOUN	O	I-Entity
can	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
cerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
in	ADP	O	O
previously	ADV	O	O
hypertensive	ADJ	O	I-Entity
animals	NOUN	O	O
when	ADV	O	O
administered	VERB	O	O
in	ADP	O	O
greater	ADJ	O	O
than	ADP	O	O
the	DET	O	O
allowed	VERB	O	O
dosage	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6637851)

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
amiodarone	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
or	CCONJ	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
.	PUNCT	O	O

Amiodarone	PROPN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
154	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
sustained	VERB	O	O
,	PUNCT	O	O
symptomatic	NOUN	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
(	PUNCT	O	O
VT	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
n	VERB	O	O
=	SYM	O	O
118	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
36	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
who	NOUN	O	O
were	VERB	O	O
refractory	ADJ	O	O
to	ADP	O	O
conventional	ADJ	O	O
antiarrhythmic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Sixty	NUM	O	O
-	PUNCT	O	O
nine	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
continued	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
amiodarone	NOUN	O	I-Entity
and	CCONJ	O	O
had	VERB	O	O
no	DET	O	O
recurrence	NOUN	O	O
of	ADP	O	O
symptomatic	ADJ	O	O
VT	PROPN	O	I-Entity
or	CCONJ	O	O
ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
(	PUNCT	O	O
VF	PROPN	O	I-Entity
)	PUNCT	O	O
over	ADP	O	O
a	DET	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
to	PART	O	O
52	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
+	SYM	O	O
/-	PUNCT	O	O

Six	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
nonfatal	ADJ	O	O
recurrence	NOUN	O	O
of	ADP	O	O
VT	PROPN	O	I-Entity
and	CCONJ	O	O
were	VERB	O	O
successfully	ADV	O	O
managed	VERB	O	O
by	ADP	O	O
continuing	VERB	O	O
amiodarone	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
higher	ADJ	O	O
dose	NOUN	O	O
or	CCONJ	O	O
by	ADP	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
a	DET	O	O
conventional	ADJ	O	O
antiarrhythmic	ADJ	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Adverse	ADJ	O	O
effects	NOUN	O	O
forced	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
in	ADP	O	O
41%	NUM	O	O
and	CCONJ	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
in	ADP	O	O
10%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
symptomatic	ADJ	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
were	VERB	O	O
tremor	NOUN	O	I-Entity
or	CCONJ	O	O
ataxia	NOUN	O	I-Entity
(	PUNCT	O	O
35%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
and	CCONJ	O	O
anorexia	NOUN	O	I-Entity
(	PUNCT	O	O
8%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
visual	ADJ	O	B-Entity
halos	NOUN	O	I-Entity
or	CCONJ	O	I-Entity
blurring	VERB	O	I-Entity
(	PUNCT	O	O
6%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
thyroid	NOUN	O	B-Entity
function	NOUN	O	I-Entity
abnormalities	NOUN	O	I-Entity
(	PUNCT	O	O
6%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
pulmonary	ADJ	O	B-Entity
interstitial	ADJ	O	I-Entity
infiltrates	NOUN	O	I-Entity
(	PUNCT	O	O
5%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Although	ADP	O	O
large	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
amiodarone	NOUN	O	I-Entity
is	VERB	O	O
highly	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
VT	PROPN	O	I-Entity
or	CCONJ	O	O
VF	PROPN	O	I-Entity
refractory	NOUN	O	O
to	ADP	O	O
conventional	ADJ	O	O
antiarrhythmic	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
causes	VERB	O	O
significant	ADJ	O	O
toxicity	NOUN	O	I-Entity
in	ADP	O	O
approximately	ADV	O	O
50%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
when	ADV	O	O
the	DET	O	O
dose	NOUN	O	O
is	VERB	O	O
adjusted	VERB	O	O
based	VERB	O	O
on	ADP	O	O
clinical	ADJ	O	O
response	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
75%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
VT	PROPN	O	I-Entity
or	CCONJ	O	O
VF	PROPN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
successfully	ADV	O	O
managed	VERB	O	O
with	ADP	O	O
amiodarone	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8800187)

Effect	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
and	CCONJ	O	O
4-aminopyridine	NUM	O	I-Entity
therapy	NOUN	O	O
on	ADP	O	O
desipramine	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Hypotension	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
contributor	NOUN	O	O
to	ADP	O	O
mortality	NOUN	O	O
in	ADP	O	O
tricyclic	ADJ	O	O
antidepressant	NOUN	O	O
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

Recent	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
tricyclic	ADJ	O	O
antidepressants	NOUN	O	O
inhibit	VERB	O	O
calcium	ADJ	O	I-Entity
influx	NOUN	O	O
in	ADP	O	O
some	DET	O	O
tissues	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
addressed	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blockade	NOUN	O	O
in	ADP	O	O
tricyclic	ADJ	O	O
antidepressant	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
interventions	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
that	ADJ	O	O
have	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
previously	ADV	O	O
to	PART	O	O
improve	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
with	ADP	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
blocker	NOUN	O	O
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

CaCl2	NOUN	O	I-Entity
and	CCONJ	O	O
4-aminopyridine	NUM	O	I-Entity
.	PUNCT	O	O

Anesthetized	ADJ	O	O
rats	NOUN	O	O
received	VERB	O	O
the	DET	O	O
tricyclic	ADJ	O	O
antidepressant	NOUN	O	O
desipramine	NOUN	O	I-Entity
IP	NOUN	O	O
to	PART	O	O
produce	VERB	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
QRS	PROPN	O	O
prolongation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O

min	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
animals	NOUN	O	O
received	VERB	O	O
CaCl2	PROPN	O	I-Entity
,	PUNCT	O	O
NaHCO3	PROPN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
saline	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
second	ADJ	O	O
experiment	NOUN	O	O
,	PUNCT	O	O
rats	NOUN	O	O
received	VERB	O	O
tricyclic	ADJ	O	O
antidepressant	NOUN	O	O
desipramine	NOUN	O	I-Entity
IP	PROPN	O	O
followed	VERB	O	O
in	ADP	O	O
15	NUM	O	O
min	NOUN	O	O
by	ADP	O	O
4-aminopyridine	NUM	O	I-Entity
or	CCONJ	O	O
saline	ADJ	O	O
.	PUNCT	O	O

NaHCO3	NOUN	O	I-Entity
briefly	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
reversed	VERB	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
QRS	PROPN	O	O
prolongation	NOUN	O	O
.	PUNCT	O	O

CaCl2	NOUN	O	I-Entity
and	CCONJ	O	O
4-aminopyridine	NOUN	O	I-Entity
failed	VERB	O	O
to	PART	O	O
improve	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.004	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
seizures	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
CaCl2	PROPN	O	I-Entity
group	NOUN	O	O
was	VERB	O	O
higher	ADJ	O	O
than	ADP	O	O
the	DET	O	O
other	ADJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
CaCl2	PROPN	O	I-Entity
or	CCONJ	O	O
4-aminopyridine	NUM	O	I-Entity
did	VERB	O	O
not	ADV	O	O
reverse	VERB	O	O
tricyclic	ADJ	O	O
antidepressant	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

CaCl2	NOUN	O	I-Entity
therapy	NOUN	O	O
may	VERB	O	O
possibly	ADV	O	O
worsen	VERB	O	O
both	DET	O	O
cardiovascular	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
central	ADJ	O	I-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
do	VERB	O	O
not	ADV	O	O
support	VERB	O	O
a	DET	O	O
role	NOUN	O	O
for	ADP	O	O
calcium	NOUN	O	I-Entity
channel	NOUN	O	O
inhibition	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
tricyclic	ADJ	O	O
antidepressant	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7707116)

Phase	NOUN	O	O
I	PRON	O	O
trial	NOUN	O	O
of	ADP	O	O
13-cis	NUM	O	B-Entity
-	PUNCT	O	I-Entity
retinoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
neuroblastoma	NOUN	O	I-Entity
following	VERB	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

PURPOSE	PROPN	O	O
:	PUNCT	O	O
Treatment	NOUN	O	O
of	ADP	O	O
neuroblastoma	NOUN	O	I-Entity
cell	NOUN	O	O
lines	NOUN	O	O
with	ADP	O	O
13-cis	NUM	O	B-Entity
-	PUNCT	O	I-Entity
retinoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
cis	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
RA	PROPN	O	I-Entity
)	PUNCT	O	O
can	VERB	O	O
cause	VERB	O	O
sustained	ADJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
proliferation	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
cis	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
RA	PROPN	O	I-Entity
has	VERB	O	O
demonstrated	VERB	O	O
clinical	ADJ	O	O
responses	NOUN	O	O
in	ADP	O	O
neuroblastoma	NOUN	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
may	VERB	O	O
be	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
preventing	VERB	O	O
relapse	NOUN	O	O
after	ADP	O	O
cytotoxic	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
phase	NOUN	O	O
I	PRON	O	O
trial	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
maximal	NOUN	O	O
-	PUNCT	O	O
tolerated	VERB	O	O
dosage	NOUN	O	O
(	PUNCT	O	O
MTD	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
toxicities	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
pharmacokinetics	NOUN	O	O
of	ADP	O	O
cis	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
RA	PROPN	O	I-Entity
administered	VERB	O	O
on	ADP	O	O
an	DET	O	O
intermittent	ADJ	O	O
schedule	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
neuroblastoma	NOUN	O	I-Entity
following	VERB	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplantation	NOUN	O	O
(	PUNCT	O	O
BMT	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
:	PUNCT	O	O
Fifty	NUM	O	O
-	PUNCT	O	O
one	NUM	O	O
assessable	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
2	NUM	O	O
to	PART	O	O
12	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
oral	ADJ	O	O
cis	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
RA	PROPN	O	I-Entity
administered	VERB	O	O
in	ADP	O	O
two	NUM	O	O
equally	ADV	O	O
divided	ADJ	O	O
doses	NOUN	O	O
daily	ADV	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
2-week	NUM	O	O
rest	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
up	ADP	O	O
to	PART	O	O
12	NUM	O	O
courses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
was	VERB	O	O
escalated	VERB	O	O
from	ADP	O	O
100	NUM	O	O
to	ADP	O	O
200	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2/d	NOUN	O	O
until	ADP	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
toxicity	NOUN	O	I-Entity
(	PUNCT	O	O
DLT	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
MTD	PROPN	O	O
of	ADP	O	O
cis	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
RA	PROPN	O	I-Entity
was	VERB	O	O
160	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2/d	NOUN	O	O
.	PUNCT	O	O

Dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
toxicities	NOUN	O	I-Entity
in	ADP	O	O
six	NUM	O	O
of	ADP	O	O
nine	NUM	O	O
patients	NOUN	O	O
at	ADP	O	O
200	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2/d	NOUN	O	O
included	VERB	O	O
hypercalcemia	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
3	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
rash	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
anemia	NOUN	O	I-Entity
/	SYM	O	O
thrombocytopenia	NOUN	O	I-Entity
/	SYM	O	O
emesis	NOUN	O	I-Entity
/	SYM	O	O
rash	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
toxicities	NOUN	O	I-Entity
resolved	VERB	O	O
after	ADP	O	O
cis	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
RA	PROPN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
.	PUNCT	O	O

Three	NUM	O	O
complete	ADJ	O	O
responses	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
marrow	NOUN	O	O
metastases	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
MTD	PROPN	O	O
of	ADP	O	O
cis	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
RA	PROPN	O	I-Entity
given	VERB	O	O
on	ADP	O	O
this	DET	O	O
intermittent	ADJ	O	O
schedule	NOUN	O	O
was	VERB	O	O
160	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2/d	NOUN	O	O
.	PUNCT	O	O

Serum	PROPN	O	O
levels	NOUN	O	O
known	VERB	O	O
to	PART	O	O
be	VERB	O	O
effective	ADJ	O	O
against	ADP	O	O
neuroblastoma	NOUN	O	I-Entity
in	ADP	O	O
vitro	NOUN	O	O
were	VERB	O	O
achieved	VERB	O	O
at	ADP	O	O
this	DET	O	O
dose	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
DLT	PROPN	O	O
included	VERB	O	O
hypercalcemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
predicted	VERB	O	O
by	ADP	O	O
serum	NOUN	O	O
cis	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
RA	PROPN	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

Monitoring	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
calcium	NOUN	O	I-Entity
and	CCONJ	O	O
cis	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
RA	PROPN	O	I-Entity
levels	NOUN	O	O
is	VERB	O	O
indicated	VERB	O	O
in	ADP	O	O
future	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6892185)

Effect	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
on	ADP	O	O
gross	ADJ	O	O
behavioural	ADJ	O	O
changes	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
carbachol	NOUN	O	I-Entity
and	CCONJ	O	O
eserine	NOUN	O	I-Entity
in	ADP	O	O
cats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
injected	VERB	O	O
into	ADP	O	O
the	DET	O	O
cerebral	ADJ	O	O
ventricles	NOUN	O	O
of	ADP	O	O
group	NOUN	O	O
-	PUNCT	O	O
housed	VERB	O	O
unanaesthetized	ADJ	O	O
cats	NOUN	O	O
upon	ADP	O	O
vocalization	NOUN	O	O
(	PUNCT	O	O
rage	NOUN	O	O
,	PUNCT	O	O
hissing	NOUN	O	O
and	CCONJ	O	O
snarling	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
fighting	VERB	O	O
(	PUNCT	O	O
attack	NOUN	O	O
with	ADP	O	O
paws	NOUN	O	O
and	CCONJ	O	O
claws	NOUN	O	O
,	PUNCT	O	O
defense	NOUN	O	O
with	ADP	O	O
paws	NOUN	O	O
and	CCONJ	O	O
claws	NOUN	O	O
and	CCONJ	O	O
biting	VERB	O	O
)	PUNCT	O	O
,	PUNCT	O	O
mydriasis	NOUN	O	I-Entity
,	PUNCT	O	O
tremor	NOUN	O	I-Entity
and	CCONJ	O	O
clonic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tonic	NOUN	O	I-Entity
convulsions	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
carbachol	NOUN	O	I-Entity
and	CCONJ	O	O
eserine	NOUN	O	I-Entity
injected	VERB	O	O
similarly	ADV	O	O
was	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

Calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
depressed	VERB	O	O
or	CCONJ	O	O
almost	ADV	O	O
completely	ADV	O	O
abolished	VERB	O	O
the	DET	O	O
vocalization	NOUN	O	O
and	CCONJ	O	O
fighting	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
carbachol	NOUN	O	I-Entity
and	CCONJ	O	O
eserine	NOUN	O	I-Entity
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
mydriasis	NOUN	O	I-Entity
,	PUNCT	O	O
tremor	NOUN	O	I-Entity
and	CCONJ	O	O
clonic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tonic	NOUN	O	I-Entity
convulsions	NOUN	O	I-Entity
evoked	VERB	O	O
by	ADP	O	O
carbachol	NOUN	O	I-Entity
and	CCONJ	O	O
eserine	NOUN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
changed	VERB	O	O
by	ADP	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
apparent	ADJ	O	O
that	ADP	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
can	VERB	O	O
"	PUNCT	O	O
dissociate	VERB	O	O
"	PUNCT	O	O
vocalization	NOUN	O	O
and	CCONJ	O	O
fighting	NOUN	O	O
from	ADP	O	O
autonomic	NOUN	O	O
and	CCONJ	O	O
motor	NOUN	O	O
phenomena	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
mydriasis	NOUN	O	I-Entity
,	PUNCT	O	O
tremor	NOUN	O	I-Entity
and	CCONJ	O	O
clonic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tonic	NOUN	O	I-Entity
convulsions	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
carbachol	NOUN	O	I-Entity
and	CCONJ	O	O
eserine	NOUN	O	I-Entity
.	PUNCT	O	O

Calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
inhibited	VERB	O	O
the	DET	O	O
vocalization	NOUN	O	O
and	CCONJ	O	O
fighting	VERB	O	O
produced	VERB	O	O
by	ADP	O	O
carbachol	NOUN	O	I-Entity
and	CCONJ	O	O
eserine	NOUN	O	I-Entity
most	ADV	O	O
probably	ADV	O	O
by	ADP	O	O
a	DET	O	O
nonspecific	NOUN	O	O
stabilizing	VERB	O	O
action	NOUN	O	O
on	ADP	O	O
central	ADJ	O	O
muscarinic	ADJ	O	O
cholinoceptive	ADJ	O	O
sites	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
further	ADV	O	O
support	VERB	O	O
the	DET	O	O
view	NOUN	O	O
that	ADP	O	O
calcium	NOUN	O	I-Entity
ions	NOUN	O	O
in	ADP	O	O
excess	NOUN	O	O
have	VERB	O	O
an	DET	O	O
atropine	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
action	NOUN	O	O
also	ADV	O	O
in	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6216862)

Multiple	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
penicillamine	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
with	ADP	O	O
rheumatoid	ADJ	O	B-Entity
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

Skin	NOUN	O	B-Entity
rashes	NOUN	O	I-Entity
,	PUNCT	O	O
proteinuria	NOUN	O	I-Entity
,	PUNCT	O	O
systemic	ADJ	O	B-Entity
lupus	NOUN	O	I-Entity
erythematosus	NOUN	O	I-Entity
,	PUNCT	O	O
polymyositis	NOUN	O	I-Entity
and	CCONJ	O	O
myasthenia	NOUN	O	B-Entity
gravis	NOUN	O	I-Entity
have	VERB	O	O
all	DET	O	O
been	VERB	O	O
recorded	VERB	O	O
as	ADP	O	O
complications	NOUN	O	O
of	ADP	O	O
penicillamine	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatoid	ADJ	O	B-Entity
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
skin	NOUN	O	B-Entity
lesion	NOUN	O	I-Entity
resembled	VERB	O	O
elastosis	NOUN	O	B-Entity
perforans	NOUN	O	I-Entity
serpiginosa	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
as	ADP	O	O
a	DET	O	O
rare	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
Wilson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
penicillamine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2004)

Electrocardiographic	ADJ	O	O
changes	NOUN	O	O
and	CCONJ	O	O
cardiac	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
psychotropic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Eight	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
cardiac	ADJ	O	O
manifestations	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
in	ADP	O	O
five	NUM	O	O
while	ADP	O	O
taking	VERB	O	O
psychotropic	NOUN	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
either	CCONJ	O	O
phenothiazines	NOUN	O	I-Entity
or	CCONJ	O	O
tricyclic	ADJ	O	O
antidepressants	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
most	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
receiving	VERB	O	O
several	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
Mellaril	PROPN	O	I-Entity
(	PUNCT	O	O
thioridazine	NOUN	O	I-Entity
)	PUNCT	O	O
appeared	VERB	O	O
to	PART	O	O
be	VERB	O	O
responsible	ADJ	O	O
for	ADP	O	O
five	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
,	PUNCT	O	O
one	NUM	O	O
of	ADP	O	O
which	ADJ	O	O
was	VERB	O	O
fatal	ADJ	O	O
in	ADP	O	O
a	DET	O	O
35	NUM	O	O
year	NOUN	O	O
old	ADJ	O	O
woman	NOUN	O	O
.	PUNCT	O	O

Supraventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
developed	VERB	O	O
in	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
receiving	VERB	O	O
Thorazine	PROPN	O	I-Entity
(	PUNCT	O	O
chlorpromazine	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Aventyl	PROPN	O	I-Entity
(	PUNCT	O	O
nortriptyline	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
Elavil	PROPN	O	I-Entity
(	PUNCT	O	O
amitriptyline	NOUN	O	I-Entity
)	PUNCT	O	O
each	DET	O	O
produced	VERB	O	O
left	VERB	O	B-Entity
bundle	ADJ	O	I-Entity
branch	NOUN	O	I-Entity
block	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
73	NUM	O	O
year	NOUN	O	O
old	ADJ	O	O
woman	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ventricular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
responded	VERB	O	O
to	ADP	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
and	CCONJ	O	O
to	PART	O	O
direct	VERB	O	O
current	ADJ	O	O
electric	ADJ	O	O
shock	NOUN	O	O
;	PUNCT	O	O
ventricular	ADJ	O	O
pacing	NOUN	O	O
was	VERB	O	O
required	VERB	O	O
in	ADP	O	O
some	DET	O	O
instances	NOUN	O	O
and	CCONJ	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
combined	VERB	O	O
with	ADP	O	O
ventricular	ADJ	O	O
pacing	NOUN	O	O
in	ADP	O	O
one	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
tachyarrhythmias	NOUN	O	I-Entity
generally	ADV	O	O
subsided	VERB	O	O
within	ADP	O	O
48	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drugs	NOUN	O	O
was	VERB	O	O
stopped	VERB	O	O
.	PUNCT	O	O

Five	NUM	O	O
of	ADP	O	O
the	DET	O	O
eight	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
50	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
or	CCONJ	O	O
younger	ADJ	O	O
;	PUNCT	O	O
only	ADV	O	O
one	NUM	O	O
clearly	ADV	O	O
had	VERB	O	O
antecedent	ADJ	O	O
heart	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Major	ADJ	O	O
cardiac	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
are	VERB	O	O
a	DET	O	O
potential	ADJ	O	O
hazard	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
heart	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
who	NOUN	O	O
are	VERB	O	O
receiving	VERB	O	O
customary	ADJ	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
psychotropic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
prospective	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
is	VERB	O	O
suggested	VERB	O	O
to	PART	O	O
quantify	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
to	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
phenothiazines	NOUN	O	I-Entity
or	CCONJ	O	O
tricyclic	ADJ	O	O
antidepressant	NOUN	O	O
drugs	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6118280)

Serotonergic	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
benzodiazepines	NOUN	O	I-Entity
and	CCONJ	O	O
baclofen	NOUN	O	I-Entity
block	NOUN	O	O
muscimol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myoclonic	ADJ	O	B-Entity
jerks	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
strain	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
male	ADJ	O	O
Swiss	ADJ	O	O
mice	NOUN	O	O
,	PUNCT	O	O
muscimol	ADV	O	I-Entity
produced	VERB	O	O
myoclonic	ADJ	O	B-Entity
jerks	NOUN	O	I-Entity
.	PUNCT	O	O

Increasing	VERB	O	O
the	DET	O	O
brain	NOUN	O	O
serotonin	NOUN	O	I-Entity
levels	NOUN	O	O
by	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
5-hydroxytryptophan	PROPN	O	I-Entity
(	PUNCT	O	O
80	NUM	O	O
-	SYM	O	O
160	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
a	DET	O	O
peripheral	ADJ	O	O
decarboxylase	NOUN	O	O
inhibitor	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
an	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
the	DET	O	O
muscimol	NOUN	O	I-Entity
effect	NOUN	O	O
.	PUNCT	O	O

l	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	NOUN	O	I-Entity
(	PUNCT	O	O
80	NUM	O	O
-	SYM	O	O
160	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
without	ADP	O	O
effect	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
-	SYM	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
the	DET	O	O
serotonin	NOUN	O	I-Entity
receptor	NOUN	O	O
agonist	NOUN	O	O
MK-212	PROPN	O	I-Entity
caused	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
blockade	NOUN	O	O
of	ADP	O	O
the	DET	O	O
response	NOUN	O	O
of	ADP	O	O
muscimol	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
benzodiazepines	NOUN	O	I-Entity
,	PUNCT	O	O
clonazepam	NOUN	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
-	SYM	O	O
0.3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
several	ADJ	O	O
fold	NOUN	O	O
more	ADV	O	O
potent	ADJ	O	O
than	ADP	O	O
diazepam	NOUN	O	I-Entity
(	PUNCT	O	O
0.3	NUM	O	O
-	SYM	O	O
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
blocking	VERB	O	O
the	DET	O	O
myoclonic	ADJ	O	B-Entity
jerks	NOUN	O	I-Entity
.	PUNCT	O	O

While	ADP	O	O
(	PUNCT	O	O
-)-baclofen	PROPN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
proved	VERB	O	O
to	PART	O	O
be	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
antagonist	NOUN	O	O
of	ADP	O	O
muscimol	NOUN	O	I-Entity
,	PUNCT	O	O
its	ADJ	O	O
(	PUNCT	O	O
+	CCONJ	O	O
)	PUNCT	O	O

Considering	VERB	O	O
the	DET	O	O
fact	NOUN	O	O
that	ADP	O	O
5-HTP	NUM	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
benzodiazepines	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
beneficial	ADJ	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
myoclonus	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
muscimol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myoclonus	NOUN	O	I-Entity
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
satisfactory	ADJ	O	O
animal	NOUN	O	O
model	NOUN	O	O
that	ADJ	O	O
may	VERB	O	O
prove	VERB	O	O
useful	ADJ	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
new	ADJ	O	O
drug	NOUN	O	O
treatments	NOUN	O	O
for	ADP	O	O
this	DET	O	O
condition	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
present	ADJ	O	O
study	NOUN	O	O
indicated	VERB	O	O
the	DET	O	O
possible	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
MK-212	PROPN	O	I-Entity
and	CCONJ	O	O
(	PUNCT	O	O
-)-baclofen	PUNCT	O	I-Entity
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
myoclonus	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3703509)

Hyperglycemic	PROPN	O	B-Entity
acidotic	ADJ	O	I-Entity
coma	NOUN	O	I-Entity
and	CCONJ	O	O
death	NOUN	O	O
in	ADP	O	O
Kearns	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Sayre	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
paper	NOUN	O	O
presents	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
metabolic	ADJ	O	O
findings	NOUN	O	O
in	ADP	O	O
two	NUM	O	O
young	ADJ	O	O
boys	NOUN	O	O
with	ADP	O	O
long	ADV	O	O
-	PUNCT	O	O
standing	VERB	O	O
Kearns	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Sayre	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Following	VERB	O	O
short	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
oral	ADJ	O	O
prednisone	NOUN	O	I-Entity
,	PUNCT	O	O
both	DET	O	O
boys	NOUN	O	O
developed	VERB	O	O
lethargy	NOUN	O	I-Entity
,	PUNCT	O	O
increasing	VERB	O	O
somnolence	NOUN	O	I-Entity
,	PUNCT	O	O
polydipsia	NOUN	O	I-Entity
,	PUNCT	O	O
polyphagia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
polyuria	NOUN	O	I-Entity
.	PUNCT	O	O

Both	DET	O	O
presented	VERB	O	O
in	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
room	NOUN	O	O
with	ADP	O	O
profound	ADJ	O	O
coma	NOUN	O	I-Entity
,	PUNCT	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
severe	ADJ	O	O
hyperglycemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
acidosis	NOUN	O	I-Entity
.	PUNCT	O	O

Nonketotic	ADJ	O	O
lactic	NOUN	O	B-Entity
acidosis	NOUN	O	I-Entity
was	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
one	NUM	O	O
and	CCONJ	O	O
ketosis	NOUN	O	I-Entity
without	ADP	O	O
a	DET	O	O
known	VERB	O	O
serum	NOUN	O	O
lactate	NOUN	O	I-Entity
level	NOUN	O	O
was	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
.	PUNCT	O	O

Respiratory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
rapidly	ADV	O	O
ensued	ADV	O	O
and	CCONJ	O	O
both	DET	O	O
patients	NOUN	O	O
expired	VERB	O	O
in	ADP	O	O
spite	NOUN	O	O
of	ADP	O	O
efforts	NOUN	O	O
at	ADP	O	O
resuscitation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
believe	VERB	O	O
these	DET	O	O
two	NUM	O	O
cases	NOUN	O	O
represent	VERB	O	O
a	DET	O	O
newly	ADV	O	O
described	VERB	O	O
and	CCONJ	O	O
catastrophic	ADJ	O	O
metabolic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
endocrine	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
Kearns	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Sayre	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20683499)

Effects	NOUN	O	O
of	ADP	O	O
active	ADJ	O	O
constituents	NOUN	O	O
of	ADP	O	O
Crocus	PROPN	O	O
sativus	PROPN	O	O
L.	PROPN	O	O
,	PUNCT	O	O
crocin	NOUN	O	I-Entity
on	ADP	O	O
streptozocin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
model	NOUN	O	O
of	ADP	O	O
sporadic	ADJ	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
male	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
involvement	NOUN	O	O
of	ADP	O	O
water	NOUN	O	O
-	PUNCT	O	O
soluble	ADJ	O	O
carotenoids	NOUN	O	I-Entity
,	PUNCT	O	O
crocins	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADP	O	O
the	DET	O	O
main	ADJ	O	O
and	CCONJ	O	O
active	ADJ	O	O
components	NOUN	O	O
of	ADP	O	O
Crocus	PROPN	O	O
sativus	NOUN	O	O
L.	PROPN	O	O
extract	VERB	O	O
in	ADP	O	O
learning	NOUN	O	O
and	CCONJ	O	O
memory	NOUN	O	O
processes	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
proposed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
crocins	NOUN	O	I-Entity
on	ADP	O	O
sporadic	ADJ	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
intracerebroventricular	NOUN	O	O
(	PUNCT	O	O
icv	NOUN	O	O
)	PUNCT	O	O
streptozocin	NOUN	O	I-Entity
(	PUNCT	O	O
STZ	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
male	NOUN	O	O
rats	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

Male	ADJ	O	O
adult	NOUN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
90	NUM	O	O
and	CCONJ	O	O
260	NUM	O	O
-	SYM	O	O
290	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
1	NUM	O	O
,	PUNCT	O	O
control	NOUN	O	O
;	PUNCT	O	O
2	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
,	PUNCT	O	O
crocins	NOUN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
STZ	PROPN	O	I-Entity
;	PUNCT	O	O
5	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
,	PUNCT	O	O
STZ	PROPN	O	I-Entity
+	PROPN	O	O
crocins	NOUN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
groups	NOUN	O	O
,	PUNCT	O	O
rats	NOUN	O	O
were	VERB	O	O
injected	VERB	O	O
with	ADP	O	O
STZ	PROPN	O	I-Entity
-	PUNCT	O	O
icv	PROPN	O	O
bilaterally	ADV	O	O
(	PUNCT	O	O
3	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
first	ADJ	O	O
day	NOUN	O	O
and	CCONJ	O	O
3	NUM	O	O
days	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
similar	ADJ	O	O
STZ	PROPN	O	I-Entity
-	PUNCT	O	O
icv	PROPN	O	O
application	NOUN	O	O
was	VERB	O	O
repeated	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
STZ	PROPN	O	I-Entity
+	PROPN	O	O
crocin	ADJ	O	I-Entity
animal	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
crocin	NOUN	O	I-Entity
was	VERB	O	O
applied	VERB	O	O
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
15	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O

Prescription	NOUN	O	O
of	ADP	O	O
crocin	NOUN	O	I-Entity
in	ADP	O	O
each	DET	O	O
dose	NOUN	O	O
was	VERB	O	O
repeated	VERB	O	O
once	ADV	O	O
for	ADP	O	O
two	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
found	VERB	O	O
out	PART	O	O
that	ADP	O	O
crocin	NOUN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
mg	NUM	O	O

/	SYM	O	O
kg)-treated	VERB	O	O
STZ	PROPN	O	I-Entity
-	PUNCT	O	O
injected	VERB	O	O
rats	NOUN	O	O
show	VERB	O	O
higher	ADJ	O	O
correct	ADJ	O	O
choices	NOUN	O	O
and	CCONJ	O	O
lower	ADJ	O	O
errors	NOUN	O	O
in	ADP	O	O
Y	PROPN	O	O
-	PUNCT	O	O
maze	NOUN	O	O
than	ADP	O	O
vehicle	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
STZ	PROPN	O	I-Entity
-	PUNCT	O	O
injected	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
crocin	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
mentioned	VERB	O	O
dose	NOUN	O	O
could	VERB	O	O
significantly	ADV	O	O
attenuated	VERB	O	O
learning	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
memory	NOUN	O	I-Entity
impairment	NOUN	O	I-Entity
in	ADP	O	O
treated	VERB	O	O
STZ	PROPN	O	I-Entity
-	PUNCT	O	O
injected	VERB	O	O
group	NOUN	O	O
in	ADP	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
results	NOUN	O	O
demonstrate	VERB	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
crocin	NOUN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
antagonizing	VERB	O	O
the	DET	O	O
cognitive	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
STZ	PROPN	O	I-Entity
-	PUNCT	O	O
icv	PROPN	O	O
in	ADP	O	O
rats	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
potential	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
neurodegenerative	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
such	ADJ	O	O
as	ADP	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20466178)

Rosaceiform	PROPN	O	O
dermatitis	VERB	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
topical	ADJ	O	O
tacrolimus	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
herein	ADV	O	O
3	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
rosacea	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
dermatitis	NOUN	O	I-Entity
eruptions	NOUN	O	I-Entity
while	ADP	O	O
using	VERB	O	O
0.03%	NUM	O	O
or	CCONJ	O	O
0.1%	NUM	O	O
tacrolimus	NOUN	O	I-Entity
ointment	NOUN	O	O
for	ADP	O	O
facial	ADJ	O	B-Entity
dermatitis	NOUN	O	I-Entity
.	PUNCT	O	O

Skin	NOUN	O	O
biopsy	NOUN	O	O
specimens	NOUN	O	O
showed	VERB	O	O
telangiectasia	NOUN	O	I-Entity
and	CCONJ	O	O
noncaseating	NOUN	O	O
epithelioid	ADJ	O	O
granulomatous	ADJ	O	O
tissue	NOUN	O	O
formation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
papillary	NOUN	O	O
to	ADP	O	O
mid	ADJ	O	O
dermis	NOUN	O	O
.	PUNCT	O	O

Continuous	ADJ	O	O
topical	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
immunomodulators	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
tacrolimus	NOUN	O	I-Entity
or	CCONJ	O	O
pimecrolimus	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
regarded	VERB	O	O
as	ADP	O	O
a	DET	O	O
potential	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
rosaceiform	NOUN	O	O
dermatitis	NOUN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
many	ADJ	O	O
cases	NOUN	O	O
have	VERB	O	O
not	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (19944736)

poly	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
L	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
lactid	PROPN	O	I-Entity
acid	NOUN	O	I-Entity
nanoparticles	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
colloidal	ADJ	O	O
drug	NOUN	O	O
delivery	NOUN	O	O
system	NOUN	O	O
,	PUNCT	O	O
able	ADJ	O	O
to	PART	O	O
trespass	VERB	O	O
the	DET	O	O
BBB	PROPN	O	O
.	PUNCT	O	O

Tacrine	PROPN	O	I-Entity
,	PUNCT	O	O
administered	VERB	O	O
in	ADP	O	O
LiCl	PROPN	O	I-Entity
pre	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
induces	VERB	O	O
electrocorticographic	ADJ	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
delayed	VERB	O	O
hippocampal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
tacrine	NOUN	O	I-Entity
-	PUNCT	O	O
loaded	VERB	O	O
poly	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
L	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
lactid	PROPN	O	I-Entity
acid	NOUN	O	I-Entity
nanoparticles	NOUN	O	O
(	PUNCT	O	O
5mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
saline	ADJ	O	O
solution	NOUN	O	O
of	ADP	O	O
tacrine	NOUN	O	I-Entity
(	PUNCT	O	O
5mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
an	DET	O	O
empty	ADJ	O	O
colloidal	NOUN	O	O
nanoparticle	NOUN	O	O
suspension	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
following	VERB	O	O
i.p	NOUN	O	O
.	PUNCT	O	O

administration	NOUN	O	O
in	ADP	O	O
LiCl	PROPN	O	I-Entity
-	PUNCT	O	O
pre	PROPN	O	O
-	PUNCT	O	O
treated	VERB	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

All	ADJ	O	O
the	DET	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
tacrine	NOUN	O	I-Entity
-	PUNCT	O	O
loaded	VERB	O	O
nanoparticles	NOUN	O	O
showed	VERB	O	O
an	DET	O	O
earlier	ADJ	O	O
outcome	NOUN	O	O
of	ADP	O	O
CNS	PROPN	O	O
adverse	ADJ	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
i.e.	X	O	O
epileptic	ADJ	O	I-Entity
onset	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
those	DET	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
free	ADJ	O	O
compound	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
min	NOUN	O	O
vs.	ADP	O	O
22	NUM	O	O
min	NOUN	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
tacrine	NOUN	O	I-Entity
-	PUNCT	O	O
loaded	VERB	O	O
nanoparticles	NOUN	O	O
administration	NOUN	O	O
induced	VERB	O	O
damage	NOUN	O	B-Entity
of	ADP	O	I-Entity
neuronal	ADJ	O	I-Entity
cells	NOUN	O	I-Entity
in	ADP	O	O
CA1	PROPN	O	O
field	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
in	ADP	O	O
all	DET	O	O
treated	VERB	O	O
animals	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
saline	ADJ	O	O
solution	NOUN	O	O
of	ADP	O	O
tacrine	NOUN	O	I-Entity
only	ADV	O	O
in	ADP	O	O
60%	NUM	O	O
of	ADP	O	O
animals	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
evaluation	NOUN	O	O
of	ADP	O	O
time	NOUN	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
onset	NOUN	O	O
of	ADP	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
neurodegenerative	ADJ	O	O
processes	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
tacrine	NOUN	O	I-Entity
-	PUNCT	O	O
lithium	NOUN	O	I-Entity
model	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
,	PUNCT	O	O
could	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
preliminarily	ADV	O	O
the	DET	O	O
capability	NOUN	O	O
of	ADP	O	O
a	DET	O	O
drug	NOUN	O	O
delivery	NOUN	O	O
system	NOUN	O	O
to	ADP	O	O
trespass	NOUN	O	O
(	PUNCT	O	O
or	CCONJ	O	O
not	ADV	O	O
)	PUNCT	O	O
the	DET	O	O
BBB	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19721134)

The	DET	O	O
antiarrhythmic	ADJ	O	O
effect	NOUN	O	O
and	CCONJ	O	O
possible	ADJ	O	O
ionic	ADJ	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
on	ADP	O	O
animal	NOUN	O	O
models	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
and	CCONJ	O	O
explore	VERB	O	O
the	DET	O	O
underlying	ADJ	O	O
ionic	ADJ	O	O
mechanism	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
both	DET	O	O
aconitine	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rat	NOUN	O	O
and	CCONJ	O	O
ouabain	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
guinea	NOUN	O	O
pig	NOUN	O	O
arrhythmia	NOUN	O	I-Entity
models	NOUN	O	O
.	PUNCT	O	O

Confocal	PROPN	O	O
microscopy	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
measure	VERB	O	O
intracellular	ADJ	O	O
free	ADJ	O	O
-	PUNCT	O	O
calcium	NOUN	O	I-Entity
concentrations	NOUN	O	O
(	PUNCT	O	O
[	PUNCT	O	O
Ca(2+)](i	PROPN	O	I-Entity
)	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
isolated	ADJ	O	O
myocytes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
current	ADJ	O	O
data	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
pilocarpine	NOUN	O	I-Entity
significantly	ADV	O	O
delayed	VERB	O	O
onset	NOUN	O	O
of	ADP	O	O
arrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
decreased	VERB	O	O
the	DET	O	O
time	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
fibrillation	NOUN	O	I-Entity
,	PUNCT	O	O
reduced	VERB	O	O
arrhythmia	NOUN	O	I-Entity
score	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
the	DET	O	O
survival	NOUN	O	O
time	NOUN	O	O
of	ADP	O	O
arrhythmic	ADJ	O	I-Entity
rats	NOUN	O	O
and	CCONJ	O	O
guinea	NOUN	O	O
pigs	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Ca(2+)](i	PROPN	O	I-Entity
)	PUNCT	O	O
overload	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
aconitine	NOUN	O	I-Entity
or	CCONJ	O	O
ouabain	NOUN	O	I-Entity
was	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
isolated	ADJ	O	O
myocytes	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
pilocarpine	NOUN	O	I-Entity
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
M(3)-muscarinic	ADJ	O	O
acetylcholine	NOUN	O	I-Entity
receptor	NOUN	O	O
(	PUNCT	O	O
mAChR	PROPN	O	O
)	PUNCT	O	O

antagonist	NOUN	O	O
4-DAMP	NOUN	O	I-Entity
(	PUNCT	O	O
4-diphenylacetoxy	NUM	O	B-Entity
-	PUNCT	O	I-Entity
N	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
methylpiperidine	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
methiodide	NOUN	O	I-Entity
)	PUNCT	O	O
partially	ADV	O	O
abolished	VERB	O	O
the	DET	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
pilocarpine	ADV	O	I-Entity
produced	VERB	O	O
antiarrhythmic	ADJ	O	O
actions	NOUN	O	O
on	ADP	O	O
arrhythmic	ADJ	O	I-Entity
rat	NOUN	O	O
and	CCONJ	O	O
guinea	NOUN	O	O
pig	NOUN	O	O
models	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
aconitine	NOUN	O	I-Entity
or	CCONJ	O	O
ouabain	NOUN	O	I-Entity
via	ADP	O	O
stimulating	VERB	O	O
the	DET	O	O
cardiac	ADJ	O	O
M(3)-mAChR.	NOUN	O	O
The	DET	O	O
mechanism	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
Ca(2	PROPN	O	I-Entity
+	PROPN	O	O
)	PUNCT	O	O
handling	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17786501)

Disulfiram	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
transient	ADJ	O	O
optic	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
peripheral	ADJ	O	I-Entity
neuropathy	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
optic	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
peripheral	ADJ	O	I-Entity
neuropathy	NOUN	O	I-Entity
after	ADP	O	O
chronic	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
disulfiram	NOUN	O	I-Entity
for	ADP	O	O
alcohol	NOUN	O	B-Entity
dependence	NOUN	O	I-Entity
management	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
57-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
gradual	ADJ	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
vision	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
eyes	NOUN	O	O
with	ADP	O	O
intermittent	ADJ	O	O
headaches	NOUN	O	I-Entity
for	ADP	O	O
2	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
also	ADV	O	O
complained	VERB	O	O
of	ADP	O	O
paraesthesia	NOUN	O	I-Entity
with	ADP	O	O
numbness	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
feet	NOUN	O	O
.	PUNCT	O	O

Visual	ADJ	O	O
field	NOUN	O	O
testing	NOUN	O	O
confirmed	VERB	O	O
bilateral	ADJ	O	O
central	ADJ	O	O
-	PUNCT	O	O
caecal	ADJ	O	O
scotomata	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
had	VERB	O	O
been	VERB	O	O
taking	VERB	O	O
disulfiram	NOUN	O	I-Entity
for	ADP	O	O
alcohol	NOUN	O	B-Entity
dependence	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
preceding	VERB	O	O
3	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Disulfiram	PROPN	O	I-Entity
discontinuation	NOUN	O	O
lead	NOUN	O	O
to	ADP	O	O
an	DET	O	O
immediate	ADJ	O	O
symptomatic	ADJ	O	O
improvement	NOUN	O	O
.	PUNCT	O	O

Physicians	NOUN	O	O
initiating	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
disulfiram	NOUN	O	I-Entity
therapy	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
these	DET	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16960342)

Sustained	ADJ	O	O
clinical	ADJ	O	O
improvement	NOUN	O	O
of	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
decompensated	VERB	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
cirrhosis	NOUN	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
lamivudine	NOUN	O	I-Entity
monotherapy	NOUN	O	O
.	PUNCT	O	O

Hepatitis	PROPN	O	B-Entity
B	PROPN	O	I-Entity
virus	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
HBV	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
infection	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
causes	VERB	O	O
liver	NOUN	O	B-Entity
cirrhosis	NOUN	O	I-Entity
and	CCONJ	O	O
hepatocellular	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
,	PUNCT	O	O
remains	VERB	O	O
a	DET	O	O
major	ADJ	O	O
health	NOUN	O	O
problem	NOUN	O	O
in	ADP	O	O
Asian	ADJ	O	O
countries	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
report	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
encountered	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
decompensated	VERB	O	O
HBV	PROPN	O	O
-	PUNCT	O	O
related	VERB	O	O
cirrhosis	NOUN	O	I-Entity
who	NOUN	O	O
exhibited	VERB	O	O
the	DET	O	O
dramatic	ADJ	O	O
improvements	NOUN	O	O
after	ADP	O	O
antiviral	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
lamivudine	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
reverse	NOUN	O	O
transcriptase	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
23	NUM	O	O
months	NOUN	O	O
dramatically	ADV	O	O
improved	VERB	O	O
her	ADJ	O	O
liver	NOUN	O	O
severity	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
both	DET	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
surface	NOUN	O	I-Entity
antigen	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
e	NOUN	O	I-Entity
antigen	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
to	PART	O	O
have	VERB	O	O
disappeared	VERB	O	O
in	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
lamivudine	NOUN	O	I-Entity
to	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
HBV	PROPN	O	O
-	PUNCT	O	O
related	VERB	O	O
cirrhosis	NOUN	O	I-Entity
,	PUNCT	O	O
like	ADP	O	O
our	ADJ	O	O
present	ADJ	O	O
case	NOUN	O	O
,	PUNCT	O	O
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
as	ADP	O	O
an	DET	O	O
initial	ADJ	O	O
medical	ADJ	O	O
therapeutic	ADJ	O	O
option	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
countries	NOUN	O	O
where	ADV	O	O
liver	NOUN	O	O
transplantation	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
reliably	ADV	O	O
available	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (11226639)

Dual	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
melatonin	NOUN	O	I-Entity
on	ADP	O	O
barbiturate	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
narcosis	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Melatonin	PROPN	O	I-Entity
affects	VERB	O	O
the	DET	O	O
circadian	NOUN	O	O
sleep	NOUN	O	O
/	SYM	O	O
wake	VERB	O	O
cycle	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
is	VERB	O	O
not	ADV	O	O
clear	ADJ	O	O
whether	ADP	O	O
it	PRON	O	O
may	VERB	O	O
influence	VERB	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
narcosis	NOUN	O	I-Entity
.	PUNCT	O	O

Sodium	NOUN	O	B-Entity
thiopenthal	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
intraperitoneally	ADV	O	O
into	ADP	O	O
male	ADJ	O	O
rats	NOUN	O	O
pre	ADV	O	O
-	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
melatonin	NOUN	O	I-Entity
(	PUNCT	O	O
0.05	NUM	O	O
,	PUNCT	O	O
0.5	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
and	CCONJ	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Melatonin	PROPN	O	I-Entity
pre	NOUN	O	O
-	PUNCT	O	O
treatment	NOUN	O	O
affected	VERB	O	O
in	ADP	O	O
a	DET	O	O
dual	ADJ	O	O
manner	NOUN	O	O
barbiturate	NOUN	O	I-Entity
narcosis	NOUN	O	I-Entity
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
no	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
correlation	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
particular	ADJ	O	O
,	PUNCT	O	O
low	ADJ	O	O
doses	NOUN	O	O
reduced	VERB	O	O
the	DET	O	O
latency	NOUN	O	O
to	ADP	O	O
and	CCONJ	O	O
prolonged	VERB	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
barbiturate	NOUN	O	I-Entity
narcosis	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
highest	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
melatonin	NOUN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
caused	VERB	O	O
a	DET	O	O
paradoxical	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
latency	NOUN	O	O
and	CCONJ	O	O
produced	VERB	O	O
a	DET	O	O
sustained	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
narcosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

Melatonin	PROPN	O	I-Entity
0.5	NUM	O	O
and	CCONJ	O	O
5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
influenced	VERB	O	O
the	DET	O	O
duration	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
the	DET	O	O
latency	NOUN	O	O
of	ADP	O	O
ketamine-	NOUN	O	I-Entity
or	CCONJ	O	O
diazepam	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
narcosis	NOUN	O	I-Entity
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
dual	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
melatonin	NOUN	O	I-Entity
on	ADP	O	O
pharmacological	ADJ	O	O
narcosis	NOUN	O	I-Entity
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
specific	ADJ	O	O
for	ADP	O	O
the	DET	O	O
barbiturate	NOUN	O	I-Entity
mechanism	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9228650)

Effects	NOUN	O	O
of	ADP	O	O
NIK-247	PROPN	O	I-Entity
on	ADP	O	O
cholinesterase	NOUN	O	O
and	CCONJ	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
NIK-247	PROPN	O	I-Entity
on	ADP	O	O
cholinesterase	NOUN	O	O
,	PUNCT	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
and	CCONJ	O	O
spontaneous	ADJ	O	O
movement	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
and	CCONJ	O	O
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
of	ADP	O	O
the	DET	O	O
well	ADV	O	O
-	PUNCT	O	O
known	VERB	O	O
cholinesterase	NOUN	O	O
inhibitors	NOUN	O	O
tacrine	VERB	O	I-Entity
and	CCONJ	O	O
E-2020	PROPN	O	I-Entity
.	PUNCT	O	O

NIK-247	PROPN	O	I-Entity
,	PUNCT	O	O
tacrine	NOUN	O	I-Entity
and	CCONJ	O	O
E-2020	VERB	O	I-Entity
all	DET	O	O
strongly	ADV	O	O
inhibited	VERB	O	O
acetylcholinesterase	NOUN	O	O
(	PUNCT	O	O
AChE	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
human	ADJ	O	O
red	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
(	PUNCT	O	O
IC50s	PROPN	O	O
=	SYM	O	O
1.0	NUM	O	O
x	SYM	O	O
10(-6	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
2.9	NUM	O	O
x	SYM	O	O
10(-7	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
3.7	NUM	O	O
x	SYM	O	O
10(-8	NUM	O	O
)	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
NIK-247	PROPN	O	I-Entity
and	CCONJ	O	O
tacrine	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
E-2020	NUM	O	I-Entity
,	PUNCT	O	O
strongly	ADV	O	O
inhibited	VERB	O	O
butyrylcholinestrase	NOUN	O	O
(	PUNCT	O	O
BuChE	PROPN	O	O
)	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
inhibitory	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
NIK-247	PROPN	O	I-Entity
on	ADP	O	O
AChE	PROPN	O	O
was	VERB	O	O
reversible	ADJ	O	O
.	PUNCT	O	O

significantly	ADV	O	O
improved	VERB	O	O
the	DET	O	O
amnesia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
scopolamine	NOUN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
s.c	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
NIK-247	PROPN	O	I-Entity
at	ADP	O	O
a	DET	O	O
low	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
0.1	NUM	O	O
-	SYM	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
p.o	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

improves	VERB	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
but	CCONJ	O	O
does	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
spontaneous	ADJ	O	O
movement	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
NIK-247	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
drug	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8766220)

Nightmares	NOUN	O	O
and	CCONJ	O	O
hallucinations	NOUN	O	I-Entity
after	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
intake	NOUN	O	O
of	ADP	O	O
tramadol	NOUN	O	I-Entity
combined	VERB	O	O
with	ADP	O	O
antidepressants	NOUN	O	O
.	PUNCT	O	O

Tramadol	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
weak	ADJ	O	O
opioid	NOUN	O	O
with	ADP	O	O
effects	NOUN	O	O
on	ADP	O	O
adrenergic	NOUN	O	O
and	CCONJ	O	O
serotonergic	ADJ	O	O
neurotransmission	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
used	VERB	O	O
to	PART	O	O
treat	VERB	O	O
cancer	NOUN	O	I-Entity
pain	NOUN	O	I-Entity
and	CCONJ	O	O
chronic	ADJ	O	O
non	ADJ	O	O
malignant	NOUN	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
drug	NOUN	O	O
was	VERB	O	O
initiated	VERB	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
paroxetine	NOUN	O	I-Entity
and	CCONJ	O	O
dosulepine	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
tetraparetic	ADJ	O	I-Entity
patient	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Fifty	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
the	DET	O	O
patient	NOUN	O	O
presented	VERB	O	O
hallucinations	NOUN	O	I-Entity
that	ADP	O	O
only	ADV	O	O
stopped	VERB	O	O
after	ADP	O	O
the	DET	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
psycho	NOUN	O	O
-	PUNCT	O	O
active	ADJ	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
tramadol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
questions	VERB	O	O
the	DET	O	O
long	ADJ	O	O
term	NOUN	O	O
use	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
killers	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
psycho	NOUN	O	O
-	PUNCT	O	O
active	ADJ	O	O
drugs	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
non	ADJ	O	O
malignant	NOUN	O	O
pain	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
if	ADP	O	O
pain	NOUN	O	I-Entity
is	VERB	O	O
under	ADP	O	O
control	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8441146)

Apparent	ADJ	O	O
cure	NOUN	O	O
of	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
by	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
sustained	ADJ	O	O
remissions	NOUN	O	O
and	CCONJ	O	O
possible	ADJ	O	O
cure	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
erosive	ADJ	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
(	PUNCT	O	O
RA	PROPN	O	I-Entity
)	PUNCT	O	O
by	ADP	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplantation	NOUN	O	O
(	PUNCT	O	O
BMT	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
2	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

BMT	PROPN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
treat	VERB	O	O
severe	ADJ	O	O
aplastic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
which	ADJ	O	O
was	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
gold	NOUN	O	I-Entity
in	ADP	O	O
one	NUM	O	O
case	NOUN	O	O
and	CCONJ	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
8	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
years	NOUN	O	O
since	ADP	O	O
the	DET	O	O
transplants	NOUN	O	O
(	PUNCT	O	O
representing	VERB	O	O
8	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
years	NOUN	O	O
since	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
all	DET	O	O
immunosuppressive	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
RA	PROPN	O	I-Entity
in	ADP	O	O
each	DET	O	O
case	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
completely	ADV	O	O
quiescent	ADJ	O	O
.	PUNCT	O	O

Although	ADP	O	O
short	ADJ	O	O
term	NOUN	O	O
remission	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
RA	PROPN	O	I-Entity
following	VERB	O	O
BMT	PROPN	O	O
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
,	PUNCT	O	O
these	DET	O	O
are	VERB	O	O
the	DET	O	O
first	ADJ	O	O
cases	NOUN	O	O
for	ADP	O	O
which	ADJ	O	O
prolonged	ADJ	O	O
followup	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
available	ADJ	O	O
.	PUNCT	O	O

This	DET	O	O
experience	NOUN	O	O
raises	VERB	O	O
the	DET	O	O
question	NOUN	O	O
of	ADP	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
BMT	PROPN	O	O
itself	PRON	O	O
as	ADP	O	O
a	DET	O	O
therapeutic	ADJ	O	O
option	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
uncontrolled	ADJ	O	O
destructive	ADJ	O	O
synovitis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3653576)

Urinary	ADJ	O	O
enzymes	NOUN	O	O
and	CCONJ	O	O
protein	NOUN	O	O
patterns	NOUN	O	O
as	ADP	O	O
indicators	NOUN	O	O
of	ADP	O	O
injury	NOUN	O	B-Entity
to	ADP	O	I-Entity
different	ADJ	O	I-Entity
regions	NOUN	O	I-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
kidney	NOUN	O	I-Entity
.	PUNCT	O	O

Acute	PROPN	O	B-Entity
experimental	ADJ	O	I-Entity
models	NOUN	O	I-Entity
of	ADP	O	I-Entity
renal	ADJ	O	I-Entity
damage	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
proximal	ADJ	O	O
tubular	NOUN	O	O
,	PUNCT	O	O
glomerular	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
papillary	ADJ	O	O
regions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
were	VERB	O	O
produced	VERB	O	O
by	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
hexachloro-1:3-butadiene	NOUN	O	I-Entity
(	PUNCT	O	O
HCBD	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
PAN	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2-bromoethylamine	NUM	O	I-Entity
(	PUNCT	O	O
BEA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Several	ADJ	O	O
routine	ADJ	O	O
indicators	NOUN	O	O
of	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
enzymes	NOUN	O	O
alkaline	ADJ	O	O
phosphatase	NOUN	O	O
and	CCONJ	O	O
N	NOUN	O	O
-	PUNCT	O	O
acetyl	NOUN	O	O
-	PUNCT	O	O
beta	NOUN	O	O
-	PUNCT	O	O
glucosaminidase	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
molecular	ADJ	O	O
weight	NOUN	O	O
of	ADP	O	O
protein	NOUN	O	B-Entity
excretion	NOUN	O	I-Entity
were	VERB	O	O
determined	VERB	O	O
on	ADP	O	O
urine	NOUN	O	O
samples	NOUN	O	O
.	PUNCT	O	O

Tubular	ADJ	O	O
damage	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
HCBD	PROPN	O	I-Entity
or	CCONJ	O	O
BEA	PROPN	O	I-Entity
was	VERB	O	O
discriminated	VERB	O	O
both	DET	O	O
quantitatively	ADV	O	O
and	CCONJ	O	O
qualitatively	ADV	O	O
from	ADP	O	O
glomerular	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
PAN	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
latter	ADJ	O	O
was	VERB	O	O
characterized	VERB	O	O
by	ADP	O	O
a	DET	O	O
pronounced	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
protein	NOUN	O	B-Entity
excretion	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
proteins	NOUN	O	O
with	ADP	O	O
molecular	ADJ	O	O
weight	NOUN	O	O
greater	ADJ	O	O
than	ADP	O	O
40,000	NUM	O	O
Da	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
protein	NOUN	O	B-Entity
excretion	NOUN	O	I-Entity
in	ADP	O	O
tubular	ADJ	O	O
damage	NOUN	O	O
was	VERB	O	O
raised	VERB	O	O
only	ADV	O	O
slightly	ADV	O	O
and	CCONJ	O	O
characterized	VERB	O	O
by	ADP	O	O
excretion	NOUN	O	B-Entity
of	ADP	O	I-Entity
proteins	NOUN	O	I-Entity
of	ADP	O	O
a	DET	O	O
wide	ADJ	O	O
range	NOUN	O	O
of	ADP	O	O
molecular	ADJ	O	O
weights	NOUN	O	O
.	PUNCT	O	O

Proximal	ADJ	O	O
tubular	ADJ	O	O
damage	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
HCBD	PROPN	O	I-Entity
and	CCONJ	O	O
papillary	ADJ	O	O
damage	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
BEA	PROPN	O	I-Entity
were	VERB	O	O
distinguished	VERB	O	O
both	DET	O	O
by	ADP	O	O
conventional	ADJ	O	O
urinalysis	NOUN	O	O
(	PUNCT	O	O
volume	NOUN	O	O
and	CCONJ	O	O
specific	ADJ	O	O
gravity	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
by	ADP	O	O
measurement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
urinary	ADJ	O	O
enzymes	NOUN	O	O
.	PUNCT	O	O

Alkaline	ADJ	O	O
phosphatase	NOUN	O	O
and	CCONJ	O	O
glucose	NOUN	O	I-Entity
were	VERB	O	O
markedly	ADV	O	O
and	CCONJ	O	O
transiently	ADV	O	O
elevated	VERB	O	O
in	ADP	O	O
proximal	ADJ	O	O
tubular	ADJ	O	O
damage	NOUN	O	O
and	CCONJ	O	O
N	NOUN	O	O
-	PUNCT	O	O
acetyl	NOUN	O	O
-	PUNCT	O	O
beta	NOUN	O	O
-	PUNCT	O	O
glucosaminidase	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
sustained	ADJ	O	O
elevation	NOUN	O	O
in	ADP	O	O
papillary	ADJ	O	O
damage	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
both	DET	O	O
selective	ADJ	O	O
urinary	ADJ	O	O
enzymes	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
molecular	ADJ	O	O
weight	NOUN	O	O
pattern	NOUN	O	O
of	ADP	O	O
urinary	ADJ	O	O
proteins	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
provide	VERB	O	O
diagnostic	ADJ	O	O
information	NOUN	O	O
about	ADP	O	O
the	DET	O	O
possible	ADJ	O	O
site	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2750819)

Neuromuscular	ADJ	O	B-Entity
blockade	NOUN	O	I-Entity
with	ADP	O	O
magnesium	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
and	CCONJ	O	O
nifedipine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
tocolysis	NOUN	O	O
with	ADP	O	O
nifedipine	NOUN	O	I-Entity
developed	VERB	O	O
neuromuscular	ADJ	O	B-Entity
blockade	NOUN	O	I-Entity
after	ADP	O	O
500	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
magnesium	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
reaction	NOUN	O	O
demonstrates	VERB	O	O
that	ADP	O	O
nifedipine	NOUN	O	I-Entity
can	VERB	O	O
seriously	ADV	O	O
potentiate	VERB	O	O
the	DET	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
magnesium	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1899352)

Ifosfamide	ADV	O	I-Entity
continuous	ADJ	O	O
infusion	NOUN	O	O
without	ADP	O	O
mesna	NOUN	O	I-Entity
.	PUNCT	O	O

Twenty	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
27	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
administered	VERB	O	O
as	ADP	O	O
a	DET	O	O
24-hour	NUM	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
without	ADP	O	O
Mesna	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
goal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
deliver	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
total	ADJ	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
that	ADJ	O	O
would	VERB	O	O
be	VERB	O	O
comparable	ADJ	O	O
to	ADP	O	O
standard	ADJ	O	O
bolus	NOUN	O	O
or	CCONJ	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
infusions	NOUN	O	O
administered	VERB	O	O
with	ADP	O	O
Mesna	PROPN	O	I-Entity
.	PUNCT	O	O

Four	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
transient	ADJ	O	O
microscopic	ADJ	O	O
hematuria	NOUN	O	I-Entity
at	ADP	O	O
400	NUM	O	O
,	PUNCT	O	O
450	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2/d	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
no	DET	O	O
instances	NOUN	O	O
of	ADP	O	O
macroscopic	ADJ	O	O
hematuria	NOUN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
550	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2/d	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
patients	NOUN	O	O
experienced	VERB	O	O
nonurologic	ADJ	O	O
toxicity	NOUN	O	I-Entity
;	PUNCT	O	O
confusion	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nausea	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Grade	PROPN	O	O
2	NUM	O	O
leukopenia	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
predictability	NOUN	O	O
of	ADP	O	O
hematuria	NOUN	O	I-Entity
are	VERB	O	O
not	ADV	O	O
precise	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
least	ADJ	O	O
daily	ADJ	O	O
monitoring	NOUN	O	O
by	ADP	O	O
urine	NOUN	O	O

Hematest	PROPN	O	O
is	VERB	O	O
essential	ADJ	O	O
,	PUNCT	O	O
adding	VERB	O	O
Mesna	PROPN	O	I-Entity
to	ADP	O	O
the	DET	O	O
infusate	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
persistent	ADJ	O	O
hematuria	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
protracted	ADJ	O	O
infusion	NOUN	O	O
schedule	NOUN	O	O
for	ADP	O	O
ifosfamide	NOUN	O	I-Entity
permits	NOUN	O	O
convenient	ADJ	O	O
outpatient	ADJ	O	O
administration	NOUN	O	O
without	ADP	O	O
Mesna	PROPN	O	I-Entity
and	CCONJ	O	O
reduces	VERB	O	O
the	DET	O	O
drug	NOUN	O	O
cost	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
usage	NOUN	O	O
of	ADP	O	O
this	DET	O	O
agent	NOUN	O	O
by	ADP	O	O
up	ADP	O	O
to	PART	O	O
890	NUM	O	O
per	ADP	O	O
cycle	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18161408)

Myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
in	ADP	O	O
pregnancy	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
clomiphene	NOUN	O	B-Entity
citrate	NOUN	O	I-Entity
for	ADP	O	O
ovulation	NOUN	O	O
induction	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Clomiphene	NOUN	O	B-Entity
citrate	NOUN	O	I-Entity
(	PUNCT	O	O
CC	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
commonly	ADV	O	O
prescribed	VERB	O	O
for	ADP	O	O
ovulation	NOUN	O	O
induction	NOUN	O	O
.	PUNCT	O	O

Thromboembolism	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
but	CCONJ	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
complication	NOUN	O	O
that	ADJ	O	O
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
after	ADP	O	O
ovulation	NOUN	O	O
induction	NOUN	O	O
with	ADP	O	O
CC	PROPN	O	I-Entity
.	PUNCT	O	O

coronary	ADJ	O	B-Entity
thrombosis	NOUN	O	I-Entity
or	CCONJ	O	O
thromboembolism	NOUN	O	I-Entity
with	ADP	O	O
subsequent	ADJ	O	O
clot	NOUN	O	O
lysis	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
suggested	VERB	O	O
as	ADP	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
causes	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
(	PUNCT	O	O
MI	PROPN	O	I-Entity
)	PUNCT	O	O
during	ADP	O	O
pregnancy	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
subsequently	ADV	O	O
normal	ADJ	O	O
coronary	ADJ	O	O
angiogram	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
33-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
a	DET	O	O
5-week	NUM	O	O
gestation	NOUN	O	O
had	VERB	O	O
recently	ADV	O	O
received	VERB	O	O
CC	PROPN	O	I-Entity
for	ADP	O	O
ovulation	NOUN	O	O
induction	NOUN	O	O
and	CCONJ	O	O
presented	VERB	O	O
with	ADP	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
electrocardiogram	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
lateral	ADJ	O	O
and	CCONJ	O	O
anterior	ADJ	O	O
wall	NOUN	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
admission	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
at	ADP	O	O
high	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
radiation	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
fetus	NOUN	O	O
,	PUNCT	O	O
so	ADV	O	O
a	DET	O	O
coronary	ADJ	O	O
angiogram	NOUN	O	O
was	VERB	O	O
postponed	VERB	O	O
until	ADP	O	O
the	DET	O	O
second	ADJ	O	O
trimester	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
first	ADJ	O	O
reported	VERB	O	O
case	NOUN	O	O
documenting	VERB	O	O
a	DET	O	O
possible	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
CC	PROPN	O	I-Entity
and	CCONJ	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Thrombosis	NOUN	O	I-Entity
might	VERB	O	O
be	VERB	O	O
a	DET	O	O
rare	ADJ	O	O
but	CCONJ	O	O
hazardous	ADJ	O	O
complication	NOUN	O	O
of	ADP	O	O
CC	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17574447)

Hepatonecrosis	NOUN	O	I-Entity
and	CCONJ	O	O
cholangitis	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
phenobarbital	NOUN	O	I-Entity
therapy	NOUN	O	O
:	PUNCT	O	O
an	DET	O	O
autopsy	ADJ	O	O
report	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Phenobarbital	PROPN	O	I-Entity
(	PUNCT	O	O
PB	PROPN	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
a	DET	O	O
reputation	NOUN	O	O
for	ADP	O	O
safety	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
it	PRON	O	O
is	VERB	O	O
commonly	ADV	O	O
believed	VERB	O	O
that	ADP	O	O
PB	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
increases	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
aminotransferase	NOUN	O	O
levels	NOUN	O	O
do	VERB	O	O
not	ADV	O	O
indicate	VERB	O	O
or	CCONJ	O	O
predict	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
significant	ADJ	O	O
chronic	ADJ	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Here	ADV	O	O
we	PRON	O	O
report	VERB	O	O
of	ADP	O	O
two	NUM	O	O
adult	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
long	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
epilepsy	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
PB	PROPN	O	I-Entity
who	NOUN	O	O
died	VERB	O	O
suddenly	ADV	O	O
:	PUNCT	O	O
one	NUM	O	O
as	ADP	O	O
consequence	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
other	ADJ	O	O
of	ADP	O	O
acute	ADJ	O	O
bronchopneumonia	NOUN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
autopsy	NOUN	O	O
,	PUNCT	O	O
analysis	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	O
parenchyma	NOUN	O	O
revealed	VERB	O	O
rich	ADJ	O	O
portal	ADJ	O	O
inflammatory	ADJ	O	O
infiltrate	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
consisted	VERB	O	O
of	ADP	O	O
mixed	ADJ	O	O
eosinophil	NOUN	O	O
and	CCONJ	O	O
monocyte	NOUN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
several	ADJ	O	O
foci	NOUN	O	O
of	ADP	O	O
necrosis	NOUN	O	I-Entity
surrounded	VERB	O	O
by	ADP	O	O
a	DET	O	O
hard	ADJ	O	O
ring	NOUN	O	O
of	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
specific	ADJ	O	O
granulomatous	ADJ	O	O
tissue	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
findings	NOUN	O	O
illustrate	VERB	O	O
that	ADP	O	O
PB	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
chronic	ADJ	O	O
liver	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
more	ADV	O	O
serious	ADJ	O	O
and	CCONJ	O	O
deleterious	ADJ	O	O
consequences	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
this	DET	O	O
reason	NOUN	O	O
,	PUNCT	O	O
each	DET	O	O
clinician	NOUN	O	O
should	VERB	O	O
recognize	VERB	O	O
this	DET	O	O
entity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
differential	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
PB	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
asymptomatic	ADJ	O	O
chronic	ADJ	O	B-Entity
hepatic	ADJ	O	I-Entity
enzyme	NOUN	O	I-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16710500)

Ethambutol	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
optic	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Ethambutol	PROPN	O	I-Entity
is	VERB	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
tuberculosis	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
still	ADV	O	O
prevalent	ADJ	O	O
in	ADP	O	O
Southeast	PROPN	O	O
Asia	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
can	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
permanent	ADJ	O	O
visual	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
3	NUM	O	O
cases	NOUN	O	O
which	ADJ	O	O
presented	VERB	O	O
with	ADP	O	O
bitemporal	ADJ	O	B-Entity
hemianopia	NOUN	O	I-Entity
.	PUNCT	O	O

Three	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
ethambutol	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
toxic	ADJ	O	O
optic	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
are	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

All	DET	O	O
3	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
central	ADJ	O	I-Entity
visual	ADJ	O	I-Entity
acuity	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
colour	ADJ	O	I-Entity
vision	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
Ishihara	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
visual	ADJ	O	I-Entity
field	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
visual	ADJ	O	B-Entity
field	NOUN	O	I-Entity
loss	NOUN	O	I-Entity
had	VERB	O	O
a	DET	O	O
bitemporal	ADJ	O	O
flavour	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
involvement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
optic	NOUN	O	O
chiasm	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
stopping	VERB	O	O
ethambutol	NOUN	O	I-Entity
on	ADP	O	O
diagnosis	NOUN	O	O
,	PUNCT	O	O
visual	ADJ	O	O
function	NOUN	O	O
continued	VERB	O	O
to	PART	O	O
deteriorate	VERB	O	O
for	ADP	O	O
a	DET	O	O
few	ADJ	O	O
months	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
3	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
some	DET	O	O
permanent	ADJ	O	O
loss	NOUN	O	B-Entity
of	ADP	O	I-Entity
visual	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O

Ethambutol	NOUN	O	I-Entity
usage	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
permanent	ADJ	O	O
visual	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
and	CCONJ	O	O
should	VERB	O	O
be	VERB	O	O
avoided	VERB	O	O
if	ADP	O	O
possible	ADJ	O	O
or	CCONJ	O	O
used	VERB	O	O
with	ADP	O	O
caution	NOUN	O	O
and	CCONJ	O	O
proper	ADJ	O	O
ophthalmological	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
author	NOUN	O	O
postulates	VERB	O	O
that	ADP	O	O
in	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
ethambutol	NOUN	O	I-Entity
associated	VERB	O	O
chiasmopathy	NOUN	O	O
,	PUNCT	O	O
ethambutol	NOUN	O	I-Entity
may	VERB	O	O
initially	ADV	O	O
affect	VERB	O	O
the	DET	O	O
optic	ADJ	O	O
nerves	NOUN	O	O
and	CCONJ	O	O
subsequently	ADV	O	O
progress	NOUN	O	O
to	PART	O	O
involve	VERB	O	O
the	DET	O	O
optic	ADJ	O	O
chiasm	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11694026)

Tolerability	NOUN	O	O
of	ADP	O	O
nimesulide	NOUN	O	I-Entity
and	CCONJ	O	O
paracetamol	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
NSAID	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
urticaria	NOUN	O	I-Entity
/	SYM	O	O
angioedema	NOUN	O	I-Entity
.	PUNCT	O	O

Previous	ADJ	O	O
studies	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
tolerance	NOUN	O	O
of	ADP	O	O
nimesulide	NOUN	O	I-Entity
and	CCONJ	O	O
paracetamol	NOUN	O	I-Entity
in	ADP	O	O
subjects	NOUN	O	O
with	ADP	O	O
cutaneous	ADJ	O	O
,	PUNCT	O	O
respiratory	ADJ	O	O
and	CCONJ	O	O
anaphylactoid	ADJ	O	O
reactions	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
nonsteroidal	ADJ	O	B-Entity
anti	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
inflammatory	ADJ	O	I-Entity
drugs	NOUN	O	I-Entity
(	PUNCT	O	O
NSAIDs	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
we	PRON	O	O
investigated	VERB	O	O
tolerability	NOUN	O	O
and	CCONJ	O	O
reliability	NOUN	O	O
of	ADP	O	O
nimesulide	NOUN	O	I-Entity
and	CCONJ	O	O
paracetamol	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
very	ADV	O	O
large	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
an	DET	O	O
exclusive	ADJ	O	O
well	NOUN	O	O
-	PUNCT	O	O
documented	VERB	O	O
history	NOUN	O	O
of	ADP	O	O
NSAID	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
urticaria	NOUN	O	I-Entity
/	SYM	O	O
angioedema	NOUN	O	I-Entity
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
evaluated	VERB	O	O
whether	ADP	O	O
some	DET	O	O
factors	NOUN	O	O
have	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
to	PART	O	O
increase	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
reaction	NOUN	O	O
to	ADP	O	O
paracetamol	VERB	O	I-Entity
and	CCONJ	O	O
nimesulide	VERB	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
single	ADJ	O	O
-	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
oral	ADJ	O	O
challenge	NOUN	O	O
procedure	NOUN	O	O
with	ADP	O	O
nimesulide	NOUN	O	I-Entity
or	CCONJ	O	O
paracetamol	NOUN	O	I-Entity
was	VERB	O	O
applied	VERB	O	O
to	ADP	O	O
829	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
NSAID	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
urticaria	NOUN	O	I-Entity
/	SYM	O	O
angioedema	NOUN	O	I-Entity
.	PUNCT	O	O

patients	NOUN	O	O
experienced	VERB	O	O
reactions	NOUN	O	O
to	PART	O	O
nimesulide	VERB	O	I-Entity
or	CCONJ	O	O
paracetamol	VERB	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
715	NUM	O	O
patients	NOUN	O	O
tested	VERB	O	O
with	ADP	O	O
nimesulide	NOUN	O	I-Entity
62	NUM	O	O
(	PUNCT	O	O
8.6%	NUM	O	O
)	PUNCT	O	O
showed	VERB	O	O
a	DET	O	O
positive	ADJ	O	O
test	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
of	ADP	O	O
114	NUM	O	O
subjects	NOUN	O	O
submitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
challenge	NOUN	O	O
with	ADP	O	O
paracetamol	NOUN	O	I-Entity
,	PUNCT	O	O
13	NUM	O	O
(	PUNCT	O	O
9.6%	NUM	O	O
)	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
tolerate	VERB	O	O
this	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
18.28%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
urticaria	NOUN	O	I-Entity
and	CCONJ	O	O
11.8%	NUM	O	O
of	ADP	O	O
subjects	NOUN	O	O
with	ADP	O	O
an	DET	O	O
history	NOUN	O	O
of	ADP	O	O
NSAID	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
urticaria	NOUN	O	I-Entity
/	SYM	O	O
angioedema	NOUN	O	I-Entity
or	CCONJ	O	O
angioedema	NOUN	O	I-Entity
alone	ADV	O	O
(	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
chronic	ADJ	O	O
urticaria	NOUN	O	I-Entity
)	PUNCT	O	O
resulted	VERB	O	O
to	PART	O	O
be	VERB	O	O
intolerant	ADJ	O	O
to	PART	O	O
alternative	VERB	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Taken	VERB	O	O
together	ADV	O	O
,	PUNCT	O	O
our	ADJ	O	O
results	NOUN	O	O
confirm	VERB	O	O
the	DET	O	O
good	ADJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
nimesulide	NOUN	O	I-Entity
and	CCONJ	O	O
paracetamol	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
experienced	VERB	O	O
urticaria	PROPN	O	I-Entity
/	SYM	O	O
angioedema	ADV	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
NSAIDs	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
reaction	NOUN	O	O
to	ADP	O	O
these	DET	O	O
alternative	ADJ	O	O
study	NOUN	O	O
drugs	NOUN	O	O
is	VERB	O	O
statistically	ADV	O	O
increased	VERB	O	O
by	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
urticaria	NOUN	O	I-Entity
and	CCONJ	O	O
,	PUNCT	O	O
above	ADV	O	O
all	DET	O	O
,	PUNCT	O	O
by	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
NSAID	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
angioedema	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11282081)

Effects	NOUN	O	O
of	ADP	O	O
verapamil	NOUN	O	I-Entity
on	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
electrophysiological	ADJ	O	O
determinants	NOUN	O	O
in	ADP	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

Atrial	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
remodeling	NOUN	O	O
promotes	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
and	CCONJ	O	O
maintenance	NOUN	O	O
of	ADP	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
(	PUNCT	O	O
AF	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
decreases	VERB	O	O
L	PROPN	O	O
-	PUNCT	O	O
type	NOUN	O	O
Ca(2	NOUN	O	I-Entity
+	PUNCT	O	O
)	PUNCT	O	O
current	ADJ	O	O
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
also	ADV	O	O
a	DET	O	O
clinical	ADJ	O	O
suggestion	NOUN	O	O
that	ADP	O	O
acute	ADJ	O	O
L	NOUN	O	O
-	PUNCT	O	O
type	NOUN	O	O
Ca(2	PROPN	O	I-Entity
)	PUNCT	O	O
channel	NOUN	O	O
blockade	NOUN	O	O
can	VERB	O	O
promote	VERB	O	O
AF	PROPN	O	I-Entity
,	PUNCT	O	O
consistent	ADJ	O	O
with	ADP	O	O
an	DET	O	O
AF	PROPN	O	I-Entity
promoting	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
Ca(2	PROPN	O	I-Entity
+	PUNCT	O	O
)	PUNCT	O	O
channel	NOUN	O	O
inhibition	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
AF	PROPN	O	I-Entity
promotion	NOUN	O	O
by	ADP	O	O
Ca(2	PROPN	O	I-Entity
+	SYM	O	O
)	PUNCT	O	O
channel	NOUN	O	O
blockers	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
administered	VERB	O	O
verapamil	NOUN	O	I-Entity
to	ADP	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
chloralose	NOUN	O	I-Entity
anesthetized	ADJ	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

Diltiazem	PROPN	O	I-Entity
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
comparison	NOUN	O	O
drug	NOUN	O	O
and	CCONJ	O	O
autonomic	ADJ	O	O
blockade	NOUN	O	O
with	ADP	O	O
atropine	NOUN	O	I-Entity
and	CCONJ	O	O
nadolol	NOUN	O	I-Entity
was	VERB	O	O
applied	VERB	O	O
in	ADP	O	O
some	DET	O	O
experiments	NOUN	O	O
.	PUNCT	O	O

Epicardial	ADJ	O	O
mapping	NOUN	O	O
with	ADP	O	O
240	NUM	O	O
epicardial	ADJ	O	O
electrodes	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
activation	NOUN	O	O
during	ADP	O	O
AF	PROPN	O	I-Entity
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Verapamil	ADV	O	I-Entity
caused	VERB	O	O
AF	PROPN	O	I-Entity
promotion	NOUN	O	O
in	ADP	O	O
six	NUM	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
increasing	VERB	O	O
mean	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
AF	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
burst	NOUN	O	O
pacing	NOUN	O	O
,	PUNCT	O	O
from	ADP	O	O
8+/-4	NUM	O	O
s	NOUN	O	O
(	PUNCT	O	O
mean+/-S.E.	PROPN	O	O
)	PUNCT	O	O
to	ADP	O	O
95+/-39	NUM	O	O
s	NOUN	O	O
(	PUNCT	O	O
P<0.01	PROPN	O	O
vs.	X	O	O
control	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
loading	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
0.1	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
and	CCONJ	O	O
228+/-101	NUM	O	O
s	NOUN	O	O
(	PUNCT	O	O
P<0.0005	PROPN	O	O
vs.	X	O	O
control	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
0.2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
.	PUNCT	O	O

Underlying	VERB	O	O
electrophysiological	ADJ	O	O
mechanisms	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
detail	NOUN	O	O
in	ADP	O	O
five	NUM	O	O
additional	ADJ	O	O
dogs	NOUN	O	O
under	ADP	O	O
control	NOUN	O	O
conditions	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
higher	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
verapamil	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
these	DET	O	O
experiments	NOUN	O	O
,	PUNCT	O	O
verapamil	ADV	O	I-Entity
shortened	VERB	O	O
mean	ADJ	O	O
effective	ADJ	O	O
refractory	ADJ	O	O
period	NOUN	O	O
(	PUNCT	O	O
ERP	PROPN	O	O
)	PUNCT	O	O
from	ADP	O	O
122+/-5	NUM	O	O
to	ADP	O	O
114+/-4	NUM	O	O
ms	NOUN	O	O
(	PUNCT	O	O
P<0.02	PROPN	O	O
)	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
cycle	NOUN	O	O
length	NOUN	O	O
of	ADP	O	O
300	NUM	O	O
ms	NOUN	O	O
,	PUNCT	O	O
decreased	VERB	O	O
ERP	PROPN	O	O
heterogeneity	NOUN	O	O
(	PUNCT	O	O
from	ADP	O	O
15+/-1	NUM	O	O
to	ADP	O	O
10+/-1%	NUM	O	O
,	PUNCT	O	O
P<0.05	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
heterogeneously	ADV	O	O
accelerated	VERB	O	O
atrial	ADJ	O	O
conduction	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
the	DET	O	O
cycle	NOUN	O	O
length	NOUN	O	O
of	ADP	O	O
AF	PROPN	O	I-Entity
(	PUNCT	O	O
94+/-4	NUM	O	O
to	PART	O	O
84+/-3	NUM	O	O
ms	NOUN	O	O
,	PUNCT	O	O
P<0.005	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Diltiazem	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
affect	VERB	O	O
ERP	PROPN	O	O
,	PUNCT	O	O
AF	PROPN	O	I-Entity
cycle	NOUN	O	O
length	NOUN	O	O
or	CCONJ	O	O
AF	PROPN	O	I-Entity
duration	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
produced	VERB	O	O
conduction	NOUN	O	O
acceleration	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
caused	VERB	O	O
by	ADP	O	O
verapamil	NOUN	O	I-Entity
(	PUNCT	O	O
n=5	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
autonomic	ADJ	O	O
blockade	NOUN	O	O
,	PUNCT	O	O
verapamil	ADV	O	I-Entity
failed	VERB	O	O
to	PART	O	O
promote	VERB	O	O
AF	PROPN	O	I-Entity
and	CCONJ	O	O
increased	VERB	O	O
,	PUNCT	O	O
rather	ADV	O	O
than	ADP	O	O
decreasing	VERB	O	O
,	PUNCT	O	O
refractoriness	NOUN	O	O
.	PUNCT	O	O

Neither	DET	O	O
verapamil	ADJ	O	I-Entity
nor	CCONJ	O	O
diltiazem	NOUN	O	I-Entity
affected	VERB	O	O
atrial	ADJ	O	O
conduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
autonomic	ADJ	O	O
blockade	NOUN	O	O
.	PUNCT	O	O

Epicardial	ADJ	O	O
mapping	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
verapamil	ADV	O	I-Entity
promoted	VERB	O	O
AF	PROPN	O	I-Entity
by	ADP	O	O
increasing	VERB	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
simultaneous	ADJ	O	O
wavefronts	NOUN	O	O
reflected	VERB	O	O
by	ADP	O	O
separate	ADJ	O	O
zones	NOUN	O	O
of	ADP	O	O
reactivation	NOUN	O	O
in	ADP	O	O
each	DET	O	O
cycle	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
Verapamil	PROPN	O	I-Entity
promotes	VERB	O	O
AF	PROPN	O	I-Entity
in	ADP	O	O
normal	ADJ	O	O
dogs	NOUN	O	O
by	ADP	O	O
promoting	VERB	O	O
multiple	ADJ	O	O
circuit	NOUN	O	O
reentry	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
effect	NOUN	O	O
dependent	NOUN	O	O
on	ADP	O	O
intact	ADJ	O	O
autonomic	ADJ	O	O
tone	NOUN	O	O
and	CCONJ	O	O
not	ADV	O	O
shared	VERB	O	O
by	ADP	O	O
diltiazem	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10074612)

Hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
asystole	NOUN	O	I-Entity
after	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
intravenous	ADJ	O	O
methylprednisolone	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
monitored	ADJ	O	O
patient	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
asystole	NOUN	O	I-Entity
after	ADP	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
methylprednisolone	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
73-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
patient	NOUN	O	O
who	NOUN	O	O
underwent	VERB	O	O
electrocardiographic	ADJ	O	O
(	PUNCT	O	O
ECG	PROPN	O	O
)	PUNCT	O	O
monitoring	NOUN	O	O
throughout	ADP	O	O
the	DET	O	O
episode	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
ischemic	ADJ	O	I-Entity
cardiac	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
9	NUM	O	O
years	NOUN	O	O
earlier	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
admitted	VERB	O	O
with	ADP	O	O
a	DET	O	O
pulmonary	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
renal	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
with	ADP	O	O
hemoptysis	NOUN	O	I-Entity
,	PUNCT	O	O
rapidly	ADV	O	O
progressive	ADJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hypoxemia	NOUN	O	I-Entity
that	ADJ	O	O
required	VERB	O	O
mechanical	ADJ	O	O
ventilation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intensive	ADJ	O	O
care	NOUN	O	O
unit	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
ECG	PROPN	O	O
showed	VERB	O	O
a	DET	O	O
junctional	ADJ	O	O
rhythm	NOUN	O	O
without	ADP	O	O
ventricular	ADJ	O	B-Entity
arrhythmia	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
reviews	VERB	O	O
the	DET	O	O
current	ADJ	O	O
proposed	VERB	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
sudden	ADJ	O	B-Entity
death	NOUN	O	I-Entity
after	ADP	O	O
a	DET	O	O
high	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
methylprednisolone	NOUN	O	I-Entity
(	PUNCT	O	O
IVMP	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Rapid	ADJ	O	O
infusion	NOUN	O	O
and	CCONJ	O	O
underlying	ADJ	O	O
cardiac	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
were	VERB	O	O
important	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
case	NOUN	O	O
reported	VERB	O	O
here	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
authors	NOUN	O	O
discount	VERB	O	O
ventricular	ADJ	O	B-Entity
arrhythmia	NOUN	O	I-Entity
as	ADP	O	O
the	DET	O	O
main	ADJ	O	O
mechanism	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9209318)

Lifetime	PROPN	O	O
treatment	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
with	ADP	O	O
azidothymidine	NOUN	O	I-Entity
(	PUNCT	O	O
AZT	PROPN	O	I-Entity
)	PUNCT	O	O
produces	VERB	O	O
myelodysplasia	NOUN	O	I-Entity
.	PUNCT	O	O

AZT	PROPN	O	I-Entity
has	VERB	O	O
induced	VERB	O	O
a	DET	O	O
macrocytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
in	ADP	O	O
AIDS	PROPN	O	I-Entity
patients	NOUN	O	O
on	ADP	O	O
long	ADJ	O	O
term	NOUN	O	O
AZT	PROPN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
generally	ADV	O	O
assumed	VERB	O	O
that	ADP	O	O
DNA	PROPN	O	O
elongation	NOUN	O	O
is	VERB	O	O
stopped	VERB	O	O
by	ADP	O	O
the	DET	O	O
insertion	NOUN	O	O
of	ADP	O	O
AZT	PROPN	O	I-Entity
into	ADP	O	O
the	DET	O	O
chain	NOUN	O	O
in	ADP	O	O
place	NOUN	O	O
of	ADP	O	O
thymidine	NOUN	O	I-Entity
thus	ADV	O	O
preventing	VERB	O	O
the	DET	O	O
phosphate	NOUN	O	I-Entity
hydroxyl	NOUN	O	O
linkages	NOUN	O	O
and	CCONJ	O	O
therefore	ADV	O	O
suppresses	VERB	O	O
hemopoietic	ADJ	O	O
progenitor	NOUN	O	O
cell	NOUN	O	O
proliferation	NOUN	O	O
in	ADP	O	O
an	DET	O	O
early	ADJ	O	O
stage	NOUN	O	O
of	ADP	O	O
differentiation	NOUN	O	O
.	PUNCT	O	O

CBA	PROPN	O	O
/	SYM	O	O
Ca	PROPN	O	O
male	ADJ	O	O
mice	NOUN	O	O
started	VERB	O	O
on	ADP	O	O
AZT	PROPN	O	I-Entity
0.75	NUM	O	O
mg	NUM	O	O
/	SYM	O	O

ml	INTJ	O	O
H2O	PROPN	O	O
at	ADP	O	O
84	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
kept	VERB	O	O
on	ADP	O	O
it	PRON	O	O
for	ADP	O	O
687	NUM	O	O
days	NOUN	O	O
when	ADV	O	O
dosage	NOUN	O	O
reduced	VERB	O	O
to	ADP	O	O
0.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
ml	INTJ	O	O
H2O	PROPN	O	O
for	ADP	O	O
a	DET	O	O
group	NOUN	O	O
,	PUNCT	O	O
another	DET	O	O
group	NOUN	O	O
removed	VERB	O	O
from	ADP	O	O
AZT	PROPN	O	I-Entity
to	PART	O	O
see	VERB	O	O
recovery	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
third	ADJ	O	O
group	NOUN	O	O
remained	VERB	O	O
on	ADP	O	O
0.75	NUM	O	O
mg	NUM	O	O
.	PUNCT	O	O

Histological	ADJ	O	O
examination	NOUN	O	O
on	ADP	O	O
9	NUM	O	O
of	ADP	O	O
10	NUM	O	O
mice	NOUN	O	O
with	ADP	O	O
such	ADJ	O	O
thrombocytopenia	NOUN	O	I-Entity
showed	VERB	O	O
changes	NOUN	O	O
compatible	ADJ	O	O
with	ADP	O	O
myelodysplastic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
MDS	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
hypocellular	ADJ	O	O
myelodysplasia	NOUN	O	I-Entity
,	PUNCT	O	O
two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
hypersegmented	VERB	O	O
myelodysplastic	ADJ	O	I-Entity
granulocytosis	NOUN	O	O
,	PUNCT	O	O
two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
hypercellular	ADJ	O	O
marrow	NOUN	O	O
with	ADP	O	O
abnormal	ADJ	O	O
megakaryocytes	NOUN	O	O
with	ADP	O	O
bizarre	ADJ	O	O
nuclei	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
case	NOUN	O	O
of	ADP	O	O
megakaryocytic	ADJ	O	O
myelosis	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
hyperplastic	ADJ	O	B-Entity
marrow	NOUN	O	I-Entity
,	PUNCT	O	O
dysmyelopoiesis	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
hypocellular	ADJ	O	B-Entity
marrow	NOUN	O	I-Entity
and	CCONJ	O	O
two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
myelodysplasia	NOUN	O	I-Entity
with	ADP	O	O
dyserythropoiesis	NOUN	O	I-Entity
,	PUNCT	O	O
hemosiderosis	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
hypocellular	ADJ	O	B-Entity
marrow	NOUN	O	I-Entity
.	PUNCT	O	O

Above	ADP	O	O
mentioned	VERB	O	O
AZT	PROPN	O	I-Entity
incorporation	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
induced	VERB	O	O
an	DET	O	O
ineffective	ADJ	O	O
hemopoiesis	NOUN	O	O
in	ADP	O	O
the	DET	O	O
primitive	ADJ	O	O
hemopoietic	ADJ	O	O
progenitor	NOUN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
known	VERB	O	O
to	PART	O	O
be	VERB	O	O
seen	VERB	O	O
commonly	ADV	O	O
in	ADP	O	O
the	DET	O	O
myelodysplastic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8742498)

Influence	NOUN	O	O
of	ADP	O	O
diet	NOUN	O	O
free	ADJ	O	O
of	ADP	O	O
NAD	PROPN	O	I-Entity
-	PUNCT	O	O
precursors	NOUN	O	O
on	ADP	O	O
acetaminophen	NOUN	O	I-Entity
hepatotoxicity	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Recently	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
demonstrated	VERB	O	O
the	DET	O	O
hepatoprotective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
nicotinic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
amide	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
selective	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
poly(ADP	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
ribose	NOUN	O	I-Entity
)	PUNCT	O	I-Entity
polymerase	NOUN	O	O
(	PUNCT	O	O
PARP	PROPN	O	O
;	PUNCT	O	O
EC	PROPN	O	O
2.4.2.30	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
mice	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
acetaminophen	NOUN	O	I-Entity
(	PUNCT	O	O
AAP)-hepatitis	PROPN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
the	DET	O	O
AAP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
liver	NOUN	O	B-Entity
injury	NOUN	O	I-Entity
involves	VERB	O	O
a	DET	O	O
step	NOUN	O	O
which	ADJ	O	O
depends	VERB	O	O
on	ADP	O	O
adenoribosylation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
investigates	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
diet	NOUN	O	O
free	ADJ	O	O
of	ADP	O	O
precursors	NOUN	O	O
of	ADP	O	O
NAD	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
substrate	NOUN	O	O
on	ADP	O	O
which	ADJ	O	O
PARP	PROPN	O	O
acts	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
female	ADJ	O	O
NMRI	PROPN	O	O
mice	NOUN	O	O
with	ADP	O	O
AAP	PROPN	O	I-Entity
hepatitis	NOUN	O	I-Entity
and	CCONJ	O	O
evaluates	VERB	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
simultaneous	ADJ	O	O
ethanol	NOUN	O	I-Entity
consumption	NOUN	O	O
in	ADP	O	O
these	DET	O	O
animals	NOUN	O	O
.	PUNCT	O	O

Liver	NOUN	O	B-Entity
injuries	NOUN	O	I-Entity
were	VERB	O	O
quantified	VERB	O	O
as	ADP	O	O
serum	NOUN	O	O
activities	NOUN	O	O
of	ADP	O	O
glutamate	NOUN	O	I-Entity
-	PUNCT	O	O
oxaloacetate	NOUN	O	I-Entity
transaminase	NOUN	O	O
(	PUNCT	O	O
GOT	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
glutamate	NOUN	O	I-Entity
-	PUNCT	O	O
pyruvate	NOUN	O	I-Entity
transaminase	NOUN	O	O
(	PUNCT	O	O
GPT	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

While	ADP	O	O
AAP	PROPN	O	I-Entity
caused	VERB	O	O
a	DET	O	O
117-fold	NUM	O	O
elevation	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
transaminase	NOUN	O	O
activities	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
kept	VERB	O	O
on	ADP	O	O
a	DET	O	O
standard	ADJ	O	O
laboratory	NOUN	O	O
diet	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
significantly	ADV	O	O
exacerbated	VERB	O	O
by	ADP	O	O
ethanol	NOUN	O	I-Entity
and	CCONJ	O	O
inhibited	VERB	O	O
by	ADP	O	O
nicotinic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
amide	NOUN	O	I-Entity
(	PUNCT	O	O
NAA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
fed	VERB	O	O
a	DET	O	O
diet	NOUN	O	O
free	ADJ	O	O
of	ADP	O	O
precursors	NOUN	O	O
of	ADP	O	O
NAD	PROPN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
these	DET	O	O
animals	NOUN	O	O
,	PUNCT	O	O
only	ADV	O	O
minor	ADJ	O	O
increases	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
transaminase	NOUN	O	O
activities	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
AAP	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
unlike	ADP	O	O
the	DET	O	O
exacerbation	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
ethanol	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
on	ADP	O	O
a	DET	O	O
standard	ADJ	O	O
diet	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
liver	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
was	VERB	O	O
inhibited	VERB	O	O
by	ADP	O	O
50%	NUM	O	O
by	ADP	O	O
ethanol	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
further	ADJ	O	O
64%	NUM	O	O
reduction	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
,	PUNCT	O	O
when	ADV	O	O
NAA	PROPN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
to	ADP	O	O
ethanol	NOUN	O	I-Entity
/	SYM	O	O
AAP	PROPN	O	I-Entity
-	PUNCT	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
provide	VERB	O	O
evidence	NOUN	O	O
that	ADP	O	O
the	DET	O	O
AAP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hepatitis	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
exacerbation	NOUN	O	O
by	ADP	O	O
ethanol	NOUN	O	I-Entity
can	VERB	O	O
either	DET	O	O
be	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
end	NOUN	O	O
-	PUNCT	O	O
product	NOUN	O	O
inhibition	NOUN	O	O
of	ADP	O	O
PARP	PROPN	O	O
by	ADP	O	O
NAA	PROPN	O	I-Entity
or	CCONJ	O	O
by	ADP	O	O
dietary	ADJ	O	O
depletion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
enzyme	NOUN	O	O
's	PART	O	O
substrate	NOUN	O	O
NAD	PROPN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
see	VERB	O	O
the	DET	O	O
main	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
NAA	PROPN	O	I-Entity
as	ADP	O	O
for	ADP	O	O
the	DET	O	O
combinational	ADJ	O	O
use	NOUN	O	O
in	ADP	O	O
pharmaceutical	ADJ	O	O
preparations	NOUN	O	O
of	ADP	O	O
acetaminophen	NOUN	O	I-Entity
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
avoid	VERB	O	O
hepatic	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
this	DET	O	O
widely	ADV	O	O
used	VERB	O	O
analgesic	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2435991)

Antiarrhythmic	ADJ	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
cibenzoline	NOUN	O	I-Entity
on	ADP	O	O
canine	ADJ	O	O
ventricular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

Using	VERB	O	O
two	NUM	O	O
-	PUNCT	O	O
stage	NOUN	O	O
coronary	ADJ	O	O
ligation-	NOUN	O	O
,	PUNCT	O	O
digitalis-	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
adrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
canine	NOUN	O	O
ventricular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
antiarrhythmic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cibenzoline	NOUN	O	I-Entity
were	VERB	O	O
examined	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
minimum	NOUN	O	O
effective	ADJ	O	O
plasma	NOUN	O	O
concentration	NOUN	O	O
for	ADP	O	O
each	DET	O	O
arrhythmia	NOUN	O	I-Entity
model	NOUN	O	O
was	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

Cibenzoline	PROPN	O	I-Entity
suppressed	VERB	O	O
all	ADJ	O	O
the	DET	O	O
arrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
minimum	NOUN	O	O
effective	ADJ	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
for	ADP	O	O
arrhythmias	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
24-h	NUM	O	O
coronary	ADJ	O	O
ligation	NOUN	O	O
,	PUNCT	O	O
48-h	NUM	O	O
coronary	ADJ	O	O
ligation	NOUN	O	O
,	PUNCT	O	O
digitalis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
adrenaline	NOUN	O	I-Entity
were	VERB	O	O
1.9	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

The	DET	O	O
concentration	NOUN	O	O
for	ADP	O	O
adrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
arrhythmia	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
than	ADP	O	O
those	DET	O	O
for	ADP	O	O
the	DET	O	O
other	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
arrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
pharmacological	ADJ	O	O
profile	NOUN	O	O
is	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
of	ADP	O	O
mexiletine	NOUN	O	I-Entity
and	CCONJ	O	O
tocainide	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
all	DET	O	O
three	NUM	O	O
drugs	NOUN	O	O
have	VERB	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
(	PUNCT	O	O
CNS	PROPN	O	O
)	PUNCT	O	O
stimulant	ADJ	O	O
action	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
cibenzoline	NOUN	O	I-Entity
had	VERB	O	O
only	ADV	O	O
weak	ADJ	O	O
hypotensive	ADJ	O	I-Entity
and	CCONJ	O	O
sinus	ADJ	O	O
node	NOUN	O	O
depressive	ADJ	O	I-Entity
effects	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
orally	ADV	O	O
active	ADJ	O	O
when	ADV	O	O
given	VERB	O	O
to	ADP	O	O
coronary	ADJ	O	O
ligation	NOUN	O	O
arrhythmia	NOUN	O	I-Entity
dogs	NOUN	O	O
,	PUNCT	O	O
its	ADJ	O	O
clinical	ADJ	O	O
usefulness	NOUN	O	O
is	VERB	O	O
expected	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (950631)

Immunopathology	NOUN	O	O
of	ADP	O	O
penicillamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
glomerular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Four	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
developed	VERB	O	O
heavy	ADJ	O	O
proteinuria	NOUN	O	I-Entity
after	ADP	O	O
five	NUM	O	O
to	PART	O	O
12	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
findings	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
in	ADP	O	O
early	ADJ	O	O
membranous	ADJ	O	B-Entity
glomerulonephritis	NOUN	O	I-Entity
,	PUNCT	O	O
differences	NOUN	O	O
being	VERB	O	O
observed	VERB	O	O
however	ADV	O	O
in	ADP	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
staining	VERB	O	O
for	ADP	O	O
the	DET	O	O
early	ADJ	O	O
-	PUNCT	O	O
acting	VERB	O	O
complement	NOUN	O	O
components	NOUN	O	O
C1q	PROPN	O	O
and	CCONJ	O	O
C4	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (663266)

Ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
from	ADP	O	O
diatrizoate	NOUN	O	I-Entity
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
chelating	VERB	O	O
agents	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
Renografin	PROPN	O	B-Entity
76%	NUM	O	I-Entity
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
that	DET	O	O
of	ADP	O	O
Hypaque	PROPN	O	B-Entity
76%	NUM	O	I-Entity
by	ADP	O	O
selective	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
each	DET	O	O
into	ADP	O	O
the	DET	O	O
right	ADJ	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
of	ADP	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

Renografin	PROPN	O	I-Entity
contains	VERB	O	O
the	DET	O	O
chelating	VERB	O	O
agents	NOUN	O	O
sodium	NOUN	O	B-Entity
citrate	NOUN	O	I-Entity
and	CCONJ	O	O
disodium	NOUN	O	B-Entity
edetate	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
Hypaque	PROPN	O	I-Entity
contains	VERB	O	O
calcium	NOUN	O	B-Entity
disodium	NOUN	O	I-Entity
edetate	NOUN	O	I-Entity
and	CCONJ	O	O
no	DET	O	O
sodium	NOUN	O	B-Entity
citrate	NOUN	O	I-Entity
.	PUNCT	O	O

Ventricular	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
occurred	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
often	ADV	O	O
with	ADP	O	O
Renografin	PROPN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
chelating	VERB	O	O
agents	NOUN	O	O
contribute	VERB	O	O
to	ADP	O	O
toxicity	NOUN	O	I-Entity
in	ADP	O	O
coronary	ADJ	O	O
angiography	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19319147)

Rapid	ADJ	O	O
reversal	NOUN	O	O
of	ADP	O	O
anticoagulation	NOUN	O	O
reduces	VERB	O	O
hemorrhage	NOUN	O	I-Entity
volume	NOUN	O	O
in	ADP	O	O
a	DET	O	O
mouse	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
warfarin	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O

Warfarin	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
intracerebral	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
(	PUNCT	O	O
W	PROPN	O	O
-	PUNCT	O	O
ICH	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
severe	ADJ	O	O
type	NOUN	O	O
of	ADP	O	O
stroke	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
no	DET	O	O
consensus	NOUN	O	O
on	ADP	O	O
the	DET	O	O
optimal	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
W	PROPN	O	O
-	PUNCT	O	O
ICH	PROPN	O	I-Entity
.	PUNCT	O	O

Using	VERB	O	O
a	DET	O	O
mouse	NOUN	O	O
model	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
tested	VERB	O	O
whether	ADP	O	O
the	DET	O	O
rapid	ADJ	O	O
reversal	NOUN	O	O
of	ADP	O	O
anticoagulation	NOUN	O	O
using	VERB	O	O
human	ADJ	O	O
prothrombin	NOUN	O	B-Entity
complex	ADJ	O	I-Entity
concentrate	NOUN	O	I-Entity
(	PUNCT	O	O
PCC	PROPN	O	I-Entity
)	PUNCT	O	O
can	VERB	O	O
reduce	VERB	O	O
hemorrhagic	ADJ	O	O
blood	NOUN	O	O
volume	NOUN	O	O
.	PUNCT	O	O

Male	NOUN	O	O
CD-1	NOUN	O	O
mice	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
warfarin	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
over	ADP	O	O
24	NUM	O	O
h	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
/-s.d	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

First	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
showed	VERB	O	O
that	ADP	O	O
an	DET	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
PCC	PROPN	O	I-Entity
rapidly	ADV	O	O
reversed	VERB	O	O
anticoagulation	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Second	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
stereotactic	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
collagenase	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
to	PART	O	O
induce	VERB	O	O
hemorrhage	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
right	NOUN	O	O
striatum	NOUN	O	O
.	PUNCT	O	O

Forty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
minutes	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
animals	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
PCC	PROPN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
saline	ADJ	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
hemorrhage	NOUN	O	I-Entity
induction	NOUN	O	O
,	PUNCT	O	O
hemorrhagic	ADJ	O	O
blood	NOUN	O	O
volume	NOUN	O	O
was	VERB	O	O
quantified	VERB	O	O
using	VERB	O	O
a	DET	O	O
photometric	ADJ	O	O
hemoglobin	NOUN	O	O
assay	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
hemorrhagic	ADJ	O	O
blood	NOUN	O	O
volume	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
in	ADP	O	O
PCC	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
(	PUNCT	O	O
6.5+/-3.1	NUM	O	O
microL	NOUN	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
saline	ADJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
15.3+/-11.2	NUM	O	O
microL	NOUN	O	O
,	PUNCT	O	O
P=0.015	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
saline	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
45%	NUM	O	O
of	ADP	O	O
the	DET	O	O
mice	NOUN	O	O
developed	VERB	O	O
large	ADJ	O	O
hematomas	NOUN	O	I-Entity
(	PUNCT	O	O
i.e.	X	O	O
,	PUNCT	O	O
>	X	O	O
15	NUM	O	O
microL	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
extensive	ADJ	O	O
lesions	NOUN	O	O
were	VERB	O	O
never	ADV	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
PCC	PROPN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
provide	VERB	O	O
experimental	ADJ	O	O
data	NOUN	O	O
suggesting	VERB	O	O
PCC	PROPN	O	I-Entity
to	PART	O	O
be	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
acute	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
W	PROPN	O	O
-	PUNCT	O	O
ICH	PROPN	O	I-Entity
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
reducing	VERB	O	O
hemorrhagic	ADJ	O	O
blood	NOUN	O	O
volume	NOUN	O	O
.	PUNCT	O	O

Future	ADJ	O	O
studies	NOUN	O	O
are	VERB	O	O
needed	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
therapeutic	ADJ	O	O
potential	NOUN	O	O
emerging	VERB	O	O
from	ADP	O	O
our	ADJ	O	O
finding	VERB	O	O
for	ADP	O	O
human	ADJ	O	O
W	NOUN	O	O
-	PUNCT	O	O
ICH	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16634859)

Impact	PROPN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
exposure	NOUN	O	O
after	ADP	O	O
pregnancy	NOUN	O	O
recognition	NOUN	O	O
on	ADP	O	O
ultrasonographic	ADJ	O	O
fetal	ADJ	O	O
growth	NOUN	O	O
measures	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
More	ADJ	O	O
than	ADP	O	O
3	NUM	O	O
decades	NOUN	O	O
after	ADP	O	O
Jones	PROPN	O	O
and	CCONJ	O	O
Smith	PROPN	O	O
(	PUNCT	O	O
1973	NUM	O	O
)	PUNCT	O	O
reported	VERB	O	O
on	ADP	O	O
the	DET	O	O
devastation	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
alcohol	NOUN	O	I-Entity
exposure	NOUN	O	O
on	ADP	O	O
fetal	ADJ	O	O
development	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
rates	NOUN	O	O
of	ADP	O	O
heavy	ADJ	O	O
drinking	NOUN	O	O
during	ADP	O	O
pregnancy	NOUN	O	O
remain	VERB	O	O
relatively	ADV	O	O
unchanged	ADJ	O	O
.	PUNCT	O	O

Early	ADJ	O	O
identification	NOUN	O	O
of	ADP	O	O
fetal	ADJ	O	O
alcohol	NOUN	O	I-Entity
exposure	NOUN	O	O
and	CCONJ	O	O
maternal	ADJ	O	O
abstinence	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
better	ADJ	O	O
infant	NOUN	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
utility	NOUN	O	O
of	ADP	O	O
biometry	NOUN	O	O
for	ADP	O	O
detecting	VERB	O	O
alcohol	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
fetal	ADJ	O	O
growth	NOUN	O	B-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
obtained	VERB	O	O
fetal	ADJ	O	O
ultrasound	NOUN	O	O
measures	NOUN	O	O
from	ADP	O	O
routine	ADJ	O	O
ultrasound	ADJ	O	O
examinations	NOUN	O	O
for	ADP	O	O
167	NUM	O	O
pregnant	ADJ	O	O
hazardous	ADJ	O	O
drinkers	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
in	ADP	O	O
a	DET	O	O
brief	ADJ	O	O
alcohol	NOUN	O	I-Entity
intervention	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
intensity	NOUN	O	O
of	ADP	O	O
alcohol	NOUN	O	I-Entity
consumption	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
poorer	ADJ	O	O
fetal	ADJ	O	O
outcomes	NOUN	O	O
,	PUNCT	O	O
separate	ADJ	O	O
analyses	NOUN	O	O
were	VERB	O	O
conducted	VERB	O	O
for	ADP	O	O
the	DET	O	O
heavy	ADJ	O	O
(	PUNCT	O	O
average	NOUN	O	O
of	ADP	O	O
>	PROPN	O	O
or=5	ADJ	O	O
drinks	NOUN	O	O
per	ADP	O	O
drinking	NOUN	O	O
day	NOUN	O	O
)	PUNCT	O	O
alcohol	NOUN	O	I-Entity
consumers	NOUN	O	O
.	PUNCT	O	O

Analyses	NOUN	O	O
of	ADP	O	O
covariance	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
there	ADV	O	O
were	VERB	O	O
differences	NOUN	O	O
between	ADP	O	O
groups	NOUN	O	O
after	ADP	O	O
controlling	VERB	O	O
for	ADP	O	O
influences	NOUN	O	O
of	ADP	O	O
gestational	ADJ	O	O
age	NOUN	O	O
and	CCONJ	O	O
drug	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
.	PUNCT	O	O

When	ADV	O	O
women	NOUN	O	O
reportedly	ADV	O	O
quit	VERB	O	O
drinking	VERB	O	O
early	ADV	O	O
in	ADP	O	O
their	ADJ	O	O
pregnancies	NOUN	O	O
,	PUNCT	O	O
fetal	ADJ	O	O
growth	NOUN	O	O
measures	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
alcohol	NOUN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
group	NOUN	O	O
,	PUNCT	O	O
regardless	ADV	O	O
of	ADP	O	O
prior	ADJ	O	O
drinking	NOUN	O	O
patterns	NOUN	O	O
.	PUNCT	O	O

Any	DET	O	O
alcohol	NOUN	O	I-Entity
consumption	NOUN	O	O
postpregnancy	NOUN	O	O
recognition	NOUN	O	O
among	ADP	O	O
the	DET	O	O
heavy	ADJ	O	O
drinkers	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
reduced	VERB	O	B-Entity
cerebellar	ADJ	O	I-Entity
growth	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
decreased	VERB	O	B-Entity
cranial	NOUN	O	I-Entity
to	ADP	O	I-Entity
body	NOUN	O	I-Entity
growth	NOUN	O	I-Entity
in	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
either	CCONJ	O	O
quit	VERB	O	O
drinking	NOUN	O	O
or	CCONJ	O	O
who	NOUN	O	O
were	VERB	O	O
nondrinkers	NOUN	O	O
.	PUNCT	O	O

Amphetamine	PROPN	O	I-Entity
abuse	NOUN	O	O
was	VERB	O	O
predictive	ADJ	O	O
of	ADP	O	O
larger	ADJ	O	O
cranial	NOUN	O	O
to	ADP	O	O
body	NOUN	O	O
growth	NOUN	O	O
ratios	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
reliance	NOUN	O	O
on	ADP	O	O
self	NOUN	O	O
-	PUNCT	O	O
reported	VERB	O	O
drinking	NOUN	O	O
is	VERB	O	O
a	DET	O	O
limitation	NOUN	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
these	DET	O	O
findings	NOUN	O	O
support	VERB	O	O
the	DET	O	O
benefits	NOUN	O	O
of	ADP	O	O
early	ADJ	O	O
abstinence	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
potential	NOUN	O	O
for	ADP	O	O
ultrasound	ADJ	O	O
examinations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
fetal	ADJ	O	O
alcohol	NOUN	O	I-Entity
effects	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16471092)

Urinary	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
Thai	PROPN	O	O
women	NOUN	O	O
with	ADP	O	O
overactive	ADJ	O	B-Entity
bladder	NOUN	O	I-Entity
after	ADP	O	O
tolterodine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
study	VERB	O	O
the	DET	O	O
urinary	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
Thai	PROPN	O	O
women	NOUN	O	O
with	ADP	O	O
overactive	ADJ	O	B-Entity
bladder	NOUN	O	I-Entity
(	PUNCT	O	O
OAB	PROPN	O	I-Entity
)	PUNCT	O	O
after	ADP	O	O
tolterodine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

MATERIAL	NOUN	O	O
AND	CCONJ	O	O
METHOD	NOUN	O	O
:	PUNCT	O	O
Thirty	NUM	O	O
women	NOUN	O	O
(	PUNCT	O	O
aged	VERB	O	O
30	NUM	O	O
-	SYM	O	O
77	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
diagnosed	VERB	O	O
as	ADP	O	O
having	VERB	O	O
OAB	PROPN	O	I-Entity
at	ADP	O	O
the	DET	O	O
Gynecology	PROPN	O	O
Clinic	PROPN	O	O
,	PUNCT	O	O
King	PROPN	O	O
Chulalongkorn	PROPN	O	O
Memorial	PROPN	O	O
Hospital	PROPN	O	O
from	ADP	O	O
January	PROPN	O	O
to	ADP	O	O
April	PROPN	O	O
2004	NUM	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Tolterodine	PROPN	O	I-Entity
2	NUM	O	O
mg	NUM	O	O
,	PUNCT	O	O
twice	ADV	O	O
daily	ADV	O	O
was	VERB	O	O
given	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
nocturia	NOUN	O	I-Entity
episodes	NOUN	O	O
decreased	VERB	O	O
from	ADP	O	O
5.4	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
was	VERB	O	O
dry	ADJ	O	B-Entity
month	NOUN	O	I-Entity
in	ADP	O	O
5	NUM	O	O
cases	NOUN	O	O
(	PUNCT	O	O
16.7%	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
2	NUM	O	O
cases	NOUN	O	O
reporting	VERB	O	O
a	DET	O	O
moderate	ADJ	O	O
degree	NOUN	O	O
and	CCONJ	O	O
1	NUM	O	O
case	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
degree	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
one	NUM	O	O
case	NOUN	O	O
(	PUNCT	O	O
3.3%	NUM	O	O
)	PUNCT	O	O
withdrew	VERB	O	O
from	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
due	ADP	O	O
to	ADP	O	O
a	DET	O	O
severe	ADJ	O	O
dry	ADJ	O	B-Entity
mouth	NOUN	O	I-Entity
.	PUNCT	O	O

Tolterodine	PROPN	O	I-Entity
was	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
and	CCONJ	O	O
its	ADJ	O	O
effects	NOUN	O	O
improved	VERB	O	O
the	DET	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
in	ADP	O	O
Thai	PROPN	O	O
women	NOUN	O	O
with	ADP	O	O
OAB	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16174948)

Absence	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
cerebral	ADJ	O	O
vasoconstriction	NOUN	O	O
after	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
subarachnoid	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O

Cocaine	NOUN	O	I-Entity
use	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
neurovascular	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
arterial	ADJ	O	O
vasoconstriction	NOUN	O	O
and	CCONJ	O	O
vasculitis	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
are	VERB	O	O
few	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
angiographic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
on	ADP	O	O
human	ADJ	O	O
cerebral	ADJ	O	O
arteries	NOUN	O	O
.	PUNCT	O	O

Information	NOUN	O	O
on	ADP	O	O
these	DET	O	O
effects	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
obtained	VERB	O	O
from	ADP	O	O
angiograms	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
subarachnoid	ADJ	O	B-Entity
hemorrhage	NOUN	O	I-Entity
(	PUNCT	O	O
SAH	PROPN	O	I-Entity
)	PUNCT	O	O
who	NOUN	O	O
underwent	VERB	O	O
angiography	NOUN	O	O
shortly	ADV	O	O
after	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
screened	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
SAH	PROPN	O	I-Entity
retrospectively	ADV	O	O
and	CCONJ	O	O
identified	VERB	O	O
those	DET	O	O
with	ADP	O	O
positive	ADJ	O	O
urine	NOUN	O	O
toxicology	NOUN	O	O
for	ADP	O	O
cocaine	NOUN	O	I-Entity
or	CCONJ	O	O
its	ADJ	O	O
metabolites	NOUN	O	O
.	PUNCT	O	O

Quantitative	ADJ	O	O
arterial	NOUN	O	O
diameter	NOUN	O	O
measurements	NOUN	O	O
from	ADP	O	O
angiograms	NOUN	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
measurements	NOUN	O	O
from	ADP	O	O
control	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
SAH	PROPN	O	I-Entity
who	NOUN	O	O
were	VERB	O	O
matched	VERB	O	O
for	ADP	O	O
factors	NOUN	O	O
known	VERB	O	O
to	PART	O	O
influence	VERB	O	O
arterial	ADJ	O	O
diameter	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Thirteen	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
positive	ADJ	O	O
cocaine	NOUN	O	I-Entity
toxicology	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
26	NUM	O	O
controls	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
quantitative	ADJ	O	O
evidence	NOUN	O	O
for	ADP	O	O
narrowing	NOUN	O	O
of	ADP	O	O
large	ADJ	O	O
cerebral	ADJ	O	O
arteries	NOUN	O	O
or	CCONJ	O	O
qualitative	ADJ	O	O
angiographic	ADJ	O	O
evidence	NOUN	O	O
for	ADP	O	O
distal	ADJ	O	O
narrowing	NOUN	O	O
or	CCONJ	O	O
vasculitis	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
found	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
underwent	VERB	O	O
angiography	NOUN	O	O
after	ADP	O	O
aneurysmal	ADJ	O	I-Entity
SAH	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15042318)

Atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
following	VERB	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
stage	NOUN	O	O
IIIE	PROPN	O	O
diffuse	NOUN	O	O
large	ADJ	O	O
B	NOUN	O	O
-	PUNCT	O	O
cell	NOUN	O	O
gastric	NOUN	O	B-Entity
lymphoma	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
myotonic	ADJ	O	B-Entity
dystrophy	NOUN	O	I-Entity
(	PUNCT	O	O
Steinert	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
describe	VERB	O	O
the	DET	O	O
unusual	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
diffuse	NOUN	O	O
B	PROPN	O	O
-	PUNCT	O	O
cell	PROPN	O	O
gastric	NOUN	O	B-Entity
lymphoma	NOUN	O	I-Entity
and	CCONJ	O	O
myotonic	ADJ	O	B-Entity
dystrophy	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
adult	NOUN	O	O
muscular	ADJ	O	B-Entity
dystrophy	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
sudden	ADJ	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
following	VERB	O	O
one	NUM	O	O
cycle	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
based	VERB	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
patient	NOUN	O	O
.	PUNCT	O	O

Atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
or	CCONJ	O	O
other	ADJ	O	O
cardiac	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
are	VERB	O	O
unusual	ADJ	O	O
complications	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
intrinsically	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
aggressive	ADJ	O	O
chemotherapy	NOUN	O	O
employed	VERB	O	O
could	VERB	O	O
function	VERB	O	O
as	ADP	O	O
a	DET	O	O
triggering	VERB	O	O
factor	NOUN	O	O
for	ADP	O	O
the	DET	O	O
arrhythmia	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
predisposed	ADJ	O	O
myocardium	NOUN	O	O
of	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12448656)

A	DET	O	O
phase	NOUN	O	O
II	PROPN	O	O
study	NOUN	O	O
of	ADP	O	O
thalidomide	NOUN	O	I-Entity
in	ADP	O	O
advanced	ADJ	O	O
metastatic	ADJ	O	O
renal	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
activity	NOUN	O	O
of	ADP	O	O
thalidomide	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
metastatic	ADJ	O	O
renal	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
cancer	NOUN	O	I-Entity
and	CCONJ	O	O
to	PART	O	O
measure	VERB	O	O
changes	NOUN	O	O
of	ADP	O	O
one	NUM	O	O
angiogenic	ADJ	O	O
factor	NOUN	O	O
,	PUNCT	O	O
vascular	ADJ	O	O
endothelial	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
(	PUNCT	O	O
VEGF)165	PROPN	O	O
,	PUNCT	O	O
with	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

29	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
on	ADP	O	O
a	DET	O	O
study	NOUN	O	O
of	ADP	O	O
thalidomide	NOUN	O	I-Entity
using	VERB	O	O
an	DET	O	O
intra	NOUN	O	O
-	PUNCT	O	O
patient	NOUN	O	O
dose	NOUN	O	O
escalation	NOUN	O	O
schedule	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
began	VERB	O	O
thalidomide	ADV	O	I-Entity
at	ADP	O	O
400	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
d	NOUN	O	O
and	CCONJ	O	O
escalated	VERB	O	O
as	ADP	O	O
tolerated	VERB	O	O
to	ADP	O	O
1200	NUM	O	O
mg	PROPN	O	O
/	PUNCT	O	O
d	NOUN	O	O
by	ADP	O	O
day	NOUN	O	O
54	NUM	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
24	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
evaluable	ADJ	O	O
for	ADP	O	O
response	NOUN	O	O
with	ADP	O	O
one	NUM	O	O
partial	ADJ	O	O
response	NOUN	O	O
of	ADP	O	O
11	NUM	O	O
months	NOUN	O	O
duration	NOUN	O	O
of	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
hepatic	ADJ	O	O
and	CCONJ	O	O
pulmonary	ADJ	O	O
metastases	NOUN	O	I-Entity
(	PUNCT	O	O
4%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
one	NUM	O	O
minor	ADJ	O	O
response	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
patients	NOUN	O	O
stable	ADJ	O	O
for	ADP	O	O
over	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Somnolence	PROPN	O	I-Entity
and	CCONJ	O	O
constipation	NOUN	O	I-Entity
were	VERB	O	O
prominent	ADJ	O	O
toxicities	NOUN	O	I-Entity
and	CCONJ	O	O
most	ADJ	O	O
patients	NOUN	O	O
could	VERB	O	O
not	ADV	O	O
tolerate	VERB	O	O
the	DET	O	O
1200	NUM	O	O
mg	NUM	O	O
/	DET	O	O
day	NOUN	O	O
dose	NOUN	O	O
level	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
These	DET	O	O
results	NOUN	O	O
are	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
a	DET	O	O
low	ADJ	O	O
level	NOUN	O	O
of	ADP	O	O
activity	NOUN	O	O
of	ADP	O	O
thalidomide	NOUN	O	I-Entity
in	ADP	O	O
renal	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
response	NOUN	O	O
relationship	NOUN	O	O
,	PUNCT	O	O
if	ADP	O	O
any	DET	O	O
,	PUNCT	O	O
of	ADP	O	O
thalidomide	NOUN	O	I-Entity
for	ADP	O	O
renal	ADJ	O	B-Entity
cell	NOUN	O	I-Entity
carcinoma	NOUN	O	I-Entity
is	VERB	O	O
unclear	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (12231232)

The	DET	O	O
striatum	NOUN	O	O
as	ADP	O	O
a	DET	O	O
target	NOUN	O	O
for	ADP	O	O
anti	ADJ	O	O
-	PUNCT	O	O
rigor	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
an	DET	O	O
antagonist	NOUN	O	O
of	ADP	O	O
mGluR1	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
an	DET	O	O
agonist	NOUN	O	O
of	ADP	O	O
group	NOUN	O	O
II	PROPN	O	O
metabotropic	NOUN	O	O
glutamate	NOUN	O	I-Entity
receptors	NOUN	O	O
.	PUNCT	O	O

Haloperidol	PROPN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
ip	NOUN	O	O
)	PUNCT	O	O
induced	VERB	O	O
parkinsonian	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
measured	VERB	O	O
as	ADP	O	O
an	DET	O	O
increased	VERB	O	O
resistance	NOUN	O	O
of	ADP	O	O
a	DET	O	O
rat	NOUN	O	O
's	PART	O	O
hind	ADJ	O	O
foot	NOUN	O	O
to	ADP	O	O
passive	ADJ	O	O
flexion	NOUN	O	O
and	CCONJ	O	O
extension	NOUN	O	O
at	ADP	O	O
the	DET	O	O
ankle	NOUN	O	O
joint	NOUN	O	O
.	PUNCT	O	O

(	PUNCT	O	B-Entity
RS)-1-aminoindan-1,5-dicarboxylic	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
AIDA	PROPN	O	I-Entity
;	PUNCT	O	O
0.5	NUM	O	O
-	SYM	O	O
15	NUM	O	O
microg/0.5	NOUN	O	O
microl	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
potent	ADJ	O	O
and	CCONJ	O	O
selective	ADJ	O	O
mGluR1	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
(	PUNCT	O	B-Entity
2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate	NOUN	O	I-Entity
(	PUNCT	O	O
2R,4R	NUM	O	B-Entity
-	PUNCT	O	I-Entity
APDC	PROPN	O	I-Entity
;	PUNCT	O	O
7.5	NUM	O	O
-	PUNCT	O	O
15	NUM	O	O
microg/0.5	NOUN	O	O
microl	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
selective	ADJ	O	O
group	NOUN	O	O
II	PROPN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
injected	VERB	O	O
bilaterally	ADV	O	O
into	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
.	PUNCT	O	O

AIDA	PROPN	O	I-Entity
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
7.5	NUM	O	O
-	SYM	O	O
15	NUM	O	O
microg/0.5	NOUN	O	O
microl	NOUN	O	O
diminished	VERB	O	O
the	DET	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
2R,4R	NUM	O	B-Entity
-	PUNCT	O	I-Entity
APDC	NOUN	O	I-Entity
injections	NOUN	O	O
were	VERB	O	O
ineffective	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
results	NOUN	O	O
may	VERB	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
blockade	NOUN	O	O
of	ADP	O	O
striatal	NOUN	O	O
mGluR1	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
the	DET	O	O
stimulation	NOUN	O	O
of	ADP	O	O
group	NOUN	O	O
II	PROPN	O	O
mGluRs	PROPN	O	O
,	PUNCT	O	O
may	VERB	O	O
ameliorate	VERB	O	O
parkinsonian	ADJ	O	I-Entity
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11847945)

Acute	PROPN	O	O
cholestatic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
isoflurane	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
cholestatic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
following	VERB	O	O
exposure	NOUN	O	O
to	ADP	O	O
the	DET	O	O
inhalational	ADJ	O	O
anesthetic	NOUN	O	O
isoflurane	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
70-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
healthy	ADJ	O	O
woman	NOUN	O	O
from	ADP	O	O
Iraq	PROPN	O	O
developed	VERB	O	O
acute	ADJ	O	O
cholestatic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
3	NUM	O	O
weeks	NOUN	O	O
following	VERB	O	O
repair	NOUN	O	O
of	ADP	O	O
the	DET	O	O
right	ADJ	O	O
rotator	NOUN	O	O
cuff	NOUN	O	O
under	ADP	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
evidence	NOUN	O	O
for	ADP	O	O
viral	ADJ	O	O
,	PUNCT	O	O
autoimmune	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
metabolic	ADJ	O	O
causes	NOUN	O	O
of	ADP	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
other	ADJ	O	O
medications	NOUN	O	O
were	VERB	O	O
involved	VERB	O	O
except	ADP	O	O
for	ADP	O	O
dipyrone	NOUN	O	I-Entity
for	ADP	O	O
analgesia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
alanine	NOUN	O	I-Entity
aminotransferase	NOUN	O	O
was	VERB	O	O
elevated	VERB	O	O
to	ADP	O	O
a	DET	O	O
peak	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
1533	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
and	CCONJ	O	O
the	DET	O	O
serum	NOUN	O	O
bilirubin	NOUN	O	I-Entity
reached	VERB	O	O
a	DET	O	O
peak	NOUN	O	O
of	ADP	O	O
17.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL.	NOUN	O	O

Accidental	ADJ	O	O
reexposure	NOUN	O	O
by	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
to	ADP	O	O
dipyrone	NOUN	O	I-Entity
was	VERB	O	O
uneventful	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
histologic	ADJ	O	O
picture	NOUN	O	O
of	ADP	O	O
this	DET	O	O
case	NOUN	O	O
resembles	VERB	O	O
halothane	NOUN	O	B-Entity
hepatitis	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
has	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
mortality	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

Isoflurane	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
common	ADJ	O	O
anesthetic	NOUN	O	O
agent	NOUN	O	O
,	PUNCT	O	O
can	VERB	O	O
cause	VERB	O	O
severe	ADJ	O	O
cholestatic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11284996)

Calcitonin	PROPN	O	O
gene	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
peptide	NOUN	O	O
levels	NOUN	O	O
during	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
headache	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
tension	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
type	NOUN	O	I-Entity
headache	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
has	VERB	O	O
been	VERB	O	O
proposed	VERB	O	O
that	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
(	PUNCT	O	O
NO	PROPN	O	I-Entity
)	PUNCT	O	O
induced	VERB	O	O
headache	NOUN	O	I-Entity
in	ADP	O	O
primary	ADJ	O	B-Entity
headaches	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
release	NOUN	O	O
of	ADP	O	O
calcitonin	ADJ	O	O
gene	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
peptide	NOUN	O	O
(	PUNCT	O	O
CGRP	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
we	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
CGRP	PROPN	O	O
during	ADP	O	O
headache	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
NO	NOUN	O	I-Entity
donor	NOUN	O	O
glyceryl	NOUN	O	B-Entity
trinitrate	NOUN	O	I-Entity
(	PUNCT	O	O
GTN	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
16	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
tension	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
type	NOUN	O	I-Entity
headache	NOUN	O	I-Entity
and	CCONJ	O	O
16	NUM	O	O
healthy	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
subjects	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	PART	O	O
receive	VERB	O	O
0.5	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
GTN	PROPN	O	I-Entity
or	CCONJ	O	O
placebo	NOUN	O	O
over	ADP	O	O
20	NUM	O	O
min	NOUN	O	O
on	ADP	O	O
two	NUM	O	O
headache	NOUN	O	I-Entity
-	PUNCT	O	O
free	ADJ	O	O
days	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
patients	NOUN	O	O
and	CCONJ	O	O
controls	NOUN	O	O
developed	VERB	O	O
significantly	ADV	O	O
stronger	ADJ	O	O
immediate	ADJ	O	O
headache	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
GTN	PROPN	O	I-Entity
day	NOUN	O	O
than	ADP	O	O
on	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
day	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
headache	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
more	ADJ	O	O
pronounced	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
CGRP	PROPN	O	O
curve	NOUN	O	O
(	PUNCT	O	O
AUCCGRP	PROPN	O	O
)	PUNCT	O	O
on	ADP	O	O
GTN	PROPN	O	I-Entity
vs.	ADP	O	O
placebo	NOUN	O	O
day	NOUN	O	O
in	ADP	O	O
either	DET	O	O
patients	NOUN	O	O
(	PUNCT	O	O
P=0.65	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
P=0.48	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
AUCCGRP	PROPN	O	O
recorded	VERB	O	O
on	ADP	O	O
the	DET	O	O
GTN	PROPN	O	I-Entity
day	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
between	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
P=0.36	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	DET	O	O
in	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
controls	NOUN	O	O
,	PUNCT	O	O
CGRP	PROPN	O	O
levels	NOUN	O	O
changed	VERB	O	O
significantly	ADV	O	O
over	ADP	O	O
time	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
GTN	PROPN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
days	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
NO	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
immediate	ADJ	O	O
headache	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
release	NOUN	O	O
of	ADP	O	O
CGRP	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (11078231)

Myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
spasm	NOUN	O	I-Entity
during	ADP	O	O
dobutamine	ADJ	O	I-Entity
stress	NOUN	O	O
echocardiography	NOUN	O	O
.	PUNCT	O	O

Dobutamine	PROPN	O	I-Entity
stress	NOUN	O	O
echocardiography	NOUN	O	O
(	PUNCT	O	O
DSE	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
and	CCONJ	O	O
safe	ADJ	O	O
provocation	NOUN	O	O
test	NOUN	O	O
for	ADP	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
.	PUNCT	O	O

Until	ADP	O	O
now	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
test	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
focused	VERB	O	O
only	ADV	O	O
on	ADP	O	O
the	DET	O	O
organic	ADJ	O	O
lesion	NOUN	O	O
in	ADP	O	O
the	DET	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
positive	ADJ	O	O
DSE	PROPN	O	O
has	VERB	O	O
indicated	VERB	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
significant	ADJ	O	O
fixed	VERB	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
stenosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
is	VERB	O	O
to	PART	O	O
examine	VERB	O	O
whether	ADP	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
coronary	ADJ	O	B-Entity
spasm	NOUN	O	I-Entity
is	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
dobutamine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
performed	VERB	O	O
DSE	PROPN	O	O
on	ADP	O	O
51	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
spastic	ADJ	O	I-Entity
angina	NOUN	O	I-Entity
but	CCONJ	O	O
without	ADP	O	O
significant	ADJ	O	O
fixed	VERB	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
stenosis	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
anginal	ADJ	O	I-Entity
attacks	NOUN	O	O
at	ADP	O	O
rest	NOUN	O	O
with	ADP	O	O
ST	PROPN	O	O
elevation	NOUN	O	O
on	ADP	O	O
the	DET	O	O
electrocardiogram	NOUN	O	O
(	PUNCT	O	O
variant	NOUN	O	B-Entity
angina	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Coronary	ADJ	O	O
spasm	NOUN	O	O
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
intracoronary	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
acetylcholine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
fixed	VERB	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
stenosis	NOUN	O	I-Entity
was	VERB	O	O
documented	VERB	O	O
on	ADP	O	O
angiograms	NOUN	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

DSE	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
dobutamine	NOUN	O	I-Entity
infusion	NOUN	O	O
with	ADP	O	O
an	DET	O	O
incremental	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
5	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
20	NUM	O	O
,	PUNCT	O	O
30	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
40	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
min	VERB	O	O
every	DET	O	O
5	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
7	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
13.7%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
during	ADP	O	O
asynergy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
both	DET	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
and	CCONJ	O	O
electrocardiographic	ADJ	O	O
changes	NOUN	O	O
were	VERB	O	O
preceded	VERB	O	O
by	ADP	O	O
asynergy	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
dobutamine	NOUN	O	I-Entity
can	VERB	O	O
provoke	VERB	O	O
coronary	ADJ	O	B-Entity
spasm	NOUN	O	I-Entity
in	ADP	O	O
some	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
spastic	ADJ	O	I-Entity
angina	NOUN	O	I-Entity
.	PUNCT	O	O

When	ADV	O	O
DSE	PROPN	O	O
is	VERB	O	O
performed	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
not	ADV	O	O
only	ADV	O	O
fixed	VERB	O	O
coronary	ADJ	O	B-Entity
stenosis	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
also	ADV	O	O
coronary	ADJ	O	B-Entity
spasm	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
as	ADP	O	O
a	DET	O	O
genesis	NOUN	O	O
of	ADP	O	O
asynergy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10523326)

Nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
synthase	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
lead	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
recently	ADV	O	O
showed	VERB	O	O
elevated	ADJ	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
species	NOUN	O	O
(	PUNCT	O	O
ROS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
reduced	VERB	O	O
urinary	ADJ	O	O
excretion	NOUN	O	O
of	ADP	O	O
NO	PROPN	O	I-Entity
metabolites	NOUN	O	O
(	PUNCT	O	O
NOx	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
NO	DET	O	I-Entity
sequestration	NOUN	O	O
as	ADP	O	O
nitrotyrosine	NOUN	O	I-Entity
in	ADP	O	O
various	ADJ	O	O
tissues	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
lead	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
discern	VERB	O	O
whether	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
urinary	ADJ	O	O
NOx	NOUN	O	O
in	ADP	O	O
lead	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
is	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
part	NOUN	O	O
,	PUNCT	O	O
due	ADP	O	O
to	ADP	O	O
depressed	ADJ	O	O
NO	NOUN	O	I-Entity
synthase	NOUN	O	O
(	PUNCT	O	O
NOS	PROPN	O	O
)	PUNCT	O	O
expression	NOUN	O	O
.	PUNCT	O	O

Male	PROPN	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
a	DET	O	O
lead	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
(	PUNCT	O	O
given	VERB	O	O
lead	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
,	PUNCT	O	O
100	NUM	O	O
ppm	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
drinking	NOUN	O	O
water	NOUN	O	O
and	CCONJ	O	O
regular	ADJ	O	O
rat	NOUN	O	O
chow	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
group	NOUN	O	O
given	VERB	O	O
lead	NOUN	O	I-Entity
and	CCONJ	O	O
vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
-	PUNCT	O	O
fortified	VERB	O	O
chow	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
normal	ADJ	O	O
control	NOUN	O	O
group	NOUN	O	O
given	VERB	O	O
either	CCONJ	O	O
regular	ADJ	O	O
food	NOUN	O	O
and	CCONJ	O	O
water	NOUN	O	O
or	CCONJ	O	O
vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
-	PUNCT	O	O
fortified	VERB	O	O
food	NOUN	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Tail	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
urinary	ADJ	O	O
NOx	PROPN	O	O
excretion	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
malondialdehyde	NOUN	O	I-Entity
(	PUNCT	O	O
MDA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
endothelial	ADJ	O	O
and	CCONJ	O	O
inducible	ADJ	O	O
NOS	PROPN	O	O
(	PUNCT	O	O
eNOS	PROPN	O	O
and	CCONJ	O	O
iNOS	PROPN	O	O
)	PUNCT	O	O
isotypes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
aorta	NOUN	O	O
and	CCONJ	O	O
kidney	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
lead	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
exhibited	VERB	O	O
a	DET	O	O
rise	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
MDA	PROPN	O	I-Entity
concentration	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
fall	NOUN	O	O
in	ADP	O	O
urinary	ADJ	O	O
NOx	PROPN	O	O
excretion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
paradoxical	ADJ	O	O
rise	NOUN	O	O
in	ADP	O	O
vascular	ADJ	O	O
and	CCONJ	O	O
renal	ADJ	O	O
tissue	NOUN	O	O
eNOS	NOUN	O	O
and	CCONJ	O	O
iNOS	ADJ	O	O
expression	NOUN	O	O
.	PUNCT	O	O

Vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
supplementation	NOUN	O	O
ameliorated	VERB	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
lowered	VERB	O	O
plasma	NOUN	O	O
MDA	PROPN	O	I-Entity
concentration	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
raised	VERB	O	O
urinary	ADJ	O	O
NOx	PROPN	O	O
excretion	NOUN	O	O
while	ADP	O	O
significantly	ADV	O	O
lowering	VERB	O	O
vascular	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
renal	ADJ	O	O
,	PUNCT	O	O
tissue	NOUN	O	O
eNOS	PROPN	O	O
and	CCONJ	O	O
iNOS	PROPN	O	O
expression	NOUN	O	O
.	PUNCT	O	O

Vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
supplementation	NOUN	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
either	DET	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
MDA	PROPN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
NOS	PROPN	O	O
expression	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
also	ADV	O	O
revealed	VERB	O	O
significant	ADJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
NOS	PROPN	O	O
enzymatic	ADJ	O	O
activity	NOUN	O	O
by	ADP	O	O
lead	NOUN	O	I-Entity
in	ADP	O	O
cell	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
preparations	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
lead	VERB	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
model	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
compensatory	NOUN	O	O
upregulation	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
and	CCONJ	O	O
vascular	ADJ	O	O
eNOS	NOUN	O	O
and	CCONJ	O	O
iNOS	ADJ	O	O
expression	NOUN	O	O
.	PUNCT	O	O

NO	DET	O	I-Entity
inactivation	NOUN	O	O
,	PUNCT	O	O
lead	VERB	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
inhibition	NOUN	O	O
of	ADP	O	O
NOS	PROPN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
perhaps	ADV	O	O
stimulatory	ADJ	O	O
actions	NOUN	O	O
of	ADP	O	O
increased	VERB	O	O
shear	ADJ	O	O
stress	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9867728)

Risk	NOUN	O	O
for	ADP	O	O
valvular	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
among	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
fenfluramine	NOUN	O	I-Entity
and	CCONJ	O	O
dexfenfluramine	NOUN	O	I-Entity
who	NOUN	O	O
underwent	VERB	O	O
echocardiography	NOUN	O	O
before	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
medication	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
uncontrolled	ADJ	O	O
echocardiographic	ADJ	O	O
surveys	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
up	ADP	O	O
to	PART	O	O
30%	NUM	O	O
to	ADP	O	O
38%	NUM	O	O
of	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
fenfluramine	NOUN	O	I-Entity
and	CCONJ	O	O
dexfenfluramine	NOUN	O	I-Entity
had	VERB	O	O
valvular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
these	DET	O	O
drugs	NOUN	O	O
were	VERB	O	O
withdrawn	VERB	O	O
from	ADP	O	O
the	DET	O	O
market	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
determine	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
for	ADP	O	O
new	ADJ	O	O
or	CCONJ	O	O
worsening	VERB	O	O
valvular	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
among	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
fenfluramine	NOUN	O	I-Entity
or	CCONJ	O	O
dexfenfluramine	NOUN	O	I-Entity
who	NOUN	O	O
underwent	VERB	O	O
echocardiography	NOUN	O	O
before	ADP	O	O
they	PRON	O	O
began	VERB	O	O
to	PART	O	O
take	VERB	O	O
these	DET	O	O
medications	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
:	PUNCT	O	O
46	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
used	VERB	O	O
fenfluramine	NOUN	O	I-Entity
or	CCONJ	O	O
dexfenfluramine	NOUN	O	I-Entity
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
or	CCONJ	O	O
more	ADJ	O	O
and	CCONJ	O	O
had	VERB	O	O
echocardiograms	NOUN	O	O
obtained	VERB	O	O
before	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
was	VERB	O	O
new	ADJ	O	O
or	CCONJ	O	O
worsening	VERB	O	O
valvulopathy	NOUN	O	I-Entity
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
progression	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
aortic	ADJ	O	B-Entity
or	CCONJ	O	I-Entity
mitral	ADJ	O	I-Entity
regurgitation	NOUN	O	I-Entity
by	ADP	O	O
at	ADV	O	O
least	ADV	O	O
one	NUM	O	O
degree	NOUN	O	O
of	ADP	O	O
severity	NOUN	O	O
and	CCONJ	O	O
disease	NOUN	O	O
that	ADJ	O	O
met	VERB	O	O
U.S.	PROPN	O	O
Food	PROPN	O	O
and	CCONJ	O	O
Drug	PROPN	O	O
Administration	PROPN	O	O
criteria	NOUN	O	O
(	PUNCT	O	O
at	ADP	O	O
least	ADJ	O	O
mild	ADJ	O	O
aortic	ADJ	O	B-Entity
regurgitation	NOUN	O	I-Entity
or	CCONJ	O	O
moderate	ADJ	O	O
mitral	ADJ	O	B-Entity
regurgitation	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Two	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
4.3%	NUM	O	O
[	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
,	PUNCT	O	O
0.6%	NUM	O	O
to	PART	O	O
14.8%	NUM	O	O
]	PUNCT	O	O
)	PUNCT	O	O
receiving	VERB	O	O
fenfluramine	NOUN	O	I-Entity
-	PUNCT	O	O
phentermine	NOUN	O	I-Entity
developed	VERB	O	O
valvular	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
had	VERB	O	O
baseline	NOUN	O	O
bicuspid	NOUN	O	B-Entity
aortic	ADJ	O	I-Entity
valve	NOUN	O	I-Entity
and	CCONJ	O	O
mild	ADJ	O	O
aortic	ADJ	O	B-Entity
regurgitation	NOUN	O	I-Entity
that	ADJ	O	O
progressed	VERB	O	O
to	ADP	O	O
moderate	ADJ	O	O
regurgitation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
second	ADJ	O	O
patient	NOUN	O	O
developed	VERB	O	O
new	ADJ	O	O
moderate	ADJ	O	O
aortic	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
.	PUNCT	O	O

Users	NOUN	O	O
of	ADP	O	O
diet	NOUN	O	O
medications	NOUN	O	O
are	VERB	O	O
at	ADP	O	O
risk	NOUN	O	O
for	ADP	O	O
valvular	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9636837)

Carboplatin	PROPN	O	I-Entity
toxic	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
most	ADV	O	O
striking	ADJ	O	O
of	ADP	O	O
carboplatin	NOUN	O	I-Entity
's	PART	O	O
advantages	NOUN	O	O
(	PUNCT	O	O
CBDCA	PROPN	O	I-Entity
)	PUNCT	O	O
over	ADP	O	O
cisplatin	NOUN	O	I-Entity
(	PUNCT	O	O
CDDP	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
its	ADJ	O	O
markedly	ADV	O	O
reduced	VERB	O	O
rate	NOUN	O	O
of	ADP	O	O
neurotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
CBDCA	PROPN	O	I-Entity
higher	ADV	O	O
-	PUNCT	O	O
intensity	NOUN	O	O
schedules	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
association	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
neurotoxic	ADJ	O	I-Entity
drugs	NOUN	O	O
in	ADP	O	O
polychemotherapy	NOUN	O	O
may	VERB	O	O
cause	VERB	O	O
some	DET	O	O
concern	NOUN	O	O
about	ADP	O	O
its	ADJ	O	O
safety	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
peripheral	ADJ	O	B-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
different	ADJ	O	O
schedules	NOUN	O	O
of	ADP	O	O
CBDCA	PROPN	O	I-Entity
administration	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
and	CCONJ	O	O
15	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O

Neurotoxicity	PROPN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
for	ADP	O	O
behavioral	ADJ	O	O
(	PUNCT	O	O
tail	NOUN	O	O
-	PUNCT	O	O
flick	NOUN	O	O
test	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
neurophysiological	ADJ	O	O
(	PUNCT	O	O
nerve	ADJ	O	O
conduction	NOUN	O	O
velocity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
tail	NOUN	O	O
nerve	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
morphological	ADJ	O	O
,	PUNCT	O	O
morphometrical	ADJ	O	O
and	CCONJ	O	O
analytical	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

CBDCA	PROPN	O	I-Entity
administration	NOUN	O	O
induced	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
peripheral	ADJ	O	B-Entity
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Pain	PROPN	O	I-Entity
perception	NOUN	O	O
and	CCONJ	O	O
nerve	NOUN	O	O
conduction	NOUN	O	O
velocity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
tail	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
impaired	VERB	O	O
,	PUNCT	O	O
particularly	ADV	O	O
after	ADP	O	O
the	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dorsal	NOUN	O	O
root	NOUN	O	O
ganglia	NOUN	O	O
sensory	ADJ	O	O
neurons	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
lesser	ADJ	O	O
extent	NOUN	O	O
,	PUNCT	O	O
satellite	NOUN	O	O
cells	NOUN	O	O
showed	VERB	O	O
the	DET	O	O
same	ADJ	O	O
changes	NOUN	O	O
as	ADP	O	O
those	DET	O	O
induced	VERB	O	O
by	ADP	O	O
CDDP	PROPN	O	I-Entity
,	PUNCT	O	O
mainly	ADV	O	O
affecting	VERB	O	O
the	DET	O	O
nucleus	NOUN	O	O
and	CCONJ	O	O
nucleolus	NOUN	O	O
of	ADP	O	O
ganglionic	ADJ	O	O
sensory	ADJ	O	O
neurons	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
significant	ADJ	O	O
amounts	NOUN	O	O
of	ADP	O	O
platinum	NOUN	O	I-Entity
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
the	DET	O	O
dorsal	NOUN	O	O
root	NOUN	O	O
ganglia	NOUN	O	O
and	CCONJ	O	O
kidney	NOUN	O	O
after	ADP	O	O
CBDCA	PROPN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

CBDCA	NOUN	O	I-Entity
is	VERB	O	O
neurotoxic	ADJ	O	I-Entity
in	ADP	O	O
our	ADJ	O	O
model	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
pathological	ADJ	O	O
changes	NOUN	O	O
it	PRON	O	O
induces	VERB	O	O
are	VERB	O	O
so	ADV	O	O
closely	ADV	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
caused	VERB	O	O
by	ADP	O	O
CDDP	PROPN	O	I-Entity
that	ADP	O	O
it	PRON	O	O
is	VERB	O	O
probable	ADJ	O	O
that	ADP	O	O
neurotoxicity	NOUN	O	I-Entity
is	VERB	O	O
induced	VERB	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
drugs	NOUN	O	O
by	ADP	O	O
the	DET	O	O
same	ADJ	O	O
mechanism	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
model	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
used	VERB	O	O
alone	ADV	O	O
or	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
drugs	NOUN	O	O
to	PART	O	O
explore	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
CBDCA	PROPN	O	I-Entity
on	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9579567)

Iatrogenic	ADJ	O	O
risks	NOUN	O	O
of	ADP	O	O
endometrial	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
large	ADJ	O	O
French	ADJ	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
tamoxifen	NOUN	O	I-Entity
is	VERB	O	O
widely	ADV	O	O
used	VERB	O	O
in	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
treatment	NOUN	O	O
and	CCONJ	O	O
has	VERB	O	O
been	VERB	O	O
proposed	VERB	O	O
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
its	ADJ	O	O
endometrial	ADJ	O	O
iatrogenic	ADJ	O	O
effects	NOUN	O	O
must	VERB	O	O
be	VERB	O	O
carefully	ADV	O	O
examined	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
investigated	VERB	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
endometrial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
and	CCONJ	O	O
tamoxifen	NOUN	O	I-Entity
use	NOUN	O	O
or	CCONJ	O	O
other	ADJ	O	O
treatments	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
treated	VERB	O	O
for	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Cases	NOUN	O	O
of	ADP	O	O
endometrial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
diagnosed	VERB	O	O
after	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
135	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
467	NUM	O	O
controls	NOUN	O	O
matched	VERB	O	O
for	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
year	NOUN	O	O
of	ADP	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
and	CCONJ	O	O
hospital	NOUN	O	O
and	CCONJ	O	O
survival	NOUN	O	O
time	NOUN	O	O
with	ADP	O	O
an	DET	O	O
intact	ADJ	O	O
uterus	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
.	PUNCT	O	O

Women	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
received	VERB	O	O
tamoxifen	NOUN	O	I-Entity
were	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
have	VERB	O	O
endometrial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
diagnosed	VERB	O	O
than	ADP	O	O
those	DET	O	O
who	NOUN	O	O
had	VERB	O	O
not	ADV	O	O
(	PUNCT	O	O
crude	ADJ	O	O
relative	ADJ	O	O
risk	NOUN	O	O
=	SYM	O	O
4.9	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Univariate	PROPN	O	O
and	CCONJ	O	O
adjusted	VERB	O	O
analyses	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
increased	VERB	O	O
with	ADP	O	O
the	DET	O	O
length	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	I-Entity
received	VERB	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
irrespective	ADV	O	O
of	ADP	O	O
the	DET	O	O
daily	ADJ	O	O
dose	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
adjusting	VERB	O	O
for	ADP	O	O
confounding	VERB	O	O
factors	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
risk	NOUN	O	O
was	VERB	O	O
higher	ADJ	O	O
for	ADP	O	O
tamoxifen	NOUN	O	I-Entity
users	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0012	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O

Women	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
endometrial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
and	CCONJ	O	O
had	VERB	O	O
received	VERB	O	O
tamoxifen	PRON	O	I-Entity
had	VERB	O	O
more	ADV	O	O
advanced	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
and	CCONJ	O	O
poorer	ADJ	O	O
prognosis	NOUN	O	O
than	ADP	O	O
those	DET	O	O
with	ADP	O	O
endometrial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
who	NOUN	O	O
had	VERB	O	O
not	ADV	O	O
received	VERB	O	O
this	DET	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
a	DET	O	O
causal	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	I-Entity
in	ADP	O	O
endometrial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
particularly	ADV	O	O
when	ADV	O	O
used	VERB	O	O
as	ADP	O	O
currently	ADV	O	O
proposed	VERB	O	O
for	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
prevention	NOUN	O	O
.	PUNCT	O	O

Pelvic	ADJ	O	O
radiotherapy	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
an	DET	O	O
additional	ADJ	O	O
iatrogenic	ADJ	O	O
factor	NOUN	O	O
for	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Endometrial	ADJ	O	B-Entity
cancers	NOUN	O	I-Entity
diagnosed	VERB	O	O
in	ADP	O	O
women	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
tamoxifen	NOUN	O	I-Entity
have	VERB	O	O
poorer	ADJ	O	O
prognosis	NOUN	O	O
.	PUNCT	O	O

Women	NOUN	O	O
who	NOUN	O	O
receive	VERB	O	O
tamoxifen	NOUN	O	I-Entity
for	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
offered	VERB	O	O
gynaecological	ADJ	O	O
surveillance	NOUN	O	O
during	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
-	PUNCT	O	O
benefit	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
preventive	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
is	VERB	O	O
clearly	ADV	O	O
warranted	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (9205462)

Granulosa	PROPN	O	B-Entity
cell	NOUN	O	I-Entity
tumor	NOUN	O	I-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
ovary	ADJ	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
antecedent	NOUN	O	O
tamoxifen	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Increased	VERB	O	O
attention	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
focused	VERB	O	O
recently	ADV	O	O
on	ADP	O	O
the	DET	O	O
estrogenic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	I-Entity
.	PUNCT	O	O

Review	NOUN	O	O
of	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
reveals	VERB	O	O
an	DET	O	O
association	NOUN	O	O
between	ADP	O	O
tamoxifen	NOUN	O	I-Entity
use	NOUN	O	O
and	CCONJ	O	O
gynecologic	ADJ	O	O
tumors	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
52-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
postmenopausal	NOUN	O	O
woman	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
tamoxifen	NOUN	O	I-Entity
for	ADP	O	O
stage	NOUN	O	O
II	NUM	O	O
estrogen	NOUN	O	I-Entity
receptor	NOUN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
breast	NOUN	O	B-Entity
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

Her	ADJ	O	O
aspartate	NOUN	O	I-Entity
transaminase	NOUN	O	O
and	CCONJ	O	O
alanine	NOUN	O	I-Entity
transaminase	DET	O	O
levels	NOUN	O	O
increase	VERB	O	O
markedly	ADV	O	O
after	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
tamoxifen	NOUN	O	I-Entity
use	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
an	DET	O	O
additional	ADJ	O	O
17	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
elevated	ADJ	O	O
serum	NOUN	O	O
transaminases	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
have	VERB	O	O
a	DET	O	O
stage	NOUN	O	O
Ic	PROPN	O	O
granulosa	NOUN	O	B-Entity
cell	NOUN	O	I-Entity
tumor	NOUN	O	I-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
ovary	ADJ	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
tamoxifen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
liver	NOUN	O	B-Entity
dysfunction	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
at	ADP	O	O
increased	VERB	O	O
risk	NOUN	O	O
for	ADP	O	O
granulosa	NOUN	O	B-Entity
cell	NOUN	O	I-Entity
tumors	NOUN	O	I-Entity
because	ADP	O	O
of	ADP	O	O
alterations	NOUN	O	O
in	ADP	O	O
tamoxifen	NOUN	O	I-Entity
metabolism	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9098464)

A	DET	O	O
murine	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
adenomyosis	NOUN	O	I-Entity
:	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
fluoxetine	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
selective	ADJ	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
adenomyosis	NOUN	O	I-Entity
induction	NOUN	O	O
in	ADP	O	O
Wistar	PROPN	O	O
albino	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
whether	ADP	O	O
fluoxetine	NOUN	O	I-Entity
given	VERB	O	O
to	ADP	O	O
castrated	VERB	O	O
and	CCONJ	O	O
noncastrated	VERB	O	O
rats	NOUN	O	O
caused	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
effects	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
adenomyosis	NOUN	O	I-Entity
.	PUNCT	O	O

Fluoxetine	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
given	VERB	O	O
to	ADP	O	O
Wistar	PROPN	O	O
Albino	PROPN	O	O
rats	NOUN	O	O
for	ADP	O	O
98	NUM	O	O
days	NOUN	O	O
to	PART	O	O
produce	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
prolactin	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
castrated	VERB	O	O
and	CCONJ	O	O
noncastrated	VERB	O	O
groups	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
fluoxetine	NOUN	O	I-Entity
were	VERB	O	O
statistically	ADV	O	O
significantly	ADV	O	O
higher	ADJ	O	O
when	ADV	O	O
compared	VERB	O	O
to	ADP	O	O
their	ADJ	O	O
respective	ADJ	O	O
control	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Histological	ADJ	O	O
studies	NOUN	O	O
revealed	VERB	O	O
11	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
adenomyosis	NOUN	O	I-Entity
,	PUNCT	O	O
all	DET	O	O
within	ADP	O	O
the	DET	O	O
noncastrated	ADJ	O	O
group	NOUN	O	O
receiving	VERB	O	O
fluoxetine	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
high	ADJ	O	O
serum	NOUN	O	O
prolactin	NOUN	O	O
levels	NOUN	O	O
cause	VERB	O	O
degeneration	NOUN	O	O
of	ADP	O	O
myometrial	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
ovarian	ADJ	O	O
steroids	NOUN	O	I-Entity
that	ADJ	O	O
results	NOUN	O	O
in	ADP	O	O
a	DET	O	O
myometrial	ADJ	O	O
invasion	NOUN	O	O
by	ADP	O	O
endometrial	ADJ	O	O
stroma	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
invasion	NOUN	O	O
eventually	ADV	O	O
progresses	VERB	O	O
to	ADP	O	O
adenomyosis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8424298)

Effects	NOUN	O	O
of	ADP	O	O
deliberate	ADJ	O	O
hypotension	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
labetalol	NOUN	O	I-Entity
with	ADP	O	O
isoflurane	NOUN	O	I-Entity
on	ADP	O	O
neuropsychological	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
deliberate	ADJ	O	O
hypotension	NOUN	O	I-Entity
on	ADP	O	O
brain	NOUN	O	O
function	NOUN	O	O
measured	VERB	O	O
by	ADP	O	O
neuropsychological	ADJ	O	O
tests	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
41	NUM	O	O
adult	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
anaesthetized	VERB	O	O
for	ADP	O	O
middle	ADJ	O	O
-	PUNCT	O	O
ear	NOUN	O	O
surgery	NOUN	O	O
with	ADP	O	O
deliberate	ADJ	O	O
hypotension	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
labetalol	NOUN	O	I-Entity
with	ADP	O	O
isoflurane	NOUN	O	I-Entity
(	PUNCT	O	O
hypotensive	ADJ	O	I-Entity
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Seventeen	NUM	O	O
patients	NOUN	O	O
without	ADP	O	O
hypotension	NOUN	O	I-Entity
served	VERB	O	O
as	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

0.3	NUM	O	O
kPa	PROPN	O	O
)	PUNCT	O	O
before	ADP	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
50	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

0.0	NUM	O	O
kPa	PROPN	O	O
)	PUNCT	O	O
during	ADP	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
hypotensive	ADJ	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
86	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

The	DET	O	O
following	VERB	O	O
psychological	ADJ	O	O
tests	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
:	PUNCT	O	O
four	NUM	O	O
subtests	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Wechsler	PROPN	O	O
Adult	PROPN	O	O
Intelligence	PROPN	O	O
Scale	PROPN	O	O
(	PUNCT	O	O
similarities	NOUN	O	O
,	PUNCT	O	O
digit	NOUN	O	O
span	NOUN	O	O
,	PUNCT	O	O
vocabulary	NOUN	O	O
and	CCONJ	O	O
digit	NOUN	O	O
symbol	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Trail	PROPN	O	O
-	PUNCT	O	O
Making	PROPN	O	O
tests	VERB	O	O
A	NOUN	O	O
and	CCONJ	O	O
B	NOUN	O	O
,	PUNCT	O	O
Zung	PROPN	O	O
tests	NOUN	O	O
(	PUNCT	O	O
self	NOUN	O	O
-	PUNCT	O	O
rating	VERB	O	O
anxiety	NOUN	O	I-Entity
scale	NOUN	O	O
and	CCONJ	O	O
self	NOUN	O	O
-	PUNCT	O	O
rating	VERB	O	O
depression	NOUN	O	I-Entity
scale	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
-	PUNCT	O	O
part	NOUN	O	O
memory	NOUN	O	O
test	NOUN	O	O
battery	NOUN	O	O
with	ADP	O	O
immediate	ADJ	O	O
and	CCONJ	O	O
delayed	VERB	O	O
recall	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
hypotension	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
labetalol	NOUN	O	I-Entity
with	ADP	O	O
isoflurane	NOUN	O	I-Entity
has	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
harmful	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
mental	ADJ	O	O
functions	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
normotensive	ADJ	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7880714)

Bupivacaine	PROPN	O	I-Entity
0.75%	NUM	O	O
with	ADP	O	O
adrenaline	NOUN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
24-hr	NUM	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
0.25%	NUM	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
four	NUM	O	O
patients	NOUN	O	O
hearing	VERB	O	B-Entity
impairment	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
side	NOUN	O	O
of	ADP	O	O
the	DET	O	O
block	NOUN	O	O
was	VERB	O	O
demonstrated	VERB	O	O
after	ADP	O	O
operation	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
three	NUM	O	O
measurements	NOUN	O	O
on	ADP	O	O
the	DET	O	O
day	NOUN	O	O
of	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
one	NUM	O	O
on	ADP	O	O
the	DET	O	O
following	VERB	O	O
day	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
maximum	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
threshold	NOUN	O	O
was	VERB	O	O
35	NUM	O	O
dB	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
kHz	NOUN	O	O
measured	VERB	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
.	PUNCT	O	O

IBPB	NOUN	O	O
may	VERB	O	O
cause	VERB	O	O
transient	ADJ	O	O
auditory	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
ipsilateral	ADJ	O	O
ear	NOUN	O	O
,	PUNCT	O	O
possibly	ADV	O	O
via	ADP	O	O
an	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
sympathetic	ADJ	O	O
innervation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7102237)

Midazolam	PROPN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
thiopentone	NOUN	O	I-Entity
as	ADP	O	O
an	DET	O	O
induction	NOUN	O	O
agent	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
premedicated	VERB	O	O
with	ADP	O	O
scopolamine	NOUN	O	I-Entity
+	CCONJ	O	O
morphine	NOUN	O	I-Entity
(	PUNCT	O	O
+	SYM	O	O
5	NUM	O	O
mg	NUM	O	O
nitrazepam	NOUN	O	I-Entity
the	DET	O	O
evening	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
sleep	NOUN	O	O
-	PUNCT	O	O
inducing	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
midazolam	NOUN	O	I-Entity
0.15	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
was	VERB	O	O
clearly	ADV	O	O
slower	ADJ	O	O
in	ADP	O	O
onset	NOUN	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
thiopentone	NOUN	O	I-Entity
4.67	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

Somewhat	ADV	O	O
fewer	ADJ	O	O
cardiovascular	ADJ	O	O
and	CCONJ	O	O
local	ADJ	O	O
sequelae	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
midazolam	NOUN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
,	PUNCT	O	O
although	ADP	O	O
apnoea	NOUN	O	I-Entity
occurred	VERB	O	O
less	ADV	O	O
often	ADV	O	O
in	ADP	O	O
the	DET	O	O
midazolam	NOUN	O	I-Entity
group	NOUN	O	O
it	PRON	O	O
lasted	VERB	O	O
longer	ADV	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
whole	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
differences	NOUN	O	O
between	ADP	O	O
midazolam	NOUN	O	I-Entity
and	CCONJ	O	O
thiopentone	NOUN	O	I-Entity
had	VERB	O	O
no	DET	O	O
apparent	ADJ	O	O
clinical	ADJ	O	O
consequences	NOUN	O	O
.	PUNCT	O	O

Midazolam	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
new	ADJ	O	O
alternative	NOUN	O	O
agent	NOUN	O	O
for	ADP	O	O
induction	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6769133)

Cardiotoxic	PROPN	O	I-Entity
and	CCONJ	O	O
possible	ADJ	O	O
leukemogenic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
adriamycin	ADV	O	I-Entity
in	ADP	O	O
nonhuman	NOUN	O	O
primates	NOUN	O	O
.	PUNCT	O	O

10	NUM	O	O
monkeys	NOUN	O	O
(	PUNCT	O	O
macaques	NOUN	O	O
)	PUNCT	O	O
received	VERB	O	O
adriamycin	ADJ	O	I-Entity
by	ADP	O	O
monthly	ADJ	O	O
intravenous	ADJ	O	O
injections	NOUN	O	O
at	ADP	O	O
12	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

8	NUM	O	O
of	ADP	O	O
the	DET	O	O
10	NUM	O	O
monkeys	NOUN	O	O
developed	VERB	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
at	ADP	O	O
an	DET	O	O
average	ADJ	O	O
cumulative	ADJ	O	O
adriamycin	ADJ	O	I-Entity
dose	NOUN	O	O
(	PUNCT	O	O
310	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
)	PUNCT	O	O
well	ADV	O	O
below	ADP	O	O
that	DET	O	O
considered	VERB	O	O
the	DET	O	O
safe	ADJ	O	O
upper	ADJ	O	O
limit	NOUN	O	O
(	PUNCT	O	O
550	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
man	NOUN	O	O
.	PUNCT	O	O

Histologically	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
myocardial	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
resembled	VERB	O	O
those	DET	O	O
found	VERB	O	O
in	ADP	O	O
human	ADJ	O	O
anthracycline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O

1	NUM	O	O
of	ADP	O	O
the	DET	O	O
10	NUM	O	O
monkeys	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	B-Entity
myeloblastic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
after	ADP	O	O
receiving	VERB	O	O
324	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
of	ADP	O	O
adriamycin	ADV	O	I-Entity
;	PUNCT	O	O
the	DET	O	O
10th	ADJ	O	O
monkey	NOUN	O	O
is	VERB	O	O
alive	ADJ	O	O
and	CCONJ	O	O
well	ADV	O	O
26	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
the	DET	O	O
last	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
adriamycin	ADV	O	I-Entity
is	VERB	O	O
a	DET	O	O
more	ADV	O	O
potent	ADJ	O	O
cardiotoxin	NOUN	O	O
in	ADP	O	O
monkeys	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
man	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
leukemia	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
consequence	NOUN	O	O
of	ADP	O	O
prolonged	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6292680)

Doxorubicin	PROPN	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
left	VERB	O	O
-	PUNCT	O	O
sided	ADJ	O	O
Wilms	PROPN	O	B-Entity
tumor	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
Wilms	PROPN	O	B-Entity
tumor	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
left	ADJ	O	O
kidney	NOUN	O	O
experienced	VERB	O	O
severe	ADJ	O	O
anthracycline	NOUN	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
after	ADP	O	O
irradiation	NOUN	O	O
to	ADP	O	O
the	DET	O	O
tumor	NOUN	O	I-Entity
bed	NOUN	O	O
and	CCONJ	O	O
conventional	ADJ	O	O
dosage	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
cardiomyopathy	NOUN	O	I-Entity
is	VERB	O	O
attributed	VERB	O	O
1	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
fact	NOUN	O	O
that	ADP	O	O
radiation	NOUN	O	O
fields	NOUN	O	O
for	ADP	O	O
left	ADJ	O	O
Wilms	PROPN	O	B-Entity
tumor	NOUN	O	I-Entity
include	VERB	O	O
the	DET	O	O
lower	ADJ	O	O
portion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
interaction	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
and	CCONJ	O	O
irradiation	NOUN	O	O
on	ADP	O	O
cardiac	ADJ	O	O
muscle	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
recommended	VERB	O	O
that	ADP	O	O
doxorubicin	NOUN	O	I-Entity
dosage	NOUN	O	O
be	VERB	O	O
sharply	ADV	O	O
restricted	VERB	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
Wilms	PROPN	O	B-Entity
tumor	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
left	ADJ	O	O
kidney	NOUN	O	O
who	NOUN	O	O
receive	VERB	O	O
postoperative	ADJ	O	O
irradiation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3969369)

Promotional	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
testosterone	NOUN	O	I-Entity
and	CCONJ	O	O
dietary	ADJ	O	O
fat	NOUN	O	O
on	ADP	O	O
prostate	NOUN	O	O
carcinogenesis	NOUN	O	I-Entity
in	ADP	O	O
genetically	ADV	O	O
susceptible	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Wistar	PROPN	O	O
(	PUNCT	O	O
LW	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
,	PUNCT	O	O
fed	VERB	O	O
vegetable	NOUN	O	O
diet	NOUN	O	O
L-485	PROPN	O	O
,	PUNCT	O	O
have	VERB	O	O
developed	VERB	O	O
prostate	ADJ	O	B-Entity
adenocarcinomas	NOUN	O	I-Entity
spontaneously	ADV	O	O
(	PUNCT	O	O
10%	NUM	O	O
incidence	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
average	ADJ	O	O
age	NOUN	O	O
34	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Conventional	ADJ	O	O
LW	PROPN	O	O
rats	NOUN	O	O
,	PUNCT	O	O
implanted	VERB	O	O
with	ADP	O	O
testosterone	NOUN	O	I-Entity
at	ADP	O	O
age	NOUN	O	O
4	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
developed	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
after	ADP	O	O
an	DET	O	O
average	ADJ	O	O
interval	NOUN	O	O
of	ADP	O	O
14	NUM	O	O
months	NOUN	O	O
:	PUNCT	O	O
24%	NUM	O	O
had	VERB	O	O
developed	VERB	O	O
gross	ADJ	O	O
tumors	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
40%	NUM	O	O
when	ADV	O	O
it	PRON	O	O
included	VERB	O	O
microscopic	ADJ	O	O
tumors	NOUN	O	I-Entity
.	PUNCT	O	O

Preliminary	ADJ	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
testosterone	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
LW	PROPN	O	O
rats	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
fed	VERB	O	O
the	DET	O	O
same	ADJ	O	O
diet	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
supplemented	VERB	O	O
with	ADP	O	O
corn	NOUN	O	O
oil	NOUN	O	O
up	PART	O	O
to	ADP	O	O
20%	NUM	O	O
fat	NOUN	O	O
,	PUNCT	O	O
developed	VERB	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
after	ADP	O	O
intervals	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
-	SYM	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

rats	NOUN	O	O
have	VERB	O	O
not	ADV	O	O
developed	VERB	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
spontaneously	ADV	O	O
.	PUNCT	O	O

Conventional	ADJ	O	O
SD	NOUN	O	O
rats	NOUN	O	O
fed	VERB	O	O
diet	NOUN	O	O
L-485	PROPN	O	O
and	CCONJ	O	O
treated	VERB	O	O
with	ADP	O	O
testosterone	NOUN	O	I-Entity
developed	VERB	O	O
only	ADV	O	O
prostatitis	NOUN	O	I-Entity
.	PUNCT	O	O

Experimental	ADJ	O	O
designs	NOUN	O	O
should	VERB	O	O
consider	VERB	O	O
genetic	ADJ	O	O
susceptibility	NOUN	O	O
as	ADP	O	O
a	DET	O	O
basic	ADJ	O	O
prerequisite	NOUN	O	O
for	ADP	O	O
studies	NOUN	O	O
on	ADP	O	O
experimental	ADJ	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3108839)

Mitomycin	PROPN	O	B-Entity
C	PROPN	O	I-Entity
associated	VERB	O	O
hemolytic	ADJ	O	B-Entity
uremic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Mitomycin	PROPN	O	B-Entity
C	PROPN	O	I-Entity
associated	VERB	O	O
Hemolytic	PROPN	O	B-Entity
Uremic	PROPN	O	I-Entity
Syndrome	PROPN	O	I-Entity
(	PUNCT	O	O
HUS	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
potentially	ADV	O	O
fatal	ADJ	O	O
but	CCONJ	O	O
uncommon	ADJ	O	O
condition	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
not	ADV	O	O
yet	ADV	O	O
widely	ADV	O	O
recognised	VERB	O	O
.	PUNCT	O	O

It	PRON	O	O
consists	VERB	O	O
of	ADP	O	O
microangiopathic	ADJ	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
thrombocytopenia	NOUN	O	I-Entity
and	CCONJ	O	O
progressive	ADJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
mitomycin	NOUN	O	B-Entity
C	PROPN	O	I-Entity
treatment	NOUN	O	O
and	CCONJ	O	O
affects	VERB	O	O
about	ADP	O	O
10%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
this	DET	O	O
agent	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
usually	ADV	O	O
develops	VERB	O	O
about	ADP	O	O
8	NUM	O	O
-	SYM	O	O
10	NUM	O	O
mth	NOUN	O	O
after	ADP	O	O
start	NOUN	O	O
of	ADP	O	O
mitomycin	NOUN	O	B-Entity
C	PROPN	O	I-Entity
treatment	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
mortality	NOUN	O	O
is	VERB	O	O
approximately	ADV	O	O
60%	NUM	O	O
from	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
or	CCONJ	O	O
pulmonary	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
.	PUNCT	O	O

Renal	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
are	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
seen	VERB	O	O
in	ADP	O	O
idiopathic	ADJ	O	O
HUS	PROPN	O	I-Entity
and	CCONJ	O	O
include	VERB	O	O
arteriolar	ADJ	O	O
fibrin	NOUN	O	O
thrombi	NOUN	O	I-Entity
,	PUNCT	O	O
expanded	VERB	O	O
subendothelial	ADJ	O	O
zones	NOUN	O	O
in	ADP	O	O
glomerular	ADJ	O	O
capillary	ADJ	O	O
walls	NOUN	O	O
,	PUNCT	O	O
ischemic	ADJ	O	I-Entity
wrinkling	NOUN	O	O
of	ADP	O	O
glomerular	ADJ	O	O
basement	NOUN	O	O
membranes	NOUN	O	O
and	CCONJ	O	O
mesangiolysis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
is	VERB	O	O
postulated	VERB	O	O
as	ADP	O	O
mitomycin	NOUN	O	B-Entity
C	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
endothelial	ADJ	O	O
cell	NOUN	O	O
damage	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
the	DET	O	O
clinical	ADJ	O	O
course	NOUN	O	O
and	CCONJ	O	O
pathological	ADJ	O	O
findings	NOUN	O	O
in	ADP	O	O
a	DET	O	O
65	NUM	O	O
yr	NOUN	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
gastric	ADJ	O	B-Entity
adenocarcinoma	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
thrombocytopenia	NOUN	O	I-Entity
while	ADP	O	O
on	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
mitomycin	NOUN	O	B-Entity
C	NOUN	O	I-Entity
and	CCONJ	O	O
died	VERB	O	O
in	ADP	O	O
pulmonary	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2466960)

Continuous	ADJ	O	O
ambulatory	NOUN	O	O
ECG	PROPN	O	O
monitoring	NOUN	O	O
during	ADP	O	O
fluorouracil	NOUN	O	I-Entity
therapy	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
there	ADV	O	O
have	VERB	O	O
been	VERB	O	O
anecdotal	ADJ	O	O
reports	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
fluorouracil	NOUN	O	I-Entity
(	PUNCT	O	O
5-FU	PROPN	O	I-Entity
)	PUNCT	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
phenomenon	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
a	DET	O	O
systematic	ADJ	O	O
fashion	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
prospectively	ADV	O	O
performed	VERB	O	O
continuous	ADJ	O	O
ambulatory	ADJ	O	O
ECG	PROPN	O	O
monitoring	NOUN	O	O
on	ADP	O	O
25	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
5-FU	NUM	O	I-Entity
infusion	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
solid	ADJ	O	O
tumors	NOUN	O	I-Entity
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
ischemic	ADJ	O	I-Entity
ST	PROPN	O	O
changes	NOUN	O	O
.	PUNCT	O	O

4	NUM	O	O
hours	NOUN	O	O
before	ADP	O	O
5-FU	NUM	O	I-Entity
infusion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
98	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

9	NUM	O	O
hours	NOUN	O	O
during	ADP	O	O
5-FU	NUM	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

Anginal	ADJ	O	I-Entity
episodes	NOUN	O	O
were	VERB	O	O
rare	ADJ	O	O
:	PUNCT	O	O
only	ADV	O	O
one	NUM	O	O
patient	NOUN	O	O
had	VERB	O	O
angina	NOUN	O	I-Entity
(	PUNCT	O	O
during	ADP	O	O
5-FU	NUM	O	I-Entity
infusion	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
asymptomatic	ADJ	O	O
ST	PROPN	O	O
changes	NOUN	O	O
(	PUNCT	O	O
greater	ADJ	O	O
than	ADP	O	O
or	CCONJ	O	O
equal	ADJ	O	O
to	ADP	O	O
1	NUM	O	O
mm	PROPN	O	O
ST	PROPN	O	O
deviation	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
common	ADJ	O	O
:	PUNCT	O	O
six	NUM	O	O
of	ADP	O	O
25	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
24%	NUM	O	O
)	PUNCT	O	O
had	VERB	O	O
ST	PROPN	O	O
changes	NOUN	O	O
before	ADP	O	O
5-FU	NUM	O	I-Entity
infusion	NOUN	O	O
v	ADP	O	O
17	NUM	O	O
(	PUNCT	O	O
68%	NUM	O	O
)	PUNCT	O	O
during	ADP	O	O
5-FU	NUM	O	I-Entity
infusion	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
.002	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
ischemic	ADJ	O	I-Entity
episodes	NOUN	O	O
per	ADP	O	O
patient	NOUN	O	O
per	ADP	O	O
hour	NOUN	O	O
was	VERB	O	O
0.05	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.02	NUM	O	O
prior	ADV	O	O
to	ADP	O	O
5-FU	NUM	O	I-Entity
infusion	NOUN	O	O
v	ADP	O	O
0.13	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.03	PUNCT	O	O
during	ADP	O	O
5-FU	NUM	O	I-Entity
infusion	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
.001	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
ECG	PROPN	O	O
changes	NOUN	O	O
was	VERB	O	O
0.6	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.3	NUM	O	O
minutes	NOUN	O	O
per	ADP	O	O
patient	NOUN	O	O
per	ADP	O	O
hour	NOUN	O	O
before	ADP	O	O
5-FU	NUM	O	I-Entity
v	ADP	O	O
1.9	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

0.5	NUM	O	O
minutes	NOUN	O	O
per	ADP	O	O
patient	NOUN	O	O
per	ADP	O	O
hour	NOUN	O	O
during	ADP	O	O
5-FU	PROPN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

ECG	PROPN	O	O
changes	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
common	ADJ	O	O
among	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
known	VERB	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
two	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
sudden	ADJ	O	B-Entity
death	NOUN	O	I-Entity
,	PUNCT	O	O
both	DET	O	O
of	ADP	O	O
which	ADJ	O	O
occurred	VERB	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
course	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
5-FU	ADJ	O	I-Entity
infusion	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
silent	ADJ	O	O
ST	PROPN	O	O
segment	ADJ	O	O
deviation	NOUN	O	O
suggestive	ADJ	O	O
of	ADP	O	O
ischemia	NOUN	O	I-Entity
,	PUNCT	O	O
particularly	ADV	O	O
among	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2320800)

Lethal	ADJ	O	O
anuria	NOUN	O	I-Entity
complicating	VERB	O	O
high	ADJ	O	O
dose	NOUN	O	O
ifosfamide	NOUN	O	I-Entity
chemotherapy	NOUN	O	O
in	ADP	O	O
a	DET	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
patient	NOUN	O	O
with	ADP	O	O
an	DET	O	O
impaired	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
function	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
sixty	NUM	O	O
-	PUNCT	O	O
year	NOUN	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
advanced	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
previously	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
cisplatin	NOUN	O	I-Entity
,	PUNCT	O	O
developed	VERB	O	O
an	DET	O	O
irreversible	ADJ	O	O
lethal	ADJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
with	ADP	O	O
anuria	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
day	NOUN	O	O
after	ADP	O	O
5	NUM	O	O
g	SYM	O	O
/	SYM	O	O
m2	NOUN	O	O
bolus	NOUN	O	O
ifosfamide	NOUN	O	I-Entity
.	PUNCT	O	O

Postrenal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
was	VERB	O	O
excluded	VERB	O	O
by	ADP	O	O
echography	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
prerenal	ADJ	O	O
component	NOUN	O	O
could	VERB	O	O
have	VERB	O	O
contributed	VERB	O	O
to	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
because	ADP	O	O
of	ADP	O	O
a	DET	O	O
transient	ADJ	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
due	ADJ	O	O
to	ADP	O	O
an	DET	O	O
increasing	VERB	O	O
ascitis	NOUN	O	O
,	PUNCT	O	O
occurring	VERB	O	O
just	ADV	O	O
before	ADP	O	O
anuria	NOUN	O	I-Entity
.	PUNCT	O	O

Ifosfamide	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
known	VERB	O	O
nephrotoxic	ADJ	O	I-Entity
drug	NOUN	O	O
with	ADP	O	O
demonstrated	VERB	O	O
tubulopathies	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
strongly	ADV	O	O
suspect	VERB	O	O
that	ADP	O	O
this	DET	O	O
lethal	ADJ	O	O
anuria	NOUN	O	I-Entity
was	VERB	O	O
mainly	ADV	O	O
due	ADJ	O	O
to	ADP	O	O
ifosfamide	NOUN	O	I-Entity
,	PUNCT	O	O
occurring	VERB	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
having	VERB	O	O
received	VERB	O	O
previous	ADJ	O	O
cisplatin	NOUN	O	I-Entity
chemotherapy	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
poor	ADJ	O	O
kidney	NOUN	O	O
perfusion	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
transient	ADJ	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
recommend	VERB	O	O
careful	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
nephrotoxic	ADJ	O	I-Entity
chemotherapy	NOUN	O	O
and	CCONJ	O	O
inadequate	ADJ	O	O
renal	ADJ	O	O
perfusion	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2220369)

Central	ADJ	O	O
vein	NOUN	O	B-Entity
thrombosis	NOUN	O	I-Entity
and	CCONJ	O	O
topical	ADJ	O	O
dipivalyl	ADJ	O	B-Entity
epinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
report	NOUN	O	O
is	VERB	O	O
given	VERB	O	O
on	ADP	O	O
an	DET	O	O
83-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
female	NOUN	O	O
who	NOUN	O	O
acquired	VERB	O	O
central	ADJ	O	O
vein	NOUN	O	B-Entity
thrombosis	NOUN	O	I-Entity
in	ADP	O	O
her	ADJ	O	O
seeing	VERB	O	O
eye	NOUN	O	O
one	NUM	O	O
day	NOUN	O	O
after	ADP	O	O
having	VERB	O	O
started	VERB	O	O
topical	ADJ	O	O
medication	NOUN	O	O
with	ADP	O	O
dipivalyl	NOUN	O	B-Entity
epinephrine	NOUN	O	I-Entity
for	ADP	O	O
advanced	ADJ	O	O
glaucoma	NOUN	O	I-Entity
discovered	VERB	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
eye	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (326460)

Amelioration	NOUN	O	O
of	ADP	O	O
bendrofluazide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypokalemia	NOUN	O	I-Entity
by	ADP	O	O
timolol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
beta	NOUN	O	O
adrenergic	VERB	O	O
blocking	VERB	O	O
drug	NOUN	O	O
,	PUNCT	O	O
timolol	NOUN	O	I-Entity
,	PUNCT	O	O
tended	VERB	O	O
to	PART	O	O
correct	VERB	O	O
the	DET	O	O
hypokalemia	NOUN	O	I-Entity
of	ADP	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
bendrofluazide	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
6	NUM	O	O
healthy	ADJ	O	O
male	ADJ	O	O
subjects	NOUN	O	O
and	CCONJ	O	O
although	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
small	ADJ	O	O
it	PRON	O	O
was	VERB	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Timolol	PROPN	O	I-Entity
also	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
rise	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
aldosterone	NOUN	O	I-Entity
and	CCONJ	O	O
urine	NOUN	O	O
potassium	NOUN	O	I-Entity
excretion	NOUN	O	O
following	VERB	O	O
bendrofluazide	NOUN	O	I-Entity
and	CCONJ	O	O
increased	VERB	O	O
the	DET	O	O
urine	NOUN	O	O
sodium	NOUN	O	I-Entity
/	SYM	O	O
potassium	NOUN	O	I-Entity
ratio	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
shift	NOUN	O	O
of	ADP	O	O
potassium	NOUN	O	I-Entity
from	ADP	O	O
the	DET	O	O
intracellular	NOUN	O	O
to	ADP	O	O
the	DET	O	O
extracellular	ADJ	O	O
space	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20331935)

A	DET	O	O
cross	NOUN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
risperidone	NOUN	O	I-Entity
and	CCONJ	O	O
selective	ADJ	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitors	NOUN	O	O
on	ADP	O	O
bone	NOUN	O	O
mineral	NOUN	O	O
density	NOUN	O	O
in	ADP	O	O
boys	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
risperidone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
on	ADP	O	O
trabecular	ADJ	O	O
bone	NOUN	O	O
mineral	NOUN	O	O
density	NOUN	O	O
(	PUNCT	O	O
BMD	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
.	PUNCT	O	O

Medically	ADV	O	O
healthy	ADJ	O	O
7-	NUM	O	O
to	PART	O	O
17-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
males	NOUN	O	O
chronically	ADV	O	O
treated	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
naturalistic	ADJ	O	O
setting	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
were	VERB	O	O
recruited	VERB	O	O
for	ADP	O	O
this	DET	O	O
cross	NOUN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
study	NOUN	O	O
through	ADP	O	O
child	NOUN	O	O
psychiatry	NOUN	O	O
outpatient	NOUN	O	O
clinics	NOUN	O	O
between	ADP	O	O
November	PROPN	O	O
2005	NUM	O	O
and	CCONJ	O	O
June	PROPN	O	O
2007	NUM	O	O
.	PUNCT	O	O

Hyperprolactinemia	NOUN	O	I-Entity
was	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
49%	NUM	O	O
of	ADP	O	O
83	NUM	O	O
boys	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
41	NUM	O	O
)	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
for	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
of	ADP	O	O
2.9	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Serum	VERB	O	O
testosterone	NOUN	O	I-Entity
concentration	NOUN	O	O
increased	VERB	O	O
with	ADP	O	O
pubertal	NOUN	O	O
status	NOUN	O	O
but	CCONJ	O	O
was	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
.	PUNCT	O	O

Controlling	VERB	O	O
for	ADP	O	O
relevant	ADJ	O	O
covariates	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
also	ADV	O	O
found	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
selective	ADJ	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitors	NOUN	O	O
(	PUNCT	O	O
SSRIs	PROPN	O	O
)	PUNCT	O	O
to	PART	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
lower	ADJ	O	O
trabecular	ADJ	O	O
BMD	PROPN	O	O
at	ADP	O	O
the	DET	O	O
radius	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.03	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
BMD	PROPN	O	O
z	X	O	O
score	NOUN	O	O
at	ADP	O	O
the	DET	O	O
lumbar	NOUN	O	O
spine	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Of	ADP	O	O
13	NUM	O	O
documented	VERB	O	O
fractures	NOUN	O	I-Entity
,	PUNCT	O	O
3	NUM	O	O
occurred	VERB	O	O
after	ADP	O	O
risperidone	NOUN	O	I-Entity
and	CCONJ	O	O
SSRIs	NOUN	O	O
were	VERB	O	O
started	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
none	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
study	NOUN	O	O
to	PART	O	O
link	VERB	O	O
risperidone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperprolactinemia	NOUN	O	I-Entity
and	CCONJ	O	O
SSRI	PROPN	O	O
treatment	NOUN	O	O
to	ADP	O	O
lower	ADJ	O	O
BMD	PROPN	O	O
in	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adolescents	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19707748)

Seizures	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
levofloxacin	NOUN	O	I-Entity
:	PUNCT	O	O
case	NOUN	O	O
presentation	NOUN	O	O
and	CCONJ	O	O
literature	NOUN	O	O
review	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
present	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
seizures	NOUN	O	I-Entity
shortly	ADV	O	O
after	ADP	O	O
initiating	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
levofloxacin	NOUN	O	I-Entity
and	CCONJ	O	O
to	PART	O	O
discuss	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
drug	NOUN	O	O
-	PUNCT	O	O
drug	NOUN	O	O
interactions	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
cytochrome	NOUN	O	O
P450	PROPN	O	O
(	PUNCT	O	O
CYP	PROPN	O	O
)	PUNCT	O	O
1A2	NUM	O	O
in	ADP	O	O
this	DET	O	O
case	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
in	ADP	O	O
other	ADJ	O	O
cases	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
levofloxacin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
search	NOUN	O	O
terms	NOUN	O	O
utilized	VERB	O	O
were	VERB	O	O
case	NOUN	O	O
report	NOUN	O	O
and	CCONJ	O	O
levofloxacin	NOUN	O	I-Entity
.	PUNCT	O	O

Six	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
levofloxacin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

Drug	PROPN	O	O
-	PUNCT	O	O
drug	NOUN	O	O
interactions	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
CYP1A2	PROPN	O	O
by	ADP	O	O
levofloxacin	NOUN	O	I-Entity
are	VERB	O	O
likely	ADJ	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
of	ADP	O	O
these	DET	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Clinicians	NOUN	O	O
are	VERB	O	O
exhorted	VERB	O	O
to	PART	O	O
pay	VERB	O	O
close	ADJ	O	O
attention	NOUN	O	O
when	ADV	O	O
initiating	VERB	O	O
levofloxacin	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
taking	VERB	O	O
medications	NOUN	O	O
with	ADP	O	O
epileptogenic	ADJ	O	O
properties	NOUN	O	O
that	ADJ	O	O
are	VERB	O	O
CYP1A2	ADJ	O	O
substrates	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19692487)

Mice	NOUN	O	O
lacking	VERB	O	O
mPGES-1	NOUN	O	O
are	VERB	O	O
resistant	ADJ	O	O
to	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
polyuria	NOUN	O	I-Entity
.	PUNCT	O	O

Cyclooxygenase-2	NOUN	O	O
activity	NOUN	O	O
is	VERB	O	O
required	VERB	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
polyuria	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
involvement	NOUN	O	O
of	ADP	O	O
a	DET	O	O
specific	ADJ	O	O
,	PUNCT	O	O
terminal	ADJ	O	O
prostaglandin	NOUN	O	I-Entity
(	PUNCT	O	O
PG	PROPN	O	I-Entity
)	PUNCT	O	O
isomerase	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
assess	VERB	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
polyuria	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
deficient	ADJ	O	O
in	ADP	O	O
microsomal	ADJ	O	O
prostaglandin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
synthase-1	NOUN	O	O
(	PUNCT	O	O
mPGES-1	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
2-wk	NUM	O	O
administration	NOUN	O	O
of	ADP	O	O
LiCl	PROPN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
mmol.kg(-1).day(-1	NUM	O	O
)	PUNCT	O	O

ip	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
mPGES-1	NOUN	O	O
+	CCONJ	O	O
/+	ADJ	O	O
mice	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
a	DET	O	O
marked	ADJ	O	O
polyuria	NOUN	O	I-Entity
with	ADP	O	O
hyposmotic	ADJ	O	O
urine	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
elevated	ADJ	O	O
renal	ADJ	O	O
mPGES-1	NOUN	O	O
protein	NOUN	O	O
expression	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
urine	NOUN	O	O
PGE(2	PROPN	O	B-Entity
)	PUNCT	O	I-Entity

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
mPGES-1	NOUN	O	O
-/-	PUNCT	O	O
mice	NOUN	O	O
were	VERB	O	O
largely	ADV	O	O
resistant	ADJ	O	O
to	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
polyuria	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
urine	NOUN	O	O
concentrating	VERB	O	O
defect	NOUN	O	O
,	PUNCT	O	O
accompanied	VERB	O	O
by	ADP	O	O
nearly	ADV	O	O
complete	ADJ	O	O
blockade	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
urine	NOUN	O	O
PGE(2	NOUN	O	B-Entity
)	PUNCT	O	I-Entity
and	CCONJ	O	O
cAMP	NOUN	O	O
output	NOUN	O	O
.	PUNCT	O	O

RT	PROPN	O	O
-	PUNCT	O	O
PCR	PROPN	O	O
consistently	ADV	O	O
detected	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
aquaporin-2	NOUN	O	O
(	PUNCT	O	O
AQP2	PROPN	O	O
)	PUNCT	O	O
protein	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
renal	ADJ	O	O
cortex	NOUN	O	O
and	CCONJ	O	O
medulla	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
+	PUNCT	O	O
/+	NUM	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
total	ADJ	O	O
protein	NOUN	O	O
abundance	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Na	PROPN	O	I-Entity
-	PUNCT	O	O
K-2Cl	PROPN	O	I-Entity
cotransporter	NOUN	O	O
(	PUNCT	O	O
NKCC2	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
medulla	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
cortex	NOUN	O	O
of	ADP	O	O
the	DET	O	O
+	PROPN	O	O
/+	PROPN	O	O
mice	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
by	ADP	O	O
lithium	ADJ	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
mPGES-1-derived	VERB	O	O
PGE(2	PROPN	O	B-Entity
)	PUNCT	O	I-Entity
mediates	VERB	O	O
lithium	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
polyuria	NOUN	O	I-Entity
likely	ADJ	O	O
via	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
AQP2	PROPN	O	O
and	CCONJ	O	O
NKCC2	PROPN	O	O
expression	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19289093)

Identification	NOUN	O	O
of	ADP	O	O
a	DET	O	O
simple	ADJ	O	O
and	CCONJ	O	O
sensitive	ADJ	O	O
microplate	NOUN	O	O
method	NOUN	O	O
for	ADP	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
oversulfated	ADJ	O	O
chondroitin	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
in	ADP	O	O
heparin	NOUN	O	I-Entity
products	NOUN	O	O
.	PUNCT	O	O

Heparin	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
commonly	ADV	O	O
implemented	VERB	O	O
anticoagulant	NOUN	O	O
used	VERB	O	O
to	PART	O	O
treat	VERB	O	O
critically	ADV	O	O
ill	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Recently	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
number	NOUN	O	O
of	ADP	O	O
commercial	ADJ	O	O
lots	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
products	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
contaminated	VERB	O	O
with	ADP	O	O
an	DET	O	O
oversulfated	ADJ	O	O
chondroitin	NOUN	O	B-Entity
sulfate	NOUN	O	I-Entity
(	PUNCT	O	O
OSCS	PROPN	O	O
)	PUNCT	O	O
derivative	ADJ	O	O
that	ADJ	O	O
could	VERB	O	O
elicit	VERB	O	O
a	DET	O	O
hypotensive	ADJ	O	I-Entity
response	NOUN	O	O
in	ADP	O	O
pigs	NOUN	O	O
following	VERB	O	O
a	DET	O	O
single	ADJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
infusion	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
both	DET	O	O
contaminated	VERB	O	O
heparin	NOUN	O	I-Entity
products	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
synthetically	ADV	O	O
produced	VERB	O	O
derivative	ADJ	O	O
,	PUNCT	O	O
we	PRON	O	O
showed	VERB	O	O
that	ADP	O	O
the	DET	O	O
OSCS	PROPN	O	O
produces	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
pigs	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
demonstrated	VERB	O	O
that	ADP	O	O
OSCS	PROPN	O	O
can	VERB	O	O
be	VERB	O	O
identified	VERB	O	O
in	ADP	O	O
heparin	NOUN	O	I-Entity
products	NOUN	O	O
using	VERB	O	O
a	DET	O	O
simple	ADJ	O	O
,	PUNCT	O	O
inexpensive	ADJ	O	O
,	PUNCT	O	O
commercially	ADV	O	O
available	ADJ	O	O
heparin	NOUN	O	I-Entity
enzyme	NOUN	O	O
immunoassay	NOUN	O	O
(	PUNCT	O	O
EIA	PROPN	O	O
)	PUNCT	O	O
kit	NOUN	O	O
that	ADJ	O	O
has	VERB	O	O
a	DET	O	O
limit	NOUN	O	O
of	ADP	O	O
detection	NOUN	O	O
of	ADP	O	O
approximately	ADV	O	O
0.1%	NUM	O	O
,	PUNCT	O	O
well	INTJ	O	O
below	ADP	O	O
the	DET	O	O
NOEL	PROPN	O	O
.	PUNCT	O	O

This	DET	O	O
kit	NOUN	O	O
may	VERB	O	O
provide	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
method	NOUN	O	O
to	PART	O	O
test	VERB	O	O
heparin	NOUN	O	I-Entity
products	NOUN	O	O
for	ADP	O	O
contamination	NOUN	O	O
with	ADP	O	O
oversulfated	ADJ	O	O
GAG	PROPN	O	O
derivatives	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18627295)

Doxorubicin	PROPN	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
inflammation	NOUN	O	I-Entity
and	CCONJ	O	O
apoptosis	NOUN	O	O
are	VERB	O	O
attenuated	VERB	O	O
by	ADP	O	O
gene	NOUN	O	O
deletion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
kinin	NOUN	O	O
B1	PROPN	O	O
receptor	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
anthracycline	NOUN	O	I-Entity
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
DOX	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
limited	VERB	O	O
by	ADP	O	O
its	ADJ	O	O
cardiotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
are	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
apoptosis	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
elucidate	VERB	O	O
the	DET	O	O
possible	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
the	DET	O	O
kinin	NOUN	O	O
B1	PROPN	O	O
receptor	NOUN	O	O
(	PUNCT	O	O
B1R	PROPN	O	O
)	PUNCT	O	O
during	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
DOX	PROPN	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
B1R	PROPN	O	O
knockout	NOUN	O	O
mice	NOUN	O	O
(	PUNCT	O	O
B1R(-/-	PROPN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
by	ADP	O	O
investigating	VERB	O	O
cardiac	ADJ	O	O
inflammation	NOUN	O	I-Entity
and	CCONJ	O	O
apoptosis	NOUN	O	O
after	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
DOX	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O

DOX	PROPN	O	I-Entity
control	NOUN	O	O
mice	NOUN	O	O
showed	VERB	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
measured	VERB	O	O
by	ADP	O	O
pressure	NOUN	O	O
-	PUNCT	O	O
volume	NOUN	O	O
loops	NOUN	O	O
in	ADP	O	O
vivo	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
reduced	ADJ	O	O
activation	NOUN	O	O
state	NOUN	O	O
of	ADP	O	O
AKT	PROPN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
an	DET	O	O
increased	VERB	O	O
bax	NOUN	O	O
/	SYM	O	O
bcl2	NOUN	O	O
ratio	NOUN	O	O
in	ADP	O	O
Western	ADJ	O	O
blots	NOUN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
cardiac	ADJ	O	B-Entity
apoptosis	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
DOX	PROPN	O	I-Entity
B1R(-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
,	PUNCT	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
was	VERB	O	O
improved	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
DOX	PROPN	O	I-Entity
control	NOUN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
normalization	NOUN	O	O
of	ADP	O	O
the	DET	O	O
bax	NOUN	O	O
/	SYM	O	O
bcl-2	NOUN	O	O
ratio	NOUN	O	O
and	CCONJ	O	O
interleukin	NOUN	O	O
6	NUM	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
AKT	PROPN	O	O
activation	NOUN	O	O
state	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
B1R	PROPN	O	O
is	VERB	O	O
detrimental	ADJ	O	O
in	ADP	O	O
DOX	PROPN	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
in	ADP	O	O
that	DET	O	O
it	PRON	O	O
mediates	VERB	O	O
the	DET	O	O
inflammatory	ADJ	O	O
response	NOUN	O	O
and	CCONJ	O	O
apoptosis	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
insights	NOUN	O	O
might	VERB	O	O
have	VERB	O	O
useful	ADJ	O	O
implications	NOUN	O	O
for	ADP	O	O
future	ADJ	O	O
studies	NOUN	O	O
utilizing	VERB	O	O
B1R	ADJ	O	O
antagonists	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
DOX	PROPN	O	I-Entity
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18405372)

Hepatotoxicity	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
sulfasalazine	NOUN	O	I-Entity
in	ADP	O	O
inflammatory	ADJ	O	O
arthritis	NOUN	O	I-Entity
:	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
an	DET	O	O
investigation	NOUN	O	O
from	ADP	O	O
a	DET	O	O
local	ADJ	O	O
surveillance	NOUN	O	O
for	ADP	O	O
serious	ADJ	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
reactions	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
disease	NOUN	O	O
modifying	VERB	O	O
anti	ADJ	O	O
-	PUNCT	O	O
rheumatic	ADJ	O	O
drugs	NOUN	O	O
that	ADJ	O	O
was	VERB	O	O
triggered	VERB	O	O
by	ADP	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
two	NUM	O	O
of	ADP	O	O
our	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
'	PART	O	O
,	PUNCT	O	O
who	NOUN	O	O
had	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
on	ADP	O	O
sulfasalazine	NOUN	O	I-Entity
and	CCONJ	O	O
met	VERB	O	O
a	DET	O	O
definition	NOUN	O	O
of	ADP	O	O
a	DET	O	O
serious	ADJ	O	O
ADR	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
identified	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
likely	ADJ	O	O
frequency	NOUN	O	O
of	ADP	O	O
hepatotoxicity	NOUN	O	I-Entity
with	ADP	O	O
sulfasalazine	NOUN	O	I-Entity
was	VERB	O	O
estimated	VERB	O	O
by	ADP	O	O
making	VERB	O	O
a	DET	O	O
series	NOUN	O	O
of	ADP	O	O
conservative	ADJ	O	O
assumptions	NOUN	O	O
.	PUNCT	O	O

Eight	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
hospitalised	VERB	O	O
,	PUNCT	O	O
two	NUM	O	O
in	ADP	O	O
hepatic	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
-	PUNCT	O	O
one	NUM	O	O
died	VERB	O	O
after	ADP	O	O
a	DET	O	O
liver	NOUN	O	O
transplant	NOUN	O	O
.	PUNCT	O	O

Seven	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
skin	NOUN	O	B-Entity
rash	NOUN	O	I-Entity
,	PUNCT	O	O
three	NUM	O	O
eosinophilia	NOUN	O	I-Entity
and	CCONJ	O	O
one	NUM	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
.	PUNCT	O	O

Drug	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
was	VERB	O	O
judged	VERB	O	O
probable	ADJ	O	O
or	CCONJ	O	O
highly	ADV	O	O
probable	ADJ	O	O
in	ADP	O	O
8	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
likely	ADJ	O	O
frequency	NOUN	O	O
of	ADP	O	O
serious	ADJ	O	O
hepatotoxicity	NOUN	O	I-Entity
with	ADP	O	O
sulfasalazine	NOUN	O	I-Entity
was	VERB	O	O
estimated	VERB	O	O
at	ADP	O	O
0.4%	NUM	O	O
of	ADP	O	O
treated	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Serious	ADJ	O	O
hepatotoxicity	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
sulfasalazine	NOUN	O	I-Entity
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
under	ADP	O	O
-	PUNCT	O	O
appreciated	VERB	O	O
and	CCONJ	O	O
intensive	ADJ	O	O
monitoring	NOUN	O	O
and	CCONJ	O	O
vigilance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
6	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
is	VERB	O	O
especially	ADV	O	O
important	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (18356633)

An	DET	O	O
evaluation	NOUN	O	O
of	ADP	O	O
amikacin	DET	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
hematology	NOUN	O	O
/	SYM	O	O
oncology	NOUN	O	O
population	NOUN	O	O
.	PUNCT	O	O

Amikacin	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
aminoglycoside	NOUN	O	I-Entity
commonly	ADV	O	O
used	VERB	O	O
to	PART	O	O
provide	VERB	O	O
empirical	ADJ	O	O
double	ADJ	O	O
gram	NOUN	O	O
-	PUNCT	O	O
negative	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
febrile	NOUN	O	B-Entity
neutropenia	NOUN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
suspected	VERB	O	O
infections	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
evaluate	VERB	O	O
amikacin	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
adult	NOUN	O	O
hematology	NOUN	O	O
/	SYM	O	O
oncology	NOUN	O	O
population	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
trial	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
at	ADP	O	O
a	DET	O	O
university	NOUN	O	O
-	PUNCT	O	O
affiliated	VERB	O	O
medical	ADJ	O	O
center	NOUN	O	O
.	PUNCT	O	O

Forty	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
diagnosis	NOUN	O	O
consistent	NOUN	O	O
with	ADP	O	O
a	DET	O	O
hematologic	NOUN	O	B-Entity
/	SYM	O	I-Entity
oncologic	ADJ	O	I-Entity
disorder	NOUN	O	I-Entity
that	ADJ	O	O
required	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
an	DET	O	O
aminoglycoside	NOUN	O	I-Entity
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
conventional	ADJ	O	O
or	CCONJ	O	O
extended	VERB	O	O
-	PUNCT	O	O
interval	NOUN	O	O
amikacin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
and	CCONJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
via	ADP	O	O
amikacin	NOUN	O	I-Entity
serum	NOUN	O	O
concentrations	NOUN	O	O
with	ADP	O	O
respective	ADJ	O	O
pathogens	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
was	VERB	O	O
similar	ADJ	O	O
between	ADP	O	O
the	DET	O	O
conventional	ADJ	O	O
and	CCONJ	O	O
extended	VERB	O	O
-	PUNCT	O	O
interval	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
10%	NUM	O	O
and	CCONJ	O	O
5%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
1.00	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
was	VERB	O	O
similar	ADJ	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
dosing	VERB	O	O
regimens	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
distribution	NOUN	O	O
of	ADP	O	O
risk	NOUN	O	O
factors	NOUN	O	O
was	VERB	O	O
variable	ADJ	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16574713)

Memory	NOUN	O	O
function	NOUN	O	O
and	CCONJ	O	O
serotonin	NOUN	O	I-Entity
transporter	NOUN	O	O
promoter	NOUN	O	O
gene	NOUN	O	O
polymorphism	NOUN	O	O
in	ADP	O	O
ecstasy	NOUN	O	I-Entity
(	PUNCT	O	O
MDMA	PROPN	O	I-Entity
)	PUNCT	O	O
users	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
3,4-methylenedioxymethamphetamine	NUM	O	I-Entity
(	PUNCT	O	O
MDMA	NOUN	O	I-Entity
or	CCONJ	O	O
ecstasy	NOUN	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
shown	VERB	O	O
to	ADP	O	O
damage	NOUN	O	O
brain	NOUN	O	O
serotonin	NOUN	O	I-Entity
(	PUNCT	O	O
5-HT	PROPN	O	I-Entity
)	PUNCT	O	O
neurons	NOUN	O	O
in	ADP	O	O
animals	NOUN	O	O
and	CCONJ	O	O
possibly	ADV	O	O
humans	NOUN	O	O
,	PUNCT	O	O
little	ADJ	O	O
is	VERB	O	O
known	VERB	O	O
about	ADP	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
consequences	NOUN	O	O
of	ADP	O	O
MDMA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
5-HT	ADJ	O	I-Entity
neurotoxic	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
on	ADP	O	O
functions	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
5-HT	NOUN	O	I-Entity
is	VERB	O	O
involved	VERB	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
cognitive	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
5-HT	PROPN	O	I-Entity
transporters	NOUN	O	O
play	VERB	O	O
a	DET	O	O
key	ADJ	O	O
element	NOUN	O	O
in	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
synaptic	ADJ	O	O
5-HT	NUM	O	I-Entity
transmission	NOUN	O	O
it	PRON	O	O
may	VERB	O	O
be	VERB	O	O
important	ADJ	O	O
to	PART	O	O
control	VERB	O	O
for	ADP	O	O
the	DET	O	O
potential	ADJ	O	O
covariance	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
polymorphism	NOUN	O	O
in	ADP	O	O
the	DET	O	O
5-HT	ADJ	O	I-Entity
transporter	NOUN	O	O
promoter	NOUN	O	O
gene	NOUN	O	O
region	NOUN	O	O
(	PUNCT	O	O
5-HTTLPR	PROPN	O	O
)	PUNCT	O	O
when	ADV	O	O
studying	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
MDMA	PROPN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
cognitive	ADJ	O	O
functioning	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
moderate	ADJ	O	O
and	CCONJ	O	O
heavy	ADJ	O	O
MDMA	PROPN	O	I-Entity
use	NOUN	O	O
on	ADP	O	O
cognitive	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
abstention	NOUN	O	O
from	ADP	O	O
MDMA	PROPN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
subjects	NOUN	O	O
genotyped	VERB	O	O
for	ADP	O	O
5-HTTLPR	NUM	O	O
.	PUNCT	O	O

Fifteen	NUM	O	O
moderate	ADJ	O	O
MDMA	PROPN	O	I-Entity
users	NOUN	O	O
(	PUNCT	O	O
<	SYM	O	O
55	NUM	O	O
lifetime	NOUN	O	O
tablets	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
22	NUM	O	O
heavy	ADJ	O	O
MDMA+	NOUN	O	I-Entity
users	NOUN	O	O
(	PUNCT	O	O
>	SYM	O	O
55	NUM	O	O
lifetime	NOUN	O	O
tablets	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
16	NUM	O	O
ex	NOUN	O	O
-	PUNCT	O	O
MDMA+	PROPN	O	I-Entity
users	NOUN	O	O
(	PUNCT	O	O
last	ADJ	O	O
tablet	NOUN	O	O
>	X	O	O
1	NUM	O	O
year	NOUN	O	O
ago	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
13	NUM	O	O
controls	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
on	ADP	O	O
a	DET	O	O
battery	NOUN	O	O
of	ADP	O	O
neuropsychological	ADJ	O	O
tests	NOUN	O	O
.	PUNCT	O	O

Heavy	PROPN	O	O
and	CCONJ	O	O
ex	NOUN	O	O
-	PUNCT	O	O
MDMA+	NOUN	O	I-Entity
users	NOUN	O	O
performed	VERB	O	O
significantly	ADV	O	O
poorer	ADJ	O	O
on	ADP	O	O
memory	NOUN	O	O
tasks	NOUN	O	O
than	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
memory	NOUN	O	B-Entity
impairment	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
moderate	ADJ	O	O
MDMA	PROPN	O	I-Entity
users	NOUN	O	O
.	PUNCT	O	O

While	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
MDMA	PROPN	O	I-Entity
in	ADP	O	O
quantities	NOUN	O	O
that	ADJ	O	O
may	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
"	PUNCT	O	O
moderate	ADJ	O	O
"	PUNCT	O	O
is	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
impaired	ADJ	O	B-Entity
memory	NOUN	O	I-Entity
functioning	NOUN	O	I-Entity
,	PUNCT	O	O
heavy	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
MDMA	PROPN	O	I-Entity
use	NOUN	O	O
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
long	ADJ	O	O
lasting	ADJ	O	O
memory	NOUN	O	B-Entity
impairments	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
5-HTTLPR	NUM	O	O
or	CCONJ	O	O
gender	NOUN	O	O
on	ADP	O	O
memory	NOUN	O	O
function	NOUN	O	O
or	CCONJ	O	O
MDMA	PROPN	O	I-Entity
use	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (15638391)

Aging	VERB	O	O
process	NOUN	O	O
of	ADP	O	O
epithelial	ADJ	O	O
cells	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
prostate	NOUN	O	O
lateral	ADJ	O	O
lobe	NOUN	O	O
in	ADP	O	O
experimental	ADJ	O	O
hyperprolactinemia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
haloperidol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
hyperprolactinemia	NOUN	O	I-Entity
,	PUNCT	O	O
induced	VERB	O	O
by	ADP	O	O
haloperidol	NOUN	O	I-Entity
(	PUNCT	O	O
HAL	PROPN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
age	NOUN	O	O
related	VERB	O	O
morphology	NOUN	O	O
and	CCONJ	O	O
function	NOUN	O	O
changes	NOUN	O	O
of	ADP	O	O
epithelial	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
rat	NOUN	O	O
prostate	NOUN	O	O
lateral	ADJ	O	O
lobe	NOUN	O	O
.	PUNCT	O	O

Serum	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
prolactin	NOUN	O	O
(	PUNCT	O	O
PRL	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
testosterone	NOUN	O	I-Entity
(	PUNCT	O	O
T	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
rats	NOUN	O	O
of	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mean	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
:	PUNCT	O	O
PRL	PROPN	O	I-Entity
was	VERB	O	O
more	ADV	O	O
than	ADP	O	O
twice	ADV	O	O
higher	ADJ	O	O
,	PUNCT	O	O
whereas	ADP	O	O
T	PROPN	O	I-Entity
concentration	NOUN	O	O
was	VERB	O	O
almost	ADV	O	O
twice	ADV	O	O
lower	ADJ	O	O
than	ADP	O	O
that	DET	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Light	PROPN	O	O
microscopy	NOUN	O	O
visualized	VERB	O	O
the	DET	O	O
following	VERB	O	O
:	PUNCT	O	O
hypertrophy	NOUN	O	I-Entity
and	CCONJ	O	O
epithelium	NOUN	O	O
hyperplasia	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
glandular	ADJ	O	O
ducts	NOUN	O	O
,	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
PCNA	PROPN	O	O
expression	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15531665)

Does	VERB	O	O
supplemental	NOUN	O	O
vitamin	NOUN	O	B-Entity
C	NOUN	O	I-Entity
increase	NOUN	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
risk	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	I-Entity
?	PUNCT	O	O

Vitamin	NOUN	O	B-Entity
C	NOUN	O	I-Entity
acts	VERB	O	O
as	ADP	O	O
a	DET	O	O
potent	ADJ	O	O
antioxidant	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
can	VERB	O	O
also	ADV	O	O
be	VERB	O	O
a	DET	O	O
prooxidant	NOUN	O	O
and	CCONJ	O	O
glycate	NOUN	O	O
protein	NOUN	O	O
under	ADP	O	O
certain	ADJ	O	O
circumstances	NOUN	O	O
in	ADP	O	O
vitro	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
observations	NOUN	O	O
led	VERB	O	O
us	PRON	O	O
to	PART	O	O
hypothesize	VERB	O	O
that	ADP	O	O
a	DET	O	O
high	ADJ	O	O
intake	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
C	NOUN	O	I-Entity
in	ADP	O	O
diabetic	ADJ	O	I-Entity
persons	NOUN	O	O
might	VERB	O	O
promote	VERB	O	O
atherosclerosis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
was	VERB	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
relation	NOUN	O	O
between	ADP	O	O
vitamin	NOUN	O	B-Entity
C	NOUN	O	I-Entity
intake	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
from	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

DESIGN	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
relation	NOUN	O	O
between	ADP	O	O
vitamin	NOUN	O	B-Entity
C	NOUN	O	I-Entity
intake	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
from	ADP	O	O
total	ADJ	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
281	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
175	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
stroke	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
57	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
1923	NUM	O	O
postmenopausal	NOUN	O	O
women	NOUN	O	O
who	NOUN	O	O
reported	VERB	O	O
being	VERB	O	O
diabetic	ADJ	O	I-Entity
at	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

Diet	PROPN	O	O
was	VERB	O	O
assessed	VERB	O	O
with	ADP	O	O
a	DET	O	O
food	NOUN	O	O
-	PUNCT	O	O
frequency	NOUN	O	O
questionnaire	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
subjects	NOUN	O	O
initially	ADV	O	O
free	ADJ	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
were	VERB	O	O
prospectively	ADV	O	O
followed	VERB	O	O
for	ADP	O	O
15	NUM	O	O
y.	NOUN	O	O
RESULTS	NOUN	O	O
:	PUNCT	O	O

After	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
risk	NOUN	O	O
factors	NOUN	O	O
,	PUNCT	O	O
type	NOUN	O	O
of	ADP	O	O
diabetes	NOUN	O	I-Entity
medication	NOUN	O	O
used	VERB	O	O
,	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
diabetes	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
intakes	NOUN	O	O
of	ADP	O	O
folate	NOUN	O	I-Entity
,	PUNCT	O	O
vitamin	NOUN	O	B-Entity
E	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
carotene	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
adjusted	ADJ	O	O
relative	ADJ	O	O
risks	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
mortality	NOUN	O	O
were	VERB	O	O
1.0	NUM	O	O
,	PUNCT	O	O
0.97	NUM	O	O
,	PUNCT	O	O
1.11	NUM	O	O
,	PUNCT	O	O
1.47	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1.84	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
for	ADP	O	O
trend	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
across	ADP	O	O
quintiles	NOUN	O	O
of	ADP	O	O
total	NOUN	O	O
vitamin	NOUN	O	B-Entity
C	NOUN	O	I-Entity
intake	NOUN	O	O
from	ADP	O	O
food	NOUN	O	O
and	CCONJ	O	O
supplements	NOUN	O	O
.	PUNCT	O	O

Adjusted	VERB	O	O
relative	ADJ	O	O
risks	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
were	VERB	O	O
1.0	NUM	O	O
,	PUNCT	O	O
0.81	NUM	O	O
,	PUNCT	O	O
0.99	NUM	O	O
,	PUNCT	O	O
1.26	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1.91	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
for	ADP	O	O
trend	NOUN	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
of	ADP	O	O
stroke	NOUN	O	I-Entity
were	VERB	O	O
1.0	NUM	O	O
,	PUNCT	O	O
0.52	NUM	O	O
,	PUNCT	O	O
1.23	NUM	O	O
,	PUNCT	O	O
2.22	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2.57	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
for	ADP	O	O
trend	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

When	ADV	O	O
dietary	ADJ	O	O
and	CCONJ	O	O
supplemental	ADJ	O	O
vitamin	NOUN	O	B-Entity
C	NOUN	O	I-Entity
were	VERB	O	O
analyzed	VERB	O	O
separately	ADV	O	O
,	PUNCT	O	O
only	ADV	O	O
supplemental	ADJ	O	O
vitamin	NOUN	O	B-Entity
C	NOUN	O	I-Entity
showed	VERB	O	O
a	DET	O	O
positive	ADJ	O	O
association	NOUN	O	O
with	ADP	O	O
mortality	NOUN	O	O
endpoints	NOUN	O	O
.	PUNCT	O	O

Vitamin	NOUN	O	B-Entity
C	NOUN	O	I-Entity
intake	NOUN	O	O
was	VERB	O	O
unrelated	ADJ	O	O
to	ADP	O	O
mortality	NOUN	O	O
from	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
nondiabetic	ADJ	O	O
subjects	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
A	DET	O	O
high	ADJ	O	O
vitamin	NOUN	O	B-Entity
C	NOUN	O	I-Entity
intake	NOUN	O	O
from	ADP	O	O
supplements	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
mortality	NOUN	O	O
in	ADP	O	O
postmenopausal	NOUN	O	O
women	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12851669)

Absolute	ADJ	O	O
and	CCONJ	O	O
attributable	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
on	ADP	O	O
combined	VERB	O	O
cyproterone	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
and	CCONJ	O	O
ethinylestradiol	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
achieve	VERB	O	O
absolute	ADJ	O	O
risk	NOUN	O	O
estimates	NOUN	O	O
of	ADP	O	O
venous	ADJ	O	B-Entity
thromboembolism	NOUN	O	I-Entity
(	PUNCT	O	O
VTE	PROPN	O	I-Entity
)	PUNCT	O	O
among	ADP	O	O
women	NOUN	O	O
on	ADP	O	O
cyproterone	NOUN	O	B-Entity
acetate	NOUN	O	I-Entity
plus	CCONJ	O	O
ethinylestradiol	NOUN	O	I-Entity
(	PUNCT	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
among	ADP	O	O
women	NOUN	O	O
on	ADP	O	O
combined	VERB	O	B-Entity
oral	ADJ	O	I-Entity
contraceptives	NOUN	O	I-Entity
(	PUNCT	O	O
COCs	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

From	ADP	O	O
the	DET	O	O
Danish	PROPN	O	O
National	PROPN	O	O
Register	PROPN	O	O
of	ADP	O	O
Patients	PROPN	O	O
(	PUNCT	O	O
NRP	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
1996	NUM	O	O
to	ADP	O	O
1998	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
records	NOUN	O	O
of	ADP	O	O
1.1	NUM	O	O
million	NUM	O	O
Danish	ADJ	O	O
women	NOUN	O	O
,	PUNCT	O	O
ages	NOUN	O	O
15	NUM	O	O
to	PART	O	O
44	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
searched	VERB	O	O
for	ADP	O	O
evidence	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
.	PUNCT	O	O

COC	PROPN	O	I-Entity
use	NOUN	O	O
was	VERB	O	O
ascertained	VERB	O	O
through	ADP	O	O
mailed	VERB	O	O
questionnaires	NOUN	O	O
.	PUNCT	O	O

Sales	NOUN	O	O
statistics	NOUN	O	O
of	ADP	O	O
COCs	NOUN	O	I-Entity
and	CCONJ	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
were	VERB	O	O
provided	VERB	O	O
through	ADP	O	O
Danish	PROPN	O	O
Drug	PROPN	O	O
Statistics	PROPN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
time	NOUN	O	O
frame	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
330	NUM	O	O
women	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
have	VERB	O	O
had	VERB	O	O
VTE	PROPN	O	I-Entity
while	ADP	O	O
on	ADP	O	O
COCs	NOUN	O	I-Entity
.	PUNCT	O	O

Of	ADP	O	O
these	DET	O	O
women	NOUN	O	O
,	PUNCT	O	O
67	NUM	O	O
were	VERB	O	O
on	ADP	O	O
levonorgestrel	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
COCs	NOUN	O	I-Entity
.	PUNCT	O	O

Eleven	NUM	O	O
were	VERB	O	O
on	ADP	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
corresponding	ADJ	O	O
absolute	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
was	VERB	O	O
3.4	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
3.1	NUM	O	O
-	SYM	O	O
3.8	NUM	O	O
)	PUNCT	O	O
per	ADP	O	O
10	NUM	O	O
000	NUM	O	O
women	NOUN	O	O
years	NOUN	O	O
among	ADP	O	O
the	DET	O	O
women	NOUN	O	O
on	ADP	O	O
COCs	NOUN	O	I-Entity
,	PUNCT	O	O
4.2	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
3.2	NUM	O	O
-	SYM	O	O
5.2	NUM	O	O
)	PUNCT	O	O
per	ADP	O	O
10	NUM	O	O
000	NUM	O	O
women	NOUN	O	O
years	NOUN	O	O
among	ADP	O	O
women	NOUN	O	O
on	ADP	O	O
levonorgestrel	NOUN	O	I-Entity
-	PUNCT	O	O
containing	VERB	O	O
COCs	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
3.1	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
1.3	NUM	O	O
-	SYM	O	O
4.9	NUM	O	O
)	PUNCT	O	O
per	ADP	O	O
10	NUM	O	O
000	NUM	O	O
women	NOUN	O	O
years	NOUN	O	O
among	ADP	O	O
the	DET	O	O
women	NOUN	O	O
on	ADP	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Our	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
the	DET	O	O
absolute	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
VTE	PROPN	O	I-Entity
among	ADP	O	O
Danish	ADJ	O	O
women	NOUN	O	O
on	ADP	O	O
COCs	PROPN	O	I-Entity
is	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
among	ADP	O	O
women	NOUN	O	O
taking	VERB	O	O
CPA	PROPN	O	I-Entity
/	SYM	O	O
EE	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12842176)

Effect	NOUN	O	O
of	ADP	O	O
lindane	NOUN	O	I-Entity
on	ADP	O	O
hepatic	NOUN	O	O
and	CCONJ	O	O
brain	NOUN	O	O
cytochrome	NOUN	O	O
P450s	PROPN	O	O
and	CCONJ	O	O
influence	NOUN	O	O
of	ADP	O	O
P450	PROPN	O	O
modulation	NOUN	O	O
in	ADP	O	O
lindane	NOUN	O	I-Entity
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
lindane	NOUN	O	I-Entity
(	PUNCT	O	O
2.5	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
and	CCONJ	O	O
15	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
body	NOUN	O	O
weight	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
produce	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
P450	PROPN	O	O
dependent	ADJ	O	O
7-ethoxyresorufin	NUM	O	O
-	PUNCT	O	O
O	NOUN	O	O
-	PUNCT	O	O
deethylase	NOUN	O	O
(	PUNCT	O	O
EROD	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
7-pentoxyresorufin	NUM	O	O
-	PUNCT	O	O
O	NOUN	O	O
-	PUNCT	O	O
dealkylase	NOUN	O	O
(	PUNCT	O	O
PROD	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
nitrosodimethylamine	ADJ	O	I-Entity
demethylase	NOUN	O	O
(	PUNCT	O	O
NDMA	PROPN	O	I-Entity
-	PUNCT	O	O
d	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
rat	NOUN	O	O
brain	NOUN	O	O
and	CCONJ	O	O
liver	NOUN	O	O
.	PUNCT	O	O

brain	NOUN	O	O
P450	PROPN	O	O
monooxygenases	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
observed	VERB	O	O
when	ADV	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
exposure	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
2.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
lindane	NOUN	O	I-Entity
was	VERB	O	O
increased	VERB	O	O
from	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
to	PART	O	O
15	NUM	O	O
or	CCONJ	O	O
21	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
vitro	ADJ	O	O
studies	NOUN	O	O
using	VERB	O	O
organic	ADJ	O	O
inhibitors	NOUN	O	O
specific	ADJ	O	O
for	ADP	O	O
individual	ADJ	O	O
P450	PROPN	O	O
isoenzymes	NOUN	O	O
and	CCONJ	O	O
antibody	NOUN	O	O
inhibition	NOUN	O	O
experiments	NOUN	O	O
have	VERB	O	O
further	ADV	O	O
demonstrated	VERB	O	O
that	ADP	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
PROD	PROPN	O	O
,	PUNCT	O	O
EROD	PROPN	O	O
and	CCONJ	O	O
NDMA	PROPN	O	I-Entity
-	PUNCT	O	O
d	PROPN	O	O
are	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
P450	PROPN	O	O
2B1/2B2	NUM	O	O
,	PUNCT	O	O
1A1/1A2	NUM	O	O
and	CCONJ	O	O
2E1	NUM	O	O
isoenzymes	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Induction	NOUN	O	O
studies	NOUN	O	O
have	VERB	O	O
further	ADV	O	O
shown	VERB	O	O
that	ADP	O	O
while	ADP	O	O
pretreatment	NOUN	O	O
of	ADP	O	O
3-methylcholanthrene	NOUN	O	I-Entity
(	PUNCT	O	O
MC	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
inducer	NOUN	O	O
of	ADP	O	O
P4501A1/1A2	PROPN	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
produce	VERB	O	O
any	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
lindane	NOUN	O	I-Entity
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
,	PUNCT	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
phenobarbital	NOUN	O	I-Entity
(	PUNCT	O	O
PB	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
inducer	NOUN	O	O
of	ADP	O	O
P450	PROPN	O	O
2B1/2B2	NUM	O	O
or	CCONJ	O	O
ethanol	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
inducer	NOUN	O	O
of	ADP	O	O
P450	PROPN	O	O
2E1	NUM	O	O

catalysed	VERB	O	O
reactions	NOUN	O	O
,	PUNCT	O	O
significantly	ADV	O	O
increased	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
lindane	NOUN	O	I-Entity
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
when	ADV	O	O
the	DET	O	O
P450-mediated	ADJ	O	O
metabolism	NOUN	O	O
of	ADP	O	O
lindane	NOUN	O	I-Entity
was	VERB	O	O
blocked	VERB	O	O
by	ADP	O	O
cobalt	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
incidence	NOUN	O	O
of	ADP	O	O
convulsions	NOUN	O	I-Entity
was	VERB	O	O
increased	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
lindane	NOUN	O	I-Entity
indicating	VERB	O	O
that	ADP	O	O
lindane	NOUN	O	I-Entity
per	X	O	O
se	X	O	O
or	CCONJ	O	O
its	ADJ	O	O
metabolites	NOUN	O	O
formed	VERB	O	O
by	ADP	O	O
PB	PROPN	O	O
or	CCONJ	O	O
ethanol	NOUN	O	I-Entity
inducible	ADJ	O	O

P450	NOUN	O	O
isoenzymes	NOUN	O	O
are	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
its	ADJ	O	O
neurobehavioral	ADJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12745515)

Seizure	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
sleep	NOUN	O	B-Entity
deprivation	NOUN	O	I-Entity
and	CCONJ	O	O
sustained	VERB	O	O
-	PUNCT	O	O
release	NOUN	O	O
bupropion	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
describes	VERB	O	O
a	DET	O	O
generalized	ADJ	O	O
seizure	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
sustained	ADJ	O	O
-	PUNCT	O	O
release	NOUN	O	O
bupropion	NOUN	O	I-Entity
use	NOUN	O	O
and	CCONJ	O	O
sleep	NOUN	O	B-Entity
deprivation	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
subject	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
31-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
female	ADJ	O	O
smoker	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
participating	VERB	O	O
in	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
evaluating	VERB	O	O
an	DET	O	O
investigational	ADJ	O	O
medication	NOUN	O	O
for	ADP	O	O
smoking	NOUN	O	O
cessation	NOUN	O	O
that	ADJ	O	O
used	VERB	O	O
sustained	VERB	O	O
-	PUNCT	O	O
release	NOUN	O	O
bupropion	NOUN	O	I-Entity
as	ADP	O	O
an	DET	O	O
active	ADJ	O	O
control	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
5	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	I-Entity
use	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
subject	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
generalized	ADJ	O	O
tonic	NOUN	O	O
clonic	NOUN	O	O
seizure	NOUN	O	I-Entity
after	ADP	O	O
staying	VERB	O	O
up	PART	O	O
nearly	ADV	O	O
all	DET	O	O
night	NOUN	O	O
packing	VERB	O	O
and	CCONJ	O	O
moving	VERB	O	O
to	ADP	O	O
a	DET	O	O
new	ADJ	O	O
residence	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
no	DET	O	O
other	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
sleep	NOUN	O	B-Entity
deprivation	NOUN	O	I-Entity
may	VERB	O	O
add	VERB	O	O
to	ADP	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12571256)

Nephrotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
in	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
risk	NOUN	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
angiography	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
iodinated	ADJ	O	O
contrast	NOUN	O	O
medium	NOUN	O	O
can	VERB	O	O
result	VERB	O	O
in	ADP	O	O
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Whether	ADP	O	O
iso	PROPN	O	O
-	PUNCT	O	O
osmolar	ADJ	O	O
contrast	NOUN	O	O
medium	NOUN	O	O
is	VERB	O	O
less	ADJ	O	O
nephrotoxic	ADJ	O	I-Entity
than	ADP	O	O
low	ADJ	O	O
-	PUNCT	O	O
osmolar	ADJ	O	O
contrast	NOUN	O	O
medium	NOUN	O	O
in	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
risk	NOUN	O	O
patients	NOUN	O	O
is	VERB	O	O
uncertain	ADJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
multicenter	ADJ	O	O
study	NOUN	O	O
comparing	VERB	O	O
the	DET	O	O
nephrotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
an	DET	O	O
iso	NOUN	O	O
-	PUNCT	O	O
osmolar	NOUN	O	O
,	PUNCT	O	O
dimeric	NOUN	O	O
,	PUNCT	O	O
nonionic	ADJ	O	O
contrast	NOUN	O	O
medium	NOUN	O	O
,	PUNCT	O	O
iodixanol	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
those	DET	O	O
of	ADP	O	O
a	DET	O	O
low	ADJ	O	O
-	PUNCT	O	O
osmolar	NOUN	O	O
,	PUNCT	O	O
nonionic	ADJ	O	O
,	PUNCT	O	O
monomeric	ADJ	O	O
contrast	NOUN	O	O
medium	NOUN	O	O
,	PUNCT	O	O
iohexol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
involved	VERB	O	O
129	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
diabetes	NOUN	O	I-Entity
with	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
concentrations	NOUN	O	O
of	ADP	O	O
1.5	NUM	O	O
to	PART	O	O
3.5	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
deciliter	NOUN	O	O
who	NOUN	O	O
underwent	VERB	O	O
coronary	ADJ	O	O
or	CCONJ	O	O
aortofemoral	ADJ	O	O
angiography	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
was	VERB	O	O
the	DET	O	O
peak	NOUN	O	O
increase	NOUN	O	O
from	ADP	O	O
base	NOUN	O	O
line	NOUN	O	O
in	ADP	O	O
the	DET	O	O
creatinine	NOUN	O	I-Entity
concentration	NOUN	O	O
during	ADP	O	O
the	DET	O	O
three	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
angiography	NOUN	O	O
.	PUNCT	O	O

Other	ADJ	O	O
end	NOUN	O	O
points	NOUN	O	O
were	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
creatinine	NOUN	O	I-Entity
concentration	NOUN	O	O
of	ADP	O	O
0.5	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
deciliter	NOUN	O	O
or	CCONJ	O	O
more	ADJ	O	O
,	PUNCT	O	O
an	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
1.0	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
deciliter	NOUN	O	O
or	CCONJ	O	O
more	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
change	NOUN	O	O
in	ADP	O	O
the	DET	O	O
creatinine	NOUN	O	I-Entity
concentration	NOUN	O	O
from	ADP	O	O
day	NOUN	O	O
0	NUM	O	O
to	ADP	O	O
day	NOUN	O	O
7	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
creatinine	NOUN	O	I-Entity
concentration	NOUN	O	O
increased	VERB	O	O
significantly	ADV	O	O
less	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
iodixanol	NOUN	O	I-Entity
.	PUNCT	O	O

From	ADP	O	O
day	NOUN	O	O
0	NUM	O	O
to	PART	O	O
day	NOUN	O	O
3	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
mean	ADJ	O	O
peak	NOUN	O	O
increase	NOUN	O	O
in	ADP	O	O
creatinine	NOUN	O	I-Entity
was	VERB	O	O
0.13	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
deciliter	NOUN	O	O
in	ADP	O	O
the	DET	O	O
iodixanol	NOUN	O	I-Entity
group	NOUN	O	O
and	CCONJ	O	O
0.55	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
deciliter	NOUN	O	O
in	ADP	O	O
the	DET	O	O
iohexol	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
P=0.001	PROPN	O	O
;	PUNCT	O	O
the	DET	O	O
increase	NOUN	O	O
with	ADP	O	O
iodixanol	NOUN	O	I-Entity
minus	CCONJ	O	O
the	DET	O	O
increase	NOUN	O	O
with	ADP	O	O
iohexol	NOUN	O	I-Entity
,	PUNCT	O	O
-0.42	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
deciliter	NOUN	O	O
[	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
-0.73	X	O	O
to	ADP	O	O
-0.22	PROPN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Two	NUM	O	O
of	ADP	O	O
the	DET	O	O
64	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
iodixanol	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
had	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
creatinine	NOUN	O	I-Entity
concentration	NOUN	O	O
of	ADP	O	O
0.5	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
deciliter	NOUN	O	O
or	CCONJ	O	O
more	ADJ	O	O
,	PUNCT	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
17	NUM	O	O
of	ADP	O	O
the	DET	O	O
65	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
iohexol	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
26	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P=0.002	NOUN	O	O
;	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
for	ADP	O	O
such	ADJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
iodixanol	NOUN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
0.09	NUM	O	O
[	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.02	NUM	O	O
to	PART	O	O
0.41	NUM	O	O
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
patient	NOUN	O	O
receiving	VERB	O	O
iodixanol	NOUN	O	I-Entity
had	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
1.0	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
deciliter	NOUN	O	O
or	CCONJ	O	O
more	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
10	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
iohexol	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
percent	NOUN	O	O
)	PUNCT	O	O
did	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
the	DET	O	O
creatinine	NOUN	O	I-Entity
concentration	NOUN	O	O
from	ADP	O	O
day	NOUN	O	O
0	NUM	O	O
to	ADP	O	O
day	NOUN	O	O
7	NUM	O	O
was	VERB	O	O
0.07	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
deciliter	NOUN	O	O
in	ADP	O	O
the	DET	O	O
iodixanol	NOUN	O	I-Entity
group	NOUN	O	O
and	CCONJ	O	O
0.24	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
deciliter	NOUN	O	O
in	ADP	O	O
the	DET	O	O
iohexol	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
P=0.003	PROPN	O	O
;	PUNCT	O	O
value	NOUN	O	O
in	ADP	O	O
the	DET	O	O
iodixanol	NOUN	O	I-Entity
group	NOUN	O	O
minus	CCONJ	O	O
the	DET	O	O
value	NOUN	O	O
in	ADP	O	O
the	DET	O	O
iohexol	NOUN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
-0.17	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
deciliter	NOUN	O	O
[	PUNCT	O	O
95	NUM	O	O
percent	NOUN	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
-0.34	X	O	O
to	ADP	O	O
-0.07	PROPN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Nephropathy	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
contrast	NOUN	O	O
medium	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
less	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
develop	VERB	O	O
in	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
risk	NOUN	O	O
patients	NOUN	O	O
when	ADV	O	O
iodixanol	NOUN	O	I-Entity
is	VERB	O	O
used	VERB	O	O
rather	ADV	O	O
than	ADP	O	O
a	DET	O	O
low	ADJ	O	O
-	PUNCT	O	O
osmolar	NOUN	O	O
,	PUNCT	O	O
nonionic	ADJ	O	O
contrast	NOUN	O	O
medium	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9514561)

Experimental	ADJ	O	O
cranial	ADJ	O	O
pain	NOUN	O	I-Entity
elicited	VERB	O	O
by	ADP	O	O
capsaicin	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
PET	PROPN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
a	DET	O	O
positron	NOUN	O	O
emission	NOUN	O	O
tomography	NOUN	O	O
(	PUNCT	O	O
PET	PROPN	O	O
)	PUNCT	O	O
study	NOUN	O	O
it	PRON	O	O
was	VERB	O	O
shown	VERB	O	O
recently	ADV	O	O
that	DET	O	O
in	ADP	O	O
migraine	NOUN	O	I-Entity
without	ADP	O	O
aura	NOUN	O	O
certain	ADJ	O	O
areas	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
stem	NOUN	O	O
were	VERB	O	O
activated	VERB	O	O
during	ADP	O	O
the	DET	O	O
headache	NOUN	O	I-Entity
state	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
the	DET	O	O
headache	NOUN	O	I-Entity
free	ADJ	O	O
interval	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
this	DET	O	O
brain	NOUN	O	O
stem	NOUN	O	O
activation	NOUN	O	O
is	VERB	O	O
inherent	ADJ	O	O
to	ADP	O	O
the	DET	O	O
migraine	ADJ	O	I-Entity
attack	NOUN	O	O
itself	PRON	O	O
and	CCONJ	O	O
represents	VERB	O	O
the	DET	O	O
so	ADV	O	O
called	VERB	O	O
'	PUNCT	O	O
migraine	ADJ	O	I-Entity
generator	NOUN	O	O
'	PUNCT	O	O
.	PUNCT	O	O

To	PART	O	O
test	VERB	O	O
this	DET	O	O
hypothesis	NOUN	O	O
we	PRON	O	O
performed	VERB	O	O
an	DET	O	O
experimental	ADJ	O	O
pain	NOUN	O	I-Entity
study	NOUN	O	O
in	ADP	O	O
seven	NUM	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
the	DET	O	O
same	ADJ	O	O
positioning	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PET	PROPN	O	O
scanner	NOUN	O	O
as	ADP	O	O
in	ADP	O	O
the	DET	O	O
migraine	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
small	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
capsaicin	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
subcutaneously	ADV	O	O
in	ADP	O	O
the	DET	O	O
right	ADJ	O	O
forehead	NOUN	O	O
to	PART	O	O
evoke	VERB	O	O
a	DET	O	O
burning	VERB	O	O
painful	ADJ	O	I-Entity
sensation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
division	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trigeminal	ADJ	O	O
nerve	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
the	DET	O	O
same	ADJ	O	O
stereotactic	ADJ	O	O
space	NOUN	O	O
limits	NOUN	O	O
as	ADP	O	O
in	ADP	O	O
the	DET	O	O
above	ADV	O	O
mentioned	VERB	O	O
migraine	ADJ	O	I-Entity
study	NOUN	O	O
no	DET	O	O
brain	NOUN	O	O
stem	NOUN	O	O
activation	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
pain	NOUN	O	I-Entity
state	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
pain	NOUN	O	I-Entity
free	ADJ	O	O
state	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
activation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
region	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cavernous	ADJ	O	O
sinus	NOUN	O	O
however	ADV	O	O
,	PUNCT	O	O
suggests	VERB	O	O
that	ADP	O	O
this	DET	O	O
structure	NOUN	O	O
is	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
be	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
trigeminal	ADJ	O	O
transmitted	VERB	O	O
pain	NOUN	O	I-Entity
as	ADP	O	O
such	ADJ	O	O
,	PUNCT	O	O
rather	ADV	O	O
than	ADP	O	O
in	ADP	O	O
a	DET	O	O
specific	ADJ	O	O
type	NOUN	O	O
of	ADP	O	O
headache	NOUN	O	I-Entity
as	ADP	O	O
was	VERB	O	O
suggested	VERB	O	O
for	ADP	O	O
cluster	NOUN	O	B-Entity
headache	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9165568)

Neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
with	ADP	O	O
risperidone	NOUN	O	I-Entity
.	PUNCT	O	O

Neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
is	VERB	O	O
thought	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
D2	PROPN	O	O
receptor	NOUN	O	O
blockade	NOUN	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
of	ADP	O	O
the	DET	O	O
basal	NOUN	O	O
ganglia	NOUN	O	O
.	PUNCT	O	O

Risperidone	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
benzisoxazole	NOUN	O	I-Entity
derivative	ADJ	O	O
antipsychotic	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
high	ADJ	O	O
serotonin	NOUN	O	I-Entity
5-HT2	NUM	O	O
receptor	NOUN	O	O
blockade	NOUN	O	O
and	CCONJ	O	O
dose	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
D2	PROPN	O	O
receptor	NOUN	O	O
blockade	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
high	ADJ	O	O
ratio	NOUN	O	O
is	VERB	O	O
believed	VERB	O	O
to	PART	O	O
impart	VERB	O	O
the	DET	O	O
low	ADJ	O	O
frequency	NOUN	O	O
of	ADP	O	O
extrapyramidal	NOUN	O	B-Entity
symptoms	NOUN	O	I-Entity
with	ADP	O	O
risperidone	NOUN	O	I-Entity
at	ADP	O	O
low	ADJ	O	O
dosages	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
this	DET	O	O
low	ADJ	O	O
frequency	NOUN	O	O
of	ADP	O	O
extrapyramidal	NOUN	O	B-Entity
symptoms	NOUN	O	I-Entity
,	PUNCT	O	O
it	PRON	O	O
was	VERB	O	O
thought	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
of	ADP	O	O
neuroleptic	ADJ	O	B-Entity
malignant	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
might	VERB	O	O
also	ADV	O	O
be	VERB	O	O
lowered	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
73-year	NOUN	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
developed	VERB	O	O
neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
after	ADP	O	O
monotherapy	NOUN	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
syndrome	NOUN	O	O
reversed	VERB	O	O
after	ADP	O	O
discontinuing	VERB	O	O
risperidone	NOUN	O	I-Entity
and	CCONJ	O	O
starting	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
dantrolene	NOUN	O	I-Entity
and	CCONJ	O	O
bromocriptine	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
appears	VERB	O	O
that	ADP	O	O
the	DET	O	O
protection	NOUN	O	O
from	ADP	O	O
extrapyramidal	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
observed	VERB	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
ensure	VERB	O	O
protection	NOUN	O	O
from	ADP	O	O
neuroleptic	ADJ	O	B-Entity
malignant	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9154656)

Hepatic	PROPN	O	O
and	CCONJ	O	O
extrahepatic	ADJ	O	O
angiotensinogen	NOUN	O	O
gene	NOUN	O	O
expression	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Plasma	PROPN	O	O
concentration	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
excretion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renin	NOUN	O	O
-	PUNCT	O	O
angiotensin	NOUN	O	I-Entity
system	NOUN	O	O
proteins	NOUN	O	O
are	VERB	O	O
altered	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
NS	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
work	NOUN	O	O
the	DET	O	O
messenger	NOUN	O	O
ribonucleic	NOUN	O	O
acid	NOUN	O	O
(	PUNCT	O	O
mRNA	PROPN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
angiotensinogen	NOUN	O	O
(	PUNCT	O	O
Ao	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
analyzed	VERB	O	O
with	ADP	O	O
the	DET	O	O
slot	NOUN	O	O
-	PUNCT	O	O
blot	NOUN	O	O
hybridization	NOUN	O	O
technique	NOUN	O	O
in	ADP	O	O
liver	NOUN	O	O
and	CCONJ	O	O
other	ADJ	O	O
extrahepatic	ADJ	O	O
tissues	NOUN	O	O
:	PUNCT	O	O
kidney	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	O
,	PUNCT	O	O
brain	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
adrenal	ADJ	O	O
gland	NOUN	O	O
from	ADP	O	O
control	NOUN	O	O
,	PUNCT	O	O
nephrotic	ADJ	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
pair	NOUN	O	O
-	PUNCT	O	O
fed	NOUN	O	O
(	PUNCT	O	O
PF	PROPN	O	O
)	PUNCT	O	O
rats	NOUN	O	O
.	PUNCT	O	O

NS	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
single	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
puromycin	ADJ	O	B-Entity
amino	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
nucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
PAN	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Although	ADP	O	O
a	DET	O	O
great	ADJ	O	O
urinary	ADJ	O	O
excretion	NOUN	O	O
and	CCONJ	O	O
half	NOUN	O	O
-	PUNCT	O	O
normal	ADJ	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
Ao	PROPN	O	O
were	VERB	O	O
observed	VERB	O	O
on	ADP	O	O
day	NOUN	O	O
6	NUM	O	O
after	ADP	O	O
PAN	PROPN	O	I-Entity
injection	NOUN	O	O
,	PUNCT	O	O
when	ADV	O	O
NS	PROPN	O	I-Entity
was	VERB	O	O
clearly	ADV	O	O
established	VERB	O	O
,	PUNCT	O	O
hepatic	ADJ	O	O
Ao	PROPN	O	O
mRNA	PROPN	O	O
levels	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
Ao	PROPN	O	O
mRNA	PROPN	O	O
levels	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
in	ADP	O	O
any	DET	O	O
of	ADP	O	O
the	DET	O	O
extrahepatic	ADJ	O	O
tissues	NOUN	O	O
studied	VERB	O	O
on	ADP	O	O
day	NOUN	O	O
6	NUM	O	O
,	PUNCT	O	O
nor	CCONJ	O	O
did	VERB	O	O
its	ADJ	O	O
hepatic	ADJ	O	O
levels	NOUN	O	O
at	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
7	NUM	O	O
after	ADP	O	O
PAN	PROPN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
hepatic	NOUN	O	O
and	CCONJ	O	O
extrahepatic	ADJ	O	O
Ao	PROPN	O	O
mRNA	PROPN	O	O
levels	NOUN	O	O
are	VERB	O	O
unaltered	ADJ	O	O
during	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
NS	PROPN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
PAN	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8911359)

Cyclophosphamide	PROPN	O	I-Entity
associated	VERB	O	O
bladder	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
--	PUNCT	O	O
a	DET	O	O
highly	ADV	O	O
aggressive	ADJ	O	O
disease	NOUN	O	O
:	PUNCT	O	O
analysis	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
cases	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
gained	VERB	O	O
knowledge	NOUN	O	O
of	ADP	O	O
the	DET	O	O
etiology	NOUN	O	O
,	PUNCT	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
associated	VERB	O	O
urothelial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
medical	ADJ	O	O
records	NOUN	O	O
of	ADP	O	O
6	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
6	NUM	O	O
women	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
age	ADJ	O	O
55	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
associated	VERB	O	O
bladder	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
were	VERB	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

RESULTS	VERB	O	O
:	PUNCT	O	O
All	DET	O	O
tumors	NOUN	O	I-Entity
were	VERB	O	O
grade	NOUN	O	O
3	NUM	O	O
or	CCONJ	O	O
4	NUM	O	O
transitional	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
remaining	VERB	O	O
patient	NOUN	O	O
with	ADP	O	O
extensive	ADJ	O	O
cancer	NOUN	O	I-Entity
underwent	VERB	O	O
partial	ADJ	O	O
cystectomy	NOUN	O	O
for	ADP	O	O
palliation	NOUN	O	O
and	CCONJ	O	O
died	VERB	O	O
3	NUM	O	O
months	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

Cyclophosphamide	PROPN	O	I-Entity
associated	VERB	O	O
bladder	NOUN	O	B-Entity
tumor	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
aggressive	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
survival	NOUN	O	O
is	VERB	O	O
possible	ADJ	O	O
when	ADV	O	O
radical	ADJ	O	O
cystectomy	NOUN	O	O
is	VERB	O	O
performed	VERB	O	O
for	ADP	O	O
bladder	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
with	ADP	O	O
any	DET	O	O
sign	NOUN	O	O
of	ADP	O	O
invasion	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
recurrent	ADJ	O	O
high	ADJ	O	O
grade	NOUN	O	O
disease	NOUN	O	O
,	PUNCT	O	O
even	ADV	O	O
when	ADV	O	O
noninvasive	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (8686832)

Leg	PROPN	O	B-Entity
and	CCONJ	O	I-Entity
back	ADJ	O	I-Entity
pain	NOUN	O	I-Entity
after	ADP	O	O
spinal	ADJ	O	O
anaesthesia	NOUN	O	O
involving	VERB	O	O
hyperbaric	NOUN	O	O
5%	NUM	O	O
lignocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Fifty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
aged	VERB	O	O
27	NUM	O	O
-	SYM	O	O
90	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
who	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
lignocaine	NOUN	O	I-Entity
5%	NUM	O	O
in	ADP	O	O
6.8%	NUM	O	O
glucose	NOUN	O	I-Entity
solution	NOUN	O	O
for	ADP	O	O
spinal	ADJ	O	O
anaesthesia	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

Thirteen	NUM	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
experienced	VERB	O	O
pain	NOUN	O	B-Entity
in	ADP	O	I-Entity
the	DET	O	I-Entity
legs	NOUN	O	I-Entity
and/or	CCONJ	O	I-Entity
back	ADV	O	I-Entity
after	ADP	O	O
recovery	NOUN	O	O
from	ADP	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
affected	VERB	O	O
were	VERB	O	O
younger	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
site	NOUN	O	O
of	ADP	O	O
the	DET	O	O
dural	ADJ	O	O
puncture	NOUN	O	O
was	VERB	O	O
higher	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
than	ADP	O	O
those	DET	O	O
individuals	NOUN	O	O
without	ADP	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Five	NUM	O	O
of	ADP	O	O
the	DET	O	O
13	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
38%	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
pain	NOUN	O	I-Entity
and	CCONJ	O	O
seven	NUM	O	O
of	ADP	O	O
the	DET	O	O
41	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
17%	NUM	O	O
)	PUNCT	O	O
without	ADP	O	O
pain	NOUN	O	I-Entity
admitted	VERB	O	O
to	ADP	O	O
a	DET	O	O
high	ADJ	O	O
alcohol	NOUN	O	I-Entity
intake	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
might	VERB	O	O
be	VERB	O	O
a	DET	O	O
contributing	VERB	O	O
factor	NOUN	O	O
.	PUNCT	O	O

Leg	VERB	O	B-Entity
and/or	CCONJ	O	I-Entity
back	VERB	O	I-Entity
pain	NOUN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
intrathecal	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
hyperbaric	ADJ	O	O
5%	NUM	O	O
lignocaine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8607407)

Acute	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
elevations	NOUN	O	O
with	ADP	O	O
caffeine	NOUN	O	I-Entity
in	ADP	O	O
men	NOUN	O	O
with	ADP	O	O
borderline	ADJ	O	O
systemic	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Whether	ADP	O	O
the	DET	O	O
vasoconstrictive	ADJ	O	O
actions	NOUN	O	O
of	ADP	O	O
caffeine	NOUN	O	I-Entity
are	VERB	O	O
enhanced	VERB	O	O
in	ADP	O	O
hypertensive	ADJ	O	I-Entity
persons	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
demonstrated	VERB	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
caffeine	NOUN	O	I-Entity
(	PUNCT	O	O
3.3	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
versus	ADP	O	O
placebo	NOUN	O	O
was	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
48	NUM	O	O
healthy	ADJ	O	O
men	NOUN	O	O
(	PUNCT	O	O
aged	VERB	O	O
20	NUM	O	O
to	PART	O	O
35	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
selected	VERB	O	O
after	ADP	O	O
screening	VERB	O	O
on	ADP	O	O
2	NUM	O	O
separate	ADJ	O	O
occasions	NOUN	O	O
.	PUNCT	O	O

Borderline	VERB	O	O
hypertensive	ADJ	O	I-Entity
men	NOUN	O	O
(	PUNCT	O	O
n	ADV	O	O
=	SYM	O	O
24	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
selected	VERB	O	O
with	ADP	O	O
screening	VERB	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
BP	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
140	NUM	O	O
to	PART	O	O
160	NUM	O	O
mm	NOUN	O	O
Hg	PROPN	O	O
and/or	CCONJ	O	O
diastolic	NOUN	O	O
BP	PROPN	O	O
90	NUM	O	O
to	ADP	O	O
99	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
.	PUNCT	O	O

Low	ADJ	O	O
-	PUNCT	O	O
risk	NOUN	O	O
controls	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
24	NUM	O	O
)	PUNCT	O	O
reported	VERB	O	O
no	DET	O	O
parental	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
had	VERB	O	O
screening	NOUN	O	O
BP	PROPN	O	O
<	X	O	O
130/85	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
were	VERB	O	O
then	ADV	O	O
tested	VERB	O	O
on	ADP	O	O
2	NUM	O	O
occasions	NOUN	O	O
after	ADP	O	O
12-hour	ADJ	O	O
abstinence	NOUN	O	O
from	ADP	O	O
caffeine	NOUN	O	I-Entity
in	ADP	O	O
each	DET	O	O
of	ADP	O	O
2	NUM	O	O
protocols	NOUN	O	O
;	PUNCT	O	O
this	DET	O	O
required	VERB	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
laboratory	NOUN	O	O
visits	NOUN	O	O
.	PUNCT	O	O

Caffeine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
diastolic	NOUN	O	O
BP	PROPN	O	O
were	VERB	O	O
2	NUM	O	O
to	ADP	O	O
3	NUM	O	O
times	NOUN	O	O
larger	ADJ	O	O
in	ADP	O	O
borderline	ADJ	O	O
subjects	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
8.4	NUM	O	O
vs	ADP	O	O
+	SYM	O	O
3.8	NUM	O	O
mm	NOUN	O	O
Hg	PROPN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
attributable	ADJ	O	O
to	ADP	O	O
larger	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
impedance	NOUN	O	O
-	PUNCT	O	O
derived	VERB	O	O
measures	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
135	NUM	O	O
vs	ADP	O	O
+	SYM	O	O
45	NUM	O	O
dynes.s.cm-5	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O

Consequently	ADV	O	O
,	PUNCT	O	O
whereas	ADP	O	O
all	DET	O	O
participants	NOUN	O	O
exhibited	VERB	O	O
normotensive	ADJ	O	O
levels	NOUN	O	O
during	ADP	O	O
the	DET	O	O
resting	VERB	O	O
predrug	NOUN	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
33%	NUM	O	O
of	ADP	O	O
borderline	ADJ	O	O
subjects	NOUN	O	O
achieved	VERB	O	O
hypertensive	ADJ	O	I-Entity
BP	PROPN	O	O
levels	NOUN	O	O
after	ADP	O	O
caffeine	NOUN	O	I-Entity
ingestion	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
borderline	ADJ	O	O
hypertensive	ADJ	O	I-Entity
men	NOUN	O	O
,	PUNCT	O	O
exaggerated	ADJ	O	O
responses	NOUN	O	O
to	ADP	O	O
caffeine	NOUN	O	I-Entity
were	VERB	O	O
:	PUNCT	O	O
selective	ADJ	O	O
for	ADP	O	O
diastolic	NOUN	O	O
BP	PROPN	O	O
,	PUNCT	O	O
consistent	ADJ	O	O
with	ADP	O	O
greater	ADJ	O	O
vasoconstriction	NOUN	O	O
,	PUNCT	O	O
replicated	VERB	O	O
in	ADP	O	O
2	NUM	O	O
protocols	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
representative	NOUN	O	O
of	ADP	O	O
nearly	ADV	O	O
all	DET	O	O
borderline	ADJ	O	O
hypertensives	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
suspect	VERB	O	O
that	ADP	O	O
the	DET	O	O
potential	NOUN	O	O
for	ADP	O	O
caffeine	NOUN	O	I-Entity
to	PART	O	O
stabilize	VERB	O	O
high	ADJ	O	O
resistance	NOUN	O	O
states	NOUN	O	O
in	ADP	O	O
susceptible	ADJ	O	O
persons	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
its	ADJ	O	O
use	NOUN	O	O
may	VERB	O	O
facilitate	VERB	O	O
their	ADJ	O	O
disease	NOUN	O	O
progression	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
hinder	NOUN	O	O
accurate	ADJ	O	O
diagnosis	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8111719)

Hallucinations	NOUN	O	I-Entity
and	CCONJ	O	O
ifosfamide	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Hallucinations	NOUN	O	I-Entity
as	ADP	O	O
a	DET	O	O
symptom	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
are	VERB	O	O
a	DET	O	O
known	VERB	O	O
but	CCONJ	O	O
poorly	ADV	O	O
described	VERB	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
.	PUNCT	O	O

Most	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
ifosfamide	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hallucinations	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
with	ADP	O	O
other	ADJ	O	O
mental	ADJ	O	O
status	NOUN	O	O
changes	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
The	DET	O	O
authors	NOUN	O	O
interviewed	VERB	O	O
six	NUM	O	O
persons	NOUN	O	O
with	ADP	O	O
ifosfamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hallucinations	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
clear	ADJ	O	O
sensorium	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
receiving	VERB	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
ifosfamide	NOUN	O	I-Entity
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
their	ADJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplant	NOUN	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

Hallucinations	NOUN	O	I-Entity
occurred	VERB	O	O
only	ADV	O	O
when	ADV	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
eyes	NOUN	O	O
were	VERB	O	O
closed	ADJ	O	O
and	CCONJ	O	O
,	PUNCT	O	O
in	ADP	O	O
all	DET	O	O
but	ADP	O	O
one	NUM	O	O
case	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
reported	VERB	O	O
as	ADP	O	O
disturbing	ADJ	O	O
or	CCONJ	O	O
frightening	ADJ	O	O
.	PUNCT	O	O

Underreporting	VERB	O	O
of	ADP	O	O
these	DET	O	O
hallucinations	NOUN	O	I-Entity
by	ADP	O	O
patients	NOUN	O	O
is	VERB	O	O
likely	ADJ	O	O
.	PUNCT	O	O

Hallucinations	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
sole	ADJ	O	O
or	CCONJ	O	O
first	ADJ	O	O
manifestation	NOUN	O	O
of	ADP	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
clinician	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
alerted	VERB	O	O
for	ADP	O	O
possible	ADJ	O	O
ifosfamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hallucinations	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
may	VERB	O	O
occur	VERB	O	O
without	ADP	O	O
other	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

"	PUNCT	O	O
Eyes	NOUN	O	O
-	PUNCT	O	O
closed	ADJ	O	O
"	PUNCT	O	O
hallucinatory	ADJ	O	I-Entity
experiences	NOUN	O	O
appear	VERB	O	O
to	PART	O	O
be	VERB	O	O
an	DET	O	O
unusual	ADJ	O	O
feature	NOUN	O	O
of	ADP	O	O
this	DET	O	O
presentation	NOUN	O	O
.	PUNCT	O	O

If	ADP	O	O
agitation	NOUN	O	I-Entity
becomes	VERB	O	O
marked	ADJ	O	O
,	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
potency	NOUN	O	O
neuroleptics	NOUN	O	O
(	PUNCT	O	O
i.e.	X	O	O
,	PUNCT	O	O
haloperidol	PUNCT	O	I-Entity
)	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
effective	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (7059267)

Chlorpropamide	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
optic	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
65-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
adult	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
onset	NOUN	O	I-Entity
diabetes	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
chlorpropamide	NOUN	O	I-Entity
(	PUNCT	O	O
Diabenese	PROPN	O	I-Entity
)	PUNCT	O	O
had	VERB	O	O
a	DET	O	O
toxic	ADJ	O	B-Entity
optic	NOUN	O	I-Entity
neuropathy	NOUN	O	I-Entity
that	ADJ	O	O
resolved	VERB	O	O
with	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
chlorpropamide	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Visual	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
occurs	VERB	O	O
in	ADP	O	O
diabetics	NOUN	O	I-Entity
for	ADP	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
reasons	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
accurate	ADJ	O	O
diagnosis	NOUN	O	O
is	VERB	O	O
necessary	ADJ	O	O
to	PART	O	O
institute	VERB	O	O
appropriate	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
a	DET	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
optic	NOUN	O	B-Entity
neuropathy	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
in	ADP	O	O
the	DET	O	O
differential	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	B-Entity
loss	NOUN	O	I-Entity
in	ADP	O	O
diabetics	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6381653)

Levodopa	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesia	NOUN	O	I-Entity
and	CCONJ	O	O
thalamotomy	NOUN	O	O
.	PUNCT	O	O

Levodopa	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesia	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
limbs	NOUN	O	O
in	ADP	O	O
thirteen	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
Parkinsonism	PROPN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
choreic	NOUN	O	O
,	PUNCT	O	O
ballistic	ADJ	O	O
or	CCONJ	O	O
dystonic	ADJ	O	I-Entity
in	ADP	O	O
type	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
alleviated	VERB	O	O
almost	ADV	O	O
completely	ADV	O	O
by	ADP	O	O
stereotaxic	ADJ	O	O
surgery	NOUN	O	O
using	VERB	O	O
a	DET	O	O
microelectrode	NOUN	O	O
technique	NOUN	O	O
for	ADP	O	O
the	DET	O	O
ventralis	NOUN	O	O
oralis	NOUN	O	O
anterior	NOUN	O	O
and	CCONJ	O	O
posterior	ADJ	O	O
nuclei	NOUN	O	O
of	ADP	O	O
the	DET	O	O
thalamus	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
much	ADV	O	O
less	ADJ	O	O
by	ADP	O	O
the	DET	O	O
ventralis	NOUN	O	O
intermedius	NOUN	O	O
nucleus	NOUN	O	O
.	PUNCT	O	O

Control	NOUN	O	O
of	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
by	ADP	O	O
thalamic	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
routine	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
Parkinsonism	PROPN	O	I-Entity
is	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (3950060)

Factors	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
amikacin	NOUN	O	I-Entity
.	PUNCT	O	O

Data	NOUN	O	O
from	ADP	O	O
60	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
amikacin	NOUN	O	I-Entity
were	VERB	O	O
analyzed	VERB	O	O
for	ADP	O	O
factors	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Variables	NOUN	O	O
evaluated	VERB	O	O
included	VERB	O	O
patient	ADJ	O	O
weight	NOUN	O	O
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
level	NOUN	O	O
,	PUNCT	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
,	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
total	ADJ	O	O
dose	NOUN	O	O
,	PUNCT	O	O
mean	ADJ	O	O
daily	ADJ	O	O
dose	NOUN	O	O
,	PUNCT	O	O
organism	NOUN	O	O
minimum	NOUN	O	O
inhibitory	ADJ	O	O
concentration	NOUN	O	O
(	PUNCT	O	O
MIC	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
mean	VERB	O	O
peak	ADJ	O	O
levels	NOUN	O	O
,	PUNCT	O	O
mean	VERB	O	O
trough	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O

When	ADV	O	O
the	DET	O	O
parameters	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
individually	ADV	O	O
,	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
total	ADJ	O	O
AUC	PROPN	O	O
correlated	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
.05	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
this	DET	O	O
model	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
Bayes	PROPN	O	O
'	PART	O	O
theorem	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
predictive	ADJ	O	O
accuracy	NOUN	O	O
of	ADP	O	O
identifying	VERB	O	O
"	PUNCT	O	O
nephrotoxic	NOUN	O	I-Entity
"	PUNCT	O	O
patients	NOUN	O	O
increased	VERB	O	O
from	ADP	O	O
0.17	NUM	O	O
to	ADP	O	O
0.39	NUM	O	O
.	PUNCT	O	O


-DOCSTART- (3311455)

In	ADP	O	O
group	NOUN	O	O
I	PRON	O	O
,	PUNCT	O	O
cyclosporine	NOUN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
before	ADP	O	O
the	DET	O	O
procedure	NOUN	O	O
at	ADP	O	O
a	DET	O	O
loading	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
17.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
continued	VERB	O	O
after	ADP	O	O
the	DET	O	O
procedure	NOUN	O	O
to	PART	O	O
keep	VERB	O	O
a	DET	O	O
whole	ADJ	O	O
blood	NOUN	O	O
level	NOUN	O	O
about	ADP	O	O
1000	NUM	O	O
ng	PROPN	O	O
/	SYM	O	O
ml	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
group	NOUN	O	O
II	PROPN	O	O
,	PUNCT	O	O
cyclosporine	NOUN	O	I-Entity
was	VERB	O	O
started	VERB	O	O
only	ADV	O	O
after	ADP	O	O
the	DET	O	O
procedure	NOUN	O	O
at	ADP	O	O
a	DET	O	O
lower	ADJ	O	O
dosage	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
complemented	VERB	O	O
by	ADP	O	O
azathioprine	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
used	VERB	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
postoperative	ADJ	O	O
week	NOUN	O	O
.	PUNCT	O	O

Group	PROPN	O	O
II	PROPN	O	O
showed	VERB	O	O
a	DET	O	O
better	ADJ	O	O
perioperative	ADJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
as	ADP	O	O
determined	VERB	O	O
by	ADP	O	O
serum	NOUN	O	O
blood	NOUN	O	O
urea	NOUN	O	B-Entity
nitrogen	NOUN	O	I-Entity
and	CCONJ	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
.	PUNCT	O	O

Group	PROPN	O	O
II	PROPN	O	O
also	ADV	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
nephrotoxicity	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
cyclosporine	NOUN	O	I-Entity
.	PUNCT	O	O

Despite	ADP	O	O
this	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
late	ADJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
group	NOUN	O	O
II	PROPN	O	O
still	ADV	O	O
shows	VERB	O	O
a	DET	O	O
slow	ADJ	O	O
rise	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
think	VERB	O	O
that	ADP	O	O
even	ADV	O	O
these	DET	O	O
lower	ADJ	O	O
dosages	NOUN	O	O
of	ADP	O	O
cyclosporine	NOUN	O	I-Entity
can	VERB	O	O
cause	VERB	O	O
chronic	ADJ	O	O
nephrotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
that	ADP	O	O
further	ADJ	O	O
modification	NOUN	O	O
of	ADP	O	O
the	DET	O	O
immunosuppressive	ADJ	O	O
regimen	NOUN	O	O
is	VERB	O	O
required	VERB	O	O
to	PART	O	O
completely	ADV	O	O
abolish	VERB	O	O
this	DET	O	O
toxic	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2051906)

Reversible	ADJ	O	O
cholestasis	NOUN	O	I-Entity
with	ADP	O	O
bile	NOUN	O	B-Entity
duct	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
following	VERB	O	O
azathioprine	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
67-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
patient	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
primary	ADJ	O	O
polymyositis	NOUN	O	I-Entity
and	CCONJ	O	O
without	ADP	O	O
previous	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
developed	VERB	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
biochemical	ADJ	O	O
features	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
cholestasis	NOUN	O	I-Entity
3	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
azathioprine	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Liver	NOUN	O	O
biopsy	NOUN	O	O
showed	VERB	O	O
cholestasis	NOUN	O	I-Entity
with	ADP	O	O
both	DET	O	O
cytological	ADJ	O	O
and	CCONJ	O	O
architectural	ADJ	O	O
alterations	NOUN	O	O
of	ADP	O	O
interlobular	ADJ	O	O
bile	NOUN	O	O
ducts	NOUN	O	O
.	PUNCT	O	O

Azathioprine	PROPN	O	I-Entity
withdrawal	NOUN	O	O
resulted	VERB	O	O
after	ADP	O	O
7	NUM	O	O
weeks	NOUN	O	O
in	ADP	O	O
the	DET	O	O
resolution	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
biochemical	ADJ	O	O
abnormalities	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
believed	VERB	O	O
that	ADP	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
reported	VERB	O	O
case	NOUN	O	O
of	ADP	O	O
reversible	ADJ	O	O
azathioprine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cholestasis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
histological	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
bile	NOUN	O	B-Entity
duct	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2021202)

Renal	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
hemodynamics	NOUN	O	O
during	ADP	O	O
prolonged	ADJ	O	O
isoflurane	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
isoflurane	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
on	ADP	O	O
glomerular	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
renal	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
20	NUM	O	O
human	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

Glomerular	ADJ	O	O
filtration	NOUN	O	O
rate	NOUN	O	O
(	PUNCT	O	O
GFR	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
effective	ADJ	O	O
renal	ADJ	O	O
plasma	NOUN	O	O
flow	NOUN	O	O
(	PUNCT	O	O
ERPF	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
inulin	NOUN	O	O
and	CCONJ	O	O
para	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminohippurate	NOUN	O	I-Entity
(	PUNCT	O	O
PAH	PROPN	O	I-Entity
)	PUNCT	O	O
clearance	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Anesthesia	PROPN	O	O
was	VERB	O	O
maintained	VERB	O	O
with	ADP	O	O
fentanyl	NOUN	O	I-Entity
,	PUNCT	O	O
nitrous	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
,	PUNCT	O	O
oxygen	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
isoflurane	NOUN	O	I-Entity
.	PUNCT	O	O

Hypotension	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
for	ADP	O	O
236.9	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

15.1	NUM	O	O
min	NOUN	O	O
by	ADP	O	O
increasing	VERB	O	O
the	DET	O	O
isoflurane	NOUN	O	I-Entity
inspired	VERB	O	O
concentration	NOUN	O	O
to	PART	O	O
maintain	VERB	O	O
a	DET	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
of	ADP	O	O
59.8	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

GFR	PROPN	O	O
and	CCONJ	O	O
ERPF	PROPN	O	O
decreased	VERB	O	O
with	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
anesthesia	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
significantly	ADV	O	O
more	ADJ	O	O
during	ADP	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Renal	ADJ	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
increased	VERB	O	O
during	ADP	O	O
anesthesia	NOUN	O	O
but	CCONJ	O	O
decreased	VERB	O	O
when	ADV	O	O
hypotension	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
,	PUNCT	O	O
allowing	VERB	O	O
the	DET	O	O
maintenance	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
renal	ADJ	O	O
compensatory	NOUN	O	O
mechanisms	NOUN	O	O
are	VERB	O	O
preserved	VERB	O	O
during	ADP	O	O
isoflurane	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
that	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
hemodynamics	NOUN	O	O
quickly	ADV	O	O
return	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
when	ADV	O	O
normotension	NOUN	O	O
is	VERB	O	O
resumed	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (1848636)

Debrisoquine	PROPN	O	I-Entity
phenotype	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
pharmacokinetics	NOUN	O	O
and	CCONJ	O	O
beta-2	ADJ	O	O
receptor	NOUN	O	O
pharmacodynamics	NOUN	O	O
of	ADP	O	O
metoprolol	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
enantiomers	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
metabolism	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cardioselective	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocker	NOUN	O	O
metoprolol	NOUN	O	I-Entity
is	VERB	O	O
under	ADP	O	O
genetic	ADJ	O	O
control	NOUN	O	O
of	ADP	O	O
the	DET	O	O
debrisoquine	NOUN	O	I-Entity
/	PUNCT	O	O
sparteine	ADJ	O	I-Entity
type	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
two	NUM	O	O
metabolic	NOUN	O	O
phenotypes	NOUN	O	O
,	PUNCT	O	O
extensive	ADJ	O	O
(	PUNCT	O	O
EM	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
poor	ADJ	O	O
metabolizers	NOUN	O	O
(	PUNCT	O	O
PM	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
show	VERB	O	O
different	ADJ	O	O
stereoselective	ADJ	O	O
metabolism	NOUN	O	O
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
apparently	ADV	O	O
higher	ADJ	O	O
beta-1	ADJ	O	O
adrenoceptor	NOUN	O	O
antagonistic	ADJ	O	O
potency	NOUN	O	O
of	ADP	O	O
racemic	ADJ	O	O
metoprolol	NOUN	O	I-Entity
in	ADP	O	O
EMs	PROPN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
if	ADP	O	O
the	DET	O	O
latter	NOUN	O	O
also	ADV	O	O
applies	VERB	O	O
to	ADP	O	O
the	DET	O	O
beta-2	NOUN	O	O
adrenoceptor	NOUN	O	O
antagonism	NOUN	O	O
by	ADP	O	O
metoprolol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
drug	NOUN	O	O
effect	NOUN	O	O
studied	VERB	O	O
was	VERB	O	O
the	DET	O	O
antagonism	NOUN	O	O
by	ADP	O	O
metoprolol	NOUN	O	I-Entity
of	ADP	O	O
terbutaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypokalemia	NOUN	O	I-Entity
.	PUNCT	O	O

By	ADP	O	O
using	VERB	O	O
pharmacokinetic	ADJ	O	O
pharmacodynamic	ADJ	O	O
modeling	VERB	O	O
the	DET	O	O
pharmacodynamics	NOUN	O	O
of	ADP	O	O
racemic	ADJ	O	O
metoprolol	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
active	ADJ	O	O
S	NOUN	O	O
-	PUNCT	O	O
isomer	NOUN	O	O

,	PUNCT	O	O
were	VERB	O	O
quantitated	VERB	O	O
in	ADP	O	O
EMs	PROPN	O	O
and	CCONJ	O	O
PMs	PROPN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
IC50	PROPN	O	O
values	NOUN	O	O
,	PUNCT	O	O
representing	VERB	O	O
metoprolol	ADJ	O	I-Entity
plasma	NOUN	O	O
concentrations	NOUN	O	O
resulting	VERB	O	O
in	ADP	O	O
half	NOUN	O	O
-	PUNCT	O	O
maximum	ADJ	O	O
receptor	NOUN	O	O
occupancy	NOUN	O	O
.	PUNCT	O	O

Six	NUM	O	O
EMs	NOUN	O	O
received	VERB	O	O
0.5	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
terbutaline	NOUN	O	I-Entity
s.c	NOUN	O	O
.	PUNCT	O	O

on	ADP	O	O
two	NUM	O	O
different	ADJ	O	O
occasions	NOUN	O	O
:	PUNCT	O	O
1	PUNCT	O	O
)	PUNCT	O	O
1	NUM	O	O
hr	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
a	DET	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
)	PUNCT	O	O
1	NUM	O	O
hr	NOUN	O	O
after	ADP	O	O
150	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
metoprolol	NOUN	O	I-Entity
p.o	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
PMs	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
same	ADJ	O	O
protocol	NOUN	O	O
,	PUNCT	O	O
except	ADP	O	O
for	ADP	O	O
a	DET	O	O
higher	ADJ	O	O
terbutaline	NOUN	O	I-Entity
dose	NOUN	O	O
(	PUNCT	O	O
0.75	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
2	NUM	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
samples	NOUN	O	O
for	ADP	O	O
the	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
potassium	NOUN	O	I-Entity
,	PUNCT	O	O
terbutaline	NOUN	O	I-Entity
,	PUNCT	O	O
metoprolol	NOUN	O	I-Entity
(	PUNCT	O	O
racemic	NOUN	O	O
,	PUNCT	O	O
R-	PROPN	O	O
and	CCONJ	O	O
S	PROPN	O	O
-	PUNCT	O	O
isomer	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O

alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
hydroxymetoprolol	NOUN	O	I-Entity
concentrations	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
at	ADP	O	O
regular	ADJ	O	O
time	NOUN	O	O
intervals	NOUN	O	O
,	PUNCT	O	O
during	ADP	O	O
8	NUM	O	O
hr	NOUN	O	O
after	ADP	O	O
metoprolol	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
PMs	PROPN	O	O
,	PUNCT	O	O
metoprolol	NOUN	O	I-Entity
increased	VERB	O	O
the	DET	O	O
terbutaline	NOUN	O	I-Entity
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
plasma	NOUN	O	O
concentration	NOUN	O	O
vs.	ADP	O	O
time	NOUN	O	O
curve	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
67%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Higher	ADJ	O	O
metoprolol	NOUN	O	I-Entity
/	SYM	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
hydroxymetoprolol	NOUN	O	I-Entity
ratios	NOUN	O	O
in	ADP	O	O
PMs	NOUN	O	O
were	VERB	O	O
predictive	ADJ	O	O
for	ADP	O	O
higher	ADJ	O	O
R-/S	PROPN	O	O
-	PUNCT	O	O
isomer	ADJ	O	O
ratios	NOUN	O	O
of	ADP	O	O
unchanged	ADJ	O	O
drug	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
a	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
metoprolol	NOUN	O	I-Entity
potency	NOUN	O	O
with	ADP	O	O
higher	ADJ	O	O
racemic	NOUN	O	O
metoprolol	NOUN	O	I-Entity
IC50	PROPN	O	O
values	NOUN	O	O
in	ADP	O	O
PMs	PROPN	O	O
(	PUNCT	O	O
72	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O


-DOCSTART- (1445986)

Cefotetan	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
immune	ADJ	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

Immune	PROPN	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
a	DET	O	O
drug	NOUN	O	O
-	PUNCT	O	O
adsorption	NOUN	O	O
mechanism	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
described	VERB	O	O
primarily	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
penicillins	NOUN	O	I-Entity
and	CCONJ	O	O
first	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
cephalosporins	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
anemia	NOUN	O	I-Entity
while	ADP	O	O
receiving	VERB	O	O
intravenous	ADJ	O	O
cefotetan	NOUN	O	I-Entity
.	PUNCT	O	O

Cefotetan	PROPN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
antibodies	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
serum	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
an	DET	O	O
eluate	NOUN	O	O
prepared	VERB	O	O
from	ADP	O	O
his	ADJ	O	O
red	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
eluate	NOUN	O	O
also	ADV	O	O
reacted	VERB	O	O
weakly	ADV	O	O
with	ADP	O	O
red	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
cefotetan	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
the	DET	O	O
concomitant	ADJ	O	O
formation	NOUN	O	O
of	ADP	O	O
warm	ADJ	O	O
-	PUNCT	O	O
reactive	ADJ	O	O
autoantibodies	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
observations	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
laboratory	NOUN	O	O
evidence	NOUN	O	O
of	ADP	O	O
extravascular	ADJ	O	O
hemolysis	NOUN	O	I-Entity
,	PUNCT	O	O
are	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
possibly	ADV	O	O
involving	VERB	O	O
both	DET	O	O
drug	NOUN	O	O
-	PUNCT	O	O
adsorption	NOUN	O	O
and	CCONJ	O	O
autoantibody	NOUN	O	O
formation	NOUN	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
emphasizes	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
increased	VERB	O	O
awareness	NOUN	O	O
of	ADP	O	O
hemolytic	ADJ	O	O
reactions	NOUN	O	O
to	ADP	O	O
all	DET	O	O
cephalosporins	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (982002)

Acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
subsequent	ADJ	O	O
to	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
rifampicin	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
clinical	ADJ	O	O
presentation	NOUN	O	O
is	VERB	O	O
made	VERB	O	O
of	ADP	O	O
a	DET	O	O
2	NUM	O	O
-	SYM	O	O
3	NUM	O	O
year	NOUN	O	O
follow	VERB	O	O
-	PUNCT	O	O
up	NOUN	O	O
of	ADP	O	O
six	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
that	ADJ	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
earlier	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
developed	VERB	O	O
transient	ADJ	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
intermittent	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
rifampicin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
stage	NOUN	O	O
of	ADP	O	O
olig	NOUN	O	O
-	PUNCT	O	O
anuria	NOUN	O	I-Entity
lasted	VERB	O	O
for	ADP	O	O
1	NUM	O	O
-	SYM	O	O
3	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
five	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
hemodialysis	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
in	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
stage	NOUN	O	O
the	DET	O	O
renal	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
histologically	ADV	O	O
appeared	VERB	O	O
toxic	ADJ	O	O
,	PUNCT	O	O
evidence	NOUN	O	O
suggestive	ADJ	O	O
of	ADP	O	O
an	DET	O	O
immunological	ADJ	O	O
mechanism	NOUN	O	O
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (343678)

Type	NOUN	O	B-Entity
B	PROPN	O	I-Entity
hepatitis	NOUN	O	I-Entity
after	ADP	O	O
needle	NOUN	O	O
-	PUNCT	O	O
stick	NOUN	O	O
exposure	NOUN	O	O
:	PUNCT	O	O

prevention	NOUN	O	O
with	ADP	O	O
hepatitis	NOUN	O	B-Entity
B	PROPN	O	I-Entity
immune	ADJ	O	O
globulin	NOUN	O	O
.	PUNCT	O	O

Hepatitis	PROPN	O	B-Entity
B	PROPN	O	I-Entity
immune	ADJ	O	O
globulin	NOUN	O	O
(	PUNCT	O	O
HBIG	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
immune	ADJ	O	O
serum	NOUN	O	O
globulin	NOUN	O	O
(	PUNCT	O	O
ISG	PROPN	O	O
)	PUNCT	O	O
were	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
trial	NOUN	O	O
to	PART	O	O
assess	VERB	O	O
their	ADJ	O	O
relative	ADJ	O	O
efficacies	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
type	NOUN	O	B-Entity
B	PROPN	O	I-Entity
hepatitis	NOUN	O	I-Entity
after	ADP	O	O
needle	NOUN	O	O
-	PUNCT	O	O
stick	NOUN	O	O
exposure	NOUN	O	O
to	ADP	O	O
hepatitis	PROPN	O	B-Entity
B	PROPN	O	I-Entity
surface	NOUN	O	I-Entity
antigen	NOUN	O	I-Entity
(	PUNCT	O	O
HBsAG)-positive	ADJ	O	I-Entity
donors	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
hepatitis	NOUN	O	I-Entity
developed	VERB	O	O
in	ADP	O	O
1.4%	NUM	O	O
of	ADP	O	O
HBIG	PROPN	O	O
and	CCONJ	O	O
in	ADP	O	O
5.9%	NUM	O	O
of	ADP	O	O
ISG	PROPN	O	O
recipients	NOUN	O	O
(	PUNCT	O	O

Available	ADJ	O	O
donor	NOUN	O	O
sera	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
for	ADP	O	O
DNA	PROPN	O	O
polymerase	NOUN	O	O
(	PUNCT	O	O
DNAP	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
e	X	O	O
antigen	NOUN	O	O
and	CCONJ	O	O
antibody	NOUN	O	O
(	PUNCT	O	O
HBeAg	PROPN	O	I-Entity
;	PUNCT	O	O
anti	ADJ	O	O
-	PUNCT	O	O
HBE	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	DET	O	O
DNAP	PROPN	O	O
and	CCONJ	O	O
HBeAg	PROPN	O	I-Entity
showed	VERB	O	O
a	DET	O	O
highly	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
correlation	NOUN	O	O
with	ADP	O	O
the	DET	O	O
infectivity	NOUN	O	O
of	ADP	O	O
HBsAg	PROPN	O	I-Entity
-	PUNCT	O	O
positive	ADJ	O	O
donors	NOUN	O	O
.	PUNCT	O	O

Hepatitis	PROPN	O	B-Entity
B	PROPN	O	I-Entity
immune	NOUN	O	O
globulin	NOUN	O	O
remained	VERB	O	O
significantly	ADV	O	O
superior	ADJ	O	O
to	ADP	O	O
ISG	PROPN	O	O
in	ADP	O	O
preventing	VERB	O	O
type	NOUN	O	B-Entity
B	PROPN	O	I-Entity
hepatitis	NOUN	O	I-Entity
even	ADV	O	O
when	ADV	O	O
the	DET	O	O
analysis	NOUN	O	O
was	VERB	O	O
confined	VERB	O	O
to	ADP	O	O
these	DET	O	O
two	NUM	O	O
high	ADJ	O	O
-	PUNCT	O	O
risk	NOUN	O	O
subgroups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
ISG	PROPN	O	O
in	ADP	O	O
preventing	VERB	O	O
type	NOUN	O	B-Entity
B	NOUN	O	I-Entity
hepatitis	NOUN	O	I-Entity
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
ascertained	VERB	O	O
because	ADP	O	O
a	DET	O	O
true	ADJ	O	O
placebo	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
included	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (8888541)

Serotonin	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
from	ADP	O	O
venlafaxine	NOUN	O	I-Entity
-	PUNCT	O	O
tranylcypromine	NOUN	O	I-Entity
interaction	NOUN	O	O
.	PUNCT	O	O

Excessive	ADJ	O	O
stimulation	NOUN	O	O
of	ADP	O	O
serotonin	NOUN	O	I-Entity
5HT1A	NUM	O	O
receptors	NOUN	O	O
causes	VERB	O	O
a	DET	O	O
syndrome	NOUN	O	O
of	ADP	O	O
serotonin	NOUN	O	I-Entity
excess	NOUN	O	O
that	ADJ	O	O
consists	VERB	O	O
of	ADP	O	O
shivering	NOUN	O	O
,	PUNCT	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
salivation	NOUN	O	I-Entity
,	PUNCT	O	O
confusion	NOUN	O	I-Entity
,	PUNCT	O	O
agitation	NOUN	O	I-Entity
and	CCONJ	O	O
hyperthermia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
common	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
this	DET	O	O
syndrome	NOUN	O	O
is	VERB	O	O
an	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
a	DET	O	O
monoamine	NOUN	O	O
oxidase	NOUN	O	O
inhibitor	NOUN	O	O
(	PUNCT	O	O
MAOI	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
specific	ADJ	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitor	NOUN	O	O
.	PUNCT	O	O

Venlafaxine	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
new	ADJ	O	O
antidepressant	NOUN	O	O
agent	NOUN	O	O
that	ADJ	O	O
inhibits	VERB	O	O
the	DET	O	O
reuptake	NOUN	O	O
of	ADP	O	O
serotonin	NOUN	O	I-Entity
and	CCONJ	O	O
norepinephrine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
venlafaxine	NOUN	O	I-Entity
-	PUNCT	O	O
MAOI	PROPN	O	O
interaction	NOUN	O	O
that	ADJ	O	O
resulted	VERB	O	O
in	ADP	O	O
the	DET	O	O
serotonin	NOUN	O	B-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
23-y	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
male	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
taking	VERB	O	O
tranylcypromine	NOUN	O	I-Entity
for	ADP	O	O
depression	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
had	VERB	O	O
been	VERB	O	O
well	ADV	O	O
until	ADP	O	O
the	DET	O	O
morning	NOUN	O	O
of	ADP	O	O
presentation	NOUN	O	O
when	ADV	O	O
he	PRON	O	O
took	VERB	O	O
1/2	NUM	O	O
tab	NOUN	O	O
of	ADP	O	O
venlafaxine	NOUN	O	I-Entity
.	PUNCT	O	O

Within	ADP	O	O
2	NUM	O	O
h	X	O	O
he	PRON	O	O
became	VERB	O	O
confused	ADJ	O	O
with	ADP	O	O
jerking	VERB	O	O
movements	NOUN	O	O
of	ADP	O	O
his	ADJ	O	O
extremities	NOUN	O	O
,	PUNCT	O	O
tremors	NOUN	O	I-Entity
and	CCONJ	O	O
rigidity	NOUN	O	I-Entity
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
brought	VERB	O	O
directly	ADV	O	O
to	ADP	O	O
a	DET	O	O
hospital	NOUN	O	O
where	ADV	O	O
he	PRON	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
agitated	ADJ	O	O
and	CCONJ	O	O
confused	ADJ	O	O
with	ADP	O	O
shivering	NOUN	O	O
,	PUNCT	O	O
myoclonic	ADJ	O	B-Entity
jerks	NOUN	O	I-Entity
,	PUNCT	O	O
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
salivation	NOUN	O	I-Entity
and	CCONJ	O	O
diaphoresis	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
180	NUM	O	O
mg	NUM	O	O
of	ADP	O	O
diazepam	NOUN	O	I-Entity
i.v	NOUN	O	O
.	PUNCT	O	O

he	PRON	O	O
remained	VERB	O	O
tremulous	ADJ	O	O
with	ADP	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
and	CCONJ	O	O
clenched	ADJ	O	O
jaws	NOUN	O	O
.	PUNCT	O	O

He	PRON	O	O
was	VERB	O	O
intubated	VERB	O	O
for	ADP	O	O
airway	NOUN	O	O
protection	NOUN	O	O
and	CCONJ	O	O
because	ADP	O	O
of	ADP	O	O
hypoventilation	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
paralyzed	VERB	O	I-Entity
to	PART	O	O
control	VERB	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
.	PUNCT	O	O

His	ADJ	O	O
subsequent	ADJ	O	O
course	NOUN	O	O
was	VERB	O	O
remarkable	ADJ	O	O
for	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
immune	ADJ	O	O
thrombocytopenia	NOUN	O	I-Entity
which	ADJ	O	O
resolved	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
's	PART	O	O
maximal	ADJ	O	O
temperature	NOUN	O	O
was	VERB	O	O
101.2	NUM	O	O
F	PROPN	O	O
and	CCONJ	O	O
his	ADJ	O	O
CPK	PROPN	O	O
remained	VERB	O	O
<	X	O	O
500	NUM	O	O
units	NOUN	O	O
/	SYM	O	O
L	NOUN	O	O
with	ADP	O	O
no	DET	O	O
other	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
rhabdomyolysis	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
patient	NOUN	O	O
survived	VERB	O	O
without	ADP	O	O
sequelae	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
the	DET	O	O
aggressive	ADJ	O	O
sedation	NOUN	O	O
and	CCONJ	O	O
neuromuscular	ADJ	O	O
paralysis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8106150)

Effect	NOUN	O	O
of	ADP	O	O
nondopaminergic	ADJ	O	O
drugs	NOUN	O	O
on	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
in	ADP	O	O
MPTP	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
monkeys	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
group	NOUN	O	O
of	ADP	O	O
four	NUM	O	O
monkeys	NOUN	O	O
was	VERB	O	O
rendered	VERB	O	O
parkinsonian	ADJ	O	I-Entity
with	ADP	O	O
the	DET	O	O
toxin	NOUN	O	O
MPTP	PROPN	O	I-Entity
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
then	ADV	O	O
treated	VERB	O	O
chronically	ADV	O	O
with	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
DOPA	PROPN	O	I-Entity
/	PUNCT	O	I-Entity
benserazide	ADV	O	I-Entity
50/12.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
given	VERB	O	O
orally	ADV	O	O
daily	ADJ	O	O
for	ADP	O	O
2	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
dose	NOUN	O	O
produced	VERB	O	O
a	DET	O	O
striking	ADJ	O	O
antiparkinsonian	ADJ	O	O
effect	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
all	DET	O	O
animals	NOUN	O	O
manifested	VERB	O	O
dyskinesia	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
series	NOUN	O	O
of	ADP	O	O
agents	NOUN	O	O
acting	VERB	O	O
primarily	ADV	O	O
on	ADP	O	O
neurotransmitters	NOUN	O	O
other	ADJ	O	O
than	ADP	O	O
dopamine	NOUN	O	I-Entity
were	VERB	O	O
then	ADV	O	O
tested	VERB	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
DOPA	PROPN	O	I-Entity
to	PART	O	O
see	VERB	O	O
if	ADP	O	O
the	DET	O	O
dyskinetic	ADJ	O	I-Entity
movements	NOUN	O	O
would	VERB	O	O
be	VERB	O	O
modified	VERB	O	O
.	PUNCT	O	O

Several	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
clonidine	NOUN	O	I-Entity
,	PUNCT	O	O
physostigmine	NOUN	O	I-Entity
,	PUNCT	O	O
methysergide	NOUN	O	I-Entity
,	PUNCT	O	O
5-MDOT	PROPN	O	I-Entity
,	PUNCT	O	O
propranolol	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
MK-801	PROPN	O	I-Entity
,	PUNCT	O	O
markedly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
dyskinetic	ADJ	O	I-Entity
movements	NOUN	O	O
but	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
cost	NOUN	O	O
of	ADP	O	O
a	DET	O	O
return	NOUN	O	O
of	ADP	O	O
parkinsonian	ADJ	O	I-Entity
symptomatology	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
yohimbine	NOUN	O	I-Entity
and	CCONJ	O	O
meperidine	NOUN	O	I-Entity
reduced	VERB	O	O
predominantly	ADV	O	O
the	DET	O	O
dyskinetic	ADJ	O	I-Entity
movements	NOUN	O	O
.	PUNCT	O	O

Baclofen	PROPN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
useful	ADJ	O	O
in	ADP	O	O
one	NUM	O	O
monkey	NOUN	O	O
against	ADP	O	O
a	DET	O	O
more	ADV	O	O
dystonic	ADJ	O	I-Entity
form	NOUN	O	O
of	ADP	O	O
dyskinesia	NOUN	O	I-Entity
.	PUNCT	O	O

Atropine	NOUN	O	I-Entity
converted	VERB	O	O
the	DET	O	O
dystonic	ADJ	O	I-Entity
movements	NOUN	O	O
into	ADP	O	O
chorea	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (21418164)

CCNU	PROPN	O	I-Entity
(	PUNCT	O	O
lomustine	NOUN	O	I-Entity
)	PUNCT	O	O
toxicity	NOUN	O	I-Entity
in	ADP	O	O
dogs	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
retrospective	ADJ	O	O
study	NOUN	O	O
(	PUNCT	O	O
2002	NUM	O	O
-	SYM	O	O
07	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
describe	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
haematological	NOUN	O	B-Entity
,	PUNCT	O	I-Entity
renal	NOUN	O	I-Entity
,	PUNCT	O	I-Entity
hepatic	ADJ	O	I-Entity
and	CCONJ	O	I-Entity
gastrointestinal	ADJ	O	I-Entity
toxicities	NOUN	O	I-Entity
in	ADP	O	O
tumour	NOUN	O	O
-	PUNCT	O	O
bearing	VERB	O	O
dogs	NOUN	O	O
receiving	VERB	O	O
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea	NUM	O	I-Entity
(	PUNCT	O	O
CCNU	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
medical	ADJ	O	O
records	NOUN	O	O
of	ADP	O	O
206	NUM	O	O
dogs	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
CCNU	PROPN	O	I-Entity
at	ADP	O	O
the	DET	O	O
Melbourne	PROPN	O	O
Veterinary	PROPN	O	O
Specialist	PROPN	O	O
Centre	PROPN	O	O
between	ADP	O	O
February	PROPN	O	O
2002	NUM	O	O
and	CCONJ	O	O
December	PROPN	O	O
2007	NUM	O	O
were	VERB	O	O
retrospectively	ADV	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
206	NUM	O	O
dogs	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
CCNU	PROPN	O	I-Entity
,	PUNCT	O	O
185	NUM	O	O
met	VERB	O	O
the	DET	O	O
inclusion	NOUN	O	O
criteria	NOUN	O	O
for	ADP	O	O
at	ADV	O	O
least	ADV	O	O
one	NUM	O	O
class	NOUN	O	O
of	ADP	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

CCNU	PROPN	O	I-Entity
was	VERB	O	O
used	VERB	O	O
most	ADV	O	O
commonly	ADV	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
lymphoma	NOUN	O	I-Entity
,	PUNCT	O	O
mast	NOUN	O	B-Entity
cell	NOUN	O	I-Entity
tumour	NOUN	O	I-Entity
,	PUNCT	O	O
brain	NOUN	O	B-Entity
tumour	NOUN	O	I-Entity
,	PUNCT	O	O
histiocytic	ADJ	O	B-Entity
tumours	NOUN	O	I-Entity
and	CCONJ	O	O
epitheliotropic	VERB	O	B-Entity
lymphoma	NOUN	O	I-Entity
.	PUNCT	O	O

experienced	VERB	O	O
neutropenia	NOUN	O	I-Entity
,	PUNCT	O	O
34.2%	NUM	O	O
experienced	VERB	O	O
anaemia	NOUN	O	I-Entity
and	CCONJ	O	O
14.2%	NUM	O	O
experienced	ADJ	O	O
thrombocytopenia	NOUN	O	I-Entity
.	PUNCT	O	O

Gastrointestinal	ADJ	O	B-Entity
toxicosis	NOUN	O	I-Entity
was	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
37.8%	NUM	O	O
of	ADP	O	O
dogs	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
most	ADV	O	O
common	ADJ	O	O
sign	NOUN	O	O
of	ADP	O	O
which	ADJ	O	O
was	VERB	O	O
vomiting	VERB	O	I-Entity
(	PUNCT	O	O
24.3%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Potential	ADJ	O	O
renal	ADJ	O	O
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
elevated	VERB	O	O
alanine	NOUN	O	I-Entity
transaminase	NOUN	O	O
(	PUNCT	O	O
ALT	PROPN	O	O
)	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
hepatic	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
was	VERB	O	O
1.2%	NUM	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
CCNU	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
toxicity	NOUN	O	I-Entity
in	ADP	O	O
dogs	NOUN	O	O
is	VERB	O	O
common	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
is	VERB	O	O
usually	ADV	O	O
not	ADV	O	O
life	NOUN	O	O
threatening	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (9121607)

Neuroactive	ADJ	O	O
steroids	NOUN	O	I-Entity
protect	VERB	O	O
against	ADP	O	O
pilocarpine-	NOUN	O	I-Entity
and	CCONJ	O	O
kainic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
limbic	NOUN	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Several	ADJ	O	O
structurally	ADV	O	O
related	ADJ	O	O
metabolites	NOUN	O	O
of	ADP	O	O
progesterone	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	B-Entity
alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
hydroxy	NOUN	O	I-Entity
pregnane-20-ones	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
deoxycorticosterone	NOUN	O	I-Entity
(	PUNCT	O	O
3	NUM	O	B-Entity
alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
hydroxy	NOUN	O	I-Entity
pregnane-21-diol-20-ones	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
3	NUM	O	O
beta	NOUN	O	O
-	PUNCT	O	O
epimers	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
for	ADP	O	O
protective	ADJ	O	O
activity	NOUN	O	O
against	ADP	O	O
pilocarpine-	NOUN	O	I-Entity
,	PUNCT	O	O
kainic	ADJ	O	B-Entity
acid-	NOUN	O	I-Entity
and	CCONJ	O	O
N	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA)-induced	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Steroids	NOUN	O	I-Entity
with	ADP	O	O
the	DET	O	O
3-hydroxy	NUM	O	O
group	NOUN	O	O
in	ADP	O	O
the	DET	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
position	NOUN	O	O
and	CCONJ	O	O
5-H	NUM	O	O
in	ADP	O	O
the	DET	O	O
alpha-	NOUN	O	O
or	CCONJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
configurations	NOUN	O	O
were	VERB	O	O
highly	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
protecting	VERB	O	O
against	ADP	O	O
pilocarpine	NOUN	O	I-Entity
(	PUNCT	O	O
416	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
s.c.)-induced	VERB	O	O
limbic	ADJ	O	O
motor	NOUN	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
(	PUNCT	O	O
ED50	PROPN	O	O
values	NOUN	O	O
,	PUNCT	O	O
7.0	NUM	O	O
-	SYM	O	O
18.7	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
neuroactive	ADJ	O	O
steroids	NOUN	O	I-Entity
were	VERB	O	O
considerably	ADV	O	O
less	ADV	O	O
potent	ADJ	O	O
than	ADP	O	O
the	DET	O	O
benzodiazepine	NOUN	O	I-Entity
clonazepam	NOUN	O	I-Entity
in	ADP	O	O
protecting	VERB	O	O
against	ADP	O	O
pilocarpine	NOUN	O	I-Entity
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
steroids	NOUN	O	I-Entity
with	ADP	O	O
the	DET	O	O
5	NUM	O	O
alpha,3	ADJ	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
configuration	NOUN	O	O
had	VERB	O	O
comparable	ADJ	O	O
or	CCONJ	O	O
higher	ADJ	O	O
protective	ADJ	O	O
index	NOUN	O	O
values	NOUN	O	O
(	PUNCT	O	O
TD50	PROPN	O	O
for	ADP	O	O
motor	NOUN	O	O
impairment	NOUN	O	O
divided	VERB	O	O
by	ADP	O	O
ED50	PROPN	O	O
for	ADP	O	O
seizure	NOUN	O	I-Entity
protection	NOUN	O	O
)	PUNCT	O	O
than	ADP	O	O
clonazepam	NOUN	O	I-Entity
,	PUNCT	O	O
indicating	VERB	O	O
that	ADP	O	O
some	DET	O	O
neuroactive	ADJ	O	O
steroids	NOUN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
lower	ADJ	O	O
relative	ADJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Steroids	NOUN	O	I-Entity
with	ADP	O	O
the	DET	O	O
5	NUM	O	O
alpha,3	SYM	O	O
alpha-	NOUN	O	O
or	CCONJ	O	O
5	NUM	O	O
beta,3	NUM	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
configurations	NOUN	O	O
also	ADV	O	O
produced	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
delay	NOUN	O	O
in	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
limbic	ADJ	O	O
seizures	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
kainic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
32	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
s.c	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
completely	ADV	O	O
protect	VERB	O	O
against	ADP	O	O
the	DET	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
when	ADV	O	O
a	DET	O	O
second	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
steroid	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
1	NUM	O	O
hr	NOUN	O	O
after	ADP	O	O
the	DET	O	O
first	ADJ	O	O
dose	NOUN	O	O
,	PUNCT	O	O
complete	ADJ	O	O
protection	NOUN	O	O
from	ADP	O	O
the	DET	O	O
kainic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
limbic	NOUN	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
was	VERB	O	O
obtained	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
steroids	NOUN	O	I-Entity
also	ADV	O	O
caused	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
delay	NOUN	O	O
in	ADP	O	O
NMDA	PROPN	O	I-Entity
(	PUNCT	O	O
257	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
s.c.)-induced	VERB	O	O
lethality	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
completely	ADV	O	O
protect	VERB	O	O
against	ADP	O	O
NMDA	PROPN	O	I-Entity
seizures	NOUN	O	I-Entity
or	CCONJ	O	O
lethality	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
neuroactive	ADJ	O	O
steroids	NOUN	O	I-Entity
are	VERB	O	O
highly	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
protecting	VERB	O	O
against	ADP	O	O
pilocarpine-	NOUN	O	I-Entity
and	CCONJ	O	O
kainic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
of	ADP	O	O
utility	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
some	DET	O	O
forms	NOUN	O	O
of	ADP	O	O
status	NOUN	O	B-Entity
epilepticus	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7905523)

The	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
combination	NOUN	O	O
N	NUM	O	B-Entity
-	PUNCT	O	I-Entity
butyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
deoxynojirimycin	NOUN	O	I-Entity
(	PUNCT	O	O
SC-48334	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
zidovudine	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
HIV-1	PROPN	O	B-Entity
infection	NOUN	O	I-Entity
and	CCONJ	O	O
200	NUM	O	O
-	SYM	O	O
500	NUM	O	O
CD4	PROPN	O	O
cells	NOUN	O	O
/	SYM	O	O
mm3	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
phase	NOUN	O	O
II	PROPN	O	O
study	NOUN	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
activity	NOUN	O	O
of	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
butyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
deoxynojirimycin	NOUN	O	I-Entity
(	PUNCT	O	O
SC-48334	PROPN	O	I-Entity
)	PUNCT	O	O
(	PUNCT	O	O
an	DET	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
glucosidase	NOUN	O	O
I	PRON	O	O
inhibitor	VERB	O	O
)	PUNCT	O	O
and	CCONJ	O	O
zidovudine	VERB	O	I-Entity
versus	ADP	O	O
zidovudine	NOUN	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O

mm3	NOUN	O	O
who	NOUN	O	O
tolerated	VERB	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
12	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
prior	ADJ	O	O
zidovudine	NOUN	O	I-Entity
therapy	NOUN	O	O
received	VERB	O	O
SC-48334	PROPN	O	I-Entity
(	PUNCT	O	O
1000	NUM	O	O
mg	NUM	O	O
every	DET	O	O
8	NUM	O	O
h	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
zidovudine	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
mg	NUM	O	O
every	DET	O	O
8	NUM	O	O
h	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
zidovudine	NOUN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Sixty	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
58	NUM	O	O
,	PUNCT	O	O
zidovudine	NOUN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
three	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
38%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
15	NUM	O	O
(	PUNCT	O	O
26%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
and	CCONJ	O	O
zidovudine	NOUN	O	I-Entity
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
discontinued	VERB	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.15	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADJ	O	O
SC-48334	PROPN	O	I-Entity
steady	ADJ	O	O
-	PUNCT	O	O
state	NOUN	O	O
trough	NOUN	O	O
level	NOUN	O	O
(	PUNCT	O	O
4.04	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.99	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
ml	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
below	ADP	O	O
the	DET	O	O
in	ADP	O	O
vitro	NOUN	O	O
inhibitory	ADJ	O	O
concentration	NOUN	O	O
for	ADP	O	O
human	ADJ	O	O
immunodeficiency	NOUN	O	I-Entity
virus	NOUN	O	O
(	PUNCT	O	O
HIV	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

/	SYM	O	O
mm3	NOUN	O	O
for	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
and	CCONJ	O	O
zidovudine	NOUN	O	I-Entity
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	X	O	O
0.36	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

For	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
prior	ADJ	O	O
zidovudine	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mean	ADJ	O	O
change	NOUN	O	O
in	ADP	O	O
CD4	PROPN	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
and	CCONJ	O	O
zidovudine	NOUN	O	I-Entity
groups	NOUN	O	O
was	VERB	O	O
63.7	NUM	O	O
cells	NOUN	O	O
/	SYM	O	O
mm3	NOUN	O	O
and	CCONJ	O	O
4.9	NUM	O	O
cells	NOUN	O	O
/	SYM	O	O
mm3	ADV	O	O
at	ADP	O	O
week	NOUN	O	O
8	NUM	O	O
and	CCONJ	O	O
6.8	NUM	O	O
cells	NOUN	O	O
/	SYM	O	O
mm3	NOUN	O	O
and	CCONJ	O	O
-45.1	PROPN	O	O
cells	NOUN	O	O
/	SYM	O	O
mm3	ADV	O	O
at	ADP	O	O
week	NOUN	O	O
16	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
suppression	NOUN	O	O
of	ADP	O	O
HIV	PROPN	O	O
p24	PROPN	O	O
antigenemia	NOUN	O	O
in	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
and	CCONJ	O	O
zidovudine	NOUN	O	I-Entity
groups	NOUN	O	O
was	VERB	O	O
six	NUM	O	O
(	PUNCT	O	O
40%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
(	PUNCT	O	O
11%	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
week	NOUN	O	O
4	NUM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.10	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
five	NUM	O	O
(	PUNCT	O	O
45%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
(	PUNCT	O	O
14%	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
week	NOUN	O	O
24	NUM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.08	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Diarrhea	NOUN	O	I-Entity
,	PUNCT	O	O
flatulence	NOUN	O	I-Entity
,	PUNCT	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
weight	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
were	VERB	O	O
common	ADJ	O	O
for	ADP	O	O
combination	NOUN	O	O
recipients.(ABSTRACT	NUM	O	O
TRUNCATED	ADJ	O	O
AT	NOUN	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O


-DOCSTART- (3431591)

Recent	ADJ	O	O
preclinical	ADJ	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
with	ADP	O	O
the	DET	O	O
thymidylate	NOUN	O	O
synthase	NOUN	O	O
inhibitor	NOUN	O	O
N10-propargyl-5,8-dideazafolic	PROPN	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
CB	PROPN	O	B-Entity
3717	NUM	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

CB	NOUN	O	B-Entity
3717	NUM	O	I-Entity
,	PUNCT	O	O
N10-propargyl-5,8-dideazafolic	PROPN	O	B-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
tight	ADJ	O	O
-	PUNCT	O	O
binding	VERB	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
thymidylate	NOUN	O	O
synthase	NOUN	O	O
(	PUNCT	O	O
TS	PROPN	O	O
)	PUNCT	O	O
whose	ADJ	O	O
cytotoxicity	NOUN	O	I-Entity
is	VERB	O	O
mediated	VERB	O	O
solely	ADV	O	O
through	ADP	O	O
the	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
this	DET	O	O
enzyme	NOUN	O	O
.	PUNCT	O	O

Recent	ADJ	O	O
preclinical	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
focused	VERB	O	O
on	ADP	O	O
the	DET	O	O
intracellular	ADJ	O	O
formation	NOUN	O	O
of	ADP	O	O
CB	PROPN	O	B-Entity
3717	NUM	O	I-Entity
polyglutamates	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
a	DET	O	O
12-hour	NUM	O	O
exposure	NOUN	O	O
of	ADP	O	O
L1210	PROPN	O	O
cells	NOUN	O	O
to	ADP	O	O
50	NUM	O	O
microM	NOUN	O	O
[	PUNCT	O	O
3H]CB	NUM	O	B-Entity
3717	NUM	O	I-Entity
,	PUNCT	O	O
30%	NUM	O	O
of	ADP	O	O
the	DET	O	O
extractable	ADJ	O	O
radioactivity	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
accounted	VERB	O	O
for	ADP	O	O
as	ADP	O	O
CB	PROPN	O	B-Entity
3717	NUM	O	I-Entity
tetra-	NOUN	O	O
and	CCONJ	O	O
pentaglutamate	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
determined	VERB	O	O
by	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
pressure	NOUN	O	O
liquid	NOUN	O	O
chromatography	NOUN	O	O
(	PUNCT	O	O
HPLC	PROPN	O	O
)	PUNCT	O	O
analyses	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
inhibitors	NOUN	O	O
of	ADP	O	O
isolated	ADJ	O	O
L1210	PROPN	O	O
TS	PROPN	O	O
,	PUNCT	O	O
CB	PROPN	O	O
3717	NUM	O	O
di-	X	O	O
,	PUNCT	O	O
tri-	X	O	O
,	PUNCT	O	O
tetra-	X	O	O
and	CCONJ	O	O
pentaglutamate	NOUN	O	O
are	VERB	O	O
26-	NUM	O	O
,	PUNCT	O	O
87-	NUM	O	O
,	PUNCT	O	O
119-	NUM	O	O
and	CCONJ	O	O
114-fold	NUM	O	O
more	ADJ	O	O
potent	ADJ	O	O
than	ADP	O	O
CB	PROPN	O	B-Entity
3717	NUM	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
formation	NOUN	O	O
may	VERB	O	O
,	PUNCT	O	O
therefore	ADV	O	O
,	PUNCT	O	O
be	VERB	O	O
an	DET	O	O
important	ADJ	O	O
determinant	NOUN	O	O
of	ADP	O	O
CB	PROPN	O	B-Entity
3717	NUM	O	I-Entity
cytotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
early	ADJ	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
with	ADP	O	O
CB	PROPN	O	B-Entity
3717	NUM	O	I-Entity
,	PUNCT	O	O
activity	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
ovarian	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
,	PUNCT	O	O
hepatoma	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
mesothelioma	NOUN	O	I-Entity
.	PUNCT	O	O

Toxicities	NOUN	O	I-Entity
included	VERB	O	O
hepatotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
malaise	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
dose	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
latter	ADJ	O	O
effect	NOUN	O	O
is	VERB	O	O
thought	VERB	O	O
to	PART	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
drug	NOUN	O	O
precipitation	NOUN	O	O
within	ADP	O	O
the	DET	O	O
renal	ADJ	O	O
tubule	NOUN	O	O
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
the	DET	O	O
poor	ADJ	O	O
solubility	NOUN	O	O
of	ADP	O	O
CB	PROPN	O	B-Entity
3717	NUM	O	I-Entity
under	ADP	O	O
acidic	ADJ	O	O
conditions	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
an	DET	O	O
attempt	NOUN	O	O
to	PART	O	O
overcome	VERB	O	O
this	DET	O	O
problem	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
CB	PROPN	O	B-Entity
3717	NUM	O	I-Entity
administered	VERB	O	O
with	ADP	O	O
alkaline	NOUN	O	O
diuresis	NOUN	O	O
is	VERB	O	O
under	ADP	O	O
way	NOUN	O	O
.	PUNCT	O	O

Preliminary	ADJ	O	O
results	NOUN	O	O
at	ADP	O	O
400	NUM	O	O
and	CCONJ	O	O
500	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
nephrotoxicity	NOUN	O	I-Entity
may	VERB	O	O
have	VERB	O	O
been	VERB	O	O
achieved	VERB	O	O
with	ADP	O	O
only	ADV	O	O
1	NUM	O	O
instance	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
in	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Hepatotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
malaise	NOUN	O	I-Entity
are	VERB	O	O
again	ADV	O	O
the	DET	O	O
most	ADV	O	O
frequent	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Pharmacokinetic	ADJ	O	O
investigations	NOUN	O	O
have	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
alkaline	NOUN	O	O
diuresis	NOUN	O	O
does	VERB	O	O
not	ADV	O	O
alter	VERB	O	O
CB	PROPN	O	B-Entity
3717	NUM	O	I-Entity
plasma	NOUN	O	O
levels	NOUN	O	O
or	CCONJ	O	O
urinary	ADJ	O	O
excretion	NOUN	O	O
and	CCONJ	O	O
that	DET	O	O
satisfactory	ADJ	O	O
urinary	ADJ	O	O
alkalinization	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
readily	ADV	O	O
achieved	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (33969)

Ethopropazine	PROPN	O	I-Entity
and	CCONJ	O	O
benztropine	NOUN	O	I-Entity
in	ADP	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
parkinsonism	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
12-week	NOUN	O	O
controlled	VERB	O	O
study	NOUN	O	O
ethopropazine	NOUN	O	I-Entity
was	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
benztropine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
parkinsonism	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
fluphenazine	NOUN	O	B-Entity
enanthate	NOUN	O	I-Entity
in	ADP	O	O
60	NUM	O	O
schizophrenic	ADJ	O	I-Entity
outpatients	NOUN	O	O
.	PUNCT	O	O

Ethopropazine	PROPN	O	I-Entity
and	CCONJ	O	O
benztropine	NOUN	O	I-Entity
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
equally	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
controlling	VERB	O	O
parkinsonian	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
and	CCONJ	O	O
were	VERB	O	O
as	ADV	O	O
efficacious	ADJ	O	O
as	ADP	O	O
procyclidine	NOUN	O	I-Entity
,	PUNCT	O	O
their	ADJ	O	O
previous	ADJ	O	O
antiparkinsonian	ADJ	O	O
drug	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
benztropine	NOUN	O	I-Entity
treated	VERB	O	O
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
tardive	ADJ	O	B-Entity
dyskinesia	NOUN	O	I-Entity
compared	VERB	O	O
to	ADP	O	O
their	ADJ	O	O
condition	NOUN	O	O
during	ADP	O	O
procyclindine	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
significantly	ADV	O	O
more	ADJ	O	O
anxiety	NOUN	O	I-Entity
and	CCONJ	O	O
depression	NOUN	O	I-Entity
than	ADP	O	O
ethopropazine	NOUN	O	I-Entity
treated	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
suggests	VERB	O	O
that	ADP	O	O
benztropine	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
the	DET	O	O
anticholinergic	ADJ	O	O
drug	NOUN	O	O
of	ADP	O	O
choice	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
parkinsonian	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
,	PUNCT	O	O
because	ADP	O	O
of	ADP	O	O
its	ADJ	O	O
more	ADJ	O	O
toxic	ADJ	O	O
central	ADJ	O	O
and	CCONJ	O	O
peripheral	ADJ	O	O
atropinic	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16844102)

Effect	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tocopherol	NOUN	O	I-Entity
and	CCONJ	O	O
deferoxamine	NOUN	O	I-Entity
on	ADP	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Methamphetamine	NOUN	O	I-Entity

(	PUNCT	O	O
MA)-induced	VERB	O	I-Entity
dopaminergic	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
is	VERB	O	O
believed	VERB	O	O
to	PART	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
increased	ADJ	O	O
formation	NOUN	O	O
of	ADP	O	O
free	ADJ	O	O
radicals	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tocopherol	NOUN	O	I-Entity
(	PUNCT	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
TC	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
scavenger	NOUN	O	O
of	ADP	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
species	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
deferoxamine	NOUN	O	I-Entity
(	PUNCT	O	O
DFO	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
iron	NOUN	O	I-Entity
chelator	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
MA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Male	NOUN	O	O
rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
MA	PROPN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
every	DET	O	O
2	NUM	O	O
h	NOUN	O	O
for	ADP	O	O
four	NUM	O	O
injections	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
rat	NOUN	O	O
received	VERB	O	O
either	CCONJ	O	O
alpha	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
TC	PROPN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
intraperitoneally	ADV	O	O
for	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
and	CCONJ	O	O
30	NUM	O	O
min	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
MA	PROPN	O	I-Entity
administration	NOUN	O	O
or	CCONJ	O	O
DFO	PROPN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O

min	NOUN	O	O
before	ADP	O	O
MA	PROPN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
concentrations	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
(	PUNCT	O	O
DA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
serotonin	NOUN	O	I-Entity
and	CCONJ	O	O
their	ADJ	O	O
metabolites	NOUN	O	O
decreased	VERB	O	O
significantly	ADV	O	O
after	ADP	O	O
MA	PROPN	O	I-Entity
administration	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
inhibited	VERB	O	O
by	ADP	O	O
the	DET	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
TC	PROPN	O	I-Entity
and	CCONJ	O	O
DFO	PROPN	O	I-Entity
pretreatment	NOUN	O	O
.	PUNCT	O	O

alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
TC	PROPN	O	I-Entity
and	CCONJ	O	O
DFO	PROPN	O	I-Entity
attenuated	VERB	O	O
the	DET	O	O
MA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperthermia	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
the	DET	O	O
alterations	NOUN	O	O
in	ADP	O	O
the	DET	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
level	NOUN	O	O
of	ADP	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
was	VERB	O	O
higher	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
reduced	ADJ	O	O
glutathione	NOUN	O	I-Entity
concentration	NOUN	O	O
was	VERB	O	O
lower	ADJ	O	O
in	ADP	O	O
the	DET	O	O
MA	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
changes	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
attenuated	VERB	O	O
by	ADP	O	O
alpha	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
TC	NOUN	O	I-Entity
and	CCONJ	O	O
DFO	PROPN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
suggests	VERB	O	O
that	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
TC	PROPN	O	I-Entity
and	CCONJ	O	O
DFO	PROPN	O	I-Entity
ameliorate	VERB	O	O
the	DET	O	O
MA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neuronal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
by	ADP	O	O
decreasing	VERB	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (14633084)

Use	NOUN	O	O
of	ADP	O	O
dexamethasone	NOUN	O	I-Entity
with	ADP	O	O
mesna	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

AIM	PROPN	O	O
:	PUNCT	O	O
Hemorrhagic	ADJ	O	B-Entity
cystitis	NOUN	O	I-Entity
(	PUNCT	O	O
HC	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
limiting	VERB	O	O
side	NOUN	O	O
-	PUNCT	O	O
effect	NOUN	O	O
of	ADP	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
ifosfamide	NOUN	O	I-Entity
(	PUNCT	O	O
IFS	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
study	NOUN	O	O
presented	VERB	O	O
here	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
dexamethasone	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
mesna	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
IFS	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
HC	PROPN	O	I-Entity
.	PUNCT	O	O

Male	PROPN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
(	PUNCT	O	O
150	NUM	O	O
-	SYM	O	O
200	NUM	O	O
g	NOUN	O	O
;	PUNCT	O	O
6	NUM	O	O
rats	NOUN	O	O
per	ADP	O	O
group	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
or	CCONJ	O	O
mesna	NOUN	O	I-Entity
5	NUM	O	O
min	NOUN	O	O
(	PUNCT	O	O
i.p	X	O	O
.	PUNCT	O	O
)	PUNCT	O	O
before	ADP	O	O
and	CCONJ	O	O
2	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
(	PUNCT	O	O
v.o	X	O	O
.	PUNCT	O	O
)	PUNCT	O	O

administration	NOUN	O	O
of	ADP	O	O
IFS	PROPN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
,	PUNCT	O	O
two	NUM	O	O
or	CCONJ	O	O
three	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
mesna	NOUN	O	I-Entity
were	VERB	O	O
replaced	VERB	O	O
with	ADP	O	O
dexamethasone	NOUN	O	I-Entity
alone	ADV	O	O
or	CCONJ	O	O
with	ADP	O	O
dexamethasone	NOUN	O	I-Entity
plus	CCONJ	O	O
mesna	NOUN	O	I-Entity
.	PUNCT	O	O

Cystitis	PROPN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
its	ADJ	O	O
induction	NOUN	O	O
by	ADP	O	O
the	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
bladder	NOUN	O	O
wet	ADJ	O	O
weight	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
macroscopic	ADJ	O	O
and	CCONJ	O	O
microscopic	ADJ	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
replacement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
last	ADJ	O	O
dose	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
last	ADJ	O	O
two	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
mesna	NOUN	O	I-Entity
with	ADP	O	O
dexamethasone	NOUN	O	I-Entity
reduced	VERB	O	O
the	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
bladder	NOUN	O	O
wet	ADJ	O	O
weight	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
IFS	NOUN	O	I-Entity
by	ADP	O	O
84.79%	NUM	O	O
and	CCONJ	O	O
89.13%	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
almost	ADV	O	O
abolished	VERB	O	O
the	DET	O	O
macroscopic	NOUN	O	O
and	CCONJ	O	O
microscopic	ADJ	O	O
alterations	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
IFS	PROPN	O	I-Entity
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
addition	NOUN	O	O
of	ADP	O	O
dexamethasone	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
last	ADJ	O	O
two	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
mesna	NOUN	O	I-Entity
was	VERB	O	O
more	ADV	O	O
efficient	ADJ	O	O
than	ADP	O	O
three	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
mesna	NOUN	O	I-Entity
alone	ADV	O	O
when	ADV	O	O
evaluated	VERB	O	O
microscopically	ADV	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Dexamethasone	PROPN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
mesna	NOUN	O	I-Entity
was	VERB	O	O
efficient	ADJ	O	O
in	ADP	O	O
blocking	VERB	O	O
IFS	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
HC	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
replacement	NOUN	O	O
of	ADP	O	O
last	ADJ	O	O
two	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
mesna	NOUN	O	I-Entity
with	ADP	O	O
saline	NOUN	O	O
or	CCONJ	O	O
all	DET	O	O
of	ADP	O	O
the	DET	O	O
mesna	NOUN	O	I-Entity
doses	NOUN	O	O
with	ADP	O	O
dexamethasone	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
prevent	VERB	O	O
HC	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11999899)

Behavioral	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
MK-801	PROPN	O	I-Entity
on	ADP	O	O
reserpine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
dizocilpine	NOUN	O	I-Entity
(	PUNCT	O	O
MK-801	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
noncompetitive	ADJ	O	O
N	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA	PROPN	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
studied	VERB	O	O
on	ADP	O	O
dopamine	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
behaviors	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
reserpine	NOUN	O	I-Entity
treatments	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
focuses	VERB	O	O
on	ADP	O	O
behavioral	ADJ	O	O
syndromes	NOUN	O	O
that	ADJ	O	O
may	VERB	O	O
used	VERB	O	O
as	ADP	O	O
models	NOUN	O	O
for	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
tardive	ADJ	O	B-Entity
dyskinesia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
its	ADJ	O	O
response	NOUN	O	O
after	ADP	O	O
glutamatergic	ADJ	O	O
blockage	NOUN	O	O
.	PUNCT	O	O

Reserpine	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
administered	VERB	O	O
once	ADV	O	O
every	DET	O	O
other	ADJ	O	O
day	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
produced	VERB	O	O
increases	NOUN	O	O
in	ADP	O	O
orofacial	ADJ	O	B-Entity
dyskinesia	NOUN	O	I-Entity
,	PUNCT	O	O
tongue	NOUN	O	O
protrusion	NOUN	O	O
and	CCONJ	O	O
vacuous	ADJ	O	O
chewing	NOUN	O	O
in	ADP	O	O
mice	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
are	VERB	O	O
signs	NOUN	O	O
indicative	ADJ	O	O
of	ADP	O	O
tardive	ADJ	O	B-Entity
dyskinesia	NOUN	O	I-Entity
.	PUNCT	O	O

Reserpine	PROPN	O	I-Entity
also	ADV	O	O
produced	VERB	O	O
tremor	NOUN	O	I-Entity
and	CCONJ	O	O
catalepsy	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
are	VERB	O	O
signs	NOUN	O	O
suggestive	ADJ	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

MK-801	NOUN	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
administered	VERB	O	O
30	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
the	DET	O	O
observation	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
prevented	VERB	O	O
the	DET	O	O
vacuous	ADJ	O	O
chewing	NOUN	O	O
movements	NOUN	O	O
,	PUNCT	O	O
tongue	NOUN	O	O
protrusions	NOUN	O	O
and	CCONJ	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
reserpine	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
MK-801	PROPN	O	I-Entity
injection	NOUN	O	O
produced	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
of	ADP	O	O
tremor	NOUN	O	I-Entity
in	ADP	O	O
reserpine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Reserpine	PROPN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
administered	VERB	O	O
90	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
the	DET	O	O
test	NOUN	O	O
and	CCONJ	O	O
followed	VERB	O	O
by	ADP	O	O
apomophine	NOUN	O	I-Entity
injection	NOUN	O	O
(	PUNCT	O	O
0.1	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O

5	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
the	DET	O	O
test	NOUN	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
produce	VERB	O	O
oral	ADJ	O	B-Entity
dyskinesia	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
reserpine	NOUN	O	I-Entity
induced	VERB	O	O
increases	NOUN	O	O
in	ADP	O	O
tremor	NOUN	O	I-Entity
and	CCONJ	O	O
catalepsy	NOUN	O	I-Entity
compared	VERB	O	O
to	ADP	O	O
control	NOUN	O	O
mice	NOUN	O	O
.	PUNCT	O	O

MK-801	NOUN	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
administration	NOUN	O	O
attenuated	VERB	O	O
the	DET	O	O
catalepsy	NOUN	O	I-Entity
and	CCONJ	O	O
tremor	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
reserpine	NOUN	O	I-Entity
.	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
reserpine	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
24	NUM	O	O

h	PRON	O	O
before	ADP	O	O
the	DET	O	O
observation	NOUN	O	O
test	NOUN	O	O
produced	VERB	O	O
increases	NOUN	O	O
in	ADP	O	O
vacuous	ADJ	O	O
chewing	NOUN	O	O
movements	NOUN	O	O
and	CCONJ	O	O
tongue	NOUN	O	O
protrusion	NOUN	O	O
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
increases	NOUN	O	O
in	ADP	O	O
tremor	NOUN	O	I-Entity
and	CCONJ	O	O
catalepsy	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
MK-801	PROPN	O	I-Entity
(	PUNCT	O	O
0.1	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
injection	NOUN	O	O
90	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
the	DET	O	O
test	NOUN	O	O
reversed	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
reserpine	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
reserpine	NOUN	O	I-Entity
produces	VERB	O	O
different	ADJ	O	O
and	CCONJ	O	O
abnormal	ADJ	O	B-Entity
movements	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
are	VERB	O	O
related	VERB	O	O
to	ADP	O	O
dose	NOUN	O	O
and	CCONJ	O	O
schedule	NOUN	O	O
employed	VERB	O	O
and	CCONJ	O	O
can	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
as	ADP	O	O
parkinsonian	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
and	CCONJ	O	O
tardive	ADJ	O	B-Entity
dsykinesia	NOUN	O	I-Entity
signs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
glutamatergic	ADJ	O	O
blockage	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
NMDA	PROPN	O	I-Entity
can	VERB	O	O
restore	VERB	O	O
these	DET	O	O
signs	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
vacuous	ADJ	O	O
chewing	NOUN	O	O
movements	NOUN	O	O
,	PUNCT	O	O
tongue	NOUN	O	O
protrusions	NOUN	O	O
,	PUNCT	O	O
catalepsy	NOUN	O	I-Entity
and	CCONJ	O	O
tremor	NOUN	O	I-Entity
according	VERB	O	O
to	ADP	O	O
the	DET	O	O
employed	VERB	O	O
model	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9431903)

Effect	NOUN	O	O
of	ADP	O	O
glyceryl	NOUN	O	B-Entity
trinitrate	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
sphincter	NOUN	O	B-Entity
of	ADP	O	I-Entity
Oddi	PROPN	O	I-Entity
spasm	NOUN	O	I-Entity
evoked	VERB	O	O
by	ADP	O	O
prostigmine	NOUN	O	I-Entity
-	PUNCT	O	O
morphine	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
glyceryl	NOUN	O	B-Entity
trinitrate	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
prostigmine	NOUN	O	I-Entity
-	PUNCT	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
sphincter	NOUN	O	B-Entity
of	ADP	O	I-Entity
Oddi	PROPN	O	I-Entity
spasm	NOUN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
nine	NUM	O	O
female	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
sphincter	NOUN	O	B-Entity
of	ADP	O	I-Entity
Oddi	PROPN	O	I-Entity
dyskinesia	NOUN	O	I-Entity
.	PUNCT	O	O

METHOD	NOUN	O	O
:	PUNCT	O	O
Sphincter	NOUN	O	B-Entity
of	ADP	O	I-Entity
Oddi	PROPN	O	I-Entity
spasm	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
prostigmine	NOUN	O	I-Entity
-	PUNCT	O	O
morphine	NOUN	O	I-Entity
administration	NOUN	O	O
(	PUNCT	O	O
0.5	NUM	O	O
mg	NUM	O	O
prostigmine	NOUN	O	I-Entity
intramuscularly	ADJ	O	O
and	CCONJ	O	O
10	NUM	O	O
mg	NUM	O	O
morphine	NOUN	O	I-Entity
subcutaneously	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
visualized	VERB	O	O
by	ADP	O	O
quantitative	ADJ	O	O
hepatobiliary	NOUN	O	O
scintigraphy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
entire	ADJ	O	O
procedure	NOUN	O	O
was	VERB	O	O
repeated	VERB	O	O
during	ADP	O	O
glyceryl	NOUN	O	B-Entity
trinitrate	ADJ	O	I-Entity
infusion	NOUN	O	O
(	PUNCT	O	O
Nitrolingual	PROPN	O	I-Entity
1	NUM	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Prostigmine	NOUN	O	I-Entity
-	PUNCT	O	O
morphine	NOUN	O	I-Entity
provocation	NOUN	O	O
caused	VERB	O	O
significant	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
the	DET	O	O
time	NOUN	O	O
to	PART	O	O
peak	VERB	O	O
activity	NOUN	O	O
(	PUNCT	O	O
Tmax	PROPN	O	O
)	PUNCT	O	O
over	ADP	O	O
the	DET	O	O
hepatic	ADJ	O	O
hilum	NOUN	O	O
(	PUNCT	O	O
HH	PROPN	O	O
:	PUNCT	O	O
34.33	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

6.24	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
indicating	VERB	O	O
a	DET	O	O
complete	ADJ	O	O
spasm	NOUN	O	I-Entity
at	ADP	O	O
the	DET	O	O
level	NOUN	O	O
of	ADP	O	O
the	DET	O	O
sphincter	NOUN	O	O
of	ADP	O	O
Oddi	PROPN	O	O
.	PUNCT	O	O

Glyceryl	PROPN	O	B-Entity
trinitrate	NOUN	O	I-Entity
infusion	NOUN	O	O
completely	ADV	O	O
normalized	VERB	O	O
the	DET	O	O
prostigmine	NOUN	O	I-Entity
-	PUNCT	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
alterations	NOUN	O	O
in	ADP	O	O
these	DET	O	O
quantitative	ADJ	O	O
parameters	NOUN	O	O
(	PUNCT	O	O
TmaX	PROPN	O	O
over	ADP	O	O
the	DET	O	O
LP	PROPN	O	O
:	PUNCT	O	O
11.33	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

6.33	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
sphincter	NOUN	O	O
-	PUNCT	O	O
relaxing	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
glyceryl	NOUN	O	B-Entity
trinitrate	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
These	DET	O	O
results	NOUN	O	O
provide	VERB	O	O
the	DET	O	O
first	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
glyceryl	NOUN	O	B-Entity
trinitrate	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
sphincter	NOUN	O	B-Entity
of	ADP	O	I-Entity
Oddi	PROPN	O	I-Entity
spasm	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
glyceryl	NOUN	O	B-Entity
trinitrate	NOUN	O	I-Entity
is	VERB	O	O
able	ADJ	O	O
to	PART	O	O
overcome	VERB	O	O
even	ADV	O	O
the	DET	O	O
drastic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
it	PRON	O	O
might	VERB	O	O
be	VERB	O	O
of	ADP	O	O
relevance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
sphincter	NOUN	O	B-Entity
of	ADP	O	I-Entity
Oddi	PROPN	O	I-Entity
dyskinesia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8665051)

Effects	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
steroid	NOUN	O	I-Entity
administration	NOUN	O	O
on	ADP	O	O
ventilatory	NOUN	O	O
and	CCONJ	O	O
peripheral	ADJ	O	O
muscles	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Occasional	ADJ	O	O
case	NOUN	O	O
reports	NOUN	O	O
have	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
acute	ADJ	O	O
myopathy	NOUN	O	I-Entity
may	VERB	O	O
occur	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
massive	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
corticosteroids	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
this	DET	O	O
myopathy	NOUN	O	I-Entity
is	VERB	O	O
poorly	ADV	O	O
understood	VERB	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
60	NUM	O	O
male	ADJ	O	O
rats	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	VERB	O	O
daily	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
saline	NOUN	O	O
(	PUNCT	O	O
C	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
methylprednisolone	NOUN	O	I-Entity
(	PUNCT	O	O
M	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
triamcinolone	NOUN	O	I-Entity
(	PUNCT	O	O
T	PROPN	O	I-Entity
)	PUNCT	O	O
80	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
d	NOUN	O	O
for	ADP	O	O
5	NUM	O	O
d.	PROPN	O	O
Nutritional	PROPN	O	O
intake	NOUN	O	O
,	PUNCT	O	O
measured	VERB	O	O
daily	ADV	O	O
in	ADP	O	O
15	NUM	O	O
animals	NOUN	O	O
,	PUNCT	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	B-Entity
of	ADP	O	I-Entity
food	NOUN	O	I-Entity
intake	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
steroid	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
groups	NOUN	O	O
(	PUNCT	O	O
-50	PUNCT	O	O
and	CCONJ	O	O
-79%	PROPN	O	O
in	ADP	O	O
M	PROPN	O	I-Entity
and	CCONJ	O	O
T	PROPN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
similar	ADJ	O	O
loss	NOUN	O	B-Entity
in	ADP	O	I-Entity
body	NOUN	O	I-Entity
weight	NOUN	O	I-Entity
.	PUNCT	O	O

Weights	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	O
and	CCONJ	O	O
peripheral	ADJ	O	O
muscles	NOUN	O	O
were	VERB	O	O
similarly	ADV	O	O
decreased	VERB	O	O
after	ADP	O	O
steroid	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

174	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
cm(2	NOUN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
M	PROPN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
837	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

p	X	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
T	NOUN	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
765	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Half	NOUN	O	O
-	PUNCT	O	O
relaxation	NOUN	O	O
time	NOUN	O	O
was	VERB	O	O
prolonged	VERB	O	O
in	ADP	O	O
both	DET	O	O
steroid	NOUN	O	I-Entity
groups	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
time	NOUN	O	O
to	PART	O	O
peak	VERB	O	O
tension	NOUN	O	O
was	VERB	O	O
longer	ADV	O	O
with	ADP	O	O
M	PROPN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
tetanic	ADJ	O	I-Entity
tensions	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
.	PUNCT	O	O

Steroid	ADJ	O	I-Entity
treatment	NOUN	O	O
also	ADV	O	O
induced	VERB	O	O
a	DET	O	O
leftward	ADJ	O	O
shift	NOUN	O	O
of	ADP	O	O
the	DET	O	O
force	NOUN	O	O
-	PUNCT	O	O
frequency	NOUN	O	O
curve	NOUN	O	O
at	ADP	O	O
25	NUM	O	O
and	CCONJ	O	O
50	NUM	O	O
Hz	NOUN	O	O
when	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
saline	ADJ	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

ATPase	PROPN	O	O
staining	NOUN	O	O
of	ADP	O	O
the	DET	O	O
diaphragm	NOUN	O	O
,	PUNCT	O	O
scalenus	NOUN	O	O
medius	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
gastrocnemius	NOUN	O	O
showed	VERB	O	O
type	NOUN	O	O
IIb	NOUN	O	O
fiber	NOUN	O	O
atrophy	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
steroid	NOUN	O	I-Entity
groups	NOUN	O	O
and	CCONJ	O	O
also	ADV	O	O
diaphragmatic	ADJ	O	O
type	NOUN	O	O
IIa	PROPN	O	O
atrophy	VERB	O	I-Entity
with	ADP	O	O
T	PROPN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
histologic	ADJ	O	O
examinations	NOUN	O	O
revealed	VERB	O	O
a	DET	O	O
normal	ADJ	O	O
muscular	ADJ	O	O
pattern	NOUN	O	O
with	ADP	O	O
absence	NOUN	O	O
of	ADP	O	O
necrosis	NOUN	O	I-Entity
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
pair	NOUN	O	O
-	PUNCT	O	O
fed	NOUN	O	O
(	PUNCT	O	O
PF	PROPN	O	O
)	PUNCT	O	O
study	NOUN	O	O
,	PUNCT	O	O
performed	VERB	O	O
in	ADP	O	O
18	NUM	O	O
rats	NOUN	O	O
(	PUNCT	O	O
C	PROPN	O	O
,	PUNCT	O	O
T	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
PF	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
showed	VERB	O	O
that	ADP	O	O
muscle	NOUN	O	B-Entity
atrophy	NOUN	O	I-Entity
was	VERB	O	O
considerably	ADV	O	O
less	ADV	O	O
pronounced	VERB	O	O
in	ADP	O	O
PF	PROPN	O	O
animals	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
T	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
(	PUNCT	O	O
1	PUNCT	O	O
)	PUNCT	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
massive	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
steroids	NOUN	O	I-Entity
induced	VERB	O	O
severe	ADJ	O	O
respiratory	ADJ	O	O
and	CCONJ	O	O
limb	NOUN	O	O
muscle	NOUN	O	O
wasting	VERB	O	O
;	PUNCT	O	O
(	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
both	DET	O	O
types	NOUN	O	O
of	ADP	O	O
steroids	NOUN	O	I-Entity
induced	VERB	O	O
predominantly	ADV	O	O
type	NOUN	O	O
IIb	NOUN	O	O
atrophy	NOUN	O	I-Entity
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
the	DET	O	O
expected	VERB	O	O
alterations	NOUN	O	O
in	ADP	O	O
diaphragm	NOUN	O	O
contractile	NOUN	O	O
properties	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
3	PUNCT	O	O
)	PUNCT	O	O
neither	CCONJ	O	O
steroid	NOUN	O	I-Entity
caused	VERB	O	O
muscle	NOUN	O	O
necrosis	NOUN	O	I-Entity
;	PUNCT	O	O
(	PUNCT	O	O
4	PUNCT	O	O
)	PUNCT	O	O
type	NOUN	O	O
IIb	NOUN	O	O
atrophy	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
caused	VERB	O	O
by	ADP	O	O
acute	ADJ	O	O
nutritional	ADJ	O	O
deprivation	NOUN	O	O
alone	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (7785794)

Refractory	ADJ	O	O
cardiogenic	ADJ	O	B-Entity
shock	NOUN	O	I-Entity
and	CCONJ	O	O
complete	ADJ	O	O
heart	NOUN	O	B-Entity
block	NOUN	O	I-Entity
after	ADP	O	O
verapamil	ADJ	O	I-Entity
SR	NOUN	O	O
and	CCONJ	O	O
metoprolol	ADJ	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
seventy	NUM	O	O
-	PUNCT	O	O
eight	NUM	O	O
-	PUNCT	O	O
year	NOUN	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
complete	ADJ	O	O
heart	NOUN	O	B-Entity
block	NOUN	O	I-Entity
and	CCONJ	O	O
refractory	ADJ	O	O
hypotension	NOUN	O	I-Entity
two	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
a	DET	O	O
therapeutic	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
sustained	VERB	O	O
-	PUNCT	O	O
release	NOUN	O	O
verapamil	NOUN	O	I-Entity
with	ADP	O	O
concomitant	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
metoprolol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
continued	VERB	O	O
to	PART	O	O
remain	VERB	O	O
hypotensive	ADJ	O	I-Entity
with	ADP	O	O
complete	ADJ	O	O
heart	NOUN	O	B-Entity
block	NOUN	O	I-Entity
,	PUNCT	O	O
even	ADV	O	O
with	ADP	O	O
multiple	ADJ	O	O
uses	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
atropine	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
pressor	NOUN	O	O
agents	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
dopamine	NOUN	O	I-Entity
and	CCONJ	O	O
dobutamine	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
shortly	ADV	O	O
after	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
refractory	ADJ	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
complete	ADJ	O	O
heart	NOUN	O	B-Entity
block	NOUN	O	I-Entity
resolved	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (8958188)

A	DET	O	O
phase	NOUN	O	O
I	PRON	O	O
clinical	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
antipurine	NOUN	O	I-Entity
antifolate	NOUN	O	O
lometrexol	NOUN	O	I-Entity
(	PUNCT	O	O
DDATHF	PROPN	O	I-Entity
)	PUNCT	O	O
given	VERB	O	O
with	ADP	O	O
oral	ADJ	O	O
folic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
.	PUNCT	O	O

Lometrexol	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
antifolate	NOUN	O	O
which	ADJ	O	O
inhibits	VERB	O	O
glycinamide	NOUN	O	B-Entity
ribonucleotide	NOUN	O	I-Entity
formyltransferase	NOUN	O	O
(	PUNCT	O	O
GARFT	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
enzyme	NOUN	O	O
essential	ADJ	O	O
for	ADP	O	O
de	X	O	O
novo	X	O	O
purine	ADJ	O	I-Entity
synthesis	NOUN	O	O
.	PUNCT	O	O

Extensive	ADJ	O	O
experimental	ADJ	O	O
and	CCONJ	O	O
limited	ADJ	O	O
clinical	ADJ	O	O
data	NOUN	O	O
have	VERB	O	O
shown	VERB	O	O
that	ADP	O	O
lometrexol	NOUN	O	I-Entity
has	VERB	O	O
activity	NOUN	O	O
against	ADP	O	O
tumours	NOUN	O	I-Entity
which	ADJ	O	O
are	VERB	O	O
refractory	ADJ	O	O
to	ADP	O	O
other	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
notably	ADV	O	O
methotrexate	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
initial	ADJ	O	O
clinical	ADJ	O	O
development	NOUN	O	O
of	ADP	O	O
lometrexol	NOUN	O	I-Entity
was	VERB	O	O
curtailed	VERB	O	O
because	ADP	O	O
of	ADP	O	O
severe	ADJ	O	O
and	CCONJ	O	O
cumulative	ADJ	O	O
antiproliferative	ADJ	O	O
toxicities	NOUN	O	I-Entity
.	PUNCT	O	O

Preclinical	ADJ	O	O
murine	NOUN	O	O
studies	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
the	DET	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
lometrexol	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
low	ADJ	O	O
dose	NOUN	O	O
folic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
administration	NOUN	O	O
,	PUNCT	O	O
i.e.	X	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
prior	ADV	O	O
to	ADP	O	O
and	CCONJ	O	O
7	NUM	O	O
days	NOUN	O	O
following	VERB	O	O
a	DET	O	O
single	ADJ	O	O
bolus	NOUN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
observation	NOUN	O	O
prompted	VERB	O	O
a	DET	O	O
Phase	NOUN	O	O
I	PRON	O	O
clinical	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
lometrexol	NOUN	O	I-Entity
given	VERB	O	O
with	ADP	O	O
folic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
supplementation	NOUN	O	O
which	ADJ	O	O
has	VERB	O	O
confirmed	VERB	O	O
that	ADP	O	O
the	DET	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
lometrexol	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
markedly	ADV	O	O
reduced	VERB	O	O
by	ADP	O	O
folic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
supplementation	NOUN	O	O
.	PUNCT	O	O

Thrombocytopenia	PROPN	O	I-Entity
and	CCONJ	O	O
mucositis	NOUN	O	I-Entity
were	VERB	O	O
the	DET	O	O
major	ADJ	O	O
toxicities	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
clear	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
clinical	ADJ	O	O
toxicity	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
folate	NOUN	O	I-Entity
elevation	NOUN	O	O
.	PUNCT	O	O

Associated	VERB	O	O
studies	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
lometrexol	NOUN	O	I-Entity
plasma	NOUN	O	O
pharmacokinetics	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
altered	VERB	O	O
by	ADP	O	O
folic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
administration	NOUN	O	O
indicating	VERB	O	O
that	ADP	O	O
supplementation	NOUN	O	O
is	VERB	O	O
unlikely	ADJ	O	O
to	PART	O	O
reduce	VERB	O	O
toxicity	NOUN	O	I-Entity
by	ADP	O	O
enhancing	VERB	O	O
lometrexol	ADJ	O	I-Entity
plasma	NOUN	O	O
clearance	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
information	NOUN	O	O
will	VERB	O	O
facilitate	VERB	O	O
the	DET	O	O
future	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
this	DET	O	O
class	NOUN	O	O
of	ADP	O	O
compounds	NOUN	O	O
in	ADP	O	O
cancer	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2557556)

Involvement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mu	NOUN	O	O
-	PUNCT	O	O
opiate	NOUN	O	O
receptor	NOUN	O	O
in	ADP	O	O
peripheral	ADJ	O	O
analgesia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
intradermal	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
mu	NOUN	O	O
(	PUNCT	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
Tyr	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
D	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
Ala	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
Gly	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
NMe	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
Phe	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
Gly	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
ol	NOUN	O	I-Entity
and	CCONJ	O	O
morphiceptin	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
kappa	NOUN	O	O
(	PUNCT	O	O
trans-3,4-dichloro	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
N	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
N[2-(1-pyrrolidinyl	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
cyclohexyl]benzeneactemide	NOUN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
delta	NOUN	O	O
(	PUNCT	O	O
[	PUNCT	O	B-Entity
D	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
Pen2.5]-enkephalin	PROPN	O	I-Entity
and	CCONJ	O	O
[	PUNCT	O	B-Entity
D	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
Ser2]-[Leu]enkephalin	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
Thr	PROPN	O	I-Entity
)	PUNCT	O	O
selective	ADJ	O	O
opioid	NOUN	O	O
-	PUNCT	O	O
agonists	NOUN	O	O
,	PUNCT	O	O
by	ADP	O	O
themselves	PRON	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
affect	VERB	O	O
the	DET	O	O
mechanical	ADJ	O	O
nociceptive	ADJ	O	O
threshold	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hindpaw	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
produced	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
inhibition	NOUN	O	O
of	ADP	O	O
prostaglandin	NOUN	O	B-Entity
E2-induced	ADJ	O	I-Entity
hyperalgesia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
analgesic	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mu	NOUN	O	O
-	PUNCT	O	O
agonist	NOUN	O	O
morphine	NOUN	O	I-Entity
was	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
antagonized	VERB	O	O
by	ADP	O	O
naloxone	NOUN	O	I-Entity
and	CCONJ	O	O
prevented	VERB	O	O
by	ADP	O	O
co	NOUN	O	O
-	PUNCT	O	O
injection	NOUN	O	O
of	ADP	O	O
pertussis	NOUN	O	O
toxin	NOUN	O	O
.	PUNCT	O	O

Morphine	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
alter	VERB	O	O
the	DET	O	O
hyperalgesia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
8-bromo	NUM	O	B-Entity
cyclic	ADJ	O	I-Entity
adenosine	NOUN	O	I-Entity
monophosphate	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
the	DET	O	O
analgesic	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
opioids	NOUN	O	O
on	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
terminals	NOUN	O	O
of	ADP	O	O
primary	ADJ	O	O
afferents	NOUN	O	O
is	VERB	O	O
via	ADP	O	O
a	DET	O	O
binding	VERB	O	O
site	NOUN	O	O
with	ADP	O	O
characteristics	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mu	NOUN	O	O
-	PUNCT	O	O
opioid	ADJ	O	O
receptor	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
this	DET	O	O
action	NOUN	O	O
is	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cyclic	ADJ	O	B-Entity
adenosine	NOUN	O	I-Entity
monophosphate	NOUN	O	I-Entity
second	ADJ	O	O
messenger	NOUN	O	O
system	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15580403)

Adequate	ADJ	O	O
timing	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
reduction	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hemolysis	NOUN	O	I-Entity
during	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
of	ADP	O	O
interferon	NOUN	O	I-Entity
and	CCONJ	O	O
ribavirin	NOUN	O	I-Entity
for	ADP	O	O
chronic	ADJ	O	B-Entity
hepatitis	NOUN	O	I-Entity
C.	PROPN	O	I-Entity
BACKGROUND	NOUN	O	O
:	PUNCT	O	O

Hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
is	VERB	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
major	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
of	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
of	ADP	O	O
interferon	NOUN	O	I-Entity
and	CCONJ	O	O
ribavirin	NOUN	O	I-Entity
.	PUNCT	O	O

Because	ADP	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
is	VERB	O	O
a	DET	O	O
common	ADJ	O	O
event	NOUN	O	O
in	ADP	O	O
this	DET	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
clinical	ADJ	O	O
retrospective	NOUN	O	O
cohort	NOUN	O	O
study	NOUN	O	O
we	PRON	O	O
have	VERB	O	O
examined	VERB	O	O
the	DET	O	O
suitable	ADJ	O	O
timing	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
reduction	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hemolysis	NOUN	O	I-Entity
during	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Thirty	NUM	O	O
-	PUNCT	O	O
seven	NUM	O	O
of	ADP	O	O
160	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
HCV	PROPN	O	O
-	PUNCT	O	O
genotype	NOUN	O	O
1b	NUM	O	O
,	PUNCT	O	O
had	VERB	O	O
high	ADJ	O	O
virus	NOUN	O	O
load	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
received	VERB	O	O
24-week	NUM	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
developed	VERB	O	O
anemia	NOUN	O	I-Entity
with	ADP	O	O
hemoglobin	NOUN	O	O
level	NOUN	O	O
<	X	O	O
10	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
dl	NOUN	O	O
or	CCONJ	O	O
anemia	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
signs	NOUN	O	O
during	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
that	DET	O	O
,	PUNCT	O	O
these	DET	O	O
37	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
reduced	VERB	O	O
one	NUM	O	O
tablet	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
(	PUNCT	O	O
200	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
per	ADP	O	O
day	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
reduction	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
,	PUNCT	O	O
27	NUM	O	O
of	ADP	O	O
37	NUM	O	O
patients	NOUN	O	O
could	VERB	O	O
continue	VERB	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
A	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
10	NUM	O	O
of	ADP	O	O
37	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
reduction	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
could	VERB	O	O
not	ADV	O	O
continue	VERB	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
because	ADP	O	O

their	ADJ	O	O
<	X	O	O
8.5	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
dl	ADP	O	O
hemoglobin	NOUN	O	O
values	NOUN	O	O
decreased	VERB	O	O
to	ADP	O	O
or	CCONJ	O	O
anemia	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
severe	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
occurred	VERB	O	O
(	PUNCT	O	O
group	NOUN	O	O
B	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
assessed	VERB	O	O
the	DET	O	O
final	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
after	ADP	O	O
reduction	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
in	ADP	O	O
groups	NOUN	O	O
A	PROPN	O	O
and	CCONJ	O	O
B.	PROPN	O	O
RESULTS	PROPN	O	O
:	PUNCT	O	O

With	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
hemoglobin	NOUN	O	O
level	NOUN	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
reduction	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
continuation	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
>	NOUN	O	O
or	CCONJ	O	O
=	SYM	O	O
10	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
dl	ADP	O	O
hemoglobin	NOUN	O	O
was	VERB	O	O
higher	ADJ	O	O
than	ADP	O	O
that	DET	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
<	SYM	O	O
10	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
dl	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.036	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Reduction	NOUN	O	O
of	ADP	O	O
ribavirin	NOUN	O	I-Entity
at	ADP	O	O
hemoglobin	NOUN	O	O
level	NOUN	O	O
>	X	O	O
or	CCONJ	O	O
=	SYM	O	O


-DOCSTART- (15075188)

Increased	ADJ	O	O
expression	NOUN	O	O
and	CCONJ	O	O
apical	ADJ	O	O
targeting	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
ENaC	PROPN	O	O
subunits	NOUN	O	O
in	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Nephrotic	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
is	VERB	O	O
often	ADV	O	O
accompanied	VERB	O	O
by	ADP	O	O
sodium	NOUN	O	I-Entity
retention	NOUN	O	O
and	CCONJ	O	O
generalized	ADJ	O	O
edema	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
molecular	ADJ	O	O
basis	NOUN	O	O
for	ADP	O	O
the	DET	O	O
decreased	ADJ	O	O
renal	ADJ	O	O
sodium	NOUN	O	I-Entity
excretion	NOUN	O	O
remains	VERB	O	O
undefined	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
epithelial	ADJ	O	O
Na	PROPN	O	I-Entity
channel	NOUN	O	O
(	PUNCT	O	O
ENaC	PROPN	O	O
)	PUNCT	O	O
subunit	NOUN	O	O
dysregulation	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
responsible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
increased	VERB	O	O
sodium	NOUN	O	I-Entity
retention	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
(	PUNCT	O	O
PAN	PROPN	O	I-Entity
;	PUNCT	O	O
180	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	X	O	O
iv	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
only	ADV	O	O
vehicle	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
PAN	PROPN	O	I-Entity
treatment	NOUN	O	O
induced	VERB	O	O
significant	ADJ	O	O
proteinuria	NOUN	O	I-Entity
,	PUNCT	O	O
hypoalbuminemia	NOUN	O	I-Entity
,	PUNCT	O	O
decreased	VERB	O	O
urinary	ADJ	O	O
sodium	NOUN	O	I-Entity
excretion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
extensive	ADJ	O	O
ascites	NOUN	O	I-Entity
.	PUNCT	O	O

Immunoelectron	PROPN	O	O
microscopy	VERB	O	O
further	ADV	O	O
revealed	VERB	O	O
an	DET	O	O
increased	VERB	O	O
labeling	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
ENaC	PROPN	O	O
in	ADP	O	O
the	DET	O	O
apical	ADJ	O	O
plasma	NOUN	O	O
membrane	NOUN	O	O
of	ADP	O	O
cortical	ADJ	O	O
collecting	VERB	O	O
duct	NOUN	O	O
principal	NOUN	O	O
cells	NOUN	O	O
of	ADP	O	O
PAN	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
indicating	VERB	O	O
enhanced	VERB	O	O
apical	ADJ	O	O
targeting	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
ENaC	PROPN	O	O
subunits	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
protein	NOUN	O	O
abundances	NOUN	O	O
of	ADP	O	O
Na(+)/H(+	PROPN	O	I-Entity
)	PUNCT	O	O
exchanger	NOUN	O	O
type	NOUN	O	O
3	NUM	O	O
(	PUNCT	O	O
NHE3	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Na(+)-K(+)-2Cl(-	PROPN	O	I-Entity
)	PUNCT	O	O

cotransporter	NOUN	O	O
(	PUNCT	O	O
BSC-1	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
thiazide	ADV	O	I-Entity
-	PUNCT	O	O
sensitive	ADJ	O	O
Na(+)-Cl(-	PROPN	O	I-Entity
)	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
abundance	NOUN	O	O
of	ADP	O	O
the	DET	O	O
alpha(1)-subunit	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Na	PROPN	O	I-Entity
-	PUNCT	O	O
K	PROPN	O	I-Entity
-	PUNCT	O	O
ATPase	PROPN	O	O
was	VERB	O	O
decreased	VERB	O	O
in	ADP	O	O
the	DET	O	O
cortex	NOUN	O	O
and	CCONJ	O	O
ISOM	PROPN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
remained	VERB	O	O
unchanged	ADJ	O	O
in	ADP	O	O
the	DET	O	O
IM	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
increased	VERB	O	O
or	CCONJ	O	O
sustained	VERB	O	O
expression	NOUN	O	O
of	ADP	O	O
ENaC	PROPN	O	O
subunits	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
apical	ADJ	O	O
targeting	VERB	O	O
in	ADP	O	O
the	DET	O	O
DCT2	PROPN	O	O
,	PUNCT	O	O
connecting	VERB	O	O
tubule	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
collecting	VERB	O	O
duct	NOUN	O	O
are	VERB	O	O
likely	ADJ	O	O
to	PART	O	O
play	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
sodium	NOUN	O	I-Entity
retention	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
PAN	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
decreased	ADJ	O	O
abundance	NOUN	O	O
of	ADP	O	O
NHE3	PROPN	O	O
,	PUNCT	O	O
BSC-1	PROPN	O	O
,	PUNCT	O	O
TSC	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Na	PROPN	O	I-Entity
-	PUNCT	O	O
K	PROPN	O	I-Entity
-	PUNCT	O	O
ATPase	PROPN	O	O
may	VERB	O	O
play	VERB	O	O
a	DET	O	O
compensatory	ADJ	O	O
role	NOUN	O	O
to	PART	O	O
promote	VERB	O	O
sodium	NOUN	O	I-Entity
excretion	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (14745746)

Does	VERB	O	O
hormone	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
have	VERB	O	O
a	DET	O	O
detrimental	ADJ	O	B-Entity
effect	NOUN	O	I-Entity
on	ADP	O	I-Entity
memory	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
cognition	NOUN	O	I-Entity
?	PUNCT	O	O

This	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
examines	VERB	O	O
whether	ADP	O	O
hormone	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
affects	VERB	O	O
cognition	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
participating	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomised	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
anastrozole	NOUN	O	I-Entity
,	PUNCT	O	O
tamoxifen	NOUN	O	I-Entity
alone	ADV	O	O
or	CCONJ	O	O
combined	VERB	O	O
(	PUNCT	O	O
ATAC	PROPN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
n=94	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
women	NOUN	O	O
without	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
(	PUNCT	O	O
n=35	PROPN	O	O
)	PUNCT	O	O
completed	VERB	O	O
a	DET	O	O
battery	NOUN	O	O
of	ADP	O	O
neuropsychological	ADJ	O	O
measures	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
showed	VERB	O	O
specific	ADJ	O	O
impairments	NOUN	O	O
in	ADP	O	O
processing	VERB	O	O
speed	NOUN	O	O
and	CCONJ	O	O
verbal	ADJ	O	O
memory	NOUN	O	O
in	ADP	O	O
women	NOUN	O	O
receiving	VERB	O	O
hormonal	ADJ	O	O
therapy	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Verbal	ADJ	O	O
memory	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
especially	ADV	O	O
sensitive	ADJ	O	O
to	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
oestrogen	NOUN	O	I-Entity
levels	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
finding	VERB	O	O
commonly	ADV	O	O
reported	VERB	O	O
in	ADP	O	O
studies	NOUN	O	O
of	ADP	O	O
hormone	NOUN	O	O
replacement	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11208990)

Association	PROPN	O	O
of	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
production	NOUN	O	O
and	CCONJ	O	O
apoptosis	NOUN	O	O
in	ADP	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
experimental	ADJ	O	O
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
recent	ADJ	O	O
studies	NOUN	O	O
increased	VERB	O	O
amounts	NOUN	O	O
of	ADP	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
(	PUNCT	O	O
NO	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
apoptosis	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
various	ADJ	O	O
pathological	ADJ	O	O
conditions	NOUN	O	O
in	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
studied	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
NO	PROPN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
association	NOUN	O	O
with	ADP	O	O
apoptosis	NOUN	O	O
in	ADP	O	O
an	DET	O	O
experimental	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
single	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
adriamycin	ADJ	O	I-Entity
(	PUNCT	O	O
ADR	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
alteration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
NO	PROPN	O	I-Entity
pathway	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
measuring	VERB	O	O
nitrite	ADJ	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
/	SYM	O	O
urine	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
evaluating	VERB	O	O
the	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
vascular	ADJ	O	O
reactivity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
isolated	ADJ	O	O
perfused	ADJ	O	O
rat	NOUN	O	O
kidney	NOUN	O	O
(	PUNCT	O	O
IPRK	PROPN	O	O
)	PUNCT	O	O
system	NOUN	O	O
.	PUNCT	O	O

Rats	NOUN	O	O
were	VERB	O	O
stratified	VERB	O	O
into	ADP	O	O
control	NOUN	O	O
groups	NOUN	O	O
and	CCONJ	O	O
ADR	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephropathy	ADJ	O	I-Entity
groups	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
then	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
:	PUNCT	O	O
group	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
animals	NOUN	O	O
receiving	VERB	O	O
saline	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
group	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
animals	NOUN	O	O
receiving	VERB	O	O
aminoguanidine	NOUN	O	I-Entity
(	PUNCT	O	O
AG	PROPN	O	I-Entity
)	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
a	DET	O	O
specific	ADJ	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
inducible	ADJ	O	O
-	PUNCT	O	O
NO	NOUN	O	I-Entity
synthase	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Histopathological	ADJ	O	O
examination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
kidneys	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
ADR	PROPN	O	I-Entity
revealed	VERB	O	O
focal	ADJ	O	O
areas	NOUN	O	O
of	ADP	O	O
mesangial	ADJ	O	B-Entity
proliferation	NOUN	O	I-Entity
and	CCONJ	O	O
mild	ADJ	O	O
tubulointerstitial	ADJ	O	B-Entity
inflammation	NOUN	O	I-Entity
.	PUNCT	O	O

They	PRON	O	O
also	ADV	O	O
had	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
proteinuria	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Urine	PROPN	O	O
nitrite	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
ADR	PROPN	O	I-Entity
-	PUNCT	O	O
nephropathy	ADJ	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
P	PROPN	O	O
<	PROPN	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
IPRK	PROPN	O	O
phenylephrine	NOUN	O	I-Entity
and	CCONJ	O	O
acetylcholine	NOUN	O	I-Entity
related	VERB	O	O
responses	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
impaired	VERB	O	O
in	ADP	O	O
the	DET	O	O
ADR	PROPN	O	I-Entity
-	PUNCT	O	O
nephropathy	ADJ	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
ADR	PROPN	O	I-Entity
-	PUNCT	O	O
nephropathy	ADJ	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
numerous	ADJ	O	O
apoptotic	ADJ	O	O
cells	NOUN	O	O
were	VERB	O	O
identified	VERB	O	O
in	ADP	O	O
the	DET	O	O
tubulointerstitial	ADJ	O	O
areas	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
AG	PROPN	O	I-Entity
prevented	VERB	O	O
the	DET	O	O
impairment	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
vascular	ADJ	O	O
bed	NOUN	O	O
responses	NOUN	O	O
and	CCONJ	O	O
reduced	VERB	O	O
both	DET	O	O
urine	NOUN	O	O
nitrite	ADJ	O	I-Entity
levels	NOUN	O	O
and	CCONJ	O	O
apoptosis	NOUN	O	O
to	PART	O	O
control	VERB	O	O
levels	NOUN	O	O
.	PUNCT	O	O

:	PUNCT	O	O
We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
interactions	NOUN	O	O
between	ADP	O	O
NO	PROPN	O	I-Entity
and	CCONJ	O	O
apoptosis	NOUN	O	O
are	VERB	O	O
important	ADJ	O	O
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ADR	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrosis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9201797)

The	DET	O	O
attenuating	VERB	O	O
effect	NOUN	O	O
of	ADP	O	O
carteolol	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
known	VERB	O	O
that	ADP	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
antagonists	NOUN	O	O
are	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
akathisia	NOUN	O	I-Entity
,	PUNCT	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
extrapyramidal	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
that	ADJ	O	O
occur	VERB	O	O
during	ADP	O	O
neuroleptic	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
extrapyramidal	NOUN	O	O
side	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
considered	VERB	O	O
suitable	ADJ	O	O
as	ADP	O	O
a	DET	O	O
model	NOUN	O	O
for	ADP	O	O
predicting	VERB	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
akathisia	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
considered	VERB	O	O
a	DET	O	O
specific	ADJ	O	O
test	NOUN	O	O
for	ADP	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
akathisia	NOUN	O	I-Entity
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
carteolol	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
were	VERB	O	O
behaviorally	ADV	O	O
studied	VERB	O	O
and	CCONJ	O	O
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
and	CCONJ	O	O
biperiden	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
muscarinic	ADJ	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
.	PUNCT	O	O

Carteolol	PROPN	O	I-Entity
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
propranolol	NOUN	O	I-Entity
and	CCONJ	O	O
biperiden	NOUN	O	I-Entity
,	PUNCT	O	O
inhibited	VERB	O	O
the	DET	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
inhibitory	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
carteolol	NOUN	O	I-Entity
was	VERB	O	O
almost	ADV	O	O
comparable	ADJ	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
propranolol	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
was	VERB	O	O
weaker	ADJ	O	O
than	ADP	O	O
that	DET	O	O
of	ADP	O	O
biperiden	NOUN	O	I-Entity
.	PUNCT	O	O

Carteolol	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
evoke	VERB	O	O
postsynaptic	ADJ	O	O

dopamine	NOUN	O	I-Entity
receptor	NOUN	O	O
-	PUNCT	O	O
stimulating	VERB	O	O
behavioral	ADJ	O	O
signs	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
stereotypy	NOUN	O	O
and	CCONJ	O	O
hyperlocomotion	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Carteolol	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
antagonize	VERB	O	O
the	DET	O	O
inhibitory	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
on	ADP	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
stereotypy	NOUN	O	O
and	CCONJ	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
carteolol	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
evoke	VERB	O	O
5-HT1A	NUM	O	O
receptor	NOUN	O	O
-	PUNCT	O	O
stimulating	VERB	O	O
behavioral	ADJ	O	O
signs	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
flat	ADJ	O	O
body	NOUN	O	O
posture	NOUN	O	O
and	CCONJ	O	O
forepaw	NOUN	O	O
treading	NOUN	O	O
and	CCONJ	O	O
did	VERB	O	O
not	ADV	O	O
inhibit	VERB	O	O
5-hydroxytryptophan	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
head	NOUN	O	O
twitch	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
carteolol	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
inhibit	VERB	O	O
physostigmine	ADJ	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
lethality	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
strongly	ADV	O	O
suggest	VERB	O	O
that	ADP	O	O
carteolol	NOUN	O	I-Entity
improves	VERB	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
via	ADP	O	O
its	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
antagonistic	ADJ	O	O
activity	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
expected	VERB	O	O
to	PART	O	O
be	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
akathisia	NOUN	O	I-Entity
without	ADP	O	O
attenuating	VERB	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
antipsychotic	ADJ	O	O
effects	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
its	ADJ	O	O
postsynaptic	ADJ	O	O
dopamine	NOUN	O	I-Entity
receptor	NOUN	O	O
antagonistic	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8267029)

Penicillamine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rapidly	ADV	O	O
progressive	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
rheumatoid	ADJ	O	B-Entity
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
67-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
rheumatoid	ADJ	O	B-Entity
arthritis	NOUN	O	I-Entity
presented	VERB	O	O
rapidly	ADV	O	O
progressive	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
(	PUNCT	O	O
RPGN	PROPN	O	I-Entity
)	PUNCT	O	O
after	ADP	O	O
5	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
(	PUNCT	O	O
250	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Light	NOUN	O	O
microscopy	NOUN	O	O
study	NOUN	O	O
showed	VERB	O	O
severe	ADJ	O	O
glomerulonephritis	NOUN	O	I-Entity
with	ADP	O	O
crescent	NOUN	O	O
formation	NOUN	O	O
in	ADP	O	O
60%	NUM	O	O
of	ADP	O	O
the	DET	O	O
glomeruli	NOUN	O	O
and	CCONJ	O	O
infiltration	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
wall	NOUN	O	O
of	ADP	O	O
an	DET	O	O
arteriole	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
steroid	NOUN	O	I-Entity
pulse	NOUN	O	O
,	PUNCT	O	O
plasmapheresis	NOUN	O	O
,	PUNCT	O	O
cyclophosphamide	NOUN	O	I-Entity
and	CCONJ	O	O
antiplatelet	NOUN	O	B-Entity
agents	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
new	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
RPGN	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
treatment	NOUN	O	O
emphasizes	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
frequent	ADJ	O	O
monitoring	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
urinary	ADJ	O	O
sediment	NOUN	O	O
and	CCONJ	O	O
proteinuria	NOUN	O	I-Entity
in	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
prompt	ADJ	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
and	CCONJ	O	O
vigorous	ADJ	O	O
treatment	NOUN	O	O
measures	NOUN	O	O
could	VERB	O	O
allow	VERB	O	O
for	ADP	O	O
a	DET	O	O
good	ADJ	O	O
prognosis	NOUN	O	O
as	ADP	O	O
in	ADP	O	O
this	DET	O	O
case	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2528969)

Nature	PROPN	O	O
,	PUNCT	O	O
time	NOUN	O	O
course	NOUN	O	O
and	CCONJ	O	O
dose	NOUN	O	O
dependence	NOUN	O	O
of	ADP	O	O
zidovudine	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
side	NOUN	O	O
effects	NOUN	O	O
:	PUNCT	O	O
results	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Multicenter	PROPN	O	O
Canadian	PROPN	O	O
Azidothymidine	PROPN	O	I-Entity
Trial	PROPN	O	O
.	PUNCT	O	O

To	PART	O	O
characterize	VERB	O	O
the	DET	O	O
nature	NOUN	O	O
,	PUNCT	O	O
time	NOUN	O	O
course	NOUN	O	O
and	CCONJ	O	O
dose	NOUN	O	O
dependency	NOUN	O	O
of	ADP	O	O
zidovudine	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
side	NOUN	O	O
effects	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
undertook	VERB	O	O
a	DET	O	O
multicenter	ADJ	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
dose	ADJ	O	O
-	PUNCT	O	O
range	NOUN	O	O
finding	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
study	NOUN	O	O
group	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
74	NUM	O	O
HIV	PROPN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
homosexual	ADJ	O	O
men	NOUN	O	O
belonging	VERB	O	O
to	ADP	O	O
groups	NOUN	O	O
II	PROPN	O	O
B	PROPN	O	O
,	PUNCT	O	O
III	PROPN	O	O
and	CCONJ	O	O
IV	PROPN	O	O
C2	PROPN	O	O
from	ADP	O	O
the	DET	O	O
Centers	PROPN	O	O
for	ADP	O	O
Disease	PROPN	O	O
Control	PROPN	O	O
(	PUNCT	O	O
CDC	PROPN	O	O
)	PUNCT	O	O
classification	NOUN	O	O
of	ADP	O	O
HIV	PROPN	O	B-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Following	VERB	O	O
a	DET	O	O
3-week	NUM	O	O
observation	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
volunteers	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
zidovudine	NOUN	O	I-Entity
600	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
18	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
900	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
9	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
1200	NUM	O	O
mg	NUM	O	O

Symptomatic	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
96%	NUM	O	O
of	ADP	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
most	ADV	O	O
commonly	ADV	O	O
nausea	NOUN	O	I-Entity
(	PUNCT	O	O
64%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
fatigue	NOUN	O	I-Entity
(	PUNCT	O	O
55%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
headache	NOUN	O	I-Entity
(	PUNCT	O	O
49%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Bone	PROPN	O	O
marrow	NOUN	O	O
changes	NOUN	O	O
occurred	VERB	O	O
rapidly	ADV	O	O
as	ADP	O	O
demonstrated	VERB	O	O
by	ADP	O	O
megaloblastosis	NOUN	O	I-Entity
in	ADP	O	O
95%	NUM	O	O
of	ADP	O	O
65	NUM	O	O
specimens	NOUN	O	O
at	ADP	O	O
week	NOUN	O	O
18.(ABSTRACT	NUM	O	O
TRUNCATED	ADJ	O	O
AT	NOUN	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O


-DOCSTART- (384871)

Bilateral	ADJ	O	B-Entity
optic	NOUN	O	I-Entity
neuropathy	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
combined	VERB	O	O
ethambutol	NOUN	O	I-Entity
and	CCONJ	O	O
isoniazid	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
40-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
patient	NOUN	O	O
who	NOUN	O	O
underwent	VERB	O	O
an	DET	O	O
unsuccessful	ADJ	O	O
cadaver	NOUN	O	O
kidney	NOUN	O	O
transplantation	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
ethambutol	NOUN	O	I-Entity
and	CCONJ	O	O
isoniazid	NOUN	O	I-Entity
is	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
bilateral	ADJ	O	B-Entity
retrobulbar	NOUN	O	I-Entity
neuropathy	NOUN	O	I-Entity
with	ADP	O	O
an	DET	O	O
unusual	ADJ	O	O
central	ADJ	O	O
bitemporal	ADJ	O	O
hemianopic	NOUN	O	O
scotoma	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

Ethambutol	PROPN	O	I-Entity
was	VERB	O	O
stopped	VERB	O	O
and	CCONJ	O	O
only	ADV	O	O
small	ADJ	O	O
improvement	NOUN	O	O
of	ADP	O	O
the	DET	O	O
visual	ADJ	O	O
acuity	NOUN	O	O
followed	VERB	O	O
.	PUNCT	O	O

Isoniazid	PROPN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
later	ADV	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
dramatic	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
visual	ADJ	O	O
acuity	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hazards	NOUN	O	O
of	ADP	O	O
optic	ADJ	O	O
nerve	NOUN	O	O
toxicity	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
ethambutol	NOUN	O	I-Entity
are	VERB	O	O
known	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
emphasize	VERB	O	O
the	DET	O	O
potential	ADJ	O	O
danger	NOUN	O	O
in	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
ethambutol	NOUN	O	I-Entity
and	CCONJ	O	O
isoniazid	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (133615)

Progestational	ADJ	O	O
agents	NOUN	O	O
and	CCONJ	O	O
blood	NOUN	O	B-Entity
coagulation	NOUN	O	I-Entity
.	PUNCT	O	O

Thromboembolic	PROPN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
complications	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	B-Entity
contraceptive	NOUN	O	I-Entity
therapy	NOUN	O	O
in	ADP	O	O
relationship	NOUN	O	O
to	ADP	O	O
pretreatment	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	B-Entity
coagulation	NOUN	O	I-Entity
factors	NOUN	O	O
:	PUNCT	O	O
summary	ADJ	O	O
report	NOUN	O	O
of	ADP	O	O
a	DET	O	O
ten	NUM	O	O
-	PUNCT	O	O
year	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
a	DET	O	O
ten	NUM	O	O
-	PUNCT	O	O
year	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
348	NUM	O	O
women	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
for	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
5,877	NUM	O	O
patient	ADJ	O	O
months	NOUN	O	O
in	ADP	O	O
four	NUM	O	O
separate	ADJ	O	O
studies	NOUN	O	O
relating	VERB	O	O
oral	ADJ	O	B-Entity
contraceptives	NOUN	O	I-Entity
to	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
hematologic	ADJ	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
certain	ADJ	O	O
factors	NOUN	O	O
of	ADP	O	O
the	DET	O	O
blood	NOUN	O	B-Entity
coagulation	NOUN	O	I-Entity
and	CCONJ	O	O
fibrinolysin	NOUN	O	O
systems	NOUN	O	O
(	PUNCT	O	O
factors	NOUN	O	O
I	PRON	O	O
,	PUNCT	O	O
II	PROPN	O	O
,	PUNCT	O	O
VII	PROPN	O	O
,	PUNCT	O	O
VIII	PROPN	O	O
,	PUNCT	O	O
IX	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
X	PROPN	O	O
and	CCONJ	O	O
plasminogen	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
treated	VERB	O	O
groups	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
four	NUM	O	O
had	VERB	O	O
an	DET	O	O
abnormal	ADJ	O	O
blood	NOUN	O	B-Entity
coagulation	NOUN	O	I-Entity
profile	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
"	PUNCT	O	O
hypercoagulability	NOUN	O	I-Entity
"	PUNCT	O	O
before	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
before	ADP	O	O
receiving	VERB	O	O
any	DET	O	O
medication	NOUN	O	O
,	PUNCT	O	O
shortly	ADV	O	O
after	ADP	O	O
the	DET	O	O
base	NOUN	O	O
-	PUNCT	O	O
line	NOUN	O	O
values	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
developed	VERB	O	O
retinopathy	ADJ	O	I-Entity
19	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
she	PRON	O	O
began	VERB	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
another	DET	O	O
developed	VERB	O	O
thrombophlebitis	NOUN	O	I-Entity
after	ADP	O	O
27	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
fourth	ADJ	O	O
patient	NOUN	O	O
developed	VERB	O	O
thrombophlebitis	ADJ	O	I-Entity
14	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
contraceptive	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
studies	NOUN	O	O
suggested	VERB	O	O
the	DET	O	O
possiblility	NOUN	O	O
of	ADP	O	O
increased	VERB	O	O
propensity	NOUN	O	O
for	ADP	O	O
thromboembolic	ADJ	O	B-Entity
episodes	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
possessing	VERB	O	O
the	DET	O	O
A	PROPN	O	O
antigen	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
appears	VERB	O	O
from	ADP	O	O
these	DET	O	O
data	NOUN	O	O
that	ADJ	O	O
hematologic	ADJ	O	O
work	NOUN	O	O
-	PUNCT	O	O
ups	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
in	ADP	O	O
women	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
about	ADP	O	O
to	PART	O	O
start	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
oral	ADJ	O	B-Entity
contraceptive	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17263743)

Cardiac	PROPN	O	B-Entity
arrest	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
child	NOUN	O	O
with	ADP	O	O
cerebral	ADJ	O	B-Entity
palsy	NOUN	O	I-Entity
undergoing	VERB	O	O
sevoflurane	ADJ	O	I-Entity
induction	NOUN	O	O
of	ADP	O	O
anesthesia	NOUN	O	O
after	ADP	O	O
preoperative	ADJ	O	O
clonidine	NOUN	O	I-Entity
.	PUNCT	O	O

Clonidine	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
frequently	ADV	O	O
administered	VERB	O	O
alpha2-adrenergic	ADJ	O	O
agonist	NOUN	O	O
which	ADJ	O	O
can	VERB	O	O
decrease	VERB	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
present	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
5-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
child	NOUN	O	O
with	ADP	O	O
cerebral	ADJ	O	B-Entity
palsy	NOUN	O	I-Entity
and	CCONJ	O	O
seizure	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
,	PUNCT	O	O
receiving	VERB	O	O
clonidine	NOUN	O	I-Entity
for	ADP	O	O
restlessness	NOUN	O	I-Entity
,	PUNCT	O	O
who	NOUN	O	O
presented	VERB	O	O
for	ADP	O	O
placement	NOUN	O	O
of	ADP	O	O
a	DET	O	O
baclofen	NOUN	O	I-Entity
pump	NOUN	O	O
.	PUNCT	O	O

Without	ADP	O	O
the	DET	O	O
knowledge	NOUN	O	O
of	ADP	O	O
the	DET	O	O
medical	ADJ	O	O
personnel	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
mother	NOUN	O	O
administered	VERB	O	O
three	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
evening	NOUN	O	O
before	ADV	O	O
and	CCONJ	O	O
morning	NOUN	O	O
of	ADP	O	O
surgery	NOUN	O	O
to	PART	O	O
reduce	VERB	O	O
anxiety	NOUN	O	I-Entity
.	PUNCT	O	O

During	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
anesthesia	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
bradycardia	NOUN	O	I-Entity
and	CCONJ	O	O
hypotension	NOUN	O	I-Entity
requiring	VERB	O	O
cardiac	ADJ	O	O
resuscitation	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
are	VERB	O	O
no	DET	O	O
previous	ADJ	O	O
reports	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
child	NOUN	O	O
undergoing	VERB	O	O
induction	NOUN	O	O
of	ADP	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17241657)

Effects	NOUN	O	O
of	ADP	O	O
UMB24	PROPN	O	I-Entity
and	CCONJ	O	O
(	PUNCT	O	O
+	SYM	O	O
/-)-SM	PROPN	O	B-Entity
21	NUM	O	I-Entity
,	PUNCT	O	O
putative	ADJ	O	O
sigma2-preferring	NOUN	O	O
antagonists	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
behavioral	ADJ	O	O
toxic	ADJ	O	O
and	CCONJ	O	O
stimulant	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Earlier	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
demonstrated	VERB	O	O
that	ADP	O	O
antagonism	NOUN	O	O
of	ADP	O	O
sigma1	NOUN	O	O
receptors	NOUN	O	O
attenuates	VERB	O	O
the	DET	O	O
convulsive	ADJ	O	I-Entity
,	PUNCT	O	O
lethal	ADJ	O	O
,	PUNCT	O	O
locomotor	NOUN	O	O
stimulatory	ADJ	O	O
and	CCONJ	O	O
rewarding	ADJ	O	O
actions	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
begin	VERB	O	O
addressing	VERB	O	O
this	DET	O	O
need	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
characterized	VERB	O	O
UMB24	PROPN	O	I-Entity
(	PUNCT	O	O
1-(2-phenethyl)-4-(2-pyridyl)-piperazine	NUM	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
+	SYM	O	O
/-)-SM	PROPN	O	B-Entity
21	NUM	O	I-Entity
(	PUNCT	O	O
3alpha	NUM	O	B-Entity
-	PUNCT	O	I-Entity
tropanyl-2-(4-chorophenoxy)butyrate	NOUN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
receptor	NOUN	O	O
binding	NOUN	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

Receptor	NOUN	O	O
binding	VERB	O	O
studies	NOUN	O	O
confirmed	VERB	O	O
that	ADP	O	O
UMB24	PROPN	O	I-Entity
and	CCONJ	O	O
(	PUNCT	O	O
+	SYM	O	O
/-)-SM	NUM	O	B-Entity
21	NUM	O	I-Entity
display	NOUN	O	O
preferential	ADJ	O	O
affinity	NOUN	O	O
for	ADP	O	O
sigma2	NOUN	O	O
over	ADP	O	O
sigma1	NOUN	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
behavioral	ADJ	O	O
studies	NOUN	O	O
,	PUNCT	O	O
pretreatment	NOUN	O	O
of	ADP	O	O
Swiss	PROPN	O	O
Webster	PROPN	O	O
mice	NOUN	O	O
with	ADP	O	O
UMB24	PROPN	O	I-Entity
or	CCONJ	O	O
(	PUNCT	O	O
+	SYM	O	O
/-)-SM	PROPN	O	B-Entity
21	NUM	O	I-Entity
significantly	ADV	O	O
attenuated	VERB	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
and	CCONJ	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
lethality	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
administered	VERB	O	O
alone	ADV	O	O
,	PUNCT	O	O
(	PUNCT	O	O
+	CCONJ	O	O
/-)-SM	PROPN	O	B-Entity
21	NUM	O	I-Entity
produced	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
effects	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
control	NOUN	O	O
injections	NOUN	O	O
of	ADP	O	O
saline	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
UMB24	PROPN	O	I-Entity
had	VERB	O	O
locomotor	NOUN	O	O
depressant	NOUN	O	O
actions	NOUN	O	O
.	PUNCT	O	O

Together	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
sigma2	ADJ	O	O
receptor	NOUN	O	O
antagonists	NOUN	O	O
have	VERB	O	O
the	DET	O	O
potential	NOUN	O	O
to	PART	O	O
attenuate	VERB	O	O
some	DET	O	O
of	ADP	O	O
the	DET	O	O
behavioral	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
further	ADJ	O	O
development	NOUN	O	O
of	ADP	O	O
more	ADV	O	O
selective	ADJ	O	O
,	PUNCT	O	O
high	ADJ	O	O
affinity	NOUN	O	O
ligands	NOUN	O	O
are	VERB	O	O
warranted	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (14982270)

Methimazole	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cholestatic	NOUN	O	B-Entity
jaundice	NOUN	O	I-Entity
.	PUNCT	O	O

Methimazole	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
widely	ADV	O	O
used	VERB	O	O
and	CCONJ	O	O
generally	ADV	O	O
well	ADV	O	O
-	PUNCT	O	O
tolerated	VERB	O	O
antithyroid	ADJ	O	O
agent	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
43-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
had	VERB	O	O
severe	ADJ	O	O
jaundice	ADV	O	I-Entity
and	CCONJ	O	O
itching	VERB	O	I-Entity
1	NUM	O	O
month	NOUN	O	O
after	ADP	O	O
receiving	VERB	O	O
methimazole	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
tid	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
propranolol	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O
tid	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
hyperthyroidism	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
continued	VERB	O	O
treatment	NOUN	O	O
for	ADP	O	O
another	DET	O	O
4	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
the	DET	O	O
appearance	NOUN	O	O
of	ADP	O	O
jaundice	NOUN	O	I-Entity
until	ADP	O	O
she	PRON	O	O
finished	VERB	O	O
both	DET	O	O
medications	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
seen	VERB	O	O
at	ADP	O	O
the	DET	O	O
emergency	NOUN	O	O
department	NOUN	O	O
2	NUM	O	O
weeks	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
she	PRON	O	O
still	ADV	O	O
had	VERB	O	O
severe	ADJ	O	O
icterus	NOUN	O	I-Entity
,	PUNCT	O	O
pruritus	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hyperbilirubinemia	NOUN	O	I-Entity
,	PUNCT	O	O
formed	VERB	O	O
mainly	ADV	O	O
of	ADP	O	O
the	DET	O	O
conjugated	VERB	O	O
fraction	NOUN	O	O
.	PUNCT	O	O

Methimazole	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cholestasis	NOUN	O	I-Entity
was	VERB	O	O
diagnosed	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
propranolol	NOUN	O	I-Entity
therapy	NOUN	O	O
was	VERB	O	O
resumed	VERB	O	O
.	PUNCT	O	O

Over	ADP	O	O
the	DET	O	O
following	VERB	O	O
9	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
symptoms	NOUN	O	O
improved	VERB	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
bilirubin	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
normal	ADJ	O	O
after	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
without	ADP	O	O
methimazole	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
rare	ADJ	O	O
cases	NOUN	O	O
within	ADP	O	O
the	DET	O	O
first	ADJ	O	O
few	ADJ	O	O
weeks	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
drug	NOUN	O	O
can	VERB	O	O
cause	VERB	O	O
severe	ADJ	O	O
and	CCONJ	O	O
reversible	ADJ	O	O
cholestatic	NOUN	O	B-Entity
jaundice	NOUN	O	I-Entity
.	PUNCT	O	O

Physicians	NOUN	O	O
and	CCONJ	O	O
patients	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
this	DET	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
so	ADP	O	O
that	ADP	O	O
,	PUNCT	O	O
upon	ADP	O	O
occurrence	NOUN	O	O
,	PUNCT	O	O
they	PRON	O	O
can	VERB	O	O
discontinue	VERB	O	O
methimazole	NOUN	O	I-Entity
therapy	NOUN	O	O
and	CCONJ	O	O
avoid	VERB	O	O
unnecessary	ADJ	O	O
invasive	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12911170)

Ciprofloxacin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
and	CCONJ	O	O
autoimmune	ADJ	O	B-Entity
hemolytic	ADJ	O	I-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

Ciprofloxacin	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
several	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
including	VERB	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
and	CCONJ	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
report	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
describe	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
ciprofloxacin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
and	CCONJ	O	O
autoimmune	ADJ	O	B-Entity
hemolytic	ADJ	O	I-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

Hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
improved	VERB	O	O
after	ADP	O	O
stopping	VERB	O	O
the	DET	O	O
drug	NOUN	O	O
and	CCONJ	O	O
initiation	NOUN	O	O
of	ADP	O	O
steroid	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Unfortunately	ADV	O	O
,	PUNCT	O	O
acute	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
was	VERB	O	O
irreversible	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
end	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
stage	NOUN	O	I-Entity
renal	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11195262)

Contribution	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	B-Entity
valproate	NOUN	O	I-Entity
to	ADP	O	O
the	DET	O	O
syndrome	NOUN	O	B-Entity
of	ADP	O	I-Entity
inappropriate	ADJ	O	I-Entity
secretion	NOUN	O	I-Entity
of	ADP	O	I-Entity
antidiuretic	ADJ	O	I-Entity
hormone	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
62-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
sodium	NOUN	O	B-Entity
valproate	NOUN	O	I-Entity
(	PUNCT	O	O
VPA	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
who	NOUN	O	O
subsequently	ADV	O	O
developed	VERB	O	O
the	DET	O	O
syndrome	NOUN	O	B-Entity
of	ADP	O	I-Entity
inappropriate	ADJ	O	I-Entity
secretion	NOUN	O	I-Entity
of	ADP	O	I-Entity
antidiuretic	ADJ	O	I-Entity
hormone	NOUN	O	I-Entity
(	PUNCT	O	O
SIADH	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

He	PRON	O	O
had	VERB	O	O
been	VERB	O	O
taking	VERB	O	O
VPA	PROPN	O	I-Entity
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
idiopathic	NOUN	O	O
generalized	ADJ	O	O
tonic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
clonic	ADJ	O	I-Entity
convulsions	NOUN	O	I-Entity
since	ADP	O	O
he	PRON	O	O
was	VERB	O	O
56	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
.	PUNCT	O	O

After	ADP	O	O
substituting	VERB	O	O
VPA	PROPN	O	I-Entity
with	ADP	O	O
zonisamide	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
serum	NOUN	O	O
sodium	NOUN	O	I-Entity
level	NOUN	O	O
returned	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
consider	VERB	O	O
this	DET	O	O
episode	NOUN	O	O
of	ADP	O	O
SIADH	PROPN	O	I-Entity
to	PART	O	O
be	VERB	O	O
the	DET	O	O
result	NOUN	O	O
of	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
factors	NOUN	O	O
including	VERB	O	O
a	DET	O	O
weakness	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
central	ADJ	O	I-Entity
nervous	ADJ	O	I-Entity
system	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
administration	NOUN	O	O
of	ADP	O	O
VPA	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10728962)

Vasopressin	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
milrinone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
in	ADP	O	O
severe	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
phosphodiesterase	NOUN	O	O
inhibitors	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
milrinone	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
is	VERB	O	O
frequently	ADV	O	O
restricted	VERB	O	O
because	ADP	O	O
they	PRON	O	O
cause	VERB	O	O
vasodilation	NOUN	O	O
and	CCONJ	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
decompensated	ADJ	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
with	ADP	O	O
hypotension	NOUN	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
milrinone	NOUN	O	I-Entity
,	PUNCT	O	O
low	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
vasopressin	NOUN	O	I-Entity
restored	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
without	ADP	O	O
inhibiting	VERB	O	O
the	DET	O	O
inotropic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
milrinone	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7647582)

Halogenated	ADJ	O	O
anesthetics	NOUN	O	O
form	NOUN	O	O
liver	NOUN	O	O
adducts	NOUN	O	O
and	CCONJ	O	O
antigens	NOUN	O	O
that	ADJ	O	O
cross	VERB	O	O
-	PUNCT	O	O
react	VERB	O	O
with	ADP	O	O
halothane	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
antibodies	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
halogenated	ADJ	O	O
anesthetics	NOUN	O	O
,	PUNCT	O	O
enflurane	NOUN	O	I-Entity
and	CCONJ	O	O
isoflurane	NOUN	O	I-Entity
,	PUNCT	O	O
have	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
allergic	ADJ	O	O
-	PUNCT	O	O
type	NOUN	O	O
hepatic	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
both	DET	O	O
alone	ADV	O	O
and	CCONJ	O	O
following	VERB	O	O
previous	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
halothane	NOUN	O	I-Entity
.	PUNCT	O	O

Halothane	PROPN	O	I-Entity
hepatitis	NOUN	O	I-Entity
appears	VERB	O	O
to	PART	O	O
involve	VERB	O	O
an	DET	O	O
aberrant	ADJ	O	O
immune	ADJ	O	O
response	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
antibody	NOUN	O	O
response	NOUN	O	O
to	ADP	O	O
a	DET	O	O
protein	NOUN	O	O
-	PUNCT	O	O
bound	VERB	O	O
biotransformation	NOUN	O	O
product	NOUN	O	O
(	PUNCT	O	O
trifluoroacetyl	X	O	I-Entity
adduct	NOUN	O	O
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
detected	VERB	O	O
on	ADP	O	O
halothane	NOUN	O	I-Entity
hepatitis	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
to	PART	O	O
determine	VERB	O	O
cross	NOUN	O	O
-	PUNCT	O	O
reactivity	NOUN	O	O
between	ADP	O	O
enflurane	NOUN	O	I-Entity
and	CCONJ	O	O
isoflurane	NOUN	O	I-Entity
with	ADP	O	O
the	DET	O	O
hypersensitivity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
halothane	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
subcellular	ADJ	O	O
and	CCONJ	O	O
lobular	ADJ	O	O
production	NOUN	O	O
of	ADP	O	O
hepatic	NOUN	O	O
neoantigens	NOUN	O	O
recognized	VERB	O	O
by	ADP	O	O
halothane	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
antibodies	NOUN	O	O
following	VERB	O	O
enflurane	NOUN	O	I-Entity
and	CCONJ	O	O
isoflurane	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
biochemical	ADJ	O	O
nature	NOUN	O	O
of	ADP	O	O
these	DET	O	O
neoantigens	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
two	NUM	O	O
animal	NOUN	O	O
models	NOUN	O	O
.	PUNCT	O	O

Enflurane	PROPN	O	I-Entity
administration	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
neoantigens	NOUN	O	O
detected	VERB	O	O
in	ADP	O	O
both	DET	O	O
the	DET	O	O
microsomal	ADJ	O	O
and	CCONJ	O	O
cytosolic	ADJ	O	O
fraction	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	O
homogenates	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
centrilobular	ADJ	O	O
region	NOUN	O	O
of	ADP	O	O
the	DET	O	O
liver	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
supports	VERB	O	O
and	CCONJ	O	O
extends	VERB	O	O
previous	ADJ	O	O
evidence	NOUN	O	O
for	ADP	O	O
a	DET	O	O
mechanism	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
enflurane	NOUN	O	I-Entity
and/or	CCONJ	O	O
isoflurane	NOUN	O	I-Entity
could	VERB	O	O
produce	VERB	O	O
a	DET	O	O
hypersensitivity	ADJ	O	I-Entity
condition	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
halothane	NOUN	O	I-Entity
hepatitis	NOUN	O	I-Entity
either	ADV	O	O
alone	ADV	O	O
or	CCONJ	O	O
subsequent	ADJ	O	O
to	ADP	O	O
halothane	VERB	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (4090988)

Induction	NOUN	O	O
by	ADP	O	O
paracetamol	NOUN	O	I-Entity
of	ADP	O	O
bladder	NOUN	O	B-Entity
and	CCONJ	O	I-Entity
liver	NOUN	O	I-Entity
tumours	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Groups	NOUN	O	O
of	ADP	O	O
male	ADJ	O	O
and	CCONJ	O	O
female	ADJ	O	O
inbred	ADJ	O	O
Leeds	PROPN	O	O
strain	NOUN	O	O
rats	NOUN	O	O
were	VERB	O	O
fed	VERB	O	O
diets	NOUN	O	O
containing	VERB	O	O
either	CCONJ	O	O
0.5%	NUM	O	O
or	CCONJ	O	O
1.0%	NUM	O	O
paracetamol	NOUN	O	I-Entity
by	ADP	O	O
weight	NOUN	O	O
for	ADP	O	O
up	ADP	O	O
to	PART	O	O
18	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Papillomas	PROPN	O	I-Entity
of	ADP	O	O
the	DET	O	O
transitional	ADJ	O	O
epithelium	NOUN	O	O
of	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
developed	VERB	O	O
in	ADP	O	O
all	DET	O	O
paracetamol	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
groups	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
three	NUM	O	O
rats	NOUN	O	O
bore	VERB	O	O
bladder	NOUN	O	B-Entity
carcinomas	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
significant	ADJ	O	O
yields	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	B-Entity
tumours	NOUN	O	I-Entity
were	VERB	O	O
only	ADV	O	O
obtained	VERB	O	O
from	ADP	O	O
low	ADJ	O	O
dosage	NOUN	O	O
females	NOUN	O	O
and	CCONJ	O	O
high	ADJ	O	O
dosage	NOUN	O	O
males	NOUN	O	O
.	PUNCT	O	O

Additionally	ADV	O	O
,	PUNCT	O	O
20	NUM	O	O
to	PART	O	O
25%	NUM	O	O
of	ADP	O	O
paracetamol	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
developed	VERB	O	O
hyperplasia	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
epithelium	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
not	ADV	O	O
coincident	ADJ	O	O
with	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	B-Entity
calculi	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
low	ADJ	O	O
yield	NOUN	O	O
of	ADP	O	O
tumours	NOUN	O	I-Entity
at	ADP	O	O
various	ADJ	O	O
other	ADJ	O	O
sites	NOUN	O	O
also	ADV	O	O
arose	VERB	O	O
following	VERB	O	O
paracetamol	NOUN	O	I-Entity
feeding	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
electron	NOUN	O	O
microscope	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
livers	NOUN	O	O
of	ADP	O	O
paracetamol	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
revealed	VERB	O	O
ultrastructural	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hepatocytes	NOUN	O	O
that	ADJ	O	O
resemble	VERB	O	O
those	DET	O	O
that	ADJ	O	O
result	VERB	O	O
from	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
known	VERB	O	O
hepatocarcinogens	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (4038130)

Local	ADJ	O	O
anesthetics	NOUN	O	O
that	ADJ	O	O
are	VERB	O	O
commonly	ADV	O	O
used	VERB	O	O
in	ADP	O	O
ophthalmic	ADJ	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
0.75%	NUM	O	O
bupivacaine	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
,	PUNCT	O	O
2.0%	NUM	O	O
mepivacaine	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
2.0%	NUM	O	O
lidocaine	NOUN	O	B-Entity
hydrochloride	NOUN	O	I-Entity
plus	CCONJ	O	O
1:100,000	NUM	O	O
epinephrine	NOUN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
injected	VERB	O	O
into	ADP	O	O
the	DET	O	O
retrobulbar	NOUN	O	O
area	NOUN	O	O
of	ADP	O	O
rat	NOUN	O	O
eyes	NOUN	O	O
.	PUNCT	O	O

Muscle	PROPN	O	B-Entity
degeneration	NOUN	O	I-Entity
is	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
regeneration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
damaged	VERB	O	O
muscle	NOUN	O	O
fibers	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
muscle	NOUN	O	B-Entity
damage	NOUN	O	I-Entity
,	PUNCT	O	O
severe	ADJ	O	O
damage	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
seen	VERB	O	O
in	ADP	O	O
harderian	ADJ	O	O
glands	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
after	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
mepivacaine	VERB	O	I-Entity
and	CCONJ	O	O
lidocaine	VERB	O	I-Entity
plus	CCONJ	O	O
epinephrine	VERB	O	I-Entity
.	PUNCT	O	O

With	ADP	O	O
these	DET	O	O
findings	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
hypothesized	VERB	O	O
that	ADP	O	O
the	DET	O	O
temporary	ADJ	O	O
diplopia	NOUN	O	I-Entity
sometimes	ADV	O	O
seen	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
after	ADP	O	O
ophthalmic	ADJ	O	O
surgery	NOUN	O	O
might	VERB	O	O
be	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
anesthetic	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
damage	NOUN	O	O
to	ADP	O	O
the	DET	O	O
extraocular	ADJ	O	O
muscles	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2907585)

Reversal	NOUN	O	O
of	ADP	O	O
neuroleptic	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
by	ADP	O	O
novel	NOUN	O	O
aryl	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
piperazine	NOUN	O	I-Entity
anxiolytic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
novel	NOUN	O	O
anxiolytic	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
buspirone	NOUN	O	I-Entity
,	PUNCT	O	O
reverses	VERB	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
haloperidol	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
series	NOUN	O	O
of	ADP	O	O
aryl	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
piperazine	NOUN	O	I-Entity
analogues	NOUN	O	O
of	ADP	O	O
buspirone	NOUN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
5-hydroxytryptaminergic	ADJ	O	B-Entity
agonists	NOUN	O	I-Entity
were	VERB	O	O
tested	VERB	O	O
for	ADP	O	O
their	ADJ	O	O
ability	NOUN	O	O
to	PART	O	O
reverse	VERB	O	O
haloperidol	NOUN	O	I-Entity
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
.	PUNCT	O	O

Those	DET	O	O
drugs	NOUN	O	O
with	ADP	O	O
strong	ADJ	O	O
affinity	NOUN	O	O
for	ADP	O	O
5-hydroxytryptamine1a	NUM	O	I-Entity
receptors	NOUN	O	O
were	VERB	O	O
able	ADJ	O	O
to	PART	O	O
reverse	VERB	O	O
catalepsy	NOUN	O	I-Entity
.	PUNCT	O	O

Drugs	NOUN	O	O
with	ADP	O	O
affinity	NOUN	O	O
for	ADP	O	O
other	ADJ	O	O
5-HT	ADJ	O	I-Entity
receptors	NOUN	O	O
or	CCONJ	O	O
weak	ADJ	O	O
affinity	NOUN	O	O
were	VERB	O	O
ineffective	ADJ	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
inhibition	NOUN	O	O
of	ADP	O	O
postsynaptic	ADJ	O	O
5-HT	NUM	O	I-Entity
receptors	NOUN	O	O
neither	CCONJ	O	O
inhibited	VERB	O	O
nor	CCONJ	O	O
potentiated	VERB	O	O
reversal	NOUN	O	O
of	ADP	O	O
catalepsy	NOUN	O	I-Entity
and	CCONJ	O	O
leaves	VERB	O	O
open	VERB	O	O
the	DET	O	O
question	NOUN	O	O
as	ADP	O	O
to	ADP	O	O
the	DET	O	O
site	NOUN	O	O
or	CCONJ	O	O
mechanism	NOUN	O	O
for	ADP	O	O
this	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2894433)

Diazepam	PROPN	O	I-Entity
facilitates	VERB	O	O
reflex	NOUN	O	O
bradycardia	NOUN	O	I-Entity
in	ADP	O	O
conscious	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
diazepam	NOUN	O	I-Entity
on	ADP	O	O
cardiovascular	ADJ	O	O
function	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
conscious	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
diazepam	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
-	SYM	O	O
30	NUM	O	O
mg	NUM	O	O
kg-1	NOUN	O	O
)	PUNCT	O	O
produced	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
mean	ADJ	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
reflex	NOUN	O	O
bradycardia	NOUN	O	I-Entity
was	VERB	O	O
produced	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
by	ADP	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
adrenaline	NOUN	O	I-Entity
(	PUNCT	O	O
1.25	NUM	O	O
-	SYM	O	O
2.5	NUM	O	O
micrograms	NOUN	O	O
kg-1	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Intravenous	ADJ	O	O
pretreatment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rats	NOUN	O	O
with	ADP	O	O
diazepam	NOUN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
causing	VERB	O	O
no	DET	O	O
change	NOUN	O	O
in	ADP	O	O
the	DET	O	O
adrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
pressor	NOUN	O	O
effect	NOUN	O	O
,	PUNCT	O	O
did	VERB	O	O
enhance	VERB	O	O
the	DET	O	O
adrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
reflex	NOUN	O	O
bradycardia	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
diazepam	NOUN	O	I-Entity
enhancement	NOUN	O	O
of	ADP	O	O
adrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
reflex	NOUN	O	O
bradycardia	NOUN	O	I-Entity
was	VERB	O	O
antagonized	VERB	O	O
by	ADP	O	O
pretreatment	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
an	DET	O	O
intravenous	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
picrotoxin	NOUN	O	I-Entity
(	PUNCT	O	O
an	DET	O	O
agent	NOUN	O	O
blocks	NOUN	O	O
chloride	NOUN	O	I-Entity
channels	NOUN	O	O
by	ADP	O	O
binding	VERB	O	O
to	ADP	O	O
sites	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
benzodiazepine	NOUN	O	I-Entity
-	PUNCT	O	O
GABA	PROPN	O	I-Entity
-	PUNCT	O	O
chloride	NOUN	O	I-Entity
channel	NOUN	O	O
macromolecular	ADV	O	O
complex	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
diazepam	NOUN	O	I-Entity
acts	VERB	O	O
through	ADP	O	O
the	DET	O	O
benzodiazepine	NOUN	O	I-Entity
-	PUNCT	O	O
GABA	PROPN	O	I-Entity
-	PUNCT	O	O
chloride	NOUN	O	I-Entity
channel	NOUN	O	O
macromolecular	ADV	O	O
complex	NOUN	O	O
within	ADP	O	O
the	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
to	PART	O	O
facilitate	VERB	O	O
reflex	NOUN	O	O
bradycardia	NOUN	O	I-Entity
mediated	VERB	O	O
through	ADP	O	O
baroreceptor	NOUN	O	O
reflexes	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
an	DET	O	O
acute	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
arterial	ADJ	O	O
pressure	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2790457)

Chronic	ADJ	O	O
carbamazepine	NOUN	O	I-Entity
inhibits	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
local	ADJ	O	O
anesthetic	NOUN	O	O
seizures	NOUN	O	I-Entity
kindled	VERB	O	O
by	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
lidocaine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
carbamazepine	NOUN	O	I-Entity
(	PUNCT	O	O
CBZ	PROPN	O	I-Entity
)	PUNCT	O	O
treatment	NOUN	O	O
on	ADP	O	O
local	ADJ	O	O
anesthetic	NOUN	O	O
-	PUNCT	O	O
kindled	VERB	O	O
seizures	NOUN	O	I-Entity
and	CCONJ	O	O
lethality	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
different	ADJ	O	O
stages	NOUN	O	O
of	ADP	O	O
the	DET	O	O
kindling	VERB	O	O
process	NOUN	O	O
and	CCONJ	O	O
under	ADP	O	O
different	ADJ	O	O
methods	NOUN	O	O
of	ADP	O	O
CBZ	PROPN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Chronic	ADJ	O	O
oral	ADJ	O	O
CBZ	PROPN	O	I-Entity
inhibited	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
both	CCONJ	O	O
lidocaine-	X	O	I-Entity
and	CCONJ	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
had	VERB	O	O
little	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
fully	ADV	O	O
developed	VERB	O	O
local	ADJ	O	O
anesthetic	NOUN	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Chronic	ADJ	O	O
CBZ	PROPN	O	I-Entity
also	ADV	O	O
decreased	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
mortality	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
injected	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Acute	PROPN	O	O
CBZ	PROPN	O	I-Entity
over	ADP	O	O
a	DET	O	O
range	NOUN	O	O
of	ADP	O	O
doses	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
-	SYM	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	INTJ	O	O
)	PUNCT	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
completed	VERB	O	O
lidocaine	NOUN	O	I-Entity
-	PUNCT	O	O
kindled	VERB	O	O
or	CCONJ	O	O
acute	ADJ	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

injection	NOUN	O	O
of	ADP	O	O
CBZ	PROPN	O	I-Entity
(	PUNCT	O	O
15	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
also	ADV	O	O
was	VERB	O	O
without	ADP	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
lidocaine-	ADJ	O	I-Entity
or	CCONJ	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
kindled	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
differential	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
CBZ	PROPN	O	I-Entity
depending	VERB	O	O
upon	ADP	O	O
stage	NOUN	O	O
of	ADP	O	O
seizure	NOUN	O	I-Entity
development	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
distinct	ADJ	O	O
mechanisms	NOUN	O	O
underlie	VERB	O	O
the	DET	O	O
development	NOUN	O	O
versus	ADP	O	O
maintenance	NOUN	O	O
of	ADP	O	O
local	ADJ	O	O
anesthetic	NOUN	O	O
-	PUNCT	O	O
kindled	VERB	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
but	CCONJ	O	O
not	ADV	O	O
repeated	VERB	O	O
,	PUNCT	O	O
intermittent	ADJ	O	O
injections	NOUN	O	O
of	ADP	O	O
CBZ	PROPN	O	I-Entity
suggests	VERB	O	O
that	ADP	O	O
different	ADJ	O	O
biochemical	ADJ	O	O
consequences	NOUN	O	O
result	VERB	O	O
from	ADP	O	O
the	DET	O	O
different	ADJ	O	O
treatment	NOUN	O	O
regimens	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
utility	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
CBZ	NOUN	O	I-Entity
in	ADP	O	O
preventing	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
toxic	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
in	ADP	O	O
human	ADJ	O	O
cocaine	NOUN	O	I-Entity
users	NOUN	O	O
is	VERB	O	O
suggested	VERB	O	O
by	ADP	O	O
these	DET	O	O
data	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
remains	VERB	O	O
to	PART	O	O
be	VERB	O	O
directly	ADV	O	O
evaluated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (2334179)

D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
localized	VERB	O	B-Entity
scleroderma	NOUN	O	I-Entity
.	PUNCT	O	O

Localized	VERB	O	B-Entity
scleroderma	NOUN	O	I-Entity
has	VERB	O	O
no	DET	O	O
recognized	VERB	O	O
internal	ADJ	O	O
organ	NOUN	O	O
involvement	NOUN	O	O
but	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
disfiguring	VERB	O	O
and	CCONJ	O	O
disabling	VERB	O	O
when	ADV	O	O
the	DET	O	O
cutaneous	ADJ	O	O
lesions	NOUN	O	O
are	VERB	O	O
extensive	ADJ	O	O
or	CCONJ	O	O
affect	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
no	DET	O	O
accepted	VERB	O	O
or	CCONJ	O	O
proven	VERB	O	O
treatment	NOUN	O	O
for	ADP	O	O
localized	ADJ	O	B-Entity
scleroderma	NOUN	O	I-Entity
.	PUNCT	O	O

Case	NOUN	O	O
reports	NOUN	O	O
of	ADP	O	O
11	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
,	PUNCT	O	O
extensive	ADJ	O	O
localized	ADJ	O	B-Entity
scleroderma	NOUN	O	I-Entity
who	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
are	VERB	O	O
summarized	VERB	O	O
in	ADP	O	O
this	DET	O	O
article	NOUN	O	O
.	PUNCT	O	O

Joint	ADJ	O	O
stiffness	NOUN	O	O
and	CCONJ	O	O
contractures	NOUN	O	I-Entity
also	ADV	O	O
improved	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
favorable	ADJ	O	O
response	NOUN	O	O
was	VERB	O	O
as	ADV	O	O
low	ADJ	O	O
as	ADP	O	O
2	NUM	O	O
to	PART	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
given	VERB	O	O
over	ADP	O	O
a	DET	O	O
period	NOUN	O	O
ranging	VERB	O	O
from	ADP	O	O
15	NUM	O	O
to	ADP	O	O
53	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
Penicillamine	PROPN	O	I-Entity
caused	VERB	O	O
nephrotic	ADJ	O	B-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
and	CCONJ	O	O
milder	ADJ	O	O
reversible	ADJ	O	O
proteinuria	NOUN	O	I-Entity
in	ADP	O	O
3	NUM	O	O
other	ADJ	O	O
patients	NOUN	O	O
;	PUNCT	O	O
none	NOUN	O	O
developed	VERB	O	O
renal	ADJ	O	B-Entity
insufficiency	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
severe	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
localized	VERB	O	B-Entity
scleroderma	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1969772)

Preservation	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
during	ADP	O	O
hypotension	NOUN	O	I-Entity
induced	VERB	O	O
with	ADP	O	O
fenoldopam	NOUN	O	I-Entity
in	ADP	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
introduction	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
that	ADJ	O	O
could	VERB	O	O
induce	VERB	O	O
hypotension	NOUN	O	I-Entity
with	ADP	O	O
different	ADJ	O	O
pharmacological	ADJ	O	O
actions	NOUN	O	O
would	VERB	O	O
be	VERB	O	O
advantageous	ADJ	O	O
because	ADP	O	O
side	ADJ	O	O
effects	NOUN	O	O
unique	ADJ	O	O
to	ADP	O	O
a	DET	O	O
specific	ADJ	O	O
drug	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
minimized	VERB	O	O
by	ADP	O	O
selecting	VERB	O	O
appropriate	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Specific	ADJ	O	O
dopamine-1	NOUN	O	I-Entity
,	PUNCT	O	O
(	PUNCT	O	O
DA1	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
dopamine-2	NOUN	O	I-Entity
(	PUNCT	O	O
DA2	PROPN	O	I-Entity
)	PUNCT	O	O

Fenoldopam	PROPN	O	B-Entity
mesylate	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
specific	ADJ	O	O
DA1	PROPN	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
that	ADJ	O	O
lowers	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
by	ADP	O	O
vasodilatation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
fenoldopam	NOUN	O	I-Entity
could	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
induce	VERB	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
preserve	VERB	O	O
blood	NOUN	O	O
flow	NOUN	O	O
to	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
was	VERB	O	O
tested	VERB	O	O
.	PUNCT	O	O

Systemic	ADJ	O	O
aortic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
renal	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
continuously	ADV	O	O
with	ADP	O	O
a	DET	O	O
carotid	ADJ	O	O
arterial	NOUN	O	O
catheter	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
electromagnetic	ADJ	O	O
flow	NOUN	O	O
probe	NOUN	O	O
respectively	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
compare	VERB	O	O
the	DET	O	O
cardiovascular	NOUN	O	O
and	CCONJ	O	O
renal	ADJ	O	O
vascular	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
fenoldopam	NOUN	O	I-Entity
and	CCONJ	O	O
sodium	NOUN	O	I-Entity
nitroprusside	ADV	O	I-Entity
in	ADP	O	O
ten	NUM	O	O
dogs	NOUN	O	O
under	ADP	O	O
halothane	NOUN	O	I-Entity
general	ADJ	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

8	NUM	O	O
per	NOUN	O	O
cent	NOUN	O	O
from	ADP	O	O
control	NOUN	O	O
with	ADP	O	O
infusion	NOUN	O	O
of	ADP	O	O
fenoldopam	NOUN	O	I-Entity
(	PUNCT	O	O
3.4	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

4	NUM	O	O
per	ADP	O	O
cent	NOUN	O	O
with	ADP	O	O
infusion	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	I-Entity
nitroprusside	NOUN	O	I-Entity
(	PUNCT	O	O
5.9	NUM	O	O
micrograms.kg-1.min-1	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
NS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Renal	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
(	PUNCT	O	O
RBF	PROPN	O	O
)	PUNCT	O	O
increased	VERB	O	O
during	ADP	O	O
fenoldopam	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
11	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

8	NUM	O	O
per	ADP	O	O
cent	NOUN	O	O
during	ADP	O	O
sodium	NOUN	O	I-Entity
nitroprusside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Sodium	NOUN	O	O
nitroprusside	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
selective	ADJ	O	O
arteriolar	NOUN	O	O
and	CCONJ	O	O
venous	ADJ	O	O
vasodilator	NOUN	O	O
that	ADJ	O	O
can	VERB	O	O
produce	VERB	O	O
redistribution	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
flow	VERB	O	O
away	ADV	O	O
from	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
during	ADP	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O

Fenoldopam	PROPN	O	O
is	VERB	O	O
a	DET	O	O
selective	ADJ	O	O
dopamine-1	NOUN	O	I-Entity
(	PUNCT	O	O
DA1	PROPN	O	O
)	PUNCT	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
that	ADJ	O	O
causes	VERB	O	O
vasodilatation	NOUN	O	O
to	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
and	CCONJ	O	O
other	ADJ	O	O
organs	NOUN	O	O
with	ADP	O	O
DA1	NOUN	O	O
receptors	NOUN	O	O
and	CCONJ	O	O
preserves	VERB	O	O
blood	NOUN	O	O
flow	NOUN	O	O
to	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
during	ADP	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1700207)

Antiarrhythmic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
optical	ADJ	O	O
isomers	NOUN	O	O
of	ADP	O	O
cibenzoline	NOUN	O	I-Entity
on	ADP	O	O
canine	ADJ	O	O
ventricular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

Antiarrhythmic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
(	PUNCT	O	O
+	PUNCT	O	O
)	PUNCT	O	O
-cibenzoline	NOUN	O	I-Entity
and	CCONJ	O	O
(	PUNCT	O	O
-)-cibenzoline	PUNCT	O	I-Entity
were	VERB	O	O
examined	VERB	O	O
using	VERB	O	O
two	NUM	O	O
canine	ADJ	O	O
ventricular	ADJ	O	B-Entity
arrhythmia	NOUN	O	I-Entity
models	NOUN	O	O
.	PUNCT	O	O

Digitalis	PROPN	O	I-Entity
arrhythmia	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
suppressed	VERB	O	O
by	ADP	O	O
Na	PROPN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
intermittent	ADJ	O	O
intravenous	ADJ	O	O
(	PUNCT	O	O
i.v	X	O	O
.	PUNCT	O	O
)	PUNCT	O	O

injection	NOUN	O	O
of	ADP	O	O
ouabain	NOUN	O	I-Entity
in	ADP	O	O
pentobarbital	NOUN	O	I-Entity
-	PUNCT	O	O
anesthetized	VERB	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

Adrenaline	NOUN	O	B-Entity
arrhythmia	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
suppressed	VERB	O	O
by	ADP	O	O
Ca	PROPN	O	I-Entity
channel	NOUN	O	O
blockers	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
adrenaline	NOUN	O	I-Entity
infusion	NOUN	O	O
in	ADP	O	O
halothane	NOUN	O	I-Entity
-	PUNCT	O	O
anesthetized	VERB	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

(	PUNCT	O	O
+	PUNCT	O	O
)	PUNCT	O	O
-cibenzoline	PUNCT	O	I-Entity
suppressed	VERB	O	O
digitalis-	NOUN	O	I-Entity
and	CCONJ	O	O
adrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
arrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
minimum	ADJ	O	O
effective	ADJ	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
(	PUNCT	O	O
+	PUNCT	O	O
)	PUNCT	O	O
-cibenzoline	NOUN	O	I-Entity
for	ADP	O	O
digitalis-	NOUN	O	I-Entity
and	CCONJ	O	O
adrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
arrhythmias	NOUN	O	I-Entity
were	VERB	O	O
1.4	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

(	PUNCT	O	O
-)-cibenzoline	PUNCT	O	I-Entity
suppressed	VERB	O	O
the	DET	O	O
digitalis	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
arrhythmia	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

was	VERB	O	O
needed	VERB	O	O
to	PART	O	O
suppress	VERB	O	O
adrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
arrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
minimum	ADJ	O	O
effective	ADJ	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
(	PUNCT	O	O
-)-cibenzoline	PUNCT	O	I-Entity
for	ADP	O	O
digitalis-	NOUN	O	I-Entity
and	CCONJ	O	O
adrenaline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
arrhythmia	NOUN	O	I-Entity
were	VERB	O	O
0.06	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

The	DET	O	O
stronger	ADJ	O	O
antiarrhythmic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
(	PUNCT	O	O
-)-cibenzoline	PROPN	O	I-Entity
indicates	VERB	O	O
that	ADP	O	O
(	PUNCT	O	O
-)-isomer	PUNCT	O	O
may	VERB	O	O
have	VERB	O	O
an	DET	O	O
effect	NOUN	O	O
nearly	ADV	O	O
5	NUM	O	O
-	SYM	O	O
20	NUM	O	O
times	NOUN	O	O
stronger	ADJ	O	O
in	ADP	O	O
suppressing	VERB	O	O
Na	PROPN	O	I-Entity
channels	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
effects	NOUN	O	O
of	ADP	O	O
both	DET	O	O
drugs	NOUN	O	O
on	ADP	O	O
Ca	NOUN	O	I-Entity
channels	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
almost	ADV	O	O
equipotent	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19761039)

Effect	NOUN	O	O
of	ADP	O	O
Hibiscus	PROPN	O	B-Entity
rosa	VERB	O	I-Entity
sinensis	NOUN	O	I-Entity
on	ADP	O	O
reserpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurobehavioral	ADJ	O	O
and	CCONJ	O	O
biochemical	ADJ	O	O
alterations	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Effect	PROPN	O	O
of	ADP	O	O
methanolic	ADJ	O	O
extract	NOUN	O	O
of	ADP	O	O
Hibiscus	PROPN	O	B-Entity
rosa	VERB	O	I-Entity
sinensis	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
-	SYM	O	O
300	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
studied	VERB	O	O
on	ADP	O	O
reserpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
orofacial	ADJ	O	O
dyskinesia	NOUN	O	I-Entity
and	CCONJ	O	O
neurochemical	ADJ	O	O
alterations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
intraperitoneal	ADJ	O	O
reserpine	NOUN	O	I-Entity

Reserpine	PROPN	O	I-Entity
treated	VERB	O	O
rats	NOUN	O	O
significantly	ADV	O	O
developed	VERB	O	O
vacuous	ADJ	O	O
chewing	NOUN	O	O
movements	NOUN	O	O
and	CCONJ	O	O
tongue	NOUN	O	O
protrusions	NOUN	O	O
however	ADV	O	O
,	PUNCT	O	O
coadministration	NOUN	O	O
of	ADP	O	O
Hibiscus	PROPN	O	B-Entity
rosa	VERB	O	I-Entity
sinensis	NOUN	O	I-Entity
roots	NOUN	O	O
extract	VERB	O	O
(	PUNCT	O	O
100	NUM	O	O
,	PUNCT	O	O
200	NUM	O	O
and	CCONJ	O	O
300	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
per	ADP	O	O
orally	ADV	O	O
)	PUNCT	O	O
attenuated	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Biochemical	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
brain	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
the	DET	O	O
reserpine	NOUN	O	I-Entity
treatment	NOUN	O	O
significantly	ADV	O	O
increased	VERB	O	O
lipid	ADJ	O	O
peroxidation	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
superoxide	NOUN	O	I-Entity
dismutase	NOUN	O	O
(	PUNCT	O	O
SOD	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
catalase	NOUN	O	O
(	PUNCT	O	O
CAT	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
glutathione	NOUN	O	I-Entity
reductase	NOUN	O	O
(	PUNCT	O	O
GSH	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
index	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
process	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
Hibiscus	PROPN	O	B-Entity
rosa	VERB	O	I-Entity
sinensis	NOUN	O	I-Entity
had	VERB	O	O
a	DET	O	O
protective	ADJ	O	O
role	NOUN	O	O
against	ADP	O	O
reserpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
orofacial	ADJ	O	O
dyskinesia	NOUN	O	I-Entity
and	CCONJ	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11704023)

Comparison	NOUN	O	O
of	ADP	O	O
aqueous	ADJ	O	O
and	CCONJ	O	O
gellan	ADJ	O	O
ophthalmic	ADJ	O	O
timolol	NOUN	O	I-Entity
with	ADP	O	O
placebo	NOUN	O	O
on	ADP	O	O
the	DET	O	O
24-hour	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
response	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
glaucoma	NOUN	O	I-Entity
.	PUNCT	O	O

Topical	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocker	NOUN	O	O
treatment	NOUN	O	O
is	VERB	O	O
routine	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
glaucoma	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
trial	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
0.5%	NUM	O	O
aqueous	ADJ	O	O
timolol	NOUN	O	I-Entity
(	PUNCT	O	O
timolol	NOUN	O	I-Entity
solution	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
0.5%	NUM	O	O
timolol	NOUN	O	I-Entity
suspension	NOUN	O	O
that	ADJ	O	O
forms	VERB	O	O
a	DET	O	O
gel	NOUN	O	O
on	ADP	O	O
application	NOUN	O	O
to	ADP	O	O
the	DET	O	O
conjunctiva	NOUN	O	O
(	PUNCT	O	O
timolol	NOUN	O	I-Entity
gellan	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
24-hour	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
currently	ADV	O	O
being	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
glaucoma	NOUN	O	I-Entity
to	PART	O	O
quantify	VERB	O	O
the	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
mean	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
:	PUNCT	O	O
Forty	NUM	O	O
-	PUNCT	O	O
three	NUM	O	O
Caucasian	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	O
open	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
angle	NOUN	O	I-Entity
glaucoma	NOUN	O	I-Entity
or	CCONJ	O	O
ocular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
/-SD	PROPN	O	O
)	PUNCT	O	O
age	NOUN	O	O
of	ADP	O	O
63	NUM	O	O
(	PUNCT	O	O
+	SYM	O	O
/-8	PROPN	O	O
)	PUNCT	O	O
years	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
and	CCONJ	O	O
crossed	VERB	O	O
over	PART	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
masked	ADJ	O	O
manner	NOUN	O	O
to	PART	O	O
14	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
morning	NOUN	O	O
and	CCONJ	O	O
evening	NOUN	O	O
in	ADP	O	O
both	DET	O	O
eyes	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
timolol	NOUN	O	I-Entity
solution	NOUN	O	O
(	PUNCT	O	O
morning	NOUN	O	O
and	CCONJ	O	O
evening	NOUN	O	O
in	ADP	O	O
both	DET	O	O
eyes	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
timolol	NOUN	O	I-Entity
gellan	NOUN	O	O
(	PUNCT	O	O
morning	NOUN	O	O
in	ADP	O	O
both	DET	O	O
eyes	NOUN	O	O
with	ADP	O	O
placebo	NOUN	O	O
in	ADP	O	O
the	DET	O	O
evening	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	DET	O	O
timolol	VERB	O	I-Entity
solution	NOUN	O	O
and	CCONJ	O	O
timolol	NOUN	O	I-Entity
gellan	NOUN	O	O
reduced	VERB	O	O
the	DET	O	O
mean	NOUN	O	O
24-hour	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
this	DET	O	O
reduction	NOUN	O	O
was	VERB	O	O
most	ADV	O	O
pronounced	VERB	O	O
during	ADP	O	O
the	DET	O	O
daytime	NOUN	O	O
(	PUNCT	O	O
-7.5%	PROPN	O	O
change	VERB	O	O
in	ADP	O	O
mean	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O

Timolol	PROPN	O	I-Entity
gellan	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
numerically	ADV	O	O
but	CCONJ	O	O
not	ADV	O	O
significantly	ADV	O	O
smaller	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
24-hour	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
timolol	NOUN	O	I-Entity
solution	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
night	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mean	ADJ	O	O
12-hour	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
on	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
timolol	NOUN	O	I-Entity
gellan	NOUN	O	O
were	VERB	O	O
both	DET	O	O
significantly	ADV	O	O
less	ADJ	O	O
than	ADP	O	O
on	ADP	O	O
timolol	DET	O	I-Entity
solution	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
solution	NOUN	O	O
and	CCONJ	O	O
gellan	NOUN	O	O
treatments	NOUN	O	O
was	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Both	DET	O	O
timolol	VERB	O	I-Entity
solution	NOUN	O	O
and	CCONJ	O	O
timolol	NOUN	O	I-Entity
gellan	NOUN	O	O
decrease	VERB	O	O
the	DET	O	O
mean	NOUN	O	O
24-hour	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
quantify	VERB	O	O
the	DET	O	O
modest	ADJ	O	O
bradycardia	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
ophthalmic	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
blocker	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
a	DET	O	O
typical	ADJ	O	O
patient	ADJ	O	O
population	NOUN	O	O
on	ADP	O	O
therapy	NOUN	O	O
for	ADP	O	O
glaucoma	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19300240)

5	NUM	O	B-Entity
flourouracil	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
apical	ADJ	O	B-Entity
ballooning	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
apical	ADJ	O	B-Entity
ballooning	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
(	PUNCT	O	O
ABS	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
recently	ADV	O	O
described	VERB	O	O
stress	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
acute	ADJ	O	B-Entity
cardiac	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
characterized	VERB	O	O
by	ADP	O	O
transient	ADJ	O	O
wall	NOUN	O	O
-	PUNCT	O	O
motion	NOUN	O	O
abnormalities	NOUN	O	O
involving	VERB	O	O
the	DET	O	O
apex	NOUN	O	O
and	CCONJ	O	O
midventricle	NOUN	O	O
with	ADP	O	O
hyperkinesis	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
basal	NOUN	O	O
left	VERB	O	O
ventricular	NOUN	O	O
(	PUNCT	O	O
LV	PROPN	O	O
)	PUNCT	O	O
segments	NOUN	O	O
without	ADP	O	O
obstructive	ADJ	O	O
epicardial	ADJ	O	B-Entity
coronary	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Cardiotoxicity	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
an	DET	O	O
uncommon	ADJ	O	O
adverse	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
chemotherapeutic	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
are	VERB	O	O
no	DET	O	O
reports	NOUN	O	O
of	ADP	O	O
ABS	PROPN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
chemotherapeutic	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
woman	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
the	DET	O	O
syndrome	NOUN	O	O
after	ADP	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
metastatic	NOUN	O	O
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
79-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
presented	VERB	O	O
with	ADP	O	O
typical	ADJ	O	O
ischemic	ADJ	O	I-Entity
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
elevated	ADJ	O	O
cardiac	ADJ	O	O
enzymes	NOUN	O	O
with	ADP	O	O
significant	ADJ	O	O
ST	PROPN	O	O
-	PUNCT	O	O
segment	NOUN	O	O
abnormalities	NOUN	O	O
on	ADP	O	O
her	ADJ	O	O
electrocardiogram	NOUN	O	O
.	PUNCT	O	O

She	PRON	O	O
underwent	VERB	O	O
recent	ADJ	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
fluorouracil	NOUN	O	I-Entity
for	ADP	O	O
metastatic	ADJ	O	O
colorectal	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Echocardiography	PROPN	O	O
revealed	VERB	O	O
a	DET	O	O
wall	NOUN	O	O
-	PUNCT	O	O
motion	NOUN	O	O
abnormality	NOUN	O	O
involving	VERB	O	O
the	DET	O	O
apical	ADJ	O	O
and	CCONJ	O	O
periapical	ADJ	O	O
segments	NOUN	O	O
which	ADJ	O	O
appeared	VERB	O	O
akinetic	ADJ	O	I-Entity
.	PUNCT	O	O

Echocardiogram	PROPN	O	O
revealed	VERB	O	O
a	DET	O	O
normal	ADJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
resolution	NOUN	O	O
of	ADP	O	O
the	DET	O	O
apical	ADJ	O	O
akinesis	NOUN	O	I-Entity
.	PUNCT	O	O

Pathogenetic	ADJ	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
in	ADP	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
undergoing	VERB	O	O
chemotherapy	NOUN	O	O
include	VERB	O	O
coronary	ADJ	O	B-Entity
vasospasm	NOUN	O	I-Entity
,	PUNCT	O	O
endothelial	ADJ	O	O
damage	NOUN	O	O
and	CCONJ	O	O
consequent	ADJ	O	O
thrombus	NOUN	O	I-Entity
formation	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
our	ADJ	O	O
patient	NOUN	O	O
,	PUNCT	O	O
both	DET	O	O
supraphysiologic	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
catecholamines	NOUN	O	I-Entity
and	CCONJ	O	O
stress	NOUN	O	O
related	VERB	O	O
neuropeptides	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
cancer	NOUN	O	I-Entity
diagnosis	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
chemotherapy	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
contributed	VERB	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
ABS	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (18006530)

Reduction	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
during	ADP	O	O
induction	NOUN	O	O
with	ADP	O	O
target	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
propofol	NOUN	O	I-Entity
and	CCONJ	O	O
remifentanil	NOUN	O	I-Entity
.	PUNCT	O	O

Pain	PROPN	O	I-Entity
on	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
is	VERB	O	O
unpleasant	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
propofol	ADJ	O	I-Entity
infusion	NOUN	O	O
pain	NOUN	O	I-Entity
might	VERB	O	O
be	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
infusing	VERB	O	O
remifentanil	NOUN	O	I-Entity
before	ADP	O	O
starting	VERB	O	O
the	DET	O	O
propofol	NOUN	O	I-Entity
infusion	NOUN	O	O
in	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
setting	NOUN	O	O
where	ADV	O	O
target	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
infusions	NOUN	O	O
(	PUNCT	O	O
TCI	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
both	DET	O	O
drugs	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
to	PART	O	O
determine	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
-	PUNCT	O	O
site	NOUN	O	O
concentration	NOUN	O	O
(	PUNCT	O	O
Ce	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
remifentanil	NOUN	O	I-Entity
to	PART	O	O
prevent	VERB	O	O
the	DET	O	O
pain	NOUN	O	I-Entity
without	ADP	O	O
producing	VERB	O	O
complications	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
128	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
general	ADJ	O	O
surgery	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	PART	O	O
receive	VERB	O	O
normal	ADJ	O	O
saline	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
remifentanil	NOUN	O	I-Entity
to	ADP	O	O
a	DET	O	O
target	NOUN	O	O
Ce	PROPN	O	O
of	ADP	O	O
2	NUM	O	O
ng	ADP	O	O
ml(-1	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
R2	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
4	NUM	O	O
ng	INTJ	O	O
ml(-1	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
R4	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
6	NUM	O	O
ng	INTJ	O	O
ml(-1	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
R6	NOUN	O	O
)	PUNCT	O	O
administered	VERB	O	O
via	ADP	O	O
TCI	PROPN	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
target	NOUN	O	O
Ce	PROPN	O	O
was	VERB	O	O
achieved	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
was	VERB	O	O
started	VERB	O	O
.	PUNCT	O	O

Remifentanil	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
complications	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
during	ADP	O	O
the	DET	O	O
remifentanil	NOUN	O	I-Entity
infusion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
pain	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
propofol	NOUN	O	I-Entity
was	VERB	O	O
evaluated	VERB	O	O
using	VERB	O	O
a	DET	O	O
four	NUM	O	O
-	PUNCT	O	O
point	NOUN	O	O
scale	NOUN	O	O
during	ADP	O	O
the	DET	O	O
propofol	ADJ	O	I-Entity
infusion	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
in	ADP	O	O
Groups	NOUN	O	O
R4	PROPN	O	O
and	CCONJ	O	O
R6	PROPN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
and	CCONJ	O	O
R2	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
12/32	NUM	O	O
and	CCONJ	O	O
6/31	NUM	O	O
vs	ADP	O	O
26/31	NUM	O	O
and	CCONJ	O	O
25/32	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
P<0.001	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Pain	PROPN	O	I-Entity
was	VERB	O	O
less	ADV	O	O
severe	ADJ	O	O
in	ADP	O	O
Groups	NOUN	O	O
R4	PROPN	O	O
and	CCONJ	O	O
R6	PROPN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
and	CCONJ	O	O
R2	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P<0.001	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
both	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
were	VERB	O	O
not	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
Groups	PROPN	O	O
R4	PROPN	O	O
and	CCONJ	O	O
R6	PROPN	O	O
.	PUNCT	O	O

During	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
anaesthesia	NOUN	O	O
with	ADP	O	O
TCI	PROPN	O	O
of	ADP	O	O
propofol	NOUN	O	I-Entity
and	CCONJ	O	O
remifentanil	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
propofol	NOUN	O	I-Entity
infusion	NOUN	O	O
pain	NOUN	O	I-Entity
was	VERB	O	O
achieved	VERB	O	O
without	ADP	O	O
significant	ADJ	O	O
complications	NOUN	O	O
by	ADP	O	O
prior	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
remifentanil	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
target	NOUN	O	O
Ce	PROPN	O	O
of	ADP	O	O
4	NUM	O	O
ng	INTJ	O	O
ml(-1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O


-DOCSTART- (17702969)

Prenatal	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
fluoxetine	NOUN	O	I-Entity
induces	VERB	O	O
fetal	ADJ	O	B-Entity
pulmonary	ADJ	O	I-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Fluoxetine	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
selective	ADJ	O	O
serotonin	NOUN	O	I-Entity
reuptake	NOUN	O	O
inhibitor	NOUN	O	O
antidepressant	NOUN	O	O
widely	ADV	O	O
used	VERB	O	O
by	ADP	O	O
pregnant	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

Epidemiological	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
fluoxetine	ADJ	O	I-Entity
exposure	NOUN	O	O
prenatally	ADV	O	O
increases	VERB	O	O
the	DET	O	O
prevalence	NOUN	O	O
of	ADP	O	O
persistent	ADJ	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
newborn	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
responsible	ADJ	O	O
for	ADP	O	O
this	DET	O	O
effect	NOUN	O	O
is	VERB	O	O
unclear	ADJ	O	O
and	CCONJ	O	O
paradoxical	ADJ	O	O
,	PUNCT	O	O
considering	VERB	O	O
the	DET	O	O
current	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
protective	ADJ	O	O
fluoxetine	NOUN	O	I-Entity
effect	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
rodents	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
fluoxetine	NOUN	O	I-Entity
effect	NOUN	O	O
on	ADP	O	O
fetal	ADJ	O	O
rat	NOUN	O	O
pulmonary	ADJ	O	O
vascular	ADJ	O	O
smooth	ADJ	O	O
muscle	NOUN	O	O
mechanical	ADJ	O	O
properties	NOUN	O	O
and	CCONJ	O	O
cell	NOUN	O	O
proliferation	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

Pregnant	ADJ	O	O
rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
fluoxetine	NOUN	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
from	ADP	O	O
Day	NOUN	O	O
11	NUM	O	O
through	ADP	O	O
Day	PROPN	O	O
21	NUM	O	O
of	ADP	O	O
gestation	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
fluoxetine	ADJ	O	I-Entity
exposure	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
fetal	ADJ	O	B-Entity
pulmonary	ADJ	O	I-Entity
hypertension	NOUN	O	I-Entity
as	ADP	O	O
evidenced	VERB	O	O
by	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
weight	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	O
the	DET	O	O
right	NOUN	O	O
ventricle	NOUN	O	O
to	ADP	O	O
the	DET	O	O
left	NOUN	O	O
ventricle	NOUN	O	O
plus	CCONJ	O	O
septum	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
by	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
pulmonary	ADJ	O	O
arterial	NOUN	O	O
medial	ADJ	O	O
thickness	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Postnatal	ADJ	O	O
mortality	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
among	ADP	O	O
experimental	ADJ	O	O
animals	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
arterial	ADJ	O	O
oxygen	NOUN	O	I-Entity
saturation	NOUN	O	O
was	VERB	O	O
96	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

1%	NUM	O	O
in	ADP	O	O
1-day	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
control	NOUN	O	O
animals	NOUN	O	O
and	CCONJ	O	O
significantly	ADV	O	O
lower	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
fluoxetine	NOUN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
pups	NOUN	O	O
(	PUNCT	O	O
79	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

In	ADP	O	O
vitro	NOUN	O	O
,	PUNCT	O	O
fluoxetine	NOUN	O	I-Entity
induced	VERB	O	O
pulmonary	ADJ	O	O
arterial	NOUN	O	O
muscle	NOUN	O	O
contraction	NOUN	O	O
in	ADP	O	O
fetal	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
adult	NOUN	O	O
,	PUNCT	O	O
animals	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
reduced	VERB	O	O
serotonin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
contraction	NOUN	O	O
at	ADP	O	O
both	DET	O	O
ages	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
in	ADP	O	O
utero	NOUN	O	O
exposure	NOUN	O	O
to	ADP	O	O
a	DET	O	O
low	ADJ	O	O
fluoxetine	NOUN	O	I-Entity
concentration	NOUN	O	O
the	DET	O	O
pulmonary	ADJ	O	O
arterial	NOUN	O	O
smooth	ADJ	O	O
muscle	NOUN	O	O
cell	NOUN	O	O
proliferation	NOUN	O	O
rate	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
in	ADP	O	O
fetal	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
adult	NOUN	O	O
,	PUNCT	O	O
cells	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
to	ADP	O	O
the	DET	O	O
adult	NOUN	O	O
,	PUNCT	O	O
fluoxetine	ADJ	O	I-Entity
exposure	NOUN	O	O
in	ADP	O	O
utero	NOUN	O	O
induces	VERB	O	O
pulmonary	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
fetal	ADJ	O	O
rat	NOUN	O	O
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
a	DET	O	O
developmentally	ADV	O	O
regulated	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
pulmonary	ADJ	O	O
vascular	ADJ	O	O
smooth	ADJ	O	O
muscle	NOUN	O	O
proliferation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17344330)

Syncope	PROPN	O	I-Entity
and	CCONJ	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
among	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
methadone	NOUN	O	I-Entity
for	ADP	O	O
heroin	NOUN	O	I-Entity
dependence	NOUN	O	O
in	ADP	O	O
the	DET	O	O
city	NOUN	O	O
of	ADP	O	O
Copenhagen	PROPN	O	O
.	PUNCT	O	O

Methadone	PROPN	O	I-Entity
is	VERB	O	O
prescribed	VERB	O	O
to	ADP	O	O
heroin	NOUN	O	I-Entity
addicts	NOUN	O	O
to	PART	O	O
decrease	VERB	O	O
illicit	ADJ	O	O
opioid	ADJ	O	O
use	NOUN	O	O
.	PUNCT	O	O

Prolongation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
QT	PROPN	O	O
interval	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ECG	PROPN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
torsade	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	X	O	I-Entity
(	PUNCT	O	O
TdP	PROPN	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
methadone	NOUN	O	I-Entity
users	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
heroin	NOUN	O	I-Entity
addicts	NOUN	O	O
sometimes	ADV	O	O
faint	ADJ	O	O
while	ADP	O	O
using	VERB	O	O
illicit	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
doctors	NOUN	O	O
might	VERB	O	O
attribute	VERB	O	O
too	ADV	O	O
many	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
syncope	NOUN	O	I-Entity
to	ADP	O	O
illicit	ADJ	O	O
drug	NOUN	O	O
use	NOUN	O	O
and	CCONJ	O	O
thereby	ADV	O	O
underestimate	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
TdP	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
special	ADJ	O	O
population	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
high	ADJ	O	O
mortality	NOUN	O	O
in	ADP	O	O
this	DET	O	O
population	NOUN	O	O
may	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
part	NOUN	O	O
,	PUNCT	O	O
be	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
the	DET	O	O
proarrhythmic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
methadone	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
cross	NOUN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
study	NOUN	O	O
interview	NOUN	O	O
,	PUNCT	O	O
ECGs	NOUN	O	O
and	CCONJ	O	O
blood	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
in	ADP	O	O
a	DET	O	O
population	NOUN	O	O
of	ADP	O	O
adult	NOUN	O	O
heroin	NOUN	O	I-Entity
addicts	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
methadone	NOUN	O	I-Entity
or	CCONJ	O	O
buprenorphine	NOUN	O	I-Entity
on	ADP	O	O
a	DET	O	O
daily	ADJ	O	O
basis	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
participants	NOUN	O	O
were	VERB	O	O
interviewed	VERB	O	O
about	ADP	O	O
any	DET	O	O
experience	NOUN	O	O
of	ADP	O	O
syncope	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
association	NOUN	O	O
between	ADP	O	O
opioid	ADJ	O	O
dose	NOUN	O	O
and	CCONJ	O	O
QT	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
methadone	NOUN	O	I-Entity
dose	NOUN	O	O
and	CCONJ	O	O
reporting	NOUN	O	O
of	ADP	O	O
syncope	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
using	VERB	O	O
multivariate	NOUN	O	O
linear	NOUN	O	O
regression	NOUN	O	O
and	CCONJ	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Methadone	PROPN	O	I-Entity
dose	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
longer	ADJ	O	O
QT	PROPN	O	O
interval	NOUN	O	O
of	ADP	O	O
0.140	NUM	O	O
ms	NOUN	O	O
/	SYM	O	O
mg	VERB	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.002	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
association	NOUN	O	O
between	ADP	O	O
buprenorphine	NOUN	O	I-Entity
and	CCONJ	O	O
QTc	PROPN	O	O
was	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

Among	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
methadone	NOUN	O	I-Entity
,	PUNCT	O	O
28%	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
32%	NUM	O	O
women	NOUN	O	O
had	VERB	O	O
prolonged	VERB	O	B-Entity
QTc	PROPN	O	I-Entity
interval	NOUN	O	I-Entity
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
buprenorphine	NOUN	O	I-Entity
had	VERB	O	O
QTc	VERB	O	O
interval	NOUN	O	O
>	X	O	O
0.440	NUM	O	O
s((1/2	NOUN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
50	NUM	O	O
mg	NUM	O	O
higher	ADJ	O	O
methadone	NOUN	O	I-Entity
dose	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
1.2	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
CI	PROPN	O	O
1.1	NUM	O	O
to	ADP	O	O
1.4	NUM	O	O
)	PUNCT	O	O
times	NOUN	O	O
higher	ADJ	O	O
odds	NOUN	O	O
for	ADP	O	O
syncope	NOUN	O	I-Entity
.	PUNCT	O	O

Methadone	PROPN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
and	CCONJ	O	O
higher	ADJ	O	O
reporting	NOUN	O	O
of	ADP	O	O
syncope	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
population	NOUN	O	O
of	ADP	O	O
heroin	NOUN	O	I-Entity
addicts	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16826348)

Peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
cytosine	NOUN	O	B-Entity
arabinoside	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
myeloid	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
central	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
cytosine	NOUN	O	B-Entity
arabinoside	NOUN	O	I-Entity
is	VERB	O	O
well	ADV	O	O
recognized	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
cytosine	NOUN	O	B-Entity
arabinoside	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
infrequently	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
49-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
Japanese	ADJ	O	O
man	NOUN	O	O
was	VERB	O	O
diagnosed	VERB	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
myeloid	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
he	PRON	O	O
achieved	VERB	O	O
complete	ADJ	O	O
remission	NOUN	O	O
,	PUNCT	O	O
he	PRON	O	O
received	VERB	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
cytosine	NOUN	O	B-Entity
arabinoside	NOUN	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
m2	NOUN	O	O
twice	ADV	O	O
a	DET	O	O
day	NOUN	O	O
for	ADP	O	O
5	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
total	ADJ	O	O
,	PUNCT	O	O
20	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
m2	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
consolidation	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
first	ADJ	O	O
course	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
cytosine	NOUN	O	B-Entity
arabinoside	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
no	DET	O	O
unusual	ADJ	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
on	ADP	O	O
day	NOUN	O	O
21	NUM	O	O
of	ADP	O	O
the	DET	O	O
second	ADJ	O	O
course	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
complained	VERB	O	O
of	ADP	O	O
numbness	NOUN	O	I-Entity
in	ADP	O	O
his	ADJ	O	O
right	ADJ	O	O
foot	NOUN	O	O
.	PUNCT	O	O

Electromyogram	PROPN	O	O
and	CCONJ	O	O
nerve	NOUN	O	O
-	PUNCT	O	O
conduction	NOUN	O	O
studies	NOUN	O	O
showed	VERB	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
in	ADP	O	O
both	DET	O	O
peroneal	ADJ	O	O
nerves	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
neuropathy	NOUN	O	I-Entity
was	VERB	O	O
gradually	ADV	O	O
resolving	VERB	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
after	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
received	VERB	O	O
allogeneic	ADJ	O	O
bone	NOUN	O	O
marrow	NOUN	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
symptoms	NOUN	O	O
worsened	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
graft	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
versus	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
host	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
symptoms	NOUN	O	O
subsequently	ADV	O	O
responded	VERB	O	O
to	ADP	O	O
methylprednisolone	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
peripheral	ADJ	O	B-Entity
neuropathy	NOUN	O	I-Entity
are	VERB	O	O
still	ADV	O	O
unclear	ADJ	O	O
,	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
cytosine	NOUN	O	B-Entity
arabinoside	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
therapy	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
potentially	ADV	O	O
toxic	ADJ	O	O
to	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
auto	NOUN	O	O
/	SYM	O	O
alloimmunity	NOUN	O	O
may	VERB	O	O
play	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
these	DET	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16820346)

Atorvastatin	PROPN	O	I-Entity
prevented	VERB	O	O
and	CCONJ	O	O
reversed	VERB	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
assess	VERB	O	O
the	DET	O	O
antioxidant	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
atorvastatin	NOUN	O	I-Entity
(	PUNCT	O	O
atorva	NOUN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
dexamethasone	NOUN	O	I-Entity
(	PUNCT	O	O
dex)-induced	ADJ	O	I-Entity
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
60	NUM	O	O
male	ADJ	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
atorva	DET	O	I-Entity
30	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
or	CCONJ	O	O
tap	VERB	O	O
water	NOUN	O	O
for	ADP	O	O
15	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Dex	PRON	O	I-Entity
increased	VERB	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
SBP	PROPN	O	O
)	PUNCT	O	O
from	ADP	O	O
109	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.6	NUM	O	O
mmHg	PROPN	O	O
and	CCONJ	O	O
plasma	NOUN	O	O
superoxide	NOUN	O	I-Entity
(	PUNCT	O	O
5711	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

392.8	NUM	O	O
U	PROPN	O	O
/	SYM	O	O
ml	PROPN	O	O
dex	NOUN	O	I-Entity
,	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
prevention	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
SBP	PROPN	O	O
in	ADP	O	O
the	DET	O	O
atorva	NOUN	O	I-Entity
+	CCONJ	O	O
dex	NOUN	O	I-Entity
group	NOUN	O	O
was	VERB	O	O
increased	VERB	O	O
from	ADP	O	O
115	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

1.5	NUM	O	O
mmHg	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
this	DET	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	ADJ	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
dex	NOUN	O	I-Entity
-	PUNCT	O	O
only	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O

Atorva	PROPN	O	I-Entity
reversed	VERB	O	O
dex	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
(	PUNCT	O	O
129	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.6	NUM	O	O
mmHg	PROPN	O	O
P	NOUN	O	O
'	PUNCT	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
decreased	VERB	O	O
plasma	NOUN	O	O
superoxide	NOUN	O	I-Entity
(	PUNCT	O	O
7931	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

392.8	NUM	O	O
dex	NOUN	O	I-Entity
,	PUNCT	O	O
1187	NUM	O	O

441.2	NUM	O	O
atorva	NOUN	O	I-Entity
+	SYM	O	O
dex	NOUN	O	I-Entity
,	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Plasma	PROPN	O	O
nitrate	NOUN	O	I-Entity
/	SYM	O	O
nitrite	NOUN	O	I-Entity
(	PUNCT	O	O
NOx	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
decreased	VERB	O	O
in	ADP	O	O
dex	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
saline	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
(	PUNCT	O	O
11.2	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Atorva	PROPN	O	I-Entity
affected	VERB	O	O
neither	CCONJ	O	O
plasma	NOUN	O	O
NOx	NOUN	O	O
nor	CCONJ	O	O
thymus	NOUN	O	O
weight	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
atorvastatin	NOUN	O	I-Entity
prevented	VERB	O	O
and	CCONJ	O	O
reversed	VERB	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15974569)

Two	NUM	O	O
prodrugs	NOUN	O	O
of	ADP	O	O
potent	ADJ	O	O
and	CCONJ	O	O
selective	ADJ	O	O
GluR5	NOUN	O	O
kainate	NOUN	O	I-Entity
receptor	NOUN	O	O
antagonists	NOUN	O	O
actives	VERB	O	O
in	ADP	O	O
three	NUM	O	O
animal	NOUN	O	O
models	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
.	PUNCT	O	O

Amino	ADJ	O	O
acids	NOUN	O	O
5	NUM	O	O
and	CCONJ	O	O
7	NUM	O	O
,	PUNCT	O	O
two	NUM	O	O
potent	ADJ	O	O
and	CCONJ	O	O
selective	ADJ	O	O
competitive	ADJ	O	O
GluR5	NOUN	O	O
KA	PROPN	O	I-Entity
receptor	NOUN	O	O
antagonists	NOUN	O	O
,	PUNCT	O	O
exhibited	VERB	O	O
high	ADJ	O	O
GluR5	ADJ	O	O
receptor	NOUN	O	O
affinity	NOUN	O	O
over	ADP	O	O
other	ADJ	O	O
glutamate	ADJ	O	I-Entity
receptors	NOUN	O	O
.	PUNCT	O	O

Their	ADJ	O	O
ester	NOUN	O	O
prodrugs	NOUN	O	O
6	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
were	VERB	O	O
orally	ADV	O	O
active	ADJ	O	O
in	ADP	O	O
three	NUM	O	O
models	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	I-Entity
:	PUNCT	O	O
reversal	NOUN	O	O
of	ADP	O	O
formalin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
paw	NOUN	O	O
licking	NOUN	O	O
,	PUNCT	O	O
carrageenan	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thermal	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
capsaicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
mechanical	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11583940)

Sirolimus	PROPN	O	I-Entity
and	CCONJ	O	O
mycophenolate	VERB	O	B-Entity
mofetil	NOUN	O	I-Entity
for	ADP	O	O
calcineurin	NOUN	O	O
-	PUNCT	O	O
free	ADJ	O	O
immunosuppression	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
transplant	NOUN	O	O
recipients	NOUN	O	O
.	PUNCT	O	O

Calcineurin	PROPN	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
cyclosporine	NOUN	O	I-Entity
and	CCONJ	O	O
tacrolimus	NOUN	O	I-Entity
,	PUNCT	O	O
have	VERB	O	O
been	VERB	O	O
available	ADJ	O	O
for	ADP	O	O
almost	ADV	O	O
20	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
are	VERB	O	O
highly	ADV	O	O
effective	ADJ	O	O
and	CCONJ	O	O
represent	VERB	O	O
the	DET	O	O
mainstay	NOUN	O	O
of	ADP	O	O
transplant	NOUN	O	O
immunosuppression	NOUN	O	O
,	PUNCT	O	O
they	PRON	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
acute	ADJ	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Acute	PROPN	O	O
nephrotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
occurs	VERB	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
period	NOUN	O	O
after	ADP	O	O
transplantation	NOUN	O	O
,	PUNCT	O	O
leads	VERB	O	O
to	ADP	O	O
a	DET	O	O
higher	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
dialysis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
nephrotoxicity	NOUN	O	I-Entity
may	VERB	O	O
eventually	ADV	O	O
result	VERB	O	O
in	ADP	O	O
graft	NOUN	O	O
loss	NOUN	O	O
.	PUNCT	O	O

Acute	PROPN	O	O
and	CCONJ	O	O
chronic	ADJ	O	O
nephrotoxicity	NOUN	O	I-Entity
is	VERB	O	O
becoming	VERB	O	O
more	ADV	O	O
common	ADJ	O	O
as	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
marginal	ADJ	O	O
kidneys	NOUN	O	O
for	ADP	O	O
transplantation	NOUN	O	O
increases	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
recently	ADV	O	O
available	ADJ	O	O
immunosuppressive	ADJ	O	O
agents	NOUN	O	O
,	PUNCT	O	O
mycophenolate	NOUN	O	B-Entity
mofetil	NOUN	O	I-Entity
and	CCONJ	O	O
sirolimus	NOUN	O	I-Entity
(	PUNCT	O	O
rapamycin	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
have	VERB	O	O
no	DET	O	O
nephrotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11245434)

Erythropoietin	ADV	O	O
restores	VERB	O	O
the	DET	O	O
anemia	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
reduction	NOUN	O	O
in	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
cytotoxicity	NOUN	O	I-Entity
in	ADP	O	O
rat	NOUN	O	O
tumors	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
anemia	NOUN	O	I-Entity
prevention	NOUN	O	O
by	ADP	O	O
recombinant	NOUN	O	O
human	ADJ	O	O
erythropoietin	NOUN	O	O
(	PUNCT	O	O
rHuEPO	PROPN	O	O
)	PUNCT	O	O
treatment	NOUN	O	O
on	ADP	O	O
the	DET	O	O
cytotoxicity	NOUN	O	I-Entity
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
in	ADP	O	O
solid	ADJ	O	O
experimental	ADJ	O	O
tumors	NOUN	O	I-Entity
.	PUNCT	O	O

Anemia	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
using	VERB	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
carboplatin	NOUN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
second	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
anemia	NOUN	O	I-Entity
was	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
rHuEPO	PROPN	O	O
(	PUNCT	O	O
1000	NUM	O	O
IU	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
administered	VERB	O	O
s.c	NOUN	O	O
.	PUNCT	O	O

three	NUM	O	O
times	NOUN	O	O
/	SYM	O	O
week	NOUN	O	O
starting	VERB	O	O
7	NUM	O	O
days	NOUN	O	O
before	ADP	O	O
carboplatin	NOUN	O	I-Entity
application	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
carboplatin	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
tumors	NOUN	O	I-Entity
(	PUNCT	O	O
DS	PROPN	O	O
-	PUNCT	O	O
sarcoma	PROPN	O	I-Entity
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
implanted	VERB	O	O
s.c	NUM	O	O
.	PUNCT	O	O

Neither	DET	O	O
carboplatin	NOUN	O	I-Entity
nor	CCONJ	O	O
rHuEPO	ADJ	O	O
treatment	NOUN	O	O
influenced	VERB	O	O
tumor	NOUN	O	I-Entity
growth	NOUN	O	O
rate	NOUN	O	O
per	ADP	O	O
se	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
tumors	NOUN	O	I-Entity
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
60	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
5	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
implantation	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
growth	NOUN	O	O
delay	NOUN	O	O
with	ADP	O	O
a	DET	O	O
subsequent	ADJ	O	O
regrowth	NOUN	O	O
of	ADP	O	O
the	DET	O	O
tumors	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
anemia	NOUN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
growth	NOUN	O	O
delay	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
shorter	ADJ	O	O
compared	VERB	O	O
with	ADP	O	O
nonanemic	ADJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
13.3	NUM	O	O
days	NOUN	O	O
versus	ADP	O	O
8.6	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
group	NOUN	O	O
where	ADV	O	O
anemia	NOUN	O	I-Entity
was	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
rHuEPO	PROPN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
growth	NOUN	O	O
delay	NOUN	O	O
was	VERB	O	O
comparable	ADJ	O	O
with	ADP	O	O
that	DET	O	O
of	ADP	O	O
nonanemic	ADJ	O	O
controls	NOUN	O	O
(	PUNCT	O	O
13.3	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
chemotherapy	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
reduces	VERB	O	O
cytotoxicity	NOUN	O	I-Entity
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
in	ADP	O	O
tumors	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
correction	NOUN	O	O
of	ADP	O	O
anemia	NOUN	O	I-Entity
by	ADP	O	O
rHuEPO	ADJ	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
epoetin	NOUN	O	O
alpha	NOUN	O	O
)	PUNCT	O	O
increases	VERB	O	O
the	DET	O	O
sensitivity	NOUN	O	O
,	PUNCT	O	O
probably	ADV	O	O
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
an	DET	O	O
improved	ADJ	O	O
oxygen	NOUN	O	I-Entity
supply	NOUN	O	O
to	ADP	O	O
tumor	NOUN	O	I-Entity
tissue	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11243580)

The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
nitrergic	ADJ	O	O
system	NOUN	O	O
in	ADP	O	O
lidocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsion	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
mouse	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
nitro	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
L	PROPN	O	I-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
ester	NOUN	O	I-Entity
(	PUNCT	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
NAME	PROPN	O	I-Entity
)	PUNCT	O	O
a	DET	O	O
nitric	ADJ	O	B-Entity
oxide	NOUN	O	I-Entity
(	PUNCT	O	O
NO	PROPN	O	I-Entity
)	PUNCT	O	O

synthase	NOUN	O	O
inhibitor	NOUN	O	O
and	CCONJ	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
NO	DET	O	I-Entity
precursor	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
investigated	VERB	O	O
on	ADP	O	O
lidocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
first	ADJ	O	O
experiment	NOUN	O	O
,	PUNCT	O	O
four	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
received	VERB	O	O
physiological	ADJ	O	O
saline	NOUN	O	O
(	PUNCT	O	O
0.9%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
(	PUNCT	O	O
300	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O

L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
NAME	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O

diazepam	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
these	DET	O	O
injections	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
mice	NOUN	O	O
received	VERB	O	O
lidocaine	NOUN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
second	ADJ	O	O
experiment	NOUN	O	O
,	PUNCT	O	O
four	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
mice	NOUN	O	O
received	VERB	O	O
similar	ADJ	O	O
treatment	NOUN	O	O
in	ADP	O	O
the	DET	O	O
first	ADJ	O	O
experiment	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
30	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
these	DET	O	O
injections	NOUN	O	O
,	PUNCT	O	O
all	DET	O	O
mice	NOUN	O	O
received	VERB	O	O
a	DET	O	O
higher	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
(	PUNCT	O	O
80	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

L	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
NAME	NOUN	O	I-Entity
(	PUNCT	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O

kg	INTJ	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
diazepam	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
significantly	ADV	O	O
decreased	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg)-induced	ADJ	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
arginine	NOUN	O	I-Entity
treatment	NOUN	O	O
increased	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
lidocaine	NOUN	O	I-Entity
(	PUNCT	O	O
80	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
i.p.)-induced	ADJ	O	O
convulsions	NOUN	O	I-Entity
significantly	ADV	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
may	VERB	O	O
suggest	VERB	O	O
that	ADP	O	O
NO	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
proconvulsant	ADJ	O	O
mediator	NOUN	O	O
in	ADP	O	O
lidocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
convulsions	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11079278)

Effect	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
metoprolol	NOUN	O	I-Entity
or	CCONJ	O	O
intravenous	ADJ	O	O
metoprolol	NOUN	O	I-Entity
plus	CCONJ	O	O
glucagon	NOUN	O	O
on	ADP	O	O
dobutamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
.	PUNCT	O	O

STUDY	NOUN	O	O
OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
determine	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
metoprolol	NOUN	O	I-Entity
on	ADP	O	O
dobutamine	NOUN	O	I-Entity
stress	NOUN	O	O
testing	NOUN	O	O
with	ADP	O	O
technetium-99	PROPN	O	B-Entity
m	NOUN	O	I-Entity
sestamibi	VERB	O	I-Entity
single	ADJ	O	O
-	PUNCT	O	O
photon	NOUN	O	O
emission	NOUN	O	O
computed	VERB	O	O
tomography	NOUN	O	O
imaging	NOUN	O	O
and	CCONJ	O	O
ST	PROPN	O	O
-	PUNCT	O	O
segment	NOUN	O	O
monitoring	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
glucagon	NOUN	O	O
on	ADP	O	O
metoprolol	NOUN	O	I-Entity
's	PART	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
underwent	VERB	O	O
dobutamine	ADJ	O	I-Entity
stress	NOUN	O	O
tests	VERB	O	O
per	ADP	O	O
standard	NOUN	O	O
protocol	NOUN	O	O
.	PUNCT	O	O

Before	ADP	O	O
dobutamine	NOUN	O	I-Entity
was	VERB	O	O
begun	VERB	O	O
,	PUNCT	O	O
no	DET	O	O
therapy	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
visit	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
on	ADP	O	O
subsequent	ADJ	O	O
visits	NOUN	O	O
to	PART	O	O
receive	VERB	O	O
metoprolol	NOUN	O	I-Entity
or	CCONJ	O	O
metoprolol	NOUN	O	I-Entity
plus	CCONJ	O	O
glucagon	NOUN	O	O
1	NUM	O	O
mg	NUM	O	O
.	PUNCT	O	O

Metoprolol	PROPN	O	I-Entity
was	VERB	O	O
dosed	VERB	O	O
to	PART	O	O
achieve	VERB	O	O
a	DET	O	O
resting	VERB	O	O
predobutamine	ADJ	O	I-Entity
heart	NOUN	O	O
rate	NOUN	O	O
below	ADP	O	O
65	NUM	O	O
beats	NOUN	O	O
/	SYM	O	O
minute	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
total	ADJ	O	O
intravenous	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
mg	NOUN	O	O
.	PUNCT	O	O

Metoprolol	PROPN	O	I-Entity
reduced	VERB	O	O
maximum	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
31%	NUM	O	O
,	PUNCT	O	O
summed	VERB	O	O
stress	NOUN	O	O
scores	NOUN	O	O
29%	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
summed	VERB	O	O
difference	NOUN	O	O
scores	NOUN	O	O
43%	NUM	O	O
versus	ADP	O	O
control	NOUN	O	O
.	PUNCT	O	O

Metoprolol	PROPN	O	I-Entity
plus	CCONJ	O	O
glucagon	NOUN	O	O
also	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
maximum	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
29%	NUM	O	O
versus	NOUN	O	O
control	NOUN	O	O
.	PUNCT	O	O

No	INTJ	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
any	DET	O	O
parameter	NOUN	O	O
between	ADP	O	O
metoprolol	NOUN	O	I-Entity
and	CCONJ	O	O
metoprolol	NOUN	O	I-Entity
-	PUNCT	O	O
glucagon	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
dobutamine	NOUN	O	I-Entity
stress	NOUN	O	O
testing	NOUN	O	O
,	PUNCT	O	O
metoprolol	NOUN	O	I-Entity
attenuates	NOUN	O	O
or	CCONJ	O	O
eliminates	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (10910842)

Prednisolone	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
muscle	NOUN	O	B-Entity
dysfunction	NOUN	O	I-Entity
is	VERB	O	O
caused	VERB	O	O
more	ADJ	O	O
by	ADP	O	O
atrophy	NOUN	O	I-Entity
than	ADP	O	O
by	ADP	O	O
altered	VERB	O	O
acetylcholine	NOUN	O	I-Entity
receptor	NOUN	O	O
expression	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
moderate	ADJ	O	O
and	CCONJ	O	O
large	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
prednisolone	NOUN	O	I-Entity
on	ADP	O	O
muscle	NOUN	O	O
function	NOUN	O	O
and	CCONJ	O	O
pharmacology	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
relationship	NOUN	O	O
to	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
muscle	NOUN	O	O
size	NOUN	O	O
and	CCONJ	O	O
acetylcholine	NOUN	O	I-Entity
receptor	NOUN	O	O
(	PUNCT	O	O
AChR	PROPN	O	O
)	PUNCT	O	O
expression	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
institutional	ADJ	O	O
approval	NOUN	O	O
,	PUNCT	O	O
35	NUM	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	PART	O	O
receive	VERB	O	O
daily	ADJ	O	O
subcutaneous	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	X	O	O
prednisolone	NOUN	O	I-Entity
(	PUNCT	O	O
P10	PROPN	O	O
group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	X	O	O
prednisolone	NOUN	O	I-Entity
(	PUNCT	O	O
P100	PROPN	O	O
group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
an	DET	O	O
equal	ADJ	O	O
volume	NOUN	O	O
of	ADP	O	O
saline	NOUN	O	O
(	PUNCT	O	O
S	PROPN	O	O
group	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
Day	PROPN	O	O
8	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
nerve	NOUN	O	O
-	PUNCT	O	O
evoked	VERB	O	O
peak	NOUN	O	O
twitch	NOUN	O	O
tensions	NOUN	O	O
,	PUNCT	O	O
tetanic	ADJ	O	I-Entity
tensions	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
fatigability	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
response	NOUN	O	O
curves	NOUN	O	O
of	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tubocurarine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
tibialis	NOUN	O	O
cranialis	NOUN	O	O
muscle	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
vivo	NOUN	O	O
and	CCONJ	O	O
related	VERB	O	O
to	ADP	O	O
muscle	NOUN	O	O
mass	NOUN	O	O
or	CCONJ	O	O
expression	NOUN	O	O
of	ADP	O	O
AChRs	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
evoked	VERB	O	O
peak	NOUN	O	O
twitch	NOUN	O	O
and	CCONJ	O	O
tetanic	ADJ	O	I-Entity
tensions	NOUN	O	O
were	VERB	O	O
less	ADJ	O	O
in	ADP	O	O
the	DET	O	O
P100	NOUN	O	O
group	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
P10	PROPN	O	O
or	CCONJ	O	O
S	PROPN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
tension	NOUN	O	O
per	ADP	O	O
milligram	NOUN	O	O
of	ADP	O	O
muscle	NOUN	O	O
mass	NOUN	O	O
was	VERB	O	O
greater	ADJ	O	O
in	ADP	O	O
the	DET	O	O
P100	NOUN	O	O
group	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
S	PROPN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
50%	NUM	O	O
effective	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tubocurarine	NOUN	O	I-Entity
(	PUNCT	O	O
microg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
tibialis	NOUN	O	O
muscle	NOUN	O	O
was	VERB	O	O
smaller	ADJ	O	O
in	ADP	O	O
the	DET	O	O
P10	PROPN	O	O
(	PUNCT	O	O
33.6	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

The	DET	O	O
50%	NUM	O	O
effective	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
d	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
tubocurarine	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
correlate	VERB	O	O
with	ADP	O	O
muscle	NOUN	O	O
mass	NOUN	O	O
or	CCONJ	O	O
AChR	PROPN	O	O
expression	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
neuromuscular	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
after	ADP	O	O
prednisolone	NOUN	O	I-Entity
is	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
derives	VERB	O	O
primarily	ADV	O	O
from	ADP	O	O
muscle	NOUN	O	B-Entity
atrophy	NOUN	O	I-Entity
and	CCONJ	O	O
derives	VERB	O	O
less	ADV	O	O
so	ADV	O	O
from	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
AChR	PROPN	O	O
expression	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
observed	ADJ	O	O
effects	NOUN	O	O
are	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
and	CCONJ	O	O
derive	ADJ	O	O
primarily	ADV	O	O
from	ADP	O	O
muscle	NOUN	O	B-Entity
atrophy	VERB	O	I-Entity
and	CCONJ	O	O
derive	VERB	O	O
less	ADJ	O	O
from	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
acetylcholine	NOUN	O	I-Entity
receptor	NOUN	O	O
expression	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10533019)

Rapid	ADJ	O	O
reversal	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
diltiazem	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
tetany	NOUN	O	I-Entity
with	ADP	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
tetany	NOUN	O	I-Entity
with	ADP	O	O
sudden	ADJ	O	O
respiratory	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
after	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
diltiazem	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
rapidly	ADV	O	O
resolved	VERB	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
tetany	NOUN	O	I-Entity
with	ADP	O	O
prompt	ADJ	O	O
recovery	NOUN	O	O
of	ADP	O	O
respiratory	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
averting	VERB	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
more	ADV	O	O
aggressive	ADJ	O	O
airway	NOUN	O	O
management	NOUN	O	O
and	CCONJ	O	O
ventilatory	NOUN	O	O
support	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
emergency	NOUN	O	O
physician	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
that	ADP	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
tetany	NOUN	O	I-Entity
may	VERB	O	O
accompany	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
diltiazem	NOUN	O	I-Entity
and	CCONJ	O	O
that	ADP	O	O
calcium	NOUN	O	B-Entity
chloride	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
rapid	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
remedy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10414674)

Effects	NOUN	O	O
of	ADP	O	O
nonsteroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drugs	NOUN	O	O
on	ADP	O	O
hemostasis	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
aneurysmal	ADJ	O	B-Entity
subarachnoid	ADJ	O	I-Entity
hemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
aneurysmal	ADJ	O	B-Entity
subarachnoid	ADJ	O	I-Entity
hemorrhage	NOUN	O	I-Entity
(	PUNCT	O	O
SAH	PROPN	O	I-Entity
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	VERB	O	O
either	CCONJ	O	O
ketoprofen	NOUN	O	I-Entity
,	PUNCT	O	O
100	NUM	O	O
mg	INTJ	O	O
,	PUNCT	O	O
three	NUM	O	O
times	NOUN	O	O
a	DET	O	O
day	NOUN	O	O
(	PUNCT	O	O
ketoprofen	NOUN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O

n	CCONJ	O	O
=	SYM	O	O
9	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
weak	ADJ	O	O
NSAID	PROPN	O	O
,	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
,	PUNCT	O	O
1	NUM	O	O
g	NOUN	O	O
,	PUNCT	O	O
three	NUM	O	O
times	NOUN	O	O
a	DET	O	O
day	NOUN	O	O
(	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O

n	CCONJ	O	O
=	SYM	O	O
9	NUM	O	O
)	PUNCT	O	O
starting	VERB	O	O
immediately	ADV	O	O
after	ADP	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
aneurysmal	ADJ	O	I-Entity
SAH	PROPN	O	I-Entity
.	PUNCT	O	O

Maximal	PROPN	O	O
platelet	NOUN	O	B-Entity
aggregation	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
6	NUM	O	O
microM	NOUN	O	O
of	ADP	O	O
adenosine	NOUN	O	B-Entity
diphosphate	NOUN	O	I-Entity
decreased	VERB	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
ketoprofen	NOUN	O	I-Entity
.	PUNCT	O	O

Aggregation	NOUN	O	O
was	VERB	O	O
lower	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
.05	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
ketoprofen	NOUN	O	I-Entity
group	NOUN	O	O
than	ADP	O	O
in	ADP	O	O
the	DET	O	O
acetaminophen	NOUN	O	I-Entity
group	NOUN	O	O
just	ADV	O	O
before	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
third	ADJ	O	O
postoperative	ADJ	O	O
day	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
maximal	ADJ	O	O
platelet	NOUN	O	B-Entity
aggregation	NOUN	O	I-Entity
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
acetaminophen	NOUN	O	I-Entity
group	NOUN	O	O
on	ADP	O	O
the	DET	O	O
third	ADJ	O	O
postoperative	ADJ	O	O
day	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
pretreatment	NOUN	O	O
platelet	NOUN	O	B-Entity
aggregation	NOUN	O	I-Entity
results	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

One	NUM	O	O
patient	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ketoprofen	NOUN	O	I-Entity
group	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
postoperative	ADJ	O	O
intracranial	ADJ	O	O
hematoma	NOUN	O	I-Entity
.	PUNCT	O	O

Ketoprofen	PROPN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
acetaminophen	ADV	O	I-Entity
impaired	VERB	O	O
platelet	NOUN	O	O
function	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
SAH	PROPN	O	I-Entity
.	PUNCT	O	O

If	ADP	O	O
ketoprofen	NOUN	O	I-Entity
is	VERB	O	O
used	VERB	O	O
before	ADP	O	O
surgery	NOUN	O	O
on	ADP	O	O
cerebral	ADJ	O	O
artery	NOUN	O	B-Entity
aneurysms	NOUN	O	I-Entity
,	PUNCT	O	O
it	PRON	O	O
may	VERB	O	O
pose	VERB	O	O
an	DET	O	O
additional	ADJ	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
hemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (9523850)

Value	NOUN	O	O
of	ADP	O	O
methylprednisolone	NOUN	O	I-Entity
in	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
the	DET	O	O
arthralgia	NOUN	O	I-Entity
-	PUNCT	O	O
myalgia	NOUN	O	I-Entity
syndrome	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
total	ADJ	O	O
dose	NOUN	O	O
infusion	NOUN	O	O
of	ADP	O	O
iron	NOUN	O	B-Entity
dextran	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADJ	O	O
randomized	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
dose	NOUN	O	O
infusion	NOUN	O	O
(	PUNCT	O	O
TDI	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
iron	NOUN	O	B-Entity
dextran	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
well	ADV	O	O
documented	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
40%	NUM	O	O
of	ADP	O	O
treated	VERB	O	O
patients	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
arthralgia	NOUN	O	I-Entity
-	PUNCT	O	O
myalgia	NOUN	O	I-Entity
syndrome	NOUN	O	O
develops	VERB	O	O
.	PUNCT	O	O

administration	NOUN	O	O
of	ADP	O	O
methylprednisolone	NOUN	O	I-Entity
(	PUNCT	O	O
MP	PROPN	O	I-Entity
)	PUNCT	O	O
prevents	VERB	O	O
this	DET	O	O
complication	NOUN	O	O
.	PUNCT	O	O

MP	PROPN	O	I-Entity
before	ADV	O	O
and	CCONJ	O	O
saline	NOUN	O	O
after	ADP	O	O
TDI	PROPN	O	O
(	PUNCT	O	O
group	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
125	NUM	O	O
mg	NUM	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

MP	PROPN	O	I-Entity
before	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
TDI	PROPN	O	O
(	PUNCT	O	O
group	NOUN	O	O
3	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
MP	PROPN	O	I-Entity
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
TDI	PROPN	O	O
reduces	VERB	O	O
the	DET	O	O
frequency	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
arthralgia	NOUN	O	I-Entity
-	PUNCT	O	O
myalgia	NOUN	O	I-Entity
syndrome	NOUN	O	O
.	PUNCT	O	O

MP	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
given	VERB	O	O
routinely	ADV	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
TDI	PROPN	O	O
of	ADP	O	O
iron	NOUN	O	B-Entity
dextran	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8384253)

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
vincristine	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O

Forty	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
Non	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
Hodgkin	PROPN	O	I-Entity
's	PART	O	I-Entity
Lymphoma	PROPN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
vincristine	NOUN	O	I-Entity
between	ADP	O	O
1984	NUM	O	O
and	CCONJ	O	O
1990	NUM	O	O
(	PUNCT	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
12	NUM	O	O
mg	NUM	O	O
in	ADP	O	O
18	NUM	O	O
-	SYM	O	O
24	NUM	O	O
weeks	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
long	ADJ	O	O
term	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
vincristine	NOUN	O	I-Entity
on	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
nervous	ADJ	O	O
system	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
interviewed	VERB	O	O
with	ADP	O	O
emphasis	NOUN	O	O
on	ADP	O	O
neuropathic	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O

Physical	ADJ	O	O
and	CCONJ	O	O
quantitative	ADJ	O	O
sensory	ADJ	O	O
examination	NOUN	O	O
with	ADP	O	O
determination	NOUN	O	O
of	ADP	O	O
vibratory	ADJ	O	O
perception	NOUN	O	O
and	CCONJ	O	O
thermal	ADJ	O	O
discrimination	NOUN	O	O
thresholds	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
,	PUNCT	O	O
four	NUM	O	O
to	PART	O	O
77	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
34	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
after	ADP	O	O
vincristine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
seven	NUM	O	O
patients	NOUN	O	O
reported	VERB	O	O
neuropathic	ADJ	O	B-Entity
symptoms	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
with	ADP	O	O
the	DET	O	O
above	ADV	O	O
mentioned	VERB	O	O
vincristine	NOUN	O	I-Entity
dose	NOUN	O	O
schedule	NOUN	O	O
signs	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
vincristine	NOUN	O	I-Entity
neuropathy	NOUN	O	I-Entity
are	VERB	O	O
reversible	ADJ	O	O
for	ADP	O	O
a	DET	O	O
great	ADJ	O	O
deal	NOUN	O	O
and	CCONJ	O	O
prognosis	NOUN	O	O
is	VERB	O	O
fairly	ADV	O	O
good	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (8268147)

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
polymyositis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	B-Entity
biliary	ADJ	O	I-Entity
cirrhosis	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
used	VERB	O	O
for	ADP	O	O
many	ADJ	O	O
rheumatologic	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
,	PUNCT	O	O
toxicity	NOUN	O	I-Entity
limits	VERB	O	O
its	ADJ	O	O
usefulness	NOUN	O	O
in	ADP	O	O
many	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Polymyositis	PROPN	O	I-Entity
/	SYM	O	O
dermatomyositis	NOUN	O	I-Entity
can	VERB	O	O
develop	VERB	O	O
as	ADP	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
autoimmune	ADJ	O	O
complications	NOUN	O	O
of	ADP	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
its	ADJ	O	O
exact	ADJ	O	O
pathogenesis	NOUN	O	O
remains	VERB	O	O
unclear	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
primary	ADJ	O	B-Entity
biliary	ADJ	O	I-Entity
cirrhosis	NOUN	O	I-Entity
,	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
polymyositis	NOUN	O	I-Entity
while	ADP	O	O
receiving	VERB	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
receiving	VERB	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
penicillamine	NOUN	O	I-Entity
therapy	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
followed	VERB	O	O
carefully	ADV	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
autoimmune	ADJ	O	O
complications	NOUN	O	O
like	ADP	O	O
polymyositis	NOUN	O	I-Entity
/	SYM	O	O
dermatomyositis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8251368)

Photodistributed	VERB	O	O
nifedipine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
facial	ADJ	O	O
telangiectasia	NOUN	O	I-Entity
.	PUNCT	O	O

Five	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
starting	VERB	O	O
nifedipine	NOUN	O	I-Entity
(	PUNCT	O	O
Adalat	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
two	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
photodistributed	ADJ	O	O
facial	ADJ	O	O
telangiectasia	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
became	VERB	O	O
more	ADV	O	O
noticeable	ADJ	O	O
with	ADP	O	O
time	NOUN	O	O
.	PUNCT	O	O

Neither	DET	O	O
patient	NOUN	O	O
complained	VERB	O	O
of	ADP	O	O
photosensitivity	NOUN	O	O
or	CCONJ	O	O
flushing	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
commenced	VERB	O	O
the	DET	O	O
closely	ADV	O	O
related	VERB	O	O
drug	NOUN	O	O
amlodipine	NOUN	O	I-Entity
3	NUM	O	O
years	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
with	ADP	O	O
recurrence	NOUN	O	O
of	ADP	O	O
telangiectasia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
photodistribution	NOUN	O	O
of	ADP	O	O
the	DET	O	O
telangiectasia	NOUN	O	I-Entity
suggests	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
drug	NOUN	O	O
/	SYM	O	O
light	ADJ	O	O
interaction	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7542793)

Nephrotoxicity	NOUN	O	I-Entity
of	ADP	O	O
cyclosporin	NOUN	O	B-Entity
A	NOUN	O	I-Entity
and	CCONJ	O	O
FK506	NOUN	O	I-Entity
:	PUNCT	O	O
inhibition	NOUN	O	O
of	ADP	O	O
calcineurin	NOUN	O	O
phosphatase	NOUN	O	O
.	PUNCT	O	O

Cyclosporin	PROPN	O	B-Entity
A	PROPN	O	I-Entity
(	PUNCT	O	O
CsA	PROPN	O	I-Entity
;	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Fujimycine	PROPN	O	I-Entity
(	PUNCT	O	O
FK506	PROPN	O	I-Entity
;	PUNCT	O	O
5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
the	DET	O	O
related	ADJ	O	O
macrolide	NOUN	O	I-Entity
immunosuppressant	NOUN	O	O
rapamycin	NOUN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
caused	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
rate	NOUN	O	O
,	PUNCT	O	O
degenerative	ADJ	O	O
changes	NOUN	O	O
of	ADP	O	O
proximal	ADJ	O	O
tubular	ADJ	O	O
epithelium	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
hypertrophy	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
juxtaglomerular	ADJ	O	O
apparatus	NOUN	O	O
in	ADP	O	O
male	NOUN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
when	ADV	O	O
given	VERB	O	O
for	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
molecular	ADJ	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
CsA	PROPN	O	I-Entity
and	CCONJ	O	O
FK506	PROPN	O	I-Entity
toxicity	NOUN	O	I-Entity
were	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

Cyclophilin	PROPN	O	O
A	PROPN	O	O
and	CCONJ	O	O
FK506-binding	VERB	O	I-Entity
protein	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
main	ADJ	O	O
intracytoplasmic	NOUN	O	O
receptors	NOUN	O	O
for	ADP	O	O
CsA	PROPN	O	I-Entity
and	CCONJ	O	O
FK506	PROPN	O	I-Entity
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
were	VERB	O	O
each	DET	O	O
detected	VERB	O	O
in	ADP	O	O
renal	ADJ	O	O
tissue	NOUN	O	O
extract	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
,	PUNCT	O	O
high	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
immunoreactive	ADJ	O	O
and	CCONJ	O	O
enzymatically	ADV	O	O
active	ADJ	O	O
calcineurin	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
which	ADJ	O	O
were	VERB	O	O
inhibited	VERB	O	O
by	ADP	O	O
the	DET	O	O
immunosuppressants	NOUN	O	O
CsA	PROPN	O	I-Entity
and	CCONJ	O	O
FK506	PROPN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
by	ADP	O	O
rapamycin	NOUN	O	I-Entity
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
specific	ADJ	O	O
immunophilin	NOUN	O	O
-	PUNCT	O	O
drug	NOUN	O	O
-	PUNCT	O	O
calcineurin	NOUN	O	O
complexes	NOUN	O	O
formed	VERB	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
CsA	PROPN	O	I-Entity
and	CCONJ	O	O
FK506	PROPN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
rapamycin	VERB	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
nephrotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
CsA	PROPN	O	I-Entity
and	CCONJ	O	O
FK506	PROPN	O	I-Entity
is	VERB	O	O
likely	ADJ	O	O
mediated	VERB	O	O
through	ADP	O	O
binding	VERB	O	O
to	ADP	O	O
renal	ADJ	O	O
immunophilin	NOUN	O	O
and	CCONJ	O	O
inhibiting	VERB	O	O
calcineurin	NOUN	O	O
phosphatase	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7337133)

Massive	ADJ	O	O
cerebral	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
fulminant	ADJ	O	O
hepatic	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
acetaminophen	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
:	PUNCT	O	O
possible	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
cranial	ADJ	O	O
decompression	NOUN	O	O
.	PUNCT	O	O

Cerebral	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
may	VERB	O	O
complicate	VERB	O	O
the	DET	O	O
course	NOUN	O	O
of	ADP	O	O
fulminant	ADJ	O	B-Entity
hepatic	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
present	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
fatal	ADJ	O	O
acetaminophen	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
fulminant	NOUN	O	B-Entity
hepatic	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
signs	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
cerebral	ADJ	O	B-Entity
edema	NOUN	O	I-Entity
,	PUNCT	O	O
unresponsive	ADJ	O	O
to	ADP	O	O
conventional	ADJ	O	O
medical	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (4069770)

Gentamicin	PROPN	O	I-Entity
nephropathy	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
neonate	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
autopsy	ADJ	O	O
findings	NOUN	O	O
in	ADP	O	O
a	DET	O	O
premature	ADJ	O	O
baby	NOUN	O	O
who	NOUN	O	O
died	VERB	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
gentamicin	NOUN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
penicillin	NOUN	O	I-Entity
are	VERB	O	O
presented	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
serum	NOUN	O	O
gentamicin	NOUN	O	I-Entity
concentration	NOUN	O	O
had	VERB	O	O
reached	VERB	O	O
toxic	ADJ	O	O
levels	NOUN	O	O
when	ADV	O	O
anuria	NOUN	O	I-Entity
developed	VERB	O	O
.	PUNCT	O	O

Numerous	ADJ	O	O
periodic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
Schiff	PROPN	O	O
(	PUNCT	O	O
PAS	PROPN	O	O
)	PUNCT	O	O
positive	ADJ	O	O
,	PUNCT	O	O
diastase	NOUN	O	O
resistant	ADJ	O	O
cytoplasmic	NOUN	O	O
inclusion	NOUN	O	O
bodies	NOUN	O	O
which	ADJ	O	O
appeared	VERB	O	O
as	ADP	O	O
myelin	ADJ	O	O
figures	NOUN	O	O
in	ADP	O	O
cytosegresomes	NOUN	O	O
under	ADP	O	O
the	DET	O	O
electron	NOUN	O	O
microscope	NOUN	O	O
were	VERB	O	O
identified	VERB	O	O
in	ADP	O	O
the	DET	O	O
proximal	NOUN	O	O
convoluted	ADJ	O	O
tubules	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pathological	ADJ	O	O
changes	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
gentamicin	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
human	ADJ	O	O
neonatal	ADJ	O	O
kidneys	NOUN	O	O
have	VERB	O	O
not	ADV	O	O
been	VERB	O	O
previously	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (3780814)

Anti	PROPN	O	O
-	PUNCT	O	O
carcinogenic	ADJ	O	I-Entity
action	NOUN	O	O
of	ADP	O	O
phenobarbital	NOUN	O	I-Entity
given	VERB	O	O
simultaneously	ADV	O	O
with	ADP	O	O
diethylnitrosamine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
work	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
planned	VERB	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
elucidate	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
phenobarbital	NOUN	O	I-Entity
(	PUNCT	O	O
PB	PROPN	O	I-Entity
:	PUNCT	O	O
15	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
rat	NOUN	O	O
of	ADP	O	O
ingested	VERB	O	O
dose	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
carcinogenesis	NOUN	O	I-Entity
when	ADV	O	O
it	PRON	O	O
is	VERB	O	O
administered	VERB	O	O
simultaneously	ADV	O	O
with	ADP	O	O
diethylnitrosamine	NOUN	O	I-Entity
(	PUNCT	O	O
DEN	PROPN	O	I-Entity
:	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Wistar	PROPN	O	O
rats	NOUN	O	O
(	PUNCT	O	O
180	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
DEN	PROPN	O	I-Entity
alone	ADV	O	O
or	CCONJ	O	O
by	ADP	O	O
DEN	PROPN	O	I-Entity
+	PROPN	O	O
PB	PROPN	O	I-Entity
during	ADP	O	O
2	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
weeks	NOUN	O	O
according	VERB	O	O
to	ADP	O	O
our	ADJ	O	O
schedule	NOUN	O	O
for	ADP	O	O
hepatocarcinogenesis	NOUN	O	I-Entity
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
number	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
size	NOUN	O	O
of	ADP	O	O
induced	VERB	O	O
PAS	PROPN	O	O
positive	ADJ	O	O
preneoplastic	NOUN	O	B-Entity
foci	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
when	ADV	O	O
PB	PROPN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
simultaneously	ADV	O	O
with	ADP	O	O
DEN	PROPN	O	I-Entity
for	ADP	O	O
4	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mitotic	ADJ	O	O
inhibition	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
production	NOUN	O	O
of	ADP	O	O
micronuclei	NOUN	O	O
normally	ADV	O	O
observed	VERB	O	O
after	ADP	O	O
partial	ADJ	O	O
hepatectomy	NOUN	O	O
in	ADP	O	O
DEN	PROPN	O	I-Entity
treated	VERB	O	O
rats	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
significantly	ADV	O	O
decreased	VERB	O	O
in	ADP	O	O
DEN	PROPN	O	I-Entity
+	PROPN	O	O
PB	PROPN	O	I-Entity
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

When	ADV	O	O
the	DET	O	O
treatment	NOUN	O	O
last	ADJ	O	O
only	ADV	O	O
2	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
PB	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
change	VERB	O	O
significantly	ADV	O	O
the	DET	O	O
last	ADJ	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
DEN	PROPN	O	I-Entity
+	PROPN	O	O
PB	PROPN	O	I-Entity
treated	VERB	O	O
rats	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
survival	NOUN	O	O
was	VERB	O	O
prolonged	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
tumor	NOUN	O	I-Entity
incidence	NOUN	O	O
decreased	VERB	O	O
as	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
results	NOUN	O	O
obtained	VERB	O	O
by	ADP	O	O
DEN	PROPN	O	I-Entity
alone	ADV	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
PB	PROPN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
promotes	VERB	O	O
carcinogenesis	NOUN	O	I-Entity
when	ADV	O	O
administered	VERB	O	O
after	ADP	O	O
the	DET	O	O
DEN	PROPN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
reduces	VERB	O	O
the	DET	O	O
carcinogen	NOUN	O	O
effect	NOUN	O	O
when	ADV	O	O
given	VERB	O	O
simultaneously	ADV	O	O
with	ADP	O	O
DEN	PROPN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
'	PUNCT	O	O
anti	ADJ	O	O
-	PUNCT	O	O
carcinogen	NOUN	O	O
'	PUNCT	O	O
effect	NOUN	O	O
acts	VERB	O	O
on	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
on	ADP	O	O
the	DET	O	O
promotion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
precancerous	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
.	PUNCT	O	O

Biochemical	ADJ	O	O
investigations	NOUN	O	O
are	VERB	O	O
in	ADP	O	O
progress	NOUN	O	O
to	PART	O	O
obtain	VERB	O	O
more	ADJ	O	O
information	NOUN	O	O
about	ADP	O	O
this	DET	O	O
'	PUNCT	O	O
paradoxical	ADJ	O	O
'	PUNCT	O	O
PB	PROPN	O	I-Entity
effect	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3780697)

Post	PROPN	O	O
-	PUNCT	O	O
operative	ADJ	O	O
rigidity	NOUN	O	I-Entity
after	ADP	O	O
fentanyl	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
case	NOUN	O	O
of	ADP	O	O
thoraco	NOUN	O	O
-	PUNCT	O	O
abdominal	ADJ	O	O
rigidity	NOUN	O	I-Entity
leading	VERB	O	O
to	ADP	O	O
respiratory	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
is	VERB	O	O
described	VERB	O	O
in	ADP	O	O
the	DET	O	O
post	NOUN	O	O
-	PUNCT	O	O
operative	ADJ	O	O
period	NOUN	O	O
in	ADP	O	O
an	DET	O	O
elderly	ADJ	O	O
patient	NOUN	O	O
who	NOUN	O	O
received	VERB	O	O
a	DET	O	O
moderate	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
successfully	ADV	O	O
reversed	VERB	O	O
by	ADP	O	O
naloxone	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3686155)

Postpartum	PROPN	O	O
psychosis	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
bromocriptine	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
multigravida	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
no	DET	O	O
prior	ADJ	O	O
psychiatric	ADJ	O	I-Entity
history	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
with	ADP	O	O
postpartum	NOUN	O	O
psychosis	NOUN	O	I-Entity
,	PUNCT	O	O
having	VERB	O	O
received	VERB	O	O
bromocriptine	NOUN	O	I-Entity
for	ADP	O	O
inhibition	NOUN	O	B-Entity
of	ADP	O	I-Entity
lactation	NOUN	O	I-Entity
.	PUNCT	O	O

Bromocriptine	PROPN	O	I-Entity
given	VERB	O	O
in	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
psychosis	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
the	DET	O	O
drug	NOUN	O	O
for	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
cases	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
bromocriptine	NOUN	O	I-Entity
may	VERB	O	O
cause	VERB	O	O
psychosis	NOUN	O	I-Entity
even	ADV	O	O
when	ADV	O	O
given	VERB	O	O
in	ADP	O	O
low	ADJ	O	O
doses	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3137399)

A	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
on	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
dependency	NOUN	O	O
of	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
mitomycin	NOUN	O	B-Entity
C.	PROPN	O	I-Entity

Since	ADP	O	O
1975	NUM	O	O
mitomycin	NOUN	O	B-Entity
C	PROPN	O	I-Entity
(	PUNCT	O	O
MMC	PROPN	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
been	VERB	O	O
suggested	VERB	O	O
to	PART	O	O
be	VERB	O	O
cardiotoxic	ADJ	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
when	ADV	O	O
combined	VERB	O	O
with	ADP	O	O
or	CCONJ	O	O
given	VERB	O	O
following	VERB	O	O
doxorubicin	NOUN	O	I-Entity
.	PUNCT	O	O

Forty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
MMC	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patients	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
,	PUNCT	O	O
37	NUM	O	O
of	ADP	O	O
them	PRON	O	O
could	VERB	O	O
be	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

One	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
developed	VERB	O	O
cardiac	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
30	NUM	O	O
mg	NUM	O	O
m-2	NUM	O	O
MMC	PROPN	O	I-Entity
and	CCONJ	O	O
only	ADV	O	O
150	NUM	O	O
mg	NUM	O	O
m-2	NUM	O	O
doxorubicin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
cardiac	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
was	VERB	O	O
predicted	VERB	O	O
by	ADP	O	O
a	DET	O	O
drop	NOUN	O	O
in	ADP	O	O
EF	PROPN	O	O
determined	VERB	O	O
during	ADP	O	O
a	DET	O	O
cold	ADJ	O	O
pressor	NOUN	O	O
test	NOUN	O	O
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
other	ADJ	O	O
patients	NOUN	O	O
developed	VERB	O	O
clinical	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
nor	CCONJ	O	O
did	VERB	O	O
the	DET	O	O
studied	VERB	O	O
parameters	NOUN	O	O
change	VERB	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
the	DET	O	O
combined	VERB	O	O
data	NOUN	O	O
from	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
literature	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
suggest	VERB	O	O
that	ADP	O	O
MMC	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
is	VERB	O	O
dose	NOUN	O	O
dependent	ADJ	O	O
,	PUNCT	O	O
occurring	VERB	O	O
at	ADP	O	O
cumulative	ADJ	O	O
dose	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
30	NUM	O	O
mg	NUM	O	O
m-2	NUM	O	O
or	CCONJ	O	O
more	ADJ	O	O
,	PUNCT	O	O
mainly	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
also	ADV	O	O
(	PUNCT	O	O
previously	ADV	O	O
or	CCONJ	O	O
simultaneously	ADV	O	O
)	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
doxorubicin	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2709684)

Phlorizin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
glycosuria	NOUN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
prevent	VERB	O	O
gentamicin	NOUN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
rats	NOUN	O	O
with	ADP	O	O
streptozotocin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetes	NOUN	O	B-Entity
mellitus	NOUN	O	I-Entity
(	PUNCT	O	O
DM	PROPN	O	I-Entity
)	PUNCT	O	O
have	VERB	O	O
a	DET	O	O
high	ADJ	O	O
solute	NOUN	O	O
diuresis	NOUN	O	O
(	PUNCT	O	O
glycosuria	NOUN	O	I-Entity
of	ADP	O	O
10	NUM	O	O
to	PART	O	O
12	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
we	PRON	O	O
have	VERB	O	O
suggested	VERB	O	O
that	ADP	O	O
this	DET	O	O
may	VERB	O	O
in	ADP	O	O
part	NOUN	O	O
be	VERB	O	O
responsible	ADJ	O	O
for	ADP	O	O
their	ADJ	O	O
resistance	NOUN	O	O
to	ADP	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
ARF	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
protection	NOUN	O	O
from	ADP	O	O
gentamicin	NOUN	O	I-Entity
nephrotoxicity	NOUN	O	I-Entity
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
non	ADJ	O	O
-	PUNCT	O	O
diabetic	ADJ	O	I-Entity
rats	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
solute	NOUN	O	O
diuresis	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
blockage	NOUN	O	O
of	ADP	O	O
tubular	ADJ	O	O
glucose	NOUN	O	I-Entity
reabsorption	NOUN	O	O
with	ADP	O	O
phlorizin	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

DM	PROPN	O	I-Entity
rats	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
glycosuria	NOUN	O	I-Entity
(	PUNCT	O	O
similar	ADJ	O	O
in	ADP	O	O
degree	NOUN	O	O
to	ADP	O	O
that	DET	O	O
of	ADP	O	O
the	DET	O	O
P	NOUN	O	I-Entity
treated	VERB	O	O
animals	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
also	ADV	O	O
studied	VERB	O	O
.	PUNCT	O	O

Group	PROPN	O	O
1	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	I-Entity
alone	ADV	O	O
)	PUNCT	O	O
received	VERB	O	O
P	NOUN	O	I-Entity
,	PUNCT	O	O
360	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
15	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
Group	PROPN	O	O
II	PROPN	O	O
(	PUNCT	O	O
P	NOUN	O	I-Entity
+	SYM	O	O
gentamicin	NOUN	O	I-Entity
)	PUNCT	O	O
;	PUNCT	O	O
Group	PROPN	O	O
III	PROPN	O	O
(	PUNCT	O	O
gentamicin	ADV	O	I-Entity
alone	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Group	PROPN	O	O
IV	PROPN	O	O
(	PUNCT	O	O
mild	ADJ	O	O
DM	PROPN	O	I-Entity
+	PROPN	O	O
gentamicin	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Nephrotoxic	PROPN	O	I-Entity
doses	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	X	O	O
body	NOUN	O	O
wt	X	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
gentamicin	NOUN	O	I-Entity
were	VERB	O	O
injected	VERB	O	O
during	ADP	O	O
the	DET	O	O
last	ADJ	O	O
nine	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
study	NOUN	O	O
to	ADP	O	O
the	DET	O	O
animals	NOUN	O	O
of	ADP	O	O
groups	NOUN	O	O
II	PROPN	O	O
to	ADP	O	O
IV	PROPN	O	O
.	PUNCT	O	O

In	ADP	O	O
Group	PROPN	O	O
I	PRON	O	O
,	PUNCT	O	O
P	PROPN	O	I-Entity
induced	VERB	O	O
a	DET	O	O
moderate	ADJ	O	O
and	CCONJ	O	O
stable	ADJ	O	O
glycosuria	NOUN	O	I-Entity
(	PUNCT	O	O
3.9	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

0.1	NUM	O	O
g	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
,	PUNCT	O	O
SE	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
functional	ADJ	O	O
or	CCONJ	O	O
morphologic	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
(	PUNCT	O	O
baseline	NOUN	O	O
CCr	PROPN	O	O
2.1	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

ml	PROPN	O	O
/	SYM	O	O
min	NOUN	O	O
,	PUNCT	O	O
undetectable	ADJ	O	O
lysozymuria	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
damage	NOUN	O	O
(	PUNCT	O	O
tubular	ADJ	O	B-Entity
necrosis	NOUN	O	I-Entity
score	NOUN	O	O
[	PUNCT	O	O
maximum	ADJ	O	O
4	NUM	O	O
]	PUNCT	O	O
,	PUNCT	O	O
zero	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
Group	PROPN	O	O
II	PROPN	O	O
,	PUNCT	O	O
P	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
prevent	VERB	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
ARF	PROPN	O	I-Entity
(	PUNCT	O	O
maximal	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
CCr	NOUN	O	O
at	ADP	O	O
day	NOUN	O	O
9.89%	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	I-Entity
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
;	PUNCT	O	O
peak	NOUN	O	O
lysozymuria	NOUN	O	O
,	PUNCT	O	O
1863	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

321	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
tubular	ADJ	O	B-Entity
necrosis	NOUN	O	I-Entity
score	NOUN	O	O
,	PUNCT	O	O
3.9	NUM	O	O
+	X	O	O
/-	PUNCT	O	O

These	DET	O	O
values	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
those	DET	O	O
of	ADP	O	O
Group	PROPN	O	O
III	PROPN	O	O
:	PUNCT	O	O
maximal	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
CCr	PROPN	O	O
73%	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	I-Entity
less	ADJ	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
lysozymuria	NOUN	O	O
,	PUNCT	O	O
2147	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

701	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
;	PUNCT	O	O
tubular	ADJ	O	B-Entity
necrosis	NOUN	O	I-Entity
score	NOUN	O	O
,	PUNCT	O	O
3.8	NUM	O	O
+	X	O	O
/-	PUNCT	O	O


-DOCSTART- (458486)

Tiapride	PROPN	O	I-Entity
in	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
involuntary	ADJ	O	B-Entity
movements	NOUN	O	I-Entity
.	PUNCT	O	O

Tiapride	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
substituted	VERB	O	O
benzamide	NOUN	O	I-Entity
derivative	NOUN	O	O
closely	ADV	O	O
related	VERB	O	O
to	ADP	O	O
metoclopramide	NOUN	O	I-Entity
,	PUNCT	O	O
reduced	VERB	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
peak	NOUN	O	O
dose	NOUN	O	O
involuntary	ADJ	O	B-Entity
movements	NOUN	O	I-Entity
in	ADP	O	O
16	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
idiopathic	ADJ	O	B-Entity
Parkinson	PROPN	O	I-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
an	DET	O	O
unacceptable	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
disability	NOUN	O	O
from	ADP	O	O
Parkinsonism	PROPN	O	I-Entity
with	ADP	O	O
aggravation	NOUN	O	O
of	ADP	O	O
end	NOUN	O	O
-	PUNCT	O	O
of	ADP	O	O
-	PUNCT	O	O
dose	NOUN	O	O
akinesia	NOUN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
its	ADJ	O	O
cessation	NOUN	O	O
in	ADP	O	O
14	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Tiapride	PROPN	O	I-Entity
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
early	ADJ	O	O
morning	NOUN	O	O
of	ADP	O	O
"	PUNCT	O	O
off	ADP	O	O
-	PUNCT	O	O
period	NOUN	O	O
"	PUNCT	O	O
segmental	ADJ	O	O
dystonia	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
fail	VERB	O	O
to	PART	O	O
support	VERB	O	O
the	DET	O	O
notion	NOUN	O	O
that	ADP	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
are	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
overstimulation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
separate	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
receptors	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (21294084)

Effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampal	ADJ	O	O
deep	ADJ	O	O
brain	NOUN	O	O
stimulation	NOUN	O	O
on	ADP	O	O
cortical	ADJ	O	O
epileptic	ADJ	O	I-Entity
discharges	NOUN	O	O
in	ADP	O	O
penicillin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
epilepsy	NOUN	O	I-Entity
model	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

AIM	PROPN	O	O
:	PUNCT	O	O
Experimental	PROPN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
have	VERB	O	O
revealed	VERB	O	O
that	ADP	O	O
hippocampal	ADJ	O	O
DBS	PROPN	O	O
can	VERB	O	O
control	VERB	O	O
epileptic	ADJ	O	I-Entity
activity	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
is	VERB	O	O
obscure	ADJ	O	O
and	CCONJ	O	O
optimal	ADJ	O	O
stimulation	NOUN	O	O
parameters	NOUN	O	O
are	VERB	O	O
not	ADV	O	O
clearly	ADV	O	O
defined	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
frequency	NOUN	O	O
hippocampal	ADJ	O	O
stimulation	NOUN	O	O
on	ADP	O	O
cortical	ADJ	O	O
epileptic	ADJ	O	I-Entity
activity	NOUN	O	O
in	ADP	O	O
penicillin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
epilepsy	NOUN	O	I-Entity
model	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
group-1	PROPN	O	O
(	PUNCT	O	O
n=10	PUNCT	O	O
)	PUNCT	O	O
hippocampal	ADJ	O	O
DBS	PROPN	O	O
was	VERB	O	O
off	ADV	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
group-2	NOUN	O	O
(	PUNCT	O	O
n=10	PUNCT	O	O
)	PUNCT	O	O
hippocampal	ADJ	O	O
DBS	PROPN	O	O
was	VERB	O	O
on	ADP	O	O
(	PUNCT	O	O
185	NUM	O	O
Hz	PROPN	O	O
,	PUNCT	O	O
0.5V	PROPN	O	O
,	PUNCT	O	O
1V	NUM	O	O
,	PUNCT	O	O
2V	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
5V	NUM	O	O
for	ADP	O	O
60	NUM	O	O
sec	NOUN	O	O
)	PUNCT	O	O
following	VERB	O	O
penicillin	NOUN	O	B-Entity
G	PROPN	O	I-Entity
injection	NOUN	O	O
intracortically	ADV	O	O
.	PUNCT	O	O

EEG	NOUN	O	O
recordings	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
before	ADV	O	O
and	CCONJ	O	O
15	NUM	O	O
minutes	NOUN	O	O
following	VERB	O	O
penicillin	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
G	PROPN	O	I-Entity
injection	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
at	ADP	O	O
10th	ADJ	O	O
minutes	NOUN	O	O
following	VERB	O	O
each	DET	O	O
stimulus	NOUN	O	O
for	ADP	O	O
analysis	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
frequency	NOUN	O	O
,	PUNCT	O	O
amplitude	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
power	NOUN	O	O
spectrum	NOUN	O	O
.	PUNCT	O	O

High	ADJ	O	O
frequency	NOUN	O	O
hippocampal	NOUN	O	O
DBS	PROPN	O	O
suppressed	VERB	O	O
the	DET	O	O
acute	ADJ	O	O
penicillin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cortical	ADJ	O	O
epileptic	ADJ	O	I-Entity
activity	NOUN	O	O
independent	ADJ	O	O
from	ADP	O	O
stimulus	NOUN	O	O
intensity	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Our	ADJ	O	O
results	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
continuous	ADJ	O	O
high	ADJ	O	O
frequency	NOUN	O	O
stimulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hippocampus	NOUN	O	O
suppressed	VERB	O	O
acute	ADJ	O	O
cortical	ADJ	O	O
epileptic	ADJ	O	I-Entity
activity	NOUN	O	O
effectively	ADV	O	O
without	ADP	O	O
causing	VERB	O	O
secondary	ADJ	O	O
epileptic	ADJ	O	I-Entity
discharges	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
are	VERB	O	O
important	ADJ	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
defining	VERB	O	O
the	DET	O	O
optimal	ADJ	O	O
parameters	NOUN	O	O
of	ADP	O	O
hippocampal	ADJ	O	O
DBS	PROPN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
epilepsy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20727411)

Neural	ADJ	O	O
correlates	NOUN	O	O
of	ADP	O	O
S	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
ketamine	PROPN	O	I-Entity
induced	VERB	O	O
psychosis	NOUN	O	I-Entity
during	ADP	O	O
overt	ADJ	O	O
continuous	ADJ	O	O
verbal	ADJ	O	O
fluency	NOUN	O	O
.	PUNCT	O	O

N	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
D	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
(	PUNCT	O	O
NMDA	PROPN	O	I-Entity
)	PUNCT	O	O

receptor	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
the	DET	O	O
pathophysiology	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O

Administered	VERB	O	O
to	ADP	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
subanesthetic	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
competitive	ADJ	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
antagonist	NOUN	O	O
ketamine	NOUN	O	I-Entity
leads	VERB	O	O
to	ADP	O	O
psychopathological	ADJ	O	O
symptoms	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
observed	VERB	O	O
in	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	I-Entity
,	PUNCT	O	O
ketamine	NOUN	O	I-Entity
exacerbates	VERB	O	O
the	DET	O	O
core	NOUN	O	O
symptoms	NOUN	O	O
of	ADP	O	O
illness	NOUN	O	O
,	PUNCT	O	O
supporting	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
of	ADP	O	O
a	DET	O	O
glutamatergic	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
counterbalanced	ADJ	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
study	NOUN	O	O
design	NOUN	O	O
,	PUNCT	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
a	DET	O	O
continuous	ADJ	O	O
subanesthetic	ADJ	O	O
S	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
ketamine	NOUN	O	I-Entity
infusion	NOUN	O	O
while	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
BOLD	PROPN	O	O
responses	NOUN	O	O
measured	VERB	O	O
with	ADP	O	O
fMRI	NOUN	O	O
were	VERB	O	O
detected	VERB	O	O
.	PUNCT	O	O

Ketamine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
psychopathological	ADJ	O	O
symptoms	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
with	ADP	O	O
the	DET	O	O
Positive	ADJ	O	O
and	CCONJ	O	O
Negative	ADJ	O	O
Syndrome	PROPN	O	O
Scale	PROPN	O	O
(	PUNCT	O	O
PANSS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Ketamine	PROPN	O	I-Entity
elicited	VERB	O	O
psychosis	NOUN	O	I-Entity
like	ADP	O	O
psychopathology	NOUN	O	O
.	PUNCT	O	O

Post	PROPN	O	O
-	PUNCT	O	O
hoc	PROPN	O	O
t	NOUN	O	O
-	PUNCT	O	O
tests	NOUN	O	O
revealed	VERB	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
ketamine	NOUN	O	I-Entity
for	ADP	O	O
the	DET	O	O
amounts	NOUN	O	O
of	ADP	O	O
words	NOUN	O	O
generated	VERB	O	O
during	ADP	O	O
lexical	ADJ	O	O
and	CCONJ	O	O
semantic	ADJ	O	O
verbal	ADJ	O	O
fluency	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
phonological	ADJ	O	O
domain	NOUN	O	O
remained	VERB	O	O
unaffected	ADJ	O	O
.	PUNCT	O	O

Ketamine	NOUN	O	I-Entity
led	VERB	O	O
to	ADP	O	O
enhanced	VERB	O	O
cortical	ADJ	O	O
activations	NOUN	O	O
in	ADP	O	O
supramarginal	ADJ	O	O
and	CCONJ	O	O
frontal	ADJ	O	O
brain	NOUN	O	O
regions	NOUN	O	O
for	ADP	O	O
phonological	ADJ	O	O
and	CCONJ	O	O
lexical	ADJ	O	O
verbal	ADJ	O	O
fluency	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
for	ADP	O	O
semantic	ADJ	O	O
verbal	ADJ	O	O
fluency	NOUN	O	O
.	PUNCT	O	O

Ketamine	PROPN	O	I-Entity
induces	VERB	O	O
activation	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
schizophrenia	NOUN	O	I-Entity
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
frontal	NOUN	O	O
and	CCONJ	O	O
temporal	ADJ	O	O
brain	NOUN	O	O
regions	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
provide	VERB	O	O
further	ADJ	O	O
support	NOUN	O	O
for	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
of	ADP	O	O
an	DET	O	O
NMDA	PROPN	O	I-Entity
receptor	NOUN	O	O
dysfunction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
pathophysiology	NOUN	O	O
of	ADP	O	O
schizophrenia	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (20533999)

Dopamine	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
essential	ADJ	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
methamphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
neurotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
widely	ADV	O	O
believed	VERB	O	O
that	ADP	O	O
dopamine	NOUN	O	I-Entity
(	PUNCT	O	O
DA	PROPN	O	I-Entity
)	PUNCT	O	O
mediates	VERB	O	O
methamphetamine	NOUN	O	I-Entity
(	PUNCT	O	O
METH)-induced	VERB	O	I-Entity
toxicity	NOUN	O	I-Entity
to	ADP	O	O
brain	NOUN	O	O
dopaminergic	ADJ	O	O
neurons	NOUN	O	O
,	PUNCT	O	O
because	ADP	O	O
drugs	NOUN	O	O
that	ADJ	O	O
interfere	VERB	O	O
with	ADP	O	O
DA	PROPN	O	I-Entity
neurotransmission	NOUN	O	O
decrease	NOUN	O	O
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
drugs	NOUN	O	O
that	ADJ	O	O
increase	VERB	O	O
DA	PROPN	O	I-Entity
neurotransmission	NOUN	O	O
enhance	VERB	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
temperature	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
that	ADJ	O	O
have	VERB	O	O
been	VERB	O	O
used	VERB	O	O
to	PART	O	O
manipulate	VERB	O	O
brain	NOUN	O	O
DA	PROPN	O	I-Entity
neurotransmission	NOUN	O	O
confound	VERB	O	O
interpretation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
data	NOUN	O	O
.	PUNCT	O	O

Here	ADV	O	O
we	PRON	O	O
show	VERB	O	O
that	ADP	O	O
the	DET	O	O
recently	ADV	O	O
reported	VERB	O	O
ability	NOUN	O	O
of	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dihydroxyphenylalanine	NOUN	O	I-Entity
to	PART	O	O
reverse	VERB	O	O
the	DET	O	O
protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
para	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
tyrosine	NOUN	O	I-Entity
on	ADP	O	O
METH	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
DA	PROPN	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
is	VERB	O	O
also	ADV	O	O
confounded	VERB	O	O
by	ADP	O	O
drug	NOUN	O	O
effects	NOUN	O	O
on	ADP	O	O
body	NOUN	O	O
temperature	NOUN	O	O
.	PUNCT	O	O

Further	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
show	VERB	O	O
that	ADP	O	O
mice	NOUN	O	O
genetically	ADV	O	O
engineered	VERB	O	O
to	PART	O	O
be	VERB	O	O
deficient	ADJ	O	O
in	ADP	O	O
brain	NOUN	O	O
DA	PROPN	O	I-Entity
develop	VERB	O	O
METH	PROPN	O	I-Entity
neurotoxicity	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADV	O	O
long	ADV	O	O
as	ADP	O	O
the	DET	O	O
thermic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
METH	PROPN	O	I-Entity
are	VERB	O	O
preserved	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
demonstrate	VERB	O	O
that	ADP	O	O
mice	NOUN	O	O
genetically	ADV	O	O
engineered	VERB	O	O
to	PART	O	O
have	VERB	O	O
unilateral	ADJ	O	O
brain	NOUN	O	O
DA	NOUN	O	I-Entity
deficits	NOUN	O	O
develop	VERB	O	O
METH	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dopaminergic	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
that	ADJ	O	O
are	VERB	O	O
of	ADP	O	O
comparable	ADJ	O	O
magnitude	NOUN	O	O
on	ADP	O	O
both	DET	O	O
sides	NOUN	O	O
of	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
.	PUNCT	O	O

Taken	VERB	O	O
together	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
findings	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
DA	PROPN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
essential	ADJ	O	O
for	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
METH	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dopaminergic	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
mechanisms	NOUN	O	O
independent	ADJ	O	O
of	ADP	O	O
DA	PROPN	O	I-Entity
warrant	NOUN	O	O
more	ADV	O	O
intense	ADJ	O	O
investigation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20304337)

Brainstem	PROPN	O	B-Entity
dysgenesis	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
infant	NOUN	O	O
prenatally	ADV	O	O
exposed	VERB	O	O
to	ADP	O	O
cocaine	NOUN	O	I-Entity
.	PUNCT	O	O

Many	ADJ	O	O
authors	NOUN	O	O
described	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
fetus	NOUN	O	O
of	ADP	O	O
maternal	ADJ	O	O
cocaine	NOUN	O	B-Entity
abuse	NOUN	O	I-Entity
during	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

Vasoconstriction	NOUN	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
common	ADJ	O	O
mechanism	NOUN	O	O
of	ADP	O	O
action	NOUN	O	O
leading	VERB	O	O
to	ADP	O	O
a	DET	O	O
wide	ADJ	O	O
range	NOUN	O	O
of	ADP	O	O
fetal	ADJ	O	B-Entity
anomalies	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
on	ADP	O	O
an	DET	O	O
infant	NOUN	O	O
with	ADP	O	O
multiple	ADJ	O	B-Entity
cranial	ADJ	O	I-Entity
-	PUNCT	O	I-Entity
nerve	NOUN	O	I-Entity
involvement	NOUN	O	I-Entity
attributable	ADJ	O	O
to	PART	O	O
brainstem	VERB	O	B-Entity
dysgenesis	NOUN	O	I-Entity
,	PUNCT	O	O
born	VERB	O	O
to	ADP	O	O
a	DET	O	O
cocaine	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
addicted	VERB	O	I-Entity
mother	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20103708)

The	DET	O	O
protective	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
Nrf2	PROPN	O	O
in	ADP	O	O
streptozotocin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

Diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
is	VERB	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
major	ADJ	O	O
causes	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
the	DET	O	O
production	NOUN	O	O
of	ADP	O	O
reactive	ADJ	O	O
oxygen	NOUN	O	I-Entity
species	NOUN	O	O
(	PUNCT	O	O
ROS	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Here	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
report	VERB	O	O
our	ADJ	O	O
findings	NOUN	O	O
demonstrating	VERB	O	O
a	DET	O	O
protective	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
Nrf2	PROPN	O	O
against	ADP	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
explore	VERB	O	O
the	DET	O	O
protective	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
Nrf2	PROPN	O	O
against	ADP	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
using	VERB	O	O
human	ADJ	O	O
kidney	NOUN	O	O
biopsy	NOUN	O	O
tissues	NOUN	O	O
from	ADP	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
streptozotocin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
model	NOUN	O	O
in	ADP	O	O
Nrf2(-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cultured	ADJ	O	O
human	ADJ	O	O
mesangial	ADJ	O	O
cells	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
glomeruli	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
patients	NOUN	O	O
were	VERB	O	O
under	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
and	CCONJ	O	O
had	VERB	O	O
elevated	VERB	O	O
Nrf2	PROPN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
animal	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
Nrf2	PROPN	O	O
was	VERB	O	O
demonstrated	VERB	O	O
to	PART	O	O
be	VERB	O	O
crucial	ADJ	O	O
in	ADP	O	O
ameliorating	VERB	O	O
streptozotocin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
renal	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
evident	ADJ	O	O
by	ADP	O	O
Nrf2(-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
having	VERB	O	O
higher	ADJ	O	O
ROS	PROPN	O	O
production	NOUN	O	O
and	CCONJ	O	O
suffering	NOUN	O	O
from	ADP	O	O
greater	ADJ	O	O
oxidative	ADJ	O	O
DNA	NOUN	O	O
damage	NOUN	O	O
and	CCONJ	O	O
renal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
Nrf2(+/+	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
.	PUNCT	O	O

Mechanistic	ADJ	O	O
studies	NOUN	O	O
in	ADP	O	O
both	DET	O	O
in	ADP	O	O
vivo	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vitro	NOUN	O	O
systems	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
the	DET	O	O
Nrf2-mediated	ADJ	O	O
protection	NOUN	O	O
against	ADP	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
is	VERB	O	O
,	PUNCT	O	O
at	ADP	O	O
least	ADJ	O	O
,	PUNCT	O	O
partially	ADV	O	O
through	ADP	O	O
inhibition	NOUN	O	O
of	ADP	O	O
transforming	VERB	O	O
growth	NOUN	O	O
factor	NOUN	O	O
-	PUNCT	O	O
beta1	NOUN	O	O
(	PUNCT	O	O
TGF	PROPN	O	O
-	PUNCT	O	O
beta1	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
extracellular	ADJ	O	O
matrix	NOUN	O	O
production	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
human	ADJ	O	O
renal	ADJ	O	O
mesangial	ADJ	O	O
cells	NOUN	O	O
,	PUNCT	O	O
high	ADJ	O	O
glucose	NOUN	O	I-Entity
induced	VERB	O	O
ROS	PROPN	O	O
production	NOUN	O	O
and	CCONJ	O	O
activated	VERB	O	O
expression	NOUN	O	O
of	ADP	O	O
Nrf2	PROPN	O	O
and	CCONJ	O	O
its	ADJ	O	O
downstream	ADJ	O	O
genes	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
work	NOUN	O	O
clearly	ADV	O	O
indicates	VERB	O	O
a	DET	O	O
protective	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
Nrf2	PROPN	O	O
in	ADP	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
dietary	ADJ	O	O
or	CCONJ	O	O
therapeutic	ADJ	O	O
activation	NOUN	O	O
of	ADP	O	O
Nrf2	PROPN	O	O
could	VERB	O	O
be	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
strategy	NOUN	O	O
to	PART	O	O
prevent	VERB	O	O
or	CCONJ	O	O
slow	VERB	O	O
down	PART	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
diabetic	ADJ	O	B-Entity
nephropathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (19996135)

High	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
tranexamic	NOUN	O	B-Entity
Acid	PROPN	O	I-Entity
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
nonischemic	ADJ	O	O
clinical	ADJ	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
cardiac	ADJ	O	O
surgical	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
2	NUM	O	O
separate	ADJ	O	O
centers	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
observed	VERB	O	O
a	DET	O	O
notable	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
convulsive	ADJ	O	I-Entity
seizures	NOUN	O	I-Entity
from	ADP	O	O
1.3%	NUM	O	O
to	ADP	O	O
3.8%	NUM	O	O
in	ADP	O	O
patients	NOUN	O	O
having	VERB	O	O
undergone	ADJ	O	O
major	ADJ	O	O
cardiac	ADJ	O	O
surgical	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
events	NOUN	O	O
were	VERB	O	O
temporally	ADV	O	O
coincident	ADJ	O	O
with	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
tranexamic	NOUN	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
TXA	PROPN	O	I-Entity
)	PUNCT	O	O
therapy	NOUN	O	O
after	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
aprotinin	NOUN	O	O
from	ADP	O	O
general	ADJ	O	O
clinical	ADJ	O	O
usage	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
review	NOUN	O	O
was	VERB	O	O
to	PART	O	O
perform	VERB	O	O
a	DET	O	O
retrospective	NOUN	O	O
analysis	NOUN	O	O
to	PART	O	O
examine	VERB	O	O
whether	ADP	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
relation	NOUN	O	O
between	ADP	O	O
TXA	PROPN	O	I-Entity
usage	NOUN	O	O
and	CCONJ	O	O
seizures	NOUN	O	I-Entity
after	ADP	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
in	ADP	O	O
-	PUNCT	O	O
depth	NOUN	O	O
chart	NOUN	O	O
review	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
in	ADV	O	O
all	DET	O	O
24	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
developed	VERB	O	O
perioperative	ADJ	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
24	NUM	O	O
patients	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
have	VERB	O	O
evidence	NOUN	O	O
of	ADP	O	O
new	ADJ	O	O
cerebral	ADJ	O	B-Entity
ischemic	ADJ	O	I-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
seizures	NOUN	O	I-Entity
were	VERB	O	O
likely	ADJ	O	O
due	ADJ	O	O
to	ADP	O	O
ischemic	ADJ	O	B-Entity
brain	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
seizures	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
have	VERB	O	O
permanent	ADJ	O	O
neurological	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
24	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
seizures	NOUN	O	I-Entity
received	VERB	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
TXA	PROPN	O	I-Entity
intraoperatively	ADV	O	O
ranging	VERB	O	O
from	ADP	O	O
61	NUM	O	O
to	ADP	O	O
259	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
had	VERB	O	O
a	DET	O	O
mean	ADJ	O	O
age	NOUN	O	O
of	ADP	O	O
69.9	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
21	NUM	O	O
of	ADP	O	O
24	NUM	O	O
had	VERB	O	O
undergone	VERB	O	O
open	ADJ	O	O
chamber	NOUN	O	O
rather	ADV	O	O
than	ADP	O	O
coronary	ADJ	O	O
bypass	NOUN	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
brain	NOUN	O	B-Entity
ischemic	NOUN	O	I-Entity
,	PUNCT	O	O
metabolic	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
hyperthermia	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
causes	NOUN	O	O
for	ADP	O	O
their	ADJ	O	O
seizures	NOUN	O	I-Entity
was	VERB	O	O
apparent	ADJ	O	O
.	PUNCT	O	O

:	PUNCT	O	O
Our	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
TXA	NOUN	O	I-Entity
in	ADP	O	O
older	ADJ	O	O
patients	NOUN	O	O
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
cardiopulmonary	ADJ	O	O
bypass	NOUN	O	O
and	CCONJ	O	O
open	ADJ	O	O
-	PUNCT	O	O
chamber	NOUN	O	O
cardiac	ADJ	O	O
surgery	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
clinical	ADJ	O	O
seizures	NOUN	O	I-Entity
in	ADP	O	O
susceptible	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19674115)

Recurrent	PROPN	O	O
dysosmia	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
pyrazinamide	NOUN	O	I-Entity
.	PUNCT	O	O

Pyrazinamide	PROPN	O	I-Entity
can	VERB	O	O
have	VERB	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
hepatic	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
,	PUNCT	O	O
hyperuricemia	NOUN	O	I-Entity
or	CCONJ	O	O
digestive	ADJ	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
rare	ADJ	O	O
cases	NOUN	O	O
,	PUNCT	O	O
alterations	NOUN	O	O
in	ADP	O	O
taste	NOUN	O	O
and	CCONJ	O	O
smell	NOUN	O	O
function	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
for	ADP	O	O
pyrazinamide	NOUN	O	I-Entity
when	ADV	O	O
combined	VERB	O	O
with	ADP	O	O
other	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
reversible	ADJ	O	O
olfactory	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
related	VERB	O	O
to	ADP	O	O
pyrazinamide	VERB	O	I-Entity
in	ADP	O	O
a	DET	O	O
woman	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
positive	ADJ	O	O
rechallenge	NOUN	O	O
.	PUNCT	O	O

Dysosmia	PROPN	O	I-Entity
disappeared	VERB	O	O
completely	ADV	O	O
after	ADP	O	O
pyrazinamide	NOUN	O	I-Entity
withdrawal	NOUN	O	O
and	CCONJ	O	O
recurred	VERB	O	O
after	ADP	O	O
its	ADJ	O	O
rechallenge	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19139001)

Longitudinal	ADJ	O	O
assessment	NOUN	O	O
of	ADP	O	O
air	NOUN	O	O
conduction	NOUN	O	O
audiograms	NOUN	O	O
in	ADP	O	O
a	DET	O	O
phase	NOUN	O	O
III	NUM	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
difluoromethylornithine	NOUN	O	I-Entity
and	CCONJ	O	O
sulindac	NOUN	O	I-Entity
for	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
sporadic	ADJ	O	O
colorectal	NOUN	O	B-Entity
adenomas	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
phase	NOUN	O	O
III	NUM	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
assessed	VERB	O	O
the	DET	O	O
recurrence	NOUN	O	O
of	ADP	O	O
adenomatous	ADJ	O	B-Entity
polyps	NOUN	O	I-Entity
after	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
36	NUM	O	O
months	NOUN	O	O
with	ADP	O	O
difluoromethylornithine	NOUN	O	I-Entity
(	PUNCT	O	O
DFMO	PROPN	O	I-Entity
)	PUNCT	O	O
plus	CCONJ	O	O
sulindac	NOUN	O	I-Entity
or	CCONJ	O	O
matched	VERB	O	O
placebos	NOUN	O	O
.	PUNCT	O	O

Temporary	ADJ	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
known	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
DFMO	PROPN	O	I-Entity
,	PUNCT	O	O
thus	ADV	O	O
a	DET	O	O
comprehensive	ADJ	O	O
approach	NOUN	O	O
was	VERB	O	O
developed	VERB	O	O
to	PART	O	O
analyze	VERB	O	O
serial	ADJ	O	O
air	NOUN	O	O
conduction	NOUN	O	O
audiograms	NOUN	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
290	NUM	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
an	DET	O	O
average	ADJ	O	O
difference	NOUN	O	O
of	ADP	O	O
0.50	NUM	O	O
dB	NOUN	O	O
between	ADP	O	O
subjects	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
DFMO	PROPN	O	I-Entity
plus	CCONJ	O	O
sulindac	ADJ	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
treated	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
-0.64	NUM	O	O
to	PART	O	O
1.63	NUM	O	O
dB	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.39	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
adjusted	VERB	O	O
for	ADP	O	O
baseline	NOUN	O	O
values	NOUN	O	O
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
frequencies	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
14	NUM	O	O
of	ADP	O	O
151	NUM	O	O
(	PUNCT	O	O
9.3%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
DFMO	PROPN	O	I-Entity
plus	CCONJ	O	O
sulindac	ADJ	O	I-Entity
group	NOUN	O	O
and	CCONJ	O	O
4	NUM	O	O
of	ADP	O	O
139	NUM	O	O
(	PUNCT	O	O
2.9%	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
who	NOUN	O	O
experienced	VERB	O	O
at	ADP	O	O
least	ADJ	O	O
15	NUM	O	O
dB	NOUN	O	O
hearing	NOUN	O	O
reduction	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
2	NUM	O	O
or	CCONJ	O	O
more	ADJ	O	O
consecutive	ADJ	O	O
frequencies	NOUN	O	O
across	ADP	O	O
the	DET	O	O
entire	ADJ	O	O
range	NOUN	O	O
tested	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
subjects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
DFMO	PROPN	O	I-Entity
plus	CCONJ	O	O
sulindac	ADJ	O	I-Entity
group	NOUN	O	O
who	NOUN	O	O
experienced	VERB	O	O
clinically	ADV	O	O
significant	ADJ	O	O
hearing	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
estimated	VERB	O	O
attributable	ADJ	O	O
risk	NOUN	O	O
of	ADP	O	O
ototoxicity	NOUN	O	I-Entity
from	ADP	O	O
exposure	NOUN	O	O
to	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
is	VERB	O	O
8.4%	NUM	O	O
(	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
-2.0%	X	O	O
to	ADP	O	O
18.8%	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.12	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
a	DET	O	O
<	X	O	O
2	NUM	O	O
dB	NOUN	O	O
difference	NOUN	O	O
in	ADP	O	O
mean	ADJ	O	O
threshold	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
DFMO	PROPN	O	I-Entity
plus	CCONJ	O	O
sulindac	ADJ	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
those	DET	O	O
treated	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18239197)

Increased	VERB	O	O
mental	ADJ	O	B-Entity
slowing	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
APOE	PROPN	O	O
epsilon4	PROPN	O	O
allele	NOUN	O	O
after	ADP	O	O
trihexyphenidyl	ADJ	O	I-Entity
oral	ADJ	O	O
anticholinergic	ADJ	O	O
challenge	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
elderly	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
objectives	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
were	VERB	O	O
to	PART	O	O
examine	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
APOE	PROPN	O	O
epsilon4	PROPN	O	O
and	CCONJ	O	O
subjective	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
trihexyphenidyl	NOUN	O	I-Entity
on	ADP	O	O
measures	NOUN	O	O
reflecting	VERB	O	O
sedation	NOUN	O	O
and	CCONJ	O	O
confusion	NOUN	O	I-Entity
and	CCONJ	O	O
to	PART	O	O
investigate	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
trihexyphenidyl	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
subjective	ADJ	O	O
effects	NOUN	O	O
and	CCONJ	O	O
objective	ADJ	O	O
memory	NOUN	O	O
performance	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
participants	NOUN	O	O
received	VERB	O	O
1.0	NUM	O	O
mg	NUM	O	O
or	CCONJ	O	O
2.0	NUM	O	O
mg	NUM	O	O
trihexyphenidyl	NOUN	O	I-Entity
or	CCONJ	O	O
placebo	NOUN	O	O
administered	VERB	O	O
in	ADP	O	O
counterbalanced	VERB	O	O
sequences	NOUN	O	O
over	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
consecutive	ADJ	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
2.0-mg	NUM	O	O
oral	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
trihexyphenidyl	NOUN	O	I-Entity
resulted	VERB	O	O
in	ADP	O	O
increased	VERB	O	O
subjective	ADJ	O	O
ratings	NOUN	O	O
of	ADP	O	O
mental	ADJ	O	B-Entity
slowness	NOUN	O	I-Entity
in	ADP	O	O
carriers	NOUN	O	O
of	ADP	O	O
the	DET	O	O
APOE	PROPN	O	O
epsilon4	NOUN	O	O
allele	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

Drug	ADJ	O	O
effects	NOUN	O	O
as	ADP	O	O
determined	VERB	O	O
by	ADP	O	O
difference	NOUN	O	O
scores	NOUN	O	O
between	ADP	O	O
2.0	NUM	O	O
mg	NUM	O	O
trihexyphenidyl	NOUN	O	I-Entity
and	CCONJ	O	O
placebo	NOUN	O	O
on	ADP	O	O
ratings	NOUN	O	O
of	ADP	O	O
mental	ADJ	O	B-Entity
slowness	NOUN	O	I-Entity
significantly	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
total	NOUN	O	O
and	CCONJ	O	O
delayed	VERB	O	O
recall	NOUN	O	O
on	ADP	O	O
the	DET	O	O
Buschke	PROPN	O	O
Selective	PROPN	O	O
Reminding	PROPN	O	O
Test	PROPN	O	O
in	ADP	O	O
carriers	NOUN	O	O
of	ADP	O	O
the	DET	O	O
APOE	PROPN	O	O
epsilon4	NOUN	O	O
allele	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
epsilon4	NOUN	O	O
allele	NOUN	O	O
in	ADP	O	O
healthy	ADJ	O	O
elderly	ADJ	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
subjective	ADJ	O	O
mental	ADJ	O	B-Entity
slowing	NOUN	O	I-Entity
after	ADP	O	O
trihexyphenidyl	ADJ	O	I-Entity
anticholinergic	ADJ	O	O
challenge	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17194457)

Behavioral	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
pubertal	ADJ	O	O
anabolic	ADJ	O	O
androgenic	ADJ	O	O
steroid	NOUN	O	I-Entity
exposure	NOUN	O	O
in	ADP	O	O
male	NOUN	O	O
rats	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
serotonin	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
goal	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
interactive	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
anabolic	ADJ	O	O
androgenic	ADJ	O	O
steroid	NOUN	O	I-Entity
(	PUNCT	O	O
AAS	PROPN	O	O
)	PUNCT	O	O
exposure	NOUN	O	O
and	CCONJ	O	O
brain	NOUN	O	O
serotonin	NOUN	O	I-Entity
(	PUNCT	O	O
5-hydroxytryptamine	NOUN	O	I-Entity
,	PUNCT	O	O
5-HT	PUNCT	O	I-Entity
)	PUNCT	O	O
depletion	NOUN	O	O
on	ADP	O	O
behavior	NOUN	O	O
of	ADP	O	O
pubertal	ADJ	O	O
male	ADJ	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Serotonin	NOUN	O	I-Entity
was	VERB	O	O
depleted	VERB	O	O
beginning	VERB	O	O
on	ADP	O	O
postnatal	ADJ	O	O
day	NOUN	O	O
26	NUM	O	O
with	ADP	O	O
parachlorophenylalanine	NOUN	O	I-Entity
(	PUNCT	O	O
PCPA	PROPN	O	I-Entity
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
,	PUNCT	O	O
every	DET	O	O
other	ADJ	O	O
day	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
controls	NOUN	O	O
received	VERB	O	O
saline	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
puberty	NOUN	O	O
(	PUNCT	O	O
P40	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
half	ADJ	O	O
the	DET	O	O
PCPA	PROPN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
and	CCONJ	O	O
half	ADJ	O	O
the	DET	O	O
saline	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
began	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
testosterone	NOUN	O	I-Entity
(	PUNCT	O	O
T	PROPN	O	I-Entity
,	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
,	PUNCT	O	O
5	NUM	O	O
days	NOUN	O	O
/	SYM	O	O
week	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Behavioral	ADJ	O	O
measures	NOUN	O	O
included	VERB	O	O
locomotion	NOUN	O	O
,	PUNCT	O	O
irritability	NOUN	O	I-Entity
,	PUNCT	O	O
copulation	NOUN	O	O
,	PUNCT	O	O
partner	NOUN	O	O
preference	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
aggression	NOUN	O	I-Entity
.	PUNCT	O	O

Animals	NOUN	O	O
were	VERB	O	O
tested	VERB	O	O
for	ADP	O	O
aggression	NOUN	O	I-Entity
in	ADP	O	O
their	ADJ	O	O
home	NOUN	O	O
cage	NOUN	O	O
,	PUNCT	O	O
both	CCONJ	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
physical	ADJ	O	O
provocation	NOUN	O	O
(	PUNCT	O	O
mild	ADJ	O	O
tail	NOUN	O	O
pinch	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Brain	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
5-HT	NUM	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
metabolite	NOUN	O	O
,	PUNCT	O	O
5-hydroxyindoleacetic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
5-HIAA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
were	VERB	O	O
determined	VERB	O	O
using	VERB	O	O
HPLC	PROPN	O	O
.	PUNCT	O	O

PCPA	PROPN	O	I-Entity
significantly	ADV	O	O
and	CCONJ	O	O
substantially	ADV	O	O
depleted	VERB	O	O
5-HT	NUM	O	I-Entity
and	CCONJ	O	O
5-HIAA	NUM	O	I-Entity
in	ADP	O	O
all	DET	O	O
brain	NOUN	O	O
regions	NOUN	O	O
examined	VERB	O	O
.	PUNCT	O	O

Chronic	ADJ	O	O
T	NOUN	O	I-Entity
treatment	NOUN	O	O
significantly	ADV	O	O
decreased	VERB	O	O
5-HT	NUM	O	I-Entity
and	CCONJ	O	O
5-HIAA	NUM	O	I-Entity
in	ADP	O	O
certain	ADJ	O	O
brain	NOUN	O	O
areas	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
to	ADP	O	O
a	DET	O	O
much	ADV	O	O
lesser	ADJ	O	O
extent	NOUN	O	O
than	ADP	O	O
PCPA	PROPN	O	I-Entity
.	PUNCT	O	O

Chronic	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
PCPA	PROPN	O	I-Entity
alone	ADV	O	O
significantly	ADV	O	O
decreased	VERB	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
increased	VERB	O	O
irritability	NOUN	O	I-Entity
but	CCONJ	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
sexual	ADJ	O	O
behavior	NOUN	O	O
,	PUNCT	O	O
partner	NOUN	O	O
preference	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
aggression	NOUN	O	I-Entity
.	PUNCT	O	O

T	NOUN	O	I-Entity
alone	ADV	O	O
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
locomotion	NOUN	O	O
,	PUNCT	O	O
irritability	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
sexual	ADJ	O	O
behavior	NOUN	O	O
but	CCONJ	O	O
increased	VERB	O	O
partner	NOUN	O	O
preference	NOUN	O	O
and	CCONJ	O	O
aggression	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
striking	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
combining	VERB	O	O
T+PCPA	PROPN	O	I-Entity
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
attack	NOUN	O	O
frequency	NOUN	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
latency	NOUN	O	O
to	PART	O	O
attack	VERB	O	O
,	PUNCT	O	O
particularly	ADV	O	O
following	VERB	O	O
physical	ADJ	O	O
provocation	NOUN	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
these	DET	O	O
data	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
can	VERB	O	O
be	VERB	O	O
speculated	VERB	O	O
that	ADP	O	O
pubertal	ADJ	O	O
AAS	PROPN	O	O
users	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
central	ADJ	O	O
5-HT	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
especially	ADV	O	O
prone	ADJ	O	O
to	ADP	O	O
exhibit	VERB	O	O
aggressive	ADJ	O	B-Entity
behavior	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (16132524)

Intracavitary	ADJ	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
paclitaxel	NOUN	O	I-Entity
/	SYM	O	O
carboplatin	ADV	O	I-Entity
liquid	ADJ	O	O
crystalline	NOUN	O	O
cubic	ADJ	O	O
phases	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
recurrent	ADJ	O	O
glioblastoma	NOUN	O	I-Entity
--	PUNCT	O	O
clinical	ADJ	O	O
observations	NOUN	O	O
.	PUNCT	O	O

Human	ADJ	O	O
malignant	ADJ	O	O
brain	NOUN	O	B-Entity
tumors	NOUN	O	I-Entity
have	VERB	O	O
a	DET	O	O
poor	ADJ	O	O
prognosis	NOUN	O	O
in	ADP	O	O
spite	NOUN	O	O
of	ADP	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
human	ADJ	O	O
glioblastoma	NOUN	O	I-Entity
recurrences	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
feasibility	NOUN	O	O
,	PUNCT	O	O
safety	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
surgical	ADJ	O	O
intracavitary	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
paclitaxel	NOUN	O	I-Entity
and	CCONJ	O	O
carboplatin	NOUN	O	I-Entity
encapsulated	VERB	O	O
by	ADP	O	O
liquid	NOUN	O	O
crystalline	NOUN	O	O
cubic	ADJ	O	O
phases	NOUN	O	O
are	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
a	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
recurrence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
glioblastoma	NOUN	O	I-Entity
multiforme	NOUN	O	O
underwent	VERB	O	O
re	ADP	O	O
-	PUNCT	O	O
resection	NOUN	O	O
and	CCONJ	O	O
received	VERB	O	O
an	DET	O	O
intracavitary	ADJ	O	O
application	NOUN	O	O
of	ADP	O	O
paclitaxel	NOUN	O	I-Entity
and	CCONJ	O	O
carboplatin	NOUN	O	I-Entity
cubic	ADJ	O	O
phases	NOUN	O	O
in	ADP	O	O
different	ADJ	O	O
dosages	NOUN	O	O
.	PUNCT	O	O

Six	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
more	ADJ	O	O
than	ADP	O	O
15	NUM	O	O
mg	NUM	O	O
paclitaxel	NOUN	O	I-Entity
and	CCONJ	O	O
suffered	VERB	O	O
from	ADP	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
brain	NOUN	O	B-Entity
edema	NOUN	O	I-Entity
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
patients	NOUN	O	O
received	VERB	O	O
only	ADV	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
15	NUM	O	O
mg	NUM	O	O
paclitaxel	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
latter	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
brain	NOUN	O	B-Entity
edema	NOUN	O	I-Entity
was	VERB	O	O
markedly	ADV	O	O
reduced	VERB	O	O
and	CCONJ	O	O
dealt	VERB	O	O
medically	ADV	O	O
.	PUNCT	O	O

Intracavitary	ADJ	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
recurrent	ADJ	O	O
glioblastoma	NOUN	O	I-Entity
using	VERB	O	O
cubic	ADJ	O	O
phases	NOUN	O	O
is	VERB	O	O
feasible	ADJ	O	O
and	CCONJ	O	O
safe	ADJ	O	O
,	PUNCT	O	O
yet	CCONJ	O	O
the	DET	O	O
clinical	ADJ	O	O
benefit	NOUN	O	O
remains	VERB	O	O
to	PART	O	O
be	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
phase	NOUN	O	O
II	PROPN	O	O
study	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12907924)

Methylphenidate	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
obsessive	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
compulsive	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
elderly	ADJ	O	O
man	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
82-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
treatment	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
resistant	ADJ	O	I-Entity
depression	NOUN	O	I-Entity
and	CCONJ	O	O
early	ADJ	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
was	VERB	O	O
started	VERB	O	O
on	ADP	O	O
methylphenidate	NOUN	O	I-Entity
.	PUNCT	O	O

Significant	ADJ	O	O
obsessive	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
compulsive	ADJ	O	I-Entity
behavior	NOUN	O	I-Entity
ensued	ADV	O	O
but	CCONJ	O	O
diminished	VERB	O	O
over	ADP	O	O
several	ADJ	O	O
weeks	NOUN	O	O
when	ADV	O	O
methylphenidate	NOUN	O	I-Entity
was	VERB	O	O
replaced	VERB	O	O
by	ADP	O	O
fluvoxamine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
no	DET	O	O
prior	ADJ	O	O
psychiatric	ADJ	O	I-Entity
history	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
he	PRON	O	O
had	VERB	O	O
a	DET	O	O
sister	NOUN	O	O
with	ADP	O	O
obsessive	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
compulsive	ADJ	O	I-Entity
disorder	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
appears	VERB	O	O
that	ADP	O	O
methylphenidate	NOUN	O	I-Entity
precipitated	VERB	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
pathological	ADJ	O	O
behavior	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12139551)

Cardiac	PROPN	O	B-Entity
arrest	NOUN	O	I-Entity
after	ADP	O	O
intravenous	ADJ	O	O
metoclopramide	NOUN	O	I-Entity
-	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
five	NUM	O	O
repeated	VERB	O	O
injections	NOUN	O	O
of	ADP	O	O
metoclopramide	NOUN	O	I-Entity
causing	VERB	O	O
five	NUM	O	O
episodes	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
where	ADV	O	O
intravenous	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
metoclopramide	NOUN	O	I-Entity
was	VERB	O	O
immediately	ADV	O	O
followed	VERB	O	O
by	ADP	O	O
asystole	NOUN	O	I-Entity
repeatedly	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
received	VERB	O	O
metoclopramide	NOUN	O	I-Entity
10	NUM	O	O
mg	NUM	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
interviewing	VERB	O	O
the	DET	O	O
attending	VERB	O	O
nurses	NOUN	O	O
and	CCONJ	O	O
reviewing	VERB	O	O
the	DET	O	O
written	VERB	O	O
documentation	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
clear	ADJ	O	O
that	ADP	O	O
every	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
metoclopramide	NOUN	O	I-Entity
was	VERB	O	O
immediately	ADV	O	O
(	PUNCT	O	O
within	ADP	O	O
s	NOUN	O	O
)	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
asystole	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
asystole	NOUN	O	I-Entity
lasted	VERB	O	O
15	NUM	O	O
-	SYM	O	O
30	NUM	O	O
s	NOUN	O	O
on	ADP	O	O
four	NUM	O	O
occasions	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
one	NUM	O	O
occasion	NOUN	O	O
it	PRON	O	O
lasted	VERB	O	O
2	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
received	VERB	O	O
atropine	NOUN	O	I-Entity
0.5	NUM	O	O
-	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
and	CCONJ	O	O
chest	NOUN	O	O
compressions	NOUN	O	O
,	PUNCT	O	O
before	ADP	O	O
sinus	ADJ	O	O
rhythm	NOUN	O	O
again	ADV	O	O
took	VERB	O	O
over	PART	O	O
.	PUNCT	O	O

We	PRON	O	O
interpret	VERB	O	O
this	DET	O	O
as	ADP	O	O
episodes	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
arrest	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
metoclopramide	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
rapid	ADJ	O	O
injection	NOUN	O	O
via	ADP	O	O
the	DET	O	O
central	ADJ	O	O
venous	ADJ	O	O
route	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
concomitant	ADJ	O	O
tapering	NOUN	O	O
of	ADP	O	O
dopamine	NOUN	O	I-Entity
infusion	NOUN	O	O
might	VERB	O	O
have	VERB	O	O
contributed	VERB	O	O
in	ADP	O	O
precipitating	VERB	O	O
the	DET	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
reaction	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10411803)

Severe	ADJ	O	O
immune	ADJ	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
prophylactic	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
cefotetan	NOUN	O	I-Entity
in	ADP	O	O
obstetric	NOUN	O	O
and	CCONJ	O	O
gynecologic	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

Second-	ADJ	O	O
and	CCONJ	O	O
third	ADJ	O	O
-	PUNCT	O	O
generation	NOUN	O	O
cephalosporins	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
cefotetan	ADJ	O	I-Entity
,	PUNCT	O	O
are	VERB	O	O
increasingly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
severe	ADJ	O	O
,	PUNCT	O	O
sometimes	ADV	O	O
fatal	ADJ	O	O
immune	ADJ	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
noticed	VERB	O	O
that	ADP	O	O
10	NUM	O	O
of	ADP	O	O
our	ADJ	O	O
35	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
cefotetan	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hemolytic	ADJ	O	B-Entity
anemias	NOUN	O	I-Entity
were	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
received	VERB	O	O
cefotetan	ADJ	O	I-Entity
prophylactically	ADV	O	O
for	ADP	O	O
obstetric	NOUN	O	O
and	CCONJ	O	O
gynecologic	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

Eight	NUM	O	O
of	ADP	O	O
these	DET	O	O
cases	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
immune	ADJ	O	O
hemolytic	ADJ	O	B-Entity
anemia	NOUN	O	I-Entity
are	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (10225068)

Cauda	PROPN	O	B-Entity
equina	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
after	ADP	O	O
spinal	ADJ	O	O
anaesthesia	NOUN	O	O
with	ADP	O	O
hyperbaric	NOUN	O	O
5%	NUM	O	O

lignocaine	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
review	NOUN	O	O
of	ADP	O	O
six	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
cauda	NOUN	O	B-Entity
equina	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
reported	VERB	O	O
to	ADP	O	O
the	DET	O	O
Swedish	PROPN	O	O
Pharmaceutical	PROPN	O	O
Insurance	PROPN	O	O
1993	NUM	O	O
-	SYM	O	O
1997	NUM	O	O
.	PUNCT	O	O

Six	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
cauda	NOUN	O	B-Entity
equina	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
with	ADP	O	O
varying	VERB	O	O
severity	NOUN	O	O
were	VERB	O	O
reported	VERB	O	O
to	ADP	O	O
the	DET	O	O
Swedish	PROPN	O	O
Pharmaceutical	PROPN	O	O
Insurance	PROPN	O	O
during	ADP	O	O
the	DET	O	O
period	NOUN	O	O
1993	NUM	O	O
-	SYM	O	O
1997	NUM	O	O
.	PUNCT	O	O

All	DET	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
spinal	ADJ	O	O
anaesthesia	NOUN	O	O
using	VERB	O	O
hyperbaric	NOUN	O	O
5%	NUM	O	O
lignocaine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
hyperbaric	NOUN	O	O
5%	NUM	O	O
lignocaine	NOUN	O	I-Entity
administered	VERB	O	O
ranged	VERB	O	O
from	ADP	O	O
60	NUM	O	O
to	ADP	O	O
120	NUM	O	O
mg	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
of	ADP	O	O
the	DET	O	O
cases	NOUN	O	O
were	VERB	O	O
most	ADV	O	O
likely	ADV	O	O
caused	VERB	O	O
by	ADP	O	O
direct	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
of	ADP	O	O
hyperbaric	NOUN	O	O
5%	NUM	O	O
lignocaine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
other	ADJ	O	O
3	NUM	O	O
cases	NOUN	O	O
,	PUNCT	O	O
direct	ADJ	O	O
neurotoxicity	NOUN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
probable	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
unfortunately	ADV	O	O
radiological	ADJ	O	O
investigations	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
done	VERB	O	O
to	PART	O	O
definitely	ADV	O	O
exclude	VERB	O	O
a	DET	O	O
compressive	ADJ	O	O
aetiology	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
cases	NOUN	O	O
sustained	VERB	O	O
permanent	ADJ	O	O
neurological	ADJ	O	B-Entity
deficits	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
recommend	VERB	O	O
that	ADP	O	O
hyperbaric	ADJ	O	O
lignocaine	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
administered	VERB	O	O
in	ADP	O	O
concentrations	NOUN	O	O
not	ADV	O	O
greater	ADJ	O	O
than	ADP	O	O
2%	NUM	O	O
and	CCONJ	O	O
at	ADP	O	O
a	DET	O	O
total	ADJ	O	O
dose	NOUN	O	O
preferably	ADV	O	O
not	ADV	O	O
exceeding	VERB	O	O
60	NUM	O	O
mg	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9549528)

Cortical	ADJ	O	O
motor	NOUN	O	O
overactivation	NOUN	O	O
in	ADP	O	O
parkinsonian	ADJ	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
peak	NOUN	O	O
-	PUNCT	O	O
dose	NOUN	O	O
dyskinesia	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
studied	VERB	O	O
the	DET	O	O
regional	ADJ	O	O
cerebral	ADJ	O	O
blood	NOUN	O	O
flow	NOUN	O	O
(	PUNCT	O	O
rCBF	PROPN	O	O
)	PUNCT	O	O
changes	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
the	DET	O	O
execution	NOUN	O	O
of	ADP	O	O
a	DET	O	O
finger	NOUN	O	O
-	PUNCT	O	O
to	ADP	O	O
-	PUNCT	O	O
thumb	NOUN	O	O
opposition	NOUN	O	O
motor	NOUN	O	O
task	NOUN	O	O
in	ADP	O	O
the	DET	O	O
supplementary	ADJ	O	O
and	CCONJ	O	O
primary	ADJ	O	O
motor	NOUN	O	O
cortex	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
parkinsonian	ADJ	O	I-Entity
patients	NOUN	O	O
on	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	ADJ	O	I-Entity
medication	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
first	ADJ	O	O
one	NOUN	O	O
without	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	PROPN	O	I-Entity
induced	VERB	O	O
dyskinesia	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
23	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
other	ADJ	O	O
with	ADP	O	O
moderate	ADJ	O	O
peak	NOUN	O	O
-	PUNCT	O	O
dose	NOUN	O	O
dyskinesia	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
15	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
of	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
14	NUM	O	O
normal	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dyskinetic	ADJ	O	I-Entity
parkinsonian	NOUN	O	I-Entity
patients	NOUN	O	O
exhibited	VERB	O	O
a	DET	O	O
pattern	NOUN	O	O
of	ADP	O	O
response	NOUN	O	O
which	ADJ	O	O
was	VERB	O	O
markedly	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
those	DET	O	O
of	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
subjects	NOUN	O	O
and	CCONJ	O	O
non	ADJ	O	O
-	PUNCT	O	O
dyskinetic	ADJ	O	I-Entity
parkinsonian	NOUN	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
overactivation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
supplementary	ADJ	O	O
motor	NOUN	O	O
area	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
ipsi-	NOUN	O	O
and	CCONJ	O	O
contralateral	ADJ	O	O
primary	ADJ	O	O
motor	NOUN	O	O
areas	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
are	VERB	O	O
compatible	ADJ	O	O
with	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
an	DET	O	O
hyperkinetic	ADJ	O	I-Entity
abnormal	ADJ	O	B-Entity
involuntary	ADJ	O	I-Entity
movement	NOUN	O	I-Entity
,	PUNCT	O	O
like	ADP	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
dopa	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
peak	NOUN	O	O
dose	NOUN	O	O
dyskinesia	NOUN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
due	ADJ	O	O
to	ADP	O	O
a	DET	O	O
disinhibition	NOUN	O	O
of	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
and	CCONJ	O	O
associated	ADJ	O	O
motor	NOUN	O	O
cortex	NOUN	O	O
secondary	NOUN	O	O
to	ADP	O	O
an	DET	O	O
excessive	ADJ	O	O
outflow	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pallidothalamocortical	ADJ	O	O
motor	NOUN	O	O
loop	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7843916)

Dexamethasone	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ocular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
perfusion	NOUN	O	O
-	PUNCT	O	O
cultured	VERB	O	O
human	ADJ	O	O
eyes	NOUN	O	O
.	PUNCT	O	O

Glucocorticoid	ADJ	O	O
administration	NOUN	O	O
can	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
ocular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
and	CCONJ	O	O
corticosteroid	ADJ	O	B-Entity
glaucoma	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
subset	NOUN	O	O
of	ADP	O	O
the	DET	O	O
population	NOUN	O	O
through	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
aqueous	ADJ	O	O
humor	NOUN	O	O
outflow	NOUN	O	O
facility	NOUN	O	O
.	PUNCT	O	O

M	PROPN	O	O
dexamethasone	NOUN	O	I-Entity
for	ADP	O	O
12	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
intraocular	ADJ	O	O
pressure	NOUN	O	O
developed	VERB	O	O
in	ADP	O	O
13	NUM	O	O
of	ADP	O	O
the	DET	O	O
44	NUM	O	O
pairs	NOUN	O	O
of	ADP	O	O
eyes	NOUN	O	O
perfused	VERB	O	O
with	ADP	O	O
dexamethasone	NOUN	O	I-Entity
with	ADP	O	O
an	DET	O	O
average	ADJ	O	O
pressure	NOUN	O	O
rise	NOUN	O	O
of	ADP	O	O
17.5	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

3.8	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
after	ADP	O	O
12	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
dexamethasone	NOUN	O	I-Entity
exposure	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
contralateral	ADJ	O	O
control	NOUN	O	O
eyes	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
did	VERB	O	O
not	ADV	O	O
receive	VERB	O	O
dexamethasone	NOUN	O	I-Entity
,	PUNCT	O	O
maintained	VERB	O	O
a	DET	O	O
stable	ADJ	O	O
intraocular	NOUN	O	O
pressure	NOUN	O	O
during	ADP	O	O
the	DET	O	O
same	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
hypertensive	ADJ	O	B-Entity
eyes	NOUN	O	I-Entity
had	VERB	O	O
thickened	VERB	O	O
trabecular	ADJ	O	O
beams	NOUN	O	O
,	PUNCT	O	O
decreased	VERB	O	O
intertrabecular	ADJ	O	O
spaces	NOUN	O	O
,	PUNCT	O	O
thickened	VERB	O	O
juxtacanalicular	ADJ	O	O
tissue	NOUN	O	O
,	PUNCT	O	O
activated	VERB	O	O
trabecular	ADJ	O	O
meshwork	NOUN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increased	VERB	O	O
amounts	NOUN	O	O
of	ADP	O	O
amorphogranular	ADJ	O	O
extracellular	ADJ	O	O
material	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
the	DET	O	O
juxtacanalicular	ADJ	O	O
tissue	NOUN	O	O
and	CCONJ	O	O
beneath	ADP	O	O
the	DET	O	O
endothelial	ADJ	O	O
lining	NOUN	O	O
of	ADP	O	O
the	DET	O	O
canal	NOUN	O	O
of	ADP	O	O
Schlemm	PROPN	O	O
.	PUNCT	O	O

The	DET	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
nonresponder	NOUN	O	O
eyes	NOUN	O	O
appeared	VERB	O	O
to	PART	O	O
be	VERB	O	O
morphologically	ADV	O	O
similar	ADJ	O	O
to	ADP	O	O
the	DET	O	O
untreated	ADJ	O	O
eyes	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
several	ADJ	O	O
subtle	ADJ	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
morphologic	ADJ	O	O
changes	NOUN	O	O
were	VERB	O	O
evident	ADJ	O	O
.	PUNCT	O	O

Dexamethasone	PROPN	O	I-Entity
treatment	NOUN	O	O
of	ADP	O	O
isolated	ADJ	O	O
,	PUNCT	O	O
perfusion	NOUN	O	O
-	PUNCT	O	O
cultured	VERB	O	O
human	ADJ	O	O
eyes	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
the	DET	O	O
generation	NOUN	O	O
of	ADP	O	O
ocular	ADJ	O	B-Entity
hypertension	NOUN	O	I-Entity
in	ADP	O	O
approximately	ADV	O	O
30%	NUM	O	O
of	ADP	O	O
the	DET	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
eyes	NOUN	O	O
.	PUNCT	O	O

Steroid	ADJ	O	I-Entity
treatment	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
morphologic	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
trabecular	ADJ	O	O
meshwork	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
reported	VERB	O	O
for	ADP	O	O
corticosteroid	ADJ	O	B-Entity
glaucoma	NOUN	O	I-Entity
and	CCONJ	O	O
open	ADJ	O	B-Entity
angle	NOUN	O	I-Entity
glaucoma	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
system	NOUN	O	O
may	VERB	O	O
provide	VERB	O	O
an	DET	O	O
acute	ADJ	O	O
model	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
to	PART	O	O
study	VERB	O	O
the	DET	O	O
pathogenic	ADJ	O	O
mechanisms	NOUN	O	O
involved	VERB	O	O
in	ADP	O	O
steroid	NOUN	O	B-Entity
glaucoma	NOUN	O	I-Entity
and	CCONJ	O	O
primary	ADJ	O	B-Entity
open	ADJ	O	I-Entity
angle	NOUN	O	I-Entity
glaucoma	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7803371)

Cognitive	ADJ	O	B-Entity
deterioration	NOUN	O	I-Entity
from	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
abuse	NOUN	O	O
of	ADP	O	O
dextromethorphan	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

Dextromethorphan	PROPN	O	I-Entity
(	PUNCT	O	O
DM	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
dextrorotatory	NOUN	O	O
isomer	NOUN	O	O
of	ADP	O	O
3-hydroxy	NUM	O	B-Entity
-	PUNCT	O	I-Entity
N	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
methylmorphinan	NOUN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
the	DET	O	O
main	ADJ	O	O
ingredient	NOUN	O	O
in	ADP	O	O
a	DET	O	O
number	NOUN	O	O
of	ADP	O	O
widely	ADV	O	O
available	ADJ	O	O
,	PUNCT	O	O
over	ADP	O	O
-	PUNCT	O	O
the	DET	O	O
-	PUNCT	O	O
counter	NOUN	O	O
antitussives	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
drug	NOUN	O	O
is	VERB	O	O
known	VERB	O	O
to	PART	O	O
cause	VERB	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
ranging	VERB	O	O
from	ADP	O	O
nausea	NOUN	O	I-Entity
,	PUNCT	O	O
restlessness	NOUN	O	I-Entity
,	PUNCT	O	O
insomnia	NOUN	O	I-Entity
,	PUNCT	O	O
ataxia	NOUN	O	I-Entity
,	PUNCT	O	O
slurred	VERB	O	O
speech	NOUN	O	O
and	CCONJ	O	O
nystagmus	NOUN	O	I-Entity
to	ADP	O	O
mood	NOUN	O	O
changes	NOUN	O	O
,	PUNCT	O	O
perceptual	ADJ	O	O
alterations	NOUN	O	O
,	PUNCT	O	O
inattention	NOUN	O	O
,	PUNCT	O	O
disorientation	NOUN	O	O
and	CCONJ	O	O
aggressive	ADJ	O	B-Entity
behavior	NOUN	O	I-Entity
(	PUNCT	O	O
Rammer	PROPN	O	O
et	PROPN	O	O
al	PROPN	O	O
1988	NUM	O	O
;	PUNCT	O	O
Katona	PROPN	O	O
and	CCONJ	O	O
Watson	PROPN	O	O
1986	NUM	O	O
;	PUNCT	O	O
Isbell	PROPN	O	O
and	CCONJ	O	O
Fraser	PROPN	O	O
1953	NUM	O	O
;	PUNCT	O	O

There	ADV	O	O
have	VERB	O	O
also	ADV	O	O
been	VERB	O	O
two	NUM	O	O
reported	VERB	O	O
fatalities	NOUN	O	O
from	ADP	O	O
DM	PROPN	O	I-Entity
overdoses	NOUN	O	O
(	PUNCT	O	O
Fleming	PROPN	O	O
1986	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
describes	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
cognitive	ADJ	O	B-Entity
deterioration	NOUN	O	I-Entity
resulting	VERB	O	O
from	ADP	O	O
prolonged	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
DM	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7437994)

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
lithium	NOUN	O	I-Entity
treatment	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
kidney	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
a	DET	O	O
report	NOUN	O	O
on	ADP	O	O
the	DET	O	O
first	ADJ	O	O
part	NOUN	O	O
of	ADP	O	O
our	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
lithium	NOUN	O	I-Entity
treatment	NOUN	O	O
on	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
.	PUNCT	O	O

Creatinine	PROPN	O	I-Entity
clearance	NOUN	O	O
,	PUNCT	O	O
maximum	ADJ	O	O
urinary	ADJ	O	O
osmolality	NOUN	O	O
and	CCONJ	O	O
24	NUM	O	O
hour	NOUN	O	O
urine	NOUN	O	O
volume	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
50	NUM	O	O
affectively	ADV	O	O
ill	ADJ	O	O
patients	NOUN	O	O
who	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
on	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
lithium	NOUN	O	I-Entity
for	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
one	NUM	O	O
year	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
norms	NOUN	O	O
and	CCONJ	O	O
with	ADP	O	O
values	NOUN	O	O
of	ADP	O	O
the	DET	O	O
same	ADJ	O	O
tests	NOUN	O	O
from	ADP	O	O
screening	VERB	O	O
prior	ADV	O	O
to	ADP	O	O
lithium	NOUN	O	I-Entity
,	PUNCT	O	O
available	ADJ	O	O
for	ADP	O	O
most	ADJ	O	O
of	ADP	O	O
our	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
evidence	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
for	ADP	O	O
any	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
glomerular	ADJ	O	O
filtration	NOUN	O	O
during	ADP	O	O
lithium	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Low	ADJ	O	O
clearance	NOUN	O	O
values	NOUN	O	O
found	VERB	O	O
in	ADP	O	O
several	ADJ	O	O
patients	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
accounted	VERB	O	O
for	ADP	O	O
by	ADP	O	O
their	ADJ	O	O
age	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
pre	NOUN	O	O
-	PUNCT	O	O
lithium	NOUN	O	I-Entity
values	NOUN	O	O
.	PUNCT	O	O

Polyuria	NOUN	O	I-Entity
above	ADP	O	O
3	NUM	O	O
litres/24	NOUN	O	O
hours	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
10%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6496797)

Complete	ADJ	O	O
heart	NOUN	O	B-Entity
block	NOUN	O	I-Entity
following	VERB	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
trazodone	NOUN	O	I-Entity
.	PUNCT	O	O

Forty	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
receiving	VERB	O	O
a	DET	O	O
single	ADJ	O	O
starting	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
trazodone	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
complete	ADJ	O	O
heart	NOUN	O	B-Entity
block	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
case	NOUN	O	O
illustrates	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
despite	ADP	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
earlier	ADJ	O	O
studies	NOUN	O	O
,	PUNCT	O	O
trazodone	NOUN	O	I-Entity
's	PART	O	O
effect	NOUN	O	O
on	ADP	O	O
cardiac	ADJ	O	O
conduction	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
severe	ADJ	O	O
in	ADP	O	O
individuals	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
for	ADP	O	O
conduction	NOUN	O	O
delay	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3411101)

Quinidine	ADJ	O	B-Entity
phenylethylbarbiturate	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
fulminant	NOUN	O	O
hepatitis	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
pregnant	ADJ	O	O
woman	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
19-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
Laotian	ADJ	O	O
patient	NOUN	O	O
affected	VERB	O	O
by	ADP	O	O
fulminant	NOUN	O	O
hepatitis	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
third	ADJ	O	O
trimester	NOUN	O	O
of	ADP	O	O
her	ADJ	O	O
pregnancy	NOUN	O	O
after	ADP	O	O
a	DET	O	O
1-month	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
quinidine	NOUN	O	B-Entity
phenylethylbarbiturate	NOUN	O	I-Entity
.	PUNCT	O	O

Quinidine	PROPN	O	I-Entity
itself	PRON	O	O
or	CCONJ	O	O
phenylethylbarbiturate	VERB	O	I-Entity
may	VERB	O	O
be	VERB	O	O
responsible	ADJ	O	O
for	ADP	O	O
fulminant	NOUN	O	O
hepatitis	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2598570)

The	DET	O	O
epidemiology	NOUN	O	O
of	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
flank	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
syndrome	NOUN	O	O
from	ADP	O	O
suprofen	NOUN	O	I-Entity
.	PUNCT	O	O

Suprofen	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
nonsteroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
marketed	VERB	O	O
in	ADP	O	O
early	ADJ	O	O
1986	NUM	O	O
as	ADP	O	O
an	DET	O	O
analgesic	NOUN	O	O
agent	NOUN	O	O
.	PUNCT	O	O

Until	ADP	O	O
physicians	NOUN	O	O
began	VERB	O	O
reporting	VERB	O	O
an	DET	O	O
unusual	ADJ	O	O
acute	ADJ	O	O
flank	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
syndrome	NOUN	O	O
to	ADP	O	O
the	DET	O	O
spontaneous	ADJ	O	O
reporting	NOUN	O	O
system	NOUN	O	O
,	PUNCT	O	O
700,000	NUM	O	O
persons	NOUN	O	O
used	VERB	O	O
the	DET	O	O
drug	NOUN	O	O
in	ADP	O	O
the	DET	O	O
United	PROPN	O	O
States	PROPN	O	O
.	PUNCT	O	O

To	PART	O	O
elucidate	VERB	O	O
the	DET	O	O
epidemiology	NOUN	O	O
of	ADP	O	O
the	DET	O	O
syndrome	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
,	PUNCT	O	O
comparing	VERB	O	O
62	NUM	O	O
of	ADP	O	O
the	DET	O	O
case	NOUN	O	O
patients	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	ADP	O	O
the	DET	O	O
spontaneous	ADJ	O	O
reporting	NOUN	O	O
system	NOUN	O	O
to	ADP	O	O
185	NUM	O	O
suprofen	NOUN	O	I-Entity
-	PUNCT	O	O
exposed	VERB	O	O
control	NOUN	O	O
subjects	NOUN	O	O
who	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
have	VERB	O	O
the	DET	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

Case	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
be	VERB	O	O
men	NOUN	O	O
(	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
3.8	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
1.2	NUM	O	O
-	SYM	O	O
12.1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
suffer	VERB	O	O
from	ADP	O	O
hay	NOUN	O	B-Entity
fever	NOUN	O	I-Entity
and	CCONJ	O	O
asthma	NOUN	O	I-Entity
(	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
3.4	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
1.0	NUM	O	O
-	SYM	O	O
11.9	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
to	PART	O	O
participate	VERB	O	O
in	ADP	O	O
regular	ADJ	O	O
exercise	NOUN	O	O
(	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
5.9	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
1.1	NUM	O	O
-	SYM	O	O
30.7	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
Nautilus	PROPN	O	O
equipment	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
use	VERB	O	O
alcohol	NOUN	O	I-Entity
(	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
4.4	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
1.1	NUM	O	O
-	SYM	O	O
17.5	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Possible	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
included	VERB	O	O
young	ADJ	O	O
age	NOUN	O	O
,	PUNCT	O	O
concurrent	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
other	ADJ	O	O
analgesic	NOUN	O	O
agents	NOUN	O	O
(	PUNCT	O	O
especially	ADV	O	O
ibuprofen	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
preexisting	VERB	O	O
renal	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
kidney	NOUN	O	B-Entity
stones	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
gout	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
recent	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
activity	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
recent	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
sun	NOUN	O	O
exposure	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
residence	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Sunbelt	PROPN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
are	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
postulated	ADJ	O	O
mechanism	NOUN	O	O
for	ADP	O	O
this	DET	O	O
unusual	ADJ	O	O
syndrome	NOUN	O	O
:	PUNCT	O	O
acute	ADJ	O	O
diffuse	NOUN	O	O
crystallization	NOUN	O	O
of	ADP	O	O
uric	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
in	ADP	O	O
renal	ADJ	O	O
tubules	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1415380)

Hemolytic	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
uremic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
ingestion	NOUN	O	O
of	ADP	O	O
quinine	NOUN	O	I-Entity
.	PUNCT	O	O

Hemolytic	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
uremic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
following	VERB	O	O
quinine	NOUN	O	I-Entity
ingestion	NOUN	O	O
is	VERB	O	O
a	DET	O	O
newly	ADV	O	O
described	VERB	O	O
phenomenon	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
just	ADV	O	O
two	NUM	O	O
previous	ADJ	O	O
descriptions	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
cases	NOUN	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
reaction	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
antibodies	NOUN	O	O
reactive	ADJ	O	O
against	ADP	O	O
platelets	NOUN	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
quinine	NOUN	O	I-Entity
.	PUNCT	O	O

Treatment	NOUN	O	O
has	VERB	O	O
included	VERB	O	O
use	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
exchange	NOUN	O	O
,	PUNCT	O	O
prednisone	NOUN	O	I-Entity
,	PUNCT	O	O
aspirin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
dipyridamole	NOUN	O	I-Entity
.	PUNCT	O	O

Quinine	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
hemolytic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
uremic	ADJ	O	I-Entity
syndrome	NOUN	O	I-Entity
probably	ADV	O	O
occurs	VERB	O	O
more	ADV	O	O
often	ADV	O	O
than	ADP	O	O
is	VERB	O	O
recognized	VERB	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
important	ADJ	O	O
to	PART	O	O
recognize	VERB	O	O
this	DET	O	O
reaction	NOUN	O	O
when	ADV	O	O
it	PRON	O	O
occurs	VERB	O	O
and	CCONJ	O	O
to	PART	O	O
avoid	VERB	O	O
further	ADJ	O	O
quinine	NOUN	O	I-Entity
exposure	NOUN	O	O
,	PUNCT	O	O
since	ADP	O	O
the	DET	O	O
reaction	NOUN	O	O
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
recurrent	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (1255900)

The	DET	O	O
etiology	NOUN	O	O
of	ADP	O	O
pyeloureteritis	NOUN	O	B-Entity
cystica	NOUN	O	I-Entity
has	VERB	O	O
long	ADV	O	O
been	VERB	O	O
attributed	VERB	O	O
to	ADP	O	O
chronic	ADJ	O	O
infection	NOUN	O	I-Entity
and	CCONJ	O	O
inflammation	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
no	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
antecedent	NOUN	O	O
or	CCONJ	O	O
concurrent	ADJ	O	O
infection	NOUN	O	I-Entity
in	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
disease	NOUN	O	O
occurred	VERB	O	O
subsequent	ADJ	O	O
to	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
therapy	NOUN	O	O
for	ADP	O	O
suspected	VERB	O	O
pelvic	ADJ	O	O
thrombophlebitis	NOUN	O	I-Entity
and	CCONJ	O	O
cleared	VERB	O	O
rapidly	ADV	O	O
subsequent	ADJ	O	O
to	ADP	O	O
its	ADJ	O	O
discontinuation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
resolution	NOUN	O	O
of	ADP	O	O
the	DET	O	O
radiographic	ADJ	O	O
findings	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
helpful	ADJ	O	O
in	ADP	O	O
distinguishing	VERB	O	O
between	ADP	O	O
true	ADJ	O	O
pyeloureteritis	NOUN	O	B-Entity
cystica	NOUN	O	I-Entity
and	CCONJ	O	O
submucosal	NOUN	O	B-Entity
hemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (85485)

Changes	NOUN	O	O
in	ADP	O	O
peroxisomes	NOUN	O	O
in	ADP	O	O
preneoplastic	ADJ	O	O
liver	NOUN	O	O
and	CCONJ	O	O
hepatoma	NOUN	O	I-Entity
of	ADP	O	O
mice	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
benzene	NOUN	O	I-Entity
hexachloride	NOUN	O	I-Entity
.	PUNCT	O	O

Peroxisomes	NOUN	O	O
in	ADP	O	O
hepatomas	NOUN	O	I-Entity
and	CCONJ	O	O
hyperplastic	ADJ	O	O
preneoplastic	ADJ	O	O
liver	NOUN	O	B-Entity
lesions	NOUN	O	I-Entity
induced	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
by	ADP	O	O
500	NUM	O	O
ppm	ADJ	O	O
alpha	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
benzene	NOUN	O	I-Entity
hexachloride	NOUN	O	I-Entity
were	VERB	O	O
examined	VERB	O	O
histochemically	ADV	O	O
and	CCONJ	O	O
electron	VERB	O	O
microscopically	ADV	O	O
.	PUNCT	O	O

Although	ADP	O	O
most	ADJ	O	O
of	ADP	O	O
the	DET	O	O
hepatomas	NOUN	O	I-Entity
were	VERB	O	O
well	ADV	O	O
-	PUNCT	O	O
differentiated	VERB	O	O
tumors	NOUN	O	I-Entity
and	CCONJ	O	O
contained	VERB	O	O
a	DET	O	O
considerable	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
peroxisomes	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
tumor	NOUN	O	I-Entity
cells	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
respond	VERB	O	O
to	ADP	O	O
ethyl	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
chlorophenoxyisobutyrate	NOUN	O	I-Entity
with	ADP	O	O
proliferation	NOUN	O	O
of	ADP	O	O
peroxisomes	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
cells	NOUN	O	O
proliferated	VERB	O	O
further	ADV	O	O
,	PUNCT	O	O
replacing	VERB	O	O
the	DET	O	O
most	ADJ	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
nodules	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
with	ADP	O	O
this	DET	O	O
process	NOUN	O	O
hepatomas	NOUN	O	I-Entity
appeared	VERB	O	O
to	PART	O	O
have	VERB	O	O
been	VERB	O	O
formed	VERB	O	O
.	PUNCT	O	O

No	DET	O	O
abnormal	ADJ	O	O
matrical	ADJ	O	O
inclusions	NOUN	O	O
of	ADP	O	O
peroxisomes	NOUN	O	O
were	VERB	O	O
formed	VERB	O	O
in	ADP	O	O
the	DET	O	O
cells	NOUN	O	O
of	ADP	O	O
hyperplastic	ADJ	O	O
nodules	NOUN	O	O
by	ADP	O	O
ethyl	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
alpha	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
p	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
chlorophenoxyisobutyrate	NOUN	O	I-Entity
unlike	NOUN	O	O
in	ADP	O	O
the	DET	O	O
case	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (48362)

Quinidine	PROPN	O	I-Entity
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

Long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
administration	NOUN	O	O
of	ADP	O	O
quinidine	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
persistent	ADJ	O	O
elevation	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
SGOT	PROPN	O	O
,	PUNCT	O	O
lactic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
dehydrogenase	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
alkaline	ADJ	O	O
phosphatase	NOUN	O	O
.	PUNCT	O	O

Liver	NOUN	O	O
biopsy	NOUN	O	O
showed	VERB	O	O
active	ADJ	O	O
hepatitis	NOUN	O	I-Entity
.	PUNCT	O	O

Discontinuance	NOUN	O	O
of	ADP	O	O
quinidine	NOUN	O	I-Entity
therapy	NOUN	O	O
led	VERB	O	O
to	ADP	O	O
normalization	NOUN	O	O
of	ADP	O	O
liver	NOUN	O	O
function	NOUN	O	O
tests	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
challenge	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
quinidine	NOUN	O	I-Entity
caused	VERB	O	O
clinical	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
abrupt	ADJ	O	O
elevation	NOUN	O	O
of	ADP	O	O
SGOT	PROPN	O	O
,	PUNCT	O	O
alkaline	ADJ	O	O
phosphatase	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
lactic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
dehydrogenase	NOUN	O	O
values	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
concluded	VERB	O	O
that	ADP	O	O
this	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
quinidine	NOUN	O	I-Entity
hepatotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
believe	VERB	O	O
that	ADP	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
reported	VERB	O	O
with	ADP	O	O
liver	NOUN	O	O
biopsy	NOUN	O	O
documentation	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
report	NOUN	O	O
also	ADV	O	O
suggests	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
even	ADV	O	O
after	ADP	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
hepatic	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
is	VERB	O	O
reversible	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (9067481)

Cholesteryl	PROPN	O	B-Entity
hemisuccinate	NOUN	O	I-Entity
treatment	NOUN	O	O
protects	VERB	O	O
rodents	NOUN	O	O
from	ADP	O	O
the	DET	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
acetaminophen	NOUN	O	I-Entity
,	PUNCT	O	O
adriamycin	ADV	O	I-Entity
,	PUNCT	O	O
carbon	NOUN	O	B-Entity
tetrachloride	NOUN	O	I-Entity
,	PUNCT	O	O
chloroform	NOUN	O	I-Entity
and	CCONJ	O	O
galactosamine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
its	ADJ	O	O
use	NOUN	O	O
as	ADP	O	O
a	DET	O	O
stabilizer	NOUN	O	O
/	SYM	O	O
rigidifier	NOUN	O	O
of	ADP	O	O
membranes	NOUN	O	O
,	PUNCT	O	O
cholesteryl	NOUN	O	B-Entity
hemisuccinate	NOUN	O	I-Entity
,	PUNCT	O	O
tris	ADJ	O	B-Entity
salt	NOUN	O	I-Entity
(	PUNCT	O	O
CS	PROPN	O	I-Entity
)	PUNCT	O	O
administration	NOUN	O	O
has	VERB	O	O
also	ADV	O	O
been	VERB	O	O
shown	VERB	O	O
to	PART	O	O
protect	VERB	O	O
rats	NOUN	O	O
from	ADP	O	O
the	DET	O	O
hepatotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
carbon	NOUN	O	B-Entity
tetrachloride	NOUN	O	I-Entity
(	PUNCT	O	O
CCl4	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

To	PART	O	O
further	ADV	O	O
our	ADJ	O	O
understanding	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
CS	PROPN	O	I-Entity
cytoprotection	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
examined	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
and	CCONJ	O	O
mice	NOUN	O	O
the	DET	O	O
protective	ADJ	O	O
abilities	NOUN	O	O
of	ADP	O	O
CS	PROPN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
hydrolyzable	ADJ	O	O
ether	NOUN	O	O
form	NOUN	O	O
of	ADP	O	O
CS	PROPN	O	I-Entity
,	PUNCT	O	O
gamma	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
cholesteryloxybutyric	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
,	PUNCT	O	O
tris	ADJ	O	B-Entity
salt	NOUN	O	I-Entity
(	PUNCT	O	O
CSE	PROPN	O	I-Entity
)	PUNCT	O	O
against	ADP	O	O
acetaminophen-	NOUN	O	I-Entity
,	PUNCT	O	O
adriamycin-	ADJ	O	I-Entity
,	PUNCT	O	O
carbon	NOUN	O	B-Entity
tetrachloride-	X	O	I-Entity
,	PUNCT	O	O
chloroform-	ADJ	O	I-Entity
and	CCONJ	O	O
galactosamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
these	DET	O	O
studies	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
CS	PROPN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
protection	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
selective	ADJ	O	O
for	ADP	O	O
a	DET	O	O
particular	ADJ	O	O
species	NOUN	O	O
,	PUNCT	O	O
organ	NOUN	O	O
system	NOUN	O	O
or	CCONJ	O	O
toxic	ADJ	O	O
chemical	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
24-h	NUM	O	O
pretreatment	NOUN	O	O
of	ADP	O	O
both	DET	O	O
rats	NOUN	O	O
and	CCONJ	O	O
mice	NOUN	O	O
with	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
CS	PROPN	O	I-Entity
(	PUNCT	O	O
100mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
i.p	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
resulted	VERB	O	O
in	ADP	O	O
significant	ADJ	O	O
protection	NOUN	O	O
against	ADP	O	O
the	DET	O	O
hepatotoxic	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
CCl4	PROPN	O	I-Entity
,	PUNCT	O	O
CHCl3	PROPN	O	I-Entity
,	PUNCT	O	O
acetaminophen	NOUN	O	I-Entity
and	CCONJ	O	O
galactosamine	NOUN	O	I-Entity
and	CCONJ	O	O
against	ADP	O	O
the	DET	O	O
lethal	ADJ	O	O
(	PUNCT	O	O
and	CCONJ	O	O
presumably	ADV	O	O
cardiotoxic	VERB	O	I-Entity
)	PUNCT	O	O
effect	NOUN	O	O
of	ADP	O	O
adriamycin	ADJ	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

Maximal	PROPN	O	O
CS	PROPN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
protection	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
experimental	ADJ	O	O
animals	NOUN	O	O
pretreated	VERB	O	O
24	NUM	O	O
h	X	O	O
prior	ADV	O	O
to	ADP	O	O
the	DET	O	O
toxic	ADJ	O	O
insult	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
CS	PROPN	O	I-Entity
intervenes	VERB	O	O
in	ADP	O	O
a	DET	O	O
critical	ADJ	O	O
cellular	ADJ	O	O
event	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
an	DET	O	O
important	ADJ	O	O
common	ADJ	O	O
pathway	NOUN	O	O
to	ADP	O	O
toxic	ADJ	O	O
cell	NOUN	O	O
death	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
CS	PROPN	O	I-Entity
protection	NOUN	O	O
does	VERB	O	O
not	ADV	O	O
appear	VERB	O	O
to	PART	O	O
be	VERB	O	O
dependent	ADJ	O	O
on	ADP	O	O
the	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
chemical	NOUN	O	O
bioactivation	NOUN	O	O
to	ADP	O	O
a	DET	O	O
toxic	ADJ	O	O
reactive	ADJ	O	O
intermediate	NOUN	O	O
(	PUNCT	O	O
in	ADP	O	O
light	NOUN	O	O
of	ADP	O	O
the	DET	O	O
protection	NOUN	O	O
observed	VERB	O	O
against	ADP	O	O
galactosamine	NOUN	O	I-Entity
hepatotoxicity	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
the	DET	O	O
data	NOUN	O	O
presented	VERB	O	O
,	PUNCT	O	O
we	PRON	O	O
can	VERB	O	O
not	ADV	O	O
exclude	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
CS	PROPN	O	I-Entity
administration	NOUN	O	O
inhibits	VERB	O	O
chemical	ADJ	O	O
bioactivation	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
findings	NOUN	O	O
do	VERB	O	O
suggest	VERB	O	O
that	ADP	O	O
CS	PROPN	O	I-Entity
-	PUNCT	O	O
mediated	VERB	O	O
protection	NOUN	O	O
is	VERB	O	O
dependent	ADJ	O	O
on	ADP	O	O
the	DET	O	O
action	NOUN	O	O
of	ADP	O	O
the	DET	O	O
intact	ADJ	O	O
anionic	ADJ	O	O
CS	PROPN	O	I-Entity
molecule	NOUN	O	O
(	PUNCT	O	O
non	ADJ	O	O
-	PUNCT	O	O
hydrolyzable	ADJ	O	O
CSE	PROPN	O	I-Entity
was	VERB	O	O
as	ADV	O	O
protective	ADJ	O	O
as	ADP	O	O
CS	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
whose	ADJ	O	O
mechanism	NOUN	O	O
has	VERB	O	O
yet	ADV	O	O
to	PART	O	O
be	VERB	O	O
defined	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (19274460)

DSMM	PROPN	O	O
XI	PROPN	O	O
study	NOUN	O	O
:	PUNCT	O	O
dose	NOUN	O	O
definition	NOUN	O	O
for	ADP	O	O
intravenous	ADJ	O	O
cyclophosphamide	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
bortezomib	NOUN	O	I-Entity
/	SYM	O	O
dexamethasone	NOUN	O	I-Entity
for	ADP	O	O
remission	NOUN	O	O
induction	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
newly	ADV	O	O
diagnosed	VERB	O	O
myeloma	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
was	VERB	O	O
initiated	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
recommended	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
bortezomib	NOUN	O	I-Entity
and	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
as	ADP	O	O
induction	NOUN	O	O
treatment	NOUN	O	O
before	ADP	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplantation	NOUN	O	O
for	ADP	O	O
younger	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
newly	ADV	O	O
diagnosed	VERB	O	O
multiple	ADJ	O	B-Entity
myeloma	NOUN	O	I-Entity
(	PUNCT	O	O
MM	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
three	NUM	O	O
21-day	NUM	O	O
cycles	NOUN	O	O
of	ADP	O	O
bortezomib	NOUN	O	I-Entity
1.3	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NUM	O	O
)	PUNCT	O	O
on	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
11	NUM	O	O
plus	CCONJ	O	O
dexamethasone	ADV	O	I-Entity
40	NUM	O	O
mg	NUM	O	O
on	ADP	O	O
the	DET	O	O
day	NOUN	O	O
of	ADP	O	O
bortezomib	NOUN	O	I-Entity
injection	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
day	NOUN	O	O
after	ADP	O	O
plus	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
at	ADP	O	O
900	NUM	O	O
,	PUNCT	O	O
1,200	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
1,500	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
maximum	NOUN	O	O
tolerated	VERB	O	O
dose	NOUN	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
900	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
most	ADV	O	O
frequent	ADJ	O	O
adverse	ADJ	O	O
events	NOUN	O	O
were	VERB	O	O
hematological	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
gastrointestinal	ADJ	O	I-Entity
toxicities	NOUN	O	I-Entity
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
neuropathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
bortezomib	NOUN	O	I-Entity
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
at	ADP	O	O
900	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
induction	NOUN	O	O
treatment	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
newly	ADV	O	O
diagnosed	VERB	O	O
MM	PROPN	O	I-Entity
that	ADP	O	O
warrants	VERB	O	O
further	ADJ	O	O
investigation	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18201582)

Results	NOUN	O	O
of	ADP	O	O
a	DET	O	O
comparative	ADJ	O	O
,	PUNCT	O	O
phase	NOUN	O	O
III	PROPN	O	O
,	PUNCT	O	O
12-week	ADJ	O	O
,	PUNCT	O	O
multicenter	ADJ	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
assessment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
a	DET	O	O
fixed	VERB	O	O
-	PUNCT	O	O
dose	NOUN	O	O
combination	NOUN	O	O
of	ADP	O	O
telmisartan	NOUN	O	I-Entity
and	CCONJ	O	O
amlodipine	NOUN	O	I-Entity
versus	ADP	O	O
amlodipine	NOUN	O	I-Entity
monotherapy	NOUN	O	O
in	ADP	O	O
Indian	ADJ	O	O
adults	NOUN	O	O
with	ADP	O	O
stage	NOUN	O	O
II	NUM	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
fixed	VERB	O	O
-	PUNCT	O	O
dose	NOUN	O	O
combination	NOUN	O	O
(	PUNCT	O	O
FDC	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
telmisartan	ADJ	O	I-Entity
40	NUM	O	O
mg	NUM	O	O
+	CCONJ	O	O
amlodipine	ADJ	O	I-Entity
5	NUM	O	O
mg	X	O	O
(	PUNCT	O	O
T+A	PROPN	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
amlodipine	NOUN	O	I-Entity
5-mg	NUM	O	O
monotherapy	NOUN	O	O
(	PUNCT	O	O
A	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
adult	NOUN	O	O
Indian	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
stage	NOUN	O	O
II	NUM	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
comparative	ADJ	O	O
,	PUNCT	O	O
Phase	PROPN	O	O
III	PROPN	O	O
,	PUNCT	O	O
12-week	ADJ	O	O
,	PUNCT	O	O
multicenter	ADJ	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
Indian	ADJ	O	O
patients	NOUN	O	O
aged	VERB	O	O
18	NUM	O	O
to	PART	O	O
65	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
established	VERB	O	O
stage	NOUN	O	O
II	PROPN	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

Peripheral	PROPN	O	O
edema	NOUN	O	I-Entity
was	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
8.5%	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
9/106	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
T+A	PROPN	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
13.5%	NUM	O	O
(	PUNCT	O	O
14/104	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
A	PROPN	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cough	NOUN	O	I-Entity
was	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
3.8%	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
4/106	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
T+A	PROPN	O	O
group	NOUN	O	O
and	CCONJ	O	O
1.0%	NUM	O	O
(	PUNCT	O	O
1/104	NUM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
A	PROPN	O	O
group	NOUN	O	O
;	PUNCT	O	O
these	DET	O	O
differences	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
reach	VERB	O	O
statistical	ADJ	O	O
significance	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidences	NOUN	O	O
of	ADP	O	O
headache	NOUN	O	I-Entity
,	PUNCT	O	O
dizziness	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
diarrhea	NOUN	O	I-Entity
were	VERB	O	O
similar	ADJ	O	O
between	ADP	O	O
the	DET	O	O
2	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Among	ADP	O	O
these	DET	O	O
Indian	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
stage	NOUN	O	O
II	NUM	O	O
hypertension	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
FDC	PROPN	O	O
of	ADP	O	O
T+A	PROPN	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	VERB	O	O
significantly	ADV	O	O
more	ADV	O	O
effective	ADJ	O	O
,	PUNCT	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
BP	PROPN	O	O
reductions	NOUN	O	O
,	PUNCT	O	O
than	ADP	O	O
A	DET	O	O
,	PUNCT	O	O
and	CCONJ	O	O
both	DET	O	O
treatments	NOUN	O	O
were	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (11337188)

Cutaneous	ADJ	O	B-Entity
leucocytoclastic	ADJ	O	I-Entity
vasculitis	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
oxacillin	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
67-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
oxacillin	NOUN	O	I-Entity
for	ADP	O	O
one	NUM	O	O
week	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
Staphylococcus	PROPN	O	B-Entity
aureus	PROPN	O	I-Entity
bacteremia	NOUN	O	I-Entity
,	PUNCT	O	O
developed	VERB	O	O
renal	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
diffuse	NOUN	O	O
,	PUNCT	O	O
symmetric	ADJ	O	O
,	PUNCT	O	O
palpable	ADJ	O	O
purpuric	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
on	ADP	O	O
his	ADJ	O	O
feet	NOUN	O	O
.	PUNCT	O	O

Necrotic	ADJ	O	B-Entity
blisters	NOUN	O	I-Entity
were	VERB	O	O
noted	VERB	O	O
on	ADP	O	O
his	ADJ	O	O
fingers	NOUN	O	O
.	PUNCT	O	O

Skin	NOUN	O	O
biopsies	NOUN	O	O
showed	VERB	O	O
findings	NOUN	O	O
diagnostic	ADJ	O	O
of	ADP	O	O
leucocytoclastic	ADJ	O	B-Entity
vasculitis	NOUN	O	I-Entity
.	PUNCT	O	O

Oxacillin	PROPN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
and	CCONJ	O	O
patient	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
corticosteroids	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
rash	NOUN	O	I-Entity
disappeared	VERB	O	O
after	ADP	O	O
three	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
returned	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
.	PUNCT	O	O

Leucocytoclastic	ADJ	O	B-Entity
vasculitis	NOUN	O	I-Entity
presents	VERB	O	O
as	ADP	O	O
palpable	ADJ	O	O
purpura	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
lower	ADJ	O	O
extremities	NOUN	O	O
often	ADV	O	O
accompanied	VERB	O	O
by	ADP	O	O
abdominal	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
arthralgia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
renal	ADJ	O	B-Entity
involvement	NOUN	O	I-Entity
.	PUNCT	O	O

Etiologic	ADJ	O	O
factors	NOUN	O	O
or	CCONJ	O	O
associated	VERB	O	O
disorders	NOUN	O	O
include	VERB	O	O
infections	NOUN	O	I-Entity
,	PUNCT	O	O
medications	NOUN	O	O
,	PUNCT	O	O
collagen	NOUN	O	B-Entity
vascular	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
and	CCONJ	O	O
neoplasia	NOUN	O	I-Entity
.	PUNCT	O	O

Usually	ADV	O	O
it	PRON	O	O
is	VERB	O	O
a	DET	O	O
self	NOUN	O	O
-	PUNCT	O	O
limited	VERB	O	O
disorder	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
corticosteroid	NOUN	O	I-Entity
therapy	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
needed	VERB	O	O
in	ADP	O	O
life	NOUN	O	O
-	PUNCT	O	O
threatening	VERB	O	O
cases	NOUN	O	O
since	ADP	O	O
early	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
corticosteroids	NOUN	O	I-Entity
in	ADP	O	O
severe	ADJ	O	O
cases	NOUN	O	O
can	VERB	O	O
prevent	VERB	O	O
complications	NOUN	O	O
.	PUNCT	O	O

Oxacillin	PROPN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
included	VERB	O	O
among	ADP	O	O
the	DET	O	O
drugs	NOUN	O	O
that	ADJ	O	O
can	VERB	O	O
cause	VERB	O	O
leucocytoclastic	ADJ	O	B-Entity
vasculitis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6308526)

Naloxazone	NOUN	O	I-Entity
pretreatment	NOUN	O	O
modifies	VERB	O	O
cardiorespiratory	NOUN	O	O
,	PUNCT	O	O
temperature	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O

Behavioral	PROPN	O	O
and	CCONJ	O	O
cardiorespiratory	NOUN	O	O
responses	NOUN	O	O
to	ADP	O	O
a	DET	O	O
lethal	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
were	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
or	CCONJ	O	O
naloxazone	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
antagonist	NOUN	O	O
of	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
affinity	NOUN	O	O
mu	NOUN	O	O
1	NUM	O	O
opioid	ADJ	O	O
receptors	NOUN	O	O
.	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
naloxazone	NOUN	O	I-Entity
significantly	ADV	O	O
blocked	VERB	O	O
morphine	NOUN	O	I-Entity
analgesia	NOUN	O	I-Entity
,	PUNCT	O	O
catalepsy	NOUN	O	I-Entity
and	CCONJ	O	O
hypothermia	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
which	ADJ	O	O
completely	ADV	O	O
eliminated	VERB	O	O
high	ADJ	O	O
-	PUNCT	O	O
affinity	NOUN	O	O
binding	NOUN	O	O
in	ADP	O	O
brain	NOUN	O	O
membranes	NOUN	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
naloxazone	NOUN	O	I-Entity
significantly	ADV	O	O
attenuated	VERB	O	O
the	DET	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
respiratory	ADJ	O	B-Entity
depression	NOUN	O	I-Entity
,	PUNCT	O	O
whereas	ADP	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
bradycardia	NOUN	O	I-Entity
was	VERB	O	O
less	ADV	O	O
affected	ADJ	O	O
.	PUNCT	O	O

Results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
subpopulations	NOUN	O	O
of	ADP	O	O
mu	NOUN	O	O
receptors	NOUN	O	O
may	VERB	O	O
mediate	VERB	O	O
selective	ADJ	O	O
behavioral	ADJ	O	O
and	CCONJ	O	O
cardiorespiratory	ADJ	O	O
responses	NOUN	O	O
to	ADP	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15897593)

Dexrazoxane	PROPN	O	I-Entity
protects	VERB	O	O
against	ADP	O	O
myelosuppression	NOUN	O	I-Entity
from	ADP	O	O
the	DET	O	O
DNA	NOUN	O	O
cleavage	NOUN	O	O
-	PUNCT	O	O
enhancing	VERB	O	O
drugs	NOUN	O	O
etoposide	ADV	O	I-Entity
and	CCONJ	O	O
daunorubicin	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
doxorubicin	VERB	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
anthracyclines	NOUN	O	I-Entity
daunorubicin	NOUN	O	I-Entity
and	CCONJ	O	O
doxorubicin	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
epipodophyllotoxin	NOUN	O	I-Entity
etoposide	ADV	O	I-Entity
are	VERB	O	O
potent	ADJ	O	O
DNA	NOUN	O	O
cleavage	NOUN	O	O
-	PUNCT	O	O
enhancing	VERB	O	O
drugs	NOUN	O	O
that	ADJ	O	O
are	VERB	O	O
widely	ADV	O	O
used	VERB	O	O
in	ADP	O	O
clinical	ADJ	O	O
oncology	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
myelosuppression	NOUN	O	I-Entity
and	CCONJ	O	O
cardiac	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
limit	VERB	O	O
their	ADJ	O	O
use	NOUN	O	O
.	PUNCT	O	O

Dexrazoxane	PROPN	O	I-Entity
(	PUNCT	O	O
ICRF-187	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
recommended	VERB	O	O
for	ADP	O	O
protection	NOUN	O	O
against	ADP	O	O
anthracycline	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Because	ADP	O	O
of	ADP	O	O
their	ADJ	O	O
widespread	ADJ	O	O
use	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
hematologic	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
following	VERB	O	O
coadministration	NOUN	O	O
of	ADP	O	O
dexrazoxane	NOUN	O	I-Entity
and	CCONJ	O	O
these	DET	O	O
three	NUM	O	O
structurally	ADV	O	O
different	ADJ	O	O
DNA	NOUN	O	O
cleavage	NOUN	O	O
enhancers	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
:	PUNCT	O	O

Sensitivity	PROPN	O	O
of	ADP	O	O
human	ADJ	O	O
and	CCONJ	O	O
murine	ADJ	O	O
blood	NOUN	O	O
progenitor	NOUN	O	O
cells	NOUN	O	O
to	ADP	O	O
etoposide	ADV	O	I-Entity
,	PUNCT	O	O
daunorubicin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
doxorubicin	VERB	O	I-Entity
+	X	O	O
/-	PUNCT	O	O

dexrazoxane	NOUN	O	I-Entity
was	VERB	O	O
determined	VERB	O	O
in	ADP	O	O
granulocyte	NOUN	O	O
-	PUNCT	O	O
macrophage	NOUN	O	O
colony	NOUN	O	O
forming	VERB	O	O
assays	NOUN	O	O
.	PUNCT	O	O

Likewise	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
B6D2F1	PROPN	O	O
mice	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
etoposide	ADV	O	I-Entity
,	PUNCT	O	O
daunorubicin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
doxorubicin	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
dexrazoxane	NOUN	O	I-Entity
over	ADP	O	O
a	DET	O	O
wide	ADJ	O	O
range	NOUN	O	O
of	ADP	O	O
doses	NOUN	O	O
:	PUNCT	O	O
posttreatment	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
full	ADJ	O	O
hematologic	ADJ	O	O
evaluation	NOUN	O	O
was	VERB	O	O
done	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Nontoxic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
dexrazoxane	NOUN	O	I-Entity
reduced	VERB	O	O
myelosuppression	NOUN	O	I-Entity
and	CCONJ	O	O
weight	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
from	ADP	O	O
daunorubicin	NOUN	O	I-Entity
and	CCONJ	O	O
etoposide	ADV	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
and	CCONJ	O	O
antagonized	VERB	O	O
their	ADJ	O	O
antiproliferative	ADJ	O	O
effects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
colony	NOUN	O	O
assay	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
dexrazoxane	ADP	O	I-Entity
neither	CCONJ	O	O
reduced	VERB	O	O
myelosuppression	NOUN	O	I-Entity
,	PUNCT	O	O
weight	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
,	PUNCT	O	O
nor	CCONJ	O	O
the	DET	O	O
in	ADP	O	O
vitro	ADJ	O	O
cytotoxicity	NOUN	O	I-Entity
from	ADP	O	O
doxorubicin	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Although	ADP	O	O
our	ADJ	O	O
findings	NOUN	O	O
support	VERB	O	O
the	DET	O	O
observation	NOUN	O	O
that	ADJ	O	O
dexrazoxane	NOUN	O	I-Entity
reduces	VERB	O	O
neither	DET	O	O
hematologic	ADJ	O	O
activity	NOUN	O	O
nor	CCONJ	O	O
antitumor	ADJ	O	O
activity	NOUN	O	O
from	ADP	O	O
doxorubicin	NOUN	O	I-Entity
clinically	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
potent	ADJ	O	O
antagonism	NOUN	O	O
of	ADP	O	O
daunorubicin	ADJ	O	I-Entity
activity	NOUN	O	O
raises	VERB	O	O
concern	NOUN	O	O
;	PUNCT	O	O
a	DET	O	O
possible	ADJ	O	O
interference	NOUN	O	O
with	ADP	O	O
anticancer	NOUN	O	O
efficacy	NOUN	O	O
certainly	ADV	O	O
would	VERB	O	O
call	VERB	O	O
for	ADP	O	O
renewed	VERB	O	O
attention	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
data	NOUN	O	O
also	ADV	O	O
suggest	VERB	O	O
that	ADP	O	O
significant	ADJ	O	O
etoposide	NOUN	O	I-Entity
dose	NOUN	O	O
escalation	NOUN	O	O
is	VERB	O	O
perhaps	ADV	O	O
possible	ADJ	O	O
by	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
dexrazoxane	NOUN	O	I-Entity
.	PUNCT	O	O

Clinical	ADJ	O	O
trials	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
brain	NOUN	O	O
metastases	NOUN	O	I-Entity
combining	VERB	O	O
dexrazoxane	NOUN	O	I-Entity
and	CCONJ	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
etoposide	NOUN	O	I-Entity
is	VERB	O	O
ongoing	VERB	O	O
with	ADP	O	O
the	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
improving	VERB	O	O
efficacy	NOUN	O	O
without	ADP	O	O
aggravating	VERB	O	O
hematologic	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6817363)

Effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
novel	NOUN	O	O
compound	NOUN	O	O
aniracetam	NOUN	O	I-Entity
(	PUNCT	O	O
Ro	PROPN	O	B-Entity
13	NUM	O	I-Entity
-	SYM	O	I-Entity
5057	NUM	O	I-Entity
)	PUNCT	O	O
upon	ADP	O	O
impaired	VERB	O	B-Entity
learning	NOUN	O	I-Entity
and	CCONJ	O	I-Entity
memory	NOUN	O	I-Entity
in	ADP	O	O
rodents	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
aniracetam	NOUN	O	I-Entity
(	PUNCT	O	O
Ro	PROPN	O	B-Entity
13	NUM	O	I-Entity
-	SYM	O	I-Entity
5057	NUM	O	I-Entity
,	PUNCT	O	O
1-anisoyl-2-pyrrolidinone	NUM	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
studied	VERB	O	O
on	ADP	O	O
various	ADJ	O	O
forms	NOUN	O	O
of	ADP	O	O
experimentally	ADV	O	O
impaired	VERB	O	B-Entity
cognitive	ADJ	O	I-Entity
functions	NOUN	O	I-Entity
(	PUNCT	O	O
learning	NOUN	O	O
and	CCONJ	O	O
memory	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
rodents	NOUN	O	O
and	CCONJ	O	O
produced	VERB	O	O
the	DET	O	O
following	ADJ	O	O
effects	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	PUNCT	O	O
)	PUNCT	O	O
almost	ADV	O	O
complete	ADJ	O	O
prevention	NOUN	O	O
of	ADP	O	O
the	DET	O	O
incapacity	NOUN	O	O
to	PART	O	O
learn	VERB	O	O
a	DET	O	O
discrete	ADJ	O	O
escape	NOUN	O	O
response	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
exposed	VERB	O	O
to	ADP	O	O
sublethal	VERB	O	O
hypercapnia	NOUN	O	I-Entity
immediately	ADV	O	O
before	ADP	O	O
the	DET	O	O
acquisition	NOUN	O	O
session	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
partial	ADJ	O	O
(	PUNCT	O	O
rats	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
complete	ADJ	O	O
(	PUNCT	O	O
mice	NOUN	O	O
)	PUNCT	O	O
prevention	NOUN	O	O
of	ADP	O	O
the	DET	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
amnesia	NOUN	O	I-Entity
for	ADP	O	O
a	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
task	NOUN	O	O
;	PUNCT	O	O

(	PUNCT	O	O
3	PUNCT	O	O
)	PUNCT	O	O
complete	ADJ	O	O
protection	NOUN	O	O
against	ADP	O	O
amnesia	NOUN	O	I-Entity
for	ADP	O	O
a	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
task	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
submitted	VERB	O	O
to	ADP	O	O
electroconvulsive	ADJ	O	O
shock	NOUN	O	O
immediately	ADV	O	O
after	ADP	O	O
avoidance	NOUN	O	O
acquisition	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
4	PUNCT	O	O
)	PUNCT	O	O
prevention	NOUN	O	O
of	ADP	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
retention-	NOUN	O	O
or	CCONJ	O	O
retrieval	NOUN	O	O
-	PUNCT	O	O
deficit	NOUN	O	O
for	ADP	O	O
a	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
task	NOUN	O	O
induced	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
and	CCONJ	O	O
mice	NOUN	O	O
by	ADP	O	O
chloramphenicol	NOUN	O	I-Entity
or	CCONJ	O	O
cycloheximide	NOUN	O	I-Entity
administered	VERB	O	O
immediately	ADV	O	O
after	ADP	O	O
acquisition	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
5	PUNCT	O	O
)	PUNCT	O	O
reversal	NOUN	O	O
,	PUNCT	O	O

when	ADV	O	O
administered	VERB	O	O
as	ADP	O	O
late	ADV	O	O
as	ADP	O	O
1	NUM	O	O
h	PRON	O	O
before	ADP	O	O
the	DET	O	O
retention	NOUN	O	O
test	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
deficit	NOUN	O	O
in	ADP	O	O
retention	NOUN	O	O
or	CCONJ	O	O
retrieval	NOUN	O	O
of	ADP	O	O
a	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
task	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
cycloheximide	NOUN	O	I-Entity
injected	VERB	O	O
2	NUM	O	O
days	NOUN	O	O
previously	ADV	O	O
;	PUNCT	O	O
(	PUNCT	O	O
6	PUNCT	O	O
)	PUNCT	O	O
prevention	NOUN	O	O
of	ADP	O	O
the	DET	O	O
deficit	NOUN	O	O
in	ADP	O	O
the	DET	O	O
retrieval	NOUN	O	O
of	ADP	O	O
an	DET	O	O
active	ADJ	O	O
avoidance	NOUN	O	O
task	NOUN	O	O
induced	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
by	ADP	O	O
subconvulsant	ADJ	O	O
electroshock	NOUN	O	O
or	CCONJ	O	O
hypercapnia	NOUN	O	I-Entity
applied	VERB	O	O
immediately	ADV	O	O
before	ADP	O	O
retrieval	NOUN	O	O
testing	NOUN	O	O
(	PUNCT	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
acquisition	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
improvements	NOUN	O	O
or	CCONJ	O	O
normalizations	NOUN	O	O
of	ADP	O	O
impaired	VERB	O	B-Entity
cognitive	ADJ	O	I-Entity
functions	NOUN	O	I-Entity
were	VERB	O	O
seen	VERB	O	O
at	ADP	O	O
oral	ADJ	O	O
aniracetam	NOUN	O	I-Entity
doses	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
-	SYM	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mechanisms	NOUN	O	O
underlying	VERB	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
aniracetam	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
'	PUNCT	O	O
therapeutic	ADJ	O	O
window	NOUN	O	O
'	PUNCT	O	O
are	VERB	O	O
unknown	ADJ	O	O
.	PUNCT	O	O

Piracetam	PROPN	O	I-Entity
,	PUNCT	O	O
another	DET	O	O
pyrrolidinone	NOUN	O	I-Entity
derivative	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
for	ADP	O	O
comparison	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
active	ADJ	O	O
only	ADV	O	O
in	ADP	O	O
six	NUM	O	O
of	ADP	O	O
nine	NUM	O	O
tests	NOUN	O	O
and	CCONJ	O	O
had	VERB	O	O
about	ADP	O	O
one	NUM	O	O
-	PUNCT	O	O
tenth	NOUN	O	O
the	DET	O	O
potency	NOUN	O	O
of	ADP	O	O
aniracetam	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
aniracetam	NOUN	O	I-Entity
improves	VERB	O	O
cognitive	ADJ	O	O
functions	NOUN	O	O
which	ADJ	O	O
are	VERB	O	O
impaired	VERB	O	O
by	ADP	O	O
different	ADJ	O	O
procedure	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
different	ADJ	O	O
phases	NOUN	O	O
of	ADP	O	O
the	DET	O	O
learning	NOUN	O	O
and	CCONJ	O	O
memory	NOUN	O	O
process	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11900788)

Nicotine	ADJ	O	I-Entity
potentiation	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
effects	NOUN	O	O
of	ADP	O	O
nicotine	NOUN	O	I-Entity
on	ADP	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

Morphine	NOUN	O	I-Entity
but	CCONJ	O	O
not	ADV	O	O
nicotine	NOUN	O	I-Entity
induced	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
catalepsy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
response	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
was	VERB	O	O
potentiated	VERB	O	O
by	ADP	O	O
nicotine	NOUN	O	I-Entity
.	PUNCT	O	O

Intraperitoneal	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
atropine	NOUN	O	I-Entity
,	PUNCT	O	O
naloxone	NOUN	O	I-Entity
,	PUNCT	O	O
mecamylamine	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hexamethonium	NOUN	O	I-Entity
to	ADP	O	O
mice	NOUN	O	O
reduced	VERB	O	O

catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
with	ADP	O	O
nicotine	NOUN	O	I-Entity
.	PUNCT	O	O

Intracerebroventricular	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
atropine	NOUN	O	I-Entity
,	PUNCT	O	O
hexamethonium	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
naloxone	NOUN	O	I-Entity
also	ADV	O	O
decreased	VERB	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
morphine	NOUN	O	I-Entity
plus	CCONJ	O	O
nicotine	NOUN	O	I-Entity
.	PUNCT	O	O

Intraperitoneal	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
atropine	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
intraperitoneal	ADJ	O	O
or	CCONJ	O	O
intracerebroventricular	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
hexamethonium	NOUN	O	I-Entity
,	PUNCT	O	O
decreased	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
morphine	NOUN	O	I-Entity
catalepsy	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
elicited	VERB	O	O
by	ADP	O	O
opioid	ADJ	O	O
and	CCONJ	O	O
cholinergic	ADJ	O	O
receptors	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
potentiation	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
nicotine	NOUN	O	I-Entity
may	VERB	O	O
also	ADV	O	O
be	VERB	O	O
mediated	VERB	O	O
through	ADP	O	O
cholinergic	ADJ	O	O
receptor	NOUN	O	O
mechanisms	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11230490)

Reduced	ADJ	O	O
cardiotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
preserved	VERB	O	O
antitumor	NOUN	O	O
efficacy	NOUN	O	O
of	ADP	O	O
liposome	NOUN	O	O
-	PUNCT	O	O
encapsulated	VERB	O	O
doxorubicin	NOUN	O	I-Entity
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
conventional	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
and	CCONJ	O	O
cyclophosphamide	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
multicenter	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

To	PART	O	O
determine	VERB	O	O
whether	ADP	O	O
Myocet	PROPN	O	I-Entity
(	PUNCT	O	O
liposome	NOUN	O	O
-	PUNCT	O	O
encapsulated	VERB	O	O
doxorubicin	NOUN	O	I-Entity
;	PUNCT	O	O
The	DET	O	O
Liposome	PROPN	O	O
Company	PROPN	O	O
,	PUNCT	O	O
Elan	PROPN	O	O
Corporation	PROPN	O	O
,	PUNCT	O	O
Princeton	PROPN	O	O
,	PUNCT	O	O
NJ	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
significantly	ADV	O	O
reduces	VERB	O	O
doxorubicin	ADJ	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
while	ADP	O	O
providing	VERB	O	O
comparable	ADJ	O	O
antitumor	NOUN	O	O
efficacy	NOUN	O	O
in	ADP	O	O
first	ADJ	O	O
-	PUNCT	O	O
line	NOUN	O	O
treatment	NOUN	O	O
of	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
(	PUNCT	O	O
MBC	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Two	NUM	O	O
hundred	NUM	O	O
ninety	NUM	O	O
-	PUNCT	O	O
seven	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
MBC	PROPN	O	I-Entity
and	CCONJ	O	O
no	DET	O	O
prior	ADJ	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
metastatic	ADJ	O	O
disease	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	VERB	O	O
either	CCONJ	O	O
60	NUM	O	O
mg	INTJ	O	O
/	SYM	O	O
m(2	PROPN	O	O
)	PUNCT	O	O
of	ADP	O	O
Myocet	PROPN	O	I-Entity
(	PUNCT	O	O
M	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
conventional	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
A	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
600	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
C	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
every	DET	O	O
3	NUM	O	O
weeks	NOUN	O	O
until	ADP	O	O
disease	NOUN	O	O
progression	NOUN	O	O
or	CCONJ	O	O
unacceptable	ADJ	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Cardiotoxicity	PROPN	O	I-Entity
was	VERB	O	O
defined	VERB	O	O
by	ADP	O	O
reductions	NOUN	O	O
in	ADP	O	O
left	VERB	O	O
-	PUNCT	O	O
ventricular	ADJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
,	PUNCT	O	O
assessed	VERB	O	O
by	ADP	O	O
serial	ADJ	O	O
multigated	VERB	O	O
radionuclide	NOUN	O	O
angiography	NOUN	O	O
scans	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
CHF	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Antitumor	PROPN	O	O
efficacy	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
objective	ADJ	O	O
tumor	NOUN	O	I-Entity
response	NOUN	O	O
rates	NOUN	O	O
(	PUNCT	O	O
World	PROPN	O	O
Health	PROPN	O	O
Organization	PROPN	O	O
criteria	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
time	NOUN	O	O
to	ADP	O	O
progression	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
survival	NOUN	O	O
.	PUNCT	O	O

Six	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
MC	PROPN	O	O
patients	NOUN	O	O
versus	ADP	O	O
21%	NUM	O	O
(	PUNCT	O	O
including	VERB	O	O
five	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
CHF	PROPN	O	I-Entity
)	PUNCT	O	O
of	ADP	O	O
AC	PROPN	O	O
patients	NOUN	O	O
developed	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.0002	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Median	ADJ	O	O
cumulative	ADJ	O	O
doxorubicin	NOUN	O	I-Entity
dose	NOUN	O	O
at	ADP	O	O
onset	NOUN	O	O
was	VERB	O	O
more	ADJ	O	O
than	ADP	O	O
2,220	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
MC	PROPN	O	O
versus	ADP	O	O
480	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m(2	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
AC	PROPN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.0001	NUM	O	O
,	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
5.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MC	PROPN	O	O
patients	NOUN	O	O
also	ADV	O	O
experienced	VERB	O	O
less	ADJ	O	O
grade	NOUN	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Myocet	PROPN	O	I-Entity
improves	VERB	O	O
the	DET	O	O
therapeutic	ADJ	O	O
index	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
by	ADP	O	O
significantly	ADV	O	O
reducing	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
grade	NOUN	O	O
4	NUM	O	O
neutropenia	NOUN	O	I-Entity
and	CCONJ	O	O
provides	VERB	O	O
comparable	ADJ	O	O
antitumor	NOUN	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
when	ADV	O	O
used	VERB	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
as	ADP	O	O
first	ADV	O	O
-	PUNCT	O	O
line	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
MBC	PROPN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2594614)

Protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
specific	ADJ	O	O
platelet	NOUN	O	O
-	PUNCT	O	O
activating	VERB	O	O
factor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
BN	PROPN	O	B-Entity
52021	NUM	O	I-Entity
,	PUNCT	O	O
on	ADP	O	O
bupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiovascular	ADJ	O	B-Entity
impairments	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Administration	PROPN	O	O
of	ADP	O	O
the	DET	O	O
local	ADJ	O	O
anaesthetic	ADJ	O	O
bupivacaine	NOUN	O	I-Entity
(	PUNCT	O	O
1.5	NUM	O	O
or	CCONJ	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
i.v	PROPN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

to	ADP	O	O
rats	NOUN	O	O
elicited	VERB	O	O
a	DET	O	O
marked	ADJ	O	O
decrease	NOUN	O	B-Entity
of	ADP	O	I-Entity
mean	ADJ	O	I-Entity
arterial	ADJ	O	I-Entity
blood	NOUN	O	I-Entity
pressure	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
MBP	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
and	CCONJ	O	I-Entity
heart	NOUN	O	I-Entity
rate	NOUN	O	I-Entity
(	PUNCT	O	I-Entity
HR	PROPN	O	I-Entity
)	PUNCT	O	I-Entity
leading	VERB	O	O
to	ADP	O	O
death	NOUN	O	O
(	PUNCT	O	O
in	ADP	O	O
67%	NUM	O	O
or	CCONJ	O	O
90%	NUM	O	O
of	ADP	O	O
animals	NOUN	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Intravenous	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
specific	ADJ	O	O
platelet	NOUN	O	O
-	PUNCT	O	O
activating	VERB	O	O
factor	NOUN	O	O
(	PUNCT	O	O
PAF	PROPN	O	O
)	PUNCT	O	O
antagonist	NOUN	O	O
BN	PROPN	O	B-Entity
52021	NUM	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
30	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
bupivacaine	ADJ	O	I-Entity
administration	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.v	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
suppressed	VERB	O	O
both	CCONJ	O	O
the	DET	O	O
decrease	NOUN	O	B-Entity
of	ADP	O	I-Entity
MBP	PROPN	O	I-Entity
and	CCONJ	O	I-Entity
HR	PROPN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
doses	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
BN	PROPN	O	B-Entity
52021	NUM	O	I-Entity
given	VERB	O	O
30	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
or	CCONJ	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
administered	VERB	O	O
5	NUM	O	O
min	NOUN	O	O
before	ADP	O	O
i.v	NOUN	O	O
.	PUNCT	O	O

injection	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
were	VERB	O	O
ineffective	ADJ	O	O
.	PUNCT	O	O

When	ADV	O	O
BN	PROPN	O	B-Entity
52021	NUM	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
mg	NUM	O	O

was	VERB	O	O
injected	VERB	O	O
immediately	ADV	O	O
after	ADP	O	O
bupivacaine	NOUN	O	I-Entity
(	PUNCT	O	O
2	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
partial	ADJ	O	O
reversion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
decrease	NOUN	O	B-Entity
of	ADP	O	I-Entity
MBP	PROPN	O	I-Entity
and	CCONJ	O	I-Entity
HR	PROPN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
was	VERB	O	O
ineffective	ADJ	O	O
.	PUNCT	O	O

A	DET	O	O
partial	ADJ	O	O
recovery	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
ECG	PROPN	O	O
alterations	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
after	ADP	O	O
pretreatment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rats	NOUN	O	O
with	ADP	O	O
BN	PROPN	O	B-Entity
52021	NUM	O	I-Entity
.	PUNCT	O	O

Since	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
BN	PROPN	O	B-Entity
52021	NUM	O	I-Entity
,	PUNCT	O	O
at	ADP	O	O
all	DET	O	O
doses	NOUN	O	O
studied	VERB	O	O
,	PUNCT	O	O
did	VERB	O	O
not	ADV	O	O
alter	VERB	O	O
MBP	PROPN	O	O
and	CCONJ	O	O
HR	PROPN	O	O
at	ADP	O	O
the	DET	O	O
doses	NOUN	O	O
used	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
bulk	NOUN	O	O
of	ADP	O	O
these	DET	O	O
results	NOUN	O	O
clearly	ADV	O	O
demonstrate	VERB	O	O
a	DET	O	O
protective	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
BN	PROPN	O	B-Entity
52021	NUM	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
specific	ADJ	O	O
antagonist	NOUN	O	O
of	ADP	O	O
PAF	PROPN	O	O
,	PUNCT	O	O
against	ADP	O	O
bupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiovascular	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
consistent	ADJ	O	O
with	ADP	O	O
its	ADJ	O	O
direct	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
heart	NOUN	O	O
,	PUNCT	O	O
PAF	PROPN	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
bupivacaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiovascular	ADJ	O	B-Entity
alterations	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2257294)

Benzylacyclouridine	PROPN	O	I-Entity
reverses	VERB	O	O
azidothymidine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
marrow	NOUN	O	B-Entity
suppression	NOUN	O	I-Entity
without	ADP	O	O
impairment	NOUN	O	O
of	ADP	O	O
anti	ADJ	O	O
-	PUNCT	O	O
human	ADJ	O	O
immunodeficiency	NOUN	O	I-Entity
virus	NOUN	O	O
activity	NOUN	O	O
.	PUNCT	O	O

Increased	ADJ	O	O
extracellular	ADJ	O	O
concentrations	NOUN	O	O
of	ADP	O	O
uridine	NOUN	O	I-Entity
(	PUNCT	O	O
Urd	PROPN	O	I-Entity
)	PUNCT	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
reduce	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
vitro	NOUN	O	O
,	PUNCT	O	O
azidothymidine	NOUN	O	I-Entity
(	PUNCT	O	O
AZT)-induced	ADJ	O	I-Entity
inhibition	NOUN	O	O
of	ADP	O	O
human	ADJ	O	O
granulocyte	NOUN	O	O
-	PUNCT	O	O
macrophage	NOUN	O	O
progenitor	NOUN	O	O
cells	NOUN	O	O
without	ADP	O	O
impairment	NOUN	O	O
of	ADP	O	O
its	ADJ	O	O
antihuman	ADJ	O	O
immunodeficiency	NOUN	O	I-Entity
virus	NOUN	O	O
(	PUNCT	O	O
HIV	PROPN	O	O
)	PUNCT	O	O
activity	NOUN	O	O
.	PUNCT	O	O

Because	ADP	O	O
of	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
toxicities	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
chronic	ADJ	O	O
Urd	PROPN	O	I-Entity
administration	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
benzylacyclouridine	NOUN	O	I-Entity
(	PUNCT	O	O
BAU	PROPN	O	I-Entity
)	PUNCT	O	O
to	PART	O	O
effect	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
AZT	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
and	CCONJ	O	O
leukopenia	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
agent	NOUN	O	O
inhibits	VERB	O	O
Urd	PROPN	O	I-Entity
catabolism	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
in	ADP	O	O
vivo	NOUN	O	O
,	PUNCT	O	O
increases	VERB	O	O
the	DET	O	O
plasma	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
Urd	PROPN	O	I-Entity
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
,	PUNCT	O	O
without	ADP	O	O
Urd	PROPN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
mice	NOUN	O	O
rendered	VERB	O	O
anemic	ADJ	O	I-Entity
and	CCONJ	O	O
leukopenic	ADJ	O	I-Entity
by	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
AZT	PROPN	O	I-Entity
for	ADP	O	O
28	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
drinking	NOUN	O	O
water	NOUN	O	O
(	PUNCT	O	O
1.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
mL	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
continued	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
AZT	PROPN	O	I-Entity
plus	CCONJ	O	O
daily	ADJ	O	O
BAU	PROPN	O	I-Entity
(	PUNCT	O	O
300	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	INTJ	O	O
,	PUNCT	O	O
orally	ADV	O	O
)	PUNCT	O	O
partially	ADV	O	O
reversed	VERB	O	O
AZT	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
anemia	NOUN	O	I-Entity
and	CCONJ	O	O
leukopenia	NOUN	O	I-Entity
(	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
increased	VERB	O	O
peripheral	ADJ	O	O
reticulocytes	NOUN	O	O
(	PUNCT	O	O
to	ADP	O	O
4.9%	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
.01	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
increased	VERB	O	O
cellularity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
marrow	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
improved	VERB	O	O
megaloblastosis	NOUN	O	I-Entity
.	PUNCT	O	O

When	ADV	O	O
coadministered	VERB	O	O
with	ADP	O	O
AZT	PROPN	O	I-Entity
from	ADP	O	O
the	DET	O	O
onset	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
BAU	PROPN	O	I-Entity
reduced	VERB	O	O
AZT	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
marrow	NOUN	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
vitro	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
100	NUM	O	O
mumol	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
,	PUNCT	O	O
BAU	PROPN	O	I-Entity
possesses	VERB	O	O
minimal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
HIV	NOUN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
has	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
AZT	PROPN	O	I-Entity
to	PART	O	O
reverse	VERB	O	O
the	DET	O	O
HIV	PROPN	O	O
-	PUNCT	O	O
induced	VERB	O	O
cytopathic	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
MT4	PROPN	O	O
cells	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10840460)

Cyclophosphamide	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
in	ADP	O	O
freely	ADV	O	O
-	PUNCT	O	O
moving	VERB	O	O
conscious	ADJ	O	O
rats	NOUN	O	O
:	PUNCT	O	O
behavioral	ADJ	O	O
approach	NOUN	O	O
to	ADP	O	O
a	DET	O	O
new	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
visceral	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
.	PUNCT	O	O

PURPOSE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
develop	VERB	O	O
a	DET	O	O
model	NOUN	O	O
of	ADP	O	O
visceral	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
using	VERB	O	O
a	DET	O	O
behavioral	ADJ	O	O
approach	NOUN	O	O
.	PUNCT	O	O

Cyclophosphamide	PROPN	O	I-Entity
(	PUNCT	O	O
CP	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
antitumoral	ADJ	O	O
agent	NOUN	O	O
known	VERB	O	O
to	PART	O	O
produce	VERB	O	O
toxic	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
wall	NOUN	O	O
through	ADP	O	O
its	ADJ	O	O
main	ADJ	O	O
toxic	ADJ	O	O
metabolite	NOUN	O	O
acrolein	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
induce	VERB	O	O
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

CP	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
50	NUM	O	O
,	PUNCT	O	O
100	NUM	O	O
and	CCONJ	O	O
200	NUM	O	O
mg./kg	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
to	ADP	O	O
4	NUM	O	O
mg./kg	NOUN	O	O
.	PUNCT	O	O

i.v	PUNCT	O	O
.	PUNCT	O	O
)	PUNCT	O	O
on	ADP	O	O
CP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
behavioral	ADJ	O	O
modifications	NOUN	O	O
were	VERB	O	O
tested	VERB	O	O
administered	VERB	O	O
alone	ADV	O	O
and	CCONJ	O	O
after	ADP	O	O
naloxone	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg./kg	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
90	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
CP	PROPN	O	I-Entity
injection	NOUN	O	O
,	PUNCT	O	O
that	DET	O	O
is	VERB	O	O
,	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
bladder	NOUN	O	O
was	VERB	O	O
removed	VERB	O	O
in	ADP	O	O
some	DET	O	O
rats	NOUN	O	O
for	ADP	O	O
histological	ADJ	O	O
examination	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
to	PART	O	O
show	VERB	O	O
that	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
is	VERB	O	O
essential	ADJ	O	O
for	ADP	O	O
the	DET	O	O
CP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
behavioral	ADJ	O	O
modifications	NOUN	O	O
,	PUNCT	O	O
female	ADJ	O	O
rats	NOUN	O	O
also	ADV	O	O
received	VERB	O	O
CP	PROPN	O	I-Entity
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
200	NUM	O	O
mg./kg	NOUN	O	O
.	PUNCT	O	O

by	ADP	O	O
the	DET	O	O
intravesical	ADJ	O	O
route	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
acrolein	NOUN	O	I-Entity
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
0.5	NUM	O	O
mg	NUM	O	O
.	PUNCT	O	O

CP	NOUN	O	I-Entity
dose	NOUN	O	O
-	PUNCT	O	O
relatedly	ADV	O	O
induced	VERB	O	O
marked	VERB	O	O
behavioral	ADJ	O	O
modifications	NOUN	O	O
in	ADP	O	O
male	ADJ	O	O
rats	NOUN	O	O
:	PUNCT	O	O
breathing	VERB	O	O
rate	NOUN	O	O
decrease	NOUN	O	O
,	PUNCT	O	O
closing	NOUN	O	O
of	ADP	O	O
the	DET	O	O
eyes	NOUN	O	O
and	CCONJ	O	O
occurrence	NOUN	O	O
of	ADP	O	O
specific	ADJ	O	O
postures	NOUN	O	O
.	PUNCT	O	O

Morphine	PROPN	O	I-Entity
dose	NOUN	O	O
-	PUNCT	O	O
dependently	ADV	O	O
reversed	VERB	O	O
these	DET	O	O
behavioral	ADJ	O	B-Entity
disorders	NOUN	O	I-Entity
.	PUNCT	O	O

produced	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
of	ADP	O	O
almost	ADV	O	O
50%	NUM	O	O
of	ADP	O	O
the	DET	O	O
behavioral	ADJ	O	O
score	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
CP	PROPN	O	I-Entity
200	NUM	O	O
mg./kg	PROPN	O	O
.	PUNCT	O	O

This	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
completely	ADV	O	O
prevented	VERB	O	O
by	ADP	O	O
pretreatment	NOUN	O	O
with	ADP	O	O
naloxone	NOUN	O	I-Entity
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
histological	ADJ	O	O
modifications	NOUN	O	O
of	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
wall	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
chorionic	NOUN	O	O
and	CCONJ	O	O
muscle	NOUN	O	O
layer	NOUN	O	O
edema	NOUN	O	I-Entity
,	PUNCT	O	O
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
female	ADJ	O	O
rats	NOUN	O	O
,	PUNCT	O	O
CP	PROPN	O	I-Entity
200	NUM	O	O
mg./kg	NOUN	O	O
.	PUNCT	O	O

intravesically	ADV	O	O
,	PUNCT	O	O
CP	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
produce	VERB	O	O
any	DET	O	O
behavioral	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
acrolein	NOUN	O	I-Entity
at	ADP	O	O
0.5	NUM	O	O
mg	NUM	O	O
.	PUNCT	O	O

intravesically	ADV	O	O
induced	VERB	O	O
behavioral	ADJ	O	O
modifications	NOUN	O	O
identical	ADJ	O	O
to	ADP	O	O
those	DET	O	O
under	ADP	O	O
CP	PROPN	O	I-Entity
200	NUM	O	O
mg./kg	NOUN	O	O
.	PUNCT	O	O

Conversely	ADV	O	O
,	PUNCT	O	O
acrolein	NOUN	O	I-Entity
5	NUM	O	O
mg./kg	NOUN	O	O
.	PUNCT	O	O

Overall	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
this	DET	O	O
experimental	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
CP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
an	DET	O	O
interesting	ADJ	O	O
new	ADJ	O	O
behavioral	ADJ	O	O
model	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
visceral	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
allowing	VERB	O	O
a	DET	O	O
better	ADJ	O	O
understanding	NOUN	O	O
of	ADP	O	O
these	DET	O	O
painful	ADJ	O	B-Entity
syndromes	NOUN	O	I-Entity
and	CCONJ	O	O
thus	ADV	O	O
a	DET	O	O
better	ADJ	O	O
therapeutic	ADJ	O	O
approach	NOUN	O	O
to	ADP	O	O
them	PRON	O	O
.	PUNCT	O	O


-DOCSTART- (8278214)

Hyperalgesia	PROPN	O	I-Entity
and	CCONJ	O	O
myoclonus	NOUN	O	I-Entity
in	ADP	O	O
terminal	NOUN	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
continuous	ADJ	O	O
intravenous	ADJ	O	O
morphine	NOUN	O	I-Entity
.	PUNCT	O	O

Eight	NUM	O	O
cancer	NOUN	O	I-Entity
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
terminal	ADJ	O	O
stages	NOUN	O	O
of	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
morphine	NOUN	O	I-Entity
developed	VERB	O	O
hyperalgesia	NOUN	O	I-Entity
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
developed	VERB	O	O
universal	ADJ	O	O
hyperalgesia	NOUN	O	I-Entity
and	CCONJ	O	O
hyperesthesia	NOUN	O	I-Entity
which	ADJ	O	O
in	ADP	O	O
2	NUM	O	O
cases	NOUN	O	O
were	VERB	O	O
accompanied	VERB	O	O
by	ADP	O	O
myoclonus	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
3	NUM	O	O
patients	NOUN	O	O
a	DET	O	O
pre	NOUN	O	O
-	PUNCT	O	O
existing	VERB	O	O
neuralgia	NOUN	O	I-Entity
increased	VERB	O	O
to	ADP	O	O
excruciating	ADJ	O	O
intensity	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
2	NUM	O	O
of	ADP	O	O
these	DET	O	O
cases	NOUN	O	O
myoclonus	VERB	O	I-Entity
occurred	VERB	O	O
simultaneously	ADV	O	O
.	PUNCT	O	O

Although	ADP	O	O
only	ADV	O	O
few	ADJ	O	O
clinical	ADJ	O	O
descriptions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
hyperalgesia	NOUN	O	I-Entity
/	SYM	O	O
myoclonus	NOUN	O	I-Entity
and	CCONJ	O	O
high	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
morphine	NOUN	O	I-Entity
are	VERB	O	O
available	ADJ	O	O
,	PUNCT	O	O
experimental	ADJ	O	O
support	NOUN	O	O
from	ADP	O	O
animal	NOUN	O	O
studies	NOUN	O	O
indicates	VERB	O	O
that	ADP	O	O
morphine	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
its	ADJ	O	O
metabolites	NOUN	O	O
,	PUNCT	O	O
plays	VERB	O	O
a	DET	O	O
causative	ADJ	O	O
role	NOUN	O	O
for	ADP	O	O
the	DET	O	O
observed	VERB	O	O
behavioural	ADJ	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3934126)

A	DET	O	O
prospective	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
vancomycin	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
prospective	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
vancomycin	NOUN	O	I-Entity
was	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
54	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
over	ADP	O	O
a	DET	O	O
16-month	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

Vancomycin	PROPN	O	I-Entity
was	VERB	O	O
curative	ADJ	O	O
in	ADP	O	O
95%	NUM	O	O
of	ADP	O	O
43	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
proven	VERB	O	O
infection	NOUN	O	I-Entity
.	PUNCT	O	O

Drugs	NOUN	O	O
were	VERB	O	O
ceased	VERB	O	O
in	ADP	O	O
six	NUM	O	O
patients	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
adverse	ADJ	O	O
reactions	NOUN	O	O
;	PUNCT	O	O
in	ADP	O	O
three	NUM	O	O
of	ADP	O	O
these	DET	O	O
vancomycin	NOUN	O	I-Entity
was	VERB	O	O
considered	VERB	O	O
the	DET	O	O
likely	ADJ	O	O
cause	NOUN	O	O
.	PUNCT	O	O

Reactions	NOUN	O	O
included	VERB	O	O
thrombophlebitis	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
of	ADP	O	O
54	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
rash	NOUN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
of	ADP	O	O
54	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nephrotoxicity	NOUN	O	I-Entity
(	PUNCT	O	O
4	NUM	O	O
of	ADP	O	O
50	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
proteinuria	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
of	ADP	O	O
50	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
ototoxicity	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
of	ADP	O	O
11	NUM	O	O
patients	NOUN	O	O
tested	VERB	O	O
by	ADP	O	O
audiometry	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Thrombophlebitis	PROPN	O	I-Entity
occurred	VERB	O	O
only	ADV	O	O
with	ADP	O	O
infusion	NOUN	O	O
through	ADP	O	O
peripheral	ADJ	O	O
cannulae	NOUN	O	O
;	PUNCT	O	O
nephrotoxicity	NOUN	O	I-Entity
and	CCONJ	O	O
ototoxicity	NOUN	O	I-Entity
were	VERB	O	O
confined	VERB	O	O
to	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
an	DET	O	O
aminoglycoside	NOUN	O	I-Entity
plus	CCONJ	O	O
vancomycin	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
vancomycin	NOUN	O	I-Entity
,	PUNCT	O	O
administered	VERB	O	O
appropriately	ADV	O	O
,	PUNCT	O	O
constitutes	VERB	O	O
safe	ADJ	O	O
,	PUNCT	O	O
effective	ADJ	O	O
therapy	NOUN	O	O
for	ADP	O	O
infections	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
susceptible	ADJ	O	O
bacteria	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1687392)

Blockade	PROPN	O	O
of	ADP	O	O
both	CCONJ	O	O
D-1	PROPN	O	O
and	CCONJ	O	O
D-2	PROPN	O	O
dopamine	NOUN	O	I-Entity
receptors	NOUN	O	O
may	VERB	O	O
induce	VERB	O	O
catalepsy	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
dopamine	NOUN	O	I-Entity
antagonists	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
tested	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
possible	ADJ	O	O
dopamine	NOUN	O	I-Entity
subtypes	NOUN	O	O
involved	VERB	O	O
in	ADP	O	O
catalepsy	NOUN	O	I-Entity
was	VERB	O	O
determined	ADJ	O	O
.	PUNCT	O	O

Dopamine	NOUN	O	I-Entity
antagonist	NOUN	O	O
fluphenazine	NOUN	O	I-Entity
,	PUNCT	O	O
D-1	PROPN	O	O
antagonist	NOUN	O	O
SCH	PROPN	O	B-Entity
23390	NUM	O	I-Entity
or	CCONJ	O	O

D-2	PROPN	O	O
antagonist	NOUN	O	O
sulpiride	NOUN	O	I-Entity
induced	VERB	O	O
catalepsy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
fluphenazine	NOUN	O	I-Entity
and	CCONJ	O	O
sulpiride	NOUN	O	I-Entity
was	VERB	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	NOUN	O	O
.	PUNCT	O	O

Combination	NOUN	O	O
of	ADP	O	O
SCH	PROPN	O	B-Entity
23390	NUM	O	I-Entity
with	ADP	O	O
sulpiride	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
induce	VERB	O	O
catalepsy	ADJ	O	I-Entity
potentiation	NOUN	O	O
.	PUNCT	O	O

SKF	PROPN	O	B-Entity
38393	NUM	O	I-Entity
or	CCONJ	O	O
D-2	PROPN	O	O
agonist	NOUN	O	O
quinpirole	NOUN	O	I-Entity
decreased	VERB	O	O
the	DET	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
fluphenazine	NOUN	O	I-Entity
,	PUNCT	O	O
SCH	PROPN	O	B-Entity
23390	NUM	O	I-Entity
or	CCONJ	O	O
sulpiride	NOUN	O	I-Entity
.	PUNCT	O	O

4	PUNCT	O	O
.	PUNCT	O	O
Combination	NOUN	O	O
of	ADP	O	O
SKF	PROPN	O	B-Entity
38393	NUM	O	I-Entity
with	ADP	O	O
quinpirole	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
cause	VERB	O	O
potentiated	ADJ	O	O
inhibitory	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
dopamine	NOUN	O	I-Entity
antagonists	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
may	VERB	O	O
indicate	VERB	O	O
that	ADP	O	O
although	ADP	O	O
D-2	PROPN	O	O
receptor	NOUN	O	O
blockade	NOUN	O	O
is	VERB	O	O
involved	VERB	O	O
in	ADP	O	O
catalepsy	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
D-1	PROPN	O	O
receptor	NOUN	O	O
may	VERB	O	O
plan	VERB	O	O
a	DET	O	O
role	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19719056)

Dextran	NOUN	O	I-Entity
-	PUNCT	O	O
etodolac	NOUN	O	I-Entity
conjugates	NOUN	O	O
:	PUNCT	O	O
synthesis	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
vitro	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vivo	NOUN	O	O
evaluation	NOUN	O	O
.	PUNCT	O	O

Etodolac	PROPN	O	I-Entity
(	PUNCT	O	O
E	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
narcotic	ADJ	O	O
analgesic	NOUN	O	O
and	CCONJ	O	O
antiinflammatory	ADJ	O	O
drug	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
biodegradable	ADJ	O	O
polymer	NOUN	O	O
dextran	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
utilized	VERB	O	O
as	ADP	O	O
a	DET	O	O
carrier	NOUN	O	O
for	ADP	O	O
synthesis	NOUN	O	O
of	ADP	O	O
etodolac	NOUN	O	I-Entity
-	PUNCT	O	O
dextran	NOUN	O	I-Entity
conjugates	NOUN	O	O
(	PUNCT	O	O
ED	PROPN	O	O
)	PUNCT	O	O
to	PART	O	O
improve	VERB	O	O
its	ADJ	O	O
aqueous	ADJ	O	O
solubility	NOUN	O	O
and	CCONJ	O	O
reduce	VERB	O	O
gastrointestinal	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
activated	VERB	O	O
moiety	NOUN	O	O
,	PUNCT	O	O
i.e.	X	O	O
N	CCONJ	O	B-Entity
-	PUNCT	O	I-Entity
acylimidazole	NOUN	O	I-Entity
derivative	NOUN	O	O
of	ADP	O	O
etodolac	NOUN	O	I-Entity
(	PUNCT	O	O
EAI	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
was	VERB	O	O
condensed	VERB	O	O
with	ADP	O	O
the	DET	O	O
polysaccharide	NOUN	O	O
polymer	NOUN	O	O
dextran	NOUN	O	I-Entity
of	ADP	O	O
different	ADJ	O	O
molecular	ADJ	O	O
weights	NOUN	O	O
(	PUNCT	O	O
40000	NUM	O	O
,	PUNCT	O	O
60000	NUM	O	O
,	PUNCT	O	O
110000	NUM	O	O
and	CCONJ	O	O
200000	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Etodolac	ADJ	O	I-Entity
contents	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
UV	PROPN	O	O
-	PUNCT	O	O
spectrophotometric	ADJ	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
pH	PROPN	O	O
9	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
higher	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
etodolac	ADJ	O	I-Entity
release	NOUN	O	O
from	ADP	O	O
ED	PROPN	O	O
was	VERB	O	O
observed	VERB	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
aqueous	ADJ	O	O
buffer	NOUN	O	O
of	ADP	O	O
pH	PROPN	O	O
7.4	NUM	O	O
and	CCONJ	O	O
80%	NUM	O	O
human	ADJ	O	O
plasma	NOUN	O	O
(	PUNCT	O	O
pH	PROPN	O	O
7.4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
following	VERB	O	O
first	ADV	O	O
-	PUNCT	O	O
order	NOUN	O	O
kinetics	NOUN	O	O
.	PUNCT	O	O

Acute	PROPN	O	O
analgesic	NOUN	O	O
and	CCONJ	O	O
antiinflammatory	NOUN	O	O
activities	NOUN	O	O
were	VERB	O	O
ascertained	VERB	O	O
using	VERB	O	O
acetic	ADJ	O	B-Entity
acid	PROPN	O	I-Entity
induced	VERB	O	O
writhing	VERB	O	I-Entity
model	NOUN	O	O
(	PUNCT	O	O
mice	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
carrageenan	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
rat	NOUN	O	O
paw	NOUN	O	O
edema	NOUN	O	I-Entity
model	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

In	ADP	O	O
comparison	NOUN	O	O
to	PART	O	O
control	VERB	O	O
,	PUNCT	O	O
E	PROPN	O	I-Entity
and	CCONJ	O	O
ED1-ED4	PROPN	O	O
showed	VERB	O	O
highly	ADV	O	O
significant	ADJ	O	O
analgesic	NOUN	O	O
and	CCONJ	O	O
antiinflammatory	NOUN	O	O
activities	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Biological	ADJ	O	O
evaluation	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
conjugates	NOUN	O	O
(	PUNCT	O	O
ED1-ED4	PROPN	O	O
)	PUNCT	O	O
retained	VERB	O	O
comparable	ADJ	O	O
analgesic	NOUN	O	O
and	CCONJ	O	O
antiinflammatory	NOUN	O	O
activities	NOUN	O	O
with	ADP	O	O
remarkably	ADV	O	O
reduced	VERB	O	O
ulcerogenicity	NOUN	O	O
as	ADP	O	O
compared	VERB	O	O
to	ADP	O	O
their	ADJ	O	O
parent	NOUN	O	O
drug	NOUN	O	O
--	PUNCT	O	O
etodolac	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (15266362)

Hypersensitivity	PROPN	O	I-Entity
myocarditis	NOUN	O	I-Entity
complicating	VERB	O	O
hypertrophic	ADJ	O	B-Entity
cardiomyopathy	ADJ	O	I-Entity
heart	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
report	NOUN	O	O
describes	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
eosinophilic	ADJ	O	B-Entity
myocarditis	NOUN	O	I-Entity
complicating	VERB	O	O
hypertrophic	ADJ	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
47-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
female	ADJ	O	O
patient	NOUN	O	O
,	PUNCT	O	O
known	VERB	O	O
to	PART	O	O
have	VERB	O	O
hypertrophic	ADJ	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
,	PUNCT	O	O
was	VERB	O	O
admitted	VERB	O	O
with	ADP	O	O
biventricular	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
and	CCONJ	O	O
managed	VERB	O	O
aggressively	ADV	O	O
with	ADP	O	O
dobutamine	NOUN	O	I-Entity
infusion	NOUN	O	O
and	CCONJ	O	O
other	ADJ	O	O
drugs	NOUN	O	O
while	ADP	O	O
being	VERB	O	O
assessed	VERB	O	O
for	ADP	O	O
heart	NOUN	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
transthoracic	NOUN	O	O
echocardiogram	NOUN	O	O
,	PUNCT	O	O
she	PRON	O	O
had	VERB	O	O
moderate	ADJ	O	O
left	VERB	O	B-Entity
ventricular	ADJ	O	I-Entity
dysfunction	NOUN	O	I-Entity
with	ADP	O	O
regional	ADJ	O	O
variability	NOUN	O	O
and	CCONJ	O	O
moderate	ADJ	O	O
mitral	ADJ	O	B-Entity
regurgitation	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
recipient	NOUN	O	O
's	PART	O	O
heart	NOUN	O	O
showed	VERB	O	O
the	DET	O	O
features	NOUN	O	O
of	ADP	O	O
apical	ADJ	O	O
hypertrophic	ADJ	O	B-Entity
cardiomyopathy	NOUN	O	I-Entity
and	CCONJ	O	O
myocarditis	NOUN	O	I-Entity
with	ADP	O	O
abundant	ADJ	O	O
eosinophils	NOUN	O	O
.	PUNCT	O	O

Myocarditis	PROPN	O	I-Entity
is	VERB	O	O
rare	ADJ	O	O
and	CCONJ	O	O
eosinophilic	ADJ	O	B-Entity
myocarditis	NOUN	O	I-Entity
is	VERB	O	O
rarer	ADJ	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
likely	ADJ	O	O
that	ADP	O	O
the	DET	O	O
hypersensitivity	NOUN	O	I-Entity
(	PUNCT	O	O
eosinophilic	NOUN	O	I-Entity
)	PUNCT	O	O

myocarditis	NOUN	O	I-Entity
was	VERB	O	O
related	VERB	O	O
to	ADP	O	O
dobutamine	NOUN	O	I-Entity
infusion	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Eosinophilic	PROPN	O	B-Entity
myocarditis	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
with	ADP	O	O
an	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
2.4%	NUM	O	O
to	PART	O	O
7.2%	NUM	O	O
in	ADP	O	O
explanted	ADJ	O	O
hearts	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
multidrug	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (14648024)

All-	DET	O	B-Entity
trans	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
retinoic	ADJ	O	I-Entity
acid	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
erythema	NOUN	O	B-Entity
nodosum	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
promyelocytic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
.	PUNCT	O	O

Erythema	PROPN	O	B-Entity
nodosum	ADV	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
all-	DET	O	B-Entity
trans	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
retinoic	NOUN	O	I-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
ATRA	PROPN	O	I-Entity
)	PUNCT	O	O
for	ADP	O	O
acute	ADJ	O	B-Entity
promyelocytic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
(	PUNCT	O	O
APL	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
very	ADV	O	O
rare	ADJ	O	O
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
four	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
classic	ADJ	O	O
APL	PROPN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
erythema	NOUN	O	B-Entity
nodosum	NOUN	O	I-Entity
during	ADP	O	O
ATRA	PROPN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Fever	NOUN	O	I-Entity
and	CCONJ	O	O
subsequent	ADJ	O	O
multiple	ADJ	O	O
painful	ADJ	O	I-Entity
erythematous	ADJ	O	B-Entity
nodules	NOUN	O	I-Entity
over	ADP	O	O
extremities	NOUN	O	O
developed	VERB	O	O
on	ADP	O	O
D11	PROPN	O	O
,	PUNCT	O	O
D16	PROPN	O	O
,	PUNCT	O	O
D17	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
D19	PROPN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
after	ADP	O	O
ATRA	PROPN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
skin	NOUN	O	O
biopsy	NOUN	O	O
taken	VERB	O	O
from	ADP	O	O
each	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
erythema	NOUN	O	B-Entity
nodosum	NOUN	O	I-Entity
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
received	VERB	O	O
short	ADV	O	O
course	NOUN	O	O
of	ADP	O	O
steroids	NOUN	O	I-Entity
.	PUNCT	O	O

Fever	ADV	O	I-Entity
subsided	VERB	O	O
rapidly	ADV	O	O
and	CCONJ	O	O
the	DET	O	O
skin	NOUN	O	O
lesions	NOUN	O	O
regressed	VERB	O	O
completely	ADV	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
achieved	VERB	O	O
complete	ADJ	O	O
remission	NOUN	O	O
without	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
ATRA	PROPN	O	I-Entity
.	PUNCT	O	O

ATRA	PROPN	O	I-Entity
seemed	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
most	ADV	O	O
possible	ADJ	O	O
etiology	NOUN	O	O
of	ADP	O	O
erythema	NOUN	O	B-Entity
nodosum	NOUN	O	I-Entity
in	ADP	O	O
our	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
use	NOUN	O	O
of	ADP	O	O
steroid	NOUN	O	I-Entity
is	VERB	O	O
very	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
ATRA	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
erythema	NOUN	O	B-Entity
nodosum	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11827497)

Delayed	VERB	O	O
-	PUNCT	O	O
onset	NOUN	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
.	PUNCT	O	O

Heparin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
presents	NOUN	O	O
5	NUM	O	O
to	PART	O	O
12	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
heparin	NOUN	O	I-Entity
exposure	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
arterial	NOUN	O	B-Entity
or	CCONJ	O	I-Entity
venous	ADJ	O	I-Entity
thromboemboli	NOUN	O	I-Entity
.	PUNCT	O	O

Delayed	ADJ	O	O
recognition	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
contribute	VERB	O	O
to	ADP	O	O
poor	ADJ	O	O
patient	ADJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
describe	VERB	O	O
and	CCONJ	O	O
increase	VERB	O	O
awareness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
scenario	NOUN	O	O
in	ADP	O	O
which	ADJ	O	O
the	DET	O	O
onset	NOUN	O	O
or	CCONJ	O	O
manifestations	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
are	VERB	O	O
delayed	VERB	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
:	PUNCT	O	O
14	NUM	O	O
patients	NOUN	O	O
seen	VERB	O	O
over	ADP	O	O
a	DET	O	O
3-year	ADJ	O	O
period	NOUN	O	O
in	ADP	O	O
whom	NOUN	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
became	VERB	O	O
apparent	ADJ	O	O
on	ADP	O	O
delayed	VERB	O	O
presentation	NOUN	O	O
with	ADP	O	O
thromboembolic	ADJ	O	I-Entity
complications	NOUN	O	O
.	PUNCT	O	O

MEASUREMENTS	NOUN	O	O
:	PUNCT	O	O
Platelet	PROPN	O	O
counts	NOUN	O	O
,	PUNCT	O	O
onset	NOUN	O	O
of	ADP	O	O
objectively	ADV	O	O
determined	VERB	O	O
thromboembolism	NOUN	O	I-Entity
,	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
platelet	NOUN	O	O
factor	NOUN	O	O
4	NUM	O	O
antibody	NOUN	O	O
tests	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
went	VERB	O	O
home	ADV	O	O
after	ADP	O	O
hospitalizations	NOUN	O	O
that	ADJ	O	O
had	VERB	O	O
included	VERB	O	O
heparin	NOUN	O	I-Entity
exposure	NOUN	O	O
--	PUNCT	O	O
in	ADP	O	O
most	ADJ	O	O
cases	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
thrombocytopenia	NOUN	O	I-Entity
recognized	VERB	O	O
--	PUNCT	O	O
only	ADV	O	O
to	PART	O	O
return	VERB	O	O
to	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
,	PUNCT	O	O
day	NOUN	O	O
14	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
thromboembolic	ADJ	O	I-Entity
complications	NOUN	O	O
.	PUNCT	O	O

Thromboemboli	PROPN	O	I-Entity
were	VERB	O	O
venous	ADJ	O	O
(	PUNCT	O	O
12	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
7	NUM	O	O
with	ADP	O	O
pulmonary	ADJ	O	B-Entity
emboli	NOUN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
arterial	NOUN	O	O
(	PUNCT	O	O
4	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
both	DET	O	O
.	PUNCT	O	O

On	ADP	O	O
readmission	NOUN	O	O
,	PUNCT	O	O
11	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
therapeutic	ADJ	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
worsened	VERB	O	O
the	DET	O	O
patients	NOUN	O	O
'	PART	O	O
clinical	ADJ	O	O
condition	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
in	ADP	O	O
all	DET	O	O
11	NUM	O	O
cases	NOUN	O	O
,	PUNCT	O	O
decreased	VERB	O	O
the	DET	O	O
platelet	NOUN	O	O
count	NOUN	O	O
(	PUNCT	O	O
mean	VERB	O	O
at	ADP	O	O
readmission	NOUN	O	O
,	PUNCT	O	O
143	NUM	O	O
x	SYM	O	O
10(9	NUM	O	O
)	PUNCT	O	O
cells	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
;	PUNCT	O	O
mean	VERB	O	O
nadir	NOUN	O	O
after	ADP	O	O
heparin	NOUN	O	I-Entity
re	ADP	O	O
-	PUNCT	O	O
exposure	NOUN	O	O
,	PUNCT	O	O
39	NUM	O	O
x	SYM	O	O
10(9	NUM	O	O
)	PUNCT	O	O
cells	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Results	NOUN	O	O
of	ADP	O	O
serologic	ADJ	O	O
tests	NOUN	O	O
for	ADP	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
antibodies	NOUN	O	O
were	VERB	O	O
positive	ADJ	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Subsequent	ADJ	O	O
treatments	NOUN	O	O
included	VERB	O	O
alternative	ADJ	O	O
anticoagulants	NOUN	O	O
(	PUNCT	O	O
11	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
thrombolytic	ADJ	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
inferior	ADJ	O	O
vena	NOUN	O	O
cava	NOUN	O	O
filters	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
,	PUNCT	O	O
eventually	ADV	O	O
,	PUNCT	O	O
warfarin	NOUN	O	I-Entity
(	PUNCT	O	O
11	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
is	VERB	O	O
increasingly	ADV	O	O
being	VERB	O	O
recognized	VERB	O	O
.	PUNCT	O	O

To	PART	O	O
avoid	VERB	O	O
disastrous	ADJ	O	O
outcomes	NOUN	O	O
,	PUNCT	O	O
physicians	NOUN	O	O
must	VERB	O	O
consider	VERB	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
whenever	ADV	O	O
a	DET	O	O
recently	ADV	O	O
hospitalized	VERB	O	O
patient	ADJ	O	O
returns	NOUN	O	O
with	ADP	O	O
thromboembolism	NOUN	O	I-Entity
;	PUNCT	O	O
therapy	NOUN	O	O
with	ADP	O	O
alternative	ADJ	O	O
anticoagulants	NOUN	O	O
,	PUNCT	O	O
not	ADV	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
should	VERB	O	O
be	VERB	O	O
initiated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (8841157)

Valsartan	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
angiotensin	NOUN	O	B-Entity
II	PROPN	O	I-Entity
antagonist	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
comparative	ADJ	O	O
study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
against	ADP	O	O
amlodipine	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
compare	VERB	O	O
the	DET	O	O
antihypertensive	ADJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
a	DET	O	O
new	ADJ	O	O
angiotensin	NOUN	O	B-Entity
II	PROPN	O	I-Entity
antagonist	NOUN	O	O
,	PUNCT	O	O
valsartan	NOUN	O	I-Entity
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
reference	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
amlodipine	NOUN	O	I-Entity
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
sixty	NUM	O	O
-	PUNCT	O	O
eight	NUM	O	O
adult	NOUN	O	O
outpatients	NOUN	O	O
with	ADP	O	O
mild	ADJ	O	O
to	PART	O	O
moderate	ADJ	O	O
hypertension	NOUN	O	I-Entity
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
in	ADP	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
fashion	NOUN	O	O
and	CCONJ	O	O
equal	ADJ	O	O
number	NOUN	O	O
to	PART	O	O
receive	VERB	O	O
80	NUM	O	O
mg	NUM	O	O
valsartan	NOUN	O	I-Entity
or	CCONJ	O	O
5	NUM	O	O
mg	NUM	O	O
amlodipine	NOUN	O	I-Entity
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
whose	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
remained	VERB	O	O
uncontrolled	ADJ	O	O
,	PUNCT	O	O
5	NUM	O	O
mg	CCONJ	O	O
amlodipine	NOUN	O	I-Entity
was	VERB	O	O
added	VERB	O	O
to	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
valsartan	NOUN	O	I-Entity
and	CCONJ	O	O
amlodipine	NOUN	O	I-Entity
were	VERB	O	O
effective	ADJ	O	O
at	ADP	O	O
lowering	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
at	ADP	O	O
4	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
variable	NOUN	O	O
the	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
0.5	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
in	ADP	O	O
favor	NOUN	O	O
of	ADP	O	O
valsartan	NOUN	O	I-Entity
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.68	NUM	O	O
;	PUNCT	O	O
95%	NUM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
-2.7	NUM	O	O
to	PART	O	O
1.7	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Responder	NOUN	O	O
rates	NOUN	O	O
at	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
were	VERB	O	O
66.7%	NUM	O	O
for	ADP	O	O
valsartan	NOUN	O	I-Entity
and	CCONJ	O	O
60.2%	NUM	O	O
for	ADP	O	O
amlodipine	NOUN	O	I-Entity

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
dependent	ADJ	O	O
edema	NOUN	O	I-Entity
was	VERB	O	O
somewhat	ADV	O	O
higher	ADJ	O	O
in	ADP	O	O
the	DET	O	O
amlodipine	NOUN	O	I-Entity
group	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
day	NOUN	O	O
(	PUNCT	O	O
2.4%	NUM	O	O
for	ADP	O	O
80	NUM	O	O
mg	NUM	O	O
valsartan	NOUN	O	I-Entity
;	PUNCT	O	O
3.6%	NUM	O	O
for	ADP	O	O
5	NUM	O	O
mg	NUM	O	O
amlodipine	NOUN	O	I-Entity
;	PUNCT	O	O
0%	NUM	O	O
for	ADP	O	O
valsartan	NOUN	O	I-Entity
plus	CCONJ	O	O
5	NUM	O	O
mg	NUM	O	O
amlodipine	NOUN	O	I-Entity
;	PUNCT	O	O
14.3%	NUM	O	O
for	ADP	O	O
10	NUM	O	O
mg	NUM	O	O
amlodipine	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
The	DET	O	O
data	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
valsartan	NOUN	O	I-Entity
is	VERB	O	O
at	ADV	O	O
least	ADJ	O	O
as	ADV	O	O
effective	ADJ	O	O
as	ADP	O	O
amlodipine	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
mild	ADJ	O	O
to	PART	O	O
moderate	ADJ	O	O
hypertension	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
also	ADV	O	O
show	VERB	O	O
valsartan	NOUN	O	I-Entity
to	PART	O	O
be	VERB	O	O
well	ADV	O	O
tolerated	VERB	O	O
and	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
it	PRON	O	O
is	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
characteristic	NOUN	O	O
of	ADP	O	O
this	DET	O	O
comparator	NOUN	O	O
class	NOUN	O	O
,	PUNCT	O	O
dihydropyridine	ADJ	O	I-Entity
calcium	NOUN	O	I-Entity
antagonists	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8045270)

KF17837	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
novel	NOUN	O	O
selective	ADJ	O	O
adenosine	NOUN	O	I-Entity
A2A	PROPN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
with	ADP	O	O
anticataleptic	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

KF17837	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
novel	NOUN	O	O
selective	ADJ	O	O
adenosine	NOUN	O	I-Entity
A2A	PROPN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
.	PUNCT	O	O

Oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
KF17837	PROPN	O	I-Entity
(	PUNCT	O	O
2.5	NUM	O	O
,	PUNCT	O	O
10.0	NUM	O	O
and	CCONJ	O	O
30.0	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
significantly	ADV	O	O
ameliorated	VERB	O	O
the	DET	O	O
cataleptic	ADJ	O	I-Entity
responses	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
intracerebroventricular	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
an	DET	O	O
adenosine	NOUN	O	I-Entity
A2A	PROPN	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
CGS	PROPN	O	B-Entity
21680	NUM	O	I-Entity
(	PUNCT	O	O
10	NUM	O	O
micrograms	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
manner	NOUN	O	O
.	PUNCT	O	O

KF17837	NOUN	O	I-Entity
also	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
catalepsy	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
haloperidol	NOUN	O	I-Entity
(	PUNCT	O	O
1	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
by	ADP	O	O
reserpine	NOUN	O	I-Entity
(	PUNCT	O	O
5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
KF17837	PROPN	O	I-Entity
(	PUNCT	O	O
0.625	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
p.o	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

potentiated	VERB	O	O
the	DET	O	O
anticataleptic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
subthreshold	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
L-3,4-dihydroxyphenylalanine	PROPN	O	I-Entity
(	PUNCT	O	O
L	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
DOPA	PROPN	O	I-Entity
;	PUNCT	O	O
25	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

plus	CCONJ	O	O
benserazide	NOUN	O	I-Entity
(	PUNCT	O	O
6.25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
KF17837	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
centrally	ADV	O	O
active	ADJ	O	O
adenosine	NOUN	O	I-Entity
A2A	PROPN	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
and	CCONJ	O	O
that	ADP	O	O
the	DET	O	O
dopaminergic	ADJ	O	O
function	NOUN	O	O
of	ADP	O	O
the	DET	O	O
nigrostriatal	ADJ	O	O
pathway	NOUN	O	O
is	VERB	O	O
potentiated	VERB	O	O
by	ADP	O	O
adenosine	NOUN	O	I-Entity
A2A	ADJ	O	O
receptor	NOUN	O	O
antagonists	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
KF17837	PROPN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
a	DET	O	O
useful	ADJ	O	O
drug	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
parkinsonism	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2576810)

Some	DET	O	O
central	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
repeated	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
fluvoxamine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
repeated	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
fluvoxamine	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
selective	ADJ	O	O
serotonin	NOUN	O	I-Entity
uptake	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
behavioral	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
dopaminomimetics	NOUN	O	O
and	CCONJ	O	O
methoxamine	NOUN	O	I-Entity
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
animal	NOUN	O	O
behavior	NOUN	O	O
in	ADP	O	O
the	DET	O	O
"	PUNCT	O	O
behavioral	ADJ	O	O
despair	NOUN	O	O
"	PUNCT	O	O
test	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
repeated	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
fluvoxamine	NOUN	O	I-Entity
(	PUNCT	O	O
twice	ADV	O	O
daily	ADV	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
potentiated	VERB	O	O
in	ADP	O	O
mice	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
rats	NOUN	O	O
(	PUNCT	O	O
weaker	ADJ	O	O
)	PUNCT	O	O
the	DET	O	O
amphetamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hyperactivity	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
hyperactivity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
nomifensine	NOUN	O	I-Entity
in	ADP	O	O
mice	NOUN	O	O
remained	VERB	O	O
unaffected	ADJ	O	O
by	ADP	O	O
fluvoxamine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
stimulation	NOUN	O	O
of	ADP	O	O
locomotor	NOUN	O	O
activity	NOUN	O	O
by	ADP	O	O
intracerebroventricularly	ADV	O	O
administered	VERB	O	O
methoxamine	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
repeated	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
fluvoxamine	NOUN	O	I-Entity
.	PUNCT	O	O

Given	VERB	O	O
three	NUM	O	O
times	NOUN	O	O
fluvoxamine	NOUN	O	I-Entity
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
immobilization	NOUN	O	O
time	NOUN	O	O
in	ADP	O	O
the	DET	O	O
"	PUNCT	O	O
behavioral	ADJ	O	O
despair	NOUN	O	O
"	PUNCT	O	O
test	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
fluvoxamine	NOUN	O	I-Entity
given	VERB	O	O
repeatedly	ADV	O	O
acts	NOUN	O	O
differently	ADV	O	O
than	ADP	O	O
citalopram	NOUN	O	I-Entity
,	PUNCT	O	O
another	DET	O	O
selective	ADJ	O	O
serotonin	NOUN	O	I-Entity
uptake	NOUN	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
differs	VERB	O	O
also	ADV	O	O
from	ADP	O	O
other	ADJ	O	O
antidepressant	NOUN	O	O
drugs	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20635749)

Severe	ADJ	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
patient	NOUN	O	O
on	ADP	O	O
amiodarone	NOUN	O	I-Entity
presenting	VERB	O	O
with	ADP	O	O
myxedemic	ADJ	O	B-Entity
coma	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
a	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
of	ADP	O	O
myxedema	ADJ	O	B-Entity
coma	NOUN	O	I-Entity
secondary	ADJ	O	O
to	ADP	O	O
amiodarone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypothyroidism	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
CHF	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
reviewing	VERB	O	O
the	DET	O	O
literature	NOUN	O	O
there	ADV	O	O
is	VERB	O	O
one	NUM	O	O
case	NOUN	O	O
report	NOUN	O	O
of	ADP	O	O
myxedema	NOUN	O	B-Entity
coma	NOUN	O	I-Entity
during	ADP	O	O
long	ADJ	O	O
term	NOUN	O	O
amiodarone	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O

Myxedema	PROPN	O	B-Entity
coma	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
life	NOUN	O	O
threatening	VERB	O	O
condition	NOUN	O	O
that	ADJ	O	O
carries	VERB	O	O
a	DET	O	O
mortality	NOUN	O	O
reaching	VERB	O	O
as	ADV	O	O
high	ADJ	O	O
as	ADP	O	O
20%	NUM	O	O
with	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
condition	NOUN	O	O
is	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
intravenous	ADJ	O	O
thyroxine	NOUN	O	I-Entity
(	PUNCT	O	O
T4	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
intravenous	ADJ	O	O
tri	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
iodo	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
thyronine	NOUN	O	I-Entity
(	PUNCT	O	O
T3	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
CHF	PROPN	O	I-Entity
on	ADP	O	O
amiodarone	NOUN	O	I-Entity
may	VERB	O	O
suffer	VERB	O	O
serious	ADJ	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
from	ADP	O	O
hypothyroidism	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
thus	ADV	O	O
may	VERB	O	O
deserve	VERB	O	O
closer	ADJ	O	O
follow	VERB	O	O
up	PART	O	O
for	ADP	O	O
thyroid	NOUN	O	O
stimulating	VERB	O	O
hormone	NOUN	O	O
(	PUNCT	O	O
TSH	PROPN	O	O
)	PUNCT	O	O
levels	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
report	NOUN	O	O
carries	VERB	O	O
an	DET	O	O
important	ADJ	O	O
clinical	ADJ	O	O
application	NOUN	O	O
given	VERB	O	O
the	DET	O	O
frequent	ADJ	O	O
usage	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
among	ADP	O	O
CHF	PROPN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
myriad	ADJ	O	O
clinical	ADJ	O	O
presentation	NOUN	O	O
of	ADP	O	O
myxedema	NOUN	O	B-Entity
coma	NOUN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
serious	ADJ	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
mortality	NOUN	O	O
stresses	VERB	O	O
the	DET	O	O
need	NOUN	O	O
to	PART	O	O
suspect	VERB	O	O
this	DET	O	O
clinical	ADJ	O	O
syndrome	NOUN	O	O
among	ADP	O	O
CHF	PROPN	O	I-Entity
patients	NOUN	O	O
presenting	VERB	O	O
with	ADP	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
weakness	NOUN	O	I-Entity
or	CCONJ	O	O
other	ADJ	O	O
unexplained	ADJ	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (20394767)

Fear	VERB	O	O
-	PUNCT	O	O
potentiated	VERB	O	O
startle	NOUN	O	I-Entity
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
light	ADJ	O	O
-	PUNCT	O	O
enhanced	VERB	O	O
startle	NOUN	O	I-Entity
,	PUNCT	O	O
is	VERB	O	O
enhanced	VERB	O	O
by	ADP	O	O
anxiogenic	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
light	NOUN	O	O
-	PUNCT	O	O
enhanced	VERB	O	O
startle	NOUN	O	I-Entity
paradigm	NOUN	O	O
(	PUNCT	O	O
LES	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
suggested	VERB	O	O
to	ADP	O	O
model	NOUN	O	O
anxiety	NOUN	O	I-Entity
,	PUNCT	O	O
because	ADP	O	O
of	ADP	O	O
the	DET	O	O
non	ADJ	O	O
-	PUNCT	O	O
specific	ADJ	O	O
cue	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
fear	NOUN	O	O
-	PUNCT	O	O
potentiated	VERB	O	O
startle	NOUN	O	I-Entity
(	PUNCT	O	O
FPS	PROPN	O	O
)	PUNCT	O	O
is	VERB	O	O
suggested	VERB	O	O
to	ADP	O	O
model	NOUN	O	O
conditioned	VERB	O	O
fear	NOUN	O	O
.	PUNCT	O	O

Male	PROPN	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
received	VERB	O	O
each	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
the	DET	O	O
alpha(2)-adrenoceptor	NOUN	O	O
antagonist	NOUN	O	O
yohimbine	NOUN	O	I-Entity
(	PUNCT	O	O
0.25	NUM	O	O
-	PUNCT	O	O
1.0mg	NUM	O	O
/	PUNCT	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
5-HT(2C	NUM	O	I-Entity
)	PUNCT	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
m	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
chlorophenylpiperazine	NOUN	O	I-Entity
(	PUNCT	O	O
mCPP	PROPN	O	I-Entity
,	PUNCT	O	O
0.5	NUM	O	O
-	PUNCT	O	O
2.0mg	PROPN	O	O

/	PUNCT	O	O
kg	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
GABA(A	PROPN	O	I-Entity
)	PUNCT	O	O
inverse	ADJ	O	O
receptor	NOUN	O	O
agonist	NOUN	O	O
pentylenetetrazole	NOUN	O	I-Entity
(	PUNCT	O	O
PTZ	PROPN	O	I-Entity
,	PUNCT	O	O
3	NUM	O	O
-	PUNCT	O	O
30mg	PROPN	O	O
/	PUNCT	O	O
kg	INTJ	O	O
)	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
subsequently	ADV	O	O
tested	VERB	O	O
in	ADP	O	O
either	DET	O	O
LES	PROPN	O	O
or	CCONJ	O	O
FPS	PROPN	O	O
.	PUNCT	O	O

None	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drugs	NOUN	O	O
enhanced	VERB	O	O
LES	PROPN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
mCPP	PROPN	O	I-Entity
increased	VERB	O	O
percentage	NOUN	O	O
FPS	PROPN	O	O
and	CCONJ	O	O
yohimbine	PRON	O	I-Entity
increased	VERB	O	O
absolute	ADJ	O	O
FPS	PROPN	O	O
values	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
yohimbine	PRON	O	I-Entity
increased	VERB	O	O
baseline	NOUN	O	O
startle	NOUN	O	I-Entity
amplitude	NOUN	O	O
in	ADP	O	O
the	DET	O	O
LES	PROPN	O	O
,	PUNCT	O	O
while	ADP	O	O
mCPP	PROPN	O	I-Entity
suppressed	VERB	O	O
baseline	NOUN	O	O
startle	NOUN	O	I-Entity
in	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
LES	PROPN	O	O
and	CCONJ	O	O
FPS	PROPN	O	O
and	CCONJ	O	O
PTZ	PROPN	O	I-Entity
suppressed	VERB	O	O
baseline	NOUN	O	O
startle	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
FPS	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (19203554)

Proteinase	PROPN	O	O
3-antineutrophil	NUM	O	O
cytoplasmic	NOUN	O	O
antibody-(PR3-ANCA	NOUN	O	O
)	PUNCT	O	O
positive	ADJ	O	O
necrotizing	NOUN	O	O
glomerulonephritis	NOUN	O	I-Entity
after	ADP	O	O
restarting	VERB	O	O
sulphasalazine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
59-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
ulcerative	ADJ	O	B-Entity
colitis	NOUN	O	I-Entity
developed	VERB	O	O
red	ADJ	O	B-Entity
eyes	NOUN	O	I-Entity
,	PUNCT	O	O
pleural	ADJ	O	B-Entity
effusion	NOUN	O	I-Entity
,	PUNCT	O	O
eosinophilia	NOUN	O	I-Entity
and	CCONJ	O	O
urinary	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
after	ADP	O	O
restarting	VERB	O	O
of	ADP	O	O
sulphasalazine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

Light	NOUN	O	O
microscopy	NOUN	O	O
of	ADP	O	O
a	DET	O	O
kidney	NOUN	O	O
biopsy	NOUN	O	O
revealed	VERB	O	O
segmental	ADJ	O	B-Entity
necrotizing	NOUN	O	I-Entity
glomerulonephritis	NOUN	O	I-Entity
without	ADP	O	O
deposition	NOUN	O	O
of	ADP	O	O
immunoglobulin	NOUN	O	O
or	CCONJ	O	O
complement	NOUN	O	O
.	PUNCT	O	O

PR3-ANCA	X	O	O
titer	NOUN	O	O
was	VERB	O	O
250	NUM	O	O
and	CCONJ	O	O
1,070	NUM	O	O
EU	PROPN	O	O
in	ADP	O	O
pleural	ADJ	O	B-Entity
effusions	NOUN	O	I-Entity
on	ADP	O	O
right	NOUN	O	O
and	CCONJ	O	O
left	VERB	O	O
side	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Although	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
sulphasalazine	NOUN	O	I-Entity
treatment	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
improvements	NOUN	O	O
in	ADP	O	O
fever	NOUN	O	I-Entity
,	PUNCT	O	O
red	ADJ	O	B-Entity
eyes	NOUN	O	I-Entity
,	PUNCT	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
titer	NOUN	O	O
of	ADP	O	O
C	PROPN	O	O
-	PUNCT	O	O
reactive	ADJ	O	O
protein	NOUN	O	O
and	CCONJ	O	O
volume	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pleural	ADJ	O	B-Entity
effusions	NOUN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
initiated	VERB	O	O
steroid	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
because	ADP	O	O
PR3-ANCA	PROPN	O	O
titer	NOUN	O	O
rose	VERB	O	O
to	ADP	O	O
320	NUM	O	O
EU	PROPN	O	O
,	PUNCT	O	O
eosinophil	NOUN	O	O
count	NOUN	O	O
increased	VERB	O	O
to	ADP	O	O
1,100	NUM	O	O
cells	NOUN	O	O
/	SYM	O	O
microl	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
pleural	ADJ	O	B-Entity
effusion	NOUN	O	I-Entity
remained	VERB	O	O
.	PUNCT	O	O

One	NUM	O	O
month	NOUN	O	O
after	ADP	O	O
steroid	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
pleural	ADJ	O	B-Entity
effusion	NOUN	O	I-Entity
disappeared	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
PR3-ANCA	PROPN	O	O
titer	NOUN	O	O
normalized	ADJ	O	O
3	NUM	O	O
months	NOUN	O	O
later	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
sulphasalazine	NOUN	O	I-Entity
can	VERB	O	O
induce	VERB	O	O
PR3-ANCA	PROPN	O	O
-	PUNCT	O	O
positive	ADJ	O	O
necrotizing	NOUN	O	O
glomerulonephritis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (17049862)

Is	VERB	O	O
phenytoin	ADJ	O	I-Entity
administration	NOUN	O	O
safe	ADJ	O	O
in	ADP	O	O
a	DET	O	O
hypothermic	ADJ	O	I-Entity
child	NOUN	O	O
?	PUNCT	O	O

A	DET	O	O
male	ADJ	O	O
neonate	NOUN	O	O
with	ADP	O	O
a	DET	O	O
Chiari	PROPN	O	B-Entity
malformation	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
leaking	NOUN	O	O
myelomeningocoele	NOUN	O	O
underwent	VERB	O	O
ventriculoperitoneal	NOUN	O	O
shunt	NOUN	O	O
insertion	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
repair	NOUN	O	O
of	ADP	O	O
myelomeningocoele	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
anaesthesia	NOUN	O	O
and	CCONJ	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
he	PRON	O	O
inadvertently	ADV	O	O
became	VERB	O	O
moderately	ADV	O	O
hypothermic	ADJ	O	I-Entity
.	PUNCT	O	O

Intravenous	ADJ	O	O
phenytoin	NOUN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
during	ADP	O	O
the	DET	O	O
later	ADJ	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
surgery	NOUN	O	O
for	ADP	O	O
seizure	NOUN	O	I-Entity
prophylaxis	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
phenytoin	NOUN	O	I-Entity
administration	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	O
severe	ADJ	O	O
bradycardia	NOUN	O	I-Entity
,	PUNCT	O	O
refractory	NOUN	O	O
to	ADP	O	O
atropine	NOUN	O	I-Entity
and	CCONJ	O	O
adrenaline	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
cardiac	ADJ	O	O
depressant	NOUN	O	O
actions	NOUN	O	O
of	ADP	O	O
phenytoin	NOUN	O	I-Entity
and	CCONJ	O	O
hypothermia	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
additive	ADJ	O	O
.	PUNCT	O	O

Administration	NOUN	O	O
of	ADP	O	O
phenytoin	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
hypothermia	NOUN	O	I-Entity
may	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
an	DET	O	O
adverse	ADJ	O	O
cardiac	ADJ	O	O
event	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
phenytoin	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
commonly	ADV	O	O
used	VERB	O	O
drug	NOUN	O	O
,	PUNCT	O	O
clinicians	NOUN	O	O
need	VERB	O	O
to	PART	O	O
be	VERB	O	O
aware	ADJ	O	O
of	ADP	O	O
this	DET	O	O
interaction	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16225977)

Amisulpride	ADV	O	I-Entity
related	VERB	O	O
tic	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
adolescent	ADJ	O	O
schizophrenic	ADJ	O	I-Entity
.	PUNCT	O	O

Tic	PROPN	O	B-Entity
disorders	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
effectively	ADV	O	O
treated	VERB	O	O
by	ADP	O	O
atypical	ADJ	O	O
antipsychotics	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
risperidone	NOUN	O	I-Entity
,	PUNCT	O	O
olanzapine	NOUN	O	I-Entity
and	CCONJ	O	O
ziprasidone	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
are	VERB	O	O
two	NUM	O	O
case	NOUN	O	O
reports	VERB	O	O
that	DET	O	O
show	VERB	O	O
tic	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
motor	NOUN	O	O
and	CCONJ	O	O
phonic	ADJ	O	O
variants	NOUN	O	O
,	PUNCT	O	O
occurring	VERB	O	O
during	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
quetiapine	NOUN	O	I-Entity
or	CCONJ	O	O
clozapine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
present	VERB	O	O
a	DET	O	O
15-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
girl	NOUN	O	O
schizophrenic	ADJ	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
frequent	ADJ	O	O
involuntary	ADJ	O	B-Entity
eye	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
blinking	VERB	O	I-Entity
movements	NOUN	O	I-Entity
after	ADP	O	O
5	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
amisulpride	ADJ	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
1000	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
day	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
tic	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
resolved	VERB	O	O
completely	ADV	O	O
after	ADP	O	O
we	PRON	O	O
reduced	VERB	O	O
the	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
amisulpride	ADV	O	I-Entity
down	ADV	O	O
to	ADP	O	O
800	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
day	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
her	ADJ	O	O
psychosis	NOUN	O	I-Entity
recurred	VERB	O	O
after	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
then	ADV	O	O
placed	VERB	O	O
her	PRON	O	O
on	ADP	O	O
an	DET	O	O
additional	ADJ	O	O
100	NUM	O	O
mg	NUM	O	O
per	ADP	O	O
day	NOUN	O	O
of	ADP	O	O
quetiapine	NOUN	O	I-Entity
.	PUNCT	O	O

No	DET	O	O
more	ADV	O	O
tic	ADJ	O	B-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
or	CCONJ	O	O
other	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

Together	ADV	O	O
with	ADP	O	O
previously	ADV	O	O
reported	VERB	O	O
cases	NOUN	O	O
,	PUNCT	O	O
our	ADJ	O	O
patient	NOUN	O	O
suggests	VERB	O	O
that	ADP	O	O
tic	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
like	ADJ	O	I-Entity
symptoms	NOUN	O	I-Entity
might	VERB	O	O
occur	VERB	O	O
in	ADP	O	O
certain	ADJ	O	O
vulnerable	ADJ	O	O
individuals	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
atypical	ADJ	O	O
antipsychotics	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
quetiapine	NOUN	O	I-Entity
,	PUNCT	O	O
clozapine	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
amisulpride	ADV	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12852481)

Comparison	NOUN	O	O
of	ADP	O	O
developmental	ADJ	O	O
toxicology	NOUN	O	O
of	ADP	O	O
aspirin	NOUN	O	I-Entity
(	PUNCT	O	O
acetylsalicylic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
rats	NOUN	O	O
using	VERB	O	O
selected	VERB	O	O
dosing	VERB	O	O
paradigms	NOUN	O	O
.	PUNCT	O	O

Analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
for	ADP	O	O
nonsteroidal	ADJ	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
drugs	NOUN	O	O
(	PUNCT	O	O
NSAIDs	PROPN	O	O
)	PUNCT	O	O
suggests	VERB	O	O
that	ADP	O	O
a	DET	O	O
low	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
developmental	ADJ	O	B-Entity
anomalies	NOUN	O	I-Entity
occurs	VERB	O	O
in	ADP	O	O
rats	NOUN	O	O
given	VERB	O	O
NSAIDs	NOUN	O	O
on	ADP	O	O
specific	ADJ	O	O
days	NOUN	O	O
during	ADP	O	O
organogenesis	NOUN	O	O
.	PUNCT	O	O

Aspirin	PROPN	O	I-Entity
(	PUNCT	O	O
acetylsalicylic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
[	PUNCT	O	O
ASA	PROPN	O	I-Entity
]	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
irreversible	ADJ	O	O
cyclooxygenase	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
2	NUM	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
induces	VERB	O	O
developmental	ADJ	O	B-Entity
anomalies	NOUN	O	I-Entity
when	ADV	O	O
administered	VERB	O	O
to	ADP	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
on	ADP	O	O
gestational	ADJ	O	O
day	NOUN	O	O
(	PUNCT	O	O
GD	PROPN	O	O
)	PUNCT	O	O
9	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
11	NUM	O	O

There	ADV	O	O
are	VERB	O	O
no	DET	O	O
published	VERB	O	O
ASA	PROPN	O	I-Entity
studies	NOUN	O	O
using	VERB	O	O
the	DET	O	O
multiple	ADJ	O	O
dosing	VERB	O	O
paradigm	NOUN	O	O
of	ADP	O	O
GDs	PROPN	O	O
6	NUM	O	O
to	ADP	O	O
17	NUM	O	O
.	PUNCT	O	O

Objectives	NOUN	O	O
of	ADP	O	O
the	DET	O	O
current	ADJ	O	O
study	NOUN	O	O
were	VERB	O	O
to	PART	O	O
compare	VERB	O	O
results	NOUN	O	O
between	ADP	O	O
Sprague	PROPN	O	O
-	PUNCT	O	O
Dawley	PROPN	O	O
(	PUNCT	O	O
SD	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Wistar	PROPN	O	O
strains	NOUN	O	O
when	ADV	O	O
ASA	PROPN	O	I-Entity
is	VERB	O	O
administered	VERB	O	O
on	ADP	O	O
GD	PROPN	O	O
9	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
11	NUM	O	O
;	PUNCT	O	O
to	PART	O	O
compare	VERB	O	O
the	DET	O	O
malformation	NOUN	O	O
patterns	NOUN	O	O
following	VERB	O	O
single	ADJ	O	O
and	CCONJ	O	O
multiple	ADJ	O	O
dosings	NOUN	O	O
during	ADP	O	O
organogenesis	NOUN	O	O
in	ADP	O	O
SD	PROPN	O	O
rats	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
test	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
maternal	ADJ	O	O
gastrointestinal	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
confounds	VERB	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
incidence	NOUN	O	O
malformations	NOUN	O	I-Entity
with	ADP	O	O
ASA	PROPN	O	I-Entity
when	ADV	O	O
a	DET	O	O
multiple	ADJ	O	O
dosing	NOUN	O	O
paradigm	NOUN	O	O
is	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

ASA	PROPN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
as	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
on	ADP	O	O
GD	PROPN	O	O
9	NUM	O	O
(	PUNCT	O	O
0	NUM	O	O
,	PUNCT	O	O
250	NUM	O	O
,	PUNCT	O	O
500	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
625	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
10	NUM	O	O
(	PUNCT	O	O
0	NUM	O	O
,	PUNCT	O	O
500	NUM	O	O
,	PUNCT	O	O
625	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
750	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
11	NUM	O	O
(	PUNCT	O	O
0	NUM	O	O
,	PUNCT	O	O
500	NUM	O	O
,	PUNCT	O	O
750	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
1000	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
from	ADP	O	O
GD	PROPN	O	O
6	NUM	O	O
to	PART	O	O
GD	PROPN	O	O
17	NUM	O	O
(	PUNCT	O	O
0	NUM	O	O
,	PUNCT	O	O
50	NUM	O	O
,	PUNCT	O	O
125	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
250	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	VERB	O	O
a	DET	O	O
day	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
multiple	ADJ	O	O
dose	NOUN	O	O
study	NOUN	O	O
to	ADP	O	O
SD	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
literature	NOUN	O	O
evaluation	NOUN	O	O
suggested	VERB	O	O
that	ADP	O	O
NSAIDs	PROPN	O	O
induce	VERB	O	O
ventricular	ADJ	O	B-Entity
septal	ADJ	O	I-Entity
defects	NOUN	O	I-Entity
(	PUNCT	O	O
VSDs	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
midline	NOUN	O	B-Entity
defects	NOUN	O	I-Entity
(	PUNCT	O	O
MDs	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
rats	NOUN	O	O
and	CCONJ	O	O
diaphragmatic	ADJ	O	B-Entity
hernia	NOUN	O	I-Entity
(	PUNCT	O	O
DH	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
MDs	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
VSDs	NOUN	O	I-Entity
in	ADP	O	O
rabbits	NOUN	O	O

;	PUNCT	O	O
hence	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
focused	VERB	O	O
on	ADP	O	O
these	DET	O	O
malformations	NOUN	O	I-Entity
,	PUNCT	O	O
even	ADV	O	O
though	ADP	O	O
ASA	PROPN	O	I-Entity
induces	VERB	O	O
several	ADJ	O	O
other	ADJ	O	O
low	ADJ	O	O
-	PUNCT	O	O
incidence	NOUN	O	O
malformations	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
single	ADJ	O	O
dose	NOUN	O	O
studies	NOUN	O	O
,	PUNCT	O	O
DH	PROPN	O	I-Entity
,	PUNCT	O	O
MD	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
VSD	PROPN	O	I-Entity
were	VERB	O	O
induced	VERB	O	O
on	ADP	O	O
GDs	PROPN	O	O
9	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
.	PUNCT	O	O

VSD	PROPN	O	I-Entity
also	ADV	O	O
was	VERB	O	O
noted	VERB	O	O
following	VERB	O	O
treatment	NOUN	O	O
on	ADP	O	O
GD	PROPN	O	O
11	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
DH	PROPN	O	I-Entity
and	CCONJ	O	O
MD	PROPN	O	I-Entity
were	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
the	DET	O	O
multiple	ADJ	O	O
dose	NOUN	O	O
study	NOUN	O	O
design	NOUN	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
VSD	PROPN	O	I-Entity
was	VERB	O	O
noted	VERB	O	O
across	ADP	O	O
all	DET	O	O
dose	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
High	ADJ	O	O
concordance	NOUN	O	O
in	ADP	O	O
major	ADJ	O	O
developmental	ADJ	O	B-Entity
anomalies	NOUN	O	I-Entity
between	ADP	O	O
Wistar	PROPN	O	O
and	CCONJ	O	O
SD	PROPN	O	O
rats	NOUN	O	O
were	VERB	O	O
noted	VERB	O	O
with	ADP	O	O
the	DET	O	O
exception	NOUN	O	O
of	ADP	O	O
VSD	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
SD	NOUN	O	O
rats	NOUN	O	O
and	CCONJ	O	O
hydrocephalus	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Variations	NOUN	O	O
and	CCONJ	O	O
malformations	NOUN	O	I-Entity
were	VERB	O	O
similar	ADJ	O	O
when	ADV	O	O
ASA	PROPN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
as	ADP	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
or	CCONJ	O	O
during	ADP	O	O
the	DET	O	O
period	NOUN	O	O
of	ADP	O	O
organogenesis	NOUN	O	O
(	PUNCT	O	O
GDs	PROPN	O	O
6	NUM	O	O
to	ADP	O	O
17	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

It	PRON	O	O
was	VERB	O	O
also	ADV	O	O
evident	ADJ	O	O
that	ADP	O	O
,	PUNCT	O	O
by	ADP	O	O
titrating	VERB	O	O
the	DET	O	O
dose	NOUN	O	O
to	PART	O	O
achieve	VERB	O	O
a	DET	O	O
maximum	NOUN	O	O
tolerated	VERB	O	O
dose	NOUN	O	O
,	PUNCT	O	O
malformations	NOUN	O	I-Entity
that	ADJ	O	O
normally	ADV	O	O
occur	VERB	O	O
at	ADP	O	O
low	ADJ	O	O
incidence	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
reported	VERB	O	O
from	ADP	O	O
previous	ADJ	O	O
single	ADJ	O	O
dose	NOUN	O	O
studies	NOUN	O	O
,	PUNCT	O	O
could	VERB	O	O
also	ADV	O	O
be	VERB	O	O
induced	VERB	O	O
with	ADP	O	O
ASA	PROPN	O	I-Entity
given	VERB	O	O
at	ADP	O	O
multiple	ADJ	O	O
doses	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11858397)

Torsade	PROPN	O	B-Entity
de	PROPN	O	I-Entity
pointes	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
metoclopramide	NOUN	O	I-Entity
in	ADP	O	O
an	DET	O	O
elderly	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
preexisting	VERB	O	O
complete	ADJ	O	O
left	VERB	O	B-Entity
bundle	ADJ	O	I-Entity
branch	NOUN	O	I-Entity
block	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
is	VERB	O	O
a	DET	O	O
growing	VERB	O	O
list	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
implicated	VERB	O	O
in	ADP	O	O
acquired	VERB	O	O
long	ADJ	O	B-Entity
QT	PROPN	O	I-Entity
syndrome	NOUN	O	I-Entity
and	CCONJ	O	O
torsade	VERB	O	B-Entity
de	PROPN	O	I-Entity
pointes	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
torsadogenic	ADJ	O	O
potential	NOUN	O	O
of	ADP	O	O
metoclopramide	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
commonly	ADV	O	O
used	VERB	O	O
antiemetic	NOUN	O	O
and	CCONJ	O	O
prokinetic	ADJ	O	O
drug	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
not	ADV	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
,	PUNCT	O	O
despite	ADP	O	O
its	ADJ	O	O
chemical	ADJ	O	O
similarity	NOUN	O	O
to	PART	O	O
procainamide	VERB	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
on	ADP	O	O
a	DET	O	O
92-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
preexisting	VERB	O	O
complete	ADJ	O	O
left	VERB	O	B-Entity
bundle	ADJ	O	I-Entity
branch	NOUN	O	I-Entity
block	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
torsade	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
after	ADP	O	O
intravenous	ADJ	O	O
and	CCONJ	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
metoclopramide	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
patient	NOUN	O	O
also	ADV	O	O
developed	VERB	O	O
torsade	NOUN	O	B-Entity
de	ADP	O	I-Entity
pointes	NOUN	O	I-Entity
when	ADV	O	O
cisapride	NOUN	O	I-Entity
and	CCONJ	O	O
erythromycin	NOUN	O	I-Entity
were	VERB	O	O
given	VERB	O	O
simultaneously	ADV	O	O
.	PUNCT	O	O

This	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
documentation	NOUN	O	O
that	ADJ	O	O
metoclopramide	NOUN	O	I-Entity
provokes	VERB	O	O
torsade	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	NOUN	O	I-Entity
clinically	ADV	O	O
.	PUNCT	O	O

Metoclopramide	PROPN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
used	VERB	O	O
cautiously	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
torsade	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11009181)

Apomorphine	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
underutilized	ADJ	O	O
therapy	NOUN	O	O
for	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

Apomorphine	PROPN	O	I-Entity
was	VERB	O	O
the	DET	O	O
first	ADJ	O	O
dopaminergic	ADJ	O	O
drug	NOUN	O	O
ever	ADV	O	O
used	VERB	O	O
to	PART	O	O
treat	VERB	O	O
symptoms	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
.	PUNCT	O	O

While	ADP	O	O
powerful	ADJ	O	O
antiparkinsonian	ADJ	O	O
effects	NOUN	O	O
had	VERB	O	O
been	VERB	O	O
observed	VERB	O	O
as	ADV	O	O
early	ADV	O	O
as	ADP	O	O
1951	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
potential	NOUN	O	O
of	ADP	O	O
treating	VERB	O	O
fluctuating	VERB	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
by	ADP	O	O
subcutaneous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
apomorphine	NOUN	O	I-Entity
has	VERB	O	O
only	ADV	O	O
recently	ADV	O	O
become	VERB	O	O
the	DET	O	O
subject	NOUN	O	O
of	ADP	O	O
systematic	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
number	NOUN	O	O
of	ADP	O	O
small	ADJ	O	O
scale	NOUN	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
have	VERB	O	O
unequivocally	ADV	O	O
shown	VERB	O	O
that	DET	O	O
intermittent	ADJ	O	O
subcutaneous	ADJ	O	O
apomorphine	NOUN	O	I-Entity
injections	NOUN	O	O
produce	VERB	O	O
antiparkinsonian	ADJ	O	O
benefit	VERB	O	O
close	ADJ	O	O
if	ADP	O	O
not	ADV	O	O
identical	ADJ	O	O
to	ADP	O	O
that	DET	O	O
seen	VERB	O	O
with	ADP	O	O
levodopa	NOUN	O	I-Entity
and	CCONJ	O	O
that	DET	O	O
apomorphine	NOUN	O	I-Entity
rescue	NOUN	O	O
injections	NOUN	O	O
can	VERB	O	O
reliably	ADV	O	O
revert	VERB	O	O
off	ADP	O	O
-	PUNCT	O	O
periods	NOUN	O	O
even	ADV	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
complex	ADJ	O	O
on	ADP	O	O
-	PUNCT	O	O
off	PART	O	O
motor	NOUN	O	O
swings	NOUN	O	O
.	PUNCT	O	O

Continuous	PROPN	O	O
subcutaneous	ADJ	O	O
apomorphine	NOUN	O	I-Entity
infusions	NOUN	O	O
can	VERB	O	O
reduce	VERB	O	O
daily	ADV	O	O
off	ADP	O	O
-	PUNCT	O	O
time	NOUN	O	O
by	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
50%	NUM	O	O
in	ADP	O	O
this	DET	O	O
group	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
which	ADJ	O	O
appears	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
stronger	ADJ	O	O
effect	NOUN	O	O
than	ADP	O	O
that	DET	O	O
generally	ADV	O	O
seen	VERB	O	O
with	ADP	O	O
add	VERB	O	O
-	PUNCT	O	O
on	ADP	O	O
therapy	NOUN	O	O
with	ADP	O	O
oral	ADJ	O	O
dopamine	NOUN	O	I-Entity
agonists	NOUN	O	O
or	CCONJ	O	O
COMT	PROPN	O	O
inhibitors	NOUN	O	O
.	PUNCT	O	O

Extended	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	PART	O	O
studies	NOUN	O	O
of	ADP	O	O
up	ADP	O	O
to	PART	O	O
8	NUM	O	O
years	NOUN	O	O
have	VERB	O	O
demonstrated	VERB	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
persistence	NOUN	O	O
of	ADP	O	O
apomorphine	NOUN	O	I-Entity
efficacy	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
is	VERB	O	O
convincing	VERB	O	O
clinical	ADJ	O	O
evidence	NOUN	O	O
that	ADP	O	O
monotherapy	NOUN	O	O
with	ADP	O	O
continuous	ADJ	O	O
subcutaneous	ADJ	O	O
apomorphine	NOUN	O	I-Entity
infusions	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
marked	ADJ	O	O
reductions	NOUN	O	O
of	ADP	O	O
preexisting	VERB	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
subcutaneous	ADJ	O	O
apomorphine	ADJ	O	I-Entity
treatment	NOUN	O	O
are	VERB	O	O
related	VERB	O	O
to	ADP	O	O
cutaneous	ADJ	O	O
tolerability	NOUN	O	O
problems	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
sedation	NOUN	O	O
and	CCONJ	O	O
psychiatric	ADJ	O	I-Entity
complications	NOUN	O	O
play	VERB	O	O
a	DET	O	O
lesser	ADJ	O	O
role	NOUN	O	O
.	PUNCT	O	O

Given	VERB	O	O
the	DET	O	O
marked	ADJ	O	O
degree	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
of	ADP	O	O
subcutaneous	ADJ	O	O
apomorphine	ADJ	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
fluctuating	VERB	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
this	DET	O	O
approach	NOUN	O	O
seems	VERB	O	O
to	PART	O	O
deserve	VERB	O	O
more	ADV	O	O
widespread	ADJ	O	O
clinical	ADJ	O	O
use	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8988571)

Fatal	PROPN	O	O
excited	ADJ	O	O
delirium	NOUN	O	I-Entity
following	VERB	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
:	PUNCT	O	O
epidemiologic	ADJ	O	O
findings	NOUN	O	O
provide	VERB	O	O
new	ADJ	O	O
evidence	NOUN	O	O
for	ADP	O	O
mechanisms	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
describe	VERB	O	O
an	DET	O	O
outbreak	NOUN	O	O
of	ADP	O	O
deaths	NOUN	O	O
from	ADP	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
excited	ADJ	O	O
delirium	NOUN	O	I-Entity
(	PUNCT	O	O
EDDs	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
Dade	PROPN	O	O
County	PROPN	O	O
,	PUNCT	O	O
Florida	PROPN	O	O
between	ADP	O	O
1979	NUM	O	O
and	CCONJ	O	O
1990	NUM	O	O
.	PUNCT	O	O

From	ADP	O	O
a	DET	O	O
registry	NOUN	O	O
of	ADP	O	O
all	DET	O	O
cocaine	NOUN	O	I-Entity
-	PUNCT	O	O
related	VERB	O	O
deaths	NOUN	O	O
in	ADP	O	O
Dade	PROPN	O	O
County	PROPN	O	O
,	PUNCT	O	O
Florida	PROPN	O	O
,	PUNCT	O	O
from	ADP	O	O
1969	NUM	O	O
-	SYM	O	O
1990	NUM	O	O
,	PUNCT	O	O
58	NUM	O	O
EDDs	NOUN	O	I-Entity
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
125	NUM	O	O
victims	NOUN	O	O
of	ADP	O	O
accidental	ADJ	O	O
cocaine	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
without	ADP	O	O
excited	ADJ	O	O
delirium	NOUN	O	I-Entity
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
,	PUNCT	O	O
EDDs	NOUN	O	I-Entity
were	VERB	O	O
more	ADV	O	O
frequently	ADV	O	O
black	ADJ	O	O
,	PUNCT	O	O
male	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
younger	ADJ	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
less	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
have	VERB	O	O
a	DET	O	O
low	ADJ	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
have	VERB	O	O
died	VERB	O	O
in	ADP	O	O
police	NOUN	O	O
custody	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
have	VERB	O	O
received	VERB	O	O
medical	ADJ	O	O
treatment	NOUN	O	O
immediately	ADV	O	O
before	ADP	O	O
death	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
have	VERB	O	O
survived	VERB	O	O
for	ADP	O	O
a	DET	O	O
longer	ADJ	O	O
period	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
have	VERB	O	O
developed	VERB	O	O
hyperthermia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
have	VERB	O	O
died	VERB	O	O
in	ADP	O	O
summer	NOUN	O	O
months	NOUN	O	O
.	PUNCT	O	O

EDDs	NOUN	O	I-Entity
had	VERB	O	O
concentrations	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	I-Entity
and	CCONJ	O	O
benzoylecgonine	NOUN	O	I-Entity
in	ADP	O	O
autopsy	NOUN	O	O
blood	NOUN	O	O
that	ADJ	O	O
were	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
for	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
epidemiologic	ADJ	O	O
findings	NOUN	O	O
are	VERB	O	O
most	ADV	O	O
consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADJ	O	O
chronic	ADJ	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
disrupts	VERB	O	O
dopaminergic	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
,	PUNCT	O	O
when	ADV	O	O
coupled	VERB	O	O
with	ADP	O	O
recent	ADJ	O	O
cocaine	NOUN	O	I-Entity
use	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
precipitate	VERB	O	O
agitation	NOUN	O	I-Entity
,	PUNCT	O	O
delirium	NOUN	O	I-Entity
,	PUNCT	O	O
aberrant	ADJ	O	O
thermoregulation	NOUN	O	O
,	PUNCT	O	O
rhabdomyolysis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
sudden	ADJ	O	B-Entity
death	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6615052)

Heparin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
,	PUNCT	O	O
thrombosis	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
hemorrhage	NOUN	O	I-Entity
.	PUNCT	O	O

Sixty	NUM	O	O
-	PUNCT	O	O
two	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
thrombocytopenia	NOUN	O	I-Entity
are	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
manifestations	NOUN	O	O
of	ADP	O	O
this	DET	O	O
disorder	NOUN	O	O
include	VERB	O	O
hemorrhage	NOUN	O	I-Entity
or	CCONJ	O	O
,	PUNCT	O	O
more	ADV	O	O
frequently	ADV	O	O
,	PUNCT	O	O
thromboembolic	ADJ	O	I-Entity
events	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
heparin	NOUN	O	I-Entity
.	PUNCT	O	O

Laboratory	NOUN	O	O
testing	NOUN	O	O
has	VERB	O	O
revealed	VERB	O	O
a	DET	O	B-Entity
falling	VERB	O	I-Entity
platelet	NOUN	O	I-Entity
count	NOUN	O	I-Entity
,	PUNCT	O	O
increased	VERB	O	O
resistance	NOUN	O	O
to	ADP	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
aggregation	NOUN	O	O
of	ADP	O	O
platelets	NOUN	O	O
by	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
plasma	NOUN	O	O
when	ADV	O	O
heparin	NOUN	O	I-Entity
is	VERB	O	O
added	VERB	O	O
.	PUNCT	O	O

Immunologic	ADJ	O	O
testing	NOUN	O	O
has	VERB	O	O
demonstrated	VERB	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
heparin	NOUN	O	I-Entity
-	PUNCT	O	O
dependent	ADJ	O	O
platelet	NOUN	O	O
membrane	NOUN	O	O
antibody	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
20	NUM	O	O
deaths	NOUN	O	O
,	PUNCT	O	O
52	NUM	O	O
hemorrhagic	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
thromboembolic	ADJ	O	I-Entity
complications	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
21	NUM	O	O
surgical	ADJ	O	O
procedures	NOUN	O	O
to	PART	O	O
manage	VERB	O	O
the	DET	O	O
complications	NOUN	O	O
confirm	VERB	O	O
the	DET	O	O
seriousness	NOUN	O	O
of	ADP	O	O
the	DET	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

Specific	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
have	VERB	O	O
not	ADV	O	O
been	VERB	O	O
identified	VERB	O	O
;	PUNCT	O	O
therefore	ADV	O	O
,	PUNCT	O	O
all	DET	O	O
patients	NOUN	O	O
receiving	VERB	O	O
heparin	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
monitored	VERB	O	O
.	PUNCT	O	O

If	ADP	O	O
the	DET	O	O
platelet	NOUN	O	O
count	NOUN	O	O
falls	VERB	O	O
to	ADP	O	O
less	ADJ	O	O
than	ADP	O	O
100,000/mm3	NUM	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
is	VERB	O	O
receiving	VERB	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
platelet	NOUN	O	B-Entity
aggregation	NOUN	O	I-Entity
testing	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
plasma	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
indicated	VERB	O	O
.	PUNCT	O	O

Management	NOUN	O	O
consists	VERB	O	O
of	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
heparin	NOUN	O	I-Entity
,	PUNCT	O	O
platelet	VERB	O	O
anti	ADJ	O	O
-	PUNCT	O	O
aggregating	VERB	O	O
agents	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
alternate	ADJ	O	O
forms	NOUN	O	O
of	ADP	O	O
anticoagulation	NOUN	O	O
when	ADV	O	O
indicated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (3952818)

Cardiac	PROPN	O	B-Entity
toxicity	NOUN	O	I-Entity
of	ADP	O	O
5-fluorouracil	PROPN	O	I-Entity
.	PUNCT	O	O

Report	PROPN	O	O
of	ADP	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
spontaneous	ADJ	O	O
angina	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
colon	NOUN	O	B-Entity
carcinoma	NOUN	O	I-Entity
and	CCONJ	O	O
liver	NOUN	O	O
metastasis	NOUN	O	I-Entity
who	NOUN	O	O
presented	VERB	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
after	ADP	O	O
5-fluorouracil	NOUN	O	I-Entity
(	PUNCT	O	O
5-FU	PROPN	O	I-Entity
)	PUNCT	O	O
administration	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
electrocardiographic	ADJ	O	O
evolution	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
that	DET	O	O
observed	VERB	O	O
in	ADP	O	O
Prinzmetal	PROPN	O	B-Entity
's	PART	O	I-Entity
angina	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
chest	NOUN	O	B-Entity
pain	NOUN	O	I-Entity
promptly	ADV	O	O
resolved	VERB	O	O
with	ADP	O	O
nifedipine	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
coronary	ADJ	O	B-Entity
spasm	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
cardiotoxicity	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
5-FU	NUM	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
calcium	NOUN	O	I-Entity
antagonists	NOUN	O	O
may	VERB	O	O
probably	ADV	O	O
be	VERB	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
or	CCONJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
5-FU	NUM	O	I-Entity
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (3084782)

Toxicity	PROPN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
remission	NOUN	O	O
inducing	VERB	O	O
drugs	NOUN	O	O
in	ADP	O	O
rheumatoid	NOUN	O	B-Entity
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

Twenty	NUM	O	O
-	PUNCT	O	O
five	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
rheumatoid	ADJ	O	B-Entity
arthritis	NOUN	O	I-Entity
(	PUNCT	O	O
RA	PROPN	O	I-Entity
)	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
toxicity	NOUN	O	I-Entity
while	ADP	O	O
taking	VERB	O	O
remission	NOUN	O	O
inducing	VERB	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
30	NUM	O	O
without	ADP	O	O
toxicity	NOUN	O	I-Entity
were	VERB	O	O
studied	VERB	O	O
for	ADP	O	O
possible	ADJ	O	O
associations	NOUN	O	O
with	ADP	O	O
class	NOUN	O	O
I	PRON	O	O
and	CCONJ	O	O
II	PROPN	O	O
HLA	PROPN	O	O
antigens	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
strong	ADJ	O	O
association	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
found	VERB	O	O
between	ADP	O	O
nephritis	NOUN	O	I-Entity
and	CCONJ	O	O
dermatitis	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
Tiopronin	PROPN	O	I-Entity
(	PUNCT	O	O
a	DET	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
Penicillamine	PROPN	O	I-Entity
like	INTJ	O	O
compound	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
class	NOUN	O	O
I	PRON	O	O
antigens	VERB	O	O
B35-Cw4	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
between	ADP	O	O
dermatitis	NOUN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
gold	NOUN	O	I-Entity
thiosulphate	NOUN	O	I-Entity
and	CCONJ	O	O
B35	PROPN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
to	ADP	O	O
healthy	ADJ	O	O
controls	NOUN	O	O
a	DET	O	O
lower	ADJ	O	O
DR5	PROPN	O	O
frequency	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
RA	PROPN	O	I-Entity
except	ADP	O	O
for	ADP	O	O
the	DET	O	O
Tiopronin	PROPN	O	I-Entity
related	VERB	O	O
nephritis	NOUN	O	I-Entity
group	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (430165)

Transient	PROPN	O	O
hemiparesis	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
rare	ADJ	O	O
manifestation	NOUN	O	O
of	ADP	O	O
diphenylhydantoin	NOUN	O	I-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Among	ADP	O	O
the	DET	O	O
common	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
diphenylhydantoin	NOUN	O	I-Entity
(	PUNCT	O	O
DPH	PROPN	O	I-Entity
)	PUNCT	O	O
overdose	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
most	ADV	O	O
frequently	ADV	O	O
encountered	VERB	O	O
neurological	ADJ	O	O
signs	NOUN	O	O
are	VERB	O	O
those	DET	O	O
of	ADP	O	O
cerebellar	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O

Two	NUM	O	O
patients	NOUN	O	O
are	VERB	O	O
presented	VERB	O	O
who	NOUN	O	O
suffered	VERB	O	O
progressive	ADJ	O	O
hemiparesis	NOUN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
DPH	PROPN	O	I-Entity
overdose	NOUN	O	I-Entity
.	PUNCT	O	O

Both	DET	O	O
had	VERB	O	O
brain	NOUN	O	O
surgery	NOUN	O	O
before	ADP	O	O
DPH	PROPN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
assumed	VERB	O	O
that	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
some	DET	O	O
cerebral	ADJ	O	B-Entity
damage	NOUN	O	I-Entity
are	VERB	O	O
liable	ADJ	O	O
to	PART	O	O
manifest	VERB	O	O
DPH	PROPN	O	I-Entity
toxicity	NOUN	O	I-Entity
as	ADP	O	O
focal	ADJ	O	O
neurological	ADJ	O	O
signs	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (16600756)

Nerve	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
and	CCONJ	O	O
prostaglandins	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
urine	NOUN	O	O
of	ADP	O	O
female	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
overactive	ADJ	O	B-Entity
bladder	NOUN	O	I-Entity
.	PUNCT	O	O

NGF	PROPN	O	O
and	CCONJ	O	O
PGs	PROPN	O	I-Entity
in	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
affected	VERB	O	O
by	ADP	O	O
pathological	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
bladder	NOUN	O	O
and	CCONJ	O	O
these	DET	O	O
changes	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
detected	VERB	O	O
in	ADP	O	O
urine	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
urinary	ADJ	O	O
NGF	PROPN	O	O
and	CCONJ	O	O
PGs	PROPN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
OAB	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
groups	NOUN	O	O
included	VERB	O	O
65	NUM	O	O
women	NOUN	O	O
with	ADP	O	O
OAB	PROPN	O	I-Entity
and	CCONJ	O	O
20	NUM	O	O
without	ADP	O	O
bladder	NOUN	O	O
symptoms	NOUN	O	O
who	NOUN	O	O
served	VERB	O	O
as	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

NGF	PROPN	O	O
,	PUNCT	O	O
PGE2	PROPN	O	I-Entity
,	PUNCT	O	O
PGF2alpha	PROPN	O	I-Entity
and	CCONJ	O	O
PGI2	PROPN	O	I-Entity
were	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
enzyme	NOUN	O	O
-	PUNCT	O	O
linked	VERB	O	O
immunosorbent	NOUN	O	O
assay	NOUN	O	O
and	CCONJ	O	O
compared	VERB	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
correlations	NOUN	O	O
between	ADP	O	O
urinary	ADJ	O	O
NGF	PROPN	O	O
and	CCONJ	O	O
PG	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
urodynamic	ADJ	O	O
parameters	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
OAB	PROPN	O	I-Entity
were	VERB	O	O
examined	VERB	O	O
.	PUNCT	O	O

Urinary	ADJ	O	O
NGF	PROPN	O	O
,	PUNCT	O	O
PGE2	PROPN	O	I-Entity
and	CCONJ	O	O
PGF2alpha	PROPN	O	I-Entity
were	VERB	O	O
significantly	ADV	O	O
increased	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
OAB	PROPN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
controls	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
urinary	ADJ	O	O
PGI2	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
controls	NOUN	O	O
and	CCONJ	O	O
patients	NOUN	O	O
with	ADP	O	O
OAB	PROPN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
OAB	PROPN	O	I-Entity
urinary	ADJ	O	O
PGE2	PROPN	O	I-Entity
positively	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
volume	NOUN	O	O
at	ADP	O	O
first	ADJ	O	O
desire	NOUN	O	O
to	PART	O	O
void	VERB	O	O
and	CCONJ	O	O
maximum	VERB	O	O
cystometric	ADJ	O	O
capacity	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Urinary	ADJ	O	O
NGF	PROPN	O	O
,	PUNCT	O	O
PGF2alpha	PROPN	O	I-Entity
and	CCONJ	O	O
PGI2	PROPN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
correlate	VERB	O	O
with	ADP	O	O
urodynamic	ADJ	O	O
parameters	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
OAB	PROPN	O	I-Entity
.	PUNCT	O	O

NGF	PROPN	O	O
and	CCONJ	O	O
PGs	NOUN	O	I-Entity
have	VERB	O	O
important	ADJ	O	O
roles	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
OAB	PROPN	O	I-Entity
symptoms	NOUN	O	O
in	ADP	O	O
female	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Urinary	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
these	DET	O	O
factors	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
used	VERB	O	O
as	ADP	O	O
markers	NOUN	O	O
to	PART	O	O
evaluate	VERB	O	O
OAB	PROPN	O	I-Entity
symptoms	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (15686794)

Acute	VERB	O	O
low	ADJ	O	B-Entity
back	ADV	O	I-Entity
pain	NOUN	O	I-Entity
during	ADP	O	O
intravenous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
:	PUNCT	O	O
a	DET	O	O
report	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Amiodarone	PROPN	O	I-Entity
represents	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
antiarrhythmic	ADJ	O	O
drug	NOUN	O	O
for	ADP	O	O
cardioversion	NOUN	O	O
of	ADP	O	O
recent	ADJ	O	O
-	PUNCT	O	O
onset	NOUN	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
(	PUNCT	O	O
AF	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
maintenance	NOUN	O	O
of	ADP	O	O
sinus	ADJ	O	O
rhythm	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
briefly	ADV	O	O
describe	VERB	O	O
two	NUM	O	O
patients	NOUN	O	O
suffering	VERB	O	O
from	ADP	O	O
recent	ADJ	O	O
-	PUNCT	O	O
onset	NOUN	O	O
atrial	ADJ	O	B-Entity
fibrillation	NOUN	O	I-Entity
,	PUNCT	O	O
who	NOUN	O	O
experienced	VERB	O	O
an	DET	O	O
acute	ADJ	O	O
devastating	ADJ	O	O
low	ADJ	O	B-Entity
back	NOUN	O	I-Entity
pain	NOUN	O	I-Entity
a	DET	O	O
few	ADJ	O	O
minutes	NOUN	O	O
after	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
amiodarone	NOUN	O	I-Entity
loading	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12760988)

Postoperative	ADJ	O	B-Entity
myalgia	NOUN	O	I-Entity
after	ADP	O	O
succinylcholine	NOUN	O	I-Entity
:	PUNCT	O	O
no	DET	O	O
evidence	NOUN	O	O
for	ADP	O	O
an	DET	O	O
inflammatory	ADJ	O	O
origin	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
common	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
succinylcholine	NOUN	O	I-Entity
is	VERB	O	O
postoperative	ADJ	O	B-Entity
myalgia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
this	DET	O	O
myalgia	NOUN	O	I-Entity
is	VERB	O	O
still	ADV	O	O
unclear	ADJ	O	O
;	PUNCT	O	O
inflammation	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
suggested	VERB	O	O
but	CCONJ	O	O
without	ADP	O	O
convincing	VERB	O	O
evidence	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
designed	VERB	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
to	PART	O	O
investigate	VERB	O	O
whether	ADP	O	O
an	DET	O	O
inflammatory	ADJ	O	O
reaction	NOUN	O	O
contributes	VERB	O	O
to	ADP	O	O
this	DET	O	O
myalgia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
succinylcholine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
myalgia	NOUN	O	I-Entity
was	VERB	O	O
determined	VERB	O	O
in	ADP	O	O
64	NUM	O	O
patients	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
or	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
before	ADP	O	O
succinylcholine	NOUN	O	I-Entity
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
32	NUM	O	O
for	ADP	O	O
each	DET	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
myalgia	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
differ	VERB	O	O
significantly	ADV	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
15	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dexamethasone	NOUN	O	I-Entity
group	NOUN	O	O
complained	VERB	O	O
of	ADP	O	O
myalgia	NOUN	O	I-Entity
compared	VERB	O	O
with	ADP	O	O
18	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
saline	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
severe	ADJ	O	O
myalgia	NOUN	O	I-Entity
was	VERB	O	O
reported	VERB	O	O
by	ADP	O	O
five	NUM	O	O
patients	NOUN	O	O
and	CCONJ	O	O
three	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
not	ADV	O	O
significant	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

At	ADP	O	O
48	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
12	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
still	ADV	O	O
suffered	VERB	O	O
from	ADP	O	O
myalgia	NOUN	O	I-Entity
(	PUNCT	O	O
not	ADV	O	O
significant	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
interleukin-6	NOUN	O	O
(	PUNCT	O	O
IL-6	PROPN	O	O
)	PUNCT	O	O
as	ADP	O	O
an	DET	O	O
early	ADJ	O	O
marker	NOUN	O	O
of	ADP	O	O
inflammation	NOUN	O	I-Entity
was	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
a	DET	O	O
subgroup	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
patients	NOUN	O	O
pretreated	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
an	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
IL-6	PROPN	O	O
for	ADP	O	O
only	ADV	O	O
three	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
one	NUM	O	O
patient	NOUN	O	O
reported	VERB	O	O
myalgia	NOUN	O	I-Entity
;	PUNCT	O	O
no	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
myalgia	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
IL-6	PROPN	O	O
was	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
is	VERB	O	O
no	DET	O	O
evidence	NOUN	O	O
for	ADP	O	O
an	DET	O	O
inflammatory	ADJ	O	O
origin	NOUN	O	O
of	ADP	O	O
succinylcholine	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
myalgia	NOUN	O	I-Entity
.	PUNCT	O	O

Administration	PROPN	O	O
of	ADP	O	O
dexamethasone	NOUN	O	I-Entity
before	ADP	O	O
succinylcholine	NOUN	O	I-Entity
was	VERB	O	O
not	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
decreasing	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
succinylcholine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
postoperative	ADJ	O	B-Entity
myalgia	NOUN	O	I-Entity
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
postoperative	ADJ	O	B-Entity
myalgia	NOUN	O	I-Entity
and	CCONJ	O	O
time	NOUN	O	O
course	NOUN	O	O
of	ADP	O	O
interleukin-6	ADJ	O	O
concentrations	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
marker	NOUN	O	O
of	ADP	O	O
inflammation	NOUN	O	I-Entity
.	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
dexamethasone	NOUN	O	I-Entity
is	VERB	O	O
not	ADV	O	O
justified	VERB	O	O
to	PART	O	O
prevent	VERB	O	O
postoperative	ADJ	O	B-Entity
myalgia	NOUN	O	I-Entity
after	ADP	O	O
succinylcholine	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12691807)

Levodopa	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
oromandibular	ADJ	O	O
dystonia	NOUN	O	I-Entity
in	ADP	O	O
progressive	ADJ	O	B-Entity
supranuclear	ADJ	O	I-Entity
palsy	NOUN	O	I-Entity
.	PUNCT	O	O

Levodopa	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
and	CCONJ	O	O
multiple	ADJ	O	B-Entity
system	NOUN	O	I-Entity
atrophy	VERB	O	I-Entity
.	PUNCT	O	O

Cranial	ADJ	O	O
dystonias	NOUN	O	I-Entity
are	VERB	O	O
rare	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
progressive	ADJ	O	B-Entity
supranuclear	ADJ	O	I-Entity
palsy	NOUN	O	I-Entity
(	PUNCT	O	O
PSP	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
report	NOUN	O	O
we	PRON	O	O
describe	VERB	O	O
an	DET	O	O
unusual	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
reversible	ADJ	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
Oromandibular	PROPN	O	B-Entity
dystonia	NOUN	O	I-Entity
(	PUNCT	O	O
OMD	PROPN	O	I-Entity
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
PSP	PROPN	O	I-Entity
patient	NOUN	O	O
to	PART	O	O
highlight	VERB	O	O
the	DET	O	O
importance	NOUN	O	O
of	ADP	O	O
recognizing	VERB	O	O
this	DET	O	O
drug	NOUN	O	O
related	VERB	O	O
complication	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
PSP	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
discuss	VERB	O	O
the	DET	O	O
possible	ADJ	O	O
underlying	VERB	O	O
pathophysiology	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12600698)

Protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
edaravone	NOUN	O	I-Entity
against	ADP	O	O
streptomycin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
vestibulotoxicity	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
guinea	NOUN	O	O
pig	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
investigated	VERB	O	O
alleviation	NOUN	O	O
of	ADP	O	O
streptomycin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
vestibulotoxicity	NOUN	O	I-Entity
by	ADP	O	O
edaravone	NOUN	O	I-Entity
in	ADP	O	O
guinea	NOUN	O	O
pigs	NOUN	O	O
.	PUNCT	O	O

Edaravone	PROPN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
free	ADJ	O	O
radical	ADJ	O	O
scavenger	NOUN	O	O
,	PUNCT	O	O
has	VERB	O	O
potent	ADJ	O	O
free	ADJ	O	O
radical	ADJ	O	O
quenching	NOUN	O	O
action	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
used	VERB	O	O
in	ADP	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
to	PART	O	O
treat	VERB	O	O
cerebral	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Streptomycin	PROPN	O	I-Entity
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
the	DET	O	O
inner	ADJ	O	O
ear	NOUN	O	O
by	ADP	O	O
osmotic	ADJ	O	O
pump	NOUN	O	O
for	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
edaravone	NOUN	O	I-Entity
(	PUNCT	O	O
n=8	PROPN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
saline	NOUN	O	O
(	PUNCT	O	O
n=6	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
intraperitoneally	ADV	O	O
injected	VERB	O	O
once	ADV	O	O
a	DET	O	O
day	NOUN	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Animals	NOUN	O	O
injected	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
showed	VERB	O	O
statistically	ADV	O	O
smaller	ADJ	O	O
gains	NOUN	O	O
than	ADP	O	O
those	DET	O	O
injected	VERB	O	O
with	ADP	O	O
edaravone	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
edaravone	NOUN	O	I-Entity
suppresses	VERB	O	O
streptomycin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
vestibulotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (12091028)

Ketamine	PROPN	O	I-Entity
in	ADP	O	O
war	NOUN	O	O
/	SYM	O	O
tropical	ADJ	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
final	ADJ	O	O
tribute	NOUN	O	O
to	ADP	O	O
the	DET	O	O
racemic	ADJ	O	O
mixture	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
technique	NOUN	O	O
of	ADP	O	O
continuous	ADJ	O	O
intravenous	ADJ	O	O
anaesthesia	NOUN	O	O
with	ADP	O	O
ketamine	NOUN	O	I-Entity
was	VERB	O	O
used	VERB	O	O
successfully	ADV	O	O
during	ADP	O	O
the	DET	O	O
Somalia	PROPN	O	O
civil	ADJ	O	O
war	NOUN	O	O
in	ADP	O	O
1994	NUM	O	O
and	CCONJ	O	O
in	ADP	O	O
north	NOUN	O	O
Uganda	PROPN	O	O
in	ADP	O	O
1999	NUM	O	O
for	ADP	O	O
64	NUM	O	O
operations	NOUN	O	O
in	ADP	O	O
62	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
aged	VERB	O	O
from	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
to	ADP	O	O
70	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
undergoing	VERB	O	O
limb	NOUN	O	O
and	CCONJ	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
including	VERB	O	O
caesarian	ADJ	O	O
sections	NOUN	O	O
and	CCONJ	O	O
interventions	NOUN	O	O
in	ADP	O	O
neonates	NOUN	O	O
.	PUNCT	O	O

Operations	NOUN	O	O
lasting	VERB	O	O
up	PART	O	O
to	ADP	O	O
2h	PRON	O	O
could	VERB	O	O
be	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
the	DET	O	O
absence	NOUN	O	O
of	ADP	O	O
sophisticated	ADJ	O	O
equipment	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
pulse	NOUN	O	O
oximeters	NOUN	O	O
or	CCONJ	O	O
ventilators	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
spontaneous	ADJ	O	O
ventilation	NOUN	O	O
breathing	VERB	O	O
air	NOUN	O	O
/	PUNCT	O	O
oxygen	NOUN	O	I-Entity
only	ADV	O	O
.	PUNCT	O	O

After	ADP	O	O
premedication	NOUN	O	O
with	ADP	O	O
diazepam	NOUN	O	I-Entity
,	PUNCT	O	O
glycopyrrolate	NOUN	O	I-Entity
and	CCONJ	O	O
local	ADJ	O	O
anaesthesia	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
induction	NOUN	O	O
with	ADP	O	O
standard	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
maintenance	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
-	SYM	O	O
20	NUM	O	O
microg	NOUN	O	O
/	SYM	O	O
kg	PROPN	O	O

/	SYM	O	O
min	NOUN	O	O
of	ADP	O	O
ketamine	NOUN	O	I-Entity
proved	VERB	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
.	PUNCT	O	O

Diazepam	PROPN	O	I-Entity
,	PUNCT	O	O
unless	ADP	O	O
contraindicated	ADJ	O	O
or	CCONJ	O	O
risky	ADJ	O	O
,	PUNCT	O	O
remains	VERB	O	O
the	DET	O	O
only	ADJ	O	O
necessary	ADJ	O	O
complementary	ADJ	O	O
drug	NOUN	O	O
to	PART	O	O
ketamine	VERB	O	I-Entity
as	ADP	O	O
it	PRON	O	O
buffers	VERB	O	O
its	ADJ	O	O
cardiovascular	ADJ	O	O
response	NOUN	O	O
and	CCONJ	O	O
decreases	VERB	O	O
the	DET	O	O
duration	NOUN	O	O
and	CCONJ	O	O
intensity	NOUN	O	O
of	ADP	O	O
operative	NOUN	O	O
and	CCONJ	O	O
postoperative	ADJ	O	O
hallucinations	NOUN	O	I-Entity
.	PUNCT	O	O

Local	ADJ	O	O
anaesthetic	ADJ	O	O
blocks	NOUN	O	O
were	VERB	O	O
useful	ADJ	O	O
in	ADP	O	O
decreasing	VERB	O	O
the	DET	O	O
requirement	NOUN	O	O
for	ADP	O	O
postoperative	ADJ	O	O
analgesia	NOUN	O	I-Entity
.	PUNCT	O	O

An	DET	O	O
antisialogue	NOUN	O	O
was	VERB	O	O
usually	ADV	O	O
unnecessary	ADJ	O	O
in	ADP	O	O
operations	NOUN	O	O
lasting	VERB	O	O
up	ADP	O	O
to	ADP	O	O
2	NUM	O	O
h	NOUN	O	O
,	PUNCT	O	O
glycopyrrolate	NOUN	O	I-Entity
being	VERB	O	O
the	DET	O	O
best	ADJ	O	O
choice	NOUN	O	O
for	ADP	O	O
its	ADJ	O	O
lowest	ADJ	O	O
psychotropic	NOUN	O	O
and	CCONJ	O	O
chronotropic	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
especially	ADV	O	O
in	ADP	O	O
a	DET	O	O
hot	ADJ	O	O
climate	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11860495)

Steroid	ADJ	O	I-Entity
structure	NOUN	O	O
and	CCONJ	O	O
pharmacological	ADJ	O	O
properties	NOUN	O	O
determine	VERB	O	O
the	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
amnesic	ADJ	O	I-Entity
effects	NOUN	O	O
of	ADP	O	O
pregnenolone	NOUN	O	B-Entity
sulphate	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
task	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Pregnenolone	NOUN	O	B-Entity
sulphate	NOUN	O	I-Entity
(	PUNCT	O	O
PREGS	PROPN	O	I-Entity
)	PUNCT	O	O
has	VERB	O	O
generated	VERB	O	O
interest	NOUN	O	O
as	ADP	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
most	ADV	O	O
potent	ADJ	O	O
memory	NOUN	O	O
-	PUNCT	O	O
enhancing	VERB	O	O
neurosteroids	NOUN	O	O
to	PART	O	O
be	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
rodent	NOUN	O	O
learning	NOUN	O	O
studies	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
particular	ADJ	O	O
importance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
ageing	NOUN	O	O
process	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
by	ADP	O	O
which	ADJ	O	O
this	DET	O	O
endogenous	ADJ	O	O
steroid	NOUN	O	I-Entity
enhances	VERB	O	O
memory	NOUN	O	O
formation	NOUN	O	O
is	VERB	O	O
hypothesized	VERB	O	O
to	PART	O	O
involve	VERB	O	O
actions	NOUN	O	O
on	ADP	O	O
glutamatergic	NOUN	O	O
and	CCONJ	O	O
GABAergic	PROPN	O	O
systems	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
hypothesis	NOUN	O	O
stems	VERB	O	O
from	ADP	O	O
findings	NOUN	O	O
that	ADP	O	O
PREGS	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
potent	ADJ	O	O
positive	ADJ	O	O
modulator	NOUN	O	O
of	ADP	O	O
N	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
methyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
d	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
aspartate	NOUN	O	I-Entity
receptors	NOUN	O	O
(	PUNCT	O	O
NMDARs	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
negative	ADJ	O	O
modulator	NOUN	O	O
of	ADP	O	O
gamma	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
aminobutyric	NOUN	O	I-Entity
acid(A	NOUN	O	I-Entity
)	PUNCT	O	O
receptors	NOUN	O	O
(	PUNCT	O	O
GABA(A)Rs	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
PREGS	PROPN	O	I-Entity
is	VERB	O	O
able	ADJ	O	O
to	PART	O	O
reverse	VERB	O	O
the	DET	O	O
amnesic	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
NMDAR	PROPN	O	O
and	CCONJ	O	O
GABA(A)R	PROPN	O	I-Entity
ligands	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
investigate	VERB	O	O
this	DET	O	O
hypothesis	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
memory	NOUN	O	O
-	PUNCT	O	O
altering	VERB	O	O
abilities	NOUN	O	O
of	ADP	O	O
structural	ADJ	O	O
analogs	NOUN	O	O
of	ADP	O	O
PREGS	PROPN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
differ	VERB	O	O
in	ADP	O	O
their	ADJ	O	O
modulation	NOUN	O	O
of	ADP	O	O
NMDAR	PROPN	O	O
and/or	CCONJ	O	O
GABA(A)R	PROPN	O	I-Entity
function	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
analogs	NOUN	O	O
tested	VERB	O	O
were	VERB	O	O
:	PUNCT	O	O
11-ketopregnenolone	NUM	O	B-Entity
sulphate	NOUN	O	I-Entity
(	PUNCT	O	O
an	DET	O	O
agent	NOUN	O	O
that	ADJ	O	O
is	VERB	O	O
inactive	ADJ	O	O
at	ADP	O	O
GABA(A)Rs	PROPN	O	I-Entity
and	CCONJ	O	O
NMDARs	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
epipregnanolone	NOUN	O	B-Entity
(	PUNCT	O	I-Entity
[	PUNCT	O	I-Entity
3beta	NUM	O	I-Entity
-	PUNCT	O	I-Entity
hydroxy-5beta	NUM	O	I-Entity
-	PUNCT	O	I-Entity
pregnan-20-one	NOUN	O	I-Entity
]	PUNCT	O	I-Entity
sulphate	NOUN	O	I-Entity
,	PUNCT	O	O
an	DET	O	O
inhibitor	NOUN	O	O
of	ADP	O	O
both	DET	O	O
GABA(A)Rs	PROPN	O	I-Entity
and	CCONJ	O	O
NMDARs	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
newly	ADV	O	O
synthesized	VERB	O	O
(	PUNCT	O	O
-	PUNCT	O	O
)	PUNCT	O	O

PREGS	PROPN	O	I-Entity
enantiomer	NOUN	O	O
(	PUNCT	O	O
which	ADJ	O	O
is	VERB	O	O
identical	ADJ	O	O
to	ADP	O	O
PREGS	PROPN	O	I-Entity
in	ADP	O	O
effects	NOUN	O	O
on	ADP	O	O
GABA(A)Rs	PROPN	O	I-Entity
and	CCONJ	O	O
NMDARs	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
memory	NOUN	O	O
-	PUNCT	O	O
enhancing	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
PREGS	PROPN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
analogs	NOUN	O	O
were	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
the	DET	O	O
passive	ADJ	O	O
avoidance	NOUN	O	O
task	NOUN	O	O
using	VERB	O	O
the	DET	O	O
model	NOUN	O	O
of	ADP	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
.	PUNCT	O	O

Both	DET	O	O
PREGS	PROPN	O	I-Entity
and	CCONJ	O	O
its	ADJ	O	O
(	PUNCT	O	O
-	PUNCT	O	O
)	PUNCT	O	O
enantiomer	NOUN	O	O
blocked	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
scopolamine	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
results	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
unlike	ADP	O	O
PREGS	PROPN	O	I-Entity
,	PUNCT	O	O
11-ketopregnenolone	NUM	O	B-Entity
sulphate	NOUN	O	I-Entity
and	CCONJ	O	O
epipregnanolone	NOUN	O	B-Entity
sulphate	NOUN	O	I-Entity
failed	VERB	O	O
to	PART	O	O
block	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
scopolamine	NOUN	O	I-Entity
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
altering	VERB	O	O
the	DET	O	O
modulation	NOUN	O	O
of	ADP	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
diminishes	ADP	O	O
the	DET	O	O
memory	NOUN	O	O
-	PUNCT	O	O
enhancing	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
PREGS	PROPN	O	I-Entity
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
enantioselectivity	NOUN	O	O
was	VERB	O	O
demonstrated	VERB	O	O
by	ADP	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
natural	ADJ	O	O
PREGS	PROPN	O	I-Entity
to	PART	O	O
be	VERB	O	O
an	DET	O	O
order	NOUN	O	O
of	ADP	O	O
magnitude	NOUN	O	O
more	ADV	O	O
effective	ADJ	O	O
than	ADP	O	O
its	ADJ	O	O
synthetic	ADJ	O	O
enantiomer	NOUN	O	O
in	ADP	O	O
reversing	VERB	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
amnesia	NOUN	O	I-Entity
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
identify	VERB	O	O
a	DET	O	O
novel	NOUN	O	O
neuropharmacological	ADJ	O	O
site	NOUN	O	O
for	ADP	O	O
the	DET	O	O
modulation	NOUN	O	O
of	ADP	O	O
memory	NOUN	O	O
processes	NOUN	O	O
by	ADP	O	O
neuroactive	ADJ	O	O
steroids	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11752998)

Preliminary	ADJ	O	O
efficacy	NOUN	O	O
assessment	NOUN	O	O
of	ADP	O	O
intrathecal	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
an	DET	O	O
American	ADJ	O	O
formulation	NOUN	O	O
of	ADP	O	O
adenosine	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
.	PUNCT	O	O

Preclinical	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
intrathecal	ADJ	O	O
adenosine	NOUN	O	I-Entity
suggest	VERB	O	O
it	PRON	O	O
may	VERB	O	O
be	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	B-Entity
and	CCONJ	O	I-Entity
chronic	ADJ	O	I-Entity
pain	NOUN	O	I-Entity
in	ADP	O	O
humans	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
preliminary	ADJ	O	O
studies	NOUN	O	O
in	ADP	O	O
volunteers	NOUN	O	O
and	CCONJ	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
Swedish	ADJ	O	O
formulation	NOUN	O	O
of	ADP	O	O
adenosine	NOUN	O	I-Entity
suggests	VERB	O	O
it	PRON	O	O
may	VERB	O	O
be	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
hypersensitivity	ADJ	O	I-Entity
states	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
with	ADP	O	O
acute	ADJ	O	O
noxious	ADJ	O	O
stimulation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
screen	VERB	O	O
for	ADP	O	O
efficacy	NOUN	O	O
of	ADP	O	O
a	DET	O	O
different	ADJ	O	O
formulation	NOUN	O	O
of	ADP	O	O
adenosine	NOUN	O	I-Entity
marketed	VERB	O	O
in	ADP	O	O
the	DET	O	O
US	PROPN	O	O
,	PUNCT	O	O
using	VERB	O	O
both	DET	O	O
acute	ADJ	O	O
noxious	ADJ	O	O
stimulation	NOUN	O	O
and	CCONJ	O	O
capsaicin	NOUN	O	I-Entity
-	PUNCT	O	O
evoked	VERB	O	O
mechanical	ADJ	O	O
hypersensitivity	NOUN	O	I-Entity
.	PUNCT	O	O

Following	VERB	O	O
Food	PROPN	O	O
and	CCONJ	O	O
Drug	PROPN	O	O
Administration	PROPN	O	O
and	CCONJ	O	O
institutional	ADJ	O	O
review	NOUN	O	O
board	NOUN	O	O
approval	NOUN	O	O
and	CCONJ	O	O
written	VERB	O	O
informed	ADJ	O	O
consent	NOUN	O	O
,	PUNCT	O	O
65	NUM	O	O
volunteers	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
two	NUM	O	O
trials	NOUN	O	O
:	PUNCT	O	O
an	DET	O	O
open	ADJ	O	O
-	PUNCT	O	O
label	NOUN	O	O
,	PUNCT	O	O
dose	NOUN	O	O
-	PUNCT	O	O
escalating	VERB	O	O
trial	NOUN	O	O
with	ADP	O	O
intrathecal	ADJ	O	O
adenosine	NOUN	O	I-Entity
doses	NOUN	O	O
of	ADP	O	O
0.25	NUM	O	O
-	SYM	O	O
2.0	NUM	O	O
mg	NUM	O	O
and	CCONJ	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
adenosine	NOUN	O	I-Entity
,	PUNCT	O	O
2	NUM	O	O
mg	NUM	O	O
.	PUNCT	O	O

Cerebrospinal	PROPN	O	O
fluid	NOUN	O	O
was	VERB	O	O
obtained	VERB	O	O
for	ADP	O	O
pharmacokinetic	ADJ	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
pain	NOUN	O	I-Entity
ratings	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
acute	ADJ	O	O
heat	NOUN	O	O
stimuli	NOUN	O	O
and	CCONJ	O	O
areas	NOUN	O	O
of	ADP	O	O
mechanical	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
and	CCONJ	O	O
allodynia	NOUN	O	I-Entity
after	ADP	O	O
intradermal	ADJ	O	O
capsaicin	NOUN	O	I-Entity
injection	NOUN	O	O
were	VERB	O	O
determined	ADJ	O	O
.	PUNCT	O	O

Adenosine	PROPN	O	I-Entity
produced	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
pain	NOUN	O	I-Entity
report	NOUN	O	O
to	ADP	O	O
acute	ADJ	O	O
noxious	ADJ	O	O
thermal	ADJ	O	O
or	CCONJ	O	O
chemical	ADJ	O	O
stimulation	NOUN	O	O
but	CCONJ	O	O
reduced	VERB	O	O
mechanical	ADJ	O	B-Entity
hyperalgesia	NOUN	O	I-Entity
and	CCONJ	O	O
allodynia	NOUN	O	I-Entity
from	ADP	O	O
intradermal	ADJ	O	O
capsaicin	NOUN	O	I-Entity
injection	NOUN	O	O
for	ADP	O	O
at	ADV	O	O
least	ADV	O	O
24	NUM	O	O
h.	NOUN	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
residence	NOUN	O	O
time	NOUN	O	O
of	ADP	O	O
adenosine	NOUN	O	I-Entity
in	ADP	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
was	VERB	O	O
short	ADJ	O	O
(	PUNCT	O	O
<	SYM	O	O
4	NUM	O	O
h	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
show	VERB	O	O
selective	ADJ	O	O
inhibition	NOUN	O	O
by	ADP	O	O
intrathecal	ADJ	O	O
adenosine	NOUN	O	I-Entity
of	ADP	O	O
hypersensitivity	NOUN	O	I-Entity
,	PUNCT	O	O
presumed	VERB	O	O
to	PART	O	O
reflect	VERB	O	O
central	ADJ	O	O
sensitization	NOUN	O	O
in	ADP	O	O
humans	NOUN	O	O
after	ADP	O	O
peripheral	ADJ	O	O
capsaicin	NOUN	O	I-Entity
injection	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
lasting	VERB	O	O
effect	NOUN	O	O
is	VERB	O	O
consistent	ADJ	O	O
with	ADP	O	O
that	DET	O	O
observed	VERB	O	O
in	ADP	O	O
preliminary	ADJ	O	O
reports	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
neuropathic	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
and	CCONJ	O	O
is	VERB	O	O
not	ADV	O	O
due	ADJ	O	O
to	ADP	O	O
prolonged	ADJ	O	O
residence	NOUN	O	O
of	ADP	O	O
adenosine	NOUN	O	I-Entity
in	ADP	O	O
cerebrospinal	ADJ	O	O
fluid	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10354657)

Effect	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
maintenance	NOUN	O	O
therapy	NOUN	O	O
on	ADP	O	O
thyroid	NOUN	O	O
and	CCONJ	O	O
parathyroid	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
assess	VERB	O	O
changes	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
lithium	NOUN	O	I-Entity
maintenance	NOUN	O	O
therapy	NOUN	O	O
on	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
thyroid	NOUN	O	O
,	PUNCT	O	O
parathyroid	NOUN	O	O
and	CCONJ	O	O
ion	NOUN	O	O
alterations	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
were	VERB	O	O
evaluated	VERB	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
family	NOUN	O	O
history	NOUN	O	O
(	PUNCT	O	O
whether	ADP	O	O
or	CCONJ	O	O
not	ADV	O	O
the	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
a	DET	O	O
first	ADJ	O	O
-	PUNCT	O	O
degree	NOUN	O	O
relative	NOUN	O	O
with	ADP	O	O
thyroid	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
one	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
28	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
73	NUM	O	O
women	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
bipolar	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
receiving	VERB	O	O
lithium	NOUN	O	I-Entity
maintenance	NOUN	O	O
therapy	NOUN	O	O
ranging	VERB	O	O
from	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
's	PART	O	O
to	ADP	O	O
32	NUM	O	O
years	NOUN	O	O
'	PART	O	O
duration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
82	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
no	DET	O	O
psychiatric	ADJ	O	I-Entity
or	CCONJ	O	O
endocrinological	ADJ	O	O
diagnoses	NOUN	O	O
from	ADP	O	O
the	DET	O	O
hospital	NOUN	O	O
's	PART	O	O
out	ADV	O	O
-	PUNCT	O	O
patient	ADJ	O	O
clinics	NOUN	O	O
.	PUNCT	O	O

Laboratory	PROPN	O	O
analyses	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	I-Entity
,	PUNCT	O	O
magnesium	NOUN	O	I-Entity
and	CCONJ	O	O
thyroid	NOUN	O	O
-	PUNCT	O	O
stimulating	VERB	O	O
hormone	NOUN	O	O
levels	NOUN	O	O
performed	VERB	O	O
before	ADP	O	O
beginning	VERB	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
biannual	ADJ	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
.	PUNCT	O	O

Hypothyroidism	NOUN	O	I-Entity
developed	VERB	O	O
in	ADP	O	O
40	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
excluding	VERB	O	O
8	NUM	O	O
patients	NOUN	O	O
who	NOUN	O	O
were	VERB	O	O
hypothyroid	ADJ	O	I-Entity
at	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
having	VERB	O	O
first	ADV	O	O
-	PUNCT	O	O
degree	NOUN	O	O
relatives	NOUN	O	O
affected	VERB	O	O
by	ADP	O	O
thyroid	ADJ	O	B-Entity
illness	NOUN	O	I-Entity
had	VERB	O	O
accelerated	VERB	O	O
onset	NOUN	O	O
of	ADP	O	O
hypothyroidism	NOUN	O	I-Entity
(	PUNCT	O	O
3.7	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
onset	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
a	DET	O	O
family	NOUN	O	O
history	NOUN	O	O
(	PUNCT	O	O
8.6	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
onset	NOUN	O	O
of	ADP	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Women	NOUN	O	O
over	ADP	O	O
60	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
often	ADV	O	O
affected	VERB	O	O
by	ADP	O	O
hypothyroidism	NOUN	O	I-Entity
than	ADP	O	O
women	NOUN	O	O
under	ADP	O	O
60	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
(	PUNCT	O	O
34.6%	NUM	O	O
versus	ADP	O	O
31.9%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Magnesium	PROPN	O	I-Entity
levels	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
on	ADP	O	O
lithium	NOUN	O	I-Entity
treatment	NOUN	O	O
were	VERB	O	O
unchanged	ADJ	O	O
from	ADP	O	O
baseline	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
lithium	NOUN	O	I-Entity
treatment	NOUN	O	O
,	PUNCT	O	O
calcium	NOUN	O	I-Entity
levels	NOUN	O	O
were	VERB	O	O
higher	ADJ	O	O
than	ADP	O	O
either	DET	O	O
baseline	NOUN	O	O
levels	NOUN	O	O
or	CCONJ	O	O
control	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
lithium	ADJ	O	I-Entity
treatment	NOUN	O	O
counteracted	VERB	O	O
the	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
calcium	NOUN	O	I-Entity
levels	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
aging	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
:	PUNCT	O	O
Familial	ADJ	O	O
thyroid	NOUN	O	B-Entity
illness	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
hypothyroidism	NOUN	O	I-Entity
and	CCONJ	O	O
hypercalcemia	NOUN	O	I-Entity
during	ADP	O	O
lithium	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10328196)

Systemic	ADJ	O	O
toxicity	NOUN	O	I-Entity
following	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
(	PUNCT	O	O
formerly	ADV	O	O
rapamycin	NOUN	O	I-Entity
)	PUNCT	O	O
for	ADP	O	O
psoriasis	NOUN	O	I-Entity
:	PUNCT	O	O
association	NOUN	O	O
of	ADP	O	O
capillary	ADJ	O	B-Entity
leak	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
with	ADP	O	O
apoptosis	NOUN	O	O
of	ADP	O	O
lesional	ADJ	O	O
lymphocytes	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
:	PUNCT	O	O
Sirolimus	PROPN	O	I-Entity
(	PUNCT	O	O
formerly	ADV	O	O
rapamycin	NOUN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
an	DET	O	O
immunosuppressive	ADJ	O	O
agent	NOUN	O	O
that	ADJ	O	O
interferes	VERB	O	O
with	ADP	O	O
T	PROPN	O	O
-	PUNCT	O	O
cell	NOUN	O	O
activation	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
2	NUM	O	O
individuals	NOUN	O	O
with	ADP	O	O
psoriasis	NOUN	O	I-Entity
developed	VERB	O	O
a	DET	O	O
capillary	ADJ	O	B-Entity
leak	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
following	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
oral	ADJ	O	O
sirolimus	NOUN	O	I-Entity
lesional	ADJ	O	O
skin	NOUN	O	O
cells	NOUN	O	O
and	CCONJ	O	O
activated	VERB	O	O
peripheral	ADJ	O	O
blood	NOUN	O	O
cells	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
for	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
apoptosis	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
keratome	NOUN	O	O
skin	NOUN	O	O
specimen	NOUN	O	O
from	ADP	O	O
1	NUM	O	O
patient	NOUN	O	O
with	ADP	O	O
sirolimus	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
capillary	ADJ	O	B-Entity
leak	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
had	VERB	O	O
a	DET	O	O
2.3-fold	NUM	O	O
increase	NOUN	O	O
in	ADP	O	O
percentage	NOUN	O	O
of	ADP	O	O
apoptotic	ADJ	O	O
cells	NOUN	O	O
(	PUNCT	O	O
to	ADP	O	O
48%	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
an	DET	O	O
unaffected	ADJ	O	O
sirolimus	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
patient	NOUN	O	O
with	ADP	O	O
psoriasis	NOUN	O	I-Entity
(	PUNCT	O	O
21%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Activated	VERB	O	O
peripheral	ADJ	O	O
blood	NOUN	O	O
T	NOUN	O	O
cells	NOUN	O	O
from	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
psoriasis	NOUN	O	I-Entity
tended	VERB	O	O
to	PART	O	O
exhibit	VERB	O	O
greater	ADV	O	O
spontaneous	ADJ	O	O
or	CCONJ	O	O
dexamethasone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
apoptosis	NOUN	O	O
than	ADP	O	O
did	VERB	O	O
normal	ADJ	O	O
T	NOUN	O	O
cells	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
.	PUNCT	O	O

Severe	ADV	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	I-Entity
include	VERB	O	O
fever	NOUN	O	I-Entity
,	PUNCT	O	O
anemia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
capillary	ADJ	O	B-Entity
leak	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Because	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
psoriasis	NOUN	O	I-Entity
may	VERB	O	O
develop	VERB	O	O
capillary	ADJ	O	B-Entity
leak	NOUN	O	I-Entity
from	ADP	O	O
various	ADJ	O	O
systemic	ADJ	O	O
therapies	NOUN	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
monitoring	NOUN	O	O
is	VERB	O	O
advisable	ADJ	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
inflammatory	ADJ	O	B-Entity
diseases	NOUN	O	I-Entity
who	NOUN	O	O
are	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
immune	ADJ	O	O
modulators	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9630698)

Contribution	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glycine	NOUN	O	I-Entity
site	NOUN	O	O
of	ADP	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
in	ADP	O	O
rostral	ADJ	O	O
and	CCONJ	O	O
intermediate	ADJ	O	O
-	PUNCT	O	O
caudal	ADJ	O	O
parts	NOUN	O	O
of	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
to	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
muscle	NOUN	O	O
tone	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
contribution	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glycine	NOUN	O	I-Entity
site	NOUN	O	O
of	ADP	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
to	ADP	O	O
the	DET	O	O
regulation	NOUN	O	O
of	ADP	O	O
muscle	NOUN	O	O
tone	NOUN	O	O
.	PUNCT	O	O

Muscle	PROPN	O	B-Entity
rigidity	NOUN	O	I-Entity
was	VERB	O	O
induced	VERB	O	O
by	ADP	O	O
haloperidol	NOUN	O	I-Entity
(	PUNCT	O	O
2.5	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
i.p	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

5,7-dichlorokynurenic	ADJ	O	B-Entity
acid	NOUN	O	I-Entity
(	PUNCT	O	O
5,7-DCKA	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
selective	ADJ	O	O
glycine	NOUN	O	I-Entity
site	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
injected	VERB	O	O
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
2.5	NUM	O	O
and	CCONJ	O	O
4.5	NUM	O	O
microg/0.5	ADJ	O	O
microl	NOUN	O	O
bilaterally	ADV	O	O
,	PUNCT	O	O
into	ADP	O	O
the	DET	O	O
rostral	ADJ	O	O
region	NOUN	O	O
of	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
,	PUNCT	O	O
decreased	VERB	O	O
both	CCONJ	O	O
the	DET	O	O
haloperidol	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
(	PUNCT	O	O
MMG	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
enhanced	ADJ	O	O
electromyographic	ADJ	O	O
activity	NOUN	O	O
(	PUNCT	O	O
EMG	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

5,7-DCKA	NUM	O	I-Entity
injected	VERB	O	O
bilaterally	ADV	O	O
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
4.5	NUM	O	O
microg/0.5	NOUN	O	O
microl	NOUN	O	O
into	ADP	O	O
the	DET	O	O
intermediate	ADJ	O	O
-	PUNCT	O	O
caudal	ADJ	O	O
region	NOUN	O	O
of	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
of	ADP	O	O
rats	NOUN	O	O
not	ADV	O	O
pretreated	VERB	O	O
with	ADP	O	O
haloperidol	NOUN	O	I-Entity
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
muscle	NOUN	O	O
tone	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
results	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
blockade	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glycine	NOUN	O	I-Entity
site	NOUN	O	O
of	ADP	O	O
NMDA	PROPN	O	I-Entity
receptors	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rostral	ADJ	O	O
part	NOUN	O	O
of	ADP	O	O
the	DET	O	O
striatum	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
mainly	ADV	O	O
responsible	ADJ	O	O
for	ADP	O	O
the	DET	O	O
antiparkinsonian	ADJ	O	O
action	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8480959)

Efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
lovastatin	NOUN	O	I-Entity
in	ADP	O	O
3390	NUM	O	O
women	NOUN	O	O
with	ADP	O	O
moderate	ADJ	O	O
hypercholesterolemia	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
lovastatin	NOUN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
moderate	ADJ	O	O
hypercholesterolemia	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
Expanded	PROPN	O	O
Clinical	PROPN	O	O
Evaluation	NOUN	O	O
of	ADP	O	O
Lovastatin	PROPN	O	I-Entity
(	PUNCT	O	O
EXCEL	PROPN	O	O
)	PUNCT	O	O
Study	PROPN	O	O
,	PUNCT	O	O
a	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	NOUN	O	O
,	PUNCT	O	O
diet-	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
which	ADJ	O	O
participants	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	VERB	O	O
placebo	NOUN	O	O
or	CCONJ	O	O
lovastatin	NOUN	O	I-Entity
at	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
20	NUM	O	O
or	CCONJ	O	O
40	NUM	O	O
mg	NUM	O	O
once	ADV	O	O
daily	ADV	O	O
,	PUNCT	O	O
or	CCONJ	O	O
20	NUM	O	O
or	CCONJ	O	O
40	NUM	O	O
mg	NUM	O	O
twice	ADV	O	O
daily	ADV	O	O
for	ADP	O	O
48	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

MEASUREMENTS	NOUN	O	O
:	PUNCT	O	O
Plasma	PROPN	O	O
total	NOUN	O	O
,	PUNCT	O	O
low	ADJ	O	O
-	PUNCT	O	O
density	NOUN	O	O
lipoprotein	NOUN	O	O
(	PUNCT	O	O
LDL	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
density	NOUN	O	O
lipoprotein	NOUN	O	O
(	PUNCT	O	O
HDL	PROPN	O	O
)	PUNCT	O	O
cholesterol	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
triglycerides	NOUN	O	I-Entity
;	PUNCT	O	O
and	CCONJ	O	O
laboratory	NOUN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
events	NOUN	O	O
monitored	VERB	O	O
periodically	ADV	O	O
throughout	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Among	ADP	O	O
women	NOUN	O	O
,	PUNCT	O	O
lovastatin	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
to	PART	O	O
80	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
d	NOUN	O	O
)	PUNCT	O	O
produced	VERB	O	O
sustained	ADJ	O	O
(	PUNCT	O	O
12-	NOUN	O	O
to	ADP	O	O
48-week	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
dose	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
changes	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.001	NUM	O	O
)	PUNCT	O	O
:	PUNCT	O	O
decreases	NOUN	O	O
in	ADP	O	O
LDL	PROPN	O	O
cholesterol	NOUN	O	I-Entity
(	PUNCT	O	O
24%	NUM	O	O
to	ADP	O	O
40%	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
triglycerides	NOUN	O	I-Entity
(	PUNCT	O	O
9%	NUM	O	O
to	ADP	O	O
18%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increases	VERB	O	O
in	ADP	O	O
HDL	PROPN	O	O
cholesterol	NOUN	O	I-Entity
(	PUNCT	O	O
6.7%	NUM	O	O
to	ADP	O	O
8.6%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Depending	VERB	O	O
on	ADP	O	O
the	DET	O	O
dose	NOUN	O	O
,	PUNCT	O	O
from	ADP	O	O
82%	NUM	O	O
to	ADP	O	O
95%	NUM	O	O
of	ADP	O	O
lovastatin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
women	NOUN	O	O
achieved	VERB	O	O
the	DET	O	O
National	PROPN	O	O
Cholesterol	PROPN	O	I-Entity
Education	PROPN	O	O
Program	PROPN	O	O
goal	NOUN	O	O
of	ADP	O	O
LDL	PROPN	O	O
cholesterol	NOUN	O	I-Entity
levels	NOUN	O	O
less	ADJ	O	O
than	ADP	O	O
4.14	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O
L	PROPN	O	O
(	PUNCT	O	O
160	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
40%	NUM	O	O
to	PART	O	O
87%	NUM	O	O
achieved	VERB	O	O
the	DET	O	O
goal	NOUN	O	O
of	ADP	O	O
3.36	NUM	O	O
mmol	PROPN	O	O
/	SYM	O	O
L	PROPN	O	O
(	PUNCT	O	O
130	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
dL	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Myopathy	PROPN	O	I-Entity
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
muscle	NOUN	O	O
symptoms	NOUN	O	O
with	ADP	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
elevations	NOUN	O	O
greater	ADJ	O	O
than	ADP	O	O
10	NUM	O	O
times	NOUN	O	O
the	DET	O	O
upper	ADJ	O	O
limit	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
,	PUNCT	O	O
was	VERB	O	O
rare	ADJ	O	O
and	CCONJ	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
highest	ADJ	O	O
recommended	VERB	O	O
daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
lovastatin	NOUN	O	I-Entity
(	PUNCT	O	O
80	NUM	O	O
mg	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Estrogen	PROPN	O	O
-	PUNCT	O	O
replacement	NOUN	O	O
therapy	NOUN	O	O
appeared	VERB	O	O
to	PART	O	O
have	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
efficacy	NOUN	O	O
or	CCONJ	O	O
safety	NOUN	O	O
profile	NOUN	O	O
of	ADP	O	O
lovastatin	NOUN	O	I-Entity
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
Lovastatin	PROPN	O	I-Entity
is	VERB	O	O
highly	ADV	O	O
effective	ADJ	O	O
and	CCONJ	O	O
generally	ADV	O	O
well	ADV	O	O
tolerated	VERB	O	O
as	ADP	O	O
therapy	NOUN	O	O
for	ADP	O	O
primary	ADJ	O	O
hypercholesterolemia	NOUN	O	I-Entity
in	ADP	O	O
women	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7197363)

REM	NOUN	O	B-Entity
sleep	NOUN	O	I-Entity
deprivation	NOUN	O	I-Entity
changes	VERB	O	O
behavioral	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
catecholaminergic	VERB	O	O
and	CCONJ	O	O
serotonergic	VERB	O	O
receptor	NOUN	O	O
activation	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
REM	PROPN	O	B-Entity
sleep	NOUN	O	I-Entity
deprivation	NOUN	O	I-Entity
(	PUNCT	O	O
REMD	PROPN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
apomorphine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
aggressiveness	NOUN	O	I-Entity
and	CCONJ	O	O
quipazine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
head	NOUN	O	B-Entity
twitches	NOUN	O	I-Entity
in	ADP	O	O
rats	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

hr	NOUN	O	O
of	ADP	O	O
REMD	PROPN	O	I-Entity
increased	VERB	O	O
apomorphine	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
aggressiveness	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
reduced	ADJ	O	O
(	PUNCT	O	O
immediately	ADV	O	O
after	ADP	O	O
completing	VERB	O	O
of	ADP	O	O
REMD	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
increased	VERB	O	O
(	PUNCT	O	O
96	NUM	O	O
hr	NOUN	O	O
after	ADP	O	O
completing	VERB	O	O
of	ADP	O	O
REMD	PROPN	O	I-Entity
)	PUNCT	O	O

quipazine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
head	NOUN	O	B-Entity
twitches	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7161250)

Extrapyramidal	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
and	CCONJ	O	O
oral	ADJ	O	O
haloperidol	NOUN	O	I-Entity
:	PUNCT	O	O
an	DET	O	O
analysis	NOUN	O	O
of	ADP	O	O
explanatory	ADJ	O	O
patient	NOUN	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
characteristics	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
extrapyramidal	NOUN	O	O
side	NOUN	O	O
effects	NOUN	O	O
(	PUNCT	O	O
EPS	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
98	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
haloperidol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
parkinsonism	NOUN	O	I-Entity
was	VERB	O	O
higher	ADJ	O	O
at	ADP	O	O
higher	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
and	CCONJ	O	O
in	ADP	O	O
younger	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
these	DET	O	O
medications	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
both	DET	O	O
young	ADJ	O	O
and	CCONJ	O	O
old	ADJ	O	O
patients	NOUN	O	O
when	ADV	O	O
given	VERB	O	O
after	ADP	O	O
parkinsonism	NOUN	O	I-Entity
developed	VERB	O	O
.	PUNCT	O	O

Akathisia	PROPN	O	I-Entity
was	VERB	O	O
controlled	VERB	O	O
by	ADP	O	O
the	DET	O	O
benzodiazepine	NOUN	O	I-Entity
lorazepam	NOUN	O	I-Entity
in	ADP	O	O
14	NUM	O	O
out	ADP	O	O
of	ADP	O	O
16	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
prophylactic	ADJ	O	O
antiparkinsonians	NOUN	O	O
were	VERB	O	O
ineffective	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
points	VERB	O	O
to	ADP	O	O
patient	ADJ	O	O
characteristics	NOUN	O	O
that	ADJ	O	O
may	VERB	O	O
be	VERB	O	O
of	ADP	O	O
significance	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
EPS	PROPN	O	O
due	ADJ	O	O
to	ADP	O	O
haloperidol	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7053705)

Hepatic	ADJ	O	B-Entity
veno	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
occlusive	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
6-thioguanine	NUM	O	I-Entity
.	PUNCT	O	O

Clinically	ADV	O	O
reversible	ADJ	O	O
veno	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
occlusive	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
liver	NOUN	O	I-Entity
developed	VERB	O	O
in	ADP	O	O
a	DET	O	O
23-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
man	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
lymphocytic	ADJ	O	I-Entity
leukemia	NOUN	O	I-Entity
after	ADP	O	O
10	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
6-thioguanine	NUM	O	I-Entity
.	PUNCT	O	O

Although	ADP	O	O
this	DET	O	O
disease	NOUN	O	O
was	VERB	O	O
clinically	ADV	O	O
reversible	ADJ	O	O
,	PUNCT	O	O
some	DET	O	O
subintimal	ADJ	O	O
fibrosis	NOUN	O	I-Entity
about	ADP	O	O
the	DET	O	O
terminal	NOUN	O	O
hepatic	ADJ	O	O
veins	NOUN	O	O
persisted	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
case	NOUN	O	O
presented	VERB	O	O
a	DET	O	O
unique	ADJ	O	O
opportunity	NOUN	O	O
to	PART	O	O
observe	VERB	O	O
the	DET	O	O
histologic	ADJ	O	O
features	NOUN	O	O
of	ADP	O	O
clinically	ADV	O	O
reversible	ADJ	O	O
hepatic	ADJ	O	B-Entity
veno	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
occlusive	ADJ	O	I-Entity
disease	NOUN	O	I-Entity
over	ADP	O	O
time	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
the	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
veno	NOUN	O	O
-	PUNCT	O	O
occlusive	NOUN	O	O
related	VERB	O	O
solely	ADV	O	O
to	ADP	O	O
6-thioguanine	NUM	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (6402369)

Treatment	NOUN	O	O
of	ADP	O	O
ifosfamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
urothelial	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
by	ADP	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	B-Entity
2-mercaptoethane	NUM	O	I-Entity
sulphonate	NOUN	O	I-Entity
(	PUNCT	O	O
MESNA	PROPN	O	I-Entity
)	PUNCT	O	O
to	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
inoperable	ADJ	O	O
lung	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
protective	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
thiol	NOUN	O	I-Entity
compound	NOUN	O	O
sodium	NOUN	O	B-Entity
2-mercaptoethane	NUM	O	I-Entity
sulphonate	NOUN	O	I-Entity
(	PUNCT	O	O
MESNA	PROPN	O	I-Entity
)	PUNCT	O	O
against	ADP	O	O
urothelial	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
ifosfamide	NOUN	O	I-Entity
(	PUNCT	O	O
IF	PROPN	O	I-Entity
)	PUNCT	O	O
was	VERB	O	O
tested	VERB	O	O
in	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
45	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
inoperable	ADJ	O	O
lung	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
under	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
IF	PROPN	O	I-Entity
(	PUNCT	O	O
2250	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
on	ADP	O	O
days	NOUN	O	O
2	NUM	O	O
-	SYM	O	O
5	NUM	O	O
)	PUNCT	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
a	DET	O	O
polychemotherapy	NOUN	O	O
regimen	NOUN	O	O
repeated	VERB	O	O
in	ADP	O	O
a	DET	O	O
4-week	NUM	O	O
cycle	NOUN	O	O
.	PUNCT	O	O

MESNA	PROPN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
orally	ADV	O	O
on	ADP	O	O
the	DET	O	O
days	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
IF	NOUN	O	I-Entity
in	ADP	O	O
3	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
840	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
m2	NOUN	O	O
,	PUNCT	O	O
each	DET	O	O
administered	VERB	O	O
at	ADP	O	O
0	NUM	O	O
hr	NOUN	O	O
(=	NUM	O	O
injection	NOUN	O	O
of	ADP	O	O
IF	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
4	NUM	O	O
hr	ADJ	O	O
and	CCONJ	O	O
8	NUM	O	O
hr	NOUN	O	O
p.i	NOUN	O	O
.	PUNCT	O	O

Out	ADP	O	O
of	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
88	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
this	DET	O	O
treatment	NOUN	O	O
we	PRON	O	O
observed	VERB	O	O
10	NUM	O	O
episodes	NOUN	O	O
of	ADP	O	O
asymptomatic	ADJ	O	O
microscopic	ADJ	O	O
haematuria	NOUN	O	I-Entity
and	CCONJ	O	O
no	DET	O	O
episodes	NOUN	O	O
of	ADP	O	O
gross	ADJ	O	O
haematuria	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
group	NOUN	O	O
of	ADP	O	O
45	NUM	O	O
patients	NOUN	O	O
under	ADP	O	O
protection	NOUN	O	O
with	ADP	O	O
MESNA	NOUN	O	I-Entity
there	ADV	O	O
were	VERB	O	O
5	NUM	O	O
complete	ADJ	O	O
remissions	NOUN	O	O
and	CCONJ	O	O
9	NUM	O	O
partial	ADJ	O	O
remissions	NOUN	O	O
(	PUNCT	O	O
total	ADJ	O	O
31%	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
further	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
25	NUM	O	O
patients	NOUN	O	O
under	ADP	O	O
polychemotherapy	NOUN	O	O
with	ADP	O	O
IF	PROPN	O	I-Entity
were	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
conventional	ADJ	O	O
prophylactic	ADJ	O	O
measures	NOUN	O	O
(	PUNCT	O	O
raised	VERB	O	O
fluid	NOUN	O	O
intake	NOUN	O	O
and	CCONJ	O	O
forced	VERB	O	O
diuresis	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
group	NOUN	O	O
there	ADV	O	O
were	VERB	O	O
1	NUM	O	O
complete	ADJ	O	O
and	CCONJ	O	O
5	NUM	O	O
partial	ADJ	O	O
remissions	NOUN	O	O
(	PUNCT	O	O
total	ADJ	O	O
24%	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
nearly	ADV	O	O
all	DET	O	O
patients	NOUN	O	O
developed	VERB	O	O
either	CCONJ	O	O
gross	ADJ	O	O
haematuria	NOUN	O	I-Entity
and/or	CCONJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	B-Entity
irritation	NOUN	O	I-Entity
(	PUNCT	O	O
cystitis	NOUN	O	I-Entity
and	CCONJ	O	O
pollakisuria	NOUN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

There	ADV	O	O
were	VERB	O	O
no	DET	O	O
appreciable	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
MESNA	PROPN	O	I-Entity
series	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
conventional	ADJ	O	O
prophylaxis	ADJ	O	O
series	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
either	CCONJ	O	O
haematological	ADJ	O	O
or	CCONJ	O	O
systemic	ADJ	O	O
toxicity	NOUN	O	I-Entity
of	ADP	O	O
the	DET	O	O
cytostatic	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
support	VERB	O	O
the	DET	O	O
view	NOUN	O	O
that	ADP	O	O
MESNA	PROPN	O	I-Entity
,	PUNCT	O	O
given	VERB	O	O
orally	ADV	O	O
in	ADP	O	O
conjunction	NOUN	O	O
with	ADP	O	O
combined	VERB	O	O
cytostatic	NOUN	O	O
regimens	NOUN	O	O
which	ADJ	O	O
include	VERB	O	O
IF	PROPN	O	I-Entity
,	PUNCT	O	O
simplifies	VERB	O	O
the	DET	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
provides	VERB	O	O
optimum	ADJ	O	O
protection	NOUN	O	O
for	ADP	O	O
the	DET	O	O
urinary	ADJ	O	O
epithelium	NOUN	O	O
.	PUNCT	O	O

Protection	NOUN	O	O
with	ADP	O	O
oral	ADJ	O	O
MESNA	PROPN	O	I-Entity
is	VERB	O	O
particularly	ADV	O	O
suitable	ADJ	O	O
for	ADP	O	O
outpatients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3973521)

Time	ADV	O	O
course	NOUN	O	O
alterations	NOUN	O	O
of	ADP	O	O
QTC	PROPN	O	O
interval	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
hypaque	VERB	O	B-Entity
76	NUM	O	I-Entity
.	PUNCT	O	O

Sequential	ADJ	O	O
measurement	NOUN	O	O
of	ADP	O	O
QT	PROPN	O	O
interval	NOUN	O	O
during	ADP	O	O
left	VERB	O	O
ventricular	ADJ	O	O
angiography	NOUN	O	O
was	VERB	O	O
made	VERB	O	O
30	NUM	O	O
seconds	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
,	PUNCT	O	O
three	NUM	O	O
,	PUNCT	O	O
five	NUM	O	O
and	CCONJ	O	O
ten	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
injection	NOUN	O	O
of	ADP	O	O
hypaque	NOUN	O	B-Entity
76	NUM	O	I-Entity
.	PUNCT	O	O

Significant	ADJ	O	O
QTC	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
30	NUM	O	O
seconds	NOUN	O	O
to	ADP	O	O
one	NUM	O	O
minute	NOUN	O	O
in	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
marked	VERB	O	O
hypotension	NOUN	O	I-Entity
and	CCONJ	O	O
elevation	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3461217)

Production	NOUN	O	O
of	ADP	O	O
autochthonous	ADJ	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
in	ADP	O	O
Lobund	PROPN	O	O
-	PUNCT	O	O
Wistar	PROPN	O	O
rats	NOUN	O	O
by	ADP	O	O
treatments	NOUN	O	O
with	ADP	O	O
N	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
nitroso	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
N	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
methylurea	NOUN	O	I-Entity
and	CCONJ	O	O
testosterone	NOUN	O	I-Entity
.	PUNCT	O	O

strain	NOUN	O	O
rats	NOUN	O	O
developed	VERB	O	O
large	ADJ	O	O
,	PUNCT	O	O
palpable	ADJ	O	O
prostate	NOUN	O	B-Entity
adenocarcinomas	NOUN	O	I-Entity
(	PUNCT	O	O
PAs	PROPN	O	I-Entity
)	PUNCT	O	O
following	VERB	O	O
treatments	NOUN	O	O
with	ADP	O	O
N	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
nitroso	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
N	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
methylurea	NOUN	O	I-Entity

(	PUNCT	O	O
CAS	PROPN	O	O
:	PUNCT	O	O
684	NUM	O	O
-	PUNCT	O	O
93	NUM	O	O
-	PUNCT	O	O
5	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
testosterone	NOUN	O	B-Entity
propionate	NOUN	O	I-Entity
[	PUNCT	O	O
(	PUNCT	O	O
TP	PROPN	O	I-Entity
)	PUNCT	O	O
CAS	PROPN	O	O
:	PUNCT	O	O
57	NUM	O	O
-	PUNCT	O	O
85	NUM	O	O
-	PUNCT	O	O
2	NUM	O	O
]	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
most	ADJ	O	O
of	ADP	O	O
the	DET	O	O
tumor	NOUN	O	I-Entity
-	PUNCT	O	O
bearing	VERB	O	O
rats	NOUN	O	O
manifested	VERB	O	O
metastatic	ADJ	O	O
lesions	NOUN	O	O
.	PUNCT	O	O

Within	ADP	O	O
the	DET	O	O
same	ADJ	O	O
timeframe	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
L	PROPN	O	O
-	PUNCT	O	O
W	PROPN	O	O
rat	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
similar	ADJ	O	O
palpable	ADJ	O	O
PA	NOUN	O	I-Entity
when	ADV	O	O
treated	VERB	O	O
only	ADV	O	O
with	ADP	O	O
TP	PROPN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
L	PROPN	O	O
-	PUNCT	O	O
W	PROPN	O	O
rats	NOUN	O	O
,	PUNCT	O	O
TP	PROPN	O	I-Entity
acted	VERB	O	O
as	ADP	O	O
a	DET	O	O
tumor	NOUN	O	I-Entity
enhancement	NOUN	O	O
agent	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
primary	ADJ	O	O
emphasis	NOUN	O	O
on	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
prostate	NOUN	O	B-Entity
cancer	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (2840807)

A	DET	O	O
dystonia	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
syndrome	NOUN	O	O
after	ADP	O	O
neuropeptide	NOUN	O	O
(	PUNCT	O	O
MSH	PROPN	O	I-Entity
/	SYM	O	O
ACTH	PROPN	O	I-Entity
)	PUNCT	O	O
stimulation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
locus	NOUN	O	O
ceruleus	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
movement	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
investigated	VERB	O	O
in	ADP	O	O
these	DET	O	O
studies	NOUN	O	O
has	VERB	O	O
some	DET	O	O
features	NOUN	O	O
in	ADP	O	O
common	ADJ	O	O
with	ADP	O	O
human	ADJ	O	O
idiopathic	ADJ	O	O
dystonia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
information	NOUN	O	O
obtained	VERB	O	O
in	ADP	O	O
these	DET	O	O
studies	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
of	ADP	O	O
potential	ADJ	O	O
clinical	ADJ	O	O
benefit	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
not	ADV	O	O
certain	ADJ	O	O
as	ADP	O	O
to	ADP	O	O
the	DET	O	O
following	VERB	O	O
:	PUNCT	O	O
(	PUNCT	O	O
a	PUNCT	O	O
)	PUNCT	O	O
what	NOUN	O	O
receptors	NOUN	O	O
were	VERB	O	O
stimulated	VERB	O	O
by	ADP	O	O
the	DET	O	O
ACTH	PROPN	O	I-Entity
N	PROPN	O	O
-	PUNCT	O	O
terminal	ADJ	O	O
fragments	NOUN	O	O
at	ADP	O	O
the	DET	O	O
LC	PROPN	O	O
that	ADJ	O	O
resulted	VERB	O	O
in	ADP	O	O
this	DET	O	O
disorder	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
b	PUNCT	O	O
)	PUNCT	O	O
whether	ADP	O	O
NE	PROPN	O	O
,	PUNCT	O	O
released	VERB	O	O
onto	ADP	O	O
Purkinje	PROPN	O	O
cell	NOUN	O	O
synapses	NOUN	O	O
located	VERB	O	O
at	ADP	O	O
terminals	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ceruleo	NOUN	O	O
-	PUNCT	O	O
cerebellar	ADJ	O	O
pathway	NOUN	O	O
,	PUNCT	O	O
did	VERB	O	O
indeed	ADV	O	O
cause	VERB	O	O
the	DET	O	O
long	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
depression	NOUN	O	I-Entity
at	ADP	O	O
Purkinje	PROPN	O	O
cell	NOUN	O	O
synapses	NOUN	O	O
(	PUNCT	O	O
previously	ADV	O	O
described	VERB	O	O
by	ADP	O	O
others	NOUN	O	O
)	PUNCT	O	O
that	ADJ	O	O
resulted	VERB	O	O
in	ADP	O	O
the	DET	O	O
long	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
movement	NOUN	O	B-Entity
disorder	NOUN	O	I-Entity
;	PUNCT	O	O
(	PUNCT	O	O
c	PUNCT	O	O
)	PUNCT	O	O
whether	ADP	O	O
the	DET	O	O
inhibition	NOUN	O	O
of	ADP	O	O
inhibitory	NOUN	O	O
Purkinje	PROPN	O	O
cells	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
disinhibition	NOUN	O	O
or	CCONJ	O	O
increased	VERB	O	O
excitability	NOUN	O	O
of	ADP	O	O
the	DET	O	O
unilateral	ADJ	O	O
cerebellar	ADJ	O	O


-DOCSTART- (2569282)

Dexmedetomidine	PROPN	O	I-Entity
,	PUNCT	O	O
acting	VERB	O	O
through	ADP	O	O
central	ADJ	O	O
alpha-2	ADJ	O	O
adrenoceptors	NOUN	O	O
,	PUNCT	O	O
prevents	VERB	O	O
opiate	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
highly	ADV	O	O
-	PUNCT	O	O
selective	ADJ	O	O
alpha-2	ADJ	O	O
adrenergic	ADJ	O	O
agonist	NOUN	O	O
dexmedetomidine	NOUN	O	I-Entity
(	PUNCT	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
MED	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
capable	ADJ	O	O
of	ADP	O	O
inducing	VERB	O	O
muscle	NOUN	O	B-Entity
flaccidity	NOUN	O	I-Entity
and	CCONJ	O	O
anesthesia	NOUN	O	O
in	ADP	O	O
rats	NOUN	O	O
and	CCONJ	O	O
dogs	NOUN	O	O
.	PUNCT	O	O

Intense	ADJ	O	O
generalized	ADJ	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
is	VERB	O	O
an	DET	O	O
undesirable	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
potent	ADJ	O	O
opiate	NOUN	O	O
agonists	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
the	DET	O	O
neurochemistry	NOUN	O	O
of	ADP	O	O
opiate	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
rigidity	NOUN	O	I-Entity
has	VERB	O	O
yet	ADV	O	O
to	PART	O	O
be	VERB	O	O
fully	ADV	O	O
elucidated	VERB	O	O
,	PUNCT	O	O
recent	ADJ	O	O
work	NOUN	O	O
suggests	VERB	O	O
a	DET	O	O
role	NOUN	O	O
for	ADP	O	O
a	DET	O	O
central	ADJ	O	O
adrenergic	ADJ	O	O
mechanism	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
determined	VERB	O	O
if	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
MED	PROPN	O	I-Entity
prevents	VERB	O	O
the	DET	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
caused	VERB	O	O
by	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
alfentanil	NOUN	O	I-Entity
anesthesia	NOUN	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Animals	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
42	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
intraperitoneally	ADV	O	O
with	ADP	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
following	VERB	O	O
six	NUM	O	O
regimens	NOUN	O	O
:	PUNCT	O	O
1	PUNCT	O	O
)	PUNCT	O	O
L	NOUN	O	O
-	PUNCT	O	O
MED	PROPN	O	O
(	PUNCT	O	O
the	DET	O	O
inactive	ADJ	O	O
L	NOUN	O	O
-	PUNCT	O	O
isomer	NOUN	O	O
of	ADP	O	O
medetomidine	NOUN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
30	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
;	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
MED	PROPN	O	I-Entity
,	PUNCT	O	O
10	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
;	PUNCT	O	O

3	PUNCT	O	O
)	PUNCT	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
MED	PROPN	O	I-Entity
,	PUNCT	O	O
30	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
;	PUNCT	O	O
4	PUNCT	O	O
)	PUNCT	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
MED	PROPN	O	I-Entity
[	PUNCT	O	O
30	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
]	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
central	ADJ	O	O
-	PUNCT	O	O
acting	VERB	O	O
alpha-2	PROPN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
idazoxan	NOUN	O	I-Entity
[	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
]	PUNCT	O	O
;	PUNCT	O	O
5	PUNCT	O	O
)	PUNCT	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
MED	PROPN	O	I-Entity
[	PUNCT	O	O
30	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	NOUN	O	O
]	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
peripheral	ADJ	O	O
-	PUNCT	O	O
acting	VERB	O	O
alpha-2	ADJ	O	O
antagonist	NOUN	O	O
DG-5128	PROPN	O	I-Entity
[	PUNCT	O	O
10	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
;	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O

Each	DET	O	O
rat	NOUN	O	O
was	VERB	O	O
then	ADV	O	O
injected	VERB	O	O
with	ADP	O	O
alfentanil	NOUN	O	I-Entity
(	PUNCT	O	O
ALF	PROPN	O	I-Entity
,	PUNCT	O	O
0.5	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
sc	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

ALF	NOUN	O	I-Entity
injection	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
marked	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
hindlimb	NOUN	O	O
EMG	PROPN	O	O
activity	NOUN	O	O
in	ADP	O	O
the	DET	O	O
L	PROPN	O	O
-	PUNCT	O	O
MED	PROPN	O	O
treatment	NOUN	O	O
group	NOUN	O	O
which	ADJ	O	O
was	VERB	O	O
indistinguishable	ADJ	O	O
from	ADP	O	O
that	DET	O	O
seen	VERB	O	O
in	ADP	O	O
animals	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
saline	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
D	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
MED	PROPN	O	I-Entity
prevented	VERB	O	O
alfentanil	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
muscle	NOUN	O	B-Entity
rigidity	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
fashion	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
small	ADJ	O	O
EMG	PROPN	O	O
values	NOUN	O	O
obtained	VERB	O	O
in	ADP	O	O
the	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
MED	PROPN	O	I-Entity
group	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
with	ADP	O	O
those	DET	O	O
recorded	VERB	O	O
in	ADP	O	O
earlier	ADJ	O	O
studies	NOUN	O	O
from	ADP	O	O
control	NOUN	O	O
animals	NOUN	O	O
not	ADV	O	O
given	VERB	O	O
any	DET	O	O
opiate	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
D	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
MED	PROPN	O	I-Entity
animals	NOUN	O	O
were	VERB	O	O
flaccid	ADJ	O	O
,	PUNCT	O	O
akinetic	ADJ	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
lacked	VERB	O	O
a	DET	O	O
startle	ADJ	O	I-Entity
response	NOUN	O	O
during	ADP	O	O
the	DET	O	O
entire	ADJ	O	O
experimental	ADJ	O	O
period.(ABSTRACT	NOUN	O	O
TRUNCATED	ADJ	O	O
AT	NOUN	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O


-DOCSTART- (2343592)

Seizure	NOUN	O	I-Entity
activity	NOUN	O	O
with	ADP	O	O
imipenem	NOUN	O	I-Entity
therapy	NOUN	O	O
:	PUNCT	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
either	DET	O	O
cerebral	ADJ	O	B-Entity
vascular	ADJ	O	I-Entity
accident	NOUN	O	I-Entity
(	PUNCT	O	O
CVA	PROPN	O	I-Entity
)	PUNCT	O	O
or	CCONJ	O	O
head	NOUN	O	B-Entity
trauma	NOUN	O	I-Entity
and	CCONJ	O	O
no	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	B-Entity
disease	NOUN	O	I-Entity
developed	VERB	O	O
seizures	NOUN	O	I-Entity
while	ADP	O	O
receiving	VERB	O	O
maximum	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
imipenem	NOUN	O	B-Entity
/	SYM	O	I-Entity
cilastatin	NOUN	O	I-Entity
.	PUNCT	O	O

Neither	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
reported	VERB	O	O
previous	ADJ	O	O
seizures	NOUN	O	I-Entity
or	CCONJ	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
activity	NOUN	O	O
nor	CCONJ	O	O
was	VERB	O	O
receiving	VERB	O	O
anticonvulsant	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
seizures	NOUN	O	I-Entity
were	VERB	O	O
controlled	VERB	O	O
with	ADP	O	O
therapeutic	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
phenytoin	NOUN	O	I-Entity
.	PUNCT	O	O

Both	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
received	VERB	O	O
maximum	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
other	ADJ	O	O
beta	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
lactam	NOUN	O	I-Entity
antibiotics	NOUN	O	O
without	ADP	O	O
evidence	NOUN	O	O
of	ADP	O	O
seizure	NOUN	O	I-Entity
activity	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2055425)

The	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
insulin	NOUN	O	O
treatment	NOUN	O	O
to	PART	O	O
reverse	VERB	O	O
or	CCONJ	O	O
prevent	VERB	O	O
the	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
urinary	ADJ	O	O
bladder	NOUN	O	O
function	NOUN	O	O
caused	VERB	O	O
by	ADP	O	O
streptozotocin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetes	NOUN	O	B-Entity
mellitus	NOUN	O	I-Entity
.	PUNCT	O	O
1	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
insulin	NOUN	O	O
treatment	NOUN	O	O
on	ADP	O	O
in	ADP	O	O
vivo	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
vitro	ADJ	O	O
urinary	ADJ	O	O
bladder	NOUN	O	O
function	NOUN	O	O
in	ADP	O	O
streptozotocin	NOUN	O	I-Entity
-	PUNCT	O	O
diabetic	ADJ	O	I-Entity
rats	NOUN	O	O
were	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

Diabetes	NOUN	O	I-Entity
of	ADP	O	O
2	NUM	O	O
months	NOUN	O	O
duration	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
decreases	NOUN	O	O
in	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
and	CCONJ	O	O
increases	NOUN	O	O
in	ADP	O	O
fluid	ADJ	O	O
consumption	NOUN	O	O
,	PUNCT	O	O
urine	NOUN	O	O
volume	NOUN	O	O
,	PUNCT	O	O
frequency	NOUN	O	O
of	ADP	O	O
micturition	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
average	ADJ	O	O
volume	NOUN	O	O
per	ADP	O	O
micturition	NOUN	O	O
;	PUNCT	O	O
effects	NOUN	O	O
which	ADJ	O	O
were	VERB	O	O
prevented	VERB	O	O
by	ADP	O	O
insulin	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

3	PUNCT	O	O
.	PUNCT	O	O
Insulin	PROPN	O	O
treatment	NOUN	O	O
also	ADV	O	O
prevented	VERB	O	O
the	DET	O	O
increases	NOUN	O	O
in	ADP	O	O
contractile	NOUN	O	O
responses	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	O
body	NOUN	O	O
strips	NOUN	O	O
from	ADP	O	O
diabetic	ADJ	O	I-Entity
rats	NOUN	O	O
to	ADP	O	O
nerve	NOUN	O	O
stimulation	NOUN	O	O
,	PUNCT	O	O
ATP	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
bethanechol	NOUN	O	I-Entity
.	PUNCT	O	O

Diabetes	NOUN	O	I-Entity
of	ADP	O	O
4	NUM	O	O
months	NOUN	O	O
duration	NOUN	O	O
also	ADV	O	O
resulted	VERB	O	O
in	ADP	O	O
decreases	NOUN	O	O
in	ADP	O	O
body	NOUN	O	O
weight	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
increases	VERB	O	O
in	ADP	O	O
fluid	ADJ	O	O
consumption	NOUN	O	O
,	PUNCT	O	O
urine	NOUN	O	O
volume	NOUN	O	O
,	PUNCT	O	O
frequency	NOUN	O	O
of	ADP	O	O
micturition	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
average	ADJ	O	O
volume	NOUN	O	O
per	ADP	O	O
micturition	NOUN	O	O
,	PUNCT	O	O
effects	NOUN	O	O
which	ADJ	O	O
were	VERB	O	O
reversed	VERB	O	O
by	ADP	O	O
insulin	NOUN	O	O
treatment	NOUN	O	O
for	ADP	O	O
the	DET	O	O
final	ADJ	O	O
2	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Insulin	PROPN	O	O
treatment	NOUN	O	O
reversed	VERB	O	O
the	DET	O	O
increases	NOUN	O	O
in	ADP	O	O
contractile	NOUN	O	O
responses	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	O
body	NOUN	O	O
strips	NOUN	O	O
from	ADP	O	O
diabetic	ADJ	O	I-Entity
rats	NOUN	O	O
to	ADP	O	O
nerve	NOUN	O	O
stimulation	NOUN	O	O
,	PUNCT	O	O
ATP	PROPN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
bethanechol	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
streptozotocin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
diabetes	NOUN	O	I-Entity
on	ADP	O	O
urinary	ADJ	O	O
bladder	NOUN	O	O
function	NOUN	O	O
are	VERB	O	O
both	DET	O	O
prevented	VERB	O	O
and	CCONJ	O	O
reversed	VERB	O	O
by	ADP	O	O
insulin	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1711760)

Delayed	ADJ	O	O
institution	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	I-Entity
during	ADP	O	O
focal	ADJ	O	O
cerebral	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
:	PUNCT	O	O
effect	NOUN	O	O
on	ADP	O	O
brain	NOUN	O	B-Entity
edema	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
instituted	VERB	O	O
after	ADP	O	O
a	DET	O	O
2-h	NUM	O	O
delay	NOUN	O	O
following	VERB	O	O
middle	ADJ	O	B-Entity
cerebral	ADJ	O	I-Entity
artery	NOUN	O	I-Entity
occlusion	NOUN	O	I-Entity
(	PUNCT	O	O
MCAO	PROPN	O	I-Entity
)	PUNCT	O	O
on	ADP	O	O
brain	NOUN	O	B-Entity
edema	NOUN	O	I-Entity
formation	NOUN	O	O
and	CCONJ	O	O
histochemical	ADJ	O	O
injury	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

Under	ADP	O	O
isoflurane	NOUN	O	I-Entity
anesthesia	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
MCA	PROPN	O	O
of	ADP	O	O
14	NUM	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
was	VERB	O	O
occluded	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
n	CCONJ	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
MAP	PROPN	O	O
was	VERB	O	O
elevated	VERB	O	O
by	ADP	O	O
25	NUM	O	O
-	SYM	O	O
30	NUM	O	O
mm	NOUN	O	O
Hg	PROPN	O	O
beginning	VERB	O	O
2	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
MCAO	PROPN	O	I-Entity
.	PUNCT	O	O

Four	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
MCAO	PROPN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
rats	NOUN	O	O
were	VERB	O	O
killed	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
brains	NOUN	O	O
harvested	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
brains	NOUN	O	O
were	VERB	O	O
sectioned	VERB	O	O
along	ADP	O	O
coronal	ADJ	O	O
planes	NOUN	O	O
spanning	VERB	O	O
the	DET	O	O
distribution	NOUN	O	O
of	ADP	O	O
ischemia	NOUN	O	I-Entity
produced	VERB	O	O
by	ADP	O	O
MCAO	PROPN	O	I-Entity
.	PUNCT	O	O

Specific	ADJ	O	O
gravity	NOUN	O	O
(	PUNCT	O	O
SG	PROPN	O	O
)	PUNCT	O	O
was	VERB	O	O
determined	VERB	O	O
in	ADP	O	O
the	DET	O	O
subcortex	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
two	NUM	O	O
sites	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cortex	NOUN	O	O
(	PUNCT	O	O
core	NOUN	O	O
and	CCONJ	O	O
periphery	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ischemic	ADJ	O	I-Entity
territory	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
extent	NOUN	O	O
of	ADP	O	O
neuronal	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
2,3,5-triphenyltetrazolium	NUM	O	I-Entity
staining	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
ischemic	ADJ	O	I-Entity
core	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
SG	PROPN	O	O
in	ADP	O	O
the	DET	O	O
subcortex	NOUN	O	O
and	CCONJ	O	O
cortex	NOUN	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
periphery	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ischemic	ADJ	O	I-Entity
territory	NOUN	O	O
,	PUNCT	O	O
SG	PROPN	O	O
in	ADP	O	O
the	DET	O	O
cortex	NOUN	O	O
was	VERB	O	O
greater	ADJ	O	O
(	PUNCT	O	O
less	ADJ	O	O
edema	NOUN	O	I-Entity
accumulation	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
1.041	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

The	DET	O	O
area	NOUN	O	O
of	ADP	O	O
histochemical	ADJ	O	O
injury	NOUN	O	O
(	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
percent	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cross	NOUN	O	O
-	PUNCT	O	O
sectional	ADJ	O	O
area	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hemisphere	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
less	ADJ	O	O
in	ADP	O	O
the	DET	O	O
hypertensive	ADJ	O	I-Entity
group	NOUN	O	O
(	PUNCT	O	O
33	NUM	O	O
+	NOUN	O	O
/-	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
phenylephrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertension	NOUN	O	I-Entity
instituted	VERB	O	O
2	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
MCAO	PROPN	O	I-Entity
does	VERB	O	O
not	ADV	O	O
aggravate	VERB	O	O
edema	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
ischemic	ADJ	O	I-Entity
core	NOUN	O	O
,	PUNCT	O	O
that	ADP	O	O
it	PRON	O	O
improves	VERB	O	O
edema	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
periphery	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ischemic	ADJ	O	I-Entity
territory	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	ADP	O	O
it	PRON	O	O
reduces	VERB	O	O
the	DET	O	O
area	NOUN	O	O
of	ADP	O	O
histochemical	ADJ	O	O
neuronal	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (1595783)

Amiodarone	PROPN	O	I-Entity
pulmonary	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Amiodarone	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
antiarrhythmic	ADJ	O	O
agent	NOUN	O	O
whose	ADJ	O	O
utility	NOUN	O	O
is	VERB	O	O
limited	VERB	O	O
by	ADP	O	O
many	ADJ	O	O
side	NOUN	O	O
-	PUNCT	O	O
effects	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
most	ADV	O	O
problematic	ADJ	O	O
being	VERB	O	O
pneumonitis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
pulmonary	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
is	VERB	O	O
thought	VERB	O	O
to	ADP	O	O
result	VERB	O	O
from	ADP	O	O
direct	ADJ	O	O
injury	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
the	DET	O	O
intracellular	ADJ	O	O
accumulation	NOUN	O	O
of	ADP	O	O
phospholipid	NOUN	O	O
and	CCONJ	O	O
T	PROPN	O	O
cell	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
hypersensitivity	NOUN	O	B-Entity
pneumonitis	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
and	CCONJ	O	O
radiographic	ADJ	O	O
features	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
pulmonary	ADJ	O	B-Entity
toxicity	NOUN	O	I-Entity
are	VERB	O	O
characteristic	ADJ	O	O
but	CCONJ	O	O
nonspecific	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
diagnosis	NOUN	O	O
depends	VERB	O	O
on	ADP	O	O
exclusion	NOUN	O	O
of	ADP	O	O
other	ADJ	O	O
entities	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
infection	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
malignancy	NOUN	O	I-Entity
.	PUNCT	O	O

While	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
amiodarone	NOUN	O	I-Entity
leads	VERB	O	O
to	ADP	O	O
clinical	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
majority	NOUN	O	O
of	ADP	O	O
cases	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
not	ADV	O	O
always	ADV	O	O
possible	ADJ	O	O
or	CCONJ	O	O
advisable	ADJ	O	O
.	PUNCT	O	O

Dose	VERB	O	O
reduction	NOUN	O	O
or	CCONJ	O	O
concomitant	ADJ	O	O
steroid	NOUN	O	I-Entity
therapy	NOUN	O	O
may	VERB	O	O
have	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
selected	VERB	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (804391)

Light	NOUN	O	O
chain	NOUN	O	O
proteinuria	NOUN	O	I-Entity
and	CCONJ	O	O
cellular	NOUN	O	O
mediated	VERB	O	O
immunity	NOUN	O	O
in	ADP	O	O
rifampin	NOUN	O	I-Entity
treated	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
tuberculosis	NOUN	O	I-Entity
.	PUNCT	O	O

Light	NOUN	O	O
chain	NOUN	O	O
proteinuria	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
9	NUM	O	O
of	ADP	O	O
17	NUM	O	O
tuberculosis	NOUN	O	I-Entity
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
rifampin	NOUN	O	I-Entity
.	PUNCT	O	O

Response	NOUN	O	O
to	ADP	O	O
Varidase	PROPN	O	O
skin	NOUN	O	O
test	NOUN	O	O
antigen	NOUN	O	O
was	VERB	O	O
negative	ADJ	O	O
for	ADP	O	O
all	DET	O	O
eight	NUM	O	O
tuberculosis	NOUN	O	I-Entity
patients	NOUN	O	O
tested	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
there	ADV	O	O
occurred	VERB	O	O
a	DET	O	O
hyper	ADJ	O	O
-	PUNCT	O	O
responsiveness	NOUN	O	O
of	ADP	O	O
the	DET	O	O
lymphocytes	NOUN	O	O
of	ADP	O	O
these	DET	O	O
eight	NUM	O	O
patients	NOUN	O	O
to	ADP	O	O
phytomitogen	NOUN	O	O
(	PUNCT	O	O
PHA	PROPN	O	O
-	PUNCT	O	O
P	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
of	ADP	O	O
those	DET	O	O
of	ADP	O	O
seven	NUM	O	O
other	ADJ	O	O
tuberculous	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
last	ADJ	O	O
finding	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
time	NOUN	O	O
of	ADP	O	O
testing	NOUN	O	O
and/or	CCONJ	O	O
endogenous	ADJ	O	O
serum	NOUN	O	O
binding	NOUN	O	O
of	ADP	O	O
rifampin	NOUN	O	I-Entity
which	ADJ	O	O
could	VERB	O	O
have	VERB	O	O
inhibited	VERB	O	O
mitogen	NOUN	O	O
activity	NOUN	O	O
for	ADP	O	O
the	DET	O	O
lymphocyte	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (28952)

Initial	ADJ	O	O
potassium	NOUN	O	I-Entity
loss	NOUN	O	O
and	CCONJ	O	O
hypokalaemia	NOUN	O	I-Entity
during	ADP	O	O
chlorthalidone	NOUN	O	I-Entity
administration	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	I-Entity
:	PUNCT	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
dietary	ADJ	O	O
sodium	NOUN	O	I-Entity
restriction	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
investigate	VERB	O	O
the	DET	O	O
initial	ADJ	O	O
potassium	NOUN	O	I-Entity
loss	NOUN	O	O
and	CCONJ	O	O
development	NOUN	O	O
of	ADP	O	O
hypokalaemia	NOUN	O	I-Entity
during	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
an	DET	O	O
oral	ADJ	O	O
diuretic	NOUN	O	O
,	PUNCT	O	O
metabolic	ADJ	O	O
balance	NOUN	O	O
studies	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
ten	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	I-Entity
who	NOUN	O	O
had	VERB	O	O
shown	VERB	O	O
hypokalaemia	NOUN	O	I-Entity
under	ADP	O	O
prior	ADJ	O	O
oral	ADJ	O	O
diuretic	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Chlorthalidone	PROPN	O	I-Entity
(	PUNCT	O	O
50	NUM	O	O
mg	NUM	O	O
daily	ADV	O	O
)	PUNCT	O	O
was	VERB	O	O
given	VERB	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Six	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
a	DET	O	O
normal	ADJ	O	O
-	PUNCT	O	O
sodium	NOUN	O	I-Entity
diet	NOUN	O	O
and	CCONJ	O	O
four	NUM	O	O
a	DET	O	O
low	ADJ	O	O
-	PUNCT	O	O
sodium	NOUN	O	I-Entity
(	PUNCT	O	O
17	NUM	O	O
mmol	NOUN	O	O
/	SYM	O	O
day	NOUN	O	O
)	PUNCT	O	O
diet	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
normal	ADJ	O	O
initial	ADJ	O	O
total	ADJ	O	O
body	NOUN	O	O
potassium	NOUN	O	I-Entity
(	PUNCT	O	O
40	NUM	O	O
K	PROPN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
electrolyte	NOUN	O	O
balances	NOUN	O	O
,	PUNCT	O	O
weight	NOUN	O	O
,	PUNCT	O	O
bromide	NOUN	O	O
space	NOUN	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
renin	NOUN	O	O
activity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
aldosterone	ADJ	O	I-Entity
secretion	NOUN	O	O
rate	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
a	DET	O	O
potassium	NOUN	O	I-Entity
deficit	NOUN	O	O
developed	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
proportionally	ADV	O	O
larger	ADJ	O	O
losses	NOUN	O	O
from	ADP	O	O
the	DET	O	O
extracellular	NOUN	O	O
than	ADP	O	O
from	ADP	O	O
the	DET	O	O
intracellular	ADJ	O	O
compartment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
normal	ADJ	O	O
-	PUNCT	O	O
sodium	NOUN	O	I-Entity
group	NOUN	O	O
the	DET	O	O
highest	ADJ	O	O
mean	ADJ	O	O
potassium	NOUN	O	I-Entity
deficit	NOUN	O	O
was	VERB	O	O
176	NUM	O	O
mmol	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
9	NUM	O	O
,	PUNCT	O	O
after	ADP	O	O
which	ADJ	O	O
some	DET	O	O
potassium	NOUN	O	I-Entity
was	VERB	O	O
regained	VERB	O	O
;	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
low	ADJ	O	O
-	PUNCT	O	O
sodium	NOUN	O	I-Entity
group	NOUN	O	O
the	DET	O	O
highest	ADJ	O	O
deficit	NOUN	O	O
was	VERB	O	O
276	NUM	O	O
mmol	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
13	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
normal	ADJ	O	O
-	PUNCT	O	O
sodium	NOUN	O	I-Entity
group	NOUN	O	O
showed	VERB	O	O
an	DET	O	O
immediate	ADJ	O	O
but	CCONJ	O	O
temporary	ADJ	O	O
rise	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renin	NOUN	O	O
and	CCONJ	O	O
aldosterone	NOUN	O	I-Entity
levels	NOUN	O	O
;	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
low	ADJ	O	O
-	PUNCT	O	O
sodium	NOUN	O	I-Entity
group	NOUN	O	O
renin	NOUN	O	O
and	CCONJ	O	O
aldosterone	NOUN	O	I-Entity
increased	VERB	O	O
more	ADV	O	O
slowly	ADV	O	O
but	CCONJ	O	O
remained	VERB	O	O
elevated	ADJ	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
concluded	VERB	O	O
that	ADP	O	O
dietary	ADJ	O	O
sodium	NOUN	O	I-Entity
restriction	NOUN	O	O
increases	VERB	O	O
diuretic	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
potassium	NOUN	O	I-Entity
loss	NOUN	O	O
,	PUNCT	O	O
presumably	ADV	O	O
by	ADP	O	O
an	DET	O	O
increased	VERB	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renin	NOUN	O	O
-	PUNCT	O	O
angiotensin	NOUN	O	I-Entity
-	PUNCT	O	O
aldosterone	NOUN	O	I-Entity
system	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
sodium	NOUN	O	I-Entity
delivery	NOUN	O	O
to	ADP	O	O
the	DET	O	O
distal	ADJ	O	O
renal	ADJ	O	O
tubules	NOUN	O	O
remains	VERB	O	O
sufficiently	ADV	O	O
high	ADJ	O	O
to	PART	O	O
allow	VERB	O	O
increased	VERB	O	O
potassium	NOUN	O	I-Entity
secretion	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (19893084)

Dynamic	ADJ	O	O
response	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
vessel	NOUN	O	O
in	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
we	PRON	O	O
postulated	VERB	O	O
that	ADP	O	O
during	ADP	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
gentamicin	VERB	O	I-Entity
the	DET	O	O
transient	ADJ	O	O
or	CCONJ	O	O
dynamic	ADJ	O	O
response	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
vessels	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
affected	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
that	DET	O	O
antioxidants	NOUN	O	O
can	VERB	O	O
prevent	VERB	O	O
the	DET	O	O
changes	NOUN	O	O
in	ADP	O	O
dynamic	ADJ	O	O
responses	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
vessels	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
results	NOUN	O	O
confirm	VERB	O	O
the	DET	O	O
alteration	NOUN	O	O
in	ADP	O	O
dynamic	ADJ	O	O
response	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
vessels	NOUN	O	O
during	ADP	O	O
the	DET	O	O
change	NOUN	O	O
of	ADP	O	O
pressure	NOUN	O	O
in	ADP	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
C	PROPN	O	I-Entity
administration	NOUN	O	O
to	ADP	O	O
gentamicin	VERB	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
are	VERB	O	O
also	ADV	O	O
confirmed	VERB	O	O
through	ADP	O	O
:	PUNCT	O	O
lower	ADJ	O	O
level	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
urea	NOUN	O	I-Entity
and	CCONJ	O	O
creatinine	NOUN	O	I-Entity
and	CCONJ	O	O
higher	ADJ	O	O
level	NOUN	O	O
of	ADP	O	O
potassium	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
pressure	NOUN	O	O
dynamic	ADJ	O	O
responses	NOUN	O	O
of	ADP	O	O
isolated	ADJ	O	O
blood	NOUN	O	O
vessels	NOUN	O	O
show	VERB	O	O
a	DET	O	O
faster	ADV	O	O
pressure	NOUN	O	O
change	NOUN	O	O
in	ADP	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
(	PUNCT	O	O
8.07	NUM	O	O
+	SYM	O	O
/-	PUNCT	O	O

Vitamin	NOUN	O	B-Entity
C	PROPN	O	I-Entity
administration	NOUN	O	O
induced	VERB	O	O
slowdown	NOUN	O	O
of	ADP	O	O
pressure	NOUN	O	O
change	NOUN	O	O
back	ADV	O	O
to	ADP	O	O
the	DET	O	O
control	NOUN	O	O
values	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pressure	NOUN	O	O
dynamic	ADJ	O	O
properties	NOUN	O	O
,	PUNCT	O	O
quantitatively	ADV	O	O
defined	VERB	O	O
by	ADP	O	O
comparative	ADJ	O	O
pressure	NOUN	O	O
dynamic	ADJ	O	O
and	CCONJ	O	O
total	ADJ	O	O
pressure	NOUN	O	O
dynamic	ADJ	O	O
,	PUNCT	O	O
confirm	VERB	O	O
the	DET	O	O
alteration	NOUN	O	O
in	ADP	O	O
dynamic	ADJ	O	O
response	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
vessels	NOUN	O	O
during	ADP	O	O
the	DET	O	O
change	NOUN	O	O
of	ADP	O	O
pressure	NOUN	O	O
in	ADP	O	O
gentamicin	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
animals	NOUN	O	O
and	CCONJ	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
vitamin	NOUN	O	B-Entity
C	PROPN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18513945)

The	DET	O	O
hemodynamics	NOUN	O	O
of	ADP	O	O
oxytocin	NOUN	O	I-Entity
and	CCONJ	O	O
other	ADJ	O	O
vasoactive	ADJ	O	O
agents	NOUN	O	O
during	ADP	O	O
neuraxial	ADJ	O	O
anesthesia	NOUN	O	O
for	ADP	O	O
cesarean	ADJ	O	O
delivery	NOUN	O	O
:	PUNCT	O	O
findings	NOUN	O	O
in	ADP	O	O
six	NUM	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Oxytocin	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
commonly	ADV	O	O
used	VERB	O	O
uterotonic	NOUN	O	O
that	ADJ	O	O
can	VERB	O	O
cause	VERB	O	O
significant	ADJ	O	O
and	CCONJ	O	O
even	ADV	O	O
fatal	ADJ	O	O
hypotension	NOUN	O	I-Entity
,	PUNCT	O	O
particularly	ADV	O	O
when	ADV	O	O
given	VERB	O	O
as	ADP	O	O
a	DET	O	O
bolus	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
resulting	VERB	O	O
hypotension	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
produced	VERB	O	O
by	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
systemic	ADJ	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
or	CCONJ	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
through	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
venous	ADJ	O	O
return	NOUN	O	O
.	PUNCT	O	O

Parturients	NOUN	O	O
with	ADP	O	O
normal	ADJ	O	O
volume	NOUN	O	O
status	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	O
valves	NOUN	O	O
and	CCONJ	O	O
pulmonary	ADJ	O	O
vasculature	NOUN	O	O
most	ADV	O	O
often	ADV	O	O
respond	VERB	O	O
to	ADP	O	O
this	DET	O	O
hypotension	NOUN	O	I-Entity
with	ADP	O	O
a	DET	O	O
compensatory	NOUN	O	O
increase	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
stroke	NOUN	O	I-Entity
volume	NOUN	O	O
.	PUNCT	O	O

Oxytocin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypotension	NOUN	O	I-Entity
at	ADP	O	O
cesarean	ADJ	O	O
delivery	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
incorrectly	ADV	O	O
attributed	VERB	O	O
to	ADP	O	O
blood	NOUN	O	B-Entity
loss	NOUN	O	I-Entity
.	PUNCT	O	O

Hypotension	NOUN	O	I-Entity
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
oxytocin	NOUN	O	I-Entity
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
systemic	ADJ	O	O
vascular	ADJ	O	O
resistance	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
compensatory	NOUN	O	O
increase	NOUN	O	O
in	ADP	O	O
stroke	NOUN	O	I-Entity
volume	NOUN	O	O
,	PUNCT	O	O
heart	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
.	PUNCT	O	O

Pulse	ADJ	O	O
power	NOUN	O	O
analysis	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
helpful	ADJ	O	O
in	ADP	O	O
determining	VERB	O	O
the	DET	O	O
etiology	NOUN	O	O
of	ADP	O	O
and	CCONJ	O	O
treating	VERB	O	O
hypotension	NOUN	O	I-Entity
during	ADP	O	O
cesarean	ADJ	O	O
delivery	NOUN	O	O
under	ADP	O	O
neuraxial	ADJ	O	O
anesthesia	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (18483878)

Exaggerated	ADJ	O	O
expression	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
mediators	NOUN	O	O
in	ADP	O	O
vasoactive	ADJ	O	O
intestinal	ADJ	O	O
polypeptide	NOUN	O	O
knockout	NOUN	O	O
(	PUNCT	O	O
VIP-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
with	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
CYP)-induced	VERB	O	I-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

VIP(-/-	PUNCT	O	O
)	PUNCT	O	O
mice	NOUN	O	O
exhibit	NOUN	O	O
altered	VERB	O	O
bladder	NOUN	O	O
function	NOUN	O	O
and	CCONJ	O	O
neurochemical	ADJ	O	O
properties	NOUN	O	O
in	ADP	O	O
micturition	NOUN	O	O
pathways	NOUN	O	O
after	ADP	O	O
cyclophosphamide	NOUN	O	I-Entity
(	PUNCT	O	O
CYP)-induced	VERB	O	I-Entity
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

Given	VERB	O	O
VIP	NOUN	O	O
's	PART	O	O
role	NOUN	O	O
as	ADP	O	O
an	DET	O	O
anti	ADJ	O	O
-	PUNCT	O	O
inflammatory	ADJ	O	O
mediator	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
VIP(-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
would	VERB	O	O
exhibit	VERB	O	O
enhanced	ADJ	O	O
inflammatory	ADJ	O	O
mediator	NOUN	O	O
expression	NOUN	O	O
after	ADP	O	O
cystitis	NOUN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
mouse	NOUN	O	O
inflammatory	ADJ	O	O
cytokine	NOUN	O	O
and	CCONJ	O	O
receptor	NOUN	O	O
RT2	PROPN	O	O
profiler	NOUN	O	O
array	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
determine	VERB	O	O
regulated	VERB	O	O
transcripts	NOUN	O	O
in	ADP	O	O
the	DET	O	O
urinary	ADJ	O	O
bladder	NOUN	O	O
of	ADP	O	O
wild	ADJ	O	O
type	NOUN	O	O
(	PUNCT	O	O
WT	PROPN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
VIP(-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
CYP	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cystitis	NOUN	O	I-Entity
(	PUNCT	O	O
150	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	NOUN	O	O
;	PUNCT	O	O
i.p	PUNCT	O	O
.	PUNCT	O	O
;	PUNCT	O	O
48	NUM	O	O
h	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Four	NUM	O	O
binary	ADJ	O	O
comparisons	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
:	PUNCT	O	O
WT	VERB	O	O
control	NOUN	O	O
versus	ADP	O	O
CYP	PROPN	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
48	NUM	O	O
h	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
VIP(-/-	PROPN	O	O
)	PUNCT	O	O

control	NOUN	O	O
versus	ADP	O	O
CYP	PROPN	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
48	NUM	O	O
h	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
WT	PROPN	O	O
control	NOUN	O	O
versus	ADP	O	O
VIP(-/-	PROPN	O	O
)	PUNCT	O	O
control	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
WT	PROPN	O	O
with	ADP	O	O
CYP	PROPN	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
48	NUM	O	O
h	NOUN	O	O
)	PUNCT	O	O
versus	ADP	O	O
VIP(-/-	PROPN	O	O
)	PUNCT	O	O
with	ADP	O	O
CYP	PROPN	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
48	NUM	O	O
h	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CYP	PROPN	O	I-Entity
treatment	NOUN	O	O
significantly	ADV	O	O
(	PUNCT	O	O
p	INTJ	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
increased	VERB	O	O
expression	NOUN	O	O
of	ADP	O	O
CXCL1	PROPN	O	O
and	CCONJ	O	O
IL-1beta	PROPN	O	O
in	ADP	O	O
the	DET	O	O
urinary	ADJ	O	O
bladder	NOUN	O	O
of	ADP	O	O
WT	PROPN	O	O
and	CCONJ	O	O
VIP(-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
expression	NOUN	O	O
in	ADP	O	O
VIP(-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
with	ADP	O	O
CYP	PROPN	O	I-Entity
treatment	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
p	INTJ	O	O
<	X	O	O
or	CCONJ	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
greater	ADJ	O	O
(	PUNCT	O	O
4.2-	PUNCT	O	O
to	ADP	O	O
13-fold	NUM	O	O
increase	NOUN	O	O
)	PUNCT	O	O
than	ADP	O	O
that	DET	O	O
observed	VERB	O	O
in	ADP	O	O
WT	PROPN	O	O
urinary	ADJ	O	O
bladder	NOUN	O	O
(	PUNCT	O	O
3.6-	PUNCT	O	O
to	ADP	O	O
5-fold	NUM	O	O
increase	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
in	ADP	O	O
VIP(-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
with	ADP	O	O
bladder	NOUN	O	B-Entity
inflammation	NOUN	O	I-Entity
,	PUNCT	O	O
inflammatory	ADJ	O	O
mediators	NOUN	O	O
are	VERB	O	O
increased	VERB	O	O
above	ADP	O	O
that	DET	O	O
observed	VERB	O	O
in	ADP	O	O
WT	PROPN	O	O
with	ADP	O	O
CYP	PROPN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
shift	NOUN	O	O
in	ADP	O	O
balance	NOUN	O	O
may	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
increased	VERB	O	O
bladder	NOUN	O	B-Entity
dysfunction	NOUN	O	I-Entity
in	ADP	O	O
VIP(-/-	PROPN	O	O
)	PUNCT	O	O
mice	NOUN	O	O
with	ADP	O	O
bladder	NOUN	O	B-Entity
inflammation	NOUN	O	I-Entity
and	CCONJ	O	O
altered	VERB	O	O
neurochemical	ADJ	O	O
expression	NOUN	O	O
in	ADP	O	O
micturition	NOUN	O	O
pathways	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (17923537)

Intraocular	ADJ	O	O
pressure	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
uveitis	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
fluocinolone	NOUN	O	B-Entity
acetonide	NOUN	O	I-Entity
implants	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
report	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
management	NOUN	O	O
of	ADP	O	O
elevated	ADJ	O	B-Entity
intraocular	ADJ	O	I-Entity
pressure	NOUN	O	I-Entity
(	PUNCT	O	O
IOP	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
uveitis	NOUN	O	I-Entity
treated	VERB	O	O
with	ADP	O	O
the	DET	O	O
fluocinolone	NOUN	O	B-Entity
acetonide	NOUN	O	I-Entity
(	PUNCT	O	O
FA	PROPN	O	I-Entity
)	PUNCT	O	O

DESIGN	NOUN	O	O
:	PUNCT	O	O
Pooled	VERB	O	O
data	NOUN	O	O
from	ADP	O	O
3	NUM	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
double	ADV	O	O
-	PUNCT	O	O
masked	VERB	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
,	PUNCT	O	O
phase	NOUN	O	O
2b/3	NUM	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
evaluating	VERB	O	O
the	DET	O	O
safety	NOUN	O	O
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
0.59-mg	NOUN	O	O
or	CCONJ	O	O
2.1-mg	NUM	O	O
FA	PROPN	O	I-Entity
intravitreal	ADJ	O	O
implant	NOUN	O	O
or	CCONJ	O	O
standard	NOUN	O	O
therapy	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
hypotony	NOUN	O	I-Entity
(	PUNCT	O	O
IOP	PROPN	O	O
<	X	O	O
/=	SYM	O	O
5	NUM	O	O
mm	PROPN	O	O
Hg	PROPN	O	O
)	PUNCT	O	O
following	VERB	O	O
IOP	PROPN	O	O
-	PUNCT	O	O
lowering	VERB	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
42.5%	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
that	DET	O	O
of	ADP	O	O
implanted	ADJ	O	O
eyes	NOUN	O	O
not	ADV	O	O
subjected	VERB	O	O
to	ADP	O	O
surgery	NOUN	O	O
(	PUNCT	O	O
35.4%	NUM	O	O
)	PUNCT	O	O


-DOCSTART- (15096016)

A	DET	O	O
resurgence	NOUN	O	O
of	ADP	O	O
interest	NOUN	O	O
in	ADP	O	O
the	DET	O	O
surgical	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
Parkinson	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
(	PUNCT	O	O
PD	PROPN	O	I-Entity
)	PUNCT	O	O
came	VERB	O	O
with	ADP	O	O
the	DET	O	O
rediscovery	NOUN	O	O
of	ADP	O	O
posteroventral	ADJ	O	O
pallidotomy	NOUN	O	O
by	ADP	O	O
Laitinen	PROPN	O	O
in	ADP	O	O
1985	NUM	O	O
.	PUNCT	O	O

Laitinen	PROPN	O	O
's	PART	O	O
procedure	NOUN	O	O
improved	VERB	O	O
most	ADV	O	O
symptoms	NOUN	O	O
in	ADP	O	O
drug	NOUN	O	O
-	PUNCT	O	O
resistant	ADJ	O	O
PD	PROPN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
engendered	VERB	O	O
wide	ADJ	O	O
interest	NOUN	O	O
in	ADP	O	O
the	DET	O	O
neurosurgical	ADJ	O	O
community	NOUN	O	O
.	PUNCT	O	O

According	VERB	O	O
to	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
pallidotomy	NOUN	O	O
improves	VERB	O	O
the	DET	O	O
"	PUNCT	O	O
on	ADP	O	O
"	PUNCT	O	O
symptoms	NOUN	O	O
of	ADP	O	O
PD	PROPN	O	I-Entity
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
dyskinesias	NOUN	O	I-Entity
,	PUNCT	O	O
as	ADV	O	O
well	ADV	O	O
as	ADP	O	O
the	DET	O	O
"	PUNCT	O	O
off	ADP	O	O
"	PUNCT	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
rigidity	NOUN	O	I-Entity
,	PUNCT	O	O
bradykinesia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
-	PUNCT	O	O
off	NOUN	O	O
fluctuations	NOUN	O	O
.	PUNCT	O	O

Pallidal	ADJ	O	O
stimulation	NOUN	O	O
improves	VERB	O	O
bradykinesia	NOUN	O	I-Entity
and	CCONJ	O	O
rigidity	NOUN	O	I-Entity
to	ADP	O	O
a	DET	O	O
minor	ADJ	O	O
extent	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
its	ADJ	O	O
strength	NOUN	O	O
seems	VERB	O	O
to	PART	O	O
be	VERB	O	O
in	ADP	O	O
improving	VERB	O	O
levodopa	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
dyskinesias	NOUN	O	I-Entity
.	PUNCT	O	O

Stimulation	NOUN	O	O
often	ADV	O	O
produces	VERB	O	O
an	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hyper-	NOUN	O	B-Entity
or	CCONJ	O	I-Entity
dyskinetic	ADJ	O	I-Entity
upper	ADJ	O	O
limbs	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
increases	VERB	O	O
the	DET	O	O
"	PUNCT	O	O
freezing	VERB	O	O
"	PUNCT	O	O
phenomenon	NOUN	O	O
in	ADP	O	O
the	DET	O	O
lower	ADJ	O	O
limbs	NOUN	O	O
at	ADP	O	O
the	DET	O	O
same	ADJ	O	O
time	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (12734532)

Case	NOUN	O	O
report	NOUN	O	O
:	PUNCT	O	O
Dexatrim	PROPN	O	I-Entity
(	PUNCT	O	O
Phenylpropanolamine	PROPN	O	I-Entity
)	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-Entity
infarction	NOUN	O	I-Entity
.	PUNCT	O	O

Phenylpropanolamine	PROPN	O	I-Entity
(	PUNCT	O	O
PPA	PROPN	O	I-Entity
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
sympathetic	ADJ	O	O
amine	NOUN	O	I-Entity
used	VERB	O	O
in	ADP	O	O
over	ADP	O	O
-	PUNCT	O	O
the	DET	O	O
-	PUNCT	O	O
counter	NOUN	O	O
cold	ADJ	O	O
remedies	NOUN	O	O
and	CCONJ	O	O
weight	NOUN	O	O
-	PUNCT	O	O
control	NOUN	O	O
preparations	NOUN	O	O
worldwide	ADV	O	O
.	PUNCT	O	O

Its	ADJ	O	O
use	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
hypertensive	ADJ	O	I-Entity
episodes	NOUN	O	O
and	CCONJ	O	O
hemorrhagic	ADJ	O	B-Entity
strokes	NOUN	O	I-Entity
in	ADP	O	O
younger	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

Several	ADJ	O	O
reports	NOUN	O	O
have	VERB	O	O
linked	VERB	O	O
the	DET	O	O
abuse	NOUN	O	O
of	ADP	O	O
PPA	PROPN	O	I-Entity
with	ADP	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
,	PUNCT	O	O
especially	ADV	O	O
when	ADV	O	O
overdose	NOUN	O	I-Entity
is	VERB	O	O
involved	VERB	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
here	ADV	O	O
the	DET	O	O
first	ADJ	O	O
case	NOUN	O	O
of	ADP	O	O
Dexatrim	PROPN	O	I-Entity
(	PUNCT	O	O
PPA)-induced	VERB	O	I-Entity
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
young	ADJ	O	O
woman	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
using	VERB	O	O
it	PRON	O	O
at	ADP	O	O
recommended	VERB	O	O
doses	NOUN	O	O
for	ADP	O	O
weight	NOUN	O	O
control	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
review	VERB	O	O
the	DET	O	O
7	NUM	O	O
other	ADJ	O	O
cases	NOUN	O	O
of	ADP	O	O
PPA	PROPN	O	I-Entity
related	VERB	O	O
myocardial	ADJ	O	B-Entity
injury	NOUN	O	I-Entity
that	ADJ	O	O
have	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
so	ADV	O	O
far	ADV	O	O
.	PUNCT	O	O

Physicians	NOUN	O	O
and	CCONJ	O	O
patients	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
alert	ADJ	O	O
to	ADP	O	O
the	DET	O	O
potential	ADJ	O	O
cardiac	ADJ	O	O
risk	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
PPA	PROPN	O	I-Entity
,	PUNCT	O	O
even	ADV	O	O
at	ADP	O	O
doses	NOUN	O	O
generally	ADV	O	O
considered	VERB	O	O
to	PART	O	O
be	VERB	O	O
safe	ADJ	O	O
.	PUNCT	O	O


-DOCSTART- (12013711)

Risperidone	PROPN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
,	PUNCT	O	O
benign	ADJ	O	O
transient	ADJ	O	O
visual	ADJ	O	B-Entity
disturbances	NOUN	O	I-Entity
in	ADP	O	O
schizophrenic	ADJ	O	I-Entity
patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
past	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
LSD	PROPN	O	I-Entity
abuse	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
schizophrenic	ADJ	O	I-Entity
patients	NOUN	O	O
,	PUNCT	O	O
who	NOUN	O	O
had	VERB	O	O
a	DET	O	O
prior	ADJ	O	O
history	NOUN	O	O
of	ADP	O	O
LSD	PROPN	O	I-Entity
abuse	NOUN	O	O
and	CCONJ	O	O
who	NOUN	O	O
had	VERB	O	O
previously	ADV	O	O
developed	VERB	O	O
EPS	PROPN	O	I-Entity
with	ADP	O	O
classic	ADJ	O	O
antipsychotics	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
successfully	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
.	PUNCT	O	O

They	PRON	O	O
both	DET	O	O
reported	VERB	O	O
short	ADJ	O	O
episodes	NOUN	O	O
of	ADP	O	O
transient	ADJ	O	O
visual	ADJ	O	B-Entity
disturbances	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
appeared	VERB	O	O
immediately	ADV	O	O
after	ADP	O	O
starting	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
risperidone	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
imagery	NOUN	O	O
resembled	VERB	O	O
visual	ADJ	O	B-Entity
disturbances	NOUN	O	I-Entity
previously	ADV	O	O
experienced	VERB	O	O
as	ADP	O	O
"	PUNCT	O	O
flashbacks	NOUN	O	O
"	PUNCT	O	O
related	VERB	O	O
to	ADP	O	O
prior	VERB	O	O
LSD	PROPN	O	I-Entity
consumption	NOUN	O	O
.	PUNCT	O	O

Risperidone	PROPN	O	I-Entity
administration	NOUN	O	O
was	VERB	O	O
continued	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
visual	ADJ	O	B-Entity
disturbances	NOUN	O	I-Entity
gradually	ADV	O	O
wore	VERB	O	O
off	PART	O	O
.	PUNCT	O	O

During	ADP	O	O
a	DET	O	O
six	NUM	O	O
-	PUNCT	O	O
month	NOUN	O	O
follow	NOUN	O	O
-	PUNCT	O	O
up	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
recurrence	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	B-Entity
disturbances	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
phenomenon	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
interpreted	VERB	O	O
as	ADP	O	O
a	DET	O	O
benign	ADJ	O	O
,	PUNCT	O	O
short	ADJ	O	O
-	PUNCT	O	O
term	NOUN	O	O
and	CCONJ	O	O
self	NOUN	O	O
-	PUNCT	O	O
limiting	VERB	O	O
side	NOUN	O	O
effect	NOUN	O	O
which	ADJ	O	O
does	VERB	O	O
not	ADV	O	O
contraindicate	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
risperidone	NOUN	O	I-Entity
or	CCONJ	O	O
interfere	VERB	O	O
with	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11861791)

Activation	NOUN	O	O
of	ADP	O	O
poly(ADP	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
ribose	NOUN	O	I-Entity
)	PUNCT	O	I-Entity
polymerase	NOUN	O	O
contributes	VERB	O	O
to	ADP	O	O
development	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
heart	NOUN	O	B-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Activation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
nuclear	ADJ	O	O
enzyme	NOUN	O	O
poly(ADP	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
ribose	NOUN	O	I-Entity
)	PUNCT	O	I-Entity
polymerase	NOUN	O	O
(	PUNCT	O	O
PARP	PROPN	O	O
)	PUNCT	O	O
by	ADP	O	O
oxidant	NOUN	O	O
-	PUNCT	O	O
mediated	VERB	O	O
DNA	NOUN	O	O
damage	NOUN	O	O
is	VERB	O	O
an	DET	O	O
important	ADJ	O	O
pathway	NOUN	O	O
of	ADP	O	O
cell	NOUN	O	O
dysfunction	NOUN	O	O
and	CCONJ	O	O
tissue	NOUN	O	O
injury	NOUN	O	O
in	ADP	O	O
conditions	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
.	PUNCT	O	O

Increased	VERB	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
factor	NOUN	O	O
implicated	VERB	O	O
in	ADP	O	O
the	DET	O	O
cardiotoxicity	NOUN	O	I-Entity
of	ADP	O	O
doxorubicin	NOUN	O	I-Entity
(	PUNCT	O	O
DOX	PROPN	O	I-Entity
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
widely	ADV	O	O
used	VERB	O	O
antitumor	NOUN	O	O
anthracycline	NOUN	O	I-Entity
antibiotic	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
we	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
the	DET	O	O
activation	NOUN	O	O
of	ADP	O	O
PARP	PROPN	O	O
may	VERB	O	O
contribute	VERB	O	O
to	ADP	O	O
the	DET	O	O
DOX	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
cardiotoxicity	NOUN	O	I-Entity
.	PUNCT	O	O

Using	VERB	O	O
a	DET	O	O
dual	ADJ	O	O
approach	NOUN	O	O
of	ADP	O	O
PARP-1	PROPN	O	O
suppression	NOUN	O	O
,	PUNCT	O	O
by	ADP	O	O
genetic	ADJ	O	O
deletion	NOUN	O	O
or	CCONJ	O	O
pharmacological	ADJ	O	O
inhibition	NOUN	O	O
with	ADP	O	O
the	DET	O	O
phenanthridinone	NOUN	O	O
PARP	PROPN	O	O
inhibitor	NOUN	O	O
PJ34	PROPN	O	I-Entity
,	PUNCT	O	O
we	PRON	O	O
now	ADV	O	O
demonstrate	VERB	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
PARP	PROPN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
DOX	PROPN	O	I-Entity
.	PUNCT	O	O

PARP-1+/+	NOUN	O	O
and	CCONJ	O	O
PARP-1-/-	PROPN	O	O
mice	NOUN	O	O
received	VERB	O	O
a	DET	O	O
single	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
DOX	PROPN	O	I-Entity
(	PUNCT	O	O
25	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	INTJ	O	O
i.p	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Five	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
DOX	PROPN	O	I-Entity
administration	NOUN	O	O
,	PUNCT	O	O
left	VERB	O	O
ventricular	ADJ	O	O
performance	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
depressed	VERB	O	O
in	ADP	O	O
PARP-1+/+	PROPN	O	O
mice	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
to	ADP	O	O
a	DET	O	O
smaller	ADJ	O	O
extent	NOUN	O	O
in	ADP	O	O
PARP-1-/-	PROPN	O	O
ones	NOUN	O	O
.	PUNCT	O	O

Similar	ADJ	O	O
experiments	NOUN	O	O
were	VERB	O	O
conducted	VERB	O	O
in	ADP	O	O
BALB	PROPN	O	O
/	SYM	O	O
c	NOUN	O	O
mice	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
PJ34	PROPN	O	I-Entity
or	CCONJ	O	O
vehicle	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
PJ34	PROPN	O	I-Entity
significantly	ADV	O	O
improved	VERB	O	O
cardiac	ADJ	O	B-Entity
dysfunction	NOUN	O	I-Entity
and	CCONJ	O	O
increased	VERB	O	O
the	DET	O	O
survival	NOUN	O	O
of	ADP	O	O
the	DET	O	O
animals	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
PJ34	PROPN	O	I-Entity
significantly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
DOX	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
serum	NOUN	O	O
lactate	NOUN	O	I-Entity
dehydrogenase	NOUN	O	O
and	CCONJ	O	O
creatine	NOUN	O	I-Entity
kinase	NOUN	O	O
activities	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
metalloproteinase	ADJ	O	O
activation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
PARP	PROPN	O	O
activation	NOUN	O	O
contributes	VERB	O	O
to	ADP	O	O
the	DET	O	O
cardiotoxicity	NOUN	O	I-Entity
of	ADP	O	O
DOX	PROPN	O	I-Entity
.	PUNCT	O	O

PARP	PROPN	O	O
inhibitors	NOUN	O	O
may	VERB	O	O
exert	VERB	O	O
protective	ADJ	O	O
effects	NOUN	O	O
against	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
cardiac	ADJ	O	B-Entity
complications	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
DOX	PROPN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (11302406)

Fluconazole	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
torsade	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	NOUN	O	I-Entity
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
:	PUNCT	O	O
To	PART	O	O
present	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
fluconazole	NOUN	O	I-Entity
-	PUNCT	O	O
associated	VERB	O	O
torsade	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	X	O	I-Entity
(	PUNCT	O	O
TDP	PROPN	O	I-Entity
)	PUNCT	O	O
and	CCONJ	O	O
discuss	VERB	O	O
fluconazole	NOUN	O	I-Entity
's	PART	O	O
role	NOUN	O	O
in	ADP	O	O
causing	VERB	O	O
TDP	PROPN	O	I-Entity
.	PUNCT	O	O

A	DET	O	O
68-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
white	ADJ	O	O
woman	NOUN	O	O
with	ADP	O	O
Candida	PROPN	O	O
glabrata	NOUN	O	O
isolated	VERB	O	O
from	ADP	O	O
a	DET	O	O
presacral	ADJ	O	O
abscess	NOUN	O	O
developed	VERB	O	O
TDP	PROPN	O	I-Entity
eight	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
commencing	VERB	O	O
oral	ADJ	O	O
fluconazole	NOUN	O	I-Entity

The	DET	O	O
patient	NOUN	O	O
had	VERB	O	O
no	DET	O	O
other	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
TDP	PROPN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
coronary	ADJ	O	B-Entity
artery	NOUN	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
cardiomyopathy	NOUN	O	I-Entity
,	PUNCT	O	O
congestive	ADJ	O	B-Entity
heart	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
electrolyte	NOUN	O	O
abnormalities	NOUN	O	O
There	ADV	O	O
was	VERB	O	O
a	DET	O	O
temporal	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
fluconazole	NOUN	O	I-Entity
and	CCONJ	O	O
TDP	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
TDP	PROPN	O	I-Entity
resolved	VERB	O	O
when	ADV	O	O
fluconazole	NOUN	O	I-Entity
was	VERB	O	O
discontinued	VERB	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
continued	VERB	O	O
to	PART	O	O
have	VERB	O	O
premature	ADJ	O	B-Entity
ventricular	ADJ	O	I-Entity
contractions	NOUN	O	I-Entity
and	CCONJ	O	O
nonsustained	VERB	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
(	PUNCT	O	O
NSVT	PROPN	O	I-Entity
)	PUNCT	O	O
until	ADP	O	O
six	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
drug	NOUN	O	O
cessation	NOUN	O	O
DISCUSSION	NOUN	O	O
:	PUNCT	O	O

Use	PROPN	O	O
of	ADP	O	O
the	DET	O	O
Naranjo	PROPN	O	O
probability	NOUN	O	O
scale	NOUN	O	O
indicates	VERB	O	O
a	DET	O	O
probable	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
fluconazole	NOUN	O	I-Entity
and	CCONJ	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
TDP	PROPN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
possible	ADJ	O	O
mechanism	NOUN	O	O
is	VERB	O	O
depression	NOUN	O	I-Entity
of	ADP	O	O
rapidly	ADV	O	O
activating	VERB	O	O
delayed	VERB	O	O
rectifier	NOUN	O	O
potassium	NOUN	O	I-Entity
currents	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
our	ADJ	O	O
patient	NOUN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
other	ADJ	O	O
etiology	NOUN	O	O
identified	VERB	O	O
that	ADJ	O	O
could	VERB	O	O
explain	VERB	O	O
QT	PROPN	O	B-Entity
prolongation	NOUN	O	I-Entity
or	CCONJ	O	O
TDP	PROPN	O	I-Entity

The	DET	O	O
complete	ADJ	O	O
disappearance	NOUN	O	O
of	ADP	O	O
NSVT	PROPN	O	I-Entity
and	CCONJ	O	O
premature	ADJ	O	B-Entity
ventricular	ADJ	O	I-Entity
contractions	NOUN	O	I-Entity
followed	VERB	O	O
by	ADP	O	O
normalization	NOUN	O	O
of	ADP	O	O
QT	PROPN	O	O
interval	NOUN	O	O
after	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
was	VERB	O	O
stopped	VERB	O	O
strongly	ADV	O	O
suggests	VERB	O	O
fluconazole	NOUN	O	I-Entity
as	ADP	O	O
the	DET	O	O
etiology	NOUN	O	O
.	PUNCT	O	O

Clinicians	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
aware	ADJ	O	O
that	ADP	O	O
fluconazole	NOUN	O	I-Entity
,	PUNCT	O	O
even	ADV	O	O
at	ADP	O	O
low	ADJ	O	O
doses	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
cause	VERB	O	O
prolongation	NOUN	O	B-Entity
of	ADP	O	I-Entity
the	DET	O	I-Entity
QT	PROPN	O	I-Entity
interval	NOUN	O	I-Entity
,	PUNCT	O	O
leading	VERB	O	O
to	ADP	O	O
TDP	PROPN	O	I-Entity
.	PUNCT	O	O

Serial	ADJ	O	O
electrocardiographic	ADJ	O	O
monitoring	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
when	ADV	O	O
fluconazole	NOUN	O	I-Entity
is	VERB	O	O
administered	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
who	NOUN	O	O
are	VERB	O	O
at	ADP	O	O
risk	NOUN	O	O
for	ADP	O	O
ventricular	ADJ	O	B-Entity
arrhythmias	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11058428)

High	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
methylprednisolone	NOUN	O	I-Entity
may	VERB	O	O
do	VERB	O	O
more	ADJ	O	O
harm	NOUN	O	O
for	ADP	O	O
spinal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

Because	ADP	O	O
of	ADP	O	O
the	DET	O	O
National	PROPN	O	O
Acute	PROPN	O	O
Spinal	PROPN	O	B-Entity
Cord	PROPN	O	I-Entity
Injury	PROPN	O	I-Entity
Studies	PROPN	O	O
(	PUNCT	O	O
NASCIS	PROPN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
methylprednisolone	NOUN	O	I-Entity
became	VERB	O	O
the	DET	O	O
standard	NOUN	O	O
of	ADP	O	O
care	NOUN	O	O
for	ADP	O	O
the	DET	O	O
acute	ADJ	O	O
spinal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
NASCIS	PROPN	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
no	DET	O	O
mention	NOUN	O	O
regarding	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
corticosteroid	ADJ	O	I-Entity
myopathy	NOUN	O	I-Entity
that	DET	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
methylprednisolone	NOUN	O	I-Entity
may	VERB	O	O
cause	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
dosage	NOUN	O	O
of	ADP	O	O
methylprednisolone	NOUN	O	I-Entity
recommended	VERB	O	O
by	ADP	O	O
the	DET	O	O
NASCIS	PROPN	O	O
3	NUM	O	O
is	VERB	O	O
the	DET	O	O
highest	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
steroids	NOUN	O	I-Entity
ever	ADV	O	O
being	VERB	O	O
used	VERB	O	O
during	ADP	O	O
a	DET	O	O
2-day	NUM	O	O
period	NOUN	O	O
for	ADP	O	O
any	DET	O	O
clinical	ADJ	O	O
condition	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
hypothesize	VERB	O	O
that	ADP	O	O
it	PRON	O	O
may	VERB	O	O
cause	VERB	O	O
some	DET	O	O
damage	NOUN	O	B-Entity
to	ADP	O	I-Entity
the	DET	O	I-Entity
muscle	NOUN	O	I-Entity
of	ADP	O	O
spinal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

Further	ADV	O	O
,	PUNCT	O	O
steroid	NOUN	O	I-Entity
myopathy	ADJ	O	I-Entity
recovers	NOUN	O	O
naturally	ADV	O	O
and	CCONJ	O	O
the	DET	O	O
neurological	ADJ	O	O
improvement	NOUN	O	O
shown	VERB	O	O
in	ADP	O	O
the	DET	O	O
NASCIS	PROPN	O	O
may	VERB	O	O
be	VERB	O	O
just	ADV	O	O
a	DET	O	O
recording	NOUN	O	O
of	ADP	O	O
this	DET	O	O
natural	ADJ	O	O
motor	NOUN	O	O
recovery	NOUN	O	O
from	ADP	O	O
the	DET	O	O
steroid	NOUN	O	I-Entity
myopathy	NOUN	O	I-Entity
,	PUNCT	O	O
instead	ADV	O	O
of	ADP	O	O
any	DET	O	O
protection	NOUN	O	O
that	ADP	O	O
methylprednisolone	NOUN	O	I-Entity
offers	VERB	O	O
to	ADP	O	O
the	DET	O	O
spinal	ADJ	O	B-Entity
cord	NOUN	O	I-Entity
injury	NOUN	O	I-Entity
.	PUNCT	O	O

To	ADP	O	O
our	ADJ	O	O
knowledge	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
is	VERB	O	O
the	DET	O	O
first	ADJ	O	O
discussion	NOUN	O	O
considering	VERB	O	O
the	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
the	DET	O	O
methylprednisolone	NOUN	O	I-Entity
recommended	VERB	O	O
by	ADP	O	O
NASCIS	PROPN	O	O
may	VERB	O	O
cause	VERB	O	O
acute	ADJ	O	O
corticosteroid	ADJ	O	I-Entity
myopathy	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (11022397)

The	DET	O	O
pharmacological	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
drugs	NOUN	O	O
that	ADJ	O	O
act	VERB	O	O
on	ADP	O	O
the	DET	O	O
cholinergic	ADJ	O	O
system	NOUN	O	O
of	ADP	O	O
the	DET	O	O
iris	NOUN	O	O
has	VERB	O	O
been	VERB	O	O
used	VERB	O	O
to	PART	O	O
predict	VERB	O	O
deficits	NOUN	O	O
in	ADP	O	O
central	ADJ	O	O
cholinergic	ADJ	O	O
functioning	NOUN	O	O
due	ADJ	O	O
to	ADP	O	O
diseases	NOUN	O	O
such	ADJ	O	O
as	ADP	O	O
Alzheimer	PROPN	O	B-Entity
's	PART	O	I-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
yet	CCONJ	O	O
correlations	NOUN	O	O
between	ADP	O	O
central	ADJ	O	O
and	CCONJ	O	O
peripheral	ADJ	O	O
responses	NOUN	O	O
have	VERB	O	O
not	ADV	O	O
been	VERB	O	O
properly	ADV	O	O
studied	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
assessed	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
normal	ADJ	O	O
aging	NOUN	O	O
on	ADP	O	O
(	PUNCT	O	O
1	PUNCT	O	O
)	PUNCT	O	O
the	DET	O	O
tropicamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
increase	NOUN	O	O
in	ADP	O	O
pupil	NOUN	O	O
diameter	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
2	PUNCT	O	O
)	PUNCT	O	O
the	DET	O	O
reversal	NOUN	O	O
of	ADP	O	O
this	DET	O	O
effect	NOUN	O	O
with	ADP	O	O
pilocarpine	NOUN	O	I-Entity
.	PUNCT	O	O

Scopolamine	NOUN	O	I-Entity
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
positive	ADJ	O	O
control	NOUN	O	O
to	PART	O	O
detect	VERB	O	O
age	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
changes	NOUN	O	O
in	ADP	O	O
central	ADJ	O	O
cholinergic	ADJ	O	O
functioning	NOUN	O	O
in	ADP	O	O
the	DET	O	O
elderly	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
1	NUM	O	O
session	NOUN	O	O
,	PUNCT	O	O
tropicamide	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
microL	NOUN	O	O
,	PUNCT	O	O
0.01%	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
one	NUM	O	O
eye	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
to	ADP	O	O
the	DET	O	O
other	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
another	DET	O	O
session	NOUN	O	O
,	PUNCT	O	O
tropicamide	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
microL	NOUN	O	O
,	PUNCT	O	O
0.01%	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
both	DET	O	O
eyes	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
23	NUM	O	O
minutes	NOUN	O	O
later	ADV	O	O
by	ADP	O	O
the	DET	O	O
application	NOUN	O	O
of	ADP	O	O
pilocarpine	NOUN	O	I-Entity
(	PUNCT	O	O
20	NUM	O	O
microL	NOUN	O	O
,	PUNCT	O	O
0.1%	NUM	O	O
)	PUNCT	O	O
to	ADP	O	O
one	NUM	O	O
eye	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
to	ADP	O	O
the	DET	O	O
other	ADJ	O	O
.	PUNCT	O	O

In	ADP	O	O
2	NUM	O	O
separate	ADJ	O	O
sessions	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
scopolamine	NOUN	O	I-Entity
(	PUNCT	O	O
0.5	NUM	O	O
mg	NUM	O	O
,	PUNCT	O	O
intravenously	ADV	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
effects	NOUN	O	O
on	ADP	O	O
word	NOUN	O	O
recall	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
using	VERB	O	O
the	DET	O	O
Buschke	PROPN	O	O
Selective	PROPN	O	O
Reminding	PROPN	O	O
Test	NOUN	O	O
over	ADP	O	O
2	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

Pupil	PROPN	O	O
size	NOUN	O	O
at	ADP	O	O
time	NOUN	O	O
points	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
tropicamide	NOUN	O	I-Entity
and	CCONJ	O	O
pilocarpine	NOUN	O	I-Entity
;	PUNCT	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
impairment	NOUN	O	B-Entity
in	ADP	O	I-Entity
word	NOUN	O	I-Entity
recall	NOUN	O	I-Entity
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
elderly	ADJ	O	O
and	CCONJ	O	O
young	ADJ	O	O
volunteers	NOUN	O	O
in	ADP	O	O
pupillary	ADJ	O	O
response	NOUN	O	O
to	PART	O	O
tropicamide	VERB	O	I-Entity
at	ADP	O	O
any	DET	O	O
time	NOUN	O	O
point	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
elderly	ADJ	O	O
group	NOUN	O	O
had	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
greater	ADJ	O	O
pilocarpine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
net	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
pupil	NOUN	O	O
size	NOUN	O	O
85	NUM	O	O
,	PUNCT	O	O
125	NUM	O	O
,	PUNCT	O	O
165	NUM	O	O
and	CCONJ	O	O
215	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
young	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	X	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
young	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
elderly	ADJ	O	O
group	NOUN	O	O
had	VERB	O	O
greater	ADJ	O	O
scopolamine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
impairment	NOUN	O	B-Entity
in	ADP	O	I-Entity
word	NOUN	O	I-Entity
recall	NOUN	O	I-Entity
60	NUM	O	O
,	PUNCT	O	O
90	NUM	O	O
and	CCONJ	O	O
120	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
(	PUNCT	O	O

CONCLUSION	NOUN	O	O
:	PUNCT	O	O
There	ADV	O	O
is	VERB	O	O
an	DET	O	O
age	NOUN	O	O
-	PUNCT	O	O
related	VERB	O	O
pupillary	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
pilocarpine	NOUN	O	I-Entity
that	DET	O	O
is	VERB	O	O
not	ADV	O	O
found	VERB	O	O
with	ADP	O	O
tropicamide	NOUN	O	I-Entity
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
pilocarpine	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
useful	ADJ	O	O
to	PART	O	O
assess	VERB	O	O
variations	NOUN	O	O
in	ADP	O	O
central	ADJ	O	O
cholinergic	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
elderly	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (10692744)

Acetazolamide	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
Gerstmann	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
.	PUNCT	O	O

Acute	PROPN	O	O
confusion	NOUN	O	I-Entity
induced	VERB	O	O
by	ADP	O	O
acetazolamide	NOUN	O	I-Entity
is	VERB	O	O
a	DET	O	O
well	ADV	O	O
known	VERB	O	O
adverse	ADJ	O	O
drug	NOUN	O	O
reaction	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
renal	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
case	NOUN	O	O
of	ADP	O	O
acetazolamide	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
Gerstmann	PROPN	O	B-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
patient	NOUN	O	O
with	ADP	O	O
normal	ADJ	O	O
renal	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
highlight	VERB	O	O
predisposing	NOUN	O	O
factors	NOUN	O	O
that	ADJ	O	O
are	VERB	O	O
frequently	ADV	O	O
overlooked	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (10565806)

Hypomania	PROPN	O	I-Entity
-	PUNCT	O	O
like	ADJ	O	O
syndrome	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
olanzapine	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
female	ADJ	O	O
patient	NOUN	O	O
with	ADP	O	O
a	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
a	DET	O	O
not	ADV	O	O
otherwise	ADV	O	O
specified	VERB	O	O
psychotic	ADJ	O	B-Entity
disorder	NOUN	O	I-Entity
(	PUNCT	O	O
DSM	PROPN	O	O
-	PUNCT	O	O
IV	PROPN	O	O
)	PUNCT	O	O
who	NOUN	O	O
developed	VERB	O	O
hypomania	NOUN	O	I-Entity
shortly	ADV	O	O
after	ADP	O	O
the	DET	O	O
introduction	NOUN	O	O
of	ADP	O	O
olanzapine	ADJ	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (9061311)

Neutrophil	PROPN	O	O
superoxide	NOUN	O	I-Entity
and	CCONJ	O	O
hydrogen	NOUN	O	B-Entity
peroxide	NOUN	O	I-Entity
production	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O

Defects	NOUN	O	O
in	ADP	O	O
superoxide	NOUN	O	I-Entity
and	CCONJ	O	O
hydrogen	NOUN	O	B-Entity
peroxide	NOUN	O	I-Entity
production	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
implicated	VERB	O	O
in	ADP	O	O
the	DET	O	O
high	ADJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
bacterial	ADJ	O	B-Entity
infections	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	B-Entity
liver	NOUN	O	I-Entity
failure	NOUN	O	I-Entity
(	PUNCT	O	O
ALF	PROPN	O	I-Entity
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
oxygen	NOUN	O	I-Entity
radical	ADJ	O	O
production	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ALF	PROPN	O	I-Entity
due	ADJ	O	O
to	ADP	O	O
paracetamol	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
that	DET	O	O
of	ADP	O	O
healthy	ADJ	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

Neutrophils	NOUN	O	O
from	ADP	O	O
14	NUM	O	O
ALF	NOUN	O	I-Entity
patients	NOUN	O	O
were	VERB	O	O
stimulated	VERB	O	O
via	ADP	O	O
the	DET	O	O
complement	NOUN	O	O
receptors	NOUN	O	O
using	VERB	O	O
zymosan	NOUN	O	O
opsonized	VERB	O	O
with	ADP	O	O
ALF	PROPN	O	I-Entity
or	CCONJ	O	O
control	NOUN	O	O
serum	NOUN	O	O
.	PUNCT	O	O

Superoxide	PROPN	O	I-Entity
and	CCONJ	O	O
hydrogen	NOUN	O	B-Entity
peroxide	NOUN	O	I-Entity
production	NOUN	O	O
by	ADP	O	O
ALF	PROPN	O	I-Entity
neutrophils	NOUN	O	O
stimulated	VERB	O	O
with	ADP	O	O
zymosan	PROPN	O	O
opsonized	VERB	O	O
with	ADP	O	O
ALF	PROPN	O	I-Entity
serum	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Superoxide	PROPN	O	I-Entity
and	CCONJ	O	O
hydrogen	NOUN	O	B-Entity
peroxide	NOUN	O	I-Entity
production	NOUN	O	O
in	ADP	O	O
neutrophils	NOUN	O	O
stimulated	VERB	O	O
with	ADP	O	O
formyl	NOUN	O	B-Entity
-	PUNCT	O	I-Entity
methionyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
leucyl	NOUN	O	I-Entity
-	PUNCT	O	I-Entity
phenylalanine	NOUN	O	I-Entity
(	PUNCT	O	O
fMLP	PROPN	O	I-Entity
)	PUNCT	O	O
from	ADP	O	O
a	DET	O	O
further	ADJ	O	O
18	NUM	O	O
ALF	NOUN	O	I-Entity
patients	NOUN	O	O
was	VERB	O	O
unaffected	ADJ	O	O
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
neutrophils	NOUN	O	O
.	PUNCT	O	O

Serum	PROPN	O	O
C3	PROPN	O	O
complement	NOUN	O	O
levels	NOUN	O	O
were	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
in	ADP	O	O
ALF	PROPN	O	I-Entity
patients	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	X	O	O
0.0005	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
demonstrate	VERB	O	O
a	DET	O	O
neutrophil	ADJ	O	O
defect	NOUN	O	O
in	ADP	O	O
ALF	PROPN	O	I-Entity
due	ADP	O	O
to	ADP	O	O
paracetamol	NOUN	O	I-Entity
overdose	NOUN	O	I-Entity
,	PUNCT	O	O
that	DET	O	O
is	VERB	O	O
complement	ADJ	O	O
dependent	ADJ	O	O
but	CCONJ	O	O
independent	ADJ	O	O
of	ADP	O	O
serum	NOUN	O	O
complement	NOUN	O	O
,	PUNCT	O	O
possibly	ADV	O	O
connected	VERB	O	O
to	ADP	O	O
the	DET	O	O
complement	NOUN	O	O
receptor	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8617710)

Absence	PROPN	O	O
of	ADP	O	O
effect	NOUN	O	O
of	ADP	O	O
sertraline	NOUN	O	I-Entity
on	ADP	O	O
time	NOUN	O	O
-	PUNCT	O	O
based	VERB	O	O
sensitization	NOUN	O	O
of	ADP	O	O
cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
with	ADP	O	O
haloperidol	NOUN	O	I-Entity
.	PUNCT	O	O

This	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
,	PUNCT	O	O
randomized	ADJ	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
study	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
alone	ADV	O	O
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
plus	CCONJ	O	O
sertraline	NOUN	O	I-Entity
on	ADP	O	O
cognitive	ADJ	O	O
and	CCONJ	O	O
psychomotor	NOUN	O	O
function	NOUN	O	O
in	ADP	O	O
24	NUM	O	O
healthy	ADJ	O	O
male	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
subjects	NOUN	O	O
received	VERB	O	O
placebo	NOUN	O	O
on	ADP	O	O
Day	PROPN	O	O
1	NUM	O	O
and	CCONJ	O	O
haloperidol	NOUN	O	I-Entity
2	NUM	O	O
mg	NUM	O	O
on	ADP	O	O
Days	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
25	NUM	O	O
.	PUNCT	O	O

From	ADP	O	O
Days	NOUN	O	O
9	NUM	O	O
to	ADP	O	O
25	NUM	O	O
,	PUNCT	O	O
subjects	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
either	DET	O	O
sertraline	NOUN	O	I-Entity
(	PUNCT	O	O
12	NUM	O	O
subjects	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
12	NUM	O	O
subjects	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
the	DET	O	O
sertraline	NOUN	O	I-Entity
dose	NOUN	O	O
was	VERB	O	O
titrated	VERB	O	O
from	ADP	O	O
50	NUM	O	O
to	ADP	O	O
200	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
from	ADP	O	O
Days	NOUN	O	O
9	NUM	O	O
to	ADP	O	O
16	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
remained	VERB	O	O
at	ADP	O	O
200	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
day	NOUN	O	O
for	ADP	O	O
the	DET	O	O
final	ADJ	O	O
10	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
administration	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
:	PUNCT	O	O
Impairment	NOUN	O	B-Entity
of	ADP	O	I-Entity
cognitive	ADJ	O	I-Entity
function	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
6	NUM	O	O
to	ADP	O	O
8	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
haloperidol	NOUN	O	I-Entity
on	ADP	O	O
Day	PROPN	O	O
2	NUM	O	O
but	CCONJ	O	O
was	VERB	O	O
not	ADV	O	O
evident	ADJ	O	O
23	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
dosing	VERB	O	O
.	PUNCT	O	O

When	ADV	O	O
single	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
haloperidol	NOUN	O	I-Entity
was	VERB	O	O
given	VERB	O	O
again	ADV	O	O
25	NUM	O	O
days	NOUN	O	O
later	ADV	O	O
,	PUNCT	O	O
greater	ADJ	O	O
impairment	NOUN	O	O
with	ADP	O	O
earlier	ADJ	O	O
onset	NOUN	O	O
was	VERB	O	O
noted	VERB	O	O
in	ADP	O	O
several	ADJ	O	O
tests	NOUN	O	O
in	ADP	O	O
both	DET	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
enhancement	NOUN	O	O
of	ADP	O	O
this	DET	O	O
effect	NOUN	O	O
.	PUNCT	O	O

There	ADV	O	O
was	VERB	O	O
no	DET	O	O
indication	NOUN	O	O
that	ADP	O	O
sertraline	NOUN	O	I-Entity
exacerbated	VERB	O	O
the	DET	O	O
impairment	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
haloperidol	NOUN	O	I-Entity
since	ADP	O	O
an	DET	O	O
equivalent	ADJ	O	O
effect	NOUN	O	O
also	ADV	O	O
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
on	ADP	O	O
sertraline	NOUN	O	I-Entity
and	CCONJ	O	O
1	NUM	O	O
on	ADP	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
withdrew	VERB	O	O
from	ADP	O	O
the	DET	O	O
study	NOUN	O	O
because	ADP	O	O
of	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
profiles	NOUN	O	O
of	ADP	O	O
sertraline	NOUN	O	I-Entity
and	CCONJ	O	O
of	ADP	O	O
placebo	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
.	PUNCT	O	O

Haloperidol	PROPN	O	I-Entity
produced	VERB	O	O
a	DET	O	O
clear	ADJ	O	O
profile	NOUN	O	O
of	ADP	O	O
cognitive	ADJ	O	B-Entity
impairment	NOUN	O	I-Entity
that	ADJ	O	O
was	VERB	O	O
not	ADV	O	O
worsened	VERB	O	O
by	ADP	O	O
concomitant	ADJ	O	O
sertraline	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (8494478)

Ciprofloxacin	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
nephrotoxicity	NOUN	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
cancer	NOUN	O	I-Entity
.	PUNCT	O	O

Nephrotoxicity	PROPN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
ciprofloxacin	NOUN	O	I-Entity
is	VERB	O	O
uncommon	ADJ	O	O
.	PUNCT	O	O

Five	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
cancer	NOUN	O	I-Entity
who	NOUN	O	O
developed	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
that	ADJ	O	O
followed	VERB	O	O
treatment	NOUN	O	O
with	ADP	O	O
ciprofloxacin	NOUN	O	I-Entity
are	VERB	O	O
described	VERB	O	O
and	CCONJ	O	O
an	DET	O	O
additional	ADJ	O	O
15	NUM	O	O
cases	NOUN	O	O
reported	VERB	O	O
in	ADP	O	O
the	DET	O	O
literature	NOUN	O	O
are	VERB	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

Other	ADJ	O	O
than	ADP	O	O
elevation	NOUN	O	O
of	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	I-Entity
levels	NOUN	O	O
,	PUNCT	O	O
characteristic	ADJ	O	O
clinical	ADJ	O	O
manifestations	NOUN	O	O
and	CCONJ	O	O
abnormal	ADJ	O	O
laboratory	NOUN	O	O
findings	NOUN	O	O
are	VERB	O	O
not	ADV	O	O
frequently	ADV	O	O
present	ADJ	O	O
.	PUNCT	O	O

Allergic	ADJ	O	O
interstitial	ADJ	O	B-Entity
nephritis	NOUN	O	I-Entity
is	VERB	O	O
believed	VERB	O	O
to	PART	O	O
be	VERB	O	O
the	DET	O	O
underlying	VERB	O	O
pathological	ADJ	O	O
-	PUNCT	O	O
process	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
that	ADJ	O	O
followed	VERB	O	O
the	DET	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
offending	VERB	O	O
antibiotic	NOUN	O	O
supports	VERB	O	O
the	DET	O	O
presumptive	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
ciprofloxacin	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (8475949)

Case	NOUN	O	O
report	NOUN	O	O
:	PUNCT	O	O
pentamidine	NOUN	O	I-Entity
and	CCONJ	O	O
polymorphic	VERB	O	O
ventricular	ADJ	O	B-Entity
tachycardia	NOUN	O	I-Entity
revisited	VERB	O	O
.	PUNCT	O	O

Pentamidine	PROPN	O	B-Entity
isethionate	NOUN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
ventricular	ADJ	O	B-Entity
tachyarrhythmias	NOUN	O	I-Entity
,	PUNCT	O	O
including	VERB	O	O
torsade	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	NOUN	O	I-Entity
.	PUNCT	O	O

Pentamidine	PROPN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
torsade	NOUN	O	B-Entity
de	X	O	I-Entity
pointes	NOUN	O	I-Entity
may	VERB	O	O
be	VERB	O	O
related	VERB	O	O
to	ADP	O	O
serum	NOUN	O	O
magnesium	NOUN	O	I-Entity
levels	NOUN	O	O
and	CCONJ	O	O
hypomagnesemia	NOUN	O	I-Entity
may	VERB	O	O
synergistically	ADV	O	O
induce	VERB	O	O
torsade	NOUN	O	O
.	PUNCT	O	O

Torsade	PROPN	O	B-Entity
de	PROPN	O	I-Entity
pointes	NOUN	O	I-Entity
occurred	VERB	O	O
after	ADP	O	O
an	DET	O	O
average	NOUN	O	O
of	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
pentamidine	NOUN	O	I-Entity
.	PUNCT	O	O

In	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
other	ADJ	O	O
acute	ADJ	O	O
side	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
pentamidine	NOUN	O	I-Entity
were	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Torsade	PROPN	O	B-Entity
de	PROPN	O	I-Entity
pointes	NOUN	O	I-Entity
can	VERB	O	O
be	VERB	O	O
treated	VERB	O	O
when	ADV	O	O
recognized	VERB	O	O
early	ADV	O	O
,	PUNCT	O	O
possibly	ADV	O	O
without	ADP	O	O
discontinuation	NOUN	O	O
of	ADP	O	O
pentamidine	NOUN	O	I-Entity
.	PUNCT	O	O

When	ADV	O	O
QTc	PROPN	O	B-Entity
interval	NOUN	O	I-Entity
prolongation	NOUN	O	I-Entity
is	VERB	O	O
observed	VERB	O	O
,	PUNCT	O	O
early	ADJ	O	O
magnesium	NOUN	O	I-Entity
supplementation	NOUN	O	O
is	VERB	O	O
advocated	VERB	O	O
.	PUNCT	O	O


-DOCSTART- (7710775)

Time	PROPN	O	O
dependence	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
malondialdehyde	NOUN	O	I-Entity
,	PUNCT	O	O
oxypurines	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
nucleosides	NOUN	O	I-Entity
during	ADP	O	O
incomplete	ADJ	O	O
cerebral	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
.	PUNCT	O	O

Incomplete	PROPN	O	O
cerebral	ADJ	O	B-Entity
ischemia	NOUN	O	I-Entity
(	PUNCT	O	O
30	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
induced	VERB	O	O
in	ADP	O	O
the	DET	O	O
rat	NOUN	O	O
by	ADP	O	O
bilaterally	ADV	O	O
clamping	VERB	O	O
the	DET	O	O
common	ADJ	O	O
carotid	ADJ	O	O
arteries	NOUN	O	O
.	PUNCT	O	O

Peripheral	ADJ	O	O
venous	ADJ	O	O
blood	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
withdrawn	VERB	O	O
from	ADP	O	O
the	DET	O	O
femoral	ADJ	O	O
vein	NOUN	O	O
four	NUM	O	O
times	NOUN	O	O
(	PUNCT	O	O
once	ADV	O	O
every	DET	O	O
5	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
before	ADP	O	O
ischemia	NOUN	O	I-Entity
(	PUNCT	O	O
0	NUM	O	O
time	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
5	NUM	O	O
,	PUNCT	O	O
15	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
30	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
ischemia	NOUN	O	I-Entity
.	PUNCT	O	O

Plasma	NOUN	O	O
extracts	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
by	ADP	O	O
a	DET	O	O
highly	ADV	O	O
sensitive	ADJ	O	O
high	ADJ	O	O
-	PUNCT	O	O
performance	NOUN	O	O
liquid	NOUN	O	O
chromatographic	ADJ	O	O
method	NOUN	O	O
for	ADP	O	O
the	DET	O	O
direct	ADJ	O	O
determination	NOUN	O	O
of	ADP	O	O
malondialdehyde	NOUN	O	I-Entity
,	PUNCT	O	O
oxypurines	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
nucleosides	NOUN	O	I-Entity
.	PUNCT	O	O

During	ADP	O	O
ischemia	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
time	NOUN	O	O
-	PUNCT	O	O
dependent	ADJ	O	O
increase	NOUN	O	O
of	ADP	O	O
plasma	NOUN	O	O
oxypurines	NOUN	O	I-Entity
and	CCONJ	O	O
nucleosides	NOUN	O	I-Entity
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Plasma	PROPN	O	O
malondialdehyde	NOUN	O	I-Entity
,	PUNCT	O	O
which	ADJ	O	O
was	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
minimal	ADJ	O	O
amount	NOUN	O	O
at	ADP	O	O
zero	NUM	O	O
time	NOUN	O	O
(	PUNCT	O	O
0.058	NUM	O	O
mumol	NOUN	O	O
/	SYM	O	O
liter	ADV	O	O
plasma	NOUN	O	O
;	PUNCT	O	O

SD	PROPN	O	O
0.015	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
increased	VERB	O	O
after	ADP	O	O
5	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
ischemia	NOUN	O	I-Entity
,	PUNCT	O	O
resulting	VERB	O	O
in	ADP	O	O
a	DET	O	O
fivefold	ADJ	O	O
increase	NOUN	O	O
after	ADP	O	O
30	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
carotid	ADJ	O	O
occlusion	NOUN	O	O
(	PUNCT	O	O
0.298	PUNCT	O	O
mumol	NOUN	O	O
/	SYM	O	O
liter	ADV	O	O
plasma	NOUN	O	O
;	PUNCT	O	O
SD	PROPN	O	O
0.078	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Increased	VERB	O	O
plasma	NOUN	O	O
malondialdehyde	NOUN	O	I-Entity
was	VERB	O	O
also	ADV	O	O
recorded	VERB	O	O
in	ADP	O	O
two	NUM	O	O
other	ADJ	O	O
groups	NOUN	O	O
of	ADP	O	O
animals	NOUN	O	O
subjected	VERB	O	O
to	ADP	O	O
the	DET	O	O
same	ADJ	O	O
experimental	ADJ	O	O
model	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
receiving	VERB	O	O
20	NUM	O	O
mg	NUM	O	O
/	SYM	O	O
kg	ADV	O	O
b.w	NOUN	O	O
.	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
cyclooxygenase	NOUN	O	O

inhibitor	NOUN	O	O
acetylsalicylate	NOUN	O	I-Entity
intravenously	ADV	O	O
immediately	ADV	O	O
before	ADP	O	O
ischemia	NOUN	O	I-Entity
,	PUNCT	O	O
the	DET	O	O
other	ADJ	O	O
receiving	VERB	O	O
650	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	ADV	O	O
b.w	NOUN	O	O
.	PUNCT	O	O

of	ADP	O	O
the	DET	O	O
hypotensive	ADJ	O	I-Entity
drug	NOUN	O	O
nitroprusside	NOUN	O	I-Entity
at	ADP	O	O
a	DET	O	O
flow	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
103	NUM	O	O
microliters	NOUN	O	O
/	SYM	O	O

min	NOUN	O	O
intravenously	ADV	O	O
during	ADP	O	O
ischemia	NOUN	O	I-Entity
,	PUNCT	O	O
although	ADP	O	O
in	ADP	O	O
this	DET	O	O
latter	ADJ	O	O
group	NOUN	O	O
malondialdehyde	NOUN	O	I-Entity
was	VERB	O	O
significantly	ADV	O	O
higher	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
data	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
the	DET	O	O
determination	NOUN	O	O
of	ADP	O	O
malondialdehyde	NOUN	O	I-Entity
,	PUNCT	O	O
oxypurines	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
nucleosides	NOUN	O	I-Entity
in	ADP	O	O
peripheral	ADJ	O	O
blood	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
monitor	VERB	O	O
the	DET	O	O
metabolic	NOUN	O	O
alterations	NOUN	O	O
of	ADP	O	O
tissues	NOUN	O	O
occurring	VERB	O	O
during	ADP	O	O
ischemic	ADJ	O	I-Entity
phenomena.(ABSTRACT	ADJ	O	O
TRUNCATED	ADJ	O	O
AT	NOUN	O	O
250	NUM	O	O
WORDS	NOUN	O	O
)	PUNCT	O	O


-DOCSTART- (7650771)

Cholinergic	ADJ	O	O
toxicity	NOUN	O	I-Entity
resulting	VERB	O	O
from	ADP	O	O
ocular	ADJ	O	O
instillation	NOUN	O	O
of	ADP	O	O
echothiophate	NOUN	O	B-Entity
iodide	NOUN	O	I-Entity
eye	NOUN	O	O
drops	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
patient	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
severe	ADJ	O	O
cholinergic	NOUN	O	O
syndrome	NOUN	O	O
from	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
echothiophate	NOUN	O	B-Entity
iodide	NOUN	O	I-Entity
ophthalmic	NOUN	O	O
drops	NOUN	O	O
,	PUNCT	O	O
presented	VERB	O	O
with	ADP	O	O
profound	ADJ	O	O
muscle	NOUN	O	B-Entity
weakness	NOUN	O	I-Entity
and	CCONJ	O	O
was	VERB	O	O
initially	ADV	O	O
given	VERB	O	O
the	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
myasthenia	NOUN	O	B-Entity
gravis	NOUN	O	I-Entity
.	PUNCT	O	O


-DOCSTART- (7565311)

Acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
in	ADP	O	O
high	ADJ	O	O
dose	NOUN	O	O
carboplatin	NOUN	O	I-Entity
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Carboplatin	PROPN	O	I-Entity
has	VERB	O	O
been	VERB	O	O
reported	VERB	O	O
to	PART	O	O
cause	VERB	O	O
acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
when	ADV	O	O
administered	VERB	O	O
in	ADP	O	O
high	ADJ	O	O
doses	NOUN	O	O
to	ADP	O	O
adult	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
a	DET	O	O
4	NUM	O	O
1/2-year	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
girl	NOUN	O	O
who	NOUN	O	O
was	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
high	ADJ	O	O
-	PUNCT	O	O
dose	NOUN	O	O
carboplatin	NOUN	O	I-Entity
for	ADP	O	O
metastatic	ADJ	O	O
parameningeal	NOUN	O	O
embryonal	ADJ	O	B-Entity
rhabdomyosarcoma	NOUN	O	I-Entity
.	PUNCT	O	O

Acute	ADJ	O	B-Entity
renal	ADJ	O	I-Entity
failure	NOUN	O	I-Entity
developed	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
slow	ADJ	O	O
partial	ADJ	O	O
recovery	NOUN	O	O
of	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (7421734)

Endometrial	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
after	ADP	O	O
Hodgkin	PROPN	O	B-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
childhood	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
34-year	ADJ	O	O
-	PUNCT	O	O
old	ADJ	O	O
patient	NOUN	O	O
developed	VERB	O	O
metastic	ADJ	O	O
endometrial	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
after	ADP	O	O
Hodgkin	PROPN	O	B-Entity
disease	NOUN	O	I-Entity
in	ADP	O	O
childhood	NOUN	O	O
.	PUNCT	O	O

She	PRON	O	O
had	VERB	O	O
ovarian	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
abdominal	ADJ	O	O
irradiation	NOUN	O	O
and	CCONJ	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
Hodgkin	PROPN	O	B-Entity
disease	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
received	VERB	O	O
exogenous	ADJ	O	O
estrogens	NOUN	O	I-Entity
,	PUNCT	O	O
a	DET	O	O
treatment	NOUN	O	O
implicated	VERB	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
endometrial	ADJ	O	B-Entity
cancer	NOUN	O	I-Entity
in	ADP	O	O
menopausal	NOUN	O	O
women	NOUN	O	O
.	PUNCT	O	O

Young	ADJ	O	O
women	NOUN	O	O
on	ADP	O	O
replacement	NOUN	O	O
estrogens	NOUN	O	I-Entity
for	ADP	O	O
ovarian	ADJ	O	B-Entity
failure	NOUN	O	I-Entity
after	ADP	O	O
cancer	NOUN	O	I-Entity
therapy	NOUN	O	O
may	VERB	O	O
also	ADV	O	O
have	VERB	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
endometrial	ADJ	O	B-Entity
carcinoma	NOUN	O	I-Entity
and	CCONJ	O	O
should	VERB	O	O
be	VERB	O	O
examined	VERB	O	O
periodically	ADV	O	O
.	PUNCT	O	O


-DOCSTART- (6732043)

Induction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
obstructive	ADJ	O	B-Entity
sleep	NOUN	O	I-Entity
apnea	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
in	ADP	O	O
a	DET	O	O
woman	NOUN	O	O
by	ADP	O	O
exogenous	ADJ	O	O
androgen	NOUN	O	I-Entity
administration	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
documented	VERB	O	O
airway	NOUN	O	O
occlusion	NOUN	O	O
during	ADP	O	O
sleep	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
abnormally	ADV	O	O
high	ADJ	O	O
supraglottic	ADJ	O	O
resistance	NOUN	O	O
while	ADP	O	O
awake	ADJ	O	O
in	ADP	O	O
a	DET	O	O
54-yr	NUM	O	O
-	PUNCT	O	O
old	ADJ	O	O
woman	NOUN	O	O
who	NOUN	O	O
had	VERB	O	O
developed	VERB	O	O
physical	ADJ	O	O
changes	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
syndrome	NOUN	O	B-Entity
of	ADP	O	I-Entity
obstructive	ADJ	O	I-Entity
sleep	NOUN	O	I-Entity
apnea	NOUN	O	I-Entity
while	ADP	O	O
being	VERB	O	O
administered	VERB	O	O
exogenous	ADJ	O	O
androgens	NOUN	O	I-Entity
.	PUNCT	O	O

When	ADV	O	O
the	DET	O	O
androgens	NOUN	O	I-Entity
were	VERB	O	O
withdrawn	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
's	PART	O	O
physical	ADJ	O	O
changes	NOUN	O	O
,	PUNCT	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
sleep	VERB	O	O
study	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
supraglottic	ADJ	O	O
resistance	NOUN	O	O
all	DET	O	O
returned	VERB	O	O
to	ADP	O	O
normal	ADJ	O	O
.	PUNCT	O	O

A	DET	O	O
rechallenge	NOUN	O	O
with	ADP	O	O
androgen	NOUN	O	I-Entity
produced	VERB	O	O
symptoms	NOUN	O	O
of	ADP	O	O
obstructive	ADJ	O	B-Entity
sleep	NOUN	O	I-Entity
apnea	NOUN	O	I-Entity
that	ADJ	O	O
abated	VERB	O	O
upon	ADP	O	O
withdrawal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
hormone	NOUN	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
reports	NOUN	O	O
have	VERB	O	O
favored	VERB	O	O
a	DET	O	O
role	NOUN	O	O
of	ADP	O	O
androgens	NOUN	O	I-Entity
in	ADP	O	O
the	DET	O	O
pathogenesis	NOUN	O	O
of	ADP	O	O
sleep	NOUN	O	B-Entity
apnea	NOUN	O	I-Entity
.	PUNCT	O	O

Structural	PROPN	O	O
and	CCONJ	O	O
functional	ADJ	O	O
measurements	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
androgens	VERB	O	I-Entity
exert	VERB	O	O
a	DET	O	O
permissive	ADJ	O	O
or	CCONJ	O	O
necessary	ADJ	O	O
action	NOUN	O	O
on	ADP	O	O
the	DET	O	O
structural	ADJ	O	O
configuration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
oropharynx	NOUN	O	O
that	ADJ	O	O
predisposes	VERB	O	O
to	ADP	O	O
obstruction	NOUN	O	O
during	ADP	O	O
sleep	NOUN	O	O
.	PUNCT	O	O

Development	NOUN	O	O
of	ADP	O	O
the	DET	O	O
obstructive	ADJ	O	B-Entity
sleep	NOUN	O	I-Entity
apnea	NOUN	O	I-Entity
syndrome	NOUN	O	I-Entity
must	VERB	O	O
be	VERB	O	O
considered	VERB	O	O
a	DET	O	O
possible	ADJ	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
androgen	NOUN	O	I-Entity
therapy	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (6454943)

Effect	PROPN	O	O
of	ADP	O	O
captopril	NOUN	O	I-Entity
on	ADP	O	O
pre	NOUN	O	O
-	PUNCT	O	O
existing	VERB	O	O
and	CCONJ	O	O
aminonucleoside	ADV	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
proteinuria	NOUN	O	I-Entity
in	ADP	O	O
spontaneously	ADV	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
.	PUNCT	O	O

Proteinuria	PROPN	O	I-Entity
is	VERB	O	O
a	DET	O	O
side	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
captopril	NOUN	O	I-Entity
treatment	NOUN	O	O
in	ADP	O	O
hypertensive	ADJ	O	I-Entity
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
possibility	NOUN	O	O
of	ADP	O	O
reproducing	VERB	O	O
the	DET	O	O
same	ADJ	O	O
renal	ADJ	O	B-Entity
abnormality	NOUN	O	I-Entity
with	ADP	O	O
captopril	NOUN	O	I-Entity
was	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
SHR	PROPN	O	O
.	PUNCT	O	O

Oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
captopril	NOUN	O	I-Entity
at	ADP	O	O
100	NUM	O	O
mg	PROPN	O	O
/	SYM	O	O
kg	PROPN	O	O
for	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
aggravate	VERB	O	O
proteinuria	ADJ	O	I-Entity
pre	NOUN	O	O
-	PUNCT	O	O
existing	VERB	O	O
in	ADP	O	O
SHR	PROPN	O	O
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
captopril	NOUN	O	I-Entity
treatment	NOUN	O	O
failed	VERB	O	O
to	PART	O	O
potentiate	VERB	O	O
or	CCONJ	O	O
facilitate	VERB	O	O
development	NOUN	O	O
of	ADP	O	O
massive	ADJ	O	O
proteinuria	NOUN	O	I-Entity
invoked	VERB	O	O
by	ADP	O	O
puromycin	NOUN	O	B-Entity
aminonucleoside	NOUN	O	I-Entity
in	ADP	O	O
SHR	PROPN	O	O
.	PUNCT	O	O

Captopril	PROPN	O	I-Entity
had	VERB	O	O
little	ADJ	O	O
or	CCONJ	O	O
no	DET	O	O
demonstrable	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
serum	NOUN	O	O
electrolyte	NOUN	O	O
concentrations	NOUN	O	O
,	PUNCT	O	O
excretion	NOUN	O	O
of	ADP	O	O
urine	NOUN	O	O
,	PUNCT	O	O
sodium	NOUN	O	I-Entity
and	CCONJ	O	O
potassium	NOUN	O	I-Entity
,	PUNCT	O	O
endogenous	ADJ	O	O
creatinine	NOUN	O	I-Entity
clearance	NOUN	O	O
,	PUNCT	O	O
body	NOUN	O	O
weight	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
food	NOUN	O	O
and	CCONJ	O	O
water	NOUN	O	O
consumption	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
ketone	NOUN	O	I-Entity
bodies	NOUN	O	O
were	VERB	O	O
consistently	ADV	O	O
present	ADJ	O	O
in	ADP	O	O
urine	NOUN	O	O
and	CCONJ	O	O
several	ADJ	O	O
lethalities	NOUN	O	O
occurred	VERB	O	O
during	ADP	O	O
multiple	ADJ	O	O
dosing	NOUN	O	O
of	ADP	O	O
captopril	NOUN	O	I-Entity
in	ADP	O	O
SHR	PROPN	O	O
.	PUNCT	O	O


-DOCSTART- (6153967)

Epileptogenic	ADJ	O	O
properties	NOUN	O	O
of	ADP	O	O
enflurane	NOUN	O	I-Entity
and	CCONJ	O	O
their	ADJ	O	O
clinical	ADJ	O	O
interpretation	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
EEG	PROPN	O	O
changes	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
single	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
enflurane	VERB	O	I-Entity
anesthesia	NOUN	O	O
are	VERB	O	O
reported	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
one	NUM	O	O
patient	NOUN	O	O
,	PUNCT	O	O
enflurane	NOUN	O	I-Entity
administered	VERB	O	O
during	ADP	O	O
a	DET	O	O
donor	NOUN	O	O
nephrectomy	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
unexpected	ADJ	O	O
partial	ADJ	O	O
motor	NOUN	O	O
seizures	NOUN	O	I-Entity
.	PUNCT	O	O

Until	ADP	O	O
the	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
the	DET	O	O
seizures	NOUN	O	I-Entity
was	VERB	O	O
correctly	ADV	O	O
identified	VERB	O	O
,	PUNCT	O	O
the	DET	O	O
patient	NOUN	O	O
was	VERB	O	O
inappropriately	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
anticonvulsants	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
other	ADJ	O	O
patients	NOUN	O	O
suffered	VERB	O	O
from	ADP	O	O
partial	ADJ	O	O
,	PUNCT	O	O
complex	ADJ	O	O
and	CCONJ	O	O
generalized	ADJ	O	O
seizures	NOUN	O	I-Entity
uncontrolled	VERB	O	O
by	ADP	O	O
medication	NOUN	O	O
.	PUNCT	O	O

Epileptic	ADJ	O	I-Entity
foci	NOUN	O	O
delineated	VERB	O	O
and	CCONJ	O	O
activated	VERB	O	O
by	ADP	O	O
enflurane	NOUN	O	I-Entity
were	VERB	O	O
surgically	ADV	O	O
ablated	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
patients	NOUN	O	O
are	VERB	O	O
now	ADV	O	O
seizure	NOUN	O	I-Entity
-	PUNCT	O	O
free	ADJ	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
exposures	NOUN	O	O
to	PART	O	O
enflurane	VERB	O	I-Entity
have	VERB	O	O
to	PART	O	O
be	VERB	O	O
disclosed	VERB	O	O
to	PART	O	O
avoid	VERB	O	O
mistakes	NOUN	O	O
in	ADP	O	O
clinical	ADJ	O	O
interpretation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
EEG	PROPN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
other	ADJ	O	O
hand	NOUN	O	O
,	PUNCT	O	O
enflurane	NOUN	O	I-Entity
may	VERB	O	O
prove	VERB	O	O
to	PART	O	O
be	VERB	O	O
a	DET	O	O
safe	ADJ	O	O
fast	ADJ	O	O
acting	VERB	O	O
activator	NOUN	O	O
of	ADP	O	O
epileptic	ADJ	O	I-Entity
foci	NOUN	O	O
during	ADP	O	O
corticography	NOUN	O	O
or	CCONJ	O	O
depth	NOUN	O	O
electrode	NOUN	O	O
intraoperative	ADJ	O	O
recordings	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3183120)

Reversible	ADJ	O	O
cerebral	ADJ	O	B-Entity
lesions	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
tiazofurin	NOUN	O	I-Entity
usage	NOUN	O	O
:	PUNCT	O	O
MR	PROPN	O	O
demonstration	NOUN	O	O
.	PUNCT	O	O

Tiazofurin	PROPN	O	I-Entity
is	VERB	O	O
an	DET	O	O
experimental	ADJ	O	O
chemotherapeutic	ADJ	O	O
agent	NOUN	O	O
currently	ADV	O	O
undergoing	VERB	O	O
clinical	ADJ	O	O
evaluation	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
report	VERB	O	O
our	ADJ	O	O
results	NOUN	O	O
with	ADP	O	O
magnetic	ADJ	O	O
resonance	NOUN	O	O
(	PUNCT	O	O
MR	PROPN	O	O
)	PUNCT	O	O
in	ADP	O	O
demonstrating	VERB	O	O
reversible	ADJ	O	O
cerebral	ADJ	O	B-Entity
abnormalities	NOUN	O	I-Entity
concurrent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
this	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (3120485)

Antagonism	NOUN	O	O
of	ADP	O	O
diazepam	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
sedative	NOUN	O	O
effects	NOUN	O	O
by	ADP	O	O
Ro15	NUM	O	B-Entity
-	SYM	O	I-Entity
1788	NUM	O	I-Entity
in	ADP	O	O
patients	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
under	ADP	O	O
lumbar	ADJ	O	O
epidural	ADJ	O	O
block	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
Ro15	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
1788	NUM	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
placebo	NOUN	O	O
in	ADP	O	O
reversing	VERB	O	O
diazepam	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
effects	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
under	ADP	O	O
epidural	ADJ	O	O
block	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
to	PART	O	O
evaluate	VERB	O	O
the	DET	O	O
local	ADJ	O	O
tolerance	NOUN	O	O
and	CCONJ	O	O
general	ADJ	O	O
safety	NOUN	O	O
of	ADP	O	O
Ro15	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
1788	NUM	O	I-Entity
.	PUNCT	O	O

Fifty	NUM	O	O
-	PUNCT	O	O
seven	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
sedated	VERB	O	O
with	ADP	O	O
diazepam	NOUN	O	I-Entity
for	ADP	O	O
surgery	NOUN	O	O
under	ADP	O	O
epidural	ADJ	O	O
anaesthesia	NOUN	O	O
.	PUNCT	O	O

Antagonism	NOUN	O	O
of	ADP	O	O
diazepam	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
effects	NOUN	O	O
by	ADP	O	O
Ro15	NUM	O	B-Entity
-	SYM	O	I-Entity
1788	NUM	O	I-Entity
was	VERB	O	O
investigated	VERB	O	O
postoperatively	ADV	O	O
in	ADP	O	O
a	DET	O	O
double	ADJ	O	O
-	PUNCT	O	O
blind	ADJ	O	O
placebo	NOUN	O	O
-	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
's	PART	O	O
subjective	ADJ	O	O
assessment	NOUN	O	O
of	ADP	O	O
mood	NOUN	O	O
rating	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
objective	ADJ	O	O
test	NOUN	O	O
of	ADP	O	O
performance	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
test	NOUN	O	O
for	ADP	O	O
amnesia	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
vital	ADJ	O	O
signs	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
for	ADP	O	O
up	ADV	O	O
to	PART	O	O
300	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
drug	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
for	ADP	O	O
mood	NOUN	O	O
rating	NOUN	O	O
,	PUNCT	O	O
amnesia	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
vital	ADJ	O	O
signs	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Ro15	PROPN	O	B-Entity
-	PUNCT	O	I-Entity
1788	NUM	O	I-Entity
group	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
performance	NOUN	O	O
test	NOUN	O	O
up	ADV	O	O
to	ADP	O	O
120	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (2886572)

Enhanced	ADJ	O	O
stimulus	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
neurotransmitter	NOUN	O	O
overflow	NOUN	O	O
in	ADP	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
induced	VERB	O	O
hypertensive	ADJ	O	I-Entity
rats	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
mediated	VERB	O	O
by	ADP	O	O
prejunctional	ADJ	O	O
beta	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
activation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
examines	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
6-day	NUM	O	O
epinephrine	NOUN	O	I-Entity
treatment	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
micrograms	NOUN	O	O
/	SYM	O	O
kg	ADP	O	O
per	ADP	O	O
h	NOUN	O	O
,	PUNCT	O	O
s.c	NOUN	O	O
.	PUNCT	O	O
)	PUNCT	O	O

endogenous	ADJ	O	O
neurotransmitter	NOUN	O	O
overflow	NOUN	O	O
from	ADP	O	O
the	DET	O	O
isolated	ADJ	O	O
perfused	ADJ	O	O
kidney	NOUN	O	O
of	ADP	O	O
vehicle-	PROPN	O	O
and	CCONJ	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
rats	NOUN	O	O
.	PUNCT	O	O

Renal	ADJ	O	O
catecholamine	NOUN	O	I-Entity
stores	NOUN	O	O
and	CCONJ	O	O
stimulus	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
overflow	NOUN	O	O
in	ADP	O	O
the	DET	O	O
vehicle	NOUN	O	O
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
consisted	VERB	O	O
of	ADP	O	O
norepinephrine	NOUN	O	I-Entity
only	ADV	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
epinephrine	ADJ	O	I-Entity
treatment	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
the	DET	O	O
incorporation	NOUN	O	O
of	ADP	O	O
epinephrine	NOUN	O	I-Entity
into	ADP	O	O
renal	ADJ	O	O
catecholamine	NOUN	O	I-Entity
stores	NOUN	O	O
such	ADJ	O	O
that	ADP	O	O
approximately	ADV	O	O
40%	NUM	O	O
of	ADP	O	O
the	DET	O	O
catecholamine	NOUN	O	I-Entity
present	NOUN	O	O
was	VERB	O	O
epinephrine	ADJ	O	I-Entity
while	ADP	O	O
the	DET	O	O
norepinephrine	NOUN	O	I-Entity
content	NOUN	O	O
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
a	DET	O	O
similar	ADJ	O	O
degree	NOUN	O	O
.	PUNCT	O	O

Total	ADJ	O	O
tissue	NOUN	O	O
catecholamine	NOUN	O	I-Entity
content	NOUN	O	O
of	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
on	ADP	O	O
a	DET	O	O
molar	ADJ	O	O
basis	NOUN	O	O
was	VERB	O	O
unchanged	ADJ	O	O
.	PUNCT	O	O

Stimulus	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
fractional	ADJ	O	O
overflow	NOUN	O	O
of	ADP	O	O
neurotransmitter	NOUN	O	O
from	ADP	O	O
the	DET	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
kidneys	NOUN	O	O
was	VERB	O	O
approximately	ADV	O	O
twice	ADJ	O	O
normal	ADJ	O	O
and	CCONJ	O	O
consisted	ADJ	O	O
of	ADP	O	O
both	DET	O	O
norepinephrine	NOUN	O	I-Entity
and	CCONJ	O	O
epinephrine	NOUN	O	I-Entity
in	ADP	O	O
proportions	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
kidney	NOUN	O	O
.	PUNCT	O	O

Propranolol	PROPN	O	I-Entity
had	VERB	O	O
no	DET	O	O
effect	NOUN	O	O
on	ADP	O	O
stimulus	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
overflow	NOUN	O	O
in	ADP	O	O
either	DET	O	O
group	NOUN	O	O
.	PUNCT	O	O

Phentolamine	PROPN	O	I-Entity
increased	VERB	O	O
stimulus	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
overflow	NOUN	O	O
in	ADP	O	O
both	DET	O	O
groups	NOUN	O	O
although	ADP	O	O
the	DET	O	O
increment	NOUN	O	O
in	ADP	O	O
overflow	NOUN	O	O
was	VERB	O	O
greater	ADJ	O	O
in	ADP	O	O
the	DET	O	O
epinephrine	NOUN	O	I-Entity
-	PUNCT	O	O
treated	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
chronic	ADJ	O	O
epinephrine	NOUN	O	I-Entity
treatment	NOUN	O	O
results	NOUN	O	O
in	ADP	O	O
enhanced	VERB	O	O
fractional	ADJ	O	O
neurotransmitter	NOUN	O	O
overflow	NOUN	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
data	NOUN	O	O
obtained	VERB	O	O
with	ADP	O	O
phentolamine	NOUN	O	I-Entity
alone	ADV	O	O
do	VERB	O	O
not	ADV	O	O
suggest	VERB	O	O
alpha	NOUN	O	O
-	PUNCT	O	O
adrenoceptor	NOUN	O	O
desensitization	NOUN	O	O
as	ADP	O	O
the	DET	O	O
cause	NOUN	O	O
of	ADP	O	O
the	DET	O	O
enhanced	ADJ	O	O
neurotransmitter	NOUN	O	O
overflow	NOUN	O	O
after	ADP	O	O
epinephrine	NOUN	O	I-Entity
treatment	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (1079693)

Ocular	ADJ	O	O
manifestations	NOUN	O	O
of	ADP	O	O
juvenile	NOUN	O	B-Entity
rheumatoid	NOUN	O	I-Entity
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

We	PRON	O	O
followed	VERB	O	O
210	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
juvenile	NOUN	O	B-Entity
rheumatoid	NOUN	O	I-Entity
arthritis	NOUN	O	I-Entity
closely	ADV	O	O
for	ADP	O	O
eleven	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
-	PUNCT	O	O
six	NUM	O	O
of	ADP	O	O
the	DET	O	O
210	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
17.2%	NUM	O	O
)	PUNCT	O	O
developed	VERB	O	O
iridocyclitis	NOUN	O	I-Entity
.	PUNCT	O	O

Iridocyclitis	PROPN	O	I-Entity
was	VERB	O	O
seen	VERB	O	O
most	ADV	O	O
frequently	ADV	O	O
in	ADP	O	O
young	ADJ	O	O
female	ADJ	O	O
patients	NOUN	O	O
(	PUNCT	O	O
0	PUNCT	O	O
to	ADP	O	O
4	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
monoarticular	NOUN	O	O
or	CCONJ	O	O
pauciatricular	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
the	DET	O	O
arthritis	NOUN	O	I-Entity
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
30%	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
developed	VERB	O	O
uveitis	NOUN	O	I-Entity
after	ADP	O	O
16	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
61%	NUM	O	O
of	ADP	O	O
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
noncontributory	ADJ	O	O
ocular	ADJ	O	O
history	NOUN	O	O
on	ADP	O	O
entry	NOUN	O	O
,	PUNCT	O	O
42%	NUM	O	O
had	VERB	O	O
active	ADJ	O	O
uveitis	NOUN	O	I-Entity
on	ADP	O	O
entry	NOUN	O	O
.	PUNCT	O	O

Our	ADJ	O	O
approach	NOUN	O	O
was	VERB	O	O
effective	ADJ	O	O
in	ADP	O	O
detecting	VERB	O	O
uveitis	NOUN	O	I-Entity
in	ADP	O	O
new	ADJ	O	O
cases	NOUN	O	O
and	CCONJ	O	O
exacerbations	NOUN	O	O
of	ADP	O	O
uveitis	NOUN	O	I-Entity
in	ADP	O	O
established	VERB	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Forty	NUM	O	O
-	PUNCT	O	O
four	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
uveitis	NOUN	O	I-Entity
had	VERB	O	O
one	NUM	O	O
or	CCONJ	O	O
more	ADV	O	O
identifiable	ADJ	O	O
signs	NOUN	O	O
or	CCONJ	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
such	ADJ	O	O
as	ADP	O	O
red	ADJ	O	O
eye	NOUN	O	O
,	PUNCT	O	O
ocular	ADJ	O	B-Entity
pain	NOUN	O	I-Entity
,	PUNCT	O	O
decreased	VERB	O	B-Entity
visual	ADJ	O	I-Entity
acuity	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
photophobia	NOUN	O	I-Entity
,	PUNCT	O	O
in	ADP	O	O
order	NOUN	O	O
of	ADP	O	O
decreasing	VERB	O	O
frequency	NOUN	O	O
.	PUNCT	O	O

Even	ADV	O	O
after	ADP	O	O
early	ADJ	O	O
detection	NOUN	O	O
and	CCONJ	O	O
prompt	ADJ	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
41%	NUM	O	O
of	ADP	O	O
cases	NOUN	O	O
of	ADP	O	O
uveitis	NOUN	O	I-Entity
did	VERB	O	O
not	ADV	O	O
respond	VERB	O	O
to	ADP	O	O
more	ADJ	O	O
than	ADP	O	O
six	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
intensive	ADJ	O	O
topical	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
corticosteroids	NOUN	O	I-Entity
and	CCONJ	O	O
mydriatics	NOUN	O	O
.	PUNCT	O	O

Despite	ADP	O	O
this	DET	O	O
,	PUNCT	O	O
there	ADV	O	O
was	VERB	O	O
a	DET	O	O
dramatic	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
50%	NUM	O	O
incidence	NOUN	O	O
of	ADP	O	O
blinding	ADJ	O	O
complications	NOUN	O	O
of	ADP	O	O
uveitis	NOUN	O	I-Entity
cited	VERB	O	O
in	ADP	O	O
earlier	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

Cataract	PROPN	O	I-Entity
and	CCONJ	O	O
band	NOUN	O	B-Entity
keratopathy	NOUN	O	I-Entity
occurred	VERB	O	O
in	ADP	O	O
only	ADV	O	O
22	NUM	O	O
and	CCONJ	O	O
13%	NUM	O	O
of	ADP	O	O
our	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

We	PRON	O	O
used	VERB	O	O
chloroquine	NOUN	O	I-Entity
or	CCONJ	O	O
hydroxychloroquine	NOUN	O	I-Entity
in	ADP	O	O
173	NUM	O	O
of	ADP	O	O
210	NUM	O	O
cases	NOUN	O	O
and	CCONJ	O	O
found	VERB	O	O
only	ADV	O	O
one	NUM	O	O
case	NOUN	O	O
of	ADP	O	O
chorioretinopathy	NOUN	O	I-Entity
attributable	ADJ	O	O
to	ADP	O	O
these	DET	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Systemically	ADV	O	O
administered	VERB	O	O
corticosteroids	NOUN	O	I-Entity
were	VERB	O	O
used	VERB	O	O
in	ADP	O	O
75	NUM	O	O
of	ADP	O	O
210	NUM	O	O
cases	NOUN	O	O
;	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
posterior	ADJ	O	O
subcapsular	ADJ	O	O
cataracts	NOUN	O	I-Entity
was	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

Typical	ADJ	O	O
keratoconjunctivitis	NOUN	O	I-Entity
sicca	NOUN	O	O
developed	VERB	O	O
in	ADP	O	O
three	NUM	O	O
of	ADP	O	O
the	DET	O	O
uveitis	ADJ	O	I-Entity
cases	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
association	NOUN	O	O
with	ADP	O	O
uveitis	NOUN	O	I-Entity
and	CCONJ	O	O
JRA	PROPN	O	O
was	VERB	O	O
not	ADV	O	O
noted	VERB	O	O
previously	ADV	O	O
.	PUNCT	O	O

Surgical	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
cataracts	NOUN	O	I-Entity
,	PUNCT	O	O
band	NOUN	O	B-Entity
keratopathy	NOUN	O	I-Entity
,	PUNCT	O	O
and	CCONJ	O	O
glaucoma	NOUN	O	I-Entity
achieved	VERB	O	O
uniformly	ADV	O	O
discouraging	VERB	O	O
results	NOUN	O	O
.	PUNCT	O	O


-DOCSTART- (803783)

Water	PROPN	O	B-Entity
intoxication	NOUN	O	I-Entity
associated	VERB	O	O
with	ADP	O	O
oxytocin	ADJ	O	I-Entity
administration	NOUN	O	O
during	ADP	O	O
saline	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
abortion	NOUN	O	I-Entity
.	PUNCT	O	O

Four	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
water	NOUN	O	B-Entity
intoxication	NOUN	O	I-Entity
in	ADP	O	O
connection	NOUN	O	O
with	ADP	O	O
oxytocin	ADJ	O	I-Entity
administration	NOUN	O	O
during	ADP	O	O
saline	ADJ	O	O
-	PUNCT	O	O
induced	VERB	O	O
abortions	NOUN	O	I-Entity
are	VERB	O	O
described	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
mechanism	NOUN	O	O
of	ADP	O	O
water	NOUN	O	B-Entity
intoxication	NOUN	O	I-Entity
is	VERB	O	O
discussed	VERB	O	O
in	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
these	DET	O	O
cases	NOUN	O	O
.	PUNCT	O	O

Oxytocin	PROPN	O	I-Entity
administration	NOUN	O	O
during	ADP	O	O
midtrimester	NOUN	O	O
-	PUNCT	O	O
induced	VERB	O	O
abortions	NOUN	O	I-Entity
is	VERB	O	O
advocated	VERB	O	O
only	ADV	O	O
if	ADP	O	O
it	PRON	O	O
can	VERB	O	O
be	VERB	O	O
carried	VERB	O	O
out	PART	O	O
under	ADP	O	O
careful	ADJ	O	O
observations	NOUN	O	O
of	ADP	O	O
an	DET	O	O
alert	ADJ	O	O
nursing	NOUN	O	O
staff	NOUN	O	O
,	PUNCT	O	O
aware	ADJ	O	O
of	ADP	O	O
the	DET	O	O
symptoms	NOUN	O	O
of	ADP	O	O
water	NOUN	O	B-Entity
intoxication	NOUN	O	I-Entity
and	CCONJ	O	O
instructed	VERB	O	O
to	PART	O	O
watch	VERB	O	O
the	DET	O	O
diuresis	NOUN	O	O
and	CCONJ	O	O
report	VERB	O	O
such	ADJ	O	O
early	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
the	DET	O	O
syndrome	NOUN	O	O
as	ADP	O	O
asthenia	NOUN	O	I-Entity
,	PUNCT	O	O
muscular	ADJ	O	O
irritability	NOUN	O	I-Entity
,	PUNCT	O	O
or	CCONJ	O	O
headaches	NOUN	O	I-Entity
.	PUNCT	O	O

The	DET	O	O
oxytocin	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
given	VERB	O	O
only	ADV	O	O
in	ADP	O	O
Ringers	PROPN	O	O
lactate	NOUN	O	I-Entity
or	CCONJ	O	O
,	PUNCT	O	O
alternately	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
Ringers	PROPN	O	O
lactate	NOUN	O	I-Entity
and	CCONJ	O	O
a	DET	O	O
5	NUM	O	O
per	ADP	O	O
cent	NOUN	O	O
dextrose	NOUN	O	I-Entity
and	CCONJ	O	O
water	NOUN	O	O
solutions	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
urinary	ADJ	O	O
output	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
monitored	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
oxytocin	ADJ	O	I-Entity
administration	NOUN	O	O
discontinued	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
serum	NOUN	O	O
electrolytes	VERB	O	O
checked	VERB	O	O
if	ADP	O	O
the	DET	O	O
urinary	ADJ	O	O
output	NOUN	O	O
decreases	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
oxytocin	NOUN	O	I-Entity
should	VERB	O	O
not	ADV	O	O
be	VERB	O	O
administered	VERB	O	O
in	ADP	O	O
excess	NOUN	O	O
of	ADP	O	O
36	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

If	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
has	VERB	O	O
not	ADV	O	O
aborted	VERB	O	O
by	ADP	O	O
then	ADV	O	O
the	DET	O	O
oxytocin	NOUN	O	I-Entity
should	VERB	O	O
be	VERB	O	O
discontinued	VERB	O	O
for	ADP	O	O
10	NUM	O	O
to	PART	O	O
12	NUM	O	O
hours	NOUN	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
perform	VERB	O	O
electrolyte	NOUN	O	O
determinations	NOUN	O	O
and	CCONJ	O	O
correct	VERB	O	O
any	DET	O	O
electrolyte	NOUN	O	O
imbalance	NOUN	O	O
.	PUNCT	O	O


